<SEC-DOCUMENT>0000875045-20-000022.txt : 20200722
<SEC-HEADER>0000875045-20-000022.hdr.sgml : 20200722
<ACCEPTANCE-DATETIME>20200722163751
ACCESSION NUMBER:		0000875045-20-000022
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		119
CONFORMED PERIOD OF REPORT:	20200630
FILED AS OF DATE:		20200722
DATE AS OF CHANGE:		20200722

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOGEN INC.
		CENTRAL INDEX KEY:			0000875045
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				330112644
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19311
		FILM NUMBER:		201041843

	BUSINESS ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		7814642000

	MAIL ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC.
		DATE OF NAME CHANGE:	20070427

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC
		DATE OF NAME CHANGE:	20031112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IDEC PHARMACEUTICALS CORP / DE
		DATE OF NAME CHANGE:	19970530
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>biib-2020630x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:31E3E1798CBF5AB3B56F10ECB7C4A2C0,x:a389d084b7ea4fbbac12b9c0e87a49ea-->
<!-- Document created using Wdesk  -->
<!-- Copyright 2020 Workiva -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2019-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2019-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2019-01-31" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2019-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2019-01-31" xmlns:lea="http://fasb.org/dis/lea/2019-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2019-01-31" xmlns:guar="http://fasb.org/dis/guar/2019-01-31" xmlns:ru="http://fasb.org/dis/ru/2019-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:leas="http://fasb.org/dis/leas/2019-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2019-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2019-01-31" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2019-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:fs-insa="http://fasb.org/dis/fs-insa/2019-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:cce="http://fasb.org/dis/cce/2019-01-31" xmlns:inv="http://fasb.org/dis/inv/2019-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:srt-std="http://fasb.org/srt-std/2019-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2019-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2019-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2019-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2019-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2019-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2019-01-31" xmlns:ceclcalc3l="http://fasb.org/dis/ceclcalc3l/2019-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:re="http://fasb.org/dis/re/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2019-01-31" xmlns:invco="http://fasb.org/dis/invco/2019-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2019-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2019-01-31" xmlns:currency-ent-dep="http://xbrl.sec.gov/currency-ent-dep/2019-01-31" xmlns:aro="http://fasb.org/dis/aro/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2019-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:srt-all="http://fasb.org/srt-all/2019-01-31" xmlns:codification-part="http://fasb.org/codification-part/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:sec-re="http://fasb.org/dis/sec-re/2019-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2019-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2019-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2019-01-31" xmlns:equity="http://fasb.org/dis/equity/2019-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:se="http://fasb.org/dis/se/2019-01-31" xmlns:crcrb="http://fasb.org/dis/crcrb/2019-01-31" xmlns:edco="http://fasb.org/dis/edco/2019-01-31" xmlns:te="http://fasb.org/dis/te/2019-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2019-01-31" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2019-01-31" xmlns:hco="http://fasb.org/dis/hco/2019-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:dr="http://fasb.org/dis/dr/2019-01-31" xmlns:ero="http://fasb.org/dis/ero/2019-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2019-01-31" xmlns:cecl="http://fasb.org/dis/cecl/2019-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2019-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2019-01-31" xmlns:ceclcalc2="http://fasb.org/dis/ceclcalc2/2019-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2019-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2019-01-31" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2019-01-31" xmlns:soi="http://fasb.org/stm/soi/2019-01-31" xmlns:diha="http://fasb.org/dis/diha/2019-01-31" xmlns:debt="http://fasb.org/dis/debt/2019-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2019-01-31" xmlns:bc="http://fasb.org/dis/bc/2019-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2019-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2019-01-31" xmlns:rd="http://fasb.org/dis/rd/2019-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2019-01-31" xmlns:biib="http://www.biogenidec.com/20200630" xmlns:eui="http://fasb.org/dis/eui/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ap="http://fasb.org/dis/ap/2019-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2019-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2019-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2019-01-31" xmlns:sr="http://fasb.org/dis/sr/2019-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2019-01-31" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2019-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2019-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2019-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2019-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2019-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2019-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2019-01-31" xmlns:oi="http://fasb.org/dis/oi/2019-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2019-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2019-01-31" xmlns:cc="http://fasb.org/dis/cc/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2019-01-31" xmlns:disops="http://fasb.org/dis/disops/2019-01-31" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:cn-part="http://fasb.org/cn-part/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2019-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2019-01-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2019-01-31" xmlns:ts="http://fasb.org/dis/ts/2019-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2019-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2019-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2019-01-31" xmlns:ni="http://fasb.org/dis/ni/2019-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2019-01-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2019-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2019-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2019-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2019-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2019-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2019-01-31" xmlns:ir="http://fasb.org/dis/ir/2019-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2019-01-31" xmlns:foct="http://fasb.org/dis/foct/2019-01-31" xmlns:soc="http://fasb.org/stm/soc/2019-01-31" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2019-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2019-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2019-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:con="http://fasb.org/dis/con/2019-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2019-01-31" xmlns:eps="http://fasb.org/dis/eps/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:iago="http://fasb.org/dis/iago/2019-01-31" xmlns:pay="http://fasb.org/dis/pay/2019-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:tin-part="http://fasb.org/tin-part/2019-01-31" xmlns:acec="http://fasb.org/dis/acec/2019-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2019-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:nt="http://fasb.org/dis/nt/2019-01-31" xmlns:spc="http://fasb.org/stm/spc/2019-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2019-01-31" xmlns:ides="http://fasb.org/dis/ides/2019-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2019-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:regop="http://fasb.org/dis/regop/2019-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2019-01-31" xmlns:com="http://fasb.org/stm/com/2019-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2019-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2019-01-31" xmlns:exch-ent-dep="http://xbrl.sec.gov/exch-ent-dep/2019-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ei="http://fasb.org/dis/ei/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
	<head>
		<meta http-equiv="Content-Type" content="text/html" />
		<title>Document</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="FD2019Q2YTD" name="biib:AverageMaturityOfMarketableSecurities" id="Fact-C114E491322C568ABA1A744B3E7C5BE9-wk-Fact-C114E491322C568ABA1A744B3E7C5BE9">P14M</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q2YTD" name="biib:AverageMaturityOfMarketableSecurities" id="Fact-A9C66C37062A5D9DACFC78BCD7B4DCB0-wk-Fact-A9C66C37062A5D9DACFC78BCD7B4DCB0">P14M</ix:nonNumeric><ix:nonFraction decimals="-5" unitRef="usd" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_TECFIDERAMember" name="biib:IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet" id="Fact-0F5775DED8682DC1AB675E1333B08D8C-wk-Fact-0F5775DED8682DC1AB675E1333B08D8C">56000000</ix:nonFraction><ix:nonNumeric contextRef="FD2020Q2YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" name="biib:IndefiniteLivedIntangibleAssetsUsefulLife" id="Fact-31ED2216CDAC55759A97D68277EE094E-wk-Fact-31ED2216CDAC55759A97D68277EE094E">Indefinite until commercialization</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q2YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" name="biib:IndefiniteLivedIntangibleAssetsUsefulLife" id="Fact-B3AD2CF1533A50B881F39662D60DE086-wk-Fact-B3AD2CF1533A50B881F39662D60DE086">Indefinite</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q2YTD" name="dei:AmendmentFlag" id="Fact-DB0444439B6A5E29A9239182BD978EAB-wk-Fact-DB0444439B6A5E29A9239182BD978EAB" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q2YTD" name="dei:CurrentFiscalYearEndDate" id="Fact-FC7A0569D8CC5542A90A4CD6478092D1-wk-Fact-FC7A0569D8CC5542A90A4CD6478092D1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q2YTD" name="dei:DocumentFiscalPeriodFocus" id="Fact-71F47813B6515D0CBF853EAA5A23238C-wk-Fact-71F47813B6515D0CBF853EAA5A23238C">Q2</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q2YTD" name="dei:DocumentFiscalYearFocus" id="Fact-209CEFC342B159C0AE975B87BC4FF518-wk-Fact-209CEFC342B159C0AE975B87BC4FF518">2020</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q2YTD" name="dei:EntityCentralIndexKey" id="Fact-AC6FEE9737725215A6B619A69722E8E3-wk-Fact-AC6FEE9737725215A6B619A69722E8E3">0000875045</ix:nonNumeric><ix:nonFraction decimals="0" unitRef="usd" contextRef="FD2020Q2QTD" name="us-gaap:AssetImpairmentCharges" id="Fact-58119B3F11FF595466835DD38A2CB818-wk-Fact-58119B3F11FF595466835DD38A2CB818">0</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FI2020Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" id="Fact-45B734C952ED5664A032C15EC6F136F6-wk-Fact-45B734C952ED5664A032C15EC6F136F6">0.0118</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FI2020Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" id="Fact-08A4DD95F86B5E36AAFFD5663CFC103E-wk-Fact-08A4DD95F86B5E36AAFFD5663CFC103E">0.0083</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2019Q4" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-F479CEE686A557A39B1292C500006F83-wk-Fact-F479CEE686A557A39B1292C500006F83">0.0005</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2020Q2" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-2502C2D242DF5732A98261B087729D18-wk-Fact-2502C2D242DF5732A98261B087729D18">0.0005</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_A2.25SeniorNotesdueMay12030Member" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact-5F2A418B3B6513F42C2C5DBFC13B6F54-wk-Fact-5F2A418B3B6513F42C2C5DBFC13B6F54">0.0225</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_A3.15SeniorNotesdueMay12050Member" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact-1DA94484BF276A1CE7F75DBFC4F846FB-wk-Fact-1DA94484BF276A1CE7F75DBFC4F846FB">0.0315</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact-9F6180352F51598B806CFF94F9108A7C-wk-Fact-9F6180352F51598B806CFF94F9108A7C">0.052</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact-128388B45DA758D2A43859B8919DB8D4-wk-Fact-128388B45DA758D2A43859B8919DB8D4">0.0405</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact-9EF6B4A53B3E5BBF8B1E52097CC129B7-wk-Fact-9EF6B4A53B3E5BBF8B1E52097CC129B7">0.03625</ix:nonFraction><ix:nonNumeric contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember" name="us-gaap:DerivativeRemainingMaturity1" id="Fact-381B3AA0E15A556397874933BA47AC35-wk-Fact-381B3AA0E15A556397874933BA47AC35">P15M</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember" name="us-gaap:DerivativeRemainingMaturity1" id="Fact-C98D2A938D5C5D9D8199FC945776998E-wk-Fact-C98D2A938D5C5D9D8199FC945776998E">P1M</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q2YTD_biib_DerivativeMaturityAxis_biib_ShorttermderivativeMember" name="us-gaap:DerivativeRemainingMaturity1" id="Fact-1E6B4A0D1B3B5AE6B12CE664ACCC94CB-wk-Fact-1E6B4A0D1B3B5AE6B12CE664ACCC94CB">P12M</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q2YTD_srt_RangeAxis_srt_MaximumMember" name="us-gaap:DerivativeRemainingMaturity1" id="Fact-EB615AF714EC570D828A4864F9BD6378-wk-Fact-EB615AF714EC570D828A4864F9BD6378">P18M</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q2YTD_srt_RangeAxis_srt_MinimumMember" name="us-gaap:DerivativeRemainingMaturity1" id="Fact-7E6B726C42B35215A105AE1F72093D4C-wk-Fact-7E6B726C42B35215A105AE1F72093D4C">P1M</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" name="us-gaap:DerivativeTermOfContract" id="Fact-1DE1EAFD691B5E9D80932448AAE6C850-wk-Fact-1DE1EAFD691B5E9D80932448AAE6C850">P7M</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q2YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Fact-42C76B2795FC5AE69D7638F697EF928E-wk-Fact-42C76B2795FC5AE69D7638F697EF928E">P18Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q2YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Fact-1318FC19621B5D0E890BEEFF84355E35-wk-Fact-1318FC19621B5D0E890BEEFF84355E35">P23Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q2YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Fact-8329806B71835A5E88EC70F0091F0DA3-wk-Fact-8329806B71835A5E88EC70F0091F0DA3">P28Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q2YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Fact-F868DE7617D357F58E913DA6CAEF63BD-wk-Fact-F868DE7617D357F58E913DA6CAEF63BD">P4Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q2YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Fact-509D3B79131C5C3383297F35B5EE7454-wk-Fact-509D3B79131C5C3383297F35B5EE7454">P13Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q2YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Fact-AB07A1A451725016B7E5743AB24B1640-wk-Fact-AB07A1A451725016B7E5743AB24B1640">P15Y</ix:nonNumeric><ix:nonFraction decimals="INF" unitRef="usd" contextRef="FD2019Q2QTD" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" id="Fact-A43B4C0875D58F43917D5DAFCCC6F939-wk-Fact-A43B4C0875D58F43917D5DAFCCC6F939">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usd" contextRef="FD2019Q2YTD" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" id="Fact-15336B38A3C85DAEBC9079C9DC743774-wk-Fact-15336B38A3C85DAEBC9079C9DC743774">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usd" contextRef="FD2020Q2YTD" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" id="Fact-B8C8E3BC108558E0A972BD9194F99DE6-wk-Fact-B8C8E3BC108558E0A972BD9194F99DE6">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2019Q4" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact-572BB4B7E4F653FAB76B8AB80F8F1EBF-wk-Fact-572BB4B7E4F653FAB76B8AB80F8F1EBF">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2020Q2" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact-B4A452BE6D3C5C09982B249720250AD2-wk-Fact-B4A452BE6D3C5C09982B249720250AD2">0.001</ix:nonFraction><ix:nonFraction decimals="-5" unitRef="usd" contextRef="FI2020Q2_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember" name="us-gaap:RevenueRemainingPerformanceObligation" id="Fact-BF63EE7D272656B5A0865DA5F7F8F587-wk-Fact-BF63EE7D272656B5A0865DA5F7F8F587">170600000</ix:nonFraction><ix:nonFraction decimals="-5" unitRef="usd" contextRef="FD2020Q2YTD_srt_MajorCustomersAxis_biib_ContractManufacturingCustomerMember_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember" name="us-gaap:Revenues" id="Fact-A56538F1F78F94F1DE3F5DA41DA87ECB-wk-Fact-A56538F1F78F94F1DE3F5DA41DA87ECB">329400000</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:href="biib-20200630.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="FD2020Q2YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2020Q1July21">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-07-21</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q1Mar1-Mar31_us-gaap_BusinessAcquisitionAxis_biib_BIIB118Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BIIB118Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-06-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_biib_PostacquisitionequitycompensationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">biib:PostacquisitionequitycompensationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3Denmark">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-08-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3Denmark_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-08-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_MajorCustomersAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_MajorCustomersAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_MajorCustomersAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_MajorCustomersAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FumarateMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_FumarateMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_InterferonMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_FumarateMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_FumarateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_InterferonMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FumarateMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FumarateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_FumarateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FumarateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_InterferonMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_InterferonMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_FumarateMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FumarateMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_FumarateMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FumarateMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_MajorCustomersAxis_biib_ContractManufacturingCustomerMember_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ContractManufacturingCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_MajorCustomersAxis_biib_DistributorTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_MajorCustomersAxis_biib_DistributorOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_MajorCustomersAxis_biib_DistributorTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_MajorCustomersAxis_biib_DistributorOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_MajorCustomersAxis_biib_DistributorOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_MajorCustomersAxis_biib_DistributorTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_MajorCustomersAxis_biib_DistributorTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_MajorCustomersAxis_biib_DistributorOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_MajorCustomersAxis_biib_ContractManufacturingCustomerMember_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ContractManufacturingCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_biib_ResearchanddevelopmentassetAxis_biib_TGNMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:TGNMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_A2.25SeniorNotesdueMay12030Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_A3.15SeniorNotesdueMay12050Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_A3.15SeniorNotesdueMay12050Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_A2.25SeniorNotesdueMay12030Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2020Q1April30_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2020Q1April30_dei_LegalEntityAxis_biib_SangamoCommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:SangamoCommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_CurrencyAxis_currency_JPY_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_CurrencyAxis_currency_JPY_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Nov1-Nov30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-11-01</xbrli:startDate>
			<xbrli:endDate>2018-11-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_biib_DerivativeMaturityAxis_biib_ShorttermderivativeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_biib_DerivativeMaturityAxis_biib_ShorttermderivativeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2015Q3Sept152015_us-gaap_DebtInstrumentAxis_biib_A2.90SeniorNotesDueSept152020Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.90SeniorNotesDueSept152020Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-15</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_DebtInstrumentAxis_biib_A2.90SeniorNotesDueSept152020Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.90SeniorNotesDueSept152020Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2020Q1April30_us-gaap_DebtInstrumentAxis_biib_A3.15SeniorNotesdueMay12050Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2020Q1April30_us-gaap_DebtInstrumentAxis_biib_A2.25SeniorNotesdueMay12030Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_DebtInstrumentAxis_biib_A2.90SeniorNotesDueSept152020Member_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.90SeniorNotesDueSept152020Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_ProductOrServiceAxis_biib_TECFIDERAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_TECFIDERAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_TECFIDERAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_dei_LegalEntityAxis_biib_SangamoCommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:SangamoCommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_dei_LegalEntityAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_dei_LegalEntityAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SkyhawkTherapeuticsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q1Feb01-Feb29_us-gaap_TypeOfArrangementAxis_biib_SangamoTherapeuticsInc.AgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SangamoTherapeuticsInc.AgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-02-01</xbrli:startDate>
			<xbrli:endDate>2020-02-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2020Q1Jan31_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q1Mar3120_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SkyhawkTherapeuticsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q4Oct01-Oct31_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SkyhawkTherapeuticsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-10-01</xbrli:startDate>
			<xbrli:endDate>2019-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-11-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InventoriesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SkyhawkTherapeuticsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_UCBPharmaS.A.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_UCBPharmaS.A.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_biib_FutureContingentMilestoneTypesAxis_biib_RegulatoryMilestonesMember_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_biib_NeurimmuneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryMilestonesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="biib:InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Neurimmune_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_biib_NeurimmuneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-05-01</xbrli:startDate>
			<xbrli:endDate>2018-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_biib_NeurimmuneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_biib_FutureContingentMilestoneTypesAxis_biib_RegulatoryApprovalMilestoneMember_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_biib_NeurimmuneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryApprovalMilestoneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="biib:InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_IncomeTaxAuthorityAxis_country_BR">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:BR</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:unit id="segment">
		<xbrli:measure>biib:segment</xbrli:measure>
	</xbrli:unit><xbrli:unit id="Assets">
		<xbrli:measure>biib:Assets</xbrli:measure>
	</xbrli:unit><xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit><xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit><xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit><xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit><xbrli:unit id="KRW">
		<xbrli:measure>iso4217:KRW</xbrli:measure>
	</xbrli:unit><xbrli:unit id="chf">
		<xbrli:measure>iso4217:CHF</xbrli:measure>
	</xbrli:unit></ix:resources></ix:header></div><div><a id="s1E1B6C295118555A955C131EB62BDEC0"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:14pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:14pt;font-weight:bold;">UNITED STATES</span></div><div style="line-height:120%;text-align:center;font-size:14pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Washington,&#160;D.C. 20549</span></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:18pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:18pt;font-weight:bold;">Form&#160;</span><span><ix:nonNumeric id="d13624087e799-wk-Fact-8178FA0D45D857C7B4AF36DEB1CA842F" name="dei:DocumentType" contextRef="FD2020Q2YTD"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:18pt;font-weight:bold;">10-Q</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:18pt;font-weight:bold;"> </span></div><div style="line-height:120%;font-size:14pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:14pt;"><span style="font-family:Arial Unicode MS;font-size:14pt;"><span><ix:nonNumeric id="d13624087e817-wk-Fact-D355492BBC175460B4D34ADAA9A2020E" name="dei:DocumentQuarterlyReport" contextRef="FD2020Q2YTD" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:5px;padding-left:48px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">For the quarterly period ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><span><span style="white-space:nowrap"><ix:nonNumeric id="d13624087e827-wk-Fact-111F514759615D03A3828254DC43F9F2" name="dei:DocumentPeriodEndDate" contextRef="FD2020Q2YTD" format="ixt:datemonthdayyearen">June 30, 2020</ix:nonNumeric></span></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">OR</span></div><div style="line-height:120%;font-size:14pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:14pt;"><span style="font-family:Arial Unicode MS;font-size:14pt;"><span><ix:nonNumeric id="d13624087e847-wk-Fact-18BC4385C6865292868B92C27656AE34" name="dei:DocumentTransitionReport" contextRef="FD2020Q2YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:9px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Commission File Number </span><span><ix:nonNumeric id="d13624087e857-wk-Fact-ED9B9C1469A15FEEA943203A3FCEE995" name="dei:EntityFileNumber" contextRef="FD2020Q2YTD"><span style="font-family:Franklin Gothic Book,sans-serif;font-weight:bold;">0-19311</span></ix:nonNumeric></span></div><div style="line-height:120%;padding-top:9px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"> </span><img src="biogenlogoa11.jpg" alt="biogenlogoa11.jpg" style="height:30px;width:92px;"></img></div><div style="line-height:120%;text-align:center;font-size:24pt;"><span><ix:nonNumeric id="d13624087e866-wk-Fact-EACA4FB7A446538488AD579F0D552F28" name="dei:EntityRegistrantName" contextRef="FD2020Q2YTD"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:24pt;font-weight:bold;">BIOGEN INC.</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:24pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(Exact name of registrant as specified in its charter)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:4%;"></td><td style="width:47%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d13624087e888-wk-Fact-9508AEC63A0852F498C888A918123553" name="dei:EntityIncorporationStateCountryCode" contextRef="FD2020Q2YTD" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d13624087e898-wk-Fact-60C6231898355F3A9D8A21B911ABAAFB" name="dei:EntityTaxIdentificationNumber" contextRef="FD2020Q2YTD">33-0112644</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(State or other jurisdiction of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">incorporation or organization)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(I.R.S. Employer</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">Identification No.)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span><ix:nonNumeric id="d13624087e923-wk-Fact-BC6D187A26975015B99E0E5A964C9CCE" name="dei:EntityAddressAddressLine1" contextRef="FD2020Q2YTD"><span style="font-family:Franklin Gothic Book,sans-serif;font-weight:bold;">225 Binney Street</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">, </span><span><ix:nonNumeric id="d13624087e928-wk-Fact-4CD0C4F1719253B3B7946541FE983436" name="dei:EntityAddressCityOrTown" contextRef="FD2020Q2YTD"><span style="font-family:Franklin Gothic Book,sans-serif;font-weight:bold;">Cambridge</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">, </span><span><ix:nonNumeric id="d13624087e933-wk-Fact-108B31E0A99C5522A20C439F75980955" name="dei:EntityAddressStateOrProvince" contextRef="FD2020Q2YTD"><span style="font-family:Franklin Gothic Book,sans-serif;font-weight:bold;">MA</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"> </span><span><ix:nonNumeric id="d13624087e938-wk-Fact-0F1844528FC4597786F8EADC39103EF4" name="dei:EntityAddressPostalZipCode" contextRef="FD2020Q2YTD"><span style="font-family:Franklin Gothic Book,sans-serif;">02142</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">(</span><span><ix:nonNumeric id="d13624087e946-wk-Fact-93F60ED0CED05A67B5AAFD077FCBB137" name="dei:CityAreaCode" contextRef="FD2020Q2YTD"><span style="font-family:Franklin Gothic Book,sans-serif;font-weight:bold;">617</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">)&#160;</span><span><ix:nonNumeric id="d13624087e951-wk-Fact-5BFC883A86095BF6871D808D22883601" name="dei:LocalPhoneNumber" contextRef="FD2020Q2YTD"><span style="font-family:Franklin Gothic Book,sans-serif;font-weight:bold;">679-2000</span></ix:nonNumeric></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(Address, including zip code, and telephone number, including</span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">area code, of registrant&#8217;s principal executive offices)</span></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Securities registered pursuant to Section 12(b) of the Act:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:34%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Title of each class</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Trading Symbol(s)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Name of each exchange on which registered</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d13624087e1012-wk-Fact-9FEFF7474E5D530D823A19009CF18A8A" name="dei:Security12bTitle" contextRef="FD2020Q2YTD">Common Stock, $0.0005 par value</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d13624087e1022-wk-Fact-C40F77E9325358F68D4D6B1BB86C86F6" name="dei:TradingSymbol" contextRef="FD2020Q2YTD">BIIB</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">The Nasdaq Global Select Market</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days:&#160;&#160;&#160;&#160;</span><span><ix:nonNumeric id="d13624087e1042-wk-Fact-A0FF6BBD1ECA5ED9BFF41460502D4F78" name="dei:EntityCurrentReportingStatus" contextRef="FD2020Q2YTD"><span style="font-family:Franklin Gothic Book,sans-serif;">Yes</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span><span style="font-family:Wingdings;font-size:10pt;">x</span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">No</span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span><span style="font-family:Wingdings;font-size:10pt;">o</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files):&#160;&#160;&#160;&#160;</span><span><ix:nonNumeric id="d13624087e1060-wk-Fact-B97C8FE628B45A50A6076E45E7C055E8" name="dei:EntityInteractiveDataCurrent" contextRef="FD2020Q2YTD"><span style="font-family:Franklin Gothic Book,sans-serif;">Yes</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span><span style="font-family:Wingdings;font-size:10pt;">x</span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">No</span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span><span style="font-family:Wingdings;font-size:10pt;">o</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act:</span></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:23%;"></td><td style="width:3%;"></td><td style="width:43%;"></td><td style="width:28%;"></td><td style="width:3%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d13624087e1095-wk-Fact-24829E5BA63D52CAB7F16AD2B1C40AA1" name="dei:EntityFilerCategory" contextRef="FD2020Q2YTD" format="ixt-sec:entityfilercategoryen">Large accelerated filer</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Wingdings;font-size:10pt;">x</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accelerated filer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:12pt;"><span style="font-family:Arial Unicode MS;font-size:12pt;">&#9744;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-accelerated&#160;filer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><span style="font-family:Arial Unicode MS;font-size:12pt;">&#9744;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Smaller&#160;reporting&#160;company</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:12pt;"><span style="font-family:Arial Unicode MS;font-size:12pt;"><span><ix:nonNumeric id="d13624087e1141-wk-Fact-C45F229A83AB5CB7BC1AFD0D05B0DB26" name="dei:EntitySmallBusiness" contextRef="FD2020Q2YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Emerging growth company</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:12pt;"><span style="font-family:Arial Unicode MS;font-size:12pt;"><span><ix:nonNumeric id="d13624087e1167-wk-Fact-2E10E3472D9E5D5AA8A0018C290E91F9" name="dei:EntityEmergingGrowthCompany" contextRef="FD2020Q2YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-family:Wingdings;font-size:10pt;">o</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span><ix:nonNumeric id="d13624087e1177-wk-Fact-965B83E3819E50F48D1140256A1E05E0" name="dei:EntityShellCompany" contextRef="FD2020Q2YTD" format="ixt-sec:boolballotbox"><span style="font-size:12pt;">&#9744;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;No&#160;</span><span style="font-family:inherit;font-size:10pt;">&#160;</span><span style="font-family:Wingdings;font-size:10pt;">x</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The number of shares of the issuer&#8217;s Common Stock, $0.0005&#160;par value, outstanding as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">July&#160;21, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d13624087e1195-wk-Fact-65FDFC55C6AD576A951F0041554C72D5" name="dei:EntityCommonStockSharesOutstanding" contextRef="I2020Q1July21" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">158,313,471</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div><br/></div><hr style="page-break-after:always"></hr><div><a id="s940E3527377354DCA6109BF475291A92"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">BIOGEN INC.</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">FORM&#160;10-Q &#8212; Quarterly Report</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">For the Quarterly Period Ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"> </span></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">TABLE OF CONTENTS</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:9%;"></td><td style="width:81%;"></td><td style="width:10%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">Page</span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">PART&#160;I&#160;&#8212; </span><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;" href="#sFEFA881CF63052838C0CDA01679AD0A9"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">FINANCIAL INFORMATION</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Item 1.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#s33A11BE177AE569B98349DC952E414A9"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Financial Statements (unaudited)</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#s43328B3914A759E9A2E8517119D64C11"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Condensed Consolidated Statements of Income&#160;&#8212; For the Three and Six Months Ended June 30, 2020 and 2019</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#s43328B3914A759E9A2E8517119D64C11">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#s228C92841F925BF49CECC142851CFA67"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Condensed Consolidated Statements of Comprehensive Income &#8212; For the Three and Six Months Ended June 30, 2020 and 2019</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#s228C92841F925BF49CECC142851CFA67">6</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#sF2518969463B57D09132AC6D461E56E6"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Condensed Consolidated Balance Sheets&#160;&#8212; As of June 30, 2020 and December&#160;31, 2019</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#sF2518969463B57D09132AC6D461E56E6">7</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#s1E1B6C295118555A955C131EB62BDEC0"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Condensed Consolidated Statements of Cash Flows&#160;&#8212; For the Six Months Ended June 30, 2020 and 2019</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#s97A86C4A92F052E280ABDBD88461AA4D">8</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#s4C8479CC2B45507D9F75C3144AE3D122"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Condensed Consolidated Statements of Equity &#8212; For the Three and Six Months Ended June 30, 2020 and 2019</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#s4C8479CC2B45507D9F75C3144AE3D122">9</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#sC639DB589A1350BE9DA3F828034895AB"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Notes to Condensed Consolidated Financial Statements</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#sC639DB589A1350BE9DA3F828034895AB">13</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Item 2.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#sBE09E681FDFC53839DAFD20102CADCC9"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#sBE09E681FDFC53839DAFD20102CADCC9">45</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Item 3.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#s43874FB91C6D5B3FACE69752FDB1BE50"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Quantitative and Qualitative Disclosures About Market Risk</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#s43874FB91C6D5B3FACE69752FDB1BE50">72</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Item 4.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#sE0842C0FDC02598094CB7E3D96FED5D5"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Controls and Procedures</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#sE0842C0FDC02598094CB7E3D96FED5D5">75</a></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">PART&#160;II&#160;&#8212; </span><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;" href="#s6DFCC1E8653852C0B5DB2F104A40AD43"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">OTHER INFORMATION</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Item 1.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#sDE18582F0C105D47A8A4E404ABD74D50"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Legal Proceedings</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#sDE18582F0C105D47A8A4E404ABD74D50">76</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Item&#160;1A.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#sF1E9673F137F5F78BE460C7F6D90917B"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Risk Factors</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#sF1E9673F137F5F78BE460C7F6D90917B">76</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Item 2.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#s917E2230E889577BABAA5ED78043378D"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#s917E2230E889577BABAA5ED78043378D">94</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Item 6.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#s3D1D8E898DAC5C8E8922B73F95EB3CE1"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Exhibits</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#s3D1D8E898DAC5C8E8922B73F95EB3CE1">95</a></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#s8CBDF27E2E58514CB3D0135AEC8C481E"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Signatures</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;" href="#s8CBDF27E2E58514CB3D0135AEC8C481E">96</a></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2</span></div></div><hr style="page-break-after:always"></hr><div><a id="s51A248A8D1A15F31ACAA500137189C31"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This report contains forward-looking statements that are being made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995 (the Act) with the intention of obtaining the benefits of the &#8220;Safe Harbor&#8221; provisions of the Act. These forward-looking statements may be accompanied by such words as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;possible,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and other words and terms of similar meaning. Reference is made in particular to forward-looking statements regarding:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the anticipated amount, timing and accounting of revenues; contingent, milestone, royalty and other payments under licensing, collaboration, acquisition or divestiture agreements; tax positions and contingencies; collectability of receivables; pre-approval inventory; cost of sales; research and development costs; compensation and other selling, general and administrative expenses; amortization of intangible assets; foreign currency exchange risk; estimated fair value of assets and liabilities; and impairment assessments;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">expectations, plans and prospects relating to sales, pricing, growth and launch of our marketed and pipeline products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability and other matters;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the direct and indirect impact of COVID-19 on our business and operations, including sales, expenses, supply chain, manufacturing, research and development costs, clinical trials and employees;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the potential impact of increased product competition in the markets in which we compete, including increased competition from generics, biosimilars, prodrugs and products approved under abbreviated regulatory pathways;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our plans and investments in our core and emerging growth areas, as well as implementation of our corporate strategy;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the drivers for growing our business, including our plans and intention to commit resources relating to research and development programs and business development opportunities, as well as the potential benefits and results of certain business development transactions;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our ability to finance our operations and business initiatives and obtain funding for such activities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the costs and timing of potential clinical trials, filings and approvals, and the potential therapeutic scope of the development and commercialization of our and our collaborators&#8217; pipeline products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">adverse safety events involving our marketed products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the potential impact of healthcare reform in the United States (U.S.) and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities and activities in new or existing manufacturing facilities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the impact of the continued uncertainty of the credit and economic conditions in certain countries in Europe and our collection of accounts receivable in such countries;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the potential impact on our results of operations and liquidity of the United Kingdom's (U.K.) departure from the European Union (E.U.);</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the impact of new laws, regulatory requirements, judicial decisions and accounting standards.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These forward-looking statements involve risks and uncertainties, including those that are described in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Item 1A.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> included in this report and elsewhere in this report that could cause actual results to differ materially from those reflected in such statements. You should not place undue reliance on these statements. Forward-looking statements speak only as of the date of this report. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.</span></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">NOTE REGARDING COMPANY AND PRODUCT REFERENCES</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">References in this report to:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8220;Biogen,&#8221; the &#8220;company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Biogen Inc. and its consolidated subsidiaries; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8220;RITUXAN&#8221; refers to both RITUXAN (the trade name for rituximab in the U.S., Canada and Japan) and MabThera (the trade name for rituximab outside the U.S., Canada and Japan).</span></div></td></tr></table><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">NOTE&#160;REGARDING TRADEMARKS</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">AVONEX&#174;, PLEGRIDY&#174;, RITUXAN&#174;, RITUXAN HYCELA&#174;, SPINRAZA&#174;, TECFIDERA&#174;, TYSABRI&#174;, VUMERITY&#174; and ZINBRYTA&#174; are registered trademarks of Biogen. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BENEPALI&#8482;, FLIXABI&#8482;, FUMADERM&#8482;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and IMRALDI&#8482; are trademarks of Biogen. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ENBREL&#174;, EYLEA&#174;, FAMPYRA</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, GAZYVA&#174;, HUMIRA&#174;, LUCENTIS&#174;, OCREVUS&#174;, REMICADE&#174;, SkySTAR&#8482;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and other trademarks referenced in this report are the property of their respective owners. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4</span></div></div><hr style="page-break-after:always"></hr><div><a id="sFEFA881CF63052838C0CDA01679AD0A9"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">PART&#160;I FINANCIAL INFORMATION</span></div><div><a id="s33A11BE177AE569B98349DC952E414A9"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s43328B3914A759E9A2E8517119D64C11"></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions, except per share amounts)</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Product, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13627288e1067-wk-Fact-B152D3B5F3A05C7CAA044F72EA3120C1" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,795.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13627288e1086-wk-Fact-455E60BA69055CE8AECAC5095741DB0A" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,880.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13627288e1105-wk-Fact-3718F7E632B25D27847BA0BA45120ACA" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,700.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13627288e1125-wk-Fact-EE4EC8FA691555C0A7DE82D787D37BE4" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,560.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Revenues from anti-CD20 therapeutic programs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13627288e1140-wk-Fact-FB6FCA81223F5FE7A607645477111EBC" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">478.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13627288e1159-wk-Fact-20474355737A5AB3954B4011223DE749" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">576.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13627288e1178-wk-Fact-58C037C126CE5E9782E7F6AFA1368536" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">998.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13627288e1198-wk-Fact-235F3E71E70A544C994CD254A0F195D0" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,093.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13627288e1218-wk-Fact-F3C79B768015565FA0C0EB179D69F338" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">407.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13627288e1237-wk-Fact-46C1484140125886ACF7E143442F0214" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">160.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13627288e1256-wk-Fact-E351B467EBD95DC7BA1A6E901C488CDA" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">516.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13627288e1276-wk-Fact-9E90C511A4E4588682EE0D2A0C9F3B65" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">452.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Total revenues</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13627288e1296-wk-Fact-62D84A2C364C577DA44131925927374D" name="us-gaap:Revenues" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,681.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13627288e1315-wk-Fact-6848435D107959608A78CDFF623C1FCA" name="us-gaap:Revenues" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,616.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13627288e1334-wk-Fact-4CD2481C46DE5C41BDD753FF5D2D020B" name="us-gaap:Revenues" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7,215.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13627288e1354-wk-Fact-082E3F02F0A75CC6A55785289710BF28" name="us-gaap:Revenues" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7,106.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Cost and expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Cost of sales, excluding amortization and impairment of acquired intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13627288e1456-wk-Fact-2881C54F9C785A4A804CD3438BE59ADD" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">411.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13627288e1475-wk-Fact-7B7F293170175DAFAA45517EA7FDFA3E" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">476.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13627288e1494-wk-Fact-F97C57D7B0145B379BA07A81ACDAFD4F" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">865.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13627288e1514-wk-Fact-E663E4B6D0FC538CA47ED87B47A58A20" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,078.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13627288e1534-wk-Fact-545F8B395E0B5D4D8B8302649A4D9360" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">647.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13627288e1553-wk-Fact-75B9D888AF2E5705A55276082BF4BCC6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">484.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13627288e1572-wk-Fact-8D580F88EF7955798FEE8D3F36C9AD30" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,123.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13627288e1592-wk-Fact-E2F41ABB8ADA5A018F296F5F9FE0BBA8" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,048.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13627288e1612-wk-Fact-88716ADAA8195DEFBBF65FE7C9BC363C" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">555.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13627288e1631-wk-Fact-D398926E1CFB5F33B56996E29E5025AC" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">587.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13627288e1650-wk-Fact-6ACAB8C017D75DC89D14D18DA12CC8A2" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,125.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13627288e1670-wk-Fact-1A4B579AFF0C5F47A5DA916AA054E467" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,155.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Amortization and impairment of acquired intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13627288e1691-wk-Fact-093CF28AF51D56AC9C178C57E0C20541" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">61.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13627288e1710-wk-Fact-FD9B7A01CCCF53378063A4D1471F9676" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">70.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13627288e1729-wk-Fact-5983CB099A665EB6970E589C89F1CF90" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">133.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13627288e1749-wk-Fact-9E9EE51D826850DFA48CA3605826DA50" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">138.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Collaboration profit (loss) sharing</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13627288e1769-wk-Fact-F2B388227309526097FBCFB10E17189C" name="biib:Collaborationprofitlosssharing" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">21.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13627288e1788-wk-Fact-4958ACC3384B599BB607C0620E4A8AEC" name="biib:Collaborationprofitlosssharing" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">63.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13627288e1807-wk-Fact-956C8FEE37325419B50E76DD830EBF06" name="biib:Collaborationprofitlosssharing" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">93.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13627288e1827-wk-Fact-AC7A4562CF5E526A9913062BA57B6ED9" name="biib:Collaborationprofitlosssharing" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">121.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13627288e1847-wk-Fact-CB516727D8125C199D28BC02ACC98E4A" name="us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span>(<ix:nonFraction id="d13627288e1866-wk-Fact-E0A74BB3C9805B5D91EBF354AAF2C7AA" name="us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" contextRef="FD2019Q2QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13627288e1886-wk-Fact-CCDCC0B613C752A0B4788DBA33E7F2FF" name="us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13627288e1906-wk-Fact-9468395847FA54909BD0FF3C7830EB5F" name="us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">113.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(Gain) loss on fair value remeasurement of contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13627288e1926-wk-Fact-D2590DE582FB57A4B3475521C290EA50" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">10.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span>(<ix:nonFraction id="d13627288e1945-wk-Fact-EA0A92078CAF5114A9DDE6B7E79E0436" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13627288e1965-wk-Fact-1ED69AA194385201B48524E875F0B015" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">5.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span>(<ix:nonFraction id="d13627288e1985-wk-Fact-2D5631ACC4AA55F18A9E8E1BE5DDC18B" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Restructuring charges</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13627288e2006-wk-Fact-2E35D16EC55B556AB8D14737A56D03D8" name="us-gaap:RestructuringCharges" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13627288e2025-wk-Fact-0855F5C2575157428A6870E75717EEFB" name="us-gaap:RestructuringCharges" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13627288e2044-wk-Fact-CF725BD2C041581F965E07AC347E498E" name="us-gaap:RestructuringCharges" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13627288e2064-wk-Fact-33F147C147535C44A1557A7E0A6BE656" name="us-gaap:RestructuringCharges" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Acquired in-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13627288e2084-wk-Fact-5A806CFB3DE05E50B1B040C6894B925B" name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13627288e2103-wk-Fact-5BDD4D579570542B9D02D7ADC319B453" name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13627288e2122-wk-Fact-95EEAD25F3C058EFB92E2B4BE6E5D7E0" name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">75.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13627288e2142-wk-Fact-99A3CDD007EB5D948B282C7D3865470E" name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Total cost and expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13627288e2162-wk-Fact-71EDF945C1625A23801C3AF366AD4A9E" name="us-gaap:CostsAndExpenses" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,707.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13627288e2181-wk-Fact-77E1E92DB9A7518BB5E6C7CECD5BA8DE" name="us-gaap:CostsAndExpenses" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,660.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13627288e2200-wk-Fact-A86FAAC565545FCC92B87BF26A57E37D" name="us-gaap:CostsAndExpenses" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,421.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13627288e2220-wk-Fact-65B16EB561365B3BBB931DC845B9D329" name="us-gaap:CostsAndExpenses" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,647.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Income from operations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13627288e2240-wk-Fact-56D0B955948E51E79D06EEB83E3EBEA0" name="us-gaap:OperatingIncomeLoss" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,974.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13627288e2259-wk-Fact-6267945275DA596099A006B2235C5378" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,955.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13627288e2278-wk-Fact-CF03E0F0D74C56FEB819268AF46519F0" name="us-gaap:OperatingIncomeLoss" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,794.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13627288e2298-wk-Fact-69E2755E1105526AB2DC1AB9B5BE5B2B" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,458.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Other income (expense), net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13627288e2318-wk-Fact-0D51E02D7DDE5C0E8E7A9F3566E66B60" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">63.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span>(<ix:nonFraction id="d13627288e2337-wk-Fact-55BFFA5FA59E5C88AB2D8F69B51FDAAD" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">197.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span>(<ix:nonFraction id="d13627288e2357-wk-Fact-ABD76A880BD354B29882CFA24D852D20" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">57.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13627288e2378-wk-Fact-EEF1B208E84A576484A9D98454389FE0" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">159.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Income before income tax expense and equity in loss of investee, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13627288e2398-wk-Fact-15CFF958FCA75C3DA262F3D4877F6388" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,037.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13627288e2417-wk-Fact-F92B896983605050807AF216847FD3DE" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,758.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13627288e2436-wk-Fact-7F49859E4C81541C91411139852A9A2D" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,736.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13627288e2456-wk-Fact-7437E9D01BB05863B64D1E2F608F3DB3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,618.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Income tax expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13627288e2476-wk-Fact-15FFBD4EE73D5D2B8B78CD5F725441DC" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">446.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13627288e2495-wk-Fact-3669AFE313445E4585683ADA7AAD91C7" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">248.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13627288e2514-wk-Fact-0707EC3077505826ADFEC0CF301EBA0C" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">738.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13627288e2534-wk-Fact-F3C30D754426501CB970A0480E375CC2" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">670.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Equity in (income) loss of investee, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span>(<ix:nonFraction id="d13627288e2555-wk-Fact-E82D70018EB35E49B9ED4B9D1092EC46" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13627288e2575-wk-Fact-DF75577404985E478F2563E78FEB4CFB" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">16.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span>(<ix:nonFraction id="d13627288e2594-wk-Fact-B3CD3D16C9135EFD9DA3E256B292EF4E" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13627288e2615-wk-Fact-37101BD9FBD15AA8A0298E7BE1D10035" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">45.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Net income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13627288e2635-wk-Fact-F3D57A6489675B3F80AF93FBE5F9C15F" name="us-gaap:ProfitLoss" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,606.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13627288e2654-wk-Fact-46DCDF7F62D35A1BA19A2C2DD7FB0AB9" name="us-gaap:ProfitLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,494.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13627288e2673-wk-Fact-D07F9091FDDE5F65A9EF3F12BC88C032" name="us-gaap:ProfitLoss" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,999.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13627288e2693-wk-Fact-D7A6A22966455FDB9B8B93F33634D792" name="us-gaap:ProfitLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,902.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Net&#160;income (loss) attributable to noncontrolling interests, net&#160;of&#160;tax</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13627288e2713-wk-Fact-451347AC18A553FA98E75031F387B9B7" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">64.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13627288e2732-wk-Fact-15851F6402AF567A997FB8A39BDA0FB7" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13627288e2751-wk-Fact-E773C8539D5B5296A5CA4A51C9631206" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">57.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13627288e2771-wk-Fact-85C6A3EC82A5546B843356BAC3450B72" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Net income attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13627288e2796-wk-Fact-ADD31A6A5EBE5E7D8A2551FB858970C3" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,542.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13627288e2815-wk-Fact-014416A7DF4E55AD89901C62A077D0C5" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,494.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13627288e2834-wk-Fact-B46E75E522BC521D944CD595197A0DA3" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,941.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13627288e2854-wk-Fact-91FF827803B156BD8E311A0B778D9521" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,902.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Net income per share:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Basic earnings per share attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13627288e3038-wk-Fact-1E4BD2BF91618134CDB2591CC932F0BA" name="us-gaap:EarningsPerShareBasic" contextRef="FD2020Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">9.60</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13627288e3057-wk-Fact-C63DDCBC709041645DAA591CC959CDDF" name="us-gaap:EarningsPerShareBasic" contextRef="FD2019Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">7.85</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13627288e3076-wk-Fact-91F15E7A81316F7B2EBB591CC93FA598" name="us-gaap:EarningsPerShareBasic" contextRef="FD2020Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">17.65</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13627288e3096-wk-Fact-DA41C40E2222A7CA8D44591CC91C396A" name="us-gaap:EarningsPerShareBasic" contextRef="FD2019Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">15.01</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Diluted earnings per share attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13627288e3116-wk-Fact-B4A4B94C9FC088BCD8CC591CC9292039" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2020Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">9.59</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13627288e3135-wk-Fact-03894815A9D8BA8D36F7591CC93CCEDC" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2019Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">7.85</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13627288e3154-wk-Fact-FDADD2C98C53B9EFB184591CC9268538" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2020Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">17.61</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13627288e3174-wk-Fact-EF46FEDCE6ACCA6DB4A1591CC94A2E4D" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2019Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">14.99</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Weighted-average shares used in calculating:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Basic earnings per share attributable to Biogen Inc.</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13627288e3353-wk-Fact-99FE479F6EFA52F59E2D3DD5A91BFF8C" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2020Q2QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">160.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13627288e3372-wk-Fact-0F8F00DB70B25725BDF588003BE32027" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q2QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">190.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13627288e3391-wk-Fact-A7BA3E1F65C655ACB63EFBEDF4E5AE60" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2020Q2YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">166.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13627288e3411-wk-Fact-22C74589209D549881B0B30906FF83A7" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q2YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">193.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Diluted earnings per share attributable to Biogen Inc.</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13627288e3432-wk-Fact-AC9CFA06C14752C2822D10FC87E8F4FE" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2020Q2QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">160.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13627288e3451-wk-Fact-AD06855122DD55CAA38318A14B520635" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q2QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">190.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13627288e3470-wk-Fact-8008A00FC876554890ED4AD4AC163885" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2020Q2YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">167.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13627288e3490-wk-Fact-85F20EFF251E5B3C9894F550494B41BA" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q2YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">193.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5</span></div></div><hr style="page-break-after:always"></hr><div><a id="s228C92841F925BF49CECC142851CFA67"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions)</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Net income attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13628796e985-wk-Fact-ADD31A6A5EBE5E7D8A2551FB858970C3" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,542.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13628796e1004-wk-Fact-014416A7DF4E55AD89901C62A077D0C5" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,494.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13628796e1023-wk-Fact-B46E75E522BC521D944CD595197A0DA3" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,941.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13628796e1043-wk-Fact-91FF827803B156BD8E311A0B778D9521" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,902.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Other comprehensive income:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Unrealized gains (losses) on securities available for sale, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13628796e1140-wk-Fact-20D152D8C31452398FE56BF477364DB6" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13628796e1159-wk-Fact-52749E634CF15A74B50A736D8F7F0843" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13628796e1178-wk-Fact-B30F94F9AE775858A3CD0CD084FC8566" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13628796e1198-wk-Fact-A45EA26E025E52FDB836A0B6C43C734D" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Unrealized gains (losses) on cash flow hedges, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span>(<ix:nonFraction id="d13628796e1218-wk-Fact-B50F57AD349A5CC59BB9CA686B97930A" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">51.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span>(<ix:nonFraction id="d13628796e1238-wk-Fact-676F3D74FBC558E5834EBAC3C2A8605A" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">37.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span>(<ix:nonFraction id="d13628796e1258-wk-Fact-B69D33DAE57259B88F2A294AA9BC8FC8" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">17.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span>(<ix:nonFraction id="d13628796e1279-wk-Fact-A59C250C28915DD9BD68F56692696DE0" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Gains (losses) on net investment hedges</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span>(<ix:nonFraction id="d13628796e1300-wk-Fact-BF89450180C45E2DAEF2516991C3C547" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">6.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13628796e1320-wk-Fact-BAF3E383E126596AA65390603EECEE3C" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13628796e1339-wk-Fact-D9E8471C594C5583B8E0DC5BECC2235B" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13628796e1359-wk-Fact-4923ACFE615853FA88A3F6A8706CFED0" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">25.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Unrealized gains (losses) on pension benefit obligation, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13628796e1379-wk-Fact-E3AEDCBE899E5626A888DFB01A2DA9A6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13628796e1398-wk-Fact-60B2D12DE3D85F85B3C02553D94C1D53" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13628796e1417-wk-Fact-8E1A81F213505668AE18E9A33B8189EC" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13628796e1437-wk-Fact-125C903F962B59A5BCB2C91F2D1ECCD3" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Currency translation adjustment</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13628796e1457-wk-Fact-529FB4E717A05D299B5C50666236355F" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span>(<ix:nonFraction id="d13628796e1476-wk-Fact-0EB7457C955655E6B986277FF93C757E" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">10.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span>(<ix:nonFraction id="d13628796e1496-wk-Fact-751DB29C7DBC50818F5955DF1B5C6F5D" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">47.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span>(<ix:nonFraction id="d13628796e1517-wk-Fact-DF2CD33DA9855515BF6086E959B24267" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">28.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Total other comprehensive income (loss), net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span>(<ix:nonFraction id="d13628796e1538-wk-Fact-4EE07EA71AE75C6CB808AB3BDB79D0D9" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">31.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span>(<ix:nonFraction id="d13628796e1558-wk-Fact-E2573FCDAC995132BA12E51FA532B992" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">33.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span>(<ix:nonFraction id="d13628796e1578-wk-Fact-41D6455C5A4252129BD8C5FF297E3741" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">45.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span>(<ix:nonFraction id="d13628796e1599-wk-Fact-6F359B4ACF055A4DA4E8C22AC9182DDB" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">12.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Comprehensive income attributable to Biogen Inc.</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13628796e1620-wk-Fact-A4557F57C4FD5C3C9507C78C8CB9E35C" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,510.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13628796e1639-wk-Fact-1059470360EB5CEC94D0BBABB5E145E0" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,461.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13628796e1658-wk-Fact-E6413F4D177C5620ADDE79FF42D15E8D" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,895.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13628796e1678-wk-Fact-2E3D0F6C34915E23BFD320525EFCF045" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,890.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13628796e1699-wk-Fact-F3B2169F724B597790A61F76260980CE" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">65.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span>(<ix:nonFraction id="d13628796e1718-wk-Fact-60920D850A69521281659CEB8F0D03CE" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13628796e1738-wk-Fact-20159077275B514190417592CF4D5DDD" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">59.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span>(<ix:nonFraction id="d13628796e1758-wk-Fact-11A20FC25878549F9483B5F204F0639C" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Comprehensive income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13628796e1784-wk-Fact-021FE9119133528B8258FE34D0F1532E" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,575.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13628796e1803-wk-Fact-1A89C42175935468932BEF3981E6657F" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,460.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13628796e1822-wk-Fact-BDEF3267F7A65723BF7FDD84AC535552" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,955.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13628796e1842-wk-Fact-ABD476C00A9C52A4982C4DA447D2112E" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,890.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6</span></div></div><hr style="page-break-after:always"></hr><div><a id="sF2518969463B57D09132AC6D461E56E6"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions, except per share amounts)</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:65%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;font-weight:bold;">As of June 30, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">As of December 31, <br/>2019</span></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">ASSETS</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Current assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13630831e937-wk-Fact-02522BE0D0F052DB931AED6FC05A8227" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,384.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13630831e956-wk-Fact-37A9AD9064055B35AC649A018B388FC4" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,913.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13630831e971-wk-Fact-1278CFB1A3D050DE84DEF39500038A37" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,942.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13630831e990-wk-Fact-E0941E6475ED52CB806609F597CFCDBD" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,562.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Accounts receivable, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13630831e1010-wk-Fact-A0D833B92E115601BB44711535FCEBC1" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,133.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13630831e1029-wk-Fact-545EFA543ACB5832A6E1B19B7CBA7F29" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,880.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Due from anti-CD20 therapeutic programs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13630831e1049-wk-Fact-2BBB4E43BB6753AFA583B8F9F2672F6F" name="biib:DuefromantiCD20therapeuticprograms" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">441.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13630831e1068-wk-Fact-1A781630359852B1B0C492E71833F3AD" name="biib:DuefromantiCD20therapeuticprograms" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">590.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Inventory</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13630831e1088-wk-Fact-38634221F2275B078613D9840B5268B1" name="us-gaap:InventoryNet" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">952.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13630831e1107-wk-Fact-5E24F47DCE6556D3B07F1C76326C17B7" name="us-gaap:InventoryNet" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">804.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13630831e1127-wk-Fact-14BBBBD97DE655DD92E12C0A1646466D" name="us-gaap:OtherAssetsCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">638.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13630831e1146-wk-Fact-3BCE4915C76C534BAAE166C55650DCDE" name="us-gaap:OtherAssetsCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">631.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Total current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13630831e1166-wk-Fact-2089FA578C1B5CA79F126E0F222B2A8C" name="us-gaap:AssetsCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8,493.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13630831e1185-wk-Fact-65240D2E396D56F3A678A2AAA8468C57" name="us-gaap:AssetsCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8,381.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13630831e1205-wk-Fact-5F48A45E236B5F35BA736E0F1C36E387" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">922.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13630831e1224-wk-Fact-2ED3F2528ECD544A86C1D65E3294E230" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,408.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Property, plant and equipment, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13630831e1245-wk-Fact-515C4D50A90755F2931190A6ACFFE856" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,330.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13630831e1264-wk-Fact-3366BC2DB1C653B38F93576FF5B24AD1" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,247.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Operating lease assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13630831e1284-wk-Fact-8E98B8F6497A5EA2B25F5603FFDEA49A" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">436.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13630831e1303-wk-Fact-BA1B361682BE5B62BE68C9E88A08A487" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">427.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Intangible assets, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13630831e1323-wk-Fact-BFE27979689A5391A80AEDD28844D403" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,383.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13630831e1342-wk-Fact-324FDBF1B2EA5FB9ACA38A2A6E25F4FD" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,527.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13630831e1362-wk-Fact-8FC55EF7124D59B3A1E28F099D9D8F9D" name="us-gaap:Goodwill" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,751.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13630831e1381-wk-Fact-5E02EC613C7B5C7BA41E1722B85A855E" name="us-gaap:Goodwill" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,757.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Deferred tax asset</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13630831e1401-wk-Fact-075C147AD4CF5E2198781836CFCB7672" name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,710.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13630831e1420-wk-Fact-7D3D48C5123359268F3F43D96D4CF52A" name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,232.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Investments and other assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13630831e1440-wk-Fact-C8A4557D4A705977A964BF8C62A779B9" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,483.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13630831e1459-wk-Fact-55F2168053825527956A26F8200EE397" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,252.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Total assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13630831e1484-wk-Fact-256D3819B22755B3AB35BA5509CF0E87" name="us-gaap:Assets" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">25,511.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13630831e1503-wk-Fact-56AF4C67BCE75A87A9204CE16C30C149" name="us-gaap:Assets" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">27,234.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-weight:bold;">LIABILITIES AND EQUITY</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Current liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Current portion of notes payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13630831e1605-wk-Fact-36560296280354E7A67A7F125DDEB727" name="us-gaap:NotesPayableCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13630831e1624-wk-Fact-5A083527AC9D5BA39C2E624783047AC0" name="us-gaap:NotesPayableCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,495.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Taxes payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13630831e1639-wk-Fact-AABD1CE9E1C653B7BD081D0AF91650F6" name="us-gaap:TaxesPayableCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">576.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13630831e1658-wk-Fact-DA1B4D1D86225B8D8127D0F7C0B637DB" name="us-gaap:TaxesPayableCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">71.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Accounts payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13630831e1679-wk-Fact-BCAF0DA8D933508E8260DE22573BBD6F" name="us-gaap:AccountsPayableCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">383.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13630831e1698-wk-Fact-F5A18A7F7A1153F28FED115680BC8809" name="us-gaap:AccountsPayableCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">530.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Accrued expenses and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13630831e1718-wk-Fact-96180D2EFD6F50C4AB2607CAC10392DB" name="us-gaap:OtherLiabilitiesCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,486.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13630831e1737-wk-Fact-ED32696AB6ED5D5F84AFD714902EF602" name="us-gaap:OtherLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,765.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Total current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13630831e1757-wk-Fact-5F0B5B0D752F568EB0C4E23E4E52CB76" name="us-gaap:LiabilitiesCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,447.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13630831e1776-wk-Fact-EC08852C28C95A01B284F52820CBEF97" name="us-gaap:LiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,863.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Notes payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13630831e1796-wk-Fact-9DB4BF10A6B65A17B81235FB758FC6E9" name="us-gaap:LongTermDebt" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7,423.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13630831e1815-wk-Fact-5F604C52469B533F887979C13E1DE9FE" name="us-gaap:LongTermDebt" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,459.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Deferred tax liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13630831e1835-wk-Fact-31542E7B8BB559F3A085E6889C64D1DB" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,461.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13630831e1854-wk-Fact-25AE2CEDEB2F5D6E96179B4EFAC8A93A" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,810.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Long-term operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13630831e1874-wk-Fact-48F0441D74F05508B5D80B073C365B93" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">414.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13630831e1893-wk-Fact-4831E533AE0F51EFB39B8FA20B649A8F" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">412.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13630831e1913-wk-Fact-6299100E2B9B576C82E99FBE691E586C" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,475.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13630831e1932-wk-Fact-01F0411B800C53F49F5B13CE5B5A6E2B" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,348.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Total liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13630831e1952-wk-Fact-C283D8A684275716B4D967540715195F" name="us-gaap:Liabilities" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14,222.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13630831e1971-wk-Fact-BF126DA2093C5929B5814F0E83EBDFB3" name="us-gaap:Liabilities" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,895.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Commitments and contingencies</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13630831e1991-wk-Fact-53168BA5C52C50C18CD97671EE4B3986" name="us-gaap:CommitmentsAndContingencies" contextRef="FI2020Q2" unitRef="usd" xsi:nil="true" scale="6" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13630831e2009-wk-Fact-B4F92A0FF35251DA9E5BC7724B345AE0" name="us-gaap:CommitmentsAndContingencies" contextRef="FI2019Q4" unitRef="usd" xsi:nil="true" scale="6" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Equity:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Biogen Inc. shareholders&#8217; equity:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Preferred stock, par value $0.001 per share</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13630831e2111-wk-Fact-A54BD2F7512150B5B6419C125D82AA8A" name="us-gaap:PreferredStockValue" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13630831e2130-wk-Fact-A89B2B1098805490ABF5DCB875705D5A" name="us-gaap:PreferredStockValue" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Common stock, par value $0.0005 per share</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13630831e2150-wk-Fact-619168E93F9551B5A93BE2D4F49E41B4" name="us-gaap:CommonStockValue" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13630831e2169-wk-Fact-F3541F4EA595564E8670E7546B5A1DAA" name="us-gaap:CommonStockValue" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Additional paid-in capital</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13630831e2189-wk-Fact-0D57CCD4FEE0513E8F0ECEE6B62A4765" name="us-gaap:AdditionalPaidInCapital" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13630831e2208-wk-Fact-45ED4794F81C552A886A1127AC418181" name="us-gaap:AdditionalPaidInCapital" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Accumulated other comprehensive loss</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span>(<ix:nonFraction id="d13630831e2228-wk-Fact-FAED6FE93C26545A877123C092DC11AC" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">181.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span>(<ix:nonFraction id="d13630831e2248-wk-Fact-234099FE917C5DC385F4BC4F97FA7712" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">135.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Retained earnings</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13630831e2269-wk-Fact-FA8BB677B32E5A1AB6B1A25D58B975C2" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14,466.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13630831e2288-wk-Fact-DB7806DE2CFA529EA2C50B38E6E38D99" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16,455.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Treasury stock, at cost</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span>(<ix:nonFraction id="d13630831e2308-wk-Fact-CFABA07CF44559778E3BEE4A50728D38" name="us-gaap:TreasuryStockValue" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,977.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span>(<ix:nonFraction id="d13630831e2328-wk-Fact-E7A4E5F67AF056EB92D61B8FC8D19968" name="us-gaap:TreasuryStockValue" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,977.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Total Biogen Inc. shareholders&#8217; equity</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13630831e2349-wk-Fact-95B9BAAB16A3519D9686D4B16BCB9B14" name="us-gaap:StockholdersEquity" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11,308.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13630831e2368-wk-Fact-BF917850400F5EB98164FDE8F07F89A9" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,343.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Noncontrolling interests</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span>(<ix:nonFraction id="d13630831e2388-wk-Fact-A59C4D3B638351F49150908D3A9A704F" name="us-gaap:MinorityInterest" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">19.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span>(<ix:nonFraction id="d13630831e2408-wk-Fact-1917F9CDCC4B5F0C9EF795E2F51B057A" name="us-gaap:MinorityInterest" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">4.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Total equity</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13630831e2429-wk-Fact-7FC350EACFC650A3A25E503AFF1A8CB0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11,289.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13630831e2448-wk-Fact-B97EF7525D435018B728ECB332CADA15" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,339.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Total liabilities and equity</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#257acb;"><span><ix:nonFraction id="d13630831e2473-wk-Fact-45858BB3B77F5DA09561532B04F52FE9" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">25,511.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><span><ix:nonFraction id="d13630831e2492-wk-Fact-08595EF14E4F58E98CF509D60BBD85E5" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">27,234.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7</span></div></div><hr style="page-break-after:always"></hr><div><a id="s97A86C4A92F052E280ABDBD88461AA4D"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions)</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;font-weight:bold;">Cash flows from operating activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;"><span><ix:nonFraction id="d13633138e934-wk-Fact-D07F9091FDDE5F65A9EF3F12BC88C032" name="us-gaap:ProfitLoss" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,999.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;"><span><ix:nonFraction id="d13633138e953-wk-Fact-D7A6A22966455FDB9B8B93F33634D792" name="us-gaap:ProfitLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,902.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">Adjustments to reconcile net income to net cash flows from operating activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">Depreciation, amortization and impairments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;"><span><ix:nonFraction id="d13633138e1009-wk-Fact-65268FFA54F55FB2975CA80D3CA3CF2A" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">232.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;"><span><ix:nonFraction id="d13633138e1028-wk-Fact-34B26DB9EAC65A7DAF832D2B01E4C0C0" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">238.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">Acquired in-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;"><span><ix:nonFraction id="d13633138e1048-wk-Fact-95EEAD25F3C058EFB92E2B4BE6E5D7E0" name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">75.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;"><span><ix:nonFraction id="d13633138e1067-wk-Fact-99A3CDD007EB5D948B282C7D3865470E" name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">Share-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;"><span><ix:nonFraction id="d13633138e1087-wk-Fact-7D48EE2E5C5E58028BC8B69AA478CAE6" name="us-gaap:ShareBasedCompensation" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">115.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;"><span><ix:nonFraction id="d13633138e1106-wk-Fact-C6175C1AD47A53E38DB1487A6CFBE5CD" name="us-gaap:ShareBasedCompensation" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">98.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">Gain on interest rate swap</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;"><span>(<ix:nonFraction id="d13633138e1126-wk-Fact-6B495BBB93B33EC3CFCB5960516DFFA3" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;"><span><ix:nonFraction id="d13633138e1146-wk-Fact-5333FD33C930AC55402C5960FA413A13" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">Contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;"><span><ix:nonFraction id="d13633138e1166-wk-Fact-1ED69AA194385201B48524E875F0B015" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">5.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;"><span>(<ix:nonFraction id="d13633138e1185-wk-Fact-2D5631ACC4AA55F18A9E8E1BE5DDC18B" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;"><span><ix:nonFraction id="d13633138e1206-wk-Fact-70640013A86F50FE83E833580A0074F1" name="us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;"><span><ix:nonFraction id="d13633138e1225-wk-Fact-E8F1ABBC6F325103A679627C82C8757A" name="us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">113.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">Deferred income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;"><span><ix:nonFraction id="d13633138e1246-wk-Fact-F3D6E84A1C875DAC81E2BBBB0F051BD6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">180.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;"><span><ix:nonFraction id="d13633138e1265-wk-Fact-DCE730D8D5065969B1CF63047E8623EC" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">71.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">Unrealized (gain) loss on strategic investments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;"><span>(<ix:nonFraction id="d13633138e1285-wk-Fact-8BAE2575755A59648234B4F7DFF94CB1" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">39.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;"><span>(<ix:nonFraction id="d13633138e1305-wk-Fact-3967753E14FC5FECAE863A4BEDD77692" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">199.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;"><span><ix:nonFraction id="d13633138e1326-wk-Fact-5039873BE5A1557982CD201631605B15" name="us-gaap:OtherNoncashIncomeExpense" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">85.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;"><span><ix:nonFraction id="d13633138e1345-wk-Fact-BA9F46F0DDBF545E908902B1FE1C6E13" name="us-gaap:OtherNoncashIncomeExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">91.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">Changes in operating assets and liabilities, net:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">Accounts receivable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;"><span>(<ix:nonFraction id="d13633138e1406-wk-Fact-8E917E830333598FA5C5BA244FA3B825" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">268.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;"><span>(<ix:nonFraction id="d13633138e1426-wk-Fact-30E991EF1D415855B60A8944E760A809" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">Due from anti-CD20 therapeutic programs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;"><span><ix:nonFraction id="d13633138e1447-wk-Fact-039BA42AEED85AE4B80AFF983B5E3EF0" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">149.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;"><span>(<ix:nonFraction id="d13633138e1466-wk-Fact-E6564210B3575F61894F60DAD6BDE4E4" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">30.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">Inventory</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;"><span>(<ix:nonFraction id="d13633138e1487-wk-Fact-2DA15F6B68D3527C89591ABA846D8B2E" name="us-gaap:IncreaseDecreaseInInventories" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">188.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;"><span><ix:nonFraction id="d13633138e1507-wk-Fact-BE12629DE38257A9A8FFCAB3FD4C50AD" name="us-gaap:IncreaseDecreaseInInventories" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">108.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">Accrued expenses and other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;"><span>(<ix:nonFraction id="d13633138e1527-wk-Fact-83323F5C32235D21AA4BEB7BC10941BA" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">441.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;"><span>(<ix:nonFraction id="d13633138e1547-wk-Fact-EC822C9A0C0E50959E5D37FB9FE62FC6" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">216.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">Income tax assets and liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;"><span><ix:nonFraction id="d13633138e1568-wk-Fact-CC0D4B0AED31553BAB9E43314D4A4CD4" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">504.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;"><span><ix:nonFraction id="d13633138e1587-wk-Fact-3BCAEE4731605B2BA4671AE75FC9F045" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">306.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">Other changes in operating assets and liabilities, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;"><span><ix:nonFraction id="d13633138e1607-wk-Fact-D511858A2C57595D87A757FED99BEB26" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">9.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;"><span>(<ix:nonFraction id="d13633138e1626-wk-Fact-01A20A4505FE5ED09027CCBE3C317995" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">49.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">Net cash flows provided by operating activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;"><span><ix:nonFraction id="d13633138e1647-wk-Fact-710EB4B7B600550EA3B7FFAA379DFCDE" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,415.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;"><span><ix:nonFraction id="d13633138e1666-wk-Fact-49497BB92A5F5FC8B7F8AD3020DAE31F" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,423.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;font-weight:bold;">Cash flows from investing activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">Proceeds from sales and maturities of marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;"><span><ix:nonFraction id="d13633138e1728-wk-Fact-22ABA6B6B6A35F598D8DBDA21EAD50E0" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,879.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;"><span><ix:nonFraction id="d13633138e1747-wk-Fact-1CCB591668FB51EFA12E7B8EDE0510D7" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,255.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">Purchases of marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;"><span>(<ix:nonFraction id="d13633138e1767-wk-Fact-19A7EFE2565258759A9A69D5974E16EF" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,753.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;"><span>(<ix:nonFraction id="d13633138e1787-wk-Fact-3D06CBACFC14534D876482C188871644" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,075.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">Contingent consideration paid related to Fumapharm AG acquisition</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;"><span><ix:nonFraction id="d13633138e1808-wk-Fact-BC1ACD6163DB57008263DEDC383F6580" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;"><span>(<ix:nonFraction id="d13633138e1827-wk-Fact-C0B80844E58D5F06807ABC3DD95E9B13" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">300.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">Acquisition of Nightstar Therapeutics plc, net of cash acquired</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;"><span><ix:nonFraction id="d13633138e1848-wk-Fact-11747CD28F9B5C65B7D4836C7937B004" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;"><span>(<ix:nonFraction id="d13633138e1867-wk-Fact-2EFB296C2B315DEEAB351D42394DF966" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">744.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">Purchase of Sangamo Therapeutics, Inc. stock</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;"><span>(<ix:nonFraction id="d13633138e1888-wk-Fact-8244EFC4BCDF239F3B6E59650B5FD6FB" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">141.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;"><span><ix:nonFraction id="d13633138e1908-wk-Fact-C0793CD0CF2C0F2E580559650B3F6A2A" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">Purchases of property, plant and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;"><span>(<ix:nonFraction id="d13633138e1928-wk-Fact-2ED385F9D54A51648F1D5642FCC8AF28" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">254.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;"><span>(<ix:nonFraction id="d13633138e1948-wk-Fact-C755A6BB7ADA5B47BE9928F443B03236" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">314.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">Acquired in-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;"><span>(<ix:nonFraction id="d13633138e1969-wk-Fact-C255E698DE9C5C21BF2DBD9D6E0815AA" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">75.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;"><span><ix:nonFraction id="d13633138e1989-wk-Fact-D8367C34FA075D0FBCEB2A4866BB3CA7" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">Acquisitions of intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;"><span>(<ix:nonFraction id="d13633138e2009-wk-Fact-1BAD8A112C115295B151EB56D3214CA1" name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">37.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;"><span><ix:nonFraction id="d13633138e2029-wk-Fact-DFE7CAAF34A55E0683D5D499D480ECC5" name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">Proceeds from settlement of net investment hedge</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;"><span>(<ix:nonFraction id="d13633138e2049-wk-Fact-A2026A1BC1BA53192FD7596643F49DC6" name="us-gaap:ProceedsFromHedgeInvestingActivities" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">7.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;"><span><ix:nonFraction id="d13633138e2069-wk-Fact-F835748739F0DAEE4E05596643F8C7E2" name="us-gaap:ProceedsFromHedgeInvestingActivities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">Proceeds from sales of strategic investments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;"><span><ix:nonFraction id="d13633138e2089-wk-Fact-8BA582ED504A5665864F4006F80973DE" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;"><span><ix:nonFraction id="d13633138e2108-wk-Fact-03FD556E939F594CBA7867FA4B329864" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">309.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;"><span><ix:nonFraction id="d13633138e2129-wk-Fact-30A6DC8B328F5922AAA53CCF5792058C" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;"><span>(<ix:nonFraction id="d13633138e2148-wk-Fact-A0D8B5AFE4B35D18BDA72E1EAD10EC81" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">Net cash flows provided by (used in) investing activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;"><span>(<ix:nonFraction id="d13633138e2169-wk-Fact-A9C893BB9C9C5D21A1FBB2DB10F32914" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">389.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;"><span><ix:nonFraction id="d13633138e2189-wk-Fact-9190E6A401205C26AC096EC0CCA35D9B" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">128.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;font-weight:bold;">Cash flows from financing activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">Purchases of treasury stock</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;"><span>(<ix:nonFraction id="d13633138e2250-wk-Fact-676B7B02A83D58DABA237A52DBFBD751" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,029.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;"><span>(<ix:nonFraction id="d13633138e2270-wk-Fact-2D9DDF9CFC805FEC9E6729D60CF69694" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,057.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">Payments related to issuance of stock for share-based compensation arrangements, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;"><span>(<ix:nonFraction id="d13633138e2291-wk-Fact-F424671E04BB5EB4841B84EA4B462DE0" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">19.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;"><span>(<ix:nonFraction id="d13633138e2311-wk-Fact-669BEFCF36B55876AE053C4EE2C105C2" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">23.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">Proceeds from borrowings</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;"><span><ix:nonFraction id="d13633138e2332-wk-Fact-A88891D6DF5402A65A735967316CCFDE" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,967.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;"><span><ix:nonFraction id="d13633138e2351-wk-Fact-8E32678B8AF123201D54596731632AE0" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">Repayment of borrowings</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;"><span>(<ix:nonFraction id="d13633138e2371-wk-Fact-1037A0888854550B99DA4DED3452CC76" name="us-gaap:RepaymentsOfLongTermDebt" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,500.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;"><span><ix:nonFraction id="d13633138e2391-wk-Fact-515B103726515FB39E8ABEB622AB51DB" name="us-gaap:RepaymentsOfLongTermDebt" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">Cash proceeds from settlement of swap</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;"><span><ix:nonFraction id="d13633138e2411-wk-Fact-2EC318CEE8E4E5EEC6C359689252F6A2" name="us-gaap:PaymentsForProceedsFromDerivativeInstrumentFinancingActivities" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">3.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;"><span><ix:nonFraction id="d13633138e2430-wk-Fact-D1AF4555F73AF0DE92BB5968924D88D4" name="us-gaap:PaymentsForProceedsFromDerivativeInstrumentFinancingActivities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">Net distribution to noncontrolling interest</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;"><span><ix:nonFraction id="d13633138e2450-wk-Fact-4D0951F9E9295168B5390AE1F2966E65" name="us-gaap:PaymentsToMinorityShareholders" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;"><span><ix:nonFraction id="d13633138e2469-wk-Fact-2CC0F69FA25252399E19694EB3CB72A0" name="us-gaap:PaymentsToMinorityShareholders" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">4.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;"><span><ix:nonFraction id="d13633138e2489-wk-Fact-292971BAE0985B3688C4562C837DDBBC" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">19.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;"><span><ix:nonFraction id="d13633138e2508-wk-Fact-0657E1B0B0E457E596B27CA299958E8E" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">21.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">Net cash flows used in financing activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;"><span>(<ix:nonFraction id="d13633138e2528-wk-Fact-C795D15852755CE4B5AD0323F195395F" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">3,558.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;"><span>(<ix:nonFraction id="d13633138e2548-wk-Fact-668440EA31C55C31B439E51865F39A00" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">3,055.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">Net increase (decrease) in cash and cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;"><span>(<ix:nonFraction id="d13633138e2570-wk-Fact-B09863BBA8BA5E69AB74EB67D35194D5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">532.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;"><span><ix:nonFraction id="d13633138e2590-wk-Fact-C7A757E8EE165DFA8F63518FD349F99D" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">496.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">Effect of exchange rate changes on cash and cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;"><span><ix:nonFraction id="d13633138e2610-wk-Fact-DE9C01A1C2615DB09AE2E8B9E7D04AB2" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;"><span><ix:nonFraction id="d13633138e2629-wk-Fact-D99A5E7678695484BAB7855131BC7C1B" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">Cash and cash equivalents, beginning of the period</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;"><span><ix:nonFraction id="d13633138e2649-wk-Fact-37A9AD9064055B35AC649A018B388FC4" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,913.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;"><span><ix:nonFraction id="d13633138e2668-wk-Fact-8340724A8898505298400E2A0A6C607F" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,224.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">Cash and cash equivalents, end of the period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;color:#257acb;"><span><ix:nonFraction id="d13633138e2693-wk-Fact-02522BE0D0F052DB931AED6FC05A8227" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,384.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8.8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8.8pt;"><span><ix:nonFraction id="d13633138e2712-wk-Fact-81A0C976A20C568D8E876C2ED871EB96" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,723.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8</span></div></div><hr style="page-break-after:always"></hr><div><a id="s4C8479CC2B45507D9F75C3144AE3D122"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions)</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.56647398843931%;border-collapse:collapse;text-align:left;"><tr><td colspan="45"></td></tr><tr><td style="width:16%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Preferred stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Additional<br/>paid-in<br/>capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated<br/>other<br/>comprehensive<br/>loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Retained<br/>earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Treasury stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total<br/>Biogen Inc.<br/>shareholders&#8217;<br/>equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Noncontrolling<br/>interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total<br/>equity</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance, March 31, 2020</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e1306-wk-Fact-1B2DC764BA8A5DCAA2EE61CCBBE893AD" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e1325-wk-Fact-88F246B15BEC57C7A30F4419EDB44B94" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e1339-wk-Fact-8005D3AC6C99592CBC69480F547BD483" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">191.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e1359-wk-Fact-7BA03397245E5C44A8BEE03C4B6F61CD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e1378-wk-Fact-A706A5D2BEF6556FB01B0A864C35E462" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e1397-wk-Fact-5D65436A0E18504CB51D59BEDB2C09A8" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">149.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e1418-wk-Fact-9302648CDF6C5BC0955FD672AB69A0A5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15,673.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e1432-wk-Fact-BC322FF8D7935FDD8010AB3938D52E9D" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">23.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e1452-wk-Fact-40D2CABD0EB553B2A2D1EFB39ED5840F" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2,977.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e1473-wk-Fact-99B4F5D3F9515881ADDF93E4493EF17F" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12,546.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e1492-wk-Fact-0DD4FDAD478F54459D3369AAAE49CC26" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">10.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e1512-wk-Fact-49EA246A917258E7946612AD978F6645" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12,536.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Net income</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e1634-wk-Fact-055454D5201F56C39DD4A2E57E203FB6" name="us-gaap:ProfitLoss" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,542.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e1687-wk-Fact-39F15AE6EE7B5A3AB858D60E8FF19786" name="us-gaap:ProfitLoss" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,542.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e1706-wk-Fact-20325BDCFA925C048BF441E2ACA8AD9B" name="us-gaap:ProfitLoss" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">64.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e1725-wk-Fact-F3D57A6489675B3F80AF93FBE5F9C15F" name="us-gaap:ProfitLoss" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,606.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other comprehensive income (loss), net of tax</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e1832-wk-Fact-086D2789677A5AACA693F89AB9443C62" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">31.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e1906-wk-Fact-A2F51ABD2C87585BA61CC4544CC04491" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">31.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e1926-wk-Fact-BA751F773A385D53A70B3DE38C478E3E" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e1945-wk-Fact-36DB150BC29C5EAF9C280B975056D314" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">30.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Distribution to noncontrolling interest</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e2126-wk-Fact-A670C010CECFDA682A2B5925BE234BFF" name="biib:Noncontrollinginterestincreasedecreaseother" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e2145-wk-Fact-C71DE1891D995C4894137E86ECB5BFE9" name="biib:Noncontrollinginterestincreasedecreaseother" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">75.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e2165-wk-Fact-A97980F8FA3E6F3725645925BE073225" name="biib:Noncontrollinginterestincreasedecreaseother" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">75.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Repurchase of common stock pursuant to the December 2019 Share Repurchase Program, at cost</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e2312-wk-Fact-2A8659EAFBC85B21BF7376000C0782B8" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2020Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">9.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e2327-wk-Fact-E6E0CF25B0E95478A72E3EC37242D11B" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2020Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,808.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e2348-wk-Fact-5602EF53D2CF52738A075CAC461A5D94" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2020Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,808.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e2387-wk-Fact-F606808ED6435DA0A968E1B1D1845F59" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2020Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,808.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Retirement of common stock pursuant to the December 2019 Share Repurchase Program, at cost</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e2442-wk-Fact-8AE3559C131956C98CE78E2E4DB05420" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2020Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">9.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e2458-wk-Fact-BB85F8182D9A5D66B9E2214EF8972EC4" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2020Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e2477-wk-Fact-E5536B5EACA553A1897903E07D84BA77" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2020Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">60.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e2517-wk-Fact-A92695A398FA5C83AD9AFD0AFF4AE02E" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2020Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,748.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e2537-wk-Fact-A92D222BA76F5A4398633B3419F9C249" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2020Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">9.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e2551-wk-Fact-33DED60327B858B1B81A80F77BF846B1" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2020Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2,808.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e2571-wk-Fact-CC0E6DC293F25E69B9189400B2DB7FA2" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2020Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e2609-wk-Fact-0CD3B48B7D425A40BBF64DB44F2BA767" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2020Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Issuance of common stock under stock option and stock purchase plans</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e2663-wk-Fact-5BDE632BF5845A0FBA166F3C27BE209E" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e2678-wk-Fact-0E14B49710C550DC9BB9E28A029D38DB" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e2697-wk-Fact-DFA38C52DF595A89A70D79FA24B45AF0" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e2789-wk-Fact-06EB1A181BAA5B399CBB618677236400" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e2827-wk-Fact-C9D877CF70EB57199995082C7BB184BC" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Issuance of common stock under stock award plan</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e2881-wk-Fact-BD56B7B5509D5D73920598158969E265" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e2896-wk-Fact-4CCDDBDC230457CB82D456F55DB7FCFA" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e2915-wk-Fact-945ABC9D685854B2B557A26BDA6E985D" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e2954-wk-Fact-4A3A239142AF550597443A6D3E381678" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e3008-wk-Fact-FC3D21BD011E50169296A2DAF4194550" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e3047-wk-Fact-947785AA23515C1D926EBAE830E36A6C" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Compensation related to share-based payments</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e3136-wk-Fact-3855C1B06B5459E8B3DD683B84AB6496" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">49.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e3228-wk-Fact-EA142BE8233A5F87B9E8FF4477186185" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">49.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e3266-wk-Fact-A5B92CAFC4B25B5BA89D144B3AE7354D" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">49.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e3355-wk-Fact-276A1C70835E5477BEA275BE1BAF3B51" name="us-gaap:StockholdersEquityOther" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e3447-wk-Fact-186413944BF6517AA4870947EE525761" name="us-gaap:StockholdersEquityOther" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e3485-wk-Fact-8F85328765D85E92BF0E91B6CD29C0B7" name="us-gaap:StockholdersEquityOther" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance, June 30, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e3506-wk-Fact-A3B3E04B8AF9D88B48755938480E7415" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e3525-wk-Fact-A2096089825669C9BF0459384AA9E29D" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e3538-wk-Fact-7A92727466AC29D91A3859384D92DCAA" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">182.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e3557-wk-Fact-9141911DD7BD8AA93A0359384FE25ADB" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e3575-wk-Fact-8B8F9464A5DEFF3A2386593852765E12" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e3593-wk-Fact-AF8BDA1219D93B3C238B593854B6D0F8" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">181.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e3613-wk-Fact-74A3D2473BD396D5142D593857582712" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14,466.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e3626-wk-Fact-69CC666AFE09624FE15A593859F362F4" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">23.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e3645-wk-Fact-BEFBD6012C92987CF3B159385C1F1213" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2,977.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e3665-wk-Fact-0F0344A1DC29657402F259385E2F65ED" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11,308.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e3683-wk-Fact-901F758F8737EA072A3559385F8149F6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">19.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e3702-wk-Fact-7FC350EACFC650A3A25E503AFF1A8CB0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11,289.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY - (Continued)</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="45"></td></tr><tr><td style="width:16%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Preferred stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Additional<br/>paid-in<br/>capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated<br/>other<br/>comprehensive<br/>loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Retained<br/>earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Treasury stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total<br/>Biogen Inc.<br/>shareholders&#8217;<br/>equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Noncontrolling<br/>interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total<br/>equity</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance, December 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e4275-wk-Fact-0532CEF37067C1F774F55937EE9982B1" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e4294-wk-Fact-EDA41C9816B4AE501BBF5937F1652AC7" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e4308-wk-Fact-168A5F00425A1F59CC095937F3D59A78" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">198.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e4328-wk-Fact-5A48FAB8ACF884AFFA535937F7B4608C" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e4347-wk-Fact-80A6D767A4EAABDF40755937FA521B96" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e4366-wk-Fact-8E289BD0C2C4F84833C05937FC929F60" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">135.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e4387-wk-Fact-E3696CEB303F17FD15305937FF3302FF" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16,455.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e4401-wk-Fact-864B7D23A1BE9035A323593801768548" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">23.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e4421-wk-Fact-AB5893F52AC030BD574159380421197A" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2,977.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e4442-wk-Fact-1F69B17A7EF717290A14593806112980" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,343.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e4461-wk-Fact-6FFD1B7D0230039914B1593806AE21DE" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">4.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e4481-wk-Fact-B97EF7525D435018B728ECB332CADA15" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,339.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Net income</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e4603-wk-Fact-BA0B8683C3659369DF9B59390DEA8D33" name="us-gaap:ProfitLoss" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,941.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e4656-wk-Fact-70AEAC5F2404BDE8FF9B5939122B6287" name="us-gaap:ProfitLoss" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,941.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e4675-wk-Fact-99586E27B428612A14CF593913C26D42" name="us-gaap:ProfitLoss" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">57.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e4694-wk-Fact-D07F9091FDDE5F65A9EF3F12BC88C032" name="us-gaap:ProfitLoss" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,999.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other comprehensive income (loss), net of tax</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e4801-wk-Fact-EB580169CE4FB00D98AB59391D1527C4" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">45.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e4875-wk-Fact-224DEBF842550A08D66F593922BB3B2B" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">45.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e4895-wk-Fact-1D9755227DD24929FB78593923E62C65" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e4914-wk-Fact-28C659AD2AAE4E811912593926014255" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">44.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Distribution to noncontrolling interest</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e5114-wk-Fact-487D8FC07EE6E1E84CA0593A14D062F0" name="biib:Noncontrollinginterestincreasedecreaseother" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">75.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e5134-wk-Fact-F09C816D772B0429B051593A14D6167E" name="biib:Noncontrollinginterestincreasedecreaseother" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">75.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Repurchase of common stock pursuant to the March 2019 Share Repurchase Program, at cost</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e5281-wk-Fact-6789C7CDA04E97F3CDEC593AF2AAC88D" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">4.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e5296-wk-Fact-4E11B491F48AE0F77D00593AD521D962" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,279.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e5317-wk-Fact-04AECE62EB89D8F40589593AD493362C" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,279.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e5356-wk-Fact-768CB22537EC046D99B9593AD4B14BA6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,279.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Retirement of common stock pursuant to the March 2019 Share Repurchase Program, at cost</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e5411-wk-Fact-80D0D1FCC1C026992E87593B0FEFBA7F" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">4.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e5446-wk-Fact-3963C8C969FB5329D439593B33A07439" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">71.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e5486-wk-Fact-9589E41D2FE730AD31CF593B311D87B1" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,208.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e5506-wk-Fact-D6C6F68E0ED1F69FAC30593B104C7933" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">4.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e5520-wk-Fact-B8C31CD48D306C483943593B325D7207" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1,279.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e5578-wk-Fact-A10550D33FF0748A3C73593B3384A173" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Repurchase of common stock pursuant to the December 2019 Share Repurchase Program, at cost</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e5724-wk-Fact-41D2B68D90C84F3C13E7593B578C4BB6" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">12.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e5739-wk-Fact-FCA3D771EB2CE382E427593B7E5B63DB" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,750.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e5760-wk-Fact-736E2A674C0037E3E4CC593B7E28E268" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,750.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e5799-wk-Fact-B34B64F22C63EDB87C5D593B7A78EF05" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,750.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Retirement of common stock pursuant to the December 2019 Share Repurchase Program, at cost</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e5854-wk-Fact-B98047A06023E3395318593B5774812B" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">12.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e5889-wk-Fact-92FC4732FFE7C444D398593B80CCB855" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">76.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e5929-wk-Fact-C84B0BD131C178293117593B8700D3DC" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,673.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e5949-wk-Fact-C7828FE0D65DA60F1CB4593B564F0AB3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">12.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e5963-wk-Fact-FD1B54E02DDBD0048AFC593B84D9251E" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">3,750.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e6021-wk-Fact-8D877BCB9B40C1A62E62593B852563B5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Issuance of common stock under stock option and stock purchase plans</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e6075-wk-Fact-4544BDC43028052FC4F0593ED3631944" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e6090-wk-Fact-8E8327E914AACCC88AB7593ED63007BD" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e6109-wk-Fact-E16ADC5858ACAF789143593ED91C48F7" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">29.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e6201-wk-Fact-18B9F520C64FD6041138593EDFC08C92" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">29.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e6239-wk-Fact-E7AEF4AAB874C7435F5B593EE25AF5CB" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">29.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Issuance of common stock under stock award plan</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e6294-wk-Fact-7DD502AC8AD8C0D0E6E3593EE3899E91" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e6309-wk-Fact-9714D3B3933F6F3D9245593EE675A566" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e6328-wk-Fact-6C6327D4DDC2114C57CE593EE8E8181A" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e6367-wk-Fact-9951CDA5434A93EAF401593EECF9BF9A" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">48.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e6421-wk-Fact-E91C95B6C616440C277F593EEFCFD0BF" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">48.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e6460-wk-Fact-5B50E3E75770FF1D8CE0593EF0D635C9" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">48.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Compensation related to share-based payments</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e6549-wk-Fact-1B2BA706AF398DA32BDC593FE6895B67" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">118.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e6641-wk-Fact-0D961D4A0E7D1029A3C4593FED806CE1" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">118.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e6679-wk-Fact-B131A86A6CF17219B87D593FF0B8B8B0" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">118.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e6767-wk-Fact-79BC0DF63D9737BA160C593FF244F2E0" name="us-gaap:StockholdersEquityOther" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e6860-wk-Fact-3F11C2C4BB4C9E90F06C593FF98D9D70" name="us-gaap:StockholdersEquityOther" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e6899-wk-Fact-955D6B15D4F275C0326D593FFC512783" name="us-gaap:StockholdersEquityOther" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance, June 30, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e6921-wk-Fact-A3B3E04B8AF9D88B48755938480E7415" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e6940-wk-Fact-A2096089825669C9BF0459384AA9E29D" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e6954-wk-Fact-7A92727466AC29D91A3859384D92DCAA" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">182.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e6974-wk-Fact-9141911DD7BD8AA93A0359384FE25ADB" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e6993-wk-Fact-8B8F9464A5DEFF3A2386593852765E12" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e7012-wk-Fact-AF8BDA1219D93B3C238B593854B6D0F8" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">181.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e7033-wk-Fact-74A3D2473BD396D5142D593857582712" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14,466.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e7047-wk-Fact-69CC666AFE09624FE15A593859F362F4" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">23.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e7067-wk-Fact-BEFBD6012C92987CF3B159385C1F1213" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2,977.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e7088-wk-Fact-0F0344A1DC29657402F259385E2F65ED" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11,308.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span>(<ix:nonFraction id="d13648331e7107-wk-Fact-901F758F8737EA072A3559385F8149F6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">19.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;color:#2573ba;"><span><ix:nonFraction id="d13648331e7127-wk-Fact-7FC350EACFC650A3A25E503AFF1A8CB0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11,289.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY - (Continued)</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions)</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="45"></td></tr><tr><td style="width:14%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Preferred stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Additional<br/>paid-in<br/>capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Accumulated<br/>other<br/>comprehensive<br/>loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Retained<br/>earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Treasury stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Total<br/>Biogen Inc.<br/>shareholders&#8217;<br/>equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Noncontrolling<br/>interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Total<br/>equity</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance, March 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e7693-wk-Fact-4C29DC19910C5DA8BAF23B02FDC8A34C" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e7712-wk-Fact-7C467064CD115948A03AD8654F4091F0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e7726-wk-Fact-99D54FDB981059AB90C591132366E78D" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">219.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e7746-wk-Fact-80D1FA58EED3580EBC3741055B3A69DA" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e7765-wk-Fact-AA401332E0D15FEAA0BD2DA8D40EC4C7" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e7784-wk-Fact-EAAB9B0667B35E048614D3664BBF9B9D" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">219.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e7805-wk-Fact-228E06D3060B55568279C378B9CB7DE6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">17,026.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e7819-wk-Fact-32C04627843B5CDFA24FB076F4725AAD" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">23.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e7839-wk-Fact-1E6FD9BAF9B95C438B03C29240BCABD9" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2,977.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e7860-wk-Fact-C29F4E18EDA154DF4AE15928F05E6427" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,829.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e7879-wk-Fact-77E0CFF502065AB691C0C9D573BEE2A8" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">7.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e7899-wk-Fact-B4F422DE92C52F09DA185928EFC0F0D1" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,822.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e8021-wk-Fact-672FB66A87EA5E0BAFBA991A6C11629E" name="us-gaap:ProfitLoss" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,494.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e8074-wk-Fact-AA86C73529E25D399E1FB3A477041191" name="us-gaap:ProfitLoss" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,494.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e8112-wk-Fact-46DCDF7F62D35A1BA19A2C2DD7FB0AB9" name="us-gaap:ProfitLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,494.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other comprehensive income (loss), net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e8219-wk-Fact-1C0510F54A3451559F80E49CF54C5254" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">33.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e8293-wk-Fact-0B14D1C7DA5A5984995EBA875919DB40" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">33.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e8313-wk-Fact-AF9A3F7A7D75571B90482C44AEC759AA" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e8333-wk-Fact-96F51665C2AAD64B92865928EFA2327E" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">33.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Capital contribution by noncontrolling interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e8514-wk-Fact-C0C5C9B9857D554E8DBBAC3FFA989DC7" name="biib:Noncontrollinginterestincreasedecreaseother" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e8533-wk-Fact-A88E0B1CD14F5134BAA0F0953528C594" name="biib:Noncontrollinginterestincreasedecreaseother" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e8552-wk-Fact-CA73D4CF84C0D4FB363D5928F09A46FA" name="biib:Noncontrollinginterestincreasedecreaseother" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Repurchase of common stock pursuant to the March 2019 Share Repurchase Program, at cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e8698-wk-Fact-C1095B3E6CFC8423C3D8594651092E95" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">3.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e8713-wk-Fact-5A7A4DF2BC5F1808BDCF59463E7CC545" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">909.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e8734-wk-Fact-ED79EFD9EEF7B80ECD2259463E853142" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">909.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e8773-wk-Fact-A4733C1B61EF5A8DFD9359463E8FB595" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">909.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Retirement of common stock pursuant to the March 2019 Share Repurchase Program, at cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e8828-wk-Fact-8A33C0639FD0CC4CB58B59468C986757" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">3.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e8863-wk-Fact-967D6A09D39564AEACDD5946B870863D" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">19.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e8903-wk-Fact-C136413E99F06B2D33235946B87EF718" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">890.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e8923-wk-Fact-6F2F2EBA7AB3AB888DEF59468C9D9BBE" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">3.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e8937-wk-Fact-55C85A07E640A8EA4D885946B8741AB9" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">909.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Repurchase of common stock pursuant to the 2018 Share Repurchase Program, at cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e9141-wk-Fact-659529059AA55A05BDD8F79922E4C5CC" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">6.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e9156-wk-Fact-7E796C5B4A635400A426C4F1E236D891" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,491.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e9177-wk-Fact-ABD7EA9F4F4E5FCF9CFF91B091895D40" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,491.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e9216-wk-Fact-7C5B3D41BB5D1C77C3E35928EFE3CA6C" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,491.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Retirement of common stock pursuant to the 2018 Share Repurchase Program, at cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e9271-wk-Fact-D543F465F16759D988CCC60CDB65624C" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">6.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e9287-wk-Fact-B90652F5168A5F6B9CA398CA75488291" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e9306-wk-Fact-82984F5212F951648509C10E89950195" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">44.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e9346-wk-Fact-5BC267088341533399A2C22073A182D2" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,446.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e9366-wk-Fact-B119E4201A0D52E788DEE9222E977EF8" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">6.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e9380-wk-Fact-2DF6506A9C115BFAB71CD53DFDD37489" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1,491.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e9400-wk-Fact-13CC3833BBF1592C89FA7C39A852D23D" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e9438-wk-Fact-5FDCB0EB0AB4188BBA755928F0B94C1C" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Issuance of common stock under stock option and stock purchase plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e9492-wk-Fact-D9B89DE30DBD53959E6C5BB45F43CE8D" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e9507-wk-Fact-F49154DCD2D55A02BD7BC56C085446D2" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e9526-wk-Fact-B5A55FF07A4A5847AA17292CDEF2ECAF" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e9618-wk-Fact-1F6D706154C1573F8F930304162B85FF" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e9656-wk-Fact-3B1C4A9213BC9DEFA6F65928F021BEC2" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Issuance of common stock under stock award plan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e9711-wk-Fact-A2AB96753BE05BEC82189D7E3322334E" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e9726-wk-Fact-8FF8C7E2FE105432B96EEECBB4014F3F" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e9745-wk-Fact-44F4DCF0966A5884AF590577467E5709" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e9784-wk-Fact-482C40564B4D5C1C863A338EB64BDFCA" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e9838-wk-Fact-02042DD4EACD56819C37D092CD9F59E8" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e9877-wk-Fact-A843345589DDA4F552C05928F003AA7D" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Compensation related to share-based payments</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e9966-wk-Fact-296A17D6FBB45E13B754213E4185A757" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">55.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e10005-wk-Fact-627389C020835E52B76A0DC962524ECA" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e10058-wk-Fact-3DF6C49AE7E15D6DBD70B00A6DD1042F" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">55.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e10096-wk-Fact-8D31167147F9CCD4B0D55928F07D196D" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">55.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance, June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e10117-wk-Fact-C13B50DA24E2398EFBEF594D96A4D924" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e10136-wk-Fact-537D0F816D9CCEFBE4F3594D999A8152" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e10150-wk-Fact-ADA15D4EAAC59DD07467594D9C5CE217" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">208.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e10170-wk-Fact-B1ABB7508646F331AD7B594D9F2E08D7" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e10189-wk-Fact-0E4CFA4F88D537FCFBF4594DA20A0FB2" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e10208-wk-Fact-1E3A79B575A7EC1E71B5594DA5280B7C" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">252.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e10229-wk-Fact-778F793D09F7548292C6594DA95ED636" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16,182.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e10243-wk-Fact-3FCB5A794255746B06AE594DAD864C59" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">23.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e10263-wk-Fact-7D7ECBB599437B92C082594DB18B9DB2" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2,977.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e10284-wk-Fact-6B3D4676EE46A1B02420594DB5EB2F08" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12,952.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e10303-wk-Fact-A52A44D92ECA04E2C0BE594DBA4AF661" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">4.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e10323-wk-Fact-05CB20CCB3DACA57CF01594DBDDD968F" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12,948.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY - (Continued)</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="45"></td></tr><tr><td style="width:18%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Preferred stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Additional<br/>paid-in<br/>capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Accumulated<br/>other<br/>comprehensive<br/>loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Retained<br/>earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Treasury stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Total<br/>Biogen Inc.<br/>shareholders&#8217;<br/>equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Noncontrolling<br/>interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Total<br/>equity</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e10894-wk-Fact-5688F03CB7D8654E71C4594D4D3D5515" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e10913-wk-Fact-EB5F5ACA83B2360E7AAE594D4FFA356E" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e10927-wk-Fact-69E12AEAB5BCAFA343B9594D52F33C6C" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">221.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e10947-wk-Fact-60136F9D5DD4E19FD83C594D55B36056" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e10966-wk-Fact-6AA6B07E48B69D7D2FA1594D58A02D6D" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e10985-wk-Fact-BF0F761E8AC11393C481594D5BC1653D" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">240.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e11006-wk-Fact-1E62CDF710041C8A03A1594D5F80ACE1" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16,257.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e11020-wk-Fact-7B5D48294B8105402C3D594D632CA123" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">23.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e11040-wk-Fact-D87FB8C171032E23D989594D66F7136F" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2,977.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e11061-wk-Fact-CFB4088F5566EB9C8A6D594D6A4D582B" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,039.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e11080-wk-Fact-9B79490193B2CC9D5708594D6D994EB7" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">8.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e11100-wk-Fact-DF1518A1E9E5819076BD594D72D04C80" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13,031.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e11222-wk-Fact-29791130FCE7F3F208EF594F36C860C4" name="us-gaap:ProfitLoss" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,902.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e11275-wk-Fact-530800AB1382E665F933594F3E7520EF" name="us-gaap:ProfitLoss" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,902.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e11313-wk-Fact-D7A6A22966455FDB9B8B93F33634D792" name="us-gaap:ProfitLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,902.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other comprehensive income (loss), net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e11420-wk-Fact-95B78631F8E1A3A82113594F4E9E4A70" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">12.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e11494-wk-Fact-6404A57F9255795C6F85594F59216AEF" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">12.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e11514-wk-Fact-40E7B9D04206B9F7E6F3594F5B6876F9" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e11534-wk-Fact-69E70D3A2E52066EA225594F5F5EFF33" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">12.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Capital contribution by noncontrolling interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e11715-wk-Fact-8755C73DB0197D0D8673594F700C3EE7" name="biib:Noncontrollinginterestincreasedecreaseother" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e11734-wk-Fact-B30AD01239C43C89CDEC594F7261867E" name="biib:Noncontrollinginterestincreasedecreaseother" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e11753-wk-Fact-C9AF7B8A49CF4617C29B594F74F3815A" name="biib:Noncontrollinginterestincreasedecreaseother" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Repurchase of common stock pursuant to the March 2019 Share Repurchase Program, at cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e11899-wk-Fact-C1A326C98D2EA26DB8B1594F8DF317BA" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">3.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e11914-wk-Fact-7B4D8EA326BFFF7F5A79594F9359BED0" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">909.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e11935-wk-Fact-FB55BC24FBB6607B17FF594F9880BAE5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">909.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e11974-wk-Fact-382A851FC05B74E94DFA594FA16B40BA" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">909.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Retirement of common stock pursuant to the March 2019 Share Repurchase Program, at cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e12029-wk-Fact-99F9CD0E05681E069F6D594FADC96071" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">3.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e12064-wk-Fact-587B8B7320277F40E6A6594FB587C06D" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">19.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e12104-wk-Fact-D121A9E1E6B025107DD4594FBE8A8FFE" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">890.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e12124-wk-Fact-03AADB117136774A3643594FC29C834E" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">3.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e12138-wk-Fact-EF268B90648FAF4EAFEE594FC7A24EA7" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">909.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Repurchase of common stock pursuant to the 2018 Share Repurchase Program, at cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e12342-wk-Fact-492F89FE92EFE37B93FF594FDE4EDA36" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">8.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e12357-wk-Fact-563D32318D0499B353EE594FE2A14E23" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,147.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e12378-wk-Fact-C6EE03EC936D879B540F594FE60E752D" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,147.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e12417-wk-Fact-D8AE5556255B55D27A6F594FEB935140" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,147.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Retirement of common stock pursuant to the 2018 Share Repurchase Program, at cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e12472-wk-Fact-EC689CEFA715F484ADF3594FF1F2D9A1" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">8.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e12488-wk-Fact-BAB399050FFFE946EE5D594FF65059E6" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e12507-wk-Fact-B5A1A8C2936A179D9977594FFA762024" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">110.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e12547-wk-Fact-82DFF93592EA9F4CDE59595000465365" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,036.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e12567-wk-Fact-E54D702A1C6C785F269459500440A738" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">8.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e12581-wk-Fact-AFD7E5B234EDB9D4D7215950092155F6" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2,147.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e12601-wk-Fact-91B2A0F6C2BAC2DF27BF59500D713AD8" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e12639-wk-Fact-91F65B9148EDBCA06F0059501285583D" name="us-gaap:TreasuryStockRetiredCostMethodAmount" contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Issuance of common stock under stock option and stock purchase plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e12693-wk-Fact-EA8E07ED468C486B1CFE595019468F6D" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e12708-wk-Fact-5D49EF2BE4C77F0D54BC59501BD6F6FD" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e12727-wk-Fact-F27BA03371C71C5B34BA59501EF533B6" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">26.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e12819-wk-Fact-F3ADDA3BB7C9065A36C659502933F0C4" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">26.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e12857-wk-Fact-900000DBBB6E9664D8CE59502D0A677D" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">26.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Issuance of common stock under stock award plan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e12912-wk-Fact-0A08A2600B66EA629B1A59503168CBA9" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e12927-wk-Fact-173CBD1D0F83C1F9A97D59503401BB37" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e12946-wk-Fact-A87F6402C6CBB4714A935950364B350A" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e12985-wk-Fact-245117E03C0488629C2059503A65E11B" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">50.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e13039-wk-Fact-20CB9AE7B2E13A1B095E5950413DE185" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">50.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span>(<ix:nonFraction id="d13648331e13078-wk-Fact-C36E7729510640AD5DAB595044EE7840" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">50.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Compensation related to share-based payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e13167-wk-Fact-16ED8973EAAE2409510859504E13543E" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">104.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e13206-wk-Fact-DCC2CDDB6065E968F427595052EE448A" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e13259-wk-Fact-2A4BA0B9D089D70EE32659505C3C0BF7" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">104.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;"><span><ix:nonFraction id="d13648331e13297-wk-Fact-1F8E809DBE3115C51A40595061234A27" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">104.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance, June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d13648331e13318-wk-Fact-C13B50DA24E2398EFBEF594D96A4D924" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d13648331e13337-wk-Fact-537D0F816D9CCEFBE4F3594D999A8152" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d13648331e13351-wk-Fact-ADA15D4EAAC59DD07467594D9C5CE217" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">208.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d13648331e13371-wk-Fact-B1ABB7508646F331AD7B594D9F2E08D7" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d13648331e13390-wk-Fact-0E4CFA4F88D537FCFBF4594DA20A0FB2" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;"><span>(<ix:nonFraction id="d13648331e13409-wk-Fact-1E3A79B575A7EC1E71B5594DA5280B7C" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">252.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d13648331e13430-wk-Fact-778F793D09F7548292C6594DA95ED636" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16,182.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;"><span>(<ix:nonFraction id="d13648331e13444-wk-Fact-3FCB5A794255746B06AE594DAD864C59" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">23.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;"><span>(<ix:nonFraction id="d13648331e13464-wk-Fact-7D7ECBB599437B92C082594DB18B9DB2" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2,977.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d13648331e13485-wk-Fact-6B3D4676EE46A1B02420594DB5EB2F08" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12,952.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;"><span>(<ix:nonFraction id="d13648331e13504-wk-Fact-A52A44D92ECA04E2C0BE594DBA4AF661" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">4.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d13648331e13524-wk-Fact-05CB20CCB3DACA57CF01594DBDDD968F" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12,948.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12</span></div></div><hr style="page-break-after:always"></hr><div><a id="sC639DB589A1350BE9DA3F828034895AB"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited)</span></div></div><div><br/></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div><a id="s5E64AA3F39F85646A1128193A82A7B35"></a></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">1</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Summary of Significant Accounting Policies</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"> </span></div></td></tr></table><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="TextSelection-2B37AD037F305EEA96EFD49E89A3B402-0-wk-Fact-B2D0FA33446D598D8F9FD2F6BC6D8270" continuedAt="TextSelection-2B37AD037F305EEA96EFD49E89A3B402-1" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Business Overview</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="biib:BusinessOverviewPolicyTextBlock" id="TextSelection-6305126345EF5C519A7B72BFBFD02F02-0-wk-Fact-5682166345585B75825B9811C5BCC7D9" continuedAt="TextSelection-6305126345EF5C519A7B72BFBFD02F02-1" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer's disease (AD) and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; and ophthalmology. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; neurocognitive disorders; acute neurology; and pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS and relapsing MS; and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 18, Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K).</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe and have exclusive rights to commercialize these products in China. Additionally, we have exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11 referencing LUCENTIS and SB15 referencing EYLEA, in major markets worldwide, including the United States (U.S.), Canada, Europe, Japan and Australia. For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 17, Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these unaudited condensed consolidated financial statements (condensed consolidated financial statements). </span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"><ix:continuation id="TextSelection-6305126345EF5C519A7B72BFBFD02F02-1"></ix:continuation>Basis of Presentation</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="TextSelection-60E0BBB904A256FBA1F759D1928BFBF1-0-wk-Fact-FEF216B0032A55CBBFDDD6110C20466A" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K. Our accounting policies are described in the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Notes to Consolidated Financial Statements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We operate as </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d13633581e891-wk-Fact-B117E077F8A058CF91DBC388A514A5C1" name="us-gaap:NumberOfReportableSegments" contextRef="FD2020Q2YTD" unitRef="segment" decimals="0" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.</span></div></ix:nonNumeric></ix:nonNumeric><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-2B37AD037F305EEA96EFD49E89A3B402-1" continuedAt="TextSelection-2B37AD037F305EEA96EFD49E89A3B402-2"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidation</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ConsolidationPolicyTextBlock" id="TextSelection-1D8209BA92DD577983A87D352B9A4BE1-0-wk-Fact-32216D61DC355819971FC6B44B75AA66" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d13633581e915-wk-Fact-6F125E65AC325C6198B1F3F00691A4E7" name="biib:InterestInSubsidiary" contextRef="FD2020Q2YTD" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Use of Estimates</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:UseOfEstimates" id="TextSelection-9C673B1671795322AAB342617921CF86-0-wk-Fact-B8C45CE913C05B0FB5CED566ECCA19D2" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our condensed consolidated financial statements and there may be changes to those estimates in future periods. </span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">New Accounting Pronouncements</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="TextSelection-247591EC079357DBAC0997706837BFB9-0-wk-Fact-F3FE430BA00C503D93B38B3B5CC2DFB8" continuedAt="TextSelection-247591EC079357DBAC0997706837BFB9-1" escape="true"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements or disclosures.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Credit Losses</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the FASB issued Accounting Standards Update (ASU) No. 2016-13, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2020. This standard requires entities to estimate an expected lifetime credit loss on financial assets ranging from short-term trade accounts receivable to long-term financings and report credit losses using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. This standard limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This standard became effective for us on January 1, 2020, and based on the composition of our trade receivables, investment portfolio and other financial assets, current economic conditions and historical credit loss activity, the adoption of this standard did not have a material impact on our condensed consolidated financial statements and related disclosures. During the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recorded an immaterial amount associated with expected credit losses related to outstanding trade receivables in certain foreign countries that have been disproportionately impacted by the COVID-19 pandemic.</span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-247591EC079357DBAC0997706837BFB9-1"><ix:continuation id="TextSelection-2B37AD037F305EEA96EFD49E89A3B402-2"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Fair Value Measurements</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 the FASB issued ASU No. 2018-13,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard modifies certain disclosure requirements on fair value measurements. This standard became effective for us on January 1, 2020, and did not have a material impact on our disclosures. For the new disclosures regarding our Level 3 instruments, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 7, Fair Value Measurements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Internal Use Software</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 the FASB issued ASU No. 2018-15, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard clarifies the accounting for implementation costs in cloud computing arrangements. This standard became effective for us on January 1, 2020, and was adopted on a prospective basis, resulting in an immaterial amount of additional assets being recorded on our condensed consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Collaborative Arrangements</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2018 the FASB issued ASU No. 2018-18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard makes targeted improvements for collaborative arrangements as follows:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Accounting Standards Codification (ASC) 606, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adds unit-of-account guidance to ASC 808, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Arrangements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This standard became effective for us on January 1, 2020, and did not have a material impact on our condensed consolidated financial statements and related disclosures.</span></div></ix:continuation></ix:continuation><div><a id="s786A1E0550915FC79EAD0CFE4690420D"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:18px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">2</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Acquisitions</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"> </span></div></td></tr></table><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="TextSelection-C6E355882BA75664BCD9A858BBB8D48A-0-wk-Fact-BDDD7CEB5F985EA69E2F6A393E91FA0F" continuedAt="TextSelection-C6E355882BA75664BCD9A858BBB8D48A-1" escape="true"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">BIIB118 Acquisition</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2020 we acquired BIIB118 (formerly known as PF-05251749), a novel CNS-penetrant small molecule inhibitor of casein kinase 1, for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases from Pfizer Inc. (Pfizer). We plan to develop the Phase 1 asset for the potential treatment of sundowning in AD and irregular sleep wake rhythm disorder in Parkinson&#8217;s disease. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with this acquisition, we made an upfront payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13633690e797-wk-Fact-B3250946F8C15B0B892A59AF0E2876B0" name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="D2020Q1Mar1-Mar31_us-gaap_BusinessAcquisitionAxis_biib_BIIB118Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">75.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Pfizer, which was accounted for as an asset acquisition and recorded as acquired in-process research and development (IPR&amp;D) in our condensed consolidated statements of income as BIIB118 has not yet reached technological feasibility. We may also pay Pfizer up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13633690e801-wk-Fact-F43A8ED3050A5082AA221EA054C22A24" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" contextRef="D2020Q1Mar1-Mar31_us-gaap_BusinessAcquisitionAxis_biib_BIIB118Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">635.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in potential additional development and commercialization milestone payments, as well as tiered royalties in the high single digits to sub-teens.</span></div></ix:nonNumeric><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-C6E355882BA75664BCD9A858BBB8D48A-1"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acquisition of Nightstar Therapeutics plc</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2019 we completed our acquisition of all of the outstanding shares of Nightstar Therapeutics plc (NST), a clinical-stage gene therapy company focused on adeno-associated virus (AAV) treatments for inherited retinal disorders. As a result of this acquisition, we added </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d13633690e811-wk-Fact-08424926B14D5070B8192552787B9536" name="biib:ClinicalAssetsAcquired" contextRef="D2019Q2" unitRef="Assets" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> mid- to late-stage clinical assets, as well as preclinical programs, in ophthalmology. These assets include BIIB111 (timrepigene emparvovec), which is in Phase 3 development for the potential treatment of choroideremia, a rare, degenerative, X-linked inherited retinal disorder that leads to blindness and currently has no approved treatments, and BIIB112 (RPGR gene therapy), which is in Phase 2/3 development for the potential treatment of X-linked retinitis pigmentosa, which is a rare inherited retinal disease with no currently approved treatments.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of this acquisition, we paid NST shareholders </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13633690e818-wk-Fact-B0DB27109C225CF9B0A0A0058F63687A" name="us-gaap:BusinessAcquisitionSharePrice" contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">25.50</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cash for each issued and outstanding NST share, which totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13633690e822-wk-Fact-EA168BFD5C8257D8BC64905145DB32EE" name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">847.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In addition, we paid </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13633690e826-wk-Fact-E4314AA680F9596E89F10C7D599381BD" name="us-gaap:OtherPaymentsToAcquireBusinesses" contextRef="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cash for equity compensation, which is attributable to pre-combination services and was reflected as a component of the total purchase price paid. The fair value of equity compensation attributable to the post-combination service period was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13633690e830-wk-Fact-AC9BA48EB90455E2AD50D524C6455DC3" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" contextRef="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_biib_PostacquisitionequitycompensationMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">26.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of which </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13633690e834-wk-Fact-B272205CA0305A87884AA7C290AC1C6F" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" contextRef="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">18.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recognized as a charge to selling, general and administrative expense with the remaining </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13633690e839-wk-Fact-273F13D1E60B5B798D1F1A07A841A2BB" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" contextRef="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as a charge to research and development expense in our condensed consolidated statements of income. These amounts were associated with the accelerated vesting of stock options previously granted to NST employees and were fully paid in cash as of June 30, 2019. We funded this acquisition through available cash and accounted for it as an acquisition of a business. We finalized purchase accounting for this acquisition in the fourth quarter of 2019.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our acquisition of NST, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 2, Acquisitions,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our 2019 Form 10-K.</span></div></ix:continuation><div><a id="s1E316CE17B6051B08A20773FA7EC2669"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:18px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">3</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"> </span></div></td></tr></table><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="TextSelection-E9C4B523BC785C6A981620CC94D0779E-0-wk-Fact-890DE79E24F85292BE9EAD5206F7F7D9" continuedAt="TextSelection-E9C4B523BC785C6A981620CC94D0779E-1" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Divestiture of Hiller&#248;d, Denmark Manufacturing Operations </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 we entered into a share purchase agreement with FUJIFILM Corporation (FUJIFILM) to sell all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#248;d, Denmark. We determined that the assets and liabilities related to our Hiller&#248;d, Denmark manufacturing operations met the criteria to be classified as held for sale. For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recorded a loss of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13633801e801-wk-Fact-0C57B292811C573EB9888E8920CA2E59" name="us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" contextRef="FD2019Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">174.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in our condensed consolidated statements of income. This estimated loss included a pre-tax loss of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13633801e805-wk-Fact-AF7D8846FDC8976A34F85D6C05A654F2" name="us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" contextRef="FD2019Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">113.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which reflected a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13633801e809-wk-Fact-C8E05743A5A61037708B5D6C63D25FDA" name="us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" contextRef="FD2019Q2QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> decrease to our original estimate as of March 31, 2019, reflecting our estimated fair value of the assets and liabilities held for sale as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, adjusted for our expected costs to sell our Hiller&#248;d, Denmark manufacturing operations of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13633801e818-wk-Fact-BD4D010869AB55538643FB603D47C9C1" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" contextRef="FD2019Q2QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and included our initial estimate of the fair value of an adverse commitment of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13633801e822-wk-Fact-DE09EAD8A5B25D5D8A6843763653A988" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" contextRef="FI2019Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">120.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with the guarantee of future minimum batch production at the Hiller&#248;d facility. The value of this adverse commitment was determined using a probability-weighted estimate of future manufacturing activity. In addition, we recorded a tax expense of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13633801e826-wk-Fact-ED9352CD16B65696B7CFF0284B0B2990" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" contextRef="FD2020Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">61.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the planned transaction during the six months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> this transaction closed and we received approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13633801e841-wk-Fact-9E53049ABBF95FCA814D68A67F94CA61" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" contextRef="I2019Q3Denmark_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">881.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cash, which may be adjusted based on the contractual terms discussed below. We determined that the operations disposed of in this transaction did not meet the criteria to be classified as discontinued operations under the applicable guidance.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As part of this transaction, we provided FUJIFILM with certain minimum batch production commitment guarantees. There is a risk that the minimum contractual batch production commitments will not be met. Our estimate of the adverse commitment obligation is approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13633801e848-wk-Fact-A2B0010FA02C50E3AD57943AB999D036" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" contextRef="FI2020Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">74.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We developed this estimate using a probability-weighted estimate of future manufacturing activity and may adjust this estimate based upon changes in business conditions, which may result in the increase or reduction of this adverse commitment obligation in subsequent periods. We also may be obligated to indemnify FUJIFILM for liabilities that existed relating to certain business activities incurred prior to the closing of this transaction. Our estimate of the fair value of the adverse commitment obligation is a Level 3 measurement and is based on forecasted batch production at the Hiller&#248;d facility.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we may earn certain contingent payments based on future manufacturing activities at the Hiller&#248;d facility. For the disposition of a business, our policy is to recognize contingent consideration when the consideration is realizable. Consistent with our assessment as of the transaction date, we currently believe the probability of earning these payments is remote and therefore we did not include these contingent payments in our calculation of the fair value of the operations.</span></div></ix:nonNumeric><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-E9C4B523BC785C6A981620CC94D0779E-1"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As part of this transaction, we entered into certain manufacturing services agreements with FUJIFILM pursuant to which FUJIFILM will use the Hiller&#248;d facility to produce commercial products for us, such as TYSABRI, as well as other third-party products. In addition, we sold to FUJIFILM </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13633801e874-wk-Fact-61A4865F17AD542E806318F69FA92C47" name="biib:InventoryrawmaterialssoldtoFUJIFILM" contextRef="I2019Q3Denmark" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">41.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of raw materials that were remaining at the Hiller&#248;d facility on the closing date of this transaction in the third quarter of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. These materials were sold at cost, which approximated fair value.</span></div></ix:continuation><div><a id="sBC98A152036556DFA3FC659A32E95665"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:18px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">4</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Revenues</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"> </span></div></td></tr></table><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="TextSelection-72504A8BA49F511FB69C027888491725-0-wk-Fact-5B78B6A2BED552F5AC2732C3729B2578" continuedAt="TextSelection-72504A8BA49F511FB69C027888491725-1" escape="true"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Product Revenues</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="TextSelection-D5342E96E1305769A18176AAEB496D84-0-wk-Fact-9C67282CE05256698E269FDEF5B429C1" continuedAt="TextSelection-D5342E96E1305769A18176AAEB496D84-1" escape="true"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues by product are summarized as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:30%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United<br/>States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of<br/>World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United<br/>States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of<br/>World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Multiple Sclerosis (MS):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Fumarate*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e1365-wk-Fact-7797743BEC4B5F7BB8E02226A345E945" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_FumarateMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">921.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e1384-wk-Fact-805328F0C8A6539F8ECAFD85EDC8C59E" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_FumarateMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">268.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e1404-wk-Fact-1C739B47666D56968D5BEF4F316FF605" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_FumarateMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,190.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e1423-wk-Fact-9CAC2E9FE61D56A19B329DC2F6349C9E" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FumarateMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">869.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e1442-wk-Fact-5E6D8311BCCB5D59BB8B9DEEB28F6E19" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FumarateMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">280.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e1462-wk-Fact-BBE81D675BD75B4EB80DBDDD64A1A95D" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FumarateMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,150.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Interferon**</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e1482-wk-Fact-EC53FFB747C854628685E45C41E78E1D" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">345.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e1501-wk-Fact-0E155F84DD555123B2640F864833FBDB" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">135.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e1520-wk-Fact-E758E11749B15215ACB1881E74A5349E" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_InterferonMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">481.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e1540-wk-Fact-C169BA1E3E4D54D8879C14210495F248" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">379.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e1559-wk-Fact-1EE065F9031F592DA392E381F24C803A" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">174.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e1579-wk-Fact-928990C522D555DA875AED97F2C85B93" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_InterferonMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">554.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TYSABRI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e1604-wk-Fact-BDA86516B9045D28A319EDB49631A48F" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">244.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e1623-wk-Fact-2787798ECB9858EFB2EFDE8720E026CF" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">187.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e1642-wk-Fact-0BFE98DC746152C2A90DE14102A51AEF" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">432.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e1662-wk-Fact-D361BBD2E9FA5C5390BAA3EE6430A08F" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">264.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e1681-wk-Fact-023808EEE67A550FA5BC0BF01FBC9A48" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">211.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e1701-wk-Fact-5D47AA032D235BA5A7068C7C3C5BCDC6" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">475.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FAMPYRA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e1726-wk-Fact-86EC0E43B0A05407815261E47C5AC8B7" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e1745-wk-Fact-4A2FA8ECE75E5FCBB43CD80BB44E2658" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">23.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e1764-wk-Fact-5276F4635A0E5CF7AB0351FEA0273499" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">23.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e1784-wk-Fact-C004816EA90B587BAA31C848B460D3B5" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e1803-wk-Fact-0EB1CC2D77545FEAB420C76ACAC7BC24" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e1823-wk-Fact-F0FA4C866A0850DAAA7562FFF8738AA8" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Subtotal: MS product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e1848-wk-Fact-62AF04FA50A053D9A6FC83054F973B63" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,511.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e1867-wk-Fact-33E0AD0E0F7558DC91C6CBDAE0CFC70B" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">615.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e1886-wk-Fact-8E25BFA387F655B2A5261D82BA124930" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,126.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e1906-wk-Fact-6C83493FA86853DFBC0B0B258A3C6F98" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,513.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e1925-wk-Fact-AD4EA836BEA35EBCA07F7C402AF6CB7A" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">690.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e1945-wk-Fact-A479BD01746456F6AFF67A5894B94D80" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,204.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Spinal Muscular Atrophy:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">SPINRAZA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e2225-wk-Fact-1C5F43619A195AD19A5F3C4E3B63C470" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">210.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e2244-wk-Fact-BC94AEF3EC1C5249A69F4D6D4ED6EA0D" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">284.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e2263-wk-Fact-0EA72877C8645BDDAF92BEEE5C91D3B1" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">494.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e2283-wk-Fact-4FE1448A85105E5887A4AE718AE13D3E" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">230.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e2302-wk-Fact-A3AA1D80CC5D592B89D4F4289DE72DD3" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">257.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e2322-wk-Fact-2DBEF7B5017C525D9356385222261419" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">488.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Biosimilars:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">BENEPALI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e2601-wk-Fact-E7D000E1B3B85F3A8528D2D3B1138603" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e2620-wk-Fact-BF48DFBB91F6565FA822FD8CA973C54B" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">106.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e2639-wk-Fact-73E3298C8DD85B1EA7CFE3BB9A5FEC6E" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">106.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e2659-wk-Fact-F6CF5A1A5283585E9221A8438384A92F" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e2678-wk-Fact-E196D9B4F4B15C249AB50AE9E4ABD147" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">120.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e2698-wk-Fact-39B328952E2D59FE82E4DFA297EB0941" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">120.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">IMRALDI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e2723-wk-Fact-6395540CE04C582A96DFD9C1CBD384B4" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e2742-wk-Fact-98F8D19F93F053F9B310E3F4DB8BB6D6" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">44.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e2761-wk-Fact-FCC31D53F34D8D4A61D959809BCBBDA0" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">44.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e2781-wk-Fact-1A5F571653B6590897F066DD4A0E2123" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e2800-wk-Fact-4C3742A934FB5109A2EB20BD0F532605" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">47.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e2820-wk-Fact-D0DDE0A7773FFCAA135559809B938567" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">47.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FLIXABI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e2845-wk-Fact-464AF8B9B3BE556F8A9FAA19CD4E576A" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e2864-wk-Fact-DCCF20FFC4D85A3DB242FDEDE48C2DEE" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e2883-wk-Fact-A238E691DEFDD24411F759809BB65E4B" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e2903-wk-Fact-9CD98996F2375AAAB70246448E61C847" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e2922-wk-Fact-2A32171A609356E08D78DAB85F11B9AD" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e2942-wk-Fact-0ACDAED94448377EEE2559809BA6EE63" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Subtotal: Biosimilar product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e2967-wk-Fact-ACA2876153E75958BF457EC2E2AFE9EA" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e2986-wk-Fact-B17E578AF45659E4BE8848113AA43F54" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">171.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e3005-wk-Fact-5D17F9AB0BB958C685051E02C3A5A1EB" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">171.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e3025-wk-Fact-F283E3A188D45BCC8FC4A8FD8524022A" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e3044-wk-Fact-0F4487BD63BE5F22B81963785C6F2EFF" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">184.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e3064-wk-Fact-9E41D013B3075B278D8A0B70EB7F3566" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">184.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FUMADERM</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e3345-wk-Fact-3074371F982650E3923F54C0E5C0DD18" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e3364-wk-Fact-972A2FFC08695A2B9817998D10BEAC15" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e3383-wk-Fact-9B0D9500FCDC5BD6BFFB4C787501F974" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e3403-wk-Fact-AABF35ED0BCB55328303B6FF704DA0C5" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e3422-wk-Fact-4086CD76E6B95A01B19683A4A9683DA1" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e3442-wk-Fact-3524DDC2E0E05E78848092FACE2A5938" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e3472-wk-Fact-9ADDF07A2B02504BB64590CD5937ED89" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,721.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e3491-wk-Fact-BBB2F39429605C95962E16A159CF0667" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,074.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e3511-wk-Fact-B152D3B5F3A05C7CAA044F72EA3120C1" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,795.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e3530-wk-Fact-1D73BE67E2195DBF9FB50F944B19B788" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,744.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e3549-wk-Fact-2198D70605BC592084B098656F2E804D" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,135.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e3569-wk-Fact-455E60BA69055CE8AECAC5095741DB0A" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,880.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:32%;"></td><td style="width:34%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">*Fumarate includes TECFIDERA and VUMERITY. VUMERITY became commercially available in the U.S. in November 2019.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">**Interferon includes AVONEX and PLEGRIDY.</span></div></ix:nonNumeric></ix:nonNumeric><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-72504A8BA49F511FB69C027888491725-1" continuedAt="TextSelection-72504A8BA49F511FB69C027888491725-2"><ix:continuation id="TextSelection-D5342E96E1305769A18176AAEB496D84-1" continuedAt="TextSelection-D5342E96E1305769A18176AAEB496D84-2"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United<br/>States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of<br/>World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United<br/>States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of<br/>World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Multiple Sclerosis (MS):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Fumarate*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e4171-wk-Fact-F0B2E9B3B939A20223935D7F24E19797" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_FumarateMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,699.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e4190-wk-Fact-4D1EB91FB28ACFD706105D7F2A0811AA" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_FumarateMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">591.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e4210-wk-Fact-9B6C325A1127DB880E685D7F2EEEEC9E" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_FumarateMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,291.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e4229-wk-Fact-120009E3B70C986AE48B5D7F32A28FBA" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FumarateMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,587.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e4248-wk-Fact-574C86E49849DA3F28C85D7F3A519B84" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FumarateMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">561.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e4268-wk-Fact-E7E0C3F322A1252F53145D7F3FD7B48B" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FumarateMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,149.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Interferon**</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e4288-wk-Fact-79D26EFD1F8B66EAA7D55D7F42EFF53E" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">638.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e4307-wk-Fact-7419E5E5E46D58559BCD5D7F49166D11" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">309.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e4326-wk-Fact-068CD6AC57D0BCF2F4B05D7F4F763FB6" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_InterferonMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">947.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e4346-wk-Fact-9C5CBA7D19C5A5E220F65D7F530E8992" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">707.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e4365-wk-Fact-39BA9DDB83D565232EA05D7F5864270B" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">348.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e4385-wk-Fact-3AC0E90E3EA4F19423795D7F5E453327" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_InterferonMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,055.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TYSABRI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e4410-wk-Fact-BADCD50D6540D74A4A195D7F61DC0490" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">521.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e4429-wk-Fact-31AD3468DE20AAFC37695D7F675DC163" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">432.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e4448-wk-Fact-4537839D8D70EB6C6ABF5D7F6BEBE3FA" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">954.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e4468-wk-Fact-D06714F3B4E9030A7C9F5D7F6F5E6155" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">509.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e4487-wk-Fact-D9CD90BA884646B735CF5D7F750D361E" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">426.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e4507-wk-Fact-8C0787BA79FD3A03CF3E5D7F79EC5084" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">935.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FAMPYRA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e4532-wk-Fact-D29ECCFEA44A870708915D7F7D311386" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e4551-wk-Fact-12E8B69995ADA698E0115D7F816D239D" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">51.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e4570-wk-Fact-014EC1E4C4A0FB732ADC5D7F85FAABCC" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">51.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e4590-wk-Fact-E171E8BC0C14C36177FB5D7F89676BD1" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e4609-wk-Fact-4BD88F8666F9E0F456E85D7F8E9EF235" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">47.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e4629-wk-Fact-0EFA14D07099E3DA3DF15D7F934D456E" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">47.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Subtotal: MS product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e4654-wk-Fact-A393BC433BCB92A682B55D7F95E8C65F" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,859.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e4672-wk-Fact-589F3FBC9612323764995D7F9A01E419" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,385.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e4690-wk-Fact-3DCCD0F540FA9C8E26FB5D7F9FBBE1F5" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,244.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e4709-wk-Fact-73D4B09C91950BC0FDD05D7FA3455D7E" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,803.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e4727-wk-Fact-0E736608F52B0303B1745D7FA7D9D918" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,383.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e4746-wk-Fact-2BFCDFFB8FEFF6F0A2705D7FACB919BE" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,187.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Spinal Muscular Atrophy:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">SPINRAZA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e5028-wk-Fact-1DE7AC89E23932497F1B5D7FBA421754" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">445.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e5047-wk-Fact-CAFDDA31A61611BD9BE55D7FBE7D5B71" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">613.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e5066-wk-Fact-6CD8EC4C1C4CA7920F0F5D7FC263F932" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,059.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e5086-wk-Fact-9C28DE2D705B8EE32CEE5D7FC54F91AC" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">453.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e5105-wk-Fact-DAEC50701B05891B051A5D7FC989BCAB" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">552.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e5125-wk-Fact-A3B7C42E8122AE532E6D5D7FCE188AC3" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,006.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Biosimilars:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">BENEPALI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e5406-wk-Fact-10DE7E43795121A70FE05D7FDBE5529B" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e5425-wk-Fact-9556956F9C2045EBE2325D7FE020E54E" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">239.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e5444-wk-Fact-8BE3D450FED752D93D425D7FE4B3007F" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">239.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e5464-wk-Fact-565868CDAC1F20AB84015D7FE827BC90" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e5483-wk-Fact-7CCBA3984E19176F89185D7FED5C9D77" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">244.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e5503-wk-Fact-DB27CBFCEEADF03DF08E5D7FF1E8612C" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">244.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">IMRALDI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e5528-wk-Fact-A188F304BE0B10B80C285D7FF4133400" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e5547-wk-Fact-9AC03B825FFE42BB8F695D7FF9D76AF6" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">106.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e5566-wk-Fact-AA95B542ED3CEE84C06C5D7FFD7244B0" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">106.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e5586-wk-Fact-3AD74111B26C2D7F6A255D80005A220C" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e5605-wk-Fact-A80F4FF7E9C13D2E97215D8004E8EA0E" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">83.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e5625-wk-Fact-9CC47A4B1A428C0E317D5D8008D0DCD1" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">83.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FLIXABI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e5650-wk-Fact-DE05156163515BC24BF95D800B7D34DE" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e5669-wk-Fact-03D4398DB2DCD6EC29BC5D800FFFCAD8" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">44.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e5688-wk-Fact-78B4E1590FBBBFB366755D8014DC8A78" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">44.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e5708-wk-Fact-4858F35E3516534343C95D8018F6CBDE" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e5727-wk-Fact-B7F48B12AE5FE4654CA95D801D521118" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">31.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e5747-wk-Fact-A6193C0E70A60074DE455D80211F5715" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">31.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Subtotal: Biosimilar product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e5772-wk-Fact-C70D0A9D521A6DCBF5025D802316750C" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e5790-wk-Fact-646F73F6E0E86E6DF2985D8028E7C178" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">390.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e5808-wk-Fact-7807EAF0210071F062DE5D802CD2D315" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">390.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e5827-wk-Fact-52C3A15C313BE71D94F45D802F8FEEA7" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e5845-wk-Fact-34682919FAC9AE63FDBA5D803400D5ED" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">358.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e5864-wk-Fact-97D6F5FCC922B29F5E3F5D8038E2C1AA" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">358.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FUMADERM</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e6145-wk-Fact-16206ADBE5E530EED7695D80468EEF2B" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e6164-wk-Fact-B40AF35C632ADDC12AC75D804C165557" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e6183-wk-Fact-0E3AB62D10E6611750A75D8051469434" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e6203-wk-Fact-41CA73BA4A30DB0CE6AA5D80548AC815" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e6222-wk-Fact-3DEB88C7DC00976B7A715D80591F4BCA" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e6242-wk-Fact-623AD9F080707778BD935D805DC78BBF" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e6272-wk-Fact-7593621D9903756E79D25D8060657620" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,304.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e6290-wk-Fact-C01303D29CAB1FCA2F6B5D8064A11A41" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,395.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e6309-wk-Fact-3718F7E632B25D27847BA0BA45120ACA" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,700.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e6327-wk-Fact-B69B35758403071883555D806CC4C442" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,257.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e6345-wk-Fact-DAE16EB398290235D4815D8071FBE666" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,302.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e6364-wk-Fact-EE4EC8FA691555C0A7DE82D787D37BE4" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,560.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:32%;"></td><td style="width:34%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">*Fumarate includes TECFIDERA and VUMERITY. VUMERITY became commercially available in the U.S. in November 2019.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">**Interferon includes AVONEX and PLEGRIDY.</span></div></ix:continuation><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><ix:continuation id="TextSelection-D5342E96E1305769A18176AAEB496D84-2"></ix:continuation>We recognized revenues from two wholesalers accounting for </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d13658793e6409-wk-Fact-C25A764B34675B19BF5C7A7C1A570202" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" contextRef="FD2020Q2QTD_srt_MajorCustomersAxis_biib_DistributorOneMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">31.7</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d13658793e6413-wk-Fact-4F6D0D253AA25063BADADE5DBC4F92C9" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" contextRef="FD2020Q2QTD_srt_MajorCustomersAxis_biib_DistributorTwoMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">17.9</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of gross product revenues for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d13658793e6425-wk-Fact-ADC579F62FF02E1A2F6D5D9DB40FE52C" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" contextRef="FD2020Q2YTD_srt_MajorCustomersAxis_biib_DistributorOneMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">30.8</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d13658793e6430-wk-Fact-D7E73C7C32C5AE14E29E5D9DC986396F" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" contextRef="FD2020Q2YTD_srt_MajorCustomersAxis_biib_DistributorTwoMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">16.2</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of gross product revenues for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognized revenues from two wholesalers accounting for </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d13658793e6445-wk-Fact-3CA7D13A817E54F59C447366C3D15E73" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_biib_DistributorOneMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">30.5</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d13658793e6449-wk-Fact-AED7A92713D95816A7961DEBDA76E762" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_biib_DistributorTwoMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">18.2</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of gross product revenues for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d13658793e6461-wk-Fact-EAA915138E1EE87392995D9E03956EA6" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_biib_DistributorOneMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">30.9</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d13658793e6466-wk-Fact-31CC0CD6E365CA5982085D9E1FD657CF" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_biib_DistributorTwoMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">16.3</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of gross product revenues for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" id="TextSelection-C1BA12976DDB57FC871F972D82E04AF2-0-wk-Fact-4859620AE4B551E9B080443D3568F518" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Balance, as of December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e6624-wk-Fact-D6466C88F4D5567BAEE2EE4AF24FEF51" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">131.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e6643-wk-Fact-869F723FF374547880841E9CC5735369" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,027.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e6663-wk-Fact-577E1E7BBD1755FCB0DAED9B5302AA7F" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">40.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e6682-wk-Fact-29F90B4D0AA15CF88652A2F69FEF5B8D" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,198.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Current provisions relating to sales in current year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e6702-wk-Fact-9EB295F1016C554FB939C2D9BC27AAD8" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" contextRef="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">387.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e6721-wk-Fact-8DDB9B329C415E438C8AF1B4D198B9DB" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" contextRef="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,624.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e6740-wk-Fact-BDF2435202605C04A755124AA8225FFC" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" contextRef="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e6760-wk-Fact-2B9E473E66245C0BB925166E81917B73" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,021.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Adjustments relating to prior years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13658793e6785-wk-Fact-5F3CDAD899D35F4FBE162174676FC820" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" contextRef="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13658793e6805-wk-Fact-888C767728875E048D1A2394BE0E2AE2" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" contextRef="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">25.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e6825-wk-Fact-25F7861313535C16A4E79F8AC66F49CC" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" contextRef="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13658793e6845-wk-Fact-D8C593FDE2EE576B8EEF6AEA85938A5D" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">26.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Payments/credits relating to sales in current year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13658793e6871-wk-Fact-5617EA2EF5825D128C726D4EF104A3A6" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" contextRef="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">251.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13658793e6891-wk-Fact-2EE761EC42015F25B43FBEA11D7CC6A9" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" contextRef="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,018.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e6911-wk-Fact-9C493713E0555EE1B7B706EDC084C9CA" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" contextRef="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13658793e6931-wk-Fact-7D4FD8DD23AF5A50B9B78D2ED9A704BA" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,270.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Payments/credits relating to sales in prior years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13658793e6957-wk-Fact-CE6AC519934858B887422FE789C39AE4" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" contextRef="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">126.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13658793e6977-wk-Fact-E6A56A4234BF5511BEE36E1534AA19A6" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" contextRef="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">612.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13658793e6997-wk-Fact-DA85E28A413057E6A22FAB5091FC162A" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" contextRef="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13658793e7018-wk-Fact-412B9C697E1055698673AB6357B2E367" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">749.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Balance, as of June 30, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e7049-wk-Fact-6FCCBE5DDB7B5B0DB09397085132F217" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2020Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">139.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e7068-wk-Fact-134388D683035B5BB476380CC14A8BA9" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2020Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">994.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e7088-wk-Fact-0C718AEB6EBE56A2B80CFF3F55B6D0C2" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2020Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">41.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e7107-wk-Fact-D8A0D00D9B9A5B1CA2E1F3B7297EF516" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,174.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q2YTD" name="biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" id="TextSelection-272892E34C4C5876AABF64F554440E09-0-wk-Fact-441147AC2A7550BB94A6ED9521929F7A" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:66%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>June 30,<br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Reduction of accounts receivable, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e7217-wk-Fact-D4DAB612AE2E5A25ACA440A42360E9DC" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">223.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e7236-wk-Fact-08E9AFFF9C1E5381944CF2D4F7AA0E79" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">197.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Component of accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e7256-wk-Fact-062DF7382F915519A5B9D146E1EF70DC" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">951.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e7275-wk-Fact-4231B4BD6644584EB68CBAD2CF09EF6D" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,001.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total revenue-related reserves</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e7305-wk-Fact-D8A0D00D9B9A5B1CA2E1F3B7297EF516" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,174.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e7324-wk-Fact-29F90B4D0AA15CF88652A2F69FEF5B8D" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,198.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-72504A8BA49F511FB69C027888491725-2" continuedAt="TextSelection-72504A8BA49F511FB69C027888491725-3"><div style="line-height:120%;padding-top:9px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Revenues from Anti-CD20 Therapeutic Programs</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock" id="TextSelection-45628B4DAF03538BA12A7B91C71AE4C3-0-wk-Fact-A26F447C604A5562BB3D8910C144995C" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs are summarized below. For the purposes of this footnote we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div style="line-height:120%;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:46%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e7562-wk-Fact-FF69F0DD76FB5F3893C65DACA86FCD0F" name="biib:ShareOfCoPromotionProfits" contextRef="FD2020Q2QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">257.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e7581-wk-Fact-476B170DB1E255468AD6808F5EF708AC" name="biib:ShareOfCoPromotionProfits" contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">377.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e7601-wk-Fact-9E8D68E9957D5C7FB3272B42621DB81A" name="biib:ShareOfCoPromotionProfits" contextRef="FD2020Q2YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">598.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e7620-wk-Fact-A1AB8A0C8B185CE3AE8FE08BEEF6DCB3" name="biib:ShareOfCoPromotionProfits" contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">768.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other revenues from anti-CD20 therapeutic programs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e7640-wk-Fact-110C357A15CE5A41B23F93E3A548416C" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" contextRef="FD2020Q2QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">220.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e7659-wk-Fact-01A214FC1D015C4CA9D0DFEE484001DB" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">199.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e7678-wk-Fact-D5A5D244B60D5387B064A5B788E3DC62" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" contextRef="FD2020Q2YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">399.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e7698-wk-Fact-04822A30103D5A9EA4EC742FD66632F8" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">325.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total revenues from anti-CD20 therapeutic programs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e7728-wk-Fact-FB6FCA81223F5FE7A607645477111EBC" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">478.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e7747-wk-Fact-20474355737A5AB3954B4011223DE749" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">576.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e7767-wk-Fact-58C037C126CE5E9782E7F6AFA1368536" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">998.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e7786-wk-Fact-235F3E71E70A544C994CD254A0F195D0" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,093.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Genentech, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 18,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Other Revenues</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="biib:OtherrevenuesTableTextBlock" id="TextSelection-D3D2747AD38C5B559B9966923B98BAAB-0-wk-Fact-B70C3F5A6DC65E1292BB8C9CB018FEBB" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues are summarized as follows:</span></div><div style="line-height:120%;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Revenues from collaborative and other relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Profit (loss) earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e8127-wk-Fact-22DC319828EC5DCA9AF8B73917B2A841" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13658793e8146-wk-Fact-E4B62E2E31AC5329A503BC109F552F20" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e8167-wk-Fact-9AB69968AB8E5F258534930D1F241FC3" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13658793e8186-wk-Fact-45F5EAEB7FA15630A708B40C0D2BE590" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Revenues earned under our technical development agreement, manufacturing services agreements and royalty revenues on biosimilar products with Samsung Bioepis</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e8207-wk-Fact-32E2864C068656BA9A87D6F03504DFEB" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_srt_MajorCustomersAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e8226-wk-Fact-A0B1C99BF9F95385BFFE1C7FDAE14999" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">52.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e8245-wk-Fact-4CBD1787120583228681598139AF1869" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_srt_MajorCustomersAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e8265-wk-Fact-D7B9719EA7EFFD191CB659813B74766D" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">77.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other royalty and corporate revenues:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Royalty</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e8377-wk-Fact-E872A407662D5EE08E83BD6BC59D3ED3" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e8396-wk-Fact-AD7E82BBCEFE5E95B28ACE0F14842F64" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e8415-wk-Fact-4C75EC3651E55B66BE157D66A5F37FE2" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">18.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e8435-wk-Fact-669710715ED45103A762AE04A08FB590" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other corporate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e8460-wk-Fact-935AB887DC455E09A965E7F28496CFF8" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">395.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e8479-wk-Fact-AE9942B8485C5515A0CD351D448B1146" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">105.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e8498-wk-Fact-C6B87EC6CE62505E9DC0E85640ECFCD1" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">489.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e8518-wk-Fact-3099F7FA688254B6A32186F05BB0EF12" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">369.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total other revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e8548-wk-Fact-F3C79B768015565FA0C0EB179D69F338" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">407.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e8567-wk-Fact-46C1484140125886ACF7E143442F0214" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">160.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13658793e8587-wk-Fact-E351B467EBD95DC7BA1A6E901C488CDA" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">516.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13658793e8606-wk-Fact-9E90C511A4E4588682EE0D2A0C9F3B65" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">452.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;">During the third quarter of 2019 we amended our agreement with a contract manufacturing customer, pursuant to which we licensed certain of our manufacturing-related intellectual property to the customer. In the second quarter of 2020 the customer received regulatory approval for its product that is being manufactured using certain of our manufacturing-related intellectual property. As a result, we are entitled to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13658793e8624-wk-Fact-F7FE673D71E5B0F109C35DA13E756F70" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2019Q3_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">500.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;">in a series of three payments. The first payment became due upon regulatory approval of such product and was received during the</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">second</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> quarter of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </span><span style="font-family:Franklin Gothic Book,sans-serif;">Subsequent payments are due on the first and second anniversaries of the regulatory approval.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span></div></ix:continuation><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><ix:continuation id="TextSelection-72504A8BA49F511FB69C027888491725-3" continuedAt="TextSelection-72504A8BA49F511FB69C027888491725-4"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other corporate revenues for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflect </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13658793e8664-wk-Fact-839B2A5E9F92020796AA5DA22186C835" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_srt_MajorCustomersAxis_biib_ContractManufacturingCustomerMember_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">329.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;">related to the delivery of the license for certain of our manufacturing-related intellectual property under the amended agreement discussed above. We have allocated the remaining $170.6 million of the $500.0 million transaction price to the performance of manufacturing product supply services for the customer, which we expect to perform through 2026. The value allocated to the manufacturing services was based on expected demand for supply and the fair value of comparable manufacturing and development services</span></ix:continuation><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><ix:continuation id="TextSelection-72504A8BA49F511FB69C027888491725-4">.</ix:continuation> </span></div><div><a id="s3D7251D6F4DD54C99572375028BD788F"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:18px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">5</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Inventory</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"> </span></div></td></tr></table><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="TextSelection-5789181EABBE52D09901D9B63CDF0BC9-0-wk-Fact-AE3C9F33AEA15456BA7BAD1F7B4B55D0" escape="true"><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:InventoryDisclosureTextBlock" id="TextSelection-8A8AF6FCC2F15B6CAD13C8EF817D8627-0-wk-Fact-FF97394C4F065571AEDA393E84FBC923" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The components of inventory are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:64%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>June 30,<br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13648686e886-wk-Fact-9B2ACD6C351750F3A5408420CFFA84C4" name="us-gaap:InventoryRawMaterialsNetOfReserves" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">244.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13648686e905-wk-Fact-AD28146499E453F49A59D959832635A4" name="us-gaap:InventoryRawMaterialsNetOfReserves" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">169.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Work in process</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13648686e925-wk-Fact-68E9FE242DFD5B8695407576A47210DF" name="us-gaap:InventoryWorkInProcessNetOfReserves" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">509.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13648686e944-wk-Fact-94DCFC167DB65DD4B3D72E3E2390B0FB" name="us-gaap:InventoryWorkInProcessNetOfReserves" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">460.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Finished goods</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13648686e969-wk-Fact-CBF0300875F55501B84EA26DBA399AFC" name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">198.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13648686e988-wk-Fact-0CFF6E26339E58639CA21641EC42E50E" name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">174.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total inventory</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13648686e1018-wk-Fact-CCA383FAD6DE51C2930A64B4D6F1DC7C" name="biib:Inventorynetcurrentandnoncurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">952.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13648686e1037-wk-Fact-9F732FC3A9DA51E5BDE3934413C60118" name="biib:Inventorynetcurrentandnoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">804.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:nonNumeric><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19</span></div></div><hr style="page-break-after:always"></hr><div><a id="sE514DCE224665F5CBB5CBF18917F12A6"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:18px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">6</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Intangible Assets and Goodwill</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"> </span></div></td></tr></table><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="TextSelection-32CB81C906FB5971BF1250DEC8792813-0-wk-Fact-F3A16DF07B9A54C6B8773BBB35207114" continuedAt="TextSelection-32CB81C906FB5971BF1250DEC8792813-1" escape="true"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Intangible Assets</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="biib:IntangibleAssetsExcludingGoodwillTableTextBlock" id="TextSelection-E3ED1BB8317F55259D9073C28AA0F31A-0-wk-Fact-3DB4F0B12D4E5924A9AF6039E5DBC879" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"></td></tr><tr><td style="width:21%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of June 30, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Life</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Completed technology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">4-28 years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13650096e1140-wk-Fact-05127B7A495156939083CD6BEFEB1EC1" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7,379.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13650096e1159-wk-Fact-08A5859201975E2390CEE7E8F0A9A910" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,014.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13650096e1180-wk-Fact-0D4FFB3909C550CA8F0DEBABD56556FF" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,364.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13650096e1199-wk-Fact-FA968B3EA49F5C4AA354B763BF9CA0E6" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7,379.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13650096e1218-wk-Fact-98BCD0594DA45DBDAC2BA147E24DBB2D" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,881.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13650096e1239-wk-Fact-FE195588F3EB50BDB3C94BA6B1EBDEB7" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,497.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">In-process research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Indefinite until commercialization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13650096e1264-wk-Fact-777BCC5C6A095BCEA2D29819488DA715" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2020Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">954.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13650096e1283-wk-Fact-24519E88C708541DB6D9705D7331DCA1" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2020Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13650096e1303-wk-Fact-777BCC5C6A095BCEA2D29819488DA715" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2020Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">954.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13650096e1322-wk-Fact-C60759D04ED456BDB016D4C91DAE488C" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">965.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13650096e1341-wk-Fact-641EEE7732525DC9B86C90E65ED37E80" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13650096e1361-wk-Fact-C60759D04ED456BDB016D4C91DAE488C" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">965.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Trademarks&#160;and trade names</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Indefinite</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13650096e1391-wk-Fact-C9B1868FB8345462972100FB1E95676F" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2020Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">64.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13650096e1410-wk-Fact-1F145E6108C557E58F64CC5CEB56B73A" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2020Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13650096e1430-wk-Fact-C9B1868FB8345462972100FB1E95676F" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2020Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">64.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13650096e1449-wk-Fact-286E5ADD95DD56E5988F487FE63BB252" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">64.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13650096e1468-wk-Fact-7A79C269516159098FD9BCB4A6CD451F" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13650096e1488-wk-Fact-286E5ADD95DD56E5988F487FE63BB252" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">64.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13650096e1523-wk-Fact-708E4713020F522DA09647BAA702581B" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8,398.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13650096e1542-wk-Fact-80E1262768E65172BB934DF593BDB993" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,014.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13650096e1563-wk-Fact-BFE27979689A5391A80AEDD28844D403" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,383.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13650096e1582-wk-Fact-CE00BE4D45BA5B2D8A99F668F908247F" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8,408.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13650096e1601-wk-Fact-E45BCFECB1D459E5BC1EFC4B0D2AA52E" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4,881.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13650096e1622-wk-Fact-324FDBF1B2EA5FB9ACA38A2A6E25F4FD" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,527.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, amortization and impairment of acquired intangible assets totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13650096e1654-wk-Fact-093CF28AF51D56AC9C178C57E0C20541" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">61.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$133.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13650096e1663-wk-Fact-FD9B7A01CCCF53378063A4D1471F9676" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">70.1</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$138.3 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods. We had </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d13650096e1671-wk-Fact-C49EEDE049D0ED79701B5DAF1E2410C7" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="FD2020Q2QTD" unitRef="usd" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> impairment charges for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Completed Technology</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Completed technology primarily relates to our acquisition of all remaining rights to TYSABRI from Elan Pharma International Ltd., an affiliate of Elan Corporation plc, and milestone payments made to Alkermes Pharma Ireland Limited, a subsidiary of Alkermes plc, following the approval of VUMERITY in the U.S. in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">October 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, net of accumulated amortization.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">IPR&amp;D Related to Business Combinations</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IPR&amp;D </span><span style="font-family:Franklin Gothic Book,sans-serif;">represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Included in IPR&amp;D balances are adjustments related to foreign currency exchange rate fluctuations. </span><span style="font-family:Franklin Gothic Book,sans-serif;">We review amounts capitalized as acquired IPR&amp;D for impairment annually, as of</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">October 31</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;">and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> The carrying value associated with our IPR&amp;D assets as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, relates to the various IPR&amp;D programs we acquired in connection with our acquisitions of NST, Convergence Pharmaceuticals Holdings Ltd. (Convergence) and Biogen International Neuroscience GmbH (BIN). The majority of the balance relates to our acquisition of NST in June 2019 whereby we acquired IPR&amp;D programs with an estimated fair value of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13650096e1732-wk-Fact-022E152128985C9599AF810C59F18ED8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">700.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Vixotrigine</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;">In the periods since we acquired vixotrigine (BIIB074), there have been numerous delays in the initiation of Phase 3 studies for the potential treatment of trigeminal neuralgia (TGN) as we engaged with the U.S. Food and Drug Administration (FDA) regarding the design of the Phase 3 studies and awaited data and insights from mid-stage clinical trials of vixotrigine in other indications that have since been completed.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;">The fair value of the TGN asset is not significantly in excess of carrying value.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the carrying value associated with our vixotrigine IPR&amp;D assets was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13650096e1754-wk-Fact-DDE1BD2E57B0558BBE13D7F10D498D16" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2020Q2_biib_ResearchanddevelopmentassetAxis_biib_TGNMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">160.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div></ix:nonNumeric><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-32CB81C906FB5971BF1250DEC8792813-1" continuedAt="TextSelection-32CB81C906FB5971BF1250DEC8792813-2"><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Estimated Future Amortization of Intangible Assets</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;"> </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">T<ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="TextSelection-5C5B67FEEC06598BA68DB984CEAB3E31-0-wk-Fact-B398398DA6545B478E55A4C07A2B06DE" continuedAt="TextSelection-5C5B67FEEC06598BA68DB984CEAB3E31-1" escape="true">he estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:</ix:nonNumeric></span></div><ix:continuation id="TextSelection-5C5B67FEEC06598BA68DB984CEAB3E31-1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:81%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>June 30,<br/>2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2020 (remaining six months)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13650096e1837-wk-Fact-FCC74F4CA46C52589D5472544EE627B0" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">126.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13650096e1857-wk-Fact-D689393FBED45760BE41085B28B18394" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">220.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13650096e1882-wk-Fact-50938493107A5B6D98319CFC78A266AF" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">220.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13650096e1907-wk-Fact-9558F12C3E6A57B98830775499D5A10D" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">230.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2024</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13650096e1932-wk-Fact-9EA7D3391C665604A65D8A7AC1FA9F17" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">230.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2025</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13650096e1957-wk-Fact-F493878EC51A54A3A56005716E408B97" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">220.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Goodwill</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfGoodwillTextBlock" id="TextSelection-4CFC0A475C285224B1F0C1EBCC90C5A0-0-wk-Fact-A5697B9810F451E7B71B6D9F926C4867" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:81%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>June 30,<br/>2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Goodwill, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13650096e2051-wk-Fact-5E02EC613C7B5C7BA41E1722B85A855E" name="us-gaap:Goodwill" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,757.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13650096e2071-wk-Fact-86C441EAABDD5D1A8B1ADE2BC53E64B4" name="us-gaap:GoodwillOtherIncreaseDecrease" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">6.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Goodwill, end of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13650096e2102-wk-Fact-8FC55EF7124D59B3A1E28F099D9D8F9D" name="us-gaap:Goodwill" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,751.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><ix:continuation id="TextSelection-32CB81C906FB5971BF1250DEC8792813-2" continuedAt="TextSelection-32CB81C906FB5971BF1250DEC8792813-3"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d13650096e2125-wk-Fact-F644120DD8C256C389C52377760CACEF" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span></ix:continuation><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><ix:continuation id="TextSelection-32CB81C906FB5971BF1250DEC8792813-3"> accumulated impairment losses related to goodwill. Other includes adjustments related to foreign currency exchange rate fluctuations.</ix:continuation> </span></div><div><a id="s6C5F478C59E35303882582F1E0E67ABC"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:18px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">7</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Fair Value Measurements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"> </span></div></td></tr></table><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="TextSelection-1A3EFA44622A522FAB7CA7FB68BB841B-0-wk-Fact-CD292E878AF453F7B9B0BAE93BEF6EFB" continuedAt="TextSelection-1A3EFA44622A522FAB7CA7FB68BB841B-1" escape="true"><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:FairValueDisclosuresTextBlock" id="TextSelection-05220E166C6A51B18A07BC1DEADCE9A1-0-wk-Fact-472D8A4F385B57F9A5D8F8518A0649C5" continuedAt="TextSelection-05220E166C6A51B18A07BC1DEADCE9A1-1" escape="true"><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of June 30, 2020 (In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">Assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e1047-wk-Fact-43259A0A3AA950FBA1D6CFAD9C4E840E" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,869.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e1066-wk-Fact-03BEA37116635F758AC9196E250CCA31" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e1086-wk-Fact-C9090669BB9A558D8A420E26E5F33B36" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,869.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e1105-wk-Fact-512CABF52E875F9CA83964B1FAED583A" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Marketable debt securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e1212-wk-Fact-541573CE06065C4E8BE1FB4055BDCE7B" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,790.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e1231-wk-Fact-2E6A66C5678B55D599EBAA8CE36C410A" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e1250-wk-Fact-7D79B62F0F4A5974820BFD925AD40A9D" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,790.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e1270-wk-Fact-9A6B6AB0FF555177B41746B060EA5F1A" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Government securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e1295-wk-Fact-30D17D8F4858562DB752F594ADD75B89" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">966.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e1314-wk-Fact-A58E1CC8130C58CF8CDA97F148F91B2D" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e1333-wk-Fact-BC7803F6329350578466DA38520AD727" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">966.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e1353-wk-Fact-849792336D325E91AE0760A659054837" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Mortgage and other asset backed securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e1378-wk-Fact-DD2F73F5529C50848D5AB2588A690700" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">108.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e1397-wk-Fact-7AB12618868552BF9F8AA74D829AADB3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e1416-wk-Fact-6ABFD096D53054919A20D7936FE2909F" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">108.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e1436-wk-Fact-B4525C3B3B0150C3B7C96A1BE9F7A766" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Marketable equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e1461-wk-Fact-0AEF86F5B5AD576D95CD8C2F40E2BD83" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">527.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e1480-wk-Fact-4EF5F07D746E5EB195A30170529149AF" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">344.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e1499-wk-Fact-E62EC012C7DB53D6A477190717801D4A" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">182.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e1519-wk-Fact-30C0CC84635D5C3D82E989949AE7AF96" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e1544-wk-Fact-F4E93BC4BFE555BFB9AB4C79DA12989A" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">59.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e1563-wk-Fact-D8933FB8EB865364B0A6FB12A9524184" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e1582-wk-Fact-00692A807D3F5B9187DCBC865D3F5005" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">59.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e1602-wk-Fact-9F70CEEBCB7E5BEBB9D8A1D6ABAC1221" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Plan assets for deferred compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e1627-wk-Fact-51408BD584D65293831166CBF28105D7" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">27.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e1646-wk-Fact-1563606BE68857B0A1FCD1614D0CA0CB" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e1665-wk-Fact-C39611A7258452C0BD8E9C6D55D3A70D" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">27.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e1685-wk-Fact-1CDC5591523E52B9A00FDF67A9165CD0" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e1715-wk-Fact-4468E57FBE385B66A76DB52413653676" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,349.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e1734-wk-Fact-EC76BD85C9F35AC4828096AE7F193F8F" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">344.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e1754-wk-Fact-ACE2F60454945F1FBEB8D0F8F9A0155B" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,005.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e1773-wk-Fact-F9B13E73D6775DDFBFC42AA083711808" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">Liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e1886-wk-Fact-3B0BC080347D5ACBBD076A3C5AEE3B90" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e1905-wk-Fact-9F63A8525895525FBF02126763337521" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e1925-wk-Fact-370F19437FCE5275B3BBC6B73170D0DD" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e1944-wk-Fact-174D24DA86FC53BDA86418A927E1A281" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Contingent consideration obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e1964-wk-Fact-A19C990EAFD35063A5E8C784983CFC41" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">351.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e1983-wk-Fact-D0575819235F5FD8BC24A36F61810E30" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e2002-wk-Fact-AC01EC5DE11758159F854C05EC0A9152" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e2022-wk-Fact-FD2B7FFD7E7455EAABF0B32BC4CC39F0" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">351.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e2052-wk-Fact-C4E3D53DC2C45994B38D2388FAAC56AE" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">365.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e2071-wk-Fact-C6338079BB2D5C659A1B1FFC805B4DA7" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e2091-wk-Fact-BD11EC4FDBD352D4B3C1654CF9D61E94" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e2110-wk-Fact-F31DEA33FDC25303A0532AC90625CF34" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">351.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:nonNumeric><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-05220E166C6A51B18A07BC1DEADCE9A1-1" continuedAt="TextSelection-05220E166C6A51B18A07BC1DEADCE9A1-2"><ix:continuation id="TextSelection-1A3EFA44622A522FAB7CA7FB68BB841B-1"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2019 (In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">Assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e2361-wk-Fact-84AC6FB055CC55C3A7EEFC67C2DD7FB4" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,541.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e2380-wk-Fact-D73ABFB7BA2B5136A434B700077817AD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e2400-wk-Fact-A9C6FB96DA3E577C9FB1D2377EF40C6F" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,541.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e2419-wk-Fact-93A11C3411255C9D91D99743F4BFAF94" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Marketable debt securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e2526-wk-Fact-22DB5234DB7D585CB313C40FE989CCC3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,695.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e2545-wk-Fact-672D5FB637D65A76A0CE5457A1A48C34" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e2564-wk-Fact-037FDF7E86865F9592ACBBD5C670DAEE" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,695.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e2584-wk-Fact-C147161271BF59458E54344F383CF098" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Government securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e2609-wk-Fact-CE89A364422C5873AF4B204D285EF1BD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,013.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e2628-wk-Fact-5637393B1807528BA7BCEBA75DCC7275" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e2647-wk-Fact-C43CEF12309C5C878B9EACEB8A2099EF" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,013.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e2667-wk-Fact-BE8E7ABB2CB356DAADABCCA3686B666F" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Mortgage and other asset backed securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e2692-wk-Fact-01B152C37C195238A7AA227A513DA6AD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">261.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e2711-wk-Fact-0D879F36AA4F5A508D6E3B0C8D05D5C0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e2730-wk-Fact-EDE743DD7899551B970B901EC6122067" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">261.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e2750-wk-Fact-B5518B337F95571CA5EF377DAFB67291" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Marketable equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e2775-wk-Fact-F00B97A4585A53EEA20DA5BAB7DF40D6" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">337.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e2794-wk-Fact-653F680695DD5A929AFB033318B3ED52" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e2813-wk-Fact-91C0F07C11065E9B9920ADE354DE8771" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">329.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e2833-wk-Fact-B5312CD9C6BA5C7DA1B0B0A3D523F43B" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e2858-wk-Fact-1D5C4FDC83445AD9A70261D56E620A42" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">43.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e2877-wk-Fact-086EC2D9EFC556CF8CDD18C499A8BA9C" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e2896-wk-Fact-DF18D7BE971C5658B052F8D34DBC72E5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">43.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e2916-wk-Fact-F20AA435E669597FABAAA08C9EA68611" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Plan assets for deferred compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e2941-wk-Fact-591189EC897C569C83F1C8FA127D84CD" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">27.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e2960-wk-Fact-9E97DE7ADEA0573297B96D6D23C6E155" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e2979-wk-Fact-2E7A6281F0BE5E4AA650AD77B6EA1CCD" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">27.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e2999-wk-Fact-B8CEEBF4C3DA5C908D9A7FD716630C21" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e3029-wk-Fact-AB1D42967D3755558D27EB6ED5401B77" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,920.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e3048-wk-Fact-77A3951657885B30B4524818756186F8" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e3068-wk-Fact-1946DF5D7256570785595B3650899AA6" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,912.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e3087-wk-Fact-FA962F6492AD5ECB95433417F7F92D3A" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">Liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e3200-wk-Fact-2EDAC1F8B249572E9511CAE3B3835FC6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e3219-wk-Fact-DC5695E37C715CC39E550BD16017383D" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e3239-wk-Fact-175E8740B88C5F40A6B63DECDD0066F1" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e3258-wk-Fact-2933EEE48E7A51269D5866511F68D2BE" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Contingent consideration obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e3278-wk-Fact-286F1A1625CA593B89812AAFB974A889" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">346.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e3297-wk-Fact-37CD55BDB5A058AA9971C1170743233D" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e3316-wk-Fact-C91567BF60905D56AFF6B232E09AE416" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e3336-wk-Fact-944606DE80BA58939933FF50D029FC04" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">346.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e3366-wk-Fact-14E277E8F4E655318495D16389EDD6F9" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">354.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e3385-wk-Fact-A18726FF1701522FA0FF75559185EF5F" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e3405-wk-Fact-C921A935E3075C12A387C34590E313B7" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e3424-wk-Fact-6D1689A8CC0152CCB334D64CCFDA2098" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">346.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There have been </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d13663888e3444-wk-Fact-694D6D1DA5845D70B8449FAEADE25A6E" name="us-gaap:AssetImpairmentCharges" contextRef="FD2020Q2YTD" unitRef="usd" decimals="INF" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> material impairments of our assets measured and carried at fair value during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In addition, there were </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> changes in valuation techniques during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities was determined through third-party pricing services. The fair value of Level 2 instruments classified as marketable equity securities represents our investment in Sangamo Therapeutics, Inc. (Sangamo) common stock and is valued using an option pricing valuation model as the investment is subject to certain holding period restrictions. For additional information on our investment in Sangamo common stock, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 8, Financial Instruments</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our investments in marketable equity securities also include shares of Ionis Pharmaceuticals, Inc. (Ionis) common stock acquired in June 2018. Our shares in Ionis common stock were initially subject to certain holding period restrictions that expired during the first quarter of 2020. The fair value of this investment was a Level 1 measurement as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 1, Summary of Significant Accounting Policies - Fair Value Measurements,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the significant unobservable inputs in the fair value measurement of our contingent consideration obligations as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:24%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:10%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of June 30, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Valuation Technique</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable Input</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Range</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted Average</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Contingent consideration obligation</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e3748-wk-Fact-A19C990EAFD35063A5E8C784983CFC41" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">351.6</ix:nonFraction></span></span></div></td><td rowspan="2" style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Discounted cash flow</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Discount rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">0.83% to 1.18%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e3793-wk-Fact-FD45875B2A605E7AAB1784BEBB43EDF7" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" contextRef="FI2020Q2_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">0.92</ix:nonFraction>%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Timing of achievement of development milestones</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2021 to 2027</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The weighted average discount rate was calculated based on the relative fair value of our contingent consideration obligations. In addition, we apply various probabilities of technological and regulatory success, ranging from high single digits to certain probability, to the valuation models to estimate the fair values of our contingent consideration obligations.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-05220E166C6A51B18A07BC1DEADCE9A1-2"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Debt Instruments</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="TextSelection-88DF1C200D975519BF18564769566706-0-wk-Fact-BF1609E6770B526680E49068E14329B7" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of June 30, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2.900% Senior Notes due September 15, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e4115-wk-Fact-40168E4AB5865FB1AFC923E3B86FDB4A" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e4134-wk-Fact-98DB2CCFE7155479B9C38D41283BCEA2" name="us-gaap:NotesPayable" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e4154-wk-Fact-CE8C1C62476C5B1BBC510607278C8D11" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,509.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e4173-wk-Fact-B7098BDFE9355368846B4549E3B9C2C8" name="us-gaap:NotesPayable" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,495.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3.625% Senior Notes due September 15, 2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e4193-wk-Fact-EE333E412B395204AD855AD3156CA641" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,061.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e4212-wk-Fact-2165464F11E45AF39A68F987A433EE94" name="us-gaap:NotesPayable" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">997.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e4231-wk-Fact-F35E46D042DA5C618D0484E16A86AE8A" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,038.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e4251-wk-Fact-CDC8471BE1895E219AE059AF99B58FE6" name="us-gaap:NotesPayable" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">996.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">4.050% Senior Notes due September 15, 2025</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e4276-wk-Fact-808DF43DA34D56BBB2C719F090E60A74" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,994.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e4295-wk-Fact-4189BCECB63E53E5A043DFA47398CF07" name="us-gaap:NotesPayable" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,740.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e4314-wk-Fact-2DFE8D64C3475F2E95AF00413ADC5E51" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,897.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e4334-wk-Fact-698A9443F35F56DDADA0D9E5F0A5E496" name="us-gaap:NotesPayable" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,739.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2.250% Senior Notes due May 1, 2030</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e4359-wk-Fact-E148A1FD47D7ED3A1ECC5DBD2ACDE8D3" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_A2.25SeniorNotesdueMay12030Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,514.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e4378-wk-Fact-374E21DF77AEE400670E5DBD2E555636" name="us-gaap:NotesPayable" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_A2.25SeniorNotesdueMay12030Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,490.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e4397-wk-Fact-27C6B8AE579A3CF3E61C5DBD323DDC0F" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_A2.25SeniorNotesdueMay12030Member" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e4417-wk-Fact-1AF110488411FAB471375DBD360498CD" name="us-gaap:NotesPayable" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_A2.25SeniorNotesdueMay12030Member" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">5.200% Senior Notes due September 15, 2045</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e4442-wk-Fact-248BAD0A5FE453F580A6503792AC414B" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,247.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e4461-wk-Fact-0B43F9E947835CC884220B7EBB604813" name="us-gaap:NotesPayable" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,723.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e4480-wk-Fact-9E52B1DA168F540FB119847959F5C513" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,107.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e4500-wk-Fact-AC2AF4AACBB35F2085A6A6D0942DC7D6" name="us-gaap:NotesPayable" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,722.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3.150% Senior Notes due May 1, 2050</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e4525-wk-Fact-9B93E16ECCD5D85DAA7F5DBD6455957C" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_A3.15SeniorNotesdueMay12050Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,441.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e4544-wk-Fact-6D38758F3065F55CA9355DBD6868F397" name="us-gaap:NotesPayable" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_A3.15SeniorNotesdueMay12050Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,472.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e4563-wk-Fact-44B35A17AE6B2A0562D55DBD6C044A32" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_A3.15SeniorNotesdueMay12050Member" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e4583-wk-Fact-0E3C2534F0247524064A5DBD6F604CFC" name="us-gaap:NotesPayable" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_A3.15SeniorNotesdueMay12050Member" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e4613-wk-Fact-77E75A6E53065422B10A2A429E152ABF" name="us-gaap:DebtInstrumentFairValue" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8,257.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e4632-wk-Fact-C35F2DCD15EA5A45A149BB09831F209F" name="us-gaap:NotesPayable" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7,423.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e4652-wk-Fact-4619ACE828F95026BEF4E6BF9FE10650" name="us-gaap:DebtInstrumentFairValue" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6,553.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e4671-wk-Fact-351818C4E5465B198910AB5ACA4CD886" name="us-gaap:NotesPayable" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5,954.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:1px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:32%;"></td><td style="width:34%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:1px;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1) </sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">, our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e4723-wk-Fact-AB9F17C6602BF12CDF6F5DD4ABEB3A35" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">2.900</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"> Senior Notes due September 15, 2020, were redeemed in full using the net proceeds from the issuance on April 30, 2020, of our senior unsecured notes for an aggregate principal amount of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>$<ix:nonFraction id="d13663888e4727-wk-Fact-3886DB8A1CA1AB4CFA015873BC68D740" name="us-gaap:DebtInstrumentFaceAmount" contextRef="I2020Q1April30_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="usd" decimals="INF" scale="9" format="ixt:numdotdecimal">3.0</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">. For additional information, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">Note 11, Indebtedness</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"> to these condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. For additional information related to our Senior Notes issued on September 15, 2015, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 12,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K. For additional information related to our Senior Notes issued on April 30, 2020, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 11, Indebtedness</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration Obligations</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisitions of Convergence and BIN, we agreed to make additional payments based upon the achievement of certain milestone events. <ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="TextSelection-CEA900C1716D589483FC71B4C35E43FF-0-wk-Fact-F2EF2F879EEE5DFD91E4B1DF1EFB2317" continuedAt="TextSelection-CEA900C1716D589483FC71B4C35E43FF-1" escape="true">The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:</ix:nonNumeric></span></div><ix:continuation id="TextSelection-CEA900C1716D589483FC71B4C35E43FF-1"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:42%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Fair value, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e4990-wk-Fact-85E036149B6A51AEA583829FB109BC0A" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">341.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e5009-wk-Fact-4371AA25A502533680987AD381BE5164" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">421.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e5029-wk-Fact-286F1A1625CA593B89812AAFB974A889" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">346.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e5048-wk-Fact-3964A49703DE559DBD3667AC9F121D5B" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">409.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Changes in fair value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e5068-wk-Fact-D2590DE582FB57A4B3475521C290EA50" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">10.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13663888e5087-wk-Fact-EA0A92078CAF5114A9DDE6B7E79E0436" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e5107-wk-Fact-1ED69AA194385201B48524E875F0B015" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">5.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13663888e5127-wk-Fact-2D5631ACC4AA55F18A9E8E1BE5DDC18B" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e5153-wk-Fact-1CC5BFBCD41659848F2DF6E37BCC0D9E" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e5172-wk-Fact-2EF5ADA64DE6585E9E917E7A8AB48865" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e5191-wk-Fact-63DE40A01D42512491B51527BF1D9997" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e5211-wk-Fact-C05E1A60089B57FDBA33D2D386BDC984" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Fair value, end of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e5241-wk-Fact-A19C990EAFD35063A5E8C784983CFC41" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">351.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e5260-wk-Fact-609FA712998E5C379FEC4E72D1B73259" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">401.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13663888e5280-wk-Fact-A19C990EAFD35063A5E8C784983CFC41" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">351.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13663888e5299-wk-Fact-609FA712998E5C379FEC4E72D1B73259" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">401.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13663888e5327-wk-Fact-4F86DD0D53E855908FBC53B20136CCA2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">202.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13663888e5331-wk-Fact-B3F2A9BDB0D9546EA92DBA1CE6C5F4E5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">197.7</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our condensed consolidated balance sheets with the remaining balance reflected as a component of accrued expenses and other.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, changes in the fair value of our contingent consideration obligations were primarily due to changes in the interest rates used to revalue our contingent consideration liabilities, changes in the probability and the expected timing of the achievement of certain remaining developmental milestones and the passage of time.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, changes in the fair value of our contingent consideration obligations were primarily due to changes in the probability and the expected timing of the achievement of certain remaining development milestones, partially offset by a decrease in interest rates used to revalue our contingent consideration liabilities and the passage of time.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23</span></div></div><hr style="page-break-after:always"></hr><div><a id="sE5DF13582ECD576489627BBC222E7EAE"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:18px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">8</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Financial Instruments</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"> </span></div></td></tr></table><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="TextSelection-ED477C549F0B5CE48C36AC196521EB31-0-wk-Fact-DCC7236EA564508A8A60218BE7A15509" continuedAt="TextSelection-ED477C549F0B5CE48C36AC196521EB31-1" escape="true"><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="TextSelection-A845CDDE5AD25A1EA035137098ACC8AD-0-wk-Fact-62E9757124655A50B09A9DF3EE393946" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:70%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>June 30,<br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13667934e883-wk-Fact-A4887989DB22592B8DA6647CD3146177" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2020Q2_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">139.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13667934e902-wk-Fact-15B3ED467D4751048899D7A61C9BB48D" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">384.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Overnight reverse repurchase agreements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13667934e922-wk-Fact-EADF1827BA2D525181DEEB6E79CA54CB" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2020Q2_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">247.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13667934e941-wk-Fact-31392073853D5FE998558E781E1CB262" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">368.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13667934e966-wk-Fact-02AAEA4D79685EDD8B8956960B2B5C64" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2020Q2_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,363.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13667934e985-wk-Fact-7BE4290D63FC58ACB3B02276447535EC" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,628.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Short-term debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13667934e1010-wk-Fact-038A95F16A1F5D8C85BCF78FB8BD34A8" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2020Q2_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">118.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13667934e1029-wk-Fact-FFD415E87C835D44BD98160B74C3F63A" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">159.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13667934e1059-wk-Fact-6B5BA6205AD45D43B683A2806454C88F" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,869.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13667934e1078-wk-Fact-E5DE680527745FC0A1ACE48AEBADC7AB" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,541.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and short-term debt securities approximate fair value due to their short-term maturities. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketable equity securities gains (losses) are recorded in other income (expense), net in our condensed consolidated statements of income. <ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:AvailableForSaleSecuritiesTextBlock" id="TextSelection-AC72975927385956A20AF7ABC432DC8F-0-wk-Fact-57A5D27647FC594CBEE6ACA7910FD5D1" continuedAt="TextSelection-AC72975927385956A20AF7ABC432DC8F-1" escape="true">The following tables summarize our marketable debt and equity securities:</ix:nonNumeric></span></div><ix:continuation id="TextSelection-AC72975927385956A20AF7ABC432DC8F-1"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of June 30, 2020 (In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized<br/>Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Corporate debt securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13667934e1340-wk-Fact-E42D4E6B1ADF56FBAA9D919BF234F0D4" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,282.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13667934e1359-wk-Fact-3F386F8A2C9E5DF98DF8631F897F14E0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13667934e1379-wk-Fact-682A7376BFBC53CC8348BB38CB2DF8F9" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13667934e1399-wk-Fact-52B86D2604F456BCA61A207789C17D68" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,283.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13667934e1419-wk-Fact-F7413C04E9285534BC51B79E3D506A17" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">502.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13667934e1438-wk-Fact-788C98677F795CE29DA3D7CD8A59C7DC" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13667934e1457-wk-Fact-39951E7E27125D16AFE889A00B07135A" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13667934e1478-wk-Fact-014298B959D758D69479E24A893A6695" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">506.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Government securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13667934e1590-wk-Fact-53D0EBA15FE35EB5BD704559843C967B" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">657.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13667934e1609-wk-Fact-5F04150F2D6555A4954BAAA7FFF1DCC9" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13667934e1628-wk-Fact-A65886E4002050F6B73B88C489FA3902" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13667934e1648-wk-Fact-708FCD0C93E15025B01756475BD99E3C" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">658.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13667934e1673-wk-Fact-B2FFE7A2A2785F2D8CFAC04131FB59D5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">307.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13667934e1692-wk-Fact-D27E0E5C78835B2FBF61AACFE7AF1C59" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13667934e1711-wk-Fact-4CEC26B6FBED5369B5EB04EF1495FED9" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13667934e1732-wk-Fact-4BBD9695FDEE5E82ADE400F5428061AD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">308.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Mortgage and other asset backed securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13667934e1844-wk-Fact-1C1EB5B0BD7F5483960A0F94B6C1CF70" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13667934e1863-wk-Fact-99BE94C0859F5E1AB6C07774414BC176" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13667934e1882-wk-Fact-63F96E8223525BAB9E39BBEF359664E5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13667934e1902-wk-Fact-A2FB4AEBCF1E5536A5A276D8E974808E" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13667934e1927-wk-Fact-4B00716D24F855C7995A1743B3B83B0B" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">107.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13667934e1946-wk-Fact-CCBA8537CC8256F189E38A400D14984D" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13667934e1965-wk-Fact-1E51B54FEB275284A90347DA596C6D53" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13667934e1986-wk-Fact-EFE87958595C5894BF6662832A2CDC07" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">107.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total marketable debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13667934e2016-wk-Fact-489746C7BF7C5BF2BF1AE9DB0B15E040" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,859.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13667934e2035-wk-Fact-931F8D36F0EE5210ABA1F84FEBD92195" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13667934e2055-wk-Fact-E22C14C2EE115E0E8CD4DE28B47CD700" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13667934e2075-wk-Fact-E5F70307BF6E5CFDB4F094B7B27B4EC1" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,865.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Marketable equity securities, non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13667934e2101-wk-Fact-5179C25D44E05D778BBDD2917F9B5E75" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">428.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13667934e2120-wk-Fact-25F9FB07B4665B4EBAA930A7ABD5E010" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">114.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13667934e2140-wk-Fact-CE2FE1FDB728588F85A609FD993D2810" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13667934e2160-wk-Fact-A54083F9A0775E33B371BFEFA83808D9" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">527.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2019 (In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Corporate debt securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13667934e2402-wk-Fact-7EF0A7D1AFE153158B9D83F169785EDD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,057.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13667934e2421-wk-Fact-40FF30CE2BFC5117B7DC2CE927907357" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13667934e2441-wk-Fact-909CA2503D4A517F9F58ABA553EB089B" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13667934e2460-wk-Fact-59EF3E4857DD5B2B9456FAA158E30E80" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,058.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13667934e2480-wk-Fact-E9636A4973F3530DB17C83B7E2A137A5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">633.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13667934e2499-wk-Fact-197476FE8C7C5FE086CFE3EF072E1280" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13667934e2518-wk-Fact-38E43DCD4A1A53459CCF263CE2764D89" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13667934e2538-wk-Fact-811C177311195B6BB6515EDE405544B2" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">636.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Government securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13667934e2650-wk-Fact-A3A647F014AF52FEAB4441EB978E462D" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">502.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13667934e2669-wk-Fact-8F742281F7BA583F9CD4BAE55046FD12" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13667934e2688-wk-Fact-1224358A232C52AEB53CD86B3234DC1E" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13667934e2708-wk-Fact-ECF3433F2F715FB784CC153CCF04C853" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">503.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13667934e2733-wk-Fact-575FE3D590985E75AFD3B5D2D52FAF2F" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">510.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13667934e2752-wk-Fact-C7584E20D8335EAD883A3F5EFFC7A64C" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13667934e2771-wk-Fact-B2AA1052CBC7590EA1F472141583E447" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13667934e2792-wk-Fact-DD192DE9BF435142955D2DEA1DE301C8" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">510.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Mortgage and other asset backed securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13667934e2904-wk-Fact-164B390A7D7750A5BC44A8393C30F215" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13667934e2923-wk-Fact-E8F687A1C2185A349E7EAD92A716F83C" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13667934e2942-wk-Fact-77686B47DE015725A0FA075E4B266272" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13667934e2962-wk-Fact-2625FB10B0D954AEBEC29B23AB3FD936" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13667934e2987-wk-Fact-11CC7A7B9E715564B1D5537B91B0128A" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">260.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13667934e3006-wk-Fact-B06B242467015EC1A26217C7249B5ED6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13667934e3025-wk-Fact-79E85FC32427517E9686446D3F433546" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13667934e3046-wk-Fact-38C2B2D0B33A5F38A227DE5AC54A620C" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">260.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total marketable debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13667934e3076-wk-Fact-FDC632492EB459DE960D1A700DC94738" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,965.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13667934e3095-wk-Fact-2252F3E19A5C5189898F1D282AF38228" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13667934e3115-wk-Fact-46ECB65BFDA154C19964C5CCC922FBED" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13667934e3135-wk-Fact-1D563550F864522694E8B4EE58DCD71D" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,970.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Marketable equity securities, non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13667934e3161-wk-Fact-43E3618CB8F55463B9CB5E79C0270DAC" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">218.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13667934e3180-wk-Fact-4009A687B35F56299E6DBB942CC08B5B" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">132.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13667934e3200-wk-Fact-E9223FC2E5FE506B85E89EF2039D33B7" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13667934e3220-wk-Fact-1569ED8E71BA5D5085D5F97B47E8514F" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">337.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:nonNumeric><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-ED477C549F0B5CE48C36AC196521EB31-1" continuedAt="TextSelection-ED477C549F0B5CE48C36AC196521EB31-2"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Contractual Maturities: Available-for-Sale Debt Securities</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="TextSelection-959C738AF19E5D3DB028F7DD97FD2023-0-wk-Fact-D6E5AD7C233A5BBA8C9AF2873E93904C" escape="true"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of June 30, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized<br/>Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized<br/>Cost</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Due in one year or less</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13667934e3481-wk-Fact-7DA91672D72559E1A10D4A0FEA80C1C1" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,942.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13667934e3500-wk-Fact-7E2DA530DD125EBC8E6FFF06DF3E339E" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,940.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13667934e3520-wk-Fact-D8405E3B616F5B029512DC9C7AD0C302" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,562.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13667934e3539-wk-Fact-E083DB5FE52256758F8CB96B13075EB5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,560.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Due after one year through five years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13667934e3559-wk-Fact-5239B65FCD18527596661F4FB402C687" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">862.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13667934e3578-wk-Fact-30AD363E17925B7F9F7E315DF2872650" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">858.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13667934e3597-wk-Fact-D29A0072A5185CA69F6BD429FBD154D7" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,234.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13667934e3617-wk-Fact-3F2E302EF380571FBDC4E6D627856AE3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,230.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Due after five years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13667934e3642-wk-Fact-39B79FBFAC595D5F9D5BCE76A33E9F8F" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">60.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13667934e3661-wk-Fact-69E4C9D6F6EB58A2BEDD592293B08076" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">59.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13667934e3680-wk-Fact-C609E077BA4758B3AE79590506259F37" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">173.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13667934e3700-wk-Fact-8C4A1108D35F546C80215D8B3CB44D14" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">173.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total marketable debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13667934e3730-wk-Fact-9E90798C4BF95FD7B1EB03256BAA20DD" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,865.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13667934e3749-wk-Fact-489746C7BF7C5BF2BF1AE9DB0B15E040" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,859.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13667934e3769-wk-Fact-9A51B71F22855F2CB87824B5936329CF" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,970.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13667934e3788-wk-Fact-FDC632492EB459DE960D1A700DC94738" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,965.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The average maturity of our marketable debt securities available-for-sale as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proceeds from Marketable Debt Securities</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:RealizedGainLossOnInvestmentsTableTextBlock" id="TextSelection-5063E2B7156D5A0DA4887CEEDD608AC1-0-wk-Fact-92471B2904D55C37A5468E81D83A97E4" escape="true"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:42%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Proceeds from maturities and sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13667934e4052-wk-Fact-8FC35F12C7F45A039F6BA8DBF730E0C1" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,490.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13667934e4071-wk-Fact-BC3CE604F1BC51FD9997AA298645CA25" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,766.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13667934e4091-wk-Fact-22ABA6B6B6A35F598D8DBDA21EAD50E0" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,879.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13667934e4110-wk-Fact-1CCB591668FB51EFA12E7B8EDE0510D7" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3,255.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Realized gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13667934e4130-wk-Fact-71571774D3CC54F3AC236DD3B4962540" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13667934e4149-wk-Fact-68F9BBB8EDF255CC81687117AC2CF2F8" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13667934e4168-wk-Fact-F6A9228CDECD54088EE4D954E88BF77E" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13667934e4188-wk-Fact-600D43CA2C025BC495B776F1C54E8354" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Realized losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13667934e4213-wk-Fact-A90BB57CB56454768845FF822B34886C" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13667934e4233-wk-Fact-341223BBA153527CBB98FE16E248FC08" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13667934e4253-wk-Fact-86FCAC2762F9515EA7A5938DAC205464" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13667934e4274-wk-Fact-92C31C2A877B526EBD2C256571CEC127" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Strategic Investments</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our strategic investment portfolio was comprised of investments totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13667934e4311-wk-Fact-AA8F3B18C9FC5927B9BA45DBA17FBC37" name="biib:StrategicInvestmentPortfolio" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">583.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13667934e4315-wk-Fact-D9A2DFE8AFC95C24B4AAD38FDBAE4BF2" name="biib:StrategicInvestmentPortfolio" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">393.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, which are included in investments and other assets in our condensed consolidated balance sheets. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 7, Fair Value Measurements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in our strategic investment portfolio for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was primarily due to our purchase of Sangamo common stock, as discussed below, and an increase in the fair value of our remaining investment in Ionis common stock.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our June 2018 investment in Ionis common stock, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 18,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:17px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Sangamo Therapeutics, Inc.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we entered into a collaboration and license agreement with Sangamo to develop and commercialize ST-501 for tauopathies, including AD; ST-502 for synucleinopathies, including Parkinson&#8217;s disease; a third neuromuscular disease target; and up to nine additional neurological disease targets to be identified and selected within a five-year period. The companies will leverage Sangamo&#8217;s proprietary zinc finger protein technology delivered via AAV to modulate the expression of key genes involved in neurological diseases.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the closing of this transaction in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">April 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we purchased approximately&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d13667934e4375-wk-Fact-9E9F33E523088043ABA35DD96250DFAD" name="biib:Investmentincommonstocksharespurchased" contextRef="I2020Q1April30_dei_LegalEntityAxis_biib_SangamoCommonStockMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">24</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;shares of Sangamo common stock.&#160;This equity method investment will be remeasured each reporting period and carried at fair value due to our election of the fair value option. The effects of certain holding period restrictions on the investment are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk free-interest rate to match the remaining term of the restrictions on our investment in Sangamo&#8217;s common stock and a dividend yield of zero based upon the fact that Sangamo and similar companies generally have not historically granted cash dividends.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-ED477C549F0B5CE48C36AC196521EB31-2"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration agreement with Sangamo, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 17, Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;to these condensed consolidated financial statements.</span></div></ix:continuation><div><a id="sAAA72FBC26815C14987A41E5FBE7BBCF"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:18px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">9</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Derivative Instruments</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"> </span></div></td></tr></table><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="TextSelection-1CF2C5E7CA8758C0BB1AC89D0B97AC81-0-wk-Fact-E1B265DC0F9E5A959256DE8D8C258C29" continuedAt="TextSelection-1CF2C5E7CA8758C0BB1AC89D0B97AC81-1" escape="true"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Hedging Instruments</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due to the global nature of our operations, portions of our revenues and operating expenses are recorded in currencies other than the U.S.&#160;dollar. The value of revenues and operating expenses measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes, we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues and operating expenses.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign currency forward contracts in effect as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, had durations of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months, respectively. These contracts have been designated as cash flow hedges and unrealized gains or losses on the portion of these foreign currency forward contracts that are included in the effectiveness test are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses of such contracts are recognized in revenues when the sale of product in the currency being hedged is recognized and in operating expenses when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from accumulated other comprehensive income and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that has been impacted by the hedged item.</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" id="TextSelection-1EF122B3A676563A9F65EF4772265EA8-0-wk-Fact-31990A2A65895AAEB1A72F1B0ECA9813" escape="true"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:70%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Notional Amount</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>June 30,<br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Euro</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13672625e965-wk-Fact-E79B53C33305522AB94BCAF720489D1A" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2020Q2_srt_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,477.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13672625e984-wk-Fact-41690C3B230B517299A814BF1D311471" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2019Q4_srt_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,892.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">British pound</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13672625e1004-wk-Fact-8EEC2B35785A5042AC52DBA9D0F1E596" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2020Q2_srt_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">125.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13672625e1023-wk-Fact-C9C20FD4C46F53798E87696046D8B6F6" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2019Q4_srt_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Swiss franc</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13672625e1048-wk-Fact-47CDF57957425818920D9643FDB0A89A" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2020Q2_srt_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">69.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13672625e1067-wk-Fact-3DE40B2FBE835DE3B9A4021FF6F78FDD" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2019Q4_srt_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Japanese yen</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13672625e1092-wk-Fact-502A9E7CAD3355CFB049AC97D81E405E" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2020Q2_srt_CurrencyAxis_currency_JPY_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">53.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13672625e1111-wk-Fact-7D242D3320F65446BC33CBCEE56CE9E4" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2019Q4_srt_CurrencyAxis_currency_JPY_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Canadian dollar</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13672625e1136-wk-Fact-F76E3681D4635C24BC42C1BE5C267DC3" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2020Q2_srt_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">48.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13672625e1155-wk-Fact-14491AD02A625E5484239749CAE2702B" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2019Q4_srt_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total foreign currency forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13672625e1185-wk-Fact-35234052AFDB5AAEAE1CAF544673AF34" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2020Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,773.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13672625e1204-wk-Fact-EBE23851E52D51AD854DE3BEFC1FCF9D" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,892.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net losses of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13672625e1224-wk-Fact-79B35DE3663D538184F4D3BB138079AD" name="biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">16.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and net gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13672625e1228-wk-Fact-4D7CB6EFE16C5E569E9A41416D0335E6" name="biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. We expect the net losses of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13672625e1240-wk-Fact-79B35DE3663D538184F4D3BB138079AD" name="biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">16.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to be settled over the next </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months, of which </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13672625e1249-wk-Fact-E16E1C84B32E5C4A94AAE5C6DEF64925" name="biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" contextRef="FI2020Q2_biib_DerivativeMaturityAxis_biib_ShorttermderivativeMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">7.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of these losses are expected to be settled over the next </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenues or operating expenses. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, credit risk did not materially change the fair value of our foreign currency forward contracts.</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="TextSelection-1340D95C486E5A7A8A2F618E2D47C281-0-wk-Fact-858BA349FC5D52E2AC064B7ED6ECBF40" continuedAt="TextSelection-1340D95C486E5A7A8A2F618E2D47C281-1" escape="true"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"></td></tr><tr><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:22%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months Ended June 30,</span></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income (in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Operating Income (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13672625e1620-wk-Fact-3767BCFD08C85D13A06680F269984D04" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">23.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13672625e1639-wk-Fact-13526C547A7D5F02998F08D6D786A150" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">29.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13672625e1669-wk-Fact-A30F1AB4506F51638795D6A0185F3C8B" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13672625e1689-wk-Fact-F00F7056A7C2594F97F18D18CC1C1A55" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13672625e1709-wk-Fact-C7605F45AA5254A8B3AC204F44EB832A" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13672625e1728-wk-Fact-561943D4E08E5DD7B8052B3B979D2DD2" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13672625e1759-wk-Fact-8DB80BC09BB1558FA5B0CB53D6CCA238" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13672625e1779-wk-Fact-E04A1EFA510E55A7A94927BC826C9EB4" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:nonNumeric><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-1CF2C5E7CA8758C0BB1AC89D0B97AC81-1" continuedAt="TextSelection-1CF2C5E7CA8758C0BB1AC89D0B97AC81-2"><ix:continuation id="TextSelection-1340D95C486E5A7A8A2F618E2D47C281-1" continuedAt="TextSelection-1340D95C486E5A7A8A2F618E2D47C281-2"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"></td></tr><tr><td style="width:22%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:22%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months Ended June 30,</span></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income (in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Operating Income (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13672625e2138-wk-Fact-2B356EA89B99BD51FEEE5DE4B3293436" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13672625e2157-wk-Fact-C3CFF6D7BC9FF8F82FBE5DE4B7D0D454" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">44.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13672625e2187-wk-Fact-64888DFFAC7A5A4C2E0C5DE5151B44D8" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13672625e2206-wk-Fact-FD0C3BC9E25F5DA63E4C5DE519D59555" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13672625e2226-wk-Fact-9FB5EF5D5270723FE09A5DE4BE011C5C" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13672625e2246-wk-Fact-84A80DDD500645CB84ED5DE4C31EA2E7" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13672625e2277-wk-Fact-59BCA3711DB74BF918EF5DE51DCE1B2E" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13672625e2297-wk-Fact-13851BBB1E9B3300B8885DE524EB0510" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr></table></div></div></ix:continuation><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"><ix:continuation id="TextSelection-1340D95C486E5A7A8A2F618E2D47C281-2"></ix:continuation>Interest Rate Contracts - Hedging Instruments</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have entered into interest rate lock contracts or interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes and to reduce our overall cost of borrowing. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Interest Rate Swap Contracts</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the issuance of our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d13672625e2328-wk-Fact-AB9F17C6602BF12CDF6F5DD4ABEB3A35" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">2.90</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes due September 15, 2020, we entered into interest rate swaps with an aggregate notional amount of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13672625e2332-wk-Fact-9CBCA90A2E5655C08B319903D59FE0E6" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2020Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">675.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which were originally set to expire on September 15, 2020. The interest rate swap contracts were designated as hedges of the fair value changes in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d13672625e2336-wk-Fact-AB9F17C6602BF12CDF6F5DD4ABEB3A35" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">2.90</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes attributable to changes in interest rates. The carrying value of our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d13672625e2340-wk-Fact-AB9F17C6602BF12CDF6F5DD4ABEB3A35" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">2.90</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, included approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13672625e2349-wk-Fact-B3098F00AC015641A2D5CE3378F735CE" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to changes in the fair value of these interest rate swap contracts. In </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">May 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we settled our interest rate swap contracts, in conjunction with our early redemption of our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d13672625e2363-wk-Fact-AB9F17C6602BF12CDF6F5DD4ABEB3A35" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">2.90</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes, resulting in a gain of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13672625e2367-wk-Fact-EE52AF304708393DE47958A222652E72" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and was recorded as a component of interest expense in our condensed consolidated statements of income.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Net Investment Hedges - Hedging Instruments</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d13672625e2390-wk-Fact-37E261D9A6B958FBB0B52EE61E0050D1" name="biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" contextRef="FI2019Q2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d13672625e2394-wk-Fact-68118BDBA14B59BAAE1CE2F32822EC68" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="FI2020Q2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">49.9</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The share purchase transaction was completed in November 2018 and, upon closing, we paid </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d13672625e2398-wk-Fact-CCB7C2B85AC35AB599BDF91D0763D35A" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" contextRef="D2018Q4Nov1-Nov30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="KRW" decimals="-8" scale="9" format="ixt:numdotdecimal">759.5</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13672625e2402-wk-Fact-AA624D37D2305267A7AC120F143579FD" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" contextRef="D2018Q4Nov1-Nov30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">676.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) to Samsung BioLogics. Our investment in the equity of Samsung Bioepis is exposed to the currency fluctuations in the South Korean won. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In order to mitigate the currency fluctuations between the U.S. dollar and South Korean won, we have entered into foreign currency forward contracts. Foreign currency forward contracts in effect as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, had remaining durations of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">four</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months. These contracts have been designated as net investment hedges. We recognize changes in the spot exchange rate in accumulated other comprehensive income (loss). The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13672625e2417-wk-Fact-AC59343788525076AD4FC6245FE5AE0A" name="us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and net losses of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13672625e2421-wk-Fact-991D5352EDEFD51FD8815DE6DDB927DF" name="us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. We exclude fair value changes related to the forward rate from our hedging relationship and will amortize the forward points in other income (expense), net in our condensed consolidated statements of income over the term of the contract. The pre-tax portion of the fair value of the forward points that were included in accumulated other comprehensive income (loss) in total equity reflected gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13672625e2434-wk-Fact-7E2F30D75FDB5E379EE6DBF1AA81FED4" name="us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" contextRef="FI2020Q2_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13672625e2438-wk-Fact-99286567D4A35B2194FE58F51759D581" name="us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" contextRef="FI2019Q4_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="TextSelection-8EFB0D78065B544ABA27E883B374598E-0-wk-Fact-80FA21CE0C215B3CBCDBD563ACACE51E" continuedAt="TextSelection-8EFB0D78065B544ABA27E883B374598E-1" escape="true"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the effect of our net investment hedge in our condensed consolidated financial statements:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="29"></td></tr><tr><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:22%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td></tr><tr><td colspan="29" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months Ended June 30,</span></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Net Income </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Amounts Excluded from Effectiveness Testing) (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13672625e2972-wk-Fact-4AD74C71E8085B0786C90CE7A512BD90" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">8.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13672625e2992-wk-Fact-ADD22A9C85E35D68A83D530480B684E2" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13672625e3022-wk-Fact-F3D06CAF90795DD7925F82ABFD51FBF3" name="biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13672625e3041-wk-Fact-615D2967C17A5266BA8EFC1429C5CB5F" name="biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13672625e3071-wk-Fact-49EAF5EF61055920A924E3B2DECBADB7" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13672625e3090-wk-Fact-5CE553BB11135F0185CAA1D5626366F8" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-1CF2C5E7CA8758C0BB1AC89D0B97AC81-2"><ix:continuation id="TextSelection-8EFB0D78065B544ABA27E883B374598E-1" continuedAt="TextSelection-8EFB0D78065B544ABA27E883B374598E-2"><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="29"></td></tr><tr><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:22%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td></tr><tr><td colspan="29" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months Ended June 30,</span></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Net Income </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Amounts Excluded from Effectiveness Testing) (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13672625e3612-wk-Fact-2826E72DC22A10CE8CBF5DE79B086C16" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13672625e3631-wk-Fact-F353E654ABB2E156277E5DE79DBDA46B" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">23.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13672625e3661-wk-Fact-E1F593402B9A515BA3C05DE7A22CCBB8" name="biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13672625e3680-wk-Fact-CA6FC6EF39FCC4EA0EC45DE7A4E72625" name="biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13672625e3710-wk-Fact-016C8B6C70AC4A6B3B8C5DE7A8061BC5" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13672625e3729-wk-Fact-93CFCDA2EDEAE5CE71055DE7AB709EA2" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div></ix:continuation><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><ix:continuation id="TextSelection-8EFB0D78065B544ABA27E883B374598E-2"></ix:continuation>For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 17, Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Other Derivative Instruments</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The aggregate notional amount of these outstanding foreign currency forward contracts was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13672625e3757-wk-Fact-D46B11A0E7275AAFA7F9A40D6BC8E36A" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2020Q2_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">999.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13672625e3761-wk-Fact-7718B1EAE10E5BE79A6F2F3A36686D2E" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2019Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">793.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Net gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13672625e3773-wk-Fact-35F5689C9E115EC0A3C8E6A489812EB4" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13672625e3778-wk-Fact-3C2F2372D3836A323EBA5DED3886E08D" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to these contracts were recorded as a component of other income (expense), net for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, compared to net gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13672625e3794-wk-Fact-4B1D880A2260586FAE3DC85E5A2969A9" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and net losses of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13672625e3798-wk-Fact-7EBAA2F59C99293608115DED77600F27" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">3.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Derivative Instruments</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset.</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="TextSelection-E72D0DD3FE4250FFB1AE03A931C2D9AF-0-wk-Fact-489DF5D592895C3980440A569FDB0E78" escape="true"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:39%;"></td><td style="width:1%;"></td><td style="width:30%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>June 30,<br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">Cash Flow Hedging Instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Asset derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13672625e3980-wk-Fact-84624AEC73575BA1AE3228FFB0E1B8EA" name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">32.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13672625e3999-wk-Fact-95C18B44AB015C2FB310601AA99607C6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">33.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Investments and other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13672625e4029-wk-Fact-4793A5F6EAD9528F80D840FD970DAE30" name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13672625e4048-wk-Fact-2692F55E3AB45DA6A57AE221C4DE299C" name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Liability derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13672625e4083-wk-Fact-BEBA39AE0D8056778141B67755F09A2B" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13672625e4102-wk-Fact-1CFB60B84D615D00B700E4BECBC75189" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13672625e4137-wk-Fact-54273A6F3EA95F92BEAC819BB07EDD61" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13672625e4156-wk-Fact-EE36E6BF3A3B5C9AB5799672083F48C2" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">Net Investment Hedging Instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Asset derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13672625e4303-wk-Fact-5A3B802DC4A051A1A487DFD5701EF22D" name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13672625e4322-wk-Fact-373E1458EB6550B79D635F3A3C0A1F68" name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">Fair Value Hedging Instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Liability derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13672625e4470-wk-Fact-FDCC2CEAD7E1577F8FB7CAC181C433AE" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13672625e4489-wk-Fact-B3098F00AC015641A2D5CE3378F735CE" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">Other Derivative Instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Asset derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13672625e4636-wk-Fact-FDB60388323457109F599F5057B1E633" name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13672625e4655-wk-Fact-BCB23D0E1FF0558D920D23380DF3494D" name="us-gaap:DerivativeFairValueOfDerivativeAsset" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Liability derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13672625e4690-wk-Fact-38E6893604E157B6B79408554A11D5DF" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13672625e4709-wk-Fact-29272D2A90B850B4B67A04D97C913229" name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28</span></div></div><hr style="page-break-after:always"></hr><div><a id="s5CF18BBCCBC65950B9B37508018ADB5D"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">10</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">.&#160;&#160;&#160;&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Property, Plant and Equipment</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"> </span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="TextSelection-1881D073CD44514CBFA7E4FCA73F40B8-0-wk-Fact-7B540FAF09B959D6BF478245146E000F" escape="true"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13668392e792-wk-Fact-7670470D20CA567F8D01C3A019548B51" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,687.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13668392e796-wk-Fact-45EE64AD6B305C3FB9D619D80BADA52C" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,590.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, depreciation expense totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13668392e827-wk-Fact-450352BC374651319FA896E754DE1059" name="us-gaap:Depreciation" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">51.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13668392e831-wk-Fact-99D00901D5235202BF725DEFEB7E05F6" name="us-gaap:Depreciation" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">99.7</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13668392e835-wk-Fact-A2F0B45383E5569D97491E98F1C8E84D" name="us-gaap:Depreciation" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">47.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13668392e839-wk-Fact-CBD77CAF33035CB7CF165DF01EFF0A6E" name="us-gaap:Depreciation" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">99.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Solothurn, Switzerland Manufacturing Facility</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In order to support our drug development pipeline, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be partially operational by the end of 2020. Upon completion, this facility will include 393,000 square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and 51,000 square feet of administrative space. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13668392e858-wk-Fact-9E8F08C69A4E5DFFA0EF337BBDAE5A3D" name="us-gaap:ConstructionInProgressGross" contextRef="FI2020Q2_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.7</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13668392e862-wk-Fact-2B99CF5F8F0D5C37A7758CB12C4B1627" name="us-gaap:ConstructionInProgressGross" contextRef="FI2019Q4_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.9</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, capitalized as construction in progress related to this facility. For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we placed approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13668392e875-wk-Fact-AEFF4E8456B853E0B90DBAC33AC86C39" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2020Q2_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">256.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of fixed assets in service related to this facility. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had contractual commitments of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13668392e883-wk-Fact-666C54C1EFBE5374BE99D325B077D865" name="us-gaap:OtherCommitment" contextRef="FI2020Q2_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> outstanding related to the construction of this facility.</span></div></ix:nonNumeric><div><a id="s9eb81fead3c8415dad5c9e0e3babb0b4"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">11</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#006ebf;">&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:DebtDisclosureTextBlock" id="TextSelection-FAE2D5E4F7101ABB5AF358720F4BCD96-0-wk-Fact-13792A95824C4F13FBD65872D127FAC3" continuedAt="TextSelection-FAE2D5E4F7101ABB5AF358720F4BCD96-1" escape="true"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Indebtedness</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#006ebf;"> </span></ix:nonNumeric></div><ix:continuation id="TextSelection-FAE2D5E4F7101ABB5AF358720F4BCD96-1"><div style="line-height:120%;padding-top:8px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">2020 Senior Notes </span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">April&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we issued senior unsecured notes for an aggregate principal amount of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13672729e795-wk-Fact-3886DB8A1CA1AB4CFA015873BC68D740" name="us-gaap:DebtInstrumentFaceAmount" contextRef="I2020Q1April30_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="usd" decimals="INF" scale="9" format="ixt:numdotdecimal">3.0</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> (2020 Senior Notes), consisting of the following:</span></div><div style="line-height:120%;padding-left:0px;padding-top:8px;text-indent:30px;"><span style="padding-top:8px;font-family:Franklin Gothic Book,sans-serif;font-size:10pt;padding-right:18px;">&#8226;</span><span style="font-family:Franklin Gothic Book;font-size:10pt;text-transform:default;"><span>$<ix:nonFraction id="d13672729e804-wk-Fact-6C1E93ED5342363F19085876B03B0018" name="us-gaap:DebtInstrumentFaceAmount" contextRef="I2020Q1April30_us-gaap_DebtInstrumentAxis_biib_A2.25SeniorNotesdueMay12030Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="usd" decimals="INF" scale="9" format="ixt:numdotdecimal">1.5</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;text-transform:default;"><span><ix:nonFraction id="d13672729e808-wk-Fact-F434EC30234CEDDFA811587BB95607E7" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="I2020Q1April30_us-gaap_DebtInstrumentAxis_biib_A2.25SeniorNotesdueMay12030Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">2.25</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes due </span><span style="font-family:Franklin Gothic Book;font-size:10pt;text-transform:default;">May&#160;1, 2030</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, valued at </span><span style="font-family:Franklin Gothic Book;font-size:10pt;text-transform:default;"><span><ix:nonFraction id="d13672729e816-wk-Fact-A632471F8B3BD7A05EB05882D29FCD73" name="biib:PercentageParValueOfSeniorNotes" contextRef="I2020Q1April30_us-gaap_DebtInstrumentAxis_biib_A2.25SeniorNotesdueMay12030Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">99.973</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of par; and</span></div><div style="line-height:120%;padding-left:0px;padding-top:8px;text-indent:30px;"><span style="padding-top:8px;font-family:Franklin Gothic Book,sans-serif;font-size:10pt;padding-right:18px;">&#8226;</span><span style="font-family:Franklin Gothic Book;font-size:10pt;text-transform:default;"><span>$<ix:nonFraction id="d13672729e825-wk-Fact-EB257EE1F85C1D8882145876C36D4020" name="us-gaap:DebtInstrumentFaceAmount" contextRef="I2020Q1April30_us-gaap_DebtInstrumentAxis_biib_A3.15SeniorNotesdueMay12050Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="usd" decimals="INF" scale="9" format="ixt:numdotdecimal">1.5</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;text-transform:default;"><span><ix:nonFraction id="d13672729e829-wk-Fact-B3880A9157B0B0E32107587BCA7230AB" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="I2020Q1April30_us-gaap_DebtInstrumentAxis_biib_A3.15SeniorNotesdueMay12050Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">3.15</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes due </span><span style="font-family:Franklin Gothic Book;font-size:10pt;text-transform:default;">May&#160;1, 2050</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, valued at </span><span style="font-family:Franklin Gothic Book;font-size:10pt;text-transform:default;"><span><ix:nonFraction id="d13672729e837-wk-Fact-9661B795479D4DBE09465883051D5DC5" name="biib:PercentageParValueOfSeniorNotes" contextRef="I2020Q1April30_us-gaap_DebtInstrumentAxis_biib_A3.15SeniorNotesdueMay12050Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">99.174</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of par.</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our 2020 Senior Notes are senior unsecured obligations and may be redeemed at our option at any time at </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d13672729e844-wk-Fact-2451513B60065839B0CC589BB4FC6623" name="us-gaap:DebtInstrumentRedemptionPricePercentage" contextRef="FD2020Q2YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the principal amount plus accrued interest and, until a specified period before maturity, a specified make-whole amount. Our 2020 Senior Notes contain a change-of-control provision that, under certain circumstances, may require us to purchase our 2020 Senior Notes at a price equal to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d13672729e848-wk-Fact-869397EDBCB674497B5B589C3531C9B3" name="biib:DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" contextRef="FD2020Q2YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">101</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the principal amount plus accrued and unpaid interest to the date of repurchase.</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We incurred approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13672729e855-wk-Fact-DF9A9F54F7C54EB21E6758999F9D6AE4" name="us-gaap:PaymentsOfFinancingCosts" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of costs associated with this offering which have been recorded as a reduction to the carrying amount of the debt on our condensed consolidated balance sheet. These costs will be amortized as additional interest expense using the effective interest rate method over the period from issuance through maturity. The discounts will be amortized as additional interest expense over the period from issuance through maturity using the effective interest rate method. Interest on our 2020 Senior Notes is payable </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">May 1</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">November 1</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of each year, commencing November 1, 2020. </span></div><div style="line-height:120%;padding-top:8px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">2.90% Senior Notes due September 15, 2020 </span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On September 15, 2015, we issued </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13672729e873-wk-Fact-39C934A246CA4D5C3A9F588885EC0C12" name="us-gaap:DebtInstrumentFaceAmount" contextRef="I2015Q3Sept152015_us-gaap_DebtInstrumentAxis_biib_A2.90SeniorNotesDueSept152020Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="usd" decimals="INF" scale="9" format="ixt:numdotdecimal">1.5</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> aggregate principal amount of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d13672729e877-wk-Fact-1594FE42B75E5BEC18B658886DCC9002" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="I2015Q3Sept152015_us-gaap_DebtInstrumentAxis_biib_A2.90SeniorNotesDueSept152020Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">2.90</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes due September 15, 2020, at </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d13672729e881-wk-Fact-5BA8BD220699D3789C6D5888F69D6335" name="biib:PercentageParValueOfSeniorNotes" contextRef="I2015Q3Sept152015_us-gaap_DebtInstrumentAxis_biib_A2.90SeniorNotesDueSept152020Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">99.792</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of par. Our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d13672729e885-wk-Fact-1594FE42B75E5BEC18B658886DCC9002" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="I2015Q3Sept152015_us-gaap_DebtInstrumentAxis_biib_A2.90SeniorNotesDueSept152020Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">2.90</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes were senior unsecured obligations. We also entered into interest rate swap contracts where we received a fixed rate and paid a variable rate. In May 2020 we used the net proceeds from the sale of our 2020 Senior Notes to redeem our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d13672729e889-wk-Fact-1594FE42B75E5BEC18B658886DCC9002" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="I2015Q3Sept152015_us-gaap_DebtInstrumentAxis_biib_A2.90SeniorNotesDueSept152020Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">2.90</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes prior to their maturity and recognized a net pre-tax charge of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13672729e894-wk-Fact-CA36D5972BDEE72FE7EC58A93FA8DE47" name="biib:PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain" contextRef="FD2020Q2YTD_us-gaap_DebtInstrumentAxis_biib_A2.90SeniorNotesDueSept152020Member_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upon the extinguishment of these notes. This charge, which was recognized in interest expense in other income (expense), net in our condensed consolidated statements of income for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflects the payment of a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13672729e910-wk-Fact-F02DC503537C4FDDACD058A7BEAFDF8E" name="biib:EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts" contextRef="FD2020Q2YTD_us-gaap_DebtInstrumentAxis_biib_A2.90SeniorNotesDueSept152020Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.7</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> early call premium and the write off of remaining unamortized original debt issuance costs and discount balances, partially offset by a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13672729e914-wk-Fact-EE52AF304708393DE47958A222652E72" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> gain related to the settlement of the associated interest rate swap contracts. For additional information on our interest rate swap contracts, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 9, Derivative Instruments</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">29</span></div></div><hr style="page-break-after:always"></hr><div><a id="s30EC37496C1353EEBDA7B3930618F73D"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:18px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">12</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Equity</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"> </span></div></td></tr></table><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="TextSelection-CD491248FF6B5C2D867D3BB2265A9032-0-wk-Fact-51E711DA3E8851F388489AC91AE602A8" continuedAt="TextSelection-CD491248FF6B5C2D867D3BB2265A9032-1" escape="true"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share Repurchases</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> our Board of Directors authorized a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13676089e797-wk-Fact-CF23E4E3A9685AB6B629BC240257914C" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" contextRef="FI2019Q4_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">5.0</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Share Repurchase Program). Our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Share Repurchase Program does not have an expiration date. All shares repurchased under our December 2019 Share Repurchase Program will be retired. Under our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Share Repurchase Program, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d13676089e814-wk-Fact-390A951FE1955FB1A31E81FF978C9087" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2020Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">9.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d13676089e818-wk-Fact-7A124B06819E398E555A5E03FA91B3BA" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">12.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13676089e822-wk-Fact-3B1EAB8C0D58511CBF78864485D99242" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="FD2020Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="9" format="ixt:numdotdecimal">2.8</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13676089e826-wk-Fact-92A4C4D61C1BF2CC2D2A5E0415603F07" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-5" scale="9" format="ixt:numdotdecimal">3.7</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13676089e843-wk-Fact-2DB7A19C318A2D9085055E04F1B4B045" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" contextRef="FI2020Q2_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.3</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> remained available under our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Share Repurchase Program as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 our Board of Directors authorized a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13676089e858-wk-Fact-A8D8625FFC4F5EEBB70EA51DB088EA1B" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" contextRef="FI2019Q2_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">5.0</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock (March 2019 Share Repurchase Program), which was completed as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. All shares repurchased under our March 2019 Share Repurchase Program were retired. Under our March 2019 Share Repurchase Program, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d13676089e866-wk-Fact-C95D21032E095E8DE6D65E054A2E7081" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">4.1</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13676089e870-wk-Fact-BBC02EE20EDE393E40ED5E0577D4C6F5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.3</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accumulated Other Comprehensive Income (Loss)</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="TextSelection-CBC5342090CE54FAA07C7D837655C9D9-0-wk-Fact-7BFA4E55863855648A4597A17FD6D21B" escape="true"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains (Losses) on Net Investment Hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Balance, December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13676089e1087-wk-Fact-1C7F6484D085544A9F5EFB7C6CE9977D" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13676089e1106-wk-Fact-EB3F8539AFE258C9885D79C2166782EF" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13676089e1126-wk-Fact-C4B90E05E2415FAC8164A240DD0A0249" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">25.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13676089e1145-wk-Fact-5A76F385C5C9545CAB5AFA203382C731" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">32.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13676089e1165-wk-Fact-1F0DEF179FCF5EC4ABC1CBFDC4EBDBE4" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">139.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13676089e1186-wk-Fact-234099FE917C5DC385F4BC4F97FA7712" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">135.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13676089e1207-wk-Fact-C992AF05983551B4BBD4B798A67B08F8" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">9.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13676089e1227-wk-Fact-D92825315E8C569686D85D00371444AB" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">33.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13676089e1246-wk-Fact-68548ED4811459E58DD9CC28269F0AA0" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">18.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13676089e1266-wk-Fact-7260F0C1F57458C7A3A07F61C3B2ECAC" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13676089e1285-wk-Fact-0AFA5C0058425F8486883359D9315E41" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">47.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13676089e1306-wk-Fact-4A58EB7BBED4C9DEF993597DCB7C9163" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">3.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13676089e1332-wk-Fact-448B47C9E0FE5076A279C94F0C1C6C10" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13676089e1351-wk-Fact-B9C09693F0615DB28105559DC26DAD73" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">50.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13676089e1371-wk-Fact-5598817093125E3EA145188128D379BA" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13676089e1392-wk-Fact-8365D8DCEA67529992216145497936E4" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13676089e1411-wk-Fact-CBAE1B669B9D5E4A911976017B9E5EA1" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13676089e1431-wk-Fact-98AA12E1F4E3FA935114597DCB902B96" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">42.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Net current period other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13676089e1457-wk-Fact-FCDEE87D1CC8B6D80E49597DCB9D1164" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13676089e1476-wk-Fact-808B8EC0E04ECFD582AF597DCB8048F0" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">17.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13676089e1496-wk-Fact-C8DB37BE8B88B7DB7DDF597DCBA1D2F0" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13676089e1516-wk-Fact-4C02D6B1AD8C37C0D7E6597DCB741F4C" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13676089e1535-wk-Fact-0BFEA12E5E6DEBE11E2C597DCB703334" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">47.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13676089e1556-wk-Fact-41D6455C5A4252129BD8C5FF297E3741" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">45.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Balance, June 30, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13676089e1587-wk-Fact-46191F5FB667FEBF5160597DCB94E324" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13676089e1606-wk-Fact-158091AC18BE8A5D10C4597DCB6BCBEE" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">9.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13676089e1627-wk-Fact-ED36E2C37B7FF2F1C87A597DCB871AE5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">41.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13676089e1646-wk-Fact-9DD578EFD5B8F7DCE6BD597DCB985E05" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">31.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13676089e1666-wk-Fact-258B6D72D3C8027B9D70597DCB8B307A" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">186.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13676089e1687-wk-Fact-FAED6FE93C26545A877123C092DC11AC" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">181.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains (Losses) on Net Investment Hedge</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Balance, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13676089e1877-wk-Fact-1041573FE2A15781906A192892E471F9" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">4.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13676089e1897-wk-Fact-8BD9E5866D9350ACAC3EA0A4A9D9D608" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">34.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13676089e1917-wk-Fact-81AC3A3FBE1D531181A1F4E68B85890C" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13676089e1936-wk-Fact-786F84546A795322B19367D937E68CFE" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">31.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13676089e1956-wk-Fact-B029EA30C01E5E00A9803B41BF6B392F" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">243.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13676089e1977-wk-Fact-AAF053D70C055B0286050E7AA13AE9A7" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">240.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13676089e1998-wk-Fact-D18F3861D7135E0AAF2605FBE7E8314A" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13676089e2017-wk-Fact-25F367A06ED15BB195E41FE14730BDCC" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">22.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13676089e2036-wk-Fact-2B55E7C594585AA4A1ADD7AA4233E527" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">30.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13676089e2056-wk-Fact-0FA78CA32CBC55259C097355931CB5A4" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13676089e2075-wk-Fact-0F56E7949FAA530DA33D2EB227D92900" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">28.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13676089e2096-wk-Fact-050A860F478142803FF8597DE0AA0918" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">36.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13676089e2121-wk-Fact-85CC27470BDC5138838F02286BC760EE" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13676089e2141-wk-Fact-381C985621EB57D58E4437F211B196E0" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">43.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13676089e2161-wk-Fact-6828BC38D7025DFFAB3C82077250795B" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">4.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13676089e2182-wk-Fact-89290E1A9C585B77A343B468B9AF1F2B" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13676089e2201-wk-Fact-65BE63C3F36457279D2933E065B92CF7" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13676089e2221-wk-Fact-29C59C9A341977C9D0D5597DE0BB765A" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">48.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Net current period other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13676089e2247-wk-Fact-F07F9A84714B2655533E597DE0A47986" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13676089e2266-wk-Fact-F7F2711431F1F9CBB93E597DE1419134" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13676089e2286-wk-Fact-E1C0757745C4D3992993597DE11732A9" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">25.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13676089e2306-wk-Fact-E26A696F704B64C8DCE9597DE12B9AC3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13676089e2325-wk-Fact-2D021B78D5A28A0756CB597DE151D9A9" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">28.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13676089e2346-wk-Fact-6F359B4ACF055A4DA4E8C22AC9182DDB" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">12.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Balance, June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13676089e2377-wk-Fact-DD691984067283BA036D597DE0F4766D" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13676089e2396-wk-Fact-6957A694D8D88646D706597DE1673CD5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13676089e2416-wk-Fact-DBE40AC1A4D3EA3C645B597DE0AEAD0D" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">29.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13676089e2435-wk-Fact-174252CB0BA9320B5DCC597DE0B6B7AD" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">30.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13676089e2455-wk-Fact-3A528888578747788A59597DE0B29D66" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">271.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13676089e2476-wk-Fact-BBCF323C5FF952B894C29C4F6E74AF41" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">252.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:nonNumeric><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" id="TextSelection-FFD064FD103C5E279CA43DBAF1AE10C9-0-wk-Fact-8741B41C209F53689FB933FF779B7147" escape="true"><ix:continuation id="TextSelection-CD491248FF6B5C2D867D3BB2265A9032-1"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amounts reclassified from accumulated other comprehensive income:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:33%;"></td><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amounts Reclassified from Accumulated Other Comprehensive Income</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Gains (losses) on securities available for sale</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"><span><ix:nonFraction id="d13676089e2826-wk-Fact-7C98812BD9C55A3680E2B7C16042BEBD" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2020Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13676089e2845-wk-Fact-C3777DA0F08A51D59A7D9CED3F086E89" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13676089e2865-wk-Fact-A036B8B89A065C99BDC8EA95A7667A7B" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2020Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">12.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13676089e2885-wk-Fact-F7FA80F64E4952D3971F0065F0AD8C44" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Income tax benefit (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"><span>(<ix:nonFraction id="d13676089e2910-wk-Fact-FC3592B48C7C5AF3826B00DB3958AF65" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2020Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13676089e2930-wk-Fact-BDD82F2A54975ABA803E435910753E54" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13676089e2951-wk-Fact-F96EBEC3A68F5A1FAB547270FC8B9180" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2020Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13676089e2970-wk-Fact-D8186826F1365E6ABDE9F45EEA4E23C9" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Gains (losses) on cash flow hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"><span><ix:nonFraction id="d13676089e3093-wk-Fact-0D9917016FF15EEE925FC6551CA1F796" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">23.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13676089e3112-wk-Fact-9EB84A7AE5505D85B00F9704E72A3A90" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">29.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13676089e3132-wk-Fact-53D75AB628395BDF905D547FC658B688" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13676089e3151-wk-Fact-10B4FA2B88F85E40923BF367D6DBFA73" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">44.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"><span><ix:nonFraction id="d13676089e3181-wk-Fact-90F5E68154E75D269BB60DDF32CF6EF7" name="us-gaap:OperatingExpenses" contextRef="FD2020Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13676089e3200-wk-Fact-8B96F1DF45295E458832136583101405" name="us-gaap:OperatingExpenses" contextRef="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13676089e3221-wk-Fact-CAF5B802D2395A978D5ED4FFED7435B2" name="us-gaap:OperatingExpenses" contextRef="FD2020Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13676089e3241-wk-Fact-499900F0D06C57429F53493CE85D791C" name="us-gaap:OperatingExpenses" contextRef="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"><span><ix:nonFraction id="d13676089e3272-wk-Fact-BFFC69DF9D9457C1A803555D0E73B584" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2020Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13676089e3291-wk-Fact-ACEA7E804C3D5837A99AA2061B8CFDCB" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13676089e3311-wk-Fact-5318AA7C816D5151B0E5BF2F299A4EF6" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2020Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13676089e3330-wk-Fact-D0F104797E16511797E21A10633E535A" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Income tax benefit (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"><span>(<ix:nonFraction id="d13676089e3360-wk-Fact-EA22EB726DAF52C8A03DB2090AD3D489" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2020Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13676089e3380-wk-Fact-A219BE61A8F0553A9C790FE06336C782" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13676089e3401-wk-Fact-1B3ACC4F15585F6CA57981CEFFB983F9" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2020Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13676089e3421-wk-Fact-9B44200CC55F58A0A610CB5F4D7A61D1" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"><span><ix:nonFraction id="d13676089e3545-wk-Fact-8AA5F7E66EF95B18A3D3729FC95847A0" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2020Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13676089e3564-wk-Fact-ADE4C70C5903504EBB8F4BC1ECEAE3B9" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13676089e3584-wk-Fact-DF4CE364648F500B9B9FC86411B33B8F" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2020Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13676089e3603-wk-Fact-E22EFBD831DE5EB0B70242D19773F266" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total reclassifications, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"><span><ix:nonFraction id="d13676089e3730-wk-Fact-DCA87853E94759E6890524BF606681B5" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">27.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13676089e3749-wk-Fact-9EBCFEF7A8F454238AC4B381BE7BC6D7" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">31.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13676089e3769-wk-Fact-17AC087A2DF555738B92BC2BD4CEF45B" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">42.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13676089e3788-wk-Fact-0C196FC2151D53D18666DE4B6452A52D" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">48.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:nonNumeric><div><a id="s0FDE5AE3825D5753B89F451DCF192F80"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:18px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">13</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Earnings per Share</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"> </span></div></td></tr></table><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:EarningsPerShareTextBlock" id="TextSelection-7804D1E00F3E5AA0AC274D533132565C-0-wk-Fact-5FD3FE4176E159F0B78F1B77DFA0B630" escape="true"><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="TextSelection-A06BD5DCC9955CA69500EDEC21DEA1D2-0-wk-Fact-0FDDE133DEB655BBAA520013E26645EE" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic and diluted earnings per share are calculated as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:42%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">Numerator:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Net income attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13677347e1108-wk-Fact-ADD31A6A5EBE5E7D8A2551FB858970C3" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,542.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13677347e1127-wk-Fact-014416A7DF4E55AD89901C62A077D0C5" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,494.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13677347e1147-wk-Fact-B46E75E522BC521D944CD595197A0DA3" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,941.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13677347e1166-wk-Fact-91FF827803B156BD8E311A0B778D9521" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,902.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">Denominator:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Weighted average number of common shares outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13677347e1273-wk-Fact-99FE479F6EFA52F59E2D3DD5A91BFF8C" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2020Q2QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">160.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13677347e1292-wk-Fact-0F8F00DB70B25725BDF588003BE32027" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q2QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">190.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13677347e1311-wk-Fact-A7BA3E1F65C655ACB63EFBEDF4E5AE60" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2020Q2YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">166.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13677347e1331-wk-Fact-22C74589209D549881B0B30906FF83A7" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q2YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">193.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Effect of dilutive securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Time-vested restricted stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13677347e1443-wk-Fact-EE82D1472EEE5086858B770F2D5CBB67" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2020Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13677347e1462-wk-Fact-32875F48EDE1584C8B7174F6BB2B912E" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13677347e1481-wk-Fact-78259022B47A56FF92F25CF2C6770B6F" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2020Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13677347e1501-wk-Fact-ACD45666C6C3533B9D213900413EBB9A" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Market stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13677347e1526-wk-Fact-294FBB18C1405844B7D5BF66DCAD0B7E" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2020Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13677347e1545-wk-Fact-4EEA905124E356958373DBE14037822C" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13677347e1564-wk-Fact-6C0EECD7A6FA5E67ADEAC4A2741365A9" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2020Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13677347e1584-wk-Fact-697BE0A70EEB5BBEBC574F511B547C79" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Performance stock units settled in stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13677347e1609-wk-Fact-79065ED115955ED897549FE4F81D8C42" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2020Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13677347e1628-wk-Fact-B2FAE05A4326537198DB746D8B3E4973" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13677347e1647-wk-Fact-B2BE8F3296765860BBE6B83DF15F1849" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2020Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13677347e1667-wk-Fact-FA3D4412C1BC5CBC89AC58C3D0F2BFC0" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Dilutive potential common shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13677347e1692-wk-Fact-8EED78D1E5385EF9AFDDD4CFC93C1982" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="FD2020Q2QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13677347e1711-wk-Fact-039C3ECB0BBA58DF96A44ABD1F14F475" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="FD2019Q2QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13677347e1730-wk-Fact-3E942606560D5FD29F1A901AF4C32ACE" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="FD2020Q2YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13677347e1750-wk-Fact-DCE7B5C2C4365729BD614883A3282DAB" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="FD2019Q2YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Shares used in calculating diluted earnings per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13677347e1776-wk-Fact-AC9CFA06C14752C2822D10FC87E8F4FE" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2020Q2QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">160.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13677347e1795-wk-Fact-AD06855122DD55CAA38318A14B520635" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q2QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">190.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13677347e1814-wk-Fact-8008A00FC876554890ED4AD4AC163885" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2020Q2YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">167.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13677347e1834-wk-Fact-85F20EFF251E5B3C9894F550494B41BA" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q2YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">193.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.</span></div></ix:nonNumeric><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31</span></div></div><hr style="page-break-after:always"></hr><div><a id="s425DF2D5AEF255189222D987157CA18B"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:18px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">14</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Share-based Payments</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"> </span></div></td></tr></table><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="TextSelection-172B5C53A54C559DB9E6FAE51D3E04E9-0-wk-Fact-EB93B31FF80259B889D848B8922E6F64" escape="true"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share-based Compensation Expense</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="TextSelection-DAF16CD844825DDB9C5F5806BF1D6DD5-0-wk-Fact-8E4D21CB0E2F5147880BC5CD333A728D" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Research and development </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13679699e1024-wk-Fact-6F0EE9D9CC055AE6B40BBE0098CC11E2" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13679699e1043-wk-Fact-C1C0514934005EFABD6C8C3D0E20CC0D" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">28.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13679699e1063-wk-Fact-CD4D37A660DF511FAEB66794ECD5173A" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">48.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13679699e1082-wk-Fact-ECEE7AB4F7E050F096F7F4D763DE4F9F" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">49.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Selling, general and administrative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13679699e1102-wk-Fact-3301A243A337595A9DB194D7950ECE75" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">30.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13679699e1121-wk-Fact-2B1FCDA23A37514DABA1489825AE872D" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">54.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13679699e1140-wk-Fact-64B7FA0BE7D2559194E777FF49F5A500" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">73.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13679699e1160-wk-Fact-4C9121A9138754FC937EF4B84C51B8C9" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">82.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Subtotal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13679699e1185-wk-Fact-8EA981E4D98A5A099ACA6B24DC1286A5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">45.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13679699e1204-wk-Fact-592AF4FF64B35A8EA4C153DB3223137B" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">82.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13679699e1223-wk-Fact-67DA7FAD963E5D1D87A5D89B29C0F5B9" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">121.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13679699e1243-wk-Fact-5F62E4814ABF5A718CC5F44D3C530D4A" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">132.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Capitalized share-based compensation costs </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13679699e1268-wk-Fact-3D7317494E4A5633B55AD6AB4F63D387" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13679699e1288-wk-Fact-44C5303F9BC55A3F96F5DC0EB810FD82" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13679699e1308-wk-Fact-EE13EA9512525311AC0D9E39B22F62D3" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13679699e1329-wk-Fact-472F6A1BAC9559D2AEC69ABA07E98C09" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Share-based compensation expense included in total cost and expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13679699e1355-wk-Fact-AD224E7CB4805A5FBC9500475B9AAFC0" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">44.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13679699e1374-wk-Fact-4A41B0FD52F95ABF92BBC48DDDFD9CB0" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">80.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13679699e1393-wk-Fact-7FE99B8B62FA52D49EDD3A5E6484D786" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">118.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13679699e1413-wk-Fact-FFCBA5223E3E519C81540A974D332931" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">126.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Income tax effect</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13679699e1438-wk-Fact-4FF875876C1D51EEB39DC55F57FACA47" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13679699e1458-wk-Fact-105DFF199D795062815E40395EEAAAE0" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13679699e1478-wk-Fact-1F14E7E6231554EFAC6FC00CA7C91AFD" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13679699e1499-wk-Fact-B8A211784AB255B29DE39523CFB3ED99" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Share-based compensation expense included in net income attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13679699e1530-wk-Fact-49A48BABBFA950E6B7E23888FF5918A2" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">37.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13679699e1549-wk-Fact-FD7ADE6AF913518298810363D85AD384" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">66.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13679699e1569-wk-Fact-BDEB358E43DF555BB2D7F05993D0BC1A" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">98.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13679699e1588-wk-Fact-3AC3B690105754F2AEC2AA582783EEB9" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">105.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="TextSelection-6483417850755B359E8D98C62FE62932-0-wk-Fact-7B79C7B3B3BA53FFBADDB0E790AF6DB8" escape="true"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Market stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13679699e1833-wk-Fact-A0BF9F0519B35DF3BB36BF4C267C5BB6" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q2QTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13679699e1852-wk-Fact-CC1A4774D5A85E7EA463EF154E51EBB4" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13679699e1872-wk-Fact-690824FCCBBF5E5CB7382AC36D943B5D" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q2YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">26.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13679699e1891-wk-Fact-4A98695537525365AEE844A787424297" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Time-vested restricted stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13679699e1911-wk-Fact-EC70A411CD7253E5A323D25C919302CB" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q2QTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">34.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13679699e1930-wk-Fact-40833D7E05615B98AE18285E3FD4EA80" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">31.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13679699e1949-wk-Fact-B49AB36CE73C57338E2408D24B2B66DA" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q2YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">72.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13679699e1969-wk-Fact-333A17E571065DBEBEECCA61DCE799CE" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">66.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Cash settled performance units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13679699e1994-wk-Fact-1135BFF18CF756A2A1855A79C00FB356" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q2QTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13679699e2014-wk-Fact-89E00B5AAB1B51FC92BFAE7DF55BEF23" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13679699e2033-wk-Fact-E6C917D2B4BE5EB88D33987048EF4C7C" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q2YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13679699e2054-wk-Fact-4B79B1F4651F5B20BD6F062237A47D84" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Performance units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13679699e2080-wk-Fact-0579BB5F4FEC5EB2BBCAAB0584608067" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q2QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13679699e2099-wk-Fact-362AF416DB1E519EB26928C518469988" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13679699e2118-wk-Fact-6E51247FE5A55F89B409DF3A666E7193" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q2YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13679699e2139-wk-Fact-8119EB47A1C4593EB7BA2CA76F1EF947" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Performance stock units settled in stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13679699e2164-wk-Fact-BF1E1722FF74563BBC33076F134384DB" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q2QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13679699e2183-wk-Fact-0BFC53768E3E5F2EB5F07CB3BFC08899" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13679699e2202-wk-Fact-782CBEBF0FC75D92A0FDBB8FE8932118" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q2YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13679699e2222-wk-Fact-590E627D7B125D57961C04F49B6F122B" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Performance stock units settled in cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13679699e2247-wk-Fact-586343B3C8C45292AFE900B155BC88DD" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q2QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">4.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13679699e2267-wk-Fact-028C840C1DD455A090BAEC0D538F38BC" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13679699e2286-wk-Fact-8949766D093158D18144FA44A011D330" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q2YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13679699e2306-wk-Fact-985D5CB42AB15DBCAA602A89B1A9627E" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Employee stock purchase plan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13679699e2331-wk-Fact-719D9102E96C59299B20C120962B486F" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q2QTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13679699e2350-wk-Fact-91F5F3544C1A56BF9F3EE1107E183224" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13679699e2369-wk-Fact-9878FD3EE134508089895B00D7CA8DE2" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q2YTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13679699e2389-wk-Fact-4745882D05985364B64C16EAA6CB5094" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">NST stock options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13679699e2414-wk-Fact-496FBECDDB8953098A1DCC88C4EA04F0" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" contextRef="FD2020Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13679699e2433-wk-Fact-7002510126925A2FA31C60CCC5FADD9C" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">26.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13679699e2452-wk-Fact-03518CED06F25ABDB8ACBE30AA610FC1" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" contextRef="FD2020Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13679699e2472-wk-Fact-814CE5E44C66528D8A499D9C4FED73A7" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">26.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Subtotal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13679699e2497-wk-Fact-8EA981E4D98A5A099ACA6B24DC1286A5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">45.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13679699e2516-wk-Fact-592AF4FF64B35A8EA4C153DB3223137B" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">82.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13679699e2535-wk-Fact-67DA7FAD963E5D1D87A5D89B29C0F5B9" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">121.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13679699e2555-wk-Fact-5F62E4814ABF5A718CC5F44D3C530D4A" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">132.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Capitalized share-based compensation costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13679699e2581-wk-Fact-3D7317494E4A5633B55AD6AB4F63D387" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13679699e2601-wk-Fact-44C5303F9BC55A3F96F5DC0EB810FD82" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13679699e2621-wk-Fact-EE13EA9512525311AC0D9E39B22F62D3" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13679699e2642-wk-Fact-472F6A1BAC9559D2AEC69ABA07E98C09" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Share-based compensation expense included in total cost and expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13679699e2673-wk-Fact-AD224E7CB4805A5FBC9500475B9AAFC0" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">44.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13679699e2692-wk-Fact-4A41B0FD52F95ABF92BBC48DDDFD9CB0" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">80.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13679699e2712-wk-Fact-7FE99B8B62FA52D49EDD3A5E6484D786" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">118.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13679699e2731-wk-Fact-FFCBA5223E3E519C81540A974D332931" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">126.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We estimate the fair value of our obligations associated with our performance units, cash settled performance units and performance stock units settled in cash at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recognized each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.</span></div></ix:nonNumeric><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32</span></div></div><hr style="page-break-after:always"></hr><div><a id="sF0F30F300BC6522298DFBCA407E1DDF7"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:18px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">15</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Income Taxes</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"> </span></div></td></tr></table><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:IncomeTaxDisclosureTextBlock" id="TextSelection-2250ACC617E95B4493181C83C8E519F9-0-wk-Fact-9B37EC344EB054D8878CA1A51F55697A" continuedAt="TextSelection-2250ACC617E95B4493181C83C8E519F9-1" escape="true"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Coronavirus Aid, Relief and Economic Security Act</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In response to the COVID-19 pandemic, the Coronavirus Aid, Relief and Economic Security Act (CARES Act) was signed into law in the U.S. in March 2020. The CARES Act lifts certain deduction limitations originally imposed by the Tax Cuts and Jobs Act of 2017 (2017 Tax Act). Corporate taxpayers may carryback net operating losses (NOLs) originating during 2018 through 2020 for up to five years, which was not previously allowed under the 2017 Tax Act. The CARES Act also eliminates the 80% of taxable income limitations by allowing corporate entities to fully utilize NOL carryforwards to offset taxable income in 2018, 2019 or 2020. Taxpayers may generally deduct interest up to the sum of 50% of adjusted taxable income plus business interest income (30% limit under the 2017 Tax Act) for tax years beginning January 1, 2019 and 2020. The CARES Act allows taxpayers with alternative minimum tax credits to claim a refund in 2020 for the entire amount of the credits instead of recovering the credits through refunds over a period of years, as originally enacted by the 2017 Tax Act.</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, the CARES Act raises the corporate charitable deduction limit to 25% of taxable income and makes qualified improvement property generally eligible for 15-year cost-recovery and 100% bonus depreciation. The enactment of the CARES Act did not result in any material adjustments to our income tax provision for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, or to our net deferred tax assets as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">TECFIDERA</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On June 22, 2020, the U.S. District Court for the Northern District of West Virginia (the West Virginia Court)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">entered judgment for Mylan Pharmaceuticals, Inc. (Mylan) that the asserted claims of our U.S. Patent No. 8,399,514</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(the '514 Patent) are invalid for lack of written description. The '514 Patent covers treatment of MS with 480 mg of</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">dimethyl fumarate per day as provided for in our TECFIDERA label, and the litigation was filed pursuant to the Drug</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act. We appealed the</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">judgment on June 23, 2020, to the U.S. Court of Appeals for the Federal Circuit (Federal Circuit) and filed an</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">emergency motion for an injunction pending resolution of the appeal. On June 30, 2020, the Federal Circuit entered</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">an interim injunction enjoining Mylan from launching its generic version of TECFIDERA pending the Federal Circuit's</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">consideration of our request for an injunction pending appeal. In the event that our request for an injunction pending appeal is denied, generic entry could occur during the appeal. </span><span style="font-family:Franklin Gothic Book,sans-serif;">The commercialization of a generic version of TECFIDERA would have an adverse impact on our TECFIDERA sales and our results of operations.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have assessed the realizability of our deferred tax assets that are dependent on future expected sales of TECFIDERA in the U.S. and reduced the value of certain deferred tax assets by approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13680947e861-wk-Fact-F60074E12A2158BF44B65E0CF082616B" name="biib:DeferredTaxAssetsValueReductioninValue" contextRef="FI2020Q2_srt_ProductOrServiceAxis_biib_TECFIDERAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,324.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and reduced the value of deferred tax liabilities associated with global intangible low-taxed income (GILTI) and tax credits by approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13680947e865-wk-Fact-C4B5BB1CBD4B49CBF1525E0E5625D8F2" name="biib:DeferredTaxLiabilitiesValueReductioninValue" contextRef="FI2020Q2_srt_ProductOrServiceAxis_biib_TECFIDERAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,268.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the income tax expense associated with these reductions was approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13680947e882-wk-Fact-56AF0BD7F78B356AD5BE5E124E6BAC98" name="biib:IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_TECFIDERAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">56.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For additional information, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 19, Litigation</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements.</span></div></ix:nonNumeric><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-2250ACC617E95B4493181C83C8E519F9-1"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Rate</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="TextSelection-EC4FFC5A16635319B6FDC77FAC052835-0-wk-Fact-D7570D2AF2F05A9CB32C6C65A62ABADD" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:45%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Statutory rate</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13680947e1058-wk-Fact-8C86E4D0F8755986BB7204821A887871" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="FD2020Q2QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13680947e1073-wk-Fact-B42A80FC93965EEDB6A8D896BA0ECC50" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="FD2019Q2QTD" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13680947e1088-wk-Fact-FABF826420BA5B058E39D783A6F01C17" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="FD2020Q2YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13680947e1103-wk-Fact-43A68CA1354C5221805F97E6890436DD" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="FD2019Q2YTD" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">State taxes</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13680947e1120-wk-Fact-419A67DC132D541EA471A80E90367984" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="FD2020Q2QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13680947e1134-wk-Fact-AB329A6513415B7C88A39E86367C1389" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="FD2019Q2QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13680947e1148-wk-Fact-0E7604997BD9534F86936E4C4F0D8AF0" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="FD2020Q2YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13680947e1162-wk-Fact-B100586ACFA15C89BF0CA17F11B81405" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="FD2019Q2YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Taxes on foreign earnings</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13680947e1178-wk-Fact-CE6EA9BEFCCE58CA8B1A09DB1C6BE31F" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="FD2020Q2QTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">3.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13680947e1193-wk-Fact-80B967C62AB55B8CBB1CDCC72A72063E" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="FD2019Q2QTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">4.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13680947e1208-wk-Fact-CD2840535165508FADA13B0D53F57ACF" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="FD2020Q2YTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">3.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13680947e1223-wk-Fact-DDB812C242355B1E8C5C808D7C122D64" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="FD2019Q2YTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">4.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Tax credits</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13680947e1240-wk-Fact-1644EB88FEF45BA28D76E2BC94178C67" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="FD2020Q2QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">1.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13680947e1255-wk-Fact-1347483E96725C2E9E1A82BED07632E3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="FD2019Q2QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13680947e1270-wk-Fact-53A65CABB4E250BEAF3AB7C86E13EE72" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="FD2020Q2YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">1.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13680947e1285-wk-Fact-4EF28B3D53B85B29A6E0F8C8E69A52B5" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="FD2019Q2YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Purchased intangible assets</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13680947e1302-wk-Fact-CE1BD57C122F5543801F908F6F1FB435" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" contextRef="FD2020Q2QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13680947e1316-wk-Fact-2D3A2A94E5FA59238230AD7CE0DF7844" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" contextRef="FD2019Q2QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13680947e1330-wk-Fact-B892EDB4D4DF57E69F23E9022BBE6045" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" contextRef="FD2020Q2YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13680947e1344-wk-Fact-5E54BE6A37A35C1F8B9829317C50E1AF" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" contextRef="FD2019Q2YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Divestiture of Denmark manufacturing operations</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13680947e1360-wk-Fact-216C48D536F058CEA7A0C8E2FE450B16" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets" contextRef="FD2020Q2QTD" unitRef="number" decimals="3" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13680947e1374-wk-Fact-745F5A8ECAF454148E123A5E5A1B9C64" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets" contextRef="FD2019Q2QTD" unitRef="number" decimals="INF" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13680947e1388-wk-Fact-97280AF29530543A91D25CFC66BD1E89" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets" contextRef="FD2020Q2YTD" unitRef="number" decimals="3" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13680947e1402-wk-Fact-106358C83D315EC383FEEC8EDD2CE4E9" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets" contextRef="FD2019Q2YTD" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">2.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Internal reorganization of certain intellectual property rights</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13680947e1418-wk-Fact-444A18851D2E551EAD10167AF16F4063" name="biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" contextRef="FD2020Q2QTD" unitRef="number" decimals="3" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13680947e1432-wk-Fact-BB2B9AA1D8DE51A1B8594F0BE082FC13" name="biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" contextRef="FD2019Q2QTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">5.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13680947e1447-wk-Fact-CFAD104B6DCA53A295D006770CF4E37F" name="biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" contextRef="FD2020Q2YTD" unitRef="number" decimals="3" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13680947e1461-wk-Fact-1638664F716056E69AF37DA4EEFC63C2" name="biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" contextRef="FD2019Q2YTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">2.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TECFIDERA impairment</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13680947e1478-wk-Fact-C866C04AF8D5EA3B12F75E1589C045CB" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" contextRef="FD2020Q2QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">2.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13680947e1492-wk-Fact-66DE97DA84D3D97EEF655E1589278178" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" contextRef="FD2019Q2QTD" unitRef="number" decimals="3" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13680947e1506-wk-Fact-3850E9728B93B29DA0B45E1589225D82" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" contextRef="FD2020Q2YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13680947e1520-wk-Fact-5793FD2118EB9BF3E2CE5E1589314DCA" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" contextRef="FD2019Q2YTD" unitRef="number" decimals="3" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">GILTI</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13680947e1536-wk-Fact-CA94AAA055DB550C8694FFF64D3E7E67" name="biib:EffectiveTaxRateReconciliationGILTItax" contextRef="FD2020Q2QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13680947e1550-wk-Fact-912C86EA09365137B0FBFF6F8E07C583" name="biib:EffectiveTaxRateReconciliationGILTItax" contextRef="FD2019Q2QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">1.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13680947e1564-wk-Fact-7AEA321706335F46A64D9D708E0934FD" name="biib:EffectiveTaxRateReconciliationGILTItax" contextRef="FD2020Q2YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">1.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13680947e1578-wk-Fact-D60F05ED6F6C50158F2BCB202F90C3C2" name="biib:EffectiveTaxRateReconciliationGILTItax" contextRef="FD2019Q2YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">1.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other permanent items</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13680947e1595-wk-Fact-4CFE37B185FA5FF4A13AAE800692EF6C" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" contextRef="FD2020Q2QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13680947e1609-wk-Fact-C9E55500EB3059EBAD2BEEF20490EAA5" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" contextRef="FD2019Q2QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13680947e1623-wk-Fact-4C9A6977D7645BC3A2351BFF739DE5E1" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" contextRef="FD2020Q2YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13680947e1637-wk-Fact-29255E3C02D253B2BD5D1E80ABA0E964" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" contextRef="FD2019Q2YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13680947e1653-wk-Fact-ADFA2C7D21BC5F85868D9F6004F70EE8" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="FD2020Q2QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13680947e1667-wk-Fact-2B7E95A915895135B8D687D58513A4C7" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="FD2019Q2QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13680947e1681-wk-Fact-EFCBBE408EE3588AA2FCCB396A7AE212" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="FD2020Q2YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13680947e1695-wk-Fact-61D29694A08753B4AB1FDE89FAA4154C" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="FD2019Q2YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Effective tax rate</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13680947e1711-wk-Fact-F6ACA36E8C7353019911074FADE7A3AE" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2020Q2QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">21.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13680947e1726-wk-Fact-E499BEA83FB45545B20B526B4727D893" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2019Q2QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">14.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13680947e1741-wk-Fact-2F4B80FB429F59F5A089F0B943DED0D3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2020Q2YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">19.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13680947e1756-wk-Fact-7671811DDD8556AA953C119333F24738" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2019Q2YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">18.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:17px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;">Changes in Tax Rate</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;"> the increase in our effective tax rate was primarily due to an internal reorganization of certain intellectual property rights related to the intercompany sale of the intellectual property in 2019 and the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13680947e1796-wk-Fact-56AF0BD7F78B356AD5BE5E124E6BAC98" name="biib:IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_TECFIDERAMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">56.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;">income tax expense related to the establishment of a valuation allowance against certain deferred tax assets, the realization of which is dependent on future sales of TECFIDERA in the U.S.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as discussed above. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;">the increase in our effective tax rate was primarily due to the impacts of the valuation allowance described above and the internal reorganization of certain intellectual property rights, partially offset by the</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13680947e1826-wk-Fact-A892349FA3B95B78A33DF793BCBF6D46" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" contextRef="FD2019Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">61.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> tax expense recognized in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;">related to the planned divestiture of our Hiller&#248;d, Denmark manufacturing operations. Although we recognized a loss on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, the divestiture required us to write off certain deferred tax assets and resulted in a taxable gain in certain jurisdictions.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As a result of the internal reorganization of certain intellectual property rights, we recorded a deferred tax asset of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13680947e1843-wk-Fact-66C7B9A580998D3F3E5B5E1822097DC5" name="us-gaap:DeferredTaxAssetsOther" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">856.7</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and a deferred tax liability of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13680947e1847-wk-Fact-02EBBA457EE6E35F317D5E188E3B8819" name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">685.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounting for Uncertainty in Income Taxes</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2013 or state, local or non-U.S. income tax examinations for years before 2012.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2020 we became aware of a withholding tax regulation that could be interpreted to apply to certain of our previous transactions. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have recorded an immaterial reserve reflecting this uncertain tax position.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration matters and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We estimate that it is reasonably possible that our gross unrecognized tax benefits, exclusive of interest, could decrease by up to approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13680947e1878-wk-Fact-CE2B2E6A73BD5AC1880DA4020D29EA65" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">75.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the next 12 months as a result of various audit closures, settlements and expiration of the statute of limitations.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34</span></div></div><hr style="page-break-after:always"></hr><div><a id="s20FEE613182553B795C91253DB7C5F26"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:18px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">16</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Other Consolidated Financial Statement Detail</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"> </span></div></td></tr></table><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="TextSelection-27D0A8C169D457CC9A2DBC6B13BBAB46-0-wk-Fact-DC37DC4A1F6C5BC793DCDF969535173C" continuedAt="TextSelection-27D0A8C169D457CC9A2DBC6B13BBAB46-1" escape="true"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Income (Expense), Net</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="TextSelection-C2E3A01FBA1B5C8CAB3B3CC6A0B053A2-0-wk-Fact-BADD2785A0835D759C7A313F50725FF5" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Components of other income (expense), net, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:42%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Interest income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13682938e1024-wk-Fact-A6DB1A4A55155CC3B2A39F6E39223180" name="us-gaap:InvestmentIncomeInterest" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13682938e1043-wk-Fact-0C4284452BEC56F8952754DB07A8EA5C" name="us-gaap:InvestmentIncomeInterest" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">29.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13682938e1063-wk-Fact-AD642FE8052D58C083A493F22D42CD7B" name="us-gaap:InvestmentIncomeInterest" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">32.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13682938e1082-wk-Fact-2ACBF047ACB15A2B81D168C84E59BB12" name="us-gaap:InvestmentIncomeInterest" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">60.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13682938e1102-wk-Fact-A7F9D19E8915591C85D807952C55AC71" name="us-gaap:InterestExpense" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">66.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13682938e1122-wk-Fact-147350126F4E565B9A0A9F972EF7AB5C" name="us-gaap:InterestExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">47.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13682938e1142-wk-Fact-B761067B3EC25444B16C8C2BFBF4C261" name="us-gaap:InterestExpense" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">110.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13682938e1163-wk-Fact-84DD9F21B78154E7A2B4B2A2EF0C3F23" name="us-gaap:InterestExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">95.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Gain (loss) on investments, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13682938e1189-wk-Fact-7AE6A948139B906A17205973C8002C57" name="us-gaap:RealizedInvestmentGainsLosses" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">106.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13682938e1208-wk-Fact-5E4F85BBA04990D4928959743911C491" name="us-gaap:RealizedInvestmentGainsLosses" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">173.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13682938e1228-wk-Fact-92D02ACF8AEC59B188C80D6DD23CF312" name="us-gaap:RealizedInvestmentGainsLosses" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">29.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13682938e1248-wk-Fact-B58921FC7BF55518AB3D87546F940DD9" name="us-gaap:RealizedInvestmentGainsLosses" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">203.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Foreign exchange gains (losses), net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13682938e1273-wk-Fact-32A75BE6407057B9B579834783BE53CA" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13682938e1292-wk-Fact-86D38F06B5995FF585B21D4063AF85E3" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13682938e1311-wk-Fact-E3A62912CFCB53A1ABB91CE2C7CF62EC" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">8.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13682938e1332-wk-Fact-5697BC60771753A8ABB788B3CBFA257E" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13682938e1358-wk-Fact-81252ACD8F7D58229DC4760BF522F588" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13682938e1377-wk-Fact-DE741F0FD926541286118CB4CD246922" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">7.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13682938e1397-wk-Fact-9D412F28F5F65442A5174B274F885F6F" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13682938e1418-wk-Fact-18D1CAFE5DC953748E5F44C494B8F348" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">7.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total other income (expense), net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13682938e1449-wk-Fact-0D51E02D7DDE5C0E8E7A9F3566E66B60" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">63.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13682938e1468-wk-Fact-55BFFA5FA59E5C88AB2D8F69B51FDAAD" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">197.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(<ix:nonFraction id="d13682938e1489-wk-Fact-ABD76A880BD354B29882CFA24D852D20" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">57.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13682938e1509-wk-Fact-EEF1B208E84A576484A9D98454389FE0" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">159.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the change in other income (expense), net primarily reflects net gains of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13682938e1544-wk-Fact-7AE6A948139B906A17205973C8002C57" name="us-gaap:RealizedInvestmentGainsLosses" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">106.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;">recognized on our investments related to our holdings in equity and debt securities, compared to net losses totaling</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13682938e1554-wk-Fact-5E4F85BBA04990D4928959743911C491" name="us-gaap:RealizedInvestmentGainsLosses" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">173.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the prior year comparative period. The net gains recognized during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;">primarily reflect an increase in the fair value of Ionis common stock of approximately</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13682938e1571-wk-Fact-2F13BAF8CCC9755460335E2943A44AD0" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="FD2020Q2QTD_dei_LegalEntityAxis_biib_IonisPharmaceuticalsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">67.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;">and an increase in the fair value of Sangamo common stock of approximately</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13682938e1581-wk-Fact-FD89F153532C26765B2F5E295FF03ADB" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="FD2020Q2QTD_dei_LegalEntityAxis_biib_SangamoCommonStockMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">40.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;">compared to the same period in 2019, the change in other income (expense), net was primarily due to approximately</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13682938e1601-wk-Fact-D7B70F8BB34046B6E2765E2CE8A747BD" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" contextRef="FD2019Q2QTD_dei_LegalEntityAxis_biib_IonisPharmaceuticalsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">203.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;">of net gains recognized on our investments related to our holdings in equity and debt securities during the six months ended June&#160;30, 2019.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:GainLossOnInvestmentsTextBlock" id="TextSelection-B386B15BE63B509BA15A6E56C3D94180-0-wk-Fact-0D0D74FAD15954CBA1E6007BFFAB54EA" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our gain (loss) on investments, net that relates to our equity securities held as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:42%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Net gains (losses) recognized during the period on equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13682938e1839-wk-Fact-AF1B8EED660B5C82B079531F5DFAC91C" name="us-gaap:EquitySecuritiesFvNiGainLoss" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">102.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13682938e1858-wk-Fact-A8C9D26CADD45A54BAFED15CE6E8F743" name="us-gaap:EquitySecuritiesFvNiGainLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">174.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13682938e1879-wk-Fact-AD5D2E5AF8465F6BA7F0928D4A541013" name="us-gaap:EquitySecuritiesFvNiGainLoss" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">42.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13682938e1898-wk-Fact-F001A4D780BB5451958BC1D0CF923577" name="us-gaap:EquitySecuritiesFvNiGainLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">201.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Less: Net gains (losses) recognized during the period on equity securities sold during the period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13682938e1918-wk-Fact-6F454240710456C6A5F94C4D9D3603B6" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13682938e1937-wk-Fact-4A5FFE8C8FF853E0A07C6769E52B636F" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">42.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13682938e1957-wk-Fact-90F44F41FFF25C188B014B18FBE12DC7" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13682938e1977-wk-Fact-091EFC55F8D151AFBCBADE7A1DEC5368" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">42.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Unrealized gains (losses) recognized during the period on equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13682938e2007-wk-Fact-1DF02394FA7B561FA0F3BEA943E62A65" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">102.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(<ix:nonFraction id="d13682938e2026-wk-Fact-307D2DED024D5695B77850A07C66F7A9" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">131.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13682938e2047-wk-Fact-5BCD9DCA17755FE99061B971B30AADE7" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">42.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13682938e2066-wk-Fact-1D16EA165C6957149C85B7C604AFC551" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">159.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accrued Expenses and Other</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="TextSelection-29F1AC35671D5E6C84557B01CF312989-0-wk-Fact-9DCB23BAFC2B5844A03C5B5D07F2DC9F" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other consists of the following:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:70%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>June 30,<br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Revenue-related reserves for discounts and allowances</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13682938e2175-wk-Fact-062DF7382F915519A5B9D146E1EF70DC" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">951.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13682938e2194-wk-Fact-4231B4BD6644584EB68CBAD2CF09EF6D" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,001.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Employee compensation and benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13682938e2214-wk-Fact-B6560F6A388558E4A6AF45A6C0A84F21" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">212.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13682938e2233-wk-Fact-94CE95FA92F655928086492951539203" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">309.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Royalties and licensing fees</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13682938e2258-wk-Fact-B5D68139945C5C99B92AA14C25EF478A" name="us-gaap:AccruedRoyaltiesCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">203.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13682938e2277-wk-Fact-227E91809B445AE2B1AFFA6733D104DC" name="us-gaap:AccruedRoyaltiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">220.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Collaboration expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13682938e2302-wk-Fact-CCACACF5619A5C6EA020BEA4FB444B12" name="biib:Collaborationexpensesaccrual" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">172.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13682938e2321-wk-Fact-D8E899F4350657C99531B9B8BF292289" name="biib:Collaborationexpensesaccrual" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">281.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Current portion of contingent consideration obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13682938e2346-wk-Fact-EF742BB54D96512E90B43AAF0EBCAFB4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">149.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13682938e2365-wk-Fact-5CEFAEE5CEE0569480C09A3B63836377" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">148.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Construction in progress</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13682938e2390-wk-Fact-3B6BBB6ED6BA588794839BCEC817DBD4" name="us-gaap:ConstructionPayableCurrentAndNoncurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13682938e2409-wk-Fact-0CDC22D0A32D5E169A007D1BF059FEF9" name="us-gaap:ConstructionPayableCurrentAndNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">78.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13682938e2434-wk-Fact-D654B8EE899C5BD3BBE26238073BED17" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">774.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13682938e2453-wk-Fact-FA1CDFC70074596CA6D6CB286187C4E5" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">726.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13682938e2483-wk-Fact-96180D2EFD6F50C4AB2607CAC10392DB" name="us-gaap:OtherLiabilitiesCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,486.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13682938e2502-wk-Fact-ED32696AB6ED5D5F84AFD714902EF602" name="us-gaap:OtherLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2,765.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:nonNumeric><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-27D0A8C169D457CC9A2DBC6B13BBAB46-1"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Long-term Liabilities</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities were </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13682938e2527-wk-Fact-6299100E2B9B576C82E99FBE691E586C" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,475.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13682938e2531-wk-Fact-01F0411B800C53F49F5B13CE5B5A6E2B" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,348.9</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, and included accrued income taxes totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13682938e2543-wk-Fact-AF17F52A08B95E0989B9E5304858989F" name="us-gaap:AccruedIncomeTaxesNoncurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">743.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13682938e2548-wk-Fact-184AE306B27B5D719D8275DE752FB906" name="us-gaap:AccruedIncomeTaxesNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">803.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Included within accrued taxes as of June&#160;30, 2020 and December&#160;31, 2019, is an accrual for a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings (the Transition Toll Tax) of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13682938e2552-wk-Fact-4DD9C93FD397806AE8275E32743B5258" name="us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">635.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13682938e2556-wk-Fact-71FBAFC5E34AA3C91B0C5E329C24E6F0" name="us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">697.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div></ix:continuation><div><a id="s844685FFE18E5351ACF7C97C7C81B2C7"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:18px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">17</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"> </span></div></td></tr></table><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="TextSelection-75E9AAF871F05EF0BACA6FC47390EE52-0-wk-Fact-1AD9FC307B225BCC919CDB0DDE2A897C" continuedAt="TextSelection-75E9AAF871F05EF0BACA6FC47390EE52-1" escape="true"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Eisai Co., Ltd.</span></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BAN2401 and Elenbecestat Collaboration</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize BAN2401, a monoclonal antibody that targets amyloid beta aggregates, and elenbecestat, the oral BACE (base amyloid cleaving enzyme) inhibitor, two Eisai product candidates for the potential treatment of AD (the BAN2401 and Elenbecestat Collaboration).&#160;In September 2019 we and Eisai discontinued the global Phase 3 studies of elenbecestat in early AD. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Eisai serves as the global operational and regulatory lead for BAN2401 and all costs, including research, development, sales and marketing expenses, are shared equally between us and Eisai. If BAN2401 receives marketing approval, we and Eisai will co-promote BAN2401 and share profits equally. In addition, the BAN2401 and Elenbecestat Collaboration provides both parties with certain rights and obligations in the event of a change in control of either party.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The BAN2401 and Elenbecestat Collaboration also provided Eisai with an option to jointly develop and commercialize aducanumab, our anti-amyloid beta antibody candidate for AD (Aducanumab Option), and an option to jointly develop and commercialize one of our anti-tau monoclonal antibodies (Anti-Tau Option). In October 2017 Eisai exercised its Aducanumab Option and we entered into a new collaboration agreement for the joint development and commercialization of aducanumab (Aducanumab Collaboration Agreement). Eisai has not yet exercised its Anti-Tau Option.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the Aducanumab Collaboration Agreement, the two companies will continue to jointly develop BAN2401 in accordance with the BAN2401 and Elenbecestat Collaboration; however, we are no longer required to pay Eisai any milestone payments for products containing BAN2401 and we are no longer entitled to any potential development and commercial milestone payments from Eisai in relation to aducanumab. For additional information on our BAN2401 and Elenbecestat Collaboration, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 18, Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of development and sales and marketing expense related to the BAN2401 and Elenbecestat Collaboration is as follows:</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" id="TextSelection-8BF478338FCC5DDF9973198E09645591-0-wk-Fact-BE43A789EBD95A96994C687A11562176" escape="true"><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:52%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total development expense incurred by the collaboration related to the advancement of BAN2401 and elenbecestat</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13685232e1050-wk-Fact-24B0181BF0A55FD9A3F5CDE6FC8F8E06" name="biib:ExpenseIncurredByCollaboration" contextRef="FD2020Q2QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">33.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13685232e1069-wk-Fact-06C554752E6E5BE48A5B084638301E22" name="biib:ExpenseIncurredByCollaboration" contextRef="FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">68.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13685232e1089-wk-Fact-8F8C2C626BEEA327AB885E34AC33AF19" name="biib:ExpenseIncurredByCollaboration" contextRef="FD2020Q2YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">77.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13685232e1108-wk-Fact-ACCE44D173831759796B5E34AE26126F" name="biib:ExpenseIncurredByCollaboration" contextRef="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">136.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Biogen's share of BAN2401 and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13685232e1128-wk-Fact-83ADB661E66D5CF893E48F1E9EFE2F61" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2020Q2QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">17.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13685232e1147-wk-Fact-61AC8A3FE200554F92E16235AB52871E" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">34.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13685232e1166-wk-Fact-F195CBBE14A2B47CA7005E34AF79B198" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2020Q2YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">38.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13685232e1186-wk-Fact-43DD6AE39C83065F981A5E34B16D1479" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">68.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total sales and marketing expense incurred by the collaboration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13685232e1211-wk-Fact-C7E658BB2ABC54E49B386F7F0BF50572" name="biib:Expenseincurredbythecollaboration" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">nm</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13685232e1249-wk-Fact-B6BA30C4046CA7071F665E34B2BCCC9A" name="biib:Expenseincurredbythecollaboration" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">nm</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Biogen's share of BAN2401 sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13685232e1294-wk-Fact-260224478FEB53C2A2572C6A171A12F6" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">nm</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13685232e1332-wk-Fact-76A305CD364E19D0D4E85E34B5EF9B5E" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">nm</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:32%;"></td><td style="width:34%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">nm</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"> - For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">, sales and marketing expenses related to the BAN2401 and Elenbecestat Collaboration were immaterial.</span></div></ix:nonNumeric><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-75E9AAF871F05EF0BACA6FC47390EE52-1" continuedAt="TextSelection-75E9AAF871F05EF0BACA6FC47390EE52-2"><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Aducanumab Collaboration Agreement</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the Aducanumab Collaboration Agreement, we and Eisai will co-promote aducanumab with a region-based profit split and we lead the ongoing development of aducanumab. Beginning January 1, 2019, Eisai is reimbursing us for&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d13685232e1419-wk-Fact-D8A49C8E2E0B56F18925AF5EDB45CDD2" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" contextRef="FD2020Q2YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">45</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;of development costs incurred by the collaboration for the advancement of aducanumab (aducanumab development expense). </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019, based on a pre-specified futility analysis, we discontinued the global Phase 3 trials, EMERGE and ENGAGE, designed to evaluate the efficacy and safety of aducanumab in patients with early AD. A new analysis of a larger dataset from these trials, conducted in consultation with the FDA, showed that the Phase 3 EMERGE study met its pre-specified primary and secondary endpoints. In the first quarter of 2019, as a result of the decision to discontinue the Phase 3 EMERGE and ENGAGE trials following the futility analysis, we accrued approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13685232e1426-wk-Fact-3683B50FE1FA77D97E675E3E6EA41C6F" name="us-gaap:LossOnContractTermination" contextRef="FD2019Q1QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">45.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the termination of various clinical trials and research and development contracts net of the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d13685232e1430-wk-Fact-D8A49C8E2E0B56F18925AF5EDB45CDD2" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" contextRef="FD2020Q2YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">45</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Eisai reimbursement of development costs incurred under the Aducanumab Collaboration Agreement.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2020 we completed the submission of a Biologics License Application (BLA) to the FDA for the approval of aducanumab. For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized net profit-sharing income of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13685232e1449-wk-Fact-4F45C4FAE4FCB96F81105E53E7C0F0EC" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="FD2020Q2QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">33.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to reflect Eisai's </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d13685232e1453-wk-Fact-D8A49C8E2E0B56F18925AF5EDB45CDD2" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" contextRef="FD2020Q2YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">45</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share of the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13685232e1458-wk-Fact-9F9B667CA87C4DCCC24A5E5321CB03A7" name="biib:AdditionalMilestonePayment" contextRef="FI2020Q2_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">75.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> milestone expense related to the submission of the BLA to the FDA for approval of aducanumab.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sales and marketing expense are shared in proportion to the same region-based profit split that will be utilized to co-promote aducanumab. For additional information on the Aducanumab Collaboration Agreement, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 18,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="biib:SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" id="TextSelection-7E7EE262CE55520C830A6C626AB42387-0-wk-Fact-46313772E00E5B9EBF2050BCAFE7E4D6" escape="true"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of development, sales and marketing and milestone expense related to the Aducanumab Collaboration Agreement is as follows:</span></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:52%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total aducanumab development expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13685232e1699-wk-Fact-CF0AA41EB1A25204871D449ED321A582" name="biib:Expenseincurredbythecollaboration" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">35.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13685232e1718-wk-Fact-FDA662E6D2245851B7D8F0715B193DE4" name="biib:Expenseincurredbythecollaboration" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13685232e1738-wk-Fact-2BB2BDBBF2F5562F8660DDBA27126DC3" name="biib:Expenseincurredbythecollaboration" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">55.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13685232e1757-wk-Fact-5236EE837DEC564393BAF644AD3D546F" name="biib:Expenseincurredbythecollaboration" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">165.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Biogen's share of aducanumab development expense reflected in research and development expense in our condensed consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13685232e1777-wk-Fact-18D07605A9335078BA1643DE944825F7" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">19.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13685232e1796-wk-Fact-1E07250B24DB5C3487C1888ECC9BE4BC" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13685232e1815-wk-Fact-A4B98581686255439B2F8972AED419F9" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">30.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13685232e1835-wk-Fact-72C13813E4BF51AD802FFB9634D53F20" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">91.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total aducanumab sales and marketing expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13685232e1860-wk-Fact-A487DC95556853EFBF06DB52D61C3AA6" name="biib:Expenseincurredbythecollaboration" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">45.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13685232e1879-wk-Fact-B7AFD3E4B523598894153A8D84E7B8B8" name="biib:Expenseincurredbythecollaboration" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13685232e1898-wk-Fact-A3DF0EA6866D5419919F6FAE29208E63" name="biib:Expenseincurredbythecollaboration" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">67.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13685232e1918-wk-Fact-D59347E8057459DF89B5BE7CBC1BCC17" name="biib:Expenseincurredbythecollaboration" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">21.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13685232e1943-wk-Fact-175B192DD67D59A8A80FCC03F7439565" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">25.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13685232e1962-wk-Fact-443E60B9A662563894E20892111E9069" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13685232e1981-wk-Fact-AB5567F0714F575CB47D4FC8E61BA7BD" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">37.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span><ix:nonFraction id="d13685232e2001-wk-Fact-038E559B25FC58089BBB35D93EF17BD6" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total aducanumab collaboration third party milestone expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13685232e2026-wk-Fact-9F9B667CA87C4DCCC24A5E5321CB03A7" name="biib:AdditionalMilestonePayment" contextRef="FI2020Q2_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">75.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13685232e2064-wk-Fact-9F9B667CA87C4DCCC24A5E5321CB03A7" name="biib:AdditionalMilestonePayment" contextRef="FI2020Q2_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">75.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Eisai's share of aducanumab milestone expense reflected in collaboration profit sharing in our condensed consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13685232e2109-wk-Fact-4F45C4FAE4FCB96F81105E53E7C0F0EC" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="FD2020Q2QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">33.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13685232e2147-wk-Fact-9A3820B0B6C3391C706F5E53FAA65B7F" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="FD2020Q2YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">33.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">UCB Pharma S.A.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with UCB Pharma S.A. (UCB) to jointly develop and commercialize dapirolizumab pegol, an anti-CD40L pegylated Fab, for the potential treatment of systemic lupus erythematosus and other future agreed indications. Either we or UCB may propose development of dapirolizumab pegol in additional indications. If the parties do not agree to add an indication as an agreed indication to the collaboration, we or UCB may, at the sole expense of the applicable party, pursue development in such excluded indication(s), subject to an opt-in right of the non-pursuing party after proof of clinical activity. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All costs incurred for agreed indications, including research, development, sales and marketing expenses, are shared equally between us and UCB. Upon marketing approval, we and UCB will co-promote dapirolizumab pegol and share profits equally. A summary of development expense related to the UCB Collaboration Agreement is as follows:</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-75E9AAF871F05EF0BACA6FC47390EE52-2" continuedAt="TextSelection-75E9AAF871F05EF0BACA6FC47390EE52-3"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:52%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total UCB development expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13685232e2370-wk-Fact-D0C834C43024E625D6C05E55A6E49527" name="biib:Expenseincurredbythecollaboration" contextRef="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_UCBPharmaS.A.Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">nm</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13685232e2399-wk-Fact-79AD3C5E580C1328B1FC5E55CC5297E6" name="biib:Expenseincurredbythecollaboration" contextRef="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_UCBPharmaS.A.Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">25.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">nm</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Biogen's share of UCB development expense reflected in research and development expense in our condensed consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13685232e2430-wk-Fact-33E50E24CA168CC591675E55ABF02D1A" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_UCBPharmaS.A.Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">nm</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span><ix:nonFraction id="d13685232e2459-wk-Fact-CBDF34B1C674DA9769F95E55D1079084" name="biib:Expensereflectedwithinstatementsofincome" contextRef="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_UCBPharmaS.A.Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">nm</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:32%;"></td><td style="width:34%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">nm</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"> - For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">, development expenses related to the UCB collaboration agreement were immaterial.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Research and Discovery Arrangements</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Sangamo Therapeutics, Inc.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2020 we entered into a collaboration and license agreement with Sangamo to develop and commercialize ST-501 for tauopathies, including AD; ST-502 for synucleinopathies, including Parkinson&#8217;s disease; a third neuromuscular disease target; and up to nine additional neurological disease targets to be identified and selected within a five-year period. The companies will leverage Sangamo&#8217;s proprietary zinc finger protein technology delivered via AAV to modulate the expression of key genes involved in neurological diseases. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the closing of this transaction in April 2020 we purchased </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13685232e2539-wk-Fact-04B0843A3BBB57249BCBBB65FD2A0AC1" name="biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased" contextRef="D2020Q1Feb01-Feb29_us-gaap_TypeOfArrangementAxis_biib_SangamoTherapeuticsInc.AgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">225.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of Sangamo common stock, or approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d13685232e2543-wk-Fact-3751AD56A73F54798681767AA3923998" name="biib:GlobalLicensingCollaborationAgreementSharesPurchased" contextRef="D2020Q1Feb01-Feb29_us-gaap_TypeOfArrangementAxis_biib_SangamoTherapeuticsInc.AgreementMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">24</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares at </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13685232e2547-wk-Fact-F518BEA9DC8052A48430A32643E37CD0" name="biib:GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" contextRef="D2020Q1Feb01-Feb29_us-gaap_TypeOfArrangementAxis_biib_SangamoTherapeuticsInc.AgreementMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">9.21</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> per share, which are subject to transfer restrictions. We recorded an asset in investments and other assets in our condensed consolidated balance sheets to reflect the initial fair value of the Sangamo common stock acquired and a charge of&#160;approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13685232e2551-wk-Fact-DC42B008E32B54D88FADEBD4AB2153D7" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="D2020Q1Feb01-Feb29_us-gaap_TypeOfArrangementAxis_biib_SangamoTherapeuticsInc.AgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">83.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;to research and development expense in our condensed consolidated statements of income to reflect the premium paid for the Sangamo common stock. We also made an upfront payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13685232e2555-wk-Fact-8AFB6556ABB75B9A8F4ADAA6320D4DE9" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" contextRef="D2020Q1Feb01-Feb29_us-gaap_TypeOfArrangementAxis_biib_SangamoTherapeuticsInc.AgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">125.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> that was recorded as research and development expense.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may also pay research, development, regulatory and commercial milestone payments that could total up to approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13685232e2562-wk-Fact-2B19FDC46366537EBFED67A256665C42" name="biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" contextRef="D2020Q1Feb01-Feb29_us-gaap_TypeOfArrangementAxis_biib_SangamoTherapeuticsInc.AgreementMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">2.4</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> if we select all of the targets allowed under this agreement and all the specified milestones set forth in this agreement are achieved. Of this amount, up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13685232e2566-wk-Fact-2934A70D1D655DB9B480B33DEA420588" name="biib:GlobalLicensingCollaborationAgreementPaymentSelectionofTargets" contextRef="D2020Q1Feb01-Feb29_us-gaap_TypeOfArrangementAxis_biib_SangamoTherapeuticsInc.AgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">80.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> relates to the selection of targets, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13685232e2570-wk-Fact-114ADBDA75DF5507BE71210E83D9E093" name="biib:GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones" contextRef="D2020Q1Feb01-Feb29_us-gaap_TypeOfArrangementAxis_biib_SangamoTherapeuticsInc.AgreementMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.9</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13685232e2574-wk-Fact-4906000E13805D8DA454AE321CFE1CE3" name="biib:GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones" contextRef="D2020Q1Feb01-Feb29_us-gaap_TypeOfArrangementAxis_biib_SangamoTherapeuticsInc.AgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">380.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels. In addition, we may pay tiered royalties on potential net commercial sales of any products developed under this collaboration in the high single digit to double digit sub-teen percentages.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Skyhawk Therapeutics, Inc.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2019 we entered into a collaboration and research and development services agreement with Skyhawk Therapeutics, Inc. (Skyhawk) pursuant to which the companies are leveraging Skyhawk's SkySTAR technology platform with the goal of discovering innovative small molecule treatments for patients with neurological diseases, including MS and SMA. We are responsible for the development and potential commercialization of any therapies resulting from this collaboration and we may also pay Skyhawk up to a total of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13685232e2584-wk-Fact-3B1F947F6CDE53A197831A7ECF5304EE" name="biib:AdditionalMilestonePayment" contextRef="FI2020Q2_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">2.4</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in milestone payments as well as potential royalties on net commercial sales. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with this agreement, we made an upfront payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13685232e2592-wk-Fact-66A347493A0D564196729C330CD31455" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" contextRef="FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">74.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Skyhawk, of which </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13685232e2596-wk-Fact-731CAC3F7227551AA3B59900988A6FB4" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">38.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recorded as research and development expense in our condensed consolidated statements of income and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13685232e2600-wk-Fact-1B368C4BB4325ECA89D82236FB6F0569" name="us-gaap:PrepaidExpenseAndOtherAssets" contextRef="FI2019Q2_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">35.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recorded as prepaid research and development expenditures within investments and other assets in our condensed consolidated balance sheets. These prepaid research and development services are expensed as the services are provided. In October 2019 we amended this agreement to add an additional discovery program. In connection with this amendment, we made a payment to Skyhawk of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13685232e2604-wk-Fact-4C5A960BB55953CDB324038853F07D51" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" contextRef="D2019Q4Oct01-Oct31_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-75E9AAF871F05EF0BACA6FC47390EE52-3" continuedAt="TextSelection-75E9AAF871F05EF0BACA6FC47390EE52-4"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Samsung Bioepis</span></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Joint Venture Agreement</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.&#160;In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d13685232e2617-wk-Fact-37E261D9A6B958FBB0B52EE61E0050D1" name="biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" contextRef="FI2019Q2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d13685232e2621-wk-Fact-68118BDBA14B59BAAE1CE2F32822EC68" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="FI2020Q2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">49.9</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The share purchase transaction was completed in November 2018 and, upon closing, we paid </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d13685232e2625-wk-Fact-CCB7C2B85AC35AB599BDF91D0763D35A" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" contextRef="D2018Q4Nov1-Nov30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="KRW" decimals="-8" scale="9" format="ixt:numdotdecimal">759.5</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13685232e2629-wk-Fact-A7C8464CFC3E55D48BE321B68A254770" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" contextRef="FD2018Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">676.6</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) to Samsung BioLogics. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our ownership percentage remained at approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d13685232e2638-wk-Fact-68118BDBA14B59BAAE1CE2F32822EC68" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="FI2020Q2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">49.9</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in income (loss) of investee, net of tax in our condensed consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our initial investment, we suspended recognizing additional losses. In the first quarter of 2019 we restarted recognizing our share of Samsung Bioepis' (income) losses, and we began recognizing amortization on certain basis differences resulting from our November 2018 investment. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon investment, the equity method of accounting requires us to identify and allocate differences between the fair value of our investment and the carrying value of our interest in the underlying net assets of the investee. These basis differences are amortized over their economic life. The total basis difference was approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13685232e2648-wk-Fact-16C789A91294528889D1F02E79BA1A05" name="us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" contextRef="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">675</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and relates to inventory, developed technology, IPR&amp;D and deferred tax balances. The basis differences related to inventory and developed technology will be amortized, net of tax, over their estimated useful lives of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d13685232e2652-wk-Fact-0B6D14C82B335E7A9CD913DA9CA7BA40" name="biib:Equitymethodinvestmentbasisdifferenceamortizationperiod" contextRef="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InventoriesMember" format="ixt-sec:duryear">1.5</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> years and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d13685232e2656-wk-Fact-12EC492096ED511DBF363A1E4964B12C" name="biib:Equitymethodinvestmentbasisdifferenceamortizationperiod" contextRef="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_DevelopedTechnologyRightsMember" format="ixt-sec:duryear">15</ix:nonNumeric></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> years, respectively, one quarter in arrears. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our joint venture partner, Samsung BioLogics, is currently subject to an ongoing criminal investigation that we continue to monitor. While this investigation could impact the operations of Samsung Bioepis and its business, we have assessed the value of our investment in Samsung Bioepis and continue to believe that the fair value of the investment is in excess of its net book value.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized net income on our investment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13685232e2678-wk-Fact-F14281DAC4625C73ADCEB06EEB80CA11" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" contextRef="FD2020Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.1</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13685232e2682-wk-Fact-FB2D9EDEF356A0379BA85E5742A5ADB7" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" contextRef="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, reflecting our share of income and amortization of basis differences.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the carrying value of our investment in Samsung Bioepis totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d13685232e2697-wk-Fact-0B65248DC6215903921C263A9F56BF71" name="us-gaap:EquityMethodInvestments" contextRef="FI2020Q2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="KRW" decimals="-8" scale="9" format="ixt:numdotdecimal">668.3</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13685232e2701-wk-Fact-2F81BE7E53465FE89DC4D8D0E25324BC" name="us-gaap:EquityMethodInvestments" contextRef="FI2020Q2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">557.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d13685232e2705-wk-Fact-CF87EB0D08C655F989DD20C322667660" name="us-gaap:EquityMethodInvestments" contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="KRW" decimals="-8" scale="9" format="ixt:numdotdecimal">670.8</ix:nonFraction> billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13685232e2710-wk-Fact-520631BF43805C26991934ECD0C4B51F" name="us-gaap:EquityMethodInvestments" contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">580.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">), respectively, which is classified as a component of investments and other assets in our condensed consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">2019 Transaction</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11 referencing LUCENTIS and SB15 referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. Samsung Bioepis will be responsible for development and will supply both products to us.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with this transaction, we made an upfront payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13685232e2724-wk-Fact-56BB62E9322B558A9E357ADB5BF87163" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" contextRef="D2020Q1Mar3120_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">100.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Samsung Bioepis in January 2020, of which </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13685232e2728-wk-Fact-BD5E653D992E5E9790DA24EF4834291D" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="D2020Q1Mar3120_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">63.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recorded as research and development expense in 2019 and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13685232e2732-wk-Fact-5677741AA0965A9CB136659779366973" name="us-gaap:PrepaidExpenseAndOtherAssets" contextRef="I2020Q1Jan31_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">37.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recorded as an intangible asset in 2019. We may pay Samsung Bioepis up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13685232e2736-wk-Fact-2D8CD223612154F287685C87560936FE" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" contextRef="D2020Q1Mar3120_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">210.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional development, regulatory and sales-based milestones, including a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13685232e2740-wk-Fact-1F9E981914EF59AF81A66570C479B62F" name="biib:AdditionalMilestonePayment" contextRef="I2020Q1Jan31_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> development milestone which is expected to be paid during the third quarter of 2020. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also acquired an option to extend the term of our 2013 commercial agreement for BENEPALI, IMRALDI and FLIXABI by an additional five years, subject to payment of an option exercise fee of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13685232e2747-wk-Fact-A04AF3FBFD2C57289DA2088826DD4883" name="biib:ContractOptionExerciseFee" contextRef="D2020Q1Mar3120_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">60.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and obtained exclusive rights to commercialize these products in China.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">2013 Commercial Agreement</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We reflect revenues on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenues, net in our condensed consolidated statements of income and record the related cost of revenues and sales and marketing expenses in our condensed consolidated statements of income to their respective line items when these costs are incurred. </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-75E9AAF871F05EF0BACA6FC47390EE52-4" continuedAt="TextSelection-75E9AAF871F05EF0BACA6FC47390EE52-5"><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We share </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d13685232e2760-wk-Fact-D1347BA419E959B89DD1DB9D653F4B42" name="biib:Biogenshareofcopromotionprofitsorlosses" contextRef="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized net profit-sharing expense of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13685232e2776-wk-Fact-DBABA8FE291C52C3ADA5EE60C53C31B0" name="biib:Collaborationprofitlosssharing" contextRef="FD2020Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">55.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13685232e2781-wk-Fact-C4DE89598E2BD157C2F85E57F7259ACB" name="biib:Collaborationprofitlosssharing" contextRef="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">127.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, to reflect Samsung Bioepis' </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d13685232e2785-wk-Fact-D1347BA419E959B89DD1DB9D653F4B42" name="biib:Biogenshareofcopromotionprofitsorlosses" contextRef="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> sharing of the net collaboration profits, compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13685232e2789-wk-Fact-F2D23752A84F53E8B6E3D77071794799" name="biib:Collaborationprofitlosssharing" contextRef="FD2019Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">63.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13685232e2793-wk-Fact-88EC8C3BC2D6A9AA4F825E584143FE02" name="biib:Collaborationprofitlosssharing" contextRef="FD2019Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">121.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods. As discussed above, we have an option to extend this agreement by an additional five years, subject to the payment of an option exercise fee of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13685232e2797-wk-Fact-A04AF3FBFD2C57289DA2088826DD4883" name="biib:ContractOptionExerciseFee" contextRef="D2020Q1Mar3120_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">60.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Services</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Simultaneous with the formation of Samsung Bioepis, we also entered into a technical development services agreement, a manufacturing agreement and a license agreement with Samsung Bioepis. For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13685232e2819-wk-Fact-3B5D13BCD83459CB88C1D8C6A6C98FBF" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.5</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13685232e2823-wk-Fact-22E2DF8FD1164BDE127E5E58C13899C4" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in revenues related to these services, which is reflected in collaborative and other relationships revenues as a component of other revenues in our condensed consolidated statements of income, compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13685232e2828-wk-Fact-6CCBA3F908C15427AF0457F1D0C114CF" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">52.2</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13685232e2832-wk-Fact-27AACAC2826741C1882D5E58EC94FD25" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">77.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Following the divestiture of our Hiller&#248;d, Denmark manufacturing operations in August 2019, FUJIFILM assumed </span><span style="font-family:Franklin Gothic Book,sans-serif;">responsibility for the manufacture of clinical and commercial quantities of bulk drug substance of biosimilar products for Samsung Bioepis. We no longer recognize revenues for the manufacturing completed after the Hiller&#248;d, Denmark manufacturing facility divestiture date under our technical development services and manufacturing agreements with Samsung Bioepis.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 3, Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts receivable from Samsung Bioepis related to the agreements discussed above were </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13685232e2853-wk-Fact-D78107B4063055418D99F7CA9ABC10E0" name="us-gaap:DueFromRelatedParties" contextRef="FI2020Q2_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13.3</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13685232e2857-wk-Fact-ECC96733488B5DC9BB0C21391FF08BA1" name="us-gaap:DueFromRelatedParties" contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">85.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. There were </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d13685232e2869-wk-Fact-2E6C6C7949E9F4A9E9C05E5C4933E398" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" contextRef="FI2020Q2_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> amounts payable to Samsung Bioepis as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Amounts payable to Samsung Bioepis as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, consisted of the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13685232e2882-wk-Fact-4AA6389FCDDD56ED8905CFD32ECCAF52" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">100.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upfront payment related to the 2019 transaction, as discussed above.</span></div></ix:continuation><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><ix:continuation id="TextSelection-75E9AAF871F05EF0BACA6FC47390EE52-5" continuedAt="TextSelection-75E9AAF871F05EF0BACA6FC47390EE52-6"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Samsung Bioepis and our other significant collaboration arrangements, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 18,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span></ix:continuation><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><ix:continuation id="TextSelection-75E9AAF871F05EF0BACA6FC47390EE52-6"> Form 10-K.</ix:continuation> </span></div><div><a id="sD9176E7B291D540784417C2BCF9A3A53"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:18px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">18</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Investments in Variable Interest Entities</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"> </span></div></td></tr></table><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:VariableInterestEntityDisclosureTextBlock" id="TextSelection-1FBD52E1DB64545D9E82B627EAC5D955-0-wk-Fact-516634095D045D94B24166246D159828" continuedAt="TextSelection-1FBD52E1DB64545D9E82B627EAC5D955-1" escape="true"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidated Variable Interest Entities</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Neurimmune SubOne AG</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration and license agreement with Neurimmune SubOne AG (Neurimmune) for the development and commercialization of antibodies for the potential treatment of AD, including aducanumab (as amended, the Neurimmune Agreement). We are responsible for the development, manufacturing and commercialization of all collaboration products. The Neurimmune Agreement is effective for the longer of the duration of certain patents relating to a licensed product or </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> years from the first commercial sale of any product using such a licensed compound.  </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#8217;s economic performance and we are required to fund </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the research and development costs incurred in support of the collaboration. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2017 we amended the terms of the Neurimmune Agreement and made a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13683115e819-wk-Fact-997E9435C65D5A6582F52756129940CB" name="us-gaap:PaymentsToMinorityShareholders" contextRef="D2017Q4_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_biib_NeurimmuneMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">150.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> payment to Neurimmune in exchange for a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d13683115e823-wk-Fact-EED417FA9E8E5FBFB396F61F2BD4F2EC" name="biib:Reductioninroyaltyratepayableoncommercialsales" contextRef="D2017Q4_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_biib_NeurimmuneMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">15</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reduction in the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab. In May 2018 we made an additional </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13683115e827-wk-Fact-064DA3712A435C0D8E46526DA32DB72A" name="us-gaap:PaymentsToMinorityShareholders" contextRef="D2018Q2Neurimmune_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_biib_NeurimmuneMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> payment to Neurimmune to further reduce the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab, by an additional </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d13683115e831-wk-Fact-99F74A94D145568D8F281294051F054B" name="biib:Additionalreductioninroyaltyratepayableoncommercialsales" contextRef="D2018Q2Neurimmune_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_biib_NeurimmuneMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Our royalty rates payable on products developed under the Neurimmune Agreement, including royalty rates payable on potential commercial sales of aducanumab, now range from the high single digits to sub-teens. As we consolidate the results of Neurimmune, </span></div></ix:nonNumeric><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-1FBD52E1DB64545D9E82B627EAC5D955-1"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">we treated these payments as distributions and recognized them as charges to noncontrolling interests in the fourth quarter of 2017 and the second quarter of 2018, as applicable.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additionally, under the terms of the Neurimmune Agreement, we are required to pay Neurimmune a milestone payment of&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13683115e841-wk-Fact-B7CDA7F09EBF5032A1DAC22B39CA6632" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" contextRef="FI2019Q4_biib_FutureContingentMilestoneTypesAxis_biib_RegulatoryMilestonesMember_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_biib_NeurimmuneMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">75.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;upon the regulatory filing with the FDA for approval of aducanumab and a milestone payment of&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13683115e845-wk-Fact-A929A072532E5FDBB054FD0C4F2762CC" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" contextRef="FI2019Q4_biib_FutureContingentMilestoneTypesAxis_biib_RegulatoryApprovalMilestoneMember_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_biib_NeurimmuneMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">100.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;if aducanumab is launched in the U.S. In July 2020 we and our collaboration partner Eisai announced that we completed the submission of a BLA to the FDA for the approval of aducanumab. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recorded accrued expenses of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13683115e853-wk-Fact-B7CDA7F09EBF5032A1DAC22B39CA6632" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" contextRef="FI2019Q4_biib_FutureContingentMilestoneTypesAxis_biib_RegulatoryMilestonesMember_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_biib_NeurimmuneMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">75.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;">related to this milestone payment as it was probable that the submission of the BLA would be completed and the milestone earned.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;">This milestone payment is expected to be paid during the third quarter of 2020.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized net profit-sharing income of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13683115e880-wk-Fact-4F45C4FAE4FCB96F81105E53E7C0F0EC" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="FD2020Q2QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">33.8</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to reflect Eisai's </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d13683115e884-wk-Fact-D8A49C8E2E0B56F18925AF5EDB45CDD2" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" contextRef="FD2020Q2YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">45</ix:nonFraction>%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share of the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13683115e889-wk-Fact-B7CDA7F09EBF5032A1DAC22B39CA6632" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" contextRef="FI2019Q4_biib_FutureContingentMilestoneTypesAxis_biib_RegulatoryMilestonesMember_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_biib_NeurimmuneMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">75.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> milestone expense. We treated this milestone payment as a distribution and recognized it as a charge to noncontrolling interest for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For additional information on our collaboration arrangements with Eisai, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 17, Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development costs for which we reimburse Neurimmune are reflected in research and development expense in our condensed consolidated statements of income. During the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, amounts reimbursed were immaterial.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The assets and liabilities of Neurimmune are not significant to our condensed consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than contractually required amounts.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the Aducanumab Collaboration Agreement, Eisai had an option to share in the benefit and cost associated with the royalty reductions discussed above; however, Eisai did not elect to share in the benefit and cost with respect to either the October 2017 or May 2018 royalty reductions, which will impact the amount of profits (losses) on potential commercial sales of aducanumab to be shared with Eisai. For additional information on our collaboration arrangements with Eisai, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 17, Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to these condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Unconsolidated Variable Interest Entities</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have relationships with various variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13683115e961-wk-Fact-0EC1C92334AD517690D05DC8718AED69" name="biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">22.4</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13683115e965-wk-Fact-F5D549E793FAB8ED6D735EE8D299EF61" name="biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">22.7</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our investments in Neurimmune and other variable interest entities, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 19, Investments in Variable Interest Entities,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div></ix:continuation><div><a id="s2B2C7B9F282F557C96195525BC3E7F08"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">19</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Litigation</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"> </span></div></td></tr></table><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="TextSelection-7F11942EFF075932B07CB6F0A6163135-0-wk-Fact-26C7FE6252CC5146A73DD278511C8902" continuedAt="TextSelection-7F11942EFF075932B07CB6F0A6163135-1" escape="true"><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 1, Summary of Significant Accounting Policies,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#8217; legal theories; and (v) the parties' settlement positions. </span></div></ix:nonNumeric><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">41</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-7F11942EFF075932B07CB6F0A6163135-1" continuedAt="TextSelection-7F11942EFF075932B07CB6F0A6163135-2"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Loss Contingencies </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">IMRALDI Patent Litigation</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2018 Fresenius Kabi Deutschland GmbH (Fresenius Kabi) commenced proceedings for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris, alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis UK Limited that Biogen has commercialized in Europe, infringes the French counterpart of European Patent No. 3 148 510 (the '510 Patent), which was issued in June 2018 and expires in May 2035. No hearing has been scheduled. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2018 Fresenius Kabi commenced preliminary injunction proceedings against Biogen (Denmark) Manufacturing ApS and Biogen Denmark A/S in Denmark's Maritime and Commercial High Court alleging infringement of Danish Utility Models. In June 2019 the Danish court denied Fresenius Kabi's request for a preliminary injunction and Fresenius Kabi has appealed that decision. In July 2020 the Danish Patent Board of Appeal revoked the Utility Models that were the subject of Fresenius Kabi&#8217;s October 2018 request for a preliminary injunction. Fresenius Kabi has not yet appealed those revocations.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2020 Fresenius Kabi commenced preliminary injunction proceedings against Biogen (Denmark) Manufacturing ApS and Biogen (Denmark) A/S in Denmark&#8217;s Maritime and Commercial High Court alleging infringement of another Danish Utility Model. No hearing has been scheduled in that action.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2018 Fresenius Kabi commenced infringement proceedings for damages and injunctive relief against Biogen Italia S.R.L. in the District Court of Milan relating to the Italian counterpart of the &#8216;510 Patent, and against Biogen GmbH in the D&#252;sseldorf Regional Court relating to the German counterpart of the &#8216;510 Patent. In Italy, Fresenius Kabi has surrendered the Italian counterpart of the &#8216;510 Patent and has moved to dismiss its infringement action. A hearing in the proceeding in Germany has been set for April 2021.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2019 Gedeon Richter PLC (Gedeon Richter) commenced proceedings against Biogen GmbH in the D&#252;sseldorf Regional Court alleging infringement of the German counterpart of European Patent No. 3 212 667 (the '667 Patent), which was issued in September 2018 and expires in October 2035, and seeking damages and injunctive relief. A hearing has been set for November 2020.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2019 Biogen Idec Ltd. (Biogen UK) and Samsung Bioepis UK Limited filed an action in the United Kingdom Patents Court to revoke the United Kingdom (U.K.) counterpart of the '667 Patent. In January 2020 the U.K. court revoked the patent.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2019 Biogen B.V. (Netherlands) and Samsung Bioepis UK Limited filed an action in the District Court of the Hague, Netherlands to revoke the Dutch counterpart of the '667 Patent. Gedeon Richter filed a separate action for infringement in the same court. A hearing was held in May 2020 on the request for revocation and the infringement action and a decision is pending.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An estimate of the possible loss or range of loss in the pending IMRALDI patent litigation described above cannot be made at this time. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Qui Tam Litigation</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2015 a qui tam action filed by Michael Bawduniak on behalf of the U.S. and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts and seeks single and treble damages, civil penalties, interest, attorneys&#8217; fees and costs. No trial date has been set. The U.S. has not made an intervention decision. An estimate of the possible loss or range of loss cannot be made at this time.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">42</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-7F11942EFF075932B07CB6F0A6163135-2" continuedAt="TextSelection-7F11942EFF075932B07CB6F0A6163135-3"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Dispute with Former Convergence Shareholders</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November and December 2019 Shareholder Representative Services LLC, on behalf of the former shareholders of Convergence, sent us correspondence asserting claims of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13685541e853-wk-Fact-EAF08B59FD5558EEABC2FA3752BE6C21" name="us-gaap:LossContingencyEstimateOfPossibleLoss" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">200.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for alleged breach of the contract under which we acquired Convergence. We dispute the claims.</span></div><div style="line-height:174%;padding-top:12px;text-align:left;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Dispute with Jacobs Switzerland GmbH</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Jacobs Switzerland GmbH, the general contractor for the construction of our large-scale biologics manufacturing facility in Solothurn, Switzerland, claims approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d13685541e863-wk-Fact-CA9C347139CCAD692BAB5EEC2CCFEE07" name="biib:DisputedClaimsRelatingtoConstructionCosts" contextRef="FI2020Q2" unitRef="chf" decimals="-6" scale="6" format="ixt:numdotdecimal">31.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Swiss Francs (approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13685541e867-wk-Fact-4788D1A2CD2AFB78CA345EEC7654A6ED" name="biib:DisputedClaimsRelatingtoConstructionCosts" contextRef="FI2020Q2" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">33.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) relating to construction costs. We dispute the claim.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Matters</span></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Petition for Inter Partes Review</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2018 Mylan filed a petition that was granted by the U.S. Patent Trial and Appeal Board (PTAB) for </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> review of the '514 Patent, which covers treatment of MS with 480 mg of dimethyl fumarate per day as provided for in our TECFIDERA label. In February 2020 the PTAB issued a final written decision upholding the patentability of the &#8216;514 Patent and in April 2020 Mylan filed an appeal in the Federal Circuit, which is pending.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Hatch-Waxman Act Litigation relating to TECFIDERA Orange-Book Listed Patents</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2017, 2018 and 2019 we filed patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, against Accord Healthcare Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Aurobindo Pharma U.S.A., Inc., Cipla Limited, Glenmark Pharmaceuticals Ltd., Graviti Pharmaceuticals Pvt. Ltd., Hetero USA, Inc.,&#160;Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Prinston Pharmaceutical Inc., Sandoz Inc., Sawai USA, Inc., Shilpa Medicare Limited, Slayback Pharma LLC, Torrent Pharmaceuticals Ltd., TWi Pharmaceuticals, Inc., Windlas Healthcare Pvt. Ltd. and Zydus Pharmaceuticals (USA) Inc. (the Delaware Defendants) in the U.S. District Court for the District of Delaware (the Delaware Court) and against Mylan in the West Virginia Court. The litigation against Aurobindo Pharma U.S.A., Inc., Glenmark Pharmaceuticals Ltd. and Sawai USA, Inc. was dismissed in the fourth quarter of 2019.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A trial against the remaining Delaware Defendants was held in the Delaware Court in December 2019 and we are awaiting a decision.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On June 22, 2020, the West Virginia Court entered judgment for Mylan that the asserted claims of the &#8216;514 Patent are invalid for lack of written description. We appealed the judgment on June 23, 2020, to the Federal Circuit and filed an emergency motion for an injunction pending resolution of the appeal. On June 30, 2020, the Federal Circuit entered an interim injunction enjoining Mylan from launching its generic version of TECFIDERA pending the Federal Circuit's consideration of our request for an injunction pending appeal.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have entered into settlement agreements with some of the Delaware Defendants and we now anticipate market entry of a generic product equivalent to TECFIDERA before the &#8216;514 Patent expires in February 2028.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">European Patent Office Oppositions</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2016 the European Patent Office (EPO) revoked our European Patent No. 2 137 537, which covers the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. We have appealed to the Technical Boards of Appeal of the EPO and a hearing has been set for January 2021. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2018 the EPO revoked Forward Pharma&#8217;s European Patent No. 2 801 355, which expires in October 2025. Forward Pharma has filed an appeal to the Technical Boards of Appeal of the EPO and a hearing has been set for February 2021. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TYSABRI Patent Revocation Matters</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2017 Bioeq GMBH, affiliated with the Polpharma Group, brought an action in the Polish Patent Office seeking to revoke Polish Patent No. 215263 (the Polish '263 Patent), which corresponds to our European Patent No. 1 485 127 (the E.U. '127 Patent) and covers administration of natalizumab (TYSABRI) to treat MS. The Polish '263 Patent expires in February 2023. No hearing has been set in this matter.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">43</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</span></div></div><div><br/></div><ix:continuation id="TextSelection-7F11942EFF075932B07CB6F0A6163135-3"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss Pharma International AG, also affiliated with the Polpharma Group, filed actions in the District Court of the Hague, Netherlands (January 2016), the German Patents Court (March 2016) and the Commercial Court of Rome (November 2017) seeking to invalidate the Dutch, German and Italian counterparts, respectively, of the E.U. '127 Patent, which also cover administration of natalizumab (TYSABRI) to treat MS and expire in February 2023. The Dutch and German counterparts were ruled invalid. The decision in the Dutch action was affirmed on appeal and the German appeal has been withdrawn. No hearing has been set in the Italian action.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">'755 Patent Litigation</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May&#160;2010 Biogen MA Inc. (formerly Biogen Idec MA Inc.) filed a complaint in the U.S.&#160;District Court for the District of New Jersey alleging infringement by Bayer Healthcare Pharmaceuticals Inc. (Bayer) (manufacturer, marketer and seller of BETASERON and manufacturer of EXTAVIA), EMD Serono, Inc. (EMD Serono) (manufacturer, marketer and seller of REBIF), Pfizer (co-marketer of REBIF) and Novartis Pharmaceuticals Corp. (Novartis) (marketer and seller of EXTAVIA) of our U.S. Patent No. 7,588,755 (the '755 Patent), which claims, among other things, the use of interferon beta for immunomodulation. The complaint seeks monetary damages, including lost profits and royalties. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bayer, Pfizer, Novartis and EMD Serono all filed counterclaims seeking declaratory judgments of patent invalidity and non-infringement and seeking monetary relief in the form of costs and attorneys' fees. Bayer had previously filed a complaint against us in the same court, on May 27, 2010, seeking a declaratory judgment that it does not infringe the '755 Patent and that the '755 Patent is invalid, and seeking monetary relief in the form of attorneys' fees, costs and expenses. Bayer has also requested </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">ex parte</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reexamination by the U.S. Patent and Trademark Office of Claim 1 of the &#8216;755 Patent, which request was granted in January 2020 and is pending.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2018 the trial court entered judgment against EMD Serono and Pfizer that the '755 Patent is infringed and valid and ordered a new trial on damages. EMD Serono and Pfizer filed an appeal in the U.S. Court of Appeals for the Federal Circuit, which is pending. The trial court has not yet scheduled the new damages trial or a trial against Bayer and Novartis.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Annulment Proceeding in General Court of the European Union relating to TECFIDERA</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2018 Pharmaceutical Works Polpharma SA (Polpharma) filed an application in the General Court of the European Union seeking to annul a decision of the European Medicines Agency (EMA) in which the EMA refused to validate Polpharma&#8217;s application to market a generic version of TECFIDERA on the grounds that TECFIDERA benefits from regulatory data protection (RDP). Polpharma disputes that TECFIDERA benefits from RDP. Biogen and the European Commission were granted leave to intervene in the case in support of the EMA and the case is pending. A hearing was held on</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#ff0000;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">July 13, 2020, and we are awaiting a decision.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Government Matters</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have learned that state and U.S. governmental authorities are investigating our sales and promotional practices and have received related subpoenas. We are cooperating with the investigation.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have received subpoenas and other requests from the U.S. government for documents and information relating to our relationship with non-profit organizations that assist patients taking drugs sold by Biogen and the government has challenged some of our contributions to these organizations. We have reached an agreement in principle with the government to resolve this matter.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Matter</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We previously reported that the State Treasury of Goias, Brazil issued tax assessments for the period 2013 through February 2018 relating to tax on the circulation of goods and totaling approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$<ix:nonFraction id="d13685541e961-wk-Fact-8DBEF3477A6153DFA64FFDF85A8C0D9E" name="us-gaap:LossContingencyDamagesSoughtValue" contextRef="FD2020Q2YTD_us-gaap_IncomeTaxAuthorityAxis_country_BR" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">70.0</ix:nonFraction> million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> including interest and penalties.&#160;In May 2020 the tax auditor recommended the cancellation of these assessments. We do not anticipate reporting on this matter further.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Product Liability and Other Legal Proceedings</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">44</span></div></div><hr style="page-break-after:always"></hr><div><a id="sBE09E681FDFC53839DAFD20102CADCC9"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;2.&#160;&#160;&#160;&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-style:italic;font-weight:bold;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following discussion should be read in conjunction with our unaudited condensed consolidated financial statements (condensed consolidated financial statements) and the accompanying notes beginning on page&#160;5 of this quarterly report on Form&#160;10-Q and our audited consolidated financial statements and the accompanying notes included in our Annual Report on Form&#160;10-K for the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K).</span></div><div><a id="s99c4db4ad01d46d3b731e2d0e516cd5e"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Executive Summary</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Introduction</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer's disease (AD) and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; and ophthalmology. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; neurocognitive disorders; acute neurology; and pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.  </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS and relapsing MS (RMS); and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 18,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduce the cost burden for healthcare systems. Through Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe and have exclusive rights to commercialize these products in China. Additionally, we have exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11 referencing LUCENTIS and SB15 referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 17, Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our revenues depend upon continued sales of our products, as well as the financial rights we have in our anti-CD20 therapeutic programs, and, unless we develop, acquire rights to and/or commercialize new products and technologies, we will be substantially dependent on sales from our products and our financial rights in our anti-CD20 therapeutic programs for many years. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the longer term, our revenue growth will depend upon the successful clinical development, regulatory approval and launch of new commercial products as well as additional indications for our existing products, our ability to obtain and maintain patents and other rights related to our marketed products, assets originating from our research and development efforts and/or successful execution of external business development opportunities.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Business Update Regarding COVID-19</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The COVID-19 pandemic continues to present a substantial public health and economic challenge around the world and is affecting our employees, patients, communities and business operations, as well as the U.S. and other major economies and financial markets. The length of time and full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition will depend on future developments that are highly uncertain, subject to change and are difficult to predict, including new information that may emerge concerning COVID-19, the actions taken to contain it or treat its impact and the economic impact on local, regional, national and international markets.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">45</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">To date, we and our collaboration partners have been able to continue to supply our products to our patients worldwide and currently do not anticipate any interruptions in supply. We have and are continuing to assess the actual and potential impacts of the COVID-19 pandemic on our business and operations, including our sales, expenses, manufacturing and clinical trials.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are monitoring the demand for our products, including the duration and degree to which we may see declines in customer orders or delays in starting new patients on a product due to hospitals diverting the resources that are necessary to administer certain of our products to care for COVID-19 patients, including products, such as TYSABRI and SPINRAZA, that are administered in a physician's office or hospital setting. We may also see reduced demand for immunosuppressant therapies during the COVID-19 pandemic. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have suspended the vast majority of our in-person interactions by our customer-facing professionals in healthcare settings and have engaged with these customers remotely as we seek to continue to support healthcare professionals and patient care. During the second quarter of 2020, we began limited in-person customer meetings and interactions consistent with local government mandates.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the first quarter of 2020 we believe we benefited from precautionary measures taken by our customers due to the COVID-19 pandemic, such as increasing their levels of stock in anticipation of any interruptions from the pandemic, but over the longer term we may see an impact from advance sales or fewer patients visiting their healthcare provider to initiate, change or receive therapy. </span><span style="font-family:Franklin Gothic Book,sans-serif;">During the second quarter of 2020 we believe customers began to utilize the product purchased</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;">in the first quarter of 2020, which adversely affected sales in the second quarter of 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may also see lower new prescriptions or refills of existing prescriptions due to increased unemployment as a result of the COVID-19 pandemic. The severity and duration of unemployment in the U.S. resulting from the effects of the COVID-19 pandemic may result in higher reserves for discounts and allowances in the second half of the year due to higher expected utilization of Medicaid.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and our third-party contract manufacturing partners continue to operate our manufacturing facilities at or near normal levels. While we currently do not anticipate any interruptions in our manufacturing process, it is possible that the COVID-19 pandemic and response efforts may have an impact in the future on our and/or our third-party suppliers and contract manufacturing partners' ability </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to manufacture our products or to have our products reach all markets.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While we are currently continuing the clinical trials we have underway in sites across the globe, COVID-19 precautions have impacted the timeline for some of our clinical trials and these precautions may, directly or indirectly, have a further impact on timing in the future. For example, our Phase 3 study of BIIB093 (glibenclamide IV) for large hemispheric infarction, a severe form of ischemic stroke, has been delayed as this study involves administration of BIIB093 in an acute hospital setting. We have also paused the initiation of new clinical trials for compounds that are known to be immunosuppressants. To help mitigate the impact of the COVID-19 pandemic to our clinical trials, we are pursuing innovative approaches such as remote monitoring, remote patient visits and supporting home infusions. These alternative measures have resulted in a modest increase to the cost of the clinical trials underway.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S. and in most other key markets, our office-based employees began working from home in early March 2020, while we ensured essential staffing levels in our operations remained in place, including maintaining key personnel in our laboratories and manufacturing facilities. As local regulations have permitted, we have begun to re-open certain of our offices, allowing employees to return to our offices in a phased, planned approach. To provide a safe work environment for our employees, we have, among other things, increased the cadence of sanitization of our office facilities, implemented various social distancing measures on our campuses, issued travel advisories to our employees consistent with government regulations and restricted participation of our employees in any events that have large gatherings.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are helping to increase the understanding of COVID-19 and advance research efforts and potential therapeutic options. For example, we have entered into a consortium with the Broad Institute of MIT and Harvard and Partners HealthCare to build and share a COVID-19 biobank. The biobank will help scientists study a large collection of de-identified biological and medical data to advance knowledge and search for potential vaccines and treatments for COVID-19. In May 2020 we entered into a process development and manufacturing agreement with Vir Biotechnology, Inc. (Vir) for the process development and clinical manufacturing of Vir's human monoclonal antibodies for the potential treatment of COVID-19. In addition, the Biogen Foundation has contributed </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to support the global response efforts related to the COVID-19 pandemic and the immediate needs of communities affected by it.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the various risks posed by the COVID-19 pandemic, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Item 3. </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Quantitative and Qualitative Disclosures About Market Risk </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Item 1A.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> included in this report.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Business Environment</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The biopharmaceutical industry and the markets in which we operate are intensely competitive. Many of our competitors are working to develop or have commercialized products similar to those we market or are developing and have considerable experience in undertaking clinical trials and in obtaining regulatory approval to market pharmaceutical products. In addition, the commercialization of certain of our own approved products, products of our collaborators and pipeline product candidates may negatively impact future sales of our existing products. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our products and revenue streams continue to face increasing competition in many markets from generic versions, prodrugs and biosimilars of existing products as well as products approved under abbreviated regulatory pathways. Such products are likely to be sold at substantially lower prices than branded products. Accordingly, the introduction of such products as well as other lower-priced competing products may significantly reduce both the price that we are able to charge for our products and the volume of products we sell, which will negatively impact our revenues. In addition, when a generic version of one of our products is commercialized, it may, in some cases, be automatically substituted for our product and reduce our revenues in a short period of time. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sales of our products depend, to a significant extent, on the availability and extent of adequate coverage, pricing and reimbursement from government health administration authorities, private health insurers and other organizations. When a new pharmaceutical product is approved, the availability of government and private reimbursement for that product may be uncertain, as is the pricing and amount for which that product will be reimbursed.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Drug prices are under significant scrutiny in the markets in which our products are prescribed.&#160;We expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis.&#160;</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our failure to obtain or maintain adequate coverage, pricing or reimbursement for our products could have an adverse effect on our business, reputation, revenues and results of operations, could curtail or eliminate our ability to adequately fund research and development programs for the discovery and commercialization of new products or could cause a decline or volatility in our stock price.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to&#160;the impact of competition, pricing actions and other measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, our sales </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and operations could also be affected by other risks of doing business internationally, including the impact of public health epidemics, such as the COVID-19 pandemic, on employees, the global economy and the delivery of healthcare treatments, foreign currency exchange fluctuations, changes in intellectual property legal protections and changes in trade regulations and procedures.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the competition and pricing risks that could negatively impact our product sales, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Item 3. Quantitative and Qualitative Disclosures About Market Risk </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Item 1A.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> included in this report.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TECFIDERA</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On June 22, 2020, the U.S. District Court for the Northern District of West Virginia (the West Virginia Court) entered judgment for Mylan Pharmaceuticals, Inc. (Mylan) that the asserted claims of our U.S. Patent No. 8,399,514 (the '514 Patent) are invalid for lack of written description. </span><span style="font-family:Franklin Gothic Book,sans-serif;">The '514 Patent covers treatment of MS with 480 mg of dimethyl fumarate per day as provided for in our TECFIDERA label, and the litigation was filed pursuant to the</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Drug Competition and Patent Term Restoration Act of 1984, commonly known as the </span><span style="font-family:Franklin Gothic Book,sans-serif;">Hatch-Waxman Act. We appealed the judgment on June 23, 2020, to the U.S. Court of Appeals for the Federal Circuit (Federal Circuit) and filed an emergency motion for an injunction pending resolution of the appeal.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;">On June 30, 2020, </span><span style="background-color:#ffffff;font-family:Franklin Gothic Book,sans-serif;">the Federal Circuit entered an interim injunction enjoining Mylan from launching its generic version of TECFIDERA pending the Federal Circuit's consideration of our request for an injunction pending appeal. In the event that our request for an injunction pending appeal is denied, generic entry could occur during the appeal.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;">The '514 Patent has also been challenged in the U.S. District Court of Delaware in litigation filed pursuant to the Hatch-Waxman Act </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(the Delaware action) and we are awaiting a decision.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;">We have entered into settlement agreements with some of the defendants in the Delaware action and we now anticipate market entry of a generic product equivalent to TECFIDERA before the '514 Patent expires in February 2028.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;">In February 2020, in an </span><span style="font-family:Franklin Gothic Book,sans-serif;font-style:italic;">inter partes</span><span style="font-family:Franklin Gothic Book,sans-serif;"> review proceeding filed by Mylan, the</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> U.S. Patent Trial and Appeal Board (PTAB) </span><span style="font-family:Franklin Gothic Book,sans-serif;">ruled that the challenged claims of the '514 Patent are patentable. Mylan has appealed and the appeal is pending.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;">The commercialization of a generic version of TECFIDERA would have an adverse impact on our TECFIDERA sales and our results of operations.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 19, Litigation</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Brexit </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the U.K. electorate voted in a referendum to voluntarily depart from the E.U., known as Brexit. In March 2017 the U.K. government formally notified the European Council of its intention to leave the E.U. and began to negotiate the terms of its withdrawal and outline the future relationship between the U.K. and the E.U. upon exit, which occurred on January 31, 2020. Following the U.K.&#8217;s departure, there is now a transition period during which existing arrangements will remain in place until the end of 2020, allowing detailed discussions on the future relationship between the U.K. and the E.U. to take place.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The actual effects of Brexit will depend upon many factors and significant uncertainty remains with respect to the future relationship between the U.K. and the E.U. The final outcome of the discussions during the transition period may impact certain of our research, commercial and general business operations in the U.K. and the E.U., including the approval and supply of our products. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Compliance with any resulting regulatory mandates may prove challenging and the macroeconomic impact on our sales and consolidated results of operations from these developments remains unknown. We do not expect Brexit to have a material impact on our consolidated results of operations as less than </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our total product revenues for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, were derived from U.K. sales, which is consistent with full year product sales in 2019.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have implemented measures to meet E.U. legal and regulatory requirements and continue to modify our business operations to prepare for the end of the transition period and the finalization of the terms of the U.K.'s separation from the E.U. However, we cannot predict the direction Brexit-related developments will take nor the impact of those developments on our European operations and the economies of the markets where we operate. Therefore, we will continue to monitor developments in this area and assess any potential impact on our business and results of operations.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">48</span></div></div><hr style="page-break-after:always"></hr><div><a id="s3FA623AE14D959F2A033DEB46577BD6B"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Financial Highlights</span></div><div style="line-height:120%;text-align:justify;"><img src="chart-48bec865e66533dbc2f.jpg" alt="chart-48bec865e66533dbc2f.jpg" style="height:426px;width:317px;"></img></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc. was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$9.59</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22.2%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> over </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.85</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As further described below under </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Results of Operations</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our net income and diluted earnings per share attributable to Biogen Inc. for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflects the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues were </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$3,681.6 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">second</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> quarter of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">1.8%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> over </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$3,616.7 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the same period in </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net totaled </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$2,795.7 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">second</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> quarter of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing a decrease of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2.9%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> over </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$2,880.3 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the same period in </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This decrease was primarily due to a </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">3.5%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> decrease in MS product revenues and a </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">6.9%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> decrease in our biosimilar products, partially offset by a </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">1.3%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> increase in revenues from SPINRAZA. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We believe that, due to the COVID-19 pandemic, there was an acceleration in sales in the first quarter of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, primarily in the E.U., that increased revenues by approximately </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$100.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </span><span style="font-family:Franklin Gothic Book,sans-serif;">During the second quarter of </span></div></td></tr></table></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-left:96px;padding-top:8px;text-align:left;"><span style="font-family:Franklin Gothic Book,sans-serif;">2020 we believe customers began to utilize the product purchased</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> (approximately </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$75.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) </span><span style="font-family:Franklin Gothic Book,sans-serif;">in the first quarter of 2020, which adversely affected sales in the second quarter of 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs totaled </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$478.3 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">second</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> quarter of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing a decrease of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">17.0%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> from </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$576.4 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the same period in </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This decrease was primarily due to a </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">33.0%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> decrease in RITUXAN revenues, partially offset by a </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">14.0%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> increase in royalty revenues on sales of OCREVUS. We believe that sales of RITUXAN have been adversely affected by the onset of biosimilars competition and adverse impacts that we believe were due to the COVID-19 pandemic, </span><span style="font-family:Franklin Gothic Book,sans-serif;">as hospitals prioritize the treatment of COVID-19 patients and/or patients decide to delay treatment.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues totaled </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$407.6 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">second</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> quarter of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase from </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$160.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the same period in </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This increase reflects </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$329.4 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;">related to the delivery of the license for certain of our manufacturing-related intellectual property to a contract manufacturing customer</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses were </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$1,707.1 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">second</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> quarter of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2.8%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> from </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$1,660.8 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the same period in </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This increase was primarily due to a </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">33.6%</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">increase in research and development expense, partially offset by a</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">13.7%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> decrease in cost of sales.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in research and development expense was primarily due to </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$208.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in charges recognized upon the closing of our collaboration with Sangamo Therapeutics, Inc. (Sangamo) in the </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">second</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> quarter of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As described below under </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Financial Condition, Liquidity and Capital Resources:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash, cash equivalents and marketable securities totaled approximately </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$5.3 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$5.9 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">9.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$2.8 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">second</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> quarter of 2020 under a program authorized by our Board of Directors in </span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-left:48px;padding-top:8px;text-align:left;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 2019 to repurchase up to </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$5.0 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock (December 2019 Share Repurchase Program).</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">April&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we issued senior unsecured notes for an aggregate principal amount of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;">$3.0 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> (2020 Senior Notes).</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acquisitions and Collaborative and Other Relationships</span></div><div style="line-height:120%;padding-top:8px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BIIB118 Acquisition</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2020 we acquired BIIB118 (formerly known as PF-05251749), a novel CNS-penetrant small molecule inhibitor of casein kinase 1, for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases from Pfizer Inc. (Pfizer). We plan to develop this Phase 1 asset for the potential treatment of sundowning in AD and irregular sleep wake rhythm in Parkinson&#8217;s disease.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our acquisition of BIIB118, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 2, Acquisitions</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our condensed consolidated financial statements included in this report</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Sangamo Therapeutics, Inc.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2020 we closed a collaboration and license agreement with Sangamo to develop and commercialize ST-501 for tauopathies, including AD; ST-502 for synucleinopathies, including, Parkinson&#8217;s disease; a third neuromuscular disease target; and up to nine additional neurological disease targets to be identified and selected within a five-year period.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with Sangamo, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 17, Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Key Developments</span></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Aducanumab (AB mAb)</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2020 we and our collaboration partner Eisai Co., Ltd. (Eisai) announced that we completed the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the approval of aducanumab, an anti-amyloid beta antibody candidate for the potential treatment of AD. The completed submission followed ongoing collaboration with the FDA and includes clinical data from the Phase 3 EMERGE and ENGAGE studies as well as the Phase 1b PRIME study.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the first quarter of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we initiated the EMBARK global re-dosing clinical study, which is designed to evaluate aducanumab in eligible AD patients who were actively enrolled in aducanumab </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">studies (PRIME, EVOLVE, EMERGE and ENGAGE) in March 2019.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50</span></div></div><hr style="page-break-after:always"></hr><div><a id="sA163EE0E8C2A5EBD857A0A597D483C6C"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:17px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Results of Operations</span></div><div style="line-height:120%;padding-top:8px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Revenues</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="29"></td></tr><tr><td style="width:28%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Product revenues, net:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">1,721.7</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">46.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,744.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">48.2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">3,304.9</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">45.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3,257.7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">45.8</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Rest of world</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">1,074.0</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">29.2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,135.9</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">31.4</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">2,395.4</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">33.2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,302.6</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">32.4</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total product revenues, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">2,795.7</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">75.9</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,880.3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">79.6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">5,700.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">79.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">5,560.3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">78.2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Revenues from anti-CD20 therapeutic programs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">478.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">13.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">576.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">15.9</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">998.7</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">13.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,093.8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">15.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">407.6</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">11.1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">160.0</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">4.4</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">516.9</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">7.2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">452.4</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">6.4</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">3,681.6</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">100.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3,616.7</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">100.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">7,215.9</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">100.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">7,106.5</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">100.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a id="sDCB2542A0C3059AABC6F23D2FA6BE39F"></a></div><div style="line-height:120%;padding-top:8px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Product Revenues</span></div></div></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="29"></td></tr><tr><td style="width:28%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Multiple Sclerosis:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Fumarate*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">1,190.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">42.6</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,150.2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">39.9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">2,291.1</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">40.2</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,149.0</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">38.6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Interferon**</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">481.4</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">17.2</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">554.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">19.2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">947.4</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">16.6</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,055.3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">19.0</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TYSABRI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">432.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">15.5</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">475.3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">16.5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">954.4</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">16.7</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">935.7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">16.8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FAMPYRA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">23.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">0.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">24.1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">0.8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">51.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">0.9</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">47.0</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">0.8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Subtotal: MS product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">2,126.7</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">76.1</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,204.0</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">76.5</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">4,244.2</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">74.5</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">4,187.0</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">75.3</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Spinal Muscular Atrophy:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">SPINRAZA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">494.6</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">17.7</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">488.2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">16.9</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">1,059.6</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">18.6</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,006.7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">18.1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Biosimilars:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">BENEPALI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">106.2</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">3.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">120.3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">4.2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">239.7</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">4.2</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">244.3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">4.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">IMRALDI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">44.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">1.6</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">47.3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1.6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">106.4</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">1.9</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">83.0</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1.5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FLIXABI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">20.6</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">0.7</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">16.8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">0.6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">44.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">0.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">31.5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">0.6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Subtotal: Biosimilar product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">171.6</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">6.1</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">184.4</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">6.4</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">390.4</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">6.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">358.8</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">6.5</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FUMADERM</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">2.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">0.1</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3.7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">0.1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">6.1</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">0.1</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">7.8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">0.1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">2,795.7</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">100.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,880.3</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">100.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">5,700.3</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">100.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">5,560.3</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">100.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">*Fumarate includes TECFIDERA and VUMERITY. VUMERITY became commercially available in the U.S. in November 2019.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">**Interferon includes AVONEX and PLEGRIDY.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Multiple Sclerosis (MS)</span></div><div style="line-height:120%;padding-top:8px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Fumarate</span></div><div style="line-height:120%;"><img src="chart-45031cdc71e753f6a7b.jpg" alt="chart-45031cdc71e753f6a7b.jpg" style="height:293px;width:317px;"></img></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fumarate revenues include sales from TECFIDERA and VUMERITY. In October 2019 the FDA approved VUMERITY for the treatment of RMS and VUMERITY became commercially available in the U.S. in November 2019.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increases of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.0%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.0%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in U.S. Fumarate revenues were primarily due to net price increases and increases in Fumarate sales volumes of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.4%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.0%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Volume in the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">second</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> quarter of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reflected favorable channel dynamics of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$33.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.2%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in rest of world Fumarate revenues was primarily due to pricing reductions in certain European countries and unfavorable foreign currency impact, partially offset by an increase in sales volumes of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.5%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We believe that, due to the COVID-19 pandemic, there was an acceleration in sales during the first quarter of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> that increased Fumarate revenues by approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the U.S. and approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$28.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in rest of world. </span><span style="font-family:Franklin Gothic Book,sans-serif;">During the second quarter of 2020 we believe customers began to utilize the product purchased</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> (approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the U.S. and approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$17.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in rest of world) </span><span style="font-family:Franklin Gothic Book,sans-serif;">in the first quarter of 2020, which adversely affected sales in the second quarter of 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.4%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in rest of world Fumarate revenues was primarily due to an increase in sales volumes of </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.1%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which was primarily related to our European and Japanese markets, partially offset by pricing reductions in certain European countries. The increase in volumes was primarily due to continued strong patient growth in our E.U. direct markets, including Italy, Spain and the U.K., as well as growth in Asia (Japan) and Latin America (Brazil).</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On June 22, 2020, the West Virginia Court entered judgment for Mylan that the asserted claims of the '514 Patent are invalid for lack of written description. </span><span style="font-family:Franklin Gothic Book,sans-serif;">The '514 Patent covers treatment of MS with 480 mg of dimethyl fumarate per day as provided for in our TECFIDERA label, and the litigation was filed pursuant to the</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Hatch-Waxman Act. We appealed the judgment on June 23, 2020, to the Federal Circuit and filed an emergency motion for an injunction pending resolution of the appeal.</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;">On June 30, 2020, </span><span style="background-color:#ffffff;font-family:Franklin Gothic Book,sans-serif;">the Federal Circuit entered an interim injunction enjoining Mylan from launching its generic version of TECFIDERA pending the Federal Circuit's consideration of our request for an injunction pending appeal. In the event that our request for an injunction pending appeal is denied, generic entry could occur during the appeal.</span></div><div style="line-height:120%;padding-top:8px;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The '514 Patent has also been challenged in the Delaware action and we are awaiting a decision.</span></div><div style="line-height:120%;padding-top:8px;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;">We have entered into settlement agreements with some of the defendants in the Delaware action and we now anticipate market entry of a generic product equivalent to TECFIDERA before the '514 Patent expires in February 2028.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;">In February 2020, in an </span><span style="font-family:Franklin Gothic Book,sans-serif;font-style:italic;">inter partes</span><span style="font-family:Franklin Gothic Book,sans-serif;"> review proceeding filed by Mylan, the</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> PTAB </span><span style="font-family:Franklin Gothic Book,sans-serif;">ruled that the challenged claims of the '514 Patent are patentable. Mylan has appealed and the appeal is pending.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;">The commercialization of a generic version of TECFIDERA would have an adverse impact on our TECFIDERA sales and our results of operations.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 19, Litigation</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We anticipate an increase in TECFIDERA demand in rest of world in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, notwithstanding the increasing competition from additional treatments for MS and potential disruptions from the COVID-19 pandemic. We expect volume growth in our rest of world markets to offset volume declines in the U.S in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, assuming no generic TECFIDERA competition in the U.S. Due to the COVID-19 pandemic, we may experience variability in sales between quarters within the year.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">52</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Interferon</span></div><div style="line-height:120%;text-align:left;"><img src="chart-5cd5aa12b0d45778869.jpg" alt="chart-5cd5aa12b0d45778869.jpg" style="height:293px;width:317px;"></img></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decreases of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.0%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.7%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in U.S. Interferon revenues were primarily due to decreases in Interferon sales volumes of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.8%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.6%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. The net declines in sales volumes reflect the continued decline of the Interferon market as patients transition to other higher efficacy and oral MS therapies, which negatively impacted comparative revenues by </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$55.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$95.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. The declines were partially offset by favorable channel dynamics of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$27.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decreases of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22.3%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.2%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in rest of world Interferon revenues were primarily due to decreases in Interferon sales volumes of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17.8%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.0%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We believe that, due to the COVID-19 pandemic, there was an acceleration in sales during the first quarter of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> that increased Interferon revenues by approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the U.S. and approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in rest of world. </span><span style="font-family:Franklin Gothic Book,sans-serif;">During the second quarter of 2020 we believe customers began to utilize the product purchased</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> (approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the U.S. and approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in rest of world) </span><span style="font-family:Franklin Gothic Book,sans-serif;">in the first quarter of 2020, which adversely affected sales in the second quarter of 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due to the COVID-19 pandemic, we may experience variability in sales between quarters within the year.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect that Interferon revenues will continue to decline in both the U.S. and rest of world markets </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as a result of increasing competition from our other MS products as well as other treatments for MS, including biosimilars, and pricing reductions in certain European markets.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TYSABRI</span></div><div style="line-height:120%;"><img src="chart-225be0f1a328510aba7.jpg" alt="chart-225be0f1a328510aba7.jpg" style="height:333px;width:317px;"></img></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.6%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in U.S. TYSABRI revenues was primarily due to unfavorable inventory channel dynamics of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$9.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and lower demand of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$14.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> due to site of care closures resulting from the COVID-19 pandemic.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.5%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in U.S. TYSABRI revenues was primarily due to price increases, partially offset by higher discounts and allowance rates.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.9%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in rest of world TYSABRI revenues was primarily due to an unfavorable foreign currency impact of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and an unfavorable volume impact of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which we believe reflects the utilization of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of product purchased in the first quarter of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> due to the COVID-19 pandemic and site of care closures resulting from the COVID-19 pandemic.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#ff0000;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, rest of world TYSABRI revenues remained flat.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due to the COVID-19 pandemic, we may experience variability in sales between quarters within the year.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">53</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We anticipate TYSABRI demand to be stable on a global basis in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, despite increasing competition from additional treatments for MS, including OCREVUS. We believe that some TYSABRI infusions may be delayed </span><span style="font-family:Franklin Gothic Book,sans-serif;">as hospitals prioritize the treatment of COVID-19 patients and/or patients decide to delay treatment.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Spinal Muscular Atrophy</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">SPINRAZA</span></div><div style="line-height:120%;text-align:left;"><img src="chart-8629c965f44558b0817.jpg" alt="chart-8629c965f44558b0817.jpg" style="height:293px;width:317px;"></img></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.8%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in U.S. SPINRAZA revenues was primarily due to a decrease in sales volumes of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.4%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as a result of lower loading and maintenance doses due to site of care closures in April and May 2020 as a result of the COVID-19 pandemic.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.8%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in U.S. SPINRAZA revenues was primarily due to a decrease in sales volumes of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as a result of lower loading and maintenance doses due to site of care closures in April and May 2020 resulting from the COVID-19 pandemic and higher discount and allowance rates, partially offset by price increases.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increases of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.4%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.1%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in rest of world SPINRAZA revenues were primarily due to increases in sales volumes of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18.4%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23.9%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, partially offset by the impact of a shift from loading to maintenance doses, lower net prices and the unfavorable impact of foreign currency exchange.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We believe that, due to the COVID-19 pandemic, there was an acceleration in sales during the first quarter of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> that increased SPINRAZA revenues by </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the U.S. and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in rest of world. </span><span style="font-family:Franklin Gothic Book,sans-serif;">During the second quarter of 2020 we believe customers began to utilize the product purchased</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> (approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the U.S. and approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in rest of world) </span><span style="font-family:Franklin Gothic Book,sans-serif;">in the first quarter of 2020, which adversely affected sales in the second quarter of 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due to the COVID-19 pandemic, we may experience variability in sales between quarters within the year.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect that the rate at which SPINRAZA revenues will grow will be modest in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, primarily due to a lower rate of new patient starts combined with the impact of loading dose dynamics as patients transition to dosing once every four months, lower prices in certain rest of world countries and the potential impact of the COVID-19 pandemic. We are evaluating the impact of the COVID-19 pandemic on the ability of hospitals to provide SPINRAZA dosing to patients. We believe that some SPINRAZA doses may be delayed as hospitals prioritize the treatment of COVID-19 patients and/or patients decide to delay treatment.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We face competition from a new gene therapy product that was approved in the U.S. in May 2019 and in the E.U. in May 2020 for the treatment of SMA. Additionally, we are aware of other products in development that, if successfully developed and approved, may compete with SPINRAZA in the SMA market, including potential oral products. Future sales of SPINRAZA may be adversely affected by the commercialization of competing products.</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For information on our collaboration arrangements with Ionis Pharmaceuticals, Inc. (Ionis), please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 18,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K. </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Biosimilars</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BENEPALI, IMRALDI and FLIXABI</span></div><div style="line-height:120%;"><img src="chart-3bef3451f3d85124b28.jpg" alt="chart-3bef3451f3d85124b28.jpg" style="height:333px;width:317px;"></img></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.9%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in biosimilar revenues was primarily due to the unfavorable impact of price decreases, partially offset by increased volumes. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.8%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in biosimilar revenues was primarily due to the continued launch of IMRALDI in Europe, partially offset by the unfavorable impact of price decreases.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additionally, we believe that, due to the COVID-19 pandemic, there was an acceleration in sales during the first quarter of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> that increased biosimilar revenues by approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </span><span style="font-family:Franklin Gothic Book,sans-serif;">During the second quarter of 2020 we believe customers began to utilize the product purchased</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> (approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$9.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) </span><span style="font-family:Franklin Gothic Book,sans-serif;">in the first quarter of 2020, which adversely affected sales in the second quarter of 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due to the COVID-19 pandemic, we may experience variability in sales between quarters within the year. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2020 we expect modest to moderate revenue growth for our biosimilars business depending on the impact of the COVID-19 pandemic. We expect growth to be primarily driven by the continued launch of IMRALDI in Europe, partially offset by price reductions in certain European countries.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 17, Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">condensed consolidated financial statements included in this report.</span></div><div><a id="sA99BE2CF9DAA5769B0447689911B240F"></a></div><div style="line-height:120%;padding-top:8px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Revenues from Anti-CD20 Therapeutic Programs</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Genentech (Roche Group)</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share of RITUXAN, including RITUXAN HYCELA, and GAZYVA collaboration operating profits in the U.S. and other revenues from anti-CD20 therapeutic programs are summarized in the table below. For purposes of this discussion, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div style="line-height:120%;"><img src="chart-e53e3e38390450fb989.jpg" alt="chart-e53e3e38390450fb989.jpg" style="height:346px;width:317px;"></img></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Biogen&#8217;s Share of Pre-tax Profits in the U.S. for RITUXAN and GAZYVA</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables provide a summary of amounts comprising our share of pre-tax profits in the U.S. for RITUXAN and GAZYVA:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:52%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:20%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:20%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Product revenues, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">807.9</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,165.0</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Cost and expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">121.5</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">158.5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Pre-tax profits in the U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">686.4</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,006.5</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Biogen's share of pre-tax profits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">257.5</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">377.2</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:52%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:20%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:20%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Product revenues, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">1,886.1</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,391.7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Cost and expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">268.9</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">331.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Pre-tax profits in the U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">1,617.2</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,060.3</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Biogen's share of pre-tax profits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">598.8</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">768.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">55</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decreases in U.S.&#160;product revenues, net were primarily due to decreased sales volume of RITUXAN in the U.S. of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28.7%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19.4%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, due to the onset of biosimilars competition and the adverse impacts that we believe were due to the COVID-19 pandemic, </span><span style="font-family:Franklin Gothic Book,sans-serif;">as hospitals prioritize the treatment of COVID-19 patients and/or patients decide to delay treatment.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increases in U.S. product revenues, net also reflects increases in GAZYVA sales volume of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.9%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36.8%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decreases in collaboration costs and expenses were primarily due to lower cost of sales on RITUXAN.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are aware of anti-CD20 molecules, including biosimilar products, in development that if successfully developed and approved, could compete with RITUXAN and GAZYVA in the oncology market. The introduction of a biosimilar product can result in a significant reduction in net sales for the relevant product, as other manufacturers typically offer their versions at lower prices. In November 2019 and January 2020 biosimilar products referencing RITUXAN were launched in the U.S. and this could adversely affect the pre-tax profits of our collaboration arrangements with Genentech, which could, in turn, adversely affect in a significant manner our co-promotion profits in the U.S. in future years.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Revenues from Anti-CD20 Therapeutic Programs</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from anti-CD20 therapeutic programs consist of royalty revenues on sales of OCREVUS and our share of pre-tax co-promotion profits from RITUXAN in Canada. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increases in other revenues from anti-CD20 therapeutic programs were primarily due to sales growth of OCREVUS. Royalty revenues recognized on sales of OCREVUS for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$208.2 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$370.5 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$182.7 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$294.3 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">OCREVUS royalty revenues are based on our estimates from third party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenues will be adjusted for in the period in which they become known, which is expected to be the following quarter.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Genentech, including information regarding the pre-tax profit-sharing formula and its impact on future revenues from anti-CD20 therapeutic programs, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note&#160;18, Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div></div></div><div><a id="s99B3885FE3B95B3A933F6CD226ABB908"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Other Revenues</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues are summarized as follows:</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="29"></td></tr><tr><td style="width:28%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Revenues from collaborative and other relationships</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">5.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">1.2</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">52.1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">32.6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">8.9</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">1.7</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">76.5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">16.9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other royalty and corporate revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">402.6</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">98.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">107.9</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">67.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">508.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">98.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">375.9</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">83.1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total other revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">407.6</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">100.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">160.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">100.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">516.9</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">100.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">452.4</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">100.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">%</span></div></td></tr></table></div></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Revenues from Collaborative and Other Relationships</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from collaborative and other relationships primarily include revenues from our technical development services and manufacturing agreements with Samsung Bioepis and royalty revenues on biosimilar products from Samsung Bioepis.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Following the divestiture of our Hiller&#248;d, Denmark manufacturing operations in August 2019, </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FUJIFILM Corporation (FUJIFILM) assumed responsibility for the manufacture of clinical and commercial quantities of bulk drug substance of biosimilar products for Samsung Bioepis. We no longer recognize revenues for the manufacturing completed after the manufacturing facility divestiture date under our technical development services and manufacturing agreements with Samsung Bioepis. </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">56</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaborative and other relationships, including revenues recognized under our technical development services and manufacturing agreements with Samsung Bioepis, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 17, Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 3, Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report.</span></div><div style="line-height:120%;padding-top:8px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Royalty and Corporate Revenues</span></div><div style="line-height:120%;"><img src="chart-25c6349f335257b28b2.jpg" alt="chart-25c6349f335257b28b2.jpg" style="height:400px;width:317px;"></img></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We receive royalties from net sales on products related to patents that we have out-licensed and we record other corporate revenues primarily from amounts earned under contract manufacturing agreements.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;">During the third quarter of 2019 we amended our agreement with a contract manufacturing customer, pursuant to which we licensed certain of our manufacturing-related intellectual property to the customer. In the second quarter of 2020 the customer received regulatory approval for its product that is being manufactured using certain of our manufacturing-related intellectual property. As a result, we are entitled to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$500.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;">in a series of three payments. The first payment became due upon regulatory approval of such product and was received during the</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">second</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> quarter of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </span><span style="font-family:Franklin Gothic Book,sans-serif;">Subsequent </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;">payments are due on the first and second anniversaries of the regulatory approval.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other corporate revenues for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflect </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$329.4 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;">related to the delivery of the license for certain of our manufacturing-related intellectual property under the amended agreement discussed above. We have allocated the remaining $170.6 million of the $500.0 million transaction price to the performance of manufacturing product supply services for the customer, which we expect to perform through 2026. The value allocated to the manufacturing services was based on expected demand for supply and the fair value of comparable manufacturing and development services</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increases in other royalty and corporate revenues were due to higher contract manufacturing revenues, primarily resulting from </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$329.4 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in revenues </span><span style="font-family:Franklin Gothic Book,sans-serif;">related to the delivery of the license for certain of our manufacturing-related intellectual property to a contract manufacturing customer</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> discussed above. The increase was partially offset by revenues recognized in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> under the manufacturing and supply agreement with Bioverativ Inc. (Bioverativ) entered into in connection with the spin-off of our hemophilia business as well as revenues recognized in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> under our technical development services and manufacturing agreements with Samsung Bioepis prior to the divestiture of our Hiller&#248;d, Denmark manufacturing facility operations.</span></div><div><a id="sE3F1682E24B75A279968676726396658"></a></div><div style="line-height:120%;padding-top:8px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Reserves for Discounts and Allowances</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recorded net of reserves established for applicable discounts and allowances, including those associated with the implementation of pricing actions in certain international markets where we operate.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). These estimates reflect our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reserves for discounts, contractual adjustments and returns that reduced gross product revenues are summarized as follows:</span></div><div style="line-height:120%;text-align:left;"><img src="chart-8e7d74fd3876590095c.jpg" alt="chart-8e7d74fd3876590095c.jpg" style="height:466px;width:317px;"></img></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reserves for discounts and allowances as a percentage of gross product revenues were </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26.0%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25.8%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23.1%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in both prior year comparative periods. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The severity and duration of unemployment in the U.S. resulting from the effects of the COVID-19 pandemic may result in higher reserves for discounts and allowances in the second half of the year due to higher expected utilization of Medicaid.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Discounts</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discounts include trade term discounts and wholesaler incentives.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in discounts were primarily driven by an increase in sales. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contractual Adjustments</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contractual adjustments primarily relate to Medicaid and managed care rebates, co-payment assistance, Veterans Administration, Public Health Service discounts, specialty pharmacy program fees and other government rebates or applicable allowances. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increases in contractual adjustments were primarily due to higher managed care rebates and governmental rebates in the U.S. as well as higher governmental rebates and allowances in the rest of world, due in part to increases in SPINRAZA sales volumes worldwide.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Returns</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product return reserves are established for returns made by wholesalers. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Provisions for product returns are recognized in the period the related revenues are recognized, resulting in a reduction to product sales.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, return reserves were relatively consistent.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our revenue reserves, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 4, Revenues</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">58</span></div></div><hr style="page-break-after:always"></hr><div><a id="sC58B02B5E63458B2B69F30415B04739B"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Cost and Expenses</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of total cost and expenses is as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Change&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Change&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Cost of sales, excluding amortization and impairment of acquired intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">411.1</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">476.3</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">(13.7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">865.5</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,078.3</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">(19.7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">647.6</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">484.8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">33.6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">1,123.9</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,048.5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">7.2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Selling, general and administrative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">555.1</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">587.6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">(5.5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">1,125.2</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,155.3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">(2.6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Amortization and impairment of acquired intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">61.5</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">70.1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">(12.3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">133.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">138.3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">(3.8</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Collaboration profit (loss) sharing</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">21.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">63.5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">(65.7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">93.5</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">121.6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">(23.1</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">(2.3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">**</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">113.2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">**</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">(Gain) loss on fair value remeasurement of contingent consideration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">10.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">(20.0</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">(150.0</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">5.5</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">(8.5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">(164.7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Restructuring charges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">0.8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">(100.0</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1.2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">(100.0</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Acquired in-process research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">**</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">75.0</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">**</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total cost and expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">1,707.1</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,660.8</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2.8</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">3,421.6</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3,647.9</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">(6.2</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)%</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">** Percentage not meaningful.</span></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a id="s44ED55F3014B50A4B3B21ADD54CB3B85"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cost of Sales, Excluding Amortization and Impairment of Acquired Intangible Assets</span></div><div style="line-height:120%;"><img src="chart-3395c23c9be152f4b2f.jpg" alt="chart-3395c23c9be152f4b2f.jpg" style="height:293px;width:317px;"></img></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Cost of Sales</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in product cost of sales was primarily due to lower cost of sales from contract manufacturing agreements, primarily resulting from FUJIFILM assuming </span><span style="font-family:Franklin Gothic Book,sans-serif;">responsibility for the manufacture of clinical and commercial quantities of bulk drug substance of biosimilar products for Samsung Bioepis. We no longer recognize revenues for the manufacturing completed after the Hiller&#248;d, Denmark manufacturing facility divestiture date under our technical development services and manufacturing agreements with Samsung Bioepis.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in product cost of sales was primarily due to lower cost of sales from contract manufacturing agreements, primarily resulting from the sale of hemophilia inventory, with a cost basis of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$173.5 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to Bioverativ in the first quarter of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and FUJIFILM assuming responsibility for the manufacture of clinical and commercial quantities of bulk drug substance of biosimilar products for Samsung Bioepis.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Royalty Cost of Sales</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in royalty cost of sales was primarily due to lower royalties payable on lower sales of TYSABRI. For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in royalty cost of sales was primarily due to higher royalties payable on higher sales of SPINRAZA.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">59</span></div></div><hr style="page-break-after:always"></hr><div><a id="s81AD2C93C8195EACB4B6D87CCF04EC23"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Research and Development</span></div><div style="line-height:120%;"><img src="chart-95f4f71dfede5b0db43.jpg" alt="chart-95f4f71dfede5b0db43.jpg" style="height:366px;width:317px;"></img></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;"><img src="chart-5fb3afa34aee5813b17.jpg" alt="chart-5fb3afa34aee5813b17.jpg" style="height:766px;width:317px;"></img></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A significant amount of our research and development costs consist of indirect costs incurred in support of overall research and development activities and non-specific programs, including activities that benefit multiple programs, such as </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">60</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">management costs, as well as depreciation, information technology and facility-based expenses. These costs are considered other research and development costs in the table above and are not allocated to a specific program or stage.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development expense incurred in support of our marketed products includes costs associated with product lifecycle management activities including, if applicable, costs associated with the development of new indications for existing products. Late stage programs are programs in Phase 3 development or in registration stage. Early stage programs are programs in Phase 1 or Phase 2 development. Research and discovery represents costs incurred to support our discovery research and translational science efforts. Costs are reflected in the development stage based upon the program status when incurred. Therefore, the same program could be reflected in different development stages in the same year. For several of our programs, the research and development activities are part of our collaborative and other relationships. Our costs reflect our share of the total costs incurred.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increases in research and development expense were primarily due to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$208.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in charges recognized upon the closing of our collaboration with Sangamo in the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">second</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> quarter of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While we are currently continuing the clinical trials we have underway in sites across the globe, COVID-19 precautions have impacted the timeline for some of our clinical trials and these precautions may, directly or indirectly, have a further impact on timing in the future. For example, our Phase 3 study of BIIB093 for large hemispheric infarction has been delayed as this study involves administration of BIIB093 in an acute hospital setting. We have also paused the initiation of new clinical trials for compounds that are known to be immunosuppressants.</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We intend to continue committing significant resources to targeted research and development opportunities where there is a significant unmet need and where a drug candidate has the potential to be highly differentiated.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Milestone and Upfront Expenses</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in 2019, the increases in milestone and upfront expenses were primarily due to a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$208.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> charge to research and development expense related to our collaboration and license agreement with Sangamo in the second quarter of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with Sangamo, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 17, </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our condensed consolidated financial statements included in this report.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Early Stage Programs</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decreases in spending related to our early stage programs were primarily due to the discontinuation of gosuranemab (BIIB092) in progressive supraneuclear palsy and the advancement of toferson (BIIB067) in ALS into late stage. The decreases were partially offset by increases in spending in the development of  BIIB112 (RPGR gene therapy) in X-linked retinitis pigmentosa.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Late Stage Programs</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decreases in spending associated with our late stage programs were primarily due to:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a decrease in spending related to the discontinuation of the global Phase 3 trials of aducanumab, net of reimbursement from our collaboration partner Eisai in the first quarter of 2019;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a decrease in spending related to the discontinuation of the global Phase 3 trials, MISSION AD1 and MISSION AD2, of elenbecestat (development code: E2609) in patients with early AD in the third quarter of 2019; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a decrease in spending related to VUMERITY, which was approved by the FDA in the fourth quarter of 2019.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These decreases were partially offset by an increase in spending due to the advancement of toferson in ALS into late stage, an increase in spending related to BAN2401 in early AD, an increase in spending related to our EMBARK redosing study for aducanumab and an increase in spending in the development of BIIB111 (timrepigene emparvovec) in choroideremia.</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the first quarter of 2019, as a result of the decision to discontinue the Phase 3 EMERGE and ENGAGE trials following a futility analysis, we accrued approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$45.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the termination of various clinical trials and research and development contracts net of the expected </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">45%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Eisai reimbursement of development costs incurred by the collaboration for the advancement of aducanumab. In July 2020 we and our collaboration partner Eisai announced that we completed the submission of a BLA to the FDA for the approval of aducanumab.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 Eisai initiated a global Phase 3 trial for the development of BAN2401 in early AD. Under our collaboration arrangement, Eisai serves as the global operational and regulatory lead for BAN2401 and all costs, including research, development, sales and marketing expenses, are shared equally between us and Eisai.</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Eisai, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 17, Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our condensed consolidated financial statements included in this report.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Selling, General and Administrative</span></div><div style="line-height:120%;"><img src="chart-54b677add07d50a682a.jpg" alt="chart-54b677add07d50a682a.jpg" style="height:293px;width:317px;"></img></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, selling, general and administrative expense decreased </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.5%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.6%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, primarily due to the timing of spend.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative expense for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, included expenses of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$14.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$27.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, related to the COVID-19 pandemic. Due to the COVID-19 pandemic, we may experience variability in selling, general and administrative expense between quarters within the year.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div><a id="sA8ECBB27C2BB539E9FA7380E104957B0"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Amortization and Impairment of Acquired Intangible Assets</span></div><div style="line-height:120%;"><img src="chart-ca66c4c36dc65756984.jpg" alt="chart-ca66c4c36dc65756984.jpg" style="height:293px;width:317px;"></img></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our amortization expense is based on the economic consumption and impairment of intangible assets. Our most significant intangible assets are related to our TYSABRI, AVONEX, SPINRAZA, VUMERITY and TECFIDERA (rest of world) products and other programs acquired through business combinations. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization and impairment of acquired intangible assets for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, decreased primarily due to a lower rate of amortization for acquired intangible assets, primarily related to TYSABRI. We had </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> impairment charges for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We monitor events and expectations regarding product performance. If new information indicates that the assumptions underlying our most recent analysis are substantially different than those utilized in our current estimates, our analysis would be updated and may result in a significant change in the anticipated lifetime revenues of the relevant products. The occurrence of an adverse event could substantially increase the amount of amortization expense related to our acquired intangible assets as compared to previous periods or our current expectations, which may result in a significant negative impact on our future results of operations.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">IPR&amp;D related to Business Combinations</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development (IPR&amp;D) </span><span style="font-family:Franklin Gothic Book,sans-serif;">represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;">We review amounts capitalized as acquired IPR&amp;D for </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">62</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;">impairment annually, as of</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> October 31, </span><span style="font-family:Franklin Gothic Book,sans-serif;">and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overall, the value of our acquired IPR&amp;D assets is dependent upon several variables, including estimates of future revenues and the effects of competition, our ability to secure sufficient pricing in a competitive market, our ability to confirm safety and efficacy based on data from clinical trials and regulatory feedback, the level of anticipated development costs and the probability and timing of successfully advancing a particular research program from one clinical trial phase to the next. We are continually reevaluating our estimates concerning these and other variables, including our life cycle management strategies, research and development priorities and development risk, changes in program and portfolio economics and related impact of foreign currency exchange rates and economic trends and evaluating industry and company data regarding the productivity of clinical research and the development process. Changes in our estimates and prioritization of these programs may result in a significant change to our valuation of our IPR&amp;D assets.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Vixotrigine</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the periods since we acquired vixotrigine (BIIB074), there have been numerous delays in the initiation of Phase 3 studies for the potential treatment of trigeminal neuralgia (TGN) as we engaged with the FDA regarding the design of the Phase 3 studies and awaited data and insights from mid-stage clinical trials of vixotrigine in other indications that have since been completed. </span><span style="font-family:Franklin Gothic Book,sans-serif;">The fair value of the TGN asset is not significantly in excess of carrying value.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the carrying value associated with our vixotrigine IPR&amp;D assets was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$160.2 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the amortization and impairment of our acquired intangible assets, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 6, Intangible Assets and Goodwill</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div><a id="s287292E6CF5850B4B5DF44A6698084C0"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Collaboration Profit (Loss) Sharing</span></div><div style="line-height:120%;"><img src="chart-f590ec5e15305a15b12.jpg" alt="chart-f590ec5e15305a15b12.jpg" style="height:293px;width:317px;"></img></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration profit (loss) sharing primarily includes Samsung Bioepis' </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share of the profit or loss related to our biosimilars commercial agreement with Samsung Bioepis.</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized net profit-sharing expense of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$55.4 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$127.2 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, to reflect Samsung Bioepis' </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> sharing of the net collaboration profits compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$63.4 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$121.5 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods. </span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we also recognized net profit-sharing income of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$33.8 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to reflect Eisai's </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">45%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share of the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> milestone expense related to the completed submission of the BLA to the FDA for approval of aducanumab.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Samsung Bioepis and Eisai, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 17, Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report. </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">63</span></div></div><hr style="page-break-after:always"></hr><div><a id="s0C5666BE1E6D5AC0974659800BDCA018"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Loss on Divestiture of Hiller&#248;d, Denmark Manufacturing Operations</span></div><div style="line-height:120%;"><img src="chart-ca42041222025d3abbc.jpg" alt="chart-ca42041222025d3abbc.jpg" style="height:293px;width:317px;"></img></div><div style="line-height:120%;padding-top:4px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Divestiture of Hiller&#248;d, Denmark Manufacturing Operations </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 we entered into a share purchase agreement with FUJIFILM to sell all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#248;d, Denmark. The transaction closed in August 2019.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recorded a loss of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$174.5 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in our condensed consolidated statements of income. This estimated loss included a pre-tax loss of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$113.2 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which reflected a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.3 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> decrease to our original estimate as of March 31, 2019, reflecting our estimated fair value of the assets and liabilities held for sale as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, adjusted for our expected costs to sell our Hiller&#248;d, Denmark manufacturing operations of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and included our initial estimate of the fair value of an adverse commitment of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$120.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with the guarantee of future minimum batch production at the Hiller&#248;d facility. The value of this adverse commitment was determined using a probability-weighted estimate of future manufacturing activity. In addition, we recorded a tax expense of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$61.3 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the planned transaction during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our estimate of the fair value of the adverse commitment is a Level 3 measurement and is based on forecasted batch production at the Hiller&#248;d facility.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 3, Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div><a id="s52C18A37B1405B7DA1E4FACD55EE53FD"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">(Gain) Loss on Fair Value Remeasurement of Contingent Consideration</span></div><div style="line-height:120%;"><img src="chart-7e6903008512512eaee.jpg" alt="chart-7e6903008512512eaee.jpg" style="height:293px;width:317px;"></img></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consideration payable for certain of our business combinations includes future payments that are contingent upon the occurrence of a particular event or events. We record an obligation for such contingent consideration payments at fair value on the acquisition date. We then revalue our contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations, other than changes due to payments, are recognized as a (gain) loss on fair value remeasurement of contingent consideration in our consolidated statements of income. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, changes in the fair value of our contingent consideration obligations were primarily due to changes in the interest rates, changes in the probability and the expected timing of the achievement of certain remaining developmental milestones and the passage of time.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64</span></div></div><hr style="page-break-after:always"></hr><div><a id="sE36C486E8F865A75BBF11EDC54E0472E"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acquired In-Process Research and Development</span></div><div style="line-height:120%;"><img src="chart-900b27e36dcb52c1a00.jpg" alt="chart-900b27e36dcb52c1a00.jpg" style="height:293px;width:317px;"></img></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BIIB118 Acquisition</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2020 we acquired BIIB118 for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases from Pfizer. In connection with this acquisition, we made an upfront payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Pfizer, which was accounted for as an asset acquisition and recorded as acquired IPR&amp;D in our condensed consolidated statements of income as BIIB118 has not yet reached technological feasibility. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our acquisition of BIIB118, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 2, Acquisitions</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report.</span></div><div><a id="s4286DACA94EE5B14A4A3110551F17DA3"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Other Income (Expense), Net</span></div><div style="line-height:120%;"><img src="chart-25639f4e732a5a1ea99.jpg" alt="chart-25639f4e732a5a1ea99.jpg" style="height:266px;width:317px;"></img></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the change in other income (expense), net primarily reflects net </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">gains of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$106.8 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;">recognized on our investments related to our holdings in equity and debt securities, compared to net losses totaling</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$173.4 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the prior year comparative period. The net gains recognized during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;">primarily reflect an increase in the fair value of Ionis common stock of approximately</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$67.2 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;">and an increase in the fair value of Sangamo common stock of approximately</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$40.9 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;">compared to the same period in 2019, the change in other income (expense), net was primarily due to approximately</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$203.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;">of net gains recognized on our investments related to our holdings in equity and debt securities during the six months ended June&#160;30, 2019.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect interest expense will continue to increase as a result of the issuance of our 2020 Senior Notes. For additional information related to our 2020 Senior Notes, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 11, Indebtedness</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report.</span></div><div><a id="s3E4364506B145FE3A80B57815724B7FC"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Income Tax Provision</span></div><div style="line-height:120%;"><img src="chart-0b610af5b7e35be4879.jpg" alt="chart-0b610af5b7e35be4879.jpg" style="height:400px;width:317px;"></img></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our effective tax rate fluctuates from year to year due to the global nature of our operations. The factors that most significantly impact our effective tax rate include changes in tax laws, variability in the allocation of our taxable earnings among multiple jurisdictions, the amount and characterization of our </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">research and development expenses, the levels of certain deductions and credits, acquisitions and licensing transactions.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;"> the increase in our effective tax rate was primarily due to an internal reorganization of certain intellectual property rights related to the intercompany sale of the intellectual property in 2019 and the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$56.0 million</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;">income tax expense related to the establishment of a valuation allowance against certain deferred tax assets, the realization of which is dependent on future sales of TECFIDERA in the U.S.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> For additional information, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 15, Income Taxes</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;">the increase in our effective tax rate was primarily due to the impacts of the valuation allowance described above and the internal reorganization of certain intellectual property rights, partially offset by the</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$61.3 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> tax expense recognized in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;">related to the planned divestiture of our Hiller&#248;d, Denmark manufacturing operations. Although we recognized a loss on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, the divestiture required us to write off certain deferred tax assets and resulted in a taxable gain in certain jurisdictions.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 3, Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our condensed consolidated financial statements included in this report.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 19, Litigation</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our uncertain tax positions and income tax rate reconciliation for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 15, Income Taxes</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div><a id="sDB537E0919B45C058DE6D9A28C2A7BD6"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Equity in (Income) Loss of Investee, Net of Tax</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;"><img src="chart-9591fb6751065456834.jpg" alt="chart-9591fb6751065456834.jpg" style="height:266px;width:317px;"></img></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.9%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The share purchase transaction was completed in November 2018 and, upon closing, we paid </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">759.5 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$676.6 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) to Samsung BioLogics. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our ownership percentage remained at approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.9%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in (income) loss of investee, net of tax in our condensed consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our investment, we suspended recognizing additional losses. In the first quarter of 2019 we restarted recognizing our share of Samsung Bioepis' (income) losses, and we began recognizing amortization on certain basis differences resulting from our November 2018 investment. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our joint venture partner, Samsung BioLogics, is currently subject to an ongoing criminal investigation that we continue to monitor. While this investigation could impact the operations of Samsung Bioepis and its business, we have assessed the value of our investment in Samsung Bioepis and continue to believe that the fair value of the investment is in excess of its net book value.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">66</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized net income on our investment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.1 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.4 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. This reflects our share of income and amortization of basis differences.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 17, Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report.</span></div><div><a id="sEDB7B29CF8B75B5FBCD2CC51DE160E1F"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Noncontrolling Interest</span></div><div style="line-height:120%;"><img src="chart-aeab2001c05c53f8b61.jpg" alt="chart-aeab2001c05c53f8b61.jpg" style="height:293px;width:317px;"></img></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the change in net income (loss) attributable to noncontrolling interests, net of tax was primarily due to the accrual of the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> milestone payment related to the completed submission of the BLA to the FDA for approval of aducanumab.</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 18, Investments in Variable Interest Entities</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">67</span></div></div><hr style="page-break-after:always"></hr><div><a id="sC9F02102D58A5530B8F12DCAD63FDBCB"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Financial Condition, Liquidity and Capital Resources</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our financial condition is summarized as follows:</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.484375%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:52%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>June 30,<br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Change&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Financial assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">2,384.9</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,913.7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">(18.1</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Marketable securities &#8212; current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">1,942.7</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,562.2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">24.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Marketable securities &#8212; non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">922.8</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,408.1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">(34.5</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total cash, cash equivalents and marketable securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">5,250.4</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">5,884.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">(10.8</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Borrowings:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Current portion of notes payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,495.8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">(100.0</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Notes payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">7,423.8</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">4,459.0</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">66.5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total borrowings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">7,423.8</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">5,954.8</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">24.7</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Working capital:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">8,493.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">8,381.8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1.3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">(3,447.1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">(4,863.8</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">(29.1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total working capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">5,046.7</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3,518.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">43.5</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;%</span></div></td></tr></table></div></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a id="sE3BEA461260059EBA0DD8FF3F8DC646E"></a></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, certain significant cash flows were as follows:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$3.4 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in net cash flows provided by operating activities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$3.0 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in net proceeds received from the issuance of our 2020 Senior Notes;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$1.5 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> payment made for the redemption of our 2.90% Senior Notes due September 15, 2020, prior to their maturity;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$5.0 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> used for share repurchases;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$141.8 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> used to purchase the Sangamo common stock;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$37.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> payment to Samsung Bioepis in connection with the 2019 transaction;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$75.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> payment related to our acquisition of BIIB118 from Pfizer; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$254.7 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> used for purchases of property, plant and equipment.</span></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Overview</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have historically financed our operating and capital expenditures primarily through cash flows earned through our operations. On </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">April&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we issued our 2020 Senior Notes for an aggregate principal amount of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.0 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We expect our operating expenditures, particularly those related to research and development, clinical trials, commercialization of new products and international expansion to continue to grow. However, we expect to continue funding our current and planned operating requirements primarily through cash flows earned from our operations, as well as our existing cash resources and proceeds received from the issuance </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">of our 2020 Senior Notes. We believe that our existing funds, when combined with cash generated from operations and our access to additional financing resources, if needed, are sufficient to satisfy our operating, working capital, strategic alliance, milestone payment, capital expenditure and debt service requirements for the foreseeable future. In addition, we may choose to opportunistically return cash to shareholders and pursue other business initiatives, including acquisition and licensing activities. We may, from time to time, also seek additional funding through a combination of new collaborative agreements, strategic alliances and additional equity and debt financings or from other sources should we identify a significant new opportunity.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on certain risks that could negatively impact our financial position or future results of operations, please read</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> Item 3. Quantitative and Qualitative Disclosures About Market Risk</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> Item 1A.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> included in this report.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash, Cash Equivalents and Marketable Securities</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Until required for another use in our business, we typically invest our cash reserves in bank deposits, certificates of deposit, commercial paper, corporate notes, U.S.&#160;and foreign government instruments, overnight reverse repurchase agreements and other interest-bearing marketable debt instruments in accordance with our investment policy. It is our policy to mitigate credit risk in our cash reserves and marketable securities by maintaining a well-diversified portfolio that limits the amount of exposure as to institution, maturity and investment type. In March 2020 there was a severe liquidity crisis in the capital markets, particularly with respect to securities with </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">68</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">maturities of less than one year, due to the COVID-19 pandemic. This issue impacted pricing of securities in our portfolio as we attempted to decrease our marketable securities level and increase cash, leading to approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.5 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in realized losses for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We believe that recent actions taken by the U.S. Federal Reserve to enhance liquidity have stabilized the capital markets for the time being.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had cash, cash equivalents and marketable securities totaling approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.3 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.9 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The net decrease in cash, cash equivalents and marketable securities at </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, from </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was primarily due to cash used for share repurchases, the redemption of our 2.90% Senior Notes due September 15, 2020, the purchase of Sangamo common stock, net purchases of property, plant and equipment and upfront payments made to Samsung Bioepis and Pfizer, partially offset by cash flows from operations, net proceeds from the issuance of our 2020 Senior Notes and net proceeds from sales of marketable securities.</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets in our condensed consolidated balance sheets as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, include the carrying value of our investment in Samsung Bioepis of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$557.5 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$580.2 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. As Samsung Bioepis is a privately-held entity, our ability to liquidate our investment in Samsung Bioepis may be limited and we may realize significantly less than the value of such investment. This investment is also subject to foreign currency exchange fluctuations. Investments and other assets, as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, also include the fair value of our investment in Ionis common stock of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$339.1 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$329.6 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. In connection with our collaboration and license agreement with Sangamo, we purchased approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of Sangamo common stock in April 2020. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the fair value of this investment was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$182.7 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our acquisition of BIIB118 from Pfizer, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 2, Acquisitions</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report. For additional information on our collaboration arrangements with Samsung Bioepis and Sangamo, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 17, Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our condensed consolidated financial statements included in this report</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">. </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Borrowings</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2020 we issued our 2020 Senior Notes for an aggregate principal amount of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.0 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, consisting of the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$1.5 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> aggregate principal amount of 2.25% Senior Notes due May 1, 2030; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$1.5 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> aggregate principal amount of 3.15% Senior Notes due May 1, 2050.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following is a summary of our currently outstanding senior secured notes issued in 2015 (2015 Senior Notes):</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$1.0 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> aggregate principal amount of 3.625% Senior Notes due September 15, 2022;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$1.75 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> aggregate principal amount of 4.05% Senior Notes due September 15, 2025; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book;font-size:10pt;">$1.75 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> aggregate principal amount of 5.20% Senior Notes due September 15,&#160;2045.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The 2020 Senior Notes and the 2015 Senior Notes were issued at a discount, which are amortized as additional interest expense over the period from issuance through maturity.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2020 we redeemed our 2.90% Senior Notes due September 15, 2020, with an aggregate principal amount of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.50 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a summary of the fair and carrying values of our outstanding borrowings as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 7, Fair Value Measurements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">2020 Credit Facility</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2020 we entered into a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, five-year senior unsecured revolving credit facility under which we are permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility include a financial covenant that requires us not to exceed a maximum consolidated leverage ratio. This revolving credit facility replaced the revolving credit facility that we entered into in August 2015. As of June 30, 2020, we had no outstanding borrowings and were in compliance with all covenants under this facility.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Working Capital</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Working capital is defined as current assets less current liabilities. The change in working capital at </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, from </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflects an increase in total current assets of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$112.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and a decrease in total current liabilities of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,416.7 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in total current assets was primarily driven by an increase in net cash, cash </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">69</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">equivalents and marketable securities, due to the issuance of our 2020 Senior Notes, partially offset by purchases of our common stock and the redemption of our 2.90% Senior Notes due September 15, 2020.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The net decrease in current liabilities was primarily due to the redemption of our 2.90% Senior Notes due September 15, 2020, which was classified within current liabilities, and a reduction in accrued expenses and other, which was primarily related to the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$100.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upfront payment made to Samsung Bioepis in connection with the 2019 transaction, which was accrued as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share Repurchase Programs</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2019 our Board of Directors authorized our December 2019 Share Repurchase Program, which is a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock. Our December 2019 Share Repurchase Program does not have an expiration date. All shares repurchased under our </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 2019 Share Repurchase Program will be retired. Under our December 2019 Share Repurchase Program, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.2 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.8 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.7 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.3 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> remained available under our December 2019 Share Repurchase Program as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 our Board of Directors authorized a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock (March 2019 Share Repurchase Program), which was completed as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. All shares repurchased under our March 2019 Share Repurchase Program were retired. Under our March 2019 Share Repurchase Program, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.1 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.3 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div></div></div><div><a id="sA20F70DE54E45C19B27EE77CDBDD967D"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash Flows</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our cash flow activity:</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:55%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">%&#160;Change</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Net cash flows provided by operating activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">3,415.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3,423.5</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">(0.2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Net cash flows provided by investing activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">(389.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">128.0</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">(404.5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Net cash flows used in financing activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">(3,558.7</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">(3,055.0</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">16.5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Operating Activities</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from operating activities represent the cash receipts and disbursements related to all of our activities other than investing and financing activities. We expect cash provided from operating activities will continue to be our primary source of funds to finance operating needs and capital expenditures for the foreseeable future.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating cash flow is derived by adjusting our net income for:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">non-cash operating items such as depreciation and amortization, impairment charges, unrealized gain (loss) on strategic investments, acquired IPR&amp;D and share-based compensation;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in operating assets and liabilities, which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in results of operations;&#160;and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in the fair value of contingent payments associated with our acquisitions of businesses and payments related to collaborations.</span></div></td></tr></table></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, net cash flows provided by operating activities were consistent.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Investing Activities</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">decrease</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in net cash flows provided by investing activities was primarily due to higher net proceeds related to sales of marketable securities in 2019. </span></div><div style="line-height:120%;padding-top:8px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Financing Activities</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">increase</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in net cash flows used in financing activities was primarily due to the greater number of shares repurchased in 2020 as compared to the comparative period in 2019 and the redemption of our 2.90% Senior Notes due September 15, 2020, partially offset by the net proceeds received from the issuance of our 2020 Senior Notes.</span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">70</span></div></div><hr style="page-break-after:always"></hr><div><a id="s92B33162D5A35321BC0E5221AAC6BB3C"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Contractual Obligations and Off-Balance Sheet Arrangements</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contractual Obligations</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our contractual obligations primarily consist of our obligations under non-cancellable operating leases, long-term debt obligations and defined benefit and other purchase obligations, excluding amounts related to uncertain tax positions, funding commitments, contingent development, regulatory and commercial milestone payments, contingent payments and contingent consideration related to our business combinations, as described below.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There have been </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> material changes in our contractual obligations since </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Payments</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TYSABRI</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2013 we acquired from Elan Pharma International Ltd. (Elan), an affiliate of Elan Corporation plc, full ownership of all remaining rights to TYSABRI that we did not already own or control. Under the acquisition agreement, we are obligated to make contingent payments to Elan of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> on annual worldwide net sales up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> on annual worldwide net sales that exceed </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Royalty payments to Elan and other third parties are recognized as cost of sales in our condensed consolidated statements of income. Elan was acquired by Perrigo Company plc (Perrigo) in December 2013 and Perrigo subsequently sold its rights to these payments to a third-party effective January 2017.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">SPINRAZA</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2016 we exercised our option to develop and commercialize SPINRAZA from Ionis. Under our agreement with Ionis, we make royalty payments to Ionis on annual worldwide net sales of SPINRAZA using a tiered royalty rate between </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which are recognized as cost of sales in our condensed consolidated statements of income. For additional information on our collaboration arrangements with Ionis, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 18, Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">VUMERITY</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2019 the FDA approved VUMERITY for the treatment of RMS. Under our agreement with Alkermes Pharma Ireland Limited, a subsidiary of Alkermes plc (Alkermes), we make royalty payments to Alkermes on worldwide net commercial sales of VUMERITY using a royalty rate of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which are recorded as cost of sales in our consolidated statements of income. Royalties payable on net commercial sales of VUMERITY are subject, under </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">certain circumstances, to tiered minimum annual payment requirements for a period of five years following FDA approval. For additional information on our collaboration arrangement with Alkermes, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 18, Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration related to Business Combinations</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisitions of Convergence Pharmaceuticals Ltd. and Biogen International Neuroscience GmbH, we agreed to make additional payments based upon the achievement of certain milestone events. We recognized the contingent consideration liabilities associated with these transactions at their fair value on the acquisition date and revalue these obligations each reporting period. We may pay up to approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$735.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in remaining milestones related to these acquisitions.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Development, Regulatory and Commercial Milestone Payments</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on our development plans as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we could trigger potential future milestone payments to third parties of up to approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.9 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, including approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.4 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in development milestones, approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.3 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in regulatory milestones and approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.2 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in commercial milestones, as part of our various collaborations, including licensing and development programs. Payments under these agreements generally become due and payable upon achievement of certain development, regulatory or commercial milestones. Because the achievement of these milestones was not considered probable as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, such contingencies have not been recorded in our financial statements. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory or commercial milestones.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Provided various development, regulatory or commercial milestones are achieved, we anticipate that we may pay approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$237.5 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of milestone payments for the remainder of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, including approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$100.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> if aducanumab is launched in the U.S. In July 2020 we and our collaboration partner Eisai announced that we completed the submission of a BLA to the FDA for the approval of aducanumab. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recorded accrued expenses of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;">related to this milestone payment as it was probable that the submission of the BLA would be completed and the milestone earned.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;">This milestone payment is expected to be paid during the third quarter of 2020.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized net profit-sharing income of </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$33.8 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to reflect Eisai's </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">45%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share of the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> milestone expense.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Eisai, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 17, Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with Neurimmune, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 18, Investments in Variable Interest Entities</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Funding Commitments</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have several ongoing clinical studies in various clinical trial stages. Our most significant clinical trial expenditures are to contract research organizations (CROs). The contracts with CROs are generally cancellable, with notice, at our option. We recorded accrued expenses of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$9.1 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in our condensed consolidated balance sheet for expenditures incurred by CROs as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We have approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$567.1 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cancellable future commitments based on existing CRO contracts as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As part of the sale of our Hiller&#248;d, Denmark manufacturing operations to FUJIFILM, we provided FUJIFILM with certain minimum batch production commitment guarantees. There is a risk that the minimum contractual batch production commitments will not be met. Our estimate of the adverse commitment obligation is approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$74.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We developed this estimate using a probability-weighted estimate of future manufacturing activity and may adjust this estimate based upon changes in business conditions, which may result in the increase or reduction of this adverse commitment obligation in subsequent periods.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Related Obligations</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$158.2 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of liabilities associated with uncertain tax positions.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, included in other long-term liabilities we have accrued approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$635.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$697.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, under a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings (the Transition Toll Tax). The decrease of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$62.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> between </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, is related to the amount that </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">is expected to be paid within one year. The Transition Toll Tax will be paid in installments over an eight-year period, which started in 2018, and will not accrue interest.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Off-Balance Sheet Arrangements</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We do not have any relationships with entities often referred to as structured finance or special purpose entities that were established for the purpose of facilitating off-balance sheet arrangements. As such, we are not exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in such relationships. We consolidate variable interest entities if we are the primary beneficiary.</span></div><div><a id="sF467B23B6944518193A50DD122F962C3"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">New Accounting Standards</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a discussion of new accounting standards please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 1, Summary of Significant Accounting Policies</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report.</span></div><div><a id="s0A0EB125C4775795B41CC63A99DF8341"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Critical Accounting Estimates</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S., requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a discussion of our critical accounting estimates, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Part&#160;II,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in our 2019 Form&#160;10-K. There have been no material changes to our critical accounting estimates since our 2019 Form&#160;10-K.</span></div><div><a id="s43874FB91C6D5B3FACE69752FDB1BE50"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;3.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are subject to certain risks that may affect our results of operations, cash flows and fair values of assets and liabilities, including volatility in foreign currency exchange rates, interest rate movements and pricing pressures worldwide as well as changes in economic conditions in the markets in which we operate as a result of the COVID-19 pandemic. We manage the impact of foreign currency exchange rates </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">72</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and interest rates through various financial instruments, including derivative instruments such as foreign currency forward contracts, interest rate lock contracts and interest rate swap contracts. We do not enter into financial instruments for trading or speculative purposes. The counterparties to these contracts are major financial institutions, and there is no significant concentration of exposure with any one counterparty.  </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Exchange Risk</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our results of operations are subject to foreign currency exchange rate fluctuations due to the global nature of our operations, including the impact of the COVID-19 pandemic. As a result, our consolidated financial position, results of operations and cash flows can be affected by market fluctuations in foreign currency exchange rates, primarily with respect to the Euro, British pound sterling, Canadian dollar, Swiss franc, Japanese yen and South Korean won.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While the financial results of our global activities are reported in U.S. dollars, the functional currency for most of our foreign subsidiaries is their respective local currency. Fluctuations in the foreign currency exchange rates of the countries in which we do business will affect our operating results, often in ways that are difficult to predict. In particular, as the U.S. dollar strengthens versus other currencies, the value of the non-U.S. revenues will decline when reported in U.S. dollars. The impact to net income as a result of a strengthening U.S. dollar will be partially mitigated by the value of non-U.S. expenses, which will also decline when reported in U.S. dollars. As the U.S. dollar weakens versus other currencies, the value of the non-U.S. revenues and expenses will increase when reported in U.S. dollars.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have established revenue and operating expense hedging and balance sheet risk management programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by volatility in foreign currency exchange rates.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the second quarter of 2018 the International Practices Task Force of the Center for Audit Quality categorized Argentina as a country with a projected three-year cumulative inflation rate greater than 100%, which indicated that Argentina's economy is highly inflationary. This categorization did not have a material impact on our results of operations or financial position as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and is not expected to have a material impact on our results of operations or financial position in the future.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Revenue and Operating Expense Hedging Program</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our foreign currency hedging program is designed to mitigate, over time, a portion of the impact resulting from volatility in exchange rate changes on revenues and operating expenses. We </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">use foreign currency forward contracts to manage foreign currency risk, with the majority of our forward contracts used to hedge certain forecasted revenue and operating expense transactions denominated in foreign currencies in the next </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months. We do not engage in currency speculation. For a more detailed disclosure of our revenue and operating expense hedging program, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 9, Derivative Instruments</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our ability to mitigate the impact of foreign currency exchange rate changes on revenues and net income diminishes as significant foreign currency exchange rate fluctuations are sustained over extended periods of time. In particular, devaluation or significant deterioration of foreign currency exchange rates are difficult to mitigate and likely to negatively impact earnings. The cash flows from these contracts are reported as operating activities in our condensed consolidated statements of cash flows.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Balance Sheet Risk Management Hedging Program</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also use forward contracts to mitigate the foreign currency exposure related to certain balance sheet items. The primary objective of our balance sheet risk management program is to mitigate the exposure of foreign currency denominated net monetary assets and liabilities of foreign affiliates. In these instances, we principally utilize currency forward contracts. We have not elected hedge accounting for the balance sheet related items. The cash flows from these contracts are reported as operating activities in our condensed consolidated statements of cash flows.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following quantitative information includes the impact of currency movements on forward contracts used in our revenue, operating expense and balance sheet hedging programs. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, a hypothetical adverse 10% movement in foreign currency exchange rates compared to the U.S. dollar across all maturities would result in a hypothetical decrease in the fair value of forward contracts of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$375.5 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$265.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. The estimated fair value change was determined by measuring the impact of the hypothetical exchange rate movement on outstanding forward contracts. Our use of this methodology to quantify the market risk of such instruments is subject to assumptions and actual impact could be significantly different. The quantitative information about market risk is limited because it does not take into account all foreign currency operating transactions. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Net Investment Hedge Program</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our net investment hedging program is designed to mitigate currency fluctuations between the U.S. </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">73</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">dollar and the South Korean won as a result of our approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.9%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> ownership percentage in Samsung Bioepis. We entered into foreign currency forward contracts to manage the foreign currency risk with our forward contracts used to hedge changes in the spot rate over the next </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">four</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, a hypothetical adverse </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> movement would result in a hypothetical decrease in fair value of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$41.7 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$43.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. The estimated fair value was determined by measuring the impact of the hypothetical spot rate movement on outstanding forward contracts.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Interest Rate Risk</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our investment portfolio includes cash equivalents and short-term investments. The fair value of our marketable securities is subject to change as a result of potential changes in market interest rates, including changes resulting from the impact of the COVID-19 pandemic. The potential change in fair value for interest rate sensitive instruments has been assessed on a hypothetical 100 basis point adverse movement across all maturities. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we estimate that such hypothetical 100 basis point adverse movement would result in a hypothetical loss in fair value of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$17.6 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$21.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, to our interest rate sensitive instruments. The fair values of our investments were determined using third-party pricing services or other market observable data.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">To achieve a desired mix of fixed and floating interest rate debt, we entered into interest rate swap contracts during 2015 for certain of our fixed-rate debt. These derivative contracts effectively converted a fixed-rate interest coupon to a floating-rate LIBOR-based coupon over the life of the respective note. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, a 100 basis-point adverse movement (increase in LIBOR) would increase annual interest expense by approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.8 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">May 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we settled our interest rate swap contracts in conjunction with our early redemption of our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Pricing Pressure</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Governments in certain international markets in which we operate have implemented measures, and may in the future implement new or additional measures, to reduce health care costs to limit the overall level of government expenditures. These measures vary by country and may include, among other things, patient access restrictions, suspensions on price increases, prospective and possible retroactive price reductions and other recoupments and increased mandatory discounts or rebates, recoveries of past price increases and greater importation of drugs from lower-cost countries. In </span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">addition, certain countries set prices by reference to the prices in other countries where our products are marketed. Thus, our inability to obtain and maintain adequate prices in a particular country may adversely affect our ability to secure acceptable prices in existing and potential new markets, which may limit market growth. The continued implementation of pricing actions throughout Europe may also lead to higher levels of parallel trade.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and regulatory proposals, enactments to reform health care insurance programs and increasing pressure from social sources could significantly influence the way our products are prescribed and purchased. It is possible that additional federal health care reform measures will be adopted in the future, which could result in increased pricing pressure and reduced reimbursement for our products and otherwise have an adverse impact on our consolidated financial position or results of operations. There is also significant economic pressure on state budgets that may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for our drugs. Managed care organizations are also continuing to seek price discounts and, in some cases, impose restrictions on the coverage of certain drugs.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our products continue to face increasing competition in many markets from generic versions, prodrugs and biosimilars of existing products as well as products approved under abbreviated regulatory pathways.&#160;Such products are likely to be sold at substantially lower prices than branded products.&#160;Accordingly, the introduction of such products as well as other lower-priced competing products may significantly reduce both the price that we are able to charge for our products and the volume of products we sell, which will negatively impact our revenues. In addition, when a generic version of one of our products is commercialized, it may, in some cases, be automatically substituted for our product and reduce our revenues in a short period of time.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Credit Risk</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are subject to credit risk from our accounts receivable related to our product sales. The majority of our accounts receivable arise from product sales in the U.S.&#160;and Europe with concentrations of credit risk limited due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. Our accounts receivable are primarily due from wholesale and other third-party distributors, public hospitals, pharmacies and other government entities. We monitor the financial performance and </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">74</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We operate in certain countries where weakness in economic conditions, including as a result of the COVID-19 pandemic, can result in extended collection periods. We continue to monitor these conditions, including the volatility associated with international economies and the relevant financial markets, and assess their possible impact on our business. Additionally, we could see an increase in the amount of time our trade receivables are paid by certain foreign countries that have been disproportionately impacted by the COVID-19 pandemic. To date, we have not experienced any significant losses with respect to the collection of our accounts receivable. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We believe that our allowance for doubtful accounts was adequate as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. However, if significant changes occur in the availability of government funding or the reimbursement practices of these or other governments, we may not be able to collect on amounts due to us from customers in such countries and our results of operations could be adversely affected.</span></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div><a id="sE0842C0FDC02598094CB7E3D96FED5D5"></a></div><div style="line-height:120%;padding-top:16px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;4.&#160;&#160;&#160;&#160;Controls and Procedures</span></div><div style="line-height:120%;padding-top:10px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Disclosure Controls and Procedures and Internal Control over Financial Reporting</span></div><div style="line-height:120%;padding-top:10px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Controls and Procedures</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules&#160;13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended), as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective in ensuring that (a)&#160;the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized and reported within the time periods specified in the U.S. Securities and Exchange Commission&#8217;s rules and forms, and (b)&#160;such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="line-height:120%;padding-top:10px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Changes in Internal Control over Financial Reporting</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There were no changes in our internal control over financial reporting during the quarter ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">75</span></div></div><hr style="page-break-after:always"></hr><div><a id="s6DFCC1E8653852C0B5DB2F104A40AD43"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Part&#160;II&#160;&#8212; OTHER INFORMATION</span></div><div><a id="sDE18582F0C105D47A8A4E404ABD74D50"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;1.&#160;&#160;&#160;&#160;Legal Proceedings</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a discussion of legal proceedings as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 19, Litigation</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our condensed consolidated financial statements included in this report, which is incorporated into this item by reference.</span></div><div><a id="sF1E9673F137F5F78BE460C7F6D90917B"></a></div><div style="line-height:120%;padding-top:8px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;1A.&#160;&#160;&#160;&#160;Risk Factors</span></div><div style="line-height:120%;padding-top:8px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We are substantially dependent on revenues from our products. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our revenues depend upon continued sales of our products, as well as the financial rights we have in our anti-CD20 therapeutic programs, and, unless we develop, acquire rights to and/or commercialize new products and technologies, we will be substantially dependent on sales from our products and our financial rights in our anti-CD20 therapeutic programs for many years. Additionally, a significant portion of our revenues are concentrated on sales of our products in increasingly competitive markets and in markets affected directly and indirectly by the COVID-19 pandemic. Any of the following negative developments relating to any of our products or any of our anti-CD20 therapeutic programs may adversely affect our revenues and results of operations or could cause a decline in our stock price: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">safety or efficacy issues; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction or greater acceptance of competing products, including generics, prodrugs, biosimilars and products approved under abbreviated regulatory pathways; for example, TECFIDERA may face generic competition in the U.S. in the near future;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">limitations and additional pressures on product pricing or price increases, including those resulting from governmental or regulatory requirements, increased competition, including from generic versions of our products, or changes in, or implementation of, reimbursement policies and practices of payors and other third parties;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">adverse legal, administrative, regulatory or legislative developments; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our ability to maintain a positive reputation among patients, healthcare providers and others, which may be impacted by our pricing and reimbursement decisions; or</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the inability of patients to receive a diagnosis, receive prescriptions or administration of our products or a decision to prescribe and administer competitive therapies as a direct or indirect result of the COVID-19 pandemic.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA has been approved by, among others, the FDA, the European Commission and the Japanese Ministry of Health, Labor and Welfare, and is in the early stages of commercial launch in certain markets.&#160;In addition to risks associated with new product launches and the other factors described in these </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our ability to successfully commercialize SPINRAZA may be adversely affected due to:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction of a new gene therapy product that was approved in the U.S. in May 2019 and in the E.U. in May 2020 for the treatment of SMA, and other products in development that, if successfully developed and approved, may compete with SPINRAZA in the SMA market, including potential oral products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the delay of SPINRAZA doses as hospitals prioritize the treatment of COVID-19 patients and/or patients decide to delay treatment as a result of the COVID-19 pandemic;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the lack of readiness of healthcare providers within certain SMA markets to treat patients with SMA; or</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our limited marketing experience within certain SMA markets, which may impact our ability to develop additional relationships with the associated medical and scientific community.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">If we are unable to obtain and maintain adequate protection for our data, intellectual property and other proprietary rights, our business may be harmed. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our success depends in part on our ability to obtain and defend patent and other intellectual property rights that are important to the commercialization of our products and product candidates. The degree of patent protection afforded to our products and processes in the U.S. and in other important markets remains uncertain and depends, in part, upon decisions of the patent offices, courts, administrative bodies and lawmakers in these countries. We may fail to successfully obtain or preserve patent protection for the technologies incorporated into our products and processes, or the protection we obtain may not be of sufficient breadth and degree to protect our commercial </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">76</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">interests in all countries where we conduct business. Under the Hatch-Waxman Act, a manufacturer may file an Abbreviated New Drug Application, seeking approval of a generic copy of an approved innovator product, or a New Drug Application under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act, which may be for a new or improved version of the original innovator product. The manufacturers are allowed to rely on the safety and efficacy data of the innovator's product, may not need to conduct clinical trials, can market a competing version of a product after the expiration or loss of patent exclusivity or the expiration or loss of regulatory exclusivity and often charge significantly lower prices. Upon the expiration or loss of patent protection or the expiration or loss of regulatory exclusivity for a product, a major portion of revenues for that product may be reduced in a short period of time. When others exploit our inventions, the expected benefit from them are reduced. Furthermore, our products may be determined to infringe patents or other intellectual property rights held by third parties, which could result in financial, legal, business or reputational harm to us.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also rely on regulatory exclusivity for protection of our products. Implementation and enforcement of regulatory exclusivity, which may consist of regulatory data protection and market protection, varies widely from country to country.&#160;Failure to qualify for regulatory exclusivity, or failure to obtain or maintain the extent or duration of such protections that we expect in each of the markets for our products due to challenges, changes or interpretations in the law or otherwise, could affect our revenues for our products or our decision on whether to market our products in a particular country or countries or could otherwise have an adverse impact on our results of operations.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Litigation, interferences, oppositions, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reviews, administrative challenges or other similar types of proceedings are, have been and may in the future be necessary in some instances to determine the validity and scope of certain of our patents, regulatory exclusivities or other proprietary rights, and in other instances to determine the validity, scope or non-infringement of certain patent rights claimed by third parties to be pertinent to the manufacture, use or sale of our products.&#160;We also face challenges to our patent and regulatory protections covering our products by third parties, including manufacturers of generics and biosimilars that may choose to launch or attempt to launch their products before the expiration of our patent or regulatory exclusivity.&#160;Litigation, interference, oppositions, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reviews, administrative challenges or other similar types of proceedings are unpredictable and are often protracted, expensive and distracting to management. Negative outcomes of such proceedings adversely affect the validity and scope of our patent or other proprietary rights. Settlements of Hatch-Waxman litigation typically result in reducing the period of patent protection, accelerating reduction in revenue from affected products. Adverse outcomes in intellectual property litigation also could hinder our ability to manufacture and market our products, require us to seek a license for the infringed product or technology or result in the assessment of significant monetary damages against us that may exceed amounts, if any, accrued in our financial statements. An adverse determination in a judicial or administrative proceeding or a failure to obtain necessary licenses could prevent us from manufacturing or selling our products. Furthermore, payments under any licenses that we are able to obtain would reduce our profits derived from the covered products and services. Any of these circumstances could result in financial, business or reputational harm to us or could cause a decline or volatility in our stock price.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">The ongoing COVID-19 pandemic may, directly or indirectly, adversely affect our business, results of operations and financial condition.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our business could be materially adversely affected, directly or indirectly, by the widespread outbreak of contagious disease, including the ongoing COVID-19 pandemic, which has spread to many of the countries in which we, our customers, our suppliers and our collaboration partners do business. National, state and local governments in affected regions have implemented and may continue to implement safety precautions, including quarantines, border closures, increased border controls, travel restrictions, shelter in place orders and shutdowns, business closures, cancellations of public gatherings and other measures. Organizations and individuals are taking additional steps to avoid or reduce infection, including limiting travel and staying home from work. These measures are disrupting normal business operations both in and outside of affected areas and have had significant negative impacts on businesses and financial markets worldwide.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We continue to monitor our operations and applicable government recommendations, and we have made modifications to our normal operations because of the COVID-19 pandemic. In the U.S. and in most other key markets, our office-based employees began working from home in early March 2020, while ensuring essential staffing levels in our operations remained in place, including maintaining key personnel in our laboratories and manufacturing facilities, and many may continue to work remotely for an indefinite period of time. Remote working arrangements could impact employees&#8217; productivity and morale. Further, as our employees work from geographic areas across the globe, we have required, and will in the future require, investment of resources and close </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">77</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">monitoring of local regulations and requirements that may continually change due to the COVID-19 pandemic and we may experience unpredictability in our expenses, employee productivity and employee work culture. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notwithstanding the protective measures we have taken to ensure the health and safety of our workers, the COVID-19 pandemic could affect the health and availability of our workforce as well as those of the third parties we rely on taking similar measures. If members of our management and other key personnel in critical functions across our organization are unable to perform their duties or have limited availability due to COVID-19, we may not be able to execute on our business strategy and/or our operations may be negatively impacted. We may also experience limitations in employee resources, including because of sickness of employees or their families or the desire of employees to avoid contact with individuals or large groups of people. In addition, we have experienced and will continue to experience disruptions to our business operations resulting from quarantines, self-isolations and other restrictions on the ability of our employees to perform their jobs.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additionally, with so many of our employees now working remotely, the risk of cyber-attacks or other privacy or data security incidents may be heightened as a result of our moving increasingly towards a remote working environment. Remote working environments may be less secure and more susceptible to hacking attacks, including phishing and social engineering attempts that seek to exploit the COVID-19 pandemic. An extended period of remote working by our employees could also strain our technology resources and introduce operational risks, including heightened cybersecurity risk.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The COVID-19 pandemic has disrupted business operations. The extent and severity of the impact on our business and clinical trials will be determined largely by the extent of disruptions in the supply chains for our products and product candidates; disruptions in access by patients to our therapies; and delays in the conduct of current and future clinical trials. For example, our Phase 3 study of BIIB093 for large hemispheric infarction has been delayed as this study involves administration of BIIB093 in an acute hospital setting. We have also paused the initiation of new clinical trials for compounds that are known to be immunosuppressants. In addition, the impact of the COVID-19 pandemic on the operations of the FDA and other health authorities may delay potential approvals of our product candidates. We may also see lower new prescriptions or refills of existing prescriptions due to increased unemployment as a result of the COVID-19 pandemic.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While it is not possible at this time to estimate the entirety of the impact that the COVID-19 pandemic will have on our business, operations, employees, customers, suppliers or our collaboration partners, continued spread of COVID-19, measures taken by governments, actions taken to protect employees and the broad impact of the pandemic on all business activities may materially and adversely affect our business, results of operations and financial condition.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our long-term success depends upon the successful development of new products and additional indications for existing products. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our long-term viability and growth will depend upon the successful development of additional indications for our existing products as well as the successful development of new products and technologies from our research and development activities, our biosimilars joint venture with Samsung BioLogics or licenses or acquisitions from third parties. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product development is very expensive and involves a high degree of uncertainty and risk. Only a small number of research and development programs result in the commercialization of a product. Furthermore, the development of novel approaches for the treatment of diseases, including development efforts in new modalities such as those based on the antisense oligonucleotide platform and gene therapy, may present additional challenges and risks, including obtaining regulatory approval from the FDA and other regulatory agencies that have limited experience with the development of such therapies. In addition, clinical trial data are subject to differing interpretations and, even if we view data as sufficient to support the safety, effectiveness and/or approval of an investigational therapy, regulatory authorities may disagree and may require additional data, may limit the scope of the approval or may deny approval altogether. Consequently, it may be difficult to predict the time and cost of product development of novel approaches for the treatment of diseases. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, success in preclinical work or early stage clinical trials does not ensure that later stage or larger scale clinical trials will be successful. Clinical trials may indicate that our product candidates lack efficacy, have harmful side effects, result in unexpected adverse events or raise other concerns that may significantly reduce the likelihood of regulatory approval. This may result in terminated programs, significant restrictions on use and safety warnings in an approved label, adverse placement within the treatment paradigm or significant reduction in the commercial potential of the product candidate.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">78</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may be required to delay the development of a product candidate or delay ongoing clinical trials as a direct or indirect result of the COVID-19 pandemic. For example, our Phase 3 study of BIIB093 for large hemispheric infarction has been delayed as this study involves administration of BIIB093 in an acute hospital setting. We have also paused the initiation of new clinical trials for compounds that are known to be immunosuppressants. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Even if we could successfully develop new products or indications, we may make a strategic decision to discontinue development of a product candidate or indication if, for example, we believe commercialization will be difficult relative to the standard of care or other opportunities in our pipeline.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">If we fail to compete effectively, our business and market position would suffer.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The biopharmaceutical industry and the markets in which we operate are intensely competitive. We compete in the marketing and sale of our products, the development of new products and processes, the acquisition of rights to new products with commercial potential and the hiring and retention of personnel. We compete with biotechnology and pharmaceutical companies that have a greater number of products on the market and in the product pipeline, substantially greater financial, marketing, research and development and other resources and other technological or competitive advantages. One or more of our competitors may benefit from significantly greater sales and marketing capabilities, may develop products that are accepted more widely than ours or may receive patent protection that dominates, blocks or adversely affects our product development or business. In addition, as a result of the COVID-19 pandemic, we have suspended the vast majority of our in-person interactions by our customer-facing professionals in healthcare settings, which will limit our ability to market our products and educate physicians, which, in turn, could have an adverse effect on our ability to compete in the marketing and sales of our products. Further, our ability to compete may be impacted by the inability of patients to receive a diagnosis, receive prescriptions or administration of our products or a decision to prescribe and administer competitive therapies as a direct or indirect result of the COVID-19 pandemic.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our products continue to face increasing competition in many markets from the introduction of generics, prodrugs and biosimilars of existing products as well as products approved under abbreviated regulatory pathways.&#160;Such products are likely to be sold at substantially lower prices than branded products.&#160;Accordingly, the introduction of such products as well as other lower-priced competing products may significantly reduce both the price that we are able to charge for our products and the volume of products we sell, which will negatively impact our revenues. In addition, when a generic version of one of our products is commercialized, it may, in some cases, be automatically substituted for our product and reduce our revenues in a short period of time.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the MS market, we face intense competition as the number of products and competitors continues to expand. Due to our significant reliance on sales of our MS products, including TECFIDERA, our business could be harmed if we are unable to successfully compete in the MS market. More specifically, our ability to compete, maintain and grow our share in the MS market may be adversely affected due to a number of factors, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction of more efficacious, safer, less expensive or more convenient alternatives to our MS products, including our own products and products of our collaborators; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction of generic versions of branded MS products, including our own products, biosimilars, follow-on products, prodrugs or products approved under abbreviated regulatory pathways, which would be significantly less costly than our products to bring to market and would be offered for sale at lower prices, and could result in a significant percentage of the sales of our products being lost to such generic versions of branded MS products, biosimilars, follow-on products, prodrugs or products approved under abbreviated regulatory pathways;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the off-label use by physicians of therapies indicated for other conditions to treat MS patients; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">patient dynamics, including the size of the patient population and our ability to attract and maintain new and current patients to our therapies; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">damage to physician and patient confidence in any of our MS products, generic or biosimilars of our MS products or any other product from the same class as one of our products, or to our sales and reputation as a result of label changes or adverse experiences or events that may occur with patients treated with our MS products or generic or biosimilars of our MS products; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">inability to obtain appropriate pricing and reimbursement for our MS products compared to our competitors in key international markets; or</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our ability to obtain and maintain patent, data or market exclusivity for our MS products.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">79</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the SMA market, we face competition from a new gene therapy product that was approved in the U.S. in May 2019 and in the E.U. in May 2020 for the treatment of SMA. Additionally, we are aware of other products in development that, if successfully developed and approved, may compete with SPINRAZA in the SMA market, including potential oral products. Future sales of SPINRAZA may be adversely affected by the commercialization of competing products. In addition, future sales of SPINRAZA may also be adversely affected by the delay of SPINRAZA doses as hospitals prioritize the treatment of COVID-19 patients and/or patients decide to delay treatment.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our business may be adversely affected if we do not successfully execute or realize the anticipated benefits of our strategic and growth initiatives.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The successful execution of our strategic and growth initiatives may depend upon internal development projects, commercial initiatives, external opportunities, which may include the acquisition, partnering and in-licensing of products, technologies and companies or the entry into strategic alliances and collaborations, or the disposition of certain of our assets or operations. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While we believe we have a number of promising programs in our pipeline, failure or delay of internal development projects to advance or difficulties in executing on our commercial initiatives could impact our current and future growth, resulting in additional reliance on external development opportunities for growth. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Supporting the further development of our existing products and potential new products in our pipeline will require significant capital expenditures and management resources, including investments in research and development, sales and marketing, manufacturing capabilities and other areas of our business. We have in the past made, and may continue to make, significant operating and capital expenditures for potential new products in our pipeline prior to regulatory approval with no assurance that such investment will be recouped, which may adversely affect our financial condition, business and operations.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The availability of high quality, fairly valued external product development is limited and the opportunity for their acquisition is highly competitive. As such, we are not certain that we will be able to identify suitable candidates for acquisition or if we will be able to reach agreement. Furthermore, if we decide to dispose of certain of our assets or operations, we are not certain that we will be able to identify a suitable counterparty or if we will be able to reach agreement.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may fail to initiate or complete transactions for many reasons and we may not be able to achieve the full strategic and financial benefits expected to result from transactions, or the benefits may be delayed or not occur at all. We may also face additional costs or liabilities in completed transactions that were not contemplated prior to completion.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any failure in the execution of a transaction, in the integration of an acquired asset or business or in achieving expected synergies could result in slower growth, higher than expected costs, the recording of asset impairment charges and other actions which could adversely affect our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Successful preclinical work or early stage clinical trials does not ensure success in later stage trials, regulatory approval or commercial viability of a product.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Positive results in a clinical trial may not be replicated in subsequent or confirmatory trials. Additionally, success in preclinical work or early stage clinical trials does not ensure that later stage or larger scale clinical trials will be successful or that regulatory approval will be obtained. In addition, even if later stage clinical trials are successful, regulatory authorities may delay or decline approval of our product candidates. Regulatory authorities may disagree with our view of the data, require additional studies or disagree with our trial design or endpoints. Regulatory authorities may also fail to approve the facilities or processes used to manufacture a product candidate, our dosing or delivery methods or companion devices. Regulatory authorities may grant marketing approval that is more restricted than anticipated. These restrictions may include limiting indications to narrow patient populations and the imposition of safety monitoring, educational requirements and risk evaluation and mitigation strategies. The occurrence of any of these events could result in significant costs and expenses, have an adverse effect on our business, financial condition and results of operations and cause our stock price to decline or experience periods of volatility.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Even if we are able to successfully develop new products or indications, sales of new products or products with additional indications may not meet investor expectations. We may also make a strategic decision to discontinue development of a product candidate or indication if, for example, we believe commercialization will be difficult relative to the standard of care or other opportunities in our pipeline.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">80</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Clinical trials and the development of biopharmaceutical products is a lengthy and complex process. If we fail to adequately manage our clinical activities, our clinical trials or potential regulatory approvals may be delayed or denied. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Conducting clinical trials is a complex, time-consuming and expensive process. Our ability to complete clinical trials in a timely fashion depends on a number of key factors. These factors include protocol design, regulatory and institutional review board approval, patient enrollment rates and compliance with current Good Clinical Practices. If we or our third-party clinical trial providers or third-party CROs do not successfully carry out these clinical activities, our clinical trials or the potential regulatory approval of a product candidate may be delayed or be unsuccessful.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have opened clinical trial sites and are enrolling patients in a number of countries where our experience is limited. In most cases, we use the services of third parties to carry out our clinical trial related activities and rely on such parties to accurately report their results. Our reliance on third parties for these activities may impact our ability to control the timing, conduct, expense and quality of our clinical trials. One CRO has responsibility for a substantial portion of our activities and reporting related to our clinical trials. If this CRO does not adequately perform, many of our trials may be affected. We may need to replace our CROs. Although we believe there are a number of other CROs we could engage to continue these activities, the replacement of an existing CRO may result in the delay of the affected trials or otherwise adversely affect our efforts to obtain regulatory approvals and commercialize our product candidates.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our ability to continue our existing clinical trials or to initiate new clinical trials may be adversely affected, directly or indirectly, by the COVID-19 pandemic. For example, our Phase 3 study of BIIB093 for large hemispheric infarction has been delayed as this study involves administration of BIIB093 in an acute hospital setting. We have open clinical trial sites in countries that have had high incident rates of COVID-19 patients. Restrictions on travel and/or transport of clinical materials, as well as diversion of hospital staff and resources to COVID-19 infected patients, could disrupt trial operations as well as recruitment, possibly resulting in a slowdown in enrollment and/or deviations from or disruptions in key clinical trial activities, such as clinical trial site monitoring. These challenges may lead to difficulties in meeting protocol-specified procedures. In addition, we may need to make certain adjustments to the operation of clinical trials in an effort to minimize risks to trial data integrity during the COVID-19 pandemic. We have also paused the initiation of new trials for compounds that are known to be immunosuppressants.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Adverse safety events or restrictions on use and safety warnings for our products can negatively affect our business, product sales and stock price.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adverse safety events involving our marketed products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products may have a negative impact on our business. Discovery of safety issues with our products could create product liability and could cause additional regulatory scrutiny and requirements for additional labeling or safety monitoring, withdrawal of products from the market and the imposition of fines or criminal penalties. Adverse safety events may also damage physician, patient and/or investor confidence in our products and our reputation. Any of these could result in liabilities, loss of revenues, material write-offs of inventory, material impairments of intangible assets, goodwill and fixed assets, material restructuring charges or other adverse impacts on our results of operations. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regulatory authorities are making greater amounts of stand-alone safety information directly available to the public through periodic safety update reports, patient registries and other reporting requirements. The reporting of adverse safety events involving our products or products similar to ours and public rumors about such events may increase claims against us and may also cause our product sales or stock price to decline or experience periods of volatility. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restrictions on use or significant safety warnings that may be required to be included in the label of our products, such as the risk of developing progressive multifocal leukoencephalopathy (PML) or liver injury in the label for certain of our products, may significantly reduce expected revenues for those products and require significant expense and management time. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Sales of our products depend, to a significant extent, on adequate coverage, pricing and reimbursement from third-party payors, which are subject to increasing and intense pressure from political, social, competitive and other sources. Our inability to obtain and maintain adequate coverage, or a reduction in pricing or reimbursement, could have an adverse effect on our business, reputation, revenues and results of operations, could curtail or eliminate our ability to adequately fund research and development programs for the discovery and commercialization of new products or could cause a decline or volatility in our stock price.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sales of our products depend, to a significant extent, on the availability and extent of adequate coverage, pricing and reimbursement from government health administration authorities, private health insurers and other </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">81</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">organizations. When a new pharmaceutical product is approved, the availability of government and private reimbursement for that product may be uncertain, as is the pricing and amount for which that product will be reimbursed. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pricing and reimbursement for our products may be adversely affected by a number of factors, including: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in, and implementation of, federal, state or foreign government regulations or private third-party payors&#8217; reimbursement policies; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">pressure by employers on private health insurance plans to reduce costs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">consolidation and increasing assertiveness of payors, including managed care organizations, health insurers, pharmacy benefit managers, government health administration authorities, private health insurers and other organizations, seeking price discounts or rebates in connection with the placement of our products on their formularies and, in some cases, the imposition of restrictions on access or coverage of particular drugs or pricing determined based on perceived value; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our value-based contracting program pursuant to which we aim to tie the pricing of our products to their clinical values by either aligning price to patient outcomes or adjusting price for patients who discontinue therapy for any reason, including efficacy or tolerability concerns.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our ability to set the price for our products varies significantly from country to country and as a result so can the price of our products. Certain countries set prices by reference to the prices in other countries where our products are marketed. Thus, our inability to obtain and maintain adequate prices in a particular country may not only limit the revenues from our products within that country but may also adversely affect our ability to secure acceptable prices in existing and potential new markets. This may create the opportunity for third-party cross-border trade or influence our decision to sell or not to sell a product, thus adversely affecting our geographic expansion plans and revenues.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Drug prices are under significant scrutiny in the markets in which our products are prescribed.&#160;We expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis. In addition, competition from current and future competitors may negatively impact our ability to maintain pricing and our market share. New products or treatments brought to market by our competitors could cause revenues for our products to decrease due to potential price reductions and lower sales volumes. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payors, including managed care organizations, health insurers, pharmacy benefit managers, government health administration authorities, private health insurers and other organizations, increasingly seek ways to reduce their costs. Many payors continue to adopt benefit plan changes that shift a greater portion of prescription costs to patients. Such measures include more limited benefit plan designs, higher patient co-pay or co-insurance obligations and limitations on patients' use of commercial manufacturer co-pay payment assistance programs (including through co-pay accumulator adjustment or maximization programs). Payors also increasingly seek price discounts or rebates in connection with the placement of our products on their formularies or those they manage and control costs by imposing restrictions on access to or usage of our products, such as by requiring prior authorization or step therapy. Significant consolidation in the health insurance industry has resulted in a few large insurers and pharmacy benefit managers exerting greater pressure in pricing and usage negotiations with drug manufacturers, significantly increasing discounts and rebates required of manufacturers and limiting patient access and usage. Further consolidation among insurers, pharmacy benefit managers and other payors would increase the negotiating leverage such entities have over us and other drug manufacturers. Ultimately, additional discounts, rebates, coverage or plan changes, restrictions or exclusions as described above could have a material adverse effect on sales of our affected products.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our failure to obtain or maintain adequate coverage, pricing or reimbursement for our products could have an adverse effect on our business, reputation, revenues and results of operations, could curtail or eliminate our ability to adequately fund research and development programs for the discovery and commercialization of new products or could cause a decline or volatility in our stock price.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">A breakdown or breach of our technology systems could subject us to liability or interrupt the operation of our business.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are increasingly dependent upon technology systems and data to operate our business. In particular, the COVID-19 pandemic has caused us to modify our business practices, including the requirement that most of our office-based employees in the U.S. and our other key markets work from home. As a result, we are increasingly dependent upon our technology systems to operate our business and our ability to effectively manage our business depends on the security, reliability and adequacy of our technology systems and data, which includes use of cloud </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">82</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">technologies, including Software as a Service (SaaS), Platform as a Service (PaaS) and Infrastructure as a Service (IaaS). A breakdown, invasion, corruption, destruction or breach of our technology systems, including the cloud technologies that we utilize, and/or unauthorized access to our data and information could subject us to liability or negatively impact the operation of our business. Our technology systems, including the cloud technologies that we utilize, continue to increase in multitude and complexity, making them potentially vulnerable to breakdown, malicious intrusion and random attack.&#160;Likewise, data privacy or security breaches by individuals authorized to access our technology systems, including the cloud technologies that we utilize, may pose a risk that sensitive data, including intellectual property, trade secrets or personal information belonging to us, our patients, customers or other business partners, may be exposed to unauthorized persons or to the public. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cyber-attacks are increasing in their frequency, sophistication and intensity, and are becoming increasingly difficult to detect. They are often carried out by motivated, well-resourced, skilled and persistent actors, including nation states, organized crime groups, &#8220;hacktivists&#8221; and employees or contractors acting with malicious intent. Cyber-attacks could include the deployment of harmful malware and key loggers, ransomware, a denial-of-service attack, a malicious website, the use of social engineering and other means to affect the confidentiality, integrity and availability of our technology systems and data. Cyber-attacks could also include supply chain attacks, which could cause a delay in the manufacturing of our products or products produced for contract manufacturing. Our key business partners face similar risks and any security breach of their systems could adversely affect our security posture. In addition, our increased use of cloud technologies could heighten these and other operational risks, and any failure by cloud technology service providers to adequately safeguard their systems and prevent cyber-attacks could disrupt our operations and result in misappropriation, corruption or loss of confidential or propriety information.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While we continue to build and improve our systems and infrastructure, including our business continuity plans, there can be no assurance that our efforts will prevent breakdowns or breaches in our systems that could adversely affect our business and operations and/or result in the loss of critical or sensitive information, which could result in financial, legal, business, operational or reputational harm to us, loss of competitive advantage or loss of consumer confidence. In addition, our liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks and other related breaches. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, regulators globally are imposing new data privacy and security requirements, including new and greater monetary fines for privacy violations. For example, the E.U.&#8217;s General Data Protection Regulation, which became effective in 2018, established regulations regarding the handling of personal data, and provides an enforcement authority and imposes large penalties for noncompliance, including the potential for fines of up to &#8364;20.0 million or 4% of the annual global revenues of the infringer, whichever is greater. In addition, new U.S. data privacy and security laws, such as the California Consumer Privacy Act (CCPA) that became effective in January 2020, and others that may be passed, similarly introduce requirements with respect to personal information, and non-compliance with CCPA may result in liability through private actions (subject to statutorily defined damages in the event of certain data breaches) and enforcement. Failure to comply with these current and future laws could result in significant penalties and could have a material adverse effect on our business and results of operations.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We depend on relationships with collaborators, joint venture partners and other third parties for revenues, and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates, which are outside of our full control.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We rely on a number of significant collaborative and other third-party relationships, including joint venture partners, for revenues, and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates. We also outsource to third parties certain aspects of our regulatory affairs and clinical development relating to our products and product candidates. Reliance on collaborative and other third-party relationships, including joint venture partners, subjects us to a number of risks, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">we may be unable to control the resources our collaborators, joint venture partners or third parties devote to our programs, products or product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">delays and disruptions experienced by our collaborators, joint venture partners or third parties due to the COVID-19 pandemic could adversely impact the ability of such parties to fulfill their obligations, which could affect product sales or the clinical development or regulatory approvals of product candidates under joint control;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">disputes may arise under an agreement, including with respect to the achievement and payment of milestones or ownership of rights to technology developed with our collaborators, joint venture partners or other third parties, and the underlying agreement with our collaborators, joint venture partners or other third </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">83</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-left:54px;padding-top:8px;text-align:left;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">parties may fail to provide us with significant protection or may fail to be effectively enforced if the collaborators, joint ventures partners or third parties fail to perform; </span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the interests of our collaborators, joint venture partners or third parties may not always be aligned with our interests, and such parties may not pursue regulatory approvals or market a product in the same manner or to the same extent that we would, which could adversely affect our revenues; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">third-party relationships, joint ventures and collaborations often require the parties to cooperate, and failure to do so effectively could adversely affect product sales, or the clinical development or regulatory approvals of product candidates under joint control, could result in termination of the research, development or commercialization of product candidates or could result in litigation or arbitration;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">any failure on the part of our collaborators, joint venture partners or other third parties to comply with applicable laws, regulatory requirements and/or applicable contractual obligations in the marketing, sale and maintenance of the marketing authorization of our products or to fulfill any responsibilities our collaborators, joint venture partners or other third parties may have to protect and enforce any intellectual property rights underlying our products could have an adverse effect on our revenues as well as involve us in possible legal proceedings; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">any improper conduct or actions on the part of our collaborators, joint venture partners or other third parties could subject us to civil or criminal investigations and monetary and injunctive penalties, impact the accuracy and timing of our financial reporting and/or adversely impact our ability to conduct business, our operating results and our reputation.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Given these risks, there is considerable uncertainty regarding the success of our current and future collaborative efforts. If these efforts fail, our product development or commercialization of new products could be delayed, revenues from products could decline and/or we may not realize the anticipated benefits of the collaboration arrangements and/or joint ventures.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our results of operations may be adversely affected by current and potential future healthcare reforms.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and regulatory proposals, enactments to reform health care insurance programs and increasing pressure from social sources could significantly influence the manner in which our products are prescribed and purchased. For example, provisions of the Patient Protection and Affordable Care Act (PPACA) have resulted in changes in the way health care is paid for by both governmental and private insurers, including increased rebates owed by manufacturers under the Medicaid Drug Rebate Program, annual fees and taxes on manufacturers of certain branded prescription drugs, the requirement that manufacturers participate in a discount program for certain outpatient drugs under Medicare Part D and the expansion of the number of hospitals eligible for discounts under Section 340B of the Public Health Service Act. These changes have had and are expected to continue to have a significant impact on our business. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may face uncertainties as a result of federal and administrative efforts to repeal, substantially modify or invalidate some or all of the provisions of the PPACA. There is no assurance that the PPACA, as currently enacted or as amended in the future, will not adversely affect our business and financial results, and we cannot predict how future federal or state legislative or administrative changes relating to healthcare reform will affect our business.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The administration has also indicated an intent to address prescription drug pricing and recent Congressional hearings have brought increased public attention to the costs of prescription drugs. These actions and the uncertainty about the future of the PPACA and healthcare laws may put downward pressure on pharmaceutical pricing and increase our regulatory burdens and operating costs.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There is also significant economic pressure on state budgets that may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for our drugs. In recent years, some states have considered legislation and ballot initiatives that would control the prices of drugs, including laws to allow importation of pharmaceutical products from lower cost jurisdictions outside the U.S. and laws intended to impose price controls on state drug purchases. State Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates and requiring prior authorization by the state program for use of any drug for which supplemental rebates are not being paid. Government efforts to reduce Medicaid expenses may lead to increased use of managed care organizations by Medicaid programs. This may result in managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding limitation on prices and reimbursement for our products. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">84</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the E.U. and some other international markets, the government provides health care at low cost to consumers and regulates pharmaceutical prices, patient eligibility or reimbursement levels to control costs for the government-sponsored health care system. Many countries have announced or implemented measures, and may in the future implement new or additional measures, to reduce health care costs to limit the overall level of government expenditures. These measures vary by country and may include, among other things, patient access restrictions, suspensions on price increases, prospective and possible retroactive price reductions and other recoupments and increased mandatory discounts or rebates, recoveries of past price increases and greater importation of drugs from lower-cost countries. These measures have negatively impacted our revenues and may continue to adversely affect our revenues and results of operations in the future.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In response to the COVID-19 pandemic, the Coronavirus Aid, Relief and Economic Security Act (CARES Act) was signed into law in the U.S. in March 2020. The CARES Act is aimed at providing emergency assistance and health care for individuals, families and businesses affected by the COVID-19 pandemic and generally supporting the U.S. economy. Due to the recent enactment of the CARES Act, there is a high degree of uncertainty around its implementation. We expect that additional state and federal healthcare reform measures may be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products or additional pricing pressures. The COVID-19 pandemic may introduce temporary or permanent healthcare reform measures for which we cannot predict the financial implication of on our business.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Management and key personnel changes may disrupt our operations, and we may have difficulty retaining key personnel or attracting and retaining qualified replacements on a timely basis for management and other key personnel who may leave the Company.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have experienced changes in management and other key personnel in critical functions across our organization in recent years. Changes in management and other key personnel have the potential to disrupt our business, and any such disruption could adversely affect our operations, programs, growth, financial condition or results of operations. In addition, new members of management may have different perspectives on programs and opportunities for our business, which may cause us to focus on new business opportunities or reduce or change emphasis on our existing business programs. Further, if members of our management and other key personnel in critical functions across our organization are unable to perform their duties or have limited availability due to COVID-19, we may not be able to execute on our business strategy and/or our operations may be negatively impacted.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our success is dependent upon our ability to attract and retain qualified management and key personnel in a highly competitive environment. Qualified individuals are in high demand, and we may incur significant costs to attract them, particularly at the executive level. We may face difficulty in attracting and retaining key talent for a number of reasons, including management changes, the underperformance or discontinuation of one or more late stage programs, recruitment by competitors or delays in the recruiting and hiring process as a result of the COVID-19 pandemic. We cannot ensure that we will be able to hire or retain the personnel necessary for our operations or that the loss of any such personnel will not have a material impact on our financial condition and results of operations.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">If we fail to comply with the extensive legal and regulatory requirements affecting the health care industry, we could face increased costs, penalties and a loss of business.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our activities, and the activities of our collaborators, distributors and other third-party providers, are subject to extensive government regulation and oversight both in the U.S.&#160;and in foreign jurisdictions. The FDA and comparable agencies in other jurisdictions directly regulate many of our most critical business activities, including the conduct of preclinical and clinical studies, product manufacturing, advertising and promotion, product distribution, adverse event reporting and product risk management as well as our compliance with good practice quality guidelines and regulations. Our interactions in the U.S.&#160;or abroad with physicians and other health care providers that prescribe or purchase our products are also subject to government regulation designed to prevent fraud and abuse in the sale and use of products and place significant restrictions on the marketing practices of health care companies. Health care companies such as ours are facing heightened scrutiny of their relationships with health care providers from anti-corruption enforcement officials. In addition, health care companies such as ours have been the target of lawsuits and investigations alleging violations of government regulation, including claims asserting submission of incorrect pricing information, impermissible off-label promotion of pharmaceutical products, payments intended to influence the referral of health care business, submission of false claims for government reimbursement, antitrust violations or violations related to environmental matters. There is also enhanced scrutiny of company-sponsored patient assistance programs, including insurance premium and co-pay assistance programs and donations to third-party charities that provide such assistance. The U.S. government has challenged some of our donations to third-party charities that provide patient assistance. If we, or our vendors or donation recipients, are found to fail to </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">85</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">comply with relevant laws, regulations or government guidance in the operation of these programs, we could be subject to significant fines or penalties. Risks relating to compliance with laws and regulations may be heightened as we continue to expand our global operations and enter new therapeutic areas with different patient populations, which may have different product distribution methods, marketing programs or patient assistance programs from those we currently utilize or support. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Conditions and regulations governing the health care industry are subject to change, with possible retroactive effect, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or judicial decisions, related to health care availability, pricing or marketing practices, compliance with wage and hour laws and other employment practices, method of delivery, payment for health care products and services, compliance with health information and data privacy and security laws and regulations, tracking and reporting payments and other transfers of value made to physicians and teaching hospitals, extensive anti-bribery and anti-corruption prohibitions, product serialization and labeling requirements and used product take-back requirements; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in the FDA and foreign regulatory approval processes that may delay or prevent the approval of new products and result in lost market opportunity; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">government shutdowns or relocations may result in delays to the review and approval process, slowing the time necessary for new drug candidates to be reviewed and/or approved, which may adversely affect our business;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">government regulations that may be imposed in response to the COVID-19 pandemic may restrict the movement of our global supply chain, divert hospital resources that are necessary to administer certain of our products and/or delay the review of product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">requirements that provide for increased transparency of clinical trial results and quality data, such as the European Medicines Agency's clinical transparency policy, which could impact our ability to protect trade secrets and competitively-sensitive information contained in approval applications or could be misinterpreted leading to reputational damage, misperception or legal action, which could harm our business; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in FDA and foreign regulations that may require additional safety monitoring, labeling changes, restrictions on product distribution or use or other measures after the introduction of our products to market, which could increase our costs of doing business, adversely affect the future permitted uses of approved products or otherwise adversely affect the market for our products.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Violations of governmental regulation may be punishable by criminal and civil sanctions against us, including fines and civil monetary penalties and exclusion from participation in government programs, including Medicare and Medicaid, as well as against executives overseeing our business. In addition to penalties for violation of laws and regulations, we could be required to repay amounts we received from government payors or pay additional rebates and interest if we are found to have miscalculated the pricing information we have submitted to the government. We cannot ensure that our compliance controls, policies and procedures will in every instance protect us from acts committed by our employees, collaborators, partners or third-party providers that would violate the laws or regulations of the jurisdictions in which we operate. Whether or not we have complied with the law, an investigation into alleged unlawful conduct could increase our expenses, damage our reputation, divert management time and attention and adversely affect our business.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">86</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our sales and operations are subject to the risks of doing business internationally.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are increasing our presence in international markets, particularly emerging markets, subjecting us to many risks that could adversely affect our business and revenues. There is no guarantee that our efforts and strategies to expand sales in international markets will succeed. Emerging market countries may be especially vulnerable to periods of global and local political, legal, regulatory and financial instability and may have a higher incidence of corruption and fraudulent business practices. Further, certain countries may require local clinical trial data as part of the drug registration process in addition to global clinical trials, which can add to overall drug development and registration timelines. We may also be required to increase our reliance on third-party agents and unfamiliar operations and arrangements previously utilized by companies we partner or collaborate with or acquire in emerging markets.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our sales and operations are subject to the risks of doing business internationally, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the impact of public health epidemics, such as the COVID-19 pandemic, on employees, the global economy and the delivery of healthcare treatments;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">less favorable intellectual property or other applicable laws; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction or greater acceptance of competing products, including generics, biosimilars, prodrugs and products approved under abbreviated regulatory pathways;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the inability to obtain necessary foreign regulatory or pricing approvals of products in a timely manner; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">limitations and additional pressures on our ability to obtain and maintain product pricing or receive price increases, including those resulting from governmental or regulatory requirements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the inability to successfully complete subsequent or confirmatory clinical trials in countries where our experience is limited;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">longer payment and reimbursement cycles and uncertainties regarding the collectability of accounts receivable; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">fluctuations in foreign currency exchange rates that may adversely impact our revenues, net income and value of certain of our investments; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">difficulties in staffing and managing international operations; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the imposition of governmental controls; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">diverse data privacy and protection requirements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">increasingly complex standards for complying with foreign laws and regulations that may differ substantially from country to country and may conflict with corresponding U.S. laws and regulations; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the far-reaching anti-bribery and anti-corruption legislation in the U.K., including the U.K. Bribery Act 2010, and elsewhere and escalation of investigations and prosecutions pursuant to such laws; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the effects of the implementation of the U.K.&#8217;s departure from the E.U., known as Brexit;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">compliance with complex import and export control laws;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">restrictions on direct investments by foreign entities and trade restrictions; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">greater political or economic instability; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in tax laws; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the imposition of tariffs or embargoes and other trade restrictions, including the recent tariffs imposed by the U.S. and China and the possibility of additional tariffs or other trade restrictions relating to trade between the two countries.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, our international operations are subject to regulation under U.S. law. For example, the U.S. Foreign Corrupt Practices Act (FCPA) prohibits U.S. companies and their representatives from paying, offering to pay, promising to pay or authorizing the payment of anything of value to any foreign government official, government staff member, political party or political candidate for the purpose of obtaining or retaining business or to otherwise obtain favorable treatment or influence a person working in an official capacity. In many countries, the health care professionals we regularly interact with may meet the FCPA's definition of a foreign government official. Failure to comply with domestic or foreign laws could result in various adverse consequences, including: possible delay in approval or refusal to approve a product, recalls, seizures or withdrawal of an approved product from the market, </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">87</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">disruption in the supply or availability of our products or suspension of export or import privileges, the imposition of civil or criminal sanctions, the prosecution of executives overseeing our international operations and damage to our reputation. Any significant impairment of our ability to sell products outside of the U.S. could adversely impact our business and financial results.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We are building a large-scale biologics manufacturing facility, which will result in the incurrence of significant investment with no assurance that such investment will be recouped.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We believe we currently have sufficient large-scale manufacturing capacity to meet our near-term manufacturing requirements. However, in order to support our drug development pipeline, in 2015 we made the decision to expand our large molecule production capacity by building a large-scale biologics manufacturing facility in Solothurn, Switzerland with no assurance that the additional capacity would be required. We expect the Solothurn manufacturing facility to be partially operational by the end of 2020; however, there can be no assurance that we will be able to meet our expected timeline or that there will not be any direct or indirect delays resulting from the COVID-19 pandemic. If there are delays in bringing the Solothurn manufacturing facility online, we may not have sufficient large-scale manufacturing capacity to meet our long-term manufacturing requirements.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we have made significant investments in connection with the building of this manufacturing facility with no assurance that such investment will be recouped. If we are unable to adequately and timely manufacture and supply our products and product candidates or if we do not fully utilize our manufacturing facilities, our business may be harmed. Charges resulting from excess capacity would have a negative effect on our financial condition and results of operations.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Manufacturing issues could substantially increase our costs, limit supply of our products and/or reduce our revenues.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The process of manufacturing our products is complex, highly regulated and subject to numerous risks, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risks of Reliance on Third Parties and Single Source Providers.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> We rely on third-party suppliers and manufacturers for many aspects of our manufacturing process for our products and product candidates. In some cases, due to the unique manner in which our products are manufactured, we rely on single source providers of raw materials and manufacturing supplies. These third parties are independent entities subject to their own unique operational and financial risks that are outside of our control, including the impact of the COVID-19 pandemic. These third parties may not perform their obligations in a timely and cost-effective manner or in compliance with applicable regulations, and they may be unable or unwilling to increase production capacity commensurate with demand for our existing or future products. Finding alternative providers could take a significant amount of time and involve significant expense due to the specialized nature of the services and the need to obtain regulatory approval of any significant changes to our suppliers or manufacturing methods. We cannot be certain that we could reach agreement with alternative providers or that the FDA or other regulatory authorities would approve our use of such alternatives. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risks Relating to Compliance with current Good Manufacturing Practices (cGMP).</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> We and our third-party providers are generally required to maintain compliance with cGMP and other stringent requirements and are subject to inspections by the FDA and comparable agencies in other jurisdictions to confirm such compliance. Any delay, interruption or other issues that arise in the manufacture, fill-finish, packaging or storage of our products as a result of a failure of our facilities or the facilities or operations of third parties to pass any regulatory agency inspection could significantly impair our ability to develop and commercialize our products. Significant noncompliance could also result in the imposition of monetary penalties or other civil or criminal sanctions and damage our reputation.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Global Bulk Supply Risks. </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We rely on our principal manufacturing facilities for the production of drug substance for our large molecule products and product candidates. Our global bulk supply of these products and product candidates depends on the uninterrupted and efficient operation of these facilities, which could be adversely affected by equipment failures, labor shortages, public health epidemics, natural disasters, power failures, cyber-attacks and numerous other factors. In addition, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland, which we expect to be partially operational by the end of 2020. However, there can be no assurance that we will be able to meet our expected timeline or that there will not be any direct or indirect delays resulting from the COVID-19 pandemic. If there are delays in bringing the Solothurn manufacturing facility online, we may not have sufficient large-scale manufacturing capacity to meet our long-term manufacturing requirements.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">88</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk of Product Loss.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> The manufacturing process for our products is extremely susceptible to product loss due to contamination, oxidation, equipment failure or improper installation or operation of equipment or vendor or operator error. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our products or manufacturing facilities, we may need to close our manufacturing facilities for an extended period of time to investigate and remediate the contaminant. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Relating to Government Actions</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We and/or our third-party providers may be required by the U.S. federal government to manufacture medical supplies needed to treat COVID-19 patients under the Defense Production Act or other acts or orders of government entities, which may result in delays in the manufacturing and supply of our products.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any adverse developments affecting our manufacturing operations or the operations of our third-party suppliers and manufacturers may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls or other interruptions in the commercial supply of our products. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Such developments could increase our manufacturing costs, cause us to lose revenues or market share as patients and physicians turn to competing therapeutics, diminish our profitability or damage our reputation. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, although we have business continuity plans to reduce the potential for manufacturing disruptions or delays and reduce the severity of a disruptive event, there is no guarantee that these plans will be adequate, which could adversely affect our business and operations.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our success in commercializing biosimilars developed by Samsung Bioepis is subject to risks and uncertainties inherent in the development, manufacture and commercialization of biosimilars. If Samsung Bioepis is unsuccessful in the development, manufacture and commercialization of biosimilars, we may not realize the anticipated benefits of our investment in Samsung Bioepis.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our success in commercializing biosimilars developed by Samsung Bioepis is subject to a number of risks, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Reliance on Third Parties.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> We are dependent on the efforts of Samsung Bioepis and other third parties over whom we have limited or no control in the development and manufacturing of biosimilars products. In addition, following the divestiture of our Hiller&#248;d, Denmark manufacturing operations, we are dependent on FUJIFILM for the manufacture of biosimilar products. If Samsung Bioepis, FUJIFILM or other third parties fail to perform successfully, we may not realize the anticipated benefits of our investment in Samsung Bioepis;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Regulatory Compliance.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Biosimilar products may face regulatory hurdles or delays due to the evolving and uncertain regulatory and commercial pathway of biosimilars products in certain jurisdictions; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intellectual Property and Regulatory Challenges.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Biosimilar products may face extensive patent clearances, patent infringement litigation, injunctions or regulatory challenges, which could prevent the commercial launch of a product or delay it for many years or result in imposition of monetary damages, penalties or other civil sanctions and damage our reputation; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Failure to Gain Market and Patient Acceptance.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Market success of biosimilar products will be adversely affected if patients, physicians and/or payors do not accept biosimilar products as safe and efficacious products offering a more competitive price or other benefit over existing therapies; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Ability to Provide Adequate Supply.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;Manufacturing biosimilars is complex.&#160;If we encounter any manufacturing or supply chain difficulties, including as a result of the COVID-19 pandemic, we may be unable to meet higher than anticipated demand. In addition, following the divestiture of our Hiller&#248;d, Denmark manufacturing operations, we are dependent on FUJIFILM for the manufacture of biosimilar products. FUJIFILM may not perform their obligations in a timely and cost-effective manner or in compliance with applicable regulations and may be unable or unwilling to increase production capacity commensurate with demand for our existing or future biosimilar products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Competitive Challenges.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Biosimilar products face significant competition, including from innovator products and from biosimilar products offered by other companies. In some jurisdictions, local tendering processes may restrict biosimilar products from being marketed and sold in those jurisdictions. The number of competitors in a jurisdiction, the timing of approval and the ability to market biosimilar products successfully in a timely and cost-effective manner are additional factors that may impact our success and/or the success of Samsung Bioepis in this business area. In addition, as a result of the COVID-19 </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">89</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-left:54px;padding-top:8px;text-align:left;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">pandemic, we have suspended the vast majority of our in-person interactions by our customer-facing professionals in healthcare settings, which will limit our ability to market our products and educate physicians, which, in turn, could have an adverse effect on our ability to compete in the marketing and sales of our products; and</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Legal and Regulatory Requirements.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Any improper conduct or actions on the part of Samsung Bioepis or our joint venture partner, Samsung BioLogics, could damage our reputation and be distracting to management. In particular, Samsung BioLogics is currently subject to an ongoing criminal investigation that may impact the operations of Samsung Bioepis and its business or divert the attention of the Samsung Bioepis management team from its ongoing operations and business. </span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If Samsung Bioepis is unsuccessful in the development, manufacture and commercialization of biosimilar products, we may not realize the anticipated benefits of our investment in Samsung Bioepis.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, as Samsung Bioepis is a privately-held entity, our ability to liquidate our investment in Samsung Bioepis may be limited and we may realize significantly less than the value of such investment.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our operating results are subject to significant fluctuations.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our quarterly revenues, expenses and net income (loss) have fluctuated in the past and are likely to fluctuate significantly in the future due to the risks described in these </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as well as the timing of charges and expenses that we may take. We have recorded, or may be required to record, charges that include:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the cost of restructurings or other initiatives to streamline our operations and reallocate resources; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">impairments with respect to investments, fixed assets and long-lived assets, including IPR&amp;D and other intangible assets; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">inventory write-downs for failed quality specifications, charges for excess or obsolete inventory and charges for inventory write downs relating to product suspensions, expirations or recalls; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in the fair value of contingent consideration;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">bad debt expenses and increased bad debt reserves; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">outcomes of litigation and other legal or administrative proceedings, regulatory matters and tax matters;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">milestone payments under license and collaboration agreements; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">payments in connection with acquisitions, divestitures and other business development activities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">failure to meet certain contractual commitments, including, for example, the minimum batch production commitment guarantees we provided as part of the transaction with FUJIFILM; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the impact of public health epidemics, such as the COVID-19 pandemic, on employees, the global economy and the delivery of healthcare treatments.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our revenues and certain assets and liabilities are also subject to foreign currency exchange rate fluctuations due to the global nature of our operations. Although we have foreign currency forward contracts to hedge specific forecasted transactions denominated in foreign currencies, our efforts to mitigate the impact of fluctuating currency exchange rates may not be successful. As a result, currency fluctuations among our reporting currency, the U.S.&#160;dollar, and other currencies in which we do business will affect our operating results, often in unpredictable ways. Our net income may also fluctuate due to the impact of charges we may be required to take with respect to foreign currency hedge transactions. In particular, we may incur higher than expected charges from early termination of a hedge relationship.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our operating results during any one period do not necessarily suggest the anticipated results of future periods.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our effective tax rate fluctuates, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As a global biopharmaceutical company, we are subject to taxation in numerous countries, states and other jurisdictions. As a result, our effective tax rate is derived from a combination of applicable tax rates, including withholding taxes, in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. Our effective tax rate may be different than experienced in the past due to numerous factors, including changes in the mix of our profitability from country to country, the results of examinations and audits of our tax filings, adjustments to the value of our uncertain tax positions, interpretations by tax authorities or other bodies with jurisdiction, the result of tax cases, changes in accounting for income taxes and changes in tax laws and regulations either prospectively or retrospectively, including </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">90</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">in response to the COVID-19 pandemic. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, our inability to secure or sustain acceptable arrangements with tax authorities and future changes in the tax laws, among other things, may result in tax obligations in excess of amounts accrued in our financial statements.</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Tax Cuts and Jobs Act of 2017 (2017 Tax Act) resulted in significant changes to the U.S. corporate income tax system. These changes include a federal statutory rate reduction from </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the elimination or reduction of certain domestic deductions and credits and limitations on the deductibility of interest expense and executive compensation. The 2017 Tax Act also transitions international taxation from a worldwide system to a modified territorial system, which has the effect of subjecting certain earnings of our foreign subsidiaries and collaborations to immediate U.S. taxation as global intangible low-taxed income (GILTI) or Subpart F income, and includes base erosion prevention measures on U.S. earnings and the reduced effective tax rate on income that comes from U.S. exports, called Foreign Derived Intangible Income. These changes became effective in 2018.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The 2017 Tax Act also includes the Transition Toll Tax, which is a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings. The Transition Toll Tax will be paid over an eight-year period, which started in 2018, and will not accrue interest. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our estimates concerning the impact of the 2017 Tax Act on our accounting and on our business remain subject to developing interpretations of the provisions of the 2017 Tax Act. U.S. Treasury regulations, administrative interpretations or court decisions interpreting the 2017 Tax Act may require further adjustments and changes in our estimates, which could have a material adverse effect on our business, results of operations or financial condition. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Swiss Federal Act on Tax Reform and AHV Financing (TRAF) resulted in significant changes to the Swiss cantonal income tax system. These changes include the elimination of historic favorable cantonal tax regimes, the introduction of a patent box regime and the introduction of a research and development super deduction. The TRAF also provides for transitional rules to lessen the immediate impact of the elimination of the favorable cantonal tax regimes. These changes became effective on January 1, 2020. In response to the TRAF, each canton must enact cantonal tax reform to comply with the framework provided by the TRAF and are also expected to lower the statutory tax rate to compensate for the elimination of the historic favorable cantonal tax regimes. We accounted for the impact of the TRAF and the specific cantonal tax reform changes in the period in which each canton in which we operate enacted the cantonal tax reform. Zug, a canton in which we operate, enacted cantonal tax reform in the third quarter of 2019 and Solothurn, another canton in which we operate, enacted cantonal tax reform in the first quarter of 2020. Upon the enactment of cantonal tax reform, we were required to remeasure our Swiss deferred tax assets and liabilities, to account for the elimination of the historic favorable cantonal tax regimes, the impact of the transitional rules and the change in the statutory cantonal tax rate. Final interpretation of the transitional and new regimes of the TRAF may require further adjustments and changes in our estimates, which could have a significant adverse effect on our business, results of operations or financial condition.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, the enactment of some or all of the recommendations set forth or that may be forthcoming in the Organization for Economic Cooperation and Development&#8217;s project on &#8220;Base Erosion and Profit Shifting&#8221; (BEPS) by tax authorities and economic blocs in the countries in which we operate, could unfavorably impact our effective tax rate. These initiatives focus on common international principles for the entitlement to taxation of global corporate profits and minimum global tax rates.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our investments in properties may not be fully realized.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We own or lease real estate primarily consisting of buildings that contain research laboratories, office space and manufacturing operations. For strategic or other operational reasons, we may decide to consolidate or co-locate certain aspects of our business operations or dispose of one or more of our properties, some of which may be located in markets that are experiencing high vacancy rates and decreasing property values. If we determine that the fair value of any of our owned properties is lower than their book value, we may not realize the full investment in these properties and incur significant impairment charges or additional depreciation when the expected useful lives of certain assets have been shortened due to the anticipated closing of facilities. If we decide to fully or partially vacate an owned or leased property, we may incur significant cost, including facility closing costs, employee separation and retention expenses, lease termination fees, rent expense in excess of sublease income and impairment of leasehold improvements and accelerated depreciation of assets. Any of these events may have an adverse impact on our results of operations.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">91</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our portfolio of marketable securities is subject to market, interest and credit risk that may reduce its value.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We maintain a portfolio of marketable securities for investment of our cash. Changes in the value of our portfolio of marketable securities could adversely affect our earnings. In particular, the value of our investments may decline due to increases in interest rates, downgrades of the bonds and other securities included in our portfolio, instability in the global financial markets that reduces the liquidity of securities included in our portfolio, declines in the value of collateral underlying the securities included in our portfolio and other factors. In addition, the COVID-19 pandemic could adversely affect the financial markets in some or all countries worldwide. Each of these events may cause us to record charges to reduce the carrying value of our investment portfolio or sell investments for less than our acquisition cost. Although we attempt to mitigate these risks through diversification of our investments and continuous monitoring of our portfolio's overall risk profile, the value of our investments may nevertheless decline.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">There can be no assurance that we will continue to repurchase shares or that we will repurchase shares at favorable prices.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time our Board of Directors authorizes share repurchase programs, including, most recently, our December 2019 Share Repurchase Program. The amount and timing of share repurchases are subject to capital availability and our determination that share repurchases are in the best interest of our shareholders and are in compliance with all respective laws and our agreements applicable to the repurchase of shares. Our ability to repurchase shares will depend upon, among other factors, our cash balances and potential future capital requirements for strategic transactions, our results of operations, our financial condition and other factors beyond our control that we may deem relevant. A reduction in repurchases under, or the completion of, our December 2019 Share Repurchase Program could have a negative effect on our stock price. We can provide no assurance that we will repurchase shares at favorable prices, if at all.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We may not be able to access the capital and credit markets on terms that are favorable to us.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may seek access to the capital and credit markets to supplement our existing funds and cash generated from operations for working capital, capital expenditure and debt service requirements and other business initiatives. The capital and credit markets are experiencing, and have in the past experienced, extreme volatility and disruption, which leads to uncertainty and liquidity issues for both borrowers and investors. In the event of adverse capital and credit market conditions, we may be unable to obtain capital or credit market financing on favorable terms. Changes in credit ratings issued by nationally recognized credit rating agencies could also adversely affect our cost of financing and the market price of our securities.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our indebtedness could adversely affect our business and limit our ability to plan for or respond to changes in our business. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our indebtedness, together with our significant contingent liabilities, including milestone and royalty payment obligations, could have important consequences to our business; for example, such obligations could: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">increase our vulnerability to general adverse economic and industry conditions;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">limit our ability to access capital markets and incur additional debt in the future;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">require us to dedicate a substantial portion of our cash flow from operations to payments on our indebtedness, thereby reducing the availability of our cash flow for other purposes, including business development efforts, research and development and mergers and acquisitions;&#160;and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate, thereby placing us at a competitive disadvantage compared to our competitors that have less debt.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our business involves environmental risks, which include the cost of compliance and the risk of contamination or injury.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our business and the business of several of our strategic partners involve the controlled use of hazardous materials, chemicals, biologics and radioactive compounds. Although we believe that our safety procedures for handling and disposing of such materials comply with state, federal and foreign standards, there will always be the risk of accidental contamination or injury. If we were to become liable for an accident, or if we were to suffer an extended facility shutdown, we could incur significant costs, damages and penalties that could harm our business. Manufacturing of our products and product candidates also requires permits from government agencies for water supply and wastewater discharge. If we do not obtain appropriate permits, including permits for sufficient quantities of water and wastewater, we could incur significant costs and limits on our manufacturing volumes that could harm our business.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">92</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">The illegal distribution and sale by third parties of counterfeit or unfit versions of our products or stolen products could have a negative impact on our reputation and business.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Third parties might illegally distribute and sell counterfeit or unfit versions of our products, which do not meet our rigorous manufacturing, distribution and testing standards. A patient who receives a counterfeit or unfit drug may be at risk for a number of dangerous health consequences. Our reputation and business could suffer harm as a result of counterfeit or unfit drugs sold under our brand name. In addition, inventory that is stolen from warehouses, plants or while in-transit, and that is subsequently improperly stored and sold through unauthorized channels, could adversely impact patient safety, our reputation and our business.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">The increasing use of social media platforms presents new risks and challenges.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Social media is increasingly being used to communicate about our products and the diseases our therapies are designed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients may use social media channels to comment on the effectiveness of a product or to report an alleged adverse event. When such disclosures occur, there is a risk that we fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend the company or the public's legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our products. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face overly restrictive regulatory actions or incur other harm to our business.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Some of our collaboration agreements contain change in control provisions that may discourage a third party from attempting to acquire us.</span></div><div style="line-height:120%;padding-top:8px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Some of our collaboration agreements include change in control provisions that could reduce the potential acquisition price an acquirer is willing to pay or discourage a takeover attempt that could be viewed as beneficial to shareholders.&#160;Upon a change in control, some of these provisions could trigger reduced milestone, profit or royalty payments to us or give our collaboration partner rights to terminate our collaboration agreement, acquire operational control or force the purchase or sale of the programs that are the subject of the collaboration.&#160; </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">93</span></div></div><hr style="page-break-after:always"></hr><div><a id="s917E2230E889577BABAA5ED78043378D"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;2.&#160;&#160;&#160;&#160;Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Issuer Purchases of Equity Securities</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our common stock repurchase activity during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">second</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> quarter of 2020:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total&#160;Number&#160;of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares&#160;Purchased</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(#)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average&#160;Price</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Paid&#160;per&#160;Share</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">($)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total&#160;Number&#160;of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares&#160;Purchased</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">as&#160;Part&#160;of&#160;Publicly</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Announced Programs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(#)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Approximate Dollar Value</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">of Shares That May Yet Be Purchased Under</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Our Programs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">($ in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">April 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">5,675,000</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">314.05</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">5,675,000</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">2,276.7</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">May 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">3,306,307</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">310.52</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">3,306,307</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">1,250.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">June 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">1,250.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">8,981,307</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">312.75</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2019 our Board of Directors authorized our December 2019 Share Repurchase Program, which is a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock. Our December 2019 Share Repurchase Program does not have an expiration date. All shares repurchased under our December 2019 Share Repurchase Program will be retired. Under our December 2019 Share Repurchase Program, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.2 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.8 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.7 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.3 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> remained available under our December 2019 Share Repurchase Program as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 our Board of Directors authorized our March 2019 Share Repurchase Program, which was a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock that was completed as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. All shares repurchased under our March 2019 Share Repurchase Program were retired. Under our March 2019 Share Repurchase Program, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.1 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.3 billion</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">94</span></div></div><hr style="page-break-after:always"></hr><div><a id="s3D1D8E898DAC5C8E8922B73F95EB3CE1"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;6.&#160;&#160;&#160;&#160;Exhibits</span></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The exhibits listed below are filed or furnished as part of this Quarterly Report on Form&#160;10-Q.</span></div><div><a id="sCF4E740E99695A4B868412F17B756EC4"></a></div><div style="line-height:120%;padding-top:18px;text-align:center;padding-left:0px;text-indent:0px;-sec-extract:summary;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">EXHIBIT&#160;INDEX&#160;</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:17%;"></td><td style="width:5%;"></td><td style="width:78%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Exhibit</span></div><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Number</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description of Exhibit</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/875045/000119312520128818/d857739dex42.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Second Supplemental Indenture, dated April 30, 2020, between Biogen Inc. and U.S. Bank National Association, including the forms of Global Notes attached as Exhibit A and Exhibit B, respectively, thereto. Filed as Exhibit 4.2 to our Current Report on Form 8-K filed on April 30, 2020.</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.1+</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-2020630xex311.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification of the Chief Executive Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.2+</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-2020630xex312.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification of the Chief Financial Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32.1++</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-2020630xex321.htm"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">101++</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following materials from Biogen Inc.&#8217;s Quarterly Report on Form&#160;10-Q for the quarter ended June 30, 2020, formatted in iXBRL (Inline Extensible Business Reporting Language): (i)&#160;the Condensed Consolidated Statements of Income, (ii)&#160;the Condensed Consolidated Statements of Comprehensive Income, (iii) the Condensed Consolidated Balance Sheets, (iv)&#160;the Condensed Consolidated Statements of Cash Flows, (v) the Condensed Consolidated Statements of Equity and (vi)&#160;Notes to Condensed Consolidated Financial Statements.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">104++</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The cover page from this Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, formatted in Inline XBRL.</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">+&#160;&#160;&#160;&#160;Filed herewith </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">++&#160;&#160;&#160;&#160;Furnished herewith</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">95</span></div></div><hr style="page-break-after:always"></hr><div><a id="s8CBDF27E2E58514CB3D0135AEC8C481E"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s940E3527377354DCA6109BF475291A92"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:12pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">SIGNATURES</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="line-height:120%;padding-left:396px;text-indent:-18px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:44.7265625%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BIOGEN INC.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;Jeffrey D. Capello</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Jeffrey D. Capello</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President and</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Financial Officer</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(principal financial officer)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">July&#160;22, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">96</span></div></div>	</div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>biib-2020630xex311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s6184AD6899885726AADFCABA8EEB70AB"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Exhibit 31.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I, Michel Vounatsos, certify that:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I have reviewed this quarterly report of Biogen Inc.;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8211;15(f) and 15d&#8211;15(f)) for the registrant and have:</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;font-size:10pt;text-indent:-48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:52%;"></td><td style="width:3%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date: July 22, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ Michel Vounatsos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Michel Vounatsos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Executive Officer</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>biib-2020630xex312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s38686CC5626451CABE4F3E1D7B625A1A"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Exhibit 31.2</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I, Jeffrey D. Capello, certify that:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I have reviewed this quarterly report of Biogen Inc.;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8211;15(f) and 15d&#8211;15(f)) for the registrant and have:</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:52%;"></td><td style="width:3%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date: July 22, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ Jeffrey D. Capello</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Jeffrey D. Capello</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President and</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Financial Officer</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>biib-2020630xex321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s4B3FAB774F075AC382B24FC2C2825244"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Exhibit 32.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">CERTIFICATION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a)&#160;and (b)&#160;of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Biogen Inc., a Delaware corporation (the &#8220;Company&#8221;), does hereby certify, to such officer&#8217;s knowledge, that:</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Quarterly Report on Form 10-Q for the quarter ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;(the &#8220;Form 10-Q&#8221;) of the Company fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:52%;"></td><td style="width:3%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date: July 22, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ Michel Vounatsos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Michel Vounatsos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">[principal executive officer]</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:52%;"></td><td style="width:3%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date: July 22, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/&#160;Jeffrey D. Capello</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Jeffrey D. Capello</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President and</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">[principal financial officer]</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>biib-20200630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.biogenidec.com/20200630" xmlns:biib="http://www.biogenidec.com/20200630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2019-01-31" schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2019-01-31" schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20200630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20200630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20200630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20200630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>2430403 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossTables" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables">
        <link:definition>2330301 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisitions" roleURI="http://www.biogenidec.com/role/Acquisitions">
        <link:definition>2106100 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessAcquisitionDetails" roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetails">
        <link:definition>2406403 - Disclosure - Business Acquisition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessAcquisitionDetailsTextual" roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual">
        <link:definition>2406402 - Disclosure - Business Acquisition (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationships" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships">
        <link:definition>2135100 - Disclosure - Collaborative and Other Relationships</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsCollaborationsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails">
        <link:definition>2435402 - Disclosure - Collaborative and Other Relationships - Collaborations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails">
        <link:definition>2435403 - Disclosure - Collaborative and Other Relationships - Equity Method Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsTables" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables">
        <link:definition>2335301 - Disclosure - Collaborative and Other Relationships (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>1003000 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>1003501 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementOfEquityStatement" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement">
        <link:definition>1005000 - Statement - Condensed Consolidated Statement of Equity Statement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>1004000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited">
        <link:definition>1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfIncomeUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited">
        <link:definition>1001000 - Statement - Condensed Consolidated Statements of Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CoverPage" roleURI="http://www.biogenidec.com/role/CoverPage">
        <link:definition>0001000 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstruments" roleURI="http://www.biogenidec.com/role/DerivativeInstruments">
        <link:definition>2123100 - Disclosure - Derivative Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsDetails" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails">
        <link:definition>2423402 - Disclosure - Derivative Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsTables" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables">
        <link:definition>2323301 - Disclosure - Derivative Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DivestituresDetailsTextual" roleURI="http://www.biogenidec.com/role/DivestituresDetailsTextual">
        <link:definition>2414401 - Disclosure - Divestitures (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DivestituresDivestitures" roleURI="http://www.biogenidec.com/role/DivestituresDivestitures">
        <link:definition>2114100 - Disclosure - Divestitures Divestitures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.biogenidec.com/role/EarningsPerShare">
        <link:definition>2131100 - Disclosure - Earnings per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareDetails" roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails">
        <link:definition>2431402 - Disclosure - Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.biogenidec.com/role/EarningsPerShareTables">
        <link:definition>2331301 - Disclosure - Earnings per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.biogenidec.com/role/Equity">
        <link:definition>2130100 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.biogenidec.com/role/FairValueMeasurements">
        <link:definition>2121100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails">
        <link:definition>2421402 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails1" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1">
        <link:definition>2421403 - Disclosure - Fair Value Measurements (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails2" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2">
        <link:definition>2421404 - Disclosure - Fair Value Measurements (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetailsTextual" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual">
        <link:definition>2421405 - Disclosure - Fair Value Measurements (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails">
        <link:definition>2421406 - Disclosure - Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables">
        <link:definition>2321301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.biogenidec.com/role/FinancialInstruments">
        <link:definition>2122100 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails">
        <link:definition>2422402 - Disclosure - Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails1" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1">
        <link:definition>2422403 - Disclosure - Financial Instruments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails2" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2">
        <link:definition>2422404 - Disclosure - Financial Instruments (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails3" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3">
        <link:definition>2422405 - Disclosure - Financial Instruments (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetailsTextual" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual">
        <link:definition>2422406 - Disclosure - Financial Instruments (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFinancialInstrumentsDetailsTextual2" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2">
        <link:definition>2422407 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables">
        <link:definition>2322301 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.biogenidec.com/role/IncomeTaxes">
        <link:definition>2133100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails">
        <link:definition>2433403 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetailsTextual" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual">
        <link:definition>2433402 - Disclosure - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.biogenidec.com/role/IncomeTaxesTables">
        <link:definition>2333301 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndebtednessDetails" roleURI="http://www.biogenidec.com/role/IndebtednessDetails">
        <link:definition>2428401 - Disclosure - Indebtedness (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndebtednessNotes" roleURI="http://www.biogenidec.com/role/IndebtednessNotes">
        <link:definition>2128100 - Disclosure - Indebtedness (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwill" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill">
        <link:definition>2120100 - Disclosure - Intangible Assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwillDetails" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails">
        <link:definition>2420402 - Disclosure - Intangible Assets and Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwillDetails1" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1">
        <link:definition>2420403 - Disclosure - Intangible Assets and Goodwill (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwillTables" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables">
        <link:definition>2320301 - Disclosure - Intangible Assets and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.biogenidec.com/role/Inventory">
        <link:definition>2119100 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.biogenidec.com/role/InventoryDetails">
        <link:definition>2419402 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.biogenidec.com/role/InventoryTables">
        <link:definition>2319301 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsInVariableInterestEntities" roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities">
        <link:definition>2136100 - Disclosure - Investments in Variable Interest Entities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsInVariableInterestEntitiesDetails" roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails">
        <link:definition>2436401 - Disclosure - Investments in Variable Interest Entities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Litigation" roleURI="http://www.biogenidec.com/role/Litigation">
        <link:definition>2137100 - Disclosure - Litigation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LitigationDetails" roleURI="http://www.biogenidec.com/role/LitigationDetails">
        <link:definition>2437401 - Disclosure - Litigation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetail" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail">
        <link:definition>2134100 - Disclosure - Other Consolidated Financial Statement Detail</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailDetails" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails">
        <link:definition>2434402 - Disclosure - Other Consolidated Financial Statement Detail (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailTables" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables">
        <link:definition>2334301 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailsTextual" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual">
        <link:definition>2434403 - Disclosure - Other Consolidated Financial Statement (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherRevenuesDetails" roleURI="http://www.biogenidec.com/role/OtherRevenuesDetails">
        <link:definition>2418406 - Disclosure - Other Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipmentDetails" roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails">
        <link:definition>2424401 - Disclosure - Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipmentPropertyPlantAndEquipment" roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment">
        <link:definition>2124100 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>2430404 - Disclosure - Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesForDiscountsAndAllowancesDetails1" roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1">
        <link:definition>2418403 - Disclosure - Reserves for Discounts and Allowances (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesForDiscountsAndAllowancesDetails2" roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2">
        <link:definition>2418404 - Disclosure - Reserves for Discounts and Allowances (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesByProductDetails" roleURI="http://www.biogenidec.com/role/RevenuesByProductDetails">
        <link:definition>2418402 - Disclosure - Revenues by Product (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesDetailsTextual" roleURI="http://www.biogenidec.com/role/RevenuesDetailsTextual">
        <link:definition>2418407 - Disclosure - Revenues (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesFromAntiCd20TherapeuticProgramsDetails" roleURI="http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails">
        <link:definition>2418405 - Disclosure - Revenues from Anti-CD20 Therapeutic Programs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenues" roleURI="http://www.biogenidec.com/role/RevenuesRevenues">
        <link:definition>2118100 - Disclosure - Revenues Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.biogenidec.com/role/RevenuesTables">
        <link:definition>2318301 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPayments" roleURI="http://www.biogenidec.com/role/ShareBasedPayments">
        <link:definition>2132100 - Disclosure - Share-based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails">
        <link:definition>2432402 - Disclosure - Share-Based Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails1" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1">
        <link:definition>2432403 - Disclosure - Share-Based Payments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsTables" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables">
        <link:definition>2332301 - Disclosure - Share-Based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareRepurchasesDetails" roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails">
        <link:definition>2430402 - Disclosure - Share Repurchases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" roleURI="http://www.biogenidec.com/role/SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables">
        <link:definition>2306301 - Disclosure - Summary of separately identifiable assets acquired and liabilities assumed (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2101100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>2401402 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2201201 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="biib_A2.25SeniorNotesdueMay12030Member" name="A2.25SeniorNotesdueMay12030Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_A2.90SeniorNotesDueSept152020Member" name="A2.90SeniorNotesDueSept152020Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_A2018ShareRepurchaseProgramMember" name="A2018ShareRepurchaseProgramMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_A3.15SeniorNotesdueMay12050Member" name="A3.15SeniorNotesdueMay12050Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AVONEXMember" name="AVONEXMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AcquisitionsAbstract" name="AcquisitionsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AdditionalMilestonePayment" name="AdditionalMilestonePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_Additionalreductioninroyaltyratepayableoncommercialsales" name="Additionalreductioninroyaltyratepayableoncommercialsales" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" name="AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AducanumabMember" name="AducanumabMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" name="AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_AverageMaturityOfMarketableSecurities" name="AverageMaturityOfMarketableSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BAN2401Member" name="BAN2401Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BENEPALIMember" name="BENEPALIMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BIIB111Member" name="BIIB111Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BIIB112Member" name="BIIB112Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BIIB118Member" name="BIIB118Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BasicAndDilutedEarningsPerShareAbstract" name="BasicAndDilutedEarningsPerShareAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Biogenshareofcopromotionprofitsorlosses" name="Biogenshareofcopromotionprofitsorlosses" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BiosimilarsMember" name="BiosimilarsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BioverativMember" name="BioverativMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_BusinessOverviewPolicyTextBlock" name="BusinessOverviewPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CashSettledPerformanceSharesMember" name="CashSettledPerformanceSharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CashflowsoperatingexpensesMember" name="CashflowsoperatingexpensesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CashflowsrevenueMember" name="CashflowsrevenueMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ClinicalAssetsAcquired" name="ClinicalAssetsAcquired" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Collaborationexpensesaccrual" name="Collaborationexpensesaccrual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_Collaborationprofitlosssharing" name="Collaborationprofitlosssharing" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ContractManufacturingCustomerMember" name="ContractManufacturingCustomerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ContractOptionExerciseFee" name="ContractOptionExerciseFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ContractualAdjustmentsMember" name="ContractualAdjustmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CorporateDebtSecuritiesCurrentMember" name="CorporateDebtSecuritiesCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CorporateDebtSecuritiesNonCurrentMember" name="CorporateDebtSecuritiesNonCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" name="CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" name="DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_December2019ShareRepurchaseProgramMember" name="December2019ShareRepurchaseProgramMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_DeferredTaxAssetsValueReductioninValue" name="DeferredTaxAssetsValueReductioninValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_DeferredTaxLiabilitiesValueReductioninValue" name="DeferredTaxLiabilitiesValueReductioninValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_DeferredtaxliabilityMember" name="DeferredtaxliabilityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DenmarkManufacturingOperationsMember" name="DenmarkManufacturingOperationsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DerivativeMaturityAxis" name="DerivativeMaturityAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DerivativeMaturityDomain" name="DerivativeMaturityDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" name="Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="biib_DisputedClaimsRelatingtoConstructionCosts" name="DisputedClaimsRelatingtoConstructionCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_DistributorOneMember" name="DistributorOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DistributorTwoMember" name="DistributorTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DivestituresAbstract" name="DivestituresAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_DuefromantiCD20therapeuticprograms" name="DuefromantiCD20therapeuticprograms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_E2609andBAN2401Member" name="E2609andBAN2401Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts" name="EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" name="EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EffectiveTaxRateReconciliationGILTItax" name="EffectiveTaxRateReconciliationGILTItax" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EisaiMember" name="EisaiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ElenbecestatCollaborationMember" name="ElenbecestatCollaborationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EntityWidePercentageOfRevenueFromMajorDistributors" name="EntityWidePercentageOfRevenueFromMajorDistributors" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" name="EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" name="Equitymethodinvestmentbasisdifferenceamortizationperiod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" name="EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_ExpenseIncurredByCollaboration" name="ExpenseIncurredByCollaboration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_Expenseincurredbythecollaboration" name="Expenseincurredbythecollaboration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_Expensereflectedwithinstatementsofincome" name="Expensereflectedwithinstatementsofincome" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FAMPYRAMember" name="FAMPYRAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FLIXABIMember" name="FLIXABIMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FUMADERMMember" name="FUMADERMMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FacilityLocationAxis" name="FacilityLocationAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FacilityLocationDomain" name="FacilityLocationDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" name="FairValueIndefiniteLivedIntangibleAssetsDiscountRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_FumarateMember" name="FumarateMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FutureContingentMilestoneTypesAxis" name="FutureContingentMilestoneTypesAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FutureContingentMilestoneTypesDomain" name="FutureContingentMilestoneTypesDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased" name="GlobalLicensingCollaborationAgreementAmountSharesPurchased" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones" name="GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones" name="GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets" name="GlobalLicensingCollaborationAgreementPaymentSelectionofTargets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" name="GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_GlobalLicensingCollaborationAgreementSharesPurchased" name="GlobalLicensingCollaborationAgreementSharesPurchased" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" name="GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_GovernmentSecuritiesCurrentMember" name="GovernmentSecuritiesCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_GovernmentSecuritiesNonCurrentMember" name="GovernmentSecuritiesNonCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_IMRALDIMember" name="IMRALDIMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_InLicensedPatentsMember" name="InLicensedPatentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet" name="IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_IndefiniteLivedIntangibleAssetsUsefulLife" name="IndefiniteLivedIntangibleAssetsUsefulLife" nillable="true" substitutionGroup="xbrli:item" type="us-types:durationStringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_IntangibleAssetsExcludingGoodwillTableTextBlock" name="IntangibleAssetsExcludingGoodwillTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_InterestInSubsidiary" name="InterestInSubsidiary" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_InterferonMember" name="InterferonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Inventorynetcurrentandnoncurrent" name="Inventorynetcurrentandnoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_InventoryrawmaterialssoldtoFUJIFILM" name="InventoryrawmaterialssoldtoFUJIFILM" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" name="InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_Investmentincommonstocksharespurchased" name="Investmentincommonstocksharespurchased" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis" name="InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain" name="InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_InvestmentsInVariableInterestEntitiesAbstract" name="InvestmentsInVariableInterestEntitiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_IonisPharmaceuticalsMember" name="IonisPharmaceuticalsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MSProductRevenuesMember" name="MSProductRevenuesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_March2019ShareRepurchaseProgramMember" name="March2019ShareRepurchaseProgramMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MarketStockUnitsMember" name="MarketStockUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" name="MortgageAndOtherAssetBackedSecuritiesCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" name="MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_NeurimmuneMember" name="NeurimmuneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_NightstarMember" name="NightstarMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Noncontrollinginterestincreasedecreaseother" name="Noncontrollinginterestincreasedecreaseother" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OthercorporaterevenuesMember" name="OthercorporaterevenuesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OtherrevenuesAbstract" name="OtherrevenuesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_OtherrevenuesTableTextBlock" name="OtherrevenuesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_OtherrevenuesfromantiCD20therapeuticprograms" name="OtherrevenuesfromantiCD20therapeuticprograms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OutLicensedPatentsMember" name="OutLicensedPatentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_PercentageParValueOfSeniorNotes" name="PercentageParValueOfSeniorNotes" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" name="PercentageoffuturedevelopmentcostsrelatedtoEisai" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_PerformanceStockUnitsSettledinCashMember" name="PerformanceStockUnitsSettledinCashMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_PerformanceStockUnitsSettledinStockMember" name="PerformanceStockUnitsSettledinStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PlanAssetsForDeferredCompensationFairValueDisclosure" name="PlanAssetsForDeferredCompensationFairValueDisclosure" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_PostacquisitionequitycompensationMember" name="PostacquisitionequitycompensationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" name="PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain" name="PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" name="ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Reductioninroyaltyratepayableoncommercialsales" name="Reductioninroyaltyratepayableoncommercialsales" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RegulatoryApprovalMilestoneMember" name="RegulatoryApprovalMilestoneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RegulatoryMilestonesMember" name="RegulatoryMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ResearchanddevelopmentassetAxis" name="ResearchanddevelopmentassetAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ResearchanddevelopmentassetDomain" name="ResearchanddevelopmentassetDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ReserveforCashDiscountsMember" name="ReserveforCashDiscountsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" name="RevenuesfromantiCD20therapeuticprogramsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_Revenuesfromanticd20therapeuticprogramsMember" name="Revenuesfromanticd20therapeuticprogramsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RocheGroupGenentechMember" name="RocheGroupGenentechMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SPINRAZAMember" name="SPINRAZAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SamsungBiosimilarAgreementMember" name="SamsungBiosimilarAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SangamoCommonStockMember" name="SangamoCommonStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SangamoTherapeuticsInc.AgreementMember" name="SangamoTherapeuticsInc.AgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" name="SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" name="SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" name="SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" name="SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" name="ShareBasedCompensationExpenseIncludedInCostsAndExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_ShareOfCoPromotionProfits" name="ShareOfCoPromotionProfits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ShorttermderivativeMember" name="ShorttermderivativeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SkyhawkTherapeuticsMember" name="SkyhawkTherapeuticsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SolothurnSwitzerlandMember" name="SolothurnSwitzerlandMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_StrategicInvestmentPortfolio" name="StrategicInvestmentPortfolio" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_StrategicInvestmentsMember" name="StrategicInvestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" name="SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" name="SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" name="SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" name="SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TECFIDERAMember" name="TECFIDERAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TGNMember" name="TGNMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TimeVestedRestrictedStockUnitsMember" name="TimeVestedRestrictedStockUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TysabriProductMember" name="TysabriProductMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_UCBPharmaS.A.Member" name="UCBPharmaS.A.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" name="UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" name="UpfrontAndMilestonePaymentsMadeToCollaborativePartner" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ZINBRYTAMember" name="ZINBRYTAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>biib-20200630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20200630.xsd#AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:href="biib-20200630.xsd#AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:href="biib-20200630.xsd#Acquisitions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetails" xlink:href="biib-20200630.xsd#BusinessAcquisitionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual" xlink:href="biib-20200630.xsd#BusinessAcquisitionDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:href="biib-20200630.xsd#CollaborativeAndOtherRelationships" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:href="biib-20200630.xsd#CollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:href="biib-20200630.xsd#CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:href="biib-20200630.xsd#CollaborativeAndOtherRelationshipsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="biib-20200630.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="biib-20200630.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement" xlink:href="biib-20200630.xsd#CondensedConsolidatedStatementOfEquityStatement" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="biib-20200630.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:href="biib-20200630.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:href="biib-20200630.xsd#CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CoverPage" xlink:href="biib-20200630.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:href="biib-20200630.xsd#DerivativeInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:href="biib-20200630.xsd#DerivativeInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:href="biib-20200630.xsd#DerivativeInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDetailsTextual" xlink:href="biib-20200630.xsd#DivestituresDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDivestitures" xlink:href="biib-20200630.xsd#DivestituresDivestitures" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShare" xlink:href="biib-20200630.xsd#EarningsPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:href="biib-20200630.xsd#EarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:href="biib-20200630.xsd#EarningsPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:href="biib-20200630.xsd#Equity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:href="biib-20200630.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:href="biib-20200630.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:href="biib-20200630.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:href="biib-20200630.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:href="biib-20200630.xsd#FairValueMeasurementsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:href="biib-20200630.xsd#FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:href="biib-20200630.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:href="biib-20200630.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:href="biib-20200630.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:href="biib-20200630.xsd#FinancialInstrumentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:href="biib-20200630.xsd#FinancialInstrumentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:href="biib-20200630.xsd#FinancialInstrumentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:href="biib-20200630.xsd#FinancialInstrumentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:href="biib-20200630.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:href="biib-20200630.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:href="biib-20200630.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:href="biib-20200630.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:href="biib-20200630.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:href="biib-20200630.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails" xlink:href="biib-20200630.xsd#IndebtednessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessNotes" xlink:href="biib-20200630.xsd#IndebtednessNotes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:href="biib-20200630.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="biib-20200630.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:href="biib-20200630.xsd#IntangibleAssetsAndGoodwillDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="biib-20200630.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:href="biib-20200630.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:href="biib-20200630.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:href="biib-20200630.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:href="biib-20200630.xsd#InvestmentsInVariableInterestEntities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:href="biib-20200630.xsd#InvestmentsInVariableInterestEntitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:href="biib-20200630.xsd#Litigation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationDetails" xlink:href="biib-20200630.xsd#LitigationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:href="biib-20200630.xsd#OtherConsolidatedFinancialStatementDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:href="biib-20200630.xsd#OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:href="biib-20200630.xsd#OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:href="biib-20200630.xsd#OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherRevenuesDetails" xlink:href="biib-20200630.xsd#OtherRevenuesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:href="biib-20200630.xsd#PropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:href="biib-20200630.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20200630.xsd#ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1" xlink:href="biib-20200630.xsd#ReservesForDiscountsAndAllowancesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2" xlink:href="biib-20200630.xsd#ReservesForDiscountsAndAllowancesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesByProductDetails" xlink:href="biib-20200630.xsd#RevenuesByProductDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:href="biib-20200630.xsd#RevenuesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:href="biib-20200630.xsd#RevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenues" xlink:href="biib-20200630.xsd#RevenuesRevenues" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesTables" xlink:href="biib-20200630.xsd#RevenuesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPayments" xlink:href="biib-20200630.xsd#ShareBasedPayments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:href="biib-20200630.xsd#ShareBasedPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:href="biib-20200630.xsd#ShareBasedPaymentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:href="biib-20200630.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:href="biib-20200630.xsd#ShareRepurchasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" xlink:href="biib-20200630.xsd#SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="biib-20200630.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="biib-20200630.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="biib-20200630.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/BusinessAcquisitionDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2605fa18-bbd8-c7d7-35fc-aace43a8c019" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2605fa18-bbd8-c7d7-35fc-aace43a8c019" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2605fa18-bbd8-c7d7-35fc-aace43a8c019" xlink:to="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_928e20af-e738-4a2d-05b8-cf88fed11953" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_PreferredStockValue_928e20af-e738-4a2d-05b8-cf88fed11953" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_f05ab245-2bd1-7865-e7ed-1461a5a6155f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_CommonStockValue_f05ab245-2bd1-7865-e7ed-1461a5a6155f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_3d5a0ca6-0f59-67e6-adb5-6aecd22b693b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_AdditionalPaidInCapital_3d5a0ca6-0f59-67e6-adb5-6aecd22b693b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_988c1346-b444-a867-fe80-f3aec1443d54" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_988c1346-b444-a867-fe80-f3aec1443d54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_62305d8f-d807-0fe8-d0ab-f2c2b3d03011" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_62305d8f-d807-0fe8-d0ab-f2c2b3d03011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_e6069c8d-dfec-45ff-4b3f-643d125d5b29" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_TreasuryStockValue_e6069c8d-dfec-45ff-4b3f-643d125d5b29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_3070eb63-b0f5-1f18-a22f-cc54a94922d9" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2605fa18-bbd8-c7d7-35fc-aace43a8c019" xlink:to="loc_us-gaap_MinorityInterest_3070eb63-b0f5-1f18-a22f-cc54a94922d9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_a8f468a7-4768-419d-6f6c-e490a7380ed7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_NotesPayableCurrent_a8f468a7-4768-419d-6f6c-e490a7380ed7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_47896491-55c6-1eb9-d2fd-7a2bb89405ec" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_TaxesPayableCurrent_47896491-55c6-1eb9-d2fd-7a2bb89405ec" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_9c889623-7b4f-c89a-bbb3-2bc9fb9ad9f5" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_AccountsPayableCurrent_9c889623-7b4f-c89a-bbb3-2bc9fb9ad9f5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_ebb4c1f8-b5df-aab0-ee90-1e91fd21cf92" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_ebb4c1f8-b5df-aab0-ee90-1e91fd21cf92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_a2f199ce-3001-c200-d488-633bc54206dc" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_LongTermDebt_a2f199ce-3001-c200-d488-633bc54206dc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_64993a75-9b0c-349a-1011-cc5a81c58412" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_64993a75-9b0c-349a-1011-cc5a81c58412" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d18f979c-644d-9e92-9e89-21cfd1312948" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d18f979c-644d-9e92-9e89-21cfd1312948" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8c850143-cd0c-0f85-9038-e19d8c4f7808" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8c850143-cd0c-0f85-9038-e19d8c4f7808" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4d934b0d-59bc-ae5c-ffb9-b6ced82ff9f8" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4d934b0d-59bc-ae5c-ffb9-b6ced82ff9f8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_21c019f0-62e8-3b20-07d1-495695054dce" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_21c019f0-62e8-3b20-07d1-495695054dce" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e2b10c93-5dbd-d345-d7e4-6144b8287c24" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e2b10c93-5dbd-d345-d7e4-6144b8287c24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_dd2cbe99-77d2-db20-3c91-750589881c79" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_dd2cbe99-77d2-db20-3c91-750589881c79" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_DuefromantiCD20therapeuticprograms" xlink:label="loc_biib_DuefromantiCD20therapeuticprograms_ddaee229-3900-8fa8-8854-f625b0f95697" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_biib_DuefromantiCD20therapeuticprograms_ddaee229-3900-8fa8-8854-f625b0f95697" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_7832082e-fa39-48cc-a655-249c101debf9" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_OtherAssetsCurrent_7832082e-fa39-48cc-a655-249c101debf9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_4f186fae-5cc1-820d-f772-86ccd7a87074" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_4f186fae-5cc1-820d-f772-86ccd7a87074" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_dcf3df0d-2155-35f6-715d-83a9bc9cf3fb" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_dcf3df0d-2155-35f6-715d-83a9bc9cf3fb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8889606b-88fa-2d5e-3fb9-238bccdf9597" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8889606b-88fa-2d5e-3fb9-238bccdf9597" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_37b440e2-656c-b624-0688-b7cf681bf981" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_Goodwill_37b440e2-656c-b624-0688-b7cf681bf981" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_60654fa3-82c2-3e38-ce88-436acda713ac" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_60654fa3-82c2-3e38-ce88-436acda713ac" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_bd8545de-cfc2-6f31-bff6-ed0d4012c357" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_bd8545de-cfc2-6f31-bff6-ed0d4012c357" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_834a7bf3-d1ec-a251-04d2-cec093e0f492" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_834a7bf3-d1ec-a251-04d2-cec093e0f492" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ebef248a-da21-637d-9d28-3d42ff90e8e2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ebef248a-da21-637d-9d28-3d42ff90e8e2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_ef5710e3-3727-237d-7e98-9d98fe0017fc" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_ef5710e3-3727-237d-7e98-9d98fe0017fc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_f0b9d825-b0b9-37fd-4d25-9294a8598890" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_ShareBasedCompensation_f0b9d825-b0b9-37fd-4d25-9294a8598890" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_0bcab6d8-2bb7-f099-a199-f96923f23f8b" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_0bcab6d8-2bb7-f099-a199-f96923f23f8b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9e6dc84d-e1b8-bdee-bb74-bb4a08f8afdc" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9e6dc84d-e1b8-bdee-bb74-bb4a08f8afdc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax" xlink:label="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_cda04db3-0cc7-8cee-c106-c75d14634c49" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_cda04db3-0cc7-8cee-c106-c75d14634c49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3421bed6-296e-da4e-f0e9-a2a8fa1f6d19" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3421bed6-296e-da4e-f0e9-a2a8fa1f6d19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_a6b73ecd-af5e-680a-3d1b-b936aa25dafa" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_a6b73ecd-af5e-680a-3d1b-b936aa25dafa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_269710de-43ea-f1a2-1ab7-8a2fad8bcd72" xlink:type="locator" />
    <link:calculationArc order="10" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_269710de-43ea-f1a2-1ab7-8a2fad8bcd72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_09b7b41a-f5a1-c45e-d61b-846fff462802" xlink:type="locator" />
    <link:calculationArc order="11" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_09b7b41a-f5a1-c45e-d61b-846fff462802" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_c2ae13c3-1da7-9b11-b77f-890f8f8346e4" xlink:type="locator" />
    <link:calculationArc order="12" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_c2ae13c3-1da7-9b11-b77f-890f8f8346e4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_f2b34f8d-2445-12ee-2c68-fa0c5409d5e0" xlink:type="locator" />
    <link:calculationArc order="13" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_f2b34f8d-2445-12ee-2c68-fa0c5409d5e0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c8705fc2-a98a-ac1d-2832-812bd5cae0da" xlink:type="locator" />
    <link:calculationArc order="14" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c8705fc2-a98a-ac1d-2832-812bd5cae0da" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_6933b079-472c-4409-d821-646ed2de772d" xlink:type="locator" />
    <link:calculationArc order="15" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_6933b079-472c-4409-d821-646ed2de772d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_2d3aea93-0685-7648-d025-abd4b91cbb46" xlink:type="locator" />
    <link:calculationArc order="16" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_2d3aea93-0685-7648-d025-abd4b91cbb46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_834a7bf3-d1ec-a251-04d2-cec093e0f492" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_83cf65a5-9616-b748-1d6c-92f0b7da6e69" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_83cf65a5-9616-b748-1d6c-92f0b7da6e69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_8b51ae5f-8f14-ae0e-00e7-8f4e716f2f96" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_8b51ae5f-8f14-ae0e-00e7-8f4e716f2f96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_c609427e-97a7-37ff-0264-613508cb64bd" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_c609427e-97a7-37ff-0264-613508cb64bd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_6abb14d9-7978-302d-af6b-dbfc88f76bf2" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_6abb14d9-7978-302d-af6b-dbfc88f76bf2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_b92a22f8-1cb9-094b-2ac8-a15b13e50636" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_b92a22f8-1cb9-094b-2ac8-a15b13e50636" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0f8df60b-841f-6df5-83c3-e4049d366459" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0f8df60b-841f-6df5-83c3-e4049d366459" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_8644689e-88a2-9828-8c4d-126d8957ca8f" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_8644689e-88a2-9828-8c4d-126d8957ca8f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_fabd36b2-0d2f-8f1e-b9c9-718513456b78" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_fabd36b2-0d2f-8f1e-b9c9-718513456b78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromHedgeInvestingActivities" xlink:label="loc_us-gaap_ProceedsFromHedgeInvestingActivities_065046a1-7aa1-9703-1047-92a3e582cd94" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_ProceedsFromHedgeInvestingActivities_065046a1-7aa1-9703-1047-92a3e582cd94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_c4ba6750-a0ad-e402-704f-a43919d1eea3" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_c4ba6750-a0ad-e402-704f-a43919d1eea3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_b5cf64b6-8899-5a9a-328a-4f0a312ae378" xlink:type="locator" />
    <link:calculationArc order="11" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_b5cf64b6-8899-5a9a-328a-4f0a312ae378" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_834a7bf3-d1ec-a251-04d2-cec093e0f492" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3f804297-91a1-3939-541d-a39b6288c9f9" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3f804297-91a1-3939-541d-a39b6288c9f9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_07e50027-f2db-6d1b-93ed-b22d6bd39351" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_07e50027-f2db-6d1b-93ed-b22d6bd39351" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_f58bb86e-8b52-c30f-7b3a-554d3e73586f" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_f58bb86e-8b52-c30f-7b3a-554d3e73586f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_50c96d39-6558-6bd8-b3d6-7ed1c558807e" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_50c96d39-6558-6bd8-b3d6-7ed1c558807e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities_79790362-8a75-c331-dfb1-f074bcef144a" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities_79790362-8a75-c331-dfb1-f074bcef144a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_e7dfe01f-f85d-50a3-e5ae-55f159760a1f" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_e7dfe01f-f85d-50a3-e5ae-55f159760a1f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_3ddd0290-3d1a-2e62-5161-428d280d3fb6" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_3ddd0290-3d1a-2e62-5161-428d280d3fb6" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c4761fa8-dc2a-e270-4b5c-921deca83ad0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c4761fa8-dc2a-e270-4b5c-921deca83ad0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:to="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5e0cb0dc-b25c-aaae-62f8-cb90f31a16a1" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5e0cb0dc-b25c-aaae-62f8-cb90f31a16a1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_06dfb931-62f3-bab4-4c41-dbf77bf8befd" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5e0cb0dc-b25c-aaae-62f8-cb90f31a16a1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_06dfb931-62f3-bab4-4c41-dbf77bf8befd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_2efcb6ae-5d3a-652c-5e64-2f0332c3d5a3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5e0cb0dc-b25c-aaae-62f8-cb90f31a16a1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_2efcb6ae-5d3a-652c-5e64-2f0332c3d5a3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_fb2eba1d-18a1-c88e-44d1-389c4fe84127" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5e0cb0dc-b25c-aaae-62f8-cb90f31a16a1" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_fb2eba1d-18a1-c88e-44d1-389c4fe84127" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_bfbc3edc-1edc-bfc6-c7b6-fb403917e31e" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5e0cb0dc-b25c-aaae-62f8-cb90f31a16a1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_bfbc3edc-1edc-bfc6-c7b6-fb403917e31e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_68a2669c-01f8-c962-bf95-0b4231cd45da" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5e0cb0dc-b25c-aaae-62f8-cb90f31a16a1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_68a2669c-01f8-c962-bf95-0b4231cd45da" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_51cce957-7438-47fa-f5b3-33f2b5e56016" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c4761fa8-dc2a-e270-4b5c-921deca83ad0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_51cce957-7438-47fa-f5b3-33f2b5e56016" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:to="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d71649eb-5769-933d-7982-2a2ada9ea257" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d71649eb-5769-933d-7982-2a2ada9ea257" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d71649eb-5769-933d-7982-2a2ada9ea257" xlink:to="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_425ada39-f194-a279-47ac-dd09cf899fb1" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:to="loc_us-gaap_Revenues_425ada39-f194-a279-47ac-dd09cf899fb1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:to="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_3549c1c0-2f2a-e44b-026b-b4042153e489" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_3549c1c0-2f2a-e44b-026b-b4042153e489" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9edac52b-cd64-b6b8-351b-74213aa494c3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9edac52b-cd64-b6b8-351b-74213aa494c3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_89fcc343-1933-1e77-588e-68d1c2f1a04f" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_89fcc343-1933-1e77-588e-68d1c2f1a04f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_b15190d2-1e17-e470-df7e-3ace9efbe89b" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_b15190d2-1e17-e470-df7e-3ace9efbe89b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_725ae160-1b15-a075-fa62-729d0bc8cda1" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_725ae160-1b15-a075-fa62-729d0bc8cda1" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_84473586-4524-2f93-3b08-f625b0e9dad0" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_biib_Collaborationprofitlosssharing_84473586-4524-2f93-3b08-f625b0e9dad0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_ef5710e3-3727-237d-7e98-9d98fe0017fc" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_ef5710e3-3727-237d-7e98-9d98fe0017fc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9e6dc84d-e1b8-bdee-bb74-bb4a08f8afdc" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9e6dc84d-e1b8-bdee-bb74-bb4a08f8afdc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_d445215a-3b87-2f11-ac68-3256f2f2966f" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_RestructuringCharges_d445215a-3b87-2f11-ac68-3256f2f2966f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d71649eb-5769-933d-7982-2a2ada9ea257" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_86dec120-3352-31c8-fc61-55992f948bdd" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_86dec120-3352-31c8-fc61-55992f948bdd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a3a6becb-cb5c-3f3c-51b9-6edd8011ed69" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a3a6becb-cb5c-3f3c-51b9-6edd8011ed69" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CoverPage" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DivestituresDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DivestituresDivestitures" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShare" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8c9389ea-1fbb-7e45-ce1f-5a1d89572c0d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fbdbb03d-8583-701f-d6e2-69f8229c6051" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8c9389ea-1fbb-7e45-ce1f-5a1d89572c0d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fbdbb03d-8583-701f-d6e2-69f8229c6051" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_72ad9ebf-e829-cc37-8382-628e47c585ab" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8c9389ea-1fbb-7e45-ce1f-5a1d89572c0d" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_72ad9ebf-e829-cc37-8382-628e47c585ab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_90854703-859b-2c45-aef2-d270627b3141" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_72ad9ebf-e829-cc37-8382-628e47c585ab" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_90854703-859b-2c45-aef2-d270627b3141" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_d2b58163-9b70-93d8-8da6-4d47d94fdd3f" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0d328368-07a6-9c90-0463-ba8a9aaaab66" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_d2b58163-9b70-93d8-8da6-4d47d94fdd3f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0d328368-07a6-9c90-0463-ba8a9aaaab66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_103b152e-0ae8-d915-6e3d-c66b85fd9d6e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_d2b58163-9b70-93d8-8da6-4d47d94fdd3f" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_103b152e-0ae8-d915-6e3d-c66b85fd9d6e" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9fbaf9cb-468f-3b91-9cf2-18d26152173d" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9fbaf9cb-468f-3b91-9cf2-18d26152173d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a23ab896-034e-8e96-1a84-63ffb40e496e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a23ab896-034e-8e96-1a84-63ffb40e496e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_4d98a848-c755-bfec-4020-e17c03e4db3b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2612293f-3433-3583-52e7-9d30e9028da1" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_4d98a848-c755-bfec-4020-e17c03e4db3b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2612293f-3433-3583-52e7-9d30e9028da1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e12f97e0-5d92-eafd-b37a-c60f8d5e47e4" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_4d98a848-c755-bfec-4020-e17c03e4db3b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e12f97e0-5d92-eafd-b37a-c60f8d5e47e4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_6f3a57ea-5dc8-2042-ec7d-a8820e571190" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_4d98a848-c755-bfec-4020-e17c03e4db3b" xlink:to="loc_us-gaap_AvailableForSaleSecurities_6f3a57ea-5dc8-2042-ec7d-a8820e571190" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d870856f-841f-c3d0-a313-ca9d525216a8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d870856f-841f-c3d0-a313-ca9d525216a8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_6a2a51c8-a80d-af5e-4dc1-d2eeba9d310c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_6a2a51c8-a80d-af5e-4dc1-d2eeba9d310c" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_f9649554-34c6-3259-f927-f625b09bb302" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_f9649554-34c6-3259-f927-f625b09bb302" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_6f3a57ea-5dc8-2042-ec7d-a8820e571190" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_2689b18d-c088-f9d0-8533-bbbc6703e3ca" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_6f3a57ea-5dc8-2042-ec7d-a8820e571190" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_2689b18d-c088-f9d0-8533-bbbc6703e3ca" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_ec915ab0-b06c-8246-6113-1ffd431b1e4b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_6f3a57ea-5dc8-2042-ec7d-a8820e571190" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_ec915ab0-b06c-8246-6113-1ffd431b1e4b" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_9438dacf-8de4-0934-65dd-f625b08c8172" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_6f3a57ea-5dc8-2042-ec7d-a8820e571190" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_9438dacf-8de4-0934-65dd-f625b08c8172" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_5ef0c8c5-04c5-1c10-a59e-3eaa9cf923b4" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_5ef0c8c5-04c5-1c10-a59e-3eaa9cf923b4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_fa285cf0-c43f-6ef0-a0f2-c37d958f2fe4" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_fa285cf0-c43f-6ef0-a0f2-c37d958f2fe4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_cb745973-9398-b1e8-0b84-89b40fb91052" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_cb745973-9398-b1e8-0b84-89b40fb91052" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_760e1cd1-b180-e0c4-17a8-eef24284a1cb" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_760e1cd1-b180-e0c4-17a8-eef24284a1cb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_460bb6a1-555b-7f84-cef9-01aaeb67cc93" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_460bb6a1-555b-7f84-cef9-01aaeb67cc93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_f596c6d8-b215-4d64-bb21-cb6128455f52" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_f596c6d8-b215-4d64-bb21-cb6128455f52" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_9F3325E0F11F9E0FAFA50AFCD3C2B8CB" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_9F3325E0F11F9E0FAFA50AFCD3C2B8CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_31eb113d-20c2-89b0-7b2e-dd6b121a4c90" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_31eb113d-20c2-89b0-7b2e-dd6b121a4c90" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_EffectiveTaxRateReconciliationGILTItax" xlink:label="loc_biib_EffectiveTaxRateReconciliationGILTItax_9fa82ab8-0dc2-a508-316e-f625b06c48a9" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_biib_EffectiveTaxRateReconciliationGILTItax_9fa82ab8-0dc2-a508-316e-f625b06c48a9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_631ea6c6-f758-7a94-e1aa-04c5f19d6b4b" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_631ea6c6-f758-7a94-e1aa-04c5f19d6b4b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_c16a0eb3-02da-6ea0-91e7-3203372f71fd" xlink:type="locator" />
    <link:calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_c16a0eb3-02da-6ea0-91e7-3203372f71fd" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IndebtednessNotes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8889606b-88fa-2d5e-3fb9-238bccdf9597" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_65140cb5-12a8-2030-97e2-fa6daceadf40" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8889606b-88fa-2d5e-3fb9-238bccdf9597" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_65140cb5-12a8-2030-97e2-fa6daceadf40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_a32ca153-2a77-c1bc-f506-c7b61720c625" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8889606b-88fa-2d5e-3fb9-238bccdf9597" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_a32ca153-2a77-c1bc-f506-c7b61720c625" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_cb3c969e-ecfd-d862-86d5-39c41aa964cb" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_cb3c969e-ecfd-d862-86d5-39c41aa964cb" xlink:type="arc" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_65140cb5-12a8-2030-97e2-fa6daceadf40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e11e8784-8f2d-ca3c-a9e8-a8115d54520c" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e11e8784-8f2d-ca3c-a9e8-a8115d54520c" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20200630.xsd#biib_Inventorynetcurrentandnoncurrent" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_55035284-0577-f3b9-73f6-f625b0ba4a7d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_a142eb63-af8d-4212-6321-d7c0ac27f958" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_55035284-0577-f3b9-73f6-f625b0ba4a7d" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_a142eb63-af8d-4212-6321-d7c0ac27f958" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_f4920785-d6c0-a217-e01a-0e0ef529643a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_55035284-0577-f3b9-73f6-f625b0ba4a7d" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_f4920785-d6c0-a217-e01a-0e0ef529643a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_2dee2782-8369-5635-44bf-51d0e8aa0f1e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_55035284-0577-f3b9-73f6-f625b0ba4a7d" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_2dee2782-8369-5635-44bf-51d0e8aa0f1e" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/LitigationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_f3206833-d43a-1764-365c-1606167229ee" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_f58cdd58-ff91-98c1-35e0-767a98cb995c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_f3206833-d43a-1764-365c-1606167229ee" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_f58cdd58-ff91-98c1-35e0-767a98cb995c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_49114a85-ad4d-5281-8cd5-2f6823af0c64" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_f3206833-d43a-1764-365c-1606167229ee" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_49114a85-ad4d-5281-8cd5-2f6823af0c64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_d1f3a8d2-a9eb-dfaa-d8d8-e9a2b8c4ce0c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:to="loc_us-gaap_InvestmentIncomeInterest_d1f3a8d2-a9eb-dfaa-d8d8-e9a2b8c4ce0c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_16e9f6a6-5524-a7b1-7e7c-73ee97610ec6" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:to="loc_us-gaap_InterestExpense_16e9f6a6-5524-a7b1-7e7c-73ee97610ec6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_68d18bc3-7cf2-23ef-d8d0-e5d483687134" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_68d18bc3-7cf2-23ef-d8d0-e5d483687134" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_96cf6261-5089-1df3-fbfc-c8c8918673b4" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_96cf6261-5089-1df3-fbfc-c8c8918673b4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherRevenuesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesByProductDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_425ada39-f194-a279-47ac-dd09cf899fb1" xlink:type="locator" />
    <link:loc xlink:href="biib-20200630.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_bfbc9b8b-4c07-a9b6-40a8-f625b09bc6d8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_425ada39-f194-a279-47ac-dd09cf899fb1" xlink:to="loc_biib_ShareOfCoPromotionProfits_bfbc9b8b-4c07-a9b6-40a8-f625b09bc6d8" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenues" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_120452df-d900-40f5-e99c-a8fd93010cf5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_bf6f1c09-722a-be71-e903-4b475ab6ba01" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_120452df-d900-40f5-e99c-a8fd93010cf5" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_bf6f1c09-722a-be71-e903-4b475ab6ba01" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_640a7486-1200-5e33-ad60-f625b09bace1" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_120452df-d900-40f5-e99c-a8fd93010cf5" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_640a7486-1200-5e33-ad60-f625b09bace1" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>biib-20200630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20200630.xsd#AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:href="biib-20200630.xsd#AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:href="biib-20200630.xsd#Acquisitions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetails" xlink:href="biib-20200630.xsd#BusinessAcquisitionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual" xlink:href="biib-20200630.xsd#BusinessAcquisitionDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:href="biib-20200630.xsd#CollaborativeAndOtherRelationships" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:href="biib-20200630.xsd#CollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:href="biib-20200630.xsd#CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:href="biib-20200630.xsd#CollaborativeAndOtherRelationshipsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="biib-20200630.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="biib-20200630.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement" xlink:href="biib-20200630.xsd#CondensedConsolidatedStatementOfEquityStatement" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="biib-20200630.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:href="biib-20200630.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:href="biib-20200630.xsd#CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CoverPage" xlink:href="biib-20200630.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:href="biib-20200630.xsd#DerivativeInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:href="biib-20200630.xsd#DerivativeInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:href="biib-20200630.xsd#DerivativeInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDetailsTextual" xlink:href="biib-20200630.xsd#DivestituresDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDivestitures" xlink:href="biib-20200630.xsd#DivestituresDivestitures" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShare" xlink:href="biib-20200630.xsd#EarningsPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:href="biib-20200630.xsd#EarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:href="biib-20200630.xsd#EarningsPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:href="biib-20200630.xsd#Equity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:href="biib-20200630.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:href="biib-20200630.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:href="biib-20200630.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:href="biib-20200630.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:href="biib-20200630.xsd#FairValueMeasurementsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:href="biib-20200630.xsd#FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:href="biib-20200630.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:href="biib-20200630.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:href="biib-20200630.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:href="biib-20200630.xsd#FinancialInstrumentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:href="biib-20200630.xsd#FinancialInstrumentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:href="biib-20200630.xsd#FinancialInstrumentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:href="biib-20200630.xsd#FinancialInstrumentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:href="biib-20200630.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:href="biib-20200630.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:href="biib-20200630.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:href="biib-20200630.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:href="biib-20200630.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:href="biib-20200630.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails" xlink:href="biib-20200630.xsd#IndebtednessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessNotes" xlink:href="biib-20200630.xsd#IndebtednessNotes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:href="biib-20200630.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="biib-20200630.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:href="biib-20200630.xsd#IntangibleAssetsAndGoodwillDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="biib-20200630.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:href="biib-20200630.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:href="biib-20200630.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:href="biib-20200630.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:href="biib-20200630.xsd#InvestmentsInVariableInterestEntities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:href="biib-20200630.xsd#InvestmentsInVariableInterestEntitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:href="biib-20200630.xsd#Litigation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationDetails" xlink:href="biib-20200630.xsd#LitigationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:href="biib-20200630.xsd#OtherConsolidatedFinancialStatementDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:href="biib-20200630.xsd#OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:href="biib-20200630.xsd#OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:href="biib-20200630.xsd#OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherRevenuesDetails" xlink:href="biib-20200630.xsd#OtherRevenuesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:href="biib-20200630.xsd#PropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:href="biib-20200630.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20200630.xsd#ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1" xlink:href="biib-20200630.xsd#ReservesForDiscountsAndAllowancesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2" xlink:href="biib-20200630.xsd#ReservesForDiscountsAndAllowancesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesByProductDetails" xlink:href="biib-20200630.xsd#RevenuesByProductDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:href="biib-20200630.xsd#RevenuesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:href="biib-20200630.xsd#RevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenues" xlink:href="biib-20200630.xsd#RevenuesRevenues" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesTables" xlink:href="biib-20200630.xsd#RevenuesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPayments" xlink:href="biib-20200630.xsd#ShareBasedPayments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:href="biib-20200630.xsd#ShareBasedPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:href="biib-20200630.xsd#ShareBasedPaymentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:href="biib-20200630.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:href="biib-20200630.xsd#ShareRepurchasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" xlink:href="biib-20200630.xsd#SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="biib-20200630.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="biib-20200630.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="biib-20200630.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_88085225C3A536A053A978234D896445" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0A244574FA369DB34B8E78234D864E2B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_88085225C3A536A053A978234D896445" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0A244574FA369DB34B8E78234D864E2B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7110BD01B7A114C51CBF78234D86637F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0A244574FA369DB34B8E78234D864E2B" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7110BD01B7A114C51CBF78234D86637F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_DAE4A302311E8AA5113278234D870626_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7110BD01B7A114C51CBF78234D86637F" xlink:to="loc_us-gaap_EquityComponentDomain_DAE4A302311E8AA5113278234D870626_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_DAE4A302311E8AA5113278234D870626" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7110BD01B7A114C51CBF78234D86637F" xlink:to="loc_us-gaap_EquityComponentDomain_DAE4A302311E8AA5113278234D870626" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_DA5AA2E4E792562CF81878234D87A051" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_DAE4A302311E8AA5113278234D870626" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_DA5AA2E4E792562CF81878234D87A051" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_44E58C51BB454D9B255778234D8861AF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_DAE4A302311E8AA5113278234D870626" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_44E58C51BB454D9B255778234D8861AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_B784DB9E5BB5DDCAE6D478234D88192B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_DAE4A302311E8AA5113278234D870626" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_B784DB9E5BB5DDCAE6D478234D88192B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_B37A1E6DC361F3873A6178234D88F870" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_DAE4A302311E8AA5113278234D870626" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_B37A1E6DC361F3873A6178234D88F870" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_90C2323215EF846FD0E178234D88534C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_DAE4A302311E8AA5113278234D870626" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_90C2323215EF846FD0E178234D88534C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_D898A64164D8CFF079BE78234D8993B9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_88085225C3A536A053A978234D896445" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_D898A64164D8CFF079BE78234D8993B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_C4E9FCC29E529644E78078234D8A8CC3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_88085225C3A536A053A978234D896445" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_C4E9FCC29E529644E78078234D8A8CC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_EA4A339722FA364F3D6B78234D8A1D9F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_88085225C3A536A053A978234D896445" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_EA4A339722FA364F3D6B78234D8A1D9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4EB8B3527AB15E9259A278234D8A29E6" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_88085225C3A536A053A978234D896445" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4EB8B3527AB15E9259A278234D8A29E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_A6275A003D0FE841406378234D8B5673" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_88085225C3A536A053A978234D896445" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_A6275A003D0FE841406378234D8B5673" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/BusinessAcquisitionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_0174231270E2E8593812782350BD89B5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_14A451184C62074FDCE9782350BC3BC0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0174231270E2E8593812782350BD89B5" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_14A451184C62074FDCE9782350BC3BC0" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_B0365BFBB001CF51F1E1782350BCE1AF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_14A451184C62074FDCE9782350BC3BC0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_B0365BFBB001CF51F1E1782350BCE1AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1DFEBED13AF272A115AC782350BD0D5D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_B0365BFBB001CF51F1E1782350BCE1AF" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1DFEBED13AF272A115AC782350BD0D5D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1DFEBED13AF272A115AC782350BD0D5D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_B0365BFBB001CF51F1E1782350BCE1AF" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1DFEBED13AF272A115AC782350BD0D5D" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_NightstarMember" xlink:label="loc_biib_NightstarMember_3A71C35ABBEA5ECEE879782350BD81B5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1DFEBED13AF272A115AC782350BD0D5D" xlink:to="loc_biib_NightstarMember_3A71C35ABBEA5ECEE879782350BD81B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_A44DF8604E9ED6619FDD782350BE325E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0174231270E2E8593812782350BD89B5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_A44DF8604E9ED6619FDD782350BE325E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_A7585B52E294B54E4792782350BEB2F6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0174231270E2E8593812782350BD89B5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_A7585B52E294B54E4792782350BEB2F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_FAC9584C471F68E37E46782350BED972" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0174231270E2E8593812782350BD89B5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_FAC9584C471F68E37E46782350BED972" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_0B6C2D8D5A513ABC3F3A782350BE35DF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0174231270E2E8593812782350BD89B5" xlink:to="loc_us-gaap_Goodwill_0B6C2D8D5A513ABC3F3A782350BE35DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_894C4BEA3F0D2B1B3E2E782350BE1743" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0174231270E2E8593812782350BD89B5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_894C4BEA3F0D2B1B3E2E782350BE1743" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_8832D4F36B2A230777F8782350C07FE9" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0174231270E2E8593812782350BD89B5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_8832D4F36B2A230777F8782350C07FE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_DDF20669676AFEBB1BEB782350C000E7" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0174231270E2E8593812782350BD89B5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_DDF20669676AFEBB1BEB782350C000E7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_B2CE97D5A08D2DBD067C782350E460A8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0BBF42565AA0EC9D63C2782350DAA3AD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B2CE97D5A08D2DBD067C782350E460A8" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0BBF42565AA0EC9D63C2782350DAA3AD" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_BBDA3025ECEC5225B423782350DACB1D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0BBF42565AA0EC9D63C2782350DAA3AD" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_BBDA3025ECEC5225B423782350DACB1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_F0B553BA419A42AD2D6F782350DA2139_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_BBDA3025ECEC5225B423782350DACB1D" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_F0B553BA419A42AD2D6F782350DA2139_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_F0B553BA419A42AD2D6F782350DA2139" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_BBDA3025ECEC5225B423782350DACB1D" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_F0B553BA419A42AD2D6F782350DA2139" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_7DE50215B6D9C970F0A3782350DB99ED" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0BBF42565AA0EC9D63C2782350DAA3AD" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_7DE50215B6D9C970F0A3782350DB99ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_300CE056FE1C5F26EC10782350DB8A18_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_7DE50215B6D9C970F0A3782350DB99ED" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_300CE056FE1C5F26EC10782350DB8A18_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_300CE056FE1C5F26EC10782350DB8A18" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_7DE50215B6D9C970F0A3782350DB99ED" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_300CE056FE1C5F26EC10782350DB8A18" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_PostacquisitionequitycompensationMember" xlink:label="loc_biib_PostacquisitionequitycompensationMember_2E6D2B14D7F53C58278E782350DB861A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_300CE056FE1C5F26EC10782350DB8A18" xlink:to="loc_biib_PostacquisitionequitycompensationMember_2E6D2B14D7F53C58278E782350DB861A" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_ResearchanddevelopmentassetAxis" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_9002F6AAB8E3DA291976782350DC4384" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0BBF42565AA0EC9D63C2782350DAA3AD" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_9002F6AAB8E3DA291976782350DC4384" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_ResearchanddevelopmentassetDomain" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_D41DDDF322DEB18C33A9782350DC703F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_9002F6AAB8E3DA291976782350DC4384" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_D41DDDF322DEB18C33A9782350DC703F_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_ResearchanddevelopmentassetDomain" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_D41DDDF322DEB18C33A9782350DC703F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_9002F6AAB8E3DA291976782350DC4384" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_D41DDDF322DEB18C33A9782350DC703F" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_BIIB111Member" xlink:label="loc_biib_BIIB111Member_8D01DF0F648B1F8A1D3B782350E2B016" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_D41DDDF322DEB18C33A9782350DC703F" xlink:to="loc_biib_BIIB111Member_8D01DF0F648B1F8A1D3B782350E2B016" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_BIIB112Member" xlink:label="loc_biib_BIIB112Member_BFED354CBA4867EF98E0782350E2C79A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_D41DDDF322DEB18C33A9782350DC703F" xlink:to="loc_biib_BIIB112Member_BFED354CBA4867EF98E0782350E2C79A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_24C5DF4348E0F126DA64782350E26D6A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0BBF42565AA0EC9D63C2782350DAA3AD" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_24C5DF4348E0F126DA64782350E26D6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_713F2297D4260336A0B2782350E28DE6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_24C5DF4348E0F126DA64782350E26D6A" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_713F2297D4260336A0B2782350E28DE6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_713F2297D4260336A0B2782350E28DE6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_24C5DF4348E0F126DA64782350E26D6A" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_713F2297D4260336A0B2782350E28DE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9A051F012069369893FA782350E35EE1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_713F2297D4260336A0B2782350E28DE6" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9A051F012069369893FA782350E35EE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9C21472EEAB39FB5C2AC782350E3F465" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_713F2297D4260336A0B2782350E28DE6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9C21472EEAB39FB5C2AC782350E3F465" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3028B74A071EB334AAE8782350E3547A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0BBF42565AA0EC9D63C2782350DAA3AD" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3028B74A071EB334AAE8782350E3547A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FC87DCE790EAE1525CBC782350E33C5E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3028B74A071EB334AAE8782350E3547A" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FC87DCE790EAE1525CBC782350E33C5E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FC87DCE790EAE1525CBC782350E33C5E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3028B74A071EB334AAE8782350E3547A" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FC87DCE790EAE1525CBC782350E33C5E" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_BIIB118Member" xlink:label="loc_biib_BIIB118Member_BB2B3260300404E2B003782350E34811" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FC87DCE790EAE1525CBC782350E33C5E" xlink:to="loc_biib_BIIB118Member_BB2B3260300404E2B003782350E34811" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_NightstarMember" xlink:label="loc_biib_NightstarMember_EFBFCEDA9340DA8D861B782350E499CC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FC87DCE790EAE1525CBC782350E33C5E" xlink:to="loc_biib_NightstarMember_EFBFCEDA9340DA8D861B782350E499CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_639B8F0337375FEA343B782350E465ED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B2CE97D5A08D2DBD067C782350E460A8" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_639B8F0337375FEA343B782350E465ED" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_26EA67CD329EA4A220C1782350E415F2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B2CE97D5A08D2DBD067C782350E460A8" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_26EA67CD329EA4A220C1782350E415F2" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_ClinicalAssetsAcquired" xlink:label="loc_biib_ClinicalAssetsAcquired_685AC76389BD1DF16080782350E5A9AA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B2CE97D5A08D2DBD067C782350E460A8" xlink:to="loc_biib_ClinicalAssetsAcquired_685AC76389BD1DF16080782350E5A9AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_AB118E30A6EDEFD8419E782350E5571B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B2CE97D5A08D2DBD067C782350E460A8" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_AB118E30A6EDEFD8419E782350E5571B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_5DC37589F23788886177782350E50E62" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B2CE97D5A08D2DBD067C782350E460A8" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_5DC37589F23788886177782350E50E62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_E9F9ACC53BE27976805B782350E5509F" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B2CE97D5A08D2DBD067C782350E460A8" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_E9F9ACC53BE27976805B782350E5509F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_77BB56DA1C6461D95126782350E54C2D" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B2CE97D5A08D2DBD067C782350E460A8" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_77BB56DA1C6461D95126782350E54C2D" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" xlink:label="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_45B0A55B51B4166C45C8782350E5022F" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B2CE97D5A08D2DBD067C782350E460A8" xlink:to="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_45B0A55B51B4166C45C8782350E5022F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_10819FD921E3F7242E69782350E665B4" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B2CE97D5A08D2DBD067C782350E460A8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_10819FD921E3F7242E69782350E665B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes" xlink:label="loc_us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes_E4ED798230AFE04B5185782350E6F339" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B2CE97D5A08D2DBD067C782350E460A8" xlink:to="loc_us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes_E4ED798230AFE04B5185782350E6F339" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_EBF47384C3E7DAF90B1E782350E66624" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B2CE97D5A08D2DBD067C782350E460A8" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_EBF47384C3E7DAF90B1E782350E66624" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4464930A5FA4A0C496FA78234CB05032" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E95629B2248593F6A68778234CAA9FFF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4464930A5FA4A0C496FA78234CB05032" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E95629B2248593F6A68778234CAA9FFF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_E36AA0B66DA3B7BC67D878234CAA99ED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E95629B2248593F6A68778234CAA9FFF" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_E36AA0B66DA3B7BC67D878234CAA99ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_33D898192847460851D278234CAB3C42_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_E36AA0B66DA3B7BC67D878234CAA99ED" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_33D898192847460851D278234CAB3C42_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_33D898192847460851D278234CAB3C42" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_E36AA0B66DA3B7BC67D878234CAA99ED" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_33D898192847460851D278234CAB3C42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_02B0295294FAA79A35CA78234CAB0908" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_33D898192847460851D278234CAB3C42" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_02B0295294FAA79A35CA78234CAB0908" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_C0D7E71F5AB10E2D865F78234CAC50F9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_33D898192847460851D278234CAB3C42" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_C0D7E71F5AB10E2D865F78234CAC50F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_518CCF1557AE52DEF03578234CAC3989" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E95629B2248593F6A68778234CAA9FFF" xlink:to="loc_us-gaap_TypeOfArrangementAxis_518CCF1557AE52DEF03578234CAC3989" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_54DCDB522F95FD48A82978234CACA372_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_518CCF1557AE52DEF03578234CAC3989" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_54DCDB522F95FD48A82978234CACA372_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_54DCDB522F95FD48A82978234CACA372" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_518CCF1557AE52DEF03578234CAC3989" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_54DCDB522F95FD48A82978234CACA372" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_B884123653B1BEDDCB4178234CAC195F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_54DCDB522F95FD48A82978234CACA372" xlink:to="loc_us-gaap_CollaborativeArrangementMember_B884123653B1BEDDCB4178234CAC195F" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_7F7A55DA29F1AAC28D7C78234CAD44B4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_54DCDB522F95FD48A82978234CACA372" xlink:to="loc_biib_EisaiMember_7F7A55DA29F1AAC28D7C78234CAD44B4" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_UCBPharmaS.A.Member" xlink:label="loc_biib_UCBPharmaS.A.Member_3ECCBC0A530B9C8DDBFF78234CAD9A77" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_54DCDB522F95FD48A82978234CACA372" xlink:to="loc_biib_UCBPharmaS.A.Member_3ECCBC0A530B9C8DDBFF78234CAD9A77" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_SangamoTherapeuticsInc.AgreementMember" xlink:label="loc_biib_SangamoTherapeuticsInc.AgreementMember_9CBA4D34379B08423D4778234CAD472A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_54DCDB522F95FD48A82978234CACA372" xlink:to="loc_biib_SangamoTherapeuticsInc.AgreementMember_9CBA4D34379B08423D4778234CAD472A" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_SkyhawkTherapeuticsMember" xlink:label="loc_biib_SkyhawkTherapeuticsMember_48205DB4AEB0E05465E078234CAE62BB" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_54DCDB522F95FD48A82978234CACA372" xlink:to="loc_biib_SkyhawkTherapeuticsMember_48205DB4AEB0E05465E078234CAE62BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_7A5753EFD3E1EAD0AA8A78234CAEFC47" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E95629B2248593F6A68778234CAA9FFF" xlink:to="loc_srt_ProductOrServiceAxis_7A5753EFD3E1EAD0AA8A78234CAEFC47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_0DFDD396DF3F64B29F2C78234CAEBE0D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_7A5753EFD3E1EAD0AA8A78234CAEFC47" xlink:to="loc_srt_ProductsAndServicesDomain_0DFDD396DF3F64B29F2C78234CAEBE0D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_0DFDD396DF3F64B29F2C78234CAEBE0D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_7A5753EFD3E1EAD0AA8A78234CAEFC47" xlink:to="loc_srt_ProductsAndServicesDomain_0DFDD396DF3F64B29F2C78234CAEBE0D" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_BAN2401Member" xlink:label="loc_biib_BAN2401Member_37178110933FB79EBF8578234CAF3051" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0DFDD396DF3F64B29F2C78234CAEBE0D" xlink:to="loc_biib_BAN2401Member_37178110933FB79EBF8578234CAF3051" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_E2609andBAN2401Member" xlink:label="loc_biib_E2609andBAN2401Member_65AC9F5AB74DA0D07D9C78234CAF6D54" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0DFDD396DF3F64B29F2C78234CAEBE0D" xlink:to="loc_biib_E2609andBAN2401Member_65AC9F5AB74DA0D07D9C78234CAF6D54" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_AducanumabMember" xlink:label="loc_biib_AducanumabMember_DCA88A5C2015E746BB7778234CAF383F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0DFDD396DF3F64B29F2C78234CAEBE0D" xlink:to="loc_biib_AducanumabMember_DCA88A5C2015E746BB7778234CAF383F" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_ElenbecestatCollaborationMember" xlink:label="loc_biib_ElenbecestatCollaborationMember_74121E51F7DB72C8E53278234CAFA5F8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0DFDD396DF3F64B29F2C78234CAEBE0D" xlink:to="loc_biib_ElenbecestatCollaborationMember_74121E51F7DB72C8E53278234CAFA5F8" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_056FA1AF280C89B68B3A78234CB0CD52" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4464930A5FA4A0C496FA78234CB05032" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_056FA1AF280C89B68B3A78234CB0CD52" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_GlobalLicensingCollaborationAgreementSharesPurchased" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased_0F65951261F6CE1156CC78234CB0D6E0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4464930A5FA4A0C496FA78234CB05032" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased_0F65951261F6CE1156CC78234CB0D6E0" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_5B539463605B32B2BD1078234CB14E4E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4464930A5FA4A0C496FA78234CB05032" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_5B539463605B32B2BD1078234CB14E4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_FB91B18EBECE2C2CD2C978234CB12018" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4464930A5FA4A0C496FA78234CB05032" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_FB91B18EBECE2C2CD2C978234CB12018" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_ExpenseIncurredByCollaboration" xlink:label="loc_biib_ExpenseIncurredByCollaboration_60AFEEDBEDC149F9B33278234CB172C8" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4464930A5FA4A0C496FA78234CB05032" xlink:to="loc_biib_ExpenseIncurredByCollaboration_60AFEEDBEDC149F9B33278234CB172C8" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_Expenseincurredbythecollaboration" xlink:label="loc_biib_Expenseincurredbythecollaboration_BFC4B73BA1EB20C085D278234CB18C22" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4464930A5FA4A0C496FA78234CB05032" xlink:to="loc_biib_Expenseincurredbythecollaboration_BFC4B73BA1EB20C085D278234CB18C22" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_Expensereflectedwithinstatementsofincome" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_47713B5CDB8D6BFAB87A78234CB12ECA" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4464930A5FA4A0C496FA78234CB05032" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_47713B5CDB8D6BFAB87A78234CB12ECA" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_63EA8FCB1B4AB84BAF2B78234CB27734" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4464930A5FA4A0C496FA78234CB05032" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_63EA8FCB1B4AB84BAF2B78234CB27734" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossOnContractTermination" xlink:label="loc_us-gaap_LossOnContractTermination_7303D0AE4A0E156D688178234CB20C74" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4464930A5FA4A0C496FA78234CB05032" xlink:to="loc_us-gaap_LossOnContractTermination_7303D0AE4A0E156D688178234CB20C74" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_AdditionalMilestonePayment" xlink:label="loc_biib_AdditionalMilestonePayment_95379413D215DC9DF6DD78234CB2BA35" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4464930A5FA4A0C496FA78234CB05032" xlink:to="loc_biib_AdditionalMilestonePayment_95379413D215DC9DF6DD78234CB2BA35" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_51B19001977A5097152F78234CB3DA7F" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4464930A5FA4A0C496FA78234CB05032" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_51B19001977A5097152F78234CB3DA7F" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_AF216D8E00EA84F6152D78234CB3B70C" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4464930A5FA4A0C496FA78234CB05032" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_AF216D8E00EA84F6152D78234CB3B70C" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_D6ED035F3464AA34FB7878234CB36C98" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4464930A5FA4A0C496FA78234CB05032" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_D6ED035F3464AA34FB7878234CB36C98" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_090993B1D0085E2F3FE978234CB3781D" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4464930A5FA4A0C496FA78234CB05032" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_090993B1D0085E2F3FE978234CB3781D" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_5C9F3C5326D924C49A7778234CB38FB2" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4464930A5FA4A0C496FA78234CB05032" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_5C9F3C5326D924C49A7778234CB38FB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_DB747F9E67825269E10B78234CB4BFC0" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4464930A5FA4A0C496FA78234CB05032" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_DB747F9E67825269E10B78234CB4BFC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_3B3443D51C1255B7549978234CB4FF9E" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4464930A5FA4A0C496FA78234CB05032" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_3B3443D51C1255B7549978234CB4FF9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3A48EFF3B3CB3CD550CA78234CB488C9" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4464930A5FA4A0C496FA78234CB05032" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3A48EFF3B3CB3CD550CA78234CB488C9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_EEE0A95002C59E544E1C78234C8642BD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_EEE0A95002C59E544E1C78234C8642BD" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="biib-20200630.xsd#biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis" xlink:label="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_4CF6482C0801C5404D2278234C8755CC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_EEE0A95002C59E544E1C78234C8642BD" xlink:to="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_4CF6482C0801C5404D2278234C8755CC" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain" xlink:label="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_455CC69D14FA9276DA2978234C87E74C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_4CF6482C0801C5404D2278234C8755CC" xlink:to="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_455CC69D14FA9276DA2978234C87E74C_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain" xlink:label="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_455CC69D14FA9276DA2978234C87E74C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_4CF6482C0801C5404D2278234C8755CC" xlink:to="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_455CC69D14FA9276DA2978234C87E74C" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_55BEB725F7A030109D2278234C87A0B6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_455CC69D14FA9276DA2978234C87E74C" xlink:to="loc_biib_NeurimmuneMember_55BEB725F7A030109D2278234C87A0B6" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_FutureContingentMilestoneTypesAxis" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_DC3E0BE5CD3013926A7978234C8896D2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_EEE0A95002C59E544E1C78234C8642BD" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_DC3E0BE5CD3013926A7978234C8896D2" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_FutureContingentMilestoneTypesDomain" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_A0EA74BD8B756E18784478234C88BB79_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_DC3E0BE5CD3013926A7978234C8896D2" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_A0EA74BD8B756E18784478234C88BB79_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_FutureContingentMilestoneTypesDomain" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_A0EA74BD8B756E18784478234C88BB79" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_DC3E0BE5CD3013926A7978234C8896D2" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_A0EA74BD8B756E18784478234C88BB79" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_RegulatoryMilestonesMember" xlink:label="loc_biib_RegulatoryMilestonesMember_418296B0FE1A9A1B6C8E78234C891965" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_A0EA74BD8B756E18784478234C88BB79" xlink:to="loc_biib_RegulatoryMilestonesMember_418296B0FE1A9A1B6C8E78234C891965" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_2BDE7D12A8A4E97EAAF178234C89D1BC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_EEE0A95002C59E544E1C78234C8642BD" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_2BDE7D12A8A4E97EAAF178234C89D1BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7EE240512CE9498361D378234C8960D8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_2BDE7D12A8A4E97EAAF178234C89D1BC" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7EE240512CE9498361D378234C8960D8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7EE240512CE9498361D378234C8960D8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_2BDE7D12A8A4E97EAAF178234C89D1BC" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7EE240512CE9498361D378234C8960D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoriesMember" xlink:label="loc_us-gaap_InventoriesMember_5F168DF5FB67E7FCE6D978234C8A2EF5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7EE240512CE9498361D378234C8960D8" xlink:to="loc_us-gaap_InventoriesMember_5F168DF5FB67E7FCE6D978234C8A2EF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_1D80D2B4AAB3B0B54D1778234C8AD026" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7EE240512CE9498361D378234C8960D8" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_1D80D2B4AAB3B0B54D1778234C8AD026" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_4C3FB95D0946B03282A878234C8AAAF4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7EE240512CE9498361D378234C8960D8" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_4C3FB95D0946B03282A878234C8AAAF4" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_DeferredtaxliabilityMember" xlink:label="loc_biib_DeferredtaxliabilityMember_12A5258510BB1EE2875878234C8B5C5F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7EE240512CE9498361D378234C8960D8" xlink:to="loc_biib_DeferredtaxliabilityMember_12A5258510BB1EE2875878234C8B5C5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_EE8F18C22036BAFE45AC78234C8BFC48" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_EEE0A95002C59E544E1C78234C8642BD" xlink:to="loc_us-gaap_TypeOfArrangementAxis_EE8F18C22036BAFE45AC78234C8BFC48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A566A6A9256EA3C7DABC78234C8B819A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_EE8F18C22036BAFE45AC78234C8BFC48" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A566A6A9256EA3C7DABC78234C8B819A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A566A6A9256EA3C7DABC78234C8B819A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_EE8F18C22036BAFE45AC78234C8BFC48" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A566A6A9256EA3C7DABC78234C8B819A" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_B630F74C79689CD5A17178234C8B28D5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A566A6A9256EA3C7DABC78234C8B819A" xlink:to="loc_biib_EisaiMember_B630F74C79689CD5A17178234C8B28D5" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_1CD84A1414BE2B1DFFC078234C8CD0FF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A566A6A9256EA3C7DABC78234C8B819A" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_1CD84A1414BE2B1DFFC078234C8CD0FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_5581B1A20D328283100278234C8C5A09" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A566A6A9256EA3C7DABC78234C8B819A" xlink:to="loc_us-gaap_CollaborativeArrangementMember_5581B1A20D328283100278234C8C5A09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_94FDF0C13470CC5D4B2578234C8C45EA" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_EEE0A95002C59E544E1C78234C8642BD" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_94FDF0C13470CC5D4B2578234C8C45EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_A5E83044FCDFDF13B83178234C8C707D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_94FDF0C13470CC5D4B2578234C8C45EA" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_A5E83044FCDFDF13B83178234C8C707D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_A5E83044FCDFDF13B83178234C8C707D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_94FDF0C13470CC5D4B2578234C8C45EA" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_A5E83044FCDFDF13B83178234C8C707D" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_53B4632541268AC5BAD078234C8D6258" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_A5E83044FCDFDF13B83178234C8C707D" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_53B4632541268AC5BAD078234C8D6258" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_75962CEFC8C28192F6F678234C8E4844" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_75962CEFC8C28192F6F678234C8E4844" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossOnContractTermination" xlink:label="loc_us-gaap_LossOnContractTermination_8E374C95FBD3C30FE44478234C8E46E4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:to="loc_us-gaap_LossOnContractTermination_8E374C95FBD3C30FE44478234C8E46E4" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_BD6F9407FEFB5980989D78234C8E3E73" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_BD6F9407FEFB5980989D78234C8E3E73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_06BE162523B1AA84B96A78234C8EC2CE" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_06BE162523B1AA84B96A78234C8EC2CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_79EF885BABD225D31E4F78234C8FC07F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_79EF885BABD225D31E4F78234C8FC07F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_A100835F1C9274AF719F78234C8FF226" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:to="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_A100835F1C9274AF719F78234C8FF226" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:label="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_BF9C9930C2BBE26E863F78234C8F46E1" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:to="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_BF9C9930C2BBE26E863F78234C8F46E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_FBFDA60EB09D36DDE48A78234C90BE0C" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_FBFDA60EB09D36DDE48A78234C90BE0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_8C9FA2C5B20E16916A6E78234C90052F" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_8C9FA2C5B20E16916A6E78234C90052F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_C351022395FAB2B91D0278234C90CA27" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:to="loc_us-gaap_AdjustmentForAmortization_C351022395FAB2B91D0278234C90CA27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_BF220C7FDA1C71CE697278234C90F83C" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:to="loc_us-gaap_EquityMethodInvestments_BF220C7FDA1C71CE697278234C90F83C" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_C0A97022117C19ECD9A778234C904D7F" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_C0A97022117C19ECD9A778234C904D7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_10C680ACEBA8FFFD13A978234C913001" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_10C680ACEBA8FFFD13A978234C913001" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_6E8969EAD3AEBD04C77078234C918C80" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_6E8969EAD3AEBD04C77078234C918C80" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_1CBE683251F50EFFDCF578234C9194E3" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_1CBE683251F50EFFDCF578234C9194E3" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_AdditionalMilestonePayment" xlink:label="loc_biib_AdditionalMilestonePayment_0D4E007AB8D594882C4B78234C92986C" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:to="loc_biib_AdditionalMilestonePayment_0D4E007AB8D594882C4B78234C92986C" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_ContractOptionExerciseFee" xlink:label="loc_biib_ContractOptionExerciseFee_F12106C9EE31C577326878234C92ED45" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:to="loc_biib_ContractOptionExerciseFee_F12106C9EE31C577326878234C92ED45" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_Biogenshareofcopromotionprofitsorlosses" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_F58404A65AE38FB9B2D278234C92BC27" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:to="loc_biib_Biogenshareofcopromotionprofitsorlosses_F58404A65AE38FB9B2D278234C92BC27" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_1B53296873C0A341240578234C92EB86" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:to="loc_biib_Collaborationprofitlosssharing_1B53296873C0A341240578234C92EB86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_BD144C319E9C5710EAD178234C93CE55" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:to="loc_us-gaap_Revenues_BD144C319E9C5710EAD178234C93CE55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:label="loc_us-gaap_DueFromRelatedParties_3C802D67F2CF8CBA5FFB78234C93D32D" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:to="loc_us-gaap_DueFromRelatedParties_3C802D67F2CF8CBA5FFB78234C93D32D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_8AC991F3D79317FC434778234C93A91A" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_8AC991F3D79317FC434778234C93A91A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_957572840CDDA096E76878235120F3C5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_70DAABF87FEF5654563C7823511CEEE6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_957572840CDDA096E76878235120F3C5" xlink:to="loc_us-gaap_StatementTable_70DAABF87FEF5654563C7823511CEEE6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_178B88E1DB142917608C7823511CFFC9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_70DAABF87FEF5654563C7823511CEEE6" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_178B88E1DB142917608C7823511CFFC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_00DB7B71C21A4F2802D77823511D8D36_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_178B88E1DB142917608C7823511CFFC9" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_00DB7B71C21A4F2802D77823511D8D36_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_00DB7B71C21A4F2802D77823511D8D36" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_178B88E1DB142917608C7823511CFFC9" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_00DB7B71C21A4F2802D77823511D8D36" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_A2018ShareRepurchaseProgramMember" xlink:label="loc_biib_A2018ShareRepurchaseProgramMember_EE146F8553BED99807F27823511D3088" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_00DB7B71C21A4F2802D77823511D8D36" xlink:to="loc_biib_A2018ShareRepurchaseProgramMember_EE146F8553BED99807F27823511D3088" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_March2019ShareRepurchaseProgramMember" xlink:label="loc_biib_March2019ShareRepurchaseProgramMember_EAD5CCCE0BF3E10FF8BA7823511DBDC9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_00DB7B71C21A4F2802D77823511D8D36" xlink:to="loc_biib_March2019ShareRepurchaseProgramMember_EAD5CCCE0BF3E10FF8BA7823511DBDC9" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_December2019ShareRepurchaseProgramMember" xlink:label="loc_biib_December2019ShareRepurchaseProgramMember_1BFCEEBE871668C403EB7823511D1327" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_00DB7B71C21A4F2802D77823511D8D36" xlink:to="loc_biib_December2019ShareRepurchaseProgramMember_1BFCEEBE871668C403EB7823511D1327" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_D135A3D03D323A062B657823511ED147" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_70DAABF87FEF5654563C7823511CEEE6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_D135A3D03D323A062B657823511ED147" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_62DB2D2A048A861B6DC97823511EF56D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_D135A3D03D323A062B657823511ED147" xlink:to="loc_us-gaap_EquityComponentDomain_62DB2D2A048A861B6DC97823511EF56D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_62DB2D2A048A861B6DC97823511EF56D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_D135A3D03D323A062B657823511ED147" xlink:to="loc_us-gaap_EquityComponentDomain_62DB2D2A048A861B6DC97823511EF56D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_9A5E9BCC18E85BA800017823511EF6D2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_62DB2D2A048A861B6DC97823511EF56D" xlink:to="loc_us-gaap_PreferredStockMember_9A5E9BCC18E85BA800017823511EF6D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_9A02F2606FE9FA3D62E17823511ED5E8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_62DB2D2A048A861B6DC97823511EF56D" xlink:to="loc_us-gaap_CommonStockMember_9A02F2606FE9FA3D62E17823511ED5E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_8D702908B37DD60672887823511F115B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_62DB2D2A048A861B6DC97823511EF56D" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_8D702908B37DD60672887823511F115B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_538EE9CD30F92B34400D7823511FAB38" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_62DB2D2A048A861B6DC97823511EF56D" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_538EE9CD30F92B34400D7823511FAB38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_D5F236A3921E54B423267823511F847F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_62DB2D2A048A861B6DC97823511EF56D" xlink:to="loc_us-gaap_RetainedEarningsMember_D5F236A3921E54B423267823511F847F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_39439E99533987D9ACD77823511FF754" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_62DB2D2A048A861B6DC97823511EF56D" xlink:to="loc_us-gaap_TreasuryStockMember_39439E99533987D9ACD77823511FF754" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_7853BED506E45BB8D16A7823511F14E1" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_62DB2D2A048A861B6DC97823511EF56D" xlink:to="loc_us-gaap_ParentMember_7853BED506E45BB8D16A7823511F14E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_69D71AD174CF4B7C36C57823512080F7" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_62DB2D2A048A861B6DC97823511EF56D" xlink:to="loc_us-gaap_NoncontrollingInterestMember_69D71AD174CF4B7C36C57823512080F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_EF4DC88ACD9C6204A0EE78235120B695" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_957572840CDDA096E76878235120F3C5" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_EF4DC88ACD9C6204A0EE78235120B695" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_EB3A034F29ABF71FE33A7823512035BA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_957572840CDDA096E76878235120F3C5" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_EB3A034F29ABF71FE33A7823512035BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_19C8ACB3CBB3416804E178235120BA76" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_957572840CDDA096E76878235120F3C5" xlink:to="loc_us-gaap_ProfitLoss_19C8ACB3CBB3416804E178235120BA76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_220F5C0DB02AD87D5E3378235121F853" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_957572840CDDA096E76878235120F3C5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_220F5C0DB02AD87D5E3378235121F853" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_Noncontrollinginterestincreasedecreaseother" xlink:label="loc_biib_Noncontrollinginterestincreasedecreaseother_6D5A481FC4FD866F4A347823512193C5" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_957572840CDDA096E76878235120F3C5" xlink:to="loc_biib_Noncontrollinginterestincreasedecreaseother_6D5A481FC4FD866F4A347823512193C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_8DDAA4FB742F1237514C78235121CBDA" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_957572840CDDA096E76878235120F3C5" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_8DDAA4FB742F1237514C78235121CBDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_AFAA38B4AA5F3621768878235121B717" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_957572840CDDA096E76878235120F3C5" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_AFAA38B4AA5F3621768878235121B717" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_6E485DA19AB1E20C08DA78235121BDCE" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_957572840CDDA096E76878235120F3C5" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_6E485DA19AB1E20C08DA78235121BDCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_94E49B5419A1DAAF354B78235122EB53" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_957572840CDDA096E76878235120F3C5" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_94E49B5419A1DAAF354B78235122EB53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_0C601092D381D7E1983278235122F01E" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_957572840CDDA096E76878235120F3C5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_0C601092D381D7E1983278235122F01E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_CEDEDC0D3B62A5957FD5782351224795" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_957572840CDDA096E76878235120F3C5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_CEDEDC0D3B62A5957FD5782351224795" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A6CB225701219883EE46782351229ABB" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_957572840CDDA096E76878235120F3C5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A6CB225701219883EE46782351229ABB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_A83A37D347FEC1E2BAAA7823512203CC" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_957572840CDDA096E76878235120F3C5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_A83A37D347FEC1E2BAAA7823512203CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3E2DFA80EC1E0E3FF3AB782351221926" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_957572840CDDA096E76878235120F3C5" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3E2DFA80EC1E0E3FF3AB782351221926" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityOther" xlink:label="loc_us-gaap_StockholdersEquityOther_3507E97545FAA4043C1078235124FC78" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_957572840CDDA096E76878235120F3C5" xlink:to="loc_us-gaap_StockholdersEquityOther_3507E97545FAA4043C1078235124FC78" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_98FDD9635D731D6AF461782351BB79A0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1CC3D936D9A84F51F3E6782351B9651F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_98FDD9635D731D6AF461782351BB79A0" xlink:to="loc_us-gaap_StatementTable_1CC3D936D9A84F51F3E6782351B9651F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_240DB5AFD091F010474E782351BA4156" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1CC3D936D9A84F51F3E6782351B9651F" xlink:to="loc_srt_ProductOrServiceAxis_240DB5AFD091F010474E782351BA4156" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_A9630AF5908C66EE2AFF782351BA7C8C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_240DB5AFD091F010474E782351BA4156" xlink:to="loc_srt_ProductsAndServicesDomain_A9630AF5908C66EE2AFF782351BA7C8C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_A9630AF5908C66EE2AFF782351BA7C8C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_240DB5AFD091F010474E782351BA4156" xlink:to="loc_srt_ProductsAndServicesDomain_A9630AF5908C66EE2AFF782351BA7C8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_091A937F2A1165EBC5A3782351BA9F03" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_A9630AF5908C66EE2AFF782351BA7C8C" xlink:to="loc_us-gaap_ProductMember_091A937F2A1165EBC5A3782351BA9F03" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_DA566FEBCDF177C7ABAD782351BBF6EA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_A9630AF5908C66EE2AFF782351BA7C8C" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_DA566FEBCDF177C7ABAD782351BBF6EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_75AF6FE36763B2B68231782351BBCFCD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_A9630AF5908C66EE2AFF782351BA7C8C" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_75AF6FE36763B2B68231782351BBCFCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_E10FE7F7D7620CC8E052782351BBA6F0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98FDD9635D731D6AF461782351BB79A0" xlink:to="loc_us-gaap_Revenues_E10FE7F7D7620CC8E052782351BBA6F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_E7A05E5AFEF4EE2B3106782351BCD3CA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98FDD9635D731D6AF461782351BB79A0" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_E7A05E5AFEF4EE2B3106782351BCD3CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_C20B387C170ACC357FEC782351BCF684" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_E7A05E5AFEF4EE2B3106782351BCD3CA" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_C20B387C170ACC357FEC782351BCF684" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9F21FC13AEFC34118E6F782351BC7F18" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_E7A05E5AFEF4EE2B3106782351BCD3CA" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9F21FC13AEFC34118E6F782351BC7F18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6364E2A6FCBB97987235782351BC3C43" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_E7A05E5AFEF4EE2B3106782351BCD3CA" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6364E2A6FCBB97987235782351BC3C43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_89FA89B32E8E0D5E6A38782351BD728E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_E7A05E5AFEF4EE2B3106782351BCD3CA" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_89FA89B32E8E0D5E6A38782351BD728E" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_6BF4A55F37E0254D92F4782351BD9467" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_E7A05E5AFEF4EE2B3106782351BCD3CA" xlink:to="loc_biib_Collaborationprofitlosssharing_6BF4A55F37E0254D92F4782351BD9467" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_964D58BF92706B92E478782351BDAB50" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_E7A05E5AFEF4EE2B3106782351BCD3CA" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_964D58BF92706B92E478782351BDAB50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_506A979E04CB3FE896EA782351BD58FB" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_E7A05E5AFEF4EE2B3106782351BCD3CA" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_506A979E04CB3FE896EA782351BD58FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_0D4A26927F06E9EF7D5C782351BDF536" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_E7A05E5AFEF4EE2B3106782351BCD3CA" xlink:to="loc_us-gaap_RestructuringCharges_0D4A26927F06E9EF7D5C782351BDF536" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_3EF483A92A09AB6F3286782351BD150A" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_E7A05E5AFEF4EE2B3106782351BCD3CA" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_3EF483A92A09AB6F3286782351BD150A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_1DCF7ECA6A53C25ED69B782351BE8FDF" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_E7A05E5AFEF4EE2B3106782351BCD3CA" xlink:to="loc_us-gaap_CostsAndExpenses_1DCF7ECA6A53C25ED69B782351BE8FDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_D2E12F5AA4633EDC19CA782351BEA3AD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98FDD9635D731D6AF461782351BB79A0" xlink:to="loc_us-gaap_OperatingIncomeLoss_D2E12F5AA4633EDC19CA782351BEA3AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_A7BD73A09FC3B0139332782351BEFBAE" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98FDD9635D731D6AF461782351BB79A0" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_A7BD73A09FC3B0139332782351BEFBAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_39E6F4DE1DF56AA275BE782351BEFDD6" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98FDD9635D731D6AF461782351BB79A0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_39E6F4DE1DF56AA275BE782351BEFDD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_B5101490F6E2E8777B45782351BE9156" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98FDD9635D731D6AF461782351BB79A0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_B5101490F6E2E8777B45782351BE9156" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_8FB4D72AF0DC2E50471C782351BF5C07" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98FDD9635D731D6AF461782351BB79A0" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_8FB4D72AF0DC2E50471C782351BF5C07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_81C6A94685D29FBA6626782351BF3105" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98FDD9635D731D6AF461782351BB79A0" xlink:to="loc_us-gaap_ProfitLoss_81C6A94685D29FBA6626782351BF3105" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_B8D96204507ABF9AAC9C782351BFAE46" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98FDD9635D731D6AF461782351BB79A0" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_B8D96204507ABF9AAC9C782351BFAE46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_06827FCD92A4CC282C6A782351BF0196" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98FDD9635D731D6AF461782351BB79A0" xlink:to="loc_us-gaap_NetIncomeLoss_06827FCD92A4CC282C6A782351BF0196" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2FD6FCA6C2B1734BD98C782351BFAC7D" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98FDD9635D731D6AF461782351BB79A0" xlink:to="loc_us-gaap_EarningsPerShareAbstract_2FD6FCA6C2B1734BD98C782351BFAC7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_B35909B023B63AA7659D782351C06F6A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2FD6FCA6C2B1734BD98C782351BFAC7D" xlink:to="loc_us-gaap_EarningsPerShareBasic_B35909B023B63AA7659D782351C06F6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_45331465592B24886E17782351C0E537" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2FD6FCA6C2B1734BD98C782351BFAC7D" xlink:to="loc_us-gaap_EarningsPerShareDiluted_45331465592B24886E17782351C0E537" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_A0F7F9153381515DDD96782351C0CE2E" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98FDD9635D731D6AF461782351BB79A0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_A0F7F9153381515DDD96782351C0CE2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_75D07FEA05A8F57890CD782351C0BD1C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_A0F7F9153381515DDD96782351C0CE2E" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_75D07FEA05A8F57890CD782351C0BD1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4BF884A55F84239CAC68782351C1EDBB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_A0F7F9153381515DDD96782351C0CE2E" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4BF884A55F84239CAC68782351C1EDBB" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CoverPage" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_A4C3A2B414634120787B78234E43258D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_182EA4B9FC283DB36FD278234E333CE0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A4C3A2B414634120787B78234E43258D" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_182EA4B9FC283DB36FD278234E333CE0" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="biib-20200630.xsd#biib_DerivativeMaturityAxis" xlink:label="loc_biib_DerivativeMaturityAxis_7606227E8A5EF21EF55F78234E33027D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_182EA4B9FC283DB36FD278234E333CE0" xlink:to="loc_biib_DerivativeMaturityAxis_7606227E8A5EF21EF55F78234E33027D" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_DerivativeMaturityDomain" xlink:label="loc_biib_DerivativeMaturityDomain_6B91976A8E988C1923F378234E3419C1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_DerivativeMaturityAxis_7606227E8A5EF21EF55F78234E33027D" xlink:to="loc_biib_DerivativeMaturityDomain_6B91976A8E988C1923F378234E3419C1_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_DerivativeMaturityDomain" xlink:label="loc_biib_DerivativeMaturityDomain_6B91976A8E988C1923F378234E3419C1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_DerivativeMaturityAxis_7606227E8A5EF21EF55F78234E33027D" xlink:to="loc_biib_DerivativeMaturityDomain_6B91976A8E988C1923F378234E3419C1" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_ShorttermderivativeMember" xlink:label="loc_biib_ShorttermderivativeMember_B2F5AF05CAC8A67528A378234E3428E5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeMaturityDomain_6B91976A8E988C1923F378234E3419C1" xlink:to="loc_biib_ShorttermderivativeMember_B2F5AF05CAC8A67528A378234E3428E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_66706C2739A8E4A99A6478234E35E105" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_182EA4B9FC283DB36FD278234E333CE0" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_66706C2739A8E4A99A6478234E35E105" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_325A87794132B76C8AEE78234E35B58A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_66706C2739A8E4A99A6478234E35E105" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_325A87794132B76C8AEE78234E35B58A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_325A87794132B76C8AEE78234E35B58A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_66706C2739A8E4A99A6478234E35E105" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_325A87794132B76C8AEE78234E35B58A" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_7ECB4312906A65D3D43478234E365285" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_325A87794132B76C8AEE78234E35B58A" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_7ECB4312906A65D3D43478234E365285" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_B5CEA25D42F66FAB157C78234E36E3FE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_182EA4B9FC283DB36FD278234E333CE0" xlink:to="loc_us-gaap_DebtInstrumentAxis_B5CEA25D42F66FAB157C78234E36E3FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_215146F8BBF1321AB54078234E379134_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_B5CEA25D42F66FAB157C78234E36E3FE" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_215146F8BBF1321AB54078234E379134_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_215146F8BBF1321AB54078234E379134" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_B5CEA25D42F66FAB157C78234E36E3FE" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_215146F8BBF1321AB54078234E379134" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_2FB91DF42FF0BB2BC4D778234E37022A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_215146F8BBF1321AB54078234E379134" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_2FB91DF42FF0BB2BC4D778234E37022A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_25E4A6CBC75B8FB27D3478234E37CF24" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_182EA4B9FC283DB36FD278234E333CE0" xlink:to="loc_srt_CurrencyAxis_25E4A6CBC75B8FB27D3478234E37CF24" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_B4A9577A520A6C0C743478234E38FC2B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_25E4A6CBC75B8FB27D3478234E37CF24" xlink:to="loc_currency_AllCurrenciesDomain_B4A9577A520A6C0C743478234E38FC2B_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_B4A9577A520A6C0C743478234E38FC2B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_25E4A6CBC75B8FB27D3478234E37CF24" xlink:to="loc_currency_AllCurrenciesDomain_B4A9577A520A6C0C743478234E38FC2B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_DC27B339F046752BD02678234E38BE8E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_B4A9577A520A6C0C743478234E38FC2B" xlink:to="loc_currency_EUR_DC27B339F046752BD02678234E38BE8E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_GBP" xlink:label="loc_currency_GBP_74B5F32447D3E6DB26F978234E39CED2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_B4A9577A520A6C0C743478234E38FC2B" xlink:to="loc_currency_GBP_74B5F32447D3E6DB26F978234E39CED2" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CHF" xlink:label="loc_currency_CHF_C3C5CA939CAA1F6E813978234E39B752" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_B4A9577A520A6C0C743478234E38FC2B" xlink:to="loc_currency_CHF_C3C5CA939CAA1F6E813978234E39B752" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_JPY" xlink:label="loc_currency_JPY_CF320C0DF573C4B7415078234E395E60" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_B4A9577A520A6C0C743478234E38FC2B" xlink:to="loc_currency_JPY_CF320C0DF573C4B7415078234E395E60" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CAD" xlink:label="loc_currency_CAD_B785FD5BB331CC7F3B1578234E394D54" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_B4A9577A520A6C0C743478234E38FC2B" xlink:to="loc_currency_CAD_B785FD5BB331CC7F3B1578234E394D54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_CC94442BBF92EC4D7D3E78234E3961C1" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_182EA4B9FC283DB36FD278234E333CE0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_CC94442BBF92EC4D7D3E78234E3961C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6F5C396C855EAF1B8F9878234E3A0963_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_CC94442BBF92EC4D7D3E78234E3961C1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6F5C396C855EAF1B8F9878234E3A0963_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6F5C396C855EAF1B8F9878234E3A0963" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_CC94442BBF92EC4D7D3E78234E3961C1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6F5C396C855EAF1B8F9878234E3A0963" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseMember" xlink:label="loc_us-gaap_InterestExpenseMember_B03CDA821E6678B020D878234E3A65DF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6F5C396C855EAF1B8F9878234E3A0963" xlink:to="loc_us-gaap_InterestExpenseMember_B03CDA821E6678B020D878234E3A65DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_F7CADF5CD0EF1441EA9F78234E3BC30E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6F5C396C855EAF1B8F9878234E3A0963" xlink:to="loc_us-gaap_SalesMember_F7CADF5CD0EF1441EA9F78234E3BC30E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="loc_us-gaap_OperatingExpenseMember_B4C8FF5847D5D6D80D1078234E3B3084" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6F5C396C855EAF1B8F9878234E3A0963" xlink:to="loc_us-gaap_OperatingExpenseMember_B4C8FF5847D5D6D80D1078234E3B3084" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_3810D2C7D1140C2F6F3A78234E3B4A35" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6F5C396C855EAF1B8F9878234E3A0963" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_3810D2C7D1140C2F6F3A78234E3B4A35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_3D001853856CF83BF2CE78234E3BA487" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_182EA4B9FC283DB36FD278234E333CE0" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_3D001853856CF83BF2CE78234E3BA487" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_7293B45C6DB379273B2578234E3B3FCF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_3D001853856CF83BF2CE78234E3BA487" xlink:to="loc_us-gaap_HedgingRelationshipDomain_7293B45C6DB379273B2578234E3B3FCF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_7293B45C6DB379273B2578234E3B3FCF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_3D001853856CF83BF2CE78234E3BA487" xlink:to="loc_us-gaap_HedgingRelationshipDomain_7293B45C6DB379273B2578234E3B3FCF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowHedgingMember" xlink:label="loc_us-gaap_CashFlowHedgingMember_2730D6E132F6ADD3801678234E3C5ABE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_7293B45C6DB379273B2578234E3B3FCF" xlink:to="loc_us-gaap_CashFlowHedgingMember_2730D6E132F6ADD3801678234E3C5ABE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueHedgingMember" xlink:label="loc_us-gaap_FairValueHedgingMember_73A5D2A170D0AE96651D78234E3C1C79" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_7293B45C6DB379273B2578234E3B3FCF" xlink:to="loc_us-gaap_FairValueHedgingMember_73A5D2A170D0AE96651D78234E3C1C79" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_CashflowsrevenueMember" xlink:label="loc_biib_CashflowsrevenueMember_640FD48F3FD50451723F78234E3D4966" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_7293B45C6DB379273B2578234E3B3FCF" xlink:to="loc_biib_CashflowsrevenueMember_640FD48F3FD50451723F78234E3D4966" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_CashflowsoperatingexpensesMember" xlink:label="loc_biib_CashflowsoperatingexpensesMember_97AB68E5CFA516CB41C678234E3DB0A2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_7293B45C6DB379273B2578234E3B3FCF" xlink:to="loc_biib_CashflowsoperatingexpensesMember_97AB68E5CFA516CB41C678234E3DB0A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetInvestmentHedgingMember" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_00F7F7A0F2099967B03078234E3DBAC0" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_7293B45C6DB379273B2578234E3B3FCF" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_00F7F7A0F2099967B03078234E3DBAC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_881785D44CF5AC906B6B78234E3D0B96" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_182EA4B9FC283DB36FD278234E333CE0" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_881785D44CF5AC906B6B78234E3D0B96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_71A186BFFC7F011F0A5478234E3DA9F4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_881785D44CF5AC906B6B78234E3D0B96" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_71A186BFFC7F011F0A5478234E3DA9F4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_71A186BFFC7F011F0A5478234E3DA9F4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_881785D44CF5AC906B6B78234E3D0B96" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_71A186BFFC7F011F0A5478234E3DA9F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_C38AB767994AF108969B78234E3EC43F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_71A186BFFC7F011F0A5478234E3DA9F4" xlink:to="loc_us-gaap_ForeignExchangeContractMember_C38AB767994AF108969B78234E3EC43F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_6476CDF19988EF57D30678234E3E06F1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_71A186BFFC7F011F0A5478234E3DA9F4" xlink:to="loc_us-gaap_InterestRateSwapMember_6476CDF19988EF57D30678234E3E06F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_0051ECFB74F843B698C178234E3E87E7" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_182EA4B9FC283DB36FD278234E333CE0" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_0051ECFB74F843B698C178234E3E87E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_16313CD22180370025B678234E3F71FE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_0051ECFB74F843B698C178234E3E87E7" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_16313CD22180370025B678234E3F71FE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_16313CD22180370025B678234E3F71FE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_0051ECFB74F843B698C178234E3E87E7" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_16313CD22180370025B678234E3F71FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_5DC61D2B5C0612675A2E78234E3FE50B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_16313CD22180370025B678234E3F71FE" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_5DC61D2B5C0612675A2E78234E3FE50B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_858F0A9830098320C9B578234E3F302D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_16313CD22180370025B678234E3F71FE" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_858F0A9830098320C9B578234E3F302D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_354FD5342FE655A2861D78234E3FE549" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_16313CD22180370025B678234E3F71FE" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_354FD5342FE655A2861D78234E3FE549" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_7411FED5179522BDC83778234E40DE8C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_16313CD22180370025B678234E3F71FE" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_7411FED5179522BDC83778234E40DE8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_D25E1340857D5B4AC5F878234E402F70" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_182EA4B9FC283DB36FD278234E333CE0" xlink:to="loc_us-gaap_HedgingDesignationAxis_D25E1340857D5B4AC5F878234E402F70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_B9795BDB4EC6978139B878234E40F2A5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_D25E1340857D5B4AC5F878234E402F70" xlink:to="loc_us-gaap_HedgingDesignationDomain_B9795BDB4EC6978139B878234E40F2A5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_B9795BDB4EC6978139B878234E40F2A5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_D25E1340857D5B4AC5F878234E402F70" xlink:to="loc_us-gaap_HedgingDesignationDomain_B9795BDB4EC6978139B878234E40F2A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_8293A31DC0A4F4DC7CCB78234E41F88B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_B9795BDB4EC6978139B878234E40F2A5" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_8293A31DC0A4F4DC7CCB78234E41F88B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_87B19D72EE4AE9D0358478234E41527C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_B9795BDB4EC6978139B878234E40F2A5" xlink:to="loc_us-gaap_NondesignatedMember_87B19D72EE4AE9D0358478234E41527C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_42BEE76DABC87E6E77CC78234E41F186" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_182EA4B9FC283DB36FD278234E333CE0" xlink:to="loc_srt_RangeAxis_42BEE76DABC87E6E77CC78234E41F186" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_F3E393863663E7D84B9378234E410EED_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_42BEE76DABC87E6E77CC78234E41F186" xlink:to="loc_srt_RangeMember_F3E393863663E7D84B9378234E410EED_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_F3E393863663E7D84B9378234E410EED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_42BEE76DABC87E6E77CC78234E41F186" xlink:to="loc_srt_RangeMember_F3E393863663E7D84B9378234E410EED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_EC9F95558EF8119873DC78234E421FF6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_F3E393863663E7D84B9378234E410EED" xlink:to="loc_srt_MinimumMember_EC9F95558EF8119873DC78234E421FF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_71338DDD22507624A2A478234E425D94" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_F3E393863663E7D84B9378234E410EED" xlink:to="loc_srt_MaximumMember_71338DDD22507624A2A478234E425D94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeRemainingMaturity1" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_B3B319A9E09C1B2005A078234E43D08E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A4C3A2B414634120787B78234E43258D" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_B3B319A9E09C1B2005A078234E43D08E" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_9D42A4C7C93D7CC7C9E978234E438900" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A4C3A2B414634120787B78234E43258D" xlink:to="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_9D42A4C7C93D7CC7C9E978234E438900" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_896C044F02F89EB888C178234E43AAF4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A4C3A2B414634120787B78234E43258D" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_896C044F02F89EB888C178234E43AAF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_56229B7CC46F08AC5CF478234E4471CC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A4C3A2B414634120787B78234E43258D" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_56229B7CC46F08AC5CF478234E4471CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_36B1F03E5C2A932BCC6278234E447E42" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A4C3A2B414634120787B78234E43258D" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_36B1F03E5C2A932BCC6278234E447E42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_ABEF647F51BA920216D578234E4415E6" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A4C3A2B414634120787B78234E43258D" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_ABEF647F51BA920216D578234E4415E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeNotionalAmount" xlink:label="loc_us-gaap_DerivativeNotionalAmount_C0C08B2C2581E464A65278234E448501" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A4C3A2B414634120787B78234E43258D" xlink:to="loc_us-gaap_DerivativeNotionalAmount_C0C08B2C2581E464A65278234E448501" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_3396CC195113EF92CA1878234E45C5A9" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A4C3A2B414634120787B78234E43258D" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_3396CC195113EF92CA1878234E45C5A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_7DDDF52BDD501182CA9478234E45AA1D" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A4C3A2B414634120787B78234E43258D" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_7DDDF52BDD501182CA9478234E45AA1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_09F94B1D334B2D02863478234E458D14" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A4C3A2B414634120787B78234E43258D" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_09F94B1D334B2D02863478234E458D14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeTermOfContract" xlink:label="loc_us-gaap_DerivativeTermOfContract_067B574A43E7593376C278234E45197E" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A4C3A2B414634120787B78234E43258D" xlink:to="loc_us-gaap_DerivativeTermOfContract_067B574A43E7593376C278234E45197E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_51BF3EE424107F7E0FB478234E46AB1C" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A4C3A2B414634120787B78234E43258D" xlink:to="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_51BF3EE424107F7E0FB478234E46AB1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_70D098D7B541443B80C278234E46FD44" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A4C3A2B414634120787B78234E43258D" xlink:to="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_70D098D7B541443B80C278234E46FD44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_36B8AF83E486DC6529C678234E469586" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A4C3A2B414634120787B78234E43258D" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_36B8AF83E486DC6529C678234E469586" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:label="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_03EC6AC09458088648A078234E4631E3" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A4C3A2B414634120787B78234E43258D" xlink:to="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_03EC6AC09458088648A078234E4631E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_6D18C130A006A1F8BD2D78234E4770F2" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A4C3A2B414634120787B78234E43258D" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_6D18C130A006A1F8BD2D78234E4770F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_BA77C049A5CC55FF05AA78234E478CFC" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A4C3A2B414634120787B78234E43258D" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_BA77C049A5CC55FF05AA78234E478CFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_0C16B33EEB390E49D1B878234E4761C6" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A4C3A2B414634120787B78234E43258D" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_0C16B33EEB390E49D1B878234E4761C6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DivestituresDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2C5D565175C079DE3348782350A48365" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_65739D734A43FDD24796782350A33436" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2C5D565175C079DE3348782350A48365" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_65739D734A43FDD24796782350A33436" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D43061457114C409FF28782350A3C506" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_65739D734A43FDD24796782350A33436" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D43061457114C409FF28782350A3C506" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_BB6B829598C67C0A880C782350A4A46A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D43061457114C409FF28782350A3C506" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_BB6B829598C67C0A880C782350A4A46A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_BB6B829598C67C0A880C782350A4A46A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D43061457114C409FF28782350A3C506" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_BB6B829598C67C0A880C782350A4A46A" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_77A729CD732C142313A3782350A47BAE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_BB6B829598C67C0A880C782350A4A46A" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_77A729CD732C142313A3782350A47BAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_115500103370BE78FB89782350A4F560" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2C5D565175C079DE3348782350A48365" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_115500103370BE78FB89782350A4F560" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_565615F0543F8E103D6F782350A5CDD2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2C5D565175C079DE3348782350A48365" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_565615F0543F8E103D6F782350A5CDD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_9AA41B2DBC9B36B4FC20782350A5F5AD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2C5D565175C079DE3348782350A48365" xlink:to="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_9AA41B2DBC9B36B4FC20782350A5F5AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_833E4403818382B2A435782350A53C79" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2C5D565175C079DE3348782350A48365" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_833E4403818382B2A435782350A53C79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_CC5D565ECC0C8BC6D941782350A591C7" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2C5D565175C079DE3348782350A48365" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_CC5D565ECC0C8BC6D941782350A591C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_CAFD1AC38717A6C45FBB782350A57C7C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2C5D565175C079DE3348782350A48365" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_CAFD1AC38717A6C45FBB782350A57C7C" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_InventoryrawmaterialssoldtoFUJIFILM" xlink:label="loc_biib_InventoryrawmaterialssoldtoFUJIFILM_68FCC7A8209F6BFA967B782350A6B258" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2C5D565175C079DE3348782350A48365" xlink:to="loc_biib_InventoryrawmaterialssoldtoFUJIFILM_68FCC7A8209F6BFA967B782350A6B258" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DivestituresDivestitures" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsPerShare" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_52F260203FC456F5600178234D61588B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_C64112BE2F2C562DB5B178234D5F596C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_52F260203FC456F5600178234D61588B" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_C64112BE2F2C562DB5B178234D5F596C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8E5A4096E3B50308124978234D5F7863" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_C64112BE2F2C562DB5B178234D5F596C" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8E5A4096E3B50308124978234D5F7863" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_F3ED5337F9F0086F778B78234D604880_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8E5A4096E3B50308124978234D5F7863" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_F3ED5337F9F0086F778B78234D604880_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_F3ED5337F9F0086F778B78234D604880" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8E5A4096E3B50308124978234D5F7863" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_F3ED5337F9F0086F778B78234D604880" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_48E470BECDE943C7C51178234D60E97D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_F3ED5337F9F0086F778B78234D604880" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_48E470BECDE943C7C51178234D60E97D" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_816ECC6AD62AAC9D973378234D6014E2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_F3ED5337F9F0086F778B78234D604880" xlink:to="loc_biib_MarketStockUnitsMember_816ECC6AD62AAC9D973378234D6014E2" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_BA480501F25CF8B4E07778234D604C1C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_F3ED5337F9F0086F778B78234D604880" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_BA480501F25CF8B4E07778234D604C1C" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_90B7562C2EC0E8DFA7EA78234D617CBB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_52F260203FC456F5600178234D61588B" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_90B7562C2EC0E8DFA7EA78234D617CBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_B2B2AB5E2982CACF70EC78234D61C972" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_90B7562C2EC0E8DFA7EA78234D617CBB" xlink:to="loc_us-gaap_NetIncomeLossAbstract_B2B2AB5E2982CACF70EC78234D61C972" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_937E2EA5AB60B99D71B678234D621226" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_B2B2AB5E2982CACF70EC78234D61C972" xlink:to="loc_us-gaap_NetIncomeLoss_937E2EA5AB60B99D71B678234D621226" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3EBB5F02CBCE075B34EA78234D62B35E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_90B7562C2EC0E8DFA7EA78234D617CBB" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3EBB5F02CBCE075B34EA78234D62B35E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3991B763E654F5D828EB78234D62CF44" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3EBB5F02CBCE075B34EA78234D62B35E" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3991B763E654F5D828EB78234D62CF44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_E4C0DC526A789408D16878234D63D508" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3EBB5F02CBCE075B34EA78234D62B35E" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_E4C0DC526A789408D16878234D63D508" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_111FEF2310C00804823178234D637DA1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_E4C0DC526A789408D16878234D63D508" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_111FEF2310C00804823178234D637DA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_A09BEC1E45689FEA1B5078234D632732" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_E4C0DC526A789408D16878234D63D508" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_A09BEC1E45689FEA1B5078234D632732" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_85068B58E43C3F2273B578234D6314BB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3EBB5F02CBCE075B34EA78234D62B35E" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_85068B58E43C3F2273B578234D6314BB" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6EA7436BFD45C514092478234F697382" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E8FFA73D5CCF155FE92078234F657E8C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6EA7436BFD45C514092478234F697382" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E8FFA73D5CCF155FE92078234F657E8C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_AE024AD99AA1C5B1418B78234F65B751" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E8FFA73D5CCF155FE92078234F657E8C" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_AE024AD99AA1C5B1418B78234F65B751" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C577A1BB689BDE59620178234F666D37_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_AE024AD99AA1C5B1418B78234F65B751" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C577A1BB689BDE59620178234F666D37_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C577A1BB689BDE59620178234F666D37" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_AE024AD99AA1C5B1418B78234F65B751" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C577A1BB689BDE59620178234F666D37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_89714192DDE9BA4395DB78234F66B816" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C577A1BB689BDE59620178234F666D37" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_89714192DDE9BA4395DB78234F66B816" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_35A4EBFD99C0EC91830878234F665DDF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C577A1BB689BDE59620178234F666D37" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_35A4EBFD99C0EC91830878234F665DDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_02B5960236A641015A6778234F66069B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C577A1BB689BDE59620178234F666D37" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_02B5960236A641015A6778234F66069B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_810402E82A9A044B2E5078234F6651CD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E8FFA73D5CCF155FE92078234F657E8C" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_810402E82A9A044B2E5078234F6651CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_8C36DC6BE29522FF1A4378234F674B9D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_810402E82A9A044B2E5078234F6651CD" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_8C36DC6BE29522FF1A4378234F674B9D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_8C36DC6BE29522FF1A4378234F674B9D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_810402E82A9A044B2E5078234F6651CD" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_8C36DC6BE29522FF1A4378234F674B9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_BECA099D67E96C9D615478234F6712B6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_8C36DC6BE29522FF1A4378234F674B9D" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_BECA099D67E96C9D615478234F6712B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_2E7078DFAB43A40913E378234F67FAE3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E8FFA73D5CCF155FE92078234F657E8C" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_2E7078DFAB43A40913E378234F67FAE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_E0EFC60FFBAF73B9A50978234F685EE6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_2E7078DFAB43A40913E378234F67FAE3" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_E0EFC60FFBAF73B9A50978234F685EE6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_E0EFC60FFBAF73B9A50978234F685EE6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_2E7078DFAB43A40913E378234F67FAE3" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_E0EFC60FFBAF73B9A50978234F685EE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_7EDFBA3312FEAD20412D78234F68AE92" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_E0EFC60FFBAF73B9A50978234F685EE6" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_7EDFBA3312FEAD20412D78234F68AE92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_A97FF738B0D3FBAF1F6D78234F683D3C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_E0EFC60FFBAF73B9A50978234F685EE6" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_A97FF738B0D3FBAF1F6D78234F683D3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_6729E6BE7E86FE4CDF9278234F682CE1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_E0EFC60FFBAF73B9A50978234F685EE6" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_6729E6BE7E86FE4CDF9278234F682CE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_8D0C19BAF099F0CEC6E778234F690E70" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6EA7436BFD45C514092478234F697382" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_8D0C19BAF099F0CEC6E778234F690E70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_3B083C756454BDCA642D78234F69F17C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_8D0C19BAF099F0CEC6E778234F690E70" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_3B083C756454BDCA642D78234F69F17C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5FEB665E8001F7FF8AF878234F69F473" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3B083C756454BDCA642D78234F69F17C" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5FEB665E8001F7FF8AF878234F69F473" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_92D311A7BA00D786139B78234F6AA812" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3B083C756454BDCA642D78234F69F17C" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_92D311A7BA00D786139B78234F6AA812" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_5EEE6688FFEF0A993CA578234F6A3ACB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3B083C756454BDCA642D78234F69F17C" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_5EEE6688FFEF0A993CA578234F6A3ACB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_546D3D5E273FEB18179C78234F6AEE02" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3B083C756454BDCA642D78234F69F17C" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_546D3D5E273FEB18179C78234F6AEE02" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_31291E139E25846362D578234F6A16E9" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3B083C756454BDCA642D78234F69F17C" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_31291E139E25846362D578234F6A16E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_715DE8EEB85BA7BD44EC78234F6B6963" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3B083C756454BDCA642D78234F69F17C" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_715DE8EEB85BA7BD44EC78234F6B6963" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_605D31F118717EE143F378234F6B6640" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_8D0C19BAF099F0CEC6E778234F690E70" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_605D31F118717EE143F378234F6B6640" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_78FA0353D93D3721C14178234F6B5125" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_605D31F118717EE143F378234F6B6640" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_78FA0353D93D3721C14178234F6B5125" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3E9ECFA0E5202B5163B478234F6BCC20" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_605D31F118717EE143F378234F6B6640" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3E9ECFA0E5202B5163B478234F6BCC20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_392E93A4082C7AD6407878234F6B2B06" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_605D31F118717EE143F378234F6B6640" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_392E93A4082C7AD6407878234F6B2B06" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6F752FEE9F8F18A3BF6D78234F4B48D7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_A5E9E7A09D5CF2C2C21478234F47E2BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6F752FEE9F8F18A3BF6D78234F4B48D7" xlink:to="loc_us-gaap_DebtInstrumentTable_A5E9E7A09D5CF2C2C21478234F47E2BE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_05B4BD76794AB22C26D478234F485E79" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_A5E9E7A09D5CF2C2C21478234F47E2BE" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_05B4BD76794AB22C26D478234F485E79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_335934BA1AB0410D680778234F48C201_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_05B4BD76794AB22C26D478234F485E79" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_335934BA1AB0410D680778234F48C201_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_335934BA1AB0410D680778234F48C201" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_05B4BD76794AB22C26D478234F485E79" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_335934BA1AB0410D680778234F48C201" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_00F2159D6BF4DB828A3D78234F484C93" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_335934BA1AB0410D680778234F48C201" xlink:to="loc_us-gaap_SeniorNotesMember_00F2159D6BF4DB828A3D78234F484C93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_C641778F31119C03145478234F497A42" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_A5E9E7A09D5CF2C2C21478234F47E2BE" xlink:to="loc_us-gaap_DebtInstrumentAxis_C641778F31119C03145478234F497A42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_A2A1E8F418D506E2B1AC78234F491A4B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_C641778F31119C03145478234F497A42" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_A2A1E8F418D506E2B1AC78234F491A4B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_A2A1E8F418D506E2B1AC78234F491A4B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_C641778F31119C03145478234F497A42" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_A2A1E8F418D506E2B1AC78234F491A4B" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_ED9B1D39D20C3C887C2078234F491AEE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A2A1E8F418D506E2B1AC78234F491A4B" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_ED9B1D39D20C3C887C2078234F491AEE" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_25F202AFFC89A3D832B378234F49282E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A2A1E8F418D506E2B1AC78234F491A4B" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_25F202AFFC89A3D832B378234F49282E" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_6F78F0A7FDC4B2C42E4578234F4A1BF7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A2A1E8F418D506E2B1AC78234F491A4B" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_6F78F0A7FDC4B2C42E4578234F4A1BF7" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_A2.25SeniorNotesdueMay12030Member" xlink:label="loc_biib_A2.25SeniorNotesdueMay12030Member_2E8BA6FB5203D8E1644178234F4A52E4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A2A1E8F418D506E2B1AC78234F491A4B" xlink:to="loc_biib_A2.25SeniorNotesdueMay12030Member_2E8BA6FB5203D8E1644178234F4A52E4" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_E742A5DC132F9765043978234F4AA9E8" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A2A1E8F418D506E2B1AC78234F491A4B" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_E742A5DC132F9765043978234F4AA9E8" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_A3.15SeniorNotesdueMay12050Member" xlink:label="loc_biib_A3.15SeniorNotesdueMay12050Member_C9199869C62069B872B178234F4AFB0D" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A2A1E8F418D506E2B1AC78234F491A4B" xlink:to="loc_biib_A3.15SeniorNotesdueMay12050Member_C9199869C62069B872B178234F4AFB0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_A1A2D9AD76DE121FD22978234F4BD412" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6F752FEE9F8F18A3BF6D78234F4B48D7" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_A1A2D9AD76DE121FD22978234F4BD412" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_2AC1BE9F705578990C3E78234F4B97F7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6F752FEE9F8F18A3BF6D78234F4B48D7" xlink:to="loc_us-gaap_NotesPayable_2AC1BE9F705578990C3E78234F4B97F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_E357519159E09500D14178234F4B28F6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6F752FEE9F8F18A3BF6D78234F4B48D7" xlink:to="loc_us-gaap_DebtInstrumentFairValue_E357519159E09500D14178234F4B28F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7770BEB27E414C193CFE78234F4C5ECA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6F752FEE9F8F18A3BF6D78234F4B48D7" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7770BEB27E414C193CFE78234F4C5ECA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_D619ADF8CD346F57A6B378234F4C4AA4" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6F752FEE9F8F18A3BF6D78234F4B48D7" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_D619ADF8CD346F57A6B378234F4C4AA4" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_691265934CDFF8A3E30878234F32D7F8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_D652FF9ACC36CE31892478234F2BA48B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_691265934CDFF8A3E30878234F32D7F8" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_D652FF9ACC36CE31892478234F2BA48B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_118F05002B42B99F5D7078234F30A283" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_D652FF9ACC36CE31892478234F2BA48B" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_118F05002B42B99F5D7078234F30A283" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_E36178B195797893477478234F3156B1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_118F05002B42B99F5D7078234F30A283" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_E36178B195797893477478234F3156B1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_E36178B195797893477478234F3156B1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_118F05002B42B99F5D7078234F30A283" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_E36178B195797893477478234F3156B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1D7AB692459188BB6EA978234F316570" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_E36178B195797893477478234F3156B1" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1D7AB692459188BB6EA978234F316570" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_A5D2C603FA1924B039A078234F32AD0D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_691265934CDFF8A3E30878234F32D7F8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_A5D2C603FA1924B039A078234F32AD0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_28D409A2DAF6AF427A4978234F334EC4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_691265934CDFF8A3E30878234F32D7F8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_28D409A2DAF6AF427A4978234F334EC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_29D09EB0C614C34FA9A578234F33F969" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_691265934CDFF8A3E30878234F32D7F8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_29D09EB0C614C34FA9A578234F33F969" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_654EFD9B0D67F472C13878234F1BB4B5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_2ED9B6D4F3CEEBC7878978234F18304B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_654EFD9B0D67F472C13878234F1BB4B5" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_2ED9B6D4F3CEEBC7878978234F18304B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_AAA3C4B5EDFABEDCC9D078234F198134" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_2ED9B6D4F3CEEBC7878978234F18304B" xlink:to="loc_us-gaap_DebtInstrumentAxis_AAA3C4B5EDFABEDCC9D078234F198134" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_07BE316A918CDD7ED2DB78234F198C14_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_AAA3C4B5EDFABEDCC9D078234F198134" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_07BE316A918CDD7ED2DB78234F198C14_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_07BE316A918CDD7ED2DB78234F198C14" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_AAA3C4B5EDFABEDCC9D078234F198134" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_07BE316A918CDD7ED2DB78234F198C14" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_F9C8753087B8BE9D360D78234F1A0E45" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_07BE316A918CDD7ED2DB78234F198C14" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_F9C8753087B8BE9D360D78234F1A0E45" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_3F08CBF4B475DBECD94778234F1A88F0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_07BE316A918CDD7ED2DB78234F198C14" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_3F08CBF4B475DBECD94778234F1A88F0" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_F353FB0EF860A866BF5778234F1B7A98" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_07BE316A918CDD7ED2DB78234F198C14" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_F353FB0EF860A866BF5778234F1B7A98" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_A7833951E7ADF410D7CC78234F1BAD5A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_07BE316A918CDD7ED2DB78234F198C14" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_A7833951E7ADF410D7CC78234F1BAD5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_A4B6A9BF74EB4CEE973978234F1BD1FC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_654EFD9B0D67F472C13878234F1BB4B5" xlink:to="loc_us-gaap_AssetImpairmentCharges_A4B6A9BF74EB4CEE973978234F1BD1FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_265940CAA3D1BF4145BE78234F1BA9DC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_654EFD9B0D67F472C13878234F1BB4B5" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_265940CAA3D1BF4145BE78234F1BA9DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_4840FF339B45E996C5C478234F1B8E5F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_654EFD9B0D67F472C13878234F1BB4B5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_4840FF339B45E996C5C478234F1B8E5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9DDBA9AE2C51FF3A40EC78234F1CF6BB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_654EFD9B0D67F472C13878234F1BB4B5" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9DDBA9AE2C51FF3A40EC78234F1CF6BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_037F4DBB5E57B68A3C3978234F1CF0C8" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_654EFD9B0D67F472C13878234F1BB4B5" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_037F4DBB5E57B68A3C3978234F1CF0C8" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F513436CEEF777DE894E78234F0685FB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_EC95D591637081B6123878234F02D53C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F513436CEEF777DE894E78234F0685FB" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_EC95D591637081B6123878234F02D53C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_A14296A47215B03741C278234F034199" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_EC95D591637081B6123878234F02D53C" xlink:to="loc_srt_RangeAxis_A14296A47215B03741C278234F034199" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_F7654E27E3D57F10C1D678234F033114_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_A14296A47215B03741C278234F034199" xlink:to="loc_srt_RangeMember_F7654E27E3D57F10C1D678234F033114_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_F7654E27E3D57F10C1D678234F033114" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_A14296A47215B03741C278234F034199" xlink:to="loc_srt_RangeMember_F7654E27E3D57F10C1D678234F033114" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_143C0E82977F1443596978234F039525" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_F7654E27E3D57F10C1D678234F033114" xlink:to="loc_srt_MinimumMember_143C0E82977F1443596978234F039525" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_3E39196111E9AFAE167E78234F04952F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_F7654E27E3D57F10C1D678234F033114" xlink:to="loc_srt_MaximumMember_3E39196111E9AFAE167E78234F04952F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_WeightedAverageMember" xlink:label="loc_srt_WeightedAverageMember_56CDC77D9A7D342098D678234F046C93" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_F7654E27E3D57F10C1D678234F033114" xlink:to="loc_srt_WeightedAverageMember_56CDC77D9A7D342098D678234F046C93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_58369FF89A2DA2F4112778234F04240B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_EC95D591637081B6123878234F02D53C" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_58369FF89A2DA2F4112778234F04240B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_B0FBD1E1B897A6971BA078234F0466B4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_58369FF89A2DA2F4112778234F04240B" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_B0FBD1E1B897A6971BA078234F0466B4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_B0FBD1E1B897A6971BA078234F0466B4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_58369FF89A2DA2F4112778234F04240B" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_B0FBD1E1B897A6971BA078234F0466B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_E9A542F203368CF24C0078234F05CBAA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_B0FBD1E1B897A6971BA078234F0466B4" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_E9A542F203368CF24C0078234F05CBAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_E6751B9D306F11E72D7E78234F05A4D4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_EC95D591637081B6123878234F02D53C" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_E6751B9D306F11E72D7E78234F05A4D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_226F9EA1494AC8CEB08178234F054F77_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_E6751B9D306F11E72D7E78234F05A4D4" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_226F9EA1494AC8CEB08178234F054F77_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_226F9EA1494AC8CEB08178234F054F77" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_E6751B9D306F11E72D7E78234F05A4D4" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_226F9EA1494AC8CEB08178234F054F77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_553DAB027FFA6A126E7478234F050F0A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_EC95D591637081B6123878234F02D53C" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_553DAB027FFA6A126E7478234F050F0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6D6188B73C4C6E5D6F8178234F065143_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_553DAB027FFA6A126E7478234F050F0A" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6D6188B73C4C6E5D6F8178234F065143_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6D6188B73C4C6E5D6F8178234F065143" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_553DAB027FFA6A126E7478234F050F0A" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6D6188B73C4C6E5D6F8178234F065143" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_6AC47037E87A5641D70278234F066107" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F513436CEEF777DE894E78234F0685FB" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_6AC47037E87A5641D70278234F066107" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4FA8F68B83979D7448FA78234F07EE39" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F513436CEEF777DE894E78234F0685FB" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4FA8F68B83979D7448FA78234F07EE39" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_480B293181A77D9802B478234EDD81FC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_261F922073DFDD702C7E78234EDA4C9B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_480B293181A77D9802B478234EDD81FC" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_261F922073DFDD702C7E78234EDA4C9B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_5CA4A60660FB69149C3E78234EDA0034" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_261F922073DFDD702C7E78234EDA4C9B" xlink:to="loc_us-gaap_InvestmentTypeAxis_5CA4A60660FB69149C3E78234EDA0034" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_CAE13082916CD16573ED78234EDA3D8D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_5CA4A60660FB69149C3E78234EDA0034" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_CAE13082916CD16573ED78234EDA3D8D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_CAE13082916CD16573ED78234EDA3D8D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_5CA4A60660FB69149C3E78234EDA0034" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_CAE13082916CD16573ED78234EDA3D8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_A6EEA421602F6CFA8D4078234EDB0756" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_CAE13082916CD16573ED78234EDA3D8D" xlink:to="loc_us-gaap_CommercialPaperMember_A6EEA421602F6CFA8D4078234EDB0756" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_C3D57353D4C9441586FB78234EDB8574" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_CAE13082916CD16573ED78234EDA3D8D" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_C3D57353D4C9441586FB78234EDB8574" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_5A6684A401052B1D964278234EDBBD1F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_CAE13082916CD16573ED78234EDA3D8D" xlink:to="loc_us-gaap_MoneyMarketFundsMember_5A6684A401052B1D964278234EDBBD1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_4D4031CFE6D800DCCFCF78234EDBDC5D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_CAE13082916CD16573ED78234EDA3D8D" xlink:to="loc_us-gaap_DebtSecuritiesMember_4D4031CFE6D800DCCFCF78234EDBDC5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_6ECA9CE58ABA1F7AB41A78234EDD0B1E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_480B293181A77D9802B478234EDD81FC" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_6ECA9CE58ABA1F7AB41A78234EDD0B1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_0995BECB7E6E71E5A36678234EDDE117" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_6ECA9CE58ABA1F7AB41A78234EDD0B1E" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_0995BECB7E6E71E5A36678234EDDE117" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3610FB7AA46300C7B49778234EC788C8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_594807FC0CE38E74B84178234EC35E00" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3610FB7AA46300C7B49778234EC788C8" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_594807FC0CE38E74B84178234EC35E00" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_686D2E8850A2A80122FF78234EC329C4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_594807FC0CE38E74B84178234EC35E00" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_686D2E8850A2A80122FF78234EC329C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2DDEB3FC7C3393DCB8C578234EC4CA48_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_686D2E8850A2A80122FF78234EC329C4" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2DDEB3FC7C3393DCB8C578234EC4CA48_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2DDEB3FC7C3393DCB8C578234EC4CA48" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_686D2E8850A2A80122FF78234EC329C4" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2DDEB3FC7C3393DCB8C578234EC4CA48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_63D42E622DCF3A50CDA778234EC41679" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2DDEB3FC7C3393DCB8C578234EC4CA48" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_63D42E622DCF3A50CDA778234EC41679" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_C441E79B27348A81961F78234EC46F9E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2DDEB3FC7C3393DCB8C578234EC4CA48" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_C441E79B27348A81961F78234EC46F9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_CC7A3C71F5BB7A4B779178234EC57EA6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_594807FC0CE38E74B84178234EC35E00" xlink:to="loc_us-gaap_FinancialInstrumentAxis_CC7A3C71F5BB7A4B779178234EC57EA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F72B48CBECE3CB71283078234EC59062_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_CC7A3C71F5BB7A4B779178234EC57EA6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F72B48CBECE3CB71283078234EC59062_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F72B48CBECE3CB71283078234EC59062" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_CC7A3C71F5BB7A4B779178234EC57EA6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F72B48CBECE3CB71283078234EC59062" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_CorporateDebtSecuritiesCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_C1852C6D28B675BC600C78234EC57733" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F72B48CBECE3CB71283078234EC59062" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_C1852C6D28B675BC600C78234EC57733" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_CorporateDebtSecuritiesNonCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_40A7607CD547745D111E78234EC66C2A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F72B48CBECE3CB71283078234EC59062" xlink:to="loc_biib_CorporateDebtSecuritiesNonCurrentMember_40A7607CD547745D111E78234EC66C2A" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_GovernmentSecuritiesCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_0ACEA705C97C0AFBF82B78234EC62669" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F72B48CBECE3CB71283078234EC59062" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_0ACEA705C97C0AFBF82B78234EC62669" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_GovernmentSecuritiesNonCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_E9F3DC15943B28DD4CAA78234EC68DFF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F72B48CBECE3CB71283078234EC59062" xlink:to="loc_biib_GovernmentSecuritiesNonCurrentMember_E9F3DC15943B28DD4CAA78234EC68DFF" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_85E2822FCC7EBF1C52DB78234EC6F4C4" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F72B48CBECE3CB71283078234EC59062" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_85E2822FCC7EBF1C52DB78234EC6F4C4" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_EA0140D266E0BCE6FE8878234EC6E797" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F72B48CBECE3CB71283078234EC59062" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_EA0140D266E0BCE6FE8878234EC6E797" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_B54C5E89489CAEF48A6278234EC7E2A9" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F72B48CBECE3CB71283078234EC59062" xlink:to="loc_us-gaap_EquitySecuritiesMember_B54C5E89489CAEF48A6278234EC7E2A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_075AE495E556ECF92EF978234EC765B0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3610FB7AA46300C7B49778234EC788C8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_075AE495E556ECF92EF978234EC765B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0813CC192AEDDD7955C478234ECDEDC5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3610FB7AA46300C7B49778234EC788C8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0813CC192AEDDD7955C478234ECDEDC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_29AF053459D656440B3378234ECDF713" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3610FB7AA46300C7B49778234EC788C8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_29AF053459D656440B3378234ECDF713" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_A64B06DDFFDC0BCEE3C778234ECDD128" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3610FB7AA46300C7B49778234EC788C8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_A64B06DDFFDC0BCEE3C778234ECDD128" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_D9CB118088444C1E90B478234ECD1B63" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3610FB7AA46300C7B49778234EC788C8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_D9CB118088444C1E90B478234ECD1B63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_10703108CA9FA0320E5278234ECD27ED" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3610FB7AA46300C7B49778234EC788C8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_10703108CA9FA0320E5278234ECD27ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_FE85476A8D800045C41178234ECEA474" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3610FB7AA46300C7B49778234EC788C8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_FE85476A8D800045C41178234ECEA474" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_00272BF809828F29FDAF78234ECE20BF" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3610FB7AA46300C7B49778234EC788C8" xlink:to="loc_us-gaap_AvailableForSaleSecurities_00272BF809828F29FDAF78234ECE20BF" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_E09775E122CC2708A39678234E7D3121" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FA764A988E2D1282989E78234E74A4CA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E09775E122CC2708A39678234E7D3121" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FA764A988E2D1282989E78234E74A4CA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_20FF1F8C0E71795435AD78234E75F05B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FA764A988E2D1282989E78234E74A4CA" xlink:to="loc_dei_LegalEntityAxis_20FF1F8C0E71795435AD78234E75F05B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_5873327B1A70D51FBC9278234E758508_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_20FF1F8C0E71795435AD78234E75F05B" xlink:to="loc_dei_EntityDomain_5873327B1A70D51FBC9278234E758508_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_5873327B1A70D51FBC9278234E758508" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_20FF1F8C0E71795435AD78234E75F05B" xlink:to="loc_dei_EntityDomain_5873327B1A70D51FBC9278234E758508" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_SangamoCommonStockMember" xlink:label="loc_biib_SangamoCommonStockMember_CA705A8548328C201D5278234E75A146" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_5873327B1A70D51FBC9278234E758508" xlink:to="loc_biib_SangamoCommonStockMember_CA705A8548328C201D5278234E75A146" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_DA9FAB448C223FD5E49078234E7B16DE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FA764A988E2D1282989E78234E74A4CA" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_DA9FAB448C223FD5E49078234E7B16DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_A0E9E80E948FA136EB3278234E7C8DA9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_DA9FAB448C223FD5E49078234E7B16DE" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_A0E9E80E948FA136EB3278234E7C8DA9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_A0E9E80E948FA136EB3278234E7C8DA9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_DA9FAB448C223FD5E49078234E7B16DE" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_A0E9E80E948FA136EB3278234E7C8DA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_7973B740329FE0586DA978234E7CC6DF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_A0E9E80E948FA136EB3278234E7C8DA9" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_7973B740329FE0586DA978234E7CC6DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_48B1C310970F014879FC78234E7C75C9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_A0E9E80E948FA136EB3278234E7C8DA9" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_48B1C310970F014879FC78234E7C75C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_814DA8531DFE0D1405A278234E7CF631" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FA764A988E2D1282989E78234E74A4CA" xlink:to="loc_us-gaap_FinancialInstrumentAxis_814DA8531DFE0D1405A278234E7CF631" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E35A225C903BCA84A0EC78234E7D83FB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_814DA8531DFE0D1405A278234E7CF631" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E35A225C903BCA84A0EC78234E7D83FB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E35A225C903BCA84A0EC78234E7D83FB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_814DA8531DFE0D1405A278234E7CF631" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E35A225C903BCA84A0EC78234E7D83FB" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_StrategicInvestmentsMember" xlink:label="loc_biib_StrategicInvestmentsMember_91199FEA85566A8417F078234E7DB52A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E35A225C903BCA84A0EC78234E7D83FB" xlink:to="loc_biib_StrategicInvestmentsMember_91199FEA85566A8417F078234E7DB52A" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_StrategicInvestmentPortfolio" xlink:label="loc_biib_StrategicInvestmentPortfolio_80F8D089D0567CFB51ED78234E7ECE52" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E09775E122CC2708A39678234E7D3121" xlink:to="loc_biib_StrategicInvestmentPortfolio_80F8D089D0567CFB51ED78234E7ECE52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_DAC350DE29933A7BEFCF78234E7E53A6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E09775E122CC2708A39678234E7D3121" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_DAC350DE29933A7BEFCF78234E7E53A6" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_Investmentincommonstocksharespurchased" xlink:label="loc_biib_Investmentincommonstocksharespurchased_33704BBB00D725B93DC678234E7E32A2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E09775E122CC2708A39678234E7D3121" xlink:to="loc_biib_Investmentincommonstocksharespurchased_33704BBB00D725B93DC678234E7E32A2" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_2D0867D3EF0C9566AFB378234D1D6752" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_68A4DD4B1B8AC932763478234D1A4EA1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2D0867D3EF0C9566AFB378234D1D6752" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_68A4DD4B1B8AC932763478234D1A4EA1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_66A47C399DFB8F4E290778234D1A95F6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_68A4DD4B1B8AC932763478234D1A4EA1" xlink:to="loc_srt_ProductOrServiceAxis_66A47C399DFB8F4E290778234D1A95F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_35057C12EA60A87909FC78234D1BD104_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_66A47C399DFB8F4E290778234D1A95F6" xlink:to="loc_srt_ProductsAndServicesDomain_35057C12EA60A87909FC78234D1BD104_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_35057C12EA60A87909FC78234D1BD104" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_66A47C399DFB8F4E290778234D1A95F6" xlink:to="loc_srt_ProductsAndServicesDomain_35057C12EA60A87909FC78234D1BD104" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_TECFIDERAMember" xlink:label="loc_biib_TECFIDERAMember_440D9B128EBAF06F29CF78234D1C2CC6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_35057C12EA60A87909FC78234D1BD104" xlink:to="loc_biib_TECFIDERAMember_440D9B128EBAF06F29CF78234D1C2CC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8AACF74FF3023C2D506378234D1C6590" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_68A4DD4B1B8AC932763478234D1A4EA1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8AACF74FF3023C2D506378234D1C6590" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_56B9999C4F63CAFAE44B78234D1C8504_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8AACF74FF3023C2D506378234D1C6590" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_56B9999C4F63CAFAE44B78234D1C8504_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_56B9999C4F63CAFAE44B78234D1C8504" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8AACF74FF3023C2D506378234D1C6590" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_56B9999C4F63CAFAE44B78234D1C8504" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_B6E73C6E7906F25B6A2778234D1C2AA9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_56B9999C4F63CAFAE44B78234D1C8504" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_B6E73C6E7906F25B6A2778234D1C2AA9" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_DeferredTaxAssetsValueReductioninValue" xlink:label="loc_biib_DeferredTaxAssetsValueReductioninValue_408F39B78C0420D48B8C78234D1DF5CC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2D0867D3EF0C9566AFB378234D1D6752" xlink:to="loc_biib_DeferredTaxAssetsValueReductioninValue_408F39B78C0420D48B8C78234D1DF5CC" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_DeferredTaxLiabilitiesValueReductioninValue" xlink:label="loc_biib_DeferredTaxLiabilitiesValueReductioninValue_861728C510B01CD4EFAF78234D1EF68D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2D0867D3EF0C9566AFB378234D1D6752" xlink:to="loc_biib_DeferredTaxLiabilitiesValueReductioninValue_861728C510B01CD4EFAF78234D1EF68D" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet" xlink:label="loc_biib_IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet_2C7A8D7F5FCD8A3B514E78234D1ED998" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2D0867D3EF0C9566AFB378234D1D6752" xlink:to="loc_biib_IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet_2C7A8D7F5FCD8A3B514E78234D1ED998" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_CC2CB21314A5E082B71178234D1E52B1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2D0867D3EF0C9566AFB378234D1D6752" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_CC2CB21314A5E082B71178234D1E52B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_F29DDBE9BB7DFB79D5E278234D1F8C63" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2D0867D3EF0C9566AFB378234D1D6752" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_F29DDBE9BB7DFB79D5E278234D1F8C63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_CB583616827F71AD877478234D1F8AAA" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2D0867D3EF0C9566AFB378234D1D6752" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_CB583616827F71AD877478234D1F8AAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_1D8346AF62D9ECF5567878234D1F6806" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2D0867D3EF0C9566AFB378234D1D6752" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_1D8346AF62D9ECF5567878234D1F6806" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_F54971E4AEE11F1E7EEB78234E0348F4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_FD8658935B1E74D4485478234DFED434" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F54971E4AEE11F1E7EEB78234E0348F4" xlink:to="loc_us-gaap_DebtInstrumentTable_FD8658935B1E74D4485478234DFED434" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7FD531B531375095EBF578234DFFA51F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_FD8658935B1E74D4485478234DFED434" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_7FD531B531375095EBF578234DFFA51F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_50A1B6E57E8F0602E59A78234DFFD9A0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7FD531B531375095EBF578234DFFA51F" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_50A1B6E57E8F0602E59A78234DFFD9A0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_50A1B6E57E8F0602E59A78234DFFD9A0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7FD531B531375095EBF578234DFFA51F" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_50A1B6E57E8F0602E59A78234DFFD9A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseMember" xlink:label="loc_us-gaap_InterestExpenseMember_37FBD55FA64CA128310078234DFF5339" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_50A1B6E57E8F0602E59A78234DFFD9A0" xlink:to="loc_us-gaap_InterestExpenseMember_37FBD55FA64CA128310078234DFF5339" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_80337CBFF92BDD4F95E078234E0080E1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_FD8658935B1E74D4485478234DFED434" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_80337CBFF92BDD4F95E078234E0080E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_C29C616EAF7D7695B36278234E00308E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_80337CBFF92BDD4F95E078234E0080E1" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_C29C616EAF7D7695B36278234E00308E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_C29C616EAF7D7695B36278234E00308E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_80337CBFF92BDD4F95E078234E0080E1" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_C29C616EAF7D7695B36278234E00308E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_6DC7D416C0F04B3405CB78234E004BD4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_C29C616EAF7D7695B36278234E00308E" xlink:to="loc_us-gaap_InterestRateSwapMember_6DC7D416C0F04B3405CB78234E004BD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_CE7097083217A93B8EA178234E01F7A9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_FD8658935B1E74D4485478234DFED434" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_CE7097083217A93B8EA178234E01F7A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_A4E6EC2C37243BFA11A778234E0192AB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_CE7097083217A93B8EA178234E01F7A9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_A4E6EC2C37243BFA11A778234E0192AB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_A4E6EC2C37243BFA11A778234E0192AB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_CE7097083217A93B8EA178234E01F7A9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_A4E6EC2C37243BFA11A778234E0192AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_3829401E5E67FEDAFB2978234E01557E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_A4E6EC2C37243BFA11A778234E0192AB" xlink:to="loc_us-gaap_SeniorNotesMember_3829401E5E67FEDAFB2978234E01557E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_18E810C5787CACEB4D6178234E02A1D3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_FD8658935B1E74D4485478234DFED434" xlink:to="loc_us-gaap_DebtInstrumentAxis_18E810C5787CACEB4D6178234E02A1D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_D0B7E880C40926BAE85978234E02A31F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_18E810C5787CACEB4D6178234E02A1D3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_D0B7E880C40926BAE85978234E02A31F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_D0B7E880C40926BAE85978234E02A31F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_18E810C5787CACEB4D6178234E02A1D3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_D0B7E880C40926BAE85978234E02A31F" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_A2.25SeniorNotesdueMay12030Member" xlink:label="loc_biib_A2.25SeniorNotesdueMay12030Member_D3CAF1C239084578A8FE78234E02222E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_D0B7E880C40926BAE85978234E02A31F" xlink:to="loc_biib_A2.25SeniorNotesdueMay12030Member_D3CAF1C239084578A8FE78234E02222E" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_A3.15SeniorNotesdueMay12050Member" xlink:label="loc_biib_A3.15SeniorNotesdueMay12050Member_FFBE327FDC11DB6F523F78234E03F337" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_D0B7E880C40926BAE85978234E02A31F" xlink:to="loc_biib_A3.15SeniorNotesdueMay12050Member_FFBE327FDC11DB6F523F78234E03F337" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_A2.90SeniorNotesDueSept152020Member" xlink:label="loc_biib_A2.90SeniorNotesDueSept152020Member_90AE65317A500594430E78234E03A59C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_D0B7E880C40926BAE85978234E02A31F" xlink:to="loc_biib_A2.90SeniorNotesDueSept152020Member_90AE65317A500594430E78234E03A59C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_DFA14428B2F2F8837FE778234E046E34" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F54971E4AEE11F1E7EEB78234E0348F4" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_DFA14428B2F2F8837FE778234E046E34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0C11E8D55B3E655FCDDE78234E04B38F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F54971E4AEE11F1E7EEB78234E0348F4" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0C11E8D55B3E655FCDDE78234E04B38F" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_PercentageParValueOfSeniorNotes" xlink:label="loc_biib_PercentageParValueOfSeniorNotes_35E8CB289240A81DD02F78234E04B359" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F54971E4AEE11F1E7EEB78234E0348F4" xlink:to="loc_biib_PercentageParValueOfSeniorNotes_35E8CB289240A81DD02F78234E04B359" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_C13201A87FEBF26D4B4A78234E048239" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F54971E4AEE11F1E7EEB78234E0348F4" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_C13201A87FEBF26D4B4A78234E048239" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" xlink:label="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_148F99714CE170FB07FE78234E0590D8" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F54971E4AEE11F1E7EEB78234E0348F4" xlink:to="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_148F99714CE170FB07FE78234E0590D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_20CEE83B7A3254022C6378234E05FAA1" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F54971E4AEE11F1E7EEB78234E0348F4" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_20CEE83B7A3254022C6378234E05FAA1" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain" xlink:label="loc_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain_FE6610747100E4C3507078234E05C65D" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F54971E4AEE11F1E7EEB78234E0348F4" xlink:to="loc_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain_FE6610747100E4C3507078234E05C65D" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts" xlink:label="loc_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts_8C8625470D56534B167978234E05CD1D" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F54971E4AEE11F1E7EEB78234E0348F4" xlink:to="loc_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts_8C8625470D56534B167978234E05CD1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_71E68D24AC8F0AE1E55578234E0691ED" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F54971E4AEE11F1E7EEB78234E0348F4" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_71E68D24AC8F0AE1E55578234E0691ED" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IndebtednessNotes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16BF20058BF8C4E64BDB78234FB586E9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C09DFF379A38D58E3F3A78234FA92F0B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16BF20058BF8C4E64BDB78234FB586E9" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C09DFF379A38D58E3F3A78234FA92F0B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="biib-20200630.xsd#biib_ResearchanddevelopmentassetAxis" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_BDB6617DC4563729C4D078234FAA1D51" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C09DFF379A38D58E3F3A78234FA92F0B" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_BDB6617DC4563729C4D078234FAA1D51" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_ResearchanddevelopmentassetDomain" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_6CBF270328EBBBDDF62C78234FAAF4D5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_BDB6617DC4563729C4D078234FAA1D51" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_6CBF270328EBBBDDF62C78234FAAF4D5_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_ResearchanddevelopmentassetDomain" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_6CBF270328EBBBDDF62C78234FAAF4D5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_BDB6617DC4563729C4D078234FAA1D51" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_6CBF270328EBBBDDF62C78234FAAF4D5" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_TGNMember" xlink:label="loc_biib_TGNMember_364B5BDB601D023ED0E378234FAAE77F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_6CBF270328EBBBDDF62C78234FAAF4D5" xlink:to="loc_biib_TGNMember_364B5BDB601D023ED0E378234FAAE77F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_F28AA96F75B33334259278234FAA2121" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C09DFF379A38D58E3F3A78234FA92F0B" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_F28AA96F75B33334259278234FAA2121" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2882A1D92C2CE3A7AD6578234FAB80E2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_F28AA96F75B33334259278234FAA2121" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2882A1D92C2CE3A7AD6578234FAB80E2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2882A1D92C2CE3A7AD6578234FAB80E2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_F28AA96F75B33334259278234FAA2121" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2882A1D92C2CE3A7AD6578234FAB80E2" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_NightstarMember" xlink:label="loc_biib_NightstarMember_23A5C4847CD062B909B678234FAB162A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2882A1D92C2CE3A7AD6578234FAB80E2" xlink:to="loc_biib_NightstarMember_23A5C4847CD062B909B678234FAB162A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_405FF7A9370EFA5DFEAA78234FAB0DE7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C09DFF379A38D58E3F3A78234FA92F0B" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_405FF7A9370EFA5DFEAA78234FAB0DE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_533A25097FA5A65FA50E78234FABC793_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_405FF7A9370EFA5DFEAA78234FAB0DE7" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_533A25097FA5A65FA50E78234FABC793_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_533A25097FA5A65FA50E78234FABC793" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_405FF7A9370EFA5DFEAA78234FAB0DE7" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_533A25097FA5A65FA50E78234FABC793" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_8DE293E47B3A0C4C1BB378234FB1D6CC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_533A25097FA5A65FA50E78234FABC793" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_8DE293E47B3A0C4C1BB378234FB1D6CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_3A7852CD09B710E9F4DB78234FB1336D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_533A25097FA5A65FA50E78234FABC793" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_3A7852CD09B710E9F4DB78234FB1336D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_868E818B5FC10726AC1F78234FB1F102" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C09DFF379A38D58E3F3A78234FA92F0B" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_868E818B5FC10726AC1F78234FB1F102" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8EC40EE2DB80D8ACE17478234FB2A9CA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_868E818B5FC10726AC1F78234FB1F102" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8EC40EE2DB80D8ACE17478234FB2A9CA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8EC40EE2DB80D8ACE17478234FB2A9CA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_868E818B5FC10726AC1F78234FB1F102" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8EC40EE2DB80D8ACE17478234FB2A9CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_BFAAA94AF21021D991B978234FB280CC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8EC40EE2DB80D8ACE17478234FB2A9CA" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_BFAAA94AF21021D991B978234FB280CC" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_OutLicensedPatentsMember" xlink:label="loc_biib_OutLicensedPatentsMember_DD035309CE164FB3058C78234FB28CC6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8EC40EE2DB80D8ACE17478234FB2A9CA" xlink:to="loc_biib_OutLicensedPatentsMember_DD035309CE164FB3058C78234FB28CC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_8CA485A3DD68CA7AD91678234FB3E0C6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8EC40EE2DB80D8ACE17478234FB2A9CA" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_8CA485A3DD68CA7AD91678234FB3E0C6" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_ECC85B19A8FFB933FFA078234FB3772C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8EC40EE2DB80D8ACE17478234FB2A9CA" xlink:to="loc_biib_InLicensedPatentsMember_ECC85B19A8FFB933FFA078234FB3772C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_4BFB124AFC5031DDB7B978234FB3161A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C09DFF379A38D58E3F3A78234FA92F0B" xlink:to="loc_srt_ProductOrServiceAxis_4BFB124AFC5031DDB7B978234FB3161A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_C54D1AF57D89137B973078234FB3009C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4BFB124AFC5031DDB7B978234FB3161A" xlink:to="loc_srt_ProductsAndServicesDomain_C54D1AF57D89137B973078234FB3009C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_C54D1AF57D89137B973078234FB3009C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4BFB124AFC5031DDB7B978234FB3161A" xlink:to="loc_srt_ProductsAndServicesDomain_C54D1AF57D89137B973078234FB3009C" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_AVONEXMember" xlink:label="loc_biib_AVONEXMember_3EA89EA94DEA39D0A80578234FB34BF8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_C54D1AF57D89137B973078234FB3009C" xlink:to="loc_biib_AVONEXMember_3EA89EA94DEA39D0A80578234FB34BF8" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_CDAA0264EEE8BC9E621578234FB43B50" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_C54D1AF57D89137B973078234FB3009C" xlink:to="loc_biib_TysabriProductMember_CDAA0264EEE8BC9E621578234FB43B50" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_FumarateMember" xlink:label="loc_biib_FumarateMember_88F71694B70875C5D01178234FB4B91D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_C54D1AF57D89137B973078234FB3009C" xlink:to="loc_biib_FumarateMember_88F71694B70875C5D01178234FB4B91D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_062C845C84D72DAF049D78234FB49377" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C09DFF379A38D58E3F3A78234FA92F0B" xlink:to="loc_srt_RangeAxis_062C845C84D72DAF049D78234FB49377" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_A07105BCA31F3F2F65E578234FB415F6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_062C845C84D72DAF049D78234FB49377" xlink:to="loc_srt_RangeMember_A07105BCA31F3F2F65E578234FB415F6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_A07105BCA31F3F2F65E578234FB415F6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_062C845C84D72DAF049D78234FB49377" xlink:to="loc_srt_RangeMember_A07105BCA31F3F2F65E578234FB415F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_F802377A1B2211A4636078234FB5D916" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_A07105BCA31F3F2F65E578234FB415F6" xlink:to="loc_srt_MinimumMember_F802377A1B2211A4636078234FB5D916" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_8E7899445981F703134078234FB52E79" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_A07105BCA31F3F2F65E578234FB415F6" xlink:to="loc_srt_MaximumMember_8E7899445981F703134078234FB52E79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_E1CDDF8FC15247E2430378234FB579C4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16BF20058BF8C4E64BDB78234FB586E9" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_E1CDDF8FC15247E2430378234FB579C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2EC95A182BC370A20B3B78234FB6DE86" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16BF20058BF8C4E64BDB78234FB586E9" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2EC95A182BC370A20B3B78234FB6DE86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_986C527AC40F30088D6A78234FB65359" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2EC95A182BC370A20B3B78234FB6DE86" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_986C527AC40F30088D6A78234FB65359" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_DD721073DEFC7A43C2B178234FB6056C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2EC95A182BC370A20B3B78234FB6DE86" xlink:to="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_DD721073DEFC7A43C2B178234FB6056C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6B4AC9E66296B6D82E3178234FB64358" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2EC95A182BC370A20B3B78234FB6DE86" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6B4AC9E66296B6D82E3178234FB64358" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_163FE67D57DFB21305DA78234FB7E56D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2EC95A182BC370A20B3B78234FB6DE86" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_163FE67D57DFB21305DA78234FB7E56D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_67C5828C7AACCAF556EC78234FB7BA1D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2EC95A182BC370A20B3B78234FB6DE86" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_67C5828C7AACCAF556EC78234FB7BA1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ADE0CCBA19CD62EAF91878234FB775BB" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2EC95A182BC370A20B3B78234FB6DE86" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ADE0CCBA19CD62EAF91878234FB775BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_0ECB4D30C676A3F3715E78234FB74151" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2EC95A182BC370A20B3B78234FB6DE86" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_0ECB4D30C676A3F3715E78234FB74151" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_50EC9954FB226187D6C178234FB857A3" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2EC95A182BC370A20B3B78234FB6DE86" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_50EC9954FB226187D6C178234FB857A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_C88B58292FBC5CF4FDD978234FB84735" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2EC95A182BC370A20B3B78234FB6DE86" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_C88B58292FBC5CF4FDD978234FB84735" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_FC7C6E31A1DFDDDFD84478234FB8734E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16BF20058BF8C4E64BDB78234FB586E9" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_FC7C6E31A1DFDDDFD84478234FB8734E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_B0A47D929CB4EABE0CBE78234FB8E6EF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16BF20058BF8C4E64BDB78234FB586E9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_B0A47D929CB4EABE0CBE78234FB8E6EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_282FFCEDF3FF87168B3B78234FB8E348" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16BF20058BF8C4E64BDB78234FB586E9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_282FFCEDF3FF87168B3B78234FB8E348" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_8793EC384F9687E0C2BB78234FB86C6E" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16BF20058BF8C4E64BDB78234FB586E9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_8793EC384F9687E0C2BB78234FB86C6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_452DBE3058B65D90A61A78234FB8F00F" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16BF20058BF8C4E64BDB78234FB586E9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_452DBE3058B65D90A61A78234FB8F00F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_A2371ED07C4A9C2D4C5C78234FB91B0E" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16BF20058BF8C4E64BDB78234FB586E9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_A2371ED07C4A9C2D4C5C78234FB91B0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_CC839212FAEEB79502DE78234FB9D410" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16BF20058BF8C4E64BDB78234FB586E9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_CC839212FAEEB79502DE78234FB9D410" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_B372BA3C760F44854F5D78234FB9DF2C" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16BF20058BF8C4E64BDB78234FB586E9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_B372BA3C760F44854F5D78234FB9DF2C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_A4ABAAD5C498E9BBCB2A78234C6A3994" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_19F29B8F037FB95C2B7778234C662169" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_A4ABAAD5C498E9BBCB2A78234C6A3994" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_19F29B8F037FB95C2B7778234C662169" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_DE741A3B66D25005CCC678234C671F27" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_19F29B8F037FB95C2B7778234C662169" xlink:to="loc_us-gaap_TypeOfArrangementAxis_DE741A3B66D25005CCC678234C671F27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ED8BA0D9E0745FE43BEF78234C67716C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_DE741A3B66D25005CCC678234C671F27" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ED8BA0D9E0745FE43BEF78234C67716C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ED8BA0D9E0745FE43BEF78234C67716C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_DE741A3B66D25005CCC678234C671F27" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ED8BA0D9E0745FE43BEF78234C67716C" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_2A81DEE4099BF4CC387678234C6774D8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ED8BA0D9E0745FE43BEF78234C67716C" xlink:to="loc_biib_EisaiMember_2A81DEE4099BF4CC387678234C6774D8" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_FutureContingentMilestoneTypesAxis" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_2842361347B424BEFCAF78234C6890CF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_19F29B8F037FB95C2B7778234C662169" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_2842361347B424BEFCAF78234C6890CF" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_FutureContingentMilestoneTypesDomain" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_31044A41FFB446F3BDFB78234C68AD95_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_2842361347B424BEFCAF78234C6890CF" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_31044A41FFB446F3BDFB78234C68AD95_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_FutureContingentMilestoneTypesDomain" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_31044A41FFB446F3BDFB78234C68AD95" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_2842361347B424BEFCAF78234C6890CF" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_31044A41FFB446F3BDFB78234C68AD95" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_RegulatoryMilestonesMember" xlink:label="loc_biib_RegulatoryMilestonesMember_CB8C74A49C4DAF72167978234C696627" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_31044A41FFB446F3BDFB78234C68AD95" xlink:to="loc_biib_RegulatoryMilestonesMember_CB8C74A49C4DAF72167978234C696627" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_RegulatoryApprovalMilestoneMember" xlink:label="loc_biib_RegulatoryApprovalMilestoneMember_C072C0AAF618AC059E5D78234C69CAA1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_31044A41FFB446F3BDFB78234C68AD95" xlink:to="loc_biib_RegulatoryApprovalMilestoneMember_C072C0AAF618AC059E5D78234C69CAA1" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis" xlink:label="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_BA48A33032B89FB6206478234C6922F3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_19F29B8F037FB95C2B7778234C662169" xlink:to="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_BA48A33032B89FB6206478234C6922F3" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain" xlink:label="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_9426A7331D0DD760FC3478234C694B52_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_BA48A33032B89FB6206478234C6922F3" xlink:to="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_9426A7331D0DD760FC3478234C694B52_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain" xlink:label="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_9426A7331D0DD760FC3478234C694B52" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_BA48A33032B89FB6206478234C6922F3" xlink:to="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_9426A7331D0DD760FC3478234C694B52" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_7517F11EB14032A097C478234C6A5AFA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_9426A7331D0DD760FC3478234C694B52" xlink:to="loc_biib_NeurimmuneMember_7517F11EB14032A097C478234C6A5AFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_0DD29C1ECA3DE8945DE578234C6B2212" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_A4ABAAD5C498E9BBCB2A78234C6A3994" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_0DD29C1ECA3DE8945DE578234C6B2212" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_Reductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Reductioninroyaltyratepayableoncommercialsales_BBC11FD3CAF1D16B14B578234C6B13E9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_A4ABAAD5C498E9BBCB2A78234C6A3994" xlink:to="loc_biib_Reductioninroyaltyratepayableoncommercialsales_BBC11FD3CAF1D16B14B578234C6B13E9" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_2B02760E96971A78433778234C6BEDE5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_A4ABAAD5C498E9BBCB2A78234C6A3994" xlink:to="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_2B02760E96971A78433778234C6BEDE5" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_370FB2EF4825033F9EFB78234C6BEBF2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_A4ABAAD5C498E9BBCB2A78234C6A3994" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_370FB2EF4825033F9EFB78234C6BEBF2" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_B4F043DFE0E3D7D4430978234C6C4C48" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_A4ABAAD5C498E9BBCB2A78234C6A3994" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_B4F043DFE0E3D7D4430978234C6C4C48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_C03939633FFE3886E14978234C6CC228" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_A4ABAAD5C498E9BBCB2A78234C6A3994" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_C03939633FFE3886E14978234C6CC228" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_4C9E680928B0674C70FD78234C6C7C08" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_A4ABAAD5C498E9BBCB2A78234C6A3994" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_4C9E680928B0674C70FD78234C6C7C08" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/LitigationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_A4B509A112DA0BDDB50378234C53AC2D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_1FFDF5F13D9B158B403478234C4FE586" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_A4B509A112DA0BDDB50378234C53AC2D" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_1FFDF5F13D9B158B403478234C4FE586" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_CEA00406A7DC8331129578234C51514B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_1FFDF5F13D9B158B403478234C4FE586" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_CEA00406A7DC8331129578234C51514B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_0765ADE117898519063578234C517E38_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_CEA00406A7DC8331129578234C51514B" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_0765ADE117898519063578234C517E38_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_0765ADE117898519063578234C517E38" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_CEA00406A7DC8331129578234C51514B" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_0765ADE117898519063578234C517E38" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="loc_country_BR_1D1005E1733B865665B878234C52F8DD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_0765ADE117898519063578234C517E38" xlink:to="loc_country_BR_1D1005E1733B865665B878234C52F8DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_6AB301D1A2466F8F5A7B78234C538F6C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_A4B509A112DA0BDDB50378234C53AC2D" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_6AB301D1A2466F8F5A7B78234C538F6C" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_DisputedClaimsRelatingtoConstructionCosts" xlink:label="loc_biib_DisputedClaimsRelatingtoConstructionCosts_493362C131ECE105C96D78234C54F2B5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_A4B509A112DA0BDDB50378234C53AC2D" xlink:to="loc_biib_DisputedClaimsRelatingtoConstructionCosts_493362C131ECE105C96D78234C54F2B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_341DE2F53FD218D8DA4078234C54004E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_A4B509A112DA0BDDB50378234C53AC2D" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_341DE2F53FD218D8DA4078234C54004E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_E631B08412BA150AD99478234CE82CB6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_37E390D71AEC3F907BD678234CE67A04" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_E631B08412BA150AD99478234CE82CB6" xlink:to="loc_us-gaap_StatementTable_37E390D71AEC3F907BD678234CE67A04" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_5BE35B3A7543A832D0D678234CE7EF1A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_37E390D71AEC3F907BD678234CE67A04" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_5BE35B3A7543A832D0D678234CE7EF1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_D118C2B9585E4622591E78234CE75513_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5BE35B3A7543A832D0D678234CE7EF1A" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_D118C2B9585E4622591E78234CE75513_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_D118C2B9585E4622591E78234CE75513" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5BE35B3A7543A832D0D678234CE7EF1A" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_D118C2B9585E4622591E78234CE75513" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_66676AEEA5CA8F1B810278234CE86EC0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_D118C2B9585E4622591E78234CE75513" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_66676AEEA5CA8F1B810278234CE86EC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNetAbstract" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract_DD0DFE036B385F1C6B2E78234CEAA3E5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_E631B08412BA150AD99478234CE82CB6" xlink:to="loc_us-gaap_InterestIncomeExpenseNetAbstract_DD0DFE036B385F1C6B2E78234CEAA3E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_41C0206D56DB05475D1C78234CEB8C74" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_DD0DFE036B385F1C6B2E78234CEAA3E5" xlink:to="loc_us-gaap_InvestmentIncomeInterest_41C0206D56DB05475D1C78234CEB8C74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_DD863616504D48D5792478234CEC46A7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_DD0DFE036B385F1C6B2E78234CEAA3E5" xlink:to="loc_us-gaap_InterestExpense_DD863616504D48D5792478234CEC46A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_340764E378C2AEDEEC3778234CECC5A6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_DD0DFE036B385F1C6B2E78234CEAA3E5" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_340764E378C2AEDEEC3778234CECC5A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_9E4F2186018167C0241978234CECBC46" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_DD0DFE036B385F1C6B2E78234CEAA3E5" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_9E4F2186018167C0241978234CECBC46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_65D8C945D6BBAE67DBEA78234CEE7232" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_DD0DFE036B385F1C6B2E78234CEAA3E5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_65D8C945D6BBAE67DBEA78234CEE7232" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_4BD484B679224FC5472B78234CEF6653" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_DD0DFE036B385F1C6B2E78234CEAA3E5" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_4BD484B679224FC5472B78234CEF6653" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_C20A9056D54F754A165D78234CF09805" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_E631B08412BA150AD99478234CE82CB6" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_C20A9056D54F754A165D78234CF09805" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_CE7BD12DF1724900D2E678234CF0E5D9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_C20A9056D54F754A165D78234CF09805" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_CE7BD12DF1724900D2E678234CF0E5D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_E540AB46A6C60966F82078234CF11B57" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_C20A9056D54F754A165D78234CF09805" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_E540AB46A6C60966F82078234CF11B57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_460A1F3C5D3EC69CD19878234CF1FF89" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_C20A9056D54F754A165D78234CF09805" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_460A1F3C5D3EC69CD19878234CF1FF89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_822D33418862F6A9FA7678234CF1DFC1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_E631B08412BA150AD99478234CE82CB6" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_822D33418862F6A9FA7678234CF1DFC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_2887B6F88BEDC6DEDFE678234CF2A76D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_822D33418862F6A9FA7678234CF1DFC1" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_2887B6F88BEDC6DEDFE678234CF2A76D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0255E377799022974A7478234CF20D60" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_822D33418862F6A9FA7678234CF1DFC1" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0255E377799022974A7478234CF20D60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_8925F88E77E67D6771BF78234CF2E849" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_822D33418862F6A9FA7678234CF1DFC1" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_8925F88E77E67D6771BF78234CF2E849" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_Collaborationexpensesaccrual" xlink:label="loc_biib_Collaborationexpensesaccrual_C546C5BB7969E53D941378234CF290DA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_822D33418862F6A9FA7678234CF1DFC1" xlink:to="loc_biib_Collaborationexpensesaccrual_C546C5BB7969E53D941378234CF290DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_A719830B76016C07173278234CF32A49" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_822D33418862F6A9FA7678234CF1DFC1" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_A719830B76016C07173278234CF32A49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_B5B7BC890E754E60528F78234CF39324" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_822D33418862F6A9FA7678234CF1DFC1" xlink:to="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_B5B7BC890E754E60528F78234CF39324" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_73283EE3101F6F9B48EF78234CF3E589" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_822D33418862F6A9FA7678234CF1DFC1" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_73283EE3101F6F9B48EF78234CF3E589" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_A208644AF3451F172EC678234CF41C15" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_822D33418862F6A9FA7678234CF1DFC1" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_A208644AF3451F172EC678234CF41C15" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_4E3DFAC71452ABCF928D78234CD19CD4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_A62082CBB3E1DCEC014B78234CD0CF6D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_4E3DFAC71452ABCF928D78234CD19CD4" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_A62082CBB3E1DCEC014B78234CD0CF6D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_064AE8757E009F41A13778234CD0876C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A62082CBB3E1DCEC014B78234CD0CF6D" xlink:to="loc_dei_LegalEntityAxis_064AE8757E009F41A13778234CD0876C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1E1AACB8944DDA08433578234CD031DB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_064AE8757E009F41A13778234CD0876C" xlink:to="loc_dei_EntityDomain_1E1AACB8944DDA08433578234CD031DB_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1E1AACB8944DDA08433578234CD031DB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_064AE8757E009F41A13778234CD0876C" xlink:to="loc_dei_EntityDomain_1E1AACB8944DDA08433578234CD031DB" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_IonisPharmaceuticalsMember" xlink:label="loc_biib_IonisPharmaceuticalsMember_324B7A01AF81934E424D78234CD1CC82" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1E1AACB8944DDA08433578234CD031DB" xlink:to="loc_biib_IonisPharmaceuticalsMember_324B7A01AF81934E424D78234CD1CC82" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_SangamoCommonStockMember" xlink:label="loc_biib_SangamoCommonStockMember_76EEBC1B1C62412AFC6078234CD1F19D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1E1AACB8944DDA08433578234CD031DB" xlink:to="loc_biib_SangamoCommonStockMember_76EEBC1B1C62412AFC6078234CD1F19D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_4CA7353C76C8797095E078234CD2AF01" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4E3DFAC71452ABCF928D78234CD19CD4" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_4CA7353C76C8797095E078234CD2AF01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_50A552E17FC7A42097E778234CD28AC6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4E3DFAC71452ABCF928D78234CD19CD4" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_50A552E17FC7A42097E778234CD28AC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_94D085833F8854E8B6E378234CD2DEB3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4E3DFAC71452ABCF928D78234CD19CD4" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_94D085833F8854E8B6E378234CD2DEB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_164EEB90D14305E0272678234CD3FEAE" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4E3DFAC71452ABCF928D78234CD19CD4" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_164EEB90D14305E0272678234CD3FEAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_188789301C0795D357C678234CD3859A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4E3DFAC71452ABCF928D78234CD19CD4" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_188789301C0795D357C678234CD3859A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense_D4F1F548C8EACD63FA2A78234CD39C15" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4E3DFAC71452ABCF928D78234CD19CD4" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense_D4F1F548C8EACD63FA2A78234CD39C15" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherRevenuesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_D66EC254191DB1F3A03B782350336223" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_28B8386985FAD0DA238478235029E5A9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_D66EC254191DB1F3A03B782350336223" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_28B8386985FAD0DA238478235029E5A9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_D8CA6503431DE986B07B782350292A89" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_28B8386985FAD0DA238478235029E5A9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_D8CA6503431DE986B07B782350292A89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_31DC80AD822E969A71C77823502A1F71_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_D8CA6503431DE986B07B782350292A89" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_31DC80AD822E969A71C77823502A1F71_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_31DC80AD822E969A71C77823502A1F71" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_D8CA6503431DE986B07B782350292A89" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_31DC80AD822E969A71C77823502A1F71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_ECA4F02275ECB21553E67823502A8BD7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_31DC80AD822E969A71C77823502A1F71" xlink:to="loc_us-gaap_CollaborativeArrangementMember_ECA4F02275ECB21553E67823502A8BD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_EB880934444AC9BAD9237823502BE93E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_28B8386985FAD0DA238478235029E5A9" xlink:to="loc_srt_ProductOrServiceAxis_EB880934444AC9BAD9237823502BE93E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_F56EB179629D0E6925277823502BC7B5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_EB880934444AC9BAD9237823502BE93E" xlink:to="loc_srt_ProductsAndServicesDomain_F56EB179629D0E6925277823502BC7B5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_F56EB179629D0E6925277823502BC7B5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_EB880934444AC9BAD9237823502BE93E" xlink:to="loc_srt_ProductsAndServicesDomain_F56EB179629D0E6925277823502BC7B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember_BA0F6590ABB8A62B8E107823502B3870" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_F56EB179629D0E6925277823502BC7B5" xlink:to="loc_us-gaap_RoyaltyMember_BA0F6590ABB8A62B8E107823502B3870" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_OthercorporaterevenuesMember" xlink:label="loc_biib_OthercorporaterevenuesMember_621334D71008C57687477823502C5451" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_F56EB179629D0E6925277823502BC7B5" xlink:to="loc_biib_OthercorporaterevenuesMember_621334D71008C57687477823502C5451" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_FBC4FE197517C5E481E17823503151A4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_F56EB179629D0E6925277823502BC7B5" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_FBC4FE197517C5E481E17823503151A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_0708F5E7A0D134B950B078235031763F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_28B8386985FAD0DA238478235029E5A9" xlink:to="loc_srt_MajorCustomersAxis_0708F5E7A0D134B950B078235031763F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_E6D6F82A747FD65565AC78235032076B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_0708F5E7A0D134B950B078235031763F" xlink:to="loc_srt_NameOfMajorCustomerDomain_E6D6F82A747FD65565AC78235032076B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_E6D6F82A747FD65565AC78235032076B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_0708F5E7A0D134B950B078235031763F" xlink:to="loc_srt_NameOfMajorCustomerDomain_E6D6F82A747FD65565AC78235032076B" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_EFB6461E842433B4785E78235032AD30" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_E6D6F82A747FD65565AC78235032076B" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_EFB6461E842433B4785E78235032AD30" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_796B77B393CACEE2565E782350338616" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_E6D6F82A747FD65565AC78235032076B" xlink:to="loc_biib_ZINBRYTAMember_796B77B393CACEE2565E782350338616" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_75AD24817D70351E1CDE78235033FC42" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_D66EC254191DB1F3A03B782350336223" xlink:to="loc_us-gaap_Revenues_75AD24817D70351E1CDE78235033FC42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_D51FF14F8CA4C634F10278235033B78D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_D66EC254191DB1F3A03B782350336223" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_D51FF14F8CA4C634F10278235033B78D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_757DC56163E11BFF79FB78234E13983A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D99EE8B070745BDABE6C78234E1241A3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_757DC56163E11BFF79FB78234E13983A" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D99EE8B070745BDABE6C78234E1241A3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="biib-20200630.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_87E277AFFFCA70CD181178234E126290" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D99EE8B070745BDABE6C78234E1241A3" xlink:to="loc_biib_FacilityLocationAxis_87E277AFFFCA70CD181178234E126290" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_BDE5BBF9E8795477C4D078234E13299D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityLocationAxis_87E277AFFFCA70CD181178234E126290" xlink:to="loc_biib_FacilityLocationDomain_BDE5BBF9E8795477C4D078234E13299D_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_BDE5BBF9E8795477C4D078234E13299D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityLocationAxis_87E277AFFFCA70CD181178234E126290" xlink:to="loc_biib_FacilityLocationDomain_BDE5BBF9E8795477C4D078234E13299D" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_SolothurnSwitzerlandMember" xlink:label="loc_biib_SolothurnSwitzerlandMember_76E4C208B6367F1BEB5878234E13E02D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityLocationDomain_BDE5BBF9E8795477C4D078234E13299D" xlink:to="loc_biib_SolothurnSwitzerlandMember_76E4C208B6367F1BEB5878234E13E02D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4D5D3821929B588D094E78234E14C8CF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_757DC56163E11BFF79FB78234E13983A" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4D5D3821929B588D094E78234E14C8CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_99F608FD5B7111E7DF8378234E140D4C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_757DC56163E11BFF79FB78234E13983A" xlink:to="loc_us-gaap_Depreciation_99F608FD5B7111E7DF8378234E140D4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_4375C3514BF34820FC9078234E141037" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_757DC56163E11BFF79FB78234E13983A" xlink:to="loc_us-gaap_ConstructionInProgressGross_4375C3514BF34820FC9078234E141037" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_C5FFCEE1E3BCE8A8901A78234E15FE1F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_757DC56163E11BFF79FB78234E13983A" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_C5FFCEE1E3BCE8A8901A78234E15FE1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_6A265DA6827BF411F99D78234E15FCB5" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_757DC56163E11BFF79FB78234E13983A" xlink:to="loc_us-gaap_OtherCommitment_6A265DA6827BF411F99D78234E15FCB5" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_037C558A45AA71B62FA878234D7ADAF7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_137F6819A77C147721A078234D77D437" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_037C558A45AA71B62FA878234D7ADAF7" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_137F6819A77C147721A078234D77D437" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0C924F759BFA2C8BE5F378234D77C921" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_137F6819A77C147721A078234D77D437" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0C924F759BFA2C8BE5F378234D77C921" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_98AC5D2AE1FB9410F53378234D78F1BF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0C924F759BFA2C8BE5F378234D77C921" xlink:to="loc_us-gaap_EquityComponentDomain_98AC5D2AE1FB9410F53378234D78F1BF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_98AC5D2AE1FB9410F53378234D78F1BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0C924F759BFA2C8BE5F378234D77C921" xlink:to="loc_us-gaap_EquityComponentDomain_98AC5D2AE1FB9410F53378234D78F1BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_F192B77F51BB1492D04578234D7880D2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_98AC5D2AE1FB9410F53378234D78F1BF" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_F192B77F51BB1492D04578234D7880D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_F0392D6F7C6956C683AF78234D78AAAD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_98AC5D2AE1FB9410F53378234D78F1BF" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_F0392D6F7C6956C683AF78234D78AAAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_50CB9759D5F8D228FFDC78234D79525D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_98AC5D2AE1FB9410F53378234D78F1BF" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_50CB9759D5F8D228FFDC78234D79525D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_47DE20C343F7E298D0D378234D79F08B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_137F6819A77C147721A078234D77D437" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_47DE20C343F7E298D0D378234D79F08B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_F17B5A6E8AB1CDED7D5178234D799F59_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_47DE20C343F7E298D0D378234D79F08B" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_F17B5A6E8AB1CDED7D5178234D799F59_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_F17B5A6E8AB1CDED7D5178234D799F59" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_47DE20C343F7E298D0D378234D79F08B" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_F17B5A6E8AB1CDED7D5178234D799F59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_A348DA05041129A0391378234D795722" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_F17B5A6E8AB1CDED7D5178234D799F59" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_A348DA05041129A0391378234D795722" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_8AC37225540F4B3BBF1278234D7AA1F0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_037C558A45AA71B62FA878234D7ADAF7" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_8AC37225540F4B3BBF1278234D7AA1F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_A868F56865C3E3EBF1E278234D7B5C19" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_037C558A45AA71B62FA878234D7ADAF7" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_A868F56865C3E3EBF1E278234D7B5C19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_C8689FEC8A25E86701A278234D7B8B73" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_037C558A45AA71B62FA878234D7ADAF7" xlink:to="loc_us-gaap_Revenues_C8689FEC8A25E86701A278234D7B8B73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_336FD2C8024A2FC5E8D878234D7B6B0A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_037C558A45AA71B62FA878234D7ADAF7" xlink:to="loc_us-gaap_OperatingExpenses_336FD2C8024A2FC5E8D878234D7B6B0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_965C7E306C0D6BECB71C78234D7B2D74" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_037C558A45AA71B62FA878234D7ADAF7" xlink:to="loc_us-gaap_NetIncomeLoss_965C7E306C0D6BECB71C78234D7B2D74" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_40502A5C323A204045EA7823505FCEC2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_C6910FCEBEE3129D5FF67823505E232A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_40502A5C323A204045EA7823505FCEC2" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_C6910FCEBEE3129D5FF67823505E232A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_9DD13D344F5B70B391D27823505EC9F8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_C6910FCEBEE3129D5FF67823505E232A" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_9DD13D344F5B70B391D27823505EC9F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_61A8CA610DA21A56CC017823505EA01E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_9DD13D344F5B70B391D27823505EC9F8" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_61A8CA610DA21A56CC017823505EA01E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_61A8CA610DA21A56CC017823505EA01E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_9DD13D344F5B70B391D27823505EC9F8" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_61A8CA610DA21A56CC017823505EA01E" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_ReserveforCashDiscountsMember" xlink:label="loc_biib_ReserveforCashDiscountsMember_DE2EBEFAC071721642A97823505F4F73" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_61A8CA610DA21A56CC017823505EA01E" xlink:to="loc_biib_ReserveforCashDiscountsMember_DE2EBEFAC071721642A97823505F4F73" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_ContractualAdjustmentsMember" xlink:label="loc_biib_ContractualAdjustmentsMember_0F76A0A996B86B7D6E2B7823505F82D5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_61A8CA610DA21A56CC017823505EA01E" xlink:to="loc_biib_ContractualAdjustmentsMember_0F76A0A996B86B7D6E2B7823505F82D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_29FEAB311664E2D8A5A87823505F41DD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_61A8CA610DA21A56CC017823505EA01E" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_29FEAB311664E2D8A5A87823505F41DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_69809C571FE69663ABEC7823505FA2BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_40502A5C323A204045EA7823505FCEC2" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_69809C571FE69663ABEC7823505FA2BF" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_1FB72C8508636607F21B78235060637B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_40502A5C323A204045EA7823505FCEC2" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_1FB72C8508636607F21B78235060637B" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_81E8E6A94E8DB3E4B312782350605E87" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_40502A5C323A204045EA7823505FCEC2" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_81E8E6A94E8DB3E4B312782350605E87" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_D78C5934C2F3B03912807823506078A6" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_40502A5C323A204045EA7823505FCEC2" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_D78C5934C2F3B03912807823506078A6" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_153014B85792DEF1BEBE78235060C880" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_40502A5C323A204045EA7823505FCEC2" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_153014B85792DEF1BEBE78235060C880" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_5DC1F15A410F1F2C29C778235053F352" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_68FAD0B05CA17140DA257823504D8821" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_5DC1F15A410F1F2C29C778235053F352" xlink:to="loc_us-gaap_StatementTable_68FAD0B05CA17140DA257823504D8821" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_F922AB58E95CE18DCD60782350525266" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_68FAD0B05CA17140DA257823504D8821" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_F922AB58E95CE18DCD60782350525266" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_82B9E6461C5CD334BBE178235052F231_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_F922AB58E95CE18DCD60782350525266" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_82B9E6461C5CD334BBE178235052F231_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_82B9E6461C5CD334BBE178235052F231" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_F922AB58E95CE18DCD60782350525266" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_82B9E6461C5CD334BBE178235052F231" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_2C37A01F019FBBCBC7E6782350536740" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_82B9E6461C5CD334BBE178235052F231" xlink:to="loc_us-gaap_AccountsReceivableMember_2C37A01F019FBBCBC7E6782350536740" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_2B4FE74BA8121FAA1399782350531119" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_82B9E6461C5CD334BBE178235052F231" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_2B4FE74BA8121FAA1399782350531119" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_B4DF18F7CABFE193AD237823505424B2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5DC1F15A410F1F2C29C778235053F352" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_B4DF18F7CABFE193AD237823505424B2" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesByProductDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_6378AF3BD30ED0DD29C17823507C4F69" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_91BAAE4C0EACCD7997EE78235077E568" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6378AF3BD30ED0DD29C17823507C4F69" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_91BAAE4C0EACCD7997EE78235077E568" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_0BFA12AAE2ACE22D2D4678235077BFD8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_91BAAE4C0EACCD7997EE78235077E568" xlink:to="loc_srt_ProductOrServiceAxis_0BFA12AAE2ACE22D2D4678235077BFD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_792B71C04E6FF0AB2F2578235078B4B3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0BFA12AAE2ACE22D2D4678235077BFD8" xlink:to="loc_srt_ProductsAndServicesDomain_792B71C04E6FF0AB2F2578235078B4B3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_792B71C04E6FF0AB2F2578235078B4B3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0BFA12AAE2ACE22D2D4678235077BFD8" xlink:to="loc_srt_ProductsAndServicesDomain_792B71C04E6FF0AB2F2578235078B4B3" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_FumarateMember" xlink:label="loc_biib_FumarateMember_03E33AF8A60DB65D5413782350784C3A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_792B71C04E6FF0AB2F2578235078B4B3" xlink:to="loc_biib_FumarateMember_03E33AF8A60DB65D5413782350784C3A" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_InterferonMember" xlink:label="loc_biib_InterferonMember_D200677E27571D377067782350788C54" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_792B71C04E6FF0AB2F2578235078B4B3" xlink:to="loc_biib_InterferonMember_D200677E27571D377067782350788C54" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_A4F20249D492CBA73AA378235079DCCD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_792B71C04E6FF0AB2F2578235078B4B3" xlink:to="loc_biib_TysabriProductMember_A4F20249D492CBA73AA378235079DCCD" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_FAMPYRAMember" xlink:label="loc_biib_FAMPYRAMember_F0EF1A4364EB7E75601E78235079562F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_792B71C04E6FF0AB2F2578235078B4B3" xlink:to="loc_biib_FAMPYRAMember_F0EF1A4364EB7E75601E78235079562F" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_EF8B20286F94AAE70C5078235079A892" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_792B71C04E6FF0AB2F2578235078B4B3" xlink:to="loc_biib_ZINBRYTAMember_EF8B20286F94AAE70C5078235079A892" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_MSProductRevenuesMember" xlink:label="loc_biib_MSProductRevenuesMember_4708B03E710C46C3DF2578235079EB6E" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_792B71C04E6FF0AB2F2578235078B4B3" xlink:to="loc_biib_MSProductRevenuesMember_4708B03E710C46C3DF2578235079EB6E" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_143CD02C02B5601658C478235079C76E" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_792B71C04E6FF0AB2F2578235078B4B3" xlink:to="loc_biib_SPINRAZAMember_143CD02C02B5601658C478235079C76E" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_BENEPALIMember" xlink:label="loc_biib_BENEPALIMember_AED9450A5F78AF0617897823507ACB1E" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_792B71C04E6FF0AB2F2578235078B4B3" xlink:to="loc_biib_BENEPALIMember_AED9450A5F78AF0617897823507ACB1E" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_IMRALDIMember" xlink:label="loc_biib_IMRALDIMember_EA46CE3776497E3AF1C27823507A2677" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_792B71C04E6FF0AB2F2578235078B4B3" xlink:to="loc_biib_IMRALDIMember_EA46CE3776497E3AF1C27823507A2677" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_FLIXABIMember" xlink:label="loc_biib_FLIXABIMember_4D4860BE6C7AD72099737823507A675B" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_792B71C04E6FF0AB2F2578235078B4B3" xlink:to="loc_biib_FLIXABIMember_4D4860BE6C7AD72099737823507A675B" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_BiosimilarsMember" xlink:label="loc_biib_BiosimilarsMember_DE0ADE2CCE0661E70E9E7823507A1BCE" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_792B71C04E6FF0AB2F2578235078B4B3" xlink:to="loc_biib_BiosimilarsMember_DE0ADE2CCE0661E70E9E7823507A1BCE" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_FUMADERMMember" xlink:label="loc_biib_FUMADERMMember_DD51AD03C102554C01EC7823507AE13C" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_792B71C04E6FF0AB2F2578235078B4B3" xlink:to="loc_biib_FUMADERMMember_DD51AD03C102554C01EC7823507AE13C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_F637A1BC70665E5F3D537823507A6B82" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_792B71C04E6FF0AB2F2578235078B4B3" xlink:to="loc_us-gaap_ProductMember_F637A1BC70665E5F3D537823507A6B82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_081BDB7A82F05F4B77547823507A9771" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_91BAAE4C0EACCD7997EE78235077E568" xlink:to="loc_srt_StatementGeographicalAxis_081BDB7A82F05F4B77547823507A9771" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_821FB6D933CE82D62F847823507BAF14_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_081BDB7A82F05F4B77547823507A9771" xlink:to="loc_srt_SegmentGeographicalDomain_821FB6D933CE82D62F847823507BAF14_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_821FB6D933CE82D62F847823507BAF14" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_081BDB7A82F05F4B77547823507A9771" xlink:to="loc_srt_SegmentGeographicalDomain_821FB6D933CE82D62F847823507BAF14" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_891B96488EA94C98CB357823507BBA1D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_821FB6D933CE82D62F847823507BAF14" xlink:to="loc_country_US_891B96488EA94C98CB357823507BBA1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember_68E984D74C8D355DB4CC7823507B20AA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_821FB6D933CE82D62F847823507BAF14" xlink:to="loc_us-gaap_NonUsMember_68E984D74C8D355DB4CC7823507B20AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_B128E1E228EACD6B8BA87823507CE70C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6378AF3BD30ED0DD29C17823507C4F69" xlink:to="loc_us-gaap_Revenues_B128E1E228EACD6B8BA87823507CE70C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_3E900075483FD4A082547823501750A9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_959F7B19B296317C416378235014EC74" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3E900075483FD4A082547823501750A9" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_959F7B19B296317C416378235014EC74" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_74629C4618A2A141AAE47823501481F1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_959F7B19B296317C416378235014EC74" xlink:to="loc_srt_ProductOrServiceAxis_74629C4618A2A141AAE47823501481F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_A618F8DB0651A248B08C78235015D756_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_74629C4618A2A141AAE47823501481F1" xlink:to="loc_srt_ProductsAndServicesDomain_A618F8DB0651A248B08C78235015D756_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_A618F8DB0651A248B08C78235015D756" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_74629C4618A2A141AAE47823501481F1" xlink:to="loc_srt_ProductsAndServicesDomain_A618F8DB0651A248B08C78235015D756" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_OthercorporaterevenuesMember" xlink:label="loc_biib_OthercorporaterevenuesMember_90865DBE22C891D4D995782350154F08" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_A618F8DB0651A248B08C78235015D756" xlink:to="loc_biib_OthercorporaterevenuesMember_90865DBE22C891D4D995782350154F08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_928D920659A3FA9402F0782350156372" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_A618F8DB0651A248B08C78235015D756" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_928D920659A3FA9402F0782350156372" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_7B42CDB4CF35B780701178235015DB48" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_959F7B19B296317C416378235014EC74" xlink:to="loc_srt_MajorCustomersAxis_7B42CDB4CF35B780701178235015DB48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_DCB9A518360D4DC7CFF078235016FBAA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_7B42CDB4CF35B780701178235015DB48" xlink:to="loc_srt_NameOfMajorCustomerDomain_DCB9A518360D4DC7CFF078235016FBAA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_DCB9A518360D4DC7CFF078235016FBAA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_7B42CDB4CF35B780701178235015DB48" xlink:to="loc_srt_NameOfMajorCustomerDomain_DCB9A518360D4DC7CFF078235016FBAA" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_DistributorOneMember" xlink:label="loc_biib_DistributorOneMember_C2D0EB3A95B5FA29127678235016F44C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_DCB9A518360D4DC7CFF078235016FBAA" xlink:to="loc_biib_DistributorOneMember_C2D0EB3A95B5FA29127678235016F44C" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_DistributorTwoMember" xlink:label="loc_biib_DistributorTwoMember_B8D32C90F9C9D1934A1E78235016290B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_DCB9A518360D4DC7CFF078235016FBAA" xlink:to="loc_biib_DistributorTwoMember_B8D32C90F9C9D1934A1E78235016290B" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_8B7927962413B588F923782350167B7F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_DCB9A518360D4DC7CFF078235016FBAA" xlink:to="loc_biib_BioverativMember_8B7927962413B588F923782350167B7F" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_ContractManufacturingCustomerMember" xlink:label="loc_biib_ContractManufacturingCustomerMember_421DE5FDD2A26DC9960D7823501769BA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_DCB9A518360D4DC7CFF078235016FBAA" xlink:to="loc_biib_ContractManufacturingCustomerMember_421DE5FDD2A26DC9960D7823501769BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_67CBC4A93278AF06C73D782350179702" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3E900075483FD4A082547823501750A9" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_67CBC4A93278AF06C73D782350179702" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_E0B66F761FBE97C5F75678235017C2BC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3E900075483FD4A082547823501750A9" xlink:to="loc_us-gaap_Revenues_E0B66F761FBE97C5F75678235017C2BC" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_6BBF904EAA1BE4D0EDB178235017287B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3E900075483FD4A082547823501750A9" xlink:to="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_6BBF904EAA1BE4D0EDB178235017287B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_337753263CEA6778744D78235043A612" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_7A8E1DD1A635C93900D0782350415743" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_337753263CEA6778744D78235043A612" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_7A8E1DD1A635C93900D0782350415743" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_7CA72F91EE3AE8C8C481782350418B8A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7A8E1DD1A635C93900D0782350415743" xlink:to="loc_srt_ProductOrServiceAxis_7CA72F91EE3AE8C8C481782350418B8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_A0E3ABC957370C543FCF782350412FA7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_7CA72F91EE3AE8C8C481782350418B8A" xlink:to="loc_srt_ProductsAndServicesDomain_A0E3ABC957370C543FCF782350412FA7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_A0E3ABC957370C543FCF782350412FA7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_7CA72F91EE3AE8C8C481782350418B8A" xlink:to="loc_srt_ProductsAndServicesDomain_A0E3ABC957370C543FCF782350412FA7" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_349244E9154DEA76DA2278235042EE25" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_A0E3ABC957370C543FCF782350412FA7" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_349244E9154DEA76DA2278235042EE25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_60E3653C6D5B110BDD3B782350421C73" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7A8E1DD1A635C93900D0782350415743" xlink:to="loc_srt_MajorCustomersAxis_60E3653C6D5B110BDD3B782350421C73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_E03627EB312F1EC21B93782350426375_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_60E3653C6D5B110BDD3B782350421C73" xlink:to="loc_srt_NameOfMajorCustomerDomain_E03627EB312F1EC21B93782350426375_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_E03627EB312F1EC21B93782350426375" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_60E3653C6D5B110BDD3B782350421C73" xlink:to="loc_srt_NameOfMajorCustomerDomain_E03627EB312F1EC21B93782350426375" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_RocheGroupGenentechMember" xlink:label="loc_biib_RocheGroupGenentechMember_CC77D4D0F3A807C6F0E3782350426708" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_E03627EB312F1EC21B93782350426375" xlink:to="loc_biib_RocheGroupGenentechMember_CC77D4D0F3A807C6F0E3782350426708" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_A270DB22B1AA14BFCD02782350434E79" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_337753263CEA6778744D78235043A612" xlink:to="loc_biib_ShareOfCoPromotionProfits_A270DB22B1AA14BFCD02782350434E79" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_EB069DFAD8D4CAA761AA7823504395DE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_337753263CEA6778744D78235043A612" xlink:to="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_EB069DFAD8D4CAA761AA7823504395DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_BB97CEF81ADBF72B7356782350430244" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_337753263CEA6778744D78235043A612" xlink:to="loc_us-gaap_Revenues_BB97CEF81ADBF72B7356782350430244" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenues" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_271652413D068ACD5AEC78234D47C9D4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_EEC40C3EFFFD25F4F32578234D457ED4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_271652413D068ACD5AEC78234D47C9D4" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_EEC40C3EFFFD25F4F32578234D457ED4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8398CAAF6488D4E4063C78234D4648EF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_EEC40C3EFFFD25F4F32578234D457ED4" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8398CAAF6488D4E4063C78234D4648EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8C3344D2844B169EA83A78234D4683A8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8398CAAF6488D4E4063C78234D4648EF" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8C3344D2844B169EA83A78234D4683A8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8C3344D2844B169EA83A78234D4683A8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8398CAAF6488D4E4063C78234D4648EF" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8C3344D2844B169EA83A78234D4683A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_E239ED17928C59750EA778234D463D02" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8C3344D2844B169EA83A78234D4683A8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_E239ED17928C59750EA778234D463D02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_C7E7F1E95FEDAC5249E378234D47F720" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8C3344D2844B169EA83A78234D4683A8" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_C7E7F1E95FEDAC5249E378234D47F720" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_7063372BE7B187D9130F78234D47659B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8C3344D2844B169EA83A78234D4683A8" xlink:to="loc_us-gaap_ParentMember_7063372BE7B187D9130F78234D47659B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2F5FAEB69B771E50BA2978234D48C4A3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_271652413D068ACD5AEC78234D47C9D4" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2F5FAEB69B771E50BA2978234D48C4A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_4F0F27D0B3CA9BAB187A78234D48CBDD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2F5FAEB69B771E50BA2978234D48C4A3" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_4F0F27D0B3CA9BAB187A78234D48CBDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_412F923F55F8957FE7A778234D48FE3D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2F5FAEB69B771E50BA2978234D48C4A3" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_412F923F55F8957FE7A778234D48FE3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_BE68D769A079D2AAA71E78234D487D9C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2F5FAEB69B771E50BA2978234D48C4A3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_BE68D769A079D2AAA71E78234D487D9C" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_2583FC3FED3305F2189C78234D498D66" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2F5FAEB69B771E50BA2978234D48C4A3" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_2583FC3FED3305F2189C78234D498D66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_ACF820DDB82348BC34D578234D491D7F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2F5FAEB69B771E50BA2978234D48C4A3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_ACF820DDB82348BC34D578234D491D7F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_878259D3271D031BEE9378234D3861E2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_EB911D15E5A8C918E03F78234D341A73" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_878259D3271D031BEE9378234D3861E2" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_EB911D15E5A8C918E03F78234D341A73" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_E2B675D1AE9E80D9861978234D35F8A1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_EB911D15E5A8C918E03F78234D341A73" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_E2B675D1AE9E80D9861978234D35F8A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_CC06E19687834B014FE078234D35DBCF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_E2B675D1AE9E80D9861978234D35F8A1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_CC06E19687834B014FE078234D35DBCF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_CC06E19687834B014FE078234D35DBCF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_E2B675D1AE9E80D9861978234D35F8A1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_CC06E19687834B014FE078234D35DBCF" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_NightstarMember" xlink:label="loc_biib_NightstarMember_BECD143703F0851CBF3C78234D35A08D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_CC06E19687834B014FE078234D35DBCF" xlink:to="loc_biib_NightstarMember_BECD143703F0851CBF3C78234D35A08D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_B2B610EE70B79959D80A78234D36B524" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_EB911D15E5A8C918E03F78234D341A73" xlink:to="loc_us-gaap_AwardTypeAxis_B2B610EE70B79959D80A78234D36B524" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_919B530C99BA3ADF6BF578234D36E5EE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_B2B610EE70B79959D80A78234D36B524" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_919B530C99BA3ADF6BF578234D36E5EE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_919B530C99BA3ADF6BF578234D36E5EE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_B2B610EE70B79959D80A78234D36B524" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_919B530C99BA3ADF6BF578234D36E5EE" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_D0753E8D9B22B4F1A75478234D36152B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_919B530C99BA3ADF6BF578234D36E5EE" xlink:to="loc_biib_MarketStockUnitsMember_D0753E8D9B22B4F1A75478234D36152B" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_ABA3C9FD7EDF4D333F3578234D37F13D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_919B530C99BA3ADF6BF578234D36E5EE" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_ABA3C9FD7EDF4D333F3578234D37F13D" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_A05AEF9BA3E91699C61778234D377F9E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_919B530C99BA3ADF6BF578234D36E5EE" xlink:to="loc_biib_CashSettledPerformanceSharesMember_A05AEF9BA3E91699C61778234D377F9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_A084307D78CD6BAD1D7978234D37003E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_919B530C99BA3ADF6BF578234D36E5EE" xlink:to="loc_us-gaap_PerformanceSharesMember_A084307D78CD6BAD1D7978234D37003E" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_70ADA87B6C8C13027D6078234D386D51" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_919B530C99BA3ADF6BF578234D36E5EE" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_70ADA87B6C8C13027D6078234D386D51" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_PerformanceStockUnitsSettledinCashMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_1E39DBDB068DDB48CE4878234D38DAA9" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_919B530C99BA3ADF6BF578234D36E5EE" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_1E39DBDB068DDB48CE4878234D38DAA9" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_EmployeeStockPurchasePlanMember" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_15EDD8BC44206DFBA6F878234D380BF9" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_919B530C99BA3ADF6BF578234D36E5EE" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_15EDD8BC44206DFBA6F878234D380BF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_151D1B0016C515D1B71678234D387E43" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_919B530C99BA3ADF6BF578234D36E5EE" xlink:to="loc_us-gaap_EmployeeStockOptionMember_151D1B0016C515D1B71678234D387E43" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_71B0DD1BA19A66D2F06878234D38E96C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_878259D3271D031BEE9378234D3861E2" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_71B0DD1BA19A66D2F06878234D38E96C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_813C67D109FBC6F210DA78234D3920C5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_71B0DD1BA19A66D2F06878234D38E96C" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_813C67D109FBC6F210DA78234D3920C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_CFB5D03DED63AB76B39178234D39AEAE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_71B0DD1BA19A66D2F06878234D38E96C" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_CFB5D03DED63AB76B39178234D39AEAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_1B644669C21567D79C2C78234D3A78B8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_71B0DD1BA19A66D2F06878234D38E96C" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_1B644669C21567D79C2C78234D3A78B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_3D1A7C44F0E9CC21AB9578234D3A83B5" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_71B0DD1BA19A66D2F06878234D38E96C" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_3D1A7C44F0E9CC21AB9578234D3A83B5" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_F8A4075C9D1D32135A2F78234D3A7234" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_71B0DD1BA19A66D2F06878234D38E96C" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_F8A4075C9D1D32135A2F78234D3A7234" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_6255A75A0598D06742BD78234D982AEA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_E0D57BC83ADF8F48006C78234D95F575" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_6255A75A0598D06742BD78234D982AEA" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_E0D57BC83ADF8F48006C78234D95F575" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_A3150D1F1865BCCCE6B878234D95AC23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_E0D57BC83ADF8F48006C78234D95F575" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_A3150D1F1865BCCCE6B878234D95AC23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_FBB74087683ADABD13CD78234D968B83_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_A3150D1F1865BCCCE6B878234D95AC23" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_FBB74087683ADABD13CD78234D968B83_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_FBB74087683ADABD13CD78234D968B83" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_A3150D1F1865BCCCE6B878234D95AC23" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_FBB74087683ADABD13CD78234D968B83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_0BF493F3FE3BC0D51DDD78234D962A89" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_FBB74087683ADABD13CD78234D968B83" xlink:to="loc_us-gaap_SubsequentEventMember_0BF493F3FE3BC0D51DDD78234D962A89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_D36BE7E13627719CE34778234D967AB0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_E0D57BC83ADF8F48006C78234D95F575" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_D36BE7E13627719CE34778234D967AB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_4A8A8CF2E44A5958809078234D96C085_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_D36BE7E13627719CE34778234D967AB0" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_4A8A8CF2E44A5958809078234D96C085_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_4A8A8CF2E44A5958809078234D96C085" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_D36BE7E13627719CE34778234D967AB0" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_4A8A8CF2E44A5958809078234D96C085" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_December2019ShareRepurchaseProgramMember" xlink:label="loc_biib_December2019ShareRepurchaseProgramMember_38E4D54451EBBC3660B578234D976E68" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_4A8A8CF2E44A5958809078234D96C085" xlink:to="loc_biib_December2019ShareRepurchaseProgramMember_38E4D54451EBBC3660B578234D976E68" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_March2019ShareRepurchaseProgramMember" xlink:label="loc_biib_March2019ShareRepurchaseProgramMember_0044C8AF3FE8053A57EE78234D973346" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_4A8A8CF2E44A5958809078234D96C085" xlink:to="loc_biib_March2019ShareRepurchaseProgramMember_0044C8AF3FE8053A57EE78234D973346" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_2849CCAFF9263DC9514478234D985AFC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6255A75A0598D06742BD78234D982AEA" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_2849CCAFF9263DC9514478234D985AFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_1C33AD38C783AC4F2B6D78234D983699" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6255A75A0598D06742BD78234D982AEA" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_1C33AD38C783AC4F2B6D78234D983699" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_535FBD5FE0F7A9FE274A78234D98847C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6255A75A0598D06742BD78234D982AEA" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_535FBD5FE0F7A9FE274A78234D98847C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_8A8532EF7B4FE9705BEC78234D99321B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6255A75A0598D06742BD78234D982AEA" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_8A8532EF7B4FE9705BEC78234D99321B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>biib-20200630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_79358C39CB6AC59DB12B78234F64D6C8_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_79358C39CB6AC59DB12B78234F64D6C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_79358C39CB6AC59DB12B78234F64D6C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_79358C39CB6AC59DB12B78234F64D6C8" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_79358C39CB6AC59DB12B78234F64D6C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E8FFA73D5CCF155FE92078234F657E8C_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E8FFA73D5CCF155FE92078234F657E8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E8FFA73D5CCF155FE92078234F657E8C_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E8FFA73D5CCF155FE92078234F657E8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E8FFA73D5CCF155FE92078234F657E8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E8FFA73D5CCF155FE92078234F657E8C" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E8FFA73D5CCF155FE92078234F657E8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_AE024AD99AA1C5B1418B78234F65B751_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_AE024AD99AA1C5B1418B78234F65B751" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_AE024AD99AA1C5B1418B78234F65B751_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_AE024AD99AA1C5B1418B78234F65B751" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_AE024AD99AA1C5B1418B78234F65B751" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_AE024AD99AA1C5B1418B78234F65B751" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_AE024AD99AA1C5B1418B78234F65B751" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C577A1BB689BDE59620178234F666D37_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C577A1BB689BDE59620178234F666D37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C577A1BB689BDE59620178234F666D37_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C577A1BB689BDE59620178234F666D37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C577A1BB689BDE59620178234F666D37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C577A1BB689BDE59620178234F666D37" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C577A1BB689BDE59620178234F666D37" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_89714192DDE9BA4395DB78234F66B816_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_89714192DDE9BA4395DB78234F66B816" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Quoted Prices in Active Markets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_89714192DDE9BA4395DB78234F66B816_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_89714192DDE9BA4395DB78234F66B816" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_89714192DDE9BA4395DB78234F66B816" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_89714192DDE9BA4395DB78234F66B816" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_89714192DDE9BA4395DB78234F66B816" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_35A4EBFD99C0EC91830878234F665DDF_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_35A4EBFD99C0EC91830878234F665DDF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_35A4EBFD99C0EC91830878234F665DDF_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_35A4EBFD99C0EC91830878234F665DDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_35A4EBFD99C0EC91830878234F665DDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_35A4EBFD99C0EC91830878234F665DDF" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_35A4EBFD99C0EC91830878234F665DDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_02B5960236A641015A6778234F66069B_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_02B5960236A641015A6778234F66069B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_02B5960236A641015A6778234F66069B_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_02B5960236A641015A6778234F66069B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_02B5960236A641015A6778234F66069B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_02B5960236A641015A6778234F66069B" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_02B5960236A641015A6778234F66069B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_810402E82A9A044B2E5078234F6651CD_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_810402E82A9A044B2E5078234F6651CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_810402E82A9A044B2E5078234F6651CD_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_810402E82A9A044B2E5078234F6651CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_810402E82A9A044B2E5078234F6651CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_810402E82A9A044B2E5078234F6651CD" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_810402E82A9A044B2E5078234F6651CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_8C36DC6BE29522FF1A4378234F674B9D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_8C36DC6BE29522FF1A4378234F674B9D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_8C36DC6BE29522FF1A4378234F674B9D_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_8C36DC6BE29522FF1A4378234F674B9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_8C36DC6BE29522FF1A4378234F674B9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_8C36DC6BE29522FF1A4378234F674B9D" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_8C36DC6BE29522FF1A4378234F674B9D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_BECA099D67E96C9D615478234F6712B6_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_BECA099D67E96C9D615478234F6712B6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_BECA099D67E96C9D615478234F6712B6_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_BECA099D67E96C9D615478234F6712B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_BECA099D67E96C9D615478234F6712B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_BECA099D67E96C9D615478234F6712B6" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_BECA099D67E96C9D615478234F6712B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_2E7078DFAB43A40913E378234F67FAE3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis_2E7078DFAB43A40913E378234F67FAE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_2E7078DFAB43A40913E378234F67FAE3_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis_2E7078DFAB43A40913E378234F67FAE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_2E7078DFAB43A40913E378234F67FAE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_2E7078DFAB43A40913E378234F67FAE3" xlink:to="lab_us-gaap_FairValueByAssetClassAxis_2E7078DFAB43A40913E378234F67FAE3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_E0EFC60FFBAF73B9A50978234F685EE6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_E0EFC60FFBAF73B9A50978234F685EE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_E0EFC60FFBAF73B9A50978234F685EE6_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_E0EFC60FFBAF73B9A50978234F685EE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_E0EFC60FFBAF73B9A50978234F685EE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_E0EFC60FFBAF73B9A50978234F685EE6" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_E0EFC60FFBAF73B9A50978234F685EE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_7EDFBA3312FEAD20412D78234F68AE92_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_7EDFBA3312FEAD20412D78234F68AE92" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_7EDFBA3312FEAD20412D78234F68AE92_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_7EDFBA3312FEAD20412D78234F68AE92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_7EDFBA3312FEAD20412D78234F68AE92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember_7EDFBA3312FEAD20412D78234F68AE92" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember_7EDFBA3312FEAD20412D78234F68AE92" xlink:type="arc" />
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_A97FF738B0D3FBAF1F6D78234F683D3C_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember_A97FF738B0D3FBAF1F6D78234F683D3C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_A97FF738B0D3FBAF1F6D78234F683D3C_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember_A97FF738B0D3FBAF1F6D78234F683D3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_A97FF738B0D3FBAF1F6D78234F683D3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember_A97FF738B0D3FBAF1F6D78234F683D3C" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember_A97FF738B0D3FBAF1F6D78234F683D3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_6729E6BE7E86FE4CDF9278234F682CE1_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember_6729E6BE7E86FE4CDF9278234F682CE1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_6729E6BE7E86FE4CDF9278234F682CE1_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember_6729E6BE7E86FE4CDF9278234F682CE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_6729E6BE7E86FE4CDF9278234F682CE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember_6729E6BE7E86FE4CDF9278234F682CE1" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember_6729E6BE7E86FE4CDF9278234F682CE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6EA7436BFD45C514092478234F697382_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6EA7436BFD45C514092478234F697382" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6EA7436BFD45C514092478234F697382_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6EA7436BFD45C514092478234F697382" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6EA7436BFD45C514092478234F697382" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6EA7436BFD45C514092478234F697382" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6EA7436BFD45C514092478234F697382" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_8D0C19BAF099F0CEC6E778234F690E70_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_8D0C19BAF099F0CEC6E778234F690E70" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_8D0C19BAF099F0CEC6E778234F690E70_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_8D0C19BAF099F0CEC6E778234F690E70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_8D0C19BAF099F0CEC6E778234F690E70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_8D0C19BAF099F0CEC6E778234F690E70" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_8D0C19BAF099F0CEC6E778234F690E70" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_3B083C756454BDCA642D78234F69F17C_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_3B083C756454BDCA642D78234F69F17C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_3B083C756454BDCA642D78234F69F17C_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_3B083C756454BDCA642D78234F69F17C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_3B083C756454BDCA642D78234F69F17C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3B083C756454BDCA642D78234F69F17C" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract_3B083C756454BDCA642D78234F69F17C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5FEB665E8001F7FF8AF878234F69F473_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5FEB665E8001F7FF8AF878234F69F473" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5FEB665E8001F7FF8AF878234F69F473_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5FEB665E8001F7FF8AF878234F69F473" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5FEB665E8001F7FF8AF878234F69F473" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5FEB665E8001F7FF8AF878234F69F473" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5FEB665E8001F7FF8AF878234F69F473" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_92D311A7BA00D786139B78234F6AA812_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_92D311A7BA00D786139B78234F6AA812" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_92D311A7BA00D786139B78234F6AA812_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_92D311A7BA00D786139B78234F6AA812" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_92D311A7BA00D786139B78234F6AA812" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_92D311A7BA00D786139B78234F6AA812" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_92D311A7BA00D786139B78234F6AA812" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_5EEE6688FFEF0A993CA578234F6A3ACB_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_5EEE6688FFEF0A993CA578234F6A3ACB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_5EEE6688FFEF0A993CA578234F6A3ACB_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_5EEE6688FFEF0A993CA578234F6A3ACB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_5EEE6688FFEF0A993CA578234F6A3ACB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure_5EEE6688FFEF0A993CA578234F6A3ACB" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure_5EEE6688FFEF0A993CA578234F6A3ACB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_546D3D5E273FEB18179C78234F6AEE02_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_546D3D5E273FEB18179C78234F6AEE02" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_546D3D5E273FEB18179C78234F6AEE02_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_546D3D5E273FEB18179C78234F6AEE02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Contract, Asset, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_546D3D5E273FEB18179C78234F6AEE02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_546D3D5E273FEB18179C78234F6AEE02" xlink:to="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_546D3D5E273FEB18179C78234F6AEE02" xlink:type="arc" />
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_31291E139E25846362D578234F6A16E9_verboseLabel_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_31291E139E25846362D578234F6A16E9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Plan assets for deferred compensation</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_31291E139E25846362D578234F6A16E9_label_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_31291E139E25846362D578234F6A16E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Assets For Deferred Compensation Fair Value Disclosure</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_31291E139E25846362D578234F6A16E9_documentation_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_31291E139E25846362D578234F6A16E9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair values as of the balance sheet date of all assets of deferred compensation plans.</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_31291E139E25846362D578234F6A16E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_31291E139E25846362D578234F6A16E9" xlink:to="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_31291E139E25846362D578234F6A16E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_715DE8EEB85BA7BD44EC78234F6B6963_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_715DE8EEB85BA7BD44EC78234F6B6963" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_715DE8EEB85BA7BD44EC78234F6B6963_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_715DE8EEB85BA7BD44EC78234F6B6963" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_715DE8EEB85BA7BD44EC78234F6B6963" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_715DE8EEB85BA7BD44EC78234F6B6963" xlink:to="lab_us-gaap_AssetsFairValueDisclosure_715DE8EEB85BA7BD44EC78234F6B6963" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_605D31F118717EE143F378234F6B6640_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_605D31F118717EE143F378234F6B6640" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_605D31F118717EE143F378234F6B6640_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_605D31F118717EE143F378234F6B6640" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_605D31F118717EE143F378234F6B6640" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_605D31F118717EE143F378234F6B6640" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_605D31F118717EE143F378234F6B6640" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_78FA0353D93D3721C14178234F6B5125_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_78FA0353D93D3721C14178234F6B5125" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_78FA0353D93D3721C14178234F6B5125_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_78FA0353D93D3721C14178234F6B5125" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Contracts, Liability, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_78FA0353D93D3721C14178234F6B5125" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_78FA0353D93D3721C14178234F6B5125" xlink:to="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_78FA0353D93D3721C14178234F6B5125" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_3E9ECFA0E5202B5163B478234F6BCC20_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_3E9ECFA0E5202B5163B478234F6BCC20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_3E9ECFA0E5202B5163B478234F6BCC20_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_3E9ECFA0E5202B5163B478234F6BCC20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3E9ECFA0E5202B5163B478234F6BCC20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3E9ECFA0E5202B5163B478234F6BCC20" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_3E9ECFA0E5202B5163B478234F6BCC20" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_392E93A4082C7AD6407878234F6B2B06_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_392E93A4082C7AD6407878234F6B2B06" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_392E93A4082C7AD6407878234F6B2B06_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_392E93A4082C7AD6407878234F6B2B06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_392E93A4082C7AD6407878234F6B2B06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_392E93A4082C7AD6407878234F6B2B06" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure_392E93A4082C7AD6407878234F6B2B06" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_DB6A3BB443E5A88B18BC78234E1AF65B_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract_DB6A3BB443E5A88B18BC78234E1AF65B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_DB6A3BB443E5A88B18BC78234E1AF65B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_DB6A3BB443E5A88B18BC78234E1AF65B" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract_DB6A3BB443E5A88B18BC78234E1AF65B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_843A4AB4993001D2D09878234E1A45E6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_843A4AB4993001D2D09878234E1A45E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_843A4AB4993001D2D09878234E1A45E6_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_843A4AB4993001D2D09878234E1A45E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_843A4AB4993001D2D09878234E1A45E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_843A4AB4993001D2D09878234E1A45E6" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_843A4AB4993001D2D09878234E1A45E6" xlink:type="arc" />
    <link:label id="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_C246C9E6A2655114014C78234D7696C3_label_en-US" xlink:label="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_C246C9E6A2655114014C78234D7696C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:label id="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_C246C9E6A2655114014C78234D7696C3_documentation_en-US" xlink:label="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_C246C9E6A2655114014C78234D7696C3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:label="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_C246C9E6A2655114014C78234D7696C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_C246C9E6A2655114014C78234D7696C3" xlink:to="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_C246C9E6A2655114014C78234D7696C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_137F6819A77C147721A078234D77D437_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_137F6819A77C147721A078234D77D437" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_137F6819A77C147721A078234D77D437_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_137F6819A77C147721A078234D77D437" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_137F6819A77C147721A078234D77D437" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_137F6819A77C147721A078234D77D437" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_137F6819A77C147721A078234D77D437" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_0C924F759BFA2C8BE5F378234D77C921_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_0C924F759BFA2C8BE5F378234D77C921" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_0C924F759BFA2C8BE5F378234D77C921_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_0C924F759BFA2C8BE5F378234D77C921" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0C924F759BFA2C8BE5F378234D77C921" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0C924F759BFA2C8BE5F378234D77C921" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_0C924F759BFA2C8BE5F378234D77C921" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_98AC5D2AE1FB9410F53378234D78F1BF_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_98AC5D2AE1FB9410F53378234D78F1BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_98AC5D2AE1FB9410F53378234D78F1BF_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_98AC5D2AE1FB9410F53378234D78F1BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_98AC5D2AE1FB9410F53378234D78F1BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_98AC5D2AE1FB9410F53378234D78F1BF" xlink:to="lab_us-gaap_EquityComponentDomain_98AC5D2AE1FB9410F53378234D78F1BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_F192B77F51BB1492D04578234D7880D2_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_F192B77F51BB1492D04578234D7880D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on securities available for sale</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_F192B77F51BB1492D04578234D7880D2_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_F192B77F51BB1492D04578234D7880D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_F192B77F51BB1492D04578234D7880D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_F192B77F51BB1492D04578234D7880D2" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_F192B77F51BB1492D04578234D7880D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_F0392D6F7C6956C683AF78234D78AAAD_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_F0392D6F7C6956C683AF78234D78AAAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on cash flow hedges</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_F0392D6F7C6956C683AF78234D78AAAD_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_F0392D6F7C6956C683AF78234D78AAAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_F0392D6F7C6956C683AF78234D78AAAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_F0392D6F7C6956C683AF78234D78AAAD" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_F0392D6F7C6956C683AF78234D78AAAD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_50CB9759D5F8D228FFDC78234D79525D_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_50CB9759D5F8D228FFDC78234D79525D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gains (losses) on net investment hedge</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_50CB9759D5F8D228FFDC78234D79525D_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_50CB9759D5F8D228FFDC78234D79525D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_50CB9759D5F8D228FFDC78234D79525D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_50CB9759D5F8D228FFDC78234D79525D" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_50CB9759D5F8D228FFDC78234D79525D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_47DE20C343F7E298D0D378234D79F08B_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_47DE20C343F7E298D0D378234D79F08B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_47DE20C343F7E298D0D378234D79F08B_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_47DE20C343F7E298D0D378234D79F08B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_47DE20C343F7E298D0D378234D79F08B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_47DE20C343F7E298D0D378234D79F08B" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_47DE20C343F7E298D0D378234D79F08B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_F17B5A6E8AB1CDED7D5178234D799F59_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_F17B5A6E8AB1CDED7D5178234D799F59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_F17B5A6E8AB1CDED7D5178234D799F59_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_F17B5A6E8AB1CDED7D5178234D799F59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_F17B5A6E8AB1CDED7D5178234D799F59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_F17B5A6E8AB1CDED7D5178234D799F59" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_F17B5A6E8AB1CDED7D5178234D799F59" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_A348DA05041129A0391378234D795722_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_A348DA05041129A0391378234D795722" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_A348DA05041129A0391378234D795722_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_A348DA05041129A0391378234D795722" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_A348DA05041129A0391378234D795722" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_A348DA05041129A0391378234D795722" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_A348DA05041129A0391378234D795722" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_037C558A45AA71B62FA878234D7ADAF7_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_037C558A45AA71B62FA878234D7ADAF7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_037C558A45AA71B62FA878234D7ADAF7_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_037C558A45AA71B62FA878234D7ADAF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_037C558A45AA71B62FA878234D7ADAF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_037C558A45AA71B62FA878234D7ADAF7" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_037C558A45AA71B62FA878234D7ADAF7" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_8AC37225540F4B3BBF1278234D7AA1F0_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_8AC37225540F4B3BBF1278234D7AA1F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_8AC37225540F4B3BBF1278234D7AA1F0_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_8AC37225540F4B3BBF1278234D7AA1F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_8AC37225540F4B3BBF1278234D7AA1F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_8AC37225540F4B3BBF1278234D7AA1F0" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_8AC37225540F4B3BBF1278234D7AA1F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_A868F56865C3E3EBF1E278234D7B5C19_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_A868F56865C3E3EBF1E278234D7B5C19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_A868F56865C3E3EBF1E278234D7B5C19_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_A868F56865C3E3EBF1E278234D7B5C19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_A868F56865C3E3EBF1E278234D7B5C19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_A868F56865C3E3EBF1E278234D7B5C19" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_A868F56865C3E3EBF1E278234D7B5C19" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_C8689FEC8A25E86701A278234D7B8B73_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_Revenues_C8689FEC8A25E86701A278234D7B8B73" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Product revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_C8689FEC8A25E86701A278234D7B8B73_label_en-US" xlink:label="lab_us-gaap_Revenues_C8689FEC8A25E86701A278234D7B8B73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_C8689FEC8A25E86701A278234D7B8B73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_C8689FEC8A25E86701A278234D7B8B73" xlink:to="lab_us-gaap_Revenues_C8689FEC8A25E86701A278234D7B8B73" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_336FD2C8024A2FC5E8D878234D7B6B0A_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_336FD2C8024A2FC5E8D878234D7B6B0A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_336FD2C8024A2FC5E8D878234D7B6B0A_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_336FD2C8024A2FC5E8D878234D7B6B0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_336FD2C8024A2FC5E8D878234D7B6B0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_336FD2C8024A2FC5E8D878234D7B6B0A" xlink:to="lab_us-gaap_OperatingExpenses_336FD2C8024A2FC5E8D878234D7B6B0A" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_965C7E306C0D6BECB71C78234D7B2D74_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_965C7E306C0D6BECB71C78234D7B2D74" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_965C7E306C0D6BECB71C78234D7B2D74_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_965C7E306C0D6BECB71C78234D7B2D74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_965C7E306C0D6BECB71C78234D7B2D74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_965C7E306C0D6BECB71C78234D7B2D74" xlink:to="lab_us-gaap_NetIncomeLoss_965C7E306C0D6BECB71C78234D7B2D74" xlink:type="arc" />
    <link:label id="lab_biib_DivestituresAbstract_41A2E905E56856B7C786782350AF5214_label_en-US" xlink:label="lab_biib_DivestituresAbstract_41A2E905E56856B7C786782350AF5214" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Divestitures [Abstract]</link:label>
    <link:label id="lab_biib_DivestituresAbstract_41A2E905E56856B7C786782350AF5214_documentation_en-US" xlink:label="lab_biib_DivestituresAbstract_41A2E905E56856B7C786782350AF5214" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Divestitures [Abstract]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_DivestituresAbstract" xlink:label="loc_biib_DivestituresAbstract_41A2E905E56856B7C786782350AF5214" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DivestituresAbstract_41A2E905E56856B7C786782350AF5214" xlink:to="lab_biib_DivestituresAbstract_41A2E905E56856B7C786782350AF5214" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_AC7C56E36A6765415D56782350AF310B_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_AC7C56E36A6765415D56782350AF310B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Divestitures</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_AC7C56E36A6765415D56782350AF310B_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_AC7C56E36A6765415D56782350AF310B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_AC7C56E36A6765415D56782350AF310B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_AC7C56E36A6765415D56782350AF310B" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_AC7C56E36A6765415D56782350AF310B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D99EE8B070745BDABE6C78234E1241A3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D99EE8B070745BDABE6C78234E1241A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D99EE8B070745BDABE6C78234E1241A3_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D99EE8B070745BDABE6C78234E1241A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D99EE8B070745BDABE6C78234E1241A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D99EE8B070745BDABE6C78234E1241A3" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D99EE8B070745BDABE6C78234E1241A3" xlink:type="arc" />
    <link:label id="lab_biib_FacilityLocationAxis_87E277AFFFCA70CD181178234E126290_terseLabel_en-US" xlink:label="lab_biib_FacilityLocationAxis_87E277AFFFCA70CD181178234E126290" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facility Location [Axis]</link:label>
    <link:label id="lab_biib_FacilityLocationAxis_87E277AFFFCA70CD181178234E126290_label_en-US" xlink:label="lab_biib_FacilityLocationAxis_87E277AFFFCA70CD181178234E126290" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facility Location [Axis]</link:label>
    <link:label id="lab_biib_FacilityLocationAxis_87E277AFFFCA70CD181178234E126290_documentation_en-US" xlink:label="lab_biib_FacilityLocationAxis_87E277AFFFCA70CD181178234E126290" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_87E277AFFFCA70CD181178234E126290" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityLocationAxis_87E277AFFFCA70CD181178234E126290" xlink:to="lab_biib_FacilityLocationAxis_87E277AFFFCA70CD181178234E126290" xlink:type="arc" />
    <link:label id="lab_biib_FacilityLocationDomain_BDE5BBF9E8795477C4D078234E13299D_terseLabel_en-US" xlink:label="lab_biib_FacilityLocationDomain_BDE5BBF9E8795477C4D078234E13299D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facility Location [Domain]</link:label>
    <link:label id="lab_biib_FacilityLocationDomain_BDE5BBF9E8795477C4D078234E13299D_label_en-US" xlink:label="lab_biib_FacilityLocationDomain_BDE5BBF9E8795477C4D078234E13299D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facility Location [Domain]</link:label>
    <link:label id="lab_biib_FacilityLocationDomain_BDE5BBF9E8795477C4D078234E13299D_documentation_en-US" xlink:label="lab_biib_FacilityLocationDomain_BDE5BBF9E8795477C4D078234E13299D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_BDE5BBF9E8795477C4D078234E13299D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityLocationDomain_BDE5BBF9E8795477C4D078234E13299D" xlink:to="lab_biib_FacilityLocationDomain_BDE5BBF9E8795477C4D078234E13299D" xlink:type="arc" />
    <link:label id="lab_biib_SolothurnSwitzerlandMember_76E4C208B6367F1BEB5878234E13E02D_terseLabel_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember_76E4C208B6367F1BEB5878234E13E02D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Solothurn, Switzerland</link:label>
    <link:label id="lab_biib_SolothurnSwitzerlandMember_76E4C208B6367F1BEB5878234E13E02D_label_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember_76E4C208B6367F1BEB5878234E13E02D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Solothurn, Switzerland [Member]</link:label>
    <link:label id="lab_biib_SolothurnSwitzerlandMember_76E4C208B6367F1BEB5878234E13E02D_documentation_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember_76E4C208B6367F1BEB5878234E13E02D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Solothurn, Switzerland [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_SolothurnSwitzerlandMember" xlink:label="loc_biib_SolothurnSwitzerlandMember_76E4C208B6367F1BEB5878234E13E02D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SolothurnSwitzerlandMember_76E4C208B6367F1BEB5878234E13E02D" xlink:to="lab_biib_SolothurnSwitzerlandMember_76E4C208B6367F1BEB5878234E13E02D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_757DC56163E11BFF79FB78234E13983A_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_757DC56163E11BFF79FB78234E13983A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_757DC56163E11BFF79FB78234E13983A_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_757DC56163E11BFF79FB78234E13983A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_757DC56163E11BFF79FB78234E13983A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_757DC56163E11BFF79FB78234E13983A" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_757DC56163E11BFF79FB78234E13983A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4D5D3821929B588D094E78234E14C8CF_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4D5D3821929B588D094E78234E14C8CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4D5D3821929B588D094E78234E14C8CF_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4D5D3821929B588D094E78234E14C8CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4D5D3821929B588D094E78234E14C8CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4D5D3821929B588D094E78234E14C8CF" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4D5D3821929B588D094E78234E14C8CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_Depreciation_99F608FD5B7111E7DF8378234E140D4C_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation_99F608FD5B7111E7DF8378234E140D4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_99F608FD5B7111E7DF8378234E140D4C_label_en-US" xlink:label="lab_us-gaap_Depreciation_99F608FD5B7111E7DF8378234E140D4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_99F608FD5B7111E7DF8378234E140D4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_99F608FD5B7111E7DF8378234E140D4C" xlink:to="lab_us-gaap_Depreciation_99F608FD5B7111E7DF8378234E140D4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionInProgressGross_4375C3514BF34820FC9078234E141037_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross_4375C3514BF34820FC9078234E141037" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_4375C3514BF34820FC9078234E141037_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross_4375C3514BF34820FC9078234E141037" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_4375C3514BF34820FC9078234E141037" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross_4375C3514BF34820FC9078234E141037" xlink:to="lab_us-gaap_ConstructionInProgressGross_4375C3514BF34820FC9078234E141037" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_C5FFCEE1E3BCE8A8901A78234E15FE1F_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_C5FFCEE1E3BCE8A8901A78234E15FE1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed assets placed into service</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_C5FFCEE1E3BCE8A8901A78234E15FE1F_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_C5FFCEE1E3BCE8A8901A78234E15FE1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_C5FFCEE1E3BCE8A8901A78234E15FE1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_C5FFCEE1E3BCE8A8901A78234E15FE1F" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_C5FFCEE1E3BCE8A8901A78234E15FE1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCommitment_6A265DA6827BF411F99D78234E15FCB5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitment_6A265DA6827BF411F99D78234E15FCB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual commitments for the construction of the facility</link:label>
    <link:label id="lab_us-gaap_OtherCommitment_6A265DA6827BF411F99D78234E15FCB5_label_en-US" xlink:label="lab_us-gaap_OtherCommitment_6A265DA6827BF411F99D78234E15FCB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_6A265DA6827BF411F99D78234E15FCB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitment_6A265DA6827BF411F99D78234E15FCB5" xlink:to="lab_us-gaap_OtherCommitment_6A265DA6827BF411F99D78234E15FCB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_E5692414FB18F0DA3F607823517ECAD6_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_E5692414FB18F0DA3F607823517ECAD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_E5692414FB18F0DA3F607823517ECAD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_E5692414FB18F0DA3F607823517ECAD6" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_E5692414FB18F0DA3F607823517ECAD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_3D93FB16BE6FC36F69497823517E86CE_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_3D93FB16BE6FC36F69497823517E86CE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_3D93FB16BE6FC36F69497823517E86CE_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_3D93FB16BE6FC36F69497823517E86CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3D93FB16BE6FC36F69497823517E86CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3D93FB16BE6FC36F69497823517E86CE" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_3D93FB16BE6FC36F69497823517E86CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_BA41F1B69532A0025EFF7823517FF741_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_BA41F1B69532A0025EFF7823517FF741" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_BA41F1B69532A0025EFF7823517FF741_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_BA41F1B69532A0025EFF7823517FF741" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_BA41F1B69532A0025EFF7823517FF741" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_BA41F1B69532A0025EFF7823517FF741" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_BA41F1B69532A0025EFF7823517FF741" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_C79EAC8E4C4BC767B792782351B98F0D_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_C79EAC8E4C4BC767B792782351B98F0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_C79EAC8E4C4BC767B792782351B98F0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_C79EAC8E4C4BC767B792782351B98F0D" xlink:to="lab_us-gaap_IncomeStatementAbstract_C79EAC8E4C4BC767B792782351B98F0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_1CC3D936D9A84F51F3E6782351B9651F_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_1CC3D936D9A84F51F3E6782351B9651F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_1CC3D936D9A84F51F3E6782351B9651F_label_en-US" xlink:label="lab_us-gaap_StatementTable_1CC3D936D9A84F51F3E6782351B9651F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1CC3D936D9A84F51F3E6782351B9651F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_1CC3D936D9A84F51F3E6782351B9651F" xlink:to="lab_us-gaap_StatementTable_1CC3D936D9A84F51F3E6782351B9651F" xlink:type="arc" />
    <link:label id="lab_srt_ProductOrServiceAxis_240DB5AFD091F010474E782351BA4156_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis_240DB5AFD091F010474E782351BA4156" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_240DB5AFD091F010474E782351BA4156_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis_240DB5AFD091F010474E782351BA4156" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_240DB5AFD091F010474E782351BA4156" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis_240DB5AFD091F010474E782351BA4156" xlink:to="lab_srt_ProductOrServiceAxis_240DB5AFD091F010474E782351BA4156" xlink:type="arc" />
    <link:label id="lab_srt_ProductsAndServicesDomain_A9630AF5908C66EE2AFF782351BA7C8C_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_A9630AF5908C66EE2AFF782351BA7C8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_A9630AF5908C66EE2AFF782351BA7C8C_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_A9630AF5908C66EE2AFF782351BA7C8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_A9630AF5908C66EE2AFF782351BA7C8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain_A9630AF5908C66EE2AFF782351BA7C8C" xlink:to="lab_srt_ProductsAndServicesDomain_A9630AF5908C66EE2AFF782351BA7C8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductMember_091A937F2A1165EBC5A3782351BA9F03_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember_091A937F2A1165EBC5A3782351BA9F03" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_091A937F2A1165EBC5A3782351BA9F03_label_en-US" xlink:label="lab_us-gaap_ProductMember_091A937F2A1165EBC5A3782351BA9F03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_091A937F2A1165EBC5A3782351BA9F03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember_091A937F2A1165EBC5A3782351BA9F03" xlink:to="lab_us-gaap_ProductMember_091A937F2A1165EBC5A3782351BA9F03" xlink:type="arc" />
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_DA566FEBCDF177C7ABAD782351BBF6EA_terseLabel_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_DA566FEBCDF177C7ABAD782351BBF6EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_DA566FEBCDF177C7ABAD782351BBF6EA_label_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_DA566FEBCDF177C7ABAD782351BBF6EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues from anti-cd20 therapeutic programs [Member]</link:label>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_DA566FEBCDF177C7ABAD782351BBF6EA_documentation_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_DA566FEBCDF177C7ABAD782351BBF6EA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues from anti-cd20 therapeutic programs</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_DA566FEBCDF177C7ABAD782351BBF6EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_DA566FEBCDF177C7ABAD782351BBF6EA" xlink:to="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_DA566FEBCDF177C7ABAD782351BBF6EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_75AF6FE36763B2B68231782351BBCFCD_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember_75AF6FE36763B2B68231782351BBCFCD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_75AF6FE36763B2B68231782351BBCFCD_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember_75AF6FE36763B2B68231782351BBCFCD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_75AF6FE36763B2B68231782351BBCFCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember_75AF6FE36763B2B68231782351BBCFCD" xlink:to="lab_us-gaap_ProductAndServiceOtherMember_75AF6FE36763B2B68231782351BBCFCD" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_98FDD9635D731D6AF461782351BB79A0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_98FDD9635D731D6AF461782351BB79A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_98FDD9635D731D6AF461782351BB79A0_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_98FDD9635D731D6AF461782351BB79A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_98FDD9635D731D6AF461782351BB79A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_98FDD9635D731D6AF461782351BB79A0" xlink:to="lab_us-gaap_StatementLineItems_98FDD9635D731D6AF461782351BB79A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_E10FE7F7D7620CC8E052782351BBA6F0_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues_E10FE7F7D7620CC8E052782351BBA6F0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_E10FE7F7D7620CC8E052782351BBA6F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_E10FE7F7D7620CC8E052782351BBA6F0" xlink:to="lab_us-gaap_Revenues_E10FE7F7D7620CC8E052782351BBA6F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_E7A05E5AFEF4EE2B3106782351BCD3CA_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_E7A05E5AFEF4EE2B3106782351BCD3CA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_E7A05E5AFEF4EE2B3106782351BCD3CA_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_E7A05E5AFEF4EE2B3106782351BCD3CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_E7A05E5AFEF4EE2B3106782351BCD3CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_E7A05E5AFEF4EE2B3106782351BCD3CA" xlink:to="lab_us-gaap_CostsAndExpensesAbstract_E7A05E5AFEF4EE2B3106782351BCD3CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_C20B387C170ACC357FEC782351BCF684_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_C20B387C170ACC357FEC782351BCF684" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales, excluding amortization and impairment of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_C20B387C170ACC357FEC782351BCF684_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_C20B387C170ACC357FEC782351BCF684" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_C20B387C170ACC357FEC782351BCF684" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold_C20B387C170ACC357FEC782351BCF684" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold_C20B387C170ACC357FEC782351BCF684" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9F21FC13AEFC34118E6F782351BC7F18_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9F21FC13AEFC34118E6F782351BC7F18" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9F21FC13AEFC34118E6F782351BC7F18_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9F21FC13AEFC34118E6F782351BC7F18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9F21FC13AEFC34118E6F782351BC7F18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9F21FC13AEFC34118E6F782351BC7F18" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9F21FC13AEFC34118E6F782351BC7F18" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_6364E2A6FCBB97987235782351BC3C43_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_6364E2A6FCBB97987235782351BC3C43" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_6364E2A6FCBB97987235782351BC3C43_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_6364E2A6FCBB97987235782351BC3C43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6364E2A6FCBB97987235782351BC3C43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6364E2A6FCBB97987235782351BC3C43" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_6364E2A6FCBB97987235782351BC3C43" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_89FA89B32E8E0D5E6A38782351BD728E_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_89FA89B32E8E0D5E6A38782351BD728E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization and impairment of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_89FA89B32E8E0D5E6A38782351BD728E_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_89FA89B32E8E0D5E6A38782351BD728E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_89FA89B32E8E0D5E6A38782351BD728E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_89FA89B32E8E0D5E6A38782351BD728E" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_89FA89B32E8E0D5E6A38782351BD728E" xlink:type="arc" />
    <link:label id="lab_biib_Collaborationprofitlosssharing_6BF4A55F37E0254D92F4782351BD9467_terseLabel_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing_6BF4A55F37E0254D92F4782351BD9467" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:label id="lab_biib_Collaborationprofitlosssharing_6BF4A55F37E0254D92F4782351BD9467_label_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing_6BF4A55F37E0254D92F4782351BD9467" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:label id="lab_biib_Collaborationprofitlosssharing_6BF4A55F37E0254D92F4782351BD9467_documentation_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing_6BF4A55F37E0254D92F4782351BD9467" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_6BF4A55F37E0254D92F4782351BD9467" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Collaborationprofitlosssharing_6BF4A55F37E0254D92F4782351BD9467" xlink:to="lab_biib_Collaborationprofitlosssharing_6BF4A55F37E0254D92F4782351BD9467" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_964D58BF92706B92E478782351BDAB50_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_964D58BF92706B92E478782351BDAB50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_964D58BF92706B92E478782351BDAB50_label_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_964D58BF92706B92E478782351BDAB50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_964D58BF92706B92E478782351BDAB50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_964D58BF92706B92E478782351BDAB50" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_964D58BF92706B92E478782351BDAB50" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_506A979E04CB3FE896EA782351BD58FB_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_506A979E04CB3FE896EA782351BD58FB" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">(Gain) loss on fair value remeasurement of contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_506A979E04CB3FE896EA782351BD58FB_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_506A979E04CB3FE896EA782351BD58FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_506A979E04CB3FE896EA782351BD58FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_506A979E04CB3FE896EA782351BD58FB" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_506A979E04CB3FE896EA782351BD58FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCharges_0D4A26927F06E9EF7D5C782351BDF536_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges_0D4A26927F06E9EF7D5C782351BDF536" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_0D4A26927F06E9EF7D5C782351BDF536_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges_0D4A26927F06E9EF7D5C782351BDF536" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_0D4A26927F06E9EF7D5C782351BDF536" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges_0D4A26927F06E9EF7D5C782351BDF536" xlink:to="lab_us-gaap_RestructuringCharges_0D4A26927F06E9EF7D5C782351BDF536" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_3EF483A92A09AB6F3286782351BD150A_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess_3EF483A92A09AB6F3286782351BD150A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_3EF483A92A09AB6F3286782351BD150A_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess_3EF483A92A09AB6F3286782351BD150A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_3EF483A92A09AB6F3286782351BD150A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess_3EF483A92A09AB6F3286782351BD150A" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess_3EF483A92A09AB6F3286782351BD150A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpenses_1DCF7ECA6A53C25ED69B782351BE8FDF_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_1DCF7ECA6A53C25ED69B782351BE8FDF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cost and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_1DCF7ECA6A53C25ED69B782351BE8FDF_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_1DCF7ECA6A53C25ED69B782351BE8FDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_1DCF7ECA6A53C25ED69B782351BE8FDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses_1DCF7ECA6A53C25ED69B782351BE8FDF" xlink:to="lab_us-gaap_CostsAndExpenses_1DCF7ECA6A53C25ED69B782351BE8FDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_D2E12F5AA4633EDC19CA782351BEA3AD_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_D2E12F5AA4633EDC19CA782351BEA3AD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_D2E12F5AA4633EDC19CA782351BEA3AD_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_D2E12F5AA4633EDC19CA782351BEA3AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_D2E12F5AA4633EDC19CA782351BEA3AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_D2E12F5AA4633EDC19CA782351BEA3AD" xlink:to="lab_us-gaap_OperatingIncomeLoss_D2E12F5AA4633EDC19CA782351BEA3AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_A7BD73A09FC3B0139332782351BEFBAE_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_A7BD73A09FC3B0139332782351BEFBAE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_A7BD73A09FC3B0139332782351BEFBAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_A7BD73A09FC3B0139332782351BEFBAE" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_A7BD73A09FC3B0139332782351BEFBAE" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_39E6F4DE1DF56AA275BE782351BEFDD6_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_39E6F4DE1DF56AA275BE782351BEFDD6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income before income tax expense and equity in loss of investee, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_39E6F4DE1DF56AA275BE782351BEFDD6_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_39E6F4DE1DF56AA275BE782351BEFDD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_39E6F4DE1DF56AA275BE782351BEFDD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_39E6F4DE1DF56AA275BE782351BEFDD6" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_39E6F4DE1DF56AA275BE782351BEFDD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_B5101490F6E2E8777B45782351BE9156_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_B5101490F6E2E8777B45782351BE9156" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_B5101490F6E2E8777B45782351BE9156" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_B5101490F6E2E8777B45782351BE9156" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_B5101490F6E2E8777B45782351BE9156" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_8FB4D72AF0DC2E50471C782351BF5C07_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_8FB4D72AF0DC2E50471C782351BF5C07" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Equity in loss of investee, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_8FB4D72AF0DC2E50471C782351BF5C07_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_8FB4D72AF0DC2E50471C782351BF5C07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_8FB4D72AF0DC2E50471C782351BF5C07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments_8FB4D72AF0DC2E50471C782351BF5C07" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments_8FB4D72AF0DC2E50471C782351BF5C07" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_81C6A94685D29FBA6626782351BF3105_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_81C6A94685D29FBA6626782351BF3105" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_81C6A94685D29FBA6626782351BF3105_label_en-US" xlink:label="lab_us-gaap_ProfitLoss_81C6A94685D29FBA6626782351BF3105" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_81C6A94685D29FBA6626782351BF3105" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_81C6A94685D29FBA6626782351BF3105" xlink:to="lab_us-gaap_ProfitLoss_81C6A94685D29FBA6626782351BF3105" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_B8D96204507ABF9AAC9C782351BFAE46_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_B8D96204507ABF9AAC9C782351BFAE46" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_B8D96204507ABF9AAC9C782351BFAE46_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_B8D96204507ABF9AAC9C782351BFAE46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_B8D96204507ABF9AAC9C782351BFAE46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_B8D96204507ABF9AAC9C782351BFAE46" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_B8D96204507ABF9AAC9C782351BFAE46" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_06827FCD92A4CC282C6A782351BF0196_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_06827FCD92A4CC282C6A782351BF0196" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Biogen Inc.</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_06827FCD92A4CC282C6A782351BF0196" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_06827FCD92A4CC282C6A782351BF0196" xlink:to="lab_us-gaap_NetIncomeLoss_06827FCD92A4CC282C6A782351BF0196" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_2FD6FCA6C2B1734BD98C782351BFAC7D_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_2FD6FCA6C2B1734BD98C782351BFAC7D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_2FD6FCA6C2B1734BD98C782351BFAC7D_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_2FD6FCA6C2B1734BD98C782351BFAC7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2FD6FCA6C2B1734BD98C782351BFAC7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2FD6FCA6C2B1734BD98C782351BFAC7D" xlink:to="lab_us-gaap_EarningsPerShareAbstract_2FD6FCA6C2B1734BD98C782351BFAC7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_B35909B023B63AA7659D782351C06F6A_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_B35909B023B63AA7659D782351C06F6A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_B35909B023B63AA7659D782351C06F6A_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_B35909B023B63AA7659D782351C06F6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_B35909B023B63AA7659D782351C06F6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_B35909B023B63AA7659D782351C06F6A" xlink:to="lab_us-gaap_EarningsPerShareBasic_B35909B023B63AA7659D782351C06F6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_45331465592B24886E17782351C0E537_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_45331465592B24886E17782351C0E537" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_45331465592B24886E17782351C0E537_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_45331465592B24886E17782351C0E537" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_45331465592B24886E17782351C0E537" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_45331465592B24886E17782351C0E537" xlink:to="lab_us-gaap_EarningsPerShareDiluted_45331465592B24886E17782351C0E537" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_A0F7F9153381515DDD96782351C0CE2E_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_A0F7F9153381515DDD96782351C0CE2E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares used in calculating:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_A0F7F9153381515DDD96782351C0CE2E_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_A0F7F9153381515DDD96782351C0CE2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_A0F7F9153381515DDD96782351C0CE2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_A0F7F9153381515DDD96782351C0CE2E" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_A0F7F9153381515DDD96782351C0CE2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_75D07FEA05A8F57890CD782351C0BD1C_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_75D07FEA05A8F57890CD782351C0BD1C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_75D07FEA05A8F57890CD782351C0BD1C_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_75D07FEA05A8F57890CD782351C0BD1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_75D07FEA05A8F57890CD782351C0BD1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_75D07FEA05A8F57890CD782351C0BD1C" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_75D07FEA05A8F57890CD782351C0BD1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4BF884A55F84239CAC68782351C1EDBB_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4BF884A55F84239CAC68782351C1EDBB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4BF884A55F84239CAC68782351C1EDBB_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4BF884A55F84239CAC68782351C1EDBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4BF884A55F84239CAC68782351C1EDBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4BF884A55F84239CAC68782351C1EDBB" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4BF884A55F84239CAC68782351C1EDBB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_9707417C11BDE773991078234E0CBD2F_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_9707417C11BDE773991078234E0CBD2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9707417C11BDE773991078234E0CBD2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9707417C11BDE773991078234E0CBD2F" xlink:to="lab_us-gaap_DebtDisclosureAbstract_9707417C11BDE773991078234E0CBD2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_67B5BDACFA1063C6D64078234E0CEA13_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_67B5BDACFA1063C6D64078234E0CEA13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indebtedness</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_67B5BDACFA1063C6D64078234E0CEA13_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_67B5BDACFA1063C6D64078234E0CEA13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_67B5BDACFA1063C6D64078234E0CEA13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_67B5BDACFA1063C6D64078234E0CEA13" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_67B5BDACFA1063C6D64078234E0CEA13" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4E48D7375C0FDF551CED78234EF01EF1_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4E48D7375C0FDF551CED78234EF01EF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4E48D7375C0FDF551CED78234EF01EF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4E48D7375C0FDF551CED78234EF01EF1" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4E48D7375C0FDF551CED78234EF01EF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_29F56403887E2934EA2678234EF06348_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_29F56403887E2934EA2678234EF06348" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_29F56403887E2934EA2678234EF06348_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_29F56403887E2934EA2678234EF06348" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_29F56403887E2934EA2678234EF06348" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_29F56403887E2934EA2678234EF06348" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_29F56403887E2934EA2678234EF06348" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_90CB2D39EB17E89EFDC278234D24F740_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_90CB2D39EB17E89EFDC278234D24F740" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_90CB2D39EB17E89EFDC278234D24F740" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_90CB2D39EB17E89EFDC278234D24F740" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_90CB2D39EB17E89EFDC278234D24F740" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_01B379D89DD883328B7C78234D25907C_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_01B379D89DD883328B7C78234D25907C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_01B379D89DD883328B7C78234D25907C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_01B379D89DD883328B7C78234D25907C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_01B379D89DD883328B7C78234D25907C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_01B379D89DD883328B7C78234D25907C" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_01B379D89DD883328B7C78234D25907C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_F3BEE401098A7E1096BA7823510FF9D5_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_F3BEE401098A7E1096BA7823510FF9D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_F3BEE401098A7E1096BA7823510FF9D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_F3BEE401098A7E1096BA7823510FF9D5" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_F3BEE401098A7E1096BA7823510FF9D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_338501976D66E4F5EF7C7823510FC68B_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_338501976D66E4F5EF7C7823510FC68B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of significant accounting policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_338501976D66E4F5EF7C7823510FC68B_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_338501976D66E4F5EF7C7823510FC68B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_338501976D66E4F5EF7C7823510FC68B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_338501976D66E4F5EF7C7823510FC68B" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_338501976D66E4F5EF7C7823510FC68B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_930E9605B14ECB910CE178234C5BCFE3_label_en-US" xlink:label="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_930E9605B14ECB910CE178234C5BCFE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Information about Litigation Matters [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_930E9605B14ECB910CE178234C5BCFE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_930E9605B14ECB910CE178234C5BCFE3" xlink:to="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_930E9605B14ECB910CE178234C5BCFE3" xlink:type="arc" />
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_317F34B4F6B4BC84003878234C5BBC61_verboseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock_317F34B4F6B4BC84003878234C5BBC61" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Litigation</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_317F34B4F6B4BC84003878234C5BBC61_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock_317F34B4F6B4BC84003878234C5BBC61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_317F34B4F6B4BC84003878234C5BBC61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock_317F34B4F6B4BC84003878234C5BBC61" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock_317F34B4F6B4BC84003878234C5BBC61" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_3F883ABE5707A59DE6D378234F7EB961_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_3F883ABE5707A59DE6D378234F7EB961" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_3F883ABE5707A59DE6D378234F7EB961_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_3F883ABE5707A59DE6D378234F7EB961" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_3F883ABE5707A59DE6D378234F7EB961" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_3F883ABE5707A59DE6D378234F7EB961" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_3F883ABE5707A59DE6D378234F7EB961" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_BAB4FB9F3B9DD2C7326178234D503CCD_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_BAB4FB9F3B9DD2C7326178234D503CCD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_BAB4FB9F3B9DD2C7326178234D503CCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_BAB4FB9F3B9DD2C7326178234D503CCD" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_BAB4FB9F3B9DD2C7326178234D503CCD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_8892E209DF91916A77C678234D502410_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_8892E209DF91916A77C678234D502410" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense included in condensed consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_8892E209DF91916A77C678234D502410_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_8892E209DF91916A77C678234D502410" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_8892E209DF91916A77C678234D502410" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_8892E209DF91916A77C678234D502410" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_8892E209DF91916A77C678234D502410" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_6233C8A203AA926BC97778234D50377B_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_6233C8A203AA926BC97778234D50377B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of share-based compensation expense associated with each of our share-based compensating programs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_6233C8A203AA926BC97778234D50377B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_6233C8A203AA926BC97778234D50377B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_6233C8A203AA926BC97778234D50377B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_6233C8A203AA926BC97778234D50377B" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_6233C8A203AA926BC97778234D50377B" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_341E8763CA32403B176D78234FCE4391_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_341E8763CA32403B176D78234FCE4391" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_341E8763CA32403B176D78234FCE4391" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_341E8763CA32403B176D78234FCE4391" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_341E8763CA32403B176D78234FCE4391" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_30B2AF81B9702A356FD378234FCEAC7A_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_30B2AF81B9702A356FD378234FCEAC7A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_30B2AF81B9702A356FD378234FCEAC7A_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_30B2AF81B9702A356FD378234FCEAC7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_30B2AF81B9702A356FD378234FCEAC7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_30B2AF81B9702A356FD378234FCEAC7A" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_30B2AF81B9702A356FD378234FCEAC7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_807E52666951E24B9A34782350F4A15D_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract_807E52666951E24B9A34782350F4A15D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_807E52666951E24B9A34782350F4A15D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_807E52666951E24B9A34782350F4A15D" xlink:to="lab_us-gaap_BusinessCombinationsAbstract_807E52666951E24B9A34782350F4A15D" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_1B2BA1B59F0962405792782350F4E5D7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_1B2BA1B59F0962405792782350F4E5D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_1B2BA1B59F0962405792782350F4E5D7_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_1B2BA1B59F0962405792782350F4E5D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_1B2BA1B59F0962405792782350F4E5D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock_1B2BA1B59F0962405792782350F4E5D7" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock_1B2BA1B59F0962405792782350F4E5D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_E549CF5C9FCEC212B4BF782350868FEA_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract_E549CF5C9FCEC212B4BF782350868FEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_E549CF5C9FCEC212B4BF782350868FEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_E549CF5C9FCEC212B4BF782350868FEA" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract_E549CF5C9FCEC212B4BF782350868FEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_75E3D1DBCA5876F2506478235086F10E_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_75E3D1DBCA5876F2506478235086F10E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues by product</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_75E3D1DBCA5876F2506478235086F10E_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_75E3D1DBCA5876F2506478235086F10E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_75E3D1DBCA5876F2506478235086F10E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_75E3D1DBCA5876F2506478235086F10E" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_75E3D1DBCA5876F2506478235086F10E" xlink:type="arc" />
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_AFBB626BB4E8118BDD0778235087F64D_terseLabel_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_AFBB626BB4E8118BDD0778235087F64D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Analysis of change In reserves</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_AFBB626BB4E8118BDD0778235087F64D_label_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_AFBB626BB4E8118BDD0778235087F64D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis Of Amount Of And Change In Product Revenue Reserves [Table Text Block]</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_AFBB626BB4E8118BDD0778235087F64D_documentation_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_AFBB626BB4E8118BDD0778235087F64D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Analysis of amount of and change in product revenue reserves.</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_AFBB626BB4E8118BDD0778235087F64D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_AFBB626BB4E8118BDD0778235087F64D" xlink:to="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_AFBB626BB4E8118BDD0778235087F64D" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_327A1EF69E63F79E33CA7823508C43BC_terseLabel_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_327A1EF69E63F79E33CA7823508C43BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total reserves included in consolidated balance sheets</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_327A1EF69E63F79E33CA7823508C43BC_label_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_327A1EF69E63F79E33CA7823508C43BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_327A1EF69E63F79E33CA7823508C43BC_documentation_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_327A1EF69E63F79E33CA7823508C43BC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of total product revenue reserves included in consolidated balance sheets.</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_327A1EF69E63F79E33CA7823508C43BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_327A1EF69E63F79E33CA7823508C43BC" xlink:to="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_327A1EF69E63F79E33CA7823508C43BC" xlink:type="arc" />
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_C1BB71816307650128267823508DCC26_terseLabel_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_C1BB71816307650128267823508DCC26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_C1BB71816307650128267823508DCC26_label_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_C1BB71816307650128267823508DCC26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs [Table Text Block]</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_C1BB71816307650128267823508DCC26_documentation_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_C1BB71816307650128267823508DCC26" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_C1BB71816307650128267823508DCC26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_C1BB71816307650128267823508DCC26" xlink:to="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_C1BB71816307650128267823508DCC26" xlink:type="arc" />
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_38DA6AFDA464AA64ECF07823508EE42F_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock_38DA6AFDA464AA64ECF07823508EE42F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_38DA6AFDA464AA64ECF07823508EE42F_label_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock_38DA6AFDA464AA64ECF07823508EE42F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other revenues [Table Text Block]</link:label>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_38DA6AFDA464AA64ECF07823508EE42F_documentation_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock_38DA6AFDA464AA64ECF07823508EE42F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other revenues [Table Text Block]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_OtherrevenuesTableTextBlock" xlink:label="loc_biib_OtherrevenuesTableTextBlock_38DA6AFDA464AA64ECF07823508EE42F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesTableTextBlock_38DA6AFDA464AA64ECF07823508EE42F" xlink:to="lab_biib_OtherrevenuesTableTextBlock_38DA6AFDA464AA64ECF07823508EE42F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8E632113CFFBF9ABC97F78234CE66EC1_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8E632113CFFBF9ABC97F78234CE66EC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8E632113CFFBF9ABC97F78234CE66EC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8E632113CFFBF9ABC97F78234CE66EC1" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8E632113CFFBF9ABC97F78234CE66EC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_5BE35B3A7543A832D0D678234CE7EF1A_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_5BE35B3A7543A832D0D678234CE7EF1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_5BE35B3A7543A832D0D678234CE7EF1A_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_5BE35B3A7543A832D0D678234CE7EF1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_5BE35B3A7543A832D0D678234CE7EF1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5BE35B3A7543A832D0D678234CE7EF1A" xlink:to="lab_us-gaap_BalanceSheetLocationAxis_5BE35B3A7543A832D0D678234CE7EF1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_D118C2B9585E4622591E78234CE75513_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_D118C2B9585E4622591E78234CE75513" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_D118C2B9585E4622591E78234CE75513_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_D118C2B9585E4622591E78234CE75513" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_D118C2B9585E4622591E78234CE75513" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_D118C2B9585E4622591E78234CE75513" xlink:to="lab_us-gaap_BalanceSheetLocationDomain_D118C2B9585E4622591E78234CE75513" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_66676AEEA5CA8F1B810278234CE86EC0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember_66676AEEA5CA8F1B810278234CE86EC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Component of accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_66676AEEA5CA8F1B810278234CE86EC0_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember_66676AEEA5CA8F1B810278234CE86EC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_66676AEEA5CA8F1B810278234CE86EC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember_66676AEEA5CA8F1B810278234CE86EC0" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember_66676AEEA5CA8F1B810278234CE86EC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestIncomeExpenseNetAbstract_DD0DFE036B385F1C6B2E78234CEAA3E5_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNetAbstract_DD0DFE036B385F1C6B2E78234CEAA3E5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other Income (Expense), Net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNetAbstract_DD0DFE036B385F1C6B2E78234CEAA3E5_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNetAbstract_DD0DFE036B385F1C6B2E78234CEAA3E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNetAbstract" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract_DD0DFE036B385F1C6B2E78234CEAA3E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_DD0DFE036B385F1C6B2E78234CEAA3E5" xlink:to="lab_us-gaap_InterestIncomeExpenseNetAbstract_DD0DFE036B385F1C6B2E78234CEAA3E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_41C0206D56DB05475D1C78234CEB8C74_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_41C0206D56DB05475D1C78234CEB8C74" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_41C0206D56DB05475D1C78234CEB8C74_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_41C0206D56DB05475D1C78234CEB8C74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_41C0206D56DB05475D1C78234CEB8C74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest_41C0206D56DB05475D1C78234CEB8C74" xlink:to="lab_us-gaap_InvestmentIncomeInterest_41C0206D56DB05475D1C78234CEB8C74" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_DD863616504D48D5792478234CEC46A7_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_DD863616504D48D5792478234CEC46A7" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_DD863616504D48D5792478234CEC46A7_label_en-US" xlink:label="lab_us-gaap_InterestExpense_DD863616504D48D5792478234CEC46A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_DD863616504D48D5792478234CEC46A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_DD863616504D48D5792478234CEC46A7" xlink:to="lab_us-gaap_InterestExpense_DD863616504D48D5792478234CEC46A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_340764E378C2AEDEEC3778234CECC5A6_terseLabel_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses_340764E378C2AEDEEC3778234CECC5A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on investments, net</link:label>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_340764E378C2AEDEEC3778234CECC5A6_label_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses_340764E378C2AEDEEC3778234CECC5A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_340764E378C2AEDEEC3778234CECC5A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedInvestmentGainsLosses_340764E378C2AEDEEC3778234CECC5A6" xlink:to="lab_us-gaap_RealizedInvestmentGainsLosses_340764E378C2AEDEEC3778234CECC5A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_9E4F2186018167C0241978234CECBC46_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_9E4F2186018167C0241978234CECBC46" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange gains (losses), net</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_9E4F2186018167C0241978234CECBC46_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_9E4F2186018167C0241978234CECBC46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_9E4F2186018167C0241978234CECBC46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_9E4F2186018167C0241978234CECBC46" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_9E4F2186018167C0241978234CECBC46" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_65D8C945D6BBAE67DBEA78234CEE7232_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_65D8C945D6BBAE67DBEA78234CEE7232" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_65D8C945D6BBAE67DBEA78234CEE7232_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_65D8C945D6BBAE67DBEA78234CEE7232" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_65D8C945D6BBAE67DBEA78234CEE7232" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_65D8C945D6BBAE67DBEA78234CEE7232" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_65D8C945D6BBAE67DBEA78234CEE7232" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_4BD484B679224FC5472B78234CEF6653_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_4BD484B679224FC5472B78234CEF6653" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_4BD484B679224FC5472B78234CEF6653" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_4BD484B679224FC5472B78234CEF6653" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_4BD484B679224FC5472B78234CEF6653" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_C20A9056D54F754A165D78234CF09805_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_C20A9056D54F754A165D78234CF09805" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_C20A9056D54F754A165D78234CF09805_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_C20A9056D54F754A165D78234CF09805" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_C20A9056D54F754A165D78234CF09805" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_C20A9056D54F754A165D78234CF09805" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_C20A9056D54F754A165D78234CF09805" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_CE7BD12DF1724900D2E678234CF0E5D9_totalLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss_CE7BD12DF1724900D2E678234CF0E5D9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net gains (losses) recognized during the period on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_CE7BD12DF1724900D2E678234CF0E5D9_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss_CE7BD12DF1724900D2E678234CF0E5D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_CE7BD12DF1724900D2E678234CF0E5D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_CE7BD12DF1724900D2E678234CF0E5D9" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss_CE7BD12DF1724900D2E678234CF0E5D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_E540AB46A6C60966F82078234CF11B57_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_E540AB46A6C60966F82078234CF11B57" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Less: Net gains (losses) recognized during the period on equity securities sold during the period</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_E540AB46A6C60966F82078234CF11B57_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_E540AB46A6C60966F82078234CF11B57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Realized Gain (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_E540AB46A6C60966F82078234CF11B57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_E540AB46A6C60966F82078234CF11B57" xlink:to="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_E540AB46A6C60966F82078234CF11B57" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_460A1F3C5D3EC69CD19878234CF1FF89_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_460A1F3C5D3EC69CD19878234CF1FF89" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) recognized during the period on equity securities held as of March 31</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_460A1F3C5D3EC69CD19878234CF1FF89_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_460A1F3C5D3EC69CD19878234CF1FF89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_460A1F3C5D3EC69CD19878234CF1FF89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_460A1F3C5D3EC69CD19878234CF1FF89" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_460A1F3C5D3EC69CD19878234CF1FF89" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_822D33418862F6A9FA7678234CF1DFC1_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_822D33418862F6A9FA7678234CF1DFC1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses and Other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_822D33418862F6A9FA7678234CF1DFC1_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_822D33418862F6A9FA7678234CF1DFC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_822D33418862F6A9FA7678234CF1DFC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_822D33418862F6A9FA7678234CF1DFC1" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_822D33418862F6A9FA7678234CF1DFC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_2887B6F88BEDC6DEDFE678234CF2A76D_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_2887B6F88BEDC6DEDFE678234CF2A76D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue-related reserves for discounts and allowances</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_2887B6F88BEDC6DEDFE678234CF2A76D_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_2887B6F88BEDC6DEDFE678234CF2A76D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_2887B6F88BEDC6DEDFE678234CF2A76D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_2887B6F88BEDC6DEDFE678234CF2A76D" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_2887B6F88BEDC6DEDFE678234CF2A76D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_0255E377799022974A7478234CF20D60_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_0255E377799022974A7478234CF20D60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_0255E377799022974A7478234CF20D60_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_0255E377799022974A7478234CF20D60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0255E377799022974A7478234CF20D60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0255E377799022974A7478234CF20D60" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_0255E377799022974A7478234CF20D60" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_8925F88E77E67D6771BF78234CF2E849_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent_8925F88E77E67D6771BF78234CF2E849" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Royalties and licensing fees</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_8925F88E77E67D6771BF78234CF2E849_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent_8925F88E77E67D6771BF78234CF2E849" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_8925F88E77E67D6771BF78234CF2E849" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent_8925F88E77E67D6771BF78234CF2E849" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent_8925F88E77E67D6771BF78234CF2E849" xlink:type="arc" />
    <link:label id="lab_biib_Collaborationexpensesaccrual_C546C5BB7969E53D941378234CF290DA_terseLabel_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual_C546C5BB7969E53D941378234CF290DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration expenses</link:label>
    <link:label id="lab_biib_Collaborationexpensesaccrual_C546C5BB7969E53D941378234CF290DA_label_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual_C546C5BB7969E53D941378234CF290DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:label id="lab_biib_Collaborationexpensesaccrual_C546C5BB7969E53D941378234CF290DA_documentation_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual_C546C5BB7969E53D941378234CF290DA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_Collaborationexpensesaccrual" xlink:label="loc_biib_Collaborationexpensesaccrual_C546C5BB7969E53D941378234CF290DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Collaborationexpensesaccrual_C546C5BB7969E53D941378234CF290DA" xlink:to="lab_biib_Collaborationexpensesaccrual_C546C5BB7969E53D941378234CF290DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_A719830B76016C07173278234CF32A49_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_A719830B76016C07173278234CF32A49" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion of contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_A719830B76016C07173278234CF32A49_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_A719830B76016C07173278234CF32A49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_A719830B76016C07173278234CF32A49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_A719830B76016C07173278234CF32A49" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_A719830B76016C07173278234CF32A49" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_B5B7BC890E754E60528F78234CF39324_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_B5B7BC890E754E60528F78234CF39324" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_B5B7BC890E754E60528F78234CF39324_label_en-US" xlink:label="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_B5B7BC890E754E60528F78234CF39324" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_B5B7BC890E754E60528F78234CF39324" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_B5B7BC890E754E60528F78234CF39324" xlink:to="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_B5B7BC890E754E60528F78234CF39324" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_73283EE3101F6F9B48EF78234CF3E589_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_73283EE3101F6F9B48EF78234CF3E589" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_73283EE3101F6F9B48EF78234CF3E589_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_73283EE3101F6F9B48EF78234CF3E589" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_73283EE3101F6F9B48EF78234CF3E589" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_73283EE3101F6F9B48EF78234CF3E589" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_73283EE3101F6F9B48EF78234CF3E589" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_A208644AF3451F172EC678234CF41C15_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_A208644AF3451F172EC678234CF41C15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_A208644AF3451F172EC678234CF41C15_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_A208644AF3451F172EC678234CF41C15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_A208644AF3451F172EC678234CF41C15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_A208644AF3451F172EC678234CF41C15" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_A208644AF3451F172EC678234CF41C15" xlink:type="arc" />
    <link:label id="lab_biib_OtherrevenuesAbstract_FDBF1A42E2E6085BCEAE782350288CDF_label_en-US" xlink:label="lab_biib_OtherrevenuesAbstract_FDBF1A42E2E6085BCEAE782350288CDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other revenues [Abstract]</link:label>
    <link:label id="lab_biib_OtherrevenuesAbstract_FDBF1A42E2E6085BCEAE782350288CDF_documentation_en-US" xlink:label="lab_biib_OtherrevenuesAbstract_FDBF1A42E2E6085BCEAE782350288CDF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other revenues [Abstract]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_OtherrevenuesAbstract" xlink:label="loc_biib_OtherrevenuesAbstract_FDBF1A42E2E6085BCEAE782350288CDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesAbstract_FDBF1A42E2E6085BCEAE782350288CDF" xlink:to="lab_biib_OtherrevenuesAbstract_FDBF1A42E2E6085BCEAE782350288CDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_28B8386985FAD0DA238478235029E5A9_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_28B8386985FAD0DA238478235029E5A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_28B8386985FAD0DA238478235029E5A9_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_28B8386985FAD0DA238478235029E5A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_28B8386985FAD0DA238478235029E5A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_28B8386985FAD0DA238478235029E5A9" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable_28B8386985FAD0DA238478235029E5A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_D8CA6503431DE986B07B782350292A89_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_D8CA6503431DE986B07B782350292A89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_D8CA6503431DE986B07B782350292A89_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_D8CA6503431DE986B07B782350292A89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_D8CA6503431DE986B07B782350292A89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_D8CA6503431DE986B07B782350292A89" xlink:to="lab_us-gaap_TypeOfArrangementAxis_D8CA6503431DE986B07B782350292A89" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_31DC80AD822E969A71C77823502A1F71_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_31DC80AD822E969A71C77823502A1F71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_31DC80AD822E969A71C77823502A1F71_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_31DC80AD822E969A71C77823502A1F71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_31DC80AD822E969A71C77823502A1F71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_31DC80AD822E969A71C77823502A1F71" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_31DC80AD822E969A71C77823502A1F71" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_ECA4F02275ECB21553E67823502A8BD7_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember_ECA4F02275ECB21553E67823502A8BD7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_ECA4F02275ECB21553E67823502A8BD7_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember_ECA4F02275ECB21553E67823502A8BD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_ECA4F02275ECB21553E67823502A8BD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember_ECA4F02275ECB21553E67823502A8BD7" xlink:to="lab_us-gaap_CollaborativeArrangementMember_ECA4F02275ECB21553E67823502A8BD7" xlink:type="arc" />
    <link:label id="lab_us-gaap_RoyaltyMember_BA0F6590ABB8A62B8E107823502B3870_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember_BA0F6590ABB8A62B8E107823502B3870" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_BA0F6590ABB8A62B8E107823502B3870_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember_BA0F6590ABB8A62B8E107823502B3870" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember_BA0F6590ABB8A62B8E107823502B3870" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember_BA0F6590ABB8A62B8E107823502B3870" xlink:to="lab_us-gaap_RoyaltyMember_BA0F6590ABB8A62B8E107823502B3870" xlink:type="arc" />
    <link:label id="lab_biib_OthercorporaterevenuesMember_621334D71008C57687477823502C5451_terseLabel_en-US" xlink:label="lab_biib_OthercorporaterevenuesMember_621334D71008C57687477823502C5451" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other corporate revenues</link:label>
    <link:label id="lab_biib_OthercorporaterevenuesMember_621334D71008C57687477823502C5451_label_en-US" xlink:label="lab_biib_OthercorporaterevenuesMember_621334D71008C57687477823502C5451" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other corporate revenues [Member]</link:label>
    <link:label id="lab_biib_OthercorporaterevenuesMember_621334D71008C57687477823502C5451_documentation_en-US" xlink:label="lab_biib_OthercorporaterevenuesMember_621334D71008C57687477823502C5451" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other corporate revenues [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_OthercorporaterevenuesMember" xlink:label="loc_biib_OthercorporaterevenuesMember_621334D71008C57687477823502C5451" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OthercorporaterevenuesMember_621334D71008C57687477823502C5451" xlink:to="lab_biib_OthercorporaterevenuesMember_621334D71008C57687477823502C5451" xlink:type="arc" />
    <link:label id="lab_srt_MajorCustomersAxis_0708F5E7A0D134B950B078235031763F_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis_0708F5E7A0D134B950B078235031763F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_0708F5E7A0D134B950B078235031763F_label_en-US" xlink:label="lab_srt_MajorCustomersAxis_0708F5E7A0D134B950B078235031763F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_0708F5E7A0D134B950B078235031763F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis_0708F5E7A0D134B950B078235031763F" xlink:to="lab_srt_MajorCustomersAxis_0708F5E7A0D134B950B078235031763F" xlink:type="arc" />
    <link:label id="lab_srt_NameOfMajorCustomerDomain_E6D6F82A747FD65565AC78235032076B_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain_E6D6F82A747FD65565AC78235032076B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_E6D6F82A747FD65565AC78235032076B_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain_E6D6F82A747FD65565AC78235032076B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_E6D6F82A747FD65565AC78235032076B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain_E6D6F82A747FD65565AC78235032076B" xlink:to="lab_srt_NameOfMajorCustomerDomain_E6D6F82A747FD65565AC78235032076B" xlink:type="arc" />
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_EFB6461E842433B4785E78235032AD30_terseLabel_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember_EFB6461E842433B4785E78235032AD30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Samsung Bioepis</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_EFB6461E842433B4785E78235032AD30_label_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember_EFB6461E842433B4785E78235032AD30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Samsung Biosimilar Agreement [Member]</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_EFB6461E842433B4785E78235032AD30_documentation_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember_EFB6461E842433B4785E78235032AD30" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Samsung bio-similar agreement.</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_EFB6461E842433B4785E78235032AD30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SamsungBiosimilarAgreementMember_EFB6461E842433B4785E78235032AD30" xlink:to="lab_biib_SamsungBiosimilarAgreementMember_EFB6461E842433B4785E78235032AD30" xlink:type="arc" />
    <link:label id="lab_biib_ZINBRYTAMember_796B77B393CACEE2565E782350338616_terseLabel_en-US" xlink:label="lab_biib_ZINBRYTAMember_796B77B393CACEE2565E782350338616" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ZINBRYTA</link:label>
    <link:label id="lab_biib_ZINBRYTAMember_796B77B393CACEE2565E782350338616_label_en-US" xlink:label="lab_biib_ZINBRYTAMember_796B77B393CACEE2565E782350338616" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ZINBRYTA [Member]</link:label>
    <link:label id="lab_biib_ZINBRYTAMember_796B77B393CACEE2565E782350338616_documentation_en-US" xlink:label="lab_biib_ZINBRYTAMember_796B77B393CACEE2565E782350338616" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ZINBRYTA [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_796B77B393CACEE2565E782350338616" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ZINBRYTAMember_796B77B393CACEE2565E782350338616" xlink:to="lab_biib_ZINBRYTAMember_796B77B393CACEE2565E782350338616" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_D66EC254191DB1F3A03B782350336223_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_D66EC254191DB1F3A03B782350336223" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_D66EC254191DB1F3A03B782350336223_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_D66EC254191DB1F3A03B782350336223" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_D66EC254191DB1F3A03B782350336223" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_D66EC254191DB1F3A03B782350336223" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems_D66EC254191DB1F3A03B782350336223" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_D51FF14F8CA4C634F10278235033B78D_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation_D51FF14F8CA4C634F10278235033B78D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues related to amendment of contract manufacturing agreement</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_D51FF14F8CA4C634F10278235033B78D_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation_D51FF14F8CA4C634F10278235033B78D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_D51FF14F8CA4C634F10278235033B78D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation_D51FF14F8CA4C634F10278235033B78D" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation_D51FF14F8CA4C634F10278235033B78D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfReportableSegments_3ACF1D8EBF11EB57DE9D782350FC5477_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments_3ACF1D8EBF11EB57DE9D782350FC5477" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_3ACF1D8EBF11EB57DE9D782350FC5477_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments_3ACF1D8EBF11EB57DE9D782350FC5477" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_3ACF1D8EBF11EB57DE9D782350FC5477" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments_3ACF1D8EBF11EB57DE9D782350FC5477" xlink:to="lab_us-gaap_NumberOfReportableSegments_3ACF1D8EBF11EB57DE9D782350FC5477" xlink:type="arc" />
    <link:label id="lab_biib_InterestInSubsidiary_B8218AAFE0A8F8ABF34F782350FD4F54_verboseLabel_en-US" xlink:label="lab_biib_InterestInSubsidiary_B8218AAFE0A8F8ABF34F782350FD4F54" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest in subsidiary (less than given percentage)</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_B8218AAFE0A8F8ABF34F782350FD4F54_label_en-US" xlink:label="lab_biib_InterestInSubsidiary_B8218AAFE0A8F8ABF34F782350FD4F54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest In Subsidiary</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_B8218AAFE0A8F8ABF34F782350FD4F54_documentation_en-US" xlink:label="lab_biib_InterestInSubsidiary_B8218AAFE0A8F8ABF34F782350FD4F54" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest in subsidiary.</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_InterestInSubsidiary" xlink:label="loc_biib_InterestInSubsidiary_B8218AAFE0A8F8ABF34F782350FD4F54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InterestInSubsidiary_B8218AAFE0A8F8ABF34F782350FD4F54" xlink:to="lab_biib_InterestInSubsidiary_B8218AAFE0A8F8ABF34F782350FD4F54" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_1A307E81C79F5B99E706782350047949_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract_1A307E81C79F5B99E706782350047949" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_1A307E81C79F5B99E706782350047949" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_1A307E81C79F5B99E706782350047949" xlink:to="lab_us-gaap_InventoryDisclosureAbstract_1A307E81C79F5B99E706782350047949" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_E751B7C87997E50944F7782350045B71_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_E751B7C87997E50944F7782350045B71" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_E751B7C87997E50944F7782350045B71_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_E751B7C87997E50944F7782350045B71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_E751B7C87997E50944F7782350045B71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock_E751B7C87997E50944F7782350045B71" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock_E751B7C87997E50944F7782350045B71" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_854F12C4A2DEEE97D9C978234E548B73_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_854F12C4A2DEEE97D9C978234E548B73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_854F12C4A2DEEE97D9C978234E548B73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_854F12C4A2DEEE97D9C978234E548B73" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_854F12C4A2DEEE97D9C978234E548B73" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_D88347F2D9CA4E06511778234E54DF9A_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_D88347F2D9CA4E06511778234E54DF9A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency forward contracts that were entered into to hedge forecasted revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_D88347F2D9CA4E06511778234E54DF9A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_D88347F2D9CA4E06511778234E54DF9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_D88347F2D9CA4E06511778234E54DF9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_D88347F2D9CA4E06511778234E54DF9A" xlink:to="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_D88347F2D9CA4E06511778234E54DF9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_6D620C4A16ADF8E7AB4F78234E55C5E9_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_6D620C4A16ADF8E7AB4F78234E55C5E9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of the effect of cash flow derivatives designated as hedging instruments on the condensed consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_6D620C4A16ADF8E7AB4F78234E55C5E9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_6D620C4A16ADF8E7AB4F78234E55C5E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_6D620C4A16ADF8E7AB4F78234E55C5E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_6D620C4A16ADF8E7AB4F78234E55C5E9" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_6D620C4A16ADF8E7AB4F78234E55C5E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_7E7B29295D01B647077778234E55E690_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_7E7B29295D01B647077778234E55E690" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of the effect of derivatives designated as net investment hedging instruments on our consolidated statement of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_7E7B29295D01B647077778234E55E690_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_7E7B29295D01B647077778234E55E690" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_7E7B29295D01B647077778234E55E690" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_7E7B29295D01B647077778234E55E690" xlink:to="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_7E7B29295D01B647077778234E55E690" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_C7335B4421F76E7897A578234E555B2E_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_C7335B4421F76E7897A578234E555B2E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of fair value and presentation of derivatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_C7335B4421F76E7897A578234E555B2E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_C7335B4421F76E7897A578234E555B2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_C7335B4421F76E7897A578234E555B2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_C7335B4421F76E7897A578234E555B2E" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_C7335B4421F76E7897A578234E555B2E" xlink:type="arc" />
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_EA0FFEB40F81228833BA78234FC6ED5D_verboseLabel_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_EA0FFEB40F81228833BA78234FC6ED5D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_EA0FFEB40F81228833BA78234FC6ED5D_label_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_EA0FFEB40F81228833BA78234FC6ED5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Excluding Goodwill [Table Text Block]</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_EA0FFEB40F81228833BA78234FC6ED5D_documentation_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_EA0FFEB40F81228833BA78234FC6ED5D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible assets excluding goodwill.</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_EA0FFEB40F81228833BA78234FC6ED5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_EA0FFEB40F81228833BA78234FC6ED5D" xlink:to="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_EA0FFEB40F81228833BA78234FC6ED5D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_371914A28BE8215129C178234FC650AE_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_371914A28BE8215129C178234FC650AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated future amortization for acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_371914A28BE8215129C178234FC650AE_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_371914A28BE8215129C178234FC650AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_371914A28BE8215129C178234FC650AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_371914A28BE8215129C178234FC650AE" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_371914A28BE8215129C178234FC650AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_9F86257A78025A6BDB1E78234FC6C604_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock_9F86257A78025A6BDB1E78234FC6C604" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_9F86257A78025A6BDB1E78234FC6C604_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock_9F86257A78025A6BDB1E78234FC6C604" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_9F86257A78025A6BDB1E78234FC6C604" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock_9F86257A78025A6BDB1E78234FC6C604" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock_9F86257A78025A6BDB1E78234FC6C604" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_DC0D336648B0E8BE2CD278234D9FFC52_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_DC0D336648B0E8BE2CD278234D9FFC52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_DC0D336648B0E8BE2CD278234D9FFC52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_DC0D336648B0E8BE2CD278234D9FFC52" xlink:to="lab_us-gaap_EquityAbstract_DC0D336648B0E8BE2CD278234D9FFC52" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_3859668CF719FB0B014578234D9F7275_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_3859668CF719FB0B014578234D9F7275" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_3859668CF719FB0B014578234D9F7275_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_3859668CF719FB0B014578234D9F7275" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_3859668CF719FB0B014578234D9F7275" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_3859668CF719FB0B014578234D9F7275" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_3859668CF719FB0B014578234D9F7275" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_14B8E5DD391D60CD579378234D9F7ED7_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_14B8E5DD391D60CD579378234D9F7ED7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_14B8E5DD391D60CD579378234D9F7ED7_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_14B8E5DD391D60CD579378234D9F7ED7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_14B8E5DD391D60CD579378234D9F7ED7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_14B8E5DD391D60CD579378234D9F7ED7" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_14B8E5DD391D60CD579378234D9F7ED7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_65739D734A43FDD24796782350A33436_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_65739D734A43FDD24796782350A33436" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_65739D734A43FDD24796782350A33436_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_65739D734A43FDD24796782350A33436" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_65739D734A43FDD24796782350A33436" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_65739D734A43FDD24796782350A33436" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_65739D734A43FDD24796782350A33436" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D43061457114C409FF28782350A3C506_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D43061457114C409FF28782350A3C506" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D43061457114C409FF28782350A3C506_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D43061457114C409FF28782350A3C506" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D43061457114C409FF28782350A3C506" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D43061457114C409FF28782350A3C506" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D43061457114C409FF28782350A3C506" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_BB6B829598C67C0A880C782350A4A46A_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_BB6B829598C67C0A880C782350A4A46A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_BB6B829598C67C0A880C782350A4A46A_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_BB6B829598C67C0A880C782350A4A46A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_BB6B829598C67C0A880C782350A4A46A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_BB6B829598C67C0A880C782350A4A46A" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_BB6B829598C67C0A880C782350A4A46A" xlink:type="arc" />
    <link:label id="lab_biib_DenmarkManufacturingOperationsMember_77A729CD732C142313A3782350A47BAE_terseLabel_en-US" xlink:label="lab_biib_DenmarkManufacturingOperationsMember_77A729CD732C142313A3782350A47BAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denmark Manufacturing Operations</link:label>
    <link:label id="lab_biib_DenmarkManufacturingOperationsMember_77A729CD732C142313A3782350A47BAE_label_en-US" xlink:label="lab_biib_DenmarkManufacturingOperationsMember_77A729CD732C142313A3782350A47BAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Denmark Manufacturing Operations [Member]</link:label>
    <link:label id="lab_biib_DenmarkManufacturingOperationsMember_77A729CD732C142313A3782350A47BAE_documentation_en-US" xlink:label="lab_biib_DenmarkManufacturingOperationsMember_77A729CD732C142313A3782350A47BAE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Denmark Manufacturing Operations [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_77A729CD732C142313A3782350A47BAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DenmarkManufacturingOperationsMember_77A729CD732C142313A3782350A47BAE" xlink:to="lab_biib_DenmarkManufacturingOperationsMember_77A729CD732C142313A3782350A47BAE" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2C5D565175C079DE3348782350A48365_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2C5D565175C079DE3348782350A48365" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2C5D565175C079DE3348782350A48365_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2C5D565175C079DE3348782350A48365" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2C5D565175C079DE3348782350A48365" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2C5D565175C079DE3348782350A48365" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2C5D565175C079DE3348782350A48365" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_115500103370BE78FB89782350A4F560_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_115500103370BE78FB89782350A4F560" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration expected to be received for sale of Denmark Manufacturing Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_115500103370BE78FB89782350A4F560_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_115500103370BE78FB89782350A4F560" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_115500103370BE78FB89782350A4F560" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_115500103370BE78FB89782350A4F560" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_115500103370BE78FB89782350A4F560" xlink:type="arc" />
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_565615F0543F8E103D6F782350A5CDD2_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_565615F0543F8E103D6F782350A5CDD2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future minimum batch production for Denmark Manufacturing Operations</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_565615F0543F8E103D6F782350A5CDD2_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_565615F0543F8E103D6F782350A5CDD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Commitment, Remaining Minimum Amount Committed</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_565615F0543F8E103D6F782350A5CDD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_565615F0543F8E103D6F782350A5CDD2" xlink:to="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_565615F0543F8E103D6F782350A5CDD2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_9AA41B2DBC9B36B4FC20782350A5F5AD_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_9AA41B2DBC9B36B4FC20782350A5F5AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations, net of tax</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_9AA41B2DBC9B36B4FC20782350A5F5AD_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_9AA41B2DBC9B36B4FC20782350A5F5AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operation, Provision for Loss (Gain) on Disposal, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_9AA41B2DBC9B36B4FC20782350A5F5AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_9AA41B2DBC9B36B4FC20782350A5F5AD" xlink:to="lab_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_9AA41B2DBC9B36B4FC20782350A5F5AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_CC5D565ECC0C8BC6D941782350A591C7_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_CC5D565ECC0C8BC6D941782350A591C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected costs to sell disposal group</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_CC5D565ECC0C8BC6D941782350A591C7_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_CC5D565ECC0C8BC6D941782350A591C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_CC5D565ECC0C8BC6D941782350A591C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_CC5D565ECC0C8BC6D941782350A591C7" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_CC5D565ECC0C8BC6D941782350A591C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_CAFD1AC38717A6C45FBB782350A57C7C_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_CAFD1AC38717A6C45FBB782350A57C7C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax expense on disposal group</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_CAFD1AC38717A6C45FBB782350A57C7C_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_CAFD1AC38717A6C45FBB782350A57C7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operation, Tax Effect of Discontinued Operation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_CAFD1AC38717A6C45FBB782350A57C7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_CAFD1AC38717A6C45FBB782350A57C7C" xlink:to="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_CAFD1AC38717A6C45FBB782350A57C7C" xlink:type="arc" />
    <link:label id="lab_biib_InventoryrawmaterialssoldtoFUJIFILM_68FCC7A8209F6BFA967B782350A6B258_terseLabel_en-US" xlink:label="lab_biib_InventoryrawmaterialssoldtoFUJIFILM_68FCC7A8209F6BFA967B782350A6B258" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory raw materials sold to FUJIFILM</link:label>
    <link:label id="lab_biib_InventoryrawmaterialssoldtoFUJIFILM_68FCC7A8209F6BFA967B782350A6B258_label_en-US" xlink:label="lab_biib_InventoryrawmaterialssoldtoFUJIFILM_68FCC7A8209F6BFA967B782350A6B258" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory raw materials sold to FUJIFILM</link:label>
    <link:label id="lab_biib_InventoryrawmaterialssoldtoFUJIFILM_68FCC7A8209F6BFA967B782350A6B258_documentation_en-US" xlink:label="lab_biib_InventoryrawmaterialssoldtoFUJIFILM_68FCC7A8209F6BFA967B782350A6B258" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory raw materials sold to FUJIFILM</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_InventoryrawmaterialssoldtoFUJIFILM" xlink:label="loc_biib_InventoryrawmaterialssoldtoFUJIFILM_68FCC7A8209F6BFA967B782350A6B258" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InventoryrawmaterialssoldtoFUJIFILM_68FCC7A8209F6BFA967B782350A6B258" xlink:to="lab_biib_InventoryrawmaterialssoldtoFUJIFILM_68FCC7A8209F6BFA967B782350A6B258" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_D652FF9ACC36CE31892478234F2BA48B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_D652FF9ACC36CE31892478234F2BA48B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_D652FF9ACC36CE31892478234F2BA48B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_D652FF9ACC36CE31892478234F2BA48B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_D652FF9ACC36CE31892478234F2BA48B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_D652FF9ACC36CE31892478234F2BA48B" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_D652FF9ACC36CE31892478234F2BA48B" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_691265934CDFF8A3E30878234F32D7F8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_691265934CDFF8A3E30878234F32D7F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_691265934CDFF8A3E30878234F32D7F8_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_691265934CDFF8A3E30878234F32D7F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_691265934CDFF8A3E30878234F32D7F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_691265934CDFF8A3E30878234F32D7F8" xlink:to="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_691265934CDFF8A3E30878234F32D7F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_A5D2C603FA1924B039A078234F32AD0D_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_A5D2C603FA1924B039A078234F32AD0D" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Fair value, beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_A5D2C603FA1924B039A078234F32AD0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_A5D2C603FA1924B039A078234F32AD0D" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_A5D2C603FA1924B039A078234F32AD0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_28D409A2DAF6AF427A4978234F334EC4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_28D409A2DAF6AF427A4978234F334EC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration impairment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_28D409A2DAF6AF427A4978234F334EC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_28D409A2DAF6AF427A4978234F334EC4" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_28D409A2DAF6AF427A4978234F334EC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_29D09EB0C614C34FA9A578234F33F969_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_29D09EB0C614C34FA9A578234F33F969" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_29D09EB0C614C34FA9A578234F33F969_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_29D09EB0C614C34FA9A578234F33F969" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_29D09EB0C614C34FA9A578234F33F969" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_29D09EB0C614C34FA9A578234F33F969" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_29D09EB0C614C34FA9A578234F33F969" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_6C2B3C3CA7723FB47A9178234F3350C4_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_6C2B3C3CA7723FB47A9178234F3350C4" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Fair value, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6C2B3C3CA7723FB47A9178234F3350C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6C2B3C3CA7723FB47A9178234F3350C4" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_6C2B3C3CA7723FB47A9178234F3350C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_6727B3AC6D6C03124973782351679914_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_6727B3AC6D6C03124973782351679914" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_6727B3AC6D6C03124973782351679914" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6727B3AC6D6C03124973782351679914" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_6727B3AC6D6C03124973782351679914" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CD9285F42E8EC36AEF22782351677FC9_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CD9285F42E8EC36AEF22782351677FC9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CD9285F42E8EC36AEF22782351677FC9_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CD9285F42E8EC36AEF22782351677FC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CD9285F42E8EC36AEF22782351677FC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CD9285F42E8EC36AEF22782351677FC9" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CD9285F42E8EC36AEF22782351677FC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_1665B328D4CA7089FBE57823516865EC_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_1665B328D4CA7089FBE57823516865EC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_1665B328D4CA7089FBE57823516865EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_1665B328D4CA7089FBE57823516865EC" xlink:to="lab_us-gaap_ProfitLoss_1665B328D4CA7089FBE57823516865EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C6A8341087E9C433E55978235168C2A7_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C6A8341087E9C433E55978235168C2A7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income to net cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C6A8341087E9C433E55978235168C2A7_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C6A8341087E9C433E55978235168C2A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C6A8341087E9C433E55978235168C2A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C6A8341087E9C433E55978235168C2A7" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C6A8341087E9C433E55978235168C2A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_6E3F0604724C218A644378235168504C_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_6E3F0604724C218A644378235168504C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation, amortization and impairments</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_6E3F0604724C218A644378235168504C_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_6E3F0604724C218A644378235168504C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_6E3F0604724C218A644378235168504C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_6E3F0604724C218A644378235168504C" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_6E3F0604724C218A644378235168504C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_D175F5EAA4B7AFD247DD78235169D7D9_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_D175F5EAA4B7AFD247DD78235169D7D9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_D175F5EAA4B7AFD247DD78235169D7D9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_D175F5EAA4B7AFD247DD78235169D7D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_D175F5EAA4B7AFD247DD78235169D7D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_D175F5EAA4B7AFD247DD78235169D7D9" xlink:to="lab_us-gaap_ShareBasedCompensation_D175F5EAA4B7AFD247DD78235169D7D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_8B427F967E47596BA45378235169BE6A_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_8B427F967E47596BA45378235169BE6A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gain on interest rate swap</link:label>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_8B427F967E47596BA45378235169BE6A_label_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_8B427F967E47596BA45378235169BE6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Derivative Instruments, Net, Pretax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_8B427F967E47596BA45378235169BE6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_8B427F967E47596BA45378235169BE6A" xlink:to="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_8B427F967E47596BA45378235169BE6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_255D526364A6D28D7FC178235169FEA5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_255D526364A6D28D7FC178235169FEA5" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_255D526364A6D28D7FC178235169FEA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_255D526364A6D28D7FC178235169FEA5" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_255D526364A6D28D7FC178235169FEA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_E86856C2BD3F3C4A3AB87823516AE854_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_E86856C2BD3F3C4A3AB87823516AE854" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_E86856C2BD3F3C4A3AB87823516AE854_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_E86856C2BD3F3C4A3AB87823516AE854" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Individually Significant Component Disposed of or Held-for-sale, Excluding Discontinued Operations, Attributable to Parent, before Income Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax" xlink:label="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_E86856C2BD3F3C4A3AB87823516AE854" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_E86856C2BD3F3C4A3AB87823516AE854" xlink:to="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_E86856C2BD3F3C4A3AB87823516AE854" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_06E66123B12C7F63F3A97823516AF0CA_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_06E66123B12C7F63F3A97823516AF0CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_06E66123B12C7F63F3A97823516AF0CA_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_06E66123B12C7F63F3A97823516AF0CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_06E66123B12C7F63F3A97823516AF0CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_06E66123B12C7F63F3A97823516AF0CA" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_06E66123B12C7F63F3A97823516AF0CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_E53F0543F371312575F07823516A30E5_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_E53F0543F371312575F07823516A30E5" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unrealized (gain) loss on strategic investments</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_E53F0543F371312575F07823516A30E5_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_E53F0543F371312575F07823516A30E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Equity Securities, FV-NI</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_E53F0543F371312575F07823516A30E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_E53F0543F371312575F07823516A30E5" xlink:to="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_E53F0543F371312575F07823516A30E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_7F4CEA0B4DC401B628E77823516A9D9D_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_7F4CEA0B4DC401B628E77823516A9D9D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_7F4CEA0B4DC401B628E77823516A9D9D_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_7F4CEA0B4DC401B628E77823516A9D9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_7F4CEA0B4DC401B628E77823516A9D9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense_7F4CEA0B4DC401B628E77823516A9D9D" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense_7F4CEA0B4DC401B628E77823516A9D9D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_90D2C31860240D8F50FC7823516B119A_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_90D2C31860240D8F50FC7823516B119A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities, net:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_90D2C31860240D8F50FC7823516B119A_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_90D2C31860240D8F50FC7823516B119A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_90D2C31860240D8F50FC7823516B119A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_90D2C31860240D8F50FC7823516B119A" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_90D2C31860240D8F50FC7823516B119A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_37F41B5A11331F09C1307823516B3DCE_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_37F41B5A11331F09C1307823516B3DCE" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_37F41B5A11331F09C1307823516B3DCE_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_37F41B5A11331F09C1307823516B3DCE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_37F41B5A11331F09C1307823516B3DCE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_37F41B5A11331F09C1307823516B3DCE" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_37F41B5A11331F09C1307823516B3DCE" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties_25A9E044A4B0DDF591C57823516B14D7_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties_25A9E044A4B0DDF591C57823516B14D7" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Due from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties_25A9E044A4B0DDF591C57823516B14D7_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties_25A9E044A4B0DDF591C57823516B14D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Due from Related Parties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_25A9E044A4B0DDF591C57823516B14D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_25A9E044A4B0DDF591C57823516B14D7" xlink:to="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties_25A9E044A4B0DDF591C57823516B14D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_4667E79733484CCCBF357823516CE513_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_4667E79733484CCCBF357823516CE513" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_4667E79733484CCCBF357823516CE513_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_4667E79733484CCCBF357823516CE513" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_4667E79733484CCCBF357823516CE513" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_4667E79733484CCCBF357823516CE513" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_4667E79733484CCCBF357823516CE513" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_70D8D3746F81E13579907823516CB334_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_70D8D3746F81E13579907823516CB334" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_70D8D3746F81E13579907823516CB334_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_70D8D3746F81E13579907823516CB334" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_70D8D3746F81E13579907823516CB334" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_70D8D3746F81E13579907823516CB334" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_70D8D3746F81E13579907823516CB334" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_BBC80044672B56B611067823516C0435_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_BBC80044672B56B611067823516C0435" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_BBC80044672B56B611067823516C0435_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_BBC80044672B56B611067823516C0435" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_BBC80044672B56B611067823516C0435" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_BBC80044672B56B611067823516C0435" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_BBC80044672B56B611067823516C0435" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_2BB6DE0683B4F71883917823516C31AD_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_2BB6DE0683B4F71883917823516C31AD" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other changes in operating assets and liabilities, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_2BB6DE0683B4F71883917823516C31AD_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_2BB6DE0683B4F71883917823516C31AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_2BB6DE0683B4F71883917823516C31AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_2BB6DE0683B4F71883917823516C31AD" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_2BB6DE0683B4F71883917823516C31AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_59FF35B4699C3F47E8D37823516C74D1_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_59FF35B4699C3F47E8D37823516C74D1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_59FF35B4699C3F47E8D37823516C74D1_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_59FF35B4699C3F47E8D37823516C74D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_59FF35B4699C3F47E8D37823516C74D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_59FF35B4699C3F47E8D37823516C74D1" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_59FF35B4699C3F47E8D37823516C74D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5C780123B870B7B166657823516D6B5B_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5C780123B870B7B166657823516D6B5B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5C780123B870B7B166657823516D6B5B_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5C780123B870B7B166657823516D6B5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5C780123B870B7B166657823516D6B5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5C780123B870B7B166657823516D6B5B" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5C780123B870B7B166657823516D6B5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_6EFD8B632B3746DCC9847823516D17BD_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_6EFD8B632B3746DCC9847823516D17BD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales and maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_6EFD8B632B3746DCC9847823516D17BD_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_6EFD8B632B3746DCC9847823516D17BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_6EFD8B632B3746DCC9847823516D17BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_6EFD8B632B3746DCC9847823516D17BD" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_6EFD8B632B3746DCC9847823516D17BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_C8733B5DF681F1EC9ACF7823516DC605_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_C8733B5DF681F1EC9ACF7823516DC605" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_C8733B5DF681F1EC9ACF7823516DC605_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_C8733B5DF681F1EC9ACF7823516DC605" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_C8733B5DF681F1EC9ACF7823516DC605" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_C8733B5DF681F1EC9ACF7823516DC605" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_C8733B5DF681F1EC9ACF7823516DC605" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_AF74F79A051C8C6929357823516D4720_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_AF74F79A051C8C6929357823516D4720" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration paid related to Fumapharm AG acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_AF74F79A051C8C6929357823516D4720_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_AF74F79A051C8C6929357823516D4720" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Other Productive Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_AF74F79A051C8C6929357823516D4720" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_AF74F79A051C8C6929357823516D4720" xlink:to="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_AF74F79A051C8C6929357823516D4720" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0A3896F80096EEBF6B5F7823516EFEAA_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0A3896F80096EEBF6B5F7823516EFEAA" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Acquisition of Nightstar Therapeutics plc, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0A3896F80096EEBF6B5F7823516EFEAA_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0A3896F80096EEBF6B5F7823516EFEAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0A3896F80096EEBF6B5F7823516EFEAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0A3896F80096EEBF6B5F7823516EFEAA" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0A3896F80096EEBF6B5F7823516EFEAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_EF0F30874AF699A24F0A7823516E2D89_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_EF0F30874AF699A24F0A7823516E2D89" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of Sangamo Therapeutics, Inc. stock</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_EF0F30874AF699A24F0A7823516E2D89_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_EF0F30874AF699A24F0A7823516E2D89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Interest in Subsidiaries and Affiliates</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_EF0F30874AF699A24F0A7823516E2D89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_EF0F30874AF699A24F0A7823516E2D89" xlink:to="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_EF0F30874AF699A24F0A7823516E2D89" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_A4B36EBA623D77D12B767823516E41C3_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_A4B36EBA623D77D12B767823516E41C3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_A4B36EBA623D77D12B767823516E41C3_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_A4B36EBA623D77D12B767823516E41C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_A4B36EBA623D77D12B767823516E41C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_A4B36EBA623D77D12B767823516E41C3" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_A4B36EBA623D77D12B767823516E41C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_3AEBA59AF97A5EAC3AE07823516E48CF_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_3AEBA59AF97A5EAC3AE07823516E48CF" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_3AEBA59AF97A5EAC3AE07823516E48CF_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_3AEBA59AF97A5EAC3AE07823516E48CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire in Process Research and Development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_3AEBA59AF97A5EAC3AE07823516E48CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_3AEBA59AF97A5EAC3AE07823516E48CF" xlink:to="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_3AEBA59AF97A5EAC3AE07823516E48CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_7D5992122B41D913EA947823516E7D7A_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_7D5992122B41D913EA947823516E7D7A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_7D5992122B41D913EA947823516E7D7A_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_7D5992122B41D913EA947823516E7D7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_7D5992122B41D913EA947823516E7D7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets_7D5992122B41D913EA947823516E7D7A" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets_7D5992122B41D913EA947823516E7D7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromHedgeInvestingActivities_F03212AB8C470DAF262B7823516F46A8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromHedgeInvestingActivities_F03212AB8C470DAF262B7823516F46A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from settlement of net investment hedge</link:label>
    <link:label id="lab_us-gaap_ProceedsFromHedgeInvestingActivities_F03212AB8C470DAF262B7823516F46A8_label_en-US" xlink:label="lab_us-gaap_ProceedsFromHedgeInvestingActivities_F03212AB8C470DAF262B7823516F46A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Hedge, Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromHedgeInvestingActivities" xlink:label="loc_us-gaap_ProceedsFromHedgeInvestingActivities_F03212AB8C470DAF262B7823516F46A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromHedgeInvestingActivities_F03212AB8C470DAF262B7823516F46A8" xlink:to="lab_us-gaap_ProceedsFromHedgeInvestingActivities_F03212AB8C470DAF262B7823516F46A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_99D0560DC79F9251B3FD7823516F37AB_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_99D0560DC79F9251B3FD7823516F37AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales of strategic investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_99D0560DC79F9251B3FD7823516F37AB_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_99D0560DC79F9251B3FD7823516F37AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Available-for-sale Securities, Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_99D0560DC79F9251B3FD7823516F37AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_99D0560DC79F9251B3FD7823516F37AB" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_99D0560DC79F9251B3FD7823516F37AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_7EB1E062E461DA7138B47823516F4796_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_7EB1E062E461DA7138B47823516F4796" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_7EB1E062E461DA7138B47823516F4796_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_7EB1E062E461DA7138B47823516F4796" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_7EB1E062E461DA7138B47823516F4796" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_7EB1E062E461DA7138B47823516F4796" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_7EB1E062E461DA7138B47823516F4796" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_65DFF159700C0E6163D27823516F5CEE_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_65DFF159700C0E6163D27823516F5CEE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_65DFF159700C0E6163D27823516F5CEE_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_65DFF159700C0E6163D27823516F5CEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_65DFF159700C0E6163D27823516F5CEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_65DFF159700C0E6163D27823516F5CEE" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_65DFF159700C0E6163D27823516F5CEE" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_E2D2651CB3BE8079C0757823517071CE_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_E2D2651CB3BE8079C0757823517071CE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_E2D2651CB3BE8079C0757823517071CE_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_E2D2651CB3BE8079C0757823517071CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_E2D2651CB3BE8079C0757823517071CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_E2D2651CB3BE8079C0757823517071CE" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_E2D2651CB3BE8079C0757823517071CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_83A617FFB8842F8DF7247823517056CB_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_83A617FFB8842F8DF7247823517056CB" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of treasury stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_83A617FFB8842F8DF7247823517056CB_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_83A617FFB8842F8DF7247823517056CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_83A617FFB8842F8DF7247823517056CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_83A617FFB8842F8DF7247823517056CB" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_83A617FFB8842F8DF7247823517056CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_073FF249301A989BD46378235170B54C_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_073FF249301A989BD46378235170B54C" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments related to issuance of stock for share-based compensation arrangements, net</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_073FF249301A989BD46378235170B54C_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_073FF249301A989BD46378235170B54C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_073FF249301A989BD46378235170B54C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_073FF249301A989BD46378235170B54C" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_073FF249301A989BD46378235170B54C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_A5084055B2A93DB1871478235170EA52_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_A5084055B2A93DB1871478235170EA52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_A5084055B2A93DB1871478235170EA52_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_A5084055B2A93DB1871478235170EA52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_A5084055B2A93DB1871478235170EA52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_A5084055B2A93DB1871478235170EA52" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_A5084055B2A93DB1871478235170EA52" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_0C4F3AEFC7AEDF33931E782351703947_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_0C4F3AEFC7AEDF33931E782351703947" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repayment of borrowings</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_0C4F3AEFC7AEDF33931E782351703947_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_0C4F3AEFC7AEDF33931E782351703947" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_0C4F3AEFC7AEDF33931E782351703947" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt_0C4F3AEFC7AEDF33931E782351703947" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt_0C4F3AEFC7AEDF33931E782351703947" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities_22726CB314369CA2EB5F7823517179E8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities_22726CB314369CA2EB5F7823517179E8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash proceeds from settlement of swap</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities_22726CB314369CA2EB5F7823517179E8_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities_22726CB314369CA2EB5F7823517179E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for (Proceeds from) Derivative Instrument, Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities_22726CB314369CA2EB5F7823517179E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities_22726CB314369CA2EB5F7823517179E8" xlink:to="lab_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities_22726CB314369CA2EB5F7823517179E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_05DD362BCB89546C54E1782351711325_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders_05DD362BCB89546C54E1782351711325" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net distribution to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_05DD362BCB89546C54E1782351711325_label_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders_05DD362BCB89546C54E1782351711325" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_05DD362BCB89546C54E1782351711325" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToMinorityShareholders_05DD362BCB89546C54E1782351711325" xlink:to="lab_us-gaap_PaymentsToMinorityShareholders_05DD362BCB89546C54E1782351711325" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9EB4A9ABFB48DDB2AF6978235171421D_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9EB4A9ABFB48DDB2AF6978235171421D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9EB4A9ABFB48DDB2AF6978235171421D_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9EB4A9ABFB48DDB2AF6978235171421D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9EB4A9ABFB48DDB2AF6978235171421D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9EB4A9ABFB48DDB2AF6978235171421D" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9EB4A9ABFB48DDB2AF6978235171421D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_6AEDB107E3194CF180D578235171AEDB_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_6AEDB107E3194CF180D578235171AEDB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_6AEDB107E3194CF180D578235171AEDB_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_6AEDB107E3194CF180D578235171AEDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6AEDB107E3194CF180D578235171AEDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6AEDB107E3194CF180D578235171AEDB" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_6AEDB107E3194CF180D578235171AEDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_E5261EDDC5C84A5FD7EE7823517156C6_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_E5261EDDC5C84A5FD7EE7823517156C6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_E5261EDDC5C84A5FD7EE7823517156C6_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_E5261EDDC5C84A5FD7EE7823517156C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_E5261EDDC5C84A5FD7EE7823517156C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_E5261EDDC5C84A5FD7EE7823517156C6" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_E5261EDDC5C84A5FD7EE7823517156C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_13EF7C27707B7CD62A4C78235171B6CF_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_13EF7C27707B7CD62A4C78235171B6CF" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_13EF7C27707B7CD62A4C78235171B6CF_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_13EF7C27707B7CD62A4C78235171B6CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_13EF7C27707B7CD62A4C78235171B6CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_13EF7C27707B7CD62A4C78235171B6CF" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_13EF7C27707B7CD62A4C78235171B6CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_29F832662267DDBA0A6978235172F04F_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_29F832662267DDBA0A6978235172F04F" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_29F832662267DDBA0A6978235172F04F_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_29F832662267DDBA0A6978235172F04F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_29F832662267DDBA0A6978235172F04F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_29F832662267DDBA0A6978235172F04F" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_29F832662267DDBA0A6978235172F04F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_E66F6C7C99BB4898DF81782351735099_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_E66F6C7C99BB4898DF81782351735099" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of the period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_E66F6C7C99BB4898DF81782351735099" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_E66F6C7C99BB4898DF81782351735099" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_E66F6C7C99BB4898DF81782351735099" xlink:type="arc" />
    <link:label id="lab_srt_RangeAxis_A14296A47215B03741C278234F034199_terseLabel_en-US" xlink:label="lab_srt_RangeAxis_A14296A47215B03741C278234F034199" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_A14296A47215B03741C278234F034199_label_en-US" xlink:label="lab_srt_RangeAxis_A14296A47215B03741C278234F034199" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_A14296A47215B03741C278234F034199" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_A14296A47215B03741C278234F034199" xlink:to="lab_srt_RangeAxis_A14296A47215B03741C278234F034199" xlink:type="arc" />
    <link:label id="lab_srt_RangeMember_F7654E27E3D57F10C1D678234F033114_terseLabel_en-US" xlink:label="lab_srt_RangeMember_F7654E27E3D57F10C1D678234F033114" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_F7654E27E3D57F10C1D678234F033114_label_en-US" xlink:label="lab_srt_RangeMember_F7654E27E3D57F10C1D678234F033114" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_F7654E27E3D57F10C1D678234F033114" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_F7654E27E3D57F10C1D678234F033114" xlink:to="lab_srt_RangeMember_F7654E27E3D57F10C1D678234F033114" xlink:type="arc" />
    <link:label id="lab_srt_MinimumMember_143C0E82977F1443596978234F039525_verboseLabel_en-US" xlink:label="lab_srt_MinimumMember_143C0E82977F1443596978234F039525" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_143C0E82977F1443596978234F039525_label_en-US" xlink:label="lab_srt_MinimumMember_143C0E82977F1443596978234F039525" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_143C0E82977F1443596978234F039525" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_143C0E82977F1443596978234F039525" xlink:to="lab_srt_MinimumMember_143C0E82977F1443596978234F039525" xlink:type="arc" />
    <link:label id="lab_srt_MaximumMember_3E39196111E9AFAE167E78234F04952F_verboseLabel_en-US" xlink:label="lab_srt_MaximumMember_3E39196111E9AFAE167E78234F04952F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_3E39196111E9AFAE167E78234F04952F_label_en-US" xlink:label="lab_srt_MaximumMember_3E39196111E9AFAE167E78234F04952F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_3E39196111E9AFAE167E78234F04952F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_3E39196111E9AFAE167E78234F04952F" xlink:to="lab_srt_MaximumMember_3E39196111E9AFAE167E78234F04952F" xlink:type="arc" />
    <link:label id="lab_srt_WeightedAverageMember_56CDC77D9A7D342098D678234F046C93_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember_56CDC77D9A7D342098D678234F046C93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_56CDC77D9A7D342098D678234F046C93_label_en-US" xlink:label="lab_srt_WeightedAverageMember_56CDC77D9A7D342098D678234F046C93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_WeightedAverageMember" xlink:label="loc_srt_WeightedAverageMember_56CDC77D9A7D342098D678234F046C93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember_56CDC77D9A7D342098D678234F046C93" xlink:to="lab_srt_WeightedAverageMember_56CDC77D9A7D342098D678234F046C93" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_58369FF89A2DA2F4112778234F04240B_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis_58369FF89A2DA2F4112778234F04240B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_58369FF89A2DA2F4112778234F04240B_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis_58369FF89A2DA2F4112778234F04240B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_58369FF89A2DA2F4112778234F04240B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_58369FF89A2DA2F4112778234F04240B" xlink:to="lab_us-gaap_MeasurementInputTypeAxis_58369FF89A2DA2F4112778234F04240B" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_B0FBD1E1B897A6971BA078234F0466B4_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain_B0FBD1E1B897A6971BA078234F0466B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_B0FBD1E1B897A6971BA078234F0466B4_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain_B0FBD1E1B897A6971BA078234F0466B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_B0FBD1E1B897A6971BA078234F0466B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_B0FBD1E1B897A6971BA078234F0466B4" xlink:to="lab_us-gaap_MeasurementInputTypeDomain_B0FBD1E1B897A6971BA078234F0466B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_E9A542F203368CF24C0078234F05CBAA_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember_E9A542F203368CF24C0078234F05CBAA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_E9A542F203368CF24C0078234F05CBAA_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember_E9A542F203368CF24C0078234F05CBAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_E9A542F203368CF24C0078234F05CBAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember_E9A542F203368CF24C0078234F05CBAA" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember_E9A542F203368CF24C0078234F05CBAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_6AC47037E87A5641D70278234F066107_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_6AC47037E87A5641D70278234F066107" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_6AC47037E87A5641D70278234F066107_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_6AC47037E87A5641D70278234F066107" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_6AC47037E87A5641D70278234F066107" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_6AC47037E87A5641D70278234F066107" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_6AC47037E87A5641D70278234F066107" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_C64112BE2F2C562DB5B178234D5F596C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_C64112BE2F2C562DB5B178234D5F596C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_C64112BE2F2C562DB5B178234D5F596C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_C64112BE2F2C562DB5B178234D5F596C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_C64112BE2F2C562DB5B178234D5F596C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_C64112BE2F2C562DB5B178234D5F596C" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_C64112BE2F2C562DB5B178234D5F596C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8E5A4096E3B50308124978234D5F7863_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8E5A4096E3B50308124978234D5F7863" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8E5A4096E3B50308124978234D5F7863_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8E5A4096E3B50308124978234D5F7863" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8E5A4096E3B50308124978234D5F7863" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8E5A4096E3B50308124978234D5F7863" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8E5A4096E3B50308124978234D5F7863" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_F3ED5337F9F0086F778B78234D604880_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_F3ED5337F9F0086F778B78234D604880" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_F3ED5337F9F0086F778B78234D604880_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_F3ED5337F9F0086F778B78234D604880" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_F3ED5337F9F0086F778B78234D604880" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_F3ED5337F9F0086F778B78234D604880" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_F3ED5337F9F0086F778B78234D604880" xlink:type="arc" />
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_48E470BECDE943C7C51178234D60E97D_verboseLabel_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember_48E470BECDE943C7C51178234D60E97D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Time-vested restricted stock units</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_48E470BECDE943C7C51178234D60E97D_label_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember_48E470BECDE943C7C51178234D60E97D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Time Vested Restricted Stock Units [Member]</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_48E470BECDE943C7C51178234D60E97D_documentation_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember_48E470BECDE943C7C51178234D60E97D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Time vested restricted stock units.</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_48E470BECDE943C7C51178234D60E97D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TimeVestedRestrictedStockUnitsMember_48E470BECDE943C7C51178234D60E97D" xlink:to="lab_biib_TimeVestedRestrictedStockUnitsMember_48E470BECDE943C7C51178234D60E97D" xlink:type="arc" />
    <link:label id="lab_biib_MarketStockUnitsMember_816ECC6AD62AAC9D973378234D6014E2_verboseLabel_en-US" xlink:label="lab_biib_MarketStockUnitsMember_816ECC6AD62AAC9D973378234D6014E2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Market stock units</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_816ECC6AD62AAC9D973378234D6014E2_label_en-US" xlink:label="lab_biib_MarketStockUnitsMember_816ECC6AD62AAC9D973378234D6014E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market Stock Units [Member]</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_816ECC6AD62AAC9D973378234D6014E2_documentation_en-US" xlink:label="lab_biib_MarketStockUnitsMember_816ECC6AD62AAC9D973378234D6014E2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Market stock units.</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_816ECC6AD62AAC9D973378234D6014E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MarketStockUnitsMember_816ECC6AD62AAC9D973378234D6014E2" xlink:to="lab_biib_MarketStockUnitsMember_816ECC6AD62AAC9D973378234D6014E2" xlink:type="arc" />
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_BA480501F25CF8B4E07778234D604C1C_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember_BA480501F25CF8B4E07778234D604C1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance stock units settled in stock</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_BA480501F25CF8B4E07778234D604C1C_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember_BA480501F25CF8B4E07778234D604C1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Stock [Member]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_BA480501F25CF8B4E07778234D604C1C_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember_BA480501F25CF8B4E07778234D604C1C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Stock [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_BA480501F25CF8B4E07778234D604C1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockMember_BA480501F25CF8B4E07778234D604C1C" xlink:to="lab_biib_PerformanceStockUnitsSettledinStockMember_BA480501F25CF8B4E07778234D604C1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_52F260203FC456F5600178234D61588B_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_52F260203FC456F5600178234D61588B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_52F260203FC456F5600178234D61588B_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_52F260203FC456F5600178234D61588B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_52F260203FC456F5600178234D61588B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_52F260203FC456F5600178234D61588B" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_52F260203FC456F5600178234D61588B" xlink:type="arc" />
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_90B7562C2EC0E8DFA7EA78234D617CBB_verboseLabel_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract_90B7562C2EC0E8DFA7EA78234D617CBB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_90B7562C2EC0E8DFA7EA78234D617CBB_label_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract_90B7562C2EC0E8DFA7EA78234D617CBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic And Diluted Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_90B7562C2EC0E8DFA7EA78234D617CBB_documentation_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract_90B7562C2EC0E8DFA7EA78234D617CBB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share.</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_90B7562C2EC0E8DFA7EA78234D617CBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_90B7562C2EC0E8DFA7EA78234D617CBB" xlink:to="lab_biib_BasicAndDilutedEarningsPerShareAbstract_90B7562C2EC0E8DFA7EA78234D617CBB" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_B2B2AB5E2982CACF70EC78234D61C972_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract_B2B2AB5E2982CACF70EC78234D61C972" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_B2B2AB5E2982CACF70EC78234D61C972_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract_B2B2AB5E2982CACF70EC78234D61C972" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_B2B2AB5E2982CACF70EC78234D61C972" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract_B2B2AB5E2982CACF70EC78234D61C972" xlink:to="lab_us-gaap_NetIncomeLossAbstract_B2B2AB5E2982CACF70EC78234D61C972" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3991B763E654F5D828EB78234D62CF44_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3991B763E654F5D828EB78234D62CF44" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3991B763E654F5D828EB78234D62CF44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3991B763E654F5D828EB78234D62CF44" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3991B763E654F5D828EB78234D62CF44" xlink:type="arc" />
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_E4C0DC526A789408D16878234D63D508_verboseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_E4C0DC526A789408D16878234D63D508" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_E4C0DC526A789408D16878234D63D508_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_E4C0DC526A789408D16878234D63D508" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_E4C0DC526A789408D16878234D63D508" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_E4C0DC526A789408D16878234D63D508" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract_E4C0DC526A789408D16878234D63D508" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_111FEF2310C00804823178234D637DA1_verboseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_111FEF2310C00804823178234D637DA1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock units</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_111FEF2310C00804823178234D637DA1_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_111FEF2310C00804823178234D637DA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_111FEF2310C00804823178234D637DA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_111FEF2310C00804823178234D637DA1" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_111FEF2310C00804823178234D637DA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_A09BEC1E45689FEA1B5078234D632732_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_A09BEC1E45689FEA1B5078234D632732" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Dilutive potential common shares</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_A09BEC1E45689FEA1B5078234D632732_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_A09BEC1E45689FEA1B5078234D632732" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_A09BEC1E45689FEA1B5078234D632732" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_A09BEC1E45689FEA1B5078234D632732" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_A09BEC1E45689FEA1B5078234D632732" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_85068B58E43C3F2273B578234D6314BB_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_85068B58E43C3F2273B578234D6314BB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Shares used in calculating diluted earnings per share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_85068B58E43C3F2273B578234D6314BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_85068B58E43C3F2273B578234D6314BB" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_85068B58E43C3F2273B578234D6314BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillRollForward_1550BCADA38AEC0CCDC978234F872970_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward_1550BCADA38AEC0CCDC978234F872970" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_1550BCADA38AEC0CCDC978234F872970_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward_1550BCADA38AEC0CCDC978234F872970" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_1550BCADA38AEC0CCDC978234F872970" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward_1550BCADA38AEC0CCDC978234F872970" xlink:to="lab_us-gaap_GoodwillRollForward_1550BCADA38AEC0CCDC978234F872970" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_BC506DBAF73845FD9E4978234F883362_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill_BC506DBAF73845FD9E4978234F883362" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Goodwill, beginning of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_BC506DBAF73845FD9E4978234F883362_label_en-US" xlink:label="lab_us-gaap_Goodwill_BC506DBAF73845FD9E4978234F883362" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_BC506DBAF73845FD9E4978234F883362" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_BC506DBAF73845FD9E4978234F883362" xlink:to="lab_us-gaap_Goodwill_BC506DBAF73845FD9E4978234F883362" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_0EF7473086153B200DC678234F88FDD6_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease_0EF7473086153B200DC678234F88FDD6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_0EF7473086153B200DC678234F88FDD6_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease_0EF7473086153B200DC678234F88FDD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_0EF7473086153B200DC678234F88FDD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease_0EF7473086153B200DC678234F88FDD6" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease_0EF7473086153B200DC678234F88FDD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_CA54124D7169DB18E9C078234F883B82_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill_CA54124D7169DB18E9C078234F883B82" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Goodwill, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_CA54124D7169DB18E9C078234F883B82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_CA54124D7169DB18E9C078234F883B82" xlink:to="lab_us-gaap_Goodwill_CA54124D7169DB18E9C078234F883B82" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_1FA10ABA1162E11462B378234F883106_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_1FA10ABA1162E11462B378234F883106" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated impairment losses related to goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_1FA10ABA1162E11462B378234F883106_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_1FA10ABA1162E11462B378234F883106" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_1FA10ABA1162E11462B378234F883106" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_1FA10ABA1162E11462B378234F883106" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_1FA10ABA1162E11462B378234F883106" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_A8C114600CB29980216B78234D6F462C_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_A8C114600CB29980216B78234D6F462C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_A8C114600CB29980216B78234D6F462C_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_A8C114600CB29980216B78234D6F462C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_A8C114600CB29980216B78234D6F462C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_A8C114600CB29980216B78234D6F462C" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_A8C114600CB29980216B78234D6F462C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_FD8658935B1E74D4485478234DFED434_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_FD8658935B1E74D4485478234DFED434" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_FD8658935B1E74D4485478234DFED434_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_FD8658935B1E74D4485478234DFED434" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_FD8658935B1E74D4485478234DFED434" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_FD8658935B1E74D4485478234DFED434" xlink:to="lab_us-gaap_DebtInstrumentTable_FD8658935B1E74D4485478234DFED434" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_7FD531B531375095EBF578234DFFA51F_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_7FD531B531375095EBF578234DFFA51F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_7FD531B531375095EBF578234DFFA51F_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_7FD531B531375095EBF578234DFFA51F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7FD531B531375095EBF578234DFFA51F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7FD531B531375095EBF578234DFFA51F" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_7FD531B531375095EBF578234DFFA51F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_50A1B6E57E8F0602E59A78234DFFD9A0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_50A1B6E57E8F0602E59A78234DFFD9A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_50A1B6E57E8F0602E59A78234DFFD9A0_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_50A1B6E57E8F0602E59A78234DFFD9A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_50A1B6E57E8F0602E59A78234DFFD9A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_50A1B6E57E8F0602E59A78234DFFD9A0" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_50A1B6E57E8F0602E59A78234DFFD9A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpenseMember_37FBD55FA64CA128310078234DFF5339_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseMember_37FBD55FA64CA128310078234DFF5339" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseMember_37FBD55FA64CA128310078234DFF5339_label_en-US" xlink:label="lab_us-gaap_InterestExpenseMember_37FBD55FA64CA128310078234DFF5339" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseMember" xlink:label="loc_us-gaap_InterestExpenseMember_37FBD55FA64CA128310078234DFF5339" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseMember_37FBD55FA64CA128310078234DFF5339" xlink:to="lab_us-gaap_InterestExpenseMember_37FBD55FA64CA128310078234DFF5339" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_80337CBFF92BDD4F95E078234E0080E1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis_80337CBFF92BDD4F95E078234E0080E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_80337CBFF92BDD4F95E078234E0080E1_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis_80337CBFF92BDD4F95E078234E0080E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_80337CBFF92BDD4F95E078234E0080E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_80337CBFF92BDD4F95E078234E0080E1" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis_80337CBFF92BDD4F95E078234E0080E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_C29C616EAF7D7695B36278234E00308E_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain_C29C616EAF7D7695B36278234E00308E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_C29C616EAF7D7695B36278234E00308E_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain_C29C616EAF7D7695B36278234E00308E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_C29C616EAF7D7695B36278234E00308E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_C29C616EAF7D7695B36278234E00308E" xlink:to="lab_us-gaap_DerivativeContractTypeDomain_C29C616EAF7D7695B36278234E00308E" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestRateSwapMember_6DC7D416C0F04B3405CB78234E004BD4_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember_6DC7D416C0F04B3405CB78234E004BD4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_6DC7D416C0F04B3405CB78234E004BD4_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember_6DC7D416C0F04B3405CB78234E004BD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_6DC7D416C0F04B3405CB78234E004BD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember_6DC7D416C0F04B3405CB78234E004BD4" xlink:to="lab_us-gaap_InterestRateSwapMember_6DC7D416C0F04B3405CB78234E004BD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_CE7097083217A93B8EA178234E01F7A9_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_CE7097083217A93B8EA178234E01F7A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_CE7097083217A93B8EA178234E01F7A9_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_CE7097083217A93B8EA178234E01F7A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_CE7097083217A93B8EA178234E01F7A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_CE7097083217A93B8EA178234E01F7A9" xlink:to="lab_us-gaap_LongtermDebtTypeAxis_CE7097083217A93B8EA178234E01F7A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_A4E6EC2C37243BFA11A778234E0192AB_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_A4E6EC2C37243BFA11A778234E0192AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_A4E6EC2C37243BFA11A778234E0192AB_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_A4E6EC2C37243BFA11A778234E0192AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_A4E6EC2C37243BFA11A778234E0192AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_A4E6EC2C37243BFA11A778234E0192AB" xlink:to="lab_us-gaap_LongtermDebtTypeDomain_A4E6EC2C37243BFA11A778234E0192AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeniorNotesMember_3829401E5E67FEDAFB2978234E01557E_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember_3829401E5E67FEDAFB2978234E01557E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_3829401E5E67FEDAFB2978234E01557E_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember_3829401E5E67FEDAFB2978234E01557E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_3829401E5E67FEDAFB2978234E01557E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember_3829401E5E67FEDAFB2978234E01557E" xlink:to="lab_us-gaap_SeniorNotesMember_3829401E5E67FEDAFB2978234E01557E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_18E810C5787CACEB4D6178234E02A1D3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_18E810C5787CACEB4D6178234E02A1D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_18E810C5787CACEB4D6178234E02A1D3_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_18E810C5787CACEB4D6178234E02A1D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_18E810C5787CACEB4D6178234E02A1D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_18E810C5787CACEB4D6178234E02A1D3" xlink:to="lab_us-gaap_DebtInstrumentAxis_18E810C5787CACEB4D6178234E02A1D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_D0B7E880C40926BAE85978234E02A31F_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_D0B7E880C40926BAE85978234E02A31F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_D0B7E880C40926BAE85978234E02A31F_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_D0B7E880C40926BAE85978234E02A31F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_D0B7E880C40926BAE85978234E02A31F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_D0B7E880C40926BAE85978234E02A31F" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_D0B7E880C40926BAE85978234E02A31F" xlink:type="arc" />
    <link:label id="lab_biib_A2.25SeniorNotesdueMay12030Member_D3CAF1C239084578A8FE78234E02222E_terseLabel_en-US" xlink:label="lab_biib_A2.25SeniorNotesdueMay12030Member_D3CAF1C239084578A8FE78234E02222E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2.250% Senior Notes due May 1, 2030</link:label>
    <link:label id="lab_biib_A2.25SeniorNotesdueMay12030Member_D3CAF1C239084578A8FE78234E02222E_label_en-US" xlink:label="lab_biib_A2.25SeniorNotesdueMay12030Member_D3CAF1C239084578A8FE78234E02222E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2.25% Senior Notes due May 1, 2030 [Member]</link:label>
    <link:label id="lab_biib_A2.25SeniorNotesdueMay12030Member_D3CAF1C239084578A8FE78234E02222E_documentation_en-US" xlink:label="lab_biib_A2.25SeniorNotesdueMay12030Member_D3CAF1C239084578A8FE78234E02222E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2.25% Senior Notes due May 1, 2030 [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_A2.25SeniorNotesdueMay12030Member" xlink:label="loc_biib_A2.25SeniorNotesdueMay12030Member_D3CAF1C239084578A8FE78234E02222E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2.25SeniorNotesdueMay12030Member_D3CAF1C239084578A8FE78234E02222E" xlink:to="lab_biib_A2.25SeniorNotesdueMay12030Member_D3CAF1C239084578A8FE78234E02222E" xlink:type="arc" />
    <link:label id="lab_biib_A3.15SeniorNotesdueMay12050Member_FFBE327FDC11DB6F523F78234E03F337_terseLabel_en-US" xlink:label="lab_biib_A3.15SeniorNotesdueMay12050Member_FFBE327FDC11DB6F523F78234E03F337" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.150% Senior Notes due May 1, 2050</link:label>
    <link:label id="lab_biib_A3.15SeniorNotesdueMay12050Member_FFBE327FDC11DB6F523F78234E03F337_label_en-US" xlink:label="lab_biib_A3.15SeniorNotesdueMay12050Member_FFBE327FDC11DB6F523F78234E03F337" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">3.15% Senior Notes due May 1, 2050 [Member]</link:label>
    <link:label id="lab_biib_A3.15SeniorNotesdueMay12050Member_FFBE327FDC11DB6F523F78234E03F337_documentation_en-US" xlink:label="lab_biib_A3.15SeniorNotesdueMay12050Member_FFBE327FDC11DB6F523F78234E03F337" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">3.15% Senior Notes due May 1, 2050 [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_A3.15SeniorNotesdueMay12050Member" xlink:label="loc_biib_A3.15SeniorNotesdueMay12050Member_FFBE327FDC11DB6F523F78234E03F337" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A3.15SeniorNotesdueMay12050Member_FFBE327FDC11DB6F523F78234E03F337" xlink:to="lab_biib_A3.15SeniorNotesdueMay12050Member_FFBE327FDC11DB6F523F78234E03F337" xlink:type="arc" />
    <link:label id="lab_biib_A2.90SeniorNotesDueSept152020Member_90AE65317A500594430E78234E03A59C_terseLabel_en-US" xlink:label="lab_biib_A2.90SeniorNotesDueSept152020Member_90AE65317A500594430E78234E03A59C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2.90% Senior Notes Due Sept 15, 2020</link:label>
    <link:label id="lab_biib_A2.90SeniorNotesDueSept152020Member_90AE65317A500594430E78234E03A59C_label_en-US" xlink:label="lab_biib_A2.90SeniorNotesDueSept152020Member_90AE65317A500594430E78234E03A59C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2.90% Senior Notes Due Sept 15, 2020 [Member]</link:label>
    <link:label id="lab_biib_A2.90SeniorNotesDueSept152020Member_90AE65317A500594430E78234E03A59C_documentation_en-US" xlink:label="lab_biib_A2.90SeniorNotesDueSept152020Member_90AE65317A500594430E78234E03A59C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2.90% Senior Notes Due Sept 15, 2020 [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_A2.90SeniorNotesDueSept152020Member" xlink:label="loc_biib_A2.90SeniorNotesDueSept152020Member_90AE65317A500594430E78234E03A59C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2.90SeniorNotesDueSept152020Member_90AE65317A500594430E78234E03A59C" xlink:to="lab_biib_A2.90SeniorNotesDueSept152020Member_90AE65317A500594430E78234E03A59C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_F54971E4AEE11F1E7EEB78234E0348F4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_F54971E4AEE11F1E7EEB78234E0348F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_F54971E4AEE11F1E7EEB78234E0348F4_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_F54971E4AEE11F1E7EEB78234E0348F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_F54971E4AEE11F1E7EEB78234E0348F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F54971E4AEE11F1E7EEB78234E0348F4" xlink:to="lab_us-gaap_DebtInstrumentLineItems_F54971E4AEE11F1E7EEB78234E0348F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_DFA14428B2F2F8837FE778234E046E34_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_DFA14428B2F2F8837FE778234E046E34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_DFA14428B2F2F8837FE778234E046E34_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_DFA14428B2F2F8837FE778234E046E34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_DFA14428B2F2F8837FE778234E046E34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_DFA14428B2F2F8837FE778234E046E34" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_DFA14428B2F2F8837FE778234E046E34" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_0C11E8D55B3E655FCDDE78234E04B38F_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_0C11E8D55B3E655FCDDE78234E04B38F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior notes interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_0C11E8D55B3E655FCDDE78234E04B38F_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_0C11E8D55B3E655FCDDE78234E04B38F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0C11E8D55B3E655FCDDE78234E04B38F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0C11E8D55B3E655FCDDE78234E04B38F" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_0C11E8D55B3E655FCDDE78234E04B38F" xlink:type="arc" />
    <link:label id="lab_biib_PercentageParValueOfSeniorNotes_35E8CB289240A81DD02F78234E04B359_terseLabel_en-US" xlink:label="lab_biib_PercentageParValueOfSeniorNotes_35E8CB289240A81DD02F78234E04B359" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage par value of senior notes</link:label>
    <link:label id="lab_biib_PercentageParValueOfSeniorNotes_35E8CB289240A81DD02F78234E04B359_label_en-US" xlink:label="lab_biib_PercentageParValueOfSeniorNotes_35E8CB289240A81DD02F78234E04B359" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Par Value Of Senior Notes</link:label>
    <link:label id="lab_biib_PercentageParValueOfSeniorNotes_35E8CB289240A81DD02F78234E04B359_documentation_en-US" xlink:label="lab_biib_PercentageParValueOfSeniorNotes_35E8CB289240A81DD02F78234E04B359" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Par Value Of Senior Notes</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_PercentageParValueOfSeniorNotes" xlink:label="loc_biib_PercentageParValueOfSeniorNotes_35E8CB289240A81DD02F78234E04B359" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageParValueOfSeniorNotes_35E8CB289240A81DD02F78234E04B359" xlink:to="lab_biib_PercentageParValueOfSeniorNotes_35E8CB289240A81DD02F78234E04B359" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_C13201A87FEBF26D4B4A78234E048239_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_C13201A87FEBF26D4B4A78234E048239" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, redemption price, percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_C13201A87FEBF26D4B4A78234E048239_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_C13201A87FEBF26D4B4A78234E048239" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_C13201A87FEBF26D4B4A78234E048239" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_C13201A87FEBF26D4B4A78234E048239" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_C13201A87FEBF26D4B4A78234E048239" xlink:type="arc" />
    <link:label id="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_148F99714CE170FB07FE78234E0590D8_terseLabel_en-US" xlink:label="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_148F99714CE170FB07FE78234E0590D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, make whole provision redemption price, percentage</link:label>
    <link:label id="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_148F99714CE170FB07FE78234E0590D8_label_en-US" xlink:label="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_148F99714CE170FB07FE78234E0590D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Make Whole Provision Redemption Price, Percentage</link:label>
    <link:label id="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_148F99714CE170FB07FE78234E0590D8_documentation_en-US" xlink:label="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_148F99714CE170FB07FE78234E0590D8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Make Whole Provision Redemption Price, Percentage</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" xlink:label="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_148F99714CE170FB07FE78234E0590D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_148F99714CE170FB07FE78234E0590D8" xlink:to="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_148F99714CE170FB07FE78234E0590D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_20CEE83B7A3254022C6378234E05FAA1_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts_20CEE83B7A3254022C6378234E05FAA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments of financing costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_20CEE83B7A3254022C6378234E05FAA1_label_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts_20CEE83B7A3254022C6378234E05FAA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Financing Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_20CEE83B7A3254022C6378234E05FAA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts_20CEE83B7A3254022C6378234E05FAA1" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts_20CEE83B7A3254022C6378234E05FAA1" xlink:type="arc" />
    <link:label id="lab_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain_FE6610747100E4C3507078234E05C65D_terseLabel_en-US" xlink:label="lab_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain_FE6610747100E4C3507078234E05C65D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-tax charge, payment of early call premium and write off of remaining unamortized debt issuance costs, net of derivative gain</link:label>
    <link:label id="lab_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain_FE6610747100E4C3507078234E05C65D_label_en-US" xlink:label="lab_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain_FE6610747100E4C3507078234E05C65D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-tax Charge, Payment of Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs, Net of Derivative Gain</link:label>
    <link:label id="lab_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain_FE6610747100E4C3507078234E05C65D_documentation_en-US" xlink:label="lab_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain_FE6610747100E4C3507078234E05C65D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre-tax Charge, Payment of Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs, Net of Derivative Gain</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain" xlink:label="loc_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain_FE6610747100E4C3507078234E05C65D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain_FE6610747100E4C3507078234E05C65D" xlink:to="lab_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain_FE6610747100E4C3507078234E05C65D" xlink:type="arc" />
    <link:label id="lab_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts_8C8625470D56534B167978234E05CD1D_terseLabel_en-US" xlink:label="lab_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts_8C8625470D56534B167978234E05CD1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment of early call premium and write off of remaining unamortized debt issuance costs</link:label>
    <link:label id="lab_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts_8C8625470D56534B167978234E05CD1D_label_en-US" xlink:label="lab_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts_8C8625470D56534B167978234E05CD1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs</link:label>
    <link:label id="lab_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts_8C8625470D56534B167978234E05CD1D_documentation_en-US" xlink:label="lab_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts_8C8625470D56534B167978234E05CD1D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts" xlink:label="loc_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts_8C8625470D56534B167978234E05CD1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts_8C8625470D56534B167978234E05CD1D" xlink:to="lab_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts_8C8625470D56534B167978234E05CD1D" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_71E68D24AC8F0AE1E55578234E0691ED_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_71E68D24AC8F0AE1E55578234E0691ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, gain on derivative</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_71E68D24AC8F0AE1E55578234E0691ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_71E68D24AC8F0AE1E55578234E0691ED" xlink:to="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_71E68D24AC8F0AE1E55578234E0691ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_97156540BCA695A2DAE6782350922AB7_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_97156540BCA695A2DAE6782350922AB7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_97156540BCA695A2DAE6782350922AB7_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_97156540BCA695A2DAE6782350922AB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_97156540BCA695A2DAE6782350922AB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_97156540BCA695A2DAE6782350922AB7" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_97156540BCA695A2DAE6782350922AB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_594807FC0CE38E74B84178234EC35E00_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_594807FC0CE38E74B84178234EC35E00" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_594807FC0CE38E74B84178234EC35E00_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_594807FC0CE38E74B84178234EC35E00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_594807FC0CE38E74B84178234EC35E00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_594807FC0CE38E74B84178234EC35E00" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_594807FC0CE38E74B84178234EC35E00" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_63D42E622DCF3A50CDA778234EC41679_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember_63D42E622DCF3A50CDA778234EC41679" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_63D42E622DCF3A50CDA778234EC41679_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember_63D42E622DCF3A50CDA778234EC41679" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_63D42E622DCF3A50CDA778234EC41679" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember_63D42E622DCF3A50CDA778234EC41679" xlink:to="lab_us-gaap_OtherCurrentAssetsMember_63D42E622DCF3A50CDA778234EC41679" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_C441E79B27348A81961F78234EC46F9E_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember_C441E79B27348A81961F78234EC46F9E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_C441E79B27348A81961F78234EC46F9E_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember_C441E79B27348A81961F78234EC46F9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_C441E79B27348A81961F78234EC46F9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember_C441E79B27348A81961F78234EC46F9E" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember_C441E79B27348A81961F78234EC46F9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_CC7A3C71F5BB7A4B779178234EC57EA6_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_CC7A3C71F5BB7A4B779178234EC57EA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_CC7A3C71F5BB7A4B779178234EC57EA6_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_CC7A3C71F5BB7A4B779178234EC57EA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_CC7A3C71F5BB7A4B779178234EC57EA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis_CC7A3C71F5BB7A4B779178234EC57EA6" xlink:to="lab_us-gaap_FinancialInstrumentAxis_CC7A3C71F5BB7A4B779178234EC57EA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F72B48CBECE3CB71283078234EC59062_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F72B48CBECE3CB71283078234EC59062" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F72B48CBECE3CB71283078234EC59062_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F72B48CBECE3CB71283078234EC59062" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F72B48CBECE3CB71283078234EC59062" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F72B48CBECE3CB71283078234EC59062" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F72B48CBECE3CB71283078234EC59062" xlink:type="arc" />
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_C1852C6D28B675BC600C78234EC57733_verboseLabel_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember_C1852C6D28B675BC600C78234EC57733" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities Current</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_C1852C6D28B675BC600C78234EC57733_label_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember_C1852C6D28B675BC600C78234EC57733" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities Current [Member]</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_C1852C6D28B675BC600C78234EC57733_documentation_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember_C1852C6D28B675BC600C78234EC57733" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate debt securities Current.</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_CorporateDebtSecuritiesCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_C1852C6D28B675BC600C78234EC57733" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateDebtSecuritiesCurrentMember_C1852C6D28B675BC600C78234EC57733" xlink:to="lab_biib_CorporateDebtSecuritiesCurrentMember_C1852C6D28B675BC600C78234EC57733" xlink:type="arc" />
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_40A7607CD547745D111E78234EC66C2A_verboseLabel_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember_40A7607CD547745D111E78234EC66C2A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities Non-current</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_40A7607CD547745D111E78234EC66C2A_label_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember_40A7607CD547745D111E78234EC66C2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities Non Current [Member]</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_40A7607CD547745D111E78234EC66C2A_documentation_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember_40A7607CD547745D111E78234EC66C2A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities Non Current.</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_CorporateDebtSecuritiesNonCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_40A7607CD547745D111E78234EC66C2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateDebtSecuritiesNonCurrentMember_40A7607CD547745D111E78234EC66C2A" xlink:to="lab_biib_CorporateDebtSecuritiesNonCurrentMember_40A7607CD547745D111E78234EC66C2A" xlink:type="arc" />
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_0ACEA705C97C0AFBF82B78234EC62669_verboseLabel_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember_0ACEA705C97C0AFBF82B78234EC62669" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government securities Current</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_0ACEA705C97C0AFBF82B78234EC62669_label_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember_0ACEA705C97C0AFBF82B78234EC62669" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Securities Current [Member]</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_0ACEA705C97C0AFBF82B78234EC62669_documentation_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember_0ACEA705C97C0AFBF82B78234EC62669" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government securities Current.</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_GovernmentSecuritiesCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_0ACEA705C97C0AFBF82B78234EC62669" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GovernmentSecuritiesCurrentMember_0ACEA705C97C0AFBF82B78234EC62669" xlink:to="lab_biib_GovernmentSecuritiesCurrentMember_0ACEA705C97C0AFBF82B78234EC62669" xlink:type="arc" />
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_E9F3DC15943B28DD4CAA78234EC68DFF_verboseLabel_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember_E9F3DC15943B28DD4CAA78234EC68DFF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government securities Non-current</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_E9F3DC15943B28DD4CAA78234EC68DFF_label_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember_E9F3DC15943B28DD4CAA78234EC68DFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Securities Non-current [Member]</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_E9F3DC15943B28DD4CAA78234EC68DFF_documentation_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember_E9F3DC15943B28DD4CAA78234EC68DFF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government Securities Non Current.</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_GovernmentSecuritiesNonCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_E9F3DC15943B28DD4CAA78234EC68DFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GovernmentSecuritiesNonCurrentMember_E9F3DC15943B28DD4CAA78234EC68DFF" xlink:to="lab_biib_GovernmentSecuritiesNonCurrentMember_E9F3DC15943B28DD4CAA78234EC68DFF" xlink:type="arc" />
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_85E2822FCC7EBF1C52DB78234EC6F4C4_verboseLabel_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_85E2822FCC7EBF1C52DB78234EC6F4C4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities Current</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_85E2822FCC7EBF1C52DB78234EC6F4C4_label_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_85E2822FCC7EBF1C52DB78234EC6F4C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mortgage And Other Asset Backed Securities Current [Member]</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_85E2822FCC7EBF1C52DB78234EC6F4C4_documentation_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_85E2822FCC7EBF1C52DB78234EC6F4C4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities Current.</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_85E2822FCC7EBF1C52DB78234EC6F4C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_85E2822FCC7EBF1C52DB78234EC6F4C4" xlink:to="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_85E2822FCC7EBF1C52DB78234EC6F4C4" xlink:type="arc" />
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_EA0140D266E0BCE6FE8878234EC6E797_verboseLabel_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_EA0140D266E0BCE6FE8878234EC6E797" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities Non-current</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_EA0140D266E0BCE6FE8878234EC6E797_label_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_EA0140D266E0BCE6FE8878234EC6E797" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mortgage And Other Asset Backed Securities Non Current [Member]</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_EA0140D266E0BCE6FE8878234EC6E797_documentation_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_EA0140D266E0BCE6FE8878234EC6E797" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mortgage And Other Asset Backed Securities Non Current.</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_EA0140D266E0BCE6FE8878234EC6E797" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_EA0140D266E0BCE6FE8878234EC6E797" xlink:to="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_EA0140D266E0BCE6FE8878234EC6E797" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesMember_B54C5E89489CAEF48A6278234EC7E2A9_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember_B54C5E89489CAEF48A6278234EC7E2A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_B54C5E89489CAEF48A6278234EC7E2A9_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember_B54C5E89489CAEF48A6278234EC7E2A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_B54C5E89489CAEF48A6278234EC7E2A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember_B54C5E89489CAEF48A6278234EC7E2A9" xlink:to="lab_us-gaap_EquitySecuritiesMember_B54C5E89489CAEF48A6278234EC7E2A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3610FB7AA46300C7B49778234EC788C8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3610FB7AA46300C7B49778234EC788C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3610FB7AA46300C7B49778234EC788C8_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3610FB7AA46300C7B49778234EC788C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3610FB7AA46300C7B49778234EC788C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3610FB7AA46300C7B49778234EC788C8" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3610FB7AA46300C7B49778234EC788C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_075AE495E556ECF92EF978234EC765B0_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_075AE495E556ECF92EF978234EC765B0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_075AE495E556ECF92EF978234EC765B0_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_075AE495E556ECF92EF978234EC765B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_075AE495E556ECF92EF978234EC765B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_075AE495E556ECF92EF978234EC765B0" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_075AE495E556ECF92EF978234EC765B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0813CC192AEDDD7955C478234ECDEDC5_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0813CC192AEDDD7955C478234ECDEDC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0813CC192AEDDD7955C478234ECDEDC5_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0813CC192AEDDD7955C478234ECDEDC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0813CC192AEDDD7955C478234ECDEDC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0813CC192AEDDD7955C478234ECDEDC5" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0813CC192AEDDD7955C478234ECDEDC5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_29AF053459D656440B3378234ECDF713_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_29AF053459D656440B3378234ECDF713" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_29AF053459D656440B3378234ECDF713_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_29AF053459D656440B3378234ECDF713" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_29AF053459D656440B3378234ECDF713" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_29AF053459D656440B3378234ECDF713" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_29AF053459D656440B3378234ECDF713" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_A64B06DDFFDC0BCEE3C778234ECDD128_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_A64B06DDFFDC0BCEE3C778234ECDD128" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_A64B06DDFFDC0BCEE3C778234ECDD128" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_A64B06DDFFDC0BCEE3C778234ECDD128" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_A64B06DDFFDC0BCEE3C778234ECDD128" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_D9CB118088444C1E90B478234ECD1B63_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_D9CB118088444C1E90B478234ECD1B63" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_D9CB118088444C1E90B478234ECD1B63_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_D9CB118088444C1E90B478234ECD1B63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_D9CB118088444C1E90B478234ECD1B63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_D9CB118088444C1E90B478234ECD1B63" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_D9CB118088444C1E90B478234ECD1B63" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_10703108CA9FA0320E5278234ECD27ED_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_10703108CA9FA0320E5278234ECD27ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities, gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_10703108CA9FA0320E5278234ECD27ED_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_10703108CA9FA0320E5278234ECD27ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_10703108CA9FA0320E5278234ECD27ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_10703108CA9FA0320E5278234ECD27ED" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_10703108CA9FA0320E5278234ECD27ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_FE85476A8D800045C41178234ECEA474_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_FE85476A8D800045C41178234ECEA474" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities, gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_FE85476A8D800045C41178234ECEA474_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_FE85476A8D800045C41178234ECEA474" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_FE85476A8D800045C41178234ECEA474" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_FE85476A8D800045C41178234ECEA474" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_FE85476A8D800045C41178234ECEA474" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_00272BF809828F29FDAF78234ECE20BF_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_00272BF809828F29FDAF78234ECE20BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities, fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_00272BF809828F29FDAF78234ECE20BF_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_00272BF809828F29FDAF78234ECE20BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_00272BF809828F29FDAF78234ECE20BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_00272BF809828F29FDAF78234ECE20BF" xlink:to="lab_us-gaap_AvailableForSaleSecurities_00272BF809828F29FDAF78234ECE20BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_D4C408D7D40695F8B19D78234D284AB2_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_D4C408D7D40695F8B19D78234D284AB2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_D4C408D7D40695F8B19D78234D284AB2_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_D4C408D7D40695F8B19D78234D284AB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_D4C408D7D40695F8B19D78234D284AB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_D4C408D7D40695F8B19D78234D284AB2" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_D4C408D7D40695F8B19D78234D284AB2" xlink:type="arc" />
    <link:label id="lab_biib_DistributorOneMember_C2D0EB3A95B5FA29127678235016F44C_terseLabel_en-US" xlink:label="lab_biib_DistributorOneMember_C2D0EB3A95B5FA29127678235016F44C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distributor One</link:label>
    <link:label id="lab_biib_DistributorOneMember_C2D0EB3A95B5FA29127678235016F44C_label_en-US" xlink:label="lab_biib_DistributorOneMember_C2D0EB3A95B5FA29127678235016F44C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distributor One [Member]</link:label>
    <link:label id="lab_biib_DistributorOneMember_C2D0EB3A95B5FA29127678235016F44C_documentation_en-US" xlink:label="lab_biib_DistributorOneMember_C2D0EB3A95B5FA29127678235016F44C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Distributor one.</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_DistributorOneMember" xlink:label="loc_biib_DistributorOneMember_C2D0EB3A95B5FA29127678235016F44C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorOneMember_C2D0EB3A95B5FA29127678235016F44C" xlink:to="lab_biib_DistributorOneMember_C2D0EB3A95B5FA29127678235016F44C" xlink:type="arc" />
    <link:label id="lab_biib_DistributorTwoMember_B8D32C90F9C9D1934A1E78235016290B_terseLabel_en-US" xlink:label="lab_biib_DistributorTwoMember_B8D32C90F9C9D1934A1E78235016290B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distributor Two</link:label>
    <link:label id="lab_biib_DistributorTwoMember_B8D32C90F9C9D1934A1E78235016290B_label_en-US" xlink:label="lab_biib_DistributorTwoMember_B8D32C90F9C9D1934A1E78235016290B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distributor Two [Member]</link:label>
    <link:label id="lab_biib_DistributorTwoMember_B8D32C90F9C9D1934A1E78235016290B_documentation_en-US" xlink:label="lab_biib_DistributorTwoMember_B8D32C90F9C9D1934A1E78235016290B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Distributor two.</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_DistributorTwoMember" xlink:label="loc_biib_DistributorTwoMember_B8D32C90F9C9D1934A1E78235016290B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorTwoMember_B8D32C90F9C9D1934A1E78235016290B" xlink:to="lab_biib_DistributorTwoMember_B8D32C90F9C9D1934A1E78235016290B" xlink:type="arc" />
    <link:label id="lab_biib_BioverativMember_8B7927962413B588F923782350167B7F_terseLabel_en-US" xlink:label="lab_biib_BioverativMember_8B7927962413B588F923782350167B7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bioverativ</link:label>
    <link:label id="lab_biib_BioverativMember_8B7927962413B588F923782350167B7F_label_en-US" xlink:label="lab_biib_BioverativMember_8B7927962413B588F923782350167B7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bioverativ [Member]</link:label>
    <link:label id="lab_biib_BioverativMember_8B7927962413B588F923782350167B7F_documentation_en-US" xlink:label="lab_biib_BioverativMember_8B7927962413B588F923782350167B7F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bioverativ [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_8B7927962413B588F923782350167B7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BioverativMember_8B7927962413B588F923782350167B7F" xlink:to="lab_biib_BioverativMember_8B7927962413B588F923782350167B7F" xlink:type="arc" />
    <link:label id="lab_biib_ContractManufacturingCustomerMember_421DE5FDD2A26DC9960D7823501769BA_terseLabel_en-US" xlink:label="lab_biib_ContractManufacturingCustomerMember_421DE5FDD2A26DC9960D7823501769BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract Manufacturing Customer</link:label>
    <link:label id="lab_biib_ContractManufacturingCustomerMember_421DE5FDD2A26DC9960D7823501769BA_label_en-US" xlink:label="lab_biib_ContractManufacturingCustomerMember_421DE5FDD2A26DC9960D7823501769BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Manufacturing Customer [Member]</link:label>
    <link:label id="lab_biib_ContractManufacturingCustomerMember_421DE5FDD2A26DC9960D7823501769BA_documentation_en-US" xlink:label="lab_biib_ContractManufacturingCustomerMember_421DE5FDD2A26DC9960D7823501769BA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract Manufacturing Customer [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_ContractManufacturingCustomerMember" xlink:label="loc_biib_ContractManufacturingCustomerMember_421DE5FDD2A26DC9960D7823501769BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContractManufacturingCustomerMember_421DE5FDD2A26DC9960D7823501769BA" xlink:to="lab_biib_ContractManufacturingCustomerMember_421DE5FDD2A26DC9960D7823501769BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_E0B66F761FBE97C5F75678235017C2BC_netLabel_en-US" xlink:label="lab_us-gaap_Revenues_E0B66F761FBE97C5F75678235017C2BC" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Other Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_E0B66F761FBE97C5F75678235017C2BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_E0B66F761FBE97C5F75678235017C2BC" xlink:to="lab_us-gaap_Revenues_E0B66F761FBE97C5F75678235017C2BC" xlink:type="arc" />
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_6BBF904EAA1BE4D0EDB178235017287B_terseLabel_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_6BBF904EAA1BE4D0EDB178235017287B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of revenues from major distributors</link:label>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_6BBF904EAA1BE4D0EDB178235017287B_label_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_6BBF904EAA1BE4D0EDB178235017287B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Wide Percentage Of Revenue From Major Distributors</link:label>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_6BBF904EAA1BE4D0EDB178235017287B_documentation_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_6BBF904EAA1BE4D0EDB178235017287B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Entity wide percentage of revenue from major distributors.</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_6BBF904EAA1BE4D0EDB178235017287B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_6BBF904EAA1BE4D0EDB178235017287B" xlink:to="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_6BBF904EAA1BE4D0EDB178235017287B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_286E63D60C033A7C192178234CC70529_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_286E63D60C033A7C192178234CC70529" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaborative and Other Relationships</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_286E63D60C033A7C192178234CC70529_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_286E63D60C033A7C192178234CC70529" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_286E63D60C033A7C192178234CC70529" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_286E63D60C033A7C192178234CC70529" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_286E63D60C033A7C192178234CC70529" xlink:type="arc" />
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_8770E92C5EFDA9C5087D78234E89BFB1_verboseLabel_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities_8770E92C5EFDA9C5087D78234E89BFB1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Average maturity of marketable securities, months</link:label>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_8770E92C5EFDA9C5087D78234E89BFB1_label_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities_8770E92C5EFDA9C5087D78234E89BFB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average Maturity Of Marketable Securities</link:label>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_8770E92C5EFDA9C5087D78234E89BFB1_documentation_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities_8770E92C5EFDA9C5087D78234E89BFB1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Average remaining time to maturity of marketable debt securities, available-for-sale securities.</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_AverageMaturityOfMarketableSecurities" xlink:label="loc_biib_AverageMaturityOfMarketableSecurities_8770E92C5EFDA9C5087D78234E89BFB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AverageMaturityOfMarketableSecurities_8770E92C5EFDA9C5087D78234E89BFB1" xlink:to="lab_biib_AverageMaturityOfMarketableSecurities_8770E92C5EFDA9C5087D78234E89BFB1" xlink:type="arc" />
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_920D8EE3DD5545B0B182782351056E69_verboseLabel_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock_920D8EE3DD5545B0B182782351056E69" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Overview</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_920D8EE3DD5545B0B182782351056E69_label_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock_920D8EE3DD5545B0B182782351056E69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Overview [Policy Text Block]</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_920D8EE3DD5545B0B182782351056E69_documentation_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock_920D8EE3DD5545B0B182782351056E69" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Describes an overview of the company and its operations.</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_BusinessOverviewPolicyTextBlock" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock_920D8EE3DD5545B0B182782351056E69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessOverviewPolicyTextBlock_920D8EE3DD5545B0B182782351056E69" xlink:to="lab_biib_BusinessOverviewPolicyTextBlock_920D8EE3DD5545B0B182782351056E69" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_AF0144013E394B38FBE078235106AAC1_verboseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_AF0144013E394B38FBE078235106AAC1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_AF0144013E394B38FBE078235106AAC1_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_AF0144013E394B38FBE078235106AAC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_AF0144013E394B38FBE078235106AAC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_AF0144013E394B38FBE078235106AAC1" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_AF0144013E394B38FBE078235106AAC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_D03B3AA90F7CD608172C782351069C51_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_D03B3AA90F7CD608172C782351069C51" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_D03B3AA90F7CD608172C782351069C51_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_D03B3AA90F7CD608172C782351069C51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_D03B3AA90F7CD608172C782351069C51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_D03B3AA90F7CD608172C782351069C51" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_D03B3AA90F7CD608172C782351069C51" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_60C7A82614F9595C49207823510666AE_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_60C7A82614F9595C49207823510666AE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_60C7A82614F9595C49207823510666AE_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_60C7A82614F9595C49207823510666AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_60C7A82614F9595C49207823510666AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_60C7A82614F9595C49207823510666AE" xlink:to="lab_us-gaap_UseOfEstimates_60C7A82614F9595C49207823510666AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8DA8165CA707EB972E40782351060E23_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8DA8165CA707EB972E40782351060E23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8DA8165CA707EB972E40782351060E23_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8DA8165CA707EB972E40782351060E23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8DA8165CA707EB972E40782351060E23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8DA8165CA707EB972E40782351060E23" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8DA8165CA707EB972E40782351060E23" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_F532A08455576B95B57178234C666A29_label_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_F532A08455576B95B57178234C666A29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Variable Interest Entities [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_F532A08455576B95B57178234C666A29_documentation_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_F532A08455576B95B57178234C666A29" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investments In Variable Interest Entities.</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_F532A08455576B95B57178234C666A29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_F532A08455576B95B57178234C666A29" xlink:to="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_F532A08455576B95B57178234C666A29" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_19F29B8F037FB95C2B7778234C662169_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_19F29B8F037FB95C2B7778234C662169" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_19F29B8F037FB95C2B7778234C662169_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_19F29B8F037FB95C2B7778234C662169" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_19F29B8F037FB95C2B7778234C662169" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_19F29B8F037FB95C2B7778234C662169" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_19F29B8F037FB95C2B7778234C662169" xlink:type="arc" />
    <link:label id="lab_biib_EisaiMember_2A81DEE4099BF4CC387678234C6774D8_terseLabel_en-US" xlink:label="lab_biib_EisaiMember_2A81DEE4099BF4CC387678234C6774D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eisai</link:label>
    <link:label id="lab_biib_EisaiMember_2A81DEE4099BF4CC387678234C6774D8_label_en-US" xlink:label="lab_biib_EisaiMember_2A81DEE4099BF4CC387678234C6774D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eisai [Member]</link:label>
    <link:label id="lab_biib_EisaiMember_2A81DEE4099BF4CC387678234C6774D8_documentation_en-US" xlink:label="lab_biib_EisaiMember_2A81DEE4099BF4CC387678234C6774D8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Eisai [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_2A81DEE4099BF4CC387678234C6774D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EisaiMember_2A81DEE4099BF4CC387678234C6774D8" xlink:to="lab_biib_EisaiMember_2A81DEE4099BF4CC387678234C6774D8" xlink:type="arc" />
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_2842361347B424BEFCAF78234C6890CF_terseLabel_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis_2842361347B424BEFCAF78234C6890CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_2842361347B424BEFCAF78234C6890CF_label_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis_2842361347B424BEFCAF78234C6890CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_2842361347B424BEFCAF78234C6890CF_documentation_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis_2842361347B424BEFCAF78234C6890CF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_FutureContingentMilestoneTypesAxis" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_2842361347B424BEFCAF78234C6890CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_2842361347B424BEFCAF78234C6890CF" xlink:to="lab_biib_FutureContingentMilestoneTypesAxis_2842361347B424BEFCAF78234C6890CF" xlink:type="arc" />
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_31044A41FFB446F3BDFB78234C68AD95_terseLabel_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain_31044A41FFB446F3BDFB78234C68AD95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Domain]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_31044A41FFB446F3BDFB78234C68AD95_label_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain_31044A41FFB446F3BDFB78234C68AD95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Domain]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_31044A41FFB446F3BDFB78234C68AD95_documentation_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain_31044A41FFB446F3BDFB78234C68AD95" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Future Contingent Milestone Types [Axis]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_FutureContingentMilestoneTypesDomain" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_31044A41FFB446F3BDFB78234C68AD95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_31044A41FFB446F3BDFB78234C68AD95" xlink:to="lab_biib_FutureContingentMilestoneTypesDomain_31044A41FFB446F3BDFB78234C68AD95" xlink:type="arc" />
    <link:label id="lab_biib_RegulatoryMilestonesMember_CB8C74A49C4DAF72167978234C696627_terseLabel_en-US" xlink:label="lab_biib_RegulatoryMilestonesMember_CB8C74A49C4DAF72167978234C696627" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:label id="lab_biib_RegulatoryMilestonesMember_CB8C74A49C4DAF72167978234C696627_label_en-US" xlink:label="lab_biib_RegulatoryMilestonesMember_CB8C74A49C4DAF72167978234C696627" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:label id="lab_biib_RegulatoryMilestonesMember_CB8C74A49C4DAF72167978234C696627_documentation_en-US" xlink:label="lab_biib_RegulatoryMilestonesMember_CB8C74A49C4DAF72167978234C696627" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_RegulatoryMilestonesMember" xlink:label="loc_biib_RegulatoryMilestonesMember_CB8C74A49C4DAF72167978234C696627" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RegulatoryMilestonesMember_CB8C74A49C4DAF72167978234C696627" xlink:to="lab_biib_RegulatoryMilestonesMember_CB8C74A49C4DAF72167978234C696627" xlink:type="arc" />
    <link:label id="lab_biib_RegulatoryApprovalMilestoneMember_C072C0AAF618AC059E5D78234C69CAA1_terseLabel_en-US" xlink:label="lab_biib_RegulatoryApprovalMilestoneMember_C072C0AAF618AC059E5D78234C69CAA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Regulatory Approval Milestone [Member]</link:label>
    <link:label id="lab_biib_RegulatoryApprovalMilestoneMember_C072C0AAF618AC059E5D78234C69CAA1_label_en-US" xlink:label="lab_biib_RegulatoryApprovalMilestoneMember_C072C0AAF618AC059E5D78234C69CAA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Regulatory Approval Milestone [Member]</link:label>
    <link:label id="lab_biib_RegulatoryApprovalMilestoneMember_C072C0AAF618AC059E5D78234C69CAA1_documentation_en-US" xlink:label="lab_biib_RegulatoryApprovalMilestoneMember_C072C0AAF618AC059E5D78234C69CAA1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Regulatory Approval Milestone [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_RegulatoryApprovalMilestoneMember" xlink:label="loc_biib_RegulatoryApprovalMilestoneMember_C072C0AAF618AC059E5D78234C69CAA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RegulatoryApprovalMilestoneMember_C072C0AAF618AC059E5D78234C69CAA1" xlink:to="lab_biib_RegulatoryApprovalMilestoneMember_C072C0AAF618AC059E5D78234C69CAA1" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_BA48A33032B89FB6206478234C6922F3_terseLabel_en-US" xlink:label="lab_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_BA48A33032B89FB6206478234C6922F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments By Consolidated And Nonconsolidated Entities [Axis]</link:label>
    <link:label id="lab_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_BA48A33032B89FB6206478234C6922F3_label_en-US" xlink:label="lab_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_BA48A33032B89FB6206478234C6922F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments By Consolidated And Nonconsolidated Entities [Axis]</link:label>
    <link:label id="lab_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_BA48A33032B89FB6206478234C6922F3_documentation_en-US" xlink:label="lab_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_BA48A33032B89FB6206478234C6922F3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investments By Consolidated And Nonconsolidated Entities [Axis]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis" xlink:label="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_BA48A33032B89FB6206478234C6922F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_BA48A33032B89FB6206478234C6922F3" xlink:to="lab_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_BA48A33032B89FB6206478234C6922F3" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_9426A7331D0DD760FC3478234C694B52_terseLabel_en-US" xlink:label="lab_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_9426A7331D0DD760FC3478234C694B52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments By Consolidated And Nonconsolidated Entities [Domain]</link:label>
    <link:label id="lab_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_9426A7331D0DD760FC3478234C694B52_label_en-US" xlink:label="lab_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_9426A7331D0DD760FC3478234C694B52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments By Consolidated And Nonconsolidated Entities [Domain]</link:label>
    <link:label id="lab_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_9426A7331D0DD760FC3478234C694B52_documentation_en-US" xlink:label="lab_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_9426A7331D0DD760FC3478234C694B52" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Investments By Consolidated And Nonconsolidated Entities [Axis]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain" xlink:label="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_9426A7331D0DD760FC3478234C694B52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_9426A7331D0DD760FC3478234C694B52" xlink:to="lab_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_9426A7331D0DD760FC3478234C694B52" xlink:type="arc" />
    <link:label id="lab_biib_NeurimmuneMember_7517F11EB14032A097C478234C6A5AFA_terseLabel_en-US" xlink:label="lab_biib_NeurimmuneMember_7517F11EB14032A097C478234C6A5AFA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Neurimmune</link:label>
    <link:label id="lab_biib_NeurimmuneMember_7517F11EB14032A097C478234C6A5AFA_label_en-US" xlink:label="lab_biib_NeurimmuneMember_7517F11EB14032A097C478234C6A5AFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Neurimmune [Member]</link:label>
    <link:label id="lab_biib_NeurimmuneMember_7517F11EB14032A097C478234C6A5AFA_documentation_en-US" xlink:label="lab_biib_NeurimmuneMember_7517F11EB14032A097C478234C6A5AFA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Neurimmune.</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_7517F11EB14032A097C478234C6A5AFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NeurimmuneMember_7517F11EB14032A097C478234C6A5AFA" xlink:to="lab_biib_NeurimmuneMember_7517F11EB14032A097C478234C6A5AFA" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_A4ABAAD5C498E9BBCB2A78234C6A3994_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems_A4ABAAD5C498E9BBCB2A78234C6A3994" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_A4ABAAD5C498E9BBCB2A78234C6A3994_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems_A4ABAAD5C498E9BBCB2A78234C6A3994" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_A4ABAAD5C498E9BBCB2A78234C6A3994" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_A4ABAAD5C498E9BBCB2A78234C6A3994" xlink:to="lab_us-gaap_VariableInterestEntityLineItems_A4ABAAD5C498E9BBCB2A78234C6A3994" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_0DD29C1ECA3DE8945DE578234C6B2212_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders_0DD29C1ECA3DE8945DE578234C6B2212" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_0DD29C1ECA3DE8945DE578234C6B2212" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToMinorityShareholders_0DD29C1ECA3DE8945DE578234C6B2212" xlink:to="lab_us-gaap_PaymentsToMinorityShareholders_0DD29C1ECA3DE8945DE578234C6B2212" xlink:type="arc" />
    <link:label id="lab_biib_Reductioninroyaltyratepayableoncommercialsales_BBC11FD3CAF1D16B14B578234C6B13E9_terseLabel_en-US" xlink:label="lab_biib_Reductioninroyaltyratepayableoncommercialsales_BBC11FD3CAF1D16B14B578234C6B13E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction in royalty rate payable on commercial sales</link:label>
    <link:label id="lab_biib_Reductioninroyaltyratepayableoncommercialsales_BBC11FD3CAF1D16B14B578234C6B13E9_label_en-US" xlink:label="lab_biib_Reductioninroyaltyratepayableoncommercialsales_BBC11FD3CAF1D16B14B578234C6B13E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reduction in royalty rate payable on commercial sales</link:label>
    <link:label id="lab_biib_Reductioninroyaltyratepayableoncommercialsales_BBC11FD3CAF1D16B14B578234C6B13E9_documentation_en-US" xlink:label="lab_biib_Reductioninroyaltyratepayableoncommercialsales_BBC11FD3CAF1D16B14B578234C6B13E9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reduction in royalty rate payable on commercial sales</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_Reductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Reductioninroyaltyratepayableoncommercialsales_BBC11FD3CAF1D16B14B578234C6B13E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Reductioninroyaltyratepayableoncommercialsales_BBC11FD3CAF1D16B14B578234C6B13E9" xlink:to="lab_biib_Reductioninroyaltyratepayableoncommercialsales_BBC11FD3CAF1D16B14B578234C6B13E9" xlink:type="arc" />
    <link:label id="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_2B02760E96971A78433778234C6BEDE5_terseLabel_en-US" xlink:label="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_2B02760E96971A78433778234C6BEDE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional reduction in royalty rate payable on commercial sales</link:label>
    <link:label id="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_2B02760E96971A78433778234C6BEDE5_label_en-US" xlink:label="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_2B02760E96971A78433778234C6BEDE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional reduction in royalty rate payable on commercial sales</link:label>
    <link:label id="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_2B02760E96971A78433778234C6BEDE5_documentation_en-US" xlink:label="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_2B02760E96971A78433778234C6BEDE5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional reduction in royalty rate payable on commercial sales</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_2B02760E96971A78433778234C6BEDE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_2B02760E96971A78433778234C6BEDE5" xlink:to="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_2B02760E96971A78433778234C6BEDE5" xlink:type="arc" />
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_370FB2EF4825033F9EFB78234C6BEBF2_terseLabel_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_370FB2EF4825033F9EFB78234C6BEBF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential Future Milestone Payments Commitment To Third Party Approximately</link:label>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_370FB2EF4825033F9EFB78234C6BEBF2_label_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_370FB2EF4825033F9EFB78234C6BEBF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Future Milestone Payments Commitment To Third Party Approximately</link:label>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_370FB2EF4825033F9EFB78234C6BEBF2_documentation_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_370FB2EF4825033F9EFB78234C6BEBF2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential future milestone payments commitment to third party approximately.</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_370FB2EF4825033F9EFB78234C6BEBF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_370FB2EF4825033F9EFB78234C6BEBF2" xlink:to="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_370FB2EF4825033F9EFB78234C6BEBF2" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_B4F043DFE0E3D7D4430978234C6C4C48_verboseLabel_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_B4F043DFE0E3D7D4430978234C6C4C48" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_B4F043DFE0E3D7D4430978234C6C4C48_label_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_B4F043DFE0E3D7D4430978234C6C4C48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_B4F043DFE0E3D7D4430978234C6C4C48_documentation_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_B4F043DFE0E3D7D4430978234C6C4C48" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_B4F043DFE0E3D7D4430978234C6C4C48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_B4F043DFE0E3D7D4430978234C6C4C48" xlink:to="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_B4F043DFE0E3D7D4430978234C6C4C48" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_C03939633FFE3886E14978234C6CC228_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_C03939633FFE3886E14978234C6CC228" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eisai's share of aducanumab milestone expense reflected in collaboration profit sharing in our condensed consolidated statements of income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_C03939633FFE3886E14978234C6CC228" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments_C03939633FFE3886E14978234C6CC228" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments_C03939633FFE3886E14978234C6CC228" xlink:type="arc" />
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_4C9E680928B0674C70FD78234C6C7C08_terseLabel_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_4C9E680928B0674C70FD78234C6C7C08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_4C9E680928B0674C70FD78234C6C7C08_label_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_4C9E680928B0674C70FD78234C6C7C08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_4C9E680928B0674C70FD78234C6C7C08_documentation_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_4C9E680928B0674C70FD78234C6C7C08" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_4C9E680928B0674C70FD78234C6C7C08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_4C9E680928B0674C70FD78234C6C7C08" xlink:to="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_4C9E680928B0674C70FD78234C6C7C08" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_8EEA9DB70C0611AF399F78234D028F2F_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_8EEA9DB70C0611AF399F78234D028F2F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other Consolidated Financial Statement Detail</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_8EEA9DB70C0611AF399F78234D028F2F_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_8EEA9DB70C0611AF399F78234D028F2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_8EEA9DB70C0611AF399F78234D028F2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_8EEA9DB70C0611AF399F78234D028F2F" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_8EEA9DB70C0611AF399F78234D028F2F" xlink:type="arc" />
    <link:label id="lab_dei_CoverAbstract_D15715C11618919C04AD782351CACC51_label_en-US" xlink:label="lab_dei_CoverAbstract_D15715C11618919C04AD782351CACC51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_D15715C11618919C04AD782351CACC51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract_D15715C11618919C04AD782351CACC51" xlink:to="lab_dei_CoverAbstract_D15715C11618919C04AD782351CACC51" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_D3AE7B05FD7E530D800A782351CA7110_terseLabel_en-US" xlink:label="lab_dei_DocumentType_D3AE7B05FD7E530D800A782351CA7110" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_D3AE7B05FD7E530D800A782351CA7110_label_en-US" xlink:label="lab_dei_DocumentType_D3AE7B05FD7E530D800A782351CA7110" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_D3AE7B05FD7E530D800A782351CA7110" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_D3AE7B05FD7E530D800A782351CA7110" xlink:to="lab_dei_DocumentType_D3AE7B05FD7E530D800A782351CA7110" xlink:type="arc" />
    <link:label id="lab_dei_DocumentQuarterlyReport_40FF1E0DEF3C6E0A1284782351CBAFAE_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport_40FF1E0DEF3C6E0A1284782351CBAFAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_40FF1E0DEF3C6E0A1284782351CBAFAE_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport_40FF1E0DEF3C6E0A1284782351CBAFAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_40FF1E0DEF3C6E0A1284782351CBAFAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport_40FF1E0DEF3C6E0A1284782351CBAFAE" xlink:to="lab_dei_DocumentQuarterlyReport_40FF1E0DEF3C6E0A1284782351CBAFAE" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_A8413427EC8849147390782351CBB3DB_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_A8413427EC8849147390782351CBB3DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_A8413427EC8849147390782351CBB3DB_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_A8413427EC8849147390782351CBB3DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_A8413427EC8849147390782351CBB3DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_A8413427EC8849147390782351CBB3DB" xlink:to="lab_dei_DocumentPeriodEndDate_A8413427EC8849147390782351CBB3DB" xlink:type="arc" />
    <link:label id="lab_dei_DocumentTransitionReport_95C1BB36A59596150E1E782351CBDD07_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport_95C1BB36A59596150E1E782351CBDD07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_95C1BB36A59596150E1E782351CBDD07_label_en-US" xlink:label="lab_dei_DocumentTransitionReport_95C1BB36A59596150E1E782351CBDD07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_95C1BB36A59596150E1E782351CBDD07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport_95C1BB36A59596150E1E782351CBDD07" xlink:to="lab_dei_DocumentTransitionReport_95C1BB36A59596150E1E782351CBDD07" xlink:type="arc" />
    <link:label id="lab_dei_EntityFileNumber_FBD8FF5B470D44CC9A7B782351CBF48D_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber_FBD8FF5B470D44CC9A7B782351CBF48D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_FBD8FF5B470D44CC9A7B782351CBF48D_label_en-US" xlink:label="lab_dei_EntityFileNumber_FBD8FF5B470D44CC9A7B782351CBF48D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_FBD8FF5B470D44CC9A7B782351CBF48D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_FBD8FF5B470D44CC9A7B782351CBF48D" xlink:to="lab_dei_EntityFileNumber_FBD8FF5B470D44CC9A7B782351CBF48D" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_E7CDFB7AA4AFEAC23E26782351CB2250_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_E7CDFB7AA4AFEAC23E26782351CB2250" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_E7CDFB7AA4AFEAC23E26782351CB2250_label_en-US" xlink:label="lab_dei_EntityRegistrantName_E7CDFB7AA4AFEAC23E26782351CB2250" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_E7CDFB7AA4AFEAC23E26782351CB2250" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_E7CDFB7AA4AFEAC23E26782351CB2250" xlink:to="lab_dei_EntityRegistrantName_E7CDFB7AA4AFEAC23E26782351CB2250" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_AFEEB291AACA57AA95E6782351CCDF6D_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_AFEEB291AACA57AA95E6782351CCDF6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_AFEEB291AACA57AA95E6782351CCDF6D_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_AFEEB291AACA57AA95E6782351CCDF6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_AFEEB291AACA57AA95E6782351CCDF6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_AFEEB291AACA57AA95E6782351CCDF6D" xlink:to="lab_dei_EntityCentralIndexKey_AFEEB291AACA57AA95E6782351CCDF6D" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_7BC5C9FA952D8D6534C9782351CC2718_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_7BC5C9FA952D8D6534C9782351CC2718" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_7BC5C9FA952D8D6534C9782351CC2718_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_7BC5C9FA952D8D6534C9782351CC2718" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_7BC5C9FA952D8D6534C9782351CC2718" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_7BC5C9FA952D8D6534C9782351CC2718" xlink:to="lab_dei_CurrentFiscalYearEndDate_7BC5C9FA952D8D6534C9782351CC2718" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_6F44A6836C18E4E8E52E782351CCC23E_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_6F44A6836C18E4E8E52E782351CCC23E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_6F44A6836C18E4E8E52E782351CCC23E_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_6F44A6836C18E4E8E52E782351CCC23E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_6F44A6836C18E4E8E52E782351CCC23E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_6F44A6836C18E4E8E52E782351CCC23E" xlink:to="lab_dei_DocumentFiscalYearFocus_6F44A6836C18E4E8E52E782351CCC23E" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_FCE476F975CA4F1BBFFB782351CCE485_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_FCE476F975CA4F1BBFFB782351CCE485" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_FCE476F975CA4F1BBFFB782351CCE485_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_FCE476F975CA4F1BBFFB782351CCE485" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_FCE476F975CA4F1BBFFB782351CCE485" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_FCE476F975CA4F1BBFFB782351CCE485" xlink:to="lab_dei_DocumentFiscalPeriodFocus_FCE476F975CA4F1BBFFB782351CCE485" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_8FB08B8D0C74434482FB782351CCC9F8_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_8FB08B8D0C74434482FB782351CCC9F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_8FB08B8D0C74434482FB782351CCC9F8_label_en-US" xlink:label="lab_dei_AmendmentFlag_8FB08B8D0C74434482FB782351CCC9F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_8FB08B8D0C74434482FB782351CCC9F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_8FB08B8D0C74434482FB782351CCC9F8" xlink:to="lab_dei_AmendmentFlag_8FB08B8D0C74434482FB782351CCC9F8" xlink:type="arc" />
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_270884B2D93C0BDA78CD782351CC2EBF_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_270884B2D93C0BDA78CD782351CC2EBF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_270884B2D93C0BDA78CD782351CC2EBF_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_270884B2D93C0BDA78CD782351CC2EBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_270884B2D93C0BDA78CD782351CC2EBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_270884B2D93C0BDA78CD782351CC2EBF" xlink:to="lab_dei_EntityIncorporationStateCountryCode_270884B2D93C0BDA78CD782351CC2EBF" xlink:type="arc" />
    <link:label id="lab_dei_EntityTaxIdentificationNumber_B0E3953D8A7ADDD9FB07782351CDA65B_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_B0E3953D8A7ADDD9FB07782351CDA65B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_B0E3953D8A7ADDD9FB07782351CDA65B_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_B0E3953D8A7ADDD9FB07782351CDA65B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_B0E3953D8A7ADDD9FB07782351CDA65B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber_B0E3953D8A7ADDD9FB07782351CDA65B" xlink:to="lab_dei_EntityTaxIdentificationNumber_B0E3953D8A7ADDD9FB07782351CDA65B" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressAddressLine1_E6D80444F4F42E097469782351CD555F_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_E6D80444F4F42E097469782351CD555F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_E6D80444F4F42E097469782351CD555F_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_E6D80444F4F42E097469782351CD555F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_E6D80444F4F42E097469782351CD555F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_E6D80444F4F42E097469782351CD555F" xlink:to="lab_dei_EntityAddressAddressLine1_E6D80444F4F42E097469782351CD555F" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressCityOrTown_C9083973DCA0D09743BA782351CDC4DC_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_C9083973DCA0D09743BA782351CDC4DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_C9083973DCA0D09743BA782351CDC4DC_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_C9083973DCA0D09743BA782351CDC4DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_C9083973DCA0D09743BA782351CDC4DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_C9083973DCA0D09743BA782351CDC4DC" xlink:to="lab_dei_EntityAddressCityOrTown_C9083973DCA0D09743BA782351CDC4DC" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressStateOrProvince_928A5EC05C6B9327C08A782351CD6793_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_928A5EC05C6B9327C08A782351CD6793" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_928A5EC05C6B9327C08A782351CD6793_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_928A5EC05C6B9327C08A782351CD6793" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_928A5EC05C6B9327C08A782351CD6793" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince_928A5EC05C6B9327C08A782351CD6793" xlink:to="lab_dei_EntityAddressStateOrProvince_928A5EC05C6B9327C08A782351CD6793" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressPostalZipCode_3309D2AE2EF01EF8238D782351CD2389_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_3309D2AE2EF01EF8238D782351CD2389" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_3309D2AE2EF01EF8238D782351CD2389_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_3309D2AE2EF01EF8238D782351CD2389" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_3309D2AE2EF01EF8238D782351CD2389" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_3309D2AE2EF01EF8238D782351CD2389" xlink:to="lab_dei_EntityAddressPostalZipCode_3309D2AE2EF01EF8238D782351CD2389" xlink:type="arc" />
    <link:label id="lab_dei_CityAreaCode_10032987D1B9BC59D53F782351CE0C55_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode_10032987D1B9BC59D53F782351CE0C55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_10032987D1B9BC59D53F782351CE0C55_label_en-US" xlink:label="lab_dei_CityAreaCode_10032987D1B9BC59D53F782351CE0C55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_10032987D1B9BC59D53F782351CE0C55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_10032987D1B9BC59D53F782351CE0C55" xlink:to="lab_dei_CityAreaCode_10032987D1B9BC59D53F782351CE0C55" xlink:type="arc" />
    <link:label id="lab_dei_LocalPhoneNumber_3A3BBF8BB3810271D26B782351CE2AE2_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber_3A3BBF8BB3810271D26B782351CE2AE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_3A3BBF8BB3810271D26B782351CE2AE2_label_en-US" xlink:label="lab_dei_LocalPhoneNumber_3A3BBF8BB3810271D26B782351CE2AE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_3A3BBF8BB3810271D26B782351CE2AE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_3A3BBF8BB3810271D26B782351CE2AE2" xlink:to="lab_dei_LocalPhoneNumber_3A3BBF8BB3810271D26B782351CE2AE2" xlink:type="arc" />
    <link:label id="lab_dei_Security12bTitle_897086EE4FFBCDDE6AE1782351CE8CE3_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle_897086EE4FFBCDDE6AE1782351CE8CE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_897086EE4FFBCDDE6AE1782351CE8CE3_label_en-US" xlink:label="lab_dei_Security12bTitle_897086EE4FFBCDDE6AE1782351CE8CE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_897086EE4FFBCDDE6AE1782351CE8CE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_897086EE4FFBCDDE6AE1782351CE8CE3" xlink:to="lab_dei_Security12bTitle_897086EE4FFBCDDE6AE1782351CE8CE3" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_968AE5B1A13128993E4C782351CEEAF4_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_968AE5B1A13128993E4C782351CEEAF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_968AE5B1A13128993E4C782351CEEAF4_label_en-US" xlink:label="lab_dei_TradingSymbol_968AE5B1A13128993E4C782351CEEAF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_968AE5B1A13128993E4C782351CEEAF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_968AE5B1A13128993E4C782351CEEAF4" xlink:to="lab_dei_TradingSymbol_968AE5B1A13128993E4C782351CEEAF4" xlink:type="arc" />
    <link:label id="lab_dei_SecurityExchangeName_75A27F0004CCC5F36A04782351CE11D5_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName_75A27F0004CCC5F36A04782351CE11D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_75A27F0004CCC5F36A04782351CE11D5_label_en-US" xlink:label="lab_dei_SecurityExchangeName_75A27F0004CCC5F36A04782351CE11D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_75A27F0004CCC5F36A04782351CE11D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_75A27F0004CCC5F36A04782351CE11D5" xlink:to="lab_dei_SecurityExchangeName_75A27F0004CCC5F36A04782351CE11D5" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_60A7DFABBEEFCB55891F782351CF90B8_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_60A7DFABBEEFCB55891F782351CF90B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_60A7DFABBEEFCB55891F782351CF90B8_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_60A7DFABBEEFCB55891F782351CF90B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_60A7DFABBEEFCB55891F782351CF90B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_60A7DFABBEEFCB55891F782351CF90B8" xlink:to="lab_dei_EntityCurrentReportingStatus_60A7DFABBEEFCB55891F782351CF90B8" xlink:type="arc" />
    <link:label id="lab_dei_EntityInteractiveDataCurrent_96787D670907EB1A9CA8782351CF79B4_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_96787D670907EB1A9CA8782351CF79B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_96787D670907EB1A9CA8782351CF79B4_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_96787D670907EB1A9CA8782351CF79B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_96787D670907EB1A9CA8782351CF79B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent_96787D670907EB1A9CA8782351CF79B4" xlink:to="lab_dei_EntityInteractiveDataCurrent_96787D670907EB1A9CA8782351CF79B4" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_56146F4791594363323A782351CF3D69_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_56146F4791594363323A782351CF3D69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_56146F4791594363323A782351CF3D69_label_en-US" xlink:label="lab_dei_EntityFilerCategory_56146F4791594363323A782351CF3D69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_56146F4791594363323A782351CF3D69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_56146F4791594363323A782351CF3D69" xlink:to="lab_dei_EntityFilerCategory_56146F4791594363323A782351CF3D69" xlink:type="arc" />
    <link:label id="lab_dei_EntitySmallBusiness_4A89994BDE019923EC1A782351CF4C3F_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness_4A89994BDE019923EC1A782351CF4C3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_4A89994BDE019923EC1A782351CF4C3F_label_en-US" xlink:label="lab_dei_EntitySmallBusiness_4A89994BDE019923EC1A782351CF4C3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_4A89994BDE019923EC1A782351CF4C3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_4A89994BDE019923EC1A782351CF4C3F" xlink:to="lab_dei_EntitySmallBusiness_4A89994BDE019923EC1A782351CF4C3F" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_32A397070D8CFFB9A495782351CFB714_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_32A397070D8CFFB9A495782351CFB714" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_32A397070D8CFFB9A495782351CFB714_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_32A397070D8CFFB9A495782351CFB714" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_32A397070D8CFFB9A495782351CFB714" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_32A397070D8CFFB9A495782351CFB714" xlink:to="lab_dei_EntityEmergingGrowthCompany_32A397070D8CFFB9A495782351CFB714" xlink:type="arc" />
    <link:label id="lab_dei_EntityShellCompany_020437E76B880B2D687A782351D00A2D_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany_020437E76B880B2D687A782351D00A2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_020437E76B880B2D687A782351D00A2D_label_en-US" xlink:label="lab_dei_EntityShellCompany_020437E76B880B2D687A782351D00A2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_020437E76B880B2D687A782351D00A2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_020437E76B880B2D687A782351D00A2D" xlink:to="lab_dei_EntityShellCompany_020437E76B880B2D687A782351D00A2D" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_401A8E060DE3129856D4782351D0A6A8_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_401A8E060DE3129856D4782351D0A6A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_401A8E060DE3129856D4782351D0A6A8_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_401A8E060DE3129856D4782351D0A6A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_401A8E060DE3129856D4782351D0A6A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_401A8E060DE3129856D4782351D0A6A8" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_401A8E060DE3129856D4782351D0A6A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_35A859A4E718C5D6EBA678234D55C5A1_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_35A859A4E718C5D6EBA678234D55C5A1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payments</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_35A859A4E718C5D6EBA678234D55C5A1_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_35A859A4E718C5D6EBA678234D55C5A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_35A859A4E718C5D6EBA678234D55C5A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_35A859A4E718C5D6EBA678234D55C5A1" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_35A859A4E718C5D6EBA678234D55C5A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_30C6DFD59EC511B50A5078235001263D_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_30C6DFD59EC511B50A5078235001263D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Components of inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_30C6DFD59EC511B50A5078235001263D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_30C6DFD59EC511B50A5078235001263D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_30C6DFD59EC511B50A5078235001263D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_30C6DFD59EC511B50A5078235001263D" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_30C6DFD59EC511B50A5078235001263D" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_F9C8753087B8BE9D360D78234F1A0E45_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_F9C8753087B8BE9D360D78234F1A0E45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2.900% Senior Notes due 2020</link:label>
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_F9C8753087B8BE9D360D78234F1A0E45_label_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_F9C8753087B8BE9D360D78234F1A0E45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_F9C8753087B8BE9D360D78234F1A0E45_documentation_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_F9C8753087B8BE9D360D78234F1A0E45" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_F9C8753087B8BE9D360D78234F1A0E45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_F9C8753087B8BE9D360D78234F1A0E45" xlink:to="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_F9C8753087B8BE9D360D78234F1A0E45" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_3F08CBF4B475DBECD94778234F1A88F0_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_3F08CBF4B475DBECD94778234F1A88F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.625% Senior Notes due 2022</link:label>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_3F08CBF4B475DBECD94778234F1A88F0_label_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_3F08CBF4B475DBECD94778234F1A88F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_3F08CBF4B475DBECD94778234F1A88F0_documentation_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_3F08CBF4B475DBECD94778234F1A88F0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_3F08CBF4B475DBECD94778234F1A88F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_3F08CBF4B475DBECD94778234F1A88F0" xlink:to="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_3F08CBF4B475DBECD94778234F1A88F0" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_F353FB0EF860A866BF5778234F1B7A98_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_F353FB0EF860A866BF5778234F1B7A98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.050% Senior Notes due 2025</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_F353FB0EF860A866BF5778234F1B7A98_label_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_F353FB0EF860A866BF5778234F1B7A98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_F353FB0EF860A866BF5778234F1B7A98_documentation_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_F353FB0EF860A866BF5778234F1B7A98" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_F353FB0EF860A866BF5778234F1B7A98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_F353FB0EF860A866BF5778234F1B7A98" xlink:to="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_F353FB0EF860A866BF5778234F1B7A98" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_A7833951E7ADF410D7CC78234F1BAD5A_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_A7833951E7ADF410D7CC78234F1BAD5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">5.200% Senior Notes due 2045</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_A7833951E7ADF410D7CC78234F1BAD5A_label_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_A7833951E7ADF410D7CC78234F1BAD5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_A7833951E7ADF410D7CC78234F1BAD5A_documentation_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_A7833951E7ADF410D7CC78234F1BAD5A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_A7833951E7ADF410D7CC78234F1BAD5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_A7833951E7ADF410D7CC78234F1BAD5A" xlink:to="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_A7833951E7ADF410D7CC78234F1BAD5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetImpairmentCharges_A4B6A9BF74EB4CEE973978234F1BD1FC_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges_A4B6A9BF74EB4CEE973978234F1BD1FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset impairment charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_A4B6A9BF74EB4CEE973978234F1BD1FC_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges_A4B6A9BF74EB4CEE973978234F1BD1FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_A4B6A9BF74EB4CEE973978234F1BD1FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges_A4B6A9BF74EB4CEE973978234F1BD1FC" xlink:to="lab_us-gaap_AssetImpairmentCharges_A4B6A9BF74EB4CEE973978234F1BD1FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_4840FF339B45E996C5C478234F1B8E5F_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_4840FF339B45E996C5C478234F1B8E5F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_4840FF339B45E996C5C478234F1B8E5F_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_4840FF339B45E996C5C478234F1B8E5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_4840FF339B45E996C5C478234F1B8E5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_4840FF339B45E996C5C478234F1B8E5F" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_4840FF339B45E996C5C478234F1B8E5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_037F4DBB5E57B68A3C3978234F1CF0C8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_037F4DBB5E57B68A3C3978234F1CF0C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future payment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_037F4DBB5E57B68A3C3978234F1CF0C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_037F4DBB5E57B68A3C3978234F1CF0C8" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_037F4DBB5E57B68A3C3978234F1CF0C8" xlink:type="arc" />
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_A79100800FB7AAD379027823505DE1C7_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract_A79100800FB7AAD379027823505DE1C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_A79100800FB7AAD379027823505DE1C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_A79100800FB7AAD379027823505DE1C7" xlink:to="lab_srt_ValuationAndQualifyingAccountsAbstract_A79100800FB7AAD379027823505DE1C7" xlink:type="arc" />
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_C6910FCEBEE3129D5FF67823505E232A_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_C6910FCEBEE3129D5FF67823505E232A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_C6910FCEBEE3129D5FF67823505E232A_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_C6910FCEBEE3129D5FF67823505E232A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_C6910FCEBEE3129D5FF67823505E232A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_C6910FCEBEE3129D5FF67823505E232A" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_C6910FCEBEE3129D5FF67823505E232A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_9DD13D344F5B70B391D27823505EC9F8_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_9DD13D344F5B70B391D27823505EC9F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_9DD13D344F5B70B391D27823505EC9F8_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_9DD13D344F5B70B391D27823505EC9F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_9DD13D344F5B70B391D27823505EC9F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_9DD13D344F5B70B391D27823505EC9F8" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_9DD13D344F5B70B391D27823505EC9F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_61A8CA610DA21A56CC017823505EA01E_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain_61A8CA610DA21A56CC017823505EA01E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_61A8CA610DA21A56CC017823505EA01E_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain_61A8CA610DA21A56CC017823505EA01E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_61A8CA610DA21A56CC017823505EA01E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_61A8CA610DA21A56CC017823505EA01E" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain_61A8CA610DA21A56CC017823505EA01E" xlink:type="arc" />
    <link:label id="lab_biib_ReserveforCashDiscountsMember_DE2EBEFAC071721642A97823505F4F73_terseLabel_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember_DE2EBEFAC071721642A97823505F4F73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discounts</link:label>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_DE2EBEFAC071721642A97823505F4F73_label_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember_DE2EBEFAC071721642A97823505F4F73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reserve for Cash Discounts [Member]</link:label>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_DE2EBEFAC071721642A97823505F4F73_documentation_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember_DE2EBEFAC071721642A97823505F4F73" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reserve for Cash Discounts [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_ReserveforCashDiscountsMember" xlink:label="loc_biib_ReserveforCashDiscountsMember_DE2EBEFAC071721642A97823505F4F73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReserveforCashDiscountsMember_DE2EBEFAC071721642A97823505F4F73" xlink:to="lab_biib_ReserveforCashDiscountsMember_DE2EBEFAC071721642A97823505F4F73" xlink:type="arc" />
    <link:label id="lab_biib_ContractualAdjustmentsMember_0F76A0A996B86B7D6E2B7823505F82D5_terseLabel_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember_0F76A0A996B86B7D6E2B7823505F82D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual adjustments</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_0F76A0A996B86B7D6E2B7823505F82D5_label_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember_0F76A0A996B86B7D6E2B7823505F82D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Adjustments [Member]</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_0F76A0A996B86B7D6E2B7823505F82D5_documentation_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember_0F76A0A996B86B7D6E2B7823505F82D5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contractual adjustments.</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_ContractualAdjustmentsMember" xlink:label="loc_biib_ContractualAdjustmentsMember_0F76A0A996B86B7D6E2B7823505F82D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContractualAdjustmentsMember_0F76A0A996B86B7D6E2B7823505F82D5" xlink:to="lab_biib_ContractualAdjustmentsMember_0F76A0A996B86B7D6E2B7823505F82D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_29FEAB311664E2D8A5A87823505F41DD_terseLabel_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember_29FEAB311664E2D8A5A87823505F41DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Returns</link:label>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_29FEAB311664E2D8A5A87823505F41DD_label_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember_29FEAB311664E2D8A5A87823505F41DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Returns and Allowances [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_29FEAB311664E2D8A5A87823505F41DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesReturnsAndAllowancesMember_29FEAB311664E2D8A5A87823505F41DD" xlink:to="lab_us-gaap_SalesReturnsAndAllowancesMember_29FEAB311664E2D8A5A87823505F41DD" xlink:type="arc" />
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_40502A5C323A204045EA7823505FCEC2_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_40502A5C323A204045EA7823505FCEC2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_40502A5C323A204045EA7823505FCEC2_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_40502A5C323A204045EA7823505FCEC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_40502A5C323A204045EA7823505FCEC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_40502A5C323A204045EA7823505FCEC2" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_40502A5C323A204045EA7823505FCEC2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_69809C571FE69663ABEC7823505FA2BF_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_69809C571FE69663ABEC7823505FA2BF" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_69809C571FE69663ABEC7823505FA2BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_69809C571FE69663ABEC7823505FA2BF" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_69809C571FE69663ABEC7823505FA2BF" xlink:type="arc" />
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_1FB72C8508636607F21B78235060637B_terseLabel_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_1FB72C8508636607F21B78235060637B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Provisions Relating To Sales In Current Year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_1FB72C8508636607F21B78235060637B_label_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_1FB72C8508636607F21B78235060637B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Provisions To Product Revenue Reserves Relating To Sales In Current Year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_1FB72C8508636607F21B78235060637B_documentation_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_1FB72C8508636607F21B78235060637B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current provisions to product revenue reserves relating to sales in current year.</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_1FB72C8508636607F21B78235060637B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_1FB72C8508636607F21B78235060637B" xlink:to="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_1FB72C8508636607F21B78235060637B" xlink:type="arc" />
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_81E8E6A94E8DB3E4B312782350605E87_negatedLabel_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_81E8E6A94E8DB3E4B312782350605E87" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Adjustments Relating To Prior Years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_81E8E6A94E8DB3E4B312782350605E87_label_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_81E8E6A94E8DB3E4B312782350605E87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments To Product Revenue Reserves Relating To Sales In Prior Years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_81E8E6A94E8DB3E4B312782350605E87_documentation_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_81E8E6A94E8DB3E4B312782350605E87" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments to product revenue reserves relating to sales in prior years.</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_81E8E6A94E8DB3E4B312782350605E87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_81E8E6A94E8DB3E4B312782350605E87" xlink:to="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_81E8E6A94E8DB3E4B312782350605E87" xlink:type="arc" />
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_D78C5934C2F3B03912807823506078A6_negatedLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_D78C5934C2F3B03912807823506078A6" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments/Returns Relating To Sales in Current Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_D78C5934C2F3B03912807823506078A6_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_D78C5934C2F3B03912807823506078A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Current Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_D78C5934C2F3B03912807823506078A6_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_D78C5934C2F3B03912807823506078A6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to current year.</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_D78C5934C2F3B03912807823506078A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_D78C5934C2F3B03912807823506078A6" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_D78C5934C2F3B03912807823506078A6" xlink:type="arc" />
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_153014B85792DEF1BEBE78235060C880_negatedLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_153014B85792DEF1BEBE78235060C880" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments/Returns Relating To Sales in Prior Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_153014B85792DEF1BEBE78235060C880_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_153014B85792DEF1BEBE78235060C880" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Prior Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_153014B85792DEF1BEBE78235060C880_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_153014B85792DEF1BEBE78235060C880" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to prior year.</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_153014B85792DEF1BEBE78235060C880" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_153014B85792DEF1BEBE78235060C880" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_153014B85792DEF1BEBE78235060C880" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_5314801DA0329DD0D694782350615148_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_5314801DA0329DD0D694782350615148" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_5314801DA0329DD0D694782350615148" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_5314801DA0329DD0D694782350615148" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_5314801DA0329DD0D694782350615148" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_1FFDF5F13D9B158B403478234C4FE586_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable_1FFDF5F13D9B158B403478234C4FE586" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_1FFDF5F13D9B158B403478234C4FE586_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable_1FFDF5F13D9B158B403478234C4FE586" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_1FFDF5F13D9B158B403478234C4FE586" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_1FFDF5F13D9B158B403478234C4FE586" xlink:to="lab_us-gaap_IncomeTaxContingencyTable_1FFDF5F13D9B158B403478234C4FE586" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_CEA00406A7DC8331129578234C51514B_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_CEA00406A7DC8331129578234C51514B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_CEA00406A7DC8331129578234C51514B_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_CEA00406A7DC8331129578234C51514B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_CEA00406A7DC8331129578234C51514B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_CEA00406A7DC8331129578234C51514B" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_CEA00406A7DC8331129578234C51514B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_0765ADE117898519063578234C517E38_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_0765ADE117898519063578234C517E38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_0765ADE117898519063578234C517E38_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_0765ADE117898519063578234C517E38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_0765ADE117898519063578234C517E38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_0765ADE117898519063578234C517E38" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain_0765ADE117898519063578234C517E38" xlink:type="arc" />
    <link:label id="lab_country_BR_1D1005E1733B865665B878234C52F8DD_terseLabel_en-US" xlink:label="lab_country_BR_1D1005E1733B865665B878234C52F8DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Brazil</link:label>
    <link:label id="lab_country_BR_1D1005E1733B865665B878234C52F8DD_label_en-US" xlink:label="lab_country_BR_1D1005E1733B865665B878234C52F8DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BRAZIL</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="loc_country_BR_1D1005E1733B865665B878234C52F8DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_BR_1D1005E1733B865665B878234C52F8DD" xlink:to="lab_country_BR_1D1005E1733B865665B878234C52F8DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_A4B509A112DA0BDDB50378234C53AC2D_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems_A4B509A112DA0BDDB50378234C53AC2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_A4B509A112DA0BDDB50378234C53AC2D_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems_A4B509A112DA0BDDB50378234C53AC2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_A4B509A112DA0BDDB50378234C53AC2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_A4B509A112DA0BDDB50378234C53AC2D" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems_A4B509A112DA0BDDB50378234C53AC2D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_6AB301D1A2466F8F5A7B78234C538F6C_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_6AB301D1A2466F8F5A7B78234C538F6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_6AB301D1A2466F8F5A7B78234C538F6C_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_6AB301D1A2466F8F5A7B78234C538F6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_6AB301D1A2466F8F5A7B78234C538F6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_6AB301D1A2466F8F5A7B78234C538F6C" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_6AB301D1A2466F8F5A7B78234C538F6C" xlink:type="arc" />
    <link:label id="lab_biib_DisputedClaimsRelatingtoConstructionCosts_493362C131ECE105C96D78234C54F2B5_terseLabel_en-US" xlink:label="lab_biib_DisputedClaimsRelatingtoConstructionCosts_493362C131ECE105C96D78234C54F2B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disputed claims relating to construction costs</link:label>
    <link:label id="lab_biib_DisputedClaimsRelatingtoConstructionCosts_493362C131ECE105C96D78234C54F2B5_label_en-US" xlink:label="lab_biib_DisputedClaimsRelatingtoConstructionCosts_493362C131ECE105C96D78234C54F2B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disputed Claims Relating to Construction Costs</link:label>
    <link:label id="lab_biib_DisputedClaimsRelatingtoConstructionCosts_493362C131ECE105C96D78234C54F2B5_documentation_en-US" xlink:label="lab_biib_DisputedClaimsRelatingtoConstructionCosts_493362C131ECE105C96D78234C54F2B5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disputed Claims Relating to Construction Costs</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_DisputedClaimsRelatingtoConstructionCosts" xlink:label="loc_biib_DisputedClaimsRelatingtoConstructionCosts_493362C131ECE105C96D78234C54F2B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DisputedClaimsRelatingtoConstructionCosts_493362C131ECE105C96D78234C54F2B5" xlink:to="lab_biib_DisputedClaimsRelatingtoConstructionCosts_493362C131ECE105C96D78234C54F2B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_341DE2F53FD218D8DA4078234C54004E_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue_341DE2F53FD218D8DA4078234C54004E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Brazil tax assessment, including interest and penalties</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_341DE2F53FD218D8DA4078234C54004E_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue_341DE2F53FD218D8DA4078234C54004E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_341DE2F53FD218D8DA4078234C54004E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue_341DE2F53FD218D8DA4078234C54004E" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue_341DE2F53FD218D8DA4078234C54004E" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_1461EF9DEF016B47C03C78234E74CFC3_label_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_1461EF9DEF016B47C03C78234E74CFC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_1461EF9DEF016B47C03C78234E74CFC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_1461EF9DEF016B47C03C78234E74CFC3" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_1461EF9DEF016B47C03C78234E74CFC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FA764A988E2D1282989E78234E74A4CA_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FA764A988E2D1282989E78234E74A4CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FA764A988E2D1282989E78234E74A4CA_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FA764A988E2D1282989E78234E74A4CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FA764A988E2D1282989E78234E74A4CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FA764A988E2D1282989E78234E74A4CA" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FA764A988E2D1282989E78234E74A4CA" xlink:type="arc" />
    <link:label id="lab_dei_LegalEntityAxis_20FF1F8C0E71795435AD78234E75F05B_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis_20FF1F8C0E71795435AD78234E75F05B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_20FF1F8C0E71795435AD78234E75F05B_label_en-US" xlink:label="lab_dei_LegalEntityAxis_20FF1F8C0E71795435AD78234E75F05B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_20FF1F8C0E71795435AD78234E75F05B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis_20FF1F8C0E71795435AD78234E75F05B" xlink:to="lab_dei_LegalEntityAxis_20FF1F8C0E71795435AD78234E75F05B" xlink:type="arc" />
    <link:label id="lab_dei_EntityDomain_5873327B1A70D51FBC9278234E758508_terseLabel_en-US" xlink:label="lab_dei_EntityDomain_5873327B1A70D51FBC9278234E758508" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_5873327B1A70D51FBC9278234E758508_label_en-US" xlink:label="lab_dei_EntityDomain_5873327B1A70D51FBC9278234E758508" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_5873327B1A70D51FBC9278234E758508" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain_5873327B1A70D51FBC9278234E758508" xlink:to="lab_dei_EntityDomain_5873327B1A70D51FBC9278234E758508" xlink:type="arc" />
    <link:label id="lab_biib_SangamoCommonStockMember_CA705A8548328C201D5278234E75A146_terseLabel_en-US" xlink:label="lab_biib_SangamoCommonStockMember_CA705A8548328C201D5278234E75A146" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sangamo</link:label>
    <link:label id="lab_biib_SangamoCommonStockMember_CA705A8548328C201D5278234E75A146_label_en-US" xlink:label="lab_biib_SangamoCommonStockMember_CA705A8548328C201D5278234E75A146" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sangamo Common Stock [Member]</link:label>
    <link:label id="lab_biib_SangamoCommonStockMember_CA705A8548328C201D5278234E75A146_documentation_en-US" xlink:label="lab_biib_SangamoCommonStockMember_CA705A8548328C201D5278234E75A146" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sangamo Common Stock [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_SangamoCommonStockMember" xlink:label="loc_biib_SangamoCommonStockMember_CA705A8548328C201D5278234E75A146" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SangamoCommonStockMember_CA705A8548328C201D5278234E75A146" xlink:to="lab_biib_SangamoCommonStockMember_CA705A8548328C201D5278234E75A146" xlink:type="arc" />
    <link:label id="lab_biib_StrategicInvestmentsMember_91199FEA85566A8417F078234E7DB52A_terseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentsMember_91199FEA85566A8417F078234E7DB52A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Strategic Investments</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_91199FEA85566A8417F078234E7DB52A_label_en-US" xlink:label="lab_biib_StrategicInvestmentsMember_91199FEA85566A8417F078234E7DB52A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Strategic Investments [Member]</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_91199FEA85566A8417F078234E7DB52A_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentsMember_91199FEA85566A8417F078234E7DB52A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Strategic investments.</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_StrategicInvestmentsMember" xlink:label="loc_biib_StrategicInvestmentsMember_91199FEA85566A8417F078234E7DB52A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentsMember_91199FEA85566A8417F078234E7DB52A" xlink:to="lab_biib_StrategicInvestmentsMember_91199FEA85566A8417F078234E7DB52A" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_E09775E122CC2708A39678234E7D3121_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_E09775E122CC2708A39678234E7D3121" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_E09775E122CC2708A39678234E7D3121_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_E09775E122CC2708A39678234E7D3121" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_E09775E122CC2708A39678234E7D3121" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E09775E122CC2708A39678234E7D3121" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems_E09775E122CC2708A39678234E7D3121" xlink:type="arc" />
    <link:label id="lab_biib_StrategicInvestmentPortfolio_80F8D089D0567CFB51ED78234E7ECE52_verboseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio_80F8D089D0567CFB51ED78234E7ECE52" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Strategic investment portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_80F8D089D0567CFB51ED78234E7ECE52_label_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio_80F8D089D0567CFB51ED78234E7ECE52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Strategic Investment Portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_80F8D089D0567CFB51ED78234E7ECE52_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio_80F8D089D0567CFB51ED78234E7ECE52" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Strategic investment portfolio.</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_StrategicInvestmentPortfolio" xlink:label="loc_biib_StrategicInvestmentPortfolio_80F8D089D0567CFB51ED78234E7ECE52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentPortfolio_80F8D089D0567CFB51ED78234E7ECE52" xlink:to="lab_biib_StrategicInvestmentPortfolio_80F8D089D0567CFB51ED78234E7ECE52" xlink:type="arc" />
    <link:label id="lab_biib_Investmentincommonstocksharespurchased_33704BBB00D725B93DC678234E7E32A2_terseLabel_en-US" xlink:label="lab_biib_Investmentincommonstocksharespurchased_33704BBB00D725B93DC678234E7E32A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment in common stock, shares purchased</link:label>
    <link:label id="lab_biib_Investmentincommonstocksharespurchased_33704BBB00D725B93DC678234E7E32A2_label_en-US" xlink:label="lab_biib_Investmentincommonstocksharespurchased_33704BBB00D725B93DC678234E7E32A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment in common stock, shares purchased</link:label>
    <link:label id="lab_biib_Investmentincommonstocksharespurchased_33704BBB00D725B93DC678234E7E32A2_documentation_en-US" xlink:label="lab_biib_Investmentincommonstocksharespurchased_33704BBB00D725B93DC678234E7E32A2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment in common stock, shares purchased</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_Investmentincommonstocksharespurchased" xlink:label="loc_biib_Investmentincommonstocksharespurchased_33704BBB00D725B93DC678234E7E32A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Investmentincommonstocksharespurchased_33704BBB00D725B93DC678234E7E32A2" xlink:to="lab_biib_Investmentincommonstocksharespurchased_33704BBB00D725B93DC678234E7E32A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_E0D57BC83ADF8F48006C78234D95F575_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_E0D57BC83ADF8F48006C78234D95F575" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_E0D57BC83ADF8F48006C78234D95F575_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_E0D57BC83ADF8F48006C78234D95F575" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_E0D57BC83ADF8F48006C78234D95F575" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_E0D57BC83ADF8F48006C78234D95F575" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable_E0D57BC83ADF8F48006C78234D95F575" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_A3150D1F1865BCCCE6B878234D95AC23_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_A3150D1F1865BCCCE6B878234D95AC23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_A3150D1F1865BCCCE6B878234D95AC23_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_A3150D1F1865BCCCE6B878234D95AC23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_A3150D1F1865BCCCE6B878234D95AC23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_A3150D1F1865BCCCE6B878234D95AC23" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_A3150D1F1865BCCCE6B878234D95AC23" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_FBB74087683ADABD13CD78234D968B83_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_FBB74087683ADABD13CD78234D968B83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_FBB74087683ADABD13CD78234D968B83_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_FBB74087683ADABD13CD78234D968B83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_FBB74087683ADABD13CD78234D968B83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_FBB74087683ADABD13CD78234D968B83" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_FBB74087683ADABD13CD78234D968B83" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventMember_0BF493F3FE3BC0D51DDD78234D962A89_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_0BF493F3FE3BC0D51DDD78234D962A89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_0BF493F3FE3BC0D51DDD78234D962A89_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_0BF493F3FE3BC0D51DDD78234D962A89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_0BF493F3FE3BC0D51DDD78234D962A89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_0BF493F3FE3BC0D51DDD78234D962A89" xlink:to="lab_us-gaap_SubsequentEventMember_0BF493F3FE3BC0D51DDD78234D962A89" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_D36BE7E13627719CE34778234D967AB0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis_D36BE7E13627719CE34778234D967AB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_D36BE7E13627719CE34778234D967AB0_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis_D36BE7E13627719CE34778234D967AB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_D36BE7E13627719CE34778234D967AB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_D36BE7E13627719CE34778234D967AB0" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis_D36BE7E13627719CE34778234D967AB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_4A8A8CF2E44A5958809078234D96C085_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain_4A8A8CF2E44A5958809078234D96C085" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_4A8A8CF2E44A5958809078234D96C085_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain_4A8A8CF2E44A5958809078234D96C085" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_4A8A8CF2E44A5958809078234D96C085" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_4A8A8CF2E44A5958809078234D96C085" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain_4A8A8CF2E44A5958809078234D96C085" xlink:type="arc" />
    <link:label id="lab_biib_December2019ShareRepurchaseProgramMember_38E4D54451EBBC3660B578234D976E68_terseLabel_en-US" xlink:label="lab_biib_December2019ShareRepurchaseProgramMember_38E4D54451EBBC3660B578234D976E68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">December 2019 Share Repurchase Program</link:label>
    <link:label id="lab_biib_December2019ShareRepurchaseProgramMember_38E4D54451EBBC3660B578234D976E68_label_en-US" xlink:label="lab_biib_December2019ShareRepurchaseProgramMember_38E4D54451EBBC3660B578234D976E68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">December 2019 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_December2019ShareRepurchaseProgramMember_38E4D54451EBBC3660B578234D976E68_documentation_en-US" xlink:label="lab_biib_December2019ShareRepurchaseProgramMember_38E4D54451EBBC3660B578234D976E68" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">December 2019 Share Repurchase Program [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_December2019ShareRepurchaseProgramMember" xlink:label="loc_biib_December2019ShareRepurchaseProgramMember_38E4D54451EBBC3660B578234D976E68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_December2019ShareRepurchaseProgramMember_38E4D54451EBBC3660B578234D976E68" xlink:to="lab_biib_December2019ShareRepurchaseProgramMember_38E4D54451EBBC3660B578234D976E68" xlink:type="arc" />
    <link:label id="lab_biib_March2019ShareRepurchaseProgramMember_0044C8AF3FE8053A57EE78234D973346_terseLabel_en-US" xlink:label="lab_biib_March2019ShareRepurchaseProgramMember_0044C8AF3FE8053A57EE78234D973346" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019 Share Repurchase Program</link:label>
    <link:label id="lab_biib_March2019ShareRepurchaseProgramMember_0044C8AF3FE8053A57EE78234D973346_label_en-US" xlink:label="lab_biib_March2019ShareRepurchaseProgramMember_0044C8AF3FE8053A57EE78234D973346" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">March 2019 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_March2019ShareRepurchaseProgramMember_0044C8AF3FE8053A57EE78234D973346_documentation_en-US" xlink:label="lab_biib_March2019ShareRepurchaseProgramMember_0044C8AF3FE8053A57EE78234D973346" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">March 2019 Share Repurchase Program [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_March2019ShareRepurchaseProgramMember" xlink:label="loc_biib_March2019ShareRepurchaseProgramMember_0044C8AF3FE8053A57EE78234D973346" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_March2019ShareRepurchaseProgramMember_0044C8AF3FE8053A57EE78234D973346" xlink:to="lab_biib_March2019ShareRepurchaseProgramMember_0044C8AF3FE8053A57EE78234D973346" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockLineItems_6255A75A0598D06742BD78234D982AEA_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_6255A75A0598D06742BD78234D982AEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_6255A75A0598D06742BD78234D982AEA_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_6255A75A0598D06742BD78234D982AEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_6255A75A0598D06742BD78234D982AEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_6255A75A0598D06742BD78234D982AEA" xlink:to="lab_us-gaap_ClassOfStockLineItems_6255A75A0598D06742BD78234D982AEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_2849CCAFF9263DC9514478234D985AFC_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_2849CCAFF9263DC9514478234D985AFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_2849CCAFF9263DC9514478234D985AFC_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_2849CCAFF9263DC9514478234D985AFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_2849CCAFF9263DC9514478234D985AFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_2849CCAFF9263DC9514478234D985AFC" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_2849CCAFF9263DC9514478234D985AFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_1C33AD38C783AC4F2B6D78234D983699_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_1C33AD38C783AC4F2B6D78234D983699" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock, at cost, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_1C33AD38C783AC4F2B6D78234D983699_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_1C33AD38C783AC4F2B6D78234D983699" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_1C33AD38C783AC4F2B6D78234D983699" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired_1C33AD38C783AC4F2B6D78234D983699" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired_1C33AD38C783AC4F2B6D78234D983699" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_535FBD5FE0F7A9FE274A78234D98847C_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_535FBD5FE0F7A9FE274A78234D98847C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for repurchase of common stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_535FBD5FE0F7A9FE274A78234D98847C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_535FBD5FE0F7A9FE274A78234D98847C" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_535FBD5FE0F7A9FE274A78234D98847C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_8A8532EF7B4FE9705BEC78234D99321B_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_8A8532EF7B4FE9705BEC78234D99321B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount remaining under 2019 Share Repurchase Program</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_8A8532EF7B4FE9705BEC78234D99321B_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_8A8532EF7B4FE9705BEC78234D99321B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_8A8532EF7B4FE9705BEC78234D99321B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_8A8532EF7B4FE9705BEC78234D99321B" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_8A8532EF7B4FE9705BEC78234D99321B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_2E12A34D243F3EA646F678235192E455_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_2E12A34D243F3EA646F678235192E455" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_2E12A34D243F3EA646F678235192E455_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_2E12A34D243F3EA646F678235192E455" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_2E12A34D243F3EA646F678235192E455" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_2E12A34D243F3EA646F678235192E455" xlink:to="lab_us-gaap_AssetsAbstract_2E12A34D243F3EA646F678235192E455" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_0089B509A9835C1C248A7823519295CA_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_0089B509A9835C1C248A7823519295CA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_0089B509A9835C1C248A7823519295CA_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_0089B509A9835C1C248A7823519295CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_0089B509A9835C1C248A7823519295CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0089B509A9835C1C248A7823519295CA" xlink:to="lab_us-gaap_AssetsCurrentAbstract_0089B509A9835C1C248A7823519295CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4F097E1F7A1DA8308459782351933FB5_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4F097E1F7A1DA8308459782351933FB5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4F097E1F7A1DA8308459782351933FB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4F097E1F7A1DA8308459782351933FB5" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4F097E1F7A1DA8308459782351933FB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_203313ED2A0FD526D110782351936A9C_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_203313ED2A0FD526D110782351936A9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_203313ED2A0FD526D110782351936A9C_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_203313ED2A0FD526D110782351936A9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_203313ED2A0FD526D110782351936A9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_203313ED2A0FD526D110782351936A9C" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_203313ED2A0FD526D110782351936A9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_2853097147B4726F507C7823519371FA_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_2853097147B4726F507C7823519371FA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_2853097147B4726F507C7823519371FA_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_2853097147B4726F507C7823519371FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_2853097147B4726F507C7823519371FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_2853097147B4726F507C7823519371FA" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_2853097147B4726F507C7823519371FA" xlink:type="arc" />
    <link:label id="lab_biib_DuefromantiCD20therapeuticprograms_77463FD28C6F4E46B3B6782351933ECD_verboseLabel_en-US" xlink:label="lab_biib_DuefromantiCD20therapeuticprograms_77463FD28C6F4E46B3B6782351933ECD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_DuefromantiCD20therapeuticprograms_77463FD28C6F4E46B3B6782351933ECD_label_en-US" xlink:label="lab_biib_DuefromantiCD20therapeuticprograms_77463FD28C6F4E46B3B6782351933ECD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_DuefromantiCD20therapeuticprograms_77463FD28C6F4E46B3B6782351933ECD_documentation_en-US" xlink:label="lab_biib_DuefromantiCD20therapeuticprograms_77463FD28C6F4E46B3B6782351933ECD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Receivable from anti-CD20 therapeutic programs for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_DuefromantiCD20therapeuticprograms" xlink:label="loc_biib_DuefromantiCD20therapeuticprograms_77463FD28C6F4E46B3B6782351933ECD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DuefromantiCD20therapeuticprograms_77463FD28C6F4E46B3B6782351933ECD" xlink:to="lab_biib_DuefromantiCD20therapeuticprograms_77463FD28C6F4E46B3B6782351933ECD" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_E513A03BB2C3EF7025CD782351947A51_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_E513A03BB2C3EF7025CD782351947A51" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_E513A03BB2C3EF7025CD782351947A51_label_en-US" xlink:label="lab_us-gaap_InventoryNet_E513A03BB2C3EF7025CD782351947A51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_E513A03BB2C3EF7025CD782351947A51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_E513A03BB2C3EF7025CD782351947A51" xlink:to="lab_us-gaap_InventoryNet_E513A03BB2C3EF7025CD782351947A51" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsCurrent_A393D32C748AABDDBDB178235194286E_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_A393D32C748AABDDBDB178235194286E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_A393D32C748AABDDBDB178235194286E_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_A393D32C748AABDDBDB178235194286E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_A393D32C748AABDDBDB178235194286E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_A393D32C748AABDDBDB178235194286E" xlink:to="lab_us-gaap_OtherAssetsCurrent_A393D32C748AABDDBDB178235194286E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_48F463688E59BDE96575782351948AAA_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_48F463688E59BDE96575782351948AAA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_48F463688E59BDE96575782351948AAA_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_48F463688E59BDE96575782351948AAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_48F463688E59BDE96575782351948AAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_48F463688E59BDE96575782351948AAA" xlink:to="lab_us-gaap_AssetsCurrent_48F463688E59BDE96575782351948AAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_720B4CA84798DAF44C1A78235194BE09_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_720B4CA84798DAF44C1A78235194BE09" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_720B4CA84798DAF44C1A78235194BE09_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_720B4CA84798DAF44C1A78235194BE09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_720B4CA84798DAF44C1A78235194BE09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_720B4CA84798DAF44C1A78235194BE09" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_720B4CA84798DAF44C1A78235194BE09" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_D30E63F0C399A5F0D91578235194BF49_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_D30E63F0C399A5F0D91578235194BF49" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_D30E63F0C399A5F0D91578235194BF49_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_D30E63F0C399A5F0D91578235194BF49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_D30E63F0C399A5F0D91578235194BF49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_D30E63F0C399A5F0D91578235194BF49" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_D30E63F0C399A5F0D91578235194BF49" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_E25701BA8B984DCC3488782351942BC9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_E25701BA8B984DCC3488782351942BC9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_E25701BA8B984DCC3488782351942BC9_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_E25701BA8B984DCC3488782351942BC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_E25701BA8B984DCC3488782351942BC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_E25701BA8B984DCC3488782351942BC9" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_E25701BA8B984DCC3488782351942BC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_BF80855F6086D3135BF478235195F15F_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_BF80855F6086D3135BF478235195F15F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_BF80855F6086D3135BF478235195F15F_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_BF80855F6086D3135BF478235195F15F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_BF80855F6086D3135BF478235195F15F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_BF80855F6086D3135BF478235195F15F" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_BF80855F6086D3135BF478235195F15F" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_20E2CE0B4A0CB347C10478235195EC3D_netLabel_en-US" xlink:label="lab_us-gaap_Goodwill_20E2CE0B4A0CB347C10478235195EC3D" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_20E2CE0B4A0CB347C10478235195EC3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_20E2CE0B4A0CB347C10478235195EC3D" xlink:to="lab_us-gaap_Goodwill_20E2CE0B4A0CB347C10478235195EC3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_FF157EE2519111598F6D782351959CD1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet_FF157EE2519111598F6D782351959CD1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_FF157EE2519111598F6D782351959CD1_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet_FF157EE2519111598F6D782351959CD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_FF157EE2519111598F6D782351959CD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet_FF157EE2519111598F6D782351959CD1" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet_FF157EE2519111598F6D782351959CD1" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_3E801507B33011D3422878235195BC85_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_3E801507B33011D3422878235195BC85" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments and other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_3E801507B33011D3422878235195BC85_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_3E801507B33011D3422878235195BC85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_3E801507B33011D3422878235195BC85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_3E801507B33011D3422878235195BC85" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_3E801507B33011D3422878235195BC85" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_83074B4B378429A052AE78235195C9B1_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_83074B4B378429A052AE78235195C9B1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_83074B4B378429A052AE78235195C9B1_label_en-US" xlink:label="lab_us-gaap_Assets_83074B4B378429A052AE78235195C9B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_83074B4B378429A052AE78235195C9B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_83074B4B378429A052AE78235195C9B1" xlink:to="lab_us-gaap_Assets_83074B4B378429A052AE78235195C9B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_AFA7D521207D63179DFB78235196EAB6_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_AFA7D521207D63179DFB78235196EAB6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_AFA7D521207D63179DFB78235196EAB6_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_AFA7D521207D63179DFB78235196EAB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_AFA7D521207D63179DFB78235196EAB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_AFA7D521207D63179DFB78235196EAB6" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_AFA7D521207D63179DFB78235196EAB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_CF74FD575911657CFF9A78235196A379_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_CF74FD575911657CFF9A78235196A379" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_CF74FD575911657CFF9A78235196A379_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_CF74FD575911657CFF9A78235196A379" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_CF74FD575911657CFF9A78235196A379" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_CF74FD575911657CFF9A78235196A379" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_CF74FD575911657CFF9A78235196A379" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayableCurrent_1C6CF9DF265F866F197578235196A003_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent_1C6CF9DF265F866F197578235196A003" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of notes payable</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_1C6CF9DF265F866F197578235196A003_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent_1C6CF9DF265F866F197578235196A003" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_1C6CF9DF265F866F197578235196A003" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent_1C6CF9DF265F866F197578235196A003" xlink:to="lab_us-gaap_NotesPayableCurrent_1C6CF9DF265F866F197578235196A003" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxesPayableCurrent_6203D82FD3D69574DB1A78235198F95B_verboseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent_6203D82FD3D69574DB1A78235198F95B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_6203D82FD3D69574DB1A78235198F95B_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent_6203D82FD3D69574DB1A78235198F95B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_6203D82FD3D69574DB1A78235198F95B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent_6203D82FD3D69574DB1A78235198F95B" xlink:to="lab_us-gaap_TaxesPayableCurrent_6203D82FD3D69574DB1A78235198F95B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_E4084FC566113F5C952D782351982061_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_E4084FC566113F5C952D782351982061" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_E4084FC566113F5C952D782351982061_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_E4084FC566113F5C952D782351982061" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_E4084FC566113F5C952D782351982061" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_E4084FC566113F5C952D782351982061" xlink:to="lab_us-gaap_AccountsPayableCurrent_E4084FC566113F5C952D782351982061" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_34E472D9622FD097DF4D78235198E087_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_34E472D9622FD097DF4D78235198E087" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_34E472D9622FD097DF4D78235198E087" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_34E472D9622FD097DF4D78235198E087" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_34E472D9622FD097DF4D78235198E087" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_D0D206B911D88001273D7823519880B5_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_D0D206B911D88001273D7823519880B5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_D0D206B911D88001273D7823519880B5_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_D0D206B911D88001273D7823519880B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_D0D206B911D88001273D7823519880B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_D0D206B911D88001273D7823519880B5" xlink:to="lab_us-gaap_LiabilitiesCurrent_D0D206B911D88001273D7823519880B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_2ECB5FA97079C64874907823519907D3_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_2ECB5FA97079C64874907823519907D3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes payable</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_2ECB5FA97079C64874907823519907D3_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_2ECB5FA97079C64874907823519907D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_2ECB5FA97079C64874907823519907D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_2ECB5FA97079C64874907823519907D3" xlink:to="lab_us-gaap_LongTermDebt_2ECB5FA97079C64874907823519907D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_CFF2F0EB3CF69F590F0E78235199E7C4_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_CFF2F0EB3CF69F590F0E78235199E7C4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_CFF2F0EB3CF69F590F0E78235199E7C4_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_CFF2F0EB3CF69F590F0E78235199E7C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_CFF2F0EB3CF69F590F0E78235199E7C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_CFF2F0EB3CF69F590F0E78235199E7C4" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_CFF2F0EB3CF69F590F0E78235199E7C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_4C23CE652C71A6517C6A78235199CB6B_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_4C23CE652C71A6517C6A78235199CB6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_4C23CE652C71A6517C6A78235199CB6B_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_4C23CE652C71A6517C6A78235199CB6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4C23CE652C71A6517C6A78235199CB6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4C23CE652C71A6517C6A78235199CB6B" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_4C23CE652C71A6517C6A78235199CB6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_3561F5F376AB3651F1AA782351992917_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_3561F5F376AB3651F1AA782351992917" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_3561F5F376AB3651F1AA782351992917_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_3561F5F376AB3651F1AA782351992917" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_3561F5F376AB3651F1AA782351992917" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_3561F5F376AB3651F1AA782351992917" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_3561F5F376AB3651F1AA782351992917" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_28E5A1447CA8E8B217A97823519AB673_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_28E5A1447CA8E8B217A97823519AB673" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_28E5A1447CA8E8B217A97823519AB673_label_en-US" xlink:label="lab_us-gaap_Liabilities_28E5A1447CA8E8B217A97823519AB673" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_28E5A1447CA8E8B217A97823519AB673" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_28E5A1447CA8E8B217A97823519AB673" xlink:to="lab_us-gaap_Liabilities_28E5A1447CA8E8B217A97823519AB673" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_26410DF393ABBCE576B37823519AC03A_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_26410DF393ABBCE576B37823519AC03A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_26410DF393ABBCE576B37823519AC03A_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_26410DF393ABBCE576B37823519AC03A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_26410DF393ABBCE576B37823519AC03A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_26410DF393ABBCE576B37823519AC03A" xlink:to="lab_us-gaap_CommitmentsAndContingencies_26410DF393ABBCE576B37823519AC03A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_E5E574E9668ED87761717823519A8AA6_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_E5E574E9668ED87761717823519A8AA6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_E5E574E9668ED87761717823519A8AA6_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_E5E574E9668ED87761717823519A8AA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_E5E574E9668ED87761717823519A8AA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_E5E574E9668ED87761717823519A8AA6" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_E5E574E9668ED87761717823519A8AA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_1976DCA743349BAEAAC47823519A43F3_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_1976DCA743349BAEAAC47823519A43F3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Biogen Idec Inc. shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_1976DCA743349BAEAAC47823519A43F3_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_1976DCA743349BAEAAC47823519A43F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_1976DCA743349BAEAAC47823519A43F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1976DCA743349BAEAAC47823519A43F3" xlink:to="lab_us-gaap_StockholdersEquityAbstract_1976DCA743349BAEAAC47823519A43F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_6CA0506ACFE100395EC17823519BCA34_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_6CA0506ACFE100395EC17823519BCA34" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value $0.001 per share</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_6CA0506ACFE100395EC17823519BCA34_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_6CA0506ACFE100395EC17823519BCA34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_6CA0506ACFE100395EC17823519BCA34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_6CA0506ACFE100395EC17823519BCA34" xlink:to="lab_us-gaap_PreferredStockValue_6CA0506ACFE100395EC17823519BCA34" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_1C65CC6440AFF75E9F9C7823519B9BB0_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_1C65CC6440AFF75E9F9C7823519B9BB0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value $0.0005 per share</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_1C65CC6440AFF75E9F9C7823519B9BB0_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_1C65CC6440AFF75E9F9C7823519B9BB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_1C65CC6440AFF75E9F9C7823519B9BB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_1C65CC6440AFF75E9F9C7823519B9BB0" xlink:to="lab_us-gaap_CommonStockValue_1C65CC6440AFF75E9F9C7823519B9BB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_2E2338D82907D8822D997823519BB0E2_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_2E2338D82907D8822D997823519BB0E2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_2E2338D82907D8822D997823519BB0E2_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_2E2338D82907D8822D997823519BB0E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_2E2338D82907D8822D997823519BB0E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_2E2338D82907D8822D997823519BB0E2" xlink:to="lab_us-gaap_AdditionalPaidInCapital_2E2338D82907D8822D997823519BB0E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_85111000B16B719AD4C17823519C1A66_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_85111000B16B719AD4C17823519C1A66" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_85111000B16B719AD4C17823519C1A66_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_85111000B16B719AD4C17823519C1A66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_85111000B16B719AD4C17823519C1A66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_85111000B16B719AD4C17823519C1A66" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_85111000B16B719AD4C17823519C1A66" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_E4DD4C8C900718C6E7B67823519C9D1F_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_E4DD4C8C900718C6E7B67823519C9D1F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_E4DD4C8C900718C6E7B67823519C9D1F_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_E4DD4C8C900718C6E7B67823519C9D1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_E4DD4C8C900718C6E7B67823519C9D1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_E4DD4C8C900718C6E7B67823519C9D1F" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_E4DD4C8C900718C6E7B67823519C9D1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockValue_E369DF2185277011179C7823519C47BC_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_E369DF2185277011179C7823519C47BC" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_E369DF2185277011179C7823519C47BC_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_E369DF2185277011179C7823519C47BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_E369DF2185277011179C7823519C47BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue_E369DF2185277011179C7823519C47BC" xlink:to="lab_us-gaap_TreasuryStockValue_E369DF2185277011179C7823519C47BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_EF1D6A22361F0A82D8B27823519CEF49_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_EF1D6A22361F0A82D8B27823519CEF49" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Biogen Inc. shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_EF1D6A22361F0A82D8B27823519CEF49_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_EF1D6A22361F0A82D8B27823519CEF49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_EF1D6A22361F0A82D8B27823519CEF49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_EF1D6A22361F0A82D8B27823519CEF49" xlink:to="lab_us-gaap_StockholdersEquity_EF1D6A22361F0A82D8B27823519CEF49" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_DD4822EA8044E65A949E7823519C9AB2_verboseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_DD4822EA8044E65A949E7823519C9AB2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_DD4822EA8044E65A949E7823519C9AB2_label_en-US" xlink:label="lab_us-gaap_MinorityInterest_DD4822EA8044E65A949E7823519C9AB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_DD4822EA8044E65A949E7823519C9AB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_DD4822EA8044E65A949E7823519C9AB2" xlink:to="lab_us-gaap_MinorityInterest_DD4822EA8044E65A949E7823519C9AB2" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_649496B00489DBA788447823519D93BA_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_649496B00489DBA788447823519D93BA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_649496B00489DBA788447823519D93BA_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_649496B00489DBA788447823519D93BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_649496B00489DBA788447823519D93BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_649496B00489DBA788447823519D93BA" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_649496B00489DBA788447823519D93BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_C4C25B858EA1E7AB2FAD7823519DF38B_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_C4C25B858EA1E7AB2FAD7823519DF38B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_C4C25B858EA1E7AB2FAD7823519DF38B_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_C4C25B858EA1E7AB2FAD7823519DF38B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_C4C25B858EA1E7AB2FAD7823519DF38B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_C4C25B858EA1E7AB2FAD7823519DF38B" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_C4C25B858EA1E7AB2FAD7823519DF38B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableMember_2C37A01F019FBBCBC7E6782350536740_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_2C37A01F019FBBCBC7E6782350536740" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction of accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_2C37A01F019FBBCBC7E6782350536740_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_2C37A01F019FBBCBC7E6782350536740" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_2C37A01F019FBBCBC7E6782350536740" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember_2C37A01F019FBBCBC7E6782350536740" xlink:to="lab_us-gaap_AccountsReceivableMember_2C37A01F019FBBCBC7E6782350536740" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_B4DF18F7CABFE193AD237823505424B2_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_B4DF18F7CABFE193AD237823505424B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_B4DF18F7CABFE193AD237823505424B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_B4DF18F7CABFE193AD237823505424B2" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_B4DF18F7CABFE193AD237823505424B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_DBF4687E4BE99DFD442E78234D698728_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_DBF4687E4BE99DFD442E78234D698728" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_DBF4687E4BE99DFD442E78234D698728_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_DBF4687E4BE99DFD442E78234D698728" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_DBF4687E4BE99DFD442E78234D698728" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_DBF4687E4BE99DFD442E78234D698728" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_DBF4687E4BE99DFD442E78234D698728" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_EEE0A95002C59E544E1C78234C8642BD_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_EEE0A95002C59E544E1C78234C8642BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_EEE0A95002C59E544E1C78234C8642BD_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_EEE0A95002C59E544E1C78234C8642BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_EEE0A95002C59E544E1C78234C8642BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_EEE0A95002C59E544E1C78234C8642BD" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_EEE0A95002C59E544E1C78234C8642BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7EE240512CE9498361D378234C8960D8_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7EE240512CE9498361D378234C8960D8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7EE240512CE9498361D378234C8960D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7EE240512CE9498361D378234C8960D8" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7EE240512CE9498361D378234C8960D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoriesMember_5F168DF5FB67E7FCE6D978234C8A2EF5_terseLabel_en-US" xlink:label="lab_us-gaap_InventoriesMember_5F168DF5FB67E7FCE6D978234C8A2EF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoriesMember_5F168DF5FB67E7FCE6D978234C8A2EF5_label_en-US" xlink:label="lab_us-gaap_InventoriesMember_5F168DF5FB67E7FCE6D978234C8A2EF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventories [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoriesMember" xlink:label="loc_us-gaap_InventoriesMember_5F168DF5FB67E7FCE6D978234C8A2EF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoriesMember_5F168DF5FB67E7FCE6D978234C8A2EF5" xlink:to="lab_us-gaap_InventoriesMember_5F168DF5FB67E7FCE6D978234C8A2EF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_1D80D2B4AAB3B0B54D1778234C8AD026_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember_1D80D2B4AAB3B0B54D1778234C8AD026" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Developed technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_1D80D2B4AAB3B0B54D1778234C8AD026_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember_1D80D2B4AAB3B0B54D1778234C8AD026" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_1D80D2B4AAB3B0B54D1778234C8AD026" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember_1D80D2B4AAB3B0B54D1778234C8AD026" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember_1D80D2B4AAB3B0B54D1778234C8AD026" xlink:type="arc" />
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_4C3FB95D0946B03282A878234C8AAAF4_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_4C3FB95D0946B03282A878234C8AAAF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In Process Research and Development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_4C3FB95D0946B03282A878234C8AAAF4_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_4C3FB95D0946B03282A878234C8AAAF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_4C3FB95D0946B03282A878234C8AAAF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember_4C3FB95D0946B03282A878234C8AAAF4" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember_4C3FB95D0946B03282A878234C8AAAF4" xlink:type="arc" />
    <link:label id="lab_biib_DeferredtaxliabilityMember_12A5258510BB1EE2875878234C8B5C5F_terseLabel_en-US" xlink:label="lab_biib_DeferredtaxliabilityMember_12A5258510BB1EE2875878234C8B5C5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_biib_DeferredtaxliabilityMember_12A5258510BB1EE2875878234C8B5C5F_label_en-US" xlink:label="lab_biib_DeferredtaxliabilityMember_12A5258510BB1EE2875878234C8B5C5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax liability [Member]</link:label>
    <link:label id="lab_biib_DeferredtaxliabilityMember_12A5258510BB1EE2875878234C8B5C5F_documentation_en-US" xlink:label="lab_biib_DeferredtaxliabilityMember_12A5258510BB1EE2875878234C8B5C5F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred tax liability [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_DeferredtaxliabilityMember" xlink:label="loc_biib_DeferredtaxliabilityMember_12A5258510BB1EE2875878234C8B5C5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DeferredtaxliabilityMember_12A5258510BB1EE2875878234C8B5C5F" xlink:to="lab_biib_DeferredtaxliabilityMember_12A5258510BB1EE2875878234C8B5C5F" xlink:type="arc" />
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_94FDF0C13470CC5D4B2578234C8C45EA_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_94FDF0C13470CC5D4B2578234C8C45EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_94FDF0C13470CC5D4B2578234C8C45EA_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_94FDF0C13470CC5D4B2578234C8C45EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_94FDF0C13470CC5D4B2578234C8C45EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_94FDF0C13470CC5D4B2578234C8C45EA" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_94FDF0C13470CC5D4B2578234C8C45EA" xlink:type="arc" />
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_A5E83044FCDFDF13B83178234C8C707D_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain_A5E83044FCDFDF13B83178234C8C707D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_A5E83044FCDFDF13B83178234C8C707D_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain_A5E83044FCDFDF13B83178234C8C707D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_A5E83044FCDFDF13B83178234C8C707D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_A5E83044FCDFDF13B83178234C8C707D" xlink:to="lab_srt_EquityMethodInvesteeNameDomain_A5E83044FCDFDF13B83178234C8C707D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossOnContractTermination_8E374C95FBD3C30FE44478234C8E46E4_terseLabel_en-US" xlink:label="lab_us-gaap_LossOnContractTermination_8E374C95FBD3C30FE44478234C8E46E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on research and development contracts terminated with Eisai</link:label>
    <link:label id="lab_us-gaap_LossOnContractTermination_8E374C95FBD3C30FE44478234C8E46E4_label_en-US" xlink:label="lab_us-gaap_LossOnContractTermination_8E374C95FBD3C30FE44478234C8E46E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss on Contract Termination</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossOnContractTermination" xlink:label="loc_us-gaap_LossOnContractTermination_8E374C95FBD3C30FE44478234C8E46E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossOnContractTermination_8E374C95FBD3C30FE44478234C8E46E4" xlink:to="lab_us-gaap_LossOnContractTermination_8E374C95FBD3C30FE44478234C8E46E4" xlink:type="arc" />
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_BD6F9407FEFB5980989D78234C8E3E73_terseLabel_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_BD6F9407FEFB5980989D78234C8E3E73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of stake in entity</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_BD6F9407FEFB5980989D78234C8E3E73_label_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_BD6F9407FEFB5980989D78234C8E3E73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_BD6F9407FEFB5980989D78234C8E3E73_documentation_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_BD6F9407FEFB5980989D78234C8E3E73" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_BD6F9407FEFB5980989D78234C8E3E73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_BD6F9407FEFB5980989D78234C8E3E73" xlink:to="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_BD6F9407FEFB5980989D78234C8E3E73" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_06BE162523B1AA84B96A78234C8EC2CE_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_06BE162523B1AA84B96A78234C8EC2CE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Percentage of stake in entity maximum</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_06BE162523B1AA84B96A78234C8EC2CE_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_06BE162523B1AA84B96A78234C8EC2CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_06BE162523B1AA84B96A78234C8EC2CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_06BE162523B1AA84B96A78234C8EC2CE" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_06BE162523B1AA84B96A78234C8EC2CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_79EF885BABD225D31E4F78234C8FC07F_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_79EF885BABD225D31E4F78234C8FC07F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments to acquire additional investment in equity method investment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_79EF885BABD225D31E4F78234C8FC07F_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_79EF885BABD225D31E4F78234C8FC07F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_79EF885BABD225D31E4F78234C8FC07F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_79EF885BABD225D31E4F78234C8FC07F" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_79EF885BABD225D31E4F78234C8FC07F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_A100835F1C9274AF719F78234C8FF226_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_A100835F1C9274AF719F78234C8FF226" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of basis differences</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_A100835F1C9274AF719F78234C8FF226_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_A100835F1C9274AF719F78234C8FF226" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Difference Between Carrying Amount and Underlying Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_A100835F1C9274AF719F78234C8FF226" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_A100835F1C9274AF719F78234C8FF226" xlink:to="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_A100835F1C9274AF719F78234C8FF226" xlink:type="arc" />
    <link:label id="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_BF9C9930C2BBE26E863F78234C8F46E1_terseLabel_en-US" xlink:label="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_BF9C9930C2BBE26E863F78234C8F46E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity method investment basis difference amortization period</link:label>
    <link:label id="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_BF9C9930C2BBE26E863F78234C8F46E1_label_en-US" xlink:label="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_BF9C9930C2BBE26E863F78234C8F46E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity method investment basis difference amortization period</link:label>
    <link:label id="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_BF9C9930C2BBE26E863F78234C8F46E1_documentation_en-US" xlink:label="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_BF9C9930C2BBE26E863F78234C8F46E1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity method investment basis difference amortization period</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:label="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_BF9C9930C2BBE26E863F78234C8F46E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_BF9C9930C2BBE26E863F78234C8F46E1" xlink:to="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_BF9C9930C2BBE26E863F78234C8F46E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_FBFDA60EB09D36DDE48A78234C90BE0C_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_FBFDA60EB09D36DDE48A78234C90BE0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss recorded on Samsung Bioepis joint venture</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_FBFDA60EB09D36DDE48A78234C90BE0C_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_FBFDA60EB09D36DDE48A78234C90BE0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments, Net of Dividends or Distributions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_FBFDA60EB09D36DDE48A78234C90BE0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_FBFDA60EB09D36DDE48A78234C90BE0C" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_FBFDA60EB09D36DDE48A78234C90BE0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_8C9FA2C5B20E16916A6E78234C90052F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_8C9FA2C5B20E16916A6E78234C90052F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Our share of Samsung Bioepis gains (losses)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_8C9FA2C5B20E16916A6E78234C90052F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments_8C9FA2C5B20E16916A6E78234C90052F" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments_8C9FA2C5B20E16916A6E78234C90052F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentForAmortization_C351022395FAB2B91D0278234C90CA27_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization_C351022395FAB2B91D0278234C90CA27" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization of basis differences</link:label>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_C351022395FAB2B91D0278234C90CA27_label_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization_C351022395FAB2B91D0278234C90CA27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_C351022395FAB2B91D0278234C90CA27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization_C351022395FAB2B91D0278234C90CA27" xlink:to="lab_us-gaap_AdjustmentForAmortization_C351022395FAB2B91D0278234C90CA27" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestments_BF220C7FDA1C71CE697278234C90F83C_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments_BF220C7FDA1C71CE697278234C90F83C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment in Samsung Bioepis</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_BF220C7FDA1C71CE697278234C90F83C_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments_BF220C7FDA1C71CE697278234C90F83C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_BF220C7FDA1C71CE697278234C90F83C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments_BF220C7FDA1C71CE697278234C90F83C" xlink:to="lab_us-gaap_EquityMethodInvestments_BF220C7FDA1C71CE697278234C90F83C" xlink:type="arc" />
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_C0A97022117C19ECD9A778234C904D7F_terseLabel_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_C0A97022117C19ECD9A778234C904D7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront and milestone payments made to collaborative partner</link:label>
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_C0A97022117C19ECD9A778234C904D7F_label_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_C0A97022117C19ECD9A778234C904D7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront And Milestone Payments Made To Collaborative Partner</link:label>
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_C0A97022117C19ECD9A778234C904D7F_documentation_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_C0A97022117C19ECD9A778234C904D7F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total upfront and milestone payments made to collaborative partner.</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_C0A97022117C19ECD9A778234C904D7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_C0A97022117C19ECD9A778234C904D7F" xlink:to="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_C0A97022117C19ECD9A778234C904D7F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_10C680ACEBA8FFFD13A978234C913001_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_10C680ACEBA8FFFD13A978234C913001" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_10C680ACEBA8FFFD13A978234C913001_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_10C680ACEBA8FFFD13A978234C913001" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_10C680ACEBA8FFFD13A978234C913001" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_10C680ACEBA8FFFD13A978234C913001" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_10C680ACEBA8FFFD13A978234C913001" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_6E8969EAD3AEBD04C77078234C918C80_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets_6E8969EAD3AEBD04C77078234C918C80" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid research and development expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_6E8969EAD3AEBD04C77078234C918C80_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets_6E8969EAD3AEBD04C77078234C918C80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_6E8969EAD3AEBD04C77078234C918C80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_6E8969EAD3AEBD04C77078234C918C80" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssets_6E8969EAD3AEBD04C77078234C918C80" xlink:type="arc" />
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_1CBE683251F50EFFDCF578234C9194E3_terseLabel_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_1CBE683251F50EFFDCF578234C9194E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated additional payments upon achievement of development and commercial milestones</link:label>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_1CBE683251F50EFFDCF578234C9194E3_label_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_1CBE683251F50EFFDCF578234C9194E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Additional Payments Upon Achievement Of Development And Commercial Milestones</link:label>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_1CBE683251F50EFFDCF578234C9194E3_documentation_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_1CBE683251F50EFFDCF578234C9194E3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated additional payments upon achievement of development and commercial milestones.</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_1CBE683251F50EFFDCF578234C9194E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_1CBE683251F50EFFDCF578234C9194E3" xlink:to="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_1CBE683251F50EFFDCF578234C9194E3" xlink:type="arc" />
    <link:label id="lab_biib_AdditionalMilestonePayment_0D4E007AB8D594882C4B78234C92986C_terseLabel_en-US" xlink:label="lab_biib_AdditionalMilestonePayment_0D4E007AB8D594882C4B78234C92986C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Milestone Payment</link:label>
    <link:label id="lab_biib_AdditionalMilestonePayment_0D4E007AB8D594882C4B78234C92986C_label_en-US" xlink:label="lab_biib_AdditionalMilestonePayment_0D4E007AB8D594882C4B78234C92986C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Milestone Payment</link:label>
    <link:label id="lab_biib_AdditionalMilestonePayment_0D4E007AB8D594882C4B78234C92986C_documentation_en-US" xlink:label="lab_biib_AdditionalMilestonePayment_0D4E007AB8D594882C4B78234C92986C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional milestone payment.</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_AdditionalMilestonePayment" xlink:label="loc_biib_AdditionalMilestonePayment_0D4E007AB8D594882C4B78234C92986C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdditionalMilestonePayment_0D4E007AB8D594882C4B78234C92986C" xlink:to="lab_biib_AdditionalMilestonePayment_0D4E007AB8D594882C4B78234C92986C" xlink:type="arc" />
    <link:label id="lab_biib_ContractOptionExerciseFee_F12106C9EE31C577326878234C92ED45_terseLabel_en-US" xlink:label="lab_biib_ContractOptionExerciseFee_F12106C9EE31C577326878234C92ED45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract Option Exercise Fee</link:label>
    <link:label id="lab_biib_ContractOptionExerciseFee_F12106C9EE31C577326878234C92ED45_label_en-US" xlink:label="lab_biib_ContractOptionExerciseFee_F12106C9EE31C577326878234C92ED45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Option Exercise Fee</link:label>
    <link:label id="lab_biib_ContractOptionExerciseFee_F12106C9EE31C577326878234C92ED45_documentation_en-US" xlink:label="lab_biib_ContractOptionExerciseFee_F12106C9EE31C577326878234C92ED45" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract Option Exercise Fee</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_ContractOptionExerciseFee" xlink:label="loc_biib_ContractOptionExerciseFee_F12106C9EE31C577326878234C92ED45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContractOptionExerciseFee_F12106C9EE31C577326878234C92ED45" xlink:to="lab_biib_ContractOptionExerciseFee_F12106C9EE31C577326878234C92ED45" xlink:type="arc" />
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_F58404A65AE38FB9B2D278234C92BC27_terseLabel_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses_F58404A65AE38FB9B2D278234C92BC27" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_F58404A65AE38FB9B2D278234C92BC27_label_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses_F58404A65AE38FB9B2D278234C92BC27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_F58404A65AE38FB9B2D278234C92BC27_documentation_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses_F58404A65AE38FB9B2D278234C92BC27" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_Biogenshareofcopromotionprofitsorlosses" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_F58404A65AE38FB9B2D278234C92BC27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Biogenshareofcopromotionprofitsorlosses_F58404A65AE38FB9B2D278234C92BC27" xlink:to="lab_biib_Biogenshareofcopromotionprofitsorlosses_F58404A65AE38FB9B2D278234C92BC27" xlink:type="arc" />
    <link:label id="lab_us-gaap_DueFromRelatedParties_3C802D67F2CF8CBA5FFB78234C93D32D_terseLabel_en-US" xlink:label="lab_us-gaap_DueFromRelatedParties_3C802D67F2CF8CBA5FFB78234C93D32D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due from Related Parties</link:label>
    <link:label id="lab_us-gaap_DueFromRelatedParties_3C802D67F2CF8CBA5FFB78234C93D32D_label_en-US" xlink:label="lab_us-gaap_DueFromRelatedParties_3C802D67F2CF8CBA5FFB78234C93D32D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due from Related Parties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:label="loc_us-gaap_DueFromRelatedParties_3C802D67F2CF8CBA5FFB78234C93D32D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromRelatedParties_3C802D67F2CF8CBA5FFB78234C93D32D" xlink:to="lab_us-gaap_DueFromRelatedParties_3C802D67F2CF8CBA5FFB78234C93D32D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_8AC991F3D79317FC434778234C93A91A_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_8AC991F3D79317FC434778234C93A91A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due to Related Parties</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_8AC991F3D79317FC434778234C93A91A_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_8AC991F3D79317FC434778234C93A91A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due to Related Parties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_8AC991F3D79317FC434778234C93A91A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_8AC991F3D79317FC434778234C93A91A" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_8AC991F3D79317FC434778234C93A91A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0A244574FA369DB34B8E78234D864E2B_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0A244574FA369DB34B8E78234D864E2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0A244574FA369DB34B8E78234D864E2B_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0A244574FA369DB34B8E78234D864E2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0A244574FA369DB34B8E78234D864E2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0A244574FA369DB34B8E78234D864E2B" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0A244574FA369DB34B8E78234D864E2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_B37A1E6DC361F3873A6178234D88F870_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_B37A1E6DC361F3873A6178234D88F870" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unfunded status of postretirement benefit plans</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_B37A1E6DC361F3873A6178234D88F870_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_B37A1E6DC361F3873A6178234D88F870" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_B37A1E6DC361F3873A6178234D88F870" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_B37A1E6DC361F3873A6178234D88F870" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_B37A1E6DC361F3873A6178234D88F870" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_90C2323215EF846FD0E178234D88534C_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember_90C2323215EF846FD0E178234D88534C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_90C2323215EF846FD0E178234D88534C_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember_90C2323215EF846FD0E178234D88534C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_90C2323215EF846FD0E178234D88534C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember_90C2323215EF846FD0E178234D88534C" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember_90C2323215EF846FD0E178234D88534C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_88085225C3A536A053A978234D896445_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_88085225C3A536A053A978234D896445" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_88085225C3A536A053A978234D896445_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_88085225C3A536A053A978234D896445" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_88085225C3A536A053A978234D896445" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_88085225C3A536A053A978234D896445" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_88085225C3A536A053A978234D896445" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_D898A64164D8CFF079BE78234D8993B9_periodStartLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_D898A64164D8CFF079BE78234D8993B9" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss), net of tax beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_D898A64164D8CFF079BE78234D8993B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_D898A64164D8CFF079BE78234D8993B9" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_D898A64164D8CFF079BE78234D8993B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8B9D229600617BE88D6878234D89A06F_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8B9D229600617BE88D6878234D89A06F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance, January 1, 2018</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8B9D229600617BE88D6878234D89A06F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8B9D229600617BE88D6878234D89A06F" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8B9D229600617BE88D6878234D89A06F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_C4E9FCC29E529644E78078234D8A8CC3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_C4E9FCC29E529644E78078234D8A8CC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), before reclassifications, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_C4E9FCC29E529644E78078234D8A8CC3_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_C4E9FCC29E529644E78078234D8A8CC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_C4E9FCC29E529644E78078234D8A8CC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_C4E9FCC29E529644E78078234D8A8CC3" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_C4E9FCC29E529644E78078234D8A8CC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_EA4A339722FA364F3D6B78234D8A1D9F_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_EA4A339722FA364F3D6B78234D8A1D9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts reclassified from accumulated other comprehensive income, net of tax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_EA4A339722FA364F3D6B78234D8A1D9F_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_EA4A339722FA364F3D6B78234D8A1D9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_EA4A339722FA364F3D6B78234D8A1D9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_EA4A339722FA364F3D6B78234D8A1D9F" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_EA4A339722FA364F3D6B78234D8A1D9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4EB8B3527AB15E9259A278234D8A29E6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4EB8B3527AB15E9259A278234D8A29E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4EB8B3527AB15E9259A278234D8A29E6_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4EB8B3527AB15E9259A278234D8A29E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4EB8B3527AB15E9259A278234D8A29E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4EB8B3527AB15E9259A278234D8A29E6" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4EB8B3527AB15E9259A278234D8A29E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0B13321A9A410CD86BE578234D8AA3E6_periodEndLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0B13321A9A410CD86BE578234D8AA3E6" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss), net of tax ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0B13321A9A410CD86BE578234D8AA3E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0B13321A9A410CD86BE578234D8AA3E6" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0B13321A9A410CD86BE578234D8AA3E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_A6275A003D0FE841406378234D8B5673_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_A6275A003D0FE841406378234D8B5673" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_A6275A003D0FE841406378234D8B5673_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_A6275A003D0FE841406378234D8B5673" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_A6275A003D0FE841406378234D8B5673" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_A6275A003D0FE841406378234D8B5673" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_A6275A003D0FE841406378234D8B5673" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_EEC40C3EFFFD25F4F32578234D457ED4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_EEC40C3EFFFD25F4F32578234D457ED4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_EEC40C3EFFFD25F4F32578234D457ED4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_EEC40C3EFFFD25F4F32578234D457ED4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_EEC40C3EFFFD25F4F32578234D457ED4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_EEC40C3EFFFD25F4F32578234D457ED4" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_EEC40C3EFFFD25F4F32578234D457ED4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_E239ED17928C59750EA778234D463D02_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_E239ED17928C59750EA778234D463D02" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_E239ED17928C59750EA778234D463D02_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_E239ED17928C59750EA778234D463D02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_E239ED17928C59750EA778234D463D02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_E239ED17928C59750EA778234D463D02" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_E239ED17928C59750EA778234D463D02" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_C7E7F1E95FEDAC5249E378234D47F720_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_C7E7F1E95FEDAC5249E378234D47F720" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_C7E7F1E95FEDAC5249E378234D47F720_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_C7E7F1E95FEDAC5249E378234D47F720" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_C7E7F1E95FEDAC5249E378234D47F720" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_C7E7F1E95FEDAC5249E378234D47F720" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_C7E7F1E95FEDAC5249E378234D47F720" xlink:type="arc" />
    <link:label id="lab_us-gaap_ParentMember_7063372BE7B187D9130F78234D47659B_verboseLabel_en-US" xlink:label="lab_us-gaap_ParentMember_7063372BE7B187D9130F78234D47659B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total share-based compensation expense, net of tax</link:label>
    <link:label id="lab_us-gaap_ParentMember_7063372BE7B187D9130F78234D47659B_label_en-US" xlink:label="lab_us-gaap_ParentMember_7063372BE7B187D9130F78234D47659B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_7063372BE7B187D9130F78234D47659B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember_7063372BE7B187D9130F78234D47659B" xlink:to="lab_us-gaap_ParentMember_7063372BE7B187D9130F78234D47659B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_271652413D068ACD5AEC78234D47C9D4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_271652413D068ACD5AEC78234D47C9D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_271652413D068ACD5AEC78234D47C9D4_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_271652413D068ACD5AEC78234D47C9D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_271652413D068ACD5AEC78234D47C9D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_271652413D068ACD5AEC78234D47C9D4" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_271652413D068ACD5AEC78234D47C9D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2F5FAEB69B771E50BA2978234D48C4A3_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2F5FAEB69B771E50BA2978234D48C4A3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Expense included in consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2F5FAEB69B771E50BA2978234D48C4A3_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2F5FAEB69B771E50BA2978234D48C4A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2F5FAEB69B771E50BA2978234D48C4A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2F5FAEB69B771E50BA2978234D48C4A3" xlink:to="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2F5FAEB69B771E50BA2978234D48C4A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_4F0F27D0B3CA9BAB187A78234D48CBDD_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_4F0F27D0B3CA9BAB187A78234D48CBDD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_4F0F27D0B3CA9BAB187A78234D48CBDD_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_4F0F27D0B3CA9BAB187A78234D48CBDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_4F0F27D0B3CA9BAB187A78234D48CBDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_4F0F27D0B3CA9BAB187A78234D48CBDD" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_4F0F27D0B3CA9BAB187A78234D48CBDD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_412F923F55F8957FE7A778234D48FE3D_totalLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_412F923F55F8957FE7A778234D48FE3D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_412F923F55F8957FE7A778234D48FE3D_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_412F923F55F8957FE7A778234D48FE3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expense, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_412F923F55F8957FE7A778234D48FE3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_412F923F55F8957FE7A778234D48FE3D" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_412F923F55F8957FE7A778234D48FE3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_BE68D769A079D2AAA71E78234D487D9C_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_BE68D769A079D2AAA71E78234D487D9C" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Capitalized share-based compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_BE68D769A079D2AAA71E78234D487D9C_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_BE68D769A079D2AAA71E78234D487D9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Amount Capitalized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_BE68D769A079D2AAA71E78234D487D9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_BE68D769A079D2AAA71E78234D487D9C" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_BE68D769A079D2AAA71E78234D487D9C" xlink:type="arc" />
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_2583FC3FED3305F2189C78234D498D66_terseLabel_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_2583FC3FED3305F2189C78234D498D66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense included in total costs and expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_2583FC3FED3305F2189C78234D498D66_label_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_2583FC3FED3305F2189C78234D498D66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Expense Included In Costs And Expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_2583FC3FED3305F2189C78234D498D66_documentation_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_2583FC3FED3305F2189C78234D498D66" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation expense included in costs and expenses.</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_2583FC3FED3305F2189C78234D498D66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_2583FC3FED3305F2189C78234D498D66" xlink:to="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_2583FC3FED3305F2189C78234D498D66" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_ACF820DDB82348BC34D578234D491D7F_negatedLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_ACF820DDB82348BC34D578234D491D7F" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax effect</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_ACF820DDB82348BC34D578234D491D7F_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_ACF820DDB82348BC34D578234D491D7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_ACF820DDB82348BC34D578234D491D7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_ACF820DDB82348BC34D578234D491D7F" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_ACF820DDB82348BC34D578234D491D7F" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNetAbstract_06EDD5B56FAC0D2B2E9878234FF86639_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract_06EDD5B56FAC0D2B2E9878234FF86639" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Components of inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNetAbstract_06EDD5B56FAC0D2B2E9878234FF86639_label_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract_06EDD5B56FAC0D2B2E9878234FF86639" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="loc_us-gaap_InventoryNetAbstract_06EDD5B56FAC0D2B2E9878234FF86639" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetAbstract_06EDD5B56FAC0D2B2E9878234FF86639" xlink:to="lab_us-gaap_InventoryNetAbstract_06EDD5B56FAC0D2B2E9878234FF86639" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_2068206D58BCF427804278234FF87F64_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves_2068206D58BCF427804278234FF87F64" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_2068206D58BCF427804278234FF87F64_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves_2068206D58BCF427804278234FF87F64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_2068206D58BCF427804278234FF87F64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves_2068206D58BCF427804278234FF87F64" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves_2068206D58BCF427804278234FF87F64" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_D07AF1CB3BFDD467719E78234FF9CDF8_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_D07AF1CB3BFDD467719E78234FF9CDF8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_D07AF1CB3BFDD467719E78234FF9CDF8_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_D07AF1CB3BFDD467719E78234FF9CDF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_D07AF1CB3BFDD467719E78234FF9CDF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves_D07AF1CB3BFDD467719E78234FF9CDF8" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves_D07AF1CB3BFDD467719E78234FF9CDF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_557641003EB751F84D6978234FF90284_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_557641003EB751F84D6978234FF90284" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_557641003EB751F84D6978234FF90284_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_557641003EB751F84D6978234FF90284" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_557641003EB751F84D6978234FF90284" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_557641003EB751F84D6978234FF90284" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_557641003EB751F84D6978234FF90284" xlink:type="arc" />
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_7EC986DB2169EE840CFE78234FF9CE06_totalLabel_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent_7EC986DB2169EE840CFE78234FF9CE06" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_7EC986DB2169EE840CFE78234FF9CE06_label_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent_7EC986DB2169EE840CFE78234FF9CE06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, net current and noncurrent</link:label>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_7EC986DB2169EE840CFE78234FF9CE06_documentation_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent_7EC986DB2169EE840CFE78234FF9CE06" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory, net current and noncurrent</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_Inventorynetcurrentandnoncurrent" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_7EC986DB2169EE840CFE78234FF9CE06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_7EC986DB2169EE840CFE78234FF9CE06" xlink:to="lab_biib_Inventorynetcurrentandnoncurrent_7EC986DB2169EE840CFE78234FF9CE06" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueAbstract_CE1DDC17C07B9C6FB0B1782350775AC0_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueAbstract_CE1DDC17C07B9C6FB0B1782350775AC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract_CE1DDC17C07B9C6FB0B1782350775AC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract_CE1DDC17C07B9C6FB0B1782350775AC0" xlink:to="lab_us-gaap_DisaggregationOfRevenueAbstract_CE1DDC17C07B9C6FB0B1782350775AC0" xlink:type="arc" />
    <link:label id="lab_biib_FumarateMember_03E33AF8A60DB65D5413782350784C3A_terseLabel_en-US" xlink:label="lab_biib_FumarateMember_03E33AF8A60DB65D5413782350784C3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fumarate</link:label>
    <link:label id="lab_biib_FumarateMember_03E33AF8A60DB65D5413782350784C3A_label_en-US" xlink:label="lab_biib_FumarateMember_03E33AF8A60DB65D5413782350784C3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fumarate [Member]</link:label>
    <link:label id="lab_biib_FumarateMember_03E33AF8A60DB65D5413782350784C3A_documentation_en-US" xlink:label="lab_biib_FumarateMember_03E33AF8A60DB65D5413782350784C3A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fumarate [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_FumarateMember" xlink:label="loc_biib_FumarateMember_03E33AF8A60DB65D5413782350784C3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FumarateMember_03E33AF8A60DB65D5413782350784C3A" xlink:to="lab_biib_FumarateMember_03E33AF8A60DB65D5413782350784C3A" xlink:type="arc" />
    <link:label id="lab_biib_InterferonMember_D200677E27571D377067782350788C54_terseLabel_en-US" xlink:label="lab_biib_InterferonMember_D200677E27571D377067782350788C54" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interferon</link:label>
    <link:label id="lab_biib_InterferonMember_D200677E27571D377067782350788C54_label_en-US" xlink:label="lab_biib_InterferonMember_D200677E27571D377067782350788C54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interferon [Member]</link:label>
    <link:label id="lab_biib_InterferonMember_D200677E27571D377067782350788C54_documentation_en-US" xlink:label="lab_biib_InterferonMember_D200677E27571D377067782350788C54" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interferon</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_InterferonMember" xlink:label="loc_biib_InterferonMember_D200677E27571D377067782350788C54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InterferonMember_D200677E27571D377067782350788C54" xlink:to="lab_biib_InterferonMember_D200677E27571D377067782350788C54" xlink:type="arc" />
    <link:label id="lab_biib_TysabriProductMember_A4F20249D492CBA73AA378235079DCCD_terseLabel_en-US" xlink:label="lab_biib_TysabriProductMember_A4F20249D492CBA73AA378235079DCCD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TYSABRI</link:label>
    <link:label id="lab_biib_TysabriProductMember_A4F20249D492CBA73AA378235079DCCD_label_en-US" xlink:label="lab_biib_TysabriProductMember_A4F20249D492CBA73AA378235079DCCD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:label id="lab_biib_TysabriProductMember_A4F20249D492CBA73AA378235079DCCD_documentation_en-US" xlink:label="lab_biib_TysabriProductMember_A4F20249D492CBA73AA378235079DCCD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_A4F20249D492CBA73AA378235079DCCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TysabriProductMember_A4F20249D492CBA73AA378235079DCCD" xlink:to="lab_biib_TysabriProductMember_A4F20249D492CBA73AA378235079DCCD" xlink:type="arc" />
    <link:label id="lab_biib_FAMPYRAMember_F0EF1A4364EB7E75601E78235079562F_terseLabel_en-US" xlink:label="lab_biib_FAMPYRAMember_F0EF1A4364EB7E75601E78235079562F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FAMPYRA</link:label>
    <link:label id="lab_biib_FAMPYRAMember_F0EF1A4364EB7E75601E78235079562F_label_en-US" xlink:label="lab_biib_FAMPYRAMember_F0EF1A4364EB7E75601E78235079562F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FAMPYRA [Member]</link:label>
    <link:label id="lab_biib_FAMPYRAMember_F0EF1A4364EB7E75601E78235079562F_documentation_en-US" xlink:label="lab_biib_FAMPYRAMember_F0EF1A4364EB7E75601E78235079562F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FAMPYRA [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_FAMPYRAMember" xlink:label="loc_biib_FAMPYRAMember_F0EF1A4364EB7E75601E78235079562F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FAMPYRAMember_F0EF1A4364EB7E75601E78235079562F" xlink:to="lab_biib_FAMPYRAMember_F0EF1A4364EB7E75601E78235079562F" xlink:type="arc" />
    <link:label id="lab_biib_MSProductRevenuesMember_4708B03E710C46C3DF2578235079EB6E_terseLabel_en-US" xlink:label="lab_biib_MSProductRevenuesMember_4708B03E710C46C3DF2578235079EB6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MS Product Revenues</link:label>
    <link:label id="lab_biib_MSProductRevenuesMember_4708B03E710C46C3DF2578235079EB6E_label_en-US" xlink:label="lab_biib_MSProductRevenuesMember_4708B03E710C46C3DF2578235079EB6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MS Product Revenues [Member]</link:label>
    <link:label id="lab_biib_MSProductRevenuesMember_4708B03E710C46C3DF2578235079EB6E_documentation_en-US" xlink:label="lab_biib_MSProductRevenuesMember_4708B03E710C46C3DF2578235079EB6E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">MS Product Revenues [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_MSProductRevenuesMember" xlink:label="loc_biib_MSProductRevenuesMember_4708B03E710C46C3DF2578235079EB6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MSProductRevenuesMember_4708B03E710C46C3DF2578235079EB6E" xlink:to="lab_biib_MSProductRevenuesMember_4708B03E710C46C3DF2578235079EB6E" xlink:type="arc" />
    <link:label id="lab_biib_SPINRAZAMember_143CD02C02B5601658C478235079C76E_terseLabel_en-US" xlink:label="lab_biib_SPINRAZAMember_143CD02C02B5601658C478235079C76E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SPINRAZA</link:label>
    <link:label id="lab_biib_SPINRAZAMember_143CD02C02B5601658C478235079C76E_label_en-US" xlink:label="lab_biib_SPINRAZAMember_143CD02C02B5601658C478235079C76E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SPINRAZA [Member]</link:label>
    <link:label id="lab_biib_SPINRAZAMember_143CD02C02B5601658C478235079C76E_documentation_en-US" xlink:label="lab_biib_SPINRAZAMember_143CD02C02B5601658C478235079C76E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SPINRAZA [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_143CD02C02B5601658C478235079C76E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SPINRAZAMember_143CD02C02B5601658C478235079C76E" xlink:to="lab_biib_SPINRAZAMember_143CD02C02B5601658C478235079C76E" xlink:type="arc" />
    <link:label id="lab_biib_BENEPALIMember_AED9450A5F78AF0617897823507ACB1E_terseLabel_en-US" xlink:label="lab_biib_BENEPALIMember_AED9450A5F78AF0617897823507ACB1E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BENEPALI</link:label>
    <link:label id="lab_biib_BENEPALIMember_AED9450A5F78AF0617897823507ACB1E_label_en-US" xlink:label="lab_biib_BENEPALIMember_AED9450A5F78AF0617897823507ACB1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BENEPALI [Member]</link:label>
    <link:label id="lab_biib_BENEPALIMember_AED9450A5F78AF0617897823507ACB1E_documentation_en-US" xlink:label="lab_biib_BENEPALIMember_AED9450A5F78AF0617897823507ACB1E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BENEPALI [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_BENEPALIMember" xlink:label="loc_biib_BENEPALIMember_AED9450A5F78AF0617897823507ACB1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BENEPALIMember_AED9450A5F78AF0617897823507ACB1E" xlink:to="lab_biib_BENEPALIMember_AED9450A5F78AF0617897823507ACB1E" xlink:type="arc" />
    <link:label id="lab_biib_IMRALDIMember_EA46CE3776497E3AF1C27823507A2677_terseLabel_en-US" xlink:label="lab_biib_IMRALDIMember_EA46CE3776497E3AF1C27823507A2677" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IMRALDI</link:label>
    <link:label id="lab_biib_IMRALDIMember_EA46CE3776497E3AF1C27823507A2677_label_en-US" xlink:label="lab_biib_IMRALDIMember_EA46CE3776497E3AF1C27823507A2677" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IMRALDI [Member]</link:label>
    <link:label id="lab_biib_IMRALDIMember_EA46CE3776497E3AF1C27823507A2677_documentation_en-US" xlink:label="lab_biib_IMRALDIMember_EA46CE3776497E3AF1C27823507A2677" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">IMRALDI [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_IMRALDIMember" xlink:label="loc_biib_IMRALDIMember_EA46CE3776497E3AF1C27823507A2677" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IMRALDIMember_EA46CE3776497E3AF1C27823507A2677" xlink:to="lab_biib_IMRALDIMember_EA46CE3776497E3AF1C27823507A2677" xlink:type="arc" />
    <link:label id="lab_biib_FLIXABIMember_4D4860BE6C7AD72099737823507A675B_terseLabel_en-US" xlink:label="lab_biib_FLIXABIMember_4D4860BE6C7AD72099737823507A675B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FLIXABI</link:label>
    <link:label id="lab_biib_FLIXABIMember_4D4860BE6C7AD72099737823507A675B_label_en-US" xlink:label="lab_biib_FLIXABIMember_4D4860BE6C7AD72099737823507A675B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FLIXABI [Member]</link:label>
    <link:label id="lab_biib_FLIXABIMember_4D4860BE6C7AD72099737823507A675B_documentation_en-US" xlink:label="lab_biib_FLIXABIMember_4D4860BE6C7AD72099737823507A675B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FLIXABI [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_FLIXABIMember" xlink:label="loc_biib_FLIXABIMember_4D4860BE6C7AD72099737823507A675B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FLIXABIMember_4D4860BE6C7AD72099737823507A675B" xlink:to="lab_biib_FLIXABIMember_4D4860BE6C7AD72099737823507A675B" xlink:type="arc" />
    <link:label id="lab_biib_BiosimilarsMember_DE0ADE2CCE0661E70E9E7823507A1BCE_terseLabel_en-US" xlink:label="lab_biib_BiosimilarsMember_DE0ADE2CCE0661E70E9E7823507A1BCE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biosimilars</link:label>
    <link:label id="lab_biib_BiosimilarsMember_DE0ADE2CCE0661E70E9E7823507A1BCE_label_en-US" xlink:label="lab_biib_BiosimilarsMember_DE0ADE2CCE0661E70E9E7823507A1BCE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biosimilars [Member]</link:label>
    <link:label id="lab_biib_BiosimilarsMember_DE0ADE2CCE0661E70E9E7823507A1BCE_documentation_en-US" xlink:label="lab_biib_BiosimilarsMember_DE0ADE2CCE0661E70E9E7823507A1BCE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biosimilars</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_BiosimilarsMember" xlink:label="loc_biib_BiosimilarsMember_DE0ADE2CCE0661E70E9E7823507A1BCE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiosimilarsMember_DE0ADE2CCE0661E70E9E7823507A1BCE" xlink:to="lab_biib_BiosimilarsMember_DE0ADE2CCE0661E70E9E7823507A1BCE" xlink:type="arc" />
    <link:label id="lab_biib_FUMADERMMember_DD51AD03C102554C01EC7823507AE13C_terseLabel_en-US" xlink:label="lab_biib_FUMADERMMember_DD51AD03C102554C01EC7823507AE13C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FUMADERM</link:label>
    <link:label id="lab_biib_FUMADERMMember_DD51AD03C102554C01EC7823507AE13C_label_en-US" xlink:label="lab_biib_FUMADERMMember_DD51AD03C102554C01EC7823507AE13C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FUMADERM [Member]</link:label>
    <link:label id="lab_biib_FUMADERMMember_DD51AD03C102554C01EC7823507AE13C_documentation_en-US" xlink:label="lab_biib_FUMADERMMember_DD51AD03C102554C01EC7823507AE13C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FUMADERM [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_FUMADERMMember" xlink:label="loc_biib_FUMADERMMember_DD51AD03C102554C01EC7823507AE13C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FUMADERMMember_DD51AD03C102554C01EC7823507AE13C" xlink:to="lab_biib_FUMADERMMember_DD51AD03C102554C01EC7823507AE13C" xlink:type="arc" />
    <link:label id="lab_srt_StatementGeographicalAxis_081BDB7A82F05F4B77547823507A9771_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis_081BDB7A82F05F4B77547823507A9771" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_081BDB7A82F05F4B77547823507A9771_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis_081BDB7A82F05F4B77547823507A9771" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_081BDB7A82F05F4B77547823507A9771" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis_081BDB7A82F05F4B77547823507A9771" xlink:to="lab_srt_StatementGeographicalAxis_081BDB7A82F05F4B77547823507A9771" xlink:type="arc" />
    <link:label id="lab_srt_SegmentGeographicalDomain_821FB6D933CE82D62F847823507BAF14_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_821FB6D933CE82D62F847823507BAF14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_821FB6D933CE82D62F847823507BAF14_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_821FB6D933CE82D62F847823507BAF14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_821FB6D933CE82D62F847823507BAF14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain_821FB6D933CE82D62F847823507BAF14" xlink:to="lab_srt_SegmentGeographicalDomain_821FB6D933CE82D62F847823507BAF14" xlink:type="arc" />
    <link:label id="lab_country_US_891B96488EA94C98CB357823507BBA1D_terseLabel_en-US" xlink:label="lab_country_US_891B96488EA94C98CB357823507BBA1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_891B96488EA94C98CB357823507BBA1D_label_en-US" xlink:label="lab_country_US_891B96488EA94C98CB357823507BBA1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_891B96488EA94C98CB357823507BBA1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_891B96488EA94C98CB357823507BBA1D" xlink:to="lab_country_US_891B96488EA94C98CB357823507BBA1D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonUsMember_68E984D74C8D355DB4CC7823507B20AA_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember_68E984D74C8D355DB4CC7823507B20AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rest of World</link:label>
    <link:label id="lab_us-gaap_NonUsMember_68E984D74C8D355DB4CC7823507B20AA_label_en-US" xlink:label="lab_us-gaap_NonUsMember_68E984D74C8D355DB4CC7823507B20AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember_68E984D74C8D355DB4CC7823507B20AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember_68E984D74C8D355DB4CC7823507B20AA" xlink:to="lab_us-gaap_NonUsMember_68E984D74C8D355DB4CC7823507B20AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_B128E1E228EACD6B8BA87823507CE70C_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues_B128E1E228EACD6B8BA87823507CE70C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_B128E1E228EACD6B8BA87823507CE70C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_B128E1E228EACD6B8BA87823507CE70C" xlink:to="lab_us-gaap_Revenues_B128E1E228EACD6B8BA87823507CE70C" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_A1A2D9AD76DE121FD22978234F4BD412_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure_A1A2D9AD76DE121FD22978234F4BD412" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes payable, fair value</link:label>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_A1A2D9AD76DE121FD22978234F4BD412_label_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure_A1A2D9AD76DE121FD22978234F4BD412" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_A1A2D9AD76DE121FD22978234F4BD412" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableFairValueDisclosure_A1A2D9AD76DE121FD22978234F4BD412" xlink:to="lab_us-gaap_NotesPayableFairValueDisclosure_A1A2D9AD76DE121FD22978234F4BD412" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayable_2AC1BE9F705578990C3E78234F4B97F7_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesPayable_2AC1BE9F705578990C3E78234F4B97F7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes payable, carrying value</link:label>
    <link:label id="lab_us-gaap_NotesPayable_2AC1BE9F705578990C3E78234F4B97F7_label_en-US" xlink:label="lab_us-gaap_NotesPayable_2AC1BE9F705578990C3E78234F4B97F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_2AC1BE9F705578990C3E78234F4B97F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable_2AC1BE9F705578990C3E78234F4B97F7" xlink:to="lab_us-gaap_NotesPayable_2AC1BE9F705578990C3E78234F4B97F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_E357519159E09500D14178234F4B28F6_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue_E357519159E09500D14178234F4B28F6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt instruments, fair value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_E357519159E09500D14178234F4B28F6_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue_E357519159E09500D14178234F4B28F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_E357519159E09500D14178234F4B28F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue_E357519159E09500D14178234F4B28F6" xlink:to="lab_us-gaap_DebtInstrumentFairValue_E357519159E09500D14178234F4B28F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_182EA4B9FC283DB36FD278234E333CE0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_182EA4B9FC283DB36FD278234E333CE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_182EA4B9FC283DB36FD278234E333CE0_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_182EA4B9FC283DB36FD278234E333CE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_182EA4B9FC283DB36FD278234E333CE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_182EA4B9FC283DB36FD278234E333CE0" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_182EA4B9FC283DB36FD278234E333CE0" xlink:type="arc" />
    <link:label id="lab_biib_DerivativeMaturityAxis_7606227E8A5EF21EF55F78234E33027D_terseLabel_en-US" xlink:label="lab_biib_DerivativeMaturityAxis_7606227E8A5EF21EF55F78234E33027D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Maturity [Axis]</link:label>
    <link:label id="lab_biib_DerivativeMaturityAxis_7606227E8A5EF21EF55F78234E33027D_label_en-US" xlink:label="lab_biib_DerivativeMaturityAxis_7606227E8A5EF21EF55F78234E33027D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Maturity [Axis]</link:label>
    <link:label id="lab_biib_DerivativeMaturityAxis_7606227E8A5EF21EF55F78234E33027D_documentation_en-US" xlink:label="lab_biib_DerivativeMaturityAxis_7606227E8A5EF21EF55F78234E33027D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative Maturity [Axis]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_DerivativeMaturityAxis" xlink:label="loc_biib_DerivativeMaturityAxis_7606227E8A5EF21EF55F78234E33027D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DerivativeMaturityAxis_7606227E8A5EF21EF55F78234E33027D" xlink:to="lab_biib_DerivativeMaturityAxis_7606227E8A5EF21EF55F78234E33027D" xlink:type="arc" />
    <link:label id="lab_biib_DerivativeMaturityDomain_6B91976A8E988C1923F378234E3419C1_terseLabel_en-US" xlink:label="lab_biib_DerivativeMaturityDomain_6B91976A8E988C1923F378234E3419C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Maturity [Domain]</link:label>
    <link:label id="lab_biib_DerivativeMaturityDomain_6B91976A8E988C1923F378234E3419C1_label_en-US" xlink:label="lab_biib_DerivativeMaturityDomain_6B91976A8E988C1923F378234E3419C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Maturity [Domain]</link:label>
    <link:label id="lab_biib_DerivativeMaturityDomain_6B91976A8E988C1923F378234E3419C1_documentation_en-US" xlink:label="lab_biib_DerivativeMaturityDomain_6B91976A8E988C1923F378234E3419C1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Derivative Maturity [Axis]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_DerivativeMaturityDomain" xlink:label="loc_biib_DerivativeMaturityDomain_6B91976A8E988C1923F378234E3419C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DerivativeMaturityDomain_6B91976A8E988C1923F378234E3419C1" xlink:to="lab_biib_DerivativeMaturityDomain_6B91976A8E988C1923F378234E3419C1" xlink:type="arc" />
    <link:label id="lab_biib_ShorttermderivativeMember_B2F5AF05CAC8A67528A378234E3428E5_terseLabel_en-US" xlink:label="lab_biib_ShorttermderivativeMember_B2F5AF05CAC8A67528A378234E3428E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term derivative</link:label>
    <link:label id="lab_biib_ShorttermderivativeMember_B2F5AF05CAC8A67528A378234E3428E5_label_en-US" xlink:label="lab_biib_ShorttermderivativeMember_B2F5AF05CAC8A67528A378234E3428E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term derivative [Member]</link:label>
    <link:label id="lab_biib_ShorttermderivativeMember_B2F5AF05CAC8A67528A378234E3428E5_documentation_en-US" xlink:label="lab_biib_ShorttermderivativeMember_B2F5AF05CAC8A67528A378234E3428E5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Short-term derivative [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_ShorttermderivativeMember" xlink:label="loc_biib_ShorttermderivativeMember_B2F5AF05CAC8A67528A378234E3428E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShorttermderivativeMember_B2F5AF05CAC8A67528A378234E3428E5" xlink:to="lab_biib_ShorttermderivativeMember_B2F5AF05CAC8A67528A378234E3428E5" xlink:type="arc" />
    <link:label id="lab_srt_CurrencyAxis_25E4A6CBC75B8FB27D3478234E37CF24_terseLabel_en-US" xlink:label="lab_srt_CurrencyAxis_25E4A6CBC75B8FB27D3478234E37CF24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_srt_CurrencyAxis_25E4A6CBC75B8FB27D3478234E37CF24_label_en-US" xlink:label="lab_srt_CurrencyAxis_25E4A6CBC75B8FB27D3478234E37CF24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_25E4A6CBC75B8FB27D3478234E37CF24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis_25E4A6CBC75B8FB27D3478234E37CF24" xlink:to="lab_srt_CurrencyAxis_25E4A6CBC75B8FB27D3478234E37CF24" xlink:type="arc" />
    <link:label id="lab_currency_AllCurrenciesDomain_B4A9577A520A6C0C743478234E38FC2B_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain_B4A9577A520A6C0C743478234E38FC2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_B4A9577A520A6C0C743478234E38FC2B_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain_B4A9577A520A6C0C743478234E38FC2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_B4A9577A520A6C0C743478234E38FC2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain_B4A9577A520A6C0C743478234E38FC2B" xlink:to="lab_currency_AllCurrenciesDomain_B4A9577A520A6C0C743478234E38FC2B" xlink:type="arc" />
    <link:label id="lab_currency_EUR_DC27B339F046752BD02678234E38BE8E_verboseLabel_en-US" xlink:label="lab_currency_EUR_DC27B339F046752BD02678234E38BE8E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Euro</link:label>
    <link:label id="lab_currency_EUR_DC27B339F046752BD02678234E38BE8E_label_en-US" xlink:label="lab_currency_EUR_DC27B339F046752BD02678234E38BE8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_DC27B339F046752BD02678234E38BE8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR_DC27B339F046752BD02678234E38BE8E" xlink:to="lab_currency_EUR_DC27B339F046752BD02678234E38BE8E" xlink:type="arc" />
    <link:label id="lab_currency_GBP_74B5F32447D3E6DB26F978234E39CED2_terseLabel_en-US" xlink:label="lab_currency_GBP_74B5F32447D3E6DB26F978234E39CED2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">British pound</link:label>
    <link:label id="lab_currency_GBP_74B5F32447D3E6DB26F978234E39CED2_label_en-US" xlink:label="lab_currency_GBP_74B5F32447D3E6DB26F978234E39CED2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">United Kingdom, Pounds</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_GBP" xlink:label="loc_currency_GBP_74B5F32447D3E6DB26F978234E39CED2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_GBP_74B5F32447D3E6DB26F978234E39CED2" xlink:to="lab_currency_GBP_74B5F32447D3E6DB26F978234E39CED2" xlink:type="arc" />
    <link:label id="lab_currency_CHF_C3C5CA939CAA1F6E813978234E39B752_terseLabel_en-US" xlink:label="lab_currency_CHF_C3C5CA939CAA1F6E813978234E39B752" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Swiss franc</link:label>
    <link:label id="lab_currency_CHF_C3C5CA939CAA1F6E813978234E39B752_label_en-US" xlink:label="lab_currency_CHF_C3C5CA939CAA1F6E813978234E39B752" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Switzerland, Francs</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CHF" xlink:label="loc_currency_CHF_C3C5CA939CAA1F6E813978234E39B752" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CHF_C3C5CA939CAA1F6E813978234E39B752" xlink:to="lab_currency_CHF_C3C5CA939CAA1F6E813978234E39B752" xlink:type="arc" />
    <link:label id="lab_currency_JPY_CF320C0DF573C4B7415078234E395E60_terseLabel_en-US" xlink:label="lab_currency_JPY_CF320C0DF573C4B7415078234E395E60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Japan, Yen</link:label>
    <link:label id="lab_currency_JPY_CF320C0DF573C4B7415078234E395E60_label_en-US" xlink:label="lab_currency_JPY_CF320C0DF573C4B7415078234E395E60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Japan, Yen</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_JPY" xlink:label="loc_currency_JPY_CF320C0DF573C4B7415078234E395E60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_JPY_CF320C0DF573C4B7415078234E395E60" xlink:to="lab_currency_JPY_CF320C0DF573C4B7415078234E395E60" xlink:type="arc" />
    <link:label id="lab_currency_CAD_B785FD5BB331CC7F3B1578234E394D54_verboseLabel_en-US" xlink:label="lab_currency_CAD_B785FD5BB331CC7F3B1578234E394D54" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Canadian dollar</link:label>
    <link:label id="lab_currency_CAD_B785FD5BB331CC7F3B1578234E394D54_label_en-US" xlink:label="lab_currency_CAD_B785FD5BB331CC7F3B1578234E394D54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Canada, Dollars</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CAD" xlink:label="loc_currency_CAD_B785FD5BB331CC7F3B1578234E394D54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CAD_B785FD5BB331CC7F3B1578234E394D54" xlink:to="lab_currency_CAD_B785FD5BB331CC7F3B1578234E394D54" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesMember_F7CADF5CD0EF1441EA9F78234E3BC30E_terseLabel_en-US" xlink:label="lab_us-gaap_SalesMember_F7CADF5CD0EF1441EA9F78234E3BC30E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesMember_F7CADF5CD0EF1441EA9F78234E3BC30E_label_en-US" xlink:label="lab_us-gaap_SalesMember_F7CADF5CD0EF1441EA9F78234E3BC30E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_F7CADF5CD0EF1441EA9F78234E3BC30E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember_F7CADF5CD0EF1441EA9F78234E3BC30E" xlink:to="lab_us-gaap_SalesMember_F7CADF5CD0EF1441EA9F78234E3BC30E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenseMember_B4C8FF5847D5D6D80D1078234E3B3084_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember_B4C8FF5847D5D6D80D1078234E3B3084" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expense</link:label>
    <link:label id="lab_us-gaap_OperatingExpenseMember_B4C8FF5847D5D6D80D1078234E3B3084_label_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember_B4C8FF5847D5D6D80D1078234E3B3084" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="loc_us-gaap_OperatingExpenseMember_B4C8FF5847D5D6D80D1078234E3B3084" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenseMember_B4C8FF5847D5D6D80D1078234E3B3084" xlink:to="lab_us-gaap_OperatingExpenseMember_B4C8FF5847D5D6D80D1078234E3B3084" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_3810D2C7D1140C2F6F3A78234E3B4A35_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_3810D2C7D1140C2F6F3A78234E3B4A35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_3810D2C7D1140C2F6F3A78234E3B4A35_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_3810D2C7D1140C2F6F3A78234E3B4A35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_3810D2C7D1140C2F6F3A78234E3B4A35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_3810D2C7D1140C2F6F3A78234E3B4A35" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_3810D2C7D1140C2F6F3A78234E3B4A35" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_3D001853856CF83BF2CE78234E3BA487_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_3D001853856CF83BF2CE78234E3BA487" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_3D001853856CF83BF2CE78234E3BA487_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_3D001853856CF83BF2CE78234E3BA487" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_3D001853856CF83BF2CE78234E3BA487" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_3D001853856CF83BF2CE78234E3BA487" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_3D001853856CF83BF2CE78234E3BA487" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_7293B45C6DB379273B2578234E3B3FCF_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain_7293B45C6DB379273B2578234E3B3FCF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_7293B45C6DB379273B2578234E3B3FCF_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain_7293B45C6DB379273B2578234E3B3FCF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_7293B45C6DB379273B2578234E3B3FCF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain_7293B45C6DB379273B2578234E3B3FCF" xlink:to="lab_us-gaap_HedgingRelationshipDomain_7293B45C6DB379273B2578234E3B3FCF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashFlowHedgingMember_2730D6E132F6ADD3801678234E3C5ABE_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember_2730D6E132F6ADD3801678234E3C5ABE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_2730D6E132F6ADD3801678234E3C5ABE_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember_2730D6E132F6ADD3801678234E3C5ABE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowHedgingMember" xlink:label="loc_us-gaap_CashFlowHedgingMember_2730D6E132F6ADD3801678234E3C5ABE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember_2730D6E132F6ADD3801678234E3C5ABE" xlink:to="lab_us-gaap_CashFlowHedgingMember_2730D6E132F6ADD3801678234E3C5ABE" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueHedgingMember_73A5D2A170D0AE96651D78234E3C1C79_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember_73A5D2A170D0AE96651D78234E3C1C79" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hedging [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueHedgingMember_73A5D2A170D0AE96651D78234E3C1C79_label_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember_73A5D2A170D0AE96651D78234E3C1C79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hedging [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueHedgingMember" xlink:label="loc_us-gaap_FairValueHedgingMember_73A5D2A170D0AE96651D78234E3C1C79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueHedgingMember_73A5D2A170D0AE96651D78234E3C1C79" xlink:to="lab_us-gaap_FairValueHedgingMember_73A5D2A170D0AE96651D78234E3C1C79" xlink:type="arc" />
    <link:label id="lab_biib_CashflowsrevenueMember_640FD48F3FD50451723F78234E3D4966_terseLabel_en-US" xlink:label="lab_biib_CashflowsrevenueMember_640FD48F3FD50451723F78234E3D4966" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows, revenue</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_640FD48F3FD50451723F78234E3D4966_label_en-US" xlink:label="lab_biib_CashflowsrevenueMember_640FD48F3FD50451723F78234E3D4966" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_640FD48F3FD50451723F78234E3D4966_documentation_en-US" xlink:label="lab_biib_CashflowsrevenueMember_640FD48F3FD50451723F78234E3D4966" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_CashflowsrevenueMember" xlink:label="loc_biib_CashflowsrevenueMember_640FD48F3FD50451723F78234E3D4966" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsrevenueMember_640FD48F3FD50451723F78234E3D4966" xlink:to="lab_biib_CashflowsrevenueMember_640FD48F3FD50451723F78234E3D4966" xlink:type="arc" />
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_97AB68E5CFA516CB41C678234E3DB0A2_terseLabel_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember_97AB68E5CFA516CB41C678234E3DB0A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows, operating expenses</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_97AB68E5CFA516CB41C678234E3DB0A2_label_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember_97AB68E5CFA516CB41C678234E3DB0A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_97AB68E5CFA516CB41C678234E3DB0A2_documentation_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember_97AB68E5CFA516CB41C678234E3DB0A2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_CashflowsoperatingexpensesMember" xlink:label="loc_biib_CashflowsoperatingexpensesMember_97AB68E5CFA516CB41C678234E3DB0A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsoperatingexpensesMember_97AB68E5CFA516CB41C678234E3DB0A2" xlink:to="lab_biib_CashflowsoperatingexpensesMember_97AB68E5CFA516CB41C678234E3DB0A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_00F7F7A0F2099967B03078234E3DBAC0_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember_00F7F7A0F2099967B03078234E3DBAC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Investment Hedging</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_00F7F7A0F2099967B03078234E3DBAC0_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember_00F7F7A0F2099967B03078234E3DBAC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetInvestmentHedgingMember" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_00F7F7A0F2099967B03078234E3DBAC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember_00F7F7A0F2099967B03078234E3DBAC0" xlink:to="lab_us-gaap_NetInvestmentHedgingMember_00F7F7A0F2099967B03078234E3DBAC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_C38AB767994AF108969B78234E3EC43F_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember_C38AB767994AF108969B78234E3EC43F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange contract</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_C38AB767994AF108969B78234E3EC43F_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember_C38AB767994AF108969B78234E3EC43F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_C38AB767994AF108969B78234E3EC43F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember_C38AB767994AF108969B78234E3EC43F" xlink:to="lab_us-gaap_ForeignExchangeContractMember_C38AB767994AF108969B78234E3EC43F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_354FD5342FE655A2861D78234E3FE549_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember_354FD5342FE655A2861D78234E3FE549" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_354FD5342FE655A2861D78234E3FE549_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember_354FD5342FE655A2861D78234E3FE549" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_354FD5342FE655A2861D78234E3FE549" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember_354FD5342FE655A2861D78234E3FE549" xlink:to="lab_us-gaap_AccruedLiabilitiesMember_354FD5342FE655A2861D78234E3FE549" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_7411FED5179522BDC83778234E40DE8C_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember_7411FED5179522BDC83778234E40DE8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_7411FED5179522BDC83778234E40DE8C_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember_7411FED5179522BDC83778234E40DE8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_7411FED5179522BDC83778234E40DE8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember_7411FED5179522BDC83778234E40DE8C" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember_7411FED5179522BDC83778234E40DE8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingDesignationAxis_D25E1340857D5B4AC5F878234E402F70_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis_D25E1340857D5B4AC5F878234E402F70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_D25E1340857D5B4AC5F878234E402F70_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis_D25E1340857D5B4AC5F878234E402F70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_D25E1340857D5B4AC5F878234E402F70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis_D25E1340857D5B4AC5F878234E402F70" xlink:to="lab_us-gaap_HedgingDesignationAxis_D25E1340857D5B4AC5F878234E402F70" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingDesignationDomain_B9795BDB4EC6978139B878234E40F2A5_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain_B9795BDB4EC6978139B878234E40F2A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_B9795BDB4EC6978139B878234E40F2A5_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain_B9795BDB4EC6978139B878234E40F2A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_B9795BDB4EC6978139B878234E40F2A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain_B9795BDB4EC6978139B878234E40F2A5" xlink:to="lab_us-gaap_HedgingDesignationDomain_B9795BDB4EC6978139B878234E40F2A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_8293A31DC0A4F4DC7CCB78234E41F88B_verboseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember_8293A31DC0A4F4DC7CCB78234E41F88B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_8293A31DC0A4F4DC7CCB78234E41F88B_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember_8293A31DC0A4F4DC7CCB78234E41F88B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_8293A31DC0A4F4DC7CCB78234E41F88B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember_8293A31DC0A4F4DC7CCB78234E41F88B" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember_8293A31DC0A4F4DC7CCB78234E41F88B" xlink:type="arc" />
    <link:label id="lab_us-gaap_NondesignatedMember_87B19D72EE4AE9D0358478234E41527C_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember_87B19D72EE4AE9D0358478234E41527C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Not designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_87B19D72EE4AE9D0358478234E41527C_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember_87B19D72EE4AE9D0358478234E41527C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_87B19D72EE4AE9D0358478234E41527C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember_87B19D72EE4AE9D0358478234E41527C" xlink:to="lab_us-gaap_NondesignatedMember_87B19D72EE4AE9D0358478234E41527C" xlink:type="arc" />
    <link:label id="lab_srt_MinimumMember_EC9F95558EF8119873DC78234E421FF6_terseLabel_en-US" xlink:label="lab_srt_MinimumMember_EC9F95558EF8119873DC78234E421FF6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_EC9F95558EF8119873DC78234E421FF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_EC9F95558EF8119873DC78234E421FF6" xlink:to="lab_srt_MinimumMember_EC9F95558EF8119873DC78234E421FF6" xlink:type="arc" />
    <link:label id="lab_srt_MaximumMember_71338DDD22507624A2A478234E425D94_terseLabel_en-US" xlink:label="lab_srt_MaximumMember_71338DDD22507624A2A478234E425D94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_71338DDD22507624A2A478234E425D94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_71338DDD22507624A2A478234E425D94" xlink:to="lab_srt_MaximumMember_71338DDD22507624A2A478234E425D94" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_A4C3A2B414634120787B78234E43258D_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems_A4C3A2B414634120787B78234E43258D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivatives [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_A4C3A2B414634120787B78234E43258D_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems_A4C3A2B414634120787B78234E43258D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_A4C3A2B414634120787B78234E43258D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A4C3A2B414634120787B78234E43258D" xlink:to="lab_us-gaap_DerivativesFairValueLineItems_A4C3A2B414634120787B78234E43258D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_B3B319A9E09C1B2005A078234E43D08E_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1_B3B319A9E09C1B2005A078234E43D08E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Range of durations of foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_B3B319A9E09C1B2005A078234E43D08E_label_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1_B3B319A9E09C1B2005A078234E43D08E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Remaining Maturity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeRemainingMaturity1" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_B3B319A9E09C1B2005A078234E43D08E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeRemainingMaturity1_B3B319A9E09C1B2005A078234E43D08E" xlink:to="lab_us-gaap_DerivativeRemainingMaturity1_B3B319A9E09C1B2005A078234E43D08E" xlink:type="arc" />
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_9D42A4C7C93D7CC7C9E978234E438900_negatedLabel_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_9D42A4C7C93D7CC7C9E978234E438900" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gain/Loss on fair value of foreign currency forward contracts</link:label>
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_9D42A4C7C93D7CC7C9E978234E438900_label_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_9D42A4C7C93D7CC7C9E978234E438900" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Losses) on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_9D42A4C7C93D7CC7C9E978234E438900_documentation_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_9D42A4C7C93D7CC7C9E978234E438900" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_9D42A4C7C93D7CC7C9E978234E438900" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_9D42A4C7C93D7CC7C9E978234E438900" xlink:to="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_9D42A4C7C93D7CC7C9E978234E438900" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_896C044F02F89EB888C178234E43AAF4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_896C044F02F89EB888C178234E43AAF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on reclassification of cash flow hedges, effective portion</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_896C044F02F89EB888C178234E43AAF4_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_896C044F02F89EB888C178234E43AAF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_896C044F02F89EB888C178234E43AAF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_896C044F02F89EB888C178234E43AAF4" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_896C044F02F89EB888C178234E43AAF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_56229B7CC46F08AC5CF478234E4471CC_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_56229B7CC46F08AC5CF478234E4471CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) recognized in net income, excluded component</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_56229B7CC46F08AC5CF478234E4471CC_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_56229B7CC46F08AC5CF478234E4471CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_56229B7CC46F08AC5CF478234E4471CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_56229B7CC46F08AC5CF478234E4471CC" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_56229B7CC46F08AC5CF478234E4471CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_ABEF647F51BA920216D578234E4415E6_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_ABEF647F51BA920216D578234E4415E6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gain on interest rate swap</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_ABEF647F51BA920216D578234E4415E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_ABEF647F51BA920216D578234E4415E6" xlink:to="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_ABEF647F51BA920216D578234E4415E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_C0C08B2C2581E464A65278234E448501_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount_C0C08B2C2581E464A65278234E448501" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_C0C08B2C2581E464A65278234E448501_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount_C0C08B2C2581E464A65278234E448501" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeNotionalAmount" xlink:label="loc_us-gaap_DerivativeNotionalAmount_C0C08B2C2581E464A65278234E448501" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount_C0C08B2C2581E464A65278234E448501" xlink:to="lab_us-gaap_DerivativeNotionalAmount_C0C08B2C2581E464A65278234E448501" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_7DDDF52BDD501182CA9478234E45AA1D_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_7DDDF52BDD501182CA9478234E45AA1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_7DDDF52BDD501182CA9478234E45AA1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_7DDDF52BDD501182CA9478234E45AA1D" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_7DDDF52BDD501182CA9478234E45AA1D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeTermOfContract_067B574A43E7593376C278234E45197E_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract_067B574A43E7593376C278234E45197E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining duration of Net Investment Hedges</link:label>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_067B574A43E7593376C278234E45197E_label_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract_067B574A43E7593376C278234E45197E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Term of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeTermOfContract" xlink:label="loc_us-gaap_DerivativeTermOfContract_067B574A43E7593376C278234E45197E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTermOfContract_067B574A43E7593376C278234E45197E" xlink:to="lab_us-gaap_DerivativeTermOfContract_067B574A43E7593376C278234E45197E" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_51BF3EE424107F7E0FB478234E46AB1C_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_51BF3EE424107F7E0FB478234E46AB1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on net investment hedges in AOCI</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_51BF3EE424107F7E0FB478234E46AB1C_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_51BF3EE424107F7E0FB478234E46AB1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_51BF3EE424107F7E0FB478234E46AB1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_51BF3EE424107F7E0FB478234E46AB1C" xlink:to="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_51BF3EE424107F7E0FB478234E46AB1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_70D098D7B541443B80C278234E46FD44_terseLabel_en-US" xlink:label="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_70D098D7B541443B80C278234E46FD44" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative qualifying as net investment hedge, excluded component</link:label>
    <link:label id="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_70D098D7B541443B80C278234E46FD44_label_en-US" xlink:label="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_70D098D7B541443B80C278234E46FD44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI, Derivative Qualifying as Hedge, Excluded Component, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_70D098D7B541443B80C278234E46FD44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_70D098D7B541443B80C278234E46FD44" xlink:to="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_70D098D7B541443B80C278234E46FD44" xlink:type="arc" />
    <link:label id="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_36B8AF83E486DC6529C678234E469586_terseLabel_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_36B8AF83E486DC6529C678234E469586" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gains (losses) on net investment hedges</link:label>
    <link:label id="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_36B8AF83E486DC6529C678234E469586_label_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_36B8AF83E486DC6529C678234E469586" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives used in Net Investment Hedge, Net of Tax, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_36B8AF83E486DC6529C678234E469586" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_36B8AF83E486DC6529C678234E469586" xlink:to="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_36B8AF83E486DC6529C678234E469586" xlink:type="arc" />
    <link:label id="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_03EC6AC09458088648A078234E4631E3_terseLabel_en-US" xlink:label="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_03EC6AC09458088648A078234E4631E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gains (losses) on net investment hedge, excluded component</link:label>
    <link:label id="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_03EC6AC09458088648A078234E4631E3_label_en-US" xlink:label="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_03EC6AC09458088648A078234E4631E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)</link:label>
    <link:label id="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_03EC6AC09458088648A078234E4631E3_documentation_en-US" xlink:label="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_03EC6AC09458088648A078234E4631E3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:label="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_03EC6AC09458088648A078234E4631E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_03EC6AC09458088648A078234E4631E3" xlink:to="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_03EC6AC09458088648A078234E4631E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_6D18C130A006A1F8BD2D78234E4770F2_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_6D18C130A006A1F8BD2D78234E4770F2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net gains (losses) of other income (expense) related to foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_6D18C130A006A1F8BD2D78234E4770F2_label_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_6D18C130A006A1F8BD2D78234E4770F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_6D18C130A006A1F8BD2D78234E4770F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_6D18C130A006A1F8BD2D78234E4770F2" xlink:to="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_6D18C130A006A1F8BD2D78234E4770F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_BA77C049A5CC55FF05AA78234E478CFC_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_BA77C049A5CC55FF05AA78234E478CFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative asset, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_BA77C049A5CC55FF05AA78234E478CFC_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_BA77C049A5CC55FF05AA78234E478CFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_BA77C049A5CC55FF05AA78234E478CFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_BA77C049A5CC55FF05AA78234E478CFC" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_BA77C049A5CC55FF05AA78234E478CFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_0C16B33EEB390E49D1B878234E4761C6_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_0C16B33EEB390E49D1B878234E4761C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative liability, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_0C16B33EEB390E49D1B878234E4761C6_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_0C16B33EEB390E49D1B878234E4761C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_0C16B33EEB390E49D1B878234E4761C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_0C16B33EEB390E49D1B878234E4761C6" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_0C16B33EEB390E49D1B878234E4761C6" xlink:type="arc" />
    <link:label id="lab_biib_AcquisitionsAbstract_D5D6EECF36B30A2025B0782350BBCA7D_label_en-US" xlink:label="lab_biib_AcquisitionsAbstract_D5D6EECF36B30A2025B0782350BBCA7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisitions [Abstract]</link:label>
    <link:label id="lab_biib_AcquisitionsAbstract_D5D6EECF36B30A2025B0782350BBCA7D_documentation_en-US" xlink:label="lab_biib_AcquisitionsAbstract_D5D6EECF36B30A2025B0782350BBCA7D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Acquisitions [Abstract]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_AcquisitionsAbstract" xlink:label="loc_biib_AcquisitionsAbstract_D5D6EECF36B30A2025B0782350BBCA7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AcquisitionsAbstract_D5D6EECF36B30A2025B0782350BBCA7D" xlink:to="lab_biib_AcquisitionsAbstract_D5D6EECF36B30A2025B0782350BBCA7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_B0365BFBB001CF51F1E1782350BCE1AF_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_B0365BFBB001CF51F1E1782350BCE1AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_B0365BFBB001CF51F1E1782350BCE1AF_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_B0365BFBB001CF51F1E1782350BCE1AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_B0365BFBB001CF51F1E1782350BCE1AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_B0365BFBB001CF51F1E1782350BCE1AF" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_B0365BFBB001CF51F1E1782350BCE1AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_1DFEBED13AF272A115AC782350BD0D5D_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_1DFEBED13AF272A115AC782350BD0D5D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_1DFEBED13AF272A115AC782350BD0D5D_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_1DFEBED13AF272A115AC782350BD0D5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1DFEBED13AF272A115AC782350BD0D5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1DFEBED13AF272A115AC782350BD0D5D" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_1DFEBED13AF272A115AC782350BD0D5D" xlink:type="arc" />
    <link:label id="lab_biib_NightstarMember_3A71C35ABBEA5ECEE879782350BD81B5_terseLabel_en-US" xlink:label="lab_biib_NightstarMember_3A71C35ABBEA5ECEE879782350BD81B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nightstar</link:label>
    <link:label id="lab_biib_NightstarMember_3A71C35ABBEA5ECEE879782350BD81B5_label_en-US" xlink:label="lab_biib_NightstarMember_3A71C35ABBEA5ECEE879782350BD81B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nightstar [Member]</link:label>
    <link:label id="lab_biib_NightstarMember_3A71C35ABBEA5ECEE879782350BD81B5_documentation_en-US" xlink:label="lab_biib_NightstarMember_3A71C35ABBEA5ECEE879782350BD81B5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nightstar [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_NightstarMember" xlink:label="loc_biib_NightstarMember_3A71C35ABBEA5ECEE879782350BD81B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NightstarMember_3A71C35ABBEA5ECEE879782350BD81B5" xlink:to="lab_biib_NightstarMember_3A71C35ABBEA5ECEE879782350BD81B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_A44DF8604E9ED6619FDD782350BE325E_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_A44DF8604E9ED6619FDD782350BE325E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_A44DF8604E9ED6619FDD782350BE325E_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_A44DF8604E9ED6619FDD782350BE325E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_A44DF8604E9ED6619FDD782350BE325E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_A44DF8604E9ED6619FDD782350BE325E" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_A44DF8604E9ED6619FDD782350BE325E" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_A7585B52E294B54E4792782350BEB2F6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_A7585B52E294B54E4792782350BEB2F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_A7585B52E294B54E4792782350BEB2F6_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_A7585B52E294B54E4792782350BEB2F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_A7585B52E294B54E4792782350BEB2F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_A7585B52E294B54E4792782350BEB2F6" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_A7585B52E294B54E4792782350BEB2F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_FAC9584C471F68E37E46782350BED972_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_FAC9584C471F68E37E46782350BED972" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_FAC9584C471F68E37E46782350BED972_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_FAC9584C471F68E37E46782350BED972" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_FAC9584C471F68E37E46782350BED972" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_FAC9584C471F68E37E46782350BED972" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_FAC9584C471F68E37E46782350BED972" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_0B6C2D8D5A513ABC3F3A782350BE35DF_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_0B6C2D8D5A513ABC3F3A782350BE35DF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_0B6C2D8D5A513ABC3F3A782350BE35DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_0B6C2D8D5A513ABC3F3A782350BE35DF" xlink:to="lab_us-gaap_Goodwill_0B6C2D8D5A513ABC3F3A782350BE35DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_894C4BEA3F0D2B1B3E2E782350BE1743_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_894C4BEA3F0D2B1B3E2E782350BE1743" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_894C4BEA3F0D2B1B3E2E782350BE1743_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_894C4BEA3F0D2B1B3E2E782350BE1743" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_894C4BEA3F0D2B1B3E2E782350BE1743" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_894C4BEA3F0D2B1B3E2E782350BE1743" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_894C4BEA3F0D2B1B3E2E782350BE1743" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_8832D4F36B2A230777F8782350C07FE9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_8832D4F36B2A230777F8782350C07FE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_8832D4F36B2A230777F8782350C07FE9_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_8832D4F36B2A230777F8782350C07FE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_8832D4F36B2A230777F8782350C07FE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_8832D4F36B2A230777F8782350C07FE9" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_8832D4F36B2A230777F8782350C07FE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_DDF20669676AFEBB1BEB782350C000E7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_DDF20669676AFEBB1BEB782350C000E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total purchase price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_DDF20669676AFEBB1BEB782350C000E7_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_DDF20669676AFEBB1BEB782350C000E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_DDF20669676AFEBB1BEB782350C000E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_DDF20669676AFEBB1BEB782350C000E7" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_DDF20669676AFEBB1BEB782350C000E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_B2B610EE70B79959D80A78234D36B524_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_B2B610EE70B79959D80A78234D36B524" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_B2B610EE70B79959D80A78234D36B524_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_B2B610EE70B79959D80A78234D36B524" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_B2B610EE70B79959D80A78234D36B524" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_B2B610EE70B79959D80A78234D36B524" xlink:to="lab_us-gaap_AwardTypeAxis_B2B610EE70B79959D80A78234D36B524" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_919B530C99BA3ADF6BF578234D36E5EE_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_919B530C99BA3ADF6BF578234D36E5EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_919B530C99BA3ADF6BF578234D36E5EE_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_919B530C99BA3ADF6BF578234D36E5EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_919B530C99BA3ADF6BF578234D36E5EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_919B530C99BA3ADF6BF578234D36E5EE" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_919B530C99BA3ADF6BF578234D36E5EE" xlink:type="arc" />
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_A05AEF9BA3E91699C61778234D377F9E_terseLabel_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember_A05AEF9BA3E91699C61778234D377F9E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash settled performance shares</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_A05AEF9BA3E91699C61778234D377F9E_label_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember_A05AEF9BA3E91699C61778234D377F9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash settled performance shares [Member]</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_A05AEF9BA3E91699C61778234D377F9E_documentation_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember_A05AEF9BA3E91699C61778234D377F9E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash settled performance shares [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_A05AEF9BA3E91699C61778234D377F9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashSettledPerformanceSharesMember_A05AEF9BA3E91699C61778234D377F9E" xlink:to="lab_biib_CashSettledPerformanceSharesMember_A05AEF9BA3E91699C61778234D377F9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PerformanceSharesMember_A084307D78CD6BAD1D7978234D37003E_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_A084307D78CD6BAD1D7978234D37003E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_A084307D78CD6BAD1D7978234D37003E_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_A084307D78CD6BAD1D7978234D37003E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_A084307D78CD6BAD1D7978234D37003E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember_A084307D78CD6BAD1D7978234D37003E" xlink:to="lab_us-gaap_PerformanceSharesMember_A084307D78CD6BAD1D7978234D37003E" xlink:type="arc" />
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_1E39DBDB068DDB48CE4878234D38DAA9_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember_1E39DBDB068DDB48CE4878234D38DAA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance stock units settled in cash</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_1E39DBDB068DDB48CE4878234D38DAA9_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember_1E39DBDB068DDB48CE4878234D38DAA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Cash [Member]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_1E39DBDB068DDB48CE4878234D38DAA9_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember_1E39DBDB068DDB48CE4878234D38DAA9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Cash [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_PerformanceStockUnitsSettledinCashMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_1E39DBDB068DDB48CE4878234D38DAA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinCashMember_1E39DBDB068DDB48CE4878234D38DAA9" xlink:to="lab_biib_PerformanceStockUnitsSettledinCashMember_1E39DBDB068DDB48CE4878234D38DAA9" xlink:type="arc" />
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_15EDD8BC44206DFBA6F878234D380BF9_verboseLabel_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember_15EDD8BC44206DFBA6F878234D380BF9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_15EDD8BC44206DFBA6F878234D380BF9_label_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember_15EDD8BC44206DFBA6F878234D380BF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_15EDD8BC44206DFBA6F878234D380BF9_documentation_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember_15EDD8BC44206DFBA6F878234D380BF9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan.</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_EmployeeStockPurchasePlanMember" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_15EDD8BC44206DFBA6F878234D380BF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EmployeeStockPurchasePlanMember_15EDD8BC44206DFBA6F878234D380BF9" xlink:to="lab_biib_EmployeeStockPurchasePlanMember_15EDD8BC44206DFBA6F878234D380BF9" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_151D1B0016C515D1B71678234D387E43_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_151D1B0016C515D1B71678234D387E43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_151D1B0016C515D1B71678234D387E43_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_151D1B0016C515D1B71678234D387E43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_151D1B0016C515D1B71678234D387E43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_151D1B0016C515D1B71678234D387E43" xlink:to="lab_us-gaap_EmployeeStockOptionMember_151D1B0016C515D1B71678234D387E43" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_71B0DD1BA19A66D2F06878234D38E96C_label_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_71B0DD1BA19A66D2F06878234D38E96C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of share based compensation expense associated with different programs [Abstract]</link:label>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_71B0DD1BA19A66D2F06878234D38E96C_documentation_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_71B0DD1BA19A66D2F06878234D38E96C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of share-based compensation expense associated with different programs.</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_71B0DD1BA19A66D2F06878234D38E96C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_71B0DD1BA19A66D2F06878234D38E96C" xlink:to="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_71B0DD1BA19A66D2F06878234D38E96C" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_CFB5D03DED63AB76B39178234D39AEAE_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_CFB5D03DED63AB76B39178234D39AEAE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">NST stock options</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_CFB5D03DED63AB76B39178234D39AEAE_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_CFB5D03DED63AB76B39178234D39AEAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_CFB5D03DED63AB76B39178234D39AEAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_CFB5D03DED63AB76B39178234D39AEAE" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_CFB5D03DED63AB76B39178234D39AEAE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_1B644669C21567D79C2C78234D3A78B8_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_1B644669C21567D79C2C78234D3A78B8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Subtotal</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_1B644669C21567D79C2C78234D3A78B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_1B644669C21567D79C2C78234D3A78B8" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_1B644669C21567D79C2C78234D3A78B8" xlink:type="arc" />
    <link:label id="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_3E4786465235312F7A2A78234CC266FE_terseLabel_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_3E4786465235312F7A2A78234CC266FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to BAN2401 and Elenbecestat Collaboration</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_3E4786465235312F7A2A78234CC266FE_label_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_3E4786465235312F7A2A78234CC266FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to E2609 and BAN2401 Collaboration [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_3E4786465235312F7A2A78234CC266FE_documentation_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_3E4786465235312F7A2A78234CC266FE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:label="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_3E4786465235312F7A2A78234CC266FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_3E4786465235312F7A2A78234CC266FE" xlink:to="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_3E4786465235312F7A2A78234CC266FE" xlink:type="arc" />
    <link:label id="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_5BCB7FAF346978F0436278234CC2D7D6_terseLabel_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_5BCB7FAF346978F0436278234CC2D7D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to Aducanumab Collaboration</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_5BCB7FAF346978F0436278234CC2D7D6_label_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_5BCB7FAF346978F0436278234CC2D7D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to Aducanumab Collaboration [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_5BCB7FAF346978F0436278234CC2D7D6_documentation_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_5BCB7FAF346978F0436278234CC2D7D6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:label="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_5BCB7FAF346978F0436278234CC2D7D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_5BCB7FAF346978F0436278234CC2D7D6" xlink:to="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_5BCB7FAF346978F0436278234CC2D7D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_9FE90EC279E6693041EF78234EA5295F_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_9FE90EC279E6693041EF78234EA5295F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of Contractual Maturities: Available-for-Sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_9FE90EC279E6693041EF78234EA5295F_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_9FE90EC279E6693041EF78234EA5295F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_9FE90EC279E6693041EF78234EA5295F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_9FE90EC279E6693041EF78234EA5295F" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_9FE90EC279E6693041EF78234EA5295F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_C49DD559E1F749946F6C78234EA5286A_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_C49DD559E1F749946F6C78234EA5286A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due in one year or less, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_C49DD559E1F749946F6C78234EA5286A_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_C49DD559E1F749946F6C78234EA5286A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_C49DD559E1F749946F6C78234EA5286A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_C49DD559E1F749946F6C78234EA5286A" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_C49DD559E1F749946F6C78234EA5286A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_0D86441FF33736C0EC5E78234EA6B529_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_0D86441FF33736C0EC5E78234EA6B529" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due in one year or less, estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_0D86441FF33736C0EC5E78234EA6B529_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_0D86441FF33736C0EC5E78234EA6B529" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_0D86441FF33736C0EC5E78234EA6B529" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_0D86441FF33736C0EC5E78234EA6B529" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_0D86441FF33736C0EC5E78234EA6B529" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_38D0558503DBCAA7082778234EA6F4CE_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_38D0558503DBCAA7082778234EA6F4CE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after one year through five years, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_38D0558503DBCAA7082778234EA6F4CE_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_38D0558503DBCAA7082778234EA6F4CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_38D0558503DBCAA7082778234EA6F4CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_38D0558503DBCAA7082778234EA6F4CE" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_38D0558503DBCAA7082778234EA6F4CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_2133E60CB74173BCBA2278234EA68AF7_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_2133E60CB74173BCBA2278234EA68AF7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after one year through five years, estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_2133E60CB74173BCBA2278234EA68AF7_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_2133E60CB74173BCBA2278234EA68AF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_2133E60CB74173BCBA2278234EA68AF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_2133E60CB74173BCBA2278234EA68AF7" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_2133E60CB74173BCBA2278234EA68AF7" xlink:type="arc" />
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_2D7BA321A0BC60BCB77E78234EA68070_verboseLabel_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_2D7BA321A0BC60BCB77E78234EA68070" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after five years, amortized cost</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_2D7BA321A0BC60BCB77E78234EA68070_label_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_2D7BA321A0BC60BCB77E78234EA68070" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available For Sale Securities Debt Maturities After Five Years Amortized Cost</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_2D7BA321A0BC60BCB77E78234EA68070_documentation_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_2D7BA321A0BC60BCB77E78234EA68070" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_2D7BA321A0BC60BCB77E78234EA68070" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_2D7BA321A0BC60BCB77E78234EA68070" xlink:to="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_2D7BA321A0BC60BCB77E78234EA68070" xlink:type="arc" />
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_F8349E787F38BF11B7B278234EA68D6D_verboseLabel_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_F8349E787F38BF11B7B278234EA68D6D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after five years, estimated fair value</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_F8349E787F38BF11B7B278234EA68D6D_label_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_F8349E787F38BF11B7B278234EA68D6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available For Sale Securities Debt Maturities After Five Years Fair Value</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_F8349E787F38BF11B7B278234EA68D6D_documentation_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_F8349E787F38BF11B7B278234EA68D6D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_F8349E787F38BF11B7B278234EA68D6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_F8349E787F38BF11B7B278234EA68D6D" xlink:to="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_F8349E787F38BF11B7B278234EA68D6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_2C0ECE20A0930743637278234EA7EA69_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_2C0ECE20A0930743637278234EA7EA69" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_2C0ECE20A0930743637278234EA7EA69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_2C0ECE20A0930743637278234EA7EA69" xlink:to="lab_us-gaap_AvailableForSaleSecurities_2C0ECE20A0930743637278234EA7EA69" xlink:type="arc" />
    <link:label id="lab_biib_IonisPharmaceuticalsMember_324B7A01AF81934E424D78234CD1CC82_terseLabel_en-US" xlink:label="lab_biib_IonisPharmaceuticalsMember_324B7A01AF81934E424D78234CD1CC82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ionis</link:label>
    <link:label id="lab_biib_IonisPharmaceuticalsMember_324B7A01AF81934E424D78234CD1CC82_label_en-US" xlink:label="lab_biib_IonisPharmaceuticalsMember_324B7A01AF81934E424D78234CD1CC82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ionis Pharmaceuticals [Member]</link:label>
    <link:label id="lab_biib_IonisPharmaceuticalsMember_324B7A01AF81934E424D78234CD1CC82_documentation_en-US" xlink:label="lab_biib_IonisPharmaceuticalsMember_324B7A01AF81934E424D78234CD1CC82" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ionis Pharmaceuticals [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_IonisPharmaceuticalsMember" xlink:label="loc_biib_IonisPharmaceuticalsMember_324B7A01AF81934E424D78234CD1CC82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IonisPharmaceuticalsMember_324B7A01AF81934E424D78234CD1CC82" xlink:to="lab_biib_IonisPharmaceuticalsMember_324B7A01AF81934E424D78234CD1CC82" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_94D085833F8854E8B6E378234CD2DEB3_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent_94D085833F8854E8B6E378234CD2DEB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued income taxes</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_94D085833F8854E8B6E378234CD2DEB3_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent_94D085833F8854E8B6E378234CD2DEB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_94D085833F8854E8B6E378234CD2DEB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent_94D085833F8854E8B6E378234CD2DEB3" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent_94D085833F8854E8B6E378234CD2DEB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_164EEB90D14305E0272678234CD3FEAE_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_164EEB90D14305E0272678234CD3FEAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net gains recognized on the increase in fair value of equity securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_164EEB90D14305E0272678234CD3FEAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_164EEB90D14305E0272678234CD3FEAE" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_164EEB90D14305E0272678234CD3FEAE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_188789301C0795D357C678234CD3859A_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_188789301C0795D357C678234CD3859A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of available-for-sale securities, equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_188789301C0795D357C678234CD3859A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_188789301C0795D357C678234CD3859A" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_188789301C0795D357C678234CD3859A" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense_D4F1F548C8EACD63FA2A78234CD39C15_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense_D4F1F548C8EACD63FA2A78234CD39C15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense</link:label>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense_D4F1F548C8EACD63FA2A78234CD39C15_label_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense_D4F1F548C8EACD63FA2A78234CD39C15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense_D4F1F548C8EACD63FA2A78234CD39C15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense_D4F1F548C8EACD63FA2A78234CD39C15" xlink:to="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense_D4F1F548C8EACD63FA2A78234CD39C15" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_261F922073DFDD702C7E78234EDA4C9B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_261F922073DFDD702C7E78234EDA4C9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_261F922073DFDD702C7E78234EDA4C9B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_261F922073DFDD702C7E78234EDA4C9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_261F922073DFDD702C7E78234EDA4C9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_261F922073DFDD702C7E78234EDA4C9B" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_261F922073DFDD702C7E78234EDA4C9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeAxis_5CA4A60660FB69149C3E78234EDA0034_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_5CA4A60660FB69149C3E78234EDA0034" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_5CA4A60660FB69149C3E78234EDA0034_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_5CA4A60660FB69149C3E78234EDA0034" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_5CA4A60660FB69149C3E78234EDA0034" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis_5CA4A60660FB69149C3E78234EDA0034" xlink:to="lab_us-gaap_InvestmentTypeAxis_5CA4A60660FB69149C3E78234EDA0034" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_CAE13082916CD16573ED78234EDA3D8D_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_CAE13082916CD16573ED78234EDA3D8D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type Categorization [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_CAE13082916CD16573ED78234EDA3D8D_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_CAE13082916CD16573ED78234EDA3D8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_CAE13082916CD16573ED78234EDA3D8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_CAE13082916CD16573ED78234EDA3D8D" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember_CAE13082916CD16573ED78234EDA3D8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommercialPaperMember_A6EEA421602F6CFA8D4078234EDB0756_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_A6EEA421602F6CFA8D4078234EDB0756" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_A6EEA421602F6CFA8D4078234EDB0756_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_A6EEA421602F6CFA8D4078234EDB0756" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_A6EEA421602F6CFA8D4078234EDB0756" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember_A6EEA421602F6CFA8D4078234EDB0756" xlink:to="lab_us-gaap_CommercialPaperMember_A6EEA421602F6CFA8D4078234EDB0756" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_C3D57353D4C9441586FB78234EDB8574_terseLabel_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember_C3D57353D4C9441586FB78234EDB8574" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Overnight reverse repurchase agreements</link:label>
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_C3D57353D4C9441586FB78234EDB8574_label_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember_C3D57353D4C9441586FB78234EDB8574" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repurchase Agreements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_C3D57353D4C9441586FB78234EDB8574" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepurchaseAgreementsMember_C3D57353D4C9441586FB78234EDB8574" xlink:to="lab_us-gaap_RepurchaseAgreementsMember_C3D57353D4C9441586FB78234EDB8574" xlink:type="arc" />
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_5A6684A401052B1D964278234EDBBD1F_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_5A6684A401052B1D964278234EDBBD1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_5A6684A401052B1D964278234EDBBD1F_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_5A6684A401052B1D964278234EDBBD1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_5A6684A401052B1D964278234EDBBD1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_5A6684A401052B1D964278234EDBBD1F" xlink:to="lab_us-gaap_MoneyMarketFundsMember_5A6684A401052B1D964278234EDBBD1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesMember_4D4031CFE6D800DCCFCF78234EDBDC5D_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember_4D4031CFE6D800DCCFCF78234EDBDC5D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Short-term debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_4D4031CFE6D800DCCFCF78234EDBDC5D_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember_4D4031CFE6D800DCCFCF78234EDBDC5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_4D4031CFE6D800DCCFCF78234EDBDC5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesMember_4D4031CFE6D800DCCFCF78234EDBDC5D" xlink:to="lab_us-gaap_DebtSecuritiesMember_4D4031CFE6D800DCCFCF78234EDBDC5D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_480B293181A77D9802B478234EDD81FC_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems_480B293181A77D9802B478234EDD81FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_480B293181A77D9802B478234EDD81FC_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems_480B293181A77D9802B478234EDD81FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_480B293181A77D9802B478234EDD81FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_480B293181A77D9802B478234EDD81FC" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems_480B293181A77D9802B478234EDD81FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_6ECA9CE58ABA1F7AB41A78234EDD0B1E_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_6ECA9CE58ABA1F7AB41A78234EDD0B1E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_6ECA9CE58ABA1F7AB41A78234EDD0B1E_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_6ECA9CE58ABA1F7AB41A78234EDD0B1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_6ECA9CE58ABA1F7AB41A78234EDD0B1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_6ECA9CE58ABA1F7AB41A78234EDD0B1E" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_6ECA9CE58ABA1F7AB41A78234EDD0B1E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_0995BECB7E6E71E5A36678234EDDE117_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue_0995BECB7E6E71E5A36678234EDDE117" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_0995BECB7E6E71E5A36678234EDDE117_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue_0995BECB7E6E71E5A36678234EDDE117" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_0995BECB7E6E71E5A36678234EDDE117" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue_0995BECB7E6E71E5A36678234EDDE117" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue_0995BECB7E6E71E5A36678234EDDE117" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_60131484ECA7EA170F2A7823511CFBE4_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_60131484ECA7EA170F2A7823511CFBE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_60131484ECA7EA170F2A7823511CFBE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_60131484ECA7EA170F2A7823511CFBE4" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_60131484ECA7EA170F2A7823511CFBE4" xlink:type="arc" />
    <link:label id="lab_biib_A2018ShareRepurchaseProgramMember_EE146F8553BED99807F27823511D3088_terseLabel_en-US" xlink:label="lab_biib_A2018ShareRepurchaseProgramMember_EE146F8553BED99807F27823511D3088" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018 Share Repurchase Program</link:label>
    <link:label id="lab_biib_A2018ShareRepurchaseProgramMember_EE146F8553BED99807F27823511D3088_label_en-US" xlink:label="lab_biib_A2018ShareRepurchaseProgramMember_EE146F8553BED99807F27823511D3088" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2018 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_A2018ShareRepurchaseProgramMember_EE146F8553BED99807F27823511D3088_documentation_en-US" xlink:label="lab_biib_A2018ShareRepurchaseProgramMember_EE146F8553BED99807F27823511D3088" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2018 Share Repurchase Program [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_A2018ShareRepurchaseProgramMember" xlink:label="loc_biib_A2018ShareRepurchaseProgramMember_EE146F8553BED99807F27823511D3088" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2018ShareRepurchaseProgramMember_EE146F8553BED99807F27823511D3088" xlink:to="lab_biib_A2018ShareRepurchaseProgramMember_EE146F8553BED99807F27823511D3088" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockMember_9A5E9BCC18E85BA800017823511EF6D2_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember_9A5E9BCC18E85BA800017823511EF6D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_9A5E9BCC18E85BA800017823511EF6D2_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember_9A5E9BCC18E85BA800017823511EF6D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_9A5E9BCC18E85BA800017823511EF6D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember_9A5E9BCC18E85BA800017823511EF6D2" xlink:to="lab_us-gaap_PreferredStockMember_9A5E9BCC18E85BA800017823511EF6D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_9A02F2606FE9FA3D62E17823511ED5E8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_9A02F2606FE9FA3D62E17823511ED5E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_9A02F2606FE9FA3D62E17823511ED5E8_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_9A02F2606FE9FA3D62E17823511ED5E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_9A02F2606FE9FA3D62E17823511ED5E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_9A02F2606FE9FA3D62E17823511ED5E8" xlink:to="lab_us-gaap_CommonStockMember_9A02F2606FE9FA3D62E17823511ED5E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_8D702908B37DD60672887823511F115B_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_8D702908B37DD60672887823511F115B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_8D702908B37DD60672887823511F115B_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_8D702908B37DD60672887823511F115B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_8D702908B37DD60672887823511F115B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_8D702908B37DD60672887823511F115B" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_8D702908B37DD60672887823511F115B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_538EE9CD30F92B34400D7823511FAB38_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_538EE9CD30F92B34400D7823511FAB38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_538EE9CD30F92B34400D7823511FAB38_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_538EE9CD30F92B34400D7823511FAB38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_538EE9CD30F92B34400D7823511FAB38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_538EE9CD30F92B34400D7823511FAB38" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_538EE9CD30F92B34400D7823511FAB38" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_D5F236A3921E54B423267823511F847F_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_D5F236A3921E54B423267823511F847F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_D5F236A3921E54B423267823511F847F_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_D5F236A3921E54B423267823511F847F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_D5F236A3921E54B423267823511F847F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_D5F236A3921E54B423267823511F847F" xlink:to="lab_us-gaap_RetainedEarningsMember_D5F236A3921E54B423267823511F847F" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockMember_39439E99533987D9ACD77823511FF754_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_39439E99533987D9ACD77823511FF754" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_39439E99533987D9ACD77823511FF754_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_39439E99533987D9ACD77823511FF754" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_39439E99533987D9ACD77823511FF754" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember_39439E99533987D9ACD77823511FF754" xlink:to="lab_us-gaap_TreasuryStockMember_39439E99533987D9ACD77823511FF754" xlink:type="arc" />
    <link:label id="lab_us-gaap_ParentMember_7853BED506E45BB8D16A7823511F14E1_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember_7853BED506E45BB8D16A7823511F14E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_7853BED506E45BB8D16A7823511F14E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember_7853BED506E45BB8D16A7823511F14E1" xlink:to="lab_us-gaap_ParentMember_7853BED506E45BB8D16A7823511F14E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_69D71AD174CF4B7C36C57823512080F7_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember_69D71AD174CF4B7C36C57823512080F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_69D71AD174CF4B7C36C57823512080F7_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember_69D71AD174CF4B7C36C57823512080F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_69D71AD174CF4B7C36C57823512080F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember_69D71AD174CF4B7C36C57823512080F7" xlink:to="lab_us-gaap_NoncontrollingInterestMember_69D71AD174CF4B7C36C57823512080F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_EF4DC88ACD9C6204A0EE78235120B695_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_EF4DC88ACD9C6204A0EE78235120B695" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_EF4DC88ACD9C6204A0EE78235120B695_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_EF4DC88ACD9C6204A0EE78235120B695" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_EF4DC88ACD9C6204A0EE78235120B695" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_EF4DC88ACD9C6204A0EE78235120B695" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_EF4DC88ACD9C6204A0EE78235120B695" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_EB3A034F29ABF71FE33A7823512035BA_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_EB3A034F29ABF71FE33A7823512035BA" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_EB3A034F29ABF71FE33A7823512035BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_EB3A034F29ABF71FE33A7823512035BA" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_EB3A034F29ABF71FE33A7823512035BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_19C8ACB3CBB3416804E178235120BA76_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_19C8ACB3CBB3416804E178235120BA76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_19C8ACB3CBB3416804E178235120BA76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_19C8ACB3CBB3416804E178235120BA76" xlink:to="lab_us-gaap_ProfitLoss_19C8ACB3CBB3416804E178235120BA76" xlink:type="arc" />
    <link:label id="lab_biib_Noncontrollinginterestincreasedecreaseother_6D5A481FC4FD866F4A347823512193C5_terseLabel_en-US" xlink:label="lab_biib_Noncontrollinginterestincreasedecreaseother_6D5A481FC4FD866F4A347823512193C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interest, increase (decrease) other</link:label>
    <link:label id="lab_biib_Noncontrollinginterestincreasedecreaseother_6D5A481FC4FD866F4A347823512193C5_label_en-US" xlink:label="lab_biib_Noncontrollinginterestincreasedecreaseother_6D5A481FC4FD866F4A347823512193C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling interest, increase (decrease) other</link:label>
    <link:label id="lab_biib_Noncontrollinginterestincreasedecreaseother_6D5A481FC4FD866F4A347823512193C5_documentation_en-US" xlink:label="lab_biib_Noncontrollinginterestincreasedecreaseother_6D5A481FC4FD866F4A347823512193C5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncontrolling interest, increase (decrease) other</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_Noncontrollinginterestincreasedecreaseother" xlink:label="loc_biib_Noncontrollinginterestincreasedecreaseother_6D5A481FC4FD866F4A347823512193C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Noncontrollinginterestincreasedecreaseother_6D5A481FC4FD866F4A347823512193C5" xlink:to="lab_biib_Noncontrollinginterestincreasedecreaseother_6D5A481FC4FD866F4A347823512193C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_8DDAA4FB742F1237514C78235121CBDA_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_8DDAA4FB742F1237514C78235121CBDA" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock, at cost, shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_8DDAA4FB742F1237514C78235121CBDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired_8DDAA4FB742F1237514C78235121CBDA" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired_8DDAA4FB742F1237514C78235121CBDA" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_AFAA38B4AA5F3621768878235121B717_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_AFAA38B4AA5F3621768878235121B717" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_AFAA38B4AA5F3621768878235121B717_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_AFAA38B4AA5F3621768878235121B717" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_AFAA38B4AA5F3621768878235121B717" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_AFAA38B4AA5F3621768878235121B717" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_AFAA38B4AA5F3621768878235121B717" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_6E485DA19AB1E20C08DA78235121BDCE_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_6E485DA19AB1E20C08DA78235121BDCE" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_6E485DA19AB1E20C08DA78235121BDCE_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_6E485DA19AB1E20C08DA78235121BDCE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_6E485DA19AB1E20C08DA78235121BDCE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_6E485DA19AB1E20C08DA78235121BDCE" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_6E485DA19AB1E20C08DA78235121BDCE" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_94E49B5419A1DAAF354B78235122EB53_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_94E49B5419A1DAAF354B78235122EB53" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Retirement of common stock pursuant to Share Repurchase Progams, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_94E49B5419A1DAAF354B78235122EB53_label_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_94E49B5419A1DAAF354B78235122EB53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Retired, Cost Method, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_94E49B5419A1DAAF354B78235122EB53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_94E49B5419A1DAAF354B78235122EB53" xlink:to="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_94E49B5419A1DAAF354B78235122EB53" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_0C601092D381D7E1983278235122F01E_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_0C601092D381D7E1983278235122F01E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under stock option and stock purchase plans, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_0C601092D381D7E1983278235122F01E_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_0C601092D381D7E1983278235122F01E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Treasury Stock Reissued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_0C601092D381D7E1983278235122F01E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_0C601092D381D7E1983278235122F01E" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_0C601092D381D7E1983278235122F01E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_CEDEDC0D3B62A5957FD5782351224795_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_CEDEDC0D3B62A5957FD5782351224795" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under stock option and stock purchase plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_CEDEDC0D3B62A5957FD5782351224795_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_CEDEDC0D3B62A5957FD5782351224795" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Treasury Stock Reissued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_CEDEDC0D3B62A5957FD5782351224795" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_CEDEDC0D3B62A5957FD5782351224795" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_CEDEDC0D3B62A5957FD5782351224795" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A6CB225701219883EE46782351229ABB_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A6CB225701219883EE46782351229ABB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under award plan, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A6CB225701219883EE46782351229ABB_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A6CB225701219883EE46782351229ABB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A6CB225701219883EE46782351229ABB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A6CB225701219883EE46782351229ABB" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A6CB225701219883EE46782351229ABB" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_A83A37D347FEC1E2BAAA7823512203CC_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_A83A37D347FEC1E2BAAA7823512203CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under stock award plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_A83A37D347FEC1E2BAAA7823512203CC_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_A83A37D347FEC1E2BAAA7823512203CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_A83A37D347FEC1E2BAAA7823512203CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_A83A37D347FEC1E2BAAA7823512203CC" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_A83A37D347FEC1E2BAAA7823512203CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_3E2DFA80EC1E0E3FF3AB782351221926_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_3E2DFA80EC1E0E3FF3AB782351221926" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Compensation related to share-based payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3E2DFA80EC1E0E3FF3AB782351221926" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_3E2DFA80EC1E0E3FF3AB782351221926" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_3E2DFA80EC1E0E3FF3AB782351221926" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityOther_3507E97545FAA4043C1078235124FC78_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther_3507E97545FAA4043C1078235124FC78" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_3507E97545FAA4043C1078235124FC78_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther_3507E97545FAA4043C1078235124FC78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityOther" xlink:label="loc_us-gaap_StockholdersEquityOther_3507E97545FAA4043C1078235124FC78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther_3507E97545FAA4043C1078235124FC78" xlink:to="lab_us-gaap_StockholdersEquityOther_3507E97545FAA4043C1078235124FC78" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_77FB0C604D1BC439085878235124D6BB_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_77FB0C604D1BC439085878235124D6BB" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_77FB0C604D1BC439085878235124D6BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_77FB0C604D1BC439085878235124D6BB" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_77FB0C604D1BC439085878235124D6BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_566ADE11023F7B3F3CA5782351249E37_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_566ADE11023F7B3F3CA5782351249E37" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_566ADE11023F7B3F3CA5782351249E37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_566ADE11023F7B3F3CA5782351249E37" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_566ADE11023F7B3F3CA5782351249E37" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C09DFF379A38D58E3F3A78234FA92F0B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C09DFF379A38D58E3F3A78234FA92F0B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C09DFF379A38D58E3F3A78234FA92F0B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C09DFF379A38D58E3F3A78234FA92F0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C09DFF379A38D58E3F3A78234FA92F0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C09DFF379A38D58E3F3A78234FA92F0B" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C09DFF379A38D58E3F3A78234FA92F0B" xlink:type="arc" />
    <link:label id="lab_biib_ResearchanddevelopmentassetAxis_BDB6617DC4563729C4D078234FAA1D51_terseLabel_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetAxis_BDB6617DC4563729C4D078234FAA1D51" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development asset [Axis]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetAxis_BDB6617DC4563729C4D078234FAA1D51_label_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetAxis_BDB6617DC4563729C4D078234FAA1D51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development asset [Axis]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetAxis_BDB6617DC4563729C4D078234FAA1D51_documentation_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetAxis_BDB6617DC4563729C4D078234FAA1D51" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and development asset [Axis]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_ResearchanddevelopmentassetAxis" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_BDB6617DC4563729C4D078234FAA1D51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_BDB6617DC4563729C4D078234FAA1D51" xlink:to="lab_biib_ResearchanddevelopmentassetAxis_BDB6617DC4563729C4D078234FAA1D51" xlink:type="arc" />
    <link:label id="lab_biib_ResearchanddevelopmentassetDomain_6CBF270328EBBBDDF62C78234FAAF4D5_terseLabel_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetDomain_6CBF270328EBBBDDF62C78234FAAF4D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development asset [Domain]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetDomain_6CBF270328EBBBDDF62C78234FAAF4D5_label_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetDomain_6CBF270328EBBBDDF62C78234FAAF4D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development asset [Domain]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetDomain_6CBF270328EBBBDDF62C78234FAAF4D5_documentation_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetDomain_6CBF270328EBBBDDF62C78234FAAF4D5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Research and development asset [Axis]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_ResearchanddevelopmentassetDomain" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_6CBF270328EBBBDDF62C78234FAAF4D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_6CBF270328EBBBDDF62C78234FAAF4D5" xlink:to="lab_biib_ResearchanddevelopmentassetDomain_6CBF270328EBBBDDF62C78234FAAF4D5" xlink:type="arc" />
    <link:label id="lab_biib_TGNMember_364B5BDB601D023ED0E378234FAAE77F_terseLabel_en-US" xlink:label="lab_biib_TGNMember_364B5BDB601D023ED0E378234FAAE77F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TGN [Member]</link:label>
    <link:label id="lab_biib_TGNMember_364B5BDB601D023ED0E378234FAAE77F_label_en-US" xlink:label="lab_biib_TGNMember_364B5BDB601D023ED0E378234FAAE77F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TGN [Member]</link:label>
    <link:label id="lab_biib_TGNMember_364B5BDB601D023ED0E378234FAAE77F_documentation_en-US" xlink:label="lab_biib_TGNMember_364B5BDB601D023ED0E378234FAAE77F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TGN</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_TGNMember" xlink:label="loc_biib_TGNMember_364B5BDB601D023ED0E378234FAAE77F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TGNMember_364B5BDB601D023ED0E378234FAAE77F" xlink:to="lab_biib_TGNMember_364B5BDB601D023ED0E378234FAAE77F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_405FF7A9370EFA5DFEAA78234FAB0DE7_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_405FF7A9370EFA5DFEAA78234FAB0DE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_405FF7A9370EFA5DFEAA78234FAB0DE7_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_405FF7A9370EFA5DFEAA78234FAB0DE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_405FF7A9370EFA5DFEAA78234FAB0DE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_405FF7A9370EFA5DFEAA78234FAB0DE7" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_405FF7A9370EFA5DFEAA78234FAB0DE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_533A25097FA5A65FA50E78234FABC793_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_533A25097FA5A65FA50E78234FABC793" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_533A25097FA5A65FA50E78234FABC793_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_533A25097FA5A65FA50E78234FABC793" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_533A25097FA5A65FA50E78234FABC793" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_533A25097FA5A65FA50E78234FABC793" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_533A25097FA5A65FA50E78234FABC793" xlink:type="arc" />
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_3A7852CD09B710E9F4DB78234FB1336D_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember_3A7852CD09B710E9F4DB78234FB1336D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trademarks and Trade Names</link:label>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_3A7852CD09B710E9F4DB78234FB1336D_label_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember_3A7852CD09B710E9F4DB78234FB1336D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_3A7852CD09B710E9F4DB78234FB1336D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksAndTradeNamesMember_3A7852CD09B710E9F4DB78234FB1336D" xlink:to="lab_us-gaap_TrademarksAndTradeNamesMember_3A7852CD09B710E9F4DB78234FB1336D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_868E818B5FC10726AC1F78234FB1F102_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_868E818B5FC10726AC1F78234FB1F102" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_868E818B5FC10726AC1F78234FB1F102_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_868E818B5FC10726AC1F78234FB1F102" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_868E818B5FC10726AC1F78234FB1F102" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_868E818B5FC10726AC1F78234FB1F102" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_868E818B5FC10726AC1F78234FB1F102" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8EC40EE2DB80D8ACE17478234FB2A9CA_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8EC40EE2DB80D8ACE17478234FB2A9CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8EC40EE2DB80D8ACE17478234FB2A9CA_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8EC40EE2DB80D8ACE17478234FB2A9CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8EC40EE2DB80D8ACE17478234FB2A9CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8EC40EE2DB80D8ACE17478234FB2A9CA" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8EC40EE2DB80D8ACE17478234FB2A9CA" xlink:type="arc" />
    <link:label id="lab_biib_OutLicensedPatentsMember_DD035309CE164FB3058C78234FB28CC6_terseLabel_en-US" xlink:label="lab_biib_OutLicensedPatentsMember_DD035309CE164FB3058C78234FB28CC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Out-licensed patents</link:label>
    <link:label id="lab_biib_OutLicensedPatentsMember_DD035309CE164FB3058C78234FB28CC6_label_en-US" xlink:label="lab_biib_OutLicensedPatentsMember_DD035309CE164FB3058C78234FB28CC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Out Licensed Patents [Member]</link:label>
    <link:label id="lab_biib_OutLicensedPatentsMember_DD035309CE164FB3058C78234FB28CC6_documentation_en-US" xlink:label="lab_biib_OutLicensedPatentsMember_DD035309CE164FB3058C78234FB28CC6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Out-licensed patents.</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_OutLicensedPatentsMember" xlink:label="loc_biib_OutLicensedPatentsMember_DD035309CE164FB3058C78234FB28CC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OutLicensedPatentsMember_DD035309CE164FB3058C78234FB28CC6" xlink:to="lab_biib_OutLicensedPatentsMember_DD035309CE164FB3058C78234FB28CC6" xlink:type="arc" />
    <link:label id="lab_biib_InLicensedPatentsMember_ECC85B19A8FFB933FFA078234FB3772C_terseLabel_en-US" xlink:label="lab_biib_InLicensedPatentsMember_ECC85B19A8FFB933FFA078234FB3772C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired and in-licensed rights and patents</link:label>
    <link:label id="lab_biib_InLicensedPatentsMember_ECC85B19A8FFB933FFA078234FB3772C_label_en-US" xlink:label="lab_biib_InLicensedPatentsMember_ECC85B19A8FFB933FFA078234FB3772C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Licensed Patents [Member]</link:label>
    <link:label id="lab_biib_InLicensedPatentsMember_ECC85B19A8FFB933FFA078234FB3772C_documentation_en-US" xlink:label="lab_biib_InLicensedPatentsMember_ECC85B19A8FFB933FFA078234FB3772C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In-licensed patents.</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_ECC85B19A8FFB933FFA078234FB3772C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InLicensedPatentsMember_ECC85B19A8FFB933FFA078234FB3772C" xlink:to="lab_biib_InLicensedPatentsMember_ECC85B19A8FFB933FFA078234FB3772C" xlink:type="arc" />
    <link:label id="lab_biib_AVONEXMember_3EA89EA94DEA39D0A80578234FB34BF8_terseLabel_en-US" xlink:label="lab_biib_AVONEXMember_3EA89EA94DEA39D0A80578234FB34BF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AVONEX</link:label>
    <link:label id="lab_biib_AVONEXMember_3EA89EA94DEA39D0A80578234FB34BF8_label_en-US" xlink:label="lab_biib_AVONEXMember_3EA89EA94DEA39D0A80578234FB34BF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AVONEX [Member]</link:label>
    <link:label id="lab_biib_AVONEXMember_3EA89EA94DEA39D0A80578234FB34BF8_documentation_en-US" xlink:label="lab_biib_AVONEXMember_3EA89EA94DEA39D0A80578234FB34BF8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AVONEX</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_AVONEXMember" xlink:label="loc_biib_AVONEXMember_3EA89EA94DEA39D0A80578234FB34BF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AVONEXMember_3EA89EA94DEA39D0A80578234FB34BF8" xlink:to="lab_biib_AVONEXMember_3EA89EA94DEA39D0A80578234FB34BF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_16BF20058BF8C4E64BDB78234FB586E9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_16BF20058BF8C4E64BDB78234FB586E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_16BF20058BF8C4E64BDB78234FB586E9_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_16BF20058BF8C4E64BDB78234FB586E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16BF20058BF8C4E64BDB78234FB586E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16BF20058BF8C4E64BDB78234FB586E9" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_16BF20058BF8C4E64BDB78234FB586E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_E1CDDF8FC15247E2430378234FB579C4_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_E1CDDF8FC15247E2430378234FB579C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_E1CDDF8FC15247E2430378234FB579C4_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_E1CDDF8FC15247E2430378234FB579C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_E1CDDF8FC15247E2430378234FB579C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_E1CDDF8FC15247E2430378234FB579C4" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_E1CDDF8FC15247E2430378234FB579C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2EC95A182BC370A20B3B78234FB6DE86_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2EC95A182BC370A20B3B78234FB6DE86" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2EC95A182BC370A20B3B78234FB6DE86_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2EC95A182BC370A20B3B78234FB6DE86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2EC95A182BC370A20B3B78234FB6DE86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2EC95A182BC370A20B3B78234FB6DE86" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2EC95A182BC370A20B3B78234FB6DE86" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_986C527AC40F30088D6A78234FB65359_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_986C527AC40F30088D6A78234FB65359" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Estimated life, (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_986C527AC40F30088D6A78234FB65359_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_986C527AC40F30088D6A78234FB65359" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_986C527AC40F30088D6A78234FB65359" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_986C527AC40F30088D6A78234FB65359" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_986C527AC40F30088D6A78234FB65359" xlink:type="arc" />
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_DD721073DEFC7A43C2B178234FB6056C_terseLabel_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_DD721073DEFC7A43C2B178234FB6056C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite lived intangible assets useful life</link:label>
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_DD721073DEFC7A43C2B178234FB6056C_label_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_DD721073DEFC7A43C2B178234FB6056C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite Lived Intangible Assets Useful Life</link:label>
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_DD721073DEFC7A43C2B178234FB6056C_documentation_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_DD721073DEFC7A43C2B178234FB6056C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Indefinite lived intangible assets useful life.</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_DD721073DEFC7A43C2B178234FB6056C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_DD721073DEFC7A43C2B178234FB6056C" xlink:to="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_DD721073DEFC7A43C2B178234FB6056C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_6B4AC9E66296B6D82E3178234FB64358_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_6B4AC9E66296B6D82E3178234FB64358" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_6B4AC9E66296B6D82E3178234FB64358_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_6B4AC9E66296B6D82E3178234FB64358" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6B4AC9E66296B6D82E3178234FB64358" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6B4AC9E66296B6D82E3178234FB64358" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross_6B4AC9E66296B6D82E3178234FB64358" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_163FE67D57DFB21305DA78234FB7E56D_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_163FE67D57DFB21305DA78234FB7E56D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost and Net</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_163FE67D57DFB21305DA78234FB7E56D_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_163FE67D57DFB21305DA78234FB7E56D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_163FE67D57DFB21305DA78234FB7E56D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_163FE67D57DFB21305DA78234FB7E56D" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_163FE67D57DFB21305DA78234FB7E56D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_ADE0CCBA19CD62EAF91878234FB775BB_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_ADE0CCBA19CD62EAF91878234FB775BB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_ADE0CCBA19CD62EAF91878234FB775BB_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_ADE0CCBA19CD62EAF91878234FB775BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ADE0CCBA19CD62EAF91878234FB775BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ADE0CCBA19CD62EAF91878234FB775BB" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_ADE0CCBA19CD62EAF91878234FB775BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_0ECB4D30C676A3F3715E78234FB74151_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_0ECB4D30C676A3F3715E78234FB74151" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total intangible assets, gross</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_0ECB4D30C676A3F3715E78234FB74151_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_0ECB4D30C676A3F3715E78234FB74151" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_0ECB4D30C676A3F3715E78234FB74151" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_0ECB4D30C676A3F3715E78234FB74151" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_0ECB4D30C676A3F3715E78234FB74151" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_50EC9954FB226187D6C178234FB857A3_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_50EC9954FB226187D6C178234FB857A3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_50EC9954FB226187D6C178234FB857A3_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_50EC9954FB226187D6C178234FB857A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_50EC9954FB226187D6C178234FB857A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_50EC9954FB226187D6C178234FB857A3" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_50EC9954FB226187D6C178234FB857A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_C88B58292FBC5CF4FDD978234FB84735_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_C88B58292FBC5CF4FDD978234FB84735" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_C88B58292FBC5CF4FDD978234FB84735" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_C88B58292FBC5CF4FDD978234FB84735" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_C88B58292FBC5CF4FDD978234FB84735" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_282FFCEDF3FF87168B3B78234FB8E348_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_282FFCEDF3FF87168B3B78234FB8E348" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2019 (remaining three months)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_282FFCEDF3FF87168B3B78234FB8E348_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_282FFCEDF3FF87168B3B78234FB8E348" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_282FFCEDF3FF87168B3B78234FB8E348" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_282FFCEDF3FF87168B3B78234FB8E348" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_282FFCEDF3FF87168B3B78234FB8E348" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_8793EC384F9687E0C2BB78234FB86C6E_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_8793EC384F9687E0C2BB78234FB86C6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2020</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_8793EC384F9687E0C2BB78234FB86C6E_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_8793EC384F9687E0C2BB78234FB86C6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_8793EC384F9687E0C2BB78234FB86C6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_8793EC384F9687E0C2BB78234FB86C6E" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_8793EC384F9687E0C2BB78234FB86C6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_452DBE3058B65D90A61A78234FB8F00F_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_452DBE3058B65D90A61A78234FB8F00F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_452DBE3058B65D90A61A78234FB8F00F_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_452DBE3058B65D90A61A78234FB8F00F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_452DBE3058B65D90A61A78234FB8F00F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_452DBE3058B65D90A61A78234FB8F00F" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_452DBE3058B65D90A61A78234FB8F00F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_A2371ED07C4A9C2D4C5C78234FB91B0E_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_A2371ED07C4A9C2D4C5C78234FB91B0E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_A2371ED07C4A9C2D4C5C78234FB91B0E_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_A2371ED07C4A9C2D4C5C78234FB91B0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_A2371ED07C4A9C2D4C5C78234FB91B0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_A2371ED07C4A9C2D4C5C78234FB91B0E" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_A2371ED07C4A9C2D4C5C78234FB91B0E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_CC839212FAEEB79502DE78234FB9D410_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_CC839212FAEEB79502DE78234FB9D410" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_CC839212FAEEB79502DE78234FB9D410_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_CC839212FAEEB79502DE78234FB9D410" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_CC839212FAEEB79502DE78234FB9D410" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_CC839212FAEEB79502DE78234FB9D410" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_CC839212FAEEB79502DE78234FB9D410" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_B372BA3C760F44854F5D78234FB9DF2C_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_B372BA3C760F44854F5D78234FB9DF2C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_B372BA3C760F44854F5D78234FB9DF2C_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_B372BA3C760F44854F5D78234FB9DF2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_B372BA3C760F44854F5D78234FB9DF2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_B372BA3C760F44854F5D78234FB9DF2C" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_B372BA3C760F44854F5D78234FB9DF2C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_447AA235E19F55E2736578234E8E1B8D_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_447AA235E19F55E2736578234E8E1B8D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturities and sales</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_447AA235E19F55E2736578234E8E1B8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_447AA235E19F55E2736578234E8E1B8D" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_447AA235E19F55E2736578234E8E1B8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_8170464C2E381753805178234E93B73E_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_8170464C2E381753805178234E93B73E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Realized gains</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_8170464C2E381753805178234E93B73E_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_8170464C2E381753805178234E93B73E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Gain</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_8170464C2E381753805178234E93B73E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_8170464C2E381753805178234E93B73E" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_8170464C2E381753805178234E93B73E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_392A6844A7EC0667088078234E94D166_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_392A6844A7EC0667088078234E94D166" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Realized losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_392A6844A7EC0667088078234E94D166_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_392A6844A7EC0667088078234E94D166" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_392A6844A7EC0667088078234E94D166" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_392A6844A7EC0667088078234E94D166" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_392A6844A7EC0667088078234E94D166" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_F2B7EEB9C2B689CBFD6178234E5BBFC0_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_F2B7EEB9C2B689CBFD6178234E5BBFC0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_F2B7EEB9C2B689CBFD6178234E5BBFC0_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_F2B7EEB9C2B689CBFD6178234E5BBFC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_F2B7EEB9C2B689CBFD6178234E5BBFC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_F2B7EEB9C2B689CBFD6178234E5BBFC0" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_F2B7EEB9C2B689CBFD6178234E5BBFC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_72C5D05F6C74A9270D3C78234CFC21CA_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_72C5D05F6C74A9270D3C78234CFC21CA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_72C5D05F6C74A9270D3C78234CFC21CA_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_72C5D05F6C74A9270D3C78234CFC21CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_72C5D05F6C74A9270D3C78234CFC21CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_72C5D05F6C74A9270D3C78234CFC21CA" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_72C5D05F6C74A9270D3C78234CFC21CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_55FD39F0B17A5EF63E8F78234CFCDDCE_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock_55FD39F0B17A5EF63E8F78234CFCDDCE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on investments in equity securities</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_55FD39F0B17A5EF63E8F78234CFCDDCE_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock_55FD39F0B17A5EF63E8F78234CFCDDCE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Securities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnInvestmentsTextBlock" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock_55FD39F0B17A5EF63E8F78234CFCDDCE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestmentsTextBlock_55FD39F0B17A5EF63E8F78234CFCDDCE" xlink:to="lab_us-gaap_GainLossOnInvestmentsTextBlock_55FD39F0B17A5EF63E8F78234CFCDDCE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_076501BF9DD2CF24366278234CFDCE1F_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_076501BF9DD2CF24366278234CFDCE1F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_076501BF9DD2CF24366278234CFDCE1F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_076501BF9DD2CF24366278234CFDCE1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_076501BF9DD2CF24366278234CFDCE1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_076501BF9DD2CF24366278234CFDCE1F" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_076501BF9DD2CF24366278234CFDCE1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7E7D6889CDF8527C9783782351AA2D3F_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7E7D6889CDF8527C9783782351AA2D3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7E7D6889CDF8527C9783782351AA2D3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7E7D6889CDF8527C9783782351AA2D3F" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7E7D6889CDF8527C9783782351AA2D3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_69C59A255650CD0696BD782351AB9660_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_69C59A255650CD0696BD782351AB9660" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_69C59A255650CD0696BD782351AB9660_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_69C59A255650CD0696BD782351AB9660" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_69C59A255650CD0696BD782351AB9660" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_69C59A255650CD0696BD782351AB9660" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_69C59A255650CD0696BD782351AB9660" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_15E15206357092A66E91782351ABF416_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_15E15206357092A66E91782351ABF416" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on securities available for sale, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_15E15206357092A66E91782351ABF416_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_15E15206357092A66E91782351ABF416" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_15E15206357092A66E91782351ABF416" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_15E15206357092A66E91782351ABF416" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_15E15206357092A66E91782351ABF416" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_490F558475F3E4D5E655782351AB6DBE_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_490F558475F3E4D5E655782351AB6DBE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on cash flow hedges, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_490F558475F3E4D5E655782351AB6DBE_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_490F558475F3E4D5E655782351AB6DBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_490F558475F3E4D5E655782351AB6DBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_490F558475F3E4D5E655782351AB6DBE" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_490F558475F3E4D5E655782351AB6DBE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_DE814B1B14277429559E782351AB9823_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_DE814B1B14277429559E782351AB9823" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on pension benefit obligation, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_DE814B1B14277429559E782351AB9823_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_DE814B1B14277429559E782351AB9823" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_DE814B1B14277429559E782351AB9823" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_DE814B1B14277429559E782351AB9823" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_DE814B1B14277429559E782351AB9823" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2DEA06E34E389B4A444A782351AB4BC2_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2DEA06E34E389B4A444A782351AB4BC2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2DEA06E34E389B4A444A782351AB4BC2_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2DEA06E34E389B4A444A782351AB4BC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2DEA06E34E389B4A444A782351AB4BC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2DEA06E34E389B4A444A782351AB4BC2" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2DEA06E34E389B4A444A782351AB4BC2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_B30AEBA1FFF73DDE52EE782351ACB60A_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_B30AEBA1FFF73DDE52EE782351ACB60A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other comprehensive income (loss), net of tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_B30AEBA1FFF73DDE52EE782351ACB60A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_B30AEBA1FFF73DDE52EE782351ACB60A" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_B30AEBA1FFF73DDE52EE782351ACB60A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_91A2179651CA43538CB0782351ACD6A5_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_91A2179651CA43538CB0782351ACD6A5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_91A2179651CA43538CB0782351ACD6A5_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_91A2179651CA43538CB0782351ACD6A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_91A2179651CA43538CB0782351ACD6A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_91A2179651CA43538CB0782351ACD6A5" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_91A2179651CA43538CB0782351ACD6A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_6DCD9F96B8E6EC017364782351AC31B1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_6DCD9F96B8E6EC017364782351AC31B1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_6DCD9F96B8E6EC017364782351AC31B1_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_6DCD9F96B8E6EC017364782351AC31B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_6DCD9F96B8E6EC017364782351AC31B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_6DCD9F96B8E6EC017364782351AC31B1" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_6DCD9F96B8E6EC017364782351AC31B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_68158B64DA3248EE37E9782351ACAC9A_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_68158B64DA3248EE37E9782351ACAC9A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_68158B64DA3248EE37E9782351ACAC9A_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_68158B64DA3248EE37E9782351ACAC9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_68158B64DA3248EE37E9782351ACAC9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_68158B64DA3248EE37E9782351ACAC9A" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_68158B64DA3248EE37E9782351ACAC9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_47A15732913F47441B7978234EE62BCB_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_47A15732913F47441B7978234EE62BCB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_47A15732913F47441B7978234EE62BCB_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_47A15732913F47441B7978234EE62BCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_47A15732913F47441B7978234EE62BCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_47A15732913F47441B7978234EE62BCB" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_47A15732913F47441B7978234EE62BCB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_8488B1756A8FFB54F36578234EE78573_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_8488B1756A8FFB54F36578234EE78573" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable debt and equity securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_8488B1756A8FFB54F36578234EE78573_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_8488B1756A8FFB54F36578234EE78573" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_8488B1756A8FFB54F36578234EE78573" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_8488B1756A8FFB54F36578234EE78573" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_8488B1756A8FFB54F36578234EE78573" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_062D8FBD4B02932BC35478234EE76DF8_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_062D8FBD4B02932BC35478234EE76DF8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of contractual maturities: available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_062D8FBD4B02932BC35478234EE76DF8_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_062D8FBD4B02932BC35478234EE76DF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_062D8FBD4B02932BC35478234EE76DF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_062D8FBD4B02932BC35478234EE76DF8" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_062D8FBD4B02932BC35478234EE76DF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_26D61F7D3F3578C286D678234EE7CE94_verboseLabel_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_26D61F7D3F3578C286D678234EE7CE94" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from marketable debt securities</link:label>
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_26D61F7D3F3578C286D678234EE7CE94_label_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_26D61F7D3F3578C286D678234EE7CE94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Realized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_26D61F7D3F3578C286D678234EE7CE94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_26D61F7D3F3578C286D678234EE7CE94" xlink:to="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_26D61F7D3F3578C286D678234EE7CE94" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_98CD76FC7A5BA8E90A8378234F76E849_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_98CD76FC7A5BA8E90A8378234F76E849" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_98CD76FC7A5BA8E90A8378234F76E849_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_98CD76FC7A5BA8E90A8378234F76E849" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_98CD76FC7A5BA8E90A8378234F76E849" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_98CD76FC7A5BA8E90A8378234F76E849" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_98CD76FC7A5BA8E90A8378234F76E849" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_0F2B8A648FCAE707626A78234F76E6C3_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_0F2B8A648FCAE707626A78234F76E6C3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of fair and carrying value of debt instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_0F2B8A648FCAE707626A78234F76E6C3_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_0F2B8A648FCAE707626A78234F76E6C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_0F2B8A648FCAE707626A78234F76E6C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_0F2B8A648FCAE707626A78234F76E6C3" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_0F2B8A648FCAE707626A78234F76E6C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_D3EFB9A76B84D501EDC278234F769421_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_D3EFB9A76B84D501EDC278234F769421" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value of contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_D3EFB9A76B84D501EDC278234F769421_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_D3EFB9A76B84D501EDC278234F769421" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_D3EFB9A76B84D501EDC278234F769421" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_D3EFB9A76B84D501EDC278234F769421" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_D3EFB9A76B84D501EDC278234F769421" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E95629B2248593F6A68778234CAA9FFF_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E95629B2248593F6A68778234CAA9FFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E95629B2248593F6A68778234CAA9FFF_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E95629B2248593F6A68778234CAA9FFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E95629B2248593F6A68778234CAA9FFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E95629B2248593F6A68778234CAA9FFF" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E95629B2248593F6A68778234CAA9FFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_02B0295294FAA79A35CA78234CAB0908_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_02B0295294FAA79A35CA78234CAB0908" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_02B0295294FAA79A35CA78234CAB0908" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_02B0295294FAA79A35CA78234CAB0908" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_02B0295294FAA79A35CA78234CAB0908" xlink:type="arc" />
    <link:label id="lab_biib_UCBPharmaS.A.Member_3ECCBC0A530B9C8DDBFF78234CAD9A77_terseLabel_en-US" xlink:label="lab_biib_UCBPharmaS.A.Member_3ECCBC0A530B9C8DDBFF78234CAD9A77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">UCB Pharma S.A. [Member]</link:label>
    <link:label id="lab_biib_UCBPharmaS.A.Member_3ECCBC0A530B9C8DDBFF78234CAD9A77_label_en-US" xlink:label="lab_biib_UCBPharmaS.A.Member_3ECCBC0A530B9C8DDBFF78234CAD9A77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UCB Pharma S.A. [Member]</link:label>
    <link:label id="lab_biib_UCBPharmaS.A.Member_3ECCBC0A530B9C8DDBFF78234CAD9A77_documentation_en-US" xlink:label="lab_biib_UCBPharmaS.A.Member_3ECCBC0A530B9C8DDBFF78234CAD9A77" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">UCB Pharma S.A. [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_UCBPharmaS.A.Member" xlink:label="loc_biib_UCBPharmaS.A.Member_3ECCBC0A530B9C8DDBFF78234CAD9A77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UCBPharmaS.A.Member_3ECCBC0A530B9C8DDBFF78234CAD9A77" xlink:to="lab_biib_UCBPharmaS.A.Member_3ECCBC0A530B9C8DDBFF78234CAD9A77" xlink:type="arc" />
    <link:label id="lab_biib_SangamoTherapeuticsInc.AgreementMember_9CBA4D34379B08423D4778234CAD472A_terseLabel_en-US" xlink:label="lab_biib_SangamoTherapeuticsInc.AgreementMember_9CBA4D34379B08423D4778234CAD472A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sangamo Therapeutics, Inc. Agreement</link:label>
    <link:label id="lab_biib_SangamoTherapeuticsInc.AgreementMember_9CBA4D34379B08423D4778234CAD472A_label_en-US" xlink:label="lab_biib_SangamoTherapeuticsInc.AgreementMember_9CBA4D34379B08423D4778234CAD472A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sangamo Therapeutics, Inc. Agreement [Member]</link:label>
    <link:label id="lab_biib_SangamoTherapeuticsInc.AgreementMember_9CBA4D34379B08423D4778234CAD472A_documentation_en-US" xlink:label="lab_biib_SangamoTherapeuticsInc.AgreementMember_9CBA4D34379B08423D4778234CAD472A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sangamo Therapeutics, Inc. Agreement [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_SangamoTherapeuticsInc.AgreementMember" xlink:label="loc_biib_SangamoTherapeuticsInc.AgreementMember_9CBA4D34379B08423D4778234CAD472A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SangamoTherapeuticsInc.AgreementMember_9CBA4D34379B08423D4778234CAD472A" xlink:to="lab_biib_SangamoTherapeuticsInc.AgreementMember_9CBA4D34379B08423D4778234CAD472A" xlink:type="arc" />
    <link:label id="lab_biib_SkyhawkTherapeuticsMember_48205DB4AEB0E05465E078234CAE62BB_terseLabel_en-US" xlink:label="lab_biib_SkyhawkTherapeuticsMember_48205DB4AEB0E05465E078234CAE62BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Skyhawk Therapeutics</link:label>
    <link:label id="lab_biib_SkyhawkTherapeuticsMember_48205DB4AEB0E05465E078234CAE62BB_label_en-US" xlink:label="lab_biib_SkyhawkTherapeuticsMember_48205DB4AEB0E05465E078234CAE62BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Skyhawk Therapeutics [Member]</link:label>
    <link:label id="lab_biib_SkyhawkTherapeuticsMember_48205DB4AEB0E05465E078234CAE62BB_documentation_en-US" xlink:label="lab_biib_SkyhawkTherapeuticsMember_48205DB4AEB0E05465E078234CAE62BB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Skyhawk Therapeutics [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_SkyhawkTherapeuticsMember" xlink:label="loc_biib_SkyhawkTherapeuticsMember_48205DB4AEB0E05465E078234CAE62BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SkyhawkTherapeuticsMember_48205DB4AEB0E05465E078234CAE62BB" xlink:to="lab_biib_SkyhawkTherapeuticsMember_48205DB4AEB0E05465E078234CAE62BB" xlink:type="arc" />
    <link:label id="lab_biib_BAN2401Member_37178110933FB79EBF8578234CAF3051_terseLabel_en-US" xlink:label="lab_biib_BAN2401Member_37178110933FB79EBF8578234CAF3051" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BAN2401</link:label>
    <link:label id="lab_biib_BAN2401Member_37178110933FB79EBF8578234CAF3051_label_en-US" xlink:label="lab_biib_BAN2401Member_37178110933FB79EBF8578234CAF3051" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BAN2401 [Member]</link:label>
    <link:label id="lab_biib_BAN2401Member_37178110933FB79EBF8578234CAF3051_documentation_en-US" xlink:label="lab_biib_BAN2401Member_37178110933FB79EBF8578234CAF3051" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BAN2401 [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_BAN2401Member" xlink:label="loc_biib_BAN2401Member_37178110933FB79EBF8578234CAF3051" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BAN2401Member_37178110933FB79EBF8578234CAF3051" xlink:to="lab_biib_BAN2401Member_37178110933FB79EBF8578234CAF3051" xlink:type="arc" />
    <link:label id="lab_biib_E2609andBAN2401Member_65AC9F5AB74DA0D07D9C78234CAF6D54_terseLabel_en-US" xlink:label="lab_biib_E2609andBAN2401Member_65AC9F5AB74DA0D07D9C78234CAF6D54" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BAN2401 and Elenbecestat</link:label>
    <link:label id="lab_biib_E2609andBAN2401Member_65AC9F5AB74DA0D07D9C78234CAF6D54_label_en-US" xlink:label="lab_biib_E2609andBAN2401Member_65AC9F5AB74DA0D07D9C78234CAF6D54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">E2609 and BAN2401 [Member]</link:label>
    <link:label id="lab_biib_E2609andBAN2401Member_65AC9F5AB74DA0D07D9C78234CAF6D54_documentation_en-US" xlink:label="lab_biib_E2609andBAN2401Member_65AC9F5AB74DA0D07D9C78234CAF6D54" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">E2609 and BAN2401 [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_E2609andBAN2401Member" xlink:label="loc_biib_E2609andBAN2401Member_65AC9F5AB74DA0D07D9C78234CAF6D54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_E2609andBAN2401Member_65AC9F5AB74DA0D07D9C78234CAF6D54" xlink:to="lab_biib_E2609andBAN2401Member_65AC9F5AB74DA0D07D9C78234CAF6D54" xlink:type="arc" />
    <link:label id="lab_biib_AducanumabMember_DCA88A5C2015E746BB7778234CAF383F_terseLabel_en-US" xlink:label="lab_biib_AducanumabMember_DCA88A5C2015E746BB7778234CAF383F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aducanumab</link:label>
    <link:label id="lab_biib_AducanumabMember_DCA88A5C2015E746BB7778234CAF383F_label_en-US" xlink:label="lab_biib_AducanumabMember_DCA88A5C2015E746BB7778234CAF383F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aducanumab [Member]</link:label>
    <link:label id="lab_biib_AducanumabMember_DCA88A5C2015E746BB7778234CAF383F_documentation_en-US" xlink:label="lab_biib_AducanumabMember_DCA88A5C2015E746BB7778234CAF383F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aducanumab [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_AducanumabMember" xlink:label="loc_biib_AducanumabMember_DCA88A5C2015E746BB7778234CAF383F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AducanumabMember_DCA88A5C2015E746BB7778234CAF383F" xlink:to="lab_biib_AducanumabMember_DCA88A5C2015E746BB7778234CAF383F" xlink:type="arc" />
    <link:label id="lab_biib_ElenbecestatCollaborationMember_74121E51F7DB72C8E53278234CAFA5F8_terseLabel_en-US" xlink:label="lab_biib_ElenbecestatCollaborationMember_74121E51F7DB72C8E53278234CAFA5F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Elenbecestat Collaboration</link:label>
    <link:label id="lab_biib_ElenbecestatCollaborationMember_74121E51F7DB72C8E53278234CAFA5F8_label_en-US" xlink:label="lab_biib_ElenbecestatCollaborationMember_74121E51F7DB72C8E53278234CAFA5F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Elenbecestat Collaboration [Member]</link:label>
    <link:label id="lab_biib_ElenbecestatCollaborationMember_74121E51F7DB72C8E53278234CAFA5F8_documentation_en-US" xlink:label="lab_biib_ElenbecestatCollaborationMember_74121E51F7DB72C8E53278234CAFA5F8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Elenbecestat Collaboration [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_ElenbecestatCollaborationMember" xlink:label="loc_biib_ElenbecestatCollaborationMember_74121E51F7DB72C8E53278234CAFA5F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ElenbecestatCollaborationMember_74121E51F7DB72C8E53278234CAFA5F8" xlink:to="lab_biib_ElenbecestatCollaborationMember_74121E51F7DB72C8E53278234CAFA5F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4464930A5FA4A0C496FA78234CB05032_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4464930A5FA4A0C496FA78234CB05032" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4464930A5FA4A0C496FA78234CB05032_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4464930A5FA4A0C496FA78234CB05032" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4464930A5FA4A0C496FA78234CB05032" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4464930A5FA4A0C496FA78234CB05032" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4464930A5FA4A0C496FA78234CB05032" xlink:type="arc" />
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_056FA1AF280C89B68B3A78234CB0CD52_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_056FA1AF280C89B68B3A78234CB0CD52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Global Licensing Collaboration Agreement, Amount, Shares Purchased</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_056FA1AF280C89B68B3A78234CB0CD52_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_056FA1AF280C89B68B3A78234CB0CD52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Global Licensing Collaboration Agreement, Amount, Shares Purchased</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_056FA1AF280C89B68B3A78234CB0CD52_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_056FA1AF280C89B68B3A78234CB0CD52" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Global Licensing Collaboration Agreement, Amount, Shares Purchased</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_056FA1AF280C89B68B3A78234CB0CD52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_056FA1AF280C89B68B3A78234CB0CD52" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_056FA1AF280C89B68B3A78234CB0CD52" xlink:type="arc" />
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchased_0F65951261F6CE1156CC78234CB0D6E0_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchased_0F65951261F6CE1156CC78234CB0D6E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Global Licensing Collaboration Agreement, Shares, Purchased</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchased_0F65951261F6CE1156CC78234CB0D6E0_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchased_0F65951261F6CE1156CC78234CB0D6E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Global Licensing Collaboration Agreement, Shares, Purchased</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchased_0F65951261F6CE1156CC78234CB0D6E0_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchased_0F65951261F6CE1156CC78234CB0D6E0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Global Licensing Collaboration Agreement, Shares, Purchased</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_GlobalLicensingCollaborationAgreementSharesPurchased" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased_0F65951261F6CE1156CC78234CB0D6E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased_0F65951261F6CE1156CC78234CB0D6E0" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchased_0F65951261F6CE1156CC78234CB0D6E0" xlink:type="arc" />
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_5B539463605B32B2BD1078234CB14E4E_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_5B539463605B32B2BD1078234CB14E4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Global Licensing Collaboration Agreement, Shares Purchased Per Share</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_5B539463605B32B2BD1078234CB14E4E_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_5B539463605B32B2BD1078234CB14E4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Global Licensing Collaboration Agreement, Shares Purchased Per Share</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_5B539463605B32B2BD1078234CB14E4E_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_5B539463605B32B2BD1078234CB14E4E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Global Licensing Collaboration Agreement, Shares Purchased Per Share</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_5B539463605B32B2BD1078234CB14E4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_5B539463605B32B2BD1078234CB14E4E" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_5B539463605B32B2BD1078234CB14E4E" xlink:type="arc" />
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_60AFEEDBEDC149F9B33278234CB172C8_terseLabel_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration_60AFEEDBEDC149F9B33278234CB172C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense Incurred By Collaboration</link:label>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_60AFEEDBEDC149F9B33278234CB172C8_label_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration_60AFEEDBEDC149F9B33278234CB172C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense Incurred By Collaboration</link:label>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_60AFEEDBEDC149F9B33278234CB172C8_documentation_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration_60AFEEDBEDC149F9B33278234CB172C8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total expense incurred by collaboration.</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_ExpenseIncurredByCollaboration" xlink:label="loc_biib_ExpenseIncurredByCollaboration_60AFEEDBEDC149F9B33278234CB172C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ExpenseIncurredByCollaboration_60AFEEDBEDC149F9B33278234CB172C8" xlink:to="lab_biib_ExpenseIncurredByCollaboration_60AFEEDBEDC149F9B33278234CB172C8" xlink:type="arc" />
    <link:label id="lab_biib_Expenseincurredbythecollaboration_BFC4B73BA1EB20C085D278234CB18C22_terseLabel_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration_BFC4B73BA1EB20C085D278234CB18C22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:label id="lab_biib_Expenseincurredbythecollaboration_BFC4B73BA1EB20C085D278234CB18C22_label_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration_BFC4B73BA1EB20C085D278234CB18C22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:label id="lab_biib_Expenseincurredbythecollaboration_BFC4B73BA1EB20C085D278234CB18C22_documentation_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration_BFC4B73BA1EB20C085D278234CB18C22" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_Expenseincurredbythecollaboration" xlink:label="loc_biib_Expenseincurredbythecollaboration_BFC4B73BA1EB20C085D278234CB18C22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Expenseincurredbythecollaboration_BFC4B73BA1EB20C085D278234CB18C22" xlink:to="lab_biib_Expenseincurredbythecollaboration_BFC4B73BA1EB20C085D278234CB18C22" xlink:type="arc" />
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_47713B5CDB8D6BFAB87A78234CB12ECA_terseLabel_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome_47713B5CDB8D6BFAB87A78234CB12ECA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_47713B5CDB8D6BFAB87A78234CB12ECA_label_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome_47713B5CDB8D6BFAB87A78234CB12ECA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_47713B5CDB8D6BFAB87A78234CB12ECA_documentation_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome_47713B5CDB8D6BFAB87A78234CB12ECA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_Expensereflectedwithinstatementsofincome" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_47713B5CDB8D6BFAB87A78234CB12ECA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Expensereflectedwithinstatementsofincome_47713B5CDB8D6BFAB87A78234CB12ECA" xlink:to="lab_biib_Expensereflectedwithinstatementsofincome_47713B5CDB8D6BFAB87A78234CB12ECA" xlink:type="arc" />
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_AF216D8E00EA84F6152D78234CB3B70C_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_AF216D8E00EA84F6152D78234CB3B70C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_AF216D8E00EA84F6152D78234CB3B70C_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_AF216D8E00EA84F6152D78234CB3B70C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_AF216D8E00EA84F6152D78234CB3B70C_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_AF216D8E00EA84F6152D78234CB3B70C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_AF216D8E00EA84F6152D78234CB3B70C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_AF216D8E00EA84F6152D78234CB3B70C" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_AF216D8E00EA84F6152D78234CB3B70C" xlink:type="arc" />
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_D6ED035F3464AA34FB7878234CB36C98_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_D6ED035F3464AA34FB7878234CB36C98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Selection of Targets</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_D6ED035F3464AA34FB7878234CB36C98_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_D6ED035F3464AA34FB7878234CB36C98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Selection of Targets</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_D6ED035F3464AA34FB7878234CB36C98_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_D6ED035F3464AA34FB7878234CB36C98" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Selection of Targets</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_D6ED035F3464AA34FB7878234CB36C98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_D6ED035F3464AA34FB7878234CB36C98" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_D6ED035F3464AA34FB7878234CB36C98" xlink:type="arc" />
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_090993B1D0085E2F3FE978234CB3781D_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_090993B1D0085E2F3FE978234CB3781D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_090993B1D0085E2F3FE978234CB3781D_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_090993B1D0085E2F3FE978234CB3781D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_090993B1D0085E2F3FE978234CB3781D_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_090993B1D0085E2F3FE978234CB3781D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_090993B1D0085E2F3FE978234CB3781D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_090993B1D0085E2F3FE978234CB3781D" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_090993B1D0085E2F3FE978234CB3781D" xlink:type="arc" />
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_5C9F3C5326D924C49A7778234CB38FB2_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_5C9F3C5326D924C49A7778234CB38FB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_5C9F3C5326D924C49A7778234CB38FB2_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_5C9F3C5326D924C49A7778234CB38FB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_5C9F3C5326D924C49A7778234CB38FB2_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_5C9F3C5326D924C49A7778234CB38FB2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_5C9F3C5326D924C49A7778234CB38FB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_5C9F3C5326D924C49A7778234CB38FB2" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_5C9F3C5326D924C49A7778234CB38FB2" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_9C3A91919AD13028A48878234D0D197A_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_9C3A91919AD13028A48878234D0D197A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_9C3A91919AD13028A48878234D0D197A_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_9C3A91919AD13028A48878234D0D197A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_9C3A91919AD13028A48878234D0D197A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_9C3A91919AD13028A48878234D0D197A" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_9C3A91919AD13028A48878234D0D197A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_F27BDE5B17A75DC69B4878234D0DFAFA_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_F27BDE5B17A75DC69B4878234D0DFAFA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_F27BDE5B17A75DC69B4878234D0DFAFA_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_F27BDE5B17A75DC69B4878234D0DFAFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_F27BDE5B17A75DC69B4878234D0DFAFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_F27BDE5B17A75DC69B4878234D0DFAFA" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_F27BDE5B17A75DC69B4878234D0DFAFA" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8F75D41E6F568EDD07D778234D0EA5F0_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8F75D41E6F568EDD07D778234D0EA5F0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">State taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8F75D41E6F568EDD07D778234D0EA5F0_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8F75D41E6F568EDD07D778234D0EA5F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8F75D41E6F568EDD07D778234D0EA5F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8F75D41E6F568EDD07D778234D0EA5F0" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8F75D41E6F568EDD07D778234D0EA5F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_B10661AECEF7704BAED478234D0E1480_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_B10661AECEF7704BAED478234D0E1480" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Taxes on foreign earnings</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_B10661AECEF7704BAED478234D0E1480_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_B10661AECEF7704BAED478234D0E1480" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_B10661AECEF7704BAED478234D0E1480" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_B10661AECEF7704BAED478234D0E1480" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_B10661AECEF7704BAED478234D0E1480" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_476442391F153EACB84178234D0ED8F5_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_476442391F153EACB84178234D0ED8F5" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Credits and net operating loss utilization</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_476442391F153EACB84178234D0ED8F5_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_476442391F153EACB84178234D0ED8F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_476442391F153EACB84178234D0ED8F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_476442391F153EACB84178234D0ED8F5" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_476442391F153EACB84178234D0ED8F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_277474AC3088BAD6A82778234D0FB4D5_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_277474AC3088BAD6A82778234D0FB4D5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Purchased intangible assets</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_277474AC3088BAD6A82778234D0FB4D5_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_277474AC3088BAD6A82778234D0FB4D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation and Amortization, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_277474AC3088BAD6A82778234D0FB4D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_277474AC3088BAD6A82778234D0FB4D5" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_277474AC3088BAD6A82778234D0FB4D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_1754B6BDCD98577BD78D78234D0F3206_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_1754B6BDCD98577BD78D78234D0F3206" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denmark assets held for sale</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_1754B6BDCD98577BD78D78234D0F3206_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_1754B6BDCD98577BD78D78234D0F3206" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Disposition of Asset, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_1754B6BDCD98577BD78D78234D0F3206" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_1754B6BDCD98577BD78D78234D0F3206" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_1754B6BDCD98577BD78D78234D0F3206" xlink:type="arc" />
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_A17EFE60069CF17C7C4378234D0F86D3_terseLabel_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_A17EFE60069CF17C7C4378234D0F86D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Internal reorganization of certain intellectual property rights</link:label>
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_A17EFE60069CF17C7C4378234D0F86D3_label_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_A17EFE60069CF17C7C4378234D0F86D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Intellectual Property Rights Reorganization</link:label>
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_A17EFE60069CF17C7C4378234D0F86D3_documentation_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_A17EFE60069CF17C7C4378234D0F86D3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Intellectual Property Rights Reorganization</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_A17EFE60069CF17C7C4378234D0F86D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_A17EFE60069CF17C7C4378234D0F86D3" xlink:to="lab_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_A17EFE60069CF17C7C4378234D0F86D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_01700F3C74648C928D1A78234D0F9F57_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_01700F3C74648C928D1A78234D0F9F57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TECFIDERA impairment</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_01700F3C74648C928D1A78234D0F9F57_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_01700F3C74648C928D1A78234D0F9F57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_01700F3C74648C928D1A78234D0F9F57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_01700F3C74648C928D1A78234D0F9F57" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_01700F3C74648C928D1A78234D0F9F57" xlink:type="arc" />
    <link:label id="lab_biib_EffectiveTaxRateReconciliationGILTItax_C63D2B381ABB16473C0D78234D0F7025_terseLabel_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationGILTItax_C63D2B381ABB16473C0D78234D0F7025" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GILTI</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationGILTItax_C63D2B381ABB16473C0D78234D0F7025_label_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationGILTItax_C63D2B381ABB16473C0D78234D0F7025" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Tax Rate Reconciliation, GILTI tax</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationGILTItax_C63D2B381ABB16473C0D78234D0F7025_documentation_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationGILTItax_C63D2B381ABB16473C0D78234D0F7025" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Tax Rate Reconciliation, GILTI tax</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_EffectiveTaxRateReconciliationGILTItax" xlink:label="loc_biib_EffectiveTaxRateReconciliationGILTItax_C63D2B381ABB16473C0D78234D0F7025" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveTaxRateReconciliationGILTItax_C63D2B381ABB16473C0D78234D0F7025" xlink:to="lab_biib_EffectiveTaxRateReconciliationGILTItax_C63D2B381ABB16473C0D78234D0F7025" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_CD45F3168C5D698F262478234D109FBE_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_CD45F3168C5D698F262478234D109FBE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Permanent items</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_CD45F3168C5D698F262478234D109FBE_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_CD45F3168C5D698F262478234D109FBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_CD45F3168C5D698F262478234D109FBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_CD45F3168C5D698F262478234D109FBE" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_CD45F3168C5D698F262478234D109FBE" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_C92D6C005D85BD313E1578234D10AC16_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_C92D6C005D85BD313E1578234D10AC16" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_C92D6C005D85BD313E1578234D10AC16_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_C92D6C005D85BD313E1578234D10AC16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_C92D6C005D85BD313E1578234D10AC16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_C92D6C005D85BD313E1578234D10AC16" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_C92D6C005D85BD313E1578234D10AC16" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_57CA91E22F1EFC6C505E78234D10D933_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_57CA91E22F1EFC6C505E78234D10D933" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_57CA91E22F1EFC6C505E78234D10D933_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_57CA91E22F1EFC6C505E78234D10D933" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_57CA91E22F1EFC6C505E78234D10D933" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_57CA91E22F1EFC6C505E78234D10D933" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_57CA91E22F1EFC6C505E78234D10D933" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_7DE50215B6D9C970F0A3782350DB99ED_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_7DE50215B6D9C970F0A3782350DB99ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_7DE50215B6D9C970F0A3782350DB99ED_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_7DE50215B6D9C970F0A3782350DB99ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_7DE50215B6D9C970F0A3782350DB99ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_7DE50215B6D9C970F0A3782350DB99ED" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_7DE50215B6D9C970F0A3782350DB99ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_300CE056FE1C5F26EC10782350DB8A18_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_300CE056FE1C5F26EC10782350DB8A18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_300CE056FE1C5F26EC10782350DB8A18_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_300CE056FE1C5F26EC10782350DB8A18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_300CE056FE1C5F26EC10782350DB8A18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_300CE056FE1C5F26EC10782350DB8A18" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_300CE056FE1C5F26EC10782350DB8A18" xlink:type="arc" />
    <link:label id="lab_biib_PostacquisitionequitycompensationMember_2E6D2B14D7F53C58278E782350DB861A_terseLabel_en-US" xlink:label="lab_biib_PostacquisitionequitycompensationMember_2E6D2B14D7F53C58278E782350DB861A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Post-acquisition equity compensation</link:label>
    <link:label id="lab_biib_PostacquisitionequitycompensationMember_2E6D2B14D7F53C58278E782350DB861A_label_en-US" xlink:label="lab_biib_PostacquisitionequitycompensationMember_2E6D2B14D7F53C58278E782350DB861A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Post-acquisition equity compensation [Member]</link:label>
    <link:label id="lab_biib_PostacquisitionequitycompensationMember_2E6D2B14D7F53C58278E782350DB861A_documentation_en-US" xlink:label="lab_biib_PostacquisitionequitycompensationMember_2E6D2B14D7F53C58278E782350DB861A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Post-acquisition equity compensation [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_PostacquisitionequitycompensationMember" xlink:label="loc_biib_PostacquisitionequitycompensationMember_2E6D2B14D7F53C58278E782350DB861A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PostacquisitionequitycompensationMember_2E6D2B14D7F53C58278E782350DB861A" xlink:to="lab_biib_PostacquisitionequitycompensationMember_2E6D2B14D7F53C58278E782350DB861A" xlink:type="arc" />
    <link:label id="lab_biib_BIIB111Member_8D01DF0F648B1F8A1D3B782350E2B016_terseLabel_en-US" xlink:label="lab_biib_BIIB111Member_8D01DF0F648B1F8A1D3B782350E2B016" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BIIB111</link:label>
    <link:label id="lab_biib_BIIB111Member_8D01DF0F648B1F8A1D3B782350E2B016_label_en-US" xlink:label="lab_biib_BIIB111Member_8D01DF0F648B1F8A1D3B782350E2B016" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BIIB111 [Member]</link:label>
    <link:label id="lab_biib_BIIB111Member_8D01DF0F648B1F8A1D3B782350E2B016_documentation_en-US" xlink:label="lab_biib_BIIB111Member_8D01DF0F648B1F8A1D3B782350E2B016" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BIIB111 [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_BIIB111Member" xlink:label="loc_biib_BIIB111Member_8D01DF0F648B1F8A1D3B782350E2B016" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BIIB111Member_8D01DF0F648B1F8A1D3B782350E2B016" xlink:to="lab_biib_BIIB111Member_8D01DF0F648B1F8A1D3B782350E2B016" xlink:type="arc" />
    <link:label id="lab_biib_BIIB112Member_BFED354CBA4867EF98E0782350E2C79A_terseLabel_en-US" xlink:label="lab_biib_BIIB112Member_BFED354CBA4867EF98E0782350E2C79A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BIIB112</link:label>
    <link:label id="lab_biib_BIIB112Member_BFED354CBA4867EF98E0782350E2C79A_label_en-US" xlink:label="lab_biib_BIIB112Member_BFED354CBA4867EF98E0782350E2C79A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BIIB112 [Member]</link:label>
    <link:label id="lab_biib_BIIB112Member_BFED354CBA4867EF98E0782350E2C79A_documentation_en-US" xlink:label="lab_biib_BIIB112Member_BFED354CBA4867EF98E0782350E2C79A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BIIB112 [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_BIIB112Member" xlink:label="loc_biib_BIIB112Member_BFED354CBA4867EF98E0782350E2C79A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BIIB112Member_BFED354CBA4867EF98E0782350E2C79A" xlink:to="lab_biib_BIIB112Member_BFED354CBA4867EF98E0782350E2C79A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9A051F012069369893FA782350E35EE1_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9A051F012069369893FA782350E35EE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9A051F012069369893FA782350E35EE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9A051F012069369893FA782350E35EE1" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9A051F012069369893FA782350E35EE1" xlink:type="arc" />
    <link:label id="lab_biib_BIIB118Member_BB2B3260300404E2B003782350E34811_terseLabel_en-US" xlink:label="lab_biib_BIIB118Member_BB2B3260300404E2B003782350E34811" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BIIB118</link:label>
    <link:label id="lab_biib_BIIB118Member_BB2B3260300404E2B003782350E34811_label_en-US" xlink:label="lab_biib_BIIB118Member_BB2B3260300404E2B003782350E34811" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BIIB118 [Member]</link:label>
    <link:label id="lab_biib_BIIB118Member_BB2B3260300404E2B003782350E34811_documentation_en-US" xlink:label="lab_biib_BIIB118Member_BB2B3260300404E2B003782350E34811" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BIIB118 [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_BIIB118Member" xlink:label="loc_biib_BIIB118Member_BB2B3260300404E2B003782350E34811" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BIIB118Member_BB2B3260300404E2B003782350E34811" xlink:to="lab_biib_BIIB118Member_BB2B3260300404E2B003782350E34811" xlink:type="arc" />
    <link:label id="lab_biib_ClinicalAssetsAcquired_685AC76389BD1DF16080782350E5A9AA_terseLabel_en-US" xlink:label="lab_biib_ClinicalAssetsAcquired_685AC76389BD1DF16080782350E5A9AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical Assets Acquired</link:label>
    <link:label id="lab_biib_ClinicalAssetsAcquired_685AC76389BD1DF16080782350E5A9AA_label_en-US" xlink:label="lab_biib_ClinicalAssetsAcquired_685AC76389BD1DF16080782350E5A9AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Assets Acquired</link:label>
    <link:label id="lab_biib_ClinicalAssetsAcquired_685AC76389BD1DF16080782350E5A9AA_documentation_en-US" xlink:label="lab_biib_ClinicalAssetsAcquired_685AC76389BD1DF16080782350E5A9AA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical Assets Acquired</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_ClinicalAssetsAcquired" xlink:label="loc_biib_ClinicalAssetsAcquired_685AC76389BD1DF16080782350E5A9AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ClinicalAssetsAcquired_685AC76389BD1DF16080782350E5A9AA" xlink:to="lab_biib_ClinicalAssetsAcquired_685AC76389BD1DF16080782350E5A9AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_AB118E30A6EDEFD8419E782350E5571B_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice_AB118E30A6EDEFD8419E782350E5571B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Price per share</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_AB118E30A6EDEFD8419E782350E5571B_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice_AB118E30A6EDEFD8419E782350E5571B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_AB118E30A6EDEFD8419E782350E5571B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice_AB118E30A6EDEFD8419E782350E5571B" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice_AB118E30A6EDEFD8419E782350E5571B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_5DC37589F23788886177782350E50E62_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_5DC37589F23788886177782350E50E62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total transaction value</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_5DC37589F23788886177782350E50E62_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_5DC37589F23788886177782350E50E62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_5DC37589F23788886177782350E50E62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross_5DC37589F23788886177782350E50E62" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross_5DC37589F23788886177782350E50E62" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherPaymentsToAcquireBusinesses_E9F9ACC53BE27976805B782350E5509F_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPaymentsToAcquireBusinesses_E9F9ACC53BE27976805B782350E5509F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for pre-combination equity compensation</link:label>
    <link:label id="lab_us-gaap_OtherPaymentsToAcquireBusinesses_E9F9ACC53BE27976805B782350E5509F_label_en-US" xlink:label="lab_us-gaap_OtherPaymentsToAcquireBusinesses_E9F9ACC53BE27976805B782350E5509F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Payments to Acquire Businesses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_E9F9ACC53BE27976805B782350E5509F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPaymentsToAcquireBusinesses_E9F9ACC53BE27976805B782350E5509F" xlink:to="lab_us-gaap_OtherPaymentsToAcquireBusinesses_E9F9ACC53BE27976805B782350E5509F" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_77BB56DA1C6461D95126782350E54C2D_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_77BB56DA1C6461D95126782350E54C2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of post-combination equity compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_77BB56DA1C6461D95126782350E54C2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_77BB56DA1C6461D95126782350E54C2D" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_77BB56DA1C6461D95126782350E54C2D" xlink:type="arc" />
    <link:label id="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_45B0A55B51B4166C45C8782350E5022F_terseLabel_en-US" xlink:label="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_45B0A55B51B4166C45C8782350E5022F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value, in-process research and development, discount rate</link:label>
    <link:label id="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_45B0A55B51B4166C45C8782350E5022F_label_en-US" xlink:label="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_45B0A55B51B4166C45C8782350E5022F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Indefinite Lived Intangible Assets, Discount Rate</link:label>
    <link:label id="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_45B0A55B51B4166C45C8782350E5022F_documentation_en-US" xlink:label="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_45B0A55B51B4166C45C8782350E5022F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value, Indefinite Lived Intangible Assets, Discount Rate</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" xlink:label="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_45B0A55B51B4166C45C8782350E5022F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_45B0A55B51B4166C45C8782350E5022F" xlink:to="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_45B0A55B51B4166C45C8782350E5022F" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes_E4ED798230AFE04B5185782350E6F339_terseLabel_en-US" xlink:label="lab_us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes_E4ED798230AFE04B5185782350E6F339" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Basis of Investments, Cost for Income Tax Purposes</link:label>
    <link:label id="lab_us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes_E4ED798230AFE04B5185782350E6F339_label_en-US" xlink:label="lab_us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes_E4ED798230AFE04B5185782350E6F339" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Basis of Investments, Cost for Income Tax Purposes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes" xlink:label="loc_us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes_E4ED798230AFE04B5185782350E6F339" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes_E4ED798230AFE04B5185782350E6F339" xlink:to="lab_us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes_E4ED798230AFE04B5185782350E6F339" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_EBF47384C3E7DAF90B1E782350E66624_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_EBF47384C3E7DAF90B1E782350E66624" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities, goodwill</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_EBF47384C3E7DAF90B1E782350E66624_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_EBF47384C3E7DAF90B1E782350E66624" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_EBF47384C3E7DAF90B1E782350E66624" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_EBF47384C3E7DAF90B1E782350E66624" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_EBF47384C3E7DAF90B1E782350E66624" xlink:type="arc" />
    <link:label id="lab_biib_RocheGroupGenentechMember_CC77D4D0F3A807C6F0E3782350426708_terseLabel_en-US" xlink:label="lab_biib_RocheGroupGenentechMember_CC77D4D0F3A807C6F0E3782350426708" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Genentech</link:label>
    <link:label id="lab_biib_RocheGroupGenentechMember_CC77D4D0F3A807C6F0E3782350426708_label_en-US" xlink:label="lab_biib_RocheGroupGenentechMember_CC77D4D0F3A807C6F0E3782350426708" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Roche Group Genentech Member</link:label>
    <link:label id="lab_biib_RocheGroupGenentechMember_CC77D4D0F3A807C6F0E3782350426708_documentation_en-US" xlink:label="lab_biib_RocheGroupGenentechMember_CC77D4D0F3A807C6F0E3782350426708" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Roche group Genentech.</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_RocheGroupGenentechMember" xlink:label="loc_biib_RocheGroupGenentechMember_CC77D4D0F3A807C6F0E3782350426708" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RocheGroupGenentechMember_CC77D4D0F3A807C6F0E3782350426708" xlink:to="lab_biib_RocheGroupGenentechMember_CC77D4D0F3A807C6F0E3782350426708" xlink:type="arc" />
    <link:label id="lab_biib_ShareOfCoPromotionProfits_A270DB22B1AA14BFCD02782350434E79_terseLabel_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits_A270DB22B1AA14BFCD02782350434E79" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</link:label>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_A270DB22B1AA14BFCD02782350434E79_label_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits_A270DB22B1AA14BFCD02782350434E79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Of Co Promotion Profits</link:label>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_A270DB22B1AA14BFCD02782350434E79_documentation_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits_A270DB22B1AA14BFCD02782350434E79" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share of co promotion profits.</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_A270DB22B1AA14BFCD02782350434E79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareOfCoPromotionProfits_A270DB22B1AA14BFCD02782350434E79" xlink:to="lab_biib_ShareOfCoPromotionProfits_A270DB22B1AA14BFCD02782350434E79" xlink:type="arc" />
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_EB069DFAD8D4CAA761AA7823504395DE_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_EB069DFAD8D4CAA761AA7823504395DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_EB069DFAD8D4CAA761AA7823504395DE_label_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_EB069DFAD8D4CAA761AA7823504395DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_EB069DFAD8D4CAA761AA7823504395DE_documentation_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_EB069DFAD8D4CAA761AA7823504395DE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_EB069DFAD8D4CAA761AA7823504395DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_EB069DFAD8D4CAA761AA7823504395DE" xlink:to="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_EB069DFAD8D4CAA761AA7823504395DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_BB97CEF81ADBF72B7356782350430244_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues_BB97CEF81ADBF72B7356782350430244" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenues from anti-CD20 therapeutic programs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_BB97CEF81ADBF72B7356782350430244" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_BB97CEF81ADBF72B7356782350430244" xlink:to="lab_us-gaap_Revenues_BB97CEF81ADBF72B7356782350430244" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_E830DE4E696678495AAA78234DA49808_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_E830DE4E696678495AAA78234DA49808" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_E830DE4E696678495AAA78234DA49808_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_E830DE4E696678495AAA78234DA49808" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_E830DE4E696678495AAA78234DA49808" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_E830DE4E696678495AAA78234DA49808" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_E830DE4E696678495AAA78234DA49808" xlink:type="arc" />
    <link:label id="lab_biib_TECFIDERAMember_440D9B128EBAF06F29CF78234D1C2CC6_terseLabel_en-US" xlink:label="lab_biib_TECFIDERAMember_440D9B128EBAF06F29CF78234D1C2CC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TECFIDERA</link:label>
    <link:label id="lab_biib_TECFIDERAMember_440D9B128EBAF06F29CF78234D1C2CC6_label_en-US" xlink:label="lab_biib_TECFIDERAMember_440D9B128EBAF06F29CF78234D1C2CC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:label id="lab_biib_TECFIDERAMember_440D9B128EBAF06F29CF78234D1C2CC6_documentation_en-US" xlink:label="lab_biib_TECFIDERAMember_440D9B128EBAF06F29CF78234D1C2CC6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_TECFIDERAMember" xlink:label="loc_biib_TECFIDERAMember_440D9B128EBAF06F29CF78234D1C2CC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TECFIDERAMember_440D9B128EBAF06F29CF78234D1C2CC6" xlink:to="lab_biib_TECFIDERAMember_440D9B128EBAF06F29CF78234D1C2CC6" xlink:type="arc" />
    <link:label id="lab_biib_DeferredTaxAssetsValueReductioninValue_408F39B78C0420D48B8C78234D1DF5CC_terseLabel_en-US" xlink:label="lab_biib_DeferredTaxAssetsValueReductioninValue_408F39B78C0420D48B8C78234D1DF5CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets, decrease in value</link:label>
    <link:label id="lab_biib_DeferredTaxAssetsValueReductioninValue_408F39B78C0420D48B8C78234D1DF5CC_label_en-US" xlink:label="lab_biib_DeferredTaxAssetsValueReductioninValue_408F39B78C0420D48B8C78234D1DF5CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Value, Reduction in Value</link:label>
    <link:label id="lab_biib_DeferredTaxAssetsValueReductioninValue_408F39B78C0420D48B8C78234D1DF5CC_documentation_en-US" xlink:label="lab_biib_DeferredTaxAssetsValueReductioninValue_408F39B78C0420D48B8C78234D1DF5CC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Value, Reduction in Value</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_DeferredTaxAssetsValueReductioninValue" xlink:label="loc_biib_DeferredTaxAssetsValueReductioninValue_408F39B78C0420D48B8C78234D1DF5CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DeferredTaxAssetsValueReductioninValue_408F39B78C0420D48B8C78234D1DF5CC" xlink:to="lab_biib_DeferredTaxAssetsValueReductioninValue_408F39B78C0420D48B8C78234D1DF5CC" xlink:type="arc" />
    <link:label id="lab_biib_DeferredTaxLiabilitiesValueReductioninValue_861728C510B01CD4EFAF78234D1EF68D_terseLabel_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesValueReductioninValue_861728C510B01CD4EFAF78234D1EF68D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities, decrease in value</link:label>
    <link:label id="lab_biib_DeferredTaxLiabilitiesValueReductioninValue_861728C510B01CD4EFAF78234D1EF68D_label_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesValueReductioninValue_861728C510B01CD4EFAF78234D1EF68D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Value, Reduction in Value</link:label>
    <link:label id="lab_biib_DeferredTaxLiabilitiesValueReductioninValue_861728C510B01CD4EFAF78234D1EF68D_documentation_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesValueReductioninValue_861728C510B01CD4EFAF78234D1EF68D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Value, Reduction in Value</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_DeferredTaxLiabilitiesValueReductioninValue" xlink:label="loc_biib_DeferredTaxLiabilitiesValueReductioninValue_861728C510B01CD4EFAF78234D1EF68D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DeferredTaxLiabilitiesValueReductioninValue_861728C510B01CD4EFAF78234D1EF68D" xlink:to="lab_biib_DeferredTaxLiabilitiesValueReductioninValue_861728C510B01CD4EFAF78234D1EF68D" xlink:type="arc" />
    <link:label id="lab_biib_IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet_2C7A8D7F5FCD8A3B514E78234D1ED998_terseLabel_en-US" xlink:label="lab_biib_IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet_2C7A8D7F5FCD8A3B514E78234D1ED998" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense associated with reductions in deferred tax assets and liabilities</link:label>
    <link:label id="lab_biib_IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet_2C7A8D7F5FCD8A3B514E78234D1ED998_label_en-US" xlink:label="lab_biib_IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet_2C7A8D7F5FCD8A3B514E78234D1ED998" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense, Reduction in Deferred Tax Assets and Liabilities, Net</link:label>
    <link:label id="lab_biib_IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet_2C7A8D7F5FCD8A3B514E78234D1ED998_documentation_en-US" xlink:label="lab_biib_IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet_2C7A8D7F5FCD8A3B514E78234D1ED998" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Tax Expense, Reduction in Deferred Tax Assets and Liabilities, Net</link:label>
    <link:loc xlink:href="biib-20200630.xsd#biib_IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet" xlink:label="loc_biib_IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet_2C7A8D7F5FCD8A3B514E78234D1ED998" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet_2C7A8D7F5FCD8A3B514E78234D1ED998" xlink:to="lab_biib_IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet_2C7A8D7F5FCD8A3B514E78234D1ED998" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_F29DDBE9BB7DFB79D5E278234D1F8C63_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_F29DDBE9BB7DFB79D5E278234D1F8C63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets, other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_F29DDBE9BB7DFB79D5E278234D1F8C63_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_F29DDBE9BB7DFB79D5E278234D1F8C63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_F29DDBE9BB7DFB79D5E278234D1F8C63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther_F29DDBE9BB7DFB79D5E278234D1F8C63" xlink:to="lab_us-gaap_DeferredTaxAssetsOther_F29DDBE9BB7DFB79D5E278234D1F8C63" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_CB583616827F71AD877478234D1F8AAA_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther_CB583616827F71AD877478234D1F8AAA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities, other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_CB583616827F71AD877478234D1F8AAA_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther_CB583616827F71AD877478234D1F8AAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_CB583616827F71AD877478234D1F8AAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther_CB583616827F71AD877478234D1F8AAA" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther_CB583616827F71AD877478234D1F8AAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_1D8346AF62D9ECF5567878234D1F6806_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_1D8346AF62D9ECF5567878234D1F6806" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease in unrecognized tax benefits is reasonably possible</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_1D8346AF62D9ECF5567878234D1F6806_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_1D8346AF62D9ECF5567878234D1F6806" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_1D8346AF62D9ECF5567878234D1F6806" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_1D8346AF62D9ECF5567878234D1F6806" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_1D8346AF62D9ECF5567878234D1F6806" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_008FA93B3869F407DD80782350F1BFF2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_008FA93B3869F407DD80782350F1BFF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_008FA93B3869F407DD80782350F1BFF2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_008FA93B3869F407DD80782350F1BFF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_008FA93B3869F407DD80782350F1BFF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_008FA93B3869F407DD80782350F1BFF2" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_008FA93B3869F407DD80782350F1BFF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_3894580D5D964DBA33A978234C73344E_verboseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_3894580D5D964DBA33A978234C73344E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments in Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_3894580D5D964DBA33A978234C73344E_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_3894580D5D964DBA33A978234C73344E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_3894580D5D964DBA33A978234C73344E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_3894580D5D964DBA33A978234C73344E" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_3894580D5D964DBA33A978234C73344E" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>biib-20200630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20200630.xsd#AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:href="biib-20200630.xsd#AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:href="biib-20200630.xsd#Acquisitions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetails" xlink:href="biib-20200630.xsd#BusinessAcquisitionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual" xlink:href="biib-20200630.xsd#BusinessAcquisitionDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:href="biib-20200630.xsd#CollaborativeAndOtherRelationships" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:href="biib-20200630.xsd#CollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:href="biib-20200630.xsd#CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:href="biib-20200630.xsd#CollaborativeAndOtherRelationshipsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="biib-20200630.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="biib-20200630.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement" xlink:href="biib-20200630.xsd#CondensedConsolidatedStatementOfEquityStatement" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="biib-20200630.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:href="biib-20200630.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:href="biib-20200630.xsd#CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CoverPage" xlink:href="biib-20200630.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:href="biib-20200630.xsd#DerivativeInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:href="biib-20200630.xsd#DerivativeInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:href="biib-20200630.xsd#DerivativeInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDetailsTextual" xlink:href="biib-20200630.xsd#DivestituresDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDivestitures" xlink:href="biib-20200630.xsd#DivestituresDivestitures" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShare" xlink:href="biib-20200630.xsd#EarningsPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:href="biib-20200630.xsd#EarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:href="biib-20200630.xsd#EarningsPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:href="biib-20200630.xsd#Equity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:href="biib-20200630.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:href="biib-20200630.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:href="biib-20200630.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:href="biib-20200630.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:href="biib-20200630.xsd#FairValueMeasurementsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:href="biib-20200630.xsd#FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:href="biib-20200630.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:href="biib-20200630.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:href="biib-20200630.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:href="biib-20200630.xsd#FinancialInstrumentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:href="biib-20200630.xsd#FinancialInstrumentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:href="biib-20200630.xsd#FinancialInstrumentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:href="biib-20200630.xsd#FinancialInstrumentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:href="biib-20200630.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:href="biib-20200630.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:href="biib-20200630.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:href="biib-20200630.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:href="biib-20200630.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:href="biib-20200630.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails" xlink:href="biib-20200630.xsd#IndebtednessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessNotes" xlink:href="biib-20200630.xsd#IndebtednessNotes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:href="biib-20200630.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="biib-20200630.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:href="biib-20200630.xsd#IntangibleAssetsAndGoodwillDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="biib-20200630.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:href="biib-20200630.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:href="biib-20200630.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:href="biib-20200630.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:href="biib-20200630.xsd#InvestmentsInVariableInterestEntities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:href="biib-20200630.xsd#InvestmentsInVariableInterestEntitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:href="biib-20200630.xsd#Litigation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationDetails" xlink:href="biib-20200630.xsd#LitigationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:href="biib-20200630.xsd#OtherConsolidatedFinancialStatementDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:href="biib-20200630.xsd#OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:href="biib-20200630.xsd#OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:href="biib-20200630.xsd#OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherRevenuesDetails" xlink:href="biib-20200630.xsd#OtherRevenuesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:href="biib-20200630.xsd#PropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:href="biib-20200630.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20200630.xsd#ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1" xlink:href="biib-20200630.xsd#ReservesForDiscountsAndAllowancesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2" xlink:href="biib-20200630.xsd#ReservesForDiscountsAndAllowancesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesByProductDetails" xlink:href="biib-20200630.xsd#RevenuesByProductDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:href="biib-20200630.xsd#RevenuesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:href="biib-20200630.xsd#RevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenues" xlink:href="biib-20200630.xsd#RevenuesRevenues" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesTables" xlink:href="biib-20200630.xsd#RevenuesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPayments" xlink:href="biib-20200630.xsd#ShareBasedPayments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:href="biib-20200630.xsd#ShareBasedPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:href="biib-20200630.xsd#ShareBasedPaymentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:href="biib-20200630.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:href="biib-20200630.xsd#ShareRepurchasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" xlink:href="biib-20200630.xsd#SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="biib-20200630.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="biib-20200630.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="biib-20200630.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_BC012B98A791D27D51F378234D86BCD1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0A244574FA369DB34B8E78234D864E2B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_BC012B98A791D27D51F378234D86BCD1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0A244574FA369DB34B8E78234D864E2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7110BD01B7A114C51CBF78234D86637F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0A244574FA369DB34B8E78234D864E2B" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7110BD01B7A114C51CBF78234D86637F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_DAE4A302311E8AA5113278234D870626" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7110BD01B7A114C51CBF78234D86637F" xlink:to="loc_us-gaap_EquityComponentDomain_DAE4A302311E8AA5113278234D870626" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_DA5AA2E4E792562CF81878234D87A051" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_DAE4A302311E8AA5113278234D870626" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_DA5AA2E4E792562CF81878234D87A051" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_44E58C51BB454D9B255778234D8861AF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_DAE4A302311E8AA5113278234D870626" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_44E58C51BB454D9B255778234D8861AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_B784DB9E5BB5DDCAE6D478234D88192B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_DAE4A302311E8AA5113278234D870626" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_B784DB9E5BB5DDCAE6D478234D88192B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_B37A1E6DC361F3873A6178234D88F870" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_DAE4A302311E8AA5113278234D870626" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_B37A1E6DC361F3873A6178234D88F870" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_90C2323215EF846FD0E178234D88534C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_DAE4A302311E8AA5113278234D870626" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_90C2323215EF846FD0E178234D88534C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_88085225C3A536A053A978234D896445" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0A244574FA369DB34B8E78234D864E2B" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_88085225C3A536A053A978234D896445" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_D898A64164D8CFF079BE78234D8993B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_88085225C3A536A053A978234D896445" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_D898A64164D8CFF079BE78234D8993B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8B9D229600617BE88D6878234D89A06F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_88085225C3A536A053A978234D896445" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8B9D229600617BE88D6878234D89A06F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_C4E9FCC29E529644E78078234D8A8CC3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_88085225C3A536A053A978234D896445" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_C4E9FCC29E529644E78078234D8A8CC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_EA4A339722FA364F3D6B78234D8A1D9F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_88085225C3A536A053A978234D896445" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_EA4A339722FA364F3D6B78234D8A1D9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4EB8B3527AB15E9259A278234D8A29E6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_88085225C3A536A053A978234D896445" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4EB8B3527AB15E9259A278234D8A29E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0B13321A9A410CD86BE578234D8AA3E6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_88085225C3A536A053A978234D896445" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0B13321A9A410CD86BE578234D8AA3E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_A6275A003D0FE841406378234D8B5673" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_88085225C3A536A053A978234D896445" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_A6275A003D0FE841406378234D8B5673" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_DC0D336648B0E8BE2CD278234D9FFC52" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_3859668CF719FB0B014578234D9F7275" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_DC0D336648B0E8BE2CD278234D9FFC52" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_3859668CF719FB0B014578234D9F7275" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_14B8E5DD391D60CD579378234D9F7ED7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_DC0D336648B0E8BE2CD278234D9FFC52" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_14B8E5DD391D60CD579378234D9F7ED7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_807E52666951E24B9A34782350F4A15D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_1B2BA1B59F0962405792782350F4E5D7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_807E52666951E24B9A34782350F4A15D" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_1B2BA1B59F0962405792782350F4E5D7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/BusinessAcquisitionDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20200630.xsd#biib_AcquisitionsAbstract" xlink:label="loc_biib_AcquisitionsAbstract_D5D6EECF36B30A2025B0782350BBCA7D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_14A451184C62074FDCE9782350BC3BC0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AcquisitionsAbstract_D5D6EECF36B30A2025B0782350BBCA7D" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_14A451184C62074FDCE9782350BC3BC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_B0365BFBB001CF51F1E1782350BCE1AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_14A451184C62074FDCE9782350BC3BC0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_B0365BFBB001CF51F1E1782350BCE1AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1DFEBED13AF272A115AC782350BD0D5D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_B0365BFBB001CF51F1E1782350BCE1AF" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1DFEBED13AF272A115AC782350BD0D5D" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_NightstarMember" xlink:label="loc_biib_NightstarMember_3A71C35ABBEA5ECEE879782350BD81B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1DFEBED13AF272A115AC782350BD0D5D" xlink:to="loc_biib_NightstarMember_3A71C35ABBEA5ECEE879782350BD81B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_0174231270E2E8593812782350BD89B5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_14A451184C62074FDCE9782350BC3BC0" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_0174231270E2E8593812782350BD89B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_A44DF8604E9ED6619FDD782350BE325E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0174231270E2E8593812782350BD89B5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_A44DF8604E9ED6619FDD782350BE325E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_A7585B52E294B54E4792782350BEB2F6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0174231270E2E8593812782350BD89B5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_A7585B52E294B54E4792782350BEB2F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_FAC9584C471F68E37E46782350BED972" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0174231270E2E8593812782350BD89B5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_FAC9584C471F68E37E46782350BED972" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_0B6C2D8D5A513ABC3F3A782350BE35DF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0174231270E2E8593812782350BD89B5" xlink:to="loc_us-gaap_Goodwill_0B6C2D8D5A513ABC3F3A782350BE35DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_894C4BEA3F0D2B1B3E2E782350BE1743" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0174231270E2E8593812782350BD89B5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_894C4BEA3F0D2B1B3E2E782350BE1743" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_8832D4F36B2A230777F8782350C07FE9" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0174231270E2E8593812782350BD89B5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_8832D4F36B2A230777F8782350C07FE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_DDF20669676AFEBB1BEB782350C000E7" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0174231270E2E8593812782350BD89B5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_DDF20669676AFEBB1BEB782350C000E7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="biib-20200630.xsd#biib_AcquisitionsAbstract" xlink:label="loc_biib_AcquisitionsAbstract_7115317295DFCABFB994782350D9D669" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0BBF42565AA0EC9D63C2782350DAA3AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AcquisitionsAbstract_7115317295DFCABFB994782350D9D669" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0BBF42565AA0EC9D63C2782350DAA3AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_BBDA3025ECEC5225B423782350DACB1D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0BBF42565AA0EC9D63C2782350DAA3AD" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_BBDA3025ECEC5225B423782350DACB1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_F0B553BA419A42AD2D6F782350DA2139" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_BBDA3025ECEC5225B423782350DACB1D" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_F0B553BA419A42AD2D6F782350DA2139" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_7DE50215B6D9C970F0A3782350DB99ED" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0BBF42565AA0EC9D63C2782350DAA3AD" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_7DE50215B6D9C970F0A3782350DB99ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_300CE056FE1C5F26EC10782350DB8A18" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_7DE50215B6D9C970F0A3782350DB99ED" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_300CE056FE1C5F26EC10782350DB8A18" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_PostacquisitionequitycompensationMember" xlink:label="loc_biib_PostacquisitionequitycompensationMember_2E6D2B14D7F53C58278E782350DB861A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_300CE056FE1C5F26EC10782350DB8A18" xlink:to="loc_biib_PostacquisitionequitycompensationMember_2E6D2B14D7F53C58278E782350DB861A" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_ResearchanddevelopmentassetAxis" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_9002F6AAB8E3DA291976782350DC4384" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0BBF42565AA0EC9D63C2782350DAA3AD" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_9002F6AAB8E3DA291976782350DC4384" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_ResearchanddevelopmentassetDomain" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_D41DDDF322DEB18C33A9782350DC703F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_9002F6AAB8E3DA291976782350DC4384" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_D41DDDF322DEB18C33A9782350DC703F" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_BIIB111Member" xlink:label="loc_biib_BIIB111Member_8D01DF0F648B1F8A1D3B782350E2B016" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_D41DDDF322DEB18C33A9782350DC703F" xlink:to="loc_biib_BIIB111Member_8D01DF0F648B1F8A1D3B782350E2B016" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_BIIB112Member" xlink:label="loc_biib_BIIB112Member_BFED354CBA4867EF98E0782350E2C79A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_D41DDDF322DEB18C33A9782350DC703F" xlink:to="loc_biib_BIIB112Member_BFED354CBA4867EF98E0782350E2C79A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_24C5DF4348E0F126DA64782350E26D6A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0BBF42565AA0EC9D63C2782350DAA3AD" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_24C5DF4348E0F126DA64782350E26D6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_713F2297D4260336A0B2782350E28DE6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_24C5DF4348E0F126DA64782350E26D6A" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_713F2297D4260336A0B2782350E28DE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9A051F012069369893FA782350E35EE1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_713F2297D4260336A0B2782350E28DE6" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9A051F012069369893FA782350E35EE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9C21472EEAB39FB5C2AC782350E3F465" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_713F2297D4260336A0B2782350E28DE6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9C21472EEAB39FB5C2AC782350E3F465" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3028B74A071EB334AAE8782350E3547A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0BBF42565AA0EC9D63C2782350DAA3AD" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3028B74A071EB334AAE8782350E3547A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FC87DCE790EAE1525CBC782350E33C5E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3028B74A071EB334AAE8782350E3547A" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FC87DCE790EAE1525CBC782350E33C5E" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_BIIB118Member" xlink:label="loc_biib_BIIB118Member_BB2B3260300404E2B003782350E34811" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FC87DCE790EAE1525CBC782350E33C5E" xlink:to="loc_biib_BIIB118Member_BB2B3260300404E2B003782350E34811" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_NightstarMember" xlink:label="loc_biib_NightstarMember_EFBFCEDA9340DA8D861B782350E499CC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FC87DCE790EAE1525CBC782350E33C5E" xlink:to="loc_biib_NightstarMember_EFBFCEDA9340DA8D861B782350E499CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_B2CE97D5A08D2DBD067C782350E460A8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0BBF42565AA0EC9D63C2782350DAA3AD" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_B2CE97D5A08D2DBD067C782350E460A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_639B8F0337375FEA343B782350E465ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B2CE97D5A08D2DBD067C782350E460A8" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_639B8F0337375FEA343B782350E465ED" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_26EA67CD329EA4A220C1782350E415F2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B2CE97D5A08D2DBD067C782350E460A8" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_26EA67CD329EA4A220C1782350E415F2" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_ClinicalAssetsAcquired" xlink:label="loc_biib_ClinicalAssetsAcquired_685AC76389BD1DF16080782350E5A9AA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B2CE97D5A08D2DBD067C782350E460A8" xlink:to="loc_biib_ClinicalAssetsAcquired_685AC76389BD1DF16080782350E5A9AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_AB118E30A6EDEFD8419E782350E5571B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B2CE97D5A08D2DBD067C782350E460A8" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_AB118E30A6EDEFD8419E782350E5571B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_5DC37589F23788886177782350E50E62" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B2CE97D5A08D2DBD067C782350E460A8" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_5DC37589F23788886177782350E50E62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_E9F9ACC53BE27976805B782350E5509F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B2CE97D5A08D2DBD067C782350E460A8" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_E9F9ACC53BE27976805B782350E5509F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_77BB56DA1C6461D95126782350E54C2D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B2CE97D5A08D2DBD067C782350E460A8" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_77BB56DA1C6461D95126782350E54C2D" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" xlink:label="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_45B0A55B51B4166C45C8782350E5022F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B2CE97D5A08D2DBD067C782350E460A8" xlink:to="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_45B0A55B51B4166C45C8782350E5022F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_10819FD921E3F7242E69782350E665B4" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B2CE97D5A08D2DBD067C782350E460A8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_10819FD921E3F7242E69782350E665B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes" xlink:label="loc_us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes_E4ED798230AFE04B5185782350E6F339" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B2CE97D5A08D2DBD067C782350E460A8" xlink:to="loc_us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes_E4ED798230AFE04B5185782350E6F339" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_EBF47384C3E7DAF90B1E782350E66624" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B2CE97D5A08D2DBD067C782350E460A8" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_EBF47384C3E7DAF90B1E782350E66624" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_573A2AD878C4021E196678234CC76550" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_286E63D60C033A7C192178234CC70529" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_573A2AD878C4021E196678234CC76550" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_286E63D60C033A7C192178234CC70529" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_E5ED29F2FEA52D2507FD78234CAA6691" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E95629B2248593F6A68778234CAA9FFF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_E5ED29F2FEA52D2507FD78234CAA6691" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E95629B2248593F6A68778234CAA9FFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_E36AA0B66DA3B7BC67D878234CAA99ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E95629B2248593F6A68778234CAA9FFF" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_E36AA0B66DA3B7BC67D878234CAA99ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_33D898192847460851D278234CAB3C42" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_E36AA0B66DA3B7BC67D878234CAA99ED" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_33D898192847460851D278234CAB3C42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_02B0295294FAA79A35CA78234CAB0908" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_33D898192847460851D278234CAB3C42" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_02B0295294FAA79A35CA78234CAB0908" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_C0D7E71F5AB10E2D865F78234CAC50F9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_33D898192847460851D278234CAB3C42" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_C0D7E71F5AB10E2D865F78234CAC50F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_518CCF1557AE52DEF03578234CAC3989" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E95629B2248593F6A68778234CAA9FFF" xlink:to="loc_us-gaap_TypeOfArrangementAxis_518CCF1557AE52DEF03578234CAC3989" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_54DCDB522F95FD48A82978234CACA372" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_518CCF1557AE52DEF03578234CAC3989" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_54DCDB522F95FD48A82978234CACA372" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_B884123653B1BEDDCB4178234CAC195F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_54DCDB522F95FD48A82978234CACA372" xlink:to="loc_us-gaap_CollaborativeArrangementMember_B884123653B1BEDDCB4178234CAC195F" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_7F7A55DA29F1AAC28D7C78234CAD44B4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_54DCDB522F95FD48A82978234CACA372" xlink:to="loc_biib_EisaiMember_7F7A55DA29F1AAC28D7C78234CAD44B4" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_UCBPharmaS.A.Member" xlink:label="loc_biib_UCBPharmaS.A.Member_3ECCBC0A530B9C8DDBFF78234CAD9A77" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_54DCDB522F95FD48A82978234CACA372" xlink:to="loc_biib_UCBPharmaS.A.Member_3ECCBC0A530B9C8DDBFF78234CAD9A77" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_SangamoTherapeuticsInc.AgreementMember" xlink:label="loc_biib_SangamoTherapeuticsInc.AgreementMember_9CBA4D34379B08423D4778234CAD472A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_54DCDB522F95FD48A82978234CACA372" xlink:to="loc_biib_SangamoTherapeuticsInc.AgreementMember_9CBA4D34379B08423D4778234CAD472A" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_SkyhawkTherapeuticsMember" xlink:label="loc_biib_SkyhawkTherapeuticsMember_48205DB4AEB0E05465E078234CAE62BB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_54DCDB522F95FD48A82978234CACA372" xlink:to="loc_biib_SkyhawkTherapeuticsMember_48205DB4AEB0E05465E078234CAE62BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_7A5753EFD3E1EAD0AA8A78234CAEFC47" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E95629B2248593F6A68778234CAA9FFF" xlink:to="loc_srt_ProductOrServiceAxis_7A5753EFD3E1EAD0AA8A78234CAEFC47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_0DFDD396DF3F64B29F2C78234CAEBE0D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_7A5753EFD3E1EAD0AA8A78234CAEFC47" xlink:to="loc_srt_ProductsAndServicesDomain_0DFDD396DF3F64B29F2C78234CAEBE0D" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_BAN2401Member" xlink:label="loc_biib_BAN2401Member_37178110933FB79EBF8578234CAF3051" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0DFDD396DF3F64B29F2C78234CAEBE0D" xlink:to="loc_biib_BAN2401Member_37178110933FB79EBF8578234CAF3051" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_E2609andBAN2401Member" xlink:label="loc_biib_E2609andBAN2401Member_65AC9F5AB74DA0D07D9C78234CAF6D54" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0DFDD396DF3F64B29F2C78234CAEBE0D" xlink:to="loc_biib_E2609andBAN2401Member_65AC9F5AB74DA0D07D9C78234CAF6D54" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_AducanumabMember" xlink:label="loc_biib_AducanumabMember_DCA88A5C2015E746BB7778234CAF383F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0DFDD396DF3F64B29F2C78234CAEBE0D" xlink:to="loc_biib_AducanumabMember_DCA88A5C2015E746BB7778234CAF383F" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_ElenbecestatCollaborationMember" xlink:label="loc_biib_ElenbecestatCollaborationMember_74121E51F7DB72C8E53278234CAFA5F8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0DFDD396DF3F64B29F2C78234CAEBE0D" xlink:to="loc_biib_ElenbecestatCollaborationMember_74121E51F7DB72C8E53278234CAFA5F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4464930A5FA4A0C496FA78234CB05032" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E95629B2248593F6A68778234CAA9FFF" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4464930A5FA4A0C496FA78234CB05032" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_056FA1AF280C89B68B3A78234CB0CD52" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4464930A5FA4A0C496FA78234CB05032" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_056FA1AF280C89B68B3A78234CB0CD52" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_GlobalLicensingCollaborationAgreementSharesPurchased" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased_0F65951261F6CE1156CC78234CB0D6E0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4464930A5FA4A0C496FA78234CB05032" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased_0F65951261F6CE1156CC78234CB0D6E0" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_5B539463605B32B2BD1078234CB14E4E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4464930A5FA4A0C496FA78234CB05032" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_5B539463605B32B2BD1078234CB14E4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_FB91B18EBECE2C2CD2C978234CB12018" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4464930A5FA4A0C496FA78234CB05032" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_FB91B18EBECE2C2CD2C978234CB12018" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_ExpenseIncurredByCollaboration" xlink:label="loc_biib_ExpenseIncurredByCollaboration_60AFEEDBEDC149F9B33278234CB172C8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4464930A5FA4A0C496FA78234CB05032" xlink:to="loc_biib_ExpenseIncurredByCollaboration_60AFEEDBEDC149F9B33278234CB172C8" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_Expenseincurredbythecollaboration" xlink:label="loc_biib_Expenseincurredbythecollaboration_BFC4B73BA1EB20C085D278234CB18C22" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4464930A5FA4A0C496FA78234CB05032" xlink:to="loc_biib_Expenseincurredbythecollaboration_BFC4B73BA1EB20C085D278234CB18C22" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_Expensereflectedwithinstatementsofincome" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_47713B5CDB8D6BFAB87A78234CB12ECA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4464930A5FA4A0C496FA78234CB05032" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_47713B5CDB8D6BFAB87A78234CB12ECA" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_63EA8FCB1B4AB84BAF2B78234CB27734" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4464930A5FA4A0C496FA78234CB05032" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_63EA8FCB1B4AB84BAF2B78234CB27734" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossOnContractTermination" xlink:label="loc_us-gaap_LossOnContractTermination_7303D0AE4A0E156D688178234CB20C74" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4464930A5FA4A0C496FA78234CB05032" xlink:to="loc_us-gaap_LossOnContractTermination_7303D0AE4A0E156D688178234CB20C74" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_AdditionalMilestonePayment" xlink:label="loc_biib_AdditionalMilestonePayment_95379413D215DC9DF6DD78234CB2BA35" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4464930A5FA4A0C496FA78234CB05032" xlink:to="loc_biib_AdditionalMilestonePayment_95379413D215DC9DF6DD78234CB2BA35" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_51B19001977A5097152F78234CB3DA7F" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4464930A5FA4A0C496FA78234CB05032" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_51B19001977A5097152F78234CB3DA7F" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_AF216D8E00EA84F6152D78234CB3B70C" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4464930A5FA4A0C496FA78234CB05032" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_AF216D8E00EA84F6152D78234CB3B70C" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_D6ED035F3464AA34FB7878234CB36C98" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4464930A5FA4A0C496FA78234CB05032" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_D6ED035F3464AA34FB7878234CB36C98" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_090993B1D0085E2F3FE978234CB3781D" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4464930A5FA4A0C496FA78234CB05032" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_090993B1D0085E2F3FE978234CB3781D" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_5C9F3C5326D924C49A7778234CB38FB2" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4464930A5FA4A0C496FA78234CB05032" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_5C9F3C5326D924C49A7778234CB38FB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_DB747F9E67825269E10B78234CB4BFC0" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4464930A5FA4A0C496FA78234CB05032" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_DB747F9E67825269E10B78234CB4BFC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_3B3443D51C1255B7549978234CB4FF9E" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4464930A5FA4A0C496FA78234CB05032" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_3B3443D51C1255B7549978234CB4FF9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3A48EFF3B3CB3CD550CA78234CB488C9" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4464930A5FA4A0C496FA78234CB05032" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3A48EFF3B3CB3CD550CA78234CB488C9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9FEF8CA3D5EA705D94DB78234C866E87" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_EEE0A95002C59E544E1C78234C8642BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9FEF8CA3D5EA705D94DB78234C866E87" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_EEE0A95002C59E544E1C78234C8642BD" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis" xlink:label="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_4CF6482C0801C5404D2278234C8755CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_EEE0A95002C59E544E1C78234C8642BD" xlink:to="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_4CF6482C0801C5404D2278234C8755CC" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain" xlink:label="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_455CC69D14FA9276DA2978234C87E74C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_4CF6482C0801C5404D2278234C8755CC" xlink:to="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_455CC69D14FA9276DA2978234C87E74C" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_55BEB725F7A030109D2278234C87A0B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_455CC69D14FA9276DA2978234C87E74C" xlink:to="loc_biib_NeurimmuneMember_55BEB725F7A030109D2278234C87A0B6" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_FutureContingentMilestoneTypesAxis" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_DC3E0BE5CD3013926A7978234C8896D2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_EEE0A95002C59E544E1C78234C8642BD" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_DC3E0BE5CD3013926A7978234C8896D2" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_FutureContingentMilestoneTypesDomain" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_A0EA74BD8B756E18784478234C88BB79" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_DC3E0BE5CD3013926A7978234C8896D2" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_A0EA74BD8B756E18784478234C88BB79" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_RegulatoryMilestonesMember" xlink:label="loc_biib_RegulatoryMilestonesMember_418296B0FE1A9A1B6C8E78234C891965" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_A0EA74BD8B756E18784478234C88BB79" xlink:to="loc_biib_RegulatoryMilestonesMember_418296B0FE1A9A1B6C8E78234C891965" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_2BDE7D12A8A4E97EAAF178234C89D1BC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_EEE0A95002C59E544E1C78234C8642BD" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_2BDE7D12A8A4E97EAAF178234C89D1BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7EE240512CE9498361D378234C8960D8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_2BDE7D12A8A4E97EAAF178234C89D1BC" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7EE240512CE9498361D378234C8960D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoriesMember" xlink:label="loc_us-gaap_InventoriesMember_5F168DF5FB67E7FCE6D978234C8A2EF5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7EE240512CE9498361D378234C8960D8" xlink:to="loc_us-gaap_InventoriesMember_5F168DF5FB67E7FCE6D978234C8A2EF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_1D80D2B4AAB3B0B54D1778234C8AD026" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7EE240512CE9498361D378234C8960D8" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_1D80D2B4AAB3B0B54D1778234C8AD026" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_4C3FB95D0946B03282A878234C8AAAF4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7EE240512CE9498361D378234C8960D8" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_4C3FB95D0946B03282A878234C8AAAF4" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_DeferredtaxliabilityMember" xlink:label="loc_biib_DeferredtaxliabilityMember_12A5258510BB1EE2875878234C8B5C5F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7EE240512CE9498361D378234C8960D8" xlink:to="loc_biib_DeferredtaxliabilityMember_12A5258510BB1EE2875878234C8B5C5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_EE8F18C22036BAFE45AC78234C8BFC48" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_EEE0A95002C59E544E1C78234C8642BD" xlink:to="loc_us-gaap_TypeOfArrangementAxis_EE8F18C22036BAFE45AC78234C8BFC48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A566A6A9256EA3C7DABC78234C8B819A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_EE8F18C22036BAFE45AC78234C8BFC48" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A566A6A9256EA3C7DABC78234C8B819A" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_B630F74C79689CD5A17178234C8B28D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A566A6A9256EA3C7DABC78234C8B819A" xlink:to="loc_biib_EisaiMember_B630F74C79689CD5A17178234C8B28D5" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_1CD84A1414BE2B1DFFC078234C8CD0FF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A566A6A9256EA3C7DABC78234C8B819A" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_1CD84A1414BE2B1DFFC078234C8CD0FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_5581B1A20D328283100278234C8C5A09" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A566A6A9256EA3C7DABC78234C8B819A" xlink:to="loc_us-gaap_CollaborativeArrangementMember_5581B1A20D328283100278234C8C5A09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_94FDF0C13470CC5D4B2578234C8C45EA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_EEE0A95002C59E544E1C78234C8642BD" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_94FDF0C13470CC5D4B2578234C8C45EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_A5E83044FCDFDF13B83178234C8C707D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_94FDF0C13470CC5D4B2578234C8C45EA" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_A5E83044FCDFDF13B83178234C8C707D" xlink:type="arc" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_A5E83044FCDFDF13B83178234C8C707D" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_1CD84A1414BE2B1DFFC078234C8CD0FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_EEE0A95002C59E544E1C78234C8642BD" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_75962CEFC8C28192F6F678234C8E4844" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_75962CEFC8C28192F6F678234C8E4844" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossOnContractTermination" xlink:label="loc_us-gaap_LossOnContractTermination_8E374C95FBD3C30FE44478234C8E46E4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:to="loc_us-gaap_LossOnContractTermination_8E374C95FBD3C30FE44478234C8E46E4" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_BD6F9407FEFB5980989D78234C8E3E73" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_BD6F9407FEFB5980989D78234C8E3E73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_06BE162523B1AA84B96A78234C8EC2CE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_06BE162523B1AA84B96A78234C8EC2CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_79EF885BABD225D31E4F78234C8FC07F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_79EF885BABD225D31E4F78234C8FC07F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_A100835F1C9274AF719F78234C8FF226" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:to="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_A100835F1C9274AF719F78234C8FF226" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:label="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_BF9C9930C2BBE26E863F78234C8F46E1" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:to="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_BF9C9930C2BBE26E863F78234C8F46E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_FBFDA60EB09D36DDE48A78234C90BE0C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_FBFDA60EB09D36DDE48A78234C90BE0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_8C9FA2C5B20E16916A6E78234C90052F" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_8C9FA2C5B20E16916A6E78234C90052F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_C351022395FAB2B91D0278234C90CA27" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:to="loc_us-gaap_AdjustmentForAmortization_C351022395FAB2B91D0278234C90CA27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_BF220C7FDA1C71CE697278234C90F83C" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:to="loc_us-gaap_EquityMethodInvestments_BF220C7FDA1C71CE697278234C90F83C" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_C0A97022117C19ECD9A778234C904D7F" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_C0A97022117C19ECD9A778234C904D7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_10C680ACEBA8FFFD13A978234C913001" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_10C680ACEBA8FFFD13A978234C913001" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_6E8969EAD3AEBD04C77078234C918C80" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_6E8969EAD3AEBD04C77078234C918C80" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_1CBE683251F50EFFDCF578234C9194E3" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_1CBE683251F50EFFDCF578234C9194E3" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_AdditionalMilestonePayment" xlink:label="loc_biib_AdditionalMilestonePayment_0D4E007AB8D594882C4B78234C92986C" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:to="loc_biib_AdditionalMilestonePayment_0D4E007AB8D594882C4B78234C92986C" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_ContractOptionExerciseFee" xlink:label="loc_biib_ContractOptionExerciseFee_F12106C9EE31C577326878234C92ED45" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:to="loc_biib_ContractOptionExerciseFee_F12106C9EE31C577326878234C92ED45" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_Biogenshareofcopromotionprofitsorlosses" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_F58404A65AE38FB9B2D278234C92BC27" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:to="loc_biib_Biogenshareofcopromotionprofitsorlosses_F58404A65AE38FB9B2D278234C92BC27" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_1B53296873C0A341240578234C92EB86" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:to="loc_biib_Collaborationprofitlosssharing_1B53296873C0A341240578234C92EB86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_BD144C319E9C5710EAD178234C93CE55" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:to="loc_us-gaap_Revenues_BD144C319E9C5710EAD178234C93CE55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:label="loc_us-gaap_DueFromRelatedParties_3C802D67F2CF8CBA5FFB78234C93D32D" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:to="loc_us-gaap_DueFromRelatedParties_3C802D67F2CF8CBA5FFB78234C93D32D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_8AC991F3D79317FC434778234C93A91A" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D92C5A57FD976945D79678234C8DA157" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_8AC991F3D79317FC434778234C93A91A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_F3CAC8CD741EAB3E8A8778234CC137B8" xlink:type="locator" />
    <link:loc xlink:href="biib-20200630.xsd#biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:label="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_3E4786465235312F7A2A78234CC266FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_F3CAC8CD741EAB3E8A8778234CC137B8" xlink:to="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_3E4786465235312F7A2A78234CC266FE" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:label="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_5BCB7FAF346978F0436278234CC2D7D6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_F3CAC8CD741EAB3E8A8778234CC137B8" xlink:to="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_5BCB7FAF346978F0436278234CC2D7D6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0775F8FC6FF614ED968C78235192EB75" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_2E12A34D243F3EA646F678235192E455" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0775F8FC6FF614ED968C78235192EB75" xlink:to="loc_us-gaap_AssetsAbstract_2E12A34D243F3EA646F678235192E455" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_0089B509A9835C1C248A7823519295CA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2E12A34D243F3EA646F678235192E455" xlink:to="loc_us-gaap_AssetsCurrentAbstract_0089B509A9835C1C248A7823519295CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4F097E1F7A1DA8308459782351933FB5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0089B509A9835C1C248A7823519295CA" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4F097E1F7A1DA8308459782351933FB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_203313ED2A0FD526D110782351936A9C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0089B509A9835C1C248A7823519295CA" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_203313ED2A0FD526D110782351936A9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_2853097147B4726F507C7823519371FA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0089B509A9835C1C248A7823519295CA" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_2853097147B4726F507C7823519371FA" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_DuefromantiCD20therapeuticprograms" xlink:label="loc_biib_DuefromantiCD20therapeuticprograms_77463FD28C6F4E46B3B6782351933ECD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0089B509A9835C1C248A7823519295CA" xlink:to="loc_biib_DuefromantiCD20therapeuticprograms_77463FD28C6F4E46B3B6782351933ECD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_E513A03BB2C3EF7025CD782351947A51" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0089B509A9835C1C248A7823519295CA" xlink:to="loc_us-gaap_InventoryNet_E513A03BB2C3EF7025CD782351947A51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_A393D32C748AABDDBDB178235194286E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0089B509A9835C1C248A7823519295CA" xlink:to="loc_us-gaap_OtherAssetsCurrent_A393D32C748AABDDBDB178235194286E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_48F463688E59BDE96575782351948AAA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0089B509A9835C1C248A7823519295CA" xlink:to="loc_us-gaap_AssetsCurrent_48F463688E59BDE96575782351948AAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_720B4CA84798DAF44C1A78235194BE09" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2E12A34D243F3EA646F678235192E455" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_720B4CA84798DAF44C1A78235194BE09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_D30E63F0C399A5F0D91578235194BF49" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2E12A34D243F3EA646F678235192E455" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_D30E63F0C399A5F0D91578235194BF49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_E25701BA8B984DCC3488782351942BC9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2E12A34D243F3EA646F678235192E455" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_E25701BA8B984DCC3488782351942BC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_BF80855F6086D3135BF478235195F15F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2E12A34D243F3EA646F678235192E455" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_BF80855F6086D3135BF478235195F15F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_20E2CE0B4A0CB347C10478235195EC3D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2E12A34D243F3EA646F678235192E455" xlink:to="loc_us-gaap_Goodwill_20E2CE0B4A0CB347C10478235195EC3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_FF157EE2519111598F6D782351959CD1" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2E12A34D243F3EA646F678235192E455" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_FF157EE2519111598F6D782351959CD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_3E801507B33011D3422878235195BC85" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2E12A34D243F3EA646F678235192E455" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_3E801507B33011D3422878235195BC85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_83074B4B378429A052AE78235195C9B1" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2E12A34D243F3EA646F678235192E455" xlink:to="loc_us-gaap_Assets_83074B4B378429A052AE78235195C9B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_AFA7D521207D63179DFB78235196EAB6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0775F8FC6FF614ED968C78235192EB75" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_AFA7D521207D63179DFB78235196EAB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_CF74FD575911657CFF9A78235196A379" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_AFA7D521207D63179DFB78235196EAB6" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_CF74FD575911657CFF9A78235196A379" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_1C6CF9DF265F866F197578235196A003" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_CF74FD575911657CFF9A78235196A379" xlink:to="loc_us-gaap_NotesPayableCurrent_1C6CF9DF265F866F197578235196A003" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_6203D82FD3D69574DB1A78235198F95B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_CF74FD575911657CFF9A78235196A379" xlink:to="loc_us-gaap_TaxesPayableCurrent_6203D82FD3D69574DB1A78235198F95B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_E4084FC566113F5C952D782351982061" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_CF74FD575911657CFF9A78235196A379" xlink:to="loc_us-gaap_AccountsPayableCurrent_E4084FC566113F5C952D782351982061" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_34E472D9622FD097DF4D78235198E087" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_CF74FD575911657CFF9A78235196A379" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_34E472D9622FD097DF4D78235198E087" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_D0D206B911D88001273D7823519880B5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_CF74FD575911657CFF9A78235196A379" xlink:to="loc_us-gaap_LiabilitiesCurrent_D0D206B911D88001273D7823519880B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_2ECB5FA97079C64874907823519907D3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_AFA7D521207D63179DFB78235196EAB6" xlink:to="loc_us-gaap_LongTermDebt_2ECB5FA97079C64874907823519907D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_CFF2F0EB3CF69F590F0E78235199E7C4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_AFA7D521207D63179DFB78235196EAB6" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_CFF2F0EB3CF69F590F0E78235199E7C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4C23CE652C71A6517C6A78235199CB6B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_AFA7D521207D63179DFB78235196EAB6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4C23CE652C71A6517C6A78235199CB6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_3561F5F376AB3651F1AA782351992917" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_AFA7D521207D63179DFB78235196EAB6" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_3561F5F376AB3651F1AA782351992917" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_28E5A1447CA8E8B217A97823519AB673" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_AFA7D521207D63179DFB78235196EAB6" xlink:to="loc_us-gaap_Liabilities_28E5A1447CA8E8B217A97823519AB673" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_26410DF393ABBCE576B37823519AC03A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_AFA7D521207D63179DFB78235196EAB6" xlink:to="loc_us-gaap_CommitmentsAndContingencies_26410DF393ABBCE576B37823519AC03A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_E5E574E9668ED87761717823519A8AA6" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_AFA7D521207D63179DFB78235196EAB6" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_E5E574E9668ED87761717823519A8AA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_1976DCA743349BAEAAC47823519A43F3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_E5E574E9668ED87761717823519A8AA6" xlink:to="loc_us-gaap_StockholdersEquityAbstract_1976DCA743349BAEAAC47823519A43F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_6CA0506ACFE100395EC17823519BCA34" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1976DCA743349BAEAAC47823519A43F3" xlink:to="loc_us-gaap_PreferredStockValue_6CA0506ACFE100395EC17823519BCA34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_1C65CC6440AFF75E9F9C7823519B9BB0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1976DCA743349BAEAAC47823519A43F3" xlink:to="loc_us-gaap_CommonStockValue_1C65CC6440AFF75E9F9C7823519B9BB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_2E2338D82907D8822D997823519BB0E2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1976DCA743349BAEAAC47823519A43F3" xlink:to="loc_us-gaap_AdditionalPaidInCapital_2E2338D82907D8822D997823519BB0E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_85111000B16B719AD4C17823519C1A66" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1976DCA743349BAEAAC47823519A43F3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_85111000B16B719AD4C17823519C1A66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_E4DD4C8C900718C6E7B67823519C9D1F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1976DCA743349BAEAAC47823519A43F3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_E4DD4C8C900718C6E7B67823519C9D1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_E369DF2185277011179C7823519C47BC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1976DCA743349BAEAAC47823519A43F3" xlink:to="loc_us-gaap_TreasuryStockValue_E369DF2185277011179C7823519C47BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_EF1D6A22361F0A82D8B27823519CEF49" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1976DCA743349BAEAAC47823519A43F3" xlink:to="loc_us-gaap_StockholdersEquity_EF1D6A22361F0A82D8B27823519CEF49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_DD4822EA8044E65A949E7823519C9AB2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_E5E574E9668ED87761717823519A8AA6" xlink:to="loc_us-gaap_MinorityInterest_DD4822EA8044E65A949E7823519C9AB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_649496B00489DBA788447823519D93BA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_E5E574E9668ED87761717823519A8AA6" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_649496B00489DBA788447823519D93BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_C4C25B858EA1E7AB2FAD7823519DF38B" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_AFA7D521207D63179DFB78235196EAB6" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_C4C25B858EA1E7AB2FAD7823519DF38B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_E5692414FB18F0DA3F607823517ECAD6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3D93FB16BE6FC36F69497823517E86CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_E5692414FB18F0DA3F607823517ECAD6" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3D93FB16BE6FC36F69497823517E86CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_BA41F1B69532A0025EFF7823517FF741" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_E5692414FB18F0DA3F607823517ECAD6" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_BA41F1B69532A0025EFF7823517FF741" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_60131484ECA7EA170F2A7823511CFBE4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_70DAABF87FEF5654563C7823511CEEE6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_60131484ECA7EA170F2A7823511CFBE4" xlink:to="loc_us-gaap_StatementTable_70DAABF87FEF5654563C7823511CEEE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_178B88E1DB142917608C7823511CFFC9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_70DAABF87FEF5654563C7823511CEEE6" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_178B88E1DB142917608C7823511CFFC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_00DB7B71C21A4F2802D77823511D8D36" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_178B88E1DB142917608C7823511CFFC9" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_00DB7B71C21A4F2802D77823511D8D36" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_A2018ShareRepurchaseProgramMember" xlink:label="loc_biib_A2018ShareRepurchaseProgramMember_EE146F8553BED99807F27823511D3088" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_00DB7B71C21A4F2802D77823511D8D36" xlink:to="loc_biib_A2018ShareRepurchaseProgramMember_EE146F8553BED99807F27823511D3088" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_March2019ShareRepurchaseProgramMember" xlink:label="loc_biib_March2019ShareRepurchaseProgramMember_EAD5CCCE0BF3E10FF8BA7823511DBDC9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_00DB7B71C21A4F2802D77823511D8D36" xlink:to="loc_biib_March2019ShareRepurchaseProgramMember_EAD5CCCE0BF3E10FF8BA7823511DBDC9" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_December2019ShareRepurchaseProgramMember" xlink:label="loc_biib_December2019ShareRepurchaseProgramMember_1BFCEEBE871668C403EB7823511D1327" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_00DB7B71C21A4F2802D77823511D8D36" xlink:to="loc_biib_December2019ShareRepurchaseProgramMember_1BFCEEBE871668C403EB7823511D1327" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_D135A3D03D323A062B657823511ED147" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_70DAABF87FEF5654563C7823511CEEE6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_D135A3D03D323A062B657823511ED147" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_62DB2D2A048A861B6DC97823511EF56D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_D135A3D03D323A062B657823511ED147" xlink:to="loc_us-gaap_EquityComponentDomain_62DB2D2A048A861B6DC97823511EF56D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_9A5E9BCC18E85BA800017823511EF6D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_62DB2D2A048A861B6DC97823511EF56D" xlink:to="loc_us-gaap_PreferredStockMember_9A5E9BCC18E85BA800017823511EF6D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_9A02F2606FE9FA3D62E17823511ED5E8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_62DB2D2A048A861B6DC97823511EF56D" xlink:to="loc_us-gaap_CommonStockMember_9A02F2606FE9FA3D62E17823511ED5E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_8D702908B37DD60672887823511F115B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_62DB2D2A048A861B6DC97823511EF56D" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_8D702908B37DD60672887823511F115B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_538EE9CD30F92B34400D7823511FAB38" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_62DB2D2A048A861B6DC97823511EF56D" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_538EE9CD30F92B34400D7823511FAB38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_D5F236A3921E54B423267823511F847F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_62DB2D2A048A861B6DC97823511EF56D" xlink:to="loc_us-gaap_RetainedEarningsMember_D5F236A3921E54B423267823511F847F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_39439E99533987D9ACD77823511FF754" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_62DB2D2A048A861B6DC97823511EF56D" xlink:to="loc_us-gaap_TreasuryStockMember_39439E99533987D9ACD77823511FF754" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_7853BED506E45BB8D16A7823511F14E1" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_62DB2D2A048A861B6DC97823511EF56D" xlink:to="loc_us-gaap_ParentMember_7853BED506E45BB8D16A7823511F14E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_69D71AD174CF4B7C36C57823512080F7" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_62DB2D2A048A861B6DC97823511EF56D" xlink:to="loc_us-gaap_NoncontrollingInterestMember_69D71AD174CF4B7C36C57823512080F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_957572840CDDA096E76878235120F3C5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_70DAABF87FEF5654563C7823511CEEE6" xlink:to="loc_us-gaap_StatementLineItems_957572840CDDA096E76878235120F3C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_EF4DC88ACD9C6204A0EE78235120B695" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_957572840CDDA096E76878235120F3C5" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_EF4DC88ACD9C6204A0EE78235120B695" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_EB3A034F29ABF71FE33A7823512035BA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_957572840CDDA096E76878235120F3C5" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_EB3A034F29ABF71FE33A7823512035BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_19C8ACB3CBB3416804E178235120BA76" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_957572840CDDA096E76878235120F3C5" xlink:to="loc_us-gaap_ProfitLoss_19C8ACB3CBB3416804E178235120BA76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_220F5C0DB02AD87D5E3378235121F853" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_957572840CDDA096E76878235120F3C5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_220F5C0DB02AD87D5E3378235121F853" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_Noncontrollinginterestincreasedecreaseother" xlink:label="loc_biib_Noncontrollinginterestincreasedecreaseother_6D5A481FC4FD866F4A347823512193C5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_957572840CDDA096E76878235120F3C5" xlink:to="loc_biib_Noncontrollinginterestincreasedecreaseother_6D5A481FC4FD866F4A347823512193C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_8DDAA4FB742F1237514C78235121CBDA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_957572840CDDA096E76878235120F3C5" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_8DDAA4FB742F1237514C78235121CBDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_AFAA38B4AA5F3621768878235121B717" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_957572840CDDA096E76878235120F3C5" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_AFAA38B4AA5F3621768878235121B717" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_6E485DA19AB1E20C08DA78235121BDCE" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_957572840CDDA096E76878235120F3C5" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_6E485DA19AB1E20C08DA78235121BDCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_94E49B5419A1DAAF354B78235122EB53" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_957572840CDDA096E76878235120F3C5" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_94E49B5419A1DAAF354B78235122EB53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_0C601092D381D7E1983278235122F01E" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_957572840CDDA096E76878235120F3C5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_0C601092D381D7E1983278235122F01E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_CEDEDC0D3B62A5957FD5782351224795" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_957572840CDDA096E76878235120F3C5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_CEDEDC0D3B62A5957FD5782351224795" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A6CB225701219883EE46782351229ABB" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_957572840CDDA096E76878235120F3C5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A6CB225701219883EE46782351229ABB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_A83A37D347FEC1E2BAAA7823512203CC" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_957572840CDDA096E76878235120F3C5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_A83A37D347FEC1E2BAAA7823512203CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3E2DFA80EC1E0E3FF3AB782351221926" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_957572840CDDA096E76878235120F3C5" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3E2DFA80EC1E0E3FF3AB782351221926" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityOther" xlink:label="loc_us-gaap_StockholdersEquityOther_3507E97545FAA4043C1078235124FC78" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_957572840CDDA096E76878235120F3C5" xlink:to="loc_us-gaap_StockholdersEquityOther_3507E97545FAA4043C1078235124FC78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_77FB0C604D1BC439085878235124D6BB" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_957572840CDDA096E76878235120F3C5" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_77FB0C604D1BC439085878235124D6BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_566ADE11023F7B3F3CA5782351249E37" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_957572840CDDA096E76878235120F3C5" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_566ADE11023F7B3F3CA5782351249E37" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_6727B3AC6D6C03124973782351679914" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CD9285F42E8EC36AEF22782351677FC9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6727B3AC6D6C03124973782351679914" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CD9285F42E8EC36AEF22782351677FC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_1665B328D4CA7089FBE57823516865EC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CD9285F42E8EC36AEF22782351677FC9" xlink:to="loc_us-gaap_ProfitLoss_1665B328D4CA7089FBE57823516865EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C6A8341087E9C433E55978235168C2A7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_CD9285F42E8EC36AEF22782351677FC9" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C6A8341087E9C433E55978235168C2A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_6E3F0604724C218A644378235168504C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C6A8341087E9C433E55978235168C2A7" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_6E3F0604724C218A644378235168504C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_0D8A557FDFE2FBB015EA782351699681" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C6A8341087E9C433E55978235168C2A7" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_0D8A557FDFE2FBB015EA782351699681" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_D175F5EAA4B7AFD247DD78235169D7D9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C6A8341087E9C433E55978235168C2A7" xlink:to="loc_us-gaap_ShareBasedCompensation_D175F5EAA4B7AFD247DD78235169D7D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_8B427F967E47596BA45378235169BE6A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C6A8341087E9C433E55978235168C2A7" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_8B427F967E47596BA45378235169BE6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_255D526364A6D28D7FC178235169FEA5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C6A8341087E9C433E55978235168C2A7" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_255D526364A6D28D7FC178235169FEA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax" xlink:label="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_E86856C2BD3F3C4A3AB87823516AE854" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C6A8341087E9C433E55978235168C2A7" xlink:to="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_E86856C2BD3F3C4A3AB87823516AE854" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_06E66123B12C7F63F3A97823516AF0CA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C6A8341087E9C433E55978235168C2A7" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_06E66123B12C7F63F3A97823516AF0CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_E53F0543F371312575F07823516A30E5" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C6A8341087E9C433E55978235168C2A7" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_E53F0543F371312575F07823516A30E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_7F4CEA0B4DC401B628E77823516A9D9D" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C6A8341087E9C433E55978235168C2A7" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_7F4CEA0B4DC401B628E77823516A9D9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_90D2C31860240D8F50FC7823516B119A" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C6A8341087E9C433E55978235168C2A7" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_90D2C31860240D8F50FC7823516B119A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_37F41B5A11331F09C1307823516B3DCE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_90D2C31860240D8F50FC7823516B119A" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_37F41B5A11331F09C1307823516B3DCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_25A9E044A4B0DDF591C57823516B14D7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_90D2C31860240D8F50FC7823516B119A" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_25A9E044A4B0DDF591C57823516B14D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_4667E79733484CCCBF357823516CE513" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_90D2C31860240D8F50FC7823516B119A" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_4667E79733484CCCBF357823516CE513" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_70D8D3746F81E13579907823516CB334" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_90D2C31860240D8F50FC7823516B119A" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_70D8D3746F81E13579907823516CB334" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_BBC80044672B56B611067823516C0435" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_90D2C31860240D8F50FC7823516B119A" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_BBC80044672B56B611067823516C0435" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_2BB6DE0683B4F71883917823516C31AD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_90D2C31860240D8F50FC7823516B119A" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_2BB6DE0683B4F71883917823516C31AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_59FF35B4699C3F47E8D37823516C74D1" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_C6A8341087E9C433E55978235168C2A7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_59FF35B4699C3F47E8D37823516C74D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5C780123B870B7B166657823516D6B5B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6727B3AC6D6C03124973782351679914" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5C780123B870B7B166657823516D6B5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_6EFD8B632B3746DCC9847823516D17BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5C780123B870B7B166657823516D6B5B" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_6EFD8B632B3746DCC9847823516D17BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_C8733B5DF681F1EC9ACF7823516DC605" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5C780123B870B7B166657823516D6B5B" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_C8733B5DF681F1EC9ACF7823516DC605" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_AF74F79A051C8C6929357823516D4720" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5C780123B870B7B166657823516D6B5B" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_AF74F79A051C8C6929357823516D4720" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0A3896F80096EEBF6B5F7823516EFEAA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5C780123B870B7B166657823516D6B5B" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0A3896F80096EEBF6B5F7823516EFEAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_EF0F30874AF699A24F0A7823516E2D89" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5C780123B870B7B166657823516D6B5B" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_EF0F30874AF699A24F0A7823516E2D89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_A4B36EBA623D77D12B767823516E41C3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5C780123B870B7B166657823516D6B5B" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_A4B36EBA623D77D12B767823516E41C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_3AEBA59AF97A5EAC3AE07823516E48CF" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5C780123B870B7B166657823516D6B5B" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_3AEBA59AF97A5EAC3AE07823516E48CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_7D5992122B41D913EA947823516E7D7A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5C780123B870B7B166657823516D6B5B" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_7D5992122B41D913EA947823516E7D7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromHedgeInvestingActivities" xlink:label="loc_us-gaap_ProceedsFromHedgeInvestingActivities_F03212AB8C470DAF262B7823516F46A8" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5C780123B870B7B166657823516D6B5B" xlink:to="loc_us-gaap_ProceedsFromHedgeInvestingActivities_F03212AB8C470DAF262B7823516F46A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_99D0560DC79F9251B3FD7823516F37AB" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5C780123B870B7B166657823516D6B5B" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_99D0560DC79F9251B3FD7823516F37AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_7EB1E062E461DA7138B47823516F4796" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5C780123B870B7B166657823516D6B5B" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_7EB1E062E461DA7138B47823516F4796" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_65DFF159700C0E6163D27823516F5CEE" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5C780123B870B7B166657823516D6B5B" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_65DFF159700C0E6163D27823516F5CEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_E2D2651CB3BE8079C0757823517071CE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6727B3AC6D6C03124973782351679914" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_E2D2651CB3BE8079C0757823517071CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_83A617FFB8842F8DF7247823517056CB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_E2D2651CB3BE8079C0757823517071CE" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_83A617FFB8842F8DF7247823517056CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_073FF249301A989BD46378235170B54C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_E2D2651CB3BE8079C0757823517071CE" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_073FF249301A989BD46378235170B54C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_A5084055B2A93DB1871478235170EA52" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_E2D2651CB3BE8079C0757823517071CE" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_A5084055B2A93DB1871478235170EA52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_0C4F3AEFC7AEDF33931E782351703947" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_E2D2651CB3BE8079C0757823517071CE" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_0C4F3AEFC7AEDF33931E782351703947" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities_22726CB314369CA2EB5F7823517179E8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_E2D2651CB3BE8079C0757823517071CE" xlink:to="loc_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities_22726CB314369CA2EB5F7823517179E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_05DD362BCB89546C54E1782351711325" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_E2D2651CB3BE8079C0757823517071CE" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_05DD362BCB89546C54E1782351711325" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9EB4A9ABFB48DDB2AF6978235171421D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_E2D2651CB3BE8079C0757823517071CE" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9EB4A9ABFB48DDB2AF6978235171421D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6AEDB107E3194CF180D578235171AEDB" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_E2D2651CB3BE8079C0757823517071CE" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6AEDB107E3194CF180D578235171AEDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_E5261EDDC5C84A5FD7EE7823517156C6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6727B3AC6D6C03124973782351679914" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_E5261EDDC5C84A5FD7EE7823517156C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_13EF7C27707B7CD62A4C78235171B6CF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6727B3AC6D6C03124973782351679914" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_13EF7C27707B7CD62A4C78235171B6CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_29F832662267DDBA0A6978235172F04F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6727B3AC6D6C03124973782351679914" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_29F832662267DDBA0A6978235172F04F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_E66F6C7C99BB4898DF81782351735099" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6727B3AC6D6C03124973782351679914" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_E66F6C7C99BB4898DF81782351735099" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7E7D6889CDF8527C9783782351AA2D3F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_33BC646E58FDE8B9B764782351AA7ABD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7E7D6889CDF8527C9783782351AA2D3F" xlink:to="loc_us-gaap_NetIncomeLoss_33BC646E58FDE8B9B764782351AA7ABD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_69C59A255650CD0696BD782351AB9660" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7E7D6889CDF8527C9783782351AA2D3F" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_69C59A255650CD0696BD782351AB9660" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_15E15206357092A66E91782351ABF416" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_69C59A255650CD0696BD782351AB9660" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_15E15206357092A66E91782351ABF416" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_490F558475F3E4D5E655782351AB6DBE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_69C59A255650CD0696BD782351AB9660" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_490F558475F3E4D5E655782351AB6DBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_8F11919A4562E8623FDF782351AB8130" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_69C59A255650CD0696BD782351AB9660" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_8F11919A4562E8623FDF782351AB8130" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_DE814B1B14277429559E782351AB9823" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_69C59A255650CD0696BD782351AB9660" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_DE814B1B14277429559E782351AB9823" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2DEA06E34E389B4A444A782351AB4BC2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_69C59A255650CD0696BD782351AB9660" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2DEA06E34E389B4A444A782351AB4BC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_B30AEBA1FFF73DDE52EE782351ACB60A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_69C59A255650CD0696BD782351AB9660" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_B30AEBA1FFF73DDE52EE782351ACB60A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_91A2179651CA43538CB0782351ACD6A5" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_69C59A255650CD0696BD782351AB9660" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_91A2179651CA43538CB0782351ACD6A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_6DCD9F96B8E6EC017364782351AC31B1" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_69C59A255650CD0696BD782351AB9660" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_6DCD9F96B8E6EC017364782351AC31B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_68158B64DA3248EE37E9782351ACAC9A" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_69C59A255650CD0696BD782351AB9660" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_68158B64DA3248EE37E9782351ACAC9A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_C79EAC8E4C4BC767B792782351B98F0D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1CC3D936D9A84F51F3E6782351B9651F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_C79EAC8E4C4BC767B792782351B98F0D" xlink:to="loc_us-gaap_StatementTable_1CC3D936D9A84F51F3E6782351B9651F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_240DB5AFD091F010474E782351BA4156" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1CC3D936D9A84F51F3E6782351B9651F" xlink:to="loc_srt_ProductOrServiceAxis_240DB5AFD091F010474E782351BA4156" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_A9630AF5908C66EE2AFF782351BA7C8C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_240DB5AFD091F010474E782351BA4156" xlink:to="loc_srt_ProductsAndServicesDomain_A9630AF5908C66EE2AFF782351BA7C8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_091A937F2A1165EBC5A3782351BA9F03" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_A9630AF5908C66EE2AFF782351BA7C8C" xlink:to="loc_us-gaap_ProductMember_091A937F2A1165EBC5A3782351BA9F03" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_DA566FEBCDF177C7ABAD782351BBF6EA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_A9630AF5908C66EE2AFF782351BA7C8C" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_DA566FEBCDF177C7ABAD782351BBF6EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_75AF6FE36763B2B68231782351BBCFCD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_A9630AF5908C66EE2AFF782351BA7C8C" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_75AF6FE36763B2B68231782351BBCFCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_98FDD9635D731D6AF461782351BB79A0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1CC3D936D9A84F51F3E6782351B9651F" xlink:to="loc_us-gaap_StatementLineItems_98FDD9635D731D6AF461782351BB79A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_E10FE7F7D7620CC8E052782351BBA6F0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98FDD9635D731D6AF461782351BB79A0" xlink:to="loc_us-gaap_Revenues_E10FE7F7D7620CC8E052782351BBA6F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_E7A05E5AFEF4EE2B3106782351BCD3CA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98FDD9635D731D6AF461782351BB79A0" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_E7A05E5AFEF4EE2B3106782351BCD3CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_C20B387C170ACC357FEC782351BCF684" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_E7A05E5AFEF4EE2B3106782351BCD3CA" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_C20B387C170ACC357FEC782351BCF684" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9F21FC13AEFC34118E6F782351BC7F18" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_E7A05E5AFEF4EE2B3106782351BCD3CA" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9F21FC13AEFC34118E6F782351BC7F18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6364E2A6FCBB97987235782351BC3C43" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_E7A05E5AFEF4EE2B3106782351BCD3CA" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6364E2A6FCBB97987235782351BC3C43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_89FA89B32E8E0D5E6A38782351BD728E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_E7A05E5AFEF4EE2B3106782351BCD3CA" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_89FA89B32E8E0D5E6A38782351BD728E" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_6BF4A55F37E0254D92F4782351BD9467" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_E7A05E5AFEF4EE2B3106782351BCD3CA" xlink:to="loc_biib_Collaborationprofitlosssharing_6BF4A55F37E0254D92F4782351BD9467" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_964D58BF92706B92E478782351BDAB50" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_E7A05E5AFEF4EE2B3106782351BCD3CA" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_964D58BF92706B92E478782351BDAB50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_506A979E04CB3FE896EA782351BD58FB" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_E7A05E5AFEF4EE2B3106782351BCD3CA" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_506A979E04CB3FE896EA782351BD58FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_0D4A26927F06E9EF7D5C782351BDF536" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_E7A05E5AFEF4EE2B3106782351BCD3CA" xlink:to="loc_us-gaap_RestructuringCharges_0D4A26927F06E9EF7D5C782351BDF536" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_3EF483A92A09AB6F3286782351BD150A" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_E7A05E5AFEF4EE2B3106782351BCD3CA" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_3EF483A92A09AB6F3286782351BD150A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_1DCF7ECA6A53C25ED69B782351BE8FDF" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_E7A05E5AFEF4EE2B3106782351BCD3CA" xlink:to="loc_us-gaap_CostsAndExpenses_1DCF7ECA6A53C25ED69B782351BE8FDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_D2E12F5AA4633EDC19CA782351BEA3AD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98FDD9635D731D6AF461782351BB79A0" xlink:to="loc_us-gaap_OperatingIncomeLoss_D2E12F5AA4633EDC19CA782351BEA3AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_A7BD73A09FC3B0139332782351BEFBAE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98FDD9635D731D6AF461782351BB79A0" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_A7BD73A09FC3B0139332782351BEFBAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_39E6F4DE1DF56AA275BE782351BEFDD6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98FDD9635D731D6AF461782351BB79A0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_39E6F4DE1DF56AA275BE782351BEFDD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_B5101490F6E2E8777B45782351BE9156" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98FDD9635D731D6AF461782351BB79A0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_B5101490F6E2E8777B45782351BE9156" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_8FB4D72AF0DC2E50471C782351BF5C07" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98FDD9635D731D6AF461782351BB79A0" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_8FB4D72AF0DC2E50471C782351BF5C07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_81C6A94685D29FBA6626782351BF3105" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98FDD9635D731D6AF461782351BB79A0" xlink:to="loc_us-gaap_ProfitLoss_81C6A94685D29FBA6626782351BF3105" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_B8D96204507ABF9AAC9C782351BFAE46" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98FDD9635D731D6AF461782351BB79A0" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_B8D96204507ABF9AAC9C782351BFAE46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_06827FCD92A4CC282C6A782351BF0196" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98FDD9635D731D6AF461782351BB79A0" xlink:to="loc_us-gaap_NetIncomeLoss_06827FCD92A4CC282C6A782351BF0196" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2FD6FCA6C2B1734BD98C782351BFAC7D" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98FDD9635D731D6AF461782351BB79A0" xlink:to="loc_us-gaap_EarningsPerShareAbstract_2FD6FCA6C2B1734BD98C782351BFAC7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_B35909B023B63AA7659D782351C06F6A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2FD6FCA6C2B1734BD98C782351BFAC7D" xlink:to="loc_us-gaap_EarningsPerShareBasic_B35909B023B63AA7659D782351C06F6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_45331465592B24886E17782351C0E537" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2FD6FCA6C2B1734BD98C782351BFAC7D" xlink:to="loc_us-gaap_EarningsPerShareDiluted_45331465592B24886E17782351C0E537" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_A0F7F9153381515DDD96782351C0CE2E" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98FDD9635D731D6AF461782351BB79A0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_A0F7F9153381515DDD96782351C0CE2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_75D07FEA05A8F57890CD782351C0BD1C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_A0F7F9153381515DDD96782351C0CE2E" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_75D07FEA05A8F57890CD782351C0BD1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4BF884A55F84239CAC68782351C1EDBB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_A0F7F9153381515DDD96782351C0CE2E" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4BF884A55F84239CAC68782351C1EDBB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_D15715C11618919C04AD782351CACC51" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_D3AE7B05FD7E530D800A782351CA7110" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D15715C11618919C04AD782351CACC51" xlink:to="loc_dei_DocumentType_D3AE7B05FD7E530D800A782351CA7110" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_40FF1E0DEF3C6E0A1284782351CBAFAE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D15715C11618919C04AD782351CACC51" xlink:to="loc_dei_DocumentQuarterlyReport_40FF1E0DEF3C6E0A1284782351CBAFAE" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_A8413427EC8849147390782351CBB3DB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D15715C11618919C04AD782351CACC51" xlink:to="loc_dei_DocumentPeriodEndDate_A8413427EC8849147390782351CBB3DB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_95C1BB36A59596150E1E782351CBDD07" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D15715C11618919C04AD782351CACC51" xlink:to="loc_dei_DocumentTransitionReport_95C1BB36A59596150E1E782351CBDD07" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_FBD8FF5B470D44CC9A7B782351CBF48D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D15715C11618919C04AD782351CACC51" xlink:to="loc_dei_EntityFileNumber_FBD8FF5B470D44CC9A7B782351CBF48D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_E7CDFB7AA4AFEAC23E26782351CB2250" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D15715C11618919C04AD782351CACC51" xlink:to="loc_dei_EntityRegistrantName_E7CDFB7AA4AFEAC23E26782351CB2250" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_AFEEB291AACA57AA95E6782351CCDF6D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D15715C11618919C04AD782351CACC51" xlink:to="loc_dei_EntityCentralIndexKey_AFEEB291AACA57AA95E6782351CCDF6D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_7BC5C9FA952D8D6534C9782351CC2718" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D15715C11618919C04AD782351CACC51" xlink:to="loc_dei_CurrentFiscalYearEndDate_7BC5C9FA952D8D6534C9782351CC2718" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_6F44A6836C18E4E8E52E782351CCC23E" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D15715C11618919C04AD782351CACC51" xlink:to="loc_dei_DocumentFiscalYearFocus_6F44A6836C18E4E8E52E782351CCC23E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_FCE476F975CA4F1BBFFB782351CCE485" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D15715C11618919C04AD782351CACC51" xlink:to="loc_dei_DocumentFiscalPeriodFocus_FCE476F975CA4F1BBFFB782351CCE485" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_8FB08B8D0C74434482FB782351CCC9F8" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D15715C11618919C04AD782351CACC51" xlink:to="loc_dei_AmendmentFlag_8FB08B8D0C74434482FB782351CCC9F8" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_270884B2D93C0BDA78CD782351CC2EBF" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D15715C11618919C04AD782351CACC51" xlink:to="loc_dei_EntityIncorporationStateCountryCode_270884B2D93C0BDA78CD782351CC2EBF" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_B0E3953D8A7ADDD9FB07782351CDA65B" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D15715C11618919C04AD782351CACC51" xlink:to="loc_dei_EntityTaxIdentificationNumber_B0E3953D8A7ADDD9FB07782351CDA65B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_E6D80444F4F42E097469782351CD555F" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D15715C11618919C04AD782351CACC51" xlink:to="loc_dei_EntityAddressAddressLine1_E6D80444F4F42E097469782351CD555F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_C9083973DCA0D09743BA782351CDC4DC" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D15715C11618919C04AD782351CACC51" xlink:to="loc_dei_EntityAddressCityOrTown_C9083973DCA0D09743BA782351CDC4DC" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_928A5EC05C6B9327C08A782351CD6793" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D15715C11618919C04AD782351CACC51" xlink:to="loc_dei_EntityAddressStateOrProvince_928A5EC05C6B9327C08A782351CD6793" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_3309D2AE2EF01EF8238D782351CD2389" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D15715C11618919C04AD782351CACC51" xlink:to="loc_dei_EntityAddressPostalZipCode_3309D2AE2EF01EF8238D782351CD2389" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_10032987D1B9BC59D53F782351CE0C55" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D15715C11618919C04AD782351CACC51" xlink:to="loc_dei_CityAreaCode_10032987D1B9BC59D53F782351CE0C55" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_3A3BBF8BB3810271D26B782351CE2AE2" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D15715C11618919C04AD782351CACC51" xlink:to="loc_dei_LocalPhoneNumber_3A3BBF8BB3810271D26B782351CE2AE2" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_897086EE4FFBCDDE6AE1782351CE8CE3" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D15715C11618919C04AD782351CACC51" xlink:to="loc_dei_Security12bTitle_897086EE4FFBCDDE6AE1782351CE8CE3" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_968AE5B1A13128993E4C782351CEEAF4" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D15715C11618919C04AD782351CACC51" xlink:to="loc_dei_TradingSymbol_968AE5B1A13128993E4C782351CEEAF4" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_75A27F0004CCC5F36A04782351CE11D5" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D15715C11618919C04AD782351CACC51" xlink:to="loc_dei_SecurityExchangeName_75A27F0004CCC5F36A04782351CE11D5" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_60A7DFABBEEFCB55891F782351CF90B8" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D15715C11618919C04AD782351CACC51" xlink:to="loc_dei_EntityCurrentReportingStatus_60A7DFABBEEFCB55891F782351CF90B8" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_96787D670907EB1A9CA8782351CF79B4" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D15715C11618919C04AD782351CACC51" xlink:to="loc_dei_EntityInteractiveDataCurrent_96787D670907EB1A9CA8782351CF79B4" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_56146F4791594363323A782351CF3D69" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D15715C11618919C04AD782351CACC51" xlink:to="loc_dei_EntityFilerCategory_56146F4791594363323A782351CF3D69" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_4A89994BDE019923EC1A782351CF4C3F" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D15715C11618919C04AD782351CACC51" xlink:to="loc_dei_EntitySmallBusiness_4A89994BDE019923EC1A782351CF4C3F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_32A397070D8CFFB9A495782351CFB714" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D15715C11618919C04AD782351CACC51" xlink:to="loc_dei_EntityEmergingGrowthCompany_32A397070D8CFFB9A495782351CFB714" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_020437E76B880B2D687A782351D00A2D" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D15715C11618919C04AD782351CACC51" xlink:to="loc_dei_EntityShellCompany_020437E76B880B2D687A782351D00A2D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_401A8E060DE3129856D4782351D0A6A8" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D15715C11618919C04AD782351CACC51" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_401A8E060DE3129856D4782351D0A6A8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_C90B6EBDAE4F536B166678234E5B384D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_F2B7EEB9C2B689CBFD6178234E5BBFC0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_C90B6EBDAE4F536B166678234E5B384D" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_F2B7EEB9C2B689CBFD6178234E5BBFC0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_DAE96FAC80E722E777D178234E33BA9A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_182EA4B9FC283DB36FD278234E333CE0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_DAE96FAC80E722E777D178234E33BA9A" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_182EA4B9FC283DB36FD278234E333CE0" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_DerivativeMaturityAxis" xlink:label="loc_biib_DerivativeMaturityAxis_7606227E8A5EF21EF55F78234E33027D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_182EA4B9FC283DB36FD278234E333CE0" xlink:to="loc_biib_DerivativeMaturityAxis_7606227E8A5EF21EF55F78234E33027D" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_DerivativeMaturityDomain" xlink:label="loc_biib_DerivativeMaturityDomain_6B91976A8E988C1923F378234E3419C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeMaturityAxis_7606227E8A5EF21EF55F78234E33027D" xlink:to="loc_biib_DerivativeMaturityDomain_6B91976A8E988C1923F378234E3419C1" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_ShorttermderivativeMember" xlink:label="loc_biib_ShorttermderivativeMember_B2F5AF05CAC8A67528A378234E3428E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeMaturityDomain_6B91976A8E988C1923F378234E3419C1" xlink:to="loc_biib_ShorttermderivativeMember_B2F5AF05CAC8A67528A378234E3428E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_66706C2739A8E4A99A6478234E35E105" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_182EA4B9FC283DB36FD278234E333CE0" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_66706C2739A8E4A99A6478234E35E105" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_325A87794132B76C8AEE78234E35B58A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_66706C2739A8E4A99A6478234E35E105" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_325A87794132B76C8AEE78234E35B58A" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_7ECB4312906A65D3D43478234E365285" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_325A87794132B76C8AEE78234E35B58A" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_7ECB4312906A65D3D43478234E365285" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_B5CEA25D42F66FAB157C78234E36E3FE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_182EA4B9FC283DB36FD278234E333CE0" xlink:to="loc_us-gaap_DebtInstrumentAxis_B5CEA25D42F66FAB157C78234E36E3FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_215146F8BBF1321AB54078234E379134" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_B5CEA25D42F66FAB157C78234E36E3FE" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_215146F8BBF1321AB54078234E379134" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_2FB91DF42FF0BB2BC4D778234E37022A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_215146F8BBF1321AB54078234E379134" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_2FB91DF42FF0BB2BC4D778234E37022A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_25E4A6CBC75B8FB27D3478234E37CF24" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_182EA4B9FC283DB36FD278234E333CE0" xlink:to="loc_srt_CurrencyAxis_25E4A6CBC75B8FB27D3478234E37CF24" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_B4A9577A520A6C0C743478234E38FC2B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_25E4A6CBC75B8FB27D3478234E37CF24" xlink:to="loc_currency_AllCurrenciesDomain_B4A9577A520A6C0C743478234E38FC2B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_DC27B339F046752BD02678234E38BE8E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_B4A9577A520A6C0C743478234E38FC2B" xlink:to="loc_currency_EUR_DC27B339F046752BD02678234E38BE8E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_GBP" xlink:label="loc_currency_GBP_74B5F32447D3E6DB26F978234E39CED2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_B4A9577A520A6C0C743478234E38FC2B" xlink:to="loc_currency_GBP_74B5F32447D3E6DB26F978234E39CED2" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CHF" xlink:label="loc_currency_CHF_C3C5CA939CAA1F6E813978234E39B752" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_B4A9577A520A6C0C743478234E38FC2B" xlink:to="loc_currency_CHF_C3C5CA939CAA1F6E813978234E39B752" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_JPY" xlink:label="loc_currency_JPY_CF320C0DF573C4B7415078234E395E60" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_B4A9577A520A6C0C743478234E38FC2B" xlink:to="loc_currency_JPY_CF320C0DF573C4B7415078234E395E60" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CAD" xlink:label="loc_currency_CAD_B785FD5BB331CC7F3B1578234E394D54" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_B4A9577A520A6C0C743478234E38FC2B" xlink:to="loc_currency_CAD_B785FD5BB331CC7F3B1578234E394D54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_CC94442BBF92EC4D7D3E78234E3961C1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_182EA4B9FC283DB36FD278234E333CE0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_CC94442BBF92EC4D7D3E78234E3961C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6F5C396C855EAF1B8F9878234E3A0963" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_CC94442BBF92EC4D7D3E78234E3961C1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6F5C396C855EAF1B8F9878234E3A0963" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseMember" xlink:label="loc_us-gaap_InterestExpenseMember_B03CDA821E6678B020D878234E3A65DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6F5C396C855EAF1B8F9878234E3A0963" xlink:to="loc_us-gaap_InterestExpenseMember_B03CDA821E6678B020D878234E3A65DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_F7CADF5CD0EF1441EA9F78234E3BC30E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6F5C396C855EAF1B8F9878234E3A0963" xlink:to="loc_us-gaap_SalesMember_F7CADF5CD0EF1441EA9F78234E3BC30E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="loc_us-gaap_OperatingExpenseMember_B4C8FF5847D5D6D80D1078234E3B3084" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6F5C396C855EAF1B8F9878234E3A0963" xlink:to="loc_us-gaap_OperatingExpenseMember_B4C8FF5847D5D6D80D1078234E3B3084" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_3810D2C7D1140C2F6F3A78234E3B4A35" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6F5C396C855EAF1B8F9878234E3A0963" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_3810D2C7D1140C2F6F3A78234E3B4A35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_3D001853856CF83BF2CE78234E3BA487" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_182EA4B9FC283DB36FD278234E333CE0" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_3D001853856CF83BF2CE78234E3BA487" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_7293B45C6DB379273B2578234E3B3FCF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_3D001853856CF83BF2CE78234E3BA487" xlink:to="loc_us-gaap_HedgingRelationshipDomain_7293B45C6DB379273B2578234E3B3FCF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowHedgingMember" xlink:label="loc_us-gaap_CashFlowHedgingMember_2730D6E132F6ADD3801678234E3C5ABE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_7293B45C6DB379273B2578234E3B3FCF" xlink:to="loc_us-gaap_CashFlowHedgingMember_2730D6E132F6ADD3801678234E3C5ABE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueHedgingMember" xlink:label="loc_us-gaap_FairValueHedgingMember_73A5D2A170D0AE96651D78234E3C1C79" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_7293B45C6DB379273B2578234E3B3FCF" xlink:to="loc_us-gaap_FairValueHedgingMember_73A5D2A170D0AE96651D78234E3C1C79" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_CashflowsrevenueMember" xlink:label="loc_biib_CashflowsrevenueMember_640FD48F3FD50451723F78234E3D4966" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_7293B45C6DB379273B2578234E3B3FCF" xlink:to="loc_biib_CashflowsrevenueMember_640FD48F3FD50451723F78234E3D4966" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_CashflowsoperatingexpensesMember" xlink:label="loc_biib_CashflowsoperatingexpensesMember_97AB68E5CFA516CB41C678234E3DB0A2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_7293B45C6DB379273B2578234E3B3FCF" xlink:to="loc_biib_CashflowsoperatingexpensesMember_97AB68E5CFA516CB41C678234E3DB0A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetInvestmentHedgingMember" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_00F7F7A0F2099967B03078234E3DBAC0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_7293B45C6DB379273B2578234E3B3FCF" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_00F7F7A0F2099967B03078234E3DBAC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_881785D44CF5AC906B6B78234E3D0B96" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_182EA4B9FC283DB36FD278234E333CE0" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_881785D44CF5AC906B6B78234E3D0B96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_71A186BFFC7F011F0A5478234E3DA9F4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_881785D44CF5AC906B6B78234E3D0B96" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_71A186BFFC7F011F0A5478234E3DA9F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_C38AB767994AF108969B78234E3EC43F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_71A186BFFC7F011F0A5478234E3DA9F4" xlink:to="loc_us-gaap_ForeignExchangeContractMember_C38AB767994AF108969B78234E3EC43F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_6476CDF19988EF57D30678234E3E06F1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_71A186BFFC7F011F0A5478234E3DA9F4" xlink:to="loc_us-gaap_InterestRateSwapMember_6476CDF19988EF57D30678234E3E06F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_0051ECFB74F843B698C178234E3E87E7" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_182EA4B9FC283DB36FD278234E333CE0" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_0051ECFB74F843B698C178234E3E87E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_16313CD22180370025B678234E3F71FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_0051ECFB74F843B698C178234E3E87E7" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_16313CD22180370025B678234E3F71FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_5DC61D2B5C0612675A2E78234E3FE50B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_16313CD22180370025B678234E3F71FE" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_5DC61D2B5C0612675A2E78234E3FE50B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_858F0A9830098320C9B578234E3F302D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_16313CD22180370025B678234E3F71FE" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_858F0A9830098320C9B578234E3F302D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_354FD5342FE655A2861D78234E3FE549" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_16313CD22180370025B678234E3F71FE" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_354FD5342FE655A2861D78234E3FE549" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_7411FED5179522BDC83778234E40DE8C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_16313CD22180370025B678234E3F71FE" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_7411FED5179522BDC83778234E40DE8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_D25E1340857D5B4AC5F878234E402F70" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_182EA4B9FC283DB36FD278234E333CE0" xlink:to="loc_us-gaap_HedgingDesignationAxis_D25E1340857D5B4AC5F878234E402F70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_B9795BDB4EC6978139B878234E40F2A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_D25E1340857D5B4AC5F878234E402F70" xlink:to="loc_us-gaap_HedgingDesignationDomain_B9795BDB4EC6978139B878234E40F2A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_8293A31DC0A4F4DC7CCB78234E41F88B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_B9795BDB4EC6978139B878234E40F2A5" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_8293A31DC0A4F4DC7CCB78234E41F88B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_87B19D72EE4AE9D0358478234E41527C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_B9795BDB4EC6978139B878234E40F2A5" xlink:to="loc_us-gaap_NondesignatedMember_87B19D72EE4AE9D0358478234E41527C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_42BEE76DABC87E6E77CC78234E41F186" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_182EA4B9FC283DB36FD278234E333CE0" xlink:to="loc_srt_RangeAxis_42BEE76DABC87E6E77CC78234E41F186" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_F3E393863663E7D84B9378234E410EED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_42BEE76DABC87E6E77CC78234E41F186" xlink:to="loc_srt_RangeMember_F3E393863663E7D84B9378234E410EED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_EC9F95558EF8119873DC78234E421FF6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_F3E393863663E7D84B9378234E410EED" xlink:to="loc_srt_MinimumMember_EC9F95558EF8119873DC78234E421FF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_71338DDD22507624A2A478234E425D94" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_F3E393863663E7D84B9378234E410EED" xlink:to="loc_srt_MaximumMember_71338DDD22507624A2A478234E425D94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_A4C3A2B414634120787B78234E43258D" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_182EA4B9FC283DB36FD278234E333CE0" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_A4C3A2B414634120787B78234E43258D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeRemainingMaturity1" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_B3B319A9E09C1B2005A078234E43D08E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A4C3A2B414634120787B78234E43258D" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_B3B319A9E09C1B2005A078234E43D08E" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_9D42A4C7C93D7CC7C9E978234E438900" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A4C3A2B414634120787B78234E43258D" xlink:to="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_9D42A4C7C93D7CC7C9E978234E438900" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_896C044F02F89EB888C178234E43AAF4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A4C3A2B414634120787B78234E43258D" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_896C044F02F89EB888C178234E43AAF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_56229B7CC46F08AC5CF478234E4471CC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A4C3A2B414634120787B78234E43258D" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_56229B7CC46F08AC5CF478234E4471CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_36B1F03E5C2A932BCC6278234E447E42" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A4C3A2B414634120787B78234E43258D" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_36B1F03E5C2A932BCC6278234E447E42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_ABEF647F51BA920216D578234E4415E6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A4C3A2B414634120787B78234E43258D" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_ABEF647F51BA920216D578234E4415E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeNotionalAmount" xlink:label="loc_us-gaap_DerivativeNotionalAmount_C0C08B2C2581E464A65278234E448501" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A4C3A2B414634120787B78234E43258D" xlink:to="loc_us-gaap_DerivativeNotionalAmount_C0C08B2C2581E464A65278234E448501" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_3396CC195113EF92CA1878234E45C5A9" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A4C3A2B414634120787B78234E43258D" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_3396CC195113EF92CA1878234E45C5A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_7DDDF52BDD501182CA9478234E45AA1D" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A4C3A2B414634120787B78234E43258D" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_7DDDF52BDD501182CA9478234E45AA1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_09F94B1D334B2D02863478234E458D14" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A4C3A2B414634120787B78234E43258D" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_09F94B1D334B2D02863478234E458D14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeTermOfContract" xlink:label="loc_us-gaap_DerivativeTermOfContract_067B574A43E7593376C278234E45197E" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A4C3A2B414634120787B78234E43258D" xlink:to="loc_us-gaap_DerivativeTermOfContract_067B574A43E7593376C278234E45197E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_51BF3EE424107F7E0FB478234E46AB1C" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A4C3A2B414634120787B78234E43258D" xlink:to="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_51BF3EE424107F7E0FB478234E46AB1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_70D098D7B541443B80C278234E46FD44" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A4C3A2B414634120787B78234E43258D" xlink:to="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_70D098D7B541443B80C278234E46FD44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_36B8AF83E486DC6529C678234E469586" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A4C3A2B414634120787B78234E43258D" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_36B8AF83E486DC6529C678234E469586" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:label="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_03EC6AC09458088648A078234E4631E3" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A4C3A2B414634120787B78234E43258D" xlink:to="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_03EC6AC09458088648A078234E4631E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_6D18C130A006A1F8BD2D78234E4770F2" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A4C3A2B414634120787B78234E43258D" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_6D18C130A006A1F8BD2D78234E4770F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_BA77C049A5CC55FF05AA78234E478CFC" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A4C3A2B414634120787B78234E43258D" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_BA77C049A5CC55FF05AA78234E478CFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_0C16B33EEB390E49D1B878234E4761C6" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_A4C3A2B414634120787B78234E43258D" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_0C16B33EEB390E49D1B878234E4761C6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_854F12C4A2DEEE97D9C978234E548B73" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_D88347F2D9CA4E06511778234E54DF9A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_854F12C4A2DEEE97D9C978234E548B73" xlink:to="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_D88347F2D9CA4E06511778234E54DF9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_6D620C4A16ADF8E7AB4F78234E55C5E9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_854F12C4A2DEEE97D9C978234E548B73" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_6D620C4A16ADF8E7AB4F78234E55C5E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_7E7B29295D01B647077778234E55E690" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_854F12C4A2DEEE97D9C978234E548B73" xlink:to="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_7E7B29295D01B647077778234E55E690" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_C7335B4421F76E7897A578234E555B2E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_854F12C4A2DEEE97D9C978234E548B73" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_C7335B4421F76E7897A578234E555B2E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DivestituresDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="biib-20200630.xsd#biib_DivestituresAbstract" xlink:label="loc_biib_DivestituresAbstract_460056BE9B3A9117801C782350A33B44" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_65739D734A43FDD24796782350A33436" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DivestituresAbstract_460056BE9B3A9117801C782350A33B44" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_65739D734A43FDD24796782350A33436" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D43061457114C409FF28782350A3C506" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_65739D734A43FDD24796782350A33436" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D43061457114C409FF28782350A3C506" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_BB6B829598C67C0A880C782350A4A46A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_D43061457114C409FF28782350A3C506" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_BB6B829598C67C0A880C782350A4A46A" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_77A729CD732C142313A3782350A47BAE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_BB6B829598C67C0A880C782350A4A46A" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_77A729CD732C142313A3782350A47BAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2C5D565175C079DE3348782350A48365" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_65739D734A43FDD24796782350A33436" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2C5D565175C079DE3348782350A48365" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_115500103370BE78FB89782350A4F560" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2C5D565175C079DE3348782350A48365" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_115500103370BE78FB89782350A4F560" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_565615F0543F8E103D6F782350A5CDD2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2C5D565175C079DE3348782350A48365" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_565615F0543F8E103D6F782350A5CDD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_9AA41B2DBC9B36B4FC20782350A5F5AD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2C5D565175C079DE3348782350A48365" xlink:to="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_9AA41B2DBC9B36B4FC20782350A5F5AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_833E4403818382B2A435782350A53C79" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2C5D565175C079DE3348782350A48365" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_833E4403818382B2A435782350A53C79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_CC5D565ECC0C8BC6D941782350A591C7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2C5D565175C079DE3348782350A48365" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_CC5D565ECC0C8BC6D941782350A591C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_CAFD1AC38717A6C45FBB782350A57C7C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2C5D565175C079DE3348782350A48365" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_CAFD1AC38717A6C45FBB782350A57C7C" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_InventoryrawmaterialssoldtoFUJIFILM" xlink:label="loc_biib_InventoryrawmaterialssoldtoFUJIFILM_68FCC7A8209F6BFA967B782350A6B258" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2C5D565175C079DE3348782350A48365" xlink:to="loc_biib_InventoryrawmaterialssoldtoFUJIFILM_68FCC7A8209F6BFA967B782350A6B258" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DivestituresDivestitures" xlink:type="extended">
    <link:loc xlink:href="biib-20200630.xsd#biib_DivestituresAbstract" xlink:label="loc_biib_DivestituresAbstract_41A2E905E56856B7C786782350AF5214" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_AC7C56E36A6765415D56782350AF310B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DivestituresAbstract_41A2E905E56856B7C786782350AF5214" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_AC7C56E36A6765415D56782350AF310B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_D37131C81C066048C1FF78234D6FBF25" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_A8C114600CB29980216B78234D6F462C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_D37131C81C066048C1FF78234D6FBF25" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_A8C114600CB29980216B78234D6F462C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_424D285D4D616CB7E48C78234D5E1853" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_C64112BE2F2C562DB5B178234D5F596C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_424D285D4D616CB7E48C78234D5E1853" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_C64112BE2F2C562DB5B178234D5F596C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8E5A4096E3B50308124978234D5F7863" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_C64112BE2F2C562DB5B178234D5F596C" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8E5A4096E3B50308124978234D5F7863" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_F3ED5337F9F0086F778B78234D604880" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8E5A4096E3B50308124978234D5F7863" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_F3ED5337F9F0086F778B78234D604880" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_48E470BECDE943C7C51178234D60E97D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_F3ED5337F9F0086F778B78234D604880" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_48E470BECDE943C7C51178234D60E97D" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_816ECC6AD62AAC9D973378234D6014E2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_F3ED5337F9F0086F778B78234D604880" xlink:to="loc_biib_MarketStockUnitsMember_816ECC6AD62AAC9D973378234D6014E2" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_BA480501F25CF8B4E07778234D604C1C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_F3ED5337F9F0086F778B78234D604880" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_BA480501F25CF8B4E07778234D604C1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_52F260203FC456F5600178234D61588B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_C64112BE2F2C562DB5B178234D5F596C" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_52F260203FC456F5600178234D61588B" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_90B7562C2EC0E8DFA7EA78234D617CBB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_52F260203FC456F5600178234D61588B" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_90B7562C2EC0E8DFA7EA78234D617CBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_B2B2AB5E2982CACF70EC78234D61C972" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_90B7562C2EC0E8DFA7EA78234D617CBB" xlink:to="loc_us-gaap_NetIncomeLossAbstract_B2B2AB5E2982CACF70EC78234D61C972" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_937E2EA5AB60B99D71B678234D621226" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_B2B2AB5E2982CACF70EC78234D61C972" xlink:to="loc_us-gaap_NetIncomeLoss_937E2EA5AB60B99D71B678234D621226" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3EBB5F02CBCE075B34EA78234D62B35E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_90B7562C2EC0E8DFA7EA78234D617CBB" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3EBB5F02CBCE075B34EA78234D62B35E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3991B763E654F5D828EB78234D62CF44" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3EBB5F02CBCE075B34EA78234D62B35E" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3991B763E654F5D828EB78234D62CF44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_E4C0DC526A789408D16878234D63D508" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3EBB5F02CBCE075B34EA78234D62B35E" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_E4C0DC526A789408D16878234D63D508" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_111FEF2310C00804823178234D637DA1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_E4C0DC526A789408D16878234D63D508" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_111FEF2310C00804823178234D637DA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_A09BEC1E45689FEA1B5078234D632732" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_E4C0DC526A789408D16878234D63D508" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_A09BEC1E45689FEA1B5078234D632732" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_85068B58E43C3F2273B578234D6314BB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3EBB5F02CBCE075B34EA78234D62B35E" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_85068B58E43C3F2273B578234D6314BB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0835ABC737B0E96F529478234D69AEAC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_DBF4687E4BE99DFD442E78234D698728" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0835ABC737B0E96F529478234D69AEAC" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_DBF4687E4BE99DFD442E78234D698728" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_2C0126E5E36C1E4ACEAF78234DA4AA4A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_E830DE4E696678495AAA78234DA49808" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2C0126E5E36C1E4ACEAF78234DA4AA4A" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_E830DE4E696678495AAA78234DA49808" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2E0E15B53D338ED3394D78234F7EEA62" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_3F883ABE5707A59DE6D378234F7EB961" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2E0E15B53D338ED3394D78234F7EEA62" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_3F883ABE5707A59DE6D378234F7EB961" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_79358C39CB6AC59DB12B78234F64D6C8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E8FFA73D5CCF155FE92078234F657E8C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_79358C39CB6AC59DB12B78234F64D6C8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E8FFA73D5CCF155FE92078234F657E8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_AE024AD99AA1C5B1418B78234F65B751" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E8FFA73D5CCF155FE92078234F657E8C" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_AE024AD99AA1C5B1418B78234F65B751" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C577A1BB689BDE59620178234F666D37" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_AE024AD99AA1C5B1418B78234F65B751" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C577A1BB689BDE59620178234F666D37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_89714192DDE9BA4395DB78234F66B816" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C577A1BB689BDE59620178234F666D37" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_89714192DDE9BA4395DB78234F66B816" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_35A4EBFD99C0EC91830878234F665DDF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C577A1BB689BDE59620178234F666D37" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_35A4EBFD99C0EC91830878234F665DDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_02B5960236A641015A6778234F66069B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C577A1BB689BDE59620178234F666D37" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_02B5960236A641015A6778234F66069B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_810402E82A9A044B2E5078234F6651CD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E8FFA73D5CCF155FE92078234F657E8C" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_810402E82A9A044B2E5078234F6651CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_8C36DC6BE29522FF1A4378234F674B9D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_810402E82A9A044B2E5078234F6651CD" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_8C36DC6BE29522FF1A4378234F674B9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_BECA099D67E96C9D615478234F6712B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_8C36DC6BE29522FF1A4378234F674B9D" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_BECA099D67E96C9D615478234F6712B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_2E7078DFAB43A40913E378234F67FAE3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E8FFA73D5CCF155FE92078234F657E8C" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_2E7078DFAB43A40913E378234F67FAE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_E0EFC60FFBAF73B9A50978234F685EE6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_2E7078DFAB43A40913E378234F67FAE3" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_E0EFC60FFBAF73B9A50978234F685EE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_7EDFBA3312FEAD20412D78234F68AE92" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_E0EFC60FFBAF73B9A50978234F685EE6" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_7EDFBA3312FEAD20412D78234F68AE92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_A97FF738B0D3FBAF1F6D78234F683D3C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_E0EFC60FFBAF73B9A50978234F685EE6" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_A97FF738B0D3FBAF1F6D78234F683D3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_6729E6BE7E86FE4CDF9278234F682CE1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_E0EFC60FFBAF73B9A50978234F685EE6" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_6729E6BE7E86FE4CDF9278234F682CE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6EA7436BFD45C514092478234F697382" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E8FFA73D5CCF155FE92078234F657E8C" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6EA7436BFD45C514092478234F697382" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_8D0C19BAF099F0CEC6E778234F690E70" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6EA7436BFD45C514092478234F697382" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_8D0C19BAF099F0CEC6E778234F690E70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_3B083C756454BDCA642D78234F69F17C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_8D0C19BAF099F0CEC6E778234F690E70" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_3B083C756454BDCA642D78234F69F17C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5FEB665E8001F7FF8AF878234F69F473" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3B083C756454BDCA642D78234F69F17C" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5FEB665E8001F7FF8AF878234F69F473" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_92D311A7BA00D786139B78234F6AA812" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3B083C756454BDCA642D78234F69F17C" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_92D311A7BA00D786139B78234F6AA812" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_5EEE6688FFEF0A993CA578234F6A3ACB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3B083C756454BDCA642D78234F69F17C" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_5EEE6688FFEF0A993CA578234F6A3ACB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_546D3D5E273FEB18179C78234F6AEE02" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3B083C756454BDCA642D78234F69F17C" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_546D3D5E273FEB18179C78234F6AEE02" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_31291E139E25846362D578234F6A16E9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3B083C756454BDCA642D78234F69F17C" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_31291E139E25846362D578234F6A16E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_715DE8EEB85BA7BD44EC78234F6B6963" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3B083C756454BDCA642D78234F69F17C" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_715DE8EEB85BA7BD44EC78234F6B6963" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_605D31F118717EE143F378234F6B6640" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_8D0C19BAF099F0CEC6E778234F690E70" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_605D31F118717EE143F378234F6B6640" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_78FA0353D93D3721C14178234F6B5125" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_605D31F118717EE143F378234F6B6640" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_78FA0353D93D3721C14178234F6B5125" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3E9ECFA0E5202B5163B478234F6BCC20" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_605D31F118717EE143F378234F6B6640" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3E9ECFA0E5202B5163B478234F6BCC20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_392E93A4082C7AD6407878234F6B2B06" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_605D31F118717EE143F378234F6B6640" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_392E93A4082C7AD6407878234F6B2B06" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_D158AF4773D5F0BD4E6178234F47A445" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_A5E9E7A09D5CF2C2C21478234F47E2BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_D158AF4773D5F0BD4E6178234F47A445" xlink:to="loc_us-gaap_DebtInstrumentTable_A5E9E7A09D5CF2C2C21478234F47E2BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_05B4BD76794AB22C26D478234F485E79" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_A5E9E7A09D5CF2C2C21478234F47E2BE" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_05B4BD76794AB22C26D478234F485E79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_335934BA1AB0410D680778234F48C201" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_05B4BD76794AB22C26D478234F485E79" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_335934BA1AB0410D680778234F48C201" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_00F2159D6BF4DB828A3D78234F484C93" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_335934BA1AB0410D680778234F48C201" xlink:to="loc_us-gaap_SeniorNotesMember_00F2159D6BF4DB828A3D78234F484C93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_C641778F31119C03145478234F497A42" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_A5E9E7A09D5CF2C2C21478234F47E2BE" xlink:to="loc_us-gaap_DebtInstrumentAxis_C641778F31119C03145478234F497A42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_A2A1E8F418D506E2B1AC78234F491A4B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_C641778F31119C03145478234F497A42" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_A2A1E8F418D506E2B1AC78234F491A4B" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_ED9B1D39D20C3C887C2078234F491AEE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A2A1E8F418D506E2B1AC78234F491A4B" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_ED9B1D39D20C3C887C2078234F491AEE" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_25F202AFFC89A3D832B378234F49282E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A2A1E8F418D506E2B1AC78234F491A4B" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_25F202AFFC89A3D832B378234F49282E" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_6F78F0A7FDC4B2C42E4578234F4A1BF7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A2A1E8F418D506E2B1AC78234F491A4B" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_6F78F0A7FDC4B2C42E4578234F4A1BF7" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_A2.25SeniorNotesdueMay12030Member" xlink:label="loc_biib_A2.25SeniorNotesdueMay12030Member_2E8BA6FB5203D8E1644178234F4A52E4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A2A1E8F418D506E2B1AC78234F491A4B" xlink:to="loc_biib_A2.25SeniorNotesdueMay12030Member_2E8BA6FB5203D8E1644178234F4A52E4" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_E742A5DC132F9765043978234F4AA9E8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A2A1E8F418D506E2B1AC78234F491A4B" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_E742A5DC132F9765043978234F4AA9E8" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_A3.15SeniorNotesdueMay12050Member" xlink:label="loc_biib_A3.15SeniorNotesdueMay12050Member_C9199869C62069B872B178234F4AFB0D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A2A1E8F418D506E2B1AC78234F491A4B" xlink:to="loc_biib_A3.15SeniorNotesdueMay12050Member_C9199869C62069B872B178234F4AFB0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6F752FEE9F8F18A3BF6D78234F4B48D7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_A5E9E7A09D5CF2C2C21478234F47E2BE" xlink:to="loc_us-gaap_DebtInstrumentLineItems_6F752FEE9F8F18A3BF6D78234F4B48D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_A1A2D9AD76DE121FD22978234F4BD412" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6F752FEE9F8F18A3BF6D78234F4B48D7" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_A1A2D9AD76DE121FD22978234F4BD412" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_2AC1BE9F705578990C3E78234F4B97F7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6F752FEE9F8F18A3BF6D78234F4B48D7" xlink:to="loc_us-gaap_NotesPayable_2AC1BE9F705578990C3E78234F4B97F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_E357519159E09500D14178234F4B28F6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6F752FEE9F8F18A3BF6D78234F4B48D7" xlink:to="loc_us-gaap_DebtInstrumentFairValue_E357519159E09500D14178234F4B28F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7770BEB27E414C193CFE78234F4C5ECA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6F752FEE9F8F18A3BF6D78234F4B48D7" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7770BEB27E414C193CFE78234F4C5ECA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_D619ADF8CD346F57A6B378234F4C4AA4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6F752FEE9F8F18A3BF6D78234F4B48D7" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_D619ADF8CD346F57A6B378234F4C4AA4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5B1133C69A52BD90401F78234F2A30A0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_D652FF9ACC36CE31892478234F2BA48B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5B1133C69A52BD90401F78234F2A30A0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_D652FF9ACC36CE31892478234F2BA48B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_118F05002B42B99F5D7078234F30A283" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_D652FF9ACC36CE31892478234F2BA48B" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_118F05002B42B99F5D7078234F30A283" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_E36178B195797893477478234F3156B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_118F05002B42B99F5D7078234F30A283" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_E36178B195797893477478234F3156B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1D7AB692459188BB6EA978234F316570" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_E36178B195797893477478234F3156B1" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1D7AB692459188BB6EA978234F316570" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_691265934CDFF8A3E30878234F32D7F8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_D652FF9ACC36CE31892478234F2BA48B" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_691265934CDFF8A3E30878234F32D7F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_A5D2C603FA1924B039A078234F32AD0D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_691265934CDFF8A3E30878234F32D7F8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_A5D2C603FA1924B039A078234F32AD0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_28D409A2DAF6AF427A4978234F334EC4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_691265934CDFF8A3E30878234F32D7F8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_28D409A2DAF6AF427A4978234F334EC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_29D09EB0C614C34FA9A578234F33F969" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_691265934CDFF8A3E30878234F32D7F8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_29D09EB0C614C34FA9A578234F33F969" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6C2B3C3CA7723FB47A9178234F3350C4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_691265934CDFF8A3E30878234F32D7F8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6C2B3C3CA7723FB47A9178234F3350C4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0D0C25E1E0A7ADACE92D78234F183E75" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_2ED9B6D4F3CEEBC7878978234F18304B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0D0C25E1E0A7ADACE92D78234F183E75" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_2ED9B6D4F3CEEBC7878978234F18304B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_AAA3C4B5EDFABEDCC9D078234F198134" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_2ED9B6D4F3CEEBC7878978234F18304B" xlink:to="loc_us-gaap_DebtInstrumentAxis_AAA3C4B5EDFABEDCC9D078234F198134" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_07BE316A918CDD7ED2DB78234F198C14" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_AAA3C4B5EDFABEDCC9D078234F198134" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_07BE316A918CDD7ED2DB78234F198C14" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_F9C8753087B8BE9D360D78234F1A0E45" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_07BE316A918CDD7ED2DB78234F198C14" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_F9C8753087B8BE9D360D78234F1A0E45" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_3F08CBF4B475DBECD94778234F1A88F0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_07BE316A918CDD7ED2DB78234F198C14" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_3F08CBF4B475DBECD94778234F1A88F0" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_F353FB0EF860A866BF5778234F1B7A98" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_07BE316A918CDD7ED2DB78234F198C14" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_F353FB0EF860A866BF5778234F1B7A98" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_A7833951E7ADF410D7CC78234F1BAD5A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_07BE316A918CDD7ED2DB78234F198C14" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_A7833951E7ADF410D7CC78234F1BAD5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_654EFD9B0D67F472C13878234F1BB4B5" xlink:type="locator" />
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_2ED9B6D4F3CEEBC7878978234F18304B" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_654EFD9B0D67F472C13878234F1BB4B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_A4B6A9BF74EB4CEE973978234F1BD1FC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_654EFD9B0D67F472C13878234F1BB4B5" xlink:to="loc_us-gaap_AssetImpairmentCharges_A4B6A9BF74EB4CEE973978234F1BD1FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_265940CAA3D1BF4145BE78234F1BA9DC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_654EFD9B0D67F472C13878234F1BB4B5" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_265940CAA3D1BF4145BE78234F1BA9DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_4840FF339B45E996C5C478234F1B8E5F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_654EFD9B0D67F472C13878234F1BB4B5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_4840FF339B45E996C5C478234F1B8E5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9DDBA9AE2C51FF3A40EC78234F1CF6BB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_654EFD9B0D67F472C13878234F1BB4B5" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9DDBA9AE2C51FF3A40EC78234F1CF6BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_037F4DBB5E57B68A3C3978234F1CF0C8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_654EFD9B0D67F472C13878234F1BB4B5" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_037F4DBB5E57B68A3C3978234F1CF0C8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5A5647F7DEAB85518B1D78234F02B48C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_EC95D591637081B6123878234F02D53C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5A5647F7DEAB85518B1D78234F02B48C" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_EC95D591637081B6123878234F02D53C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_A14296A47215B03741C278234F034199" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_EC95D591637081B6123878234F02D53C" xlink:to="loc_srt_RangeAxis_A14296A47215B03741C278234F034199" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_F7654E27E3D57F10C1D678234F033114" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_A14296A47215B03741C278234F034199" xlink:to="loc_srt_RangeMember_F7654E27E3D57F10C1D678234F033114" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_143C0E82977F1443596978234F039525" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_F7654E27E3D57F10C1D678234F033114" xlink:to="loc_srt_MinimumMember_143C0E82977F1443596978234F039525" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_3E39196111E9AFAE167E78234F04952F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_F7654E27E3D57F10C1D678234F033114" xlink:to="loc_srt_MaximumMember_3E39196111E9AFAE167E78234F04952F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_WeightedAverageMember" xlink:label="loc_srt_WeightedAverageMember_56CDC77D9A7D342098D678234F046C93" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_F7654E27E3D57F10C1D678234F033114" xlink:to="loc_srt_WeightedAverageMember_56CDC77D9A7D342098D678234F046C93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_58369FF89A2DA2F4112778234F04240B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_EC95D591637081B6123878234F02D53C" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_58369FF89A2DA2F4112778234F04240B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_B0FBD1E1B897A6971BA078234F0466B4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_58369FF89A2DA2F4112778234F04240B" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_B0FBD1E1B897A6971BA078234F0466B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_E9A542F203368CF24C0078234F05CBAA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_B0FBD1E1B897A6971BA078234F0466B4" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_E9A542F203368CF24C0078234F05CBAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_E6751B9D306F11E72D7E78234F05A4D4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_EC95D591637081B6123878234F02D53C" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_E6751B9D306F11E72D7E78234F05A4D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_226F9EA1494AC8CEB08178234F054F77" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_E6751B9D306F11E72D7E78234F05A4D4" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_226F9EA1494AC8CEB08178234F054F77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_553DAB027FFA6A126E7478234F050F0A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_EC95D591637081B6123878234F02D53C" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_553DAB027FFA6A126E7478234F050F0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6D6188B73C4C6E5D6F8178234F065143" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_553DAB027FFA6A126E7478234F050F0A" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6D6188B73C4C6E5D6F8178234F065143" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F513436CEEF777DE894E78234F0685FB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_EC95D591637081B6123878234F02D53C" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F513436CEEF777DE894E78234F0685FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_6AC47037E87A5641D70278234F066107" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F513436CEEF777DE894E78234F0685FB" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_6AC47037E87A5641D70278234F066107" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4FA8F68B83979D7448FA78234F07EE39" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F513436CEEF777DE894E78234F0685FB" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4FA8F68B83979D7448FA78234F07EE39" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_A79BD14FE5224768223878234F762377" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_98CD76FC7A5BA8E90A8378234F76E849" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_A79BD14FE5224768223878234F762377" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_98CD76FC7A5BA8E90A8378234F76E849" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_0F2B8A648FCAE707626A78234F76E6C3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_A79BD14FE5224768223878234F762377" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_0F2B8A648FCAE707626A78234F76E6C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_D3EFB9A76B84D501EDC278234F769421" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_A79BD14FE5224768223878234F762377" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_D3EFB9A76B84D501EDC278234F769421" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4E48D7375C0FDF551CED78234EF01EF1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_29F56403887E2934EA2678234EF06348" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4E48D7375C0FDF551CED78234EF01EF1" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_29F56403887E2934EA2678234EF06348" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1D620B945E184B82FA4D78234EDA4568" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_261F922073DFDD702C7E78234EDA4C9B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1D620B945E184B82FA4D78234EDA4568" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_261F922073DFDD702C7E78234EDA4C9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_5CA4A60660FB69149C3E78234EDA0034" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_261F922073DFDD702C7E78234EDA4C9B" xlink:to="loc_us-gaap_InvestmentTypeAxis_5CA4A60660FB69149C3E78234EDA0034" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_CAE13082916CD16573ED78234EDA3D8D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_5CA4A60660FB69149C3E78234EDA0034" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_CAE13082916CD16573ED78234EDA3D8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_A6EEA421602F6CFA8D4078234EDB0756" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_CAE13082916CD16573ED78234EDA3D8D" xlink:to="loc_us-gaap_CommercialPaperMember_A6EEA421602F6CFA8D4078234EDB0756" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_C3D57353D4C9441586FB78234EDB8574" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_CAE13082916CD16573ED78234EDA3D8D" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_C3D57353D4C9441586FB78234EDB8574" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_5A6684A401052B1D964278234EDBBD1F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_CAE13082916CD16573ED78234EDA3D8D" xlink:to="loc_us-gaap_MoneyMarketFundsMember_5A6684A401052B1D964278234EDBBD1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_4D4031CFE6D800DCCFCF78234EDBDC5D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_CAE13082916CD16573ED78234EDA3D8D" xlink:to="loc_us-gaap_DebtSecuritiesMember_4D4031CFE6D800DCCFCF78234EDBDC5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_480B293181A77D9802B478234EDD81FC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_261F922073DFDD702C7E78234EDA4C9B" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_480B293181A77D9802B478234EDD81FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_6ECA9CE58ABA1F7AB41A78234EDD0B1E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_480B293181A77D9802B478234EDD81FC" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_6ECA9CE58ABA1F7AB41A78234EDD0B1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_0995BECB7E6E71E5A36678234EDDE117" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_6ECA9CE58ABA1F7AB41A78234EDD0B1E" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_0995BECB7E6E71E5A36678234EDDE117" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7BF29C7B2E5CBFC6CD4C78234EC2B6CA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_594807FC0CE38E74B84178234EC35E00" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7BF29C7B2E5CBFC6CD4C78234EC2B6CA" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_594807FC0CE38E74B84178234EC35E00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_686D2E8850A2A80122FF78234EC329C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_594807FC0CE38E74B84178234EC35E00" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_686D2E8850A2A80122FF78234EC329C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2DDEB3FC7C3393DCB8C578234EC4CA48" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_686D2E8850A2A80122FF78234EC329C4" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2DDEB3FC7C3393DCB8C578234EC4CA48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_63D42E622DCF3A50CDA778234EC41679" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2DDEB3FC7C3393DCB8C578234EC4CA48" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_63D42E622DCF3A50CDA778234EC41679" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_C441E79B27348A81961F78234EC46F9E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2DDEB3FC7C3393DCB8C578234EC4CA48" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_C441E79B27348A81961F78234EC46F9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_CC7A3C71F5BB7A4B779178234EC57EA6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_594807FC0CE38E74B84178234EC35E00" xlink:to="loc_us-gaap_FinancialInstrumentAxis_CC7A3C71F5BB7A4B779178234EC57EA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F72B48CBECE3CB71283078234EC59062" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_CC7A3C71F5BB7A4B779178234EC57EA6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F72B48CBECE3CB71283078234EC59062" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_CorporateDebtSecuritiesCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_C1852C6D28B675BC600C78234EC57733" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F72B48CBECE3CB71283078234EC59062" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_C1852C6D28B675BC600C78234EC57733" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_CorporateDebtSecuritiesNonCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_40A7607CD547745D111E78234EC66C2A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F72B48CBECE3CB71283078234EC59062" xlink:to="loc_biib_CorporateDebtSecuritiesNonCurrentMember_40A7607CD547745D111E78234EC66C2A" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_GovernmentSecuritiesCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_0ACEA705C97C0AFBF82B78234EC62669" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F72B48CBECE3CB71283078234EC59062" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_0ACEA705C97C0AFBF82B78234EC62669" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_GovernmentSecuritiesNonCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_E9F3DC15943B28DD4CAA78234EC68DFF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F72B48CBECE3CB71283078234EC59062" xlink:to="loc_biib_GovernmentSecuritiesNonCurrentMember_E9F3DC15943B28DD4CAA78234EC68DFF" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_85E2822FCC7EBF1C52DB78234EC6F4C4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F72B48CBECE3CB71283078234EC59062" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_85E2822FCC7EBF1C52DB78234EC6F4C4" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_EA0140D266E0BCE6FE8878234EC6E797" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F72B48CBECE3CB71283078234EC59062" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_EA0140D266E0BCE6FE8878234EC6E797" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_B54C5E89489CAEF48A6278234EC7E2A9" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F72B48CBECE3CB71283078234EC59062" xlink:to="loc_us-gaap_EquitySecuritiesMember_B54C5E89489CAEF48A6278234EC7E2A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3610FB7AA46300C7B49778234EC788C8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_594807FC0CE38E74B84178234EC35E00" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3610FB7AA46300C7B49778234EC788C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_075AE495E556ECF92EF978234EC765B0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3610FB7AA46300C7B49778234EC788C8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_075AE495E556ECF92EF978234EC765B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0813CC192AEDDD7955C478234ECDEDC5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3610FB7AA46300C7B49778234EC788C8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0813CC192AEDDD7955C478234ECDEDC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_29AF053459D656440B3378234ECDF713" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3610FB7AA46300C7B49778234EC788C8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_29AF053459D656440B3378234ECDF713" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_A64B06DDFFDC0BCEE3C778234ECDD128" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3610FB7AA46300C7B49778234EC788C8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_A64B06DDFFDC0BCEE3C778234ECDD128" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_D9CB118088444C1E90B478234ECD1B63" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3610FB7AA46300C7B49778234EC788C8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_D9CB118088444C1E90B478234ECD1B63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_10703108CA9FA0320E5278234ECD27ED" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3610FB7AA46300C7B49778234EC788C8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_10703108CA9FA0320E5278234ECD27ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_FE85476A8D800045C41178234ECEA474" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3610FB7AA46300C7B49778234EC788C8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_FE85476A8D800045C41178234ECEA474" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_00272BF809828F29FDAF78234ECE20BF" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3610FB7AA46300C7B49778234EC788C8" xlink:to="loc_us-gaap_AvailableForSaleSecurities_00272BF809828F29FDAF78234ECE20BF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_708B192EEF4AA9B908C478234EA54B1D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_9FE90EC279E6693041EF78234EA5295F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_708B192EEF4AA9B908C478234EA54B1D" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_9FE90EC279E6693041EF78234EA5295F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_C49DD559E1F749946F6C78234EA5286A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_9FE90EC279E6693041EF78234EA5295F" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_C49DD559E1F749946F6C78234EA5286A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_0D86441FF33736C0EC5E78234EA6B529" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_9FE90EC279E6693041EF78234EA5295F" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_0D86441FF33736C0EC5E78234EA6B529" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_38D0558503DBCAA7082778234EA6F4CE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_9FE90EC279E6693041EF78234EA5295F" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_38D0558503DBCAA7082778234EA6F4CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_2133E60CB74173BCBA2278234EA68AF7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_9FE90EC279E6693041EF78234EA5295F" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_2133E60CB74173BCBA2278234EA68AF7" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_2D7BA321A0BC60BCB77E78234EA68070" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_9FE90EC279E6693041EF78234EA5295F" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_2D7BA321A0BC60BCB77E78234EA68070" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_F8349E787F38BF11B7B278234EA68D6D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_9FE90EC279E6693041EF78234EA5295F" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_F8349E787F38BF11B7B278234EA68D6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_918F5D2652451DBB9EFD78234EA7F9DF" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_9FE90EC279E6693041EF78234EA5295F" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_918F5D2652451DBB9EFD78234EA7F9DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_2C0ECE20A0930743637278234EA7EA69" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_9FE90EC279E6693041EF78234EA5295F" xlink:to="loc_us-gaap_AvailableForSaleSecurities_2C0ECE20A0930743637278234EA7EA69" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_58351A4D5B6C6DC430DA78234E8E598D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_447AA235E19F55E2736578234E8E1B8D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_58351A4D5B6C6DC430DA78234E8E598D" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_447AA235E19F55E2736578234E8E1B8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_8170464C2E381753805178234E93B73E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_58351A4D5B6C6DC430DA78234E8E598D" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_8170464C2E381753805178234E93B73E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_392A6844A7EC0667088078234E94D166" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_58351A4D5B6C6DC430DA78234E8E598D" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_392A6844A7EC0667088078234E94D166" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6A1B451556EEA7AC3F4178234E88EB25" xlink:type="locator" />
    <link:loc xlink:href="biib-20200630.xsd#biib_AverageMaturityOfMarketableSecurities" xlink:label="loc_biib_AverageMaturityOfMarketableSecurities_8770E92C5EFDA9C5087D78234E89BFB1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6A1B451556EEA7AC3F4178234E88EB25" xlink:to="loc_biib_AverageMaturityOfMarketableSecurities_8770E92C5EFDA9C5087D78234E89BFB1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_1461EF9DEF016B47C03C78234E74CFC3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FA764A988E2D1282989E78234E74A4CA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_1461EF9DEF016B47C03C78234E74CFC3" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FA764A988E2D1282989E78234E74A4CA" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_20FF1F8C0E71795435AD78234E75F05B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FA764A988E2D1282989E78234E74A4CA" xlink:to="loc_dei_LegalEntityAxis_20FF1F8C0E71795435AD78234E75F05B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_5873327B1A70D51FBC9278234E758508" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_20FF1F8C0E71795435AD78234E75F05B" xlink:to="loc_dei_EntityDomain_5873327B1A70D51FBC9278234E758508" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_SangamoCommonStockMember" xlink:label="loc_biib_SangamoCommonStockMember_CA705A8548328C201D5278234E75A146" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_5873327B1A70D51FBC9278234E758508" xlink:to="loc_biib_SangamoCommonStockMember_CA705A8548328C201D5278234E75A146" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_DA9FAB448C223FD5E49078234E7B16DE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FA764A988E2D1282989E78234E74A4CA" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_DA9FAB448C223FD5E49078234E7B16DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_A0E9E80E948FA136EB3278234E7C8DA9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_DA9FAB448C223FD5E49078234E7B16DE" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_A0E9E80E948FA136EB3278234E7C8DA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_7973B740329FE0586DA978234E7CC6DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_A0E9E80E948FA136EB3278234E7C8DA9" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_7973B740329FE0586DA978234E7CC6DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_48B1C310970F014879FC78234E7C75C9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_A0E9E80E948FA136EB3278234E7C8DA9" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_48B1C310970F014879FC78234E7C75C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_814DA8531DFE0D1405A278234E7CF631" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FA764A988E2D1282989E78234E74A4CA" xlink:to="loc_us-gaap_FinancialInstrumentAxis_814DA8531DFE0D1405A278234E7CF631" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E35A225C903BCA84A0EC78234E7D83FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_814DA8531DFE0D1405A278234E7CF631" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E35A225C903BCA84A0EC78234E7D83FB" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_StrategicInvestmentsMember" xlink:label="loc_biib_StrategicInvestmentsMember_91199FEA85566A8417F078234E7DB52A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E35A225C903BCA84A0EC78234E7D83FB" xlink:to="loc_biib_StrategicInvestmentsMember_91199FEA85566A8417F078234E7DB52A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_E09775E122CC2708A39678234E7D3121" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FA764A988E2D1282989E78234E74A4CA" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_E09775E122CC2708A39678234E7D3121" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_StrategicInvestmentPortfolio" xlink:label="loc_biib_StrategicInvestmentPortfolio_80F8D089D0567CFB51ED78234E7ECE52" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E09775E122CC2708A39678234E7D3121" xlink:to="loc_biib_StrategicInvestmentPortfolio_80F8D089D0567CFB51ED78234E7ECE52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_DAC350DE29933A7BEFCF78234E7E53A6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E09775E122CC2708A39678234E7D3121" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_DAC350DE29933A7BEFCF78234E7E53A6" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_Investmentincommonstocksharespurchased" xlink:label="loc_biib_Investmentincommonstocksharespurchased_33704BBB00D725B93DC678234E7E32A2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_E09775E122CC2708A39678234E7D3121" xlink:to="loc_biib_Investmentincommonstocksharespurchased_33704BBB00D725B93DC678234E7E32A2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_EF2116F15C08A3AE900878234EE6CB9C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_47A15732913F47441B7978234EE62BCB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_EF2116F15C08A3AE900878234EE6CB9C" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_47A15732913F47441B7978234EE62BCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_8488B1756A8FFB54F36578234EE78573" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_EF2116F15C08A3AE900878234EE6CB9C" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_8488B1756A8FFB54F36578234EE78573" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_062D8FBD4B02932BC35478234EE76DF8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_EF2116F15C08A3AE900878234EE6CB9C" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_062D8FBD4B02932BC35478234EE76DF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_26D61F7D3F3578C286D678234EE7CE94" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_EF2116F15C08A3AE900878234EE6CB9C" xlink:to="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_26D61F7D3F3578C286D678234EE7CE94" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_F37AA3453F5618EC141C78234D28DBE3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_D4C408D7D40695F8B19D78234D284AB2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_F37AA3453F5618EC141C78234D28DBE3" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_D4C408D7D40695F8B19D78234D284AB2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_59DF93AD64CF10B0632E78234D0D44AF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_9C3A91919AD13028A48878234D0D197A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_59DF93AD64CF10B0632E78234D0D44AF" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_9C3A91919AD13028A48878234D0D197A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_F27BDE5B17A75DC69B4878234D0DFAFA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_9C3A91919AD13028A48878234D0D197A" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_F27BDE5B17A75DC69B4878234D0DFAFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8F75D41E6F568EDD07D778234D0EA5F0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_9C3A91919AD13028A48878234D0D197A" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8F75D41E6F568EDD07D778234D0EA5F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_B10661AECEF7704BAED478234D0E1480" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_9C3A91919AD13028A48878234D0D197A" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_B10661AECEF7704BAED478234D0E1480" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_476442391F153EACB84178234D0ED8F5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_9C3A91919AD13028A48878234D0D197A" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_476442391F153EACB84178234D0ED8F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_277474AC3088BAD6A82778234D0FB4D5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_9C3A91919AD13028A48878234D0D197A" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_277474AC3088BAD6A82778234D0FB4D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_1754B6BDCD98577BD78D78234D0F3206" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_9C3A91919AD13028A48878234D0D197A" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_1754B6BDCD98577BD78D78234D0F3206" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_A17EFE60069CF17C7C4378234D0F86D3" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_9C3A91919AD13028A48878234D0D197A" xlink:to="loc_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_A17EFE60069CF17C7C4378234D0F86D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_01700F3C74648C928D1A78234D0F9F57" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_9C3A91919AD13028A48878234D0D197A" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_01700F3C74648C928D1A78234D0F9F57" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_EffectiveTaxRateReconciliationGILTItax" xlink:label="loc_biib_EffectiveTaxRateReconciliationGILTItax_C63D2B381ABB16473C0D78234D0F7025" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_9C3A91919AD13028A48878234D0D197A" xlink:to="loc_biib_EffectiveTaxRateReconciliationGILTItax_C63D2B381ABB16473C0D78234D0F7025" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_CD45F3168C5D698F262478234D109FBE" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_9C3A91919AD13028A48878234D0D197A" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_CD45F3168C5D698F262478234D109FBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_C92D6C005D85BD313E1578234D10AC16" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_9C3A91919AD13028A48878234D0D197A" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_C92D6C005D85BD313E1578234D10AC16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_57CA91E22F1EFC6C505E78234D10D933" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_9C3A91919AD13028A48878234D0D197A" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_57CA91E22F1EFC6C505E78234D10D933" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_DC357BC0D4BCC707841578234D1ACB2F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_68A4DD4B1B8AC932763478234D1A4EA1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_DC357BC0D4BCC707841578234D1ACB2F" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_68A4DD4B1B8AC932763478234D1A4EA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_66A47C399DFB8F4E290778234D1A95F6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_68A4DD4B1B8AC932763478234D1A4EA1" xlink:to="loc_srt_ProductOrServiceAxis_66A47C399DFB8F4E290778234D1A95F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_35057C12EA60A87909FC78234D1BD104" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_66A47C399DFB8F4E290778234D1A95F6" xlink:to="loc_srt_ProductsAndServicesDomain_35057C12EA60A87909FC78234D1BD104" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_TECFIDERAMember" xlink:label="loc_biib_TECFIDERAMember_440D9B128EBAF06F29CF78234D1C2CC6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_35057C12EA60A87909FC78234D1BD104" xlink:to="loc_biib_TECFIDERAMember_440D9B128EBAF06F29CF78234D1C2CC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8AACF74FF3023C2D506378234D1C6590" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_68A4DD4B1B8AC932763478234D1A4EA1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8AACF74FF3023C2D506378234D1C6590" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_56B9999C4F63CAFAE44B78234D1C8504" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8AACF74FF3023C2D506378234D1C6590" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_56B9999C4F63CAFAE44B78234D1C8504" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_DenmarkManufacturingOperationsMember" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_B6E73C6E7906F25B6A2778234D1C2AA9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_56B9999C4F63CAFAE44B78234D1C8504" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_B6E73C6E7906F25B6A2778234D1C2AA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_2D0867D3EF0C9566AFB378234D1D6752" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_68A4DD4B1B8AC932763478234D1A4EA1" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_2D0867D3EF0C9566AFB378234D1D6752" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_DeferredTaxAssetsValueReductioninValue" xlink:label="loc_biib_DeferredTaxAssetsValueReductioninValue_408F39B78C0420D48B8C78234D1DF5CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2D0867D3EF0C9566AFB378234D1D6752" xlink:to="loc_biib_DeferredTaxAssetsValueReductioninValue_408F39B78C0420D48B8C78234D1DF5CC" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_DeferredTaxLiabilitiesValueReductioninValue" xlink:label="loc_biib_DeferredTaxLiabilitiesValueReductioninValue_861728C510B01CD4EFAF78234D1EF68D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2D0867D3EF0C9566AFB378234D1D6752" xlink:to="loc_biib_DeferredTaxLiabilitiesValueReductioninValue_861728C510B01CD4EFAF78234D1EF68D" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet" xlink:label="loc_biib_IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet_2C7A8D7F5FCD8A3B514E78234D1ED998" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2D0867D3EF0C9566AFB378234D1D6752" xlink:to="loc_biib_IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet_2C7A8D7F5FCD8A3B514E78234D1ED998" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_CC2CB21314A5E082B71178234D1E52B1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2D0867D3EF0C9566AFB378234D1D6752" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_CC2CB21314A5E082B71178234D1E52B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_F29DDBE9BB7DFB79D5E278234D1F8C63" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2D0867D3EF0C9566AFB378234D1D6752" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_F29DDBE9BB7DFB79D5E278234D1F8C63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_CB583616827F71AD877478234D1F8AAA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2D0867D3EF0C9566AFB378234D1D6752" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_CB583616827F71AD877478234D1F8AAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_1D8346AF62D9ECF5567878234D1F6806" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2D0867D3EF0C9566AFB378234D1D6752" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_1D8346AF62D9ECF5567878234D1F6806" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_90CB2D39EB17E89EFDC278234D24F740" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_01B379D89DD883328B7C78234D25907C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_90CB2D39EB17E89EFDC278234D24F740" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_01B379D89DD883328B7C78234D25907C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_FD2EB9033DA9D28954C678234DFE88C7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_FD8658935B1E74D4485478234DFED434" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_FD2EB9033DA9D28954C678234DFE88C7" xlink:to="loc_us-gaap_DebtInstrumentTable_FD8658935B1E74D4485478234DFED434" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7FD531B531375095EBF578234DFFA51F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_FD8658935B1E74D4485478234DFED434" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_7FD531B531375095EBF578234DFFA51F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_50A1B6E57E8F0602E59A78234DFFD9A0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7FD531B531375095EBF578234DFFA51F" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_50A1B6E57E8F0602E59A78234DFFD9A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseMember" xlink:label="loc_us-gaap_InterestExpenseMember_37FBD55FA64CA128310078234DFF5339" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_50A1B6E57E8F0602E59A78234DFFD9A0" xlink:to="loc_us-gaap_InterestExpenseMember_37FBD55FA64CA128310078234DFF5339" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_80337CBFF92BDD4F95E078234E0080E1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_FD8658935B1E74D4485478234DFED434" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_80337CBFF92BDD4F95E078234E0080E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_C29C616EAF7D7695B36278234E00308E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_80337CBFF92BDD4F95E078234E0080E1" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_C29C616EAF7D7695B36278234E00308E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_6DC7D416C0F04B3405CB78234E004BD4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_C29C616EAF7D7695B36278234E00308E" xlink:to="loc_us-gaap_InterestRateSwapMember_6DC7D416C0F04B3405CB78234E004BD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_CE7097083217A93B8EA178234E01F7A9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_FD8658935B1E74D4485478234DFED434" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_CE7097083217A93B8EA178234E01F7A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_A4E6EC2C37243BFA11A778234E0192AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_CE7097083217A93B8EA178234E01F7A9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_A4E6EC2C37243BFA11A778234E0192AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_3829401E5E67FEDAFB2978234E01557E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_A4E6EC2C37243BFA11A778234E0192AB" xlink:to="loc_us-gaap_SeniorNotesMember_3829401E5E67FEDAFB2978234E01557E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_18E810C5787CACEB4D6178234E02A1D3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_FD8658935B1E74D4485478234DFED434" xlink:to="loc_us-gaap_DebtInstrumentAxis_18E810C5787CACEB4D6178234E02A1D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_D0B7E880C40926BAE85978234E02A31F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_18E810C5787CACEB4D6178234E02A1D3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_D0B7E880C40926BAE85978234E02A31F" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_A2.25SeniorNotesdueMay12030Member" xlink:label="loc_biib_A2.25SeniorNotesdueMay12030Member_D3CAF1C239084578A8FE78234E02222E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_D0B7E880C40926BAE85978234E02A31F" xlink:to="loc_biib_A2.25SeniorNotesdueMay12030Member_D3CAF1C239084578A8FE78234E02222E" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_A3.15SeniorNotesdueMay12050Member" xlink:label="loc_biib_A3.15SeniorNotesdueMay12050Member_FFBE327FDC11DB6F523F78234E03F337" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_D0B7E880C40926BAE85978234E02A31F" xlink:to="loc_biib_A3.15SeniorNotesdueMay12050Member_FFBE327FDC11DB6F523F78234E03F337" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_A2.90SeniorNotesDueSept152020Member" xlink:label="loc_biib_A2.90SeniorNotesDueSept152020Member_90AE65317A500594430E78234E03A59C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_D0B7E880C40926BAE85978234E02A31F" xlink:to="loc_biib_A2.90SeniorNotesDueSept152020Member_90AE65317A500594430E78234E03A59C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_F54971E4AEE11F1E7EEB78234E0348F4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_FD8658935B1E74D4485478234DFED434" xlink:to="loc_us-gaap_DebtInstrumentLineItems_F54971E4AEE11F1E7EEB78234E0348F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_DFA14428B2F2F8837FE778234E046E34" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F54971E4AEE11F1E7EEB78234E0348F4" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_DFA14428B2F2F8837FE778234E046E34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0C11E8D55B3E655FCDDE78234E04B38F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F54971E4AEE11F1E7EEB78234E0348F4" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0C11E8D55B3E655FCDDE78234E04B38F" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_PercentageParValueOfSeniorNotes" xlink:label="loc_biib_PercentageParValueOfSeniorNotes_35E8CB289240A81DD02F78234E04B359" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F54971E4AEE11F1E7EEB78234E0348F4" xlink:to="loc_biib_PercentageParValueOfSeniorNotes_35E8CB289240A81DD02F78234E04B359" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_C13201A87FEBF26D4B4A78234E048239" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F54971E4AEE11F1E7EEB78234E0348F4" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_C13201A87FEBF26D4B4A78234E048239" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" xlink:label="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_148F99714CE170FB07FE78234E0590D8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F54971E4AEE11F1E7EEB78234E0348F4" xlink:to="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_148F99714CE170FB07FE78234E0590D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_20CEE83B7A3254022C6378234E05FAA1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F54971E4AEE11F1E7EEB78234E0348F4" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_20CEE83B7A3254022C6378234E05FAA1" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain" xlink:label="loc_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain_FE6610747100E4C3507078234E05C65D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F54971E4AEE11F1E7EEB78234E0348F4" xlink:to="loc_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain_FE6610747100E4C3507078234E05C65D" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts" xlink:label="loc_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts_8C8625470D56534B167978234E05CD1D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F54971E4AEE11F1E7EEB78234E0348F4" xlink:to="loc_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts_8C8625470D56534B167978234E05CD1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_71E68D24AC8F0AE1E55578234E0691ED" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F54971E4AEE11F1E7EEB78234E0348F4" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_71E68D24AC8F0AE1E55578234E0691ED" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IndebtednessNotes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9707417C11BDE773991078234E0CBD2F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_67B5BDACFA1063C6D64078234E0CEA13" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9707417C11BDE773991078234E0CBD2F" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_67B5BDACFA1063C6D64078234E0CEA13" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_341E8763CA32403B176D78234FCE4391" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_30B2AF81B9702A356FD378234FCEAC7A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_341E8763CA32403B176D78234FCE4391" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_30B2AF81B9702A356FD378234FCEAC7A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4AFF54315A56F15B4E6A78234FA9BAA2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C09DFF379A38D58E3F3A78234FA92F0B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4AFF54315A56F15B4E6A78234FA9BAA2" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C09DFF379A38D58E3F3A78234FA92F0B" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_ResearchanddevelopmentassetAxis" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_BDB6617DC4563729C4D078234FAA1D51" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C09DFF379A38D58E3F3A78234FA92F0B" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_BDB6617DC4563729C4D078234FAA1D51" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_ResearchanddevelopmentassetDomain" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_6CBF270328EBBBDDF62C78234FAAF4D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_BDB6617DC4563729C4D078234FAA1D51" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_6CBF270328EBBBDDF62C78234FAAF4D5" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_TGNMember" xlink:label="loc_biib_TGNMember_364B5BDB601D023ED0E378234FAAE77F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_6CBF270328EBBBDDF62C78234FAAF4D5" xlink:to="loc_biib_TGNMember_364B5BDB601D023ED0E378234FAAE77F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_F28AA96F75B33334259278234FAA2121" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C09DFF379A38D58E3F3A78234FA92F0B" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_F28AA96F75B33334259278234FAA2121" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2882A1D92C2CE3A7AD6578234FAB80E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_F28AA96F75B33334259278234FAA2121" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2882A1D92C2CE3A7AD6578234FAB80E2" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_NightstarMember" xlink:label="loc_biib_NightstarMember_23A5C4847CD062B909B678234FAB162A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2882A1D92C2CE3A7AD6578234FAB80E2" xlink:to="loc_biib_NightstarMember_23A5C4847CD062B909B678234FAB162A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_405FF7A9370EFA5DFEAA78234FAB0DE7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C09DFF379A38D58E3F3A78234FA92F0B" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_405FF7A9370EFA5DFEAA78234FAB0DE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_533A25097FA5A65FA50E78234FABC793" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_405FF7A9370EFA5DFEAA78234FAB0DE7" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_533A25097FA5A65FA50E78234FABC793" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_8DE293E47B3A0C4C1BB378234FB1D6CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_533A25097FA5A65FA50E78234FABC793" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_8DE293E47B3A0C4C1BB378234FB1D6CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_3A7852CD09B710E9F4DB78234FB1336D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_533A25097FA5A65FA50E78234FABC793" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_3A7852CD09B710E9F4DB78234FB1336D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_868E818B5FC10726AC1F78234FB1F102" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C09DFF379A38D58E3F3A78234FA92F0B" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_868E818B5FC10726AC1F78234FB1F102" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8EC40EE2DB80D8ACE17478234FB2A9CA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_868E818B5FC10726AC1F78234FB1F102" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8EC40EE2DB80D8ACE17478234FB2A9CA" xlink:type="arc" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8EC40EE2DB80D8ACE17478234FB2A9CA" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_8DE293E47B3A0C4C1BB378234FB1D6CC" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_OutLicensedPatentsMember" xlink:label="loc_biib_OutLicensedPatentsMember_DD035309CE164FB3058C78234FB28CC6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8EC40EE2DB80D8ACE17478234FB2A9CA" xlink:to="loc_biib_OutLicensedPatentsMember_DD035309CE164FB3058C78234FB28CC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_8CA485A3DD68CA7AD91678234FB3E0C6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8EC40EE2DB80D8ACE17478234FB2A9CA" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_8CA485A3DD68CA7AD91678234FB3E0C6" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_ECC85B19A8FFB933FFA078234FB3772C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8EC40EE2DB80D8ACE17478234FB2A9CA" xlink:to="loc_biib_InLicensedPatentsMember_ECC85B19A8FFB933FFA078234FB3772C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_4BFB124AFC5031DDB7B978234FB3161A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C09DFF379A38D58E3F3A78234FA92F0B" xlink:to="loc_srt_ProductOrServiceAxis_4BFB124AFC5031DDB7B978234FB3161A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_C54D1AF57D89137B973078234FB3009C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4BFB124AFC5031DDB7B978234FB3161A" xlink:to="loc_srt_ProductsAndServicesDomain_C54D1AF57D89137B973078234FB3009C" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_AVONEXMember" xlink:label="loc_biib_AVONEXMember_3EA89EA94DEA39D0A80578234FB34BF8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_C54D1AF57D89137B973078234FB3009C" xlink:to="loc_biib_AVONEXMember_3EA89EA94DEA39D0A80578234FB34BF8" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_CDAA0264EEE8BC9E621578234FB43B50" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_C54D1AF57D89137B973078234FB3009C" xlink:to="loc_biib_TysabriProductMember_CDAA0264EEE8BC9E621578234FB43B50" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_FumarateMember" xlink:label="loc_biib_FumarateMember_88F71694B70875C5D01178234FB4B91D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_C54D1AF57D89137B973078234FB3009C" xlink:to="loc_biib_FumarateMember_88F71694B70875C5D01178234FB4B91D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_062C845C84D72DAF049D78234FB49377" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C09DFF379A38D58E3F3A78234FA92F0B" xlink:to="loc_srt_RangeAxis_062C845C84D72DAF049D78234FB49377" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_A07105BCA31F3F2F65E578234FB415F6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_062C845C84D72DAF049D78234FB49377" xlink:to="loc_srt_RangeMember_A07105BCA31F3F2F65E578234FB415F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_F802377A1B2211A4636078234FB5D916" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_A07105BCA31F3F2F65E578234FB415F6" xlink:to="loc_srt_MinimumMember_F802377A1B2211A4636078234FB5D916" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_8E7899445981F703134078234FB52E79" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_A07105BCA31F3F2F65E578234FB415F6" xlink:to="loc_srt_MaximumMember_8E7899445981F703134078234FB52E79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16BF20058BF8C4E64BDB78234FB586E9" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C09DFF379A38D58E3F3A78234FA92F0B" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16BF20058BF8C4E64BDB78234FB586E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_E1CDDF8FC15247E2430378234FB579C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16BF20058BF8C4E64BDB78234FB586E9" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_E1CDDF8FC15247E2430378234FB579C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2EC95A182BC370A20B3B78234FB6DE86" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16BF20058BF8C4E64BDB78234FB586E9" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2EC95A182BC370A20B3B78234FB6DE86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_986C527AC40F30088D6A78234FB65359" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2EC95A182BC370A20B3B78234FB6DE86" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_986C527AC40F30088D6A78234FB65359" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_DD721073DEFC7A43C2B178234FB6056C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2EC95A182BC370A20B3B78234FB6DE86" xlink:to="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_DD721073DEFC7A43C2B178234FB6056C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6B4AC9E66296B6D82E3178234FB64358" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2EC95A182BC370A20B3B78234FB6DE86" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6B4AC9E66296B6D82E3178234FB64358" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_163FE67D57DFB21305DA78234FB7E56D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2EC95A182BC370A20B3B78234FB6DE86" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_163FE67D57DFB21305DA78234FB7E56D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_67C5828C7AACCAF556EC78234FB7BA1D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2EC95A182BC370A20B3B78234FB6DE86" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_67C5828C7AACCAF556EC78234FB7BA1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ADE0CCBA19CD62EAF91878234FB775BB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2EC95A182BC370A20B3B78234FB6DE86" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ADE0CCBA19CD62EAF91878234FB775BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_0ECB4D30C676A3F3715E78234FB74151" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2EC95A182BC370A20B3B78234FB6DE86" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_0ECB4D30C676A3F3715E78234FB74151" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_50EC9954FB226187D6C178234FB857A3" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2EC95A182BC370A20B3B78234FB6DE86" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_50EC9954FB226187D6C178234FB857A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_C88B58292FBC5CF4FDD978234FB84735" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_2EC95A182BC370A20B3B78234FB6DE86" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_C88B58292FBC5CF4FDD978234FB84735" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_FC7C6E31A1DFDDDFD84478234FB8734E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16BF20058BF8C4E64BDB78234FB586E9" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_FC7C6E31A1DFDDDFD84478234FB8734E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_B0A47D929CB4EABE0CBE78234FB8E6EF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16BF20058BF8C4E64BDB78234FB586E9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_B0A47D929CB4EABE0CBE78234FB8E6EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_282FFCEDF3FF87168B3B78234FB8E348" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16BF20058BF8C4E64BDB78234FB586E9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_282FFCEDF3FF87168B3B78234FB8E348" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_8793EC384F9687E0C2BB78234FB86C6E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16BF20058BF8C4E64BDB78234FB586E9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_8793EC384F9687E0C2BB78234FB86C6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_452DBE3058B65D90A61A78234FB8F00F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16BF20058BF8C4E64BDB78234FB586E9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_452DBE3058B65D90A61A78234FB8F00F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_A2371ED07C4A9C2D4C5C78234FB91B0E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16BF20058BF8C4E64BDB78234FB586E9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_A2371ED07C4A9C2D4C5C78234FB91B0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_CC839212FAEEB79502DE78234FB9D410" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16BF20058BF8C4E64BDB78234FB586E9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_CC839212FAEEB79502DE78234FB9D410" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_B372BA3C760F44854F5D78234FB9DF2C" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16BF20058BF8C4E64BDB78234FB586E9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_B372BA3C760F44854F5D78234FB9DF2C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_DF93800E977E5EE8A51E78234F87EF0C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_1550BCADA38AEC0CCDC978234F872970" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_DF93800E977E5EE8A51E78234F87EF0C" xlink:to="loc_us-gaap_GoodwillRollForward_1550BCADA38AEC0CCDC978234F872970" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_BC506DBAF73845FD9E4978234F883362" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_1550BCADA38AEC0CCDC978234F872970" xlink:to="loc_us-gaap_Goodwill_BC506DBAF73845FD9E4978234F883362" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_0EF7473086153B200DC678234F88FDD6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_1550BCADA38AEC0CCDC978234F872970" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_0EF7473086153B200DC678234F88FDD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_CA54124D7169DB18E9C078234F883B82" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_1550BCADA38AEC0CCDC978234F872970" xlink:to="loc_us-gaap_Goodwill_CA54124D7169DB18E9C078234F883B82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_1FA10ABA1162E11462B378234F883106" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_DF93800E977E5EE8A51E78234F87EF0C" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_1FA10ABA1162E11462B378234F883106" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_F444CC5983E7E43D27B878234FC5F003" xlink:type="locator" />
    <link:loc xlink:href="biib-20200630.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_EA0FFEB40F81228833BA78234FC6ED5D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_F444CC5983E7E43D27B878234FC5F003" xlink:to="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_EA0FFEB40F81228833BA78234FC6ED5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_371914A28BE8215129C178234FC650AE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_F444CC5983E7E43D27B878234FC5F003" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_371914A28BE8215129C178234FC650AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_9F86257A78025A6BDB1E78234FC6C604" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_F444CC5983E7E43D27B878234FC5F003" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_9F86257A78025A6BDB1E78234FC6C604" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_1A307E81C79F5B99E706782350047949" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_E751B7C87997E50944F7782350045B71" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_1A307E81C79F5B99E706782350047949" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_E751B7C87997E50944F7782350045B71" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_87033A1A94F936F9C36378234FF80727" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="loc_us-gaap_InventoryNetAbstract_06EDD5B56FAC0D2B2E9878234FF86639" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_87033A1A94F936F9C36378234FF80727" xlink:to="loc_us-gaap_InventoryNetAbstract_06EDD5B56FAC0D2B2E9878234FF86639" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_2068206D58BCF427804278234FF87F64" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_06EDD5B56FAC0D2B2E9878234FF86639" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_2068206D58BCF427804278234FF87F64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_D07AF1CB3BFDD467719E78234FF9CDF8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_06EDD5B56FAC0D2B2E9878234FF86639" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_D07AF1CB3BFDD467719E78234FF9CDF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_557641003EB751F84D6978234FF90284" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_06EDD5B56FAC0D2B2E9878234FF86639" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_557641003EB751F84D6978234FF90284" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_Inventorynetcurrentandnoncurrent" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_7EC986DB2169EE840CFE78234FF9CE06" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_06EDD5B56FAC0D2B2E9878234FF86639" xlink:to="loc_biib_Inventorynetcurrentandnoncurrent_7EC986DB2169EE840CFE78234FF9CE06" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_16E338CCFB45F7DF0E02782350015270" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_30C6DFD59EC511B50A5078235001263D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_16E338CCFB45F7DF0E02782350015270" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_30C6DFD59EC511B50A5078235001263D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:type="extended">
    <link:loc xlink:href="biib-20200630.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_D1D89B40257BDB73F7B678234C728154" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_3894580D5D964DBA33A978234C73344E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_D1D89B40257BDB73F7B678234C728154" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_3894580D5D964DBA33A978234C73344E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20200630.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_F532A08455576B95B57178234C666A29" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_19F29B8F037FB95C2B7778234C662169" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_F532A08455576B95B57178234C666A29" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_19F29B8F037FB95C2B7778234C662169" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_DE741A3B66D25005CCC678234C671F27" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_19F29B8F037FB95C2B7778234C662169" xlink:to="loc_us-gaap_TypeOfArrangementAxis_DE741A3B66D25005CCC678234C671F27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ED8BA0D9E0745FE43BEF78234C67716C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_DE741A3B66D25005CCC678234C671F27" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ED8BA0D9E0745FE43BEF78234C67716C" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_2A81DEE4099BF4CC387678234C6774D8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ED8BA0D9E0745FE43BEF78234C67716C" xlink:to="loc_biib_EisaiMember_2A81DEE4099BF4CC387678234C6774D8" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_FutureContingentMilestoneTypesAxis" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_2842361347B424BEFCAF78234C6890CF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_19F29B8F037FB95C2B7778234C662169" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_2842361347B424BEFCAF78234C6890CF" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_FutureContingentMilestoneTypesDomain" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_31044A41FFB446F3BDFB78234C68AD95" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_2842361347B424BEFCAF78234C6890CF" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_31044A41FFB446F3BDFB78234C68AD95" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_RegulatoryMilestonesMember" xlink:label="loc_biib_RegulatoryMilestonesMember_CB8C74A49C4DAF72167978234C696627" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_31044A41FFB446F3BDFB78234C68AD95" xlink:to="loc_biib_RegulatoryMilestonesMember_CB8C74A49C4DAF72167978234C696627" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_RegulatoryApprovalMilestoneMember" xlink:label="loc_biib_RegulatoryApprovalMilestoneMember_C072C0AAF618AC059E5D78234C69CAA1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_31044A41FFB446F3BDFB78234C68AD95" xlink:to="loc_biib_RegulatoryApprovalMilestoneMember_C072C0AAF618AC059E5D78234C69CAA1" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis" xlink:label="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_BA48A33032B89FB6206478234C6922F3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_19F29B8F037FB95C2B7778234C662169" xlink:to="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_BA48A33032B89FB6206478234C6922F3" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain" xlink:label="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_9426A7331D0DD760FC3478234C694B52" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_BA48A33032B89FB6206478234C6922F3" xlink:to="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_9426A7331D0DD760FC3478234C694B52" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_7517F11EB14032A097C478234C6A5AFA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_9426A7331D0DD760FC3478234C694B52" xlink:to="loc_biib_NeurimmuneMember_7517F11EB14032A097C478234C6A5AFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_A4ABAAD5C498E9BBCB2A78234C6A3994" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_19F29B8F037FB95C2B7778234C662169" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_A4ABAAD5C498E9BBCB2A78234C6A3994" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_0DD29C1ECA3DE8945DE578234C6B2212" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_A4ABAAD5C498E9BBCB2A78234C6A3994" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_0DD29C1ECA3DE8945DE578234C6B2212" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_Reductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Reductioninroyaltyratepayableoncommercialsales_BBC11FD3CAF1D16B14B578234C6B13E9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_A4ABAAD5C498E9BBCB2A78234C6A3994" xlink:to="loc_biib_Reductioninroyaltyratepayableoncommercialsales_BBC11FD3CAF1D16B14B578234C6B13E9" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_2B02760E96971A78433778234C6BEDE5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_A4ABAAD5C498E9BBCB2A78234C6A3994" xlink:to="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_2B02760E96971A78433778234C6BEDE5" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_370FB2EF4825033F9EFB78234C6BEBF2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_A4ABAAD5C498E9BBCB2A78234C6A3994" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_370FB2EF4825033F9EFB78234C6BEBF2" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_B4F043DFE0E3D7D4430978234C6C4C48" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_A4ABAAD5C498E9BBCB2A78234C6A3994" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_B4F043DFE0E3D7D4430978234C6C4C48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_C03939633FFE3886E14978234C6CC228" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_A4ABAAD5C498E9BBCB2A78234C6A3994" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_C03939633FFE3886E14978234C6CC228" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_4C9E680928B0674C70FD78234C6C7C08" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_A4ABAAD5C498E9BBCB2A78234C6A3994" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_4C9E680928B0674C70FD78234C6C7C08" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_930E9605B14ECB910CE178234C5BCFE3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_317F34B4F6B4BC84003878234C5BBC61" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_930E9605B14ECB910CE178234C5BCFE3" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_317F34B4F6B4BC84003878234C5BBC61" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/LitigationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_3AEB63FADCC224D4EEB378234C4ACF5B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_1FFDF5F13D9B158B403478234C4FE586" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_3AEB63FADCC224D4EEB378234C4ACF5B" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_1FFDF5F13D9B158B403478234C4FE586" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_CEA00406A7DC8331129578234C51514B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_1FFDF5F13D9B158B403478234C4FE586" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_CEA00406A7DC8331129578234C51514B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_0765ADE117898519063578234C517E38" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_CEA00406A7DC8331129578234C51514B" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_0765ADE117898519063578234C517E38" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="loc_country_BR_1D1005E1733B865665B878234C52F8DD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_0765ADE117898519063578234C517E38" xlink:to="loc_country_BR_1D1005E1733B865665B878234C52F8DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_A4B509A112DA0BDDB50378234C53AC2D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_1FFDF5F13D9B158B403478234C4FE586" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_A4B509A112DA0BDDB50378234C53AC2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_6AB301D1A2466F8F5A7B78234C538F6C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_A4B509A112DA0BDDB50378234C53AC2D" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_6AB301D1A2466F8F5A7B78234C538F6C" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_DisputedClaimsRelatingtoConstructionCosts" xlink:label="loc_biib_DisputedClaimsRelatingtoConstructionCosts_493362C131ECE105C96D78234C54F2B5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_A4B509A112DA0BDDB50378234C53AC2D" xlink:to="loc_biib_DisputedClaimsRelatingtoConstructionCosts_493362C131ECE105C96D78234C54F2B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_341DE2F53FD218D8DA4078234C54004E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_A4B509A112DA0BDDB50378234C53AC2D" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_341DE2F53FD218D8DA4078234C54004E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_267883BB81AE1346A31378234D027C16" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_8EEA9DB70C0611AF399F78234D028F2F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_267883BB81AE1346A31378234D027C16" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_8EEA9DB70C0611AF399F78234D028F2F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8E632113CFFBF9ABC97F78234CE66EC1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_37E390D71AEC3F907BD678234CE67A04" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8E632113CFFBF9ABC97F78234CE66EC1" xlink:to="loc_us-gaap_StatementTable_37E390D71AEC3F907BD678234CE67A04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_5BE35B3A7543A832D0D678234CE7EF1A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_37E390D71AEC3F907BD678234CE67A04" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_5BE35B3A7543A832D0D678234CE7EF1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_D118C2B9585E4622591E78234CE75513" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5BE35B3A7543A832D0D678234CE7EF1A" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_D118C2B9585E4622591E78234CE75513" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_66676AEEA5CA8F1B810278234CE86EC0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_D118C2B9585E4622591E78234CE75513" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_66676AEEA5CA8F1B810278234CE86EC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_E631B08412BA150AD99478234CE82CB6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_37E390D71AEC3F907BD678234CE67A04" xlink:to="loc_us-gaap_StatementLineItems_E631B08412BA150AD99478234CE82CB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNetAbstract" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract_DD0DFE036B385F1C6B2E78234CEAA3E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_E631B08412BA150AD99478234CE82CB6" xlink:to="loc_us-gaap_InterestIncomeExpenseNetAbstract_DD0DFE036B385F1C6B2E78234CEAA3E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_41C0206D56DB05475D1C78234CEB8C74" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_DD0DFE036B385F1C6B2E78234CEAA3E5" xlink:to="loc_us-gaap_InvestmentIncomeInterest_41C0206D56DB05475D1C78234CEB8C74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_DD863616504D48D5792478234CEC46A7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_DD0DFE036B385F1C6B2E78234CEAA3E5" xlink:to="loc_us-gaap_InterestExpense_DD863616504D48D5792478234CEC46A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_340764E378C2AEDEEC3778234CECC5A6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_DD0DFE036B385F1C6B2E78234CEAA3E5" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_340764E378C2AEDEEC3778234CECC5A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_9E4F2186018167C0241978234CECBC46" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_DD0DFE036B385F1C6B2E78234CEAA3E5" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_9E4F2186018167C0241978234CECBC46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_65D8C945D6BBAE67DBEA78234CEE7232" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_DD0DFE036B385F1C6B2E78234CEAA3E5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_65D8C945D6BBAE67DBEA78234CEE7232" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_4BD484B679224FC5472B78234CEF6653" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_DD0DFE036B385F1C6B2E78234CEAA3E5" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_4BD484B679224FC5472B78234CEF6653" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_C20A9056D54F754A165D78234CF09805" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_E631B08412BA150AD99478234CE82CB6" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_C20A9056D54F754A165D78234CF09805" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_CE7BD12DF1724900D2E678234CF0E5D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_C20A9056D54F754A165D78234CF09805" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_CE7BD12DF1724900D2E678234CF0E5D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_E540AB46A6C60966F82078234CF11B57" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_C20A9056D54F754A165D78234CF09805" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_E540AB46A6C60966F82078234CF11B57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_460A1F3C5D3EC69CD19878234CF1FF89" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_C20A9056D54F754A165D78234CF09805" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_460A1F3C5D3EC69CD19878234CF1FF89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_822D33418862F6A9FA7678234CF1DFC1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_E631B08412BA150AD99478234CE82CB6" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_822D33418862F6A9FA7678234CF1DFC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_2887B6F88BEDC6DEDFE678234CF2A76D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_822D33418862F6A9FA7678234CF1DFC1" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_2887B6F88BEDC6DEDFE678234CF2A76D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0255E377799022974A7478234CF20D60" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_822D33418862F6A9FA7678234CF1DFC1" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0255E377799022974A7478234CF20D60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_8925F88E77E67D6771BF78234CF2E849" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_822D33418862F6A9FA7678234CF1DFC1" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_8925F88E77E67D6771BF78234CF2E849" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_Collaborationexpensesaccrual" xlink:label="loc_biib_Collaborationexpensesaccrual_C546C5BB7969E53D941378234CF290DA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_822D33418862F6A9FA7678234CF1DFC1" xlink:to="loc_biib_Collaborationexpensesaccrual_C546C5BB7969E53D941378234CF290DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_A719830B76016C07173278234CF32A49" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_822D33418862F6A9FA7678234CF1DFC1" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_A719830B76016C07173278234CF32A49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_B5B7BC890E754E60528F78234CF39324" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_822D33418862F6A9FA7678234CF1DFC1" xlink:to="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_B5B7BC890E754E60528F78234CF39324" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_73283EE3101F6F9B48EF78234CF3E589" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_822D33418862F6A9FA7678234CF1DFC1" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_73283EE3101F6F9B48EF78234CF3E589" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_A208644AF3451F172EC678234CF41C15" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_822D33418862F6A9FA7678234CF1DFC1" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_A208644AF3451F172EC678234CF41C15" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9A1557A9575E1F02921D78234CFC78A7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_72C5D05F6C74A9270D3C78234CFC21CA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9A1557A9575E1F02921D78234CFC78A7" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_72C5D05F6C74A9270D3C78234CFC21CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnInvestmentsTextBlock" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock_55FD39F0B17A5EF63E8F78234CFCDDCE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9A1557A9575E1F02921D78234CFC78A7" xlink:to="loc_us-gaap_GainLossOnInvestmentsTextBlock_55FD39F0B17A5EF63E8F78234CFCDDCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_076501BF9DD2CF24366278234CFDCE1F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9A1557A9575E1F02921D78234CFC78A7" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_076501BF9DD2CF24366278234CFDCE1F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_14C4A72E7A78ACF00BCC78234CCFB852" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_A62082CBB3E1DCEC014B78234CD0CF6D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_14C4A72E7A78ACF00BCC78234CCFB852" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_A62082CBB3E1DCEC014B78234CD0CF6D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_064AE8757E009F41A13778234CD0876C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A62082CBB3E1DCEC014B78234CD0CF6D" xlink:to="loc_dei_LegalEntityAxis_064AE8757E009F41A13778234CD0876C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1E1AACB8944DDA08433578234CD031DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_064AE8757E009F41A13778234CD0876C" xlink:to="loc_dei_EntityDomain_1E1AACB8944DDA08433578234CD031DB" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_IonisPharmaceuticalsMember" xlink:label="loc_biib_IonisPharmaceuticalsMember_324B7A01AF81934E424D78234CD1CC82" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1E1AACB8944DDA08433578234CD031DB" xlink:to="loc_biib_IonisPharmaceuticalsMember_324B7A01AF81934E424D78234CD1CC82" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_SangamoCommonStockMember" xlink:label="loc_biib_SangamoCommonStockMember_76EEBC1B1C62412AFC6078234CD1F19D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1E1AACB8944DDA08433578234CD031DB" xlink:to="loc_biib_SangamoCommonStockMember_76EEBC1B1C62412AFC6078234CD1F19D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_4E3DFAC71452ABCF928D78234CD19CD4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A62082CBB3E1DCEC014B78234CD0CF6D" xlink:to="loc_us-gaap_ClassOfStockLineItems_4E3DFAC71452ABCF928D78234CD19CD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_4CA7353C76C8797095E078234CD2AF01" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4E3DFAC71452ABCF928D78234CD19CD4" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_4CA7353C76C8797095E078234CD2AF01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_50A552E17FC7A42097E778234CD28AC6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4E3DFAC71452ABCF928D78234CD19CD4" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_50A552E17FC7A42097E778234CD28AC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_94D085833F8854E8B6E378234CD2DEB3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4E3DFAC71452ABCF928D78234CD19CD4" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_94D085833F8854E8B6E378234CD2DEB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_164EEB90D14305E0272678234CD3FEAE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4E3DFAC71452ABCF928D78234CD19CD4" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_164EEB90D14305E0272678234CD3FEAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_188789301C0795D357C678234CD3859A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4E3DFAC71452ABCF928D78234CD19CD4" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_188789301C0795D357C678234CD3859A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense_D4F1F548C8EACD63FA2A78234CD39C15" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4E3DFAC71452ABCF928D78234CD19CD4" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense_D4F1F548C8EACD63FA2A78234CD39C15" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherRevenuesDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20200630.xsd#biib_OtherrevenuesAbstract" xlink:label="loc_biib_OtherrevenuesAbstract_FDBF1A42E2E6085BCEAE782350288CDF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_28B8386985FAD0DA238478235029E5A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_OtherrevenuesAbstract_FDBF1A42E2E6085BCEAE782350288CDF" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_28B8386985FAD0DA238478235029E5A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_D8CA6503431DE986B07B782350292A89" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_28B8386985FAD0DA238478235029E5A9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_D8CA6503431DE986B07B782350292A89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_31DC80AD822E969A71C77823502A1F71" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_D8CA6503431DE986B07B782350292A89" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_31DC80AD822E969A71C77823502A1F71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_ECA4F02275ECB21553E67823502A8BD7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_31DC80AD822E969A71C77823502A1F71" xlink:to="loc_us-gaap_CollaborativeArrangementMember_ECA4F02275ECB21553E67823502A8BD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_EB880934444AC9BAD9237823502BE93E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_28B8386985FAD0DA238478235029E5A9" xlink:to="loc_srt_ProductOrServiceAxis_EB880934444AC9BAD9237823502BE93E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_F56EB179629D0E6925277823502BC7B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_EB880934444AC9BAD9237823502BE93E" xlink:to="loc_srt_ProductsAndServicesDomain_F56EB179629D0E6925277823502BC7B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember_BA0F6590ABB8A62B8E107823502B3870" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_F56EB179629D0E6925277823502BC7B5" xlink:to="loc_us-gaap_RoyaltyMember_BA0F6590ABB8A62B8E107823502B3870" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_OthercorporaterevenuesMember" xlink:label="loc_biib_OthercorporaterevenuesMember_621334D71008C57687477823502C5451" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_F56EB179629D0E6925277823502BC7B5" xlink:to="loc_biib_OthercorporaterevenuesMember_621334D71008C57687477823502C5451" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_FBC4FE197517C5E481E17823503151A4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_F56EB179629D0E6925277823502BC7B5" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_FBC4FE197517C5E481E17823503151A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_0708F5E7A0D134B950B078235031763F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_28B8386985FAD0DA238478235029E5A9" xlink:to="loc_srt_MajorCustomersAxis_0708F5E7A0D134B950B078235031763F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_E6D6F82A747FD65565AC78235032076B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_0708F5E7A0D134B950B078235031763F" xlink:to="loc_srt_NameOfMajorCustomerDomain_E6D6F82A747FD65565AC78235032076B" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_EFB6461E842433B4785E78235032AD30" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_E6D6F82A747FD65565AC78235032076B" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_EFB6461E842433B4785E78235032AD30" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_796B77B393CACEE2565E782350338616" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_E6D6F82A747FD65565AC78235032076B" xlink:to="loc_biib_ZINBRYTAMember_796B77B393CACEE2565E782350338616" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_D66EC254191DB1F3A03B782350336223" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_28B8386985FAD0DA238478235029E5A9" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_D66EC254191DB1F3A03B782350336223" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_75AD24817D70351E1CDE78235033FC42" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_D66EC254191DB1F3A03B782350336223" xlink:to="loc_us-gaap_Revenues_75AD24817D70351E1CDE78235033FC42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_D51FF14F8CA4C634F10278235033B78D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_D66EC254191DB1F3A03B782350336223" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_D51FF14F8CA4C634F10278235033B78D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_AA787093E7F9D0D5D1D078234E12DD4B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D99EE8B070745BDABE6C78234E1241A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_AA787093E7F9D0D5D1D078234E12DD4B" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D99EE8B070745BDABE6C78234E1241A3" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_87E277AFFFCA70CD181178234E126290" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D99EE8B070745BDABE6C78234E1241A3" xlink:to="loc_biib_FacilityLocationAxis_87E277AFFFCA70CD181178234E126290" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_BDE5BBF9E8795477C4D078234E13299D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationAxis_87E277AFFFCA70CD181178234E126290" xlink:to="loc_biib_FacilityLocationDomain_BDE5BBF9E8795477C4D078234E13299D" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_SolothurnSwitzerlandMember" xlink:label="loc_biib_SolothurnSwitzerlandMember_76E4C208B6367F1BEB5878234E13E02D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationDomain_BDE5BBF9E8795477C4D078234E13299D" xlink:to="loc_biib_SolothurnSwitzerlandMember_76E4C208B6367F1BEB5878234E13E02D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_757DC56163E11BFF79FB78234E13983A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D99EE8B070745BDABE6C78234E1241A3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_757DC56163E11BFF79FB78234E13983A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4D5D3821929B588D094E78234E14C8CF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_757DC56163E11BFF79FB78234E13983A" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4D5D3821929B588D094E78234E14C8CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_99F608FD5B7111E7DF8378234E140D4C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_757DC56163E11BFF79FB78234E13983A" xlink:to="loc_us-gaap_Depreciation_99F608FD5B7111E7DF8378234E140D4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_4375C3514BF34820FC9078234E141037" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_757DC56163E11BFF79FB78234E13983A" xlink:to="loc_us-gaap_ConstructionInProgressGross_4375C3514BF34820FC9078234E141037" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_C5FFCEE1E3BCE8A8901A78234E15FE1F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_757DC56163E11BFF79FB78234E13983A" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_C5FFCEE1E3BCE8A8901A78234E15FE1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_6A265DA6827BF411F99D78234E15FCB5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_757DC56163E11BFF79FB78234E13983A" xlink:to="loc_us-gaap_OtherCommitment_6A265DA6827BF411F99D78234E15FCB5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_DB6A3BB443E5A88B18BC78234E1AF65B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_843A4AB4993001D2D09878234E1A45E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_DB6A3BB443E5A88B18BC78234E1AF65B" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_843A4AB4993001D2D09878234E1A45E6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20200630.xsd#biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:label="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_C246C9E6A2655114014C78234D7696C3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_137F6819A77C147721A078234D77D437" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_C246C9E6A2655114014C78234D7696C3" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_137F6819A77C147721A078234D77D437" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0C924F759BFA2C8BE5F378234D77C921" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_137F6819A77C147721A078234D77D437" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0C924F759BFA2C8BE5F378234D77C921" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_98AC5D2AE1FB9410F53378234D78F1BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0C924F759BFA2C8BE5F378234D77C921" xlink:to="loc_us-gaap_EquityComponentDomain_98AC5D2AE1FB9410F53378234D78F1BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_F192B77F51BB1492D04578234D7880D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_98AC5D2AE1FB9410F53378234D78F1BF" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_F192B77F51BB1492D04578234D7880D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_F0392D6F7C6956C683AF78234D78AAAD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_98AC5D2AE1FB9410F53378234D78F1BF" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_F0392D6F7C6956C683AF78234D78AAAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_50CB9759D5F8D228FFDC78234D79525D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_98AC5D2AE1FB9410F53378234D78F1BF" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_50CB9759D5F8D228FFDC78234D79525D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_47DE20C343F7E298D0D378234D79F08B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_137F6819A77C147721A078234D77D437" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_47DE20C343F7E298D0D378234D79F08B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_F17B5A6E8AB1CDED7D5178234D799F59" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_47DE20C343F7E298D0D378234D79F08B" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_F17B5A6E8AB1CDED7D5178234D799F59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_A348DA05041129A0391378234D795722" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_F17B5A6E8AB1CDED7D5178234D799F59" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_A348DA05041129A0391378234D795722" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_037C558A45AA71B62FA878234D7ADAF7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_137F6819A77C147721A078234D77D437" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_037C558A45AA71B62FA878234D7ADAF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_8AC37225540F4B3BBF1278234D7AA1F0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_037C558A45AA71B62FA878234D7ADAF7" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_8AC37225540F4B3BBF1278234D7AA1F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_A868F56865C3E3EBF1E278234D7B5C19" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_037C558A45AA71B62FA878234D7ADAF7" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_A868F56865C3E3EBF1E278234D7B5C19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_C8689FEC8A25E86701A278234D7B8B73" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_037C558A45AA71B62FA878234D7ADAF7" xlink:to="loc_us-gaap_Revenues_C8689FEC8A25E86701A278234D7B8B73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_336FD2C8024A2FC5E8D878234D7B6B0A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_037C558A45AA71B62FA878234D7ADAF7" xlink:to="loc_us-gaap_OperatingExpenses_336FD2C8024A2FC5E8D878234D7B6B0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_965C7E306C0D6BECB71C78234D7B2D74" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_037C558A45AA71B62FA878234D7ADAF7" xlink:to="loc_us-gaap_NetIncomeLoss_965C7E306C0D6BECB71C78234D7B2D74" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_A79100800FB7AAD379027823505DE1C7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_C6910FCEBEE3129D5FF67823505E232A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_A79100800FB7AAD379027823505DE1C7" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_C6910FCEBEE3129D5FF67823505E232A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_9DD13D344F5B70B391D27823505EC9F8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_C6910FCEBEE3129D5FF67823505E232A" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_9DD13D344F5B70B391D27823505EC9F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_61A8CA610DA21A56CC017823505EA01E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_9DD13D344F5B70B391D27823505EC9F8" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_61A8CA610DA21A56CC017823505EA01E" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_ReserveforCashDiscountsMember" xlink:label="loc_biib_ReserveforCashDiscountsMember_DE2EBEFAC071721642A97823505F4F73" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_61A8CA610DA21A56CC017823505EA01E" xlink:to="loc_biib_ReserveforCashDiscountsMember_DE2EBEFAC071721642A97823505F4F73" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_ContractualAdjustmentsMember" xlink:label="loc_biib_ContractualAdjustmentsMember_0F76A0A996B86B7D6E2B7823505F82D5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_61A8CA610DA21A56CC017823505EA01E" xlink:to="loc_biib_ContractualAdjustmentsMember_0F76A0A996B86B7D6E2B7823505F82D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_29FEAB311664E2D8A5A87823505F41DD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_61A8CA610DA21A56CC017823505EA01E" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_29FEAB311664E2D8A5A87823505F41DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_40502A5C323A204045EA7823505FCEC2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_C6910FCEBEE3129D5FF67823505E232A" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_40502A5C323A204045EA7823505FCEC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_69809C571FE69663ABEC7823505FA2BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_40502A5C323A204045EA7823505FCEC2" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_69809C571FE69663ABEC7823505FA2BF" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_1FB72C8508636607F21B78235060637B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_40502A5C323A204045EA7823505FCEC2" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_1FB72C8508636607F21B78235060637B" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_81E8E6A94E8DB3E4B312782350605E87" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_40502A5C323A204045EA7823505FCEC2" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_81E8E6A94E8DB3E4B312782350605E87" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_D78C5934C2F3B03912807823506078A6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_40502A5C323A204045EA7823505FCEC2" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_D78C5934C2F3B03912807823506078A6" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_153014B85792DEF1BEBE78235060C880" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_40502A5C323A204045EA7823505FCEC2" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_153014B85792DEF1BEBE78235060C880" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_5314801DA0329DD0D694782350615148" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_40502A5C323A204045EA7823505FCEC2" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_5314801DA0329DD0D694782350615148" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_9FC3FDE8F3FB6DFC97247823504DFFBA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_68FAD0B05CA17140DA257823504D8821" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_9FC3FDE8F3FB6DFC97247823504DFFBA" xlink:to="loc_us-gaap_StatementTable_68FAD0B05CA17140DA257823504D8821" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_F922AB58E95CE18DCD60782350525266" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_68FAD0B05CA17140DA257823504D8821" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_F922AB58E95CE18DCD60782350525266" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_82B9E6461C5CD334BBE178235052F231" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_F922AB58E95CE18DCD60782350525266" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_82B9E6461C5CD334BBE178235052F231" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_2C37A01F019FBBCBC7E6782350536740" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_82B9E6461C5CD334BBE178235052F231" xlink:to="loc_us-gaap_AccountsReceivableMember_2C37A01F019FBBCBC7E6782350536740" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_2B4FE74BA8121FAA1399782350531119" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_82B9E6461C5CD334BBE178235052F231" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_2B4FE74BA8121FAA1399782350531119" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_5DC1F15A410F1F2C29C778235053F352" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_68FAD0B05CA17140DA257823504D8821" xlink:to="loc_us-gaap_StatementLineItems_5DC1F15A410F1F2C29C778235053F352" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_B4DF18F7CABFE193AD237823505424B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5DC1F15A410F1F2C29C778235053F352" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_B4DF18F7CABFE193AD237823505424B2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesByProductDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract_CE1DDC17C07B9C6FB0B1782350775AC0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_91BAAE4C0EACCD7997EE78235077E568" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract_CE1DDC17C07B9C6FB0B1782350775AC0" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_91BAAE4C0EACCD7997EE78235077E568" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_0BFA12AAE2ACE22D2D4678235077BFD8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_91BAAE4C0EACCD7997EE78235077E568" xlink:to="loc_srt_ProductOrServiceAxis_0BFA12AAE2ACE22D2D4678235077BFD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_792B71C04E6FF0AB2F2578235078B4B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0BFA12AAE2ACE22D2D4678235077BFD8" xlink:to="loc_srt_ProductsAndServicesDomain_792B71C04E6FF0AB2F2578235078B4B3" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_FumarateMember" xlink:label="loc_biib_FumarateMember_03E33AF8A60DB65D5413782350784C3A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_792B71C04E6FF0AB2F2578235078B4B3" xlink:to="loc_biib_FumarateMember_03E33AF8A60DB65D5413782350784C3A" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_InterferonMember" xlink:label="loc_biib_InterferonMember_D200677E27571D377067782350788C54" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_792B71C04E6FF0AB2F2578235078B4B3" xlink:to="loc_biib_InterferonMember_D200677E27571D377067782350788C54" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_A4F20249D492CBA73AA378235079DCCD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_792B71C04E6FF0AB2F2578235078B4B3" xlink:to="loc_biib_TysabriProductMember_A4F20249D492CBA73AA378235079DCCD" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_FAMPYRAMember" xlink:label="loc_biib_FAMPYRAMember_F0EF1A4364EB7E75601E78235079562F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_792B71C04E6FF0AB2F2578235078B4B3" xlink:to="loc_biib_FAMPYRAMember_F0EF1A4364EB7E75601E78235079562F" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_EF8B20286F94AAE70C5078235079A892" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_792B71C04E6FF0AB2F2578235078B4B3" xlink:to="loc_biib_ZINBRYTAMember_EF8B20286F94AAE70C5078235079A892" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_MSProductRevenuesMember" xlink:label="loc_biib_MSProductRevenuesMember_4708B03E710C46C3DF2578235079EB6E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_792B71C04E6FF0AB2F2578235078B4B3" xlink:to="loc_biib_MSProductRevenuesMember_4708B03E710C46C3DF2578235079EB6E" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_143CD02C02B5601658C478235079C76E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_792B71C04E6FF0AB2F2578235078B4B3" xlink:to="loc_biib_SPINRAZAMember_143CD02C02B5601658C478235079C76E" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_BENEPALIMember" xlink:label="loc_biib_BENEPALIMember_AED9450A5F78AF0617897823507ACB1E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_792B71C04E6FF0AB2F2578235078B4B3" xlink:to="loc_biib_BENEPALIMember_AED9450A5F78AF0617897823507ACB1E" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_IMRALDIMember" xlink:label="loc_biib_IMRALDIMember_EA46CE3776497E3AF1C27823507A2677" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_792B71C04E6FF0AB2F2578235078B4B3" xlink:to="loc_biib_IMRALDIMember_EA46CE3776497E3AF1C27823507A2677" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_FLIXABIMember" xlink:label="loc_biib_FLIXABIMember_4D4860BE6C7AD72099737823507A675B" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_792B71C04E6FF0AB2F2578235078B4B3" xlink:to="loc_biib_FLIXABIMember_4D4860BE6C7AD72099737823507A675B" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_BiosimilarsMember" xlink:label="loc_biib_BiosimilarsMember_DE0ADE2CCE0661E70E9E7823507A1BCE" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_792B71C04E6FF0AB2F2578235078B4B3" xlink:to="loc_biib_BiosimilarsMember_DE0ADE2CCE0661E70E9E7823507A1BCE" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_FUMADERMMember" xlink:label="loc_biib_FUMADERMMember_DD51AD03C102554C01EC7823507AE13C" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_792B71C04E6FF0AB2F2578235078B4B3" xlink:to="loc_biib_FUMADERMMember_DD51AD03C102554C01EC7823507AE13C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_F637A1BC70665E5F3D537823507A6B82" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_792B71C04E6FF0AB2F2578235078B4B3" xlink:to="loc_us-gaap_ProductMember_F637A1BC70665E5F3D537823507A6B82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_081BDB7A82F05F4B77547823507A9771" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_91BAAE4C0EACCD7997EE78235077E568" xlink:to="loc_srt_StatementGeographicalAxis_081BDB7A82F05F4B77547823507A9771" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_821FB6D933CE82D62F847823507BAF14" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_081BDB7A82F05F4B77547823507A9771" xlink:to="loc_srt_SegmentGeographicalDomain_821FB6D933CE82D62F847823507BAF14" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_891B96488EA94C98CB357823507BBA1D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_821FB6D933CE82D62F847823507BAF14" xlink:to="loc_country_US_891B96488EA94C98CB357823507BBA1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember_68E984D74C8D355DB4CC7823507B20AA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_821FB6D933CE82D62F847823507BAF14" xlink:to="loc_us-gaap_NonUsMember_68E984D74C8D355DB4CC7823507B20AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_6378AF3BD30ED0DD29C17823507C4F69" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_91BAAE4C0EACCD7997EE78235077E568" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_6378AF3BD30ED0DD29C17823507C4F69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_B128E1E228EACD6B8BA87823507CE70C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6378AF3BD30ED0DD29C17823507C4F69" xlink:to="loc_us-gaap_Revenues_B128E1E228EACD6B8BA87823507CE70C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_81012172E4F158CCEBC5782350139CF3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_959F7B19B296317C416378235014EC74" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_81012172E4F158CCEBC5782350139CF3" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_959F7B19B296317C416378235014EC74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_74629C4618A2A141AAE47823501481F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_959F7B19B296317C416378235014EC74" xlink:to="loc_srt_ProductOrServiceAxis_74629C4618A2A141AAE47823501481F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_A618F8DB0651A248B08C78235015D756" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_74629C4618A2A141AAE47823501481F1" xlink:to="loc_srt_ProductsAndServicesDomain_A618F8DB0651A248B08C78235015D756" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_OthercorporaterevenuesMember" xlink:label="loc_biib_OthercorporaterevenuesMember_90865DBE22C891D4D995782350154F08" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_A618F8DB0651A248B08C78235015D756" xlink:to="loc_biib_OthercorporaterevenuesMember_90865DBE22C891D4D995782350154F08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_928D920659A3FA9402F0782350156372" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_A618F8DB0651A248B08C78235015D756" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_928D920659A3FA9402F0782350156372" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_7B42CDB4CF35B780701178235015DB48" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_959F7B19B296317C416378235014EC74" xlink:to="loc_srt_MajorCustomersAxis_7B42CDB4CF35B780701178235015DB48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_DCB9A518360D4DC7CFF078235016FBAA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_7B42CDB4CF35B780701178235015DB48" xlink:to="loc_srt_NameOfMajorCustomerDomain_DCB9A518360D4DC7CFF078235016FBAA" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_DistributorOneMember" xlink:label="loc_biib_DistributorOneMember_C2D0EB3A95B5FA29127678235016F44C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_DCB9A518360D4DC7CFF078235016FBAA" xlink:to="loc_biib_DistributorOneMember_C2D0EB3A95B5FA29127678235016F44C" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_DistributorTwoMember" xlink:label="loc_biib_DistributorTwoMember_B8D32C90F9C9D1934A1E78235016290B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_DCB9A518360D4DC7CFF078235016FBAA" xlink:to="loc_biib_DistributorTwoMember_B8D32C90F9C9D1934A1E78235016290B" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_8B7927962413B588F923782350167B7F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_DCB9A518360D4DC7CFF078235016FBAA" xlink:to="loc_biib_BioverativMember_8B7927962413B588F923782350167B7F" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_ContractManufacturingCustomerMember" xlink:label="loc_biib_ContractManufacturingCustomerMember_421DE5FDD2A26DC9960D7823501769BA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_DCB9A518360D4DC7CFF078235016FBAA" xlink:to="loc_biib_ContractManufacturingCustomerMember_421DE5FDD2A26DC9960D7823501769BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_3E900075483FD4A082547823501750A9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_959F7B19B296317C416378235014EC74" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_3E900075483FD4A082547823501750A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_67CBC4A93278AF06C73D782350179702" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3E900075483FD4A082547823501750A9" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_67CBC4A93278AF06C73D782350179702" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_E0B66F761FBE97C5F75678235017C2BC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3E900075483FD4A082547823501750A9" xlink:to="loc_us-gaap_Revenues_E0B66F761FBE97C5F75678235017C2BC" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_6BBF904EAA1BE4D0EDB178235017287B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3E900075483FD4A082547823501750A9" xlink:to="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_6BBF904EAA1BE4D0EDB178235017287B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8029B8A1979EE56FB3CC78235040E336" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_7A8E1DD1A635C93900D0782350415743" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8029B8A1979EE56FB3CC78235040E336" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_7A8E1DD1A635C93900D0782350415743" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_7CA72F91EE3AE8C8C481782350418B8A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7A8E1DD1A635C93900D0782350415743" xlink:to="loc_srt_ProductOrServiceAxis_7CA72F91EE3AE8C8C481782350418B8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_A0E3ABC957370C543FCF782350412FA7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_7CA72F91EE3AE8C8C481782350418B8A" xlink:to="loc_srt_ProductsAndServicesDomain_A0E3ABC957370C543FCF782350412FA7" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_349244E9154DEA76DA2278235042EE25" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_A0E3ABC957370C543FCF782350412FA7" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_349244E9154DEA76DA2278235042EE25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_60E3653C6D5B110BDD3B782350421C73" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7A8E1DD1A635C93900D0782350415743" xlink:to="loc_srt_MajorCustomersAxis_60E3653C6D5B110BDD3B782350421C73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_E03627EB312F1EC21B93782350426375" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_60E3653C6D5B110BDD3B782350421C73" xlink:to="loc_srt_NameOfMajorCustomerDomain_E03627EB312F1EC21B93782350426375" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_RocheGroupGenentechMember" xlink:label="loc_biib_RocheGroupGenentechMember_CC77D4D0F3A807C6F0E3782350426708" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_E03627EB312F1EC21B93782350426375" xlink:to="loc_biib_RocheGroupGenentechMember_CC77D4D0F3A807C6F0E3782350426708" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_337753263CEA6778744D78235043A612" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7A8E1DD1A635C93900D0782350415743" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_337753263CEA6778744D78235043A612" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_A270DB22B1AA14BFCD02782350434E79" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_337753263CEA6778744D78235043A612" xlink:to="loc_biib_ShareOfCoPromotionProfits_A270DB22B1AA14BFCD02782350434E79" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_EB069DFAD8D4CAA761AA7823504395DE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_337753263CEA6778744D78235043A612" xlink:to="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_EB069DFAD8D4CAA761AA7823504395DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_BB97CEF81ADBF72B7356782350430244" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_337753263CEA6778744D78235043A612" xlink:to="loc_us-gaap_Revenues_BB97CEF81ADBF72B7356782350430244" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenues" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_A3977A03660B08AC3D68782350922A88" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_97156540BCA695A2DAE6782350922AB7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_A3977A03660B08AC3D68782350922A88" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_97156540BCA695A2DAE6782350922AB7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_E549CF5C9FCEC212B4BF782350868FEA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_75E3D1DBCA5876F2506478235086F10E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_E549CF5C9FCEC212B4BF782350868FEA" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_75E3D1DBCA5876F2506478235086F10E" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_AFBB626BB4E8118BDD0778235087F64D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_E549CF5C9FCEC212B4BF782350868FEA" xlink:to="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_AFBB626BB4E8118BDD0778235087F64D" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_327A1EF69E63F79E33CA7823508C43BC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_E549CF5C9FCEC212B4BF782350868FEA" xlink:to="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_327A1EF69E63F79E33CA7823508C43BC" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_C1BB71816307650128267823508DCC26" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_E549CF5C9FCEC212B4BF782350868FEA" xlink:to="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_C1BB71816307650128267823508DCC26" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_OtherrevenuesTableTextBlock" xlink:label="loc_biib_OtherrevenuesTableTextBlock_38DA6AFDA464AA64ECF07823508EE42F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_E549CF5C9FCEC212B4BF782350868FEA" xlink:to="loc_biib_OtherrevenuesTableTextBlock_38DA6AFDA464AA64ECF07823508EE42F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1D3C2A2A59181804685678234D555535" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_35A859A4E718C5D6EBA678234D55C5A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1D3C2A2A59181804685678234D555535" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_35A859A4E718C5D6EBA678234D55C5A1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3DF469873DBEB7F58ECE78234D458F4F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_EEC40C3EFFFD25F4F32578234D457ED4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3DF469873DBEB7F58ECE78234D458F4F" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_EEC40C3EFFFD25F4F32578234D457ED4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8398CAAF6488D4E4063C78234D4648EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_EEC40C3EFFFD25F4F32578234D457ED4" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8398CAAF6488D4E4063C78234D4648EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8C3344D2844B169EA83A78234D4683A8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8398CAAF6488D4E4063C78234D4648EF" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8C3344D2844B169EA83A78234D4683A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_E239ED17928C59750EA778234D463D02" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8C3344D2844B169EA83A78234D4683A8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_E239ED17928C59750EA778234D463D02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_C7E7F1E95FEDAC5249E378234D47F720" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8C3344D2844B169EA83A78234D4683A8" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_C7E7F1E95FEDAC5249E378234D47F720" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_7063372BE7B187D9130F78234D47659B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8C3344D2844B169EA83A78234D4683A8" xlink:to="loc_us-gaap_ParentMember_7063372BE7B187D9130F78234D47659B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_271652413D068ACD5AEC78234D47C9D4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_EEC40C3EFFFD25F4F32578234D457ED4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_271652413D068ACD5AEC78234D47C9D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2F5FAEB69B771E50BA2978234D48C4A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_271652413D068ACD5AEC78234D47C9D4" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2F5FAEB69B771E50BA2978234D48C4A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_4F0F27D0B3CA9BAB187A78234D48CBDD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2F5FAEB69B771E50BA2978234D48C4A3" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_4F0F27D0B3CA9BAB187A78234D48CBDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_412F923F55F8957FE7A778234D48FE3D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2F5FAEB69B771E50BA2978234D48C4A3" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_412F923F55F8957FE7A778234D48FE3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_BE68D769A079D2AAA71E78234D487D9C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2F5FAEB69B771E50BA2978234D48C4A3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_BE68D769A079D2AAA71E78234D487D9C" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_2583FC3FED3305F2189C78234D498D66" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2F5FAEB69B771E50BA2978234D48C4A3" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_2583FC3FED3305F2189C78234D498D66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_ACF820DDB82348BC34D578234D491D7F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2F5FAEB69B771E50BA2978234D48C4A3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_ACF820DDB82348BC34D578234D491D7F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_86036650E7369EEC44FA78234D342061" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_EB911D15E5A8C918E03F78234D341A73" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_86036650E7369EEC44FA78234D342061" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_EB911D15E5A8C918E03F78234D341A73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_E2B675D1AE9E80D9861978234D35F8A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_EB911D15E5A8C918E03F78234D341A73" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_E2B675D1AE9E80D9861978234D35F8A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_CC06E19687834B014FE078234D35DBCF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_E2B675D1AE9E80D9861978234D35F8A1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_CC06E19687834B014FE078234D35DBCF" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_NightstarMember" xlink:label="loc_biib_NightstarMember_BECD143703F0851CBF3C78234D35A08D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_CC06E19687834B014FE078234D35DBCF" xlink:to="loc_biib_NightstarMember_BECD143703F0851CBF3C78234D35A08D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_B2B610EE70B79959D80A78234D36B524" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_EB911D15E5A8C918E03F78234D341A73" xlink:to="loc_us-gaap_AwardTypeAxis_B2B610EE70B79959D80A78234D36B524" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_919B530C99BA3ADF6BF578234D36E5EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_B2B610EE70B79959D80A78234D36B524" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_919B530C99BA3ADF6BF578234D36E5EE" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_D0753E8D9B22B4F1A75478234D36152B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_919B530C99BA3ADF6BF578234D36E5EE" xlink:to="loc_biib_MarketStockUnitsMember_D0753E8D9B22B4F1A75478234D36152B" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_ABA3C9FD7EDF4D333F3578234D37F13D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_919B530C99BA3ADF6BF578234D36E5EE" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_ABA3C9FD7EDF4D333F3578234D37F13D" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_A05AEF9BA3E91699C61778234D377F9E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_919B530C99BA3ADF6BF578234D36E5EE" xlink:to="loc_biib_CashSettledPerformanceSharesMember_A05AEF9BA3E91699C61778234D377F9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_A084307D78CD6BAD1D7978234D37003E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_919B530C99BA3ADF6BF578234D36E5EE" xlink:to="loc_us-gaap_PerformanceSharesMember_A084307D78CD6BAD1D7978234D37003E" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_70ADA87B6C8C13027D6078234D386D51" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_919B530C99BA3ADF6BF578234D36E5EE" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_70ADA87B6C8C13027D6078234D386D51" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_PerformanceStockUnitsSettledinCashMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_1E39DBDB068DDB48CE4878234D38DAA9" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_919B530C99BA3ADF6BF578234D36E5EE" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_1E39DBDB068DDB48CE4878234D38DAA9" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_EmployeeStockPurchasePlanMember" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_15EDD8BC44206DFBA6F878234D380BF9" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_919B530C99BA3ADF6BF578234D36E5EE" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_15EDD8BC44206DFBA6F878234D380BF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_151D1B0016C515D1B71678234D387E43" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_919B530C99BA3ADF6BF578234D36E5EE" xlink:to="loc_us-gaap_EmployeeStockOptionMember_151D1B0016C515D1B71678234D387E43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_878259D3271D031BEE9378234D3861E2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_EB911D15E5A8C918E03F78234D341A73" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_878259D3271D031BEE9378234D3861E2" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_71B0DD1BA19A66D2F06878234D38E96C" xlink:type="locator" />
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_878259D3271D031BEE9378234D3861E2" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_71B0DD1BA19A66D2F06878234D38E96C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_813C67D109FBC6F210DA78234D3920C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_71B0DD1BA19A66D2F06878234D38E96C" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_813C67D109FBC6F210DA78234D3920C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_CFB5D03DED63AB76B39178234D39AEAE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_71B0DD1BA19A66D2F06878234D38E96C" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_CFB5D03DED63AB76B39178234D39AEAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_1B644669C21567D79C2C78234D3A78B8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_71B0DD1BA19A66D2F06878234D38E96C" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_1B644669C21567D79C2C78234D3A78B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_3D1A7C44F0E9CC21AB9578234D3A83B5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_71B0DD1BA19A66D2F06878234D38E96C" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_3D1A7C44F0E9CC21AB9578234D3A83B5" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_F8A4075C9D1D32135A2F78234D3A7234" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_71B0DD1BA19A66D2F06878234D38E96C" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_F8A4075C9D1D32135A2F78234D3A7234" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_BAB4FB9F3B9DD2C7326178234D503CCD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_8892E209DF91916A77C678234D502410" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_BAB4FB9F3B9DD2C7326178234D503CCD" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_8892E209DF91916A77C678234D502410" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_6233C8A203AA926BC97778234D50377B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_BAB4FB9F3B9DD2C7326178234D503CCD" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_6233C8A203AA926BC97778234D50377B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_4E863E08B63A051B807478234D940F12" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_E0D57BC83ADF8F48006C78234D95F575" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4E863E08B63A051B807478234D940F12" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_E0D57BC83ADF8F48006C78234D95F575" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_A3150D1F1865BCCCE6B878234D95AC23" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_E0D57BC83ADF8F48006C78234D95F575" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_A3150D1F1865BCCCE6B878234D95AC23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_FBB74087683ADABD13CD78234D968B83" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_A3150D1F1865BCCCE6B878234D95AC23" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_FBB74087683ADABD13CD78234D968B83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_0BF493F3FE3BC0D51DDD78234D962A89" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_FBB74087683ADABD13CD78234D968B83" xlink:to="loc_us-gaap_SubsequentEventMember_0BF493F3FE3BC0D51DDD78234D962A89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_D36BE7E13627719CE34778234D967AB0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_E0D57BC83ADF8F48006C78234D95F575" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_D36BE7E13627719CE34778234D967AB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_4A8A8CF2E44A5958809078234D96C085" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_D36BE7E13627719CE34778234D967AB0" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_4A8A8CF2E44A5958809078234D96C085" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_December2019ShareRepurchaseProgramMember" xlink:label="loc_biib_December2019ShareRepurchaseProgramMember_38E4D54451EBBC3660B578234D976E68" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_4A8A8CF2E44A5958809078234D96C085" xlink:to="loc_biib_December2019ShareRepurchaseProgramMember_38E4D54451EBBC3660B578234D976E68" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_March2019ShareRepurchaseProgramMember" xlink:label="loc_biib_March2019ShareRepurchaseProgramMember_0044C8AF3FE8053A57EE78234D973346" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_4A8A8CF2E44A5958809078234D96C085" xlink:to="loc_biib_March2019ShareRepurchaseProgramMember_0044C8AF3FE8053A57EE78234D973346" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_6255A75A0598D06742BD78234D982AEA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_E0D57BC83ADF8F48006C78234D95F575" xlink:to="loc_us-gaap_ClassOfStockLineItems_6255A75A0598D06742BD78234D982AEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_2849CCAFF9263DC9514478234D985AFC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6255A75A0598D06742BD78234D982AEA" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_2849CCAFF9263DC9514478234D985AFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_1C33AD38C783AC4F2B6D78234D983699" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6255A75A0598D06742BD78234D982AEA" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_1C33AD38C783AC4F2B6D78234D983699" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_535FBD5FE0F7A9FE274A78234D98847C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6255A75A0598D06742BD78234D982AEA" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_535FBD5FE0F7A9FE274A78234D98847C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_8A8532EF7B4FE9705BEC78234D99321B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6255A75A0598D06742BD78234D982AEA" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_8A8532EF7B4FE9705BEC78234D99321B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables" xlink:type="extended">
    <link:loc xlink:href="biib-20200630.xsd#biib_AcquisitionsAbstract" xlink:label="loc_biib_AcquisitionsAbstract_5A044AA8A3D1DB72F06E782350F118FB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_008FA93B3869F407DD80782350F1BFF2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AcquisitionsAbstract_5A044AA8A3D1DB72F06E782350F118FB" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_008FA93B3869F407DD80782350F1BFF2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_F3BEE401098A7E1096BA7823510FF9D5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_338501976D66E4F5EF7C7823510FC68B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_F3BEE401098A7E1096BA7823510FF9D5" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_338501976D66E4F5EF7C7823510FC68B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3340DA094398DCD9595C782350FCA061" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_3ACF1D8EBF11EB57DE9D782350FC5477" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3340DA094398DCD9595C782350FCA061" xlink:to="loc_us-gaap_NumberOfReportableSegments_3ACF1D8EBF11EB57DE9D782350FC5477" xlink:type="arc" />
    <link:loc xlink:href="biib-20200630.xsd#biib_InterestInSubsidiary" xlink:label="loc_biib_InterestInSubsidiary_B8218AAFE0A8F8ABF34F782350FD4F54" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3340DA094398DCD9595C782350FCA061" xlink:to="loc_biib_InterestInSubsidiary_B8218AAFE0A8F8ABF34F782350FD4F54" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_B58FDF645DE09E26FBB778235105567E" xlink:type="locator" />
    <link:loc xlink:href="biib-20200630.xsd#biib_BusinessOverviewPolicyTextBlock" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock_920D8EE3DD5545B0B182782351056E69" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B58FDF645DE09E26FBB778235105567E" xlink:to="loc_biib_BusinessOverviewPolicyTextBlock_920D8EE3DD5545B0B182782351056E69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_AF0144013E394B38FBE078235106AAC1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B58FDF645DE09E26FBB778235105567E" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_AF0144013E394B38FBE078235106AAC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_D03B3AA90F7CD608172C782351069C51" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B58FDF645DE09E26FBB778235105567E" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_D03B3AA90F7CD608172C782351069C51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_60C7A82614F9595C49207823510666AE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B58FDF645DE09E26FBB778235105567E" xlink:to="loc_us-gaap_UseOfEstimates_60C7A82614F9595C49207823510666AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8DA8165CA707EB972E40782351060E23" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B58FDF645DE09E26FBB778235105567E" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8DA8165CA707EB972E40782351060E23" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>biogenlogoa11.jpg
<TEXT>
begin 644 biogenlogoa11.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M4D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0
M86-S<$U31E0     245#('-21T(                  /;6  $     TRU(
M4" @
M       18W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP
M=    @0    4<EA96@   A@    49UA96@   BP    48EA96@   D     4
M9&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0
M   D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P
M!#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG
M:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M    $G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV
M-BTR+C$
M             %A96B        #S40 !     1;,6%E:(
M      !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:
M6%E:(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
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M"58 4    %<?YVUE87,          0                        */
M G-I9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M
M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H
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M# P,# P,_\  $0@!(@-H P$B  (1 0,1 ?_$ !\   $% 0$! 0$!
M   ! @,$!08'" D*"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!
M!A-180<B<10R@9&A""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y
M.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25
MEI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/D
MY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'
M" D*"__$ +41  (! @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!
M"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)
M2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*C
MI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S
M]/7V]_CY^O_:  P# 0 "$0,1 #\ _?RBBB@ HHK"^(7Q&T?X6^&9M6UJ\6UM
M8> #\SS-V1%ZLQ]!]3@ FJA"4Y*,5=LF4E%<TG9(VY)%@C9F9551EF)P *^<
M?V@O^"BWA[X:M<:?X7BC\3ZO&"IG5\6,#>[CF3'HF ?[XKP_]I/]K?Q!\;Y)
MM/M6ET;PWD@6<;XDNAZS,/O9_NCY1_M$9KPF^LL \5]QE/"\-*F,U_NK]7^B
M/C<TXDEK3PG_ ($_T7^9^BW[(/[4]I^TGX,D^T+!9^)=+PNH6D>0C _=FC!)
M.P],9)4\'JI/KS,$!9B%4<DGM7Y+_"WXGZM\$OB%8>(M'DVW5B_SQD_)<QG[
M\;>JL/R.".0#5[]IG]N7QM\>[ZYL;R\;1= 9ODTJR<K$Z]O-?AI3_O?+D9"B
MJQ7!TZF*_P!G:C3>NO3R2Z^08;BJ$,-^_3<UIIU\[]/,^X_C3_P45^&_P@DF
MM8=0D\3:K"2IMM*Q+&C>C3$B,<\':68>E?+_ ,5/^"L'C[Q3YT?A>QTGPM"0
M?+=D^VW(/NT@$?\ Y#[]Z^4CJ2^U*NI*:]RGP;ERHRI3O)R37->S5^JMHFNF
MYX.*XFQU9^Z^5=E_GO\ D=1XV_:Q^)WCN:1=6\<>)Y%8D/!'>O;PY[YCC*I^
ME<%J.JW6KS^;=W-Q=2_WYI"[>O4U>U*!=17='_KEXQW<>GU__5Z5EU_,'%_#
MN-R?'/#8J3E%ZQD[VDOT:ZKH_)IM0Q,JZYI-M^>H5T7ASXR>+O!TJR:3XI\1
M:8RG(-KJ4T/_ *"PKG:*^7C.47>+:-(R:=TSWSX>?\%-/C!X :-7\10Z_;1X
M_<:M:I.&^LB[93_WW7TE\&_^"QWAW77CM?&_A^\T&1B%-]8,;NV]V9"!(@]E
M\PU^>-.CCW-7J87/L=A_AFVNSU_/7[F=]#-,52>D[KL]3]P/A[\3_#WQ8\/I
MJGAO6+#6K!^/-M90^P_W6'56_P!E@#[5O5^)/PS^)'B'X3>(H]6\-ZQ?:-J$
M>/WMM(5WC^ZZ_==?]E@0?2OOG]E#_@I]I_CQ[70_B EOHNK/B.+58_DLKD]/
MW@/^I8\<_<))^X.*^QRSBJA7:IU_<E^#^?3Y_>?38+.J=;W:GNO\/Z_JY]>T
M4V.19D5E965AD$'((IU?5'M!1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1169XO\ %ECX&\.7>JZE-Y-G91F1V[GL% [L
M3@ =R151BY/E6XI245=[&5\6/BKIOP?\)3:MJ3%OX+>W0XDN9.RK_,GL.?8_
M#OQ@^)VL?&GQ1)J6J2,(U)6UM58^3:(>RCU.!ENI(]  -SXK?$?4/C3XQDU2
M]W1P+F.TM@V4MH\\ >K'J3W/H  ,(Z-A.E?=93EL,)'GGK-_AY+]3XK-,PEB
MI<D/@7X^;.*O-+VCI6#JECMS7H.IZ5M4\5S&LV.W-?24:USY^I3L<'J5MUKC
M_&>D-=VC21#]]#R !]X=Q7?ZQ;XW5S6IQ8)KUJ,CS:D3R<ZO@]:<FK_-UIOQ
M.TEM#U%;J-<6]T>?1'ZX_'K^=<RFK>]7*HT[,F,+JYV$.K^]32R+=CS%^]_'
M_C_GO]>.3@U;G[U:-CJVUE/7V]:^:XKX=H9Y@)86II):PE_++_)[-=O.QI3D
MZ<KHV:*9'*LR!E_B&>N<?6GJ"37\A8S"U<+7GAJZY9Q;37FCU(R35T*J[C5J
MWAS3((<UH6MM7%*1K&-Q]K;9K5L[2H[.US6O8V=<M29V4Z9](_L7?MP:A\&9
M;;P[XFFN-1\)L1'#(27FTKME>[1#NG;JO=6_0+2M5M==TRWO;*XANK2ZC66&
M:)PR2H1D,".""*_(;3[/I7U'^PM^T[)\.-3A\)Z[<?\ %/WTFVTED/&G3,?7
MM&Q//8$YX!8U]=PSQ0Z4U@\7+W'HF^GD_+\O3;Z7+L5*/[N>W0^X****_4CW
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OD_]
MK;XO-X]\:?\ "/6,S-I>BR%9BK?+<7 X8_1.5'ON]J]X_:%^)G_"J?A;J&HQ
MR!;Z8"ULAW\Y\@'_ (" S?\  :^-/#5FT[[FW,S')).237TF0X-:XJ?31>O5
MGSN>8MI+#PZZOTZ(U-'T7<HXK3DT+$?W:W/#VB[U7BMBZT'9#]W]*]JIB/>L
M>/"CH>7ZWI>Q6XKB=?L]NZO5O$^G[%;BO.?$T&-U>CA:ESAQ%.QYSKD."U<G
MJJ;2:[3Q OS-7(:NG+5]#AV>)71Q_BS1(_$&D7%K)QYB_*V/N-V/X&O!;RXE
MTN_FMIALF@<HX]"*^B;[AC7B_P"T+X=_LV_M]7A7]W<$0SX[.!\I_$ C_@(]
M:Z,1%\G.NAA0E[W*S#MM5SWK4LM4]ZXBUU/)ZUKZ?J6>]<<:AU2@>@Z#J_SK
M&S81CW/ /K_G^E=#!%FO.]-OLX^:O0/"5_\ VK9?-S)'\K>_H?\ /I7XQXM<
M-J=-9UAUJK1J>:VC+Y?"_)KL;866O(S4M;?-:5G:\TRTM<UKV-I7\^5)'K4X
M#[*TZ5LV%ES4=A9=*W-.L>E<-2H>C2IDFG6/2N@TVPQBH=-L.!Q71:1I;3.J
MJN6->?5J'JT:)]D_L:?&B3XB>!O['U&4R:MH:*@=OO7$'1&/J5^Z?^ GJ37L
M]?$OP9\4/\+_ !?I^HP[F2%\7"C_ ):QMPX_+D>X'I7VM;7"7=O'-&RR1RJ'
M5AT8'D&OVK@O.98W!>RJN\Z=D_-='^C]+]3VJ=^6S)****^R- HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFCV):***_3"3Y1_X+6?\H]O%7_7[I_\ Z5Q5^(-?M]_P6L_Y1[>*O^OW3_\
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M8?#Z;PYXRTF.^MV!:VND 6[T^3_GI#)@E&X&>H8<,""17X/?M9?LSZU^R/\
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M#^IV>L:/J"E[:\M)1+#. Q4E6'!PP(^H-<>,CCE!?6E/EO\ :YK7^?4ZL)+
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MDAAC2&*,;51!A5'L*DK]3R;):6 IZ:S>[_1=E^9E*5PHHHKVR0HHHH ^4?\
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ML3#@BUC/$I!_Y:/\G'"N"&K\U?BC\8O%7QM\32:QXN\0:MXBU*0G]_?7+2E
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M,<7SN?QZ#]:]8HKUL)P=@Z;O6;F_N7W+7\2>=F/X9\#:9X23_0[95DQ@RO\
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MQ]@,U^D?_!/#_@BI>IK&G^-/C):10V]NXN+/PLQ$C3,.5:\(RH4<'R@23T?
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M^?X*RZ'\RYSFM7,<7+%5>NR[+HOE^=V%%%?6W_!);]@:+]L#XMW&M>)+=Y/
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MP_:XT_\ 8Q_9YU3Q9.L5SJTQ^PZ+9N3B[O'!*9QSL0!G;I\J$9!(KV:OQ/\
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M_P#E^!_-'XM\(ZKX!\2WNC:WI]YI.K:;*8;JTNXC%- XZJRMR#_C6?7[;_\
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M=O'%OXB\&ZY?:'JEN1EX'_=SK_<EC.5D0_W7!'Y U^;Y]X<X;%MUL+-QJ/\
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M#V(!K^<WXI?#V^^$OQ+\0>%]2&-0\.ZC/IMQQ@,\4C(2/8[<CV(K^DZOP_\
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MFOY)S'"_5L75P_\ )*4?N;1_4V7XGZQA:>(_FBG]Z3/P;_X*O_\ *0GXE_\
M7[;_ /I)!7SO7T1_P5?_ .4A/Q+_ .OVW_\ 22"OG>OZBR'_ )%F'_Z]P_\
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M4E_:6(U?\2?_ *4S^GLDIQ>78?3[$/\ TE&7_P (3HO_ $"-+_\  5/\*/\
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M^(F1QQ>7O%P7OTM?6/5?+?Y/N?>< YU+"X]863]RKIZ2Z/Y[?-=C];J^=_\
M@K#_ ,H]?B7_ ->5O_Z5P5]$5\[_ /!6'_E'K\2_^O*W_P#2N"OQ/(?^1GA_
M^OD/_2D?LF=_\B[$?X)_^DL_!NBBBOZN/Y?"OWD_X)/?\H]?AI_UY7'_ *5S
MU^#=?O)_P2>_Y1Z_#3_KRN/_ $KGK\R\4_\ D6TO^OB_])D?HWAG_P C&I_@
M?_I43Z(K^<O]J#7/^$G_ &EOB)J6[=_:'B;4KG<5VYWW4K9QVZU_1I7\W?QQ
MB>#XU>,(Y%9'36[U65AAE(G?((KPO"F*]OB'Y1_-GN>)\G['#KSE^2.7HHHK
M]J/QT^J/^"+V@+K7_!0SP?,T;2+IMMJ%UT!53]CFC!.?0R#'?.*_<2OQ1_X(
M;RI%^WOIJLRJTFCWRJ"?O'8#@?@"?PK]KJ_ /$Z3>;Q3Z0C^<C]T\-XI95)K
MK-_E$****_.C] "BBB@ K\C_ /@X3T3R/VE/!.I;1FZ\,_9MV[D^7=3MC';'
MF]>^?:OUPK\H?^#AUA_PN?X=CO\ V+<<?]MZ^X\.Y-9W3MVE^3/B^/XIY--O
MHX_FC\\:***_HP_G\$=HG5E8JRG((."#7]+WAO5&UOPYI]XWE[KRVCG.S[N6
M4-Q[<^M?S0U_25\)+&32_A5X9M9L>;;Z3:Q/@Y&Y84!_45^0>+$5R89];S_]
MM/U?POD^?$KI:'_MQT5?DO\ \%CO^";MW\//%^H?%CP3I\MQX:UB5KG7[.WC
M+'2KEB6>X '2"0Y+'HCD]%8!?UHJIK<]G;:-=2:D]K'IZPN;EKDJ(5CP=Q<M
M\NW&<YXQ7YOP]GV(RK%K$4-4]''I)=O7L^_E='Z'GV24,TPKH5M'NGV??T[H
M_F>HKZ1_X*5:=\![7XPRR?!:^O)?-E8ZI;6L(.B12'))M)2V[&[^!5,0!^1@
M!MKYNK^F\OQGUK#QKJ+CS*]I*S7JC^<,=A?JU>5!R4N5VO%W3]&+%*T$JR1L
MR.A#*RG!4CH0:^V?V7_^"Y7Q(^"^D6^D>,;&W^(FEVRB.*>ZN3;:E&HXP9PK
M"3'7+H6/=J^):*QS+)\'F%/V6,IJ2Z7W7HUJODS7+LUQ> J>TPDW%^6S]4]'
M\T?KMH?_  <'?"FXLE;4O"'Q"M+GO';06=Q&/HS7"'_QVJ7C'_@X5^'=E9,W
MA_P+XTU.XV_*FH/;6,9//!9))B!TYVGJ?3G\EJ*^77ASDBE=PEZ<SM_G^)],
M_$#.7&W.O7E7_#?@?4G[8'_!6SXF_M9:1<:"K6O@_P )W.4FTW2W8R7B?W9Y
MV^9QZJH12.JFOENBBOK<!EN&P5+V.$@H1[+\WU;\V?*X[,,3C*OML5-REW?Z
M=EY(*=:VLE]<QPPQR333,$CC12S.Q.  !U)STKL/@E^SYXT_:-\6QZ)X*\.Z
MEX@OV(#_ &>/]U; G :60X2-?]IR!7ZU?\$\?^"1>@_LJ7%GXM\92V?B;Q]&
M \&U=UCHS>L(8 O*/^>K 8_A"]3XW$'%."RFDW5?-4Z06[]>R\W\K['K9#PS
MC,TJ)4E:'63V7IW?DOG8D_X)$?\ !/B;]E'X=S>+O%EGY7CWQ5 JM _WM'L^
M&$!])'(#2>A5%X*L3]F445_..:9E7S#%2Q>(=Y2^Y+HEY(_H3+<NHX'#1PM!
M>['[V^K?FS\W_P#@XEUTVW@/X7Z7Y@ O+_4+K9SEO*C@7/IQYWZ_6ORSK]-O
M^#C+_FCO_<:_]Q]?F37] ^'\4LBHM=>;_P!+DC\'X[DWG=9/IR_^D1"BBBOL
MSY$**]LTS_@G#\<M;TRWO+7X:>))[6\B6:&18DVR(P!5A\W0@@U8_P"'9WQZ
M_P"B7^)_^_2?_%5YO]LX!.SKP_\  H_YGH+*,<U=49_^ R_R/"Z*]T_X=G?'
MK_HE_B?_ +])_P#%4?\ #L[X]?\ 1+_$_P#WZ3_XJC^VLO\ ^?\ #_P./^8_
M['Q__/B?_@,O\CPNBO=/^'9WQZ_Z)?XG_P"_2?\ Q5'_  [.^/7_ $2_Q/\
M]^D_^*H_MK+_ /G_  _\#C_F']CX_P#Y\3_\!E_D>%T5[I_P[.^/7_1+_$__
M 'Z3_P"*H_X=G?'K_HE_B?\ [])_\51_;67_ //^'_@<?\P_L?'_ //B?_@,
MO\CPNBO=/^'9WQZ_Z)?XG_[])_\ %4?\.SOCU_T2_P 3_P#?I/\ XJC^VLO_
M .?\/_ X_P"8?V/C_P#GQ/\ \!E_D?I-_P $'-9.I_L-R0;T;^SO$E[;@+U3
M,<$N#[_O,_0BOM*OD/\ X(N? ?Q=^SW^RSKFC^--#O/#^J7GBBXOHK:Y $AA
M:UM(P^ 3P6C<?A7UY7\V<4SISS;$3I--.3=UJM?0_H;AF-2&54(U$TU%*ST9
M^#?_  5?_P"4A/Q+_P"OVW_])(*^=Z^B/^"K_P#RD)^)?_7[;_\ I)!7SO7]
M'Y#_ ,BS#_\ 7N'_ *2C^?,[_P"1C7_QS_\ 2F%?:7_!!K1/[5_;CN+CRR_]
MF>&KVYR#]S,D$6?_ "+CCUKXMK[H_P"#?C_D\OQ-_P!B7=?^EUA7#Q=)QR;$
M-?RO\=#LX5BGF^'3_F1^PE%%%?R^?TH%%%% !7X7?\%C?^4CWQ&_[AG_ *:[
M2OW1K\+O^"QO_*1[XC?]PS_TUVE?I7A;_P C6I_U[?\ Z5 _._$S_D5T_P#K
MXO\ TF9\R4445^]'X>?87_!#7_D_73_^P+??^@+7[55^*O\ P0U_Y/UT_P#[
M M]_Z M?M57\^^)G_(W7^"/YL_=O#C_D4O\ QR_)!1117YZ??!1110 4444
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MMG.8I+AWCQ[!2 /85Q-?UU@5-8:FJGQ<JOZVU/Y5QKB\1-PVYG;TOH%>S?\
M!.OQC-X%_;G^%=] TBO-XBM=..WKMNG^S-^!64Y]L]>E>,UZ!^R38R:G^U7\
M,K:$A9;CQ9I42$G #&\B Y^IK/,X*>$JPELXR3^YE9;-PQ=*<=U*+_%']%E?
M._\ P5A_Y1Z_$O\ Z\K?_P!*X*^B*^=_^"L/_*/7XE_]>5O_ .E<%?R_D/\
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M.':H5Z_=Q7W)O_VY&5XV\:Z3\.?".I:]KE];Z9H^DV[W5Y=3MB."-1DD_P"
MR2< 9) K\3_^"AW_  4^\4?ME^(;K1=)FNO#_P .K:7%KIB/LEU(*?EFNB#\
MQ) 81_<3C[S#>?I7_@X _:;NM/B\,_"?3;IHH;Z$:[K2I_RV02%+6,GT#1RN
M5/=8CV&?S#KUO#OA:E##QS3$QO.7PW^RN_J^CZ*UMSS./N)JLZ\LMP[M"/Q6
MZOMZ+JNKWV"OH#]@7_@GUXD_;J\<74-G<?V)X6T<I_:NL21>8(BWW88DR/,E
M8 G&0%'+$94-\_U^ZG_!(?P%8>!/V O S62P^=K:7&J7DL?6>:2=QECW946.
M/V$8':OIN-L^JY5E_M</\<GRI]M&V_N6GGW/G.#<CI9GC_95_@BN9KOJE;\=
M?(\K\8?\$ _A+JVCPQZ/X@\:Z-?0QA#.]Q!=1SG'+NAC7D_[+*.O'3'BGC?_
M (-X?%5G+)_PC?Q&\/ZE'U0:EI\UD>G )C,W?C./?':OU7HK\9PO'6=T=J[D
MO[R3_%J_XGZ]B."\FK;T4GY-K\G;\#\8]:_X(._'+3,^1-X)U+#;<VVJR+D?
MWOWD2<?K[5%IG_!"7XZ7Y;S5\'6.W&#-JQ.[/ILC;I[XZ]Z_:&BO3_XB7G%K
M>Y_X"_\ ,\W_ (AUE-[^_P#^!?\  /R;\%?\&\WCJ^F4>(OB!X3TN/\ B;3K
M:XU!AUZ"00=L=QU/ID_17P5_X(1?"'X>3QW7B:[U_P <W<9!,5U/]CL\CI^[
MAP_U#2,#Z=<_;5%>7C..,ZQ*Y95G%?W4H_BM?Q/2P?!>3X=\T:*D_P"\W+\'
MI^!A_#[X:^'_ (3^&H=&\,Z+I>@:5;_<M;"V6",' &2% RQQRQY/>MRBBOE)
MSE.3E)W;ZL^HC&,5RQ5D@HHHJ2C\Y?\ @XAT!KGX9?#35 ORV>J7EJ6V=#+%
M&PY[9\D\=\>U?E;7[3_\%R_AZ_C3]A.\U"./>WA76K/5&P/F",7M3^'^D GZ
M9[5^+%?T1X;XA5,EC!?8E)?CS?J?@?B%0=/.)3?VHQ?X6_0****^\/AS^CWX
M :@NK? ?P3=1AECNM L95#?> :WC(S[\UU]>&_\ !-7QU'\1/V$/A??1LK?9
M=#BTQL=FM,VI!_[\U[E7\CYC1='%U:3WC*2^YM']49?657"TZJVE&+^](***
M*XSL"BBB@ HHHH **** "BBB@#\&_P#@J_\ \I"?B7_U^V__ *205\[U]$?\
M%7_^4A/Q+_Z_;?\ ])(*^=Z_J[(?^19A_P#KW#_TE'\OYW_R,:_^.?\ Z4PK
M[H_X-^/^3R_$W_8EW7_I=85\+U]T?\&_'_)Y?B;_ +$NZ_\ 2ZPKS^,?^1+B
M/\/ZH[N$_P#D<8?_ !'["4445_,)_204444 %?A=_P %C?\ E(]\1O\ N&?^
MFNTK]T:_"[_@L;_RD>^(W_<,_P#37:5^E>%O_(UJ?]>W_P"E0/SOQ,_Y%=/_
M *^+_P!)F?,E%%%?O1^'GV%_P0U_Y/UT_P#[ M]_Z M?M57XJ_\ !#7_ )/U
MT_\ [ M]_P"@+7[55_/OB9_R-U_@C^;/W;PX_P"12_\ '+\D%%%%?GI]\%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% 'RC_P6L_Y1[>*O^OW3_P#TKBK\0:_;[_@M9_RCV\5?]?NG_P#I7%7X
M@U^_>%__ "*9_P#7R7_I,3\+\2?^1K'_  +\Y!1117Z,?GY^\G_!)[_E'K\-
M/^O*X_\ 2N>OHBOAO_@G#^WA\'_A1^Q1X"\/>(O'V@Z3K6FVLR75G<2,)(";
MF9@#A>ZL#^->X?\ #S/X"_\ 14/#/_?U_P#XFOYASK*<=+,:\HT9M.<[-1>J
MYGY'])9-FF"AE]",JT4U"-US+^5>9[I17A?_  \S^ O_ $5#PS_W]?\ ^)H_
MX>9_ 7_HJ'AG_OZ__P 37E_V-F'_ #XG_P" R_R/2_MC ?\ /Z'_ (%'_,]T
MHKPO_AYG\!?^BH>&?^_K_P#Q-8OBK_@K/^S[X1MV>;XBV-XP'RQV-E=73.><
M#*1D#IW('3U%5'(\RD[1P\W_ -N2_P B99UE\5>5>'_@4?\ ,^CJ^0?^"N7[
M=6G_ +,WP+U#PGI&H*?'OC&T:UM8H7_>:;:OE9;I\<K\NY8^A+G(R$;'A?[3
M'_!P!;OIEQIOPG\,W2W4JE%UG7551 >1NCMD9MQ[@NX (Y0CBOS=\?\ Q"US
MXK^,M0\0>(]4O-9UK5)?-NKRY??)*V,#Z    #       K]"X3\/\3*O'%9G
M'EA%W47NVMK]EW3U>UCX/BCCK#QH2PV72YI25G+HD][=WVMHM[F/1117[<?C
M(5]!?\$L/ ,GQ&_;Y^&]JJ[H]/U%M5E;;D(+6-YP3]6C4?5A7S[7Z8?\&^W[
M.TC7_B_XI7T#+$L8\/Z4S#AR2LMRX^F(%##/WI!Q@Y^=XLS".#RFO5;U<7%>
MLM%^=_D?0<+8&6+S2C26RDI/TCJ_RM\S]/*^=_\ @K#_ ,H]?B7_ ->5O_Z5
MP5]$5\[_ /!6'_E'K\2_^O*W_P#2N"OYSR'_ )&>'_Z^0_\ 2D?T!G?_ "+L
M1_@G_P"DL_!NBBBOZN/Y?"OWD_X)/?\ */7X:?\ 7E<?^E<]?@W7[R?\$GO^
M4>OPT_Z\KC_TKGK\R\4_^1;2_P"OB_\ 29'Z-X9_\C&I_@?_ *5$^B*^ O\
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M'Y?C'A]YM@'2I_Q(OFCZ]5\U^-CZ3A//EE>.52I\$M)>G1_)_A<_H2HKSO\
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M\!?:W_ :_G-UG1[KP]K%UI]["]O>6,SV\\3_ 'HI$8JRGW!!'X5_3)7XO_\
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MA/Q+_P"OVW_])(*^=Z^B/^"K_P#RD)^)?_7[;_\ I)!7SO7]6Y#_ ,BS#_\
M7N'_ *2C^8,[_P"1C7_QS_\ 2F%?='_!OQ_R>7XF_P"Q+NO_ $NL*^%Z^Z/^
M#?C_ )/+\3?]B7=?^EUA7G\8_P#(EQ'^']4=W"?_ ".,/_B/V$HHHK^83^D@
MHHHH *_"[_@L;_RD>^(W_<,_]-=I7[HU^%W_  6-_P"4CWQ&_P"X9_Z:[2OT
MKPM_Y&M3_KV__2H'YWXF?\BNG_U\7_I,SYDHHHK]Z/P\^PO^"&O_ "?KI_\
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MU6V$5W=IS;Z;&<%K>WSR>0-TAY; P%'!^KJ_ >.>+EF4_J>$?[J+U?\ ,_\
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MU=;+JG<^KZ***^=/H HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\.>'4;@KIFFPV:G\(U%1B/%7"I?N:$F_-I?ES%4/#'$M_OJ\4O)-_G8_$O\
M9Y_X),?&K]H*YMY1X7F\):/*P+ZCX@#62A3SE82/.?(Y!";3Q\PSFOTH_8N_
MX)%_#O\ 92N+76]27_A-O&5N1(FI7\(6WLG'>W@R54CC#N68$9!7.*^L**^$
MSKCK,\QBZ5_9P?2/7U>[_!/L?;9/P3EV DJMN>:ZRZ>BV7XOS"BBBOC3ZX*X
M7]I'X\Z/^S+\$?$/C?7&W66AVQE6%6P]U,2%BA7_ &G<JN>@SD\ UW5?G/\
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M47!RW<_-%?TV5^)G_!9[]F;2/V>?VL5O/#]K#8:-XTL!JRVD*;(K6XWM',J
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MBA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?$QY\/-37=-/\C\UQ6#KX>7)B(.+\TU^8VBBBNHY0HHHH **** "BO0O@_\
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M2/IY^?X+J4445\&?<!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
?!1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>chart-0b610af5b7e35be4879.jpg
<TEXT>
begin 644 chart-0b610af5b7e35be4879.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &0 3T# 2(  A$! Q$!_\0
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MI-%L=8\=^./#GA;5O!_P_P!'N=73[#'JGC/6]$M PENI)$T^TO;RV^0?#?\
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MK'3-#A@T^PT2SNK<P:'8J)I[+2UMK.[O=1N8)=0N??* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#XE_;9^(EAX;\.?!?P7I?CF
MW\/_ !"\=?M5?L@VOA[POIGB=-)\9^+?"]A^U)\)+GXE0:/HME?0:[KF@6?@
M.+Q#<>-TM+6ZTF#PG%K#>(@NC"]!_/Y?^"DGQF\0>&O@CHW@S7_@E/\ %KQ-
M\,_AY<_%W1;[0=7U2T^'/Q3\5?MX?LK_ +,&KZ%XDT/2/%L&J>'+G2/"_P 6
M?B*L_@K4=2M_$<7B?2M+N;BXM+2T>&^_<N;2=+N-1LM7N--L)M5TZ&ZM[#4I
M;.VDU"RM[[ROML%I>O$UU;0W?D0_:HH)8X[D11B=9-B;:Z^'M!26XG31=)6:
M[N_M]U,--L1+<WWG:?<?;;B40>9/=F?2=+F-S*SS^;IUA+YGF6=LT0!^$'Q9
M_P""C/[4GPWU ?#NUL/A7JOB+P/XF_:DT36OBCJT7PR^'W@SX@Z]\!_$'PTL
M_!7@^\TOXP_M(?"[3/!A\0:)\0VU+XC3>"_%GQ(\;V=GIUCK?@GP/]AO=3M]
M)_1/]K'Q!X-U3X.^ 8_BAXIT7X;:SXMU"SN]!\(>+_CYXU^!'PO\7>-%\%:M
MJMQ\._B-\:OAOH][JEMX=T^RDUC7+&UMC;6WBO7_  MI(%AJMJDNF-]FW&@:
M%=^3]JT;2KG[/J\6OP>?IUE-Y.N0?ZC68O,@;R]6A_Y9:DFV]C_@G6I]4TG2
M]<T^YTK6=.L=6TR\01W>G:G9VVH6-U&KK(J7-G>136UP@D1'"S1.H=%< ,H(
M /YK/#_Q4N]8^"?C"[^,?[0'Q/\ #WBKX=?LE^(M<_8^UN'XV^,;5?'_ ,?/
M#/QL_:N\(>)==^$.NV'B*QNOVL/[%U7PI^S[X(^#]QXW'CO7/BC\&]>\!^)-
M<\-W5]\;_%MOJ?[U:;\0M'\2_"KQC;>+OB5X9^'WC?P/X%M++XZ:GX9\6>%O
MMGP$\7ZO\,-)\;ZS<ZU=ZXFIZ-X5O/#>A>(;/QOI,OC+3WTW_A'9M&\0ZA97
M>A78,_L]QHVDW9TXW6F6%R='N4O-)-Q9VTQTN[B@EM8KK3C+$QL+F.VGFMHY
M[0PRQV\LD*.L3LAS[7PCX8LIO%4]MH6F)-XWO5U'Q>[6D4Q\1WB:%IGAA)=7
M$ZRK?!/#VCZ9HR0S*T":=90VJQ"(,K 'X :/\3O"6J^&_'/C/]GSX]^*[C]D
M'Q%XQ_9$\#_$'6M1_::UWX@?$;4OA[??&75(OC?^U;>:E?>/?$'Q!^"'@3XE
M>&-6\(_#W6_&DVI> =8USP@WC7XQ3Z-X,L-"\)^+-3[+5OBK^SYX4\+_ !"T
MGXB?';Q_XM^!.D?M*^)? _[&'PVT7]I_4/"DG[0UQ_PHOX0:]XS\*:9\6=7\
M;^%?$/B[X;? 7XLZA\4[?2?%NN_%^#X:?#,_;;;Q-?7B_#KP#;Z=^WN@_#KP
M#X6?49/#7@GPCX>?6(?L^K/H?AG0]'?4X,R,8-0;3;"U:^A+2RDQ71EC)DDR
MOSOE=7^'G@/7]-TW1M<\%>$M9TC1H1;Z1I>J^&M$U+3=*MU2"-8--L;VPGM+
M"%4MK9!%:0PQA;>%=N(D"@'\_FN^-/'F@?#SXA_\+&_:2UWQ5^U9\(O@-^RZ
M_P"Q/J'@KXO:[=^'_CGXYU?PQ$USK/@G2=&U?3=(_:+/Q/\ CTNN?!7XI:OK
M_AOQ/>:KX!\/:%J'B'3_  Q'XCN)[G]$_P#@H)^U1XY_9UTKP)I?PV\0>%M&
M\:>*M$^*'C"SMO&.B>#'T;7-.^%]IX4GN='7Q9\1OC+\'?"^F75W?^+-*MSX
M=T9O&OQ,\5:5-J%_X,\+06'AGQ1XBTC] [/PMX:T]-#BL?#VAV4?AF*>#PY'
M::1IULF@0W5N;2YBT1(+:-=)CN+4FVGCT\6R30$PR*T?RU?OM+TW4_L?]I:?
M97_]G7T&IV'VVTM[O[%J-J'6VO[3[1')]FO;<2R""[@\NXA$D@CD4.V0#\9/
M!W[>7[1_B(Z-\5FT?X<7GPZU7XQ_ +X5V7P8TCPSKK?$#5I/CK^PA\&OVFQ'
M:_$.]\4P64'B+1_B/X]N?#'AFP;P1<0:WH%R+35_LNIO8ZA9=Q^PU\<_'/QP
M_:*\2^)_%7QE\!_$^W\0_L3_ +,WCV[T?X4VNKZ'X'^'OB[QO\3_ (_:CX@\
M&3Z#?>-/&$*>*/#]JFDZ%>:EJ7]B>.Y]*T[3(/&>C65Q%IJM^L":-I$2HD>E
MZ<BQW-K>1JEC:(J7=E:PV-G=(%A 6XM;*W@M+:=0)8+:&&WA=(8HT5UEI&EZ
M<]Q+I^FV%C)=W%U=73V=E;6KW%U>W+WEY<SO!%&TT]W=R27-S-(6DN+AWGF9
MY69R ?@3\7?B?I5QXT^.VI?L2_M&>,/'_P 8OACX"_:[U'XJ>([GX_V7CW4?
MB9\3+3P1XT'ASX#?"/X _P#"1W>A:YKO[._B:]M_$]MK7@KX8Z)I?P^_X5?8
M?"9-7\;>*_&?Q7M]&]0T7Q7\.K"Z_:>\-?!/]K'Q!X?_ &5?^&=/A!XHU7XV
M0?M%)XR?P;\;/%/BOXJ6NL^'_"'QH^+VM>-X?!WC3XL_#NR\(7WC2VT_6+/7
M_!>I7/AGQQX<T_PSXS\=+KEW^P&G_#;X>Z5KQ\4Z7X%\':=XE+W4A\0V'A;0
M;+73)>I+%>.=8M=/BU+?=1SS)</]JW3I+*LI=9'#7[WP5X/U+2+OP_J/A7PY
M?Z%?WTFIWNC7NA:3=:3>:C+>?VC+?W6F7%G)8W%[+?\ ^FR7<UN]Q)=XN7E:
M<"2@#\$M=^-?A7Q+\!?V)/'OBGXUZ3\1OA?<?L;V6FZII7A;]M"S^"7BG1?V
M@]&\$?"/5=1^,.O^-K/Q]I.K?$F\\%Z=?3:;K6F6&M>+OB/X"USQ!;^(M*^%
MWC_4O&$EWX=_9[]EW5/B3K?[-7[/NL_&07(^+NK?!/X5ZE\41>V$FDWG_"P[
MWP+H5SXR:[TF6ULI-*NG\0R:A)=:9):6SZ?</+9O;P- 8D]*T[P%X(TBQMM,
MTKP?X6TW3K+6H_$=G8:?X=T:RLK7Q!$ (]<MK2UL8K>#6(PH":I%&E^@ "W
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MC_W%_P#017XA_P#!2?\ Y22?\$*?^SK?VH/_ %CGX@U^WD?^KC_W%_\ 010
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M?6:_^$M#_P":_P"K/RN6]/O7]=?S[,^P:*^/O^%S^./^?G3/_!6G_P D4?\
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M $+E]_X'Z+_\L* -ZBL'^U=4_P"A<OO_  /T7_Y84?VKJG_0N7W_ ('Z+_\
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M*M8K#3-*TK3;.*&TT_3M.LK>"TLK&VAB@M+:&.")%2-0/PFT+X7_ +//A?\
M:G^*_@4ZA\%_ QT_]J'PEXTF^'OQI\=?M(_%;Q%\1?%>N6?PX\5:;X\TK3KO
MXQ:-\)K&\OO$5E:6W@SPSJ'A3QL_A'7?"NEZQK$WV^2VTC3?WO'3\3_,_KZG
MN>>] 'X@_P#!2?\ Y22?\$*?^SK?VH/_ %CGX@U^WD?^KC_W%_\ 017XA_\
M!2?_ )22?\$*?^SK?VH/_6.?B#7[>1_ZN/\ W%_]!% #Z*** "BBB@ HHHH
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M *BX<?V_^WOU/PO_ ."C7@"\\6^%OA)K^D^#?B;XBUSP?\0M @TG6/ OPK\
M?'_P]HJ^+?B?\&[/5]-^(/P.\;WEE<^*-*\1:=HV[2/$_A>\T.\\/7.BZCX7
M\1>+/#G@[XA:[+>>!Q?"[]HG3-?\2:KXC^%=Q;?$OQ_<_L9Z[X ^&/@SX)>
MOB+^S59:5\-/ OPGT+QK\,/B9\5O$FF>(M2^%/ACX$^+M ^)7BKP)%X=\:^
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M[]3Y.HHHK^:R0HHHH *]P^ __(RZQ_V S_Z7VE>'U[A\!_\ D9=8_P"P&?\
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M?#WP?IG@#Q#'H=YH^JZD)O$FJ:YK?CZ/4VTOQ;K TVTTRUM/T7']3W)[^_\
M+H.@X%?E\^O_ !(U3]H[QE+XDU?X^>(O!LGQ-\'2?"K5?A3\=?V8O"7PDM_
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M'_U%PX_M_P#;WZGR=1117\UDA1110 5[A\!_^1EUC_L!G_TOM*\/KW#X#_\
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MSYQ <0@Q09&&N985YSBO+-4\2?\ !8O5].U#2=0_X)8?LXS66HV=Q9W<+?\
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MIR1=*I&_)2Q=2I+WI)6A"3UO:US]6/WCHKYS_9@\>?M(?$7X;W&O_M2?L_\
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MUU8)XFU#3+W4],M5TQ!JUW87=]90B2WN+B)_-O$W[-7[#-U=?#[X;^,?V?\
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MA+;V0L;UZW@W]E+X!:I+\<_B7XX_:)\4?M-_"GXLWMM=_&;P9\9-8_9O\<_
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M (2.YU*R\)>%9=&TSPM;0^#(/$$6I^.$UVUTYK;XF:WJ-BMV6MO!=CX\ENO
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M6FF:5I>F6L%AINFZ=801VMCI^GV-HD-K9V5G:Q16]K:6T45O;P1QPPQI&BJ
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M9^SW?>)_VOOV?O$OA_3?$"_#KXP6VI^%?VL])TCP[_:7A+XA^'?@%97OQ?\
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M^%]C\./!'BK2+KPWX@U/P[\6=%U/Q1XY^$"?"S69O&EEXH;]U5Z#MU./0$Y
MXXX&!QQQ1@>@ZY_' &?<X &>N.*6@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X[Q7XXT7P:;$:NM\
MW]H"Y,!L[=)P/LOD>9YFZ:+;G[0FS&[=ALXQSV-?.7Q^Z^%OIK'\]-KYOBW-
M,5DO#^/S+!>S^LX9X3V?M8.=/]]C</0GS04HM_NZDK>\K.SZ6 ZW_A=W@O\
MYYZU_P""^+_Y+KT[1]5M=<TNQU>R$HM-0MTN8!.@CF$<F=HDC#.$;CD!FQZU
M^?2]1]1_.ON/X=?\B-X8_P"P3;_R:OC^ ^+\XXBS'&87,7A72H8%XB'L*#I2
M]HJ]"E[S=2=X\LY.UEJ[WT'T3\W^%O\ ,[2BBFL,C_@2G\F!/Z5^J",S1]>T
M/Q#8C4] UG2M;TTWFI:>-0TC4;/4[(W^C:G>:+J]D+NRFG@-WI6L:??Z5J5M
MYGG6.I65W87217=M-"FGN7GYEXZ\CC'7//&/>OY\M&^%G[8GASP;\8[GPH/V
MEO \OPX^%/Q^^)?P<\#^"I]0T'0/%'QXU7]O[]J_QQX?FO?#L,#P>.K[Q!\,
M[SP)?2^"]8-QX9\5^"?%.ESZUI5])+H=[I7LOB!OVJ4M/C-):K^VBWQ17XH^
M,U^*0\/BW;X5_P##-G_#5OA5?#W_  S#'K6=,?XN?\,A_P!JOX(;X/@^)3J(
M\:CXK_\ %Y#\.%H _:C<N =RX/0Y&#@X.#GL>/K1O3&=RXSC.X8SC.,YZXYQ
MZ<U^#>O>'/VT]8\._$^]\&:[^U_I?A/PA\!/VV_'/[,,&L:IXALOB9J_C/PS
MXC_9_P!8_9?TCXL6>JPS:[XL\43^)[7XSV_@3P)\3H[OQ#XP^#]UI^B?%S2]
M6U&2_MHKGQST#]N/PWXJ\5>$O!?B7XZW?P)L?CZVKWWB*_M_C?XZ\<W6A^)_
MV8/AQK&CV'AK6/@;JN@_&JX^&EE\>[CXCG4K+PE?SZ)X3\7C0/#6L6%E\)H;
M_2=+ /W5EFA@56FECB5Y(H4:61(U>69UBAB4N5#22R,L<: EI'940,Q ,FY<
MD;ER,Y&1D8ZY';&1GTK\L/VG?A+\5/B1^Q7^S7%\4+CXO>-/B1\,_B=^QS\4
M?C'=?!IO&_PZ^(^N+X%\?^";WXKZ[9^"?A)XJU'Q#>ZKIND2:YXG?P-X8UKQ
M)=6FN::E]X274M;T?0S7S1JU]^VEJWQS^(.H6VC?M5^'/A[XIT;]K+PMXK\)
M^'1\2[W6_"^IZ;>1']F#Q+\-/'WBGQ);?!2VO_%4MMIVM^%H_A/\,M,T#PCH
M.IWGA3]H'QOXFU/3=<2\ /WFR,$Y&!G)SP,=<GV[^E&Y2,A@1ZY&..OY5^7E
MQ=?MLW/_  3U^(]II=OXBT[]M[2X?$FC^+K^6WN;_1]2\:V_CFR/Q!\4?L]P
M:O)IT-W\.-7\#3ZWJW[..E+/:W^FV,OA3PWXBFB\=Z9XD<?,5A!^W-IOPYT#
M5/#VL_'[Q;9:7\5/'.M>(]%L_"_QC\&^(IOV04\,_"VU^)WA#PE)^T#XI\4?
M&7Q/^T'=>.5U3Q)^S?JOCE_#_CV"QC^)_A70I;3PJWA?5=5 /W@W+G&X9&21
MD9 '4X]N])O3&=RX]=PQZ]<XZ5^ OBWQ-^VUXPN/C/J?[+^L_M':A\5-.\8_
MM_\ AK4+WQV8-0_9^@\ >&O&7Q$\._ [3_A5!JDD/@Z7XM^'?&FG>'-*\%:9
M93VOC&U32_%^E_%9[;PA'X9V]E\)?A_^UKXYU_X6>&?&/Q%_:9LO@WJ?Q%^.
M%QJUUX?A^/\ \(O$.G>$K;X!>#X?#6A^(O&7QJ\4^(OCY-I%Y\7WUCQ#X2UO
MQ+=^&]6MO%,.N>&_#@U'X:C38KX _<G<N0-PR>0,C)'7('T!/X4!E.<$''7!
M!QUZXZ=#^1K\.?AUJW[;B?%#]E_Q'XOM_P!H[Q9XM\4?"O\ 9PA^(?A'7=#\
M7_#KX;>!=7U;X(VUK\9?$NO:IX:.M? 3Q39Z7\2KR_\ $7Q \"_$[PY\.?CU
M8^([*XT;X.^)=0\,0^'='OO5?^";=I^V<NM:]=_M.^*/'%[=M\,/",7Q(\/^
M,/ GQ2TG2X?V@GU>ZF\7ZEX&\4_$GQGJWAR?1([?^U-.FT;X!^'X/@3-I/\
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M5-2_:$\7^)?B]X@T?4?$)CO(7\1VFDZ3I6N#Q'9^"CJ'@V317M/T'H ****
M"BBB@ HHHH **** "BBB@ HHHH **** ,;3?#NAZ/?:[J>EZ7:6.H>)K^#5-
M>N[>()-JFH6VGVFE075TV3ODCT^QM;==H5<1ERIEEE=]FBBJG.=1\U2<IRY8
M1YIR<GRTX1A"-Y-OEA",806T81C%)))$4Z=.E'DI4X4X<U2?+3A&$>>K.56K
M/EBDN:I4G.I4E:\YRE.3<I-LHHHJ2Q,#T'?L._7\^]! /4 \YY //KSWI:*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
F**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>chart-3bef3451f3d85124b28.jpg
<TEXT>
begin 644 chart-3bef3451f3d85124b28.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %- 3T# 2(  A$! Q$!_\0
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M/K;4/A+I,FD>!/"-SKGA;X=:9H>D0:UH,&J^!#X!N;S5O[0ZC]K[_@GQX/\
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M"W66 F&0-'\M7[W3=/U$VAU"QL[XV%[!J-C]LM8+K['J%L'%O?6OGQR?9[R
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M0FI11I?(  LX KJ: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+C1].D\.Z/=Q:?<6-AK$USJ;16TMM;P-)=Q_38(8!AT(!'T(S7X@_P#!2?\
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M]8Y^(-?MY'_JX_\ <7_T$4 /HI-PSC/M^.<8_,$>F>.O%)N&">2!Z*QSTZ
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MK\=_@[$BQ)XZT*- "J(GVR, =2$5;-0.N?E QUH_U:XB_P"A#G7_ (:\;_\
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M).6*BG.,LRC3::PDY_NZM1PA4H2J**JPO^YGG>(_^@=HG_@YO_\ Y15^:_\
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MROTF.R]%^1^6!1113 *_I%_X-JFOE_:._:3-A!:3R?\ "C_!^];RZFM4"_\
M"Q),%7@L[QF;.<@H@'')R<?S=5_2?_P;/_\ )R/[2O\ V0[P=_ZL66O)SW_D
M48[_ *]T_P#T_1/9X>_Y'. _Z^R_]-5#^O/Q?-XB_P"$5\2[M/T0#_A'];R1
MK%^3C^RKOH/[#&?Q(_/%?Y74?^JB_P"N4?\ Z M?ZK_C'_D5/$O_ &+^M_\
MIJO*_P J"/\ U47_ %RB_P#1:UX?"'P8_P#Q8;\JY]#QM\66?X<;^>$'T445
M]D?"A1110!^D7_!(0SK_ ,%*/V2S;)#)./'GB3RTGE>")C_PJ[Q_G?+'#<.F
M%W%2L+Y8*I !++_HGV#ZDZM_:%M8VX"Q^3]BO;B[WY!W^9Y]A9>7M^79M\W=
MEMVS:-W^=K_P1]_Y26_LD?\ 8^^)?_56_$"O]%=/N+_NK_(5\!Q9_OV'_P"P
M2/\ Z>K'Z/P9_N&*_P"PVI_ZCX4=1117RQ]B%%%% !1110 4A&01Z@C\Z6H+
MJ9;:VN+ATFD2""69DMH)KFX=8HVD9(+>W5YYYF"E8H84::60K'$K2,JD ^*+
MCX,VW@?XS^*O$V@_M%Z7\/X/B?\ $'1/B+KGPNN?!'P4FFUS7&TWP[X7OI;?
M7?$.E/X^N)_%.G^%=-TV2\34;B:U>UACT!+%K=8V^WA^?7^?].E?CUH%OHMQ
M^T+XL\>Z+X(O=1T[XK?%CP=XTS\8/^"7W[5>O_$+PMJ,&D>$/"=W#:?'/7=>
MT?2O#NE10^&[*^T"]OO"UAX?^';F>\%M/IL4EO#^P@Y'XGL1W/8_J>_6@#\0
M?^"D_P#RDD_X(4_]G6_M0?\ K'/Q!KZG_:P)'Q$T;!(_XHS3._\ U%=;KY8_
MX*3_ /*23_@A3_V=;^U!_P"L<_$&O6_VX?C%\,/ 'Q8T#1?&?C32/#NJW'P_
MT?4H;&_%\9I+&;6_$=O'<K]FL[B/RWGM;B,9<-NB;*@8)_3/":I3I<74IU9P
MIQ_L_'+FG)15W&G97;2N]3\@\<*56MP)7IT:=2K4>:9:U"E"52;BJL^9\L$W
M9+=VLNI^:O[<OB;XI^'_ (:Z"GPK\6WWA[4K[Q&G]O:7X/\ %W@+P;\7O$^A
MVL^DQPVWPKU+XDVE[X8NKO2]:U#3;SQGIA&G:C>>%IV\C6]-T^+5XM0^9_B[
M^W-H]LO[/5KX=^,GB7PGI</C[]F;6OB#XE\0_#J_T'Q)\5M*^('Q>T_P3X@\
M RV'AWPKX@\%:;IND>%K7Q5KWQ:E\%:F;6779/!WAWP-?/I]SJV/OV=OV9?V
MIM$UOP'XPU;X7>//!>G?V3K7B&U\::9<:EHFE31WSR:#>^7=:--<P7\^HV4E
MK:SZ:J7)M_MT%S*--FO8+GLK'7O@CXKMO"/@VV^('PCU"*X\36C_  T\&V.K
M1W>GZCXE^&-U8:[H=]X+L="TR?P]IC>&]2M--N_!6HRRZ)9OJ5G;+X:=Y;$K
M!^WYG*,\PS*='B'"86%3#86'LI5Z]1T7:<HODHSI1HQBZ;KU9PJU.6C[U>E2
MP\I2K_S1E6&KPRW*8UN%,=C9T\?CI^WAAJ%#V].?U:G*,IU\-B9XF;Y_JV'A
M4I48.ORQP]7$8FG3IX3X0T_]KFT\6?MP_#OX;V'Q)O\ 0O!LJ?M%_#$?"VY\
M,>(]-D\8^+_A[8_#^6V^(FOWFJ>$H6C27Q--XJT#X;1V6M6^B-X2TC4/%^K2
M7 \;Z&NGY?[2WQH^-7ASXG?%G6O &M>/;OX6?!7P#\'M=\3>*O >J^!++P#\
M$-5\0W>J>)_&_B3XX^!?$FDWOC;]H7PWJGPNN-#\8:?H?PFOI+KP]X?L;W2[
M:WTSQ9J4'B&/[\UOQ5\&=0MX?$^M^-O FK:OX0^'#^,18WLFKWGB?PI\*OBK
M;>&K&^UA+>XT<Q66@>,-,O?!Y\0:99W4E^VBWF@7>MZ9;V(62#RJQ\'?L4ZY
MHGPV\07>G_LY6&E^%; >#/A!-XC\+VEE!IFC_#&.QBL]"\.RW/AF;3=%\,>"
MKF\T_3O#\GB.YT[PUI&O7$=AH%S#JZW'DXXE5*V%Q4?]8L(_:9I&NJ]/$8BA
M4ART8*&&C"$JW-0A:.)M3C[+ZO2YXN&N*C>$HNEC<%.?">.7L\HIT)82IA:.
M*IUE',)UIXNI4<,%;$U*36 DJUZJQ-7V5:GB*47EV+^GRZ-(QA)\DRL8<L6(
MA9R8@6/+'RROS'EOO'K7ZP_!+_DD_@'_ +%K3_Y/7X3+^TY\ V*M_P +3\.$
MN0Y++K&\E_F)?=I>[>2<MN^;=G=SFOW#_9UUW2/$WP/^&&OZ!?P:IHVK>$-+
MO=-U"V\S[/>6DRR&*>+S8XI-C@$C?&C>JBOE_&.O0JY!E<*5:E5E'-(N2A.,
MW983$*[LV[7TN^Y^@_1^PN)H<29S*MA\11A+(W&,JU*I34G]?P;LG.,4Y6U:
M6O6Q^77_  6U_P"2,_!C_LKE[_Z@GB"OY\OASX9TWQEXY\,^%]7\1V_A+3M:
MU"2VG\07+V$2V3Q6-Y>6EO;S:MJ.D:1#J6KWMK;:)H\VL:OI6CPZOJ5C)JNI
M66GK<7$?]!W_  6T5F^#/P8VJS8^+EZ3M4L0/^$$\0<D ' ]Z_G9\.:W?>&-
M:L];LM/TC4IK1;N)]-\2:#:>(M U*TU"QN=-O]/U?1=1B>VOK*\L;RX@E3,%
MS 76ZL+NROX+:\@\7@E3?"])4GRU'4QJIRT]V;K349>\I+W79ZQ:TU3V/J/$
M&5./&%9UH\U)4\O=6&OO4U1I<\?=E&6L;KW91>NC3LSZR\8?LXZ)X9_:#U'P
M"=3^)7@;X9Z%-HEYXHUWQCI&G6'B/2= UGQ3'X1T'3_"=]9ZE)X=\>W?B[5I
M]/TGP%J%HUC9WNH7=_'J>G6MOX6UR4<7X:^'_P -1XF^,OA[QA>_%4:?\*K[
MXBW.O>+O#7B#PA;Z<?#OA+Q!+X,\-VEUH^K>';^[U;Q3XL\53Z3X=L[:'5;*
MPDN=:,JQVMEIE_(SO$G[6/QDU3QI)XJ\+ZM)\.-(35;;4;+P+X*-Y8^%42V\
M3:IXN\G58;B2>\U^YO-=UW7+S4=4U"X%]/\ VO?16K6$$B11^<>(?B_XV\4_
M\+8DUQK6^N_C+XD\/>)?%^H2VET;Y)O#&MZOKVE:5I,QN2MKHL=YJRQ26=S'
M>RO:Z3HT8NDELWFG]NC1S5TX1KU8K]S0IMPK6J1FJE-5JDDJ=O:^SE5E_&JT
MG*G2IM3]^I4^?KXC)E5J3PU*4O\ :,344:M%.E.#I5)4*46ZK?L76C0@_P!Q
M0K1C4K5$X?NZ5.3X/^%M'\:^(9-"U5?B'JFN7%K96_ACPO\ #N[\)Z9JFM3/
M=#^U/M'BGQUJ5GX=T'2M#L5-[';S6EW-K5Y-;VENVE1QW5\F!\4/"-OX ^)/
MCWP-::Q-XAM?"'B[7?#EOKESI]QI5SJL6E7\ML+VYTVZ9Y[*ZD*$7,)DEB,Z
MR2VL]Q9R6\\FAI?C^PL;-M+U#X3?"SQ)HMQH7A[2-2TO7O#OB%SJ>I>')=2D
M@\72ZUI?B;2_$=CXDU:/5;BT\2)I&L:=X<UZRAL8;SP\)+&UN(L#QQXQ\1?$
M7Q?XA\<^*9([GQ!XFOQJ&I26=B+"R1H[6VL+2TL;*$&.TL-/TZSL].L;<-(T
M5G:0++-/,))Y.Z"Q+Q<IR;CAG2:5.4HO][>ERRCRN32LJO,FHM.2;G74XPPO
MG5)X18*%.'++%*M&3J14U^Z<:O/&7,DF^:5#E:<E))I0H.$YXS^C;_@BI_R;
MI\2_^RV:G_Z@G@:O8/\ @L1_RC2_:[_[)C%_ZE_A:O(/^"*H(_9T^)>Y67_B
M]FI_>4J?^1$\#=B!7K__  6(_P"4:7[7?_9,8O\ U+_"U?A^>?\ )88G_L:8
M;_TJ@?T/P]KP+A;?]"?%?^DX@_SL)/\ 62?[[?\ H1IE?7/[&_[--A^U'\6[
MKP-JOB76="TK1]&;Q%J5CX.T"V\6?$3Q%:-JUEHOV'P-X9N]3TBVU*YTR;4H
M=;\1W<UU,NC>&K*]O5TZ_D=!!J?#/]FKX7?$#QS9_"=OCCX@@^)GBWQSXP\%
M>"-)M/@GXAT^RT"V\)>'DUO_ (3+X[67C/Q#X:\3?"_0=0G75+'5=)T;2O&N
MM^ K'PQXI\4>+&31].L4U7[1XFC!RA*4N:E",ZEH3DHQ:;NW&+6T6WKMYGP<
M,+6G"G.,8\M6<J=-RJ4X.<XN"<8J4TVW*<8K35OMJ?&5%?;?PW_9&TGXL?"$
M^/\ P?X\\60:O;1_#2TU'7?%GPNNO#'[/R^./B7\2_"/PXL_@]I?QAO/$3ZG
MJGQ+T-_&5CXDOGB\$IX6U72M(\31:1J+1Z7;:KJ/-?&O]FK2OAWX$U?XC>"O
M$OCWQ'X9\'?'?7_V</&Y^(OPN;X7ZC!\1=#T+4_$,.I^%;0>)_$XU?PIJUCH
M.O126NJRZ1XM\*WMGIUMXCTE3KEF\(L50<_9\S4^=TVG":M-*+LVX\JNI+E;
M:4GHFWH#PM>,%4<$X.FJJDITY7@VUS)*3;LXOF23<+7DDM3Y)K^D_P#X-G_^
M3D?VE?\ LAW@[_U8LM?B'I_PN^$NH?L_>+OBX?%_Q4TKQ-X8U#PEX-L-(U7P
M3X&_X0?QA\4/$JSZM=^$/#>OV7CV;Q6=/\.>"]-UGQCKFO7OA>'^S[&+0M/N
MK)+_ ,4:7'7[>?\ !M!C_AI']I;'3_A1W@_&>N/^%BRXS7G9U.,\HS%1O>$:
M<)7BU:7MJ$K*ZL])+5772]TSU,AIRAG.6N5O?E*<;2C+W73JQULW9WB]'9[.
MUFF_[#?&/_(J>)?^Q?UO_P!-5Y7^5!'_ *J+_KE%_P"BUK_5?\8_\BIXE_[%
M_6__ $U7E?Y<'PE\+^%O&OQ"\$>$_&WC.S^'GA37]5M].USQI?R:;!:Z#:O8
MW,T,KW6MW-EH5C+J-]#::)9ZGX@O;/P]I5[JEMJGB"ZM]$L[^5?%X2DHT\QD
M[VB\/)V3;LHUV[))MO31)-O9*Y[_ !I%RJY5%6O+ZW%7:2O*6$2NW9)7>K;2
M2U;2."HK]&?V@?V<?@A\$?C[XG\"ZEX*_:CNK+4=+\-CX/?"32?^$"O_ !9\
M3_$OB#Q&^A2Q>#?C!H^G>.O#/B/PC9VEK+/IUQ8^![OQ;K7C6Y?P(=/LK?2K
MGQ!<2>&?V+/ =S\:OC1X0U_Q_P")+GX9^#=7^*OP_P#A;XBT.#P^/$?Q#^*_
M@;X->(_B[>>')Y81K/AHZ3\*;/09-*^,^M^'Y+W36UZYT#0/"M[#<>+;"YT_
MZA8VAR*HW)0=/VJ?+>\?<YDN5M2<>>-[-Q^+EE)4ZCA\>\%7]HZ:47-5?8R7
M-;ED^;E<N9+E4N5V3M->ZI1BZE)3_.*BOKBR_9UT*Q_96\9?&/Q=JWB&P^*E
MM9?!?QUX0\"V<-E%HUE\)/BEXVU/P-8>)O&INK.358]8\;7NG7^N_#_3+&YL
ME@\&Z1#XHUA;RS\8>'HX]K]D;X"_"_\ :#UM/ OB!_B=_P )??:O>QZGK/A7
MQ%\+= \/?#7P;'H,]YI_C'_A%?%O]I>/?CIXCN]9M-1AE^%7PYL-&\0R:3IT
M$6B7VLZ_X@L+2RN6)I1A5J7;A1FX3:5DFHQDVKM)I*2U3]Y^['F;BG$<-5E4
MHT[)3KP4Z:;W4I2A%.U[-N#NG\"]Z?+%2:]5_P""/O\ RDM_9(_['WQ+_P"J
MM^(%?Z*Z?<7_ '5_D*_SJ/\ @CZ"/^"EG[(^X$-_PGGB3<"CQD-_PJSX@!@8
MY )(R&!!BD DC.8Y '5@/]%=/N+_ +J_R%?$<6?[]A_^P2/_ *>K'W_!G^X8
MG_L-G_ZCX4=1117RQ]B%%%% !1110 5'-#%<12P3Q1S031O%-#*BR12Q2*4D
MCD1@5='1BKHP*LI*L""14E% 'S;-^RO\-GN0EOKOQBTSPWY,L+> ]'^/'QBT
MCP'Y4I8FU@\-:=XTM[>QTL*S1C0=,FL?#Y@9K=M),#&.OH/2]+T[1--L-'TB
MRMM-TK2[.VT_3M/LXD@M+*RLX4M[6UMH$ 2*""&-(HHU 5$4 =*OT4 ?AW_P
M4NG@M?\ @H__ ,$+)[F:."%/VK?VGM\LKA(UW?L=_$!%W.Q &YV51D\LP'>O
MSL_X+?\ QI^'WA/]K/P-IVJZQ<O<2_ +PG>(=,T^XU2W\F7QM\0HE#7%H6B6
M;="Q:$G>J%'/#K7Z,?\ !2?_ )22?\$*?^SK?VH/_6.?B#7X@?\ !QZ2?VX_
MAMDD_P#&,'@CK_V4;XIG^9)^IKZCA"O/#9Q&K3Y>:.&KKWDVK/D6R:_,^0XW
MPM+&9'.C6<U!XK#R]QJ,KQE)[N,E^!X[^S1^W-\"?A#\1!XH\1:[\6=,@DTV
M]L(M<^'<%Q9:IIXGL=0CEM-5\/:G:7>B>,]#U2:6R6;2M4\E=-U&QTS6H&N$
MM+JRNNOM?V[_ -D7S?B!XNT_3OBI\//B;X\U37X8=9\)^ _"6N:9X+\(:MHZ
M:--I?@J*XUKP;;^'O%GBB"34Y/&GC.QT(R6,>LZEI/P\TWPKIUQ+)-^&%%?I
M%7$U*M:=>2BJM6G3I5''VG+*%*3DH.#J.#@V_>A*,HNVRYZOM/RJC@:5&A3P
MT93E2HU*M:FIJDYPJU81A*I&I&E&<9I1?).,HSBY+WG[.C[/]MM0_;[_ &>]
M0TK7-9>V^(L7Q(\9?![PG\#O%,D>CV/_  A-IX;T*S\'^'=:\6^'4P-=D\2^
M(/!O@C1])M]!U.WBT/1-7NM7UI-3OX)+#3;3L? O_!2;X$>!]'\-^';35/C>
MWAKX:>+OB1JWA'PU9V&AV.B_%/PIXYNVO;7PC\>+95:"ZMK&X>[BU1=#M/$.
ME7^D:UK&FZ9I.D7YM]=?\&**4Z[G#V<J5)T^;F46JC44J7L(QC>JW&,*#G2@
ME;EC.4E:I[Y4,*J=1585JT:G+:4E[%.;=:.(E*=J*4I3Q$(5IMI\\H1C)2II
MP?Z-0_M(?"M3$O\ :NL_+L7CP[J048P. 69@HQP"S$# +,<D_P!OO_!._P <
M^%=:_8B_9BU:SUJS6UU#X1>&+FW%Y+'9W/E/'< &:VG<2POE6#(XW*1@U_FU
MQ_ZR/_?7_P!"%?Z.O_!*0G_AW+^QQS_S0GP;_P"BKG_ ?D*^:XVQ]?%8#"4Z
MJI\L<7S+DBT[^QJ+5N4K[_UU^JX RS#X',L;4HNJY2P+@U4E&22=>BW;EA%W
MO%;MGY7?\')7B5!^SK^SF= U]HYS\>M4$YT?5)8)3"/A=XM.)FL9XW:(2>6=
MKDH'*'&[!'\>O_"4>)O^AD\0_P#@]U;_ .3*_L-_X.8B?^&</V;N?^:_:I_Z
MJOQA_B?S-?QJXZ>YP/<@9('J0.<#G'/2GPU*2RFBE)I>TKZ)M?\ +V0<51B\
MZQ#<8M^SP^K2;_@PZM>2^XW?^$H\3?\ 0R>(?_![JW_R91_PE'B;_H9/$/\
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M*MEI"A.$5MTC%*^[M=N[;/Z\_%_B/P^WA7Q*!K>EDGP_K8 %];DD_P!E7G
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MXSM..AK_ #MO^"/O_*2W]DC_ +'WQ+_ZJWX@5_HKKRJY_NC^5?#<6?[]A_\
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M-%U?XCV7@ZUT[XB:W\/+W1+'0M2\ :OJVFRV=K>QZK8:?;:1JOC.6S/CB_\
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M_E&E^UW_ -DQB_\ 4O\ "U?!8S_DI/\ NH87_P!+HGZ1@O\ DEW_ -BS$_\
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M^#5C_@GP#D?''_@H$".01^U9<9!]?^1!KZ8\(_\ !"GX=?#_ ,-:+X+\"?\
M!1C_ (+!^#/!_ANPATKP[X6\,?\ !03QUHGA_0M+M]WV?3M(TFP\+PV6GV,
M9A#;6T4<,8)"*!7CYSG=+-*%*E3H5*3IU?:-SE&2:Y)1LN76]W]Q[F19!6RG
M$5JU3$4JRJT?9*,(RBT^>$[MRT:]UK[CYS_X.8>?V</V;^O_ "7[5.H(_P":
M5^+_ %'L:_C5K^XKXH_\&]GP!^.&F:9HOQH_;G_X*O?%G1]$U%]7T;2OB+^W
M5XL\7Z?I.JR6DU@^IZ=::WX1O(+._>QN+BS:Z@1)C:SS0%_+E=3XG_Q"K_\
M!/C_ *+C_P % O\ Q*R?_P"8&NC*N(*.7X.GA9X>K4E"523G&4$GSS<K)/71
M/[_O.?-^&:^98ZKBX8JE2C4C2BH3A-R7LX1@VVM-;-KY?+^.&BO['O\ B%7_
M ."?'_1<?^"@7_B5D_\ \P-?-VE_\&V/[#5Y^USXT^!\OQN_;N_X1+P_^SG\
M,_BI8E/VI+@:U_PD?B[XI?%WP;JIN;O_ (0<^;IATSP/HQLK;[-&(+H7\AFF
M-QMA]'_6W#?] E?_ ,#I_P!=_P"GIY?^I>*_Z#</_P""ZA_+E17]CW_$*O\
M\$^/^BX_\% O_$K)_P#Y@:/^(5?_ ()\?]%Q_P""@7_B5D__ ,P-'^MN&_Z!
M*_\ X'3_ *[_ -/0_P!2\5_T&X?_ ,%U/Z[_ -/3M_\ @VL_Y,[^-/!_Y.7U
MOH"?^:6_"_T%??O_  6(.?\ @FE^UWP?^28Q=C_T-_A?VKX\^&'_  ;Z? GX
M(Z+?>&_@U^W;_P %8_A1X>U35)-<U+0OAY^W=XM\(Z3?ZU+:6EA+JUY8:+X1
MM+:XU&2QL+&S>\EC:=K:SMH6<QP1JO1>-/\ @A%\,_B1X7UGP1\0_P#@HE_P
M5_\ '/@SQ%:BQ\0>$_%G_!0'QSKWAW7+)9X;D6>K:1J/A:>RO[87%O!/Y%S#
M)'YL,;[<J#7RU?'0JYI_:"IRC#ZS2K^S;3E:FX-QOM=\CL]M3Z^AE\Z.4/+7
M4@ZCPE7#^T2?)S5*<X*5GK9.5VM[(_A1D_UDG^^W_H1IE?V/'_@U8_X)\$DG
MXX_\% B3R2?VK+C)/J?^*!H_XA5_^"?'_1<?^"@7_B5D_P#\P-?4+BW#))?5
M*^B2^.GY?\'^GI\A_J7BO^@W#_\ @NI_7?\ IZ?QPT5_4]\8/^#:?]A7P)\2
M?V5O".D?&_\ ;P.G_&?XX^)_AYXI-]^U+/-<C0='_9L^/OQ8MQH[_P#"#1FT
MU(^)OAKX=,MR%N-VCKJUF8 ;Q;JU^@/^(5?_ ()\?]%Q_P""@7_B5D__ ,P-
M/_6W#?\ 0)7_ / Z8?ZEXK_H-P__ (+J?UW_ *>G\<-?TG_\&T'_ "<A^TKU
M_P"2'>#N@)_YJ++Z?2OL_P#XA5_^"?'_ $7'_@H%_P")63__ # UZ?\ "[_@
MW$_9<^"&IZIK?P8_;'_X*B_";6=;L(=*UG5?AU^VUXB\(:AJVF6]S]MM].U&
M[T3P;9S7EE!>9NH;:=WBCN"TJ*'))XLPXDH8W!8C"QPU6$JT8Q4Y3@U%QJ0G
MJEJ[\K7W,[LMX6Q&!QV&Q<\51J1H3<I0C":E).$HV3>F\NO1>9^]WC$_\4IX
MEX/_ "+^M_PM_P! J\]J_P J&/\ U47_ %RB_P#1:U_>O/\ \$4]!N89;>X_
MX*<_\%G9X)XY(9X9?^"BWQ$>*:&5&CEBD1O#95XY(V9'5@0RL01@U\DC_@U7
M_P"">X  ^.'_  4"    '[5DX  &  /^$!X ' '85Y^2YQ3RM8E5*,ZOMW2:
MY)1CR^S]HG?FWOSJUNWGIZ>?Y)5SB6$=.O3H_5U74N>,I<WMG1M;EVY?9.]]
M[H_CAHK^Q[_B%7_X)\?]%Q_X*!?^)63_ /S U\V?M@?\&V7[#?P)_9G^,WQ<
M\(_&_P#;N;Q-X#\%7NOZ+_;?[4EQ=Z2+ZWN[*",W]K_PA%MY]N%N&+Q_:(@V
M,;P<$>[_ *VX;_H$K_\ @=/^N_\ 3T^>_P!2\5_T&X?_ ,%U/Z[_ -/3^72B
MO['%_P"#5G_@GPX)_P"%X?\ !0(?.XQ_PU9<'&UV7C/@'...,Y(Z$D\EW_$*
MO_P3X_Z+C_P4"_\ $K)__F!H_P!;<-_T"5__  .G_7?^GH?ZEXK_ *#</_X+
MJ?UW_IZ?@1_P1]_Y26?LD?\ 8^^)?_56?$"O]%=/NKU^ZO4$=O>OYQO!G_!L
M;^Q5\./%&C^-_A]^TY_P4C\#^,_#UQ+=Z!XL\)_MAZKH/B+1+N>TN+":YTK5
M]-\#V]]8SRV-W=V<DMO,C/:W5Q Q,<KJ?UF_9!_8JLOV0F\>M:?M0?MI?M'?
M\)ZOAE77]KO]HWQ'\?5\(#PR=<*GP$-?TW3_ /A%FUS^W&'B4VOF_P!LC2M#
M\[9_9D6[YO.<RAF>(I5J=*=)4Z*I.,VI-M3G.Z<=+>_;Y'U&1954RG#5:%2K
M"LZE>592A&44E*E1AROFUNG3;OV:/M6BBBO(/<"BBB@ HHHH **** "BBB@
MHHHH **^'/C)^VWI'PL\3?%FPT?X3_$#XD^#_P!FWPWI'B_]ICQUX5O/"=G8
M_"O0];\,S^.%M]+T'7]:T[Q!\2/$OA[X>PQ?$CQ?X:\)VIO=+\%ZGHDFD2^(
MO%.LV'A2;8O/VNVTGXH>$?"VO?!?XD:'\,/B#\4(O@KX"^,^H7/A--&\6?$*
M[\/ZSXDTF]TKP3'K4GCN;X8^(+;P_K.E^'_B2FE/9:GJ=D=4&CP> I[?QO*
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M2V%K>7][=V]D\[6T%S>74\422W$SO\"ZW^W[:Q?"]OC9X3_9Z^-/B?X6^$/
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MB_AN])U2&UO;VTBU&QNDM;V\MEBN9?3Z "BBB@ HHHH **** "BBB@ HHHH
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M97_X*0^.62*9U_X5)\%QN2&5UXT/5\_,B,O'<9R.]?BW);W'E2_N+C_52_\
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M"JH'0*J@*H'8  #L*=13NWNV_F*R6R2^04444AA1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
:4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>chart-5cd5aa12b0d45778869.jpg
<TEXT>
begin 644 chart-5cd5aa12b0d45778869.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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MMK"81EY*YKXN?\$XOAA\5/#_ (2MM3U'1K_Q+X%^,G[1?Q;\,:I\0/A;\/\
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MC;\-O O[9>H_$+5M5^/5A\0+[XQ_&:P^'/CP_#[]G#X9? 4^);G0]:N/@/\
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M *QS\0:_;R/_ %<?^XO_ *"* ,/^U-6_Z%R[_P#!CI'_ ,FT?VIJW_0N7?\
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MZF:RN)4O;>ZMX.0_X:H^#/\ PLB_^$!\;>&D^)6E_P!JQWWA276H(9X;W0=
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MK\1?] 73/_!]/_\ *2MVB@#"^U^(O^@+IG_@^G_^4E'VOQ%_T!=,_P#!]/\
M_*2MVB@#"^U^(O\ H"Z9_P"#Z?\ ^4E'VOQ%_P! 73/_  ?3_P#RDK=HH PO
MM?B+_H"Z9_X/I_\ Y24?:_$7_0%TS_P?3_\ RDK=HH POM?B+_H"Z9_X/I__
M )25\U?MASZQ+^S/\8$O-+TZ"W/A=/,D359;MP/[9TH?+;OI,"2'!SAI4&!U
MS@'ZRKYC_;+_ .38OC#_ -BNG_IXTNO?X4_Y*GAK_L?Y/_ZL<,>%Q1_R37$/
M_8DS7_U!KG\W[00;F_<0=3_RQB]?]RD\B#_GA!_WYB_^(KVOX&> _#7Q$\<Q
M^'_$NHW$$)M7GL-%L=4TC1=4\3W?GQ0R:;INJ:Y-#86\UE:23:O/"BW&HWMO
M9O;:?;2.TLD/3>"_A-X6\1>(_$'@^\B^(MGK&DWVKI?3Z@O@[0+OPAI-EHTF
MH:==ZOX2N;K5-<\;ZY=7<%S!?>'?!<D$@LH;:\TB>_;5+9+?^Z<3GN!P=7%4
M*\JJJ8'"T,7B+0M%4*SG%5(RE*/.HNG9\M_:590PU!UL5>A'^+\-DN+Q=+"U
MJ,*3AC,35PM"\ES2KT8TY.$E&,N1R4TUS-.%.,L165+#)5G\W>1!_P \(/\
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M#7?%7Q,\8?#;Q3\4=5U?P+XMU'QA::SXLM==T?2?A[8W5JW@*;2IK6^UF?\
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MXA=&9770M8964E65ETZY*LK#!# @$$$$$9'-?YO<?Q/^)7E1?\7"\;_ZJ/\
MYFO7?[B_]/\ 7QOT:<HJ9I2XQ]G6A2]A4R&_/&4N;VD<WVY6K64'OO?R/J/I
M$9Q3RNMPBIT9U76IY[;EE&/+[.63WO=.]U45K;6=S]S-C_W6_P"^3_A1L?\
MNM_WR?\ "OPV_P"%G_$K_HH7C?\ \*O7?_D^C_A9_P 2O^BA>-__  J]=_\
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MC@9_9S\'#)Z#_BO?B7U]J_>_HW?\G,P__8FS7_TF@?AOTAO^3=5_^QOE;_\
M*LU^I^'N3ZG\S1D^I_,U]C7_ .RWHVF?LJ^&OVAK[QOXA_M#Q/X@LK:WCTSX
M>:MXA^&6DV%XTMF_AGQ-X\T"]O[OPUX^T^XMKF_OH-9T&TT;=]E\*6DMQK6H
M:?J-W5\??LM-IGASX5Z]\-=3^(7B67XN?$6_^''@73/B/\-8OA9=_$-;;1M+
MU>S^)OPX23Q1XB?4/A7>?VG'9W^K>)$T/4O#3O;7.K1R6\FH?V3_ '=3XHR2
MK4]E'%RB_KV.RUU*F%Q=*@L9EM-UL;2>(J4(T$J-.,YNHZBIRC3JN$Y*E4Y?
MXFJ<-9S3IJI+"QDG@L%F*A3Q.%JUGA,QJ*E@ZJP].M*M)UJDH04(TW4C*I34
MHQ=2"E\AY/J?S-&3ZG\S7WI:?L=^%;OQ+XJLM'^(GB?X@>%?#?P<^!OQ1M_$
M7@'1/A]I)UN7XRZK>:/BWNOBA\0O!WA?3/!VDW6F7T^D>(M6\06NH^)+*XT1
MHM'M+S4S:0^$>"_@-K?C?X^7GP1@M_%WA:ZTS5?&?]MQ>*?";7/CWP[X>\!:
M-J_B3Q$^H^!M U"X_M+QA%HVC3P:?X8T;5I+;5]=N].LK35TT^[_ +3C=#B?
M),3#&5*>,2A@,&L?C%4HUZ52AA7AJ6+=2IAZE..(36'KTIRA[+GBY^S<?:J4
M$J_#F<8>>$A4PCY\=C'@<)R5:%6G6Q*Q%3"J$*].I*@TZ]*K!3=54W&#JJ3I
M-3?@B$[UY/WE[GU%?WJ_\$UK76)?V"_V4'MM7BMHC\&/"V(FTR.X(R+MES(]
MU&250I']T [-W5B!_$I\<?A/;_"+Q-X>T>V;Q]%%K_A>S\3#3OB3X+T_P?XE
MTL7&J:II@@,WAWQ)XQ\%>*M-N/[,^V6/B/P;XHU7309KC0]5CTWQ#HVJ6*?W
M!?\ !,S_ ),%_9/_ .R,>%/_ $7<5_.OTF\7A\?P/PSB\+/VE"MQ"ITI\LXJ
M2_L['QNE-1;BVGRRMRS5IP<HN,G^_P#T<,+7P7&?$>$Q,/9UZ.02C5AS1ER2
M_M#+I6;@Y1YDI+F5^:$KPDHR4HK\R/\ @X,@U"'X _ '[;?QWH/QPU/;LLDM
M"I/PV\2;<E)Y@P4+)Q@;O,R3\BY_E'K^LC_@X:_Y(#^S_P#]EPU'_P!5KXIK
M\.OV3_A'\(OB7\*?BO;ZWX4T[Q?\8KM8]/\ !.A^+/'/B/X60WMC-XL^%N@Z
M/_PJ'QC'X?U'P%>_$6Y\0^)=4T/5-,\97TC276I>!O#5MI#:7XPUG4K;Z/P/
MS:ADGA#D^-Q%'$5J7]K9A0E'#JDY0^LYO4I>VJ3Q%:A0HT*/.ZE:K6K4Z=.G
M%MR21\_XT976SCQ6S;!4*M"C5_LS UXRKNKRS^KY/0J^RIPH4J]:K7JN*IT:
M5*E4J5*DDE%ZGY^45]H:!X,^$OBG]G_XF:M:^"_"VF?$WX4>"?!7B9M&3Q]\
M0[OXUZE>P>-O">D^/_''Q \%:U;Z#\.M.^"%_HOB-ET_3_!44OCWPS)J/A"[
M-[J=I<Z]KH[6V\-_ S4=1^#?A_Q;\*OAIX%\9>*_A?XY^-<FFVGQ!^)'@GP5
MKMQKOAO4G_9T^$?C+Q7XV^(OB.+PI8^,IM);QKXH\4PZKX6>.T\1>#_"0U_1
M(KO4M;7]?J<3T*;Q">6YFY87$XO#5H*.!<X_5,OIYD\0H_7_ 'L)6H584Z.)
M3]FJ\HTZ[HJ<9O\ )Z?#=>HJ#689:HXG#X3$492EC5&7UO'SRY4'+ZC[N*HU
MZ<YUL.[U'1A*I159QE%?GU17TY^TE\._"_P[U+X,:SH>G>$]'F^)GPJL?'?B
M;P)X5\:W/CSPAX;\3:=X^\:^#-5T;0/%AUS7+S4M#UBU\(6VK2V]KXL\2KHE
M_?:YH^F>*]1MM-M[BV3XZQ^!M,\%_!VQTWX4^#/A_P#$/Q?X:_X6SXGN/!VJ
M?$:XL[#P1XS\V#X8>$YK#QSX[\9Q-J=]HFG3_$'5]2M_L4\-GXF\,:/&KK:Z
MC+<]N'SNABEELZ&&Q4X9G4Q5*$T\+;#2P?ME7EB+8I\U&-2A.C'$83ZU0G4E
M14*DH5Z,Y\=?)J^&>8JOB,-3EEU/"U90DL2GB8XQT'0CA[X9*-65.O"K*ABG
MAJ\*<:O/3C*C5C#^D+_@@!;ZE-^RM\6S9:C'9(/V@]6#(]@EV2P^&_P\+,&>
MXAP&#1C;M.W9D$[R!]L_\%4+75XO^"?/[4KW>JQ74/\ PKF+,*Z;';,?^*K\
M-$D2I=2$$J&7E"/FSC(%?''_  ;Y?\FI_%S_ +.%UC_U6WPYK[>_X*M_\H\_
MVIO^R=1?^I3X<K^!^*_^4AG_ -E_P[^&-RO^O/KNS^X^&/\ DPO_ '8^>>>^
M#S#OZZ=NEK(_B\_9A^,?AGX%_%K2/'_B?PWXGUJVTUF-IJO@7QMJO@3QQX7N
M56X#:AX>U&S\[2M4BU&&5M+UK0/$=A=:=>V,J7=I<:=J>GV\TWO%C^W7>W.N
M:)XF\1>#?%D>H^ /BGXA^+OPYT?P1\5[SPKX9NO$'B;0?"NE:OI?QEM_^$7N
M[[XFV.IZCX0M/$/B'6[&3PKK?BB[\1^/M,OX[33/%THT_P#/]_OM_O-_,TVO
M[PQO"^2YGBZF/QV%G7Q57"T\&ZCQ>,@H8>$:\)0H0IUX1H>UIXFM3K.BH.I"
M<[ZU*KG_ !%@N),XR["4L#@L5"AAJ6)GBU36%PDG.O*5"<9UI3H2E7=*IAJ-
M2DJSFH3IPMI3IJ'V'X'_ &GO"_P\\$7_ (=T/X9:[JTVOZ-X=T[Q1\/O&7Q)
MN_$_[-.JZYHWB7PWXBU+X@V_P:OM!-]9>,]?_P"$:CLT1?%SZ5X8&LZV^AEM
M,FM-!M=3XI?M4^&?BWIFF>&?&OAOXT>,_#(^).K?$C4)?B%\;=*\7>,/"R:A
MX:US1HOA[\&_$DGPWLH/ 'P]DU34M)U?7]+N-,U6+78/"GAO3[;2M"FT\:E)
M\444GPKDCQ3QKPU9XSVM6NL2\?CW6C6JTH495(5/K/-":ITJ<(R@XN*A%IWU
M'_K-G/U;ZG]9I?5?94J+P_U+ JC*E2J2JQISIK#*,X.I.I*49)J7.T[JQ],:
MC\7/A9'\";?X4>$/ _Q'\'>(-0TS1[OXA>(K+QEX*O='^*GCC2;Q;VUU+QBD
M_@5/&"> M"N'FN/!OPQT;Q+I^AZ)J0@\0ZM-XB\3+_;$?ZR?\&^<5W+\??VA
M%L[I+23_ (4UX6_>/;+=?\S]GA&EA7(4.O+?QYQE17X!U_0/_P &\_\ R<%^
MT)_V1KPM_P"IX]?!>+^ P^ \*^.%A_:_[32H8NM*M7K8BI4KU,URU2E*K7J5
M*C2C"%.$.;DIT:=.C3C&E3A"/W7A/CL1CO$[@MUW3_V:M5PM&-*C1H0A1I99
MC^6*IT84Z:;E*=2<N7FJ5:E2M4E*K4G.7]2GBFRUY?#/B,OKD+K_ &!K>5_L
M>%<DZ7=@'<+TD;6(;T.,'@FO\V*%F5(&1G1T2!TDC=XI(Y$5'CDBEC9)(I8W
M59(IHG26*15DC=)%5A_I=>+/^17\1_\ 8!UG_P!-MU7^:)'_ *J+_KE%_P"B
MUK\>^B?_  N.O^OG#G_I.=_Y_/Y'ZM]*'^/P3_U[XC_]*R$ZS6_''C3Q)XCU
M;QAK_BWQ+J_BO78;FWUKQ)?:WJ,NMZK:WFGG2KRSOM1%PES<6-WI9;3;FP=_
ML5Q8/)936[VTLL3T-+\2>)-"M-8T_0_$?B'1-/\ $5DNF^(;#1==U;2+'Q!I
MJERNG:]9:=>6MKK6GJ99=MCJD5W:KYLH$($L@;%HK^NUAZ"IQI*C25*,:4(T
MU3@J<846G1A&"7*HTFDZ<4DH-+E2L?RLZ]=U)576JNK*52<JCJ3=24ZR:JSE
M-OF<JJ;523=YIOF;N6Y;^_GL[+3YKZ]FT_37O)=.T^:[N9;'3Y=1>&74);"R
MDE:VLI-0EMK:6_DM8H7O9+>WDNC*\,3)NCQQXW67Q+.OC7QFL_C2)H/&<Z^+
M?$0F\8P,6+0^+I1J8D\4PL6?=%K[:C&P=P5(D<-R]%$J-&=E.E3DDVTI0BU>
M52-63LUO*K"%1OK.,9OWDF*-6K%WC5J1=DKQG).RA*FE=-:*G*5-+I"4H+W6
MT_O_ /X)8K*W_!03]E]8)1#)_P )OKVUVC$J@#X<^-BP,99,AD#)PRE=VX9*
M@'^\?3H-0A5OMU^E]N6/RMEDEIY> V_.R>;S-^5QG;MV\9W<?P>_\$J_^4A'
M[+W_ &.WB#_U6WCFO[TD^XO^ZO\ (5_"WTIO^2WR+_LE</\ ^K?-S^U?HS?\
MD=G?_93XG_U4Y..HHHK^93^CPHHHH **** "BBB@ HHHH _$#_@I/_RDD_X(
M4_\ 9UO[4'_K'/Q!K\J/^"_/'[9?P_/_ %;GX.Z]/^1]^)=?JO\ \%)_^4DG
M_!"G_LZW]J#_ -8Y^(-?E1_P7YY_;*^'YP<?\,Y^#NQ_Z'WXEU^]_1N_Y.9A
M_P#L39K_ .DT3\-^D-_R;K$?]C;*_P#T[,_.GPU^U/?>$/@A??"3P_\ "_X=
M6.L:Q>"S\2>.A9ZX?^$O\'MIFEZ?=:/XO\%)KL?@OQ'XAU.'1[+2=6\7:AHT
MEY>>'8A&MM;^)R/% 9_PU;XF\-:5%H_P8\&>&?@A:2^,M6\>ZPOA[4O$'CV*
M_P!?UKP;KG@"]LM*L/BK<^+-)\*^$/\ A$?$WB'15\,:7IT\EU::IY6KZWJD
M6G:5'9_*U%?WC_JWDCE6E/ QJK$XBKBL12KU\37P^(JU81@_K&%JUIX;$4J<
M8)8?#UJ52AA?>>&I4I2DW_$7^L.<*-&,,;*D\/0I8;#U:-'#T<1AZ5*3E'ZO
MBJ5*&(H59R;=>O1JTZ^)5EB:E6,8I?3_ (L_::G^)\VCI\9?A1\.?B=I6B?#
M'P3\-+"P:WN?ASJ%E%X(DN)8?$.F>(/AC!X8NM/N_$'VJ6V\1:%)9:AX=;3O
M)LM"L]!:VM[J*I'^TSXAC^)%U\6_^$+\(+X]U/Q%XAEUN^M[OQ;9:/JOPR\2
M?#.'X2WGP3.@VFOQQV'@NW\&+<6%IXAL;Z/X@+)<+/<>)9YK6WE'S715PX>R
M>G"5*G@U3H2P]?"?5Z=?$PPT<-B53CB:-/#0K1P]*GB52I/$QI4X+$3I4:E?
MVDZ-*4)GGV;5)JK/%N=95Z.*^L3HX>>)EB,/*<L/6J8F5%UZE3#^TJQP\JE2
M3H0JUH4>2%6HI>H?$+XD0>-[/P'X;T/P;HOP^\#?#31-5T+P9X0T75->\0BP
MC\1^([SQ7XEU+4_$GB:ZNM9UK5=;UV^>YF=EL-.L;:WM++3=,M4CN)KO^Y__
M ()F?\F"_LG_ /9&/"G_ *+N*_@23[Z_[R_S%?WV_P#!,PX_8&_9/Z_\D8\*
M=B?^6=QZ"OYR^D_AZ.$X*X=H4(RC37$LY^_4J5IRJ5L#F%:M5J5:TZE:K5K5
MJE2M6JU9SJU:LYU*DY3E*3_H+Z-M>KB>,,_K5I*527#BA[M.G2A&G1QV64:-
M.G2I0A2I4J-&G3I4J5*$*=*E"%.G",(Q2_-C_@X:_P"2 _L__P#9<-1_]5KX
MIK^9CX??'_XR_"KPQXP\&_#WXB>)?"OAKQS:_9M>TO3+^2* 2-<:;-<:GHQ8
ML_A[7+ZWTJTTG4=;T5K+4K[10^F7-P\(MVM_Z9_^#AGGX _L_P",_P#)<-1[
M'_HFOBGVK^3>OKO #"87&^%&3T<9AL/BZ/\ :.:5/98FC3KTO:4<TJU*4_9U
M8RCS4ZD8SA*UXRBFK-'ROCKBL3@_$_-JV$Q%?"UOJ&64_:X>K4HU?9U<JP].
MI#GIRC-1J0E*$U>THMIW3/6=4^.WQAUKP0OPXU7XA:]?>#/[)T7P_-I$R:2+
MF^\.>&I()O#?AK5_$4.F1>*];\,^'9;6S?0O#FM:]J&B:2;'3UL;"%-.L%ML
MFT^+/Q)L/&&D>/[/QAJD'C'0= TGPKI6NK'ILDUOX8T3PO%X)TWP[+93V$ND
MZAH<7A""/PW<:7JFG7UEJ6D>9:ZK#?":=I//**_:X9;EU.%2G3R_ PA6595H
M0PF'C"LL3&G'$JK%4TJOUB-*E&OSJ7MHTZ:J<RA%+\;GF&/G*G.>.QLYT?8^
MQG/%5Y2I?5W.6']E)U&Z?U>52HZ'(U[%U)NGRN<K^CZ]\7OB7XHF\73^(/%^
MH:K)XZT'PYX6\4"XL]%C@O?#'A#4;#5?"OAVPL[;2[>S\-:'X=OM,L)=(TKP
MI;Z%8V<=N+1(#937-M-RWB/Q1XA\7ZA;:KXFU:YUG4;30_#OAJVN[M;=9(-!
M\):)8^&_#>EQK;0V\0M='T+3;#3+3,9E^SVL9GEFG,DSX-%:4<'@\.XO#X3#
M4'"/)#V-"E2Y8>SH4N6/LX1Y8^RPV&I\JLO9X>A"W+1IJ,5<7BJZDJ^*Q%92
MESR5:O5JJ4^>M5YI*<Y)R]KB,14YG=^TKUIWYJM1R_KO_P"#?+_DU/XN?]G"
MZQ_ZK;X<U]O?\%6_^4>?[4W_ &3J+_U*?#E?$/\ P;YG'[*?Q<Z_\G"ZQV)_
MYIM\.?2OM[_@JV<_\$]/VIL9_P"2=1=B/^9I\.>HK_/?BO\ Y2&?_9?\/?\
MJ;E9_>7#'_)A?^['SS_U#S _@T?[[?[S?S--IS_?;_>;^9IM?Z(1V7HOR/X%
M"BBBF 5_0/\ \&\__)P7[0G_ &1KPM_ZGCU_/Q7] _\ P;S\?M _M"'G_DC7
MA;L?^A\>ORWQK_Y-;QA_V X3_P!6N7GZ9X.?\G-X1_[#L3_ZK,<?U8^+/^17
M\1_]@'6?_3;=5_FB1_ZJ+_KE%_Z+6O\ 2Z\6$?\ "+^(^O\ R =9['_H&W7M
M7^:+'_JHO^N4?_H"U^(_1/\ X7'7_7SAS_TG.S]B^E%_'X)_Z]\1_P#I60CZ
M***_L _E$**** /T$_X)5_\ *0C]E[_L=O$'_JMO'-?WI)]Q?]U?Y"OX+?\
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M5BZKKXK+,OQ-:2BI5L1@L-7JR44E%.I5I2FU%12BF[)*RT/YM/\ B%U_8/\
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MJ[5;FZ7P_I'[-WQY^*UHVCSCPC$+#4/^$I^&_AY9KIHKD/I1U&R\I3>">#Z
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MN>)_"7[0G[/.O>$-%_:%^$OP]^+7@?PKI7Q%\.W'B'X=?$3PE\3?^$,U_5_
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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2BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>chart-5fb3afa34aee5813b17.jpg
<TEXT>
begin 644 chart-5fb3afa34aee5813b17.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" +^ 3T# 2(  A$! Q$!_\0
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M-_\ !+SX$^#OC1X-^+'ANW\)00>&V^$&JWND:G\"/@)JVN2>*/@9X+\*>!?
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MMM916\.K1A5":G%&E\@ "S@"NIH **** "BBB@ HHHH **** "BBB@ HHHH
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M3_@A3_V=;^U!_P"L<_$&OV\C_P!7'_N+_P"@B@!]%%% !1110 4444 %%%%
M!1110 4444 %>"_M/Z[K/AKX"?$S7?#VJW^B:UIOA]9]/U72[F2SO[*<ZEI\
M7G6MS$1)#)Y<CIN4@[79>A->]5\X?M=?\FW_ !9_[%I/_3MIE 'XL']H3X[
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M **** "BBB@ HHHH _$#_@I/_P I)/\ @A3_ -G6_M0?^L<_$&OV\C_U<?\
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M?K&O:)X4M/!A\<>"K&RTW4O$VH=U_P /'_AU_P!$[\><]?\ 2/#'/_E6I/\
MAX_\.N/^+=>.^.G^D>&./I_Q-N* (OV._ GQI\(>/I(+CP[^T/X"^">D?!3P
MOX1UOPI^TS\6_"?Q7\1ZM\:]!UFVM8_$'PVD\+>*O&EEX=\*:?X-@U33/%4^
MCWG@_P #>+=3O_"=[X-^'^D-HFO7UW^D%?$'PQ_;C\$?$[QYX;\!:9X)\7Z9
M?^)KV>SMK[4)M :RMY(-/O=1:2X6TU*:X*M'9/&/*B=O,=20%W$?;XY /K0
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M_P )[7/_ ) H VZ*Q/[?M/\ GTUO_P )[7/_ ) H_M^T_P"?36__  GM<_\
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M=Y%9?$/XB22Q7DJOX+TI0+.QN[YP1KS-EX[.&=XUQT=U52<@$D$4 ?KYJ_\
MR"]2_P"O"]_])9J_EU7.Q<#)V# SC)QP,]L^M?TX:MKUH=,U$?9-;YL;P?\
M(OZWCFVE')-@ ![GBOYD%&44'H5 _2@#XXG^,WQ1TS]H_P 2?#OQ$ND>&?#,
M_AS4!\+?#>J_#WQ5<I\3+Q8?%L_AC5O#7Q?TK5[KPV/%_B:\T&:S?X<:]I&C
MR"TT?6M&T6._\2V U;4;/PH\5_%[Q'I^J^#_ !_\2/$_@SXHZK\//#7C[1I_
M&W[.WP]\'6'AS2(+ZPT_QOKNE:/I7CSQ%;^(;'2]<OXO#NKZ#X]NO#7BSPC!
M<Z1K%]H;-J8:/UA_V?OA5+\1-1^)UQX>N;KQ!JEK*EWIUUK_ (BG\'G5[E]<
M6^\6P^"I-5;PO;^,-1L_$6KZ?>>((-+CNC!>W5Y;BWUF]OM5NKNA?!#X>^'[
M7Q!:VMKXDU(^(_!=S\-[N^\3^.?&7B[6-.^'MS!=P?\ "$>'-8\2ZWJFH^&_
M#< O9I[>RTFX@G-ZEI?WEW>WFG:=-:@&3\!-7\?^*_A9:>+O&7BZ#Q)<>,IM
M4\2>!]:'@/1_!=W9_#S58XQX O->\-Z1J5]I<NLZKID<7C*ZA6ZA2*SU_3_#
M]QFXTVYNY\OX+W_Q.U/Q/\4E\6_$RQ^(G@_PCX@A^'NA7L?PQ\-?#Z]N/'/A
MV-+KXC74<GAS6-3BOM"T.\U+3?!EJERJ33>)-&\63B1;6SLDF]8B\$Z%;_\
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MQ!K]O(_]7'_N+_Z"* 'T444 %%%% !1110 4444 %%%% !1110 5\X?M=?\
M)M_Q9_[%I/\ T[:97T?7SA^UU_R;?\6?^Q:3_P!.VF4 ?S[MU/U/\Z2E;J?J
M?YTE !1110 5^BW_  3@_P"2C?$?_L2=)_\ 4@:OSIK]%O\ @G!_R4;XC_\
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M0?RH 6BBB@ HHHH [CX:_P#(]^&_^OR?_P!-]Y7VQ7Q/\-?^1[\-_P#7Y/\
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M&BVD-Q-IFGV]G+/"FH[UBE>%%9XU?YU5B0&Y S7EM>Y? O\ Y#FN?]@FV_\
M2^@#Z7NO^/:X_P"N$W_HMJ_/5>@^@_E7Z%77_'M<?]<)O_1;5^>J]!]!_*@!
M:*** "BBB@#N/AK_ ,CWX;_Z_)__ $WWE?;%?$_PU_Y'OPW_ -?D_P#Z;[RO
MMB@ HHHH **** "BBB@ HHHH **** /Q _X*3_\ *23_ ((4_P#9UO[4'_K'
M/Q!K]O(_]7'_ +B_^@BOQ#_X*3_\I)/^"%/_ &=;^U!_ZQS\0:_;R/\ U<?^
MXO\ Z"* 'T444 %%%% !1110 4444 %%%% !1110 5PGQ,_Y$7Q)_P!> _\
M2JVKNZX3XF?\B+XD_P"O ?\ I5;4 ?%;=3]3_.DI6ZGZG^=)0 4444 %>Y?
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MVE&W]COX@,-LT#QRID@!MCKN4LC95B#^TT>@VGEI_I>M_<7_ )F'7/0?]/\
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M9Q7VLZPDLMY$$TNW<&SOKNQ<DWI7#R64\+2* ?N.S(#R #S0!]177_'M<?\
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M]/LOPR^/^I^%V,9;QUI?P1\<WGAORI$#B\MK,6$?C34]-V'S4U72/!^H:;/
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M?0!]+W7_ ![7'_7";_T6U?GJO0?0?RK]"KK_ (]KC_KA-_Z+:OSU7H/H/Y4
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MMO\ TOH ^CM59ETS4&5BK+8WA5E)!!%M*001@@@@$$<@C(K^:-?B7\1-J_\
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MK^AK]EK_ )-Y^$/_ &)&D?\ H,E 'OM%%% !1110 4444 %<)\3/^1%\2?\
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M2/VGKGP;XFU1?#GP^UNR&B_#/3Y/AXOB#P!XRU34+NYL?#8U7XK>']<N-?\
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M_$/XB)?ZGJ5\B>"M)>-+W4+R\2-SXA92T:7,\JHQ7Y2R@,1P3CBOS7K]&?\
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MVS/V./&O[7'B+X8"^\6Z#H7P]\+:OJ=UX@\/Z_\ #KP+XQ\6^%Y;[P+\0/#
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MD'3[C2[7P7?:5>^"6UM/A_I5E=7,>D>"[/Q+:Z)I\EQ=744+7E_J5Q>VM/\
M@%X3TNRU&UL?%?Q9BNY_"MCX#T#7Y/B3J\_B7X?^!]/U?2=;A\)_#S6I+8S^
M'-,GN]"TBWU*\N4UCQ'J^EZ=I^DZKKUY8Z?80VN];,.#:F5SP7U?ES">"R^D
MLRPV ITH1JJM6J5XO"UN>I3>#52C1GB:>,GBLTH8=XC$XA3KRR^FY3PKI\G+
M:;A37M(P2UNV_==VN6ZBY*3E4BN9RO)P7DUM^TCJ\?Q0TOPQJE]X#AM]9^/V
MI_ AOA1;V.O?\+A\*V:_V_;^%OBSXBU#^VI]+;PQXMFTC2=:@M6\):9X=;PC
MXQ\/2Z!XVUOQ'!?:;=?NI_P3JN+N'X@_$)[2Q-Z[^"=)W1BZ@M?+7_A(&8-N
MG!5\GC:O/'N"/RJD^%GA^Y\<0^.M0U?QMJ]S8:W<^)]#\+:QXOU#4O ?ACQ-
M=Z??Z4^N^'/#%Q&387=KI^JZM!HMC/J5[H'A=]7U:\\*Z+H>H:C<W;?K%_P3
M>_Y*-\1O^Q(TC_U(VK]+\%<9D>+\;?"UY+@IX-TIXJGCU+D5.>*>4YO)1I*%
M.G*<:%&5.DZ]=U<36G%^WQ&)E#ZQ5]#*9499ME[I0<;.2FNG-[.IM9)OE5ES
M2O)O=R^)_JOJFHZT=-U -H# &QO 2=6T\  VTH)Z>G^/:OYO^R_[J_\ H(K^
ME_5_^07J7_7A>_\ I+-7\T'9?]U?_017^[/@]_#X@_QY7_Z3CS\N^D3_ !>$
M/^O>??\ I63!1117[2?S6%%%% 'OO[+CRQ_'_P"&4D$!N9EUG4#' )8X#(?^
M$;UP$>;+^[3:I+?-UV[1RPK]XM/N;VX$GVS3S8[ GEYN[>Z\W.[=C[/]S9A?
MO?>W?+T-?A'^RI_R<+\+O^PWJ'_J-:[7[V+T'T'\J_GWQ<_Y'V6_]B>G_P"I
MV./ZW^C]_P DKF__ &4-?_U694+1117Y2?O(4444 %%%% !1110 4444 ?B!
M_P %)_\ E))_P0I_[.M_:@_]8Y^(-:__  4-_P"2U>&_^R9Z)_ZD'BBLC_@I
M/_RDD_X(4_\ 9UO[4'_K'/Q!KOOV\_!7B[Q%\8/#U]H/AK6]8LX_AUHUM)=:
M=8374"7":[XDD>!I(Q@2K'+&Y3J%=2?O"@#\Z**[[_A5?Q)_Z$3Q5_X)[G_"
MC_A5?Q)_Z$3Q5_X)[G_"@#@:*[[_ (57\2?^A$\5?^">Y_PH_P"%5_$G_H1/
M%7_@GN?\* ."7J/J/YU_0U^RU_R;S\(?^Q(TC_T&2OPC7X5_$G(_XH3Q5U'_
M #![GU^E?O1^S3I]]I7P&^%6G:E:7%A?V?@W2H+NSNXFAN;:9%DW131-\R2+
MW4\B@"O\?(()]"T%9X()U769&59X(IU4_8+D959D<*<$C( ."1G!-?+RV-BC
M*Z6-BCJ<JZ6-HC*?566 $'MP>02#P:^IOCO_ ,@/0O\ L,2?^D%Q7S'0!R'_
M  KWX??V/H_AUO /@2;P_P"'K>*TT#0KGP7X8O='T.V@B,$,&C:9>Z5<66EQ
M10EHD2QA@ B9H_N,5.E;^%?"MI'ID-IX5\*VD.B&4Z'#:>&- M8M#:<%9VT.
M*WTV./16G5BLQTM;0S*2LFX$@[M% &++X:\-SP75K/X:\-SVE]<?;+ZTN/#N
MB3VE]>!X9!>7UK-8/;WMX)+>WD%W=1S7(DM[>3S=\$+)?.GV#$LUA8,Q))9K
M&S9F)Y)9C 223R2223R3FK=% 'U!\!X(8/"^JK!## IUZ9BL$,4"EO[/T\;B
ML2(I;  W$%L #.  .=_:]_Y-O^+/_8LK_P"G?2ZZ?X&?\BSJO_8=E_\ 3?I]
M<U^UVK/^SA\6%12S'PRH 4$DG^U]+. !U/!KX[Q$H5L3X?\ '.'PU&KB,17X
M/XEHT*%"G.K6K5JN38V%*E1I4U*I5JU)RC"G3A&4YR:C%-M(X\QE&.7X^4I*
M,8X/%2E*32C&*H3;E)NR223;;=DM6?SXO]]O]YOYFFU9:VN"S'R)?O'^!O7Z
M4W[+<?\ /"7_ +X;_"O\9/\ 4+CK_HB^+/\ Q',X_P#F,_%_[1R__H/P?_A5
M0_\ D_-?>045/]EN/^>$O_?#?X4?9;C_ )X2_P#?#?X4?ZA<=?\ 1%\6?^(Y
MG'_S&+^T<O\ ^@_!?^%5#_Y9YK[R"OT9_P"";W_)1OB-_P!B1I'_ *D;5^=O
MV6X_YX2_]\-_A7Z+?\$X8I8_B+\1B\;H/^$)T@ LI&3_ ,)$QXSUP.M?L7@!
MP?Q;EWC%P+C<PX6XCP.#P^8XR5?%XS(\SPV&H1ED^904JU>MA84J47.48*4Y
MQ3E*,4[R2?L\/X[!5<YP%.EC,+4J2J3484\12G.35&HVHQC-R=EJ[)Z:['ZY
M:O\ \@O4O^O"]_\ 26:OYH.R_P"ZO_H(K^E_5_\ D%ZE_P!>%[_Z2S5_,'XF
M\3:%X-T#4O%'B;4%TK0=&MH+C4;YK>[O&B2XNK73[6*WLM/M[O4-0OK_ %&]
MLM-TW3M/M;J_U+4KRTL+&VGN[F&)_P#=CP@E&%'B*4I1C&,LME*4FHQC&,<P
M<I2DVE&,4FY2;223;:2/@?I#0G4Q'!U.G"52I4CGD*<(1<ISG.IDT80A&*<I
M2E)J,8Q3<FTDFV;M%>"Z)^T5X,\0>%O"_B+2_"GQ>N=5\8:G?Z/HGPZ3X5^)
MHOB9-?Z5I2Z]JIE\-7\=A91:5IVB2VVI7'B)]<'AV07EGI=GJEUXAN4T6JM]
M^T_\);30K'Q5:W'C/7O"DO@R#XB:]XF\-_#_ ,4:MHW@#P--J>L:*WB/XD3?
M8K:[\)0V.K>'/$MCK&D265]XHT3_ (1CQ)?:OH%EI6B7VH1?KJS' .*FL9A^
M5P51/VL%[CC&;EJ[I0A.$ZE[.E"<95%&,DW_ #X\FS93<'EV+YXU'2<50FW[
M13G34=$T_:5*52G1:NJU2G.%%SE"27T)17D=K\;O =[XTB\$P/XC:6Z\6:O\
M/=-\7'PSJ'_"N-8^(_A_2[S6=<^'FC^.5+Z9?^+],T[3M3DDLTC33+R]TG6-
M$TK5]0\0:3?Z3 GCWXW^ _AOJ5UIGB,^)[@Z-X=M/&?C'4/#GA75/$>C_#GP
M3?ZE?:/8^,_B'J&G!E\-^&[O4-*UA8;I(M1OA8:%K^NS:;%X>T+5=6M-'C,*
MH3J/$453A-TYS=2*C&:7,XR=[)J#YW?14_??N+F,5EV/E5IT5@\2ZU6DJU*F
MJ,^>=*4N2,XQM=J53]TDM75:I)>T:B?<'[*G_)POPN_[#>H?^HUKM?O8O0?0
M?RK\%/V51C]H;X7C*G&N:B,JRNA_XIO7?F1T+(Z'JKHS(ZD,C,I!/[UKT'T'
M\J_!O%S_ )'V6_\ 8GI_^IV./ZJ^C]_R2V;_ /90XC_U694+1117Y2?O(444
M4 %%%% !1110 4444 ?B!_P4G_Y22?\ !"G_ +.M_:@_]8Y^(-?HA\;/^1IT
M[_L7K+_TLU&OSO\ ^"D__*23_@A3_P!G6_M0?^L<_$&OT0^-G_(TZ=_V+UE_
MZ6:C0!X]1110 4444 *O4?4?SK[<^'G_ ")7AG_L$6O\GKXC7J/J/YU]N?#S
M_D2O#/\ V"+7^3T >??'?_D!Z%_V&)/_ $@N*^8Z^G/CO_R ]"_[#$G_ *07
M%?E%\:/VL?\ A5GQW^$GP$T+X;7?CWQ1\1H(]9OU;X@> _ -_'X<N]/^([VW
M_"M])\<ZII7_  M?Q=9ZC\.KP^(/#&D7VE1:+I^J>';2?6#XD\8^%-(O0#[!
MHKP/P]\='\2_'CXF? RU^'/C'1YOA[\-='^(&G>-_%0M/#_A_P"(4FI^-_%'
M@.XL_!VERK=>(9/#.G:QX;\M/'VJ6%CI7B![JZ/AC3-6T[2FU:^\/'[67Q3T
M+5O'?A_QU\ ?"UKK7AGQG\$OA%X;C^'W[0$/C31?$OQS^/>KVD'A#X7ZUXD\
M2?!_X<6/@I]%\+ZGHOCKQKXC>#Q+!H>B>(O#.CVFD:MXN\0:=H$@!]V45\^^
M!/V@M#U_PI\;-;\<Z5%\.];_ &:_$?BWPO\ '/0XO$-GXXT[PE>>#OAYH/Q9
MOM3TCQ'I>GZ.^OZ/?_#CQ-HOB2PBO- \.>)+.XFO/#NN^'-)UO39X),GX1_M
M!ZQX^\7:-X)\=?"O4?A-K_C?X06?Q[^&EI>^-=#\:MXG^&<^LZ%H>K6^O?V-
MI>E#P;\2/!MWXO\ !,OC'P3GQ'I5G:^,-,ET3QIK[V&MQZ> ?I[\#/\ D6=5
M_P"P[+_Z;]/K%_:M_P"3>?BG_P!BXO\ Z=-.K:^!G_(LZK_V'9?_ $WZ?6+^
MU;_R;S\4_P#L7%_].FG5['#W_(_R/_L<99_ZFT#YWB__ ))/B?\ [)_.?_5=
MB#\%6ZGZG^=)2MU/U/\ .DK^P;ON_O9_GC9=OZ_I+[@HHHHN^[^]BLNR_K_A
ME]P5^@W_  3Q_P"2@?$+_L3=*_\ 3\:_/FOT&_X)X_\ )0/B%_V)NE?^GXU\
MGQTV^$L[NW_N]'K_ -1F&/T'PK2_XB#PQI_S&8C_ -5^,_R7W'ZLZO\ \@O4
MO^O"]_\ 26:OY=O'&@S^*?"&O>';>S\(ZC)K.G)8MIOCW2+W7?!>IV[W%K)>
M:9XFTO3+FTU*?2=1LXI[*:?3IC?Z;+/#JUE!>W-A%8W/]1.K_P#(+U+_ *\+
MW_TEFK^:#LO^ZO\ Z"*_/_"&$:E#B.G+6,WET)+:\9PS"+L^CLW9[K<_5_I"
MU)4<5P96@[3I?VW4@VKI3IU,EG%M/1I22NGH]GH?GS\/OA-^UE\*_@GHW@7P
M/<^#8-0UK7;-M8T&[^,WB^YN/@WX-LO#\%KJ6F_"+QYXV\ >/OM?BGQCXHCN
M->\[5O#O_"'_  O%Y/>>"M"U75I0UOU/B[X<_'*\\+_#WX4>&/A%\*++X$Z/
MX+L+/QK\.(?C]X@TG5/$&KV^J7)?P'J?BZ\^#&O7>M?#*XL;>RU;QCJ%K#HW
MC#XIZQJNJZ-XGOM/\/#68_%WV[17ZK3R>A2HQH0KXM4HT88>,'.C-*C!QE.E
M%3P\E&E7E%>WHQM0JP4*+IJA3ITH?A%7B/%5L1+%3PF =>>)J8R4XT\53E+$
M3C*%.M)T\7!RKX6$I+"XF3>*H5)3Q,:SQ56O7J_)^F_!#QM!KGAOPM>7'A(?
M"GPG^T?KG[2FFZ_;:IJ[>/KR_P!5\3^,/B'IOPXN?#8T"UT2UMM%^(/CC4[F
M\\;0^*;@:UX*TS3="3PM8ZG?ZG=6^7XM^$GQH\46OQ$NHH/A?I.K_M#_  4\
M._"?XL6DGB7Q1J>E_#+5]#L?B#X8?Q;X!N6\&PW7Q'TV?P9\1-0MU\.:[#X"
MG'BC1])U!]3&DW^L0P?8E%:O*\.X>S4JT8WER\LTG"+HO#1A%N#:A3PTZU""
M=VH5ZDFW5]G4ABL]QJJ^V<,/*;4>=RIR:J36(CC)5*D?:<LIU<;2P^*J:*,J
MF&HP48X?VM&I[M^R%I]KI'QS^#>D6/G?8='N!H]C]IE,]S]ATGP9JNG67VF9
MOFFN?LMK$;B8\S3>9*>7-?ORO0?0?RK\$_V5/^3A?A=_V&]0_P#4:UVOWL7H
M/H/Y5^'>+B2SW+4M$LFII+LECL;8_I[Z/[<N%\X;;;?$6(;;W;>6Y4VWYMZB
MT445^4G[P%%%% !1110 4444 %%%% 'X@?\ !2?_ )22?\$*?^SK?VH/_6.?
MB#7Z'_&P@>*-/)X \.V1)]A>:CFOSP_X*3_\I)/^"%/_ &=;^U!_ZQS\0:_1
M#XV?\C1I^#C_ (IZRY]/],U'F@#X(TC]I_PKK_Q[\3_ C0_!'Q.UAO!=O>6G
MB_XHZ;X:L[SX8>%O&&G36_\ :/@[Q#J,6KGQ%HYLK6]T_P _QC>^'(O! UO4
M+/PXNN->SQ7$G1?"+]HCX=?&C0OB7XJ\,MXBT/PM\+?&VL>#==\0>/\ P_>^
M!+2]M]$\#^$?B)<^.--LO$0L]9MO %WX4\9Z9K&EZ]XCTS0+J]TN&ZU@Z7;Z
M2]C>7?SQKW[)?CK7/VSM$_:3/B;X8:3HGAO2K*>PUSPUX&UGPE\;-=AT_4]7
M:+X-^/?$?A_Q/!X5\=_#.]T_4;>UU;Q7XI\,:QXIF\,:?IGA;3M*T[7-(T_Q
MM%3T;]F3XZ^.]*_:7\&?'CQ=\,_#7@[]HOXDZ;\5K_5_V<?$7CX^/M*UG2O#
M_P &?#7_  A=\WQG^'6K>#M>\!^(++X2F3QA'J>C7MSXAL?$%[X5O-*;1I[R
MZF /1M*_; TWQ7\'-8^-_@'X,_%/Q;X1\->-OBUX3\56^H:O\(OAGJOA;2?@
M_<W*:W\0-=7XI_$GPEI]KX0UK3;8>(-#A2^E\4P:)/#-XB\/:'>B:QB]1U#X
MZZ3H7P2\+_&KQ1X(^(7AL^+[#X>?V/\ "NZTG1]0^+$WB[XK:OH?A_P%\-5T
M33->GT!O'6NZ_P")-&TAK,^)HM&TJ>ZN+C6M;TZQTS4[JT^>/#O['?C72/A%
M\5OA/XA^.?B+XE6GQ>_:V?XZ^*=5\?:?X=DN+KX6:M\</"_Q1\;?#F2+P5X,
M\$6C^(OB%H/AZX\/^+=0DT^;PS<ZAJEU_9=CH_AV:;3&]_\ C?\ #SQO\7]%
M\=^"9Q\)K[P-XE\&:-/I5GXTTGXBW6M1_%K2?B!;>*$UC5-2\%>+/"=[H_A:
MTTG2])N?"NO>!]6TCXG>#/B+;P^,M*U.ZM])L-)N #I?A;\5]-^)O_"8:>?#
M?B?P-XR^'/B6R\*?$'P#XR7P^_B'PMJ^J^&M&\9^'YFU#PEK_BGPIK^@^*/"
M7B#2/$/AGQ'X<\0ZGIFJ6-S-"S6FI:?J6GVGZ8?#S_D2O#/_ &"+7^3U^1/[
M-'P!N?@E#\4==U_4],U;QW\9_'6D^-_&=QHVK>.O$FFVS>&_!>A> O#6G#QA
M\4-6UOXC>.=5@T;1'O\ Q#XV\8WEMJ&MZQJMQ:Z;H?ASPUI&A:+:?KM\//\
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M>!)1117ZF 4444 %%%% !1110 4444 ?AY_P4MABN/\ @I!_P0KBGBCFB?\
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M,4UE^,5E&W+MAUK%ZI[J45).ZBS'W,\N]CEGE+L0 H+.Y9CM4!5RQ)PH"CH
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M_P#BJZ:BO)_XIE^$7_1>>)7_ (4\*^5_^:8]?P/S_P#XBMG7_0MRK_P'&?\
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MYDF+PE2=&$JE/#_7(8C#.I"G.JI35-3YN259.;37/&]U_.LVGZAD_P#$OO\
MJ?\ ERNO7_KE2?V?J'_0/O\ _P  KK_XU7ZHF23)^=^I_B;U^M)YDG_/1_\
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M  0I_P"SK?VH/_6.?B#7Z'?&YG7Q3INUW7/AZRR%=E!_TS4>P(&??K7YX_\
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MO^H/S_!]C^B.O=_@-_R'-=_[!%O_ .EK5_++_P /IOBY_P!$+^%7_A3^.O\
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MAB</AG2P$*$\1SXB3C"2CB<1AJ?)%KWOWJDEM%GZ];D_O+QTY''ZTHD4#:'
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MLW%C:S:IH]EXB33H_$%GI=_)$UU86NN1Z1I*:Q;VLL46I)I>GK>),ME;B/\
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M;KX!T+4M OM#N=4TOQ%INM',>E:AH%]J5GJ$Z2VMK/)=0S01[/Q!^#GQ1^%
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M@U5[>XM8!:2ZA#XRNIK1'^TY,L=M,R[>$(R#^\_\31>'W_0KXN7_ '3\I_\
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M<?B;X)O_ (.6^I>-/BR++4M:TSPSX1MO&UAX&^']AK%SKD$GBCQP]GXET/\
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M'P\GT/QW::CXAUZ&^TO5/*M?UW4$#G&<D\# Y)..V<9QG&3U/)I:* "OEO\
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M;XXT27XA>&?'FF0V'PH:[\70_"7P18>)O&6F:Y;Z5=>&/.OA+_P2W^-OP[\
M?V+K&I^%?'.L^"X/V?-+ET7QE\3]-U7P)^TSIGP3^*&E?$C7$^)NA^&/V8OA
M_/X7E\97UI>>(-(UCXA7_P"T1XMT?QIJU_8^)=?\2^&SJNI^*@#]K/AS\8?
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MQSTWX?\ P3^%WA>_UK3_ !C\1=-LO%&E?%"6"*;X!I\*;SP=\/;/7O@'X?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!Y%\0OB5>>"M5L=/M]*M;]+O3_MK2SW4L#(WVF:
M#RU6.&4,N(MVXD')QCBN!;X^:H%8CPYIY(!(']HW/.!G'_'I5+X\?\C+H_\
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M?#'XY_"C2CI-U#JWC_X=:_JL?B"P\<_M*H(4 XR  <# R!S@=AZ#M0 M%%%
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M^/6EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO0O^$7\'ZAXFT7PYINFZ[>^%?#6Y_P#A'O#EUJ=K=3:'HGF/_96F/:V(;$
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MPW\-_$"(:_=_L??#CX,?$2Y\5?%OXK^-[#P]\2OAE\3_ (/_ !)U?2_@S?\
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MI_@Q_P $U_B-H_Q-T#Q;\4K#X;7_ (!M_C%\"OBG?_#34/&TOQ*L]/OOA/\
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MG6@#]:K+QKX/U*Q.J:?XJ\-WVFC0[7Q.=0L]=TFZL1X<OFO%L]?-W!>26_\
M8MVVGWZVVK>9_9UPUE=K#<N;:<1LB\<^#)VUU(?%GAF5_"^HVVC^)$CU_2';
MP_JUX81::7KBK>$Z1J-T;FW%M8ZD+6[G,T0BA?S$W?E'X?\ ^">_Q-MO%'@[
MQ8)_A'X*T;QW\7_B9?\ [0/PF\*3Z[-X1\/?L^>+_%?@/XOZ#\,?AIJ4?AG0
MHO%.L6_Q;^$UM>^)?[9\.>#/"UQ;_M&?M&ZKHNGV\][IECK/COPF_P""4_Q(
M\,>&;GPC\2=7\->/H+.;X$>&=6UGQ%\26\0Z3\9/"G@']JWX._M ?$'Q/XV\
M :1^S]\.GT_Q)XHTOP!XBN+:S\=>//C?K(\6>,O%.@?\)I;^&=<US7?$0!^Y
M>F>*/#>LVNFWND>(-$U2SUB6Y@TF[T[5M.OK;4YK..>:[ATZ>TN9HKZ6UBMK
MF2XCM7F>".WG>542*0KNU^<?[/WP8DTW]KO]H;Q=I&BW.C_ _P &:C"_PHT2
M_P# NO\ @ZUT[XV?$[0?#VF_M'WOA2/7K+3;#7?!L&E_#+X<7OACQ9X0LI?#
M]SXJ^*/QKTRSU:_"74<'Z.4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% '$^)OAK\//&MY;ZCXO\#^%/%%_:6WV*VO=?T#3-6NK>
MS\UY_LL,]];3R1V_G222^2C"/S'9]NYB3S9^ ?P0((/PB^&Q!!!!\%^'R"",
M$$?8.01P1W%>M45XF)X:X<QE>IB<9P_DF+Q-:7-6Q&)RK 5Z]65DN:I5JT)U
M)RM&*O*3=DE>R1C+#T)MRE0HRD]7*5.#;?=MQ;?S*]I:6MA:VUC8V\%G96=O
M#:6EI;1)#;VUK;1K#;V\$,86.*&"%$BBB152.-%10% %6***]F,8PC&$(QA"
M,5&,8I1C&,5:,8Q5DHI))))))66ALDDK)62T26R78****H HHHH **** "BB
MB@ HHHH **** "BBB@ Q_G_/\J*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#R+XA?$>^\&:K8Z?:Z7:7R7>G_;&DN+F>!T?[
M3+!L58HI RXC#9)!R2,8K@6^.^K@$_\ "/Z;P"?^0A>=A_U[U6^.O_(RZ-_V
M S_Z7W->(O\ <;_=;^1H _033+MK_3=/OG18WO+&TNWC4EEC:X@CF9%8@$JI
M<J"0"0 2 :O5C^'O^0!H?_8'TS_TB@K8H :[K&C.[!44%F9B J@<DDD@  <E
MB0J@$L0 37Q!8_\ !0_]E\Z;K/B;Q-XMU_X=_#^T^'GB_P"+GA;XG_$?P5XF
M\&?#KXG_  N\ 0V%QXS\=?"[Q3JUBEMXRT;1[35M(U*TAM8K;6?%6@ZMIOB?
MP5I7B7PQ>1:P?LGQ#HEGXET+6?#VH-.MAKNE:CHU\UK.UM<BSU6RGL+HV]P@
M+P7 M[B0P3*"T4H20 E:_'KQ'_P3\^.OQ:^!?@#]F[XI:K\&=.\&?L]?LT_&
M/X&?"_QAH-UXD\3ZE\5/%WC+]GW4_P!F[X<_$3Q[X.UWP=I=I\-M(\*>!=<U
MC7O$O@_1_$WQ'N-8\>WFGWFBZ[IFD^%K/^V@#]-/A_\ M"?"+XG^(_%/A;P7
MXUT/6=5\+ZY8:&1;ZGIKVWB5M0^&?P]^+4.K>![J*]EC\:>'8_!GQ/\ "-Y=
M>(/#WVW2K6[O9[&:X6:TEKNX_'_@:9==>+QEX5D3PQJW]@^)'C\1Z*ZZ!KF$
M/]C:VRWQ&D:KB2,_V;J)MKW#H?(PPS^8>C_L+^.K_P 82_%K4/!?P0^'GQ$U
M+]KG]G;XWQ)X0U6[UJ;P-\,?A9^SC\-/@EXL\#>$_%R?#KPE<H]S>^%?%,^B
M:+IGA_PUX<U/0-?^S:Q%9-?:E9#P;X'_ /!*KXB>!_!^C>"OB'J7A?QM:>'+
MS]D[PSJMYXC^([^,-#^+7@SX$?M"^ _C/XP\2>*/ MA^S_\ #.UTS7_$4?A3
M4[S2M*\:^(OC-K\FN>+O%?A[6_B+=>'=7U75O$8!^X-QXO\ "MI!H]U=>)?#
M]M;>(%LVT*XN-:TR&#65U"?3K6P;29I;I(]26]N=7TJWM#8M.+F?4M/B@\R2
M]MEESS\1?  TKQ-KI\;^$!HO@N^OM,\8:N?$VA_V9X5U+3-AU+3_ !)J'V_[
M'H-[IXEC^VVFK3V=Q:>9']HCCWKGYF^.W[+:_&+XK? ?Q9%_PC>D:!\'_!7Q
MYT?2[S[+NU_P9XN^(_A;P/X;\#>,? >F"Q.D0ZKX.&A:O=6EW+=:=/HTS:;+
MI'[\F6S_ #C^%_\ P3 ^*_@?X-^(O"'B"'PSXO\ %FE^'OV<O"_AF.]^/FJ6
M&B^)I?@!XFUOQ/IWCJ&30/V7?#^C^#/$MKJNIOJ_A6S^(_@K]HE[R74_$'AC
MXC:YXCT2ZMM30 _<";QKX/MYO"]O/XJ\-PS^-PQ\&PRZ]I,<OBP)9)J+?\(S
M&]XKZ_MT^2.^;^R%O=MG(ET<0.LAKQ?$#P+-J7B'1X?&?A.;5O")L1XJTR+Q
M)HDFH^&SJ;;-.&OV*WQNM%-^Y"V0U.*U^UL0MOYAXK\2+K_@F'\>-<\2_#S6
MO%OB_P (WEBO@CP'\/M>T;X?>-="^#VF_"K1?AY^T!\5OB[HNJ>"[/PG^RW=
M1>*/%EYX?\<^$K;Q#XD^&(_94_MSXF?#^W\6R:39:)KUCI_@J;Q7_P $S_VA
M/'OB7XJ:MXLU[X2S6_COX??M0_#;5[?3/$FI:-X2\=Z?\;OC5\)/BCX2UE_A
MCX9^#_A73OA_+I&A^"?$.C^-&O\ Q;\5?%7B#Q1J<>OMXPO'N=0U&] /U]\?
M?'SX4?#KP/XT\?:WXRT:^TCP+\+?%/QFUBQ\.:CI_B/Q%<?#GP=8W]]K?B71
M?#VE7D^J:WI\0TZZLX+G3X);6YU)5TZ*X^U.(Z])T+Q)H'B>UN+WP]K6DZY:
M6E_>:5=W&D:E8ZG!:ZIITQM]1TRYFL+BXBM]1L+@&WOK&9TNK2<&*XBCD&VO
MR7^,7[ 7CWQ5'^UCX/\ !G@3]F^ZT+X[:/\ %*[^'OQ3\52Z_I'Q*^%Z>,?V
M0O\ AFS0/A#X?T3PUX)-IH'@W2-7ADU.#Q5IWC*YTC3O OB7Q1H"?">^\3SP
M^)9?L#X'_LWW_P %OB?^TEXA\*VG@7PEX'^*\?PBNO!'AWPMISVUEH^N^"/A
MI+X*\1:QKOAJTL='TLW.HWEMHFVYL[ZXU#6M)TFS@U*^M7L[1(@#Z-M/B3\/
M;^/69;+QUX.O(_#NLKX=U^2U\4Z#<1Z)K[8VZ'K#PZ@ZZ9K#;EVZ9?&WOFR,
M6YS7(_$OX^?"CX3_  NUGXP^+?&6BIX'TKP9XE\>6U_I6I:=J]SXFT'PIX8U
M'QAJI\%V5I>M+XPOSX?TN\O[+3O#[7UU?QQ@VRNK!J_'OP!_P3%^.B:WI.I_
M$V[^#FHZ9.?V/XO'7A6P\07&H^"O$NJ?LV?M0:-\9?$WB?PYX!T;X*_#3P;X
M%\/>(_#-OJ=MX)^&L.CZ\= O)_[#U_QEJUA?7>H#H?B5_P $UOBSK7A;XT^%
M/#N@_LZ>*-+^+'@?]L/X5^#;#X@7.O6NE?L^:)\=/CG\2OBYX(\;_#33M-^'
MNMVZ:K>:9XWTO1?B!X5TK_A$/L6N^ _ >IZ)XMU'3M+N[8 '[4:YXH\.^&=.
MBU;Q%K>DZ#IL]S964%[K6IV.DVLU]J4J6^G6,=SJ-Q;6[WU_<21V]E:+*;BZ
MN'6&".20A:\]\!_'CX6?$/P7\./'.B^+M)L-,^*OPST?XN^#]-\27UEX<\2W
MG@+6=!LO$<>NW/AO5;J#5K.VT_2[^WEUJ26W,.C2>;#J$T#Q/CPG]I_]GWQC
M\5/&/P+\>>&_#?PI^),7PL;XD:9K'PL^--UJ-KX&U$?$SPQH_AR#XAV%Y9>$
M?&\9\:?#T:5>V.EVEWX8"ZSX/\<^/M(M-;\/:A?VMQ-^>_PA_P""6'Q1\!_$
M#X-7WC'Q/X?\:>$O"7AO]DI/$D^G_$6;P]:^';O]FOX'?#OX1:MX!\.>"+SX
M#^)/$WBKX?>,+[PAXCUF.R7XZ?#KP_JFB_$_Q[X?\;>"M6BN-1/C, _;36/'
M7@KP]8/JNO>+O#&B:9'#H]Q)J.K^(-'TRQ2#Q#<S66@S/>7U[!;+%K=Y;W%K
MI$C2A-3N8)H+%KB6*1%Y*+XU_#K^W/BCH>H:_;Z#)\'9_"MOX\U3Q*T/A[P_
MI#>,]!L_$6A/_;VK3VNF2PSV%_:QS3&XC2WOIDL7/VAE5OQY\0_\$QOCU>^&
MOA>]UXZ\*^*=<^#GBGQ3\/O#7AZR\:CP;8^)/V;?#G@:+X2?L\R^(_%'C3X$
M_'31H?B5X(\$IXDU/Q?ILGPMUK3+W5_B]\3E\.^++69K2YUCV"W_ &"?B=X3
MM_ %UI-A\*_BE8_"SQ5^S[KEE\,_BIXQ\47GA_XE:7\+/V0O$7[-VJ6OC3QA
MJGP]\77A\2>'/$NOV_Q"\">(M;\'^*4U.\T*&36M/T/7-0L=:\-@'ZLW/C+P
ME9ZCI.CW?B?P];:KKTD4.B:9<:WI<.H:Q+/9W6H01:58RW:76HR36-C>7L26
M4,[2VEI<W*!H()9$RXOB;\.9Y&BA\>^"Y9%U+0]':.+Q7X?D<:MXG,J^&]+*
MIJ+,-1\0-!,NB6) NM6,,HT^&Y,;[?Q=T;]@/XQPZG;?"4>%OA-<V&B_"_\
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M"FQ_^,5TE% #(XXX8XX8D2**)%CBCC4(D<:*%1$10%5$4!550 H    I]%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% 'PW^U!^U?XC^ GC/P_X8T;PA
MHGB&WUGPQ_;TMWJ>J:C8S03?VO?:;]GCBL[::-XMEHLOF,P?>[+MV@&OFA_^
M"D?CI8Y''PQ\(Y1'< ^(=;P2JE@#BPS@XP<5D?\ !1L@?%GP/D@?\6Z[G_J:
M-9K\])B/)FY'^IE[C_GFU ']/GA'6I?$?A3PSXAG@CM9]=\/Z+K,UM$[216\
MNJ:;:WTD$4CA7>.)[@QH[J&95#, 20.AKA/A=_R33X>?]B-X1_\ 4>TZN[H
M:[I$CR2,J1QJSN[$*J(@+,S$\!54$DG@ $FOA[3/^"A?[.>J_ #X._M(0:AX
MWA\ _&_XK^#/@KX/T^\\!:]:^-[/XA>,_B)/\,X]'\5^#9(_[7\+1>&]>L]1
MO_&%_JBI9^'O#>G77B"XDEL/L[7'VU>P-<V=W;+MW7%M/ N_.S=+$\8W8!.W
M+?-@$XS@'I7XM:?_ ,$T_C!IBP64'CKX=3^&-/TC]D'QCH/A9QKT2Z'\?O!/
MC;]GN#]JSQA#J*Z.\,N@^,_A?^S3X07X;"/3X-5F\<?$'XOW7B-=*L_%"78
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
G"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>chart-7e6903008512512eaee.jpg
<TEXT>
begin 644 chart-7e6903008512512eaee.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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MMK"81EY*YKXN?\$XOAA\5/#_ (2MM3U'1K_Q+X%^,G[1?Q;\,:I\0/A;\/\
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M_P -/C[\+OB]K'B;0/ 'B"?7-7\%7%_8>,;(Z'KVFR>%=7TWQAXJ\#W?A_Q
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'S!\:?VM/AE\"/C/\
MLK_ KQG8>+[OQE^U]\0/''PW^%UUX?TK3+[0-.U[X?\ PVUKXI:W<>,[Z]UO
M3+S2=+E\/:%=6NG3Z5IVO75QJ\UM;365K:-/?P?3P(8!AT(!'T(S7X@_\%)_
M^4DG_!"G_LZW]J#_ -8Y^(-?MY'_ *N/_<7_ -!% #Z*** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** /Q _X*3_\I)/^"%/_ &=;^U!_ZQS\0:_;R/\
MU<?^XO\ Z"*_#[_@I;(T7_!2#_@A4Z0R3L/VKOVG0(H?*\QMW['GC]"09I88
MP$#%W+2+A%8J&;"M^O6K_$[0_#D\%CK5AK=G=26L5TD7V.UGW0.SQI)OMK^>
M,9>*1=K.'&W)4 @GEQF-P>7T7B,=BJ&$H*48.MB*L*--3F[1BYS<8WD]E>[
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M:9'(_EQ2ZEX+\764<L@4L8XWN-%C5Y BL^Q26VJS8P":H?\ "Y?A]_T%;_\
M\)WQ%_\ *JOV.OFN5X6JZ.*S/+\-6BDY4<1C<-0JQ4DG%NG5JPFE)---JS6J
MT$>HT5Y=_P +E^'W_05O_P#PG?$7_P JJ/\ A<OP^_Z"M_\ ^$[XB_\ E56/
M]NY'_P!#K*/_  YX+_Y>!ZC17EW_  N7X??]!6__ /"=\1?_ "JH_P"%R_#[
M_H*W_P#X3OB+_P"55']NY'_T.LH_\.>"_P#EX'J-<)\3?^1#\3?]>"_^E,%0
MVGQ-\,:BC2Z;#XGU.%'\MYM.\%>+KV%)0 QB>2WT61%D",KE"0P5T;&&!.'X
MQ\20^(O#&L:)I6B^,)=1U&U$%I'<^"O%=A \@FCD(DO+_2+:SMUV(QWW$\49
M("AM[*K1F\X8O(,UGA)PQ4*^59@J,L-*->-9RPE:,52E2<U4<I>ZE!R;E[JU
MT&MUZK\SY%;J?J?YU\7?M;?LEZC^U.W@;1[WXE66@> ](UBXN/%GA#7OA;X&
M^(>V*X\'?$/PN?&/PNUGQ%:1ZI\//BM;IXVMH['Q*]QK>C:=)H7ASQ5IVAV?
MBSPCIMQJOZ GP!XU))_X1?6.3G_CV3_X[2?\*_\ &O\ T+&L?^ R?_':_E_"
MX+/<'6CB,/EF8PK04E";RRO4Y>>+BVHU,/.*DE+W96O%M.+3L%GY?>O\SXRO
M/@%XKUOX@^%=6\2?%.PU7X8>!OC98_M >&/!%K\+/#VC>/6\?:5H>KZ'HUCX
MH^+MAKH7Q+X=TN/6[RXN-7D^']C\3_%T$5EH7C?X@Z]H\-ZNJX'C_P#9]^+_
M ,2?!=[X,\1_'GPF8?B#\'+_ ."OQQU*V_9T\)->>*M"U>X\1IK>M_#66;QF
M+KX>:EJNC>(Y=)/AWQE=_%_P'I6H6%AXRT7PS8^)%U!]5^[/^%?^-?\ H6-8
M_P# 9/\ X[1_PK_QK_T+&L?^ R?_ !VM8T.((RIS668WFI**IMY-=0Y9.::3
MP;7,YR4I3:<YR5-SE)TZ?*]=-5I;[2Z?._\ E=VL</9VL%A9V=A:B1;73[.S
MT^U6:>2YF6UL+6*SM5FN9B9KF9;>",37,Q,UQ*'GE)DD8U[_ / ;_D.:[_V"
M+?\ ]+6KSC_A7_C7_H6-8_\  9/_ ([7I?PRM=5\$ZGJ=YXA\/>);>WO;"*U
MMFLO#VK:P[SQW!F=7AT:UOY8%$?(EG2.)F^17,GRU[G!>6YG2XIR>M6R_'TJ
M<,15E4JUL'B:=.*>%Q"YIU)TXQBFVE>35VTMVKEK*6VW=/JNS/IVBN'/C_2%
M!+:3XV4 $DGX?^-0 !R22="   Y))P!R:QO^%R_#X]-5O_\ PG?$7_RJK^C,
M5C\#@N3Z[C<'@_:<WL_K6*H8?VG)R\_L_;5(<_+S1YN6_+S1O:ZO)ZC17EW_
M  N7X??]!6__ /"=\1?_ "JH_P"%R_#[_H*W_P#X3OB+_P"55<O]NY'_ -#K
M*/\ PYX+_P"7@>HT5Y=_PN7X??\ 05O_ /PG?$7_ ,JJ/^%R_#[_ *"M_P#^
M$[XB_P#E51_;N1_]#K*/_#G@O_EX'J-%>9P?%WP/=31V]G>:O>7,I*PVMIX7
M\37%S,P4L5B@BTAI)&"JS$(I(568\ FNPT;Q!::X;@6MGKEK]F\K?_;/A[6]
M"#^=YFW[.=8L++[5M\L^;]G\WR=T?F[/,CW=N&QF$QL)5,'BL-BZ<9.$JF%K
MTL1",TE)PE.C.<5-1E&3BVI6DG:S0&Y11170 4444 %%%% !5#5;MK#3-1O4
M2VD>TL;RZ1+RZ:RM':WMI9E2YO%M[MK2W8Q@3W(M;DV\1>86\Q01/?JCJD5Q
M-INH0VJ+)=2V-W';HVH76DJ\\EO*D*-JEE!<WFG*TC*IO[6VN+FS!^TP02S1
M)&P!^%%_X\^&OQ(^-,4.C_%3X9+\-?BS\8_@Y\2?'/P>T']K718O"GC7XGZ.
M_P .M^K-X?O/V,M1^(KNOBKPAX<DD\(>&?C=X.\(?$R[\*Z7J.O:=HL?B[Q5
MIUW^\@Z?B?QY.3T')/)XQGIQ7XOIJEMX.^.VD?#R#Q-XJUW4_"WC7X<:+XG@
MA_X*#?\ !07XA2Z!XDU6S\)Z[J7ASQ+H>E? /Q)\.+N\LAK<4T/AGQEXWT>W
M\0^%[O0M3\91^$]/\37%KI_[0#^I[D]SZ_RZ#H.* /Q!_P""D_\ RDD_X(4_
M]G6_M0?^L<_$&OV\B $:8&/D7_T$5^(?_!2?_E))_P $*?\ LZW]J#_UCGX@
MU^WD?^KC_P!Q?_010 ^BBB@ HHHH *3 ]!^0I:* /"/CT -"T+  _P")S)_Z
M07-?+U?4/QZ_Y 6A?]AE_P#T@N:^7J_FKQ(_Y*S'?]>,#_ZB4@"BBBOA "BB
MB@#ZJ^!(!\,:KD _\3Z7_P!-^GU[;@>@_*O$O@1_R+&J_P#8>F_]-^G5[=7]
M3<$?\DKDW_8+_P"Y*@!1117U0!1110 48!ZC-%% %>Z ^S7' _U$W8?\\VK\
M[EZ#Z#^5?HE=?\>UQ_UPF_\ 1;5^=HX4$\# _E7XGXN_Q<@_PYK_ .\P!:*\
M:MOVAO@C=_&6Y_9[M_B;X5D^,UII$.M3^ A>NNIK#+]LD.FI>/"NCR^)[>PL
M+C6K[PA%J3^*+#P\JZ_>:3#I3-=)F:Y^T_\ L_>&KWP[I^N?%;PW87/BG0])
M\4Z4PMO$=]90^%?$.I7>C^'?%GB/5M+T*^T?P-X4\1ZI87MCX=\3^/-0\,:!
MKTUK<-I.HWEO!+,GY&L'BVXQ6%Q+E.G"K!*A5;E2J)NG4BE"[IS49.$U[LE&
M33:BVG9_U\O\U]Y[Q17E?Q3^-7PU^"R^'?\ A8^N:GI%QXMU#6=+\-Z;HG@?
MXB?$'7=8O/#NF#6=>6T\.?#3PCXS\0BVT;3&CN]3U&XTN#3;)9K:*>\2XNK:
M&7K/#WC/PSXJ*QZ'J@NKH^'_  QXJ?3[JPU71]6M_#WC*WO[GPSJEYHVNV&F
M:O80ZJFE:I"L-]8VUY97^FZAI>J6MCJ=E<6<>;HUE355TJJI23<:KIS]G)1E
MR-JIR\C2G[C:EI/W7[V@K?Y_U]Y['\,O^1\\-_\ 7W<?^D%W7V[@#H *^(OA
ME_R/GAO_ *^[C_T@NZ^W:_>?";_D1YA_V-ZW_J%EX!1117ZF 4444 %%%% !
M2'H<<G!P/P]^/SI:0Y )'4 X^O;IS^5 'YFK\,/C7HO[2GQ/\0Q^&?VCU\%>
M+?B[X.\4:+J'PE^(G[.O@/X27'A^'PWX,TG5+SQ9X&USQ8_Q"US51?Z1JC>.
M]>FLE\0^,]*2PM=+L((],TJS7],Q_CU^O^<>U?G+>>/_ (Z-^T5X\\/>)M5_
M:ET#PAIGQ/\ "%A\/8?A3\ ?ASKOP7U_X?WNA>$99F\1>//%O@/Q5XX.HKXD
MD\56GQ UJSUSP]IFEZ6]A_PB"0&PNM5E_1H?CU/7Z_R]/;K0!^('_!2?_E))
M_P $*?\ LZW]J#_UCGX@U^WD?^KC_P!Q?_017XA_\%)_^4DG_!"G_LZW]J#_
M -8Y^(-?MY'_ *N/_<7_ -!% #Z*** "BBB@ HHHH \(^/7_ " M"_[#+_\
MI!<U\O5]0_'K_D!:%_V&7_\ 2"YKY>K^:O$C_DK,=_UXP/\ ZB4@"BBBOA "
MBBB@#ZJ^!'_(L:K_ -AZ;_TWZ=7MU>(_ C_D6-5_[#TW_IOTZO;J_J;@C_DE
M<F_[!?\ W)4 ****^J **** "BBB@""Z_P"/:X_ZX3?^BVK\[,93& <KC!Z'
M(Q@XYP>]?HG=?\>UQ_UPF_\ 1;5^=J]!]!_*OQ/Q=_BY!_AS7_WF ?E+XZ^
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MI4(R<:S<X4G!\U9NM[2I4;I4HJ7M(PITX.E"FHR]UW_ROUM:UO3^KGQU\:=
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MXTM% "8'O^9_QHP/?\S_ (TM% "8'O\ F?\ &C ]_P S_C2T4 )@>_YG_&C
M]_S/^-+10 F![_F?\:7&/7\23_.BB@ HHHH **** "BBB@ HHHH **** /Q
M_P""D_\ RDD_X(4_]G6_M0?^L<_$&OV\C_U<?^XO_H(K\0_^"D__ "DD_P""
M%/\ V=;^U!_ZQS\0:_;R/_5Q_P"XO_H(H ?1110 4444 %%%% 'A'QZ_Y 6A
M?]AE_P#T@N:^7J^H?CU_R M"_P"PR_\ Z07-?+U?S5XD?\E9CO\ KQ@?_42D
M 4445\( 4444 ?57P(_Y%C5?^P]-_P"F_3J]NKQ'X$?\BQJO_8>F_P#3?IU>
MW5_4W!'_ "2N3?\ 8+_[DJ %%%%?5 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!^('_!2?_E))_P $*?\ LZW]J#_UCGX@
MU^WD?^KC_P!Q?_017\^'_!9GXU?#/]FW]L3_ ((Q_'SXU>)?^$(^$7PS_:A_
M:+U'QWXUFT7Q#KEAX;L=:_95\8>&],N;ZS\,:3K>K.EYK6JV%A$+;3YV\VX#
MN$@BGFB]P3_@X5_X(\A$!_;1\,@A5!'_  JSX_\ 4 9_YI)0!^T5%?B__P 1
M"W_!'C_H]'PS_P"&L^/_ /\ .DH_XB%O^"/'_1Z/AG_PUGQ__P#G24 ?M!17
MXNK_ ,'#'_!'5BP3]M3PJYC;9($^&'Q]<Q2!5<Q2A/A,3%*$=',4FV0))&Y7
M9(A9W_$0M_P1X_Z/1\,_^&L^/_\ \Z2@#]H**_%__B(6_P""/'_1Z/AG_P -
M9\?_ /YTE'_$0M_P1X_Z/1\,_P#AK/C_ /\ SI* /TI^/7_("T+_ +#+_P#I
M!<U\O5\0_%G_ (+W_P#!([Q1I6DVND?ME^&)YK;4WN)E/PL_:"PL1LYH@V4^
M$,AY=P.0!Z$GBO"O^'W/_!*[_H\'PM_X:[]H;_YSE?SUX@Y1FN*XGQE?"Y7F
M.*H3HX-1K8; XFO2DXX:G&252E2G!N,DTU>Z::>H6_JZ_K^O)GZIT5^5G_#[
MG_@E=_T>#X6_\-=^T-_\YRF_\/O?^"51<Q#]L7PD90@D,0^&/[0AE$3,R+*T
M7_"G?,6)G5D64J(V=716+HRCXK^P,^_Z$F<?^&O'?_* M_5T?JK17Y6?\/N?
M^"5W_1X/A;_PUW[0W_SG*/\ A]S_ ,$KO^CP?"W_ (:[]H;_ .<Y1_8&??\
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MW@_CY/V3_C5IGQ>;X8#PT?'0T[PK\0?#7]@#QA_;?_".&8^.?"/A87G]I_\
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MN\\:SV-_I/J+^(OCU-^TO\,;3PI\7_&?B[7/$GC"T\5_&7X(3>"/">G?!CX
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L0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>chart-8e7d74fd3876590095c.jpg
<TEXT>
begin 644 chart-8e7d74fd3876590095c.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" '2 3T# 2(  A$! Q$!_\0
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MV.L^/?'/AWPQJOA#P#H]UK4D=A'J/B_6]'M\^==NR:=:7E[;?(GAS_@E_P#
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M<_$-]0\5^#?'.A:_X2\06NIS_#FT\.:]H-UI:VVH>']:U9M,U'0M=CTK6].
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M-:?I]KJPUZVL;'0=)L[.WUQ<%=9@M;:SBMX=64@;=2BC2^7 Q.*ZF@ HHHH
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MBOQ#_P""D_\ RDD_X(4_]G6_M0?^L<_$&OV\C_U<?^XO_H(H ?1110 4444
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M>)_$3PZ#X?U+4M8N+>RECU7]M7]FS2/!&@_$";XA3WVB>)/&FJ?#G3-/\/\
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M?_)=&SQ1_P ]M!_[\:E_\EUT%% '/[/%'_/;0?\ OQJ7_P ET;/%'_/;0?\
MOQJ7_P EUT%% '/[/%'_ #VT'_OQJ7_R71L\4?\ /;0?^_&I?_)==!10!S^S
MQ1_SVT'_ +\:E_\ )=&SQ1_SVT'_ +\:E_\ )==!10!S^SQ1_P ]M!_[\:E_
M\ET;/%'_ #VT'_OQJ7_R77044 <_L\4?\]M!_P"_&I?_ "77 _%'QYKGPM\
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MS7]+T2^^"^OW[^)FA\/^#?$ED/ @-WJ=C9VGBC6?AMJYU#O^O87_ *$V6?\
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M:E_T+>J?^!>A?_+>C^U-2_Z%O5/_  +T+_Y;T ;E%8?]J:E_T+>J?^!>A?\
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MK_\ (-'_  DVD?\ /:Y_\%FJ_P#R#6_10!@?\)-I'_/:Y_\ !9JO_P @T?\
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M]Q?]U?Y"OZA=6FA.EZD!+$3]@O>DBGI:S$]^PY-?R])]Q?\ =7^0H =1110
M4444 ?1?[)/_ "<;\*?^P[J/_J,Z]7]!B]!]!_*OY\_V2B!^T;\*<G'_ !/=
M0'/J?#.N@#\3P/>OZ"HY$<?(Z/@#.U@V,CC."<9P<9]#0 ^BBB@ HHHH ***
M* "J&JW3V.F:C>QI;226EC>72)>7,EG:.]O;2S*EU=Q6M]):V[,@6>YCLKMX
M(B\J6UPR"%[]4=4BN)M-U"&T1)+J6QNX[9)+^[TI'GDMY4A5]3L(I[W3T:1E
M5KZS@FNK,$W-O%)-%&C 'X5WWC?X<?$GXUPC2?B/\.D^&_Q5^,'P=^(_CGX/
M:+^U%K-KX0\;_%#16^'ZG6YO#5[^PO?>-6EB\4>$_#DI\)^'_CCX)\$?$VZ\
M*:1JOBW2]&/BKQ582_O".GXG\>3D]!R3R>,9Z<5^+Z:M'X2^.^E?#VSU?Q3X
M@OO"?C?X<:%XI%E^WA_P4N^)(\/>)M3LO"&O:MX=\1Z?I7P?\4?"RZO=._MR
M*X3PSXU\9Z9::QX8O-"U'QU!X6L/$5W:V/[0#^I[D]SZ_P N@Z#B@#\/?^"E
MD44__!2#_@A5'-''+&W[5W[3Q:.5%D0E/V//B Z$HX925=5921E64,,$ C]J
M(_#VA>6G_$ETG[B_\PVQ]!_T[U^+?_!2?_E))_P0I_[.M_:@_P#6.?B#7[>1
M\1IG^XO_ *"* ,K_ (1[0?\ H"Z3_P""VQ_^1Z/^$>T'_H"Z3_X+;'_Y'KP*
M3]KOX 0_'2]_9UF\>6T/Q+TW0[K6[^"73-9C\+63V%G<:KJ'AZ[\>-IX\%6O
MC'3]#M9O$-]X/N->B\0VF@(=6GL$ME8KF>&OVS/@-XST'Q+K_A'5O'GB1/#7
MA+0_B NA:1\&/C+<^,_%_P /_$VH-I?A[Q_\,/ K^ H?&'Q9\":W>(R:9XQ^
M&NB^*?#MS&!<C45MI(9I0#Z0_P"$>T'_ * ND_\ @ML?_D>C_A'M!_Z ND_^
M"VQ_^1Z^4])_;N_9UUG14U6TU/XGIJ,WQ#\0_"RR\!W?[/\ \>K/XMZMXU\(
M^&M-\7^+=.T/X/S?#<?$W7=/\*^'M7T[4/$WB/2?"MWX:T!KE;#5M7M-41[%
M?8[_ ./OP@T[X/P_'NY\<Z2?A/<Z3I6L6GBVUBU&_BOH==U&ST71=.T_2;"Q
MN?$%_P")-7\07]EX9TSPE9Z1-XJOO%5W;^%[?1G\02KII /2?^$>T'_H"Z3_
M ."VQ_\ D>C_ (1[0?\ H"Z3_P""VQ_^1ZXKX6?&#P%\9=%U76_ FI:E=)X?
MU^Z\*^)M'\0^&/%/@?Q;X3\3V5CIVJ7'A[Q;X*\;Z-X>\6^%]8_LG6-'UF"P
MUS1;&:]T35])UJQ%UI6IV-Y<>FT 8_\ PCV@_P#0%TG_ ,%MC_\ (]'_  CV
M@_\ 0%TG_P %MC_\CUL44 8__"/:#_T!=)_\%MC_ /(]'_"/:#_T!=)_\%MC
M_P#(];%% &/_ ,(]H/\ T!=)_P#!;8__ "/1_P (]H/_ $!=)_\ !;8__(];
M%% &/_PCV@_] 72?_!;8_P#R/7SO^UEH^C6G[.OQ6N(=-TRU>+PVC>?'9VML
MT2C5M,+OY\5N7B4*"6D56*+EMC8VGZ@KYP_:ZQ_PS?\ %G(!!\-*"" P(.K:
M:""K JRD<%6!5@2&!!(H _D>^!7Q-^.GBOQ+\4/!7CB_TRQ^*4=\MSX3\#>-
M/AQ>^&O ^DPP:;\+5UW4/ WQ+\#Z[XDL_BM\//#TWCB*ZFM%N4\=W)UOPCJF
MJZAX6L?&$EKH/N_[/WBOQ1XZ^ _PK\<>+;BVU7Q9XC\ Z;KGB'4+32H]#TZ_
MU=S<PW-Y%I5K)-;:-8W5Q"A6SAN9HK%)5MUN[AU%Q+0T/]F[X,>%8O&T/A7P
M>_A1O'TJ?VY>>%?$OBWPQJME91#0C'HOA#6] UW3=9\!: D_AS2[P:)X+O\
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MP3@_Y*-\1_\ L2=)_P#4@:OSIK]%O^"<'_)1OB/_ -B3I/\ ZD#4 ?KCJ_\
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M+2'Q%JGA3P_-J5QJ&D>'[NV34OM:V]OK'BG6=&MH](/KX 4 #H  /H.!2T4
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M'=:C=HT(^7='^$OQ.M]?OO VJ1?$[6-"UGXK_'?7_&^M7FM^!K+X+>(?A/\
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M<TFKIN,YJ236JNM5J@.,HKL_^%<_$'_H2/%?_@AU+_Y'H_X5S\0?^A(\5_\
M@AU+_P"1ZS_M/+?^AC@?_"O#_P#RP#C**[/_ (5S\0?^A(\5_P#@AU+_ .1Z
M/^%<_$'_ *$CQ7_X(=2_^1Z/[3RW_H8X'_PKP_\ \L _4[_@GGJ<=E\)O%\;
MVFI7!;XBWCAK/3[J[0 ^&?#B[6>"-U5P4R4)#!61L88&OL7XB:Q%=>"?$4"V
M.KPM)8@"2YTJ\MX%_P!(@.9)I(ECC''5B!GC.2!7R_\ \$_-"UG0OA5XMM=<
MTC4=(N9?B'>7$5OJ=G/9S20'PUX<C69([A$=HC(DB!P"I='4'*D5];?$T >
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M$UM\)O'>B>,O!_A#QU\"=?L_$VLZS<:QJ6@R^.M,FACUH:7\0_"]SHNJ:?\
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MG["455]I)RBHPY>9MI)-M"6C7JCZ]/WLC((8D$$@@\\@CD'!(R.Q--  !
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M"&UM;:*.""*.)%4:= !7PO\ M#:_XY\6?M*_L]?LVZ1\2?%OP;\$?$;X9_M
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M96<$5K:6=I:Q)!;6MK;0)'!;VUO!''#!!#&D4,2)'&BHJJ+5 !1110 4444
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MUG6GVO#O[=?Q@U[X<_#CQDWP[^#5GJ/[3&J_!*#]GK21\5]6NIO"FG?&^_\
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MV5=5\*^+$T'6)M3\0>'$3P_\6+O[/H6I:O?7FG76H:G'<7FH0M9S* ?JE29
M."1GCC(SSG''O@X^A]#7Y5?%K_@HMJWPF^.FJ^&9?A];^.O@[I/BSXE?#&^\
M3>!K'QK<ZMIOQ%^&?[-OCW]HW5=%O?$NO:-H?@74?$<ME\/-7\'W'@+P@?%-
MQHUS?:?K.I^,XK^WUCP=IOA=U^V;^T#HWQAEN?B!'X0NX[[X;_LR>/\ PKX"
M^$/Q)UC5O!%G+X\^"7_!2GXOSP:O?7_A*UU;Q(VOP?!+P)X:U6*)+/3/$::)
MX<\;:&FC%#X=D /W*HK\M/$O[>'Q(N83I7PU^&?AOQ5XAE^$?[&/Q'O&LM4U
MSQ5=^%HOVH+?X^ZGXBU!OAWX3BE\?_$BW\$:3\&]-OM+\'_#RVNO'7B/3?$F
MH^(DLTT'PQJ-Q7B-]_P4 _:$3QSK7CSPU#\$_&GP<?\ 9F_94\1Z3X#TVX\?
M:9J5O\<?C/\ M>^)?V:?&4+^,_$_@[PQXGL]$\,W^EZE9ZSI'BGX>Z-XET._
M\/V.E7_A/3-<;Q"9@#]N:*_&[Q#_ ,%)_BU\*]'\:^*OB?\ !?P9K?A_X=7?
M[7_@'7+/X;>,?$MSXD\0?$K]E'X=>(/BX^I>&K'6_"[6MOX)\?>%-!GT-+/4
MII_$?A/Q'NOY9_$6@AFBZ?PK^V_^TQXQU?P%\,;#X&>&_#7Q-\=_%GQ)\.+'
MQ#\3-,^,'PQ\!G3]/_9V\7_'&+Q#9>&?&/A73?BA>-X?UOPO_P (#K-K/I%E
MIWB*'4-+\9>&M:@L;^\TC0P#]:J*_%GX<_MR_M3>.9_C;\5-'\$_#_Q#\.IO
MV<_V&/B9\&/@];76H+XYT#Q9^TE=:WIOCHZIX@$6FO\ $>U\-MI'B36M-\(^
M%]-3QGX]3PUX<\)>!-,L?%OB6[LY?TE_9F^,K_'/X4V'C&_E\/+XDT_Q#XP\
M&>,-.\.VGC[2(-&\4>"O$NH^']2TW4?#?Q2\(>!OB%X2UH16EI?:MX4\5>'(
M;_0+F^-A;ZKXETV.Q\2ZN ?0-%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% 'Q]^UY\!/&7QXT3P3IO@Z^\.V,_AW6]4U&^;Q#>7]G%
M)!>Z8MG$MLUCINI,\JR@F19$B4)@J['Y:^&/^'>/QO\ ^A@^&O\ X._$'_S+
MU^U%% 'A/[-WPTU_X1?"/P[X$\37.E7>L:3=^()[F?1I[FYT]TU37;_4[<0S
M7=I8SLRV]U&LP>V0+*'5"Z@.WNU%% !7ES_!#X.2?$Y/C5)\+/AZ_P 7HK(:
M='\3V\': WCU+)=/?25@7Q8; ZV%32))=(C<7OFQZ1++I22+I\LELWJ-% 'B
MGAC]F[]GWP5]I_X0_P""/PH\+?:_&.E_$*Y_X1[X?^%M'\[QSHCWTNB^+9/[
M/TNWSX@T>34]2DTK5/\ CYTU]0OGL7@:\N3+-K?[.WP%\2-ISZ_\&_AEK+:1
M)\2)=,.I>"?#UV;%OC#>WVI_%<6YFL&,<?Q)U/4K[4_',(/D^*=2N9=0UF.\
MO"LZ^RT4 >1:Q\ /@;X@^(,/Q8UWX/\ PSUGXG6YT!H/B#JG@?PW?^,H9/"E
M_#J?AF:+Q)<Z=)JT=QX>O[>"ZT6Z6Z%SIDL48LY88U"5@0_LK?LTVV@^(_"]
MK\ O@]:>'?%_BG2?''B?1;/X<^$[33==\9:#J0UG0O%.IVMMI<45SK^B:L#J
M>CZJX^V:7?M)=V$MO/-,\GOE% '@]S^RW^S9>7?CN_N_@)\'KF]^)\7B*#XC
M7<_PX\(RW/CF'Q?J6BZUXJB\5S/I)?7H_$>M>'-!UO6EU%K@:EK6D:?K%UYF
MIVL=V.H\%_!+X._#B33YO 'PL^'W@J72EUE=-E\*^$-!T"2Q'B*S\,:?X@-J
M^EV-LT+Z[9>"O"-MK,B$2:I%X9T);Y[@Z7:&+U"B@#R,_ +X''XBW'Q>/P@^
M&A^*EW>Z=J5S\1CX(\-_\)O-J6DZ5=Z#INHOXG_L[^V#J%GH=]=:+#??:_M0
MTB4Z8TS621P)Y;9_L7? +0O''PS\9>!O!ND?#*S^&/B2^\:V/@?X9^&? O@G
MP=XG\:/H'C3PSX>\3^,DT7PC!XGUBZ\$:1\2/B'!X2TBU\3Z9X7M9O&FKWNJ
M:#J]U;:)+I/U=10!\YP?L@_LJVOA;6_!%K^SC\$+7P?XDDT>;7O#5M\+_!EO
MHFJS^'-0US5O#EQ>Z=#HZ6TMQX=U/Q+X@OO#]QY8GT.YUG49-*DL_M4H/0WO
M[-W[/NHOX*DO?@E\*KAOAQHZ>'O (D\!>& G@WP_%J^C>((=#\-1IIJ1Z/H\
M&O\ AW0-<M],L4ALK?6=%TK588$O["VN(_:Z* /-9/@U\)9K@W4WPS\!37+>
M(/%WBMIIO"6AS2/XF\?:+=^'/'&ON9;)P^L>+_#]_?:)XFU!PUSKFDWEUI^I
M27%I/+$^/X%_9Y^!'PPMM"L_AS\&_AAX%M?"^O:OXI\.P>$O WAOP]'H?B77
MM!?PKK.OZ6NE:=:_8M8U/PO(?#5YJ,.VZF\/"/0S*-+BBM$]BHH \*U#]F#]
MG+5K6VL=3^!/PCU"QL_AU%\(K:QO/A[X6N;*'X6V^L6?B&T^'BVDVF/;GP98
MZ_8VNMZ=X=:-M,TW5X5U*PM[:]+3MZ1X'\!>"?AGX8TSP5\._"7ASP/X0T5)
MDTGPSX4T;3] T/3Q=7$MY=M:Z9IEO;6D4MY>3SWEY.(O/O+R>>[NI)KF:65^
MMHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,_4
M-6TO24B?5-2L--29F2%[^]MK-)74;F2-KF6(2,J_,50D@<D 5E_\)CX2_P"A
MH\._^#S2_P#Y+KX&_P""BJ(_A;X8[T1\>)]=QO17QG0T&1N!P<=Q7Y4>3#_S
MQA_[]1__ !-?JG#'AS0X@R;"YK/-JN%EB)5XNA'!QK1C[&O4HIJH\52;YE#F
M?N*SDU=V3/PKC?QBQ/"/$>-R*GD%#'0PD,)-8F>8U,/*I]9PM#$M.E'!5E'D
M]JX)JI+F2YK)Z+^FJSOK+4;=+NPN[:^M9"XCN;.XANK=S&[1N$F@>2)BCJR.
M%8E74JV&! M5\H_L4JJ_L[^#0JJH%_XNP%4*.?%>K$\* .2<GCFOJZOSO-L$
MLMS3,<NC4=:.!QN)PBJN*@ZBP]:=)3<%*2@Y\O,XJ4N6]N9VN?KV09G+.LCR
M?-YT5AY9IEF!S"5",W5C1>,PU/$.DJCA3<U3=3E4W"'-:_*KV"F[T+;0R[AU
M7<-P_#.?TI)21'(0<$(Y!]"%)!_.OY^HOCW\=]#_ &HO&6L#5_VF?[)7]O+X
MI_#:S\1:KXV^'FM_LO:G\&OA#\(5^*/C'X*^'?A2NO:E\0+;XM^(O!WAGQC;
M?#2[7P7X1CU'X@Z>VHS_ !$DT6";1?$7GGKG]!%%?A%!_P %!/VOOC!\,_AU
MXB^''PST#X.ZKXW^*/[#NOV7B'XD^ _B6GA.[^%/[3/Q7MO!>N_#-1XHTWPW
M?^)O%FE65YH=Q-\4_!$0\#:]HVJZZOA=M"\0Z+83WOT%\3_^"B/BCP#X&N?$
M5E\/?"VK^(X;G_@I!%;>%[GQ->:;<WR?L.>(/&FB^'<.\#RVJ^.CH7A[_A(K
MN6W>U\.2^)+9[;S89+03 'ZMT5^7\G[8WQ^\,_%W6O!?C3X;?"B7PCX ^/W[
M-7[/GCW5?#7BSQ<^O7WB;]IGPEX)U33=6\'6>I:*+%M'^'GB#Q[H-GJSZ^UG
M=>+]%.HWVG6WAF_L(+#4O2_V/_VKO''QUU[Q5X3^+'A/PM\-?&]KX1\+_$C1
M/ -B_CR77;3PCXFU;7=%>2+Q+K?AF#X9_%SPQIM]I6GPZ=\8/@KXW\2>#_$T
M^K-#+H/A:*'2+KQ& ?>M%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 ?)O[5WP*\7?'+1O!VG>$K
M_0+";P_K.I:A>MKUU?VT4D-YIRVD2VQL=.U%GD$JDN)$B4)@J['Y:^*/^'?O
MQE_Z&+X=?^#7Q#_\S-?L317V64<=Y_DF HY=@9X18:@ZCIJKA8U)WJU95IWF
MY)OWYNVFD=#\YX@\+>%.)LUQ&<YI2QT\;B8T(U71QLZ-*V'HTJ%/EIQBU']W
M2BI.^K;?4\2_9Y^&^N?"?X5>'_ _B.YTR[U;2KK79KB?1YKF>P=-3UN^U&W$
M,MW:64[,L%S&LH>W0+*'5"Z@.?;:**^7QN+K9AC,5CL0XNOC,15Q-9PCR0=6
MM.52;C%748N4G:*T2T/N<MR_#Y5EV!RO"*:PN783#X+#*I)SFJ&%I0HTE.;L
MY24(14I-7;NWN! (((!!&"#R"#U!'<&N!D^%7PSE1XI/A_X,>.3Q];_%61&\
M-:05?XF6EQ;W=M\0&'V3GQG!<VMM-%XE_P"0NDD$3"[^0"N^HKE.T\$LOV5_
MV:-.\+>//!&G?L__  8L/!_Q1G@N?B/X8L?AGX.L]!\<W%I>/J5G/XJTJVT>
M*SUN6QU*234M/>_AF.G:C))?V'V:[=YC?N/V;/V>KO7_ !/XJNO@=\);KQ/X
MUM=3L?&'B*X^'OA6;7/%-GK6AP>&=8M?$.JR:6U]K$&K>'K:VT35(K^>=-1T
MNW@LKT3P0QHOME% '#7GPQ^'&HWVIZG?^ _!][J6M>*O"GCG5[^Z\.:3<7FJ
M>,_ L6DP>"_%>H7,MJTUYXC\)0Z%HL7AO69W?4-%CTG34T^>W6RMQ'C?#KX'
M_!GX07/B*]^%/PH^'/PVN_%UW%?>*+GP)X+\.>$Y_$%W"]Q+#-J\NA:=8O?F
M&>\O;B%+@O%#<7U[<1(DUY=23>I44 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>chart-25c6349f335257b28b2.jpg
<TEXT>
begin 644 chart-25c6349f335257b28b2.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &0 3T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "OSS^)/[:NK>$OVN;G]F73G_9@\-6VB^!O@_P"/-3U7XY_M*W/PJ^('BO3?
MB;XA^)VFZK;_  G^&MO\+O%:^-YO!^E?#*]O;J:Y\5:);WFI:M9Z;.VEVT$V
MI-^AE?-6M?LO^ O%7Q ^/?C7Q<T_B*Q_:!^$7@'X->*/#=U:64%OIOACP5;?
M%RQNY-'UF!!K-M>>)+'XNZM;7\B7$7V(:98RV#))-=%@#B+;]O\ _96NM&AU
MM/'^O)!?:M\.](T73KCX4_%ZT\2^*I/B_:^*+OX2:GX+\)7?@2#Q/XT\-?%%
M/!GB>W^'WBSPMI&K^&_%FH:-?Z7I&IW&I0/:K4_:2_;7\+_L[^++3P%=_#OX
MD>+/$^L_LV_M%?M%Z)J&F^$O$L'P]@T_]GS1O#>JZAX9\8_$&'0M1T/P7>^(
MF\1V]G%J.JL;70;@Z9;:U%#?^+/"%EK?(>"OV#ET3Q3X!\<^-OCAXZ^)/C#X
M:ZG\'M/\,:SK/AOP3H@_X5O\#=+^*EGX,\'ZG9>'=-L[:^US5M1^+6O:_P".
M?'$8M;O7]2T[1(=+T7PWI=G+I\_J7[2?[+$'[0EYHU_%X_U?P+=6OPF^/?P,
MUXV'A_0O$$&N_#/]H?P]X5TSQE8Q1ZP(Y-$\0Z=K/@'P5KWA_P 16,\OV9=.
MU71K_3=0T_79C: &+X9_;U_9S\0^$+;Q&?$WB*'6);CP!I8\!V7PS^+&J^/]
M:UOXF>$-5\<>#;?P!X%MO :>-?B9H?B7PUX=\5Z[X>\8>!_#FL>%]6T#PAXN
MUR/4XM.\+>()]-[CXC?'?46_9PUKX_\ [/5CX$^*]O9>#[_Q[H]GXM\8>)/A
M]H&L^'=!LK_4_$-O+K&F> /&^OZ+XBLK;2]0L%T/4_"$-U9^(;:?1=?&B7%K
M>&W^:OC/_P $U/AO\9M3M_$7B+Q+'JFNZ!I_P%3P=9^-_AUX%^)7@73=9^!_
M@GXY?#E-1\1> O%=G-I7BVS\7^$?CYXNMM3TZXNM+GT+5K#0M<\-ZMI][:3_
M &CZG\+?L[>%?!W[.#?LW:!<PZ5X:?X>^)_ AU+0_"G@OPDD3>+[#6H=;UNQ
M\)>"]"\-^"=)N+C4M?U'5QIND:'8::+J4B2*5Y)[B8 ^1/A]_P %&['3KWPE
MIO[3GA#PQ\()?&/[._PN_:0M=9^'WB/XC_&3PQX?\&_%?Q9K/A?2CXVU2W^#
M?A.?P5H_AA[#3'\:^/O$UGI7@/0;K7[""?7?LJ37X^BKO]N#]G"WN=:L+7Q9
MXHU_4M#^)/BOX13:1X1^$WQ<\9:UJWQ#\ 77B6V^(?ASPEHWA7P/K&J>-I_A
MV/">L77CV]\(VFM:7X/LO[+NM?OK%=>T-=1\X\2_L#^%O$G@GQ9X)E^(OBJT
MMO%?[&'P\_8TN+^#2M":YM/#GP]O/%=Y:>-X8Y$\F3Q#J1\57$5WILP.CPI;
M1?9T!EFSSGQ<_P"";_PR^*WA_P )6NK:MI>I>)/ GQC_ &C?BSX8U+X@?##P
M%\5?"L:_M.?$'Q%X]\>>&-5^'?C&SFT#4[?3+K6=.'A7Q!!-I_B+2K_PQI.H
M3WE[97OB+1-: /H*P_;'_9RU7Q9X6\'Z/\18M;O/&%KX"N-'U[0_#/C+6? $
M-S\5=+M]<^%^BZ]\3--\.W/P]\+>)OB+H]Y8ZCX(\+^)O$VD^(?$EMJ>BG3=
M-FDU_08]3Z3XL_M+?"#X'ZEI6G?$S7->T"/4X+.]N-=M_A_\0M?\'>&=,U#4
MI-%L=8\=^./#GA;5O!_P_P!'N=73[#'JGC/6]$M PENI)$T^TO;RV^0?#?\
MP2[^!/@WXS^#?BOX;MO",%OX;?X/:M>Z1J?P(^ ^JZX_BGX%>"_"G@7P)JO@
MSQH? 5K>?"72)-)\!^$+K7/"WP]TC1M*M];T&'5? ;^ +F]U7[?U7[7_ /P3
MY\)?M?>)+C6/%WC[4=*TK4OAI#\.KS1+[P+X \?)X;;3-?UKQ-IOC3X4WWCK
M2=5;X4>.M4U#6ET_QWXH\,VKZOXO\.^'O!VFQ7N@7OA72M7C /5(_P!NK]EI
MM0\<:?<?$]=+3X=P_&B3Q/K.N>#_ ![H7A:&X_9V\17OA7XW:5I/B[5O"]IX
M8\3:_P##?6;&2/Q'X=\,ZMJ^N1V<UKJ=GI]WI]S'<5H_!3]J31OC;KG[0EAH
M'@WQ=I^G_ GQ1X4\->7K7A[Q3X9\:^)+GQ)\'?!?Q:EM[OX=>-_#?A+Q/X5U
MFT3QA#H=IHVJP2-JABM-4ANHH-2CAA\@\;?\$^/ GC_PY9>%=<^(/C6#2[3Q
MC^V)XR\_2K70;/5(=3_:Z\?^)_B/=3:==7-E>V]G=_"_Q-XAM;WP9<RV%]#J
M4VB67_"366I6]UJ%I<>T?!K]GG4_AO/\:]>\5_%7Q/\ $'QO\>M;T'Q!XS\4
M1Z/HO@9]+U#P_P##+PW\++-/!NF^&58>'[6'1/#&G:E;F6[U+4+779KV_P#[
M1E6:&&W /F3X+_\ !0V?XO?##Q%\54\+_!73O#VF^&/AQXA!T/\ :,@\:W_P
M_P!;\?\ BW2/"Y^$_P"T+X4T?X96WQ$^$'Q;T-M4+:AHUMX)\9>%DUBPU?0+
MWQ5ICZ4^H7?VQ\-OCU\+?BYJWB30?A_XBEU[5_!MQ?V/C"Q_L/Q!ILOA35M,
M\6^)_!-[H'B$ZKI=C'I7B.'Q!X.\11?V!=/'JLNF6-OXBAM9/#FL:'JVI?'U
MW_P3V7Q;XCUOQA\5OCIXJ^(OC"7X;V/P?\.^+Y/AW\+_  EXG/P^B^)_PJ^*
MFIM\1=9\)Z%I\_Q,\8ZEK/P?\+6=IXAOQH.B^&K.^\53^%?".DZCXGUB[N??
M?@C^S':_!'XB_%/XBZ3\0?%&O7?QRO8?&/Q:T?6;>P.D^)/BU:W#:79_$O3(
MH"'\-W\'PSL_"'P?DT.P,VDW'@3X8?#-)<ZYH&J:OX@ /D?QA_P4Y?PC\!OV
MO/B5/\%8[CXG_LU_$_Q_X%\%_!Y_B.EJ_P 9/#>D7_B63X=_$2V\6GP9,OA'
M0O&'ACP5X_UWQ+;MH'B)_ ]S\-?'^DB[\0_V"M]=?4VK_MR?LU^&M1\1Z1XG
M\>W.AWOA#1_%.H^);VX\&>/9_"ECJG@/X97'QA\>>";/QW:^%Y?!.N?$?P=\
M-K.^\8:]\.-$U^_\;V>B:=J=TV@EM*U6*Q\2\>?\$U/AMX\O?$>JWOQ"\>V&
MH>)O@E^U1\&M2CL1HXTB[;]I#Q7\2?$&A>/;[2);9H[WQ?\  W2OC9\;O"7P
MUF>>.Q;0OBSXR76[>[N;JTEM#QK_ ,$Z=%\;0>.O"U[\9_'=E\+O$^K?&7XA
MZ!\/+3P_X-:V\'_&?XZ?"7QY\)/&OCNS\23Z<^NZOH<=K\3?'OC?1/ &I3?V
M98>//$UW?SZM>^'[#0/#>C@'6:Y_P4;_ &?;36_A+H7A:U^*GC^^^*WQC\(?
M!^&V\,_!WXII?^%Y/'OP^\6?$CP7X^U_2=8\':=JG_"M/%?A[PE?7/AKQOI]
MI=>'M?M(=;U/2]2N-.\'^+Y]%H_!C_@I)^SW\3?A#H'Q)\2ZQ>^ =;U#X?>!
M/'>J>#)O#7Q!UZ69?B!XSTGX8Z+I/PTUJ#P/86_QONG^*NNZ-\,!_P *LM/$
M<_\ PGNL:+X:GM+?4M;TF&\T_%_[#NFZ[\0K;XJZ#\4?$7AOQUH>J_LXZWX4
MO9O#?A[7]&TC4/V??"_QC\"D7VCZ@8/[:M?&_@SXX>-=-U6$W]A<:%J2Z1KN
MAW<5Y8-%/S4/_!/'PQ9^ _A[X'L/B3JTL'PW_9DG_9HTV3Q1\/?AIX[T;7=!
MD^(GPV^()U7Q=X,\;Z!KGA778-1E^&MEX<UO07TVWM[O0M7U*?1]3\/^(;71
MM<TT ^N8/CQ\+V^$FK_''4_$%UX5^&_AW3/$>K>)-8\=^&_%/@'4?#5MX2N[
M^P\11>(O"WC+1-$\6:+J&EWVFW=G+I>H:'#J-Q<)%'8VUV;NR-SX_??MV?LW
M:9'I4.I>(_'EEX@UK7?%?AC3_ ,_P.^.*_%-O$7@KP5H_P 2?$.C7?PI'P[;
MXBZ=?VOP[U[2O'5K#?\ AFW&J^$KM==TI[RP266/F]+_ &&/ <W[)'CG]D;Q
MUXM\4>,O!OQ&C\9MK-\T6GZ;;^')/&'B ^*(=)^'7A*XBUSP]X0\"^#-92T?
MP5X N8M?\-Z786B:/J4.KZ;<WEM/S'P6_P""?7@CX/>(? GB[2=<\.Z;K/A/
M6_BIKVHZ?\-?@U\+_@WX/UZ[^)GP_P#"_P .5\SPSX"TNU\IM TCPM!J-MJ&
MJ:IXAUF]U75-3B?4[3P^FD:#I(!U7Q"_;Y^!WAF7P#I_@?6#\4=6\?\ B[]E
MO1K&3PQIGB^X\'Z;X<_:I^)?@KP7X%\0ZS\1]-\)ZOX&T34]0\+^++CXA^%O
M!_B#6]'UWQCH6E1_8H[.VUC3=1EZ:T_;K_9@OM&\2:_:?$'49M*\/VFCZC97
M1^'GQ,B'Q TSQ#XRT_X=>'=5^#44W@Z.?XX:7XA\?ZOI'@O0-1^$47C.SUGQ
M'K>@:=ITUP?$.A2:CX=X5_X)R:7X+TCX?^$/#GQO\?6/@#PXO[(FL>-_"1\/
M>#+A/B-X[_8WM_A1I/@'Q7=:U/I[ZOX5M_%GAWX.^"M&\>^'/#TZV.H?V'I=
M]H=UH,QUZ/Q'Q'PX_P""3'PA^%'AV^T3P'XDT_PGJ'AD?#Y?@IXP\*_!;X+>
M&O''@-OA5X]\._$;P1=>./%VD>%+;7_C5=PZQX1\.:)XD_X2[4=.T_Q7X6L)
M$U733XRN6\;Q@'VO^S9^T-IW[1WA[XA>)=)\.W_AW3O!'QG^)WPCMH]575K3
M5-2/PWUF#1;C5M3T/7]"\.ZYX7U&ZNI)X;[PSJVG+?Z+=6LUK//<$!Z^C*\#
M_9[^!O\ PHGPWXPTFX\:ZUX_UKQ[\3O'/Q9\3^)-<T[1](GN/$WQ O;74M:M
MK'3-#A@T^PT2SNK<P:'8J)I[+2UMK.[O=1N8)=0N??* "BBB@ HHHH ****
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MTKP?X6TW3K+6H_$=G8:?X=T:RLK7Q!$ (]<MK2UL8K>#6(PH":I%&E^@ "W
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M2;+_ ..4?V=K?_0>_P#*39?_ !R@#H**Y_\ L[6_^@]_Y2;+_P".4?V=K?\
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M_P"KC_W%_P#017XA_P#!2?\ Y22?\$*?^SK?VH/_ %CGX@U^WD?^KC_W%_\
M010 ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ ) Y)P/4T9'J*_/K_@H
MYX\^/?@3X(VMY\ -8UO2-=N=9O&\4S?#R+X<ZG\:T\*6.@:G="Z^%'AKXJW$
M'@S7[^W\2GPY'XMAN(=0UBR\&W6K7?AZPFU86[P_,'C/X[_'*_TS2?VA=/\
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MGZ/XCMOUA1MR*Q&-RJV/3(!Q^% #J*** "BBB@ HHHH **** "BBB@ HHHH
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MCOX@.N1WVNJL/<"OVEC\,>'O+3_B3V ^1>/LZ^@]>:_&#_@I/_RDD_X(4_\
M9UO[4'_K'/Q!K]O(_P#5Q_[B_P#H(H Q?^$8\/?] >P_\!T_PH_X1CP]_P!
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MBKI7;25WMN!^0^M_M*?&+X=?MX:W9_%_XD^(/"?[.!M[G1?"9\->!O OCOX
MWT,5KJWV'3O&WCC1=0?XO?#?XY3:YH7B73[I=?M/^$,N+K1;/PKIFD7<VL:?
M?/X!X'_X*6^)?BWXM_:&M?AY^T#\.=3;QM%^P1_PIOPGHUOX&\2WO[,WA#]I
MC]H7Q-\!?&WB?Q9:6Z+>^)_'OAC0-5^'/CCQEI7BW4-7\*^#/B=XK\/_  _D
MMCX=M;R77/UZC_9G_9PA^.,G[247PO\  ,?QMET;^Q7^(,>G62:P8B94?4]B
MD6/_  D\MC,^C2^+_LO_  E$OA_;X??5CHZBR'7>(?A'\'O%ES\0KKQ1X,\'
M^(I?BOX2\/>!/B.NN6=KJMOXR\(>$Y?$\_ASP]KUI?//:7NFZ-/XS\43V,)@
M5H9M:O9@YE:-XX]M2_Y^0_\  EY>?F@/SOF^)GQ=TG6OCY\-O'_[5GC#P;X!
M_9L^)OA&RN_C+I7PN^&6O?'CXGV'Q4^#G@[Q?X ^#FEZ=9?#[6/ =_\ $G0_
M&7B"_:[T[P=\"]4\9?$?PWJ_PM\.Z'I-AKFH>)-=UKT_Q[\:_P!I/X;?L%_#
M[Q[X\T>31/VD_%S?L^?#?Q&V@^#M+U^]\)>+OCC\6? ?PFD\3-X'DUM/"S>+
MM!M?&L.L2^%I_$,_@&P\>JFCZCKDG@:VNM6KTKQ#^P?^QWXH\/\ @7PUJWPF
MT 6'PV\3>)O&O@V[TOQ3XU\/^(-)\9^,=,AT3Q/XO?Q9X?\ %VE^*]5\5:UH
M=O#H=]XBUO6]2UB315.D+>IIK/:MZ':?LQ?LZ6UE-I\_P_\ #FM6EU\*+;X'
MWT7BG4=7\8?VG\++/7=0\2VWA#5G\6:SK<NK6,6NZK?:F+O4GNM7-S,&.HE8
M;=83VU+_ )^0_P# EY>?F@.!_9 ^('C3Q%#\7_ 7Q,U[XFZA\0/A;\0=+TC5
M=#^+VC_"&+QOX<T;Q/X!\*>+/#T-SXP^!!M/AE\0-)U:+4-0U;1]=TSP[X4U
MS2(;B;PAXFT>[U'P\GB+7?LJO*OA7\*?A1\$_#UQX7^&'AO0O"6DWVJ7.NZJ
M+*XGN]1UW7;N"UM+C7/$6NZM>ZCKWB/69+"PT[31JNNZGJ-^FEZ;IFEQW":?
MIUE;0>IJRNH9&5U895E(92/4$$@CW!JHSA/2,HR>]DTW;36R]5]X#J***H H
MHHH **** "N$^)O_ "(?B;_KP7_TI@KNZX3XF_\ (A^)O^O!?_2F"O)S_P#Y
M$6=?]BG,?_4.L..Z]5^9\1MU/U/\Z2E;J?J?YTE?R*(**** "O=_@-_R'-=_
M[!%O_P"EK5X17N_P&_Y#FN_]@BW_ /2UJ^KX&_Y*S)/^PFK_ .HF(&MI>GZH
M^H:**\I^.'Q4M?@E\)_'7Q4O= UGQ/:^"="FUF;1="C1KVZ1)[>V\V>XE#0:
M7H]BURNH^(=<N8Y;7P_X>M-5UVZAGM].EAD_J41ZM17YH^ OVY?B!XT_9<\)
M?M#S^ OV=O#MAJFLS6?BOQUX@_; \#Z?^S5X0\/Q:7!+;>*;_P",UGX4UG7@
MVK>*+VQ\ VOA2?X<P:]I_BV69=8>TT--/UC5K'B7]L3X_7WP:_9]^-?PL^ ?
MPTOK#X]Z7\.+#1/AS\5?C1XR\"_$RX^(WQ$O+@V?A?PW9^%?@;\0_#6N^&;/
MPY;77CB3QU?:]H$(\#:7K7BV^T+3M)TUGD /TFHK\]?AO^VOJ?C_ /:A\3?
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MFN_]@BW_ /2UJ^KX&_Y*S)/^PFK_ .HF(&MI>GZH^B/[>L?^>&L_^$YXA_\
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M ,^>A_\ @PU'_P"5-'F^)?\ GST/_P &&H__ "IH WJX3XF_\B'XF_Z\%_\
M2F"MWS?$O_/GH?\ X,-1_P#E37%_$6376\%>(1=VNDI;&R'G/;WM]+,J^?#S
M'')IT,;-G P\J#!)SQ@^3G__ "(LZ_[%.8_^H=8:W7JCXZ;J?J?YTE*W4_4_
MSI*_D404444 %>[_  &_Y#FN_P#8(M__ $M:O"*]K^";:@NLZT=/BLY9#I<
ME%[/<0(J?;&P8S;VUT68MPP94 &"&)R*^KX&_P"2LR3_ +":O_J)B!K:7I^J
M/J:Z_P"/:X_ZX3?^BVK\[5Z#Z#^5?>MS+XE^SSYL]# \F7)_M#43@;&R<?V5
MS@=N,],CK7P4.@^@K[GQ>_B9!_AS7\\M$+1117XV 4444 =W\,O^1\\-_P#7
MW<?^D%W7V[7PY\.C<#QMX?-JL#W N9S$ES))%"S?8;K(DDBBFD4;<X*Q/EMH
M( )(^U+%]3;S?[1AL80-GD_8KBYN-V=V_P S[1:6NS'R[=F_=EMVW S^^^$W
M_(BS#_L;UO\ U"P %^BBBOU, HHHH **** "@\@_3_/K_*BH;B>&U@FN;B:*
MW@MXI9IIYY$AAAAB1I)9I992L<<<4:M)))(RHB*S.0H) !^<NI_LH^.YOVD/
M&OQ8O/!/PA^(.D^)_B-X,\5Z3XK\;_%?XRV'Q!\(:%X=TCP[IJ^'M&\,^'?!
M[>!$TSP_<Z5?ZSX6T5[T6\]_JU_)KVI7,VH7-V/T@']3^IK\:K;XU^$M;_:9
M\4SWOQ8\'_%7P]XH^+7@FY^%.L^%/^"D^C> M.T3PW<Z3X/T=?"$/[/?@CQO
MHVA:_'I?B2PU74HK6]MO$FM_$B779[+6HR'M;)_V4!!&1R,GG.>Y[_T[=.U
M'X@_\%)_^4DG_!"G_LZW]J#_ -8Y^(-?H9\;_P#D:=-_[%ZS_P#2S4*_//\
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MM*^&?VI8;[XYR>-O#>F^&?'GA/Q7X-\;_$;P_P"$/#'Q/\/WGQ,O=-M+/5?
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M](T'_A*]7\5^%=(\*;()/^$JU;Q/H.E^%C'<RF"UD'B74-1MM"*74X,-JXU
MK<S Q0&20%1:U37="T/1;KQ)K>N:'HOANQLDU*]\1ZSK.EZ3X=L]-D$;1ZE>
M:_J-W;:-:Z;*LT+1:A<7T=E*DT+QSLLL99\LG:T6[RY%H]9Z+E7>5VERK75:
M:H+/L_Z_X=?>:M>[_ ;_ )#FN_\ 8(M__2UJ^9_"_B[PCXXTO^W/!'BWPIXU
MT3[5/9?VWX,\3Z#XNT7[;;"-KFR_M?PWJ.J:;]LMEFA:YM/M7VBW6:%IHD$L
M9;Z9^ P(US7<@C_B46_7_K]-?5\$)QXNR6+34EB:J::LT_JF(T:>JW0+9^GZ
MQ/IFZ_X]KC_KA-_Z+:OSM7H/H/Y5^B5U_P >UQ_UPF_]%M7YVKT'T'\J^X\7
M?XN0?X<U_P#>8(6BBC(&,D#/3W^E?C8!102!R3@>IHH [OX9?\CYX;_Z^[C_
M -(+NOMVOB+X9?\ (^>&_P#K[N/_ $@NZ^W:_??";_D1YA_V-ZW_ *A9> 44
M45^I@%%%% !1110 4444 %%%% 'X@?\ !2?_ )22?\$*?^SK?VH/_6.?B#7V
M)^T[\4_#/@KQ[I&D:Q!K<EU-X1TZ_1M.TT7D @EU+6(%#2FXAQ+OMW)3:<*5
M;<=V!\X_\%/OV?OVL?'?QL_X)X_M+?LG_"CX>?'#Q)^QU\;OBU\0O$_PN\??
M&2/X'1>)](^(WP1U[X5V2Z9XVN?!/CNUM)--N]=EU.Z631+F61+6WMHH'6[F
MN;*A_P -5_\ !9LA0W_!(K]G%RJA06_X*AZ QP.P+?LE,0/09/7J3DURXS*L
MESBC]2S_  F+QN7N4:LJ&"Q\<NKNK3;=*:Q,L)C$HQ;;E#V/OZ>_&VOGYG1S
M+$85T\JQ^'R[%^T@UB<5@'F-)4TWSP^K1Q>";E-649^W7):_)*]BS=?M#>!(
M;6ZF$/B& PVMS,)[W0V%E T,$DHGOFBU".5;& H);UHI(Y1:I,8I(Y-KK^8'
M[-G[5>N^)[3XZ>"OVBOCM^T#X>\436MY\2?^$C\!6_P6?PSH'A#PII?PTO/&
MGC3]G7XK>!](U!;/X;B]U=[:+P)XY\,WE]%X5\0Z1J>EZI/KMUXSOZ_34_M4
M?\%F""#_ ,$A_P!FX@C!!_X*@^'L$?\ B)->!^#F_P""A/P[T_XJZ7X&_P""
M#7[$OA33?CA/JMQ\6K#1?^"B_@JQL_'JZWHYT'5+'7[>']D)8KC1KO2FN+>3
M0HQ#HR/?ZK=Q6,=YJ^IW%WYBX%\.*<)0P_#V=0C4G3E5E6XCP^)JM4G*484:
MD\@BZ"<VI3<$W4Y(QE>'-%^)0R[C"$:JK\3Y36E.,52G3X8J471DI)N=O[?J
MJ=TG%QDK<LFTU)*2;^RW\<39?!3P[K?Q"\8?&3QQXF^(,NH?$?28_B8^C^)?
M$'@_PKXSA@U?P#\.IM>T32/"BZRWAOPB-&G\0:B=&%[<>*M3\5/:[=*ATJVM
M8OV;_P!H?Q<T_P"T)I7QL\2>)/&^M^$_VAM4\-Z'JFE?#!/ _AO0_#EQ\'_@
MSXL@\'^'=!.I7]_9Z+H>N>)_$1TI_$VO^)/%VI6=RNJZ_K=U<W?D6=GP_P#M
M1?\ !2SXLZ_<6-E_P1=_98U;6?V5/B5?^"-'FU+_ (*2^%8SX \;WWP8TBVO
MY?!5R/V3YC;I<?"/XQ)X8N-0M!:R#3]=UO09(46.5I,?X+Z3_P %!/V=_$>N
M^+?@I_P0G_8_^'/B3Q/8R:=XBUCPW_P4YTRWO=<MI9=+ED_M62X_98NEOKAS
MH>CQM>7"/>FWTRPM?M'V6UAA6Y<"^&D^?FX<SR]>495VN),-'X;M+#-</J6&
M7.TY*+DIP7LYJ3:J0S>6\:WK-<59.E/^"O\ 56I^Y_>1E[S?$/[U>S4J?_+M
M\TE4N^5PE]2#]H'P)D8M/%74?\P(?_)M?I]\'M9M/$'PP\$:U8+<)9ZGX?LK
MNW6[A$%RL4H8J)H0\GER#!RN]L>M?EA_PU3_ ,%F?^D1'[-__BT'P]_]"33Q
M^U=_P6=  '_!(W]G0 = /^"HV@@#V '[)8 'L*Z,%PSP=D=2>(X<RK-<!BJT
M/8UZF/SN&:4YT.:,W"%&.5X%TY^TA"7M/:27+%QY/>O'T,IP?$6&K5)9SGF
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M>$%F\726^N2S?$3X>6UKH=O\0=4N=0\>:=I6C>87WA+_ (*&:C\9=8^/,_\
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M="O_  5#\/J1]"/V201^!K[+_9*^+'[:7Q.?QV/VNOV1?AS^RTFBKX;/@)O
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M<?&CXK3_ !9UR#4OL7D:3K$_P]^'7PZ;3-'^R6UO)_92Z9\-],OU^WO=WO\
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MFG:[X=U;3]<T:_CAFDMI7LM4TJYN["[2*XAE@D:WN)!'-')$Y#HR@ W:***
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M'[]M:\LZ.MEK5]?0:9=MJOFQ_P!FBWNY#?[T-H)@PR ==1110 4444 %%%%
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MJ=Q-/;_:UC,?5>&_#/ASP=H.E>%O".@:+X6\,Z%9Q:=HGAWPYI=CH6A:/I\
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M^=+C'^>O;GUXH **** /SE_;(_9XNOB%\8_V:O%GA>W\3VUK\1/&5[^SE^U
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y/QUXRTCX>^$
MM>\::\EZ^C^';!]1OTTZW6ZO6MXWCC86UN\L"RR;I5PAEC!&3N&.?E(_M\?
M\$@V?C[@X_Y%BU[?]QJO7/VI/^3?OBM_V*EU_P"E-I7X&MU/U/\ .OUC@'@W
M)N(\LQ>+S)8MU:&/EAX?5\0J4?9K#X>JKQ=*=Y<U25W?:RMIK^">*_B-Q'P=
MG>7X#)W@%A\3E<<75^M865>I[9XK$T7RR5:FE'DI1]WE>MW?6Q^_?P>_:$\!
M_&ZXUZU\&P^(8I/#L&G7%^=<TN+3E:/5);R*V^S&.^O/-8-8S^:"(]@V$%MV
M![I7Y:?\$ZO^0Q\5O^P9X-_]+?$E?J77QW&.4X3(^(<=EF!]K]6P\,)*G[::
MJ5+U\'0KSYIJ,4_?J2M[JLK+I<_1/#O/\PXGX1RW.LT=!XW%3Q\:OU>DZ-&V
M'Q^)PU/EIN<W']W2AS>\[RN]+V17DWQ"^/?P-^$FJZ%H7Q4^,OPI^&FM^*([
MB7PSHWQ ^(O@[P9JOB**UN(+6YDT+3_$NM:9=ZNEO=7-M;3O80W"0SW$$,C+
M)+&K>LU^._[<OP-_:<^(GQ\\6^+OV??[)TJ;3?V#?BMX9BF\7?!WPW\3_#/Q
M'\5WGQ%L]6TOX0V6I^+-4LM%\(>)O$=A!<BQU&]TSQ/I:B^M]1UWPYJVE:7+
MIM]\P?;G["K)&P!5T(8!@0RD%2-P(()!!'((R".0<4XLJ_>91UZD#IUZ^F1G
MZU^%_AGP)^T3'XB\-_#'P?J/[7/PVT:VU_P5X!\":OJ=YK^@_"/P'^P7)^RU
MI/AM-4\37^JLWA[3_P!I/P;XX>^O]0N=5<_'2T^.>DZ?)$5^!WG!O'?B%\1/
MV]/C)\"M%^)W@>P^.&B^/_'?PN^,.O> +GX=7'C[Q;X*L?BY\&]'\+_#3P9X
M=M?#'P;\:^"M#:R^-GC3P?\ $'XV>!/'OQ:\:7'P+N_!/C+P]H'B'PAXQUN6
MUL;  _H<LO$&A:E=7]EIVM:3J%YI>H3Z3J=K9:E975SIVJ6MI8W]SIM_!!/)
M+9ZA;V.IZ;>SV=PD=S#::A97,D2PW=N\FO7X,:]^SI\2M=_:BT'XJ^)K']H7
MX;6.O?$+]IOPM#\0/AAJ'Q"TBR\'^)/C;^S'^R7I?@_XC>)?#?A"_CTZ3PAI
MWC#P5\0[6Z\:>+-(N?"7A_7?"6BZ;XGN;*ULM):W_1#]A'QS\4/B]\&U^-/Q
M7DU&RUWXAZE%;Z=X8FU*UOM%T32_AUI=C\,M0UOPU_9DUSH\V@_%#QMX3\9?
M%OP]JMA<7']I^#_''A032[K-(H0#[7HHHH **** "BBB@ KC?%?CG1/!K6*:
MNM\QU!;AK?[';I. +8PB7S-TT6TYG3;C=GYNF.>RKYN^/W^O\+?]<M8_]#TV
MOFN+LUQ62Y!C<QP7L_K.'>%]G[:#J4_WN,P]"?-%2BW>G5E;WE9V>MK,.Q_X
M7=X+_P">>M?^"^+_ .2Z]/TC5+;6M,L=6LQ*+74+:.Z@$Z".812KN42(&<*^
M.H#,!ZFOSY7J/J/YU]S?#W_D2/"__8&LO_18KY'@/B_-^(LPQF%S%X5TJ&"]
MO#V%!TI>T]M1I^\W4G>/+*3M9:N]Q]$_-_A;_,[&BBFN"5X_O(3[@.I8?BH(
M]\U^IB.(T_XG_#?5?&>N?#C2_B!X)U'X@^&+"'5?$G@6P\6>'[SQEX>TRX%L
MUOJ.N>%[?49-=TFPG%Y:&&[U"PM[>075N4D(GBW[]EXC\/:EJ5_HVGZ[HU_K
M&E6FE7^IZ59ZI8W6I:=8ZZEX^B7E_8P3R75G:ZPFGW[Z5<7$4<.HK8WC6;S+
M;3%/PE\._LY?$?Q1X'^!'[.NH?!OXD^'_C=\*?C-^T/XU^.G[0=MI%UX&T3Q
M3X7\?>$OV@M&\0>+O!WQ^TR]T^[\6:S^TMJ'Q*\#AO#_ (:UFY\4>"H[N\UG
MQSI_A;4_AQIT!XC]F7X$_'KX?>$M)\:^#M$_:J\&>(?A]\-?^"4OP]M]!\1G
MQW9ZCXHOO GQ7\3>"?VKM)\6Z;XP-SJGQ/\ #GA7P)XE\66<<6LW>M>#?#7@
MG^P?%?PRFLXHO#WB"$ _HIW+DC<N1U&1D?7GC\:4LH&XL #T)( .>G/3FOY\
M+/3/^"D=]'^T&NM>,_C%I?CB[TKXJZ?>67@KP-\6?L%CJNH?M#>#+;X.Z[\)
M?%/C;Q-J/P8C'A?X1G69](L?@IX-N[3Q+X1N-7D^/,5EXXT^W2Z_1;]JC0O'
M_A?PK\ /#GAR^_:'U7X-:/X[OM-^.^I?!G7/'GB3]H*^\(6OPS\;1^!+J/7_
M  W<W/Q5U73;GXK+X-?QG?\ A&XE\1RH^G-K#KX#_P"$PV@'WSN7(&X9/(&1
MDCKD#Z G\*3<O]Y>N.HZYQCKUSQ]>*_&KPL/VNG^-G@Y=4/[5\?BB#XM_!PZ
M6?%QT?\ X4A)^QZWP2\+?\+37XN-X''_  J*7]H >/C\04U@Z ?^%B)\6U\(
MOX#*_ XREOG;4O\ AJWPYX-\ ?#^'QW^VYXI_:0U+]A/X/?$_P .VVD:_<ZG
M#I7[9_BOQ)KVG0M\<M*VQ:/X9^'$&LZ-'HOB;1/%]E;?!RT\(Z+XO7Q.ESXV
MET2^O@#^A_<N2-PR.HR,CIU';J/S%)O3(&Y<G&!N&3G.,#/.<''K@U^&?Q.3
M]MZ:[^.W_"$7'[5EG\9TLOVX8O$4]O"9O@#'\*7^'WQ,_P"&-+C]G*UD23PW
M=?%V'Q&?@+-9)X623Q[)KB?&6#XQ@Z>_AZ,[7Q>T#]K'PW^TEX"\*?"VX_:<
MN?!_@SXE_LR^'+SQ!K>N_%GXAZ#\4/@GXY\8Z#:?M'>-]0\3Z/XJ\'?!WP5?
M^&=*\5>+;"]L/&^@?$/XNZ3/X:@\4?"W3_ /@JS\+7&D@'[717%O/&DL,\,T
M4F=DD4L<D;X8J=KHS*V&!4[2<,"#R,5-7\Q'@/X7?MV_"KX>?![X1?#&^_:)
M^'?A_P"'G@+QIX3TV?Q%X:_:,^*FI0?M4VWQ@UZXU'6-2O-*\=Z%I'C#X0_\
M(#<_#W4/AQ<_$W7KG]EWQ%87GQ+M[O4=+\60L+;^G.$2B*,3,CS!%\UHT:.-
MI,#>8T9G9(R^2BL[LJ;59F(+$ DHHHH **** "BBB@ HHHH Y/QUX-TCXA>$
MM>\%Z\]ZFC^(K!].OWTZX6UO5MY'CD8VUP\4ZQ2;HEPYBD &1M.>/E(_L#_
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M'RU(1DO.*?0#Q_\ X4CX+_YZ:U_X,(O_ )$KT_2-+MM%TRQTFS,IM=/MH[6
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&BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>chart-48bec865e66533dbc2f.jpg
<TEXT>
begin 644 chart-48bec865e66533dbc2f.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &J 3T# 2(  A$! Q$!_\0
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MHB66DZ?K_P CM_P47NM6\$:A\:O"/P7O+OX&?#;X<? /XD_'W7_%/C-/#?Q
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M\ED/S5X<_8P^*WAS]GSX'?LH0?&&#4_ WP/^#?PGDT+XM>)/#LNO_$H_M)?
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MK2-9=E*2]IQ!AW_,J& S&;W5E'V^'PR;UU<G!+6SE;5/,,TE_#R*O':SKX[
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MH?@OX?\ QD^)?[0GA_\ 9\/[=7[;W@CXG_$7XTZ[\4O@3XE\4^(='AU?Q?\
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MZ%O5/_ O0O\ Y;T?VIJ7_0MZI_X%Z%_\MZW** ,/^U-2_P"A;U3_ ,"]"_\
MEO1_:FI?]"WJG_@7H7_RWK<HH P_[4U+_H6]4_\  O0O_EO1_:FI?]"WJG_@
M7H7_ ,MZW** ,/\ M34O^A;U3_P+T+_Y;T?VIJ7_ $+>J?\ @7H7_P MZW**
M ,/^U-2_Z%O5/_ O0O\ Y;T?VIJ7_0MZI_X%Z%_\MZW** ,/^U-2_P"A;U3_
M ,"]"_\ EO1_:FI?]"WJG_@7H7_RWK<HH P_[4U+_H6]4_\  O0O_EO1_:FI
M?]"WJG_@7H7_ ,MZW** ,/\ M34O^A;U3_P+T+_Y;T?VIJ7_ $+>J?\ @7H7
M_P MZW** ,/^U-2_Z%O5/_ O0O\ Y;T?VIJ7_0MZI_X%Z%_\MZW** ,/^U-2
M_P"A;U3_ ,"]"_\ EO5ZRNKFY\S[1IMUI^S9L^TS6$OF[MV[9]BO+K;LP-WF
M;,[QLW8;%ZB@ HHHH **** "BBB@ K)U]2VB:PJVS7C'2]1"VJ6C7[W)-E.!
M;I9+>:>UVTY/E+:K?6;7!<0B[MB_GQZU(W*L/8]\=O7M]: /PM\,? W4?"/Q
M3\ 03_ ;PHBV/B;X<ZH-?TO]C3Q+X?MK-;N;P]K+RVNMZO\ \%$-7N-'N_#S
MW3V&H:E)X/\ $D.AZUI=]Y>C^)8K!;?4/W2']3_,^Y_^OUP.E?CE+H_A"T_:
M^^,%WXD\+?!+3]>U7X^> M1TJ^^(?[''QM^/GC_6H(_!?PTT[3O$'AO]HJVU
M#0O!?@N"2ZTY],\-^&;*PUK2/@_?:*VL:AJ]['K3Z5I7[&C^I[8[G_)/<\T
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M_P#*Q!^SA_VB;_:2_P#6I/A#7[B5_/[J.G_%&S_X.#_V>H_'GBSP#XAU=_\
M@E'^TB]E=^$?AYXB\':;;V@_:?\ A(K6]UIVL_$[QU=7MRUQY4RW<6J6$20B
M2W-D[LMTO[S^3XC_ .@EHG_@DO\ _P":"@#;HK$\GQ'_ -!+1/\ P27_ /\
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MUL ^_J*9')',B2Q.LD<BAXY$8,CHP!5T9259'4AD92592&4D$&GT ?AWX_\
M^5B#]G#_ +1-_M)?^M2?"&OW$K\._'__ "L0?LX?]HF_VDO_ %J3X0U^XE !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5\_?M1_!G4OV@?@=XS^$NFZ[I^B?\)6WA]-
M4M==TV[U?PEXQ\.:5XFT?6O$_P ,_'>FZ9J&CZS>_#_XH>'].U+P!XYMM&U?
M3M2G\+^(M4BBDNHGFTZ]^@:* /R.^%/[ 'Q)^"4^E_$OX37?P(^&WCKPM\4O
M%WC;P3\"/!_A[QGIO[,WA;PG\2_AUI'@CXJ>"]$$4L/BG0;[Q]XF\.^&OBUJ
M.O>'?#.E^'K/QCH"6UK\/C)XB\7^)-<DB_X)Y_%'PMX1^*?@;P1\5_ TFG_M
M9?#S5_!7[5OB'Q!X,\01:NOB3QAXN^+WB?X@_$SX-Z3IWB.YTG3]1\2:3\;O
M%W@O2O"'C"YNM,\.6VA> ?$TNO:]?:+XCT;Q=^MM% %#2M,LM%TS3]'TV!;7
M3M*L;33;"V1G9+>RL;>.TM(%:5WD98;:&*(,[L[!-S$L2:P_&7@W2/'6C'0M
M:O/%-C9-=6UX9_!_CCQI\/M8\ZT9FB0>(? >O^&]>6U<L1<V*ZD+*\4*EW;S
MHBJ.KHH _G^U'X<>'_!7_!P?^SUI>CZCX\O+:\_X)2?M(W4TOBSXH_$SQYJ"
M2K^T]\)( EKJWCCQ;XAU2QMMDC,UE8WEO9O.$N7@:Y1)1^\_]@V7_/QK7_A1
M:_\ _+.OQ5\?_P#*Q!^SA_VB;_:2_P#6I/A#7[B4 8O]@V7_ #\:U_X46O\
M_P LZ/[!LO\ GXUK_P *+7__ )9UM44 8O\ 8-E_S\:U_P"%%K__ ,LZ/[!L
MO^?C6O\ PHM?_P#EG6U10!B_V#9?\_&M?^%%K_\ \LZ/[!LO^?C6O_"BU_\
M^6=;5% &+_8-E_S\:U_X46O_ /RSH_L&R_Y^-:_\*+7_ /Y9UM44 8O]@V7_
M #\:U_X46O\ _P LZ/[!LO\ GXUK_P *+7__ )9UM44 8O\ 8-E_S\:U_P"%
M%K__ ,LZ/[!LO^?C6O\ PHM?_P#EG6U10!B_V#9?\_&M?^%%K_\ \LZ/[!LO
M^?C6O_"BU_\ ^6=;5% &+_8-E_S\:U_X46O_ /RSH_L&R_Y^-:_\*+7_ /Y9
MUM44 8O]@V7_ #\:U_X46O\ _P LZ/[!LO\ GXUK_P *+7__ )9UM44 8O\
M8-E_S\:U_P"%%K__ ,LZ/[!LO^?C6O\ PHM?_P#EG6U10!B_V#9?\_&M?^%%
MK_\ \LZNV=A!8^9Y,E[)YNW=]LU'4-0QLW8\O[=<W'E9W'=Y6S?A=^[:N+M%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?AWX_P#^5B#]G#_M
M$W^TE_ZU)\(:_<2OP[\?_P#*Q!^SA_VB;_:2_P#6I/A#7[B4 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5\!_M#_M*_&/P?XR^,V@_!CP[\.-3L_V9?V?_#W[
M0WQ0M_B ?$YU'XA6OBK4/B=+HGPN\!7N@W^EVO@C6IO#7P9\;:K=?$+Q!8>.
MM'M=5U+PGH2^#9X;C7-6TK[\KY>^-G[)GP[^.?B"[\0Z_KWQ#\+W'B7P(/A/
M\3;+P%XL/ANP^+OPC&K:EK:?#3X@1OINI7,WAZ"_UWQ+]BU3PI=^$_&FG6'B
MSQ=HVG>*[71?%&MZ?> 'OG@SQ9I'CSPCX7\;Z \\FA>,/#NA^*=&DNH&M;E]
M)\1:5::SIKW%LY9K>=K&^@::!F)BE+QDDKFF^+?&W@[P#I!U_P <^*_#7@W0
MUNK>R;6?%>O:3X<TH7EXS):6AU'6;RQLA<W3(RV\!G\V=E81(Y4@=!:VMK8V
MUO965O!:6=I!%;6MI:PQV]M;6T$:Q06]O!$J10P01(D4,,:+'%&BHBJJ@!EY
M8V>H0_9[^TMKV#>K^1=V\-S#O3.Q_*G21-RDDJVW<O8B@#^8?]K3]OC]D']F
M[_@N'^SE\>OBU\<_"NF?"*/_ ()H_'CX<3^-_"%KX@^+&EVGC?Q'^TA\.]:T
M3P[?0_"/1O'6H6%YJ.E^'=9O8)+RR@M1%9,)+A));>.;[9_XB'_^"/7_ $=_
M%_X87]J#_P"<E7[-66EZ;IHD73["RL!*09!96MO:"0J,*9!;QQAR!P"V2!P,
M5>P/?\S_ (T ?BO_ ,1#_P#P1Z_Z._B_\,+^U!_\Y*C_ (B'_P#@CU_T=_%_
MX87]J#_YR5?M1@>_YG_&C ]_S/\ C0!^*_\ Q$/_ /!'K_H[^+_PPO[4'_SD
MJ/\ B(?_ ."//_1W\7_AA?VH/_G)5^U&![_F?\:9(FZ-U&<LC ?,>I4@=_6@
M#\5T_P"#B/\ X(ZR;_+_ &Q+67RY'AE\KX%?M.R>5-'CS()=GP4;RIXMR^;#
M)MECW+O1=PR__B(?_P""/7_1W\7_ (87]J#_ .<E7Z"_LQ_"_P 8?#.;]H5_
M%UE;V2_$']I[XM?$WPP;?4;6_P#M?A'Q8GAA=$O9Q:2R?8KB<Z9=^9I]SLNK
M;8OG1KYBY^H\#W_,_P"- 'XK_P#$0_\ \$>O^COXO_#"_M0?_.2H_P"(A_\
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M'_\ @CU_T=_%_P"&%_:@_P#G)5^U&![_ )G_ !HP/?\ ,_XT ?BO_P 1#_\
MP1Z_Z._B_P##"_M0?_.2K[2_9 _X*)_L=?MZ/X_C_90^,*?%9_A</#)\=!?
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M:SA /K*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.I-;OJLEYK=O9QWKW&LM9V+:W<K(ESK9T_3SJTUZ;"T\GUVB@ HHHH ****
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M%FC2XACF1)XG@G19HUD5989562&50P$D4BJ\;AD=0RD5^,OQ_P#'/BO]GO\
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M!NT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'7TWXH_L[_&WX\>&;E)IM%LO&%YXKT)O@KJVA:IX/@BBG\1^']9\+^/-,O\
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M^><8>TJ2ORTX<S7-.5G:$;R=G9:&W1114EA112;EYY''!Y'!." ?3((//J*
M%HHH) QD@9.!GN?0>IX- !1110 4444 %%%% !129&<9&>F,C.< XQ]"#]"#
M2T %%%)D8)R,#.3G@8ZY],=_2@!:*** "B@D $DX Y)/0#U--#HPRK*PSC(8
M$9],@]?:@!U%%% !111D'(!&1U'IWY]..: "BBB@ HHHH **** "BBB@ HHH
MH **** $8[59L$[03A068X&<*HY)/8#DG@5X,?V@=$!(_P"%>?&\X)&1\'_&
M>#@XR#]@Y'H>XYKWJBNO"U<'2Y_K6$J8KFY>3DQ/U?DM?FO^XK<_->/\O+RO
M?FTX,=0S"M[+ZCCJ."Y>?VOM<%]<]I=PY.7_ &G#^SY%&=_CYN=?#RZ_'GQ8
M_:LB\&^"-4UG0?AY\28]8W06&FW/C'P!XC\,>&K*]OF:*WN]4U+4K>WB>.)@
M3#IT,BW.HW'E6L;PH\MQ#^0Z?$;QQ'XX_P"%D+XEU,>.!J9U8^(C*#>->$>6
MR/&5^SM8-;_Z"=*,7]G?V=_Q+Q;"T C']%&M:+I/B/2=0T+7=/M=5T?5;6:R
MU'3KV%9[6\M9U*2PS1."&5@<@C#HP62-DD56'YQR_P#!/F!OB(+F/Q?$GPN-
M\+MM*VWI\8)9;3*=#34#$; Q^=BT367D-\EB?,:VDOU^T/\ JG W$O"65X7,
MJ.-P:R^M5IRE.M7<LP^O850C&6"5J$5%N2D_8.FJ6(YKU)MPBE^$>*'!?B!G
M>-R2OEN8O-<+0JTXT\/A5'*O[+QW/>.9S3Q,^>*CRI8J-65?"^S:ITTJLI2]
MN^%/[5UKXT\%:9K.L_#WXD2:RK3:?JTW@WP#XC\4>&Y]0LMB3SZ9JFFV]Q$L
M<VY9)-/GD:[TV5GM)FF6..YG]&/[06A@$_\ "N_C?QZ?![QIG_T@KV70M"T?
MPQH^G>'_  _IUKI.BZ1:Q66G:;91"&UM+:%<)'$@R>>7DD<M+-*SS3/)+([M
MK5^?8O&Y%5Q6(J8;)<11P\ZU2=&E_:?\.E*=X0L\).UHV7+SSY;M<\OB?ZY@
M,LXIH8'!T<9Q'A,1BJ6&H4\17_L9/VM:%.G&I4NL=24N:<9/F]G3Y[\SA!R<
M5&D@DB24*Z!XUD"R(4D7<H8*Z, 4=<X92,JP*GD&OP[_ &J/VA/C[\$?$/[8
M?B.#XFZ_:_#'QI\3OAQ\%_A;?7)TU+?X$?&NP\"?LWZQX<T'P]=QV8N;?PO^
MT)I7C_QG97']N'4H].^*V@:1IFESPO\ $ZTL+/\ <BN#\2?"WX:>,=%\2>'/
M%GP^\%^)O#_C'7-(\3>+=$U_PQHNL:3XF\1>'Y/#LVA:]KVG:A97%IJVLZ+-
MX0\*2Z3J=]%/>Z=+X:T&6TFADTBP:#P7N[:+HM['U2VUU?5[7/Q=^*__  4=
M_::\1_"C]JC6_@W\*9/A[<>$? ?[4FK_  @^)'COP!X[DT'PQJ/[,?Q-E\ Z
MA>^+KW7;"P\&^/+KXAV6E^(]4T#2_ <VHP_#?6K71M \?1Z[;7]WJ=G^E_QG
M\?>*_ -A^S4->F$OB7Q)\5+3P_XM?P?J^J>'O#5WJFG? OXR^,]53[!=QZIJ
M.L^$;G6/!RBU\/:I?17+*VF7]SJCWNEJEUZA9_L^_ G3_$?CSQA8_!GX5VGB
MOXI:;J>C?$KQ';_#_P *1:WX_P!(UI436M+\9:FNDB[\2Z=K*1Q+K%EJ\MW;
M:L(HCJ4=TT497I-/^%_PXTKPYX-\(:;X$\)67A;X=QV</@/P]!X?TQ-'\&QZ
M?H6H^&+%/#&GBV^S:(+3PYJ^JZ#;?V?' 8='U*^TU,6EW/$X!^6?@S_@H+\=
M]=T+X5Z-KWPQ^$FA_$C]HOX=_L>?$'X2S0>,/%U]X"\&VO[4UG\1OMNF?%"]
MN-)L-7U+4O!D_P +-8ET6+PHUC;^.M7\3>&_!4=WX=N(Y?%>H]LO[=OQ4/B,
M+_P@OP;O?#7PV\7_ ++/PU^-*>'?BAK'B36?$?B_]J7Q_IWP\TC6/@-=67AN
M#3?$OA'P?J.LZ9<;_$=K;:CXTUJP\?\ @+3WT#7_ (>W-[K_ -ZZM\ ?@=KW
MA^;PGK7P>^&6K>&+CP5X7^&T_A[4? WAJ]T:7X?>"-0?5O!G@EM-N=-DM/\
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M/@G_ &.?#W_"H_AK_8)\#R?#(Z+_ ,(3X<_LK_A74M]_:<O@3^S_ .SOLO\
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#!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>chart-54b677add07d50a682a.jpg
<TEXT>
begin 644 chart-54b677add07d50a682a.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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MMK"81EY*YKXN?\$XOAA\5/#_ (2MM3U'1K_Q+X%^,G[1?Q;\,:I\0/A;\/\
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M_P -/C[\+OB]K'B;0/ 'B"?7-7\%7%_8>,;(Z'KVFR>%=7TWQAXJ\#W?A_Q
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'S!\:?VM/AE\"/C/\
MLK_ KQG8>+[OQE^U]\0/''PW^%UUX?TK3+[0-.U[X?\ PVUKXI:W<>,[Z]UO
M3+S2=+E\/:%=6NG3Z5IVO75QJ\UM;365K:-/?P?3P(8!AT(!'T(S7X@_\%)_
M^4DG_!"G_LZW]J#_ -8Y^(-?MY'_ *N/_<7_ -!% #Z*** "BBB@ HHHH **
M** "BBB@ HHHH ***JWM]9Z;:SWU_<PVEG;)OGN9W$<,2%@H9W;A1N91D]R!
M4SG"G"52I*,(0C*<YSDHPA"*<I2E*32C&*3<I-I))MNR M45Q_\ PL#P3_T-
M.B_^!T/_ ,51_P + \$_]#3HO_@=#_\ %5YW]M9/_P!#7+?_  NPW_RWS_/L
MQV?9_P!?\.OO.PHKC_\ A8'@G_H:=%_\#H?_ (JC_A8'@G_H:=%_\#H?_BJ/
M[:R?_H:Y;_X78;_Y;Y_GV86?9_U_PZ^\["BN/_X6!X)_Z&G1?_ Z'_XJM32O
M$OA_7)98-'UBPU*:"-99H[2X29XHV;8KNJ$E5+#:">,\5I2S3+*]2-*AF.!K
M59MJ%*EBZ%2I-I<S481J.4FDFVDF[)OH[*S[?U_37WFY144[LD$SJ<,D4CJ<
M9PRHQ!P>O(Z5^?,7[6NGS?$>?X/1_%KP!)\6+3PY;>+KGX;)JGA1O',/AJ[G
MFM[?67\,"3^UOLDCV\LNT6IN([+RM3E@33+FVO)O)X@XIP'#CPRQN'Q]=XJ&
M(J1^I4:594X85T%5G6]I7H\D4\332DN97NI./N\P?H717PQHO[0NM>))->B\
M.^-_#FOR^%?$FI>#?$\>BG0-4;P[XOT:&QN-9\*ZX+$3_P!E>(](AU/3I-5T
M2]\G4M-^VVR7UM!)*J4Q_P!HG5X_$5YX0D\=>&4\6Z?X7@\<7_A=W\/KXBL/
M!=SJ-UI%KXOOM%(_M&S\,76JV%]IMIKMS;Q:9=7UC>VUM<RRV=RL7S7_ !%/
MAZ[7U/.KI<S7U3"W4=/>:^O72U6KTU7=#^:_'_+^K/RO]U45^5^@?\%$_@UX
MJ\*^,O'/AK]ISX,:]X+^'>G:5J_CSQ9I?B+PQ=>'?!^E:[=FPT34=?U=8Q96
M-GK-]BSTN=I774+IHX+3S9)8E?TOX??M76_Q9\-_\)C\+_BAX/\ B!X3_M#4
M-*_X27PH='U71?[3TKRO[4L#?Q6ZPBYT[SHOML9(%OYBF1ADXTGXFY)24I5,
MNS^G&,E"3J8'#P49N*DH2<L:E&;C*,E%VDXM-*SN%O-?U;MZ_@S]!:*^&O@3
M^U1X9^.'BQM*\ ?&#X<_$VRT74UTWQ5%X#\0>$_$K:-<7-EJ%Q8Q:E)X?N;J
M2Q2^-A<2:==L19:FEG=_V?=72VMSY7W+7U619_A.(,/7Q&$H8S#QP^(>&J4\
M;2IT:RJ*C1KW4(5JUH.%>#3DXMN_N\MFT%%%%>X 4444 %%%% !1110 4444
M ?B!_P %)_\ E))_P0I_[.M_:@_]8Y^(-?MY'_JX_P#<7_T$5^(?_!2?_E))
M_P $*?\ LZW]J#_UCGX@U^WD?^KC_P!Q?_010 ^BBB@ HHHH **** "BBB@
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M6SXYK_[5_P ;K:P_X1W1/#?PPU'QII'[1?Q!^!6K>.?"GP\_:#^-'PT\7Q^
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M_P I)/\ @A3_ -G6_M0?^L<_$&OV\C_U<?\ N+_Z"*_$/_@I/_RDD_X(4_\
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M_D?/#?\ U]W'_I!=U]NU^^^$W_(CS#_L;UO_ %"R\ HHHK]3 **** "BBB@
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M KW?X#?\AS7?^P1;_P#I:U>$5[O\!O\ D.:[_P!@BW_]+6KZO@;_ )*S)/\
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M'S?7U#\>O^0%H7_89?\ ](+FOEZO&\2/^2LQW_7C _\ J)2$%%%%?" %%%%
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M"Q8+^V?X(8HVQPGPZ^/K&-PJL4D"_"$F-PK*VQPK[&1]NUU)=_P_#_X)1_\
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MS/!?_AN/C_\ _.@H_L#/O^A)G'_ALQO_ ,H\_P ^S _H$^!'_(L:K_V'IO\
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M3O+7T'_?*_\ Q-/_ ,_Y_(TF1C.1@]#G@YZ<^] #=B^@_P"^5_\ B:<!C_\
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M>*?4$-SI-E=^)M7\/>(8=6@V:C''X:BLV.R^N4;YYU+_ ()__LN>+K3P)/\
M$_X7>%?B9XP\ ?##P_\ ![2O'^K^'=!\'^(I?A]X9OKK5-'\+#3_ (5:=X \
M(Z/X;LM4O;C4K/PMX:\-:+X8L+YQ/I^CVK1Q>7]F16\,$$=M%&$@BB2".,$E
M5BC01H@)).%10HR2<#DD\T ?EA%\0?VNM-^%G[=^GR^.E^(?Q<^&?Q_^'&@^
M%+_P+X!\+Z$?!WPZ\7?"+]F+QOX^T/X/>#O%VHWEAXG\4^$/#_CSXB:M\-++
MXC^(/%&I>-/B$=*L]8-Y8ZE8^%+7U3]BCXM>-_&?C+]I+X;ZYJWQ5\7>"/A-
MXM^&</PW\;?''PK9>"_BUJ&E>/\ X7Z5XQUGP]XS\/6WA;P/J6GW'A_591?Z
M-#XS\%^%_':^'/$VD?V_IUS9G1-9U7TCP9^P=^R!\/[CQS<^%?V?_AWIS?$W
M0-1\,?$2&;2[G5K+QOH6JOI+7^G>*M.UR^U/3M=BN!H.BP^9J-K/<16VDZ;:
MP316]E;Q1^\?#/X4_#CX-^&4\'?"[P7X=\"^&EOKS5)-*\.:;#I\%WJVHF-M
M1UC49$#7.J:QJ#11&^U;4Y[O4KSR81<W4JPQ! #T&BBB@#\[_P!K3QI^T?\
M#;XN_";3/A/X@CNO"?[50?\ 9EL(M1MM"EC^ GQAM]+\9?$[1_C_ *7#?""[
M\1Z9-\*/#GQ3TOQ%X2N9]4M[WQWX/^"J6&DV6CZQX^U.OC3X[W/QS^%6O?\
M!1O6?#'[67[2%S#\"_V9?AEX]^%NAZYK?PVU+1?#GBGXTV/QNT[7-5%JOPN@
MNM0F\-/X/T'4?!=OJ5]J%GH^HVAEN;;4X)IK67]N==\(^&/$]YX6U#Q#H.EZ
MS?>"/$0\7>$;O4;.*ZG\.>)QH6N^&!KNCR2 M8ZH/#WB;Q!HPNX2LO\ 9VLZ
MC:Y\NZD!Y#Q9\$_A+X[LOB5IWC#X>^%/$5E\8O".G> OBC;ZKI%O<IX[\':1
M;Z[:Z7X<\2E@'U+2M.M_$WB".QM96"VHU>_,)1IV- 'S!\%-:^(?P\_:B\?_
M +-6K?$_QQ\:/!.G? 7P#\8=*\2?$D>%KWQ[X!U[7OB)X_\  =SX;UGQ#X1\
M*>$K?6O#WC:P\+IXE\(IK^ER:[IU]X:\:QP:WK&AW.GV/AS-^/&E_$GX?>"/
M[9\;_M7?%#P[IC?$#XP:GH6A?!3X<^!-4^-/Q%U7QOXJ?6?@'\&_A_::_P"%
M_&D6M'X=>&4U32+O0K'PA<ZAXZDLM.\1^,O%'A[P-X:\91ZU]3?"+X#?!WX#
M:3J>C?"#X=^%_ -EKE]%J>O-H&G+#?Z_J-O;+96M]K^KW#W.L:Y=6=BD=A8S
MZM?WCV-A''969@M8TA'-_&O]EC]GW]HK4O!^L_&KX5>%OB%K/@"#Q+:^"M7U
MR"]&J^%[7QC%IEOXKMM#U+3[VQO=/@\1V^C:7;:W#!.L>I6UC;6]TLD$8C(!
M^8'BWX[_ +6FC?#WXY_$CQ[\3F\ _&#]BSX._LNZQKGP4\,:3X)N? 'QH^)G
MC3X:>&O'?Q5M/%?VO1-;UC5M&^)_C/4]>^!WPO\ ^$!\6^'K;PQXA\+W^K:)
M=ZEJDADK]OE.1VZL.,]F('7N ,'MG..*\'D_9?\ V>Y]4^&.N77P?\!7VM_!
MK2-$T'X9:SJ7A^TU/5O"&D>&95N?#5AIFI:@+J]>#PW?J-5\/"_GO7T/62^M
M:4]GJ\DE\WO- !7QC^W'\1/B7\"?A"/VD_AW<:AK.G?L\ZG/\2?BI\)[3^PX
ME^,?P>M]'U+2/'WA2PU'6GLX]&\9>'M/U*'XB?#[4%U?2;*\\6>#K+PSK]TO
MA_Q'J3P_9U<YXO\ "'ACQ_X7U_P5XUT'2_%'A+Q3I-[H7B/P[K=G%?Z1K6CZ
ME"UM?Z;J5E.&BNK*[@=HKB"0%)(V*L,&@#\K?%/@7]HBS_:/_8J\+^._VJ?C
M7H^J?%K3/C-X@^-'@[X::OX%TGX:2>(?A[I.@_$'2O#7A6UU3X<ZIX@M/".D
MWWB6[\$27!UJ#5_$WA/1],N]3N+?6+B\N7Y7]F+XH?'#2=(_8A^)?B3X\^/_
M (JW/[77Q4^*'@KXB_##Q]!X$O-(T?3(/!?QU^(>F^,/A8WA[P?X9\2^%K3X
M;W'PLT#0-0TZZU/Q#X>O_"OBFX36(5\1+H6NK^O.I^#/"FL^)?#'C'5?#VDZ
MAXI\%IKL?A/7[NRBFU7P\GB>SMM/\0+I-XP,MDNLV5G:VNHB(C[3!;Q1R95
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D4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>chart-95f4f71dfede5b0db43.jpg
<TEXT>
begin 644 chart-95f4f71dfede5b0db43.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %N 3T# 2(  A$! Q$!_\0
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M>^.?#WAC5/"'@+2+G6I8["/4/%^MZ/!DRW;E-.M+V]MOD3PY_P $O_@-X/\
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MK?Q)X>^%/A#1_'7A[0Y_L6I'0](OM&NM"E37XO$W%?#S_@DY\'_A7X<U+0_
M6OZ7X/U+0%^'H^#?C3PE\$?@;X8\>^!9OA5\0-$^)?@:_P#''C'2/!5OX@^-
M=_:ZYX;T+1O$!\::A::;XJ\*Z<J:QI<GC2>;QTP!]I?LV_M"6'[1F@?$7Q'I
M?AV^\.Z?X&^-7Q0^$5K'JB:Q9ZGJ8^&NMQ:)-K&IZ'XAT'PYKOAC4+VY>9+S
MPSJVFK?Z-<6\EM<33/EA]%UX)^SY\#4^!/AOQ?I$OC'6?'>L^//B=XZ^+7BC
MQ'K>GZ1I5Q=>*?B%J%OJNN16>FZ)#!I]AH]M>0M%H]E&DDUGIPM[6ZN[^Y@E
MO[GWN@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$XKIZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.F:1INMZ!KWGGQBUF?6_VG/#WA_X._M#?$#Q!\:7^*/P&\4:WX2TOXF6^F?
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MOIPU&\1[6Q-S]KN%:&%P>J,HRBI1:E&24HRBTXRBU=--:--:IK1K5"-ZBOR
M_9P_;/\ VCOBK\)OVFKF6+X0^(_CY\+]6UR31/A?XF\'_%?X :C\-;)-9\4Z
M?<?\++T'Q?!XFUGQKX-\''0KBVT[QO\ #R8_\+!U?1-:\*M_PC6H(/$,/V'9
M_M):CH7["5G^UOXNT6RUC6-*_91L/VA?$GAS03/HVGZIJL'P?MOB/JFB:0]U
M+KD^C6-]?M+86,U[/JC:7:3137<]Z+>265@?7E%?F</VMOBI\"_'.M?"W]HZ
M;X:^/?&GB3X6?#CXA?"!OA7I5_\ #O3_ !'X_P#B%\1KCX4GX%3GQAXW\:P3
M36WB^^\+WWASXC/J&FIJ7@J?QGX@USPMIMI\/M6U.^^;9/\ @H=\;[;X%?LR
M^*M>U3P+#XF^)$?[57_"U/&GP8_9X^+_ .U"-/U3]G+Q_J'AC1X/!_[/7PM\
M=)\3H/ 'C&STS4#K?Q7U76M4\.^#M7@\+^&M?70=3^)OA_4]( /W#HKX)^(7
MQX^-^M_L?_![XN_"#2-$NOB5\5K;X$7>IS^ ?"&I_M'^&_"VG?$.;0[GQGJ_
MAK1O"/BCPQ;^--(TNUNKRPTSQ%<^,]&\):6ES!XF\0>(!H.FWES+[#^RE\4-
M5^*/PHCO?%?B>7Q)\1/"OBGQ3X(^)<-[\+[CX-ZOX9\::%J/GW7A76?A[/XS
M^(<6D7VDZ-J6AR1:CIGC;Q-H/BK3+S3O%OA[5[K0]<L'H ^E:*** "BBB@ H
MHHH *0]#SC@\\<>_/''6EI#T/&[@\>O'3GCGI0!_-]\97M[G]M7XD?$W2?'4
M2QV/C?3_  =JUE=^ _B?I/[1<_BKPI\>?V/]5T'X'?![7M5T6P^ /Q%OAK'@
M#1(/ASIUK\7O#,7A7P)^U#XF\8^//"]_8V/C*;7OZ!OA?\1?#/Q<^'G@SXF^
M#I[BX\,>.?#NE^)=&:\A6VOHK/5+9+A;/4+59)EM-1L)&DL-1M!+*+:^MKB
M22",.WX(_M1Z58:[^V)J4/B'X3:/X5T'4?CEX-T?PU>VFM?M.0_$CQE\3K#7
M_P!E^QN/&OPKTWP+\;O 7P<TKXD:EX/\8:)\3=)U6V\%ZS>ZIX>^ >KZAXXE
MU^+P3XB3PS^_'P[\!>%OA=X%\)?#GP3IQTKPEX(\/Z7X8\/6#W-U?3P:5H]I
M'96GVO4;Z:XO]3OI8XO/O]4U"YN=0U.]EN+^^N)[NXFE< _'+_@I/_RDD_X(
M4_\ 9UO[4'_K'/Q!K]O(_P#5Q_[B_P#H(K\/_P#@I9*D/_!2'_@A5))NV_\
M#5_[3B?*CR,6D_8]\?QH D:NYR[J.%(&<L0H)'[0Q^)M(\M/W\_W%_YA^I^@
M_P"G*@#HJ*P/^$FTC_GO/_X+M3_^0J/^$FTC_GO/_P""[4__ )"H WZ*P/\
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MCZ#K,WA?Q?IMO<ZCX/\ %=M83^&?%EC:W=WX=U;4X+2Y>+VB@ HHHH ****
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M>CZKX>UFWM[^WCNH(-6T'7+/3]:T74HHI52^TG5K"RU+3KE9;2^M+>YBDB4
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MOM*\/KW#X#_\C+K'_8#/_I?:5]5P1_R5>2_]A4O_ $Q6 ^J****_J8 HHHH
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M;016\7FS37$GE01K%&9+BXDFN)W*(I::>:6:4Y>61Y&9B ?B1_P4G_Y22?\
M!"G_ +.M_:@_]8Y^(-?HI\<Q_P 5#H?_ & $[D_\OUUZU^=?_!2?_E))_P $
M*?\ LZW]J#_UCGX@U^BGQT_Y&'0_^P G_I==5\!XF?\ )*8G_L+P/_J1$#Q*
MBBBOYN **** "OK'X&#/@^\Z_P#(P7W<C_ESTWT-?)U?67P,_P"1.O/^Q@OO
M_2+3:_0O#'_DJ:?_ &+\;_[A [7X@7=UI_@WQ!>6-S/:7=O8F2"Y@D9)H7$T
M0WQN,E6P2,^A([U\B'QUXT!(_P"$IUO@G_E]?_"OK/XE_P#(B>)O^P<?_1T-
M?$+=3]3_ #KVO%+'8W#9U@(8;&8O#0EE=.<H8?$UJ,93^MXM<THTYQ3E:*7,
MTW9)7T'T6V[Z+I8ZK_A._&G_ $-.M_\ @:_^%'_"=^-/^AIUO_P-?_"N4HK\
MR_M;-?\ H:9E_P"%V*_^6^2^X+^GW+^NGY]V=7_PG?C3_H:=;_\  U_\*/\
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M&>(;.R\6^%[JZGL"D%O!XAT:2:5S-$=L:+>DLV 3@=@37R$;FT)/^GZ7U/\
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MSC(SC.,\X]<=<4M $<444*[(8HXDR6VQ(L:[CU.U0!DX&3C)Q4E%% !1110
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MAR2SA\0^&Y]4TZYL8=?T&;4++4K"+6M&DG74M*>]T^^LUO[6W-U9W,'F0O\
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MX<T^\U2>""T>_NK?2[:W2YNELK2RT^"6?S&M=-L;'3;7R;"RM+:$ ](HHHH
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M."ZU749+K4;B"TM(9KEXK:!(^$^-?[*W[.G[1UQX>NOCK\&_ 7Q5N/"8N?\
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MGM_3I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.@:KX>\06WCVWN?#^@Z?8^,X_%G@Z_\ $$MQX7^V^';RS\2#3H%MIM#.H:X
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MA#KWQ.\4^+/AO\5?B_?RVGA7XF^*-.@\+_"?4? >C2^%XX/A7X-\9ZII.O\
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M^$C\*ZSJOA[Q ;B5SK>D:A=66J&[AF9:]WHH \MUGX(?!SQ#XZT7XGZ[\+?
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M/XZ?!/P1^T/\+_$GPB^(L>JR^$/%1TAM531-3DT?4F.B:WI^OV/V?4(HIG@
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MU\TEB\1F>2XNG1JPS3(:N'6"E2P5>5648^U5:G047RN9X1_;W_!0_G'PS_9
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M>@:-\+=?A\!^";_X=6MCHEU\/]4T75?$&B_"*WN[KP?H'CN\T:T1G /U]B\
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M$5_8_#;PG97NMZE=^)O#?C2ZOM3N8-(AFO9[GQCX/\+>+)GF=Q)XF\/:1KK
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M8^$_%M_XTT'4_!?A^70#!X<UNQUV_,T6H:3-;HJ6M@R0)<VR7)]1E^$'PFF
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< !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>chart-225be0f1a328510aba7.jpg
<TEXT>
begin 644 chart-225be0f1a328510aba7.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %- 3T# 2(  A$! Q$!_\0
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M/K;4/A+I,FD>!/"-SKGA;X=:9H>D0:UH,&J^!#X!N;S5O[0ZC]K[_@GQX/\
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M"W66 F&0-'\M7[W3=/U$VAU"QL[XV%[!J-C]LM8+K['J%L'%O?6OGQR?9[R
M22"&ZAV7$0D<1R*';(!^,/@[]N_]I+Q$='^*[:3\.KSX>ZK\9/@%\*K'X+:1
MX7UL^/-6D^.O[!_P:_:9\FV^(E[XG@M;?Q%H_P 2?'USX:\,63>"I[?6= N?
ML>LBWU*2QU&P[?\ 89^./CCXX?M%>)O%/BKXR^!?BC;^(?V*/V9O'=YI/PLL
M]6T+P1\._&/C7XH?'[4O$?@F?0+SQGXOAB\3^';9=)T*[OM4.C>/I-*T_2[?
MQMI5K<Q:;N_61-)TN,*L>FV"*EQ;7:*EE;*$NK.VBL[2Y4+$ L]M:006MO,,
M2P6\,4$3I%&B*MII>FV#SR6.GV-F]S/<W-P]K:6ULT]S>7#W=W<3-#%&TL]U
M=.]S<RR%I)[AVFE9Y6+D _ 3XN?$[1;SQO\ '>__ &(_VC/%GCSXR_#+P'^U
MW??%'Q%<_M!67CS6OBC\3;3P1XT7P_\  ;X2? $>)+O1M=UC]G?Q->P^*+/6
M_!GPPT/2OA])\,--^$UIJWC7Q-XP^+,&C>HZ)XL^&FGW/[3WAWX)_M7Z]X;_
M &4?^&=?A#XEU;XUVW[10\6?\(A\;_$_BOXJ6VL^'?"'QH^+NM>-8?!OC?XK
M_#NT\'W?CFVTW6+'Q)X,U.Y\+^-O#]EX8\;^.1KMU^Q%C\// 6F:X?$VG>"O
M"5AXB+7+G7K+PUH=GK6^\26.Z?\ M:VL(M0WW,<TT=PWVG=,DLBREUD<&]>^
M#_"FI:5=:%J'AKP_?:+?7LFHWFD7FBZ7=:7=ZA+>'4);ZYTZXM)+*>\EOS]M
MDNI8'N)+O_27D,WST ?@5KOQK\(>)O@)^Q%X^\4?&S0_B1\+IOV.;'2=4T;P
MU^V=;_!3Q+HO[0>C>"/A)JFH?%_6_&VG^.=.U7XDZGX+TZ^FTS6=)L=:\6?$
M[P'K?B"W\1:)\,/'VI^+[B[\/?M%^R[J7Q)UG]FO]GW5_C+]J_X6[J?P3^%>
MH?%'[=82:5>GXAWG@70KCQFUYI4MM9R:7=R>(9-0DN],>UMWT^Y>:S>"%H3&
MGING^"/!NE65OIVF>$_#6G:?::NGB"UL;'0-(L[.VUV, 1ZU!:VUG%;PZL@5
M0FI11I?(  LX KJ: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MWGW/FIFH>(="TJXAM-3UK2=.NKA0\%M?:E8V=Q,C.8U>*&YN(I95:160-&C
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M4 8"C"@<8Q3C^W=^RX<?\7'GX]/!_C@ ]OF T !O^!9KT_\ 4OC#_HEN(O\
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M $%M(_\ !#=__-!6W10!B?9O$7_06TC_ ,$-W_\ -!1]F\1?]!;2/_!#=_\
MS05MT4 8GV;Q%_T%M(_\$-W_ /-!1]F\1?\ 06TC_P $-W_\T%;=% &)]F\1
M?]!;2/\ P0W?_P T%'V;Q%_T%M(_\$-W_P#-!6W10!B?9O$7_06TC_P0W?\
M\T%'V;Q%_P!!;2/_  0W?_S05MT4 8GV;Q%_T%M(_P#!#=__ #04?9O$7_06
MTC_P0W?_ ,T%;=% &)]F\1?]!;2/_!#=_P#S05\T_MAP:TO[-'Q>:ZU+39H!
MX90R10:/<6TKK_:^F<).^LW*QG.#DP2# (VYP1]8U\Q_ME_\FQ?&'_L5T_\
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M']3_ /45\05_1\O0?0?RK^4/'K_DJ<I_[$%'_P!6.8G]->"7_).9G_V/*_\
MZK\M%HHHK\./V8**** "BBB@ I#T/.W@\^G'7GCCK2TAZ'/(P<CKV]#P?QH
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M]P>#24K=3]3_ #I*_P! ([+T7Y'\."Y/J?SHR?4_F:2BF N3C&3CT[5^F/\
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M7+[6K"GS<LLJYN7GE&]N97M>UU?='O5%>#?\-.? K_HH%E_X*?$7_P IZ/\
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MT445_8%EV7]?\,ON/Y1N^[_K_AE]P4444679?U_PR^X+ON_Z_P"&7W'Z"?\
M!*O_ )2$?LO?]CMX@_\ 5;>.:_O23[B_[J_R%?P6_P#!*O\ Y2$?LO?]CMX@
M_P#5;>.:_O23[B_[J_R%?PC]*;_DM\B_[)7#_P#JWS<_MGZ,W_)'9W_V4^(_
M]5.3CJ***_F4_H\**** "BBB@ J.:&*XBD@GBCF@FC>*:&5%DBEBD4I)')&X
M*O&Z,5=&!5E)5@02*DHH ^;9OV5_AH]QY=OK7QATSPV8986\!Z/\=_C'I'@+
MRI68FU@\,:=XVMK2QTL*S1_V#ILECX?,+- VDM"QC/T'I>EZ=HFFV&CZ196V
MFZ7I=G;:?IVGV4*6]I965G"EO:VMM!& D,$$,:111H JHH Z5?HH _$#_@I/
M_P I)/\ @A3_ -G6_M0?^L<_$&L__@I-Q\=?"_\ V2W0O_4C\55;_P""ETDD
M7_!1_P#X(621027+K^U;^T_M@B>%)'S^QW\0 =K7$L,(V@ER'D7(4JN7*J<K
M_@H[//<?'#PR\]E/8./AAHBB&XEM)G91XA\4D2!K*XN8@I)*@,X?*%BH5D)_
M6_!3_DN*/_8LS'_TBF?EWB__ ,D;5_[&. _]*J'D$?C+P%=? >'0-<UZ#5_%
M%A,NG^&;!_#5YI7BSPOJ$5A$+)O^$DTJ]73M=\ Z>\VH-NURUU&_EL;D>'[3
M3+*_M;6\BTX?&?A#3/%'PH\4W_Q+T_Q3J7A;P;XC\/:W=KIOCO4C/XGU;4OB
M)J=CJ?B6+6O#VFW?B7P/='Q/IVG>,;"UNGUK5=-N=1T^&PGM1([_ "917]1R
MX;PLHUX/%8WV>(KXZO."^IJ,5F&'GA:]&DOJ=J=+DJ5)I1M.I7DZV(G7D?S9
M'/\ $QE1DL-A'.A0P5&$Y+%2E)X'$0Q%&K4?UI.I5<Z<(-R]R%&*I4(48H^G
MM2\<_#X^+?AUK+2^&9)?A[X(\6.+7P=X6UG1?APWC*P&O:O\.K3PUX9U>RCO
M;)I_$%WIVI>+;^6RM=)O]97[8$"+=RR>7_#O5M-T'6]-\1:KXDTSS-2N_$OA
MOQ)I6LZ+XCU=;GP[XC\,7EAJ^JZO<Z.]K=2V6O2ZI=Z1</HM\_B?2[GS=>AM
M+N.**"Z\QHKKI9-AZ6'K8:-?%.%?#RPU24I4)3]E*KC:TE'FP[A&3J8ZK*ZA
M9*G0C;DIN,N:IFM:I7I5Y4<,I4*\<33C&-:,/:QIX.C%RY:ZG-*G@J2:E-W<
MZTK\TTX^O_%/Q+X7U6U^'WAGPA!IR:3X%\-ZGICW6E1ZZ-.NK[7O$VI>)+N*
MRN?$\<'B'4H+$WL<4FJZI9:8]_J$M_)9Z58:<EHC_OC^R7_R;;\&/^Q#T;_T
M&6OYL%ZCZC^=?T<_LIZA?Q?LY?!R.+0M0N8T\"Z.JSQ76CK'* DF'1)]2AF5
M6["2-'[%017XQXWX6G@N$\DPU.56I&.>U)NI6G[2M4JU\/C\37JU9M+FG5K5
M:E23LE>5DDK)?KG@YB9XOB?-Z]2-.$I9)"FH48>SI4Z=#$8"A1ITX)OEA3HT
MH0BKMVBKMN[/F?\ X*>?\DU^&G_90KK_ -136*_%X,0" 2 PPP!(!&Y6 8 X
M8!D5@#D!E5@-RJ1^R7_!3"[NKGX;_#9;C2KO3U7Q_<LLES/ITJR-_P (MK V
M*ME>73AL$MEU5,*?FW%5/XV5]9X-Z\!Y=_V%YE^&-J_Y'S/BS_R6V8?]@V7?
M^H5$C$,(;>(8@_)W^5'NR<Y.[;NYR<\\Y.<Y-)Y$ ! @@ (P0(8P",YP1MY&
M0#@\9 /4"I:*_4[ON_O9^:\L>R^Y>7^2^Y#%CC3&R.-,'<-D:+AB,%AM488C
M@D<D<$XIP55SM55W,6;:H7<QZLV -S'NQR?>EHHN^[!)+9)6VLC]N?\ @F7_
M ,D:\:_]E/O_ /U$_"M:G_!5O_E'G^U-_P!DZB_]2GPY7-_\$U[R[M_@[XT6
MWTF\OU/Q,OF,MO<:;$BM_P (KX6'EE;R^MI2P #$JA0A@ Y975;_ /P53O[Z
M;_@GQ^U)'-H=_:1M\.X@UQ-<Z0\<8_X2CPZ<LEOJ,\[#C'[N)R"1QS7\@YA_
MR?'!?]ESP[_ZGY:?U1@_^3,XS_LC,]_]0L>?PDO]]O\ >;^9IM=_\-_A;\0O
MC%XOM/ WPQ\):QXS\57Z75S#I6CVYE:&SM%WW5_J%W(8[+2].@W112:AJ5Q:
MV8N;BUM/.-S=VT4N]IGP"^-&K:=K>JVGPV\1PV/AO6M7\.:^^LMH_A>YTCQ#
MH%E8ZCKFAW>F^*M6T35/[7T>QU+3[K4M/@L9[FTCOK02H)+F%'_T7J9EEV'G
M*CB,?@L/6ITZ-2I2KXJA1J0A7E.%"<H5*D91C6G2J0I2:M4E3J1@VX22_P _
M*67YAB*<:U# XRO2G*K"%2CA:]6$YT(PE6A&=.$HRE2C5IRJQ3;IQJ0E))23
M?D5%>D3_  =^*UM\/X/BK<?#SQ9!\-[BVM;Z'QG+I;)HS:9?:A)I%CK+[I!?
M0:!?ZO$^DV/B.YLH?#][JBG3K35)KW$!YWQ+X+\7^#/^$?'B[PQKOAAO%?AG
M3?&?AJ/7M-N=+FUSPEK,][;Z1XDTZWNTCN)M'U2;3;Y=.O6BCCO$MGGMQ);M
M%-)K3QN#K2Y*.+PU6:JU:#A3KTJDE7H14J]!QC-M5J,91E6I->TIIISC%&=3
M!XNE%3JX7$TH.E2KJ=2A5A%T*S<:-92E!)TJTDU2J)\E1JT)29S-?T#_ /!O
M/_R<%^T)_P!D:\+?^IX]?B'/\&OBQ;> XOBA<?#SQ5!\/9[2'48?%LFGJNF2
M:5<ZC_8]MK?E>=_::>'KG5Q_9=MXDDT]/#]QJ)6R@U.2Y=(V_;+_ (-\IY[?
MX_\ [0306%Q?L?@WX7#16\MG$Z >.W(9C>W-LA!.0 CLV1@@9!/YAXRXG#8C
MPLXU>'Q%#$*CAL/0K.A5IUE2KT\UR[VE&JZ<I>SJT[KGISM.%US15T?I/A#A
MZ^'\3>#E7H5J#JXJO6I*M2J4G5HU,LQ_)6I^TC'GI3L^2I&\)6?+)V9_5WXL
M_P"17\1_]@'6?_3;=5_FB1_ZJ+_KE%_Z+6O]*'Q5J>I'PQXB!\.:FH.A:P-Q
MO-"P/^)=<\G&K$_D#Z] :_S7495AC9B%588R6/  V+U_D!U)P "2!7XO]$_^
M%QU_U\X<_P#2<[/UWZ47\?@G_KWQ'_Z5D1)174_\(-XX.OZGX43P3XQF\4Z+
M_P AGPS:^%M?OO$.D K X;4]$LM/N-3L$*7-LXDNK6*/;<0'?^^CW9I\/>(5
MDUF)O#WB%9?#B-+XDB;0=8$OAN)9#$TGB.(V0D\/QK*K1-)K*V*+*K1E@ZE1
M_72Q%"5N6M2E>,)JU2+3A5Y?9S33=X5.>/))>[/F7*W<_E9T*T?BHU5:4X.]
M.:M.E?VD'=:2IVESQWCROF2L[9%%7WTG5H],AUN32=6CT2YNY=/MM;ETO4(]
M$N=0@5FGT^VUE[9=+N+^%4=IK&"[DNX@CF2%0CD+9:1J^I0:C=:;I&K:E:Z/
M;K>:Q=Z=I6HZA::/9N6"7FL75E;3V^DV;E'"7>HR6UNQ1PLIV/MMU*:3DYPY
M8RY&^964^91Y6[V4N9J-GKS-*UR.2=U'DE=QYTN5W<>7FYDK7<>5.5]K)O9'
MWI_P2K_Y2$?LO?\ 8[>(/_5;>.:_O23[B_[J_P A7\%'_!+*1XO^"@?[,,D4
M$ETZ^-=?*P1/"DDF?AQXX&%>XDBA& 2YWR("%(4EBH/]Y-A=7-RKBXTVZT_8
ML>S[3-83";<&W;#97=UC9M&XR;-V\;-V&V_PI]*;_DM\B_[)7#_^K?-S^U_H
MS?\ )'9W_P!E/B?_ %4Y.:%%%%?S*?T>%%%% !1110 4444 %%%% 'X@?\%)
M_P#E))_P0I_[.M_:@_\ 6.?B#7D'_!5GXR?#7X??M$>$M%\8>)X=&U2?X/\
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MI/A70-:\2:1XJ3PYK?@ESI=UK\MIJ7YFA5!+!5#%0I8* Q53E5+ ;BH/(4G
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MTIO^2WR+_LE</_ZM\W/[9^C-_P D=G?_ &4^)_\ 53DXZBBBOYE/Z/"BBB@
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M+P7_ ,%$O^"P?A/PKH%E%INA>&_#G_!0WXDZ-H6BZ=!N\BPTK2[#0H+.PLX
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M2JTH0A4P>!PJI2C5?,YJ6$E)M>ZU.*W3/M:BBBOR@_4 HHHH **** "BBB@
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M)U+P%IVC7-CKOB?5_B'HGP^TGX>P76M:IH^GZ7K#-KD?B[6M<US4=.\->%_
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MJ:%;3PUX(UWP-H4&C^)[_P#:VU#]H/PEXJTRR\1ZW-9^+O"7Q[T98M&U;4_
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M\/O@G\"?A]X!\3-K]WINKZ+\-[F'Q;X8U&U\5W-OI0!](^*_VP_@OHGBS2O
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G HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>chart-900b27e36dcb52c1a00.jpg
<TEXT>
begin 644 chart-900b27e36dcb52c1a00.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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MMK"81EY*YKXN?\$XOAA\5/#_ (2MM3U'1K_Q+X%^,G[1?Q;\,:I\0/A;\/\
MXM>%XG_::\<^)?&GC[P]J?P[\<:?>>'=273I==LD\*>(H7L/$6CW_AK2;^2[
MO+"\\1:#K8![[9?MD?LZ:IXN\*>#=(^((UJ]\96O@"XT?7M%\,>,M7\ 07'Q
M8TBVU_X6:-K_ ,2]/\/7'P_\+>)?B1HM[I^I^"/#'B7Q)I/B#Q)::KH;Z=IT
MK^(- 35.F^+'[2?PE^".I:9I_P 2-6\1:)#?VMEJ%YX@M/A]\0?$'@SPKI6H
MZPGA^QUGQ[XX\.^&-5\(> ='N=:DCL(]1\8:WHUMN\Z[=DT^TO;RV^0_#G_!
M+[X#^#_C+X,^*OARR\%PP^&F^#FJW>FZG\!?@)JOB$^)O@1X+\-^!? FH^"O
M')^']K?_  DT2?2O!WA:\U_PI\.])T728==T&UU7P')\/Y[S6EU3J?VO_P#@
MGSX/_:_\2R:SXQ\<WVFZ5??#>U^'EWH=]X%\ >/$\//I/B;5/%NE>-/A;J/C
M;2=3N/A5XZU#4]42P\;^)_#,+:IXN\/:!X0TY+K0;_PKI&LP 'J47[=7[+SZ
MGX[TVX^)+Z6GPX@^,\GBG6]<\&^/=#\)Q7/[/'B2_P#"?QJTC1O&.J>%[7PO
MXJ\0_#K6=/E3Q!X<\+:MK.O)82VNJV>G7>G7,=Q6A\$OVI-(^-^M?M!6.A^"
MO&.EV'P,\3>$?#BP:_X;\6>%?''B.?Q/\&?!'Q=>"]^''COPSX/\4^$]9M$\
M90Z%::-J]LSZF8;35(KF&#4HX8?)?&W_  3[^'WC_P -6_A76_''C"WTR'Q7
M^V%XN,^E6^C6>J0ZG^UUX[\2_$+4+FPN;FUO;>WN_AMXEU^UOO!UQ<6&H6NH
MSZ)8KXCL-0M+B^LKCV3X,?L\ZE\-9/C/KWBWXI^)?B)XX^/.MZ!XA\;^+%T;
M1_ DUGJ?A_X9>&OA79CPEIOA4!?#UO#H7A;3;ZV)NK_4;369+N^_M*820QVX
M!\Q?!C_@H?-\6_AIXF^)J^'/@A8:+I7AKX=>(2GA_P#:-B\<ZE\/-9\?>+M(
M\+M\)_VB/".D?#&T^(WP>^+N@G5@=2T6#P1XP\,1:W8:UX?O_%.E/I#ZC=_:
M_P -/C[\+OB]K'B;0/ 'B"?7-7\%7%_8>,;(Z'KVFR>%=7TWQAXJ\#W?A_Q
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MOH^HZ5IC_#;5_%QT#5(],OO"-VVGW/U/XZ^!OP"^)/@_PKX#\:>"O!VM^&/
MO]G_ /"$V,LHL[GP>=+T@^'[1_"VL:9?V.N>'I!H#2Z#<2:1J=G)>Z)<76D7
MS7.G7=S;2YS_ +.G[,TEM?V#?"SX7_V5J?PHT?X&WNB+HVC)X?E^$GA_5M5U
MW0_ *^'D9=#A\.Z5K&MZIJ-C:6^G126]W=O-','CA,9S1_FC]Z_KJOO X/\
M9;\:_$&Y\9_M+_!KQYXKUSXF1_ ;XI>$_#?A7XH>(M+\,:5XBU_P[X[^#?P^
M^*4?AOQC'X.T3PSX:O?&'@C4/%=]IUUJFD>'-"CU'POJ'@ZXU"PDUPZKJ%]]
MBUY;\,OA_P#"GX.>%X_!WPTT3PYX1\/K?W^K3V>FW*/-J.LZK*)]4US6=3O;
MR[U;7==U.94DU'6];O\ 4-6OFCB^U7DHBB">@G5]+'74; ?6]M1_.:GS1>TD
M_FOZZK[P-&BLW^V-)_Z">G_^!UI_\>H_MC2?^@GI_P#X'6G_ ,>I@:5%9O\
M;&D_]!/3_P#P.M/_ (]1_;&D_P#03T__ ,#K3_X]0!I45F_VQI/_ $$]/_\
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M@?\ !2?_ )22?\$*?^SK?VH/_6.?B#7[>1_ZN/\ W%_]!%?B'_P4G_Y22?\
M!"G_ +.M_:@_]8Y^(-?MY'_JX_\ <7_T$4 /HHHH **** "BBB@ HHHH ***
M* "BBB@ KA/B;_R(?B;_ *\%_P#2F"N[KA/B;_R(?B;_ *\%_P#2F"O)S_\
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M (*3_P#*23_@A3_V=;^U!_ZQS\0:_;R/_5Q_[B_^@B@!]%%% !1110 4444
M%%%% !1110 4444 %<)\3?\ D0_$W_7@O_I3!7=UPGQ-_P"1#\3?]>"_^E,%
M>3G_ /R(LZ_[%.8_^H=8<=UZK\SXC;J?J?YTE*W4_4_SI*_D404444 %>[_
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MXO\ S$],]!_TWK\8O^"D_P#RDD_X(4_]G6_M0?\ K'/Q!K]O(_\ 5Q_[B_\
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M0?\ K'/Q!K]O(_\ 5Q_[B_\ H(H ?1110 4444 %%%% !1110 4444 %%%%
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MK5]7P-_R5F2?]A-7_P!1,0-;2]/U1]0T445_4H@HHHH **** "BBB@ HHHH
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M?$6PO8?!'B*277-1NXTL06MYK?2$BD'VB ;7:VTR"<#O^[FC;('S8R#Y.?\
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MX#?\AS7?^P1;_P#I:U?5\#?\E9DG_835_P#43$#6TO3]4?4-%%%?U*(****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\0/^"D_P#RDD_X(4_]G6_M
M0?\ K'/Q!K]O(_\ 5Q_[B_\ H(K\0_\ @I/_ ,I)/^"%/_9UO[4'_K'/Q!K]
MO(_]7'_N+_Z"* 'T444 %%&1Z]>GO10 4444 %%%% !1129&,Y&/7/'/3GWH
M 6BBB@ KA/B;_P B'XF_Z\%_]*8*[NN$^)O_ "(?B;_KP7_TI@KR<_\ ^1%G
M7_8IS'_U#K#CNO5?F?$;=3]3_.DI6ZGZG^=)7\BB"BBB@ KW?X#?\AS7?^P1
M;_\ I:U>$5[O\!O^0YKO_8(M_P#TM:OJ^!O^2LR3_L)J_P#J)B!K:7I^J/J&
MBBBOZE$%%%&1G&>>N.^/6@ HH!!Z$'!P<=CZ?6B@ HHHH **** "BBB@ HHH
MH **** "BBB@#\0/^"D__*23_@A3_P!G6_M0?^L<_$&OV\C_ -7'_N+_ .@B
MOY[?^"SGQN^%_P"S3^V'_P $8_C]\;_%*>!/A!\-/VHOVB[_ ,=^-[K2-?UC
M3O#=EK?[*OC'PYI=Q?6OAO2M9U5EO-:U6PL(5MM/G<RS[W5((IYHO;$_X.'_
M /@C<$0']MSP<"%4$?\ "MOCQU &?^:44 ?M37YP_P#!2KQU\=/!?PE\,?\
M"B_$^MZ'JNH>++4^)].^&.M_#'2_C]K/AZWN=+MH!\)K7XPK-X$U6*RU_5-(
M'CRTNXH=4_X1N^C73=1LDEO4NOG;_B(@_P""-O\ T>YX._\ #;?'C_YU%>1_
M&G_@M/\ \$#/VBO!DGP^^-W[2_PE^)?@]]1T_5TT3Q5\(OCAJ-M;:KI=S'=6
M6HV,DGPF^TZ?>Q-&T#W-C-;S3V%Q>:;.\EA?7=O, =WXB_:J^+OC#X;?M _'
MGP'\<_$VC67[)OP,^"7Q%\#^"M1\"^"O#EG^T'KFO>'M>\0^-5^+_A;4M UC
M6=/D^(/B;P]K'P%\-Z%\//%?AJW\'^//#'BO5= OM4NWTIK+]Q8V+HK,I0L,
ME&*%D)Y*,8WD0NGW'*.REE.UB,$_SV:U_P %CO\ @WM\2^(/ 'BC6/CY\!=1
MU[X3VNEZ9\/;]_@9\7?-\&:?H%S%J/A[1](AM_@_';6>G>&=1CM]8\,:3+ ]
MEX:U6.VUG0K73M22&\'M_P#Q$0?\$;?^CW/!W_AMOCQ_\ZB@#]IZ*_%C_B(@
M_P""-O\ T>YX._\ #;?'C_YU%'_$1!_P1M_Z/<\'?^&V^/'_ ,ZB@#]IZ*_%
MC_B(@_X(V_\ 1[G@[_PVWQX_^=11_P 1$'_!&W_H]SP=_P"&V^/'_P ZB@#]
M-/VD];^(?A_X+^--2^%.M>%= ^(/EZ#I_AC4/%^IZ)H^G-J&L^*M!T9]-TO4
M?$Z2^&(/&>MV5_=Z)\/%\3V]WX:N/B!J'ABV\065[H\U[:3?D[^RU\=_C'\=
MM"_9J_9_UGX^?'OP'XEU[0_B?XA^*WC;QGX3^#&E?'ZVUGP+\+OV=?&_P_\
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MD0O?\2:N?A$CQ7LUMJ-QIE[K(9-5OM&%KHE[?3Z39VEG$ ?>W[-?CSXHZ/\
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MO^'K29&,Y&/7(Q^?2@!-H_R%_P#B:-H_R%_^)IU% #=H_P A?_B:-H_R%_\
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M^(?Q^\8^*?A;\%YOB_\ &?PO\'OCA\:/C%/\(_CKXH\.>!O#OQ_\8?!WX5?
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44 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>chart-3395c23c9be152f4b2f.jpg
<TEXT>
begin 644 chart-3395c23c9be152f4b2f.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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MMK"81EY*YKXN?\$XOAA\5/#_ (2MM3U'1K_Q+X%^,G[1?Q;\,:I\0/A;\/\
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M_P -/C[\+OB]K'B;0/ 'B"?7-7\%7%_8>,;(Z'KVFR>%=7TWQAXJ\#W?A_Q
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'S!\:?VM/AE\"/C/\
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M-E;37EY*L$+S-%:6ENKSW-S($*6]O"C2SS,D4:L[J" ?E-K-MJM[^UO\2?\
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M[.SV=G;8;\<>"(_$\XC[THZY<U:4>7GCK6^*/,N9;K2^Z/M+]B+X1?&GX"_
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M%'P_^*GPSU>/XBZ[I/@#P[9MKGBOPE\-O'GP]\.^/M(*^&/BY?7OC#Q)\/\
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M\LDH4<'7LLKH.<H8J$)M1I/ QKU)TO>I.%*E4=6LG3H\ZG3G/^H,?\%#_ )
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MAK;W]Q'//'/=M?&:5)YE=V$LFYTW[-WP[N/#FL>#Y_@!X*D\)>(=9LO$>O\
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M%%% !1110 4444 %%%% 'X@?\%)_^4DG_!"G_LZW]J#_ -8Y^(-?H9\<,_\
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M\/LPC5G=E0':"S$#DU^W]%95:-'$0]G7HTJU.ZER5:<*D.9;/EFI1NNCM==
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M:,:7L(TJ<:'*X>QC3BJ7))-.'LTE#E:;3C:S3=UJ(_#/_AQ+\,O^DB'_  6
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M[[3-5LK;4=/O8&*LT%W97D4]K<PLRJQBFB="54E<@8Y_[+RS_H78#_PDP_\
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M.M?CO9^,_COK'Q%^(_C3Q5KEAI/BZ?X@6_Q*T'4(-9\*>$K8:;-X?T^]T.^
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MXB?#O2-'^&WB#2?%&C_$XZ/X5T72KKPQ<Z;KT5Y?7GZ.@8'4GDGGW)./H,X
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MI_PC:Z1]H_X2%?B=X8T'PY%Y6I+?VZ:0NAC1/M.S^S[\7ZSBW4V8A\R3Y7^
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>chart-8629c965f44558b0817.jpg
<TEXT>
begin 644 chart-8629c965f44558b0817.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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MMK"81EY*YKXN?\$XOAA\5/#_ (2MM3U'1K_Q+X%^,G[1?Q;\,:I\0/A;\/\
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M_P -/C[\+OB]K'B;0/ 'B"?7-7\%7%_8>,;(Z'KVFR>%=7TWQAXJ\#W?A_Q
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M3_@A3_V=;^U!_P"L<_$&OV\C_P!7'_N+_P"@B@!]%%% !1110 4444 %%%%
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MDX)_Y@GAS_Y44G_#27QI_P"ATD_\$GAS_P"5%?B?_$PW!O\ T*^)?_"3+/\
MY[GP'_$3<C_Z \U_\$X3R_ZC?-_=YGMW@W]B+5O"%K9?9_VCOBM<:W\.OA=!
M\%?V>?$_]A_#6/6?@Y\-X?$?@7Q)=Z=<)<>$[_2?B5KOB8?#/P#X3\:>(_&&
MEBX\0^!?#-OI$5II.NZKXD\5:WG^)?V$?^$N\'^*+3Q-\5H?%_Q$^(7Q7T3X
MO?$3Q7\0/@A\%/B'X-\1Z_X;^'VD_"_POI]E\)_&'A?5?#_AG3/!GA30]*G\
M(WVB:O%XKM?$EK)J_B/Q-XKLM1U;1+_R'_AI+XT_]#I)_P""3PY_\J*/^&DO
MC3_T.DG_ ()/#G_RHH_XF&X-_P"A7Q+_ .$F6?\ SW#_ (B;D?\ T!YK_P""
M<)Y?]1OF_N\SZ$G_ &(M /PPTOX)VGQ*\76WPM\+^&OAU>^#-%G\/_#W5-;\
M._'CX;_&"?XWZ?\ M%GQ'J7A6X.J^--6\>QZ-JNK^$+W2E^&9;2YH-.\*Z?9
M:M>V=>S? SX)7/PF?XB>(_$WCG5?B5\2_BYXML/&7Q#\::AHNB>%K2^O]%\(
M^'O ?A[3-!\*>'(DTS0M$T/PMX8TJRMH[BZUO7+ZY-Y>ZQK^HO+;0V7PK_PT
ME\:?^ATD_P#!)X<_^5%?2W[,GQ4\>^/_ !+XFL/%NOMJ]I8:%9WEI"VGZ79^
M3<2ZD8))-]A96KN6B^3;(S(.H4-S7M</>-/"_$N=8#(\#E^>TL7F-6=*C4Q6
M&P$,/"4*-2NW5E2S*M42<:4DN2E-\SBFDKR7=EG'N4YKC\-E^'PV8PK8J<H4
MY5J6&C2BXTY5'SN&*J22M"27+"6J6EG=?9[$A6(QD D9X&<<9/89Z^U?D!8?
MM!_'+0?^"A^K^"?B)X^UZP^$GB=7\&?"G2/"WAWX>^+_ -GS7M7N+GXB6GA7
MPWXD\8:3>3?&+X:?'&YUGP=KMEXDO/$MG/X*EU'PM?\ A+3M+=;_ ,/7:?L
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MW49 ?WVH:C=3!4#[5ZJFFGLT_1W_ "&FGLT_1W"BBBF,**** "BBB@ HHHH
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M_M0?^L<_$&OV\C_U<?\ N+_Z"* 'T444 %%%% !1110 4444 %%%% !1110
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M\%^&OVXH/&'[7WC;]E[PW\(/&6JZ9\.=%'_";?$*+Q!X&@U#P[XF,UDZF_\
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M^*/A75];\1P:7;W=CX@ETN%-)MKBV@-M'IVG78:1+F\O7:8RW<H++(J[ @"
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MS6EN7,2 'XG?\%)_^4DG_!"G_LZW]J#_ -8Y^(-?2/[7W'Q*T;/_ $).E?\
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MH^K:KI$TWQ;OHII=*U*^TV66(> _$+B*62QGMWEB#JKB-V9 ZJ^W< 1_-O\
M\)QXWY_XK/QAP,G_ (JGQ!P,A<G_ (F/ W$+DX&2!U(%>5XN\,U,SXVQ^+CC
M(48U,-E\?9RHRFU[/!T8-\RJ13O:_P .E^IQ\:Y3/&<08JO&O&"=+"QY7!R:
MY</36ZDM_3\M?Z)/)F_YXS?]^I/_ (FCR9O^>,W_ 'ZD_P#B:_G<_P"$W\;X
MW?\ "9^,=I)4-_PE/B#:6 R5!_M'!(&"1G(!!(Y%'_";^-QC/C/QB-P!7/BG
MQ -P;[I7_B8_,"> 1D$Y Z5^8_ZE5O\ H84O_":7_P N]?Z6OR?^K]7_ *"J
M?_@J7_R?K_2U_HC\F;_GC-_WZD_^)H\F;_GC-_WZD_\ B:_G</C?QN"0?&?C
M$$$@@^*?$ ((.""#J.00>"#R#P:#XW\;C&?&?C$;AN7/BGQ -RYQN7.H\C((
MR,C((SD&C_4JM_T,*7_A-+_Y=Z_TM3_5^I_T%4__  5+R_O^OX=M?[,/V0])
MT^\\ ^(I-0TRSN95\7W"(][90S2+&-%T9@JM/$S! S,0 =NXL>I-<C_P4@T;
M2+7]B']HN:UTK3;:9/ L92:"QM895(\1Z"05DCB5U.><@BOF/_@BCJVK:Q^S
MG\3+C5]5U/5IX_C;J<,<^J:C>ZE/'"/ ?@:00QS7L\\B1!W=Q$K! [NX7<S$
M_5W_  4G_P"3'/VC?^Q$3_U(]!K^O^&<)+ ^%V&PDIJHZ'#N80<XQ<5+]WBW
M=1;;7Q6M=^I^W911>'X1I4)24W3RO%1<DFD_<KNZ3;:W[L_B$^)/Q!LOAUI-
MOJ5QI=WK=]JFHOI>C:1:W^D:/_:%]'9W>IS0RZSK]Y8Z1IP33[&[FA%Q/)<W
M]Q''8Z?:75S,1%'XL^(MAX0C\)KJ.BZV-2\6>(_#N@)H4JV%KJVA0Z[XDT?P
MM<:SKR"\N[.WL-$U;7=*M+M;.[O3J%W?VEII$UT96GA?\4?!VH>//">I^&]/
MU#0K0WWRW-GXI\+67B_PUJT D1OL>L:3<S6ET$AD1;RSN]-OK:YANHECG2[L
MYYH!Y?K?[..EZGINB6=C\0_B9H=WI-U\/Q+/HWB>72M)NM*\!>.Y/&]C86OA
MZ&"ZM]':&6[O[+0!:7TMMH*C2)'BU0Z/&9_QO"PRAX?"2Q57DK?6JL<3"*Q$
MY2H-4E3G.2Y:=*%/FE-1HQK5:K33J13:H?#4HX)TZ+K3<9^UFJJBJC;IM046
MVE&,(Q]YVIJI4F[KF5[4_3M4^(VDZ7XYTKP(;*^O+V_T+Q3KE[J-HUNUCHY\
M-:+:^((](NT=Q<W&L:UI$\NH65K:J1:V<5K<W\D2:OI@GH_#/XBW7Q#M-0O)
M_#NEZ!'9P:3,D-C\2/!_CR^635K1KY+/6;+PJ"_AJ_M[4P-):ZF[M-+)<06[
M,UA<FN=E^"%HOQ#T/Q]I_CSXBVATW6/B#K]_X=NO%#ZGX?OM5\>Z/8Z5.;?3
M+NQ:"VTRV^P0?:M(NFOK2_T^TTS1U^RV&G11MJV'@/Q=83W6MQ>)?!L'BBT\
M%VW@3PQ<:;\/GTKPY8Z/#K]AKDM[KN@6_B:2;4;^861M;'2](U/1/#WA\7%T
M^EV+K>3QA3AE#PRC2JI8B6'H)U:RQ2G#$?6*_M6J=-2H\DJ7L6[RE[*E\$:M
M=3YTXX/V249VJ.E3O.HJMU552ISVA!.G:4/9WU:A'X5.IS.6G)XU\3P>/],\
M&W'P]=-*U9M:N+3Q7#XZ\.73+HFB6D$ESK][X2BLUUFQL)-1O=,T2**:\:X.
MI:I9*JR)]H%O^_?_  1!LK.]^-7QOCO;2VNXU^%?APK'=017"*3XT;)"2HZ@
MG:N2!GY1Z"OPJMO#_D>,O$'BM[QIEU70/#7AW3;!X@&TBQT._P#$NIWP%R&Q
M<'6;_7K>XGVQ0B-M+MPPE'E>3^[W_!#?_DMOQP_[)5X;_P#4S>O9X0E1?%>0
MJC"$>5I590=:U2M+"5YU':M.;C*'.J$U!JE.=*52G%0FD=^1N#SC+^2*5OB:
MY[2FZ%24G:<I-.-^25K1<H.44E)']&?B/P_H*^']=9=$TA6&C:K@KIMF",Z?
M<@X(A!&02/I7^?EXE\06_A7PUJOB2\M;N]M=%TY;ZXM;$1FZFB5X(6V/,R00
M11&83WMY<,+?3["*[U&YS;VDH/\ H2>)?^1=UW_L#:K_ .F^XK_/MN[:>[L6
MM[;4]1T6YDBMS!JVD/:IJ6GS1203QW%I]NM;ZR=U:()+!>6=S:W-N\UK/$T<
MS$?9^*C@L1PZZJYJ2GF'M(N4HIT^;+G-<T(RE%.-U>,925[QBW9/W>,.7VN5
M\RO'_:N97:O'FPG,KI-I-7NTFTMDW8\JTOXKR7OPN7XASZ!8/?7EK=#0=!\-
M^,=&\6Z=XHU6.SN;JSL=%\3Z9"D"0RFTNSJL^HZ;:W'A^STS5]4O+2?3[**>
MZP-5^-5]:W/@A+/3/ =C:>*O W@GQM>W7C7X@ZCX9>QC\:/.(-/TN'3_  /X
MB34$T^.TN/M.LZW/X7TA[N;3;$W$-Q?,+>/3_P!G+PF/#0TC7]5US4=;<:G/
M+XA\,:AJ?PS2/4-5\+P^#[JYM=%^'NI^'K.1+C1;:VBU%=6EU.YUN83R:I=S
M)<>5%T4?PEN+/P-I7PXTCQYX@L/"$'@&W^'.OV5[8V?B74]<T--.N--OKJS\
M0Z_<WFLZ)JFIVMW<6LK75SXDTK3['[';Z1I-A-IUO=M^>2?#_MJJBG*+Q,G&
M4EBZ5&%"3:2I2C+$UZBIJ,7#VU"E.K.<N=TZ:2C\P_[.4YI-R3JOE;5>%.--
MNRY))U:DE!)->TIQE.4I<W+%66M<_$*ZLOB'IO@6[T+3H_[8O=1M-/\ (\8Z
M3?>,(K#3]*U35%\8ZQX#M;-[O2/ E\^DSZ1!KDVLRW=IJUSIT&I:9:G48XX*
MWC+XF2^%;OQ4+?0(-4TOX>^$M/\ ''CW4+OQ'::#<:;X>U(Z\\#:!876GW<>
MNW\5IX;U6]N/M^H>'=(,D=MHEKJ]QKEV;.UT)/ %Q=^)M$UG4O%$^H:3X:\0
M#Q+H.C2>'-!@U>RNX[+5M.M-(F\;0(-9O/"NGVFLW45IHQM+>^N(H[:VUG7-
M7MHI(KCG_$?PCE\8VN@0^*O%%GK-WI^A7&@ZUK$WP\\'IK>IP7TMR=3NO#NI
M[7G\"W6JVEP-.O$L/[9L;>&*/4M&LM)\0JNLC"E_8_ML,ZKI*DJ$(XE168-2
MK>VG*52,;1J<SP\52E&-6-&G6JPJPE6A"K SA]3]I2<^3D]G%54OK+O/VC;D
MEH^9TDH2C&:IQJ3C.+G&,XK]/?\ @F^EK>_MM?LZ;EBN[2X\5:O*@DC#Q3PR
M?#_Q=/!(8Y5Y5U,<J!T#*=I*JPX_L\L].T^P#?8;&SLO-">;]DM8+;S-F=GF
M>2B;]FYMN[.W<V,9.?XR?^";BJG[;_[.B1HL<:>+-:2.- 0D<:?#_P 8K'&@
M))"1H%1 22%4 DGFO[0EZ#Z#^5?K_A7;^P\QM>W]L5;7WM]2P5K]+][=3[;@
M_P#W#%?]ALO_ %'PXM%%%?IQ]:%%%% !1110 4444 %%%% 'X@?\%)_^4DG_
M  0I_P"SK?VH/_6.?B#7P]_P6N_Y.J\$_P#9"?"O7I_R.?Q ZU]P_P#!2?\
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M /@F\"/VX?V=L@_\C=KG8_\ 0@>,1_6O[0%.0.O0=01V]Z_>?"K_ )$>8?\
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M /1S_P#P4I_\3-\0_P#S(5_1G17-_9N7?] &!_\ "3#_ /ROR_/NS'ZKA?\
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M"M)U'PGXJ\3KXT\4QW:13V?AZWD\.6FAW!:..YBU;Q%I$$B(SR(/S5_X8O\
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MPRB^*)L_$>H6UMXETB?Q58ZK=?$.W>YT2UN_#=Q;V^CS10ZPTNH1SV(!Z?\
M!S]H?5O'/CKQ3\'OB=\,=6^#OQA\*^$/#_Q#?PO=>*/#GCKP]XF\!^)-9U[P
MW:^)/!WC+PTT$.IKI/B7PYJ7A_Q1HVL:)X>U[0;Z31[J73KG1?$.AZM?8_B'
M]HOXF6UI%#X,_9<^+'C+Q!+XU^,^A-87&K>#/!&@VOA7X-^*QX;_ .$QO_&?
MC+5=,T2T_P"%H0SV.J_"3P\P>^\4V%Q>:E?WF@^'-!\0>(M-L_!SX$?$#0_B
MKXL^/7QQ\>^$/'?Q4\1> _#GPNT6U^'/@76?AYX!\$^ ] \1:]XNN[/2])\1
M^.OB'XCUCQ#XL\4:]_:7B37=7\1):)9:'X9T?0M!TA+#5K_7\+]L#X&_'CX]
MZ/X4\'_"_P"+'P]\"?#IWU\?&+P3XW\ >._$R_%W2[NULX-!\(WGBCX??%GX
M7^(O#O@5)O[4F\>>&M.N9)OB/8S6'AC5=8T_PB?$^@^*@#S&X_X*-> KW0-/
M^)/A#X;?$'Q5\$]%^'7P6^*7QE^)Z2>&=&3X.^%/CWH&E^+?!DFK^%-1U<Z[
MXHU#PWX+UK2?'GQ/L?#!N3X/\%ZG8:II<WBS4;D:*OZ+@Y&?<C\02#UQQD'!
M[CGI7YQ>+/V'?&/BZS\>^&O^%H^"_"?P^_:.\'?"GPS^U/X&\)_"N_M;#77^
M'7AG3O VMK\"KJY^(3V_PGT;XB?#O2-'^&WB#2?%&C_$XZ/X5T72KKPQ<Z;K
MT5Y?7GZ.@8'4GDGGW)./H,X [  4 +7@_P <?CUH/P#;X:ZQXWTJ]M_A[XV^
M(FE?#CQ/\1A=6EOX;^%NH>*K&_@\#Z]XZ>YV/8^$_$_C6'1OAW_;T<GV;1/$
MWBWPS+JZP:-=7VI:=[Q7@G[4GP,L/VF?V=?C1^S_ *GJ%AI-C\7_ (<^)_ ,
M^JZIH,'BBPTL>(=/DLX]1N?#]S=6,.KI8RM'="Q>\M1,\2 7$+!9% /EB7]N
M3XH:O\1/V?\ PMX'_9;UC7O"?[2MIXIU_P"&OC/7_BWX3\%W;>#?!TMOJ>J^
M*-?\&:AX>U'6](CU+P)J>A>.?#6D&XN-5U*PUJVTO4X-"U6"[BAZ#X&?MS7G
MQ3U#X47'C+X(>)_AAX%_:$\2^-_"WP+^($_C+PCXQT?Q1K?@ZS\9Z[;:#XOT
M[1FL=9^'WB#Q?X1^'_B_Q+X6M;RTUO1KM?#^H:#?>(=/\23:+I>L?0WCCX(_
M\)?\<?@#\8HO$,>EP_!"T^+5I_PC:Z1]H_X2%?B=X8T'PY%Y6I+?VZ:0NAC1
M/M.S^S[\7ZSBW4V8A\R3Y7^ 7[%/Q3^'X^ _AGXK?&;P/XV^&7[+_BSQIXV^
M$?AGP+\)]9\#Z]K?BKQ%I?C_ ,+^'->^*'BCQ%\2_'D6K_\ "&>$?B;XPM+/
M1?"&A>$K#5_$E_9^(]2N/LVD6.@T ?5WC;XWMX$U'XHPZE\,_B=K6E?#OP1\
M.?%.DZEX.\*WOBN?XD:W\0]=\=>'XO G@?2M,0SW7B/P]>^$]'E\37>IW&F^
M'?#VF>-=#UWQ'K.A^'K76-8LO&U_;#O/$G@?]FG6?A=\%_%_Q!\??M-?!O\
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MS _,@?UK]!/IA:*_.#X7_P#!06W\6>)O"J_$+X5?\*M^&/Q*\9?M ^#?AO\
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MPIUVQ\<Q:+\+[+XFW/C7P_J-O>>&Y[*^\?\ B#X?P6-@_EQS:E!<WWAR_O\
M3?$>G-=^&M;LHY'T74K]()90 ?6-%%% !1110 4444 %%%% !1110 52U'_C
MPO?^O2Z_])Y:NT4FKIKNK":NFNZL?Y]5Q;W!GF_T>X'[Z?\ Y=Y_^>S^D9K]
M0?\ @CY%*G[:6BEXID ^%_Q+RSPRHO,?AT ;G11D]AGGG&<&OZR?L%E_SZVW
M_@/!_P#&Z?':VT3;XH(8WP0&2&)& /4;D13@XY&<&ORO*O#-Y9F6!S#^VO;?
M4L51Q/L?[/\ 9^T]E.,^3VGUV?)S6:YN25KWY7;7Y#!\*?5,5A\3]?Y_J]6G
M5Y/JO+S<DE+EYOK$N6]K7Y7;>SV+%%%%?JI]@?.?Q^^"WB?XGW_P@\:?#[QK
MHW@;XD_ _P"(6I>/_!VH^*?"-WXY\':JWB#X<>./A;XC\/\ BKPUIGBKP1K%
MQ8:AX9\>:E<Z?J&B^*M(U'2->T_2;UCJ6FIJ.C:C\E:E_P $XY]7\(?&S0]0
M^,$%SX@^.'[.WCWX.>(O$@^'<%I%8>,/BC\>OC+^T%XZ\=Z7H\/BN5H- O?%
MOQCU"RTCP*^K3SZ=I6B::M]XLUB\>2Z'Z@T4 ?F=\0_^"> ^($7B[2+WXGPQ
M>%_BCX7_ &X?AI\3+#_A$;T:Q<_#7]LWQ[IOQ,FM_!FL6WC&TM_#WC+X>^*O
M#V@P1:WK.D>*-"\5>'VUK3[GPWHMW>6.H6&1\.O^">OBOX9:EX6^(_AGXH?#
MZQ^-_A3XD_\ "71>)I/AQ\6?$W@G7O"]S\,-<^$U_P"%O$N@?$;]I;QW\0;V
M[M]$\0ZAK?A35M.^*VD:?X/U9(-(T_P_=>&+G7K#7/U(HH ^0O _[,GB3X;_
M +)'@+]FCP=\4X+;6_ '@_POX3M_'VO?#O0/$^A^*;7P_J%O<ZIIWC/X:ZC?
MQZ;J?A7QQIB7OA[Q;H6E:_H6HC2-5O3X:\1^'M2BL-0M/G+P+_P3KUCX>:QH
MOC3P3\1OAU\-?&$7QJ\8?$W4] ^$7P3'@+X.^'- ^(_P0\._ [QOHWPD^&W_
M  L#6D\#>--1L_#6G_$AO'&JZOXKTG5_B?+JVL^)/ FIZ?J?V"V_4JB@#\@?
M"/\ P3%\8^%4\2^*!\=/"^I_%?4-%_9>CTOQ=?\ PR\>:GIFL^,OV4?CIXA^
M-7A#QQ\4+3Q1\>_%/C#QIJOCV?7YM$^(4&D^.O"=J@47_A5-(*&UFW?#7_!+
MS0/#OBOXI:H?%WA#6O#WC&V_:2O?"&F^+? GCGQY?>&_$G[4.J>(]:\?MXDT
M;QI\;=:^#_B?PI'=^+_$ND2:'X?^$/@+6O%GA&_L=&\5^*;K4M-N=?UG]8:*
M /F#]EGX$>,O@)X3\5Z%XS^*5]\1[GQ)XP_X232]/C;Q^WA+P!I:>&O#WAU/
M"O@E?BO\3?C+\1H-%N;G0KGQ->6>N?$G6--L];UW4;?PUI?A_1DAL#]/T44
M%?!?[:2LU[\/-JLW^B^)\X4G'[[0NN!7WI361'QN16QTW*#CZ9!KY7C7AK_6
M_AO,.'OKO]G_ %Z6#?UOZO\ 6O9?5<=AL9_ ]OAN?G^K^S_C0Y>;F][EY7X^
M?93_ &WE6)RSV_U;ZPZ#]M[+VW)['$4J_P##]I2YN;V?+\:M>^MK/\+1'("/
MD?J/X6_PK]@/@>"/A'\/ 001X4TK(/!'[DUZAY,7_/*/_OA?\*> % "@ #@
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JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>chart-9591fb6751065456834.jpg
<TEXT>
begin 644 chart-9591fb6751065456834.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $* 3T# 2(  A$! Q$!_\0
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M_P#P3'^#'BKQI\*_&UZWAO4M2\"_"WX*_"#Q%+XW^"OP8^*E_P"(O"OP$O\
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M_!W_  B5WH'P9^#/A_QWI7A[PO\ 'KX=_'^30_&'Q4T;PG9_$'XF->Z[\-=
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M%I_U30 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOAKX@:;K7PATG_AHOX\?$_PMH_A3]D#XE:U^S3XOA^+WC+28O%_[0O@OX_\
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M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !102 "20 !DD\
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M[ B_Z">O?^#F]_\ CE &[D>H_,49'J/S%87]@1?]!/7O_!S>_P#QRC^P(O\
MH)Z]_P"#F]_^.4 ;N1ZC\Q1D>H_,5A?V!%_T$]>_\'-[_P#'*/[ B_Z">O?^
M#F]_^.4 ;N1ZC\Q1D>H_,5A?V!%_T$]>_P#!S>__ !RC^P(O^@GKW_@YO?\
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M (I/^VGH?C+QG\4_A?XC\3^'_P!A7QS<:?\ &Y/V@OV7?A7\'(?&_C[7-/\
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M_H8[[_P T7_Y7T?V5JG_ $,=]_X :+_\KZ^7/^%S^./^?G3/_!6G_P D4?\
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MW5U:W1FM[F>.2SI'A[P]X?\ [2_X1_P_H'A_^VM4N=<UK^P-"TC0_P"V=<O
MHO-<UG^R;*S_ +6UJ["JMWK&H_:M2N0JB>ZD"@#7HIN<W>\I.^]Y-W]YRUUU
M]YN6OVFWNP.U^',<DOC;P_'%.]M(UU.%GC2*1XR+*Z)*I.DL1) *_/&X 8D#
M(!'VI96MU;>9]IU*?4-^S9YUO90>5MW;MOV.W@W;\C/F;\;1MVY;/QC\,O\
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MX]KC_KA-_P"BVK\[5Z#Z#^5?B?B[_%R#_#FO_O, 6BBBOQL HHHH [OX9?\
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MQ=_T)Y]/^8W+>MO^HS^\OQ#YK\?\OZL_*_3? C_D6-5_[#TW_IOTZO;J\?\
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M%:ES<WLJGP<UN7WK75SY_G_D?/=%?0G_  H*[_Z&BW_\%$G_ ,L:/^%!7?\
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M*** "BBB@ HHHH **** /Q _X*3_ /*23_@A3_V=;^U!_P"L<_$&OT,^-_\
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MM_D:E%%%?JX@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1='N-)\$Z;="QU'QAJ46HWUL]AX7T^]86E]K]V(=)M+DB">[CE(6N,?]HO\
M9_3X<CXP/\</A&GPF:__ +*7XFM\1_!P\ '4_M1L?[-_X2\ZS_8']HB^#61L
M/M_VQ;M6MV@$JL@\T_:H\/?#;P]\._&GQEU_]FW6_P!I/Q;X<\,>&]&TWX>>
M"?!]EXT\?>,[;3/B3X8\:>%_#FF:1JMQ#ILVGZ/\0],T#QO?W-]YEOHL>@3:
M]);7YTU-/N?ST^'?A[QU:>./ ?[7.M_"OXQ^*KA/VB_B[\1/CW\.+#X&>-/
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MTZ-4DEN-7L(("\EP  #],/AI\7_A3\9M#G\3?"/XE> _B?X=MKLZ?=:Y\/\
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MZ)KWQ9X?\/\ B'QAKNJ7NB3VMSI,NEZKKHUZUO-&DO+=OS/^']I\1K']G?\
M8(^(GA[X1_'KPG\3OV;O@K/^S9XO\&^-_P!E2^^(4$']N?"?X16GC&)?AOJ/
MQ,^$_B^PGU+7/ &F>%_ GQC\':OJG@&QB;Q?X=^(*6_@[7)-8TT _<&TN[6_
MM;>]LKF"\L[R"&ZM+NUFCN+:YMKB-9H+BWGA9XIX)XG26&:)WCEC=9(V9&5C
M8KY;_8G^%7C/X(_LH? 3X4_$&XFG\8>!_AOH.B:Y!<7FF:A+I-S&DUS%X=-W
MHD4&A3+X7L[FV\-HV@00Z J:2J:%$FD+9"OJ2@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
J4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>chart-25639f4e732a5a1ea99.jpg
<TEXT>
begin 644 chart-25639f4e732a5a1ea99.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $* 3T# 2(  A$! Q$!_\0
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MPU\++/\ X1/3O",<">'+>'0?"VFWML5N;W4;369+J_\ [2E,D20 'R[\%_\
M@HA/\6_AKXG^)@\/? W3](TGPU\._$+0^'_VBE\<:M\.=9\>^+]'\*M\)_VB
M?!ND_#"S^)'P@^+6A-JI_M#28/!'BWPS'K>GZUH%]XDTIM(;4KW[:^&?Q^^%
MWQ?UCQ/H'@#7KG6]7\$W.H:?XRLFT/7M-D\*ZQIGB_Q5X(O/#WB ZKIMDFE^
M)(M;\&:\XT"Z9-4ET:&P\20VTGAS7-"U74ODFY_X)^Q>*_$&J>+?BO\ '/QA
M\3/%G_"L].^#7ASQ;?>!/AAX9\41_#RW^*'PP^*VH+X\UWPIX=TV[^(OBS5=
M=^$WAFTCU_46T71M#M+CQ#/X;\):7JOB36K^]]S^!_[+UE\#_B-\5?B-H_C_
M ,5:[>_'.\C\7?%K2-:BL&TGQ-\5K;4+NVL_B5I\$ #>'-2M_AT/"_PE?1=-
M+:1<>!OAO\.8YD;6M OM5UH ^1?&?_!3>Y\'_ 3]K[XDS?!JRN/BE^S?\4/'
M_@;P+\()/B++:K\8O#.D:AXGD^'OQ 3Q=_PA$_\ PB.D>+?#'@3XAZ[XGM1X
M?\1MX)NOAOXYTF.[\0_V/%?77U/J_P"W/^S;X;U7Q'HOB7QMJ&C7?A#1?%FI
M>)=1?P1X^N_!]CJW@#X97/QB\?>!;+Q]9^%YO!6N_$GP=\-K#4O%^N_#K1->
MOO&EGHVE:M,^B>?I.JV]CX_X[_X)M?#+QY?Z_JM]XZ\=V%]XC^"G[4GP:U&.
MPDTQ=*ND_:1\4_$C7]-\:WNDR0-#>^*O@UIWQH^,_A?X<2RRI9IHOQ4\8+JT
M%S<7=M);,\9?\$[= \9IXZ\-7OQA\>VGPN\4ZO\ &'XA:+\.+;1/!S67A+XR
M?''X1>-_A!XX\>67B.?2G\0ZGI/V'XC^./&>B^!+Z[72M/\ '?B?4=3GU&^T
M.S\.^'=" .EUS_@HU\ [/6/A#HOAFR^*7C>^^+7QO\$?!2WM-"^$'Q2@U+PQ
M)\1?A]XL^)'@SXBZ]HVJ^#+/5E^%WB7P_P"$K^?0/'-K9R>'=:M[?7+_ $[4
MYK/P?XM?2*'P7_X*1? 'XF?!_0?B7XFU'4_ >M7OPY\#^/\ 5O![>%OB'KS7
M*^.O&>G_  STK2?ACK,7@?3X?C9<'XGZOHOPYW?#&T\03+XRUS0M!NK:UO\
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M:MX4\-:IIFE1K%IFG:CH.DWUCIT2K$BQV%G=6<UM9QJL,*JEM%$@6*-0 (T
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M[>RLM%TRTM(-94@C5H;:WM8X(M3!4;=0CC6\7^&<5TE !1110 4444 %%%%
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MB'_"]_#/_0)UW_OWI_\ \GT?\+W\,_\ 0)UW_OWI_P#\GUY7^N_"O_0ZPO\
MX#6_^5?U9^5W;T^]?UU_/LSV^BO$/^%[^&?^@3KO_?O3_P#Y/H_X7OX9_P"@
M3KO_ '[T_P#^3Z/]=^%?^AUA?_ :W_RK^K/RN6]/O7]=?S[,]OHKR?0/B]H/
MB'6+'1K33M7AN+^1XHI;A+,0HR0R3$R&.\D< K$P&U&.XC( R1ZQ7M9;FV79
MQ1GB,MQ5/%T:=5T9SIJ24:JA"HX/GC%W4*D&]+6DM1!1117H@%%%% !1110
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MXC_Z"6B?^"2__P#F@K;HH Q/)\1_]!+1/_!)?_\ S04>3XC_ .@EHG_@DO\
M_P":"MNB@#$\GQ'_ -!+1/\ P27_ /\ -!1Y/B/_ *"6B?\ @DO_ /YH*VZ*
M ,3R?$?_ $$M$_\ !)?_ /S04>3XC_Z"6B?^"2__ /F@K;HH Q/)\1_]!+1/
M_!)?_P#S04>3XC_Z"6B?^"2__P#F@K;HH Q/)\1_]!+1/_!)?_\ S04>3XC_
M .@EHG_@DO\ _P":"MNB@#$\GQ'_ -!+1/\ P27_ /\ -!1Y/B/_ *"6B?\
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M\VS.WYL5+2-P"<9P#P>AXZ4 ?F'X\_: _P"$.^(%GX:UK]KCQ=;^,;CXD_\
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M[2=X+<PB-IFNKU&D/F0R-N9(XU.& PHXS7YI?\%)_P#E))_P0I_[.M_:@_\
M6.?B#7Z&?&__ )&G3?\ L7K/_P!+-0KX+Q'Q.(PO#52KA<17PU7Z[@X^UP]6
MI1J<LIR4HJ=.49)2ZJ]GU Y ?$7QR2 /$NJ$G.%!MR3@$G %L2< $G X )Z
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M*UJJPC[P_P"%<>!?^A8TO_ORW_Q='_"N/ O_ $+&E_\ ?EO_ (NC_B%&>?\
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MK=6G3ES*5"3LHM6:=[MI(WJ***^R **** "BBB@ I&^ZW7H>G7IV]_2EI"0
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M .D%S7R]7\U>)'_)68[_ *\8'_U$I %%%%?" %%%% 'U5\"/^18U7_L/3?\
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ML'_A*/#_ /T%;7_OIO\ XFC_ (2CP_\ ]!6U_P"^F_\ B: -ZBL'_A*/#_\
MT%;7_OIO_B:/^$H\/_\ 05M?^^F_^)H WJ*P?^$H\/\ _05M?^^F_P#B:/\
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M7KW_  E'A_\ Z"MK_P!]-_\ $U_27!'_ "2N2OOA;K_P94$;U%8/_"4>'_\
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M-&![_F?\:6B@!,#W_,_XT8'O^9_QI:* $P/?\S_C1@>_YG_&EHH 3 ]_S/\
MC2XQZ_B2?YT44 %%%% !1110 4444 %%%% !1110!^('_!2?_E))_P $*?\
MLZW]J#_UCGX@U^WD?^KC_P!Q?_017XA_\%)_^4DG_!"G_LZW]J#_ -8Y^(-?
MMY'_ *N/_<7_ -!% #Z*** "BBB@ HHHH \(^/7_ " M"_[#+_\ I!<U\O5]
M0_'K_D!:%_V&7_\ 2"YKY>K^:O$C_DK,=_UXP/\ ZB4@"BBBOA "BBB@#ZJ^
M!'_(L:K_ -AZ;_TWZ=7MU>(_ C_D6-5_[#TW_IOTZO;J_J;@C_DE<F_[!?\
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M[]%H _';_A8'_!=[_HV'_@EU_P")A_M/?_0I4?\ "P/^"[W_ $;#_P $NO\
MQ,/]I[_Z%*OV)HH _';_ (6!_P %WO\ HV'_ ()=?^)A_M/?_0I4?\+ _P""
M[W_1L/\ P2Z_\3#_ &GO_H4J_8FB@#\=O^%@?\%WO^C8?^"77_B8?[3W_P!"
ME7F/QG_:9_X+;_ KX6>.?B]XS_9:_P"":-UX8^'^@S>(=9M= _:Y_:7OM:N;
M*"YM;9XM,M;O]EW3K.:ZW72.J76H6<)C23]_YGEQR?NO7F'QG^$OACXZ_"[Q
MK\(_&<^KVWA?Q[HDV@:U/H-W;V.L164\T$[MI]W=V6HVT%QOMXPLDUE<H%+
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MMUW^EHOB_P#:=^'GPIU/]GOXU?#KP/\ !/\ :"N?BE>_%&V_9]\40Z;^T?\
MM'#X;ZUX7U/XRWWQ-T*WN/"?@GX2&/7]634-=UG5I?&_Q1\0Q:=X?N;?PO\
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MAY]-^*^K>%/#/Q'UGQ-\6OAIK]YXS\#>,_&.C>)_BWX8@\3O_;K7>OV>K/\
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MSXE\1:I:ZSI?A+3=0 /V9?Q9X7CU/7=%?Q'H2ZQX7T;2_$7B323J]@-3\/\
MA_7'UR+1M<UNQ-P+G2M'U:3PSXC33=3OHX+*]?0-:6WGD.E7WD<7XF^.GP4\
M%^"O#GQ*\7_%[X8>%OAWXPBT>?PEX\\1>/?"NB^#?$\'B#3_ .U]"G\/>)]2
MU6VT76H=9TG.JZ7+IM[<QWVF*^H6S262/.OG7[0W@7X01^ _BAXP\=_"#6?B
M@GBWP]X!\->.?#O@OP1KWQ \5>/]"\#^*-6U7P+X>OO!WAT37OBSP_X?\0^,
M-=U2]T2>UN=)ETO5==&O6MYHTEY;M^9_P_M/B-8_L[_L$?$3P]\(_CUX3^)W
M[-WP5G_9L\7^#?&_[*E]\0H(/[<^$_PBM/&,2_#?4?B9\)_%]A/J6N> -,\+
M^!/C'X.U?5/ -C$WB_P[\04M_!VN2:QIH!^X-I=VM_:V][97,%Y9WD$-U:7=
MK-'<6US;7$:S07%O/"SQ3P3Q.DL,T3O'+&ZR1LR,K&Q7RW^Q/\*O&?P1_90^
M GPI^(-Q-/XP\#_#?0=$UR"XO-,U"72;F-)KF+PZ;O1(H-"F7PO9W-MX;1M
M@AT!4TE4T*)-(6R%?4E !1110 4444 %%%% !1110 4444 %%%% &=JND:5K
MEE+INLZ;8:MITYA:>PU.RMM0LIFMKB*ZMS+:W<4UO*8+J"&YA,D;&*XABFCV
MRQHRWO+CW;MB;LYW;5W9/4YQG/O3Z* $(# A@&!Z@@$'OR#QUYIHC0 J$0*>
M2H48)]2,8-/HH **** "FNB2*R2*KHP*LK ,K*P*L""""""001@@D'@TZB@#
M.TW1])T>PL]*TG3-/TS3-/MX[6PT[3[*UL;&RM8@1';VEG:Q0VUM!&"0D,$4
M<: G:HK1HHH 8(XUSM1!D$'"J,@]0<#D'N.E. "@!0 !T   'T XI:* "BBB
M@ (!QD X.1GL?4>AY-(54YR <C!R <CT/J.3P?6EHH 1551A5"CKA0 ,^N!2
M,B/C<JMC.-R@XSUQD'&<#/TIU% #=B?+\J_+PORCY1Z+QQ^%.HHH *" 1@@$
M'J#R#^%%% !@9!P,CH>XSUQ]::$122JJI/4A0"?J0.:=10 A 8$, P/4$ @]
M^0>.O--\N/&W8FW.<;5QGUQC&??K3Z* "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
=HH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>chart-45031cdc71e753f6a7b.jpg
<TEXT>
begin 644 chart-45031cdc71e753f6a7b.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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M !-XN\?>-=0T6+[1::"_BSQ1XCL;.P\/6FHZC;Z5IOAI7&H7!U,1V_Q+<_\
M!*/X>ZAXG\:>)]4^*&O:AK7BC0?BYX33Q+)X!^'<7Q U#P]\7OBE\-/BWJ:?
M$;XEPZ5'XT^*^M^&=>^&FGZ%X2U/Q3JJ6ND>#IX]*.C3:E9_VY=@'U!XB_;I
M_9^T'P[?ZL-:\6W.O6>N>/\ PL? $GPI^+UM\1+/Q%\-O">E^-O%4?B3P /
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MKX@?M"?#G4?VFM7^)\OBC]HV#7M/\:>/[7X1_$R/P#^QCX%^!3^)3H/B._\
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ME$V0QQ11]+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M44 %%%% !1110 4444 %%%% 'S!\:?VM/AE\"/C/^RO\"O&=AXON_&7[7WQ
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M&>'+OX:>#]<^+/A+Q1K^C^//B;X<^$EI\1_&TE_XFT#PM97'CCP_;ZS]6?\
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M)_\ E))_P0I_[.M_:@_]8Y^(-?MY'_JX_P#<7_T$5^(?_!2?_E)'_P $*?\
MLZW]I_\ 7]CKX@@?F:_;J-T\N/YE^XO\0_NCWH EHIN]/[R_]]#_ !HWI_>7
M_OH?XT .HIN]/[R_]]#_ !HWI_>7_OH?XT .HIN]/[R_]]#_ !HWI_>7_OH?
MXT .HIN]/[R_]]#_ !HWI_>7_OH?XT .HIN]/[R_]]#_ !HWI_>7_OH?XT .
MHIN]/[R_]]#_ !HWI_>7_OH?XT .KYC_ &R_^38OC#_V*Z?^GC2Z^FMZ?WE_
M[Z'^-?,G[93*?V8OC#A@?^*73H0?^8QI5>_PI_R5/#7_ &/\G_\ 5CACPN*/
M^2:XA_[$F:_^H-<_%']F73=*O_B%(^K^&+CQ!#:V,;6]\OAH>,M/\,W5Q>QQ
M?VMK/AD7UG)>V-W;BXT>*_1+\:-?7MM=-I\\DL+Q>AZ9X-L[:\3P WA^'2?$
M7B;X@>)=&M]?T+X/Z5XM\"V4-WX:\(W.EQ2ZMX]-QXJ\+Z5X?6\N[W7_  ];
MF#7_  :FHW=YJ#L=*CMV^0]'UK5_#NJ6NM:#J=]H^K6+R/9ZEIMS):7ELTL;
MPR>5-$0P62)VCD0[D=3AE.!A;37M=L+34;"QUS6[*QU<8U>SM-8U*VM=7!#*
M?[6MX;I(=3+!W#M?I<,X=PY8.P/]M8[),9BL=B<72QT:=.OAL+2IT)T_:PIU
MJ"KQ5:4*KJ4I1H^V]M&CR>SK5+IQH5/:8FM_'N"SC"X; X;"U<$ZE2CB<14J
M5H5%2G.A6^KR=&,Z?LZL95?8^RE54_:4J=FIUJ?L\-1^H8O#'A*^^'.L7#Z?
MX=L]$TGX*Z/XBL%'@_6K+Q^/B+'?Z-9RZO=>.;K18M.U3P_XOU:;4K#P^]OK
MNJZ3K&E7^F6>E^';;4=(U"XM/-?BEHUM>2?"^X\*>!&\.)K_ ,-K&]&A:/8Z
MQJ,\][;^*O'-FTUW=7,,FIZWK4FE:3;3ZK?RHL]P()+A;6RL(H;>W\I;7]>?
M3;31FUS6FT>PN1>V&D-J^HMI-C>JS.MY9:8;DV-I=J[NZW-O;QS*[NZN&=B=
M>[\?^/-0>UDO_''C*^DLIY+JRDO/%6OW4EE=2V\UG+<V;SZC(]K<2VES<VLD
M]N8Y7MKB>W9S#-*CZ8?*<=A<0JT,8ZZ6)Q590K5JT8*%7"JA"$Z=.*A6J3JI
M5ZM:JI58-2C"I*52K4J17S/!XB@Z,L*J-\-AJ+G2HTI3<Z6(5:<H3G)SHPC3
M<J-.E2<:4TXRG3C&G2IP^AO^$;\)W_PUUR\%CX<T_1=,^"6C^)M,$O@S6[#Q
M_%\1OMFC6KZOJ/C.YTB#3]3\/>+-7GU.ST6.V\0ZGI.KZ1>:?8:3H5GJ&C:A
M=V7T!_P3%_Y*9\3\=/\ A!M'Q_X435^<$NN:W-I5MH,VLZO-H5E,;BRT275+
M^71K.X;?FXM-)>X;3[:<^9+F6"V23,LA#9D<G]'?^"8A ^)?Q.R0/^*%T;J<
M?\S$U?)<>8"K@> N+E5Q,\0JZH5::FT_9T_KN @DY<L7.I-P=2K.5Y.4GS2J
M24JD_J>",;2QG''"KIX>%!T95:51QNO:3^IXV3:CS24804E"G&-HJ,?=C"+C
M3A^RFM?\@C5/^P=?_P#I)-7\G&0J*S$*JQJS,Q 55" EF)P   222  "2<5_
M6+K+*=(U3#*?^)=?]"/^?2;WK^7'X;SFU\;^%KH6.C:HUO?+-'INOZGI^C:7
M?3)8W)@MI=6U:WNM)T^[>;RSI%UJMO/ID>MKIOV^&6T,L;?GW@+5='!\8UE%
M3E264U5!SC34W"EFTE%U)M0IJ35N>;48_%)V3/N?&ZG[7%\)4G+D55YK3<U"
M51Q52KE,.94X7G-QO=0@N:;7+'5HXV2.2*1X94>*:-BDD4B/'+&X 8I)$X62
M-P""4=58 @D8()C+*IPS*IP3AF"\ @$\D< D GH"0#R1G]$?']SKNE_$KQ]/
MH5OXG\8>*M8\)Z/&_A_2O&'A'P3\1-!M],\91S_9M0UGPI'<:AXGT_5+:"&Z
M5K>WMO%.GZ++:+KMK9Z#%;224?#]MI>G7=]IOA/6_%.MW5S\6-73XE^*++Q5
MX'EGT'0[[PYX5FL-5^(FI:YIFI:=X_\ "_ABXO?&>EW]J$T_P=XAO](URYO+
ML:G?:-##^NPXO<L-3K_4:3=3#TJ\6LPA[&*=&C5K.M.6'57#4HSJ.AAJM6@E
MCZWLU@E6A54X_EL^%N7$3H_7:B5.O4HRO@*GM6U7JTJ*HTXUW3Q%24*:K8B%
M*NW@:?M'C'1E3<)?G[T..^,X[X/ ..N"00#T)!QT- !/09^E?26M:%XIO/V>
M]/9/"L,.B:!\2)]4LM7TG0(]/_M?PS-X-GMY?&FIW3O)J5_;ZIJ M8$O+N3[
M+8HEGIEC:V21/&_8?"W3O$VDZ(_@2_TKQ;HD-O\ $C6+/X@>(_"_Q1T7PJ/!
M%A>:#X<L;C5?%.F0?;%O[/1+2VN]2L+C5;I?#FJ0_P!K:38SOJSN8?2K<04J
M>%KXB-/#5)T,7B,/.C_:&'IR]E0:<JSE44??49TE/#J,JD:U6%&+G*4'+SJ6
M25*F(HT)3Q%.-?"T*\*KP->:=2NO=I)4W)<C<:KAB)2C3E2I3JR4(QDH\M^Q
MO_R<W\(?^P_J?_J*^(*_H^7H/H/Y5_.+^QZD4?[4'PFCAF$\,?B35XX;A8VB
M6XA3PSXB2&=8G^>)9XE298G^>(.(W^937]'*D$#!!X'0@]O:OYR\>7?BC*7K
MKP_1>J:>N8YCNG9I^32:ZG[[X)Z<.YHO^IY7ZI_\R_+>J;3]4VGT8ZBBBOPX
M_9@HHHH **** "BBHIU=X)ECE,$C12*DRHDC1.R,%E$<@9',;$.$<%6*A6!4
MD$ DW+S\R\'!Y'!]#Z'VI:_''XE?'/X8^$_BM<>"1K'[6GBOQ=H?Q4B\%>//
MB'IG[06I>%['PG9#6?V>_!\WC73_ (1:=XDM?!.LZ0/B+^TQ\._"FD>$/^%2
MV0\4C1O'6LZ/I^KZ5H.F_P#"4?L!IEM<V>FV%I>ZA/JUY:V=O;76JW4-G;76
MI7$$2137]S;Z=;6>GPW%Y(C7$T=C9VEFDLC+:VMO (X4 /Q*_P""ED,-Q_P4
M@_X(5Q3Q1S1-^U=^T\6CE19(V*?L>?$!T)1PRDHZJZDCY656&" :_:>/PYX>
M\M/^)%HWW%_YA=CZ#_IA7XN?\%)_^4DG_!"G_LZW]J#_ -8Y^(-?MY'_ *N/
M_<7_ -!% &3_ ,(YX>_Z 6C?^"NQ_P#C%'_".>'O^@%HW_@KL?\ XQ6S10!C
M?\(YX>_Z 6C?^"NQ_P#C%'_".>'O^@%HW_@KL?\ XQ6S10!C?\(YX>_Z 6C?
M^"NQ_P#C%'_".>'O^@%HW_@KL?\ XQ6S10!C?\(YX>_Z 6C?^"NQ_P#C%'_"
M.>'O^@%HW_@KL?\ XQ6S10!C?\(YX>_Z 6C?^"NQ_P#C%'_".>'O^@%HW_@K
ML?\ XQ6S10!C?\(YX>_Z 6C?^"NQ_P#C%'_".>'O^@%HW_@KL?\ XQ6S10!C
M?\(YX>_Z 6C?^"NQ_P#C%?*'[<L_@WP5^R=\;O%&KV^D:)INC^$4NKS5$TQ-
MUG$=<T>(2C[%:2W1_>2HF(8V;+ XP"1]D5^>G_!5O_E'G^U-_P!DZB_]2GPY
M7TW!=*-;C'A.C)M1K<39#2DXM*2C4S3"P;3::32>C::ONGL?.<85)4>$N**T
M4G*EP]G52*=[-PR[$R2=FG9M6=FG;JC^;UOVF?@6&8'XA:?D$C_D%^(?7_L#
MTG_#3/P+_P"BA:?_ ."OQ#_\IZ_'AR=[<G[S=SZFFY/J?S-?Z<+A/ 67[_%[
M+[='R_Z<>OX>9_G%_K9F'_/C!_\ @%?_ .7G[$_\-,_ O_HH6G_^"OQ#_P#*
M>C_AIGX%_P#10M/_ /!7XA_^4]?CMD^I_,T9/J?S-/\ U3P/_/\ Q?\ X'1\
MO^G'K^'F'^MF8?\ /C!_^ 5__EY^Q/\ PTS\"_\ HH6G_P#@K\0__*>OU9_X
M)-_$SX7_ !1^*GQ9TOPUK6F>*;C3/AYH=_=6LFEWVVVMYO%#6Z3_ /$TTZ"(
M[YE$>(F9P5!90N#7\CN3ZG\S7] __!O.2?V@OVA,DG_BS7A;_P!3QZ_-O&#A
MS!X/PUXKQ,*N)E.C@L+*,9RI.#;S/ 1U2HQ=M6]))[>9^A^$_$>,QGB)PMAJ
ME'"QA5QN(C*4(55-)9=C9>ZY5I*]XK>+T/ZI=9\/: NDZF5T/1U(TZ_P1IED
M"/\ 1)NA$&17\J& R*& 8-&H8, 0P9 &# Y!# D$$$$$@U_6#XBF%OH&MW!4
MN(-(U.8J" 6$5C<.5!.0"P7 )& 3DU_"PG[<OAHI&?\ A7/B3F-#_P C!HO0
MH,?\N?I7X3]'/+\7CJ7%SPM!UO9U,B52TZ<7'GCFW+\<XW3Y9;7M;6UU?]M\
M?LPP>"J\*K%UXT?:4\[Y%*%27-RRRGGM[.$[64HWO:]U:Y]TS$W#O)<?Z1)(
M_F2/.3.\DA&#)(\I=WD( !=R6QQG'%,*(=NZ.-MF-FY%.S&,!<@[0,# 7'0>
M@KX;_P"&Y/#7_1.?$G_A0:+_ /(='_#<GAK_ *)SXD_\*#1?_D.OZ760YNK)
M8*:2V2JT%;9:6JZ:.WR?8_G=Y]D[;;QL&WNW1Q#;VW_<Z_\  ]+_ ')L3=O\
MN/?G._8F_/KNQNS[YS[TACC.W,41V?<S&AV8(("97Y0" <+CD ]:^'/^&Y/#
M7_1.?$G_ (4&B_\ R'1_PW)X:_Z)SXD_\*#1?_D.G_86<?\ 0%4Z?\O:'E_T
M]Z7_  8?V]D__09#_P $XCR_Z<_U;T/UZ_8^AAN?VE_A)#<0Q7$,FOZD)(IH
MTEB<#POK[ /&X9&PRJPW X8 CD U_1M9:;IVGA_L%A967FA/-^R6L%MYFS=L
M\SR8TW[-S;=V=NYL8R<_R,?\$^?VM="\??MF? /P=:^!]<TRXU[Q5K-K'?W6
MLZ7<V]L8? _BN^+R06]LDT@9;1HP$=2&=6/R@BOZ]%.54^J@_I7\@_2$P>)P
M7%F3T\52=&<^':-2,7*$FXO,LRC>\)22UBU9N^FQ_5/@1C,-C>&<UJ86JJM.
M.?UX2DHSC:?]FY9*UIQBW926J36NXM%%%?@I^WA1110 4444 %(<X..N#CZ]
MJ6JM]=+96=W>/%=3I:VUQ<M#96TUY>2K!"\S16EI;J\]S<R!"EO;PHTL\S)%
M&K.Z@@'Y3:S;:K>_M;_$G_A-M ^)^AWES\6/A+=^"[[X<_LK_!OQ+X/\>^"O
M!.D>%+OPAKOBKXF>,/AMXI^*.JZOX%\6ZCXPM-9\66NNZ/I/P]L;JU;P%-I4
MUK?:S/\ K$.GIV].G]/3VK\0O'WPM/BK]I35=:L_ ?B/['\1_CG\!_C$WQDU
M_P#8P^->K_M!_#7_ (1JQ^%]U;_#SP+\9HM.3PAX=\'?9_#\NBW6KZGJ&B6_
MPLT?Q9\3/#6O>#/%UT^J7=[^WH&!CZ_SZ?3T]L4 ?B#_ ,%)_P#E))_P0I_[
M.M_:@_\ 6.?B#7VW^W5^UY>_L??"[P]XST[POX9UB_\ $OB:T\-VNN_$KQE+
M\-/A%X986_\ :$TOCOXBQ:'XE/AZXUBUAN-+\'VAT:5-<\0M'9R7=G%#(9OB
M3_@I/_RDD_X(4_\ 9UO[4'_K'/Q!K](/VIOV>]:_:,^&R^#?#OQ=\8?!_5H[
MNPN5UGP]IOA?Q1HFK64>J:/?WNC^+? _C;1=>\,^)=/E32HYM-DFM+74M'U6
M."ZM+\Z?/K.DZN <O??M1^*;+XJ?LK?#J3X*ZO'HW[0]KJ9U[XCMXV\)7W@W
MP1K=O\(/B/\ %73/"WAJ\T&XU>?XH:I?6_PXOA=ZOH]OHWA'3?#^JZ-K1UZZ
MU74X/#,?1_M=_M$ZY^S)\(M3^)F@?"G7OBQ=:9=Z>+[3=/UK1_"VA:!HCZGI
MMMK7B;Q7XFU9KB6QT[3+&\E;3M-T+0_$GB'Q#K9L-'L=*@M+C4-<T?PGQ#^P
MKXSTV;]G/3/@E^T;K7PG\$_LR_;M2\"^&+SX4^ ?B!/J7BS7O#'Q#\%^*_$6
MO:UJT^C".#7?#?Q*U^&W\,>'-)T#PSX;OELG\.Z;I^CV=MH4'8?'W]F'XV_M
M _#'XH?"S5OVEKSPAH'Q!^(VLZE:3:9\*? /B+4- ^$LNF>&4T+X:64NHPZ1
M!+-I_B?0K_Q1+XJU2#6-<G37)M N+FYLK&QN8@#F_C[^W+J'P7\7?&O[/\/O
M#.J_#']E[P_\*_$WQ\\1>(OB4OA#QR-)^+-S?G2I_A'X%?PGJ]AXW&CZ58RW
M+3>(_%G@>T\7>)8M0\ >#KC4/$6C:H]OJZ+^V;K]_P#$#PA/J?PQTG2OV?OB
M1^T%X_\ V7O ?Q/7Q\][XRN?BA\/]3^(?ADZUX@^'L7A)-'TOX<>-?'7PM\8
M>"?!VLZ?X^UCQ%+J!\):KJOANSTKQ7*WAW/^)'[" ^.&K> M8^-OQ5C\=W>A
M^%[/POXXN8?@I\&=%USQ3I]MX@O]<U6S\(>.'\-ZQ\1?A'I'CVVO(?#GQ'T?
MP?XPF@UW0+*,>'YO!^M7VL:UJ77Z=^Q;I6F^/[+7(?BAXS?X:^&?BOX\_:!^
M'_P=GTCP=/X;\&?''XCCQK<>(/%]OK\NB/XIUC0+'Q%\1?&_CCPQX$U2_?1-
M$\:>)[W4WN-0TS2_"NA^' #/_:?_ &N/%7[.?C#P78R^ _AYJ_A/Q;K?@3PW
MX?LM>^-ND^%/C/\ %[Q+XP\76/AG6O"W[._PAC\,:]<?$;Q'X!L=9T+Q'KFG
MZ[XB\&+JEMJ0L]-E@M;6\UV#[I!R,X(Y8<_[+$9^AQD>Q%?"?Q*_8X\8_%_P
MK:^ ?B+^T[\3O$O@?Q-X(\!>$OC1X?N?!_PH@_X6)?\ @VUTT:SXK\,7MMX0
MCF^#NL_$;4=-AU+QC#X%C_LW3KI8;_X=6O@+7;:+7*^[ ,#'N3^+$L?U)H Y
M/QUX[\)?#3PIK/C?QQK=IX>\,:!;Q7&I:I>">18_M-W;:?8VMM:V<-S?ZEJ>
MIZE>66E:/I&F6EYJNLZM>V6E:597FHWEK:R_,=M^WS^RV?@9H_[0VL_$.X\'
M_#[6]?T/PC96WC7PEXP\*^.V\8^(3HK:9X1'PVU?0[?QS<>(9+3Q!I6LRV5A
MH5Y%!X9GD\6R70\*VUSK4/M/Q[\!WGQ,^$OB_P $V'ACP/XRN]<M]+2+PS\1
M=0\1:)X5U9;'7])U6:WN?$?A*VO?$_A+54AL)+CPQXTT&QU#5?!GBJ#1/%5G
MIVH3:0MG-^/VC?LR?MJ>&_\ @GQ=? V]^&L?Q*^(?C)?#VE>#_!WC#]H+3_$
MNL?L\>$[3PQ\/I/$NDZE\9_'/AVVUGQA;>)?&7A?Q+J5MX=TVWUU?!UEXBL/
M"]IXG\0^']*@FL0#]P/%7BWPOX'\.:OXO\9>(=%\*^%O#]G-J&N>(O$6IV>B
MZ)I%C P2:[U'4]1FM[.SMT=E0RSRHI=D1-SNBM\T:K^VU\#+3X9_!CXKZ#)\
M2_B%X:_:!L)=8^%%A\,O@S\5/'_C'Q-HMKH,WB2]UJ7P)X=\*7?B[0=+T_2H
MXY+^Y\1:/I7V*[O-/TRY2/4KZVM9)[KXE_'O4]-O;:__ &3X[VZL_AGX;^(4
M.@WOQ<\%7'VCXFO\1]1M$^&$>H76AMX5%WH&@:)I_CZ'QM%K<UG%=W%GI*Z=
M97T5GJES\)_#K]G7XX7O[,_[//P_^-?[''@;QYXA^ T?B+P?>^#M7_:6ET^U
M\0:9XDT"WA_X3#1-0\*Z2_A+Q#I7]I2R:?KGA#XE:5%>6"V-AXR\*2S>(-(L
M;#4 #[Z\9?MC? KX>7/AFR\<:UXK\,W6O>%/"/CG68]2^&OQ$,?PN\)^.M0G
MT7PKKWQONK/PS=V7P3TS5]>L]1T.&[^)MSX:AAU'1?$2W3P6GAKQ!>:9WWQ:
M^/7PY^"S>&+3QA=>);_7_&MYJMEX0\&> O OC;XG>//$AT"Q34_$=[I'@CX>
M:!XE\37>D^&].EM[K7]8&FKI>E_;-,M+J[34=8TBRO\ \QY/V,_VI_#OPM^)
M7PGCN?!'Q1O?VJ/V6/ '[._Q7^)/B7X@:^MU\(-;\-:#\3_ >K>)(AKWAK4?
M%?QB\.6/PS^(FG67AB>^U31_&.O^/?!$FM^,([&'XBZSK?ACZ7^/FL_MKCPI
M8^#O@C\#=&BW>./$W@B^^)-C\<_!DWQ)T7X+Z1X?T$^'_B'X+L?'_@6'PO#\
M3_'NKO?:1_9/BF?7]%^'G]AKXSU*V^(=U<:=X74 ^V/ /CSP?\4?!?A;XB>
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MPU26SMI=1L;*]?4K.ROI(4>[M+749+/3I+^WMIS)##>2:?8O=1HLS6EN7,2
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MG4PLL1C*E/"NOB77Y:T?;8BC2I.=U4K**^G_ -HGX!?"?X-0Z+XI\,^$M/\
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MT6CJU)SES59R3GR1=1117\]'[V%%%% !1110 4444 )@9S@9Z9QSCTS2T44
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M[MQ_PIKPM\]G<RVLH_XK[=]^)E)^YMP<C:SC'S9K\ J_H'_X-Y_^3@OVA/\
MLC7A;_U/'K\M\:_^36\8?]@.$_#-<O/TSP<_Y.;PC_V'8K_U68X_J4\4Z#$G
MAGQ&W]IZZV- UH8?5[QE^;2[M<XW\E<[ESP& )!Z5_FPQ_ZJ+_KE%_Z+6O\
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M &'8G_U68X_JQ\6?\BOXC_[ .L_^FVZK_-$C_P!5%_URB_\ 1:U_I=>+"/\
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MVGM#\0?M ?M^K9?"']HJ]^%_A(Z=^U;JUI.WAB'X+?!'Q]$=7D;PE<"^U/\
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MD?S:?\0NO[!__1P?_!1'_P 2ZU3_ .8FO1?AQ_P;J_LT?!W4=2U?X2?MG_\
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M&N_[![[F_P"&@O\ @H@!YDH '[76J@!5D=5'/@ICP .K,?4GK2_\0NO[!_\
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M/V5OBU>WOQUU3X&ZV]SX,_;"?P-X._:D\!V&@^&I?B?'X9MO %Y\'?$_Q#^
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MA6#P5I.H^$_%7B=?&GBF.[2*>S\/6\GARTT.X+1QW,6K>(M(@D1&>1!^:O\
MPQ?^TCK7@/X,>&="^)_@K3/AOH-MK?Q/^)'P4_:3^%%_XSUCQ_\ M(^/?BOX
ME^,?C+Q]\5M3^ O[0OA_P/XD\.67BWQ'<ZAX5^#&GW_B/X;Z#K'DZMJNK>/'
MT3PB/#GZW1+.L$:RM"UR(E\UXHWC@:?8/,=(WEDD6)I=S*CS2.%(5I'8%R ?
M$VF_MR>#]3^'7QZ^(P^&7Q9TVU^"WQ<\&_!K2_"_B+P[8^%?''Q-\4?$O1_A
M!=?#.X\.^&/$^IZ1=>$]-\>ZW\:?"&AZ-_PLV3P;J>G12R:_XJTWP[I#(X]9
M^!GQZ'Q9U+XD^"/$O@V_^&OQ9^#NNZ#H?Q&\ :AKNA>*DTY/%WAJS\7^$-?T
M;Q/X;FDTW6= \2:'=R-9R7-KHNM6FH:7JUCJ>AV:V]I=:A\OZ!^R;^T7K,7[
M5^C_ !B^)W[-/C3PM^U#=V_B:\T+3_V<?&LNG:#XOTCX??"KX7Z)#K&D>-?C
MQXITSQ?X)?PS\+[>\US1XU\->)IM>U>34/#_ (P\.R:9I\D?M/[)W[*UG^S=
M:?$/5K_5=!UWQU\4]<\.ZOXLU'PKH7B'P]X=@M/"'A6Q\)>&=*L(/&/C?XD>
M-];N;>SM[_5=<\6^._'OBKQ7XCU[7-2GGO['1+;0?#^B@'U[1110!\C?&G]K
MWP?\!_'][\/_ !QX7\2KJ.L?"J7Q_P#"&YTS[#>+\:O%^G^+K/P5K/P5\$6C
M2PW/_"T[36O%7PRDT[1K\1VFN:1X^CUFQO!IWA#QG/HWSKXS_;^^*_PZU[]I
MK3_&?[)]_8Z)^R_\++#XJ>+=<TWXY>!M5DUS2_%VG>.;CX:Z;H6D#PY:7"WW
MBK4? >IZ;JLNHW%M:^%EN+6^FDU:'SHT^Q_C3\"M-^,7BS]G#Q3?7NG6<W[/
M?QU3XV:?%?:!;ZU/JEW'\(?BW\+!IFG7<US;OX=O,?%$:N-;@CO)1%H[Z9]D
MQJ/VNT\.^-_[&NH?%FS_ &S!IOQ%LO#NH?M5? OX8?"/2I;[PC/K-EX"U+X9
M1?%$V?B/4+:V\2Z1/XJL=5NOB';O<Z):W?ANXM[?1YHH=8:74(Y[$ ]/^#G[
M0^K>.?'7BGX/?$[X8ZM\'?C#X5\(>'_B&_A>Z\4>'/'7A[Q-X#\2:SKWANU\
M2>#O&7AIH(=372?$OAS4O#_BC1M8T3P]KV@WTFCW4NG7.B^(=#U:^Q_$/[1?
MQ,MK2*'P9^RY\6/&7B"7QK\9]":PN-6\&>"-!M?"OP;\5CPW_P )C?\ C/QE
MJNF:):?\+0AGL=5^$GAY@]]XIL+B\U*_O-!\.:#X@\1:;9^#GP(^(&A_%7Q9
M\>OCCX]\(>._BIXB\!^'/A=HMK\.? NL_#SP#X)\!Z!XBU[Q==V>EZ3XC\=?
M$/Q'K'B'Q9XHU[^TO$FNZOXB2T2RT/PSH^A:#I"6&K7^OX7[8'P-^/'Q[T?P
MIX/^%_Q8^'O@3X=.^OCXQ>"?&_@#QWXF7XNZ7=VMG!H/A&\\4?#[XL_"_P 1
M>'? J3?VI-X\\-:=<R3?$>QFL/#&JZQI_A$^)]!\5 'F-Q_P4:\!7N@:?\2?
M"'PV^(/BKX)Z+\.O@M\4OC+\3TD\,Z,GP=\*?'O0-+\6^#)-7\*:CJYUWQ1J
M'AOP7K6D^//B?8^&#<GP?X+U.PU32YO%FHW(T5?T7!R,^Y'X@D'KCC(.#W'/
M2OSB\6?L.^,?%UGX]\-?\+1\%^$_A]^T=X.^%/AG]J?P-X3^%=_:V&NO\.O#
M.G>!M;7X%75S\0GM_A/HWQ$^'>D:/\-O$&D^*-'^)QT?PKHNE77ABYTW7HKR
M^O/T= P.I/)//N2<?09P!V  H 6O!_CC\>M!^ ;?#76/&^E7MO\ #WQM\1-*
M^''B?XC"ZM+?PW\+=0\56-_!X'U[QT]SL>Q\)^)_&L.C?#O^WHY/LVB>)O%O
MAF75U@T:ZOM2T[WBO!/VI/@98?M,_LZ_&C]G_4]0L-)L?B_\.?$_@&?5=4T&
M#Q18:6/$.GR6<>HW/A^YNK&'5TL96CNA8O>6HF>) +B%@LB@'RQ+^W)\4-7^
M(G[/_A;P/^RWK&O>$_VE;3Q3K_PU\9Z_\6_"?@N[;P;X.EM]3U7Q1K_@S4/#
MVHZWI$>I>!-3T+QSX:T@W%QJNI6&M6VEZG!H6JP7<4/0? S]N:\^*>H?"BX\
M9?!#Q/\ ##P+^T)XE\;^%O@7\0)_&7A'QCH_BC6_!UGXSUVVT'Q?IVC-8ZS\
M/O$'B_PC\/\ Q?XE\+6MY::WHUVOA_4-!OO$.G^))M%TO6/H;QQ\$?\ A+_C
MC\ ?C%%XACTN'X(6GQ:M/^$;72/M'_"0K\3O#&@^'(O*U);^W32%T,:)]IV?
MV??B_6<6ZFS$/F2?*_P"_8I^*?P_'P'\,_%;XS>!_&WPR_9?\6>-/&WPC\,^
M!?A/K/@?7M;\5>(M+\?^%_#FO?%#Q1XB^)?CR+5_^$,\(_$WQA:6>B^$-"\)
M6&K^)+^S\1ZE<?9M(L=!H ^KO&WQO;P)J/Q1AU+X9_$[6M*^'?@CX<^*=)U+
MP=X5O?%<_P 2-;^(>N^.O#\7@3P/I6F(9[KQ'X>O?">CR^)KO4[C3?#OA[3/
M&NAZ[XCUG0_#UKK&L67C:_MAWGB3P/\ LTZS\+O@OXO^(/C[]IKX-_\ "^/#
M7PW7Q3X%\+W'A?X>:9X?^'FM>*KSQ3XNUS5E\-?VIH]]\4?!?A33M/T1]537
MO$FLQR17>G^%[+5_$^F?3GQ-T_XAZIX'UW3OA3K7@OP]XYNX+>WT75_B#X9U
MWQAX2M$>[@74CJGA[PUXK\$ZS?F72C>0V/V3Q+IPMM0>UNKC[5;02V<_YYZ?
M^PO\8;W]GC]G?X/^-_B+^SKXK\7?LV6FD>$_!?C.[_9^^(T>EW/@?0_ ?AOP
M/82/8Z?^T9HOCC2/%=Y%H]]+XOM],^(H^''Q T#47\&>+? 5[IJ1WT(!]]_!
M;XN^#_CS\*O ?QA\!3W<WA/XA>&]/\2Z.NH0PV^I6<5XC)<Z9JD%M<WMK#JF
MD7\-WI6IQV=[?62W]E<BSOKVU$-U-Z?7D?P&^#GAO]G[X.?#GX,>$I9[G0?A
MSX4TOPS97UU!96EUJ<EG&TE_JUS9:9!::587&KZG/>ZI-I^D6=EI&GR7;66E
M65GI]O;6T7KE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !\7'_+K<?\ /:3_ *95^O7_  0XAFC_ &^=!9X9T7_A3_Q7^9X)D4'R_#&
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@4 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>chart-aeab2001c05c53f8b61.jpg
<TEXT>
begin 644 chart-aeab2001c05c53f8b61.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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MMK"81EY*YKXN?\$XOAA\5/#_ (2MM3U'1K_Q+X%^,G[1?Q;\,:I\0/A;\/\
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M_P -/C[\+OB]K'B;0/ 'B"?7-7\%7%_8>,;(Z'KVFR>%=7TWQAXJ\#W?A_Q
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'RS\<OVN/AO\ _C%^R
MQ\#?%ND>,M4\;?M??$'QM\-OA;)X<T[1[G0=/UWP#\.-9^*&NW7C34=3U[2K
MG2-)?PYH=W;V$^DZ=K]Y<ZO+:VLEA;VK37T'T,-6U5@&'AR[P0"/^)CI'0C/
M_/[7XP?\%)_^4DG_  0I_P"SK?VH/_6.?B#7[>1_ZN/_ '%_]!% &'_:FK?]
M"Y=_^#'2/_DVC^U-6_Z%R[_\&.D?_)M;]% &!_:FK?\ 0N7?_@QTC_Y-H_M3
M5O\ H7+O_P &.D?_ ";6_10!@?VIJW_0N7?_ (,=(_\ DVC^U-6_Z%R[_P#!
MCI'_ ,FUOT4 8']J:M_T+EW_ .#'2/\ Y-H_M35O^A<N_P#P8Z1_\FUOT4 8
M']J:M_T+EW_X,=(_^3:/[4U;_H7+O_P8Z1_\FUOT4 8']J:M_P!"Y=_^#'2/
M_DVC^U-6_P"A<N__  8Z1_\ )M;]% &!_:FK?]"Y=_\ @QTC_P"3:/[4U;_H
M7+O_ ,&.D?\ R;6_10!@?VIJW_0N7?\ X,=(_P#DVC^U-6_Z%R[_ /!CI'_R
M;6_10!@?VIJW_0N7?_@QTC_Y-H_M35O^A<N__!CI'_R;6_10!@?VIJW_ $+E
MW_X,=(_^3:/[4U;_ *%R[_\ !CI'_P FUOT4 8']J:M_T+EW_P"#'2/_ )-H
M_M35O^A<N_\ P8Z1_P#)M;]% &!_:FK?]"Y=_P#@QTC_ .3:/[4U;_H7+O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-7ZIX3?\CK,?^Q7+_P!2\,/HO5_H=1_9VG_\^-G_ . T'_Q%']G:?_SXV?\
MX#0?_$5<HK]\$4_[.T__ )\;/_P&@_\ B*/[.T__ )\;/_P&@_\ B*N44 4_
M[.T__GQL_P#P&@_^(H_L[3_^?&S_ / :#_XBKE% %/\ L[3_ /GQL_\ P&@_
M^(K&\0W.D^'=%U#6KC2X+B'3X1/)#!;6HFD4R)'A#*JQYRX/S,!@'OBNEKA/
MB;_R(?B;_KP7_P!*8*\_-L15PF59GBJ#4:V&R_&8BC)Q4E&K1PU2I3;C).,D
MIQ3<6FGLU8:U:]4>;?\ "Z/"8_YE6^_[\Z1_\=H_X73X3_Z%6^_[\:1_\=KY
ML;J?J?YTE?SU_P 1(XL_Z#:'_A%AO+_IWY?B^X?)?C_G_5WY6^E/^%T>$@,#
MPI?8]/(TC'_HRC_A='A+_H5+[IC_ %&D=/3_ %G2OFNBC_B)'%G_ $&T/_"+
M"^7_ $[\OQ?</DOQ_P _ZN_*WTH/C1X2' \*WP'H(-(_^.5V?@OQKX?\:WM[
M9V>@/9O96L=T[W=OIY1UDF,(5! 9&#!AD[@!CH2:^.*]W^ W_(<UW_L$6_\
MZ6M7O\+<<\1YGQ!EF QF*HU,-B:U2G6A'"T(2E&.'JU%:<(*47S4XNZ?=;,.
MCTV7ZI?UZ^A]*_V=I_\ SXV?_@-!_P#$4?V=I_\ SXV?_@-!_P#$5<HK]V$4
M_P"SM/\ ^?&S_P# :#_XBC^SM/\ ^?&S_P# :#_XBKE% %/^SM/_ .?&S_\
M :#_ .(H_L[3_P#GQL__  &@_P#B*N44 4_[.T__ )\;/_P&@_\ B*FBM[>W
MW>1!##NQN\J)(]V,XW;%7.,G&<XR<=:FHH **** "BBB@ HHHH *BGC6:&6)
MO,VRQ21MY4LL$FUT*GRYH7CFB?!.R6*1)(VP\;JZAA+2-G!P<'!P>F#CKT/3
MZ'Z4 ?BW\2->US3/C%KOPH\(_L8?"R\\(^#OBYX0TOQ!/XA_9V\1^*KOXC^"
MO&NN_L_>#?"EQHWQ/8:=X6_X3/Q3/\0_CM\2-6\?+=>.;?X:^%_@8(/B;ING
M:AXDO==TW]EM*TVTT?3-/TFPCDBL=,L[;3[*.6YN;V5+2SA2WMDDN[V:YO+E
MUAC13-=7$]Q(1NEED<LQ_(3Q-XB\/Z7^V;XYT+QPWA+X@W>H?&CX76OA+Q'K
MO[2/[3?AB/X77'B/PUX%7P_\)M5\.^"_@3J/[.GA7Q'?:A:+XG\"?#GQ!\4-
M,\0_$N;Q=I@\10MJ7BC2;[6?V)'3\3_,_KZCL>* /Q!_X*3_ /*23_@A3_V=
M;^U!_P"L<_$&OT,^-_\ R-.F_P#8O6?_ *6:A7YY_P#!2?\ Y22?\$*?^SK?
MVH/_ %CGX@U^AGQO_P"1ITW_ +%ZS_\ 2S4*_//$_P#Y):I_V'X+_P!+F!XU
M1117\Y %%%% "KU'U'\Z^X_AU_R(WAC_ +!-O_)J^'%ZCZC^=?<?PZ_Y$;PQ
M_P!@FW_DU?JGA-_R.LQ_[%<O_4O##Z+U?Y1.THHHK]\$%%%% !1110 5PGQ-
M_P"1#\3?]>"_^E,%=W7"?$W_ )$/Q-_UX+_Z4P5Y.?\ _(BSK_L4YC_ZAUAQ
MW7JOS/B-NI^I_G24K=3]3_.DK^11!1110 5[O\!O^0YKO_8(M_\ TM:O"*]W
M^ W_ "'-=_[!%O\ ^EK5]7P-_P E9DG_ &$U?_43$#6TO3]4?4-%%%?U*(**
M** "BBB@ HHHH **** "BBB@ HHHH *H:K=M8:9J-ZB6TCVEC>72)>7365H[
M6]M+,J7-XMO=M:6[&,">Y%K<FWB+S"WF*")[]4=4BN)M-U"&U19+J6QNX[=&
MU"ZTE7GDMY4A1M4LH+F\TY6D95-_:VUQ<V8/VF""6:)(V /PHO\ QY\-?B1\
M:8H='^*GPR7X:_%GXQ_!SXD^.?@]H/[6NBQ>%/&OQ/T=_AUOU9O#]Y^QEJ/Q
M%=U\5>$/#DDGA#PS\;O!WA#XF7?A72]1U[3M%C\7>*M.N_WD'3\3^/)R>@Y)
MY/&,].*_%]-4MO!WQVTCX>0>)O%6NZGX6\:_#C1?$\$/_!0;_@H+\0I= \2:
MK9^$]=U+PYXET/2O@'XD^'%W>60UN*:'PSXR\;Z/;^(?"]WH6I^,H_">G^)K
MBUT_]H!_4]R>Y]?Y=!T'% 'X@_\ !2?_ )22?\$*?^SK?VH/_6.?B#7Z&?&_
M_D:=-_[%ZS_]+-0K\[_^"EJ/)_P4@_X(5(DTD#']J[]ITB6)8F=0O['GC]F
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M_0R:K_X"Z#_\IZ -NBL3^R]1_P"ADU7_ ,!=!_\ E/1_9>H_]#)JO_@+H/\
M\IZ -NBL3^R]1_Z&35?_  %T'_Y3U=L[6YMO,^T:E=ZAOV[/M45A%Y6W=NV?
M8K.TW;\C=YGF8V#9MRVX O4444 %%%% !1110 4AZ'')P<#\/?C\Z6D.0"1U
M ./KVZ<_E0!^9J_##XUZ+^TI\3_$,?AG]H]?!7BWXN^#O%&BZA\)?B)^SKX#
M^$EQX?A\-^#-)U2\\6>!M<\6/\0M<U47^D:HWCO7IK)?$/C/2DL+72[""/3-
M*LU_3,?X]?K_ )Q[5^<MYX_^.C?M%>//#WB;5?VI= \(:9\3_"%A\/8?A3\
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M_P#M/6?^A=D_\&NG?_%T?VGK/_0NR?\ @UT[_P"+KH** .?_ +3UG_H79/\
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MBBB@ HHHH _$#_@I/_RDD_X(4_\ 9UO[4'_K'/Q!K]#/C?\ \C3IO_8O6?\
MZ6:A7Y._\%G/C=\+_P!FG]L/_@C'\?OC?XI3P)\(/AI^U%^T7?\ COQO=:1K
M^L:=X;LM;_95\8^'-+N+ZU\-Z5K.JLMYK6JV%A"MMI\[F6?>ZI!%/-%E_%#_
M (+R_P#!)#Q+KUE>Z3^VEX-FMX='MK21F^&_Q\&)X[F\D=?D^$<@X65#U!YZ
M5\'XC87%8SAJI1P>&Q&*K?7<'+V6&HU*]7EC.7-+V=*,I<L;KF=K+JP/T1HK
M\I?^'X?_  2C_P"CS/!?_AN/C_\ _.@H_P"'X?\ P2C_ .CS/!?_ (;CX_\
M_P Z"OP'^P,^_P"A)G'_ (;,;_\ *//\^S _5JBORC'_  7&_P""4+%@O[9_
M@ABC;'"?#KX^L8W"JQ20+\(28W"LK;'"OL9'V[74EW_#\/\ X)1_]'F>"_\
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M!KKZ?JC^ARBOQ8_XB(/^"-O_ $>YX._\-M\>/_G44?\ $1!_P1M_Z/<\'?\
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MX(\->&([7X8_%73_ ![=W_@CP[KT6OWVA-\,]7-EXBNH[[4DK](*_G^^%O\
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M[0OPTLKR&WN9(I]2EE\7^/O"^GFTT])[J.&]EU"2);*RNYX?HSRU]!_WRO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
=HHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>chart-ca66c4c36dc65756984.jpg
<TEXT>
begin 644 chart-ca66c4c36dc65756984.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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MMK"81EY*YKXN?\$XOAA\5/#_ (2MM3U'1K_Q+X%^,G[1?Q;\,:I\0/A;\/\
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M_P -/C[\+OB]K'B;0/ 'B"?7-7\%7%_8>,;(Z'KVFR>%=7TWQAXJ\#W?A_Q
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'S!\:?VM/AE\"/C/\
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M.&%_^6_U9^5W9]G]W]=U]YZG17EG_"Y? ?\ T$+W_P %5_\ _&*/^%R^ _\
MH(7O_@JO_P#XQ1_K7PU_T/LH_P##AA?_ );_ %9^5RS[/^O^'7WGJ=%>6?\
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M(K%0S85OVCCUB\\M/^*=US[B_P .C^@_ZC5 '0T5@_VS>?\ 0NZY_P!\Z/\
M_+JC^V;S_H7=<_[YT?\ ^75 &]16#_;-Y_T+NN?]\Z/_ /+JC^V;S_H7=<_[
MYT?_ .75 &]16#_;-Y_T+NN?]\Z/_P#+JC^V;S_H7=<_[YT?_P"75 &]16#_
M &S>?]"[KG_?.C__ "ZH_MF\_P"A=US_ +YT?_Y=4 ;U%8/]LWG_ $+NN?\
M?.C_ /RZH_MF\_Z%W7/^^='_ /EU0!O45@_VS>?]"[KG_?.C_P#RZH_MF\_Z
M%W7/^^='_P#EU0!O5PGQ-_Y$/Q-_UX+_ .E,%;O]LWG_ $+NN?\ ?.C_ /RZ
MKB_B)J=S<>"?$43Z+JUJKV(!N+@:8(8A]H@.Z3R-4GEQVQ'"[9(XQDCR<_\
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M^0*/[?M/^?36_P#PGM<_^0* -NBL3^W[3_GTUO\ \)[7/_D"C^W[3_GTUO\
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M:^(OAE_R/GAO_K[N/_2"[K[=K]]\)O\ D1YA_P!C>M_ZA9> 4445^I@%%%%
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MH/H/Y5^B5U_Q[7'_ %PF_P#1;5^=J]!]!_*ON?%W^+D'^'-?_>8(6BBBOQL
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M:.T6XN!;(XA^T3[/->_10!^('_!2?_E))_P0I_[.M_:@_P#6.?B#7Z&?&_\
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M]\2W\+6K^-;V^U.&[MM1N;K77=KF=KZ"_OH[F*7=;2_;+ES!YL\CMJI^SO\
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MH:_??";_ )$>8?\ 8WK?^H67@7Z***_4P"BBB@ HHHH **** "BBB@#\0/\
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MF7_J/BAQW7JOS/B-NI^I_G24K=3]3_.DK^;Q!1110 5[O\!O^0YKO_8(M_\
MTM:O"*]W^ W_ "'-=_[!%O\ ^EK5]7P-_P E9DG_ &$U?_43$#6TO3]4?3-T
M!]FN.O\ J)NY_P">;>]?G<O0?0?RK]$KK_CVN/\ KA-_Z+:OSM7H/H/Y5]SX
MN_Q<@_PYK_[S!"T445^-@%%%% '=_#+_ )'SPW_U]W'_ *07=?;N,>OXDG^=
M?$7PR_Y'SPW_ -?=Q_Z07=?;M?OOA-_R(\P_[&];_P!0LO ****_4P"BBB@
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M_D?/#?\ U]W'_I!=U]NU^^^$W_(CS#_L;UO_ %"R\ HHHK]3 **** "BBB@
MHHHH **** /Q _X*3_\ *23_ ((4_P#9UO[4'_K'/Q!K]#/C?_R-.F_]B]9_
M^EFH5^3O_!9SXW?"_P#9I_;#_P"",?Q^^-_BE/ GP@^&G[47[1=_X[\;W6D:
M_K&G>&[+6_V5?&/AS2[B^M?#>E:SJK+>:UJMA80K;:?.YEGWNJ013S19?Q0_
MX+R_\$D/$NO65[I/[:7@V:WAT>VM)&;X;_'P8GCN;R1U^3X1R#A94/4'GI7P
M?B-A<5C.&JE'!X;$8JM]=P<O98:C4KU>6,Y<TO9THRERQNN9VLNK _1&BORE
M_P"'X?\ P2C_ .CS/!?_ (;CX_\ _P Z"C_A^'_P2C_Z/,\%_P#AN/C_ /\
MSH*_ ?[ S[_H29Q_X;,;_P#*//\ /LP/U:HK\HQ_P7&_X)0L6"_MG^"&*-L<
M)\.OCZQC<*K%) OPA)C<*RML<*^QD?;M=27?\/P_^"4?_1YG@O\ \-Q\?_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
?!1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>chart-ca42041222025d3abbc.jpg
<TEXT>
begin 644 chart-ca42041222025d3abbc.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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MMK"81EY*YKXN?\$XOAA\5/#_ (2MM3U'1K_Q+X%^,G[1?Q;\,:I\0/A;\/\
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M_P -/C[\+OB]K'B;0/ 'B"?7-7\%7%_8>,;(Z'KVFR>%=7TWQAXJ\#W?A_Q
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'_Y1T?V3>_\ 0QZW_P!^]!_^4= &W16)_9-[_P!#'K?_ '[T'_Y1T?V3>_\
M0QZW_P!^]!_^4= &W16)_9-[_P!#'K?_ '[T'_Y1T?V3>_\ 0QZW_P!^]!_^
M4= &W16)_9-[_P!#'K?_ '[T'_Y1T?V3>_\ 0QZW_P!^]!_^4= &W16)_9-[
M_P!#'K?_ '[T'_Y1T?V3>_\ 0QZW_P!^]!_^4= &W16)_9-[_P!#'K?_ '[T
M'_Y1T?V3>_\ 0QZW_P!^]!_^4= &W16)_9-[_P!#'K?_ '[T'_Y1T?V3>_\
M0QZW_P!^]!_^4= &W16)_9-[_P!#'K?_ '[T'_Y1T?V3>_\ 0QZW_P!^]!_^
M4= &W16)_9-[_P!#'K?_ '[T'_Y1T?V3>_\ 0QZW_P!^]!_^4= &I=?\>UQ_
MUPF_]%M7YVKT'T'\J^^+G2KP6]P?^$BUHX@EX,>A8/[MN#C1 <'V(/H0>:^!
MQT'T%?B?B[_%R#_#FO\ [S %HHHK\; **** .[^&7_(^>&_^ONX_](+NOMVO
MAWX<QO-XV\/1QSRVSO=3A9X!"98R+*Z.4%Q#<0$D J?,AD&UC@!L,/M2SM)K
M7S/.U*^U#?MV_;%L%\K;NSY?V&QLL[]PW^9YGW5V;?FW?OOA-_R(\P_[&];_
M -0LO O4445^I@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 077_'M<?\ 7";_ -%M7YVKT'T'
M\J_1*Z_X]KC_ *X3?^BVK\[5Z#Z#^5?B?B[_ !<@_P .:_\ O, 6BBBOQL H
MHHH [OX9?\CYX;_Z^[C_ -(+NOMVOB+X9?\ (^>&_P#K[N/_ $@NZ^W:_??"
M;_D1YA_V-ZW_ *A9> 4445^I@%%%% !1110 4444 %%<M/XX\&6WB"'PG<>+
M/#4'BFX17M_#<VO:3%X@G1U#(T.B27BZI*'4AE,=HP92"I((KJ?\^G\Z *UV
MEY)$%LKBWMIMZDR7-J]Y&4 .Y1%'=V;!B=I#^:0H!!1L@KF_9O$/_07TK_P1
M7/\ \OJVZ* ,3[-XA_Z"^E?^"*Y_^7U'V;Q#_P!!?2O_  17/_R^K;HH Q/L
MWB'_ *"^E?\ @BN?_E]1]F\0_P#07TK_ ,$5S_\ +ZMNB@#$^S>(?^@OI7_@
MBN?_ )?4?9O$/_07TK_P17/_ ,OJVZ* ,3[-XA_Z"^E?^"*Y_P#E]1]F\0_]
M!?2O_!%<_P#R^K;HH Q/LWB'_H+Z5_X(KG_Y?4?9O$/_ $%]*_\ !%<__+ZM
MNB@#$^S>(?\ H+Z5_P""*Y_^7U'V;Q#_ -!?2O\ P17/_P OJVZ* ,3[-XA_
MZ"^E?^"*Y_\ E]1]F\0_]!?2O_!%<_\ R^K;HH Q/LWB'_H+Z5_X(KG_ .7U
M'V;Q#_T%]*_\$5S_ /+ZMNB@#$^S>(?^@OI7_@BN?_E]1]F\0_\ 07TK_P $
M5S_\OJVZ* ,3[-XA_P"@OI7_ ((KG_Y?4?9O$/\ T%]*_P#!%<__ "^K;HH
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M5&\W^T4L$QL\G[%)<R9^]O\ ,^T0Q8Q\NW9NSEMV,#/[[X3?\B/,/^QO6_\
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M2\.>)=#TKX!^)/AQ=WED-;BFA\,^,O&^CV_B'PO=Z%J?C*/PGI_B:XM=/_:
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M\>KH** .?_M36?\ H7)O_!IIG_QZC^U-9_Z%R;_P::9_\>KH** .?_M36?\
MH7)O_!IIG_QZC^U-9_Z%R;_P::9_\>KH** .?_M36?\ H7)O_!IIG_QZC^U-
M9_Z%R;_P::9_\>KH** .?_M36?\ H7)O_!IIG_QZC^U-9_Z%R;_P::9_\>KH
M** .?_M36?\ H7)O_!IIG_QZC^U-9_Z%R;_P::9_\>KH** .?_M36?\ H7)O
M_!IIG_QZC^U-9_Z%R;_P::9_\>KH** .?_M36?\ H7)O_!IIG_QZC^U-9_Z%
MR;_P::9_\>KH** .?_M36?\ H7)O_!IIG_QZC^U-9_Z%R;_P::9_\>KH** .
M?_M36?\ H7)O_!IIG_QZC^U-9_Z%R;_P::9_\>KH** .?_M36?\ H7)O_!II
MG_QZC^U-9_Z%R;_P::9_\>KH** .9N-3U@V]P#X=F ,$V3_:>FG \MN<";/'
MM7P8.@^@K]$KK_CVN/\ KA-_Z+:OSM7H/H/Y5^)^+O\ %R#_  YK_P"\P!:*
M**_&P"BBB@#M?AU)+%XV\/R00&YE6ZG*0+)'$TA-E= @22E8UP"6RQ (7 Y(
M%?:=C=7ESYOVO37T_9L\O?=6MSYN[=NQ]G=]FS"YWXW;OES@U\9?#+_D?/#?
M_7W<?^D%W7V[7[[X3?\ (CS#_L;UO_4++P"BBBOU, HHHH **** "JM]:1WU
MG=V4H1HKNVN+:17C65&CN(7A</$_R2*5D(9&^5QE6X)JU10!^7FG?L,2>&?$
M^EW'AKX%?L<))HFLZ9J^B?$N33?BSIFN:1=Z5>6]]INH)\+[6]U'3;J^T^YM
MXKB)(?BYIMI+- NQ;2*3RH?TTTJ"^M=,T^WU2^34]3@LK:+4=2CLTT^._ODA
M1;N]CL(YKA+*.YG$DT=HMQ<"V1Q#]HGV>:]^B@ HJI>78LX1,;>[N075/+L[
M=[F8;@3N,:<A!CYFZ D#N*S/[?3_ *!.O?\ @IN* -ZBL'^WT_Z!.O?^"FXH
M_M]/^@3KW_@IN* -ZBL'^WT_Z!.O?^"FXH_M]/\ H$Z]_P""FXH WJ*P?[?3
M_H$Z]_X*;BC^WT_Z!.O?^"FXH WJ*P?[?3_H$Z]_X*;BC^WT_P"@3KW_ (*;
MB@#>HK!_M]/^@3KW_@IN*/[?3_H$Z]_X*;B@#>HK!_M]/^@3KW_@IN*/[?3_
M *!.O?\ @IN* -ZBL'^WT_Z!.O?^"FXH_M]/^@3KW_@IN* -ZBL'^WT_Z!.O
M?^"FXH_M]/\ H$Z]_P""FXH WJ*P?[?3_H$Z]_X*;BC^WT_Z!.O?^"FXH WJ
M*P?[?3_H$Z]_X*;BC^WT_P"@3KW_ (*;B@#7NO\ CVN/^N$W_HMJ_.U>@^@_
ME7WK<:\AM[@?V5KHS!*,G2K@ ?NVZD]![U\%#H/H*_$_%W^+D'^'-?\ WF +
M1117XV 4444 =W\,O^1\\-_]?=Q_Z07=?;M?#GPZF%OXV\/S&.:81W4Y,=O&
MTTSYLKI<1Q+\SD9R0.B@GH#7VI8WZWWF;;2_M?*V9^W6DEKOW[O]7YGW]NWY
M\?=RN?O"OWWPF_Y$>8?]C>M_ZA9>!?HHHK]3 **** "BBB@ HHHH **** #
M/49I,#T'Y"EHH 3 ]!^0HP/0?D*6OE?]JK]JKP[^RYX9\,ZG>^#?%/Q(\6^.
M/$/_  CO@OX?^$+KPQI.K^(;JSMTU+7)DUWQQKOACPCI\>C:+YVHFWO]<BU+
M5I$CL-&L+V9[B2S /J? ]!^0HP/0?D*^'?'/[=/@[P->ZI)>?"[XMWGA;X>^
M$_AYXU_:"\5QZ3X7T^#]G;1/B<;IM 'Q%\.ZOXLL?%>IZGHNFV=UXG\?:7X!
MT?Q=<^"?!T47B34#<VVHZ3!J'W$#G\R.>.A(_IQZCF@ P/0?D*,#T'Y"EHH
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M.Z&E?JEZNW]?\!GJO_"3:3_STN__  5:O_\ (%'_  DVD_\ /2[_ /!5J_\
M\@5Y5]J^.W_0.T'_ +[T[_Y8T?:OCO\ ] [0?^^M._\ EC7%_K9'_HG>+/\
MPQUO_EG]6?E=\OG'[U_7_#/ROZK_ ,)-I/\ STN__!5J_P#\@4?\)-I/_/2[
M_P#!5J__ ,@5Y5]J^.__ $#M!_[ZT[_Y8T?:OCO_ - [0?\ OK3O_EC1_K9'
M_HG>+/\ PQUO_EG]6?E<Y?./WK^O^&?E?U7_ (2;2?\ GI=_^"K5_P#Y H_X
M2;2?^>EW_P""K5__ ) JCX.D\7R:?<GQE!9P:B+UA;+9& QFR\B JS>1/.N_
MSS.#E@VT+\N,$]6X+*0KE"1PZA25]P'#*?Q!KZ/"8GZWAJ6)5#$X?VL.?ZOB
MZ+P^)IZM<M6E)^Y/2]G*UFG<DPO^$FTG_GI=_P#@JU?_ .0*CF\1:7)%)&ES
M?0LZ,JS1Z3J9DB9E(66,3:7-$9(R0Z>;%+'O4;XW7*'9\B?_ )_9O^_5M_\
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M1O:VG<#Y*HKZU_X4=X-_Y^-=_P# ^V_^0:/^%'>#?^?C7?\ P/MO_D&OSO\
MXAAQ1_+E_P#X6/R_Z<^;^[S'\U^/^7]6?E?Y*HKZU_X4=X-_Y^-=_P# ^V_^
M0:/^%'>#?^?C7?\ P/MO_D&C_B&'%'\N7_\ A8_+_ISYO[O,/FOQ_P OZL_*
M_P __#J>*U\;>'[B8N(H[J<N4BEF?!LKI1MBA225SEAD(C$#)( !(^T['4[3
M4?-^RM,WD[-_FVEY;8W[MNW[5;P;_N-G9NV\;L97/ Z)\)O#&@:K9:Q8S:NU
MW8R/+"MQ>020%GADA/F(MI&S#9*V '7#8.>,'TZOU7@/A_,.'<LQ>$S%455K
M8^>)@J%7VL?9RPV%I*\N2-I<]&::UTL^H@HHHK[@ HHHH **** "BBB@ HHH
MH **^;/VI_VO?V=?V*/AI:?&#]I[XE67PK^'-]XKT?P/:^)K_0O%OB&"7Q3K
M]KJEYI&DBP\&>'_$NKK)>6VC:E*MR^GK91"U99[F)Y(5D_/+_B(6_P""/'_1
MZ/AG_P -9\?_ /YTE '[045^+_\ Q$+?\$>/^CT?#/\ X:SX_P#_ ,Z2C_B(
M6_X(\?\ 1Z/AG_PUGQ__ /G24 ?M!17XNK_P<,?\$=6+!/VU/"KF-MD@3X8?
M'US%(%5S%*$^$Q,4H1T<Q2;9 DD;E=DB%G?\1"W_  1X_P"CT?#/_AK/C_\
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M'"\/QI^$/[/GPX^#OP[^'AM_VB_C#\'_ (X_%/X8Z+\;_B9%XAT#Q# GP/\
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M/1O&7A[3]2A^(GP^U!=7TFRO/%G@ZR\,Z_=+X?\ $>I/#]G5SGB_PAX8\?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
64444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>chart-e53e3e38390450fb989.jpg
<TEXT>
begin 644 chart-e53e3e38390450fb989.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %: 3T# 2(  A$! Q$!_\0
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M<^*[O6;FQDUCPU!XC\/?"GPAI'COP]H=Q]AU(Z'I%]HUSH,J:_%XFXKX>?\
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M_88UGP/\7=>O] ^.GCC5_#D+7NM?#O2])UFQTS]HQ?B+\<AJ_P (_BMK>O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M^7OC7^UM\,O@/\:/V5?@3XRTWQC>>,OVP/B!XY^&_P +[OP]I>E7OA_2]=^'
M_P -=:^*6N7/C2]O]=TN]TK2IO#VA75IIT^D:9X@NY]8FM;>>QM;)I]0M_J
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M5_\ H8I__!9IG_QB@#?HK _LS5_^ABG_ /!9IG_QBC^S-7_Z&*?_ ,%FF?\
MQB@#?HK _LS5_P#H8I__  6:9_\ &*/[,U?_ *&*?_P6:9_\8H WZ*P/[,U?
M_H8I_P#P6:9_\8H_LS5_^ABG_P#!9IG_ ,8H WZ*P/[,U?\ Z&*?_P %FF?_
M !BC^S-7_P"ABG_\%FF?_&* -^BL#^S-7_Z&*?\ \%FF?_&*/[,U?_H8I_\
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M2PM]9D^&'C!-(N+Z)2\MC!JC>.!837L2 O+:17+W$:AF>)55B/TG_P""8/\
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M^/1'0_"?P]CZ?\)LF*_ _P!3QD@ G R0.@)ZD#L.@K][_P#@@/\ \ER^//\
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M=5M[S3K>^N='\3>&#KOA76%TS418:S(;>/[1T1^BK0E+!Q7B1A.;'N<<,O\
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MK4/_ )"KXMD)\Q^3]]NY_O&F9/J?S-?W.O%C/K*V RBUE;]UC?\ YM/\S/\
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M-?P^(?\ 'E?_ *3F!_6WCW_$X6_P9U_Z5E8^BBBOVT_GH**** /TO_X(Z?\
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MP+\9-XBA2* 74K2Z$OBPZM$L=J1<R-)9JJ6Y$[$1$.<*'_@M%^US<W,-G;^
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MGS%'+)]X @D8(--^T6X$3&YM@LYVP.;F )<,>BV[F3;.QR,+$7))&!7[S?M
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MQ=>:9-J/AS5YYM/:S]T\/_!?P#IFM:=\!K_P+\.?!WQI^*WQU\>>"_!=Y/\
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M_,\[4M0\S=E=NWRMF&SOW#;_ #OXO_\ (_R[_L3TO_4W&G]1^!?_ "3>:_\
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M_K]1T\5"5*C*IC+.OB&JOUB3]M.M)\ZJJ-JDY1]I!P=.?LJ4I0=2'._[:/\
M@V=_Y,X^-G_9S6M_^JK^%U?H)_P61_Y1D_M@_P#9+XO_ %+O#%?GW_P;._\
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M\_)_?Y'PO_$'."?^@;,/_#A6_P OZN_*W^69X?\ V2/V_P#Q5>>*]/\ #O\
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M1_\ ?"_X4>3%_P \H_\ OA?\*/\ B*7%W_01@O\ PAI>7GY/[_(/^(.<$_\
M0-F'_APK?Y?U=^5OY!?^"1?[1'[4W_!/[X"?$+X5_%K_ ()'_P#!4#Q3K_BW
MXOZA\0=/O?AS\(?@WJ>CP:/>>"_!WAM+6]G\2_'KPK>1ZDM[X<NYGA@L+BV^
MRS6SB\,K2PQ_3_[>G[>WQ_\ VJOV0?CQ^SYX%_X(_?\ !5[0_%_Q1\&Q^'=
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M,0>.V\Z\M_"OA3Q'KLD;&-1IVC7TP<M$$;H_^&%_^"D__2,K]MO_ ,-[X/\
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MF^HZBBBO$/H0HHHH **** "BBB@ HHHH **** &E@" <\^BL0/\ >(!"_P#
MB*-PW;><_P"ZVWZ;L;<^V<^U?A+^V!JND+\2?VXG^+?BSQ7H'QQT'X=> ?\
MAVKH^A^)?%&D>+]3U^X^$=QJ.DWG[/'A;0;VP@\;_%K5/VF[?Q'H?Q)L=)L_
M$&J2^ ]-\'Z-\1XK7X7ZA#!<[^B^-_@-XQ_;C\$>$O /QV\*Z5^TCX*^,5UJ
MW[3'BG7_ (^6C:QJ>M2?#34;34OV)OA)\,=4\4+=^./#]A>:MHFN:GH&F^%;
MKP1\*[#P_+KQUS5?CC?W,NF@'[>$@=<],]"?; P.23T Y/84F]<;OFQZ;'W?
M]\;=WZ=.>E?$_P"UYX:^ 7@_P7\1/VA/VA/BSXX^%OPXT+X6Z7X"\>:UH'CO
M7O"&FGP?<?%#PSXG.EVY\,JFNC7?'VN06'PXE_X1VXM_$FO:#XGO/">A7%GJ
M&K07D/YC^"-=^$6NV/PZOO%7CWP%IG[ OCS]I;XOZSXG^'&B?'C0_''PT_9]
MNK;X#^!K'X(_"/XX>-O"7C36_!_@C2?%GBK2?B3\8M9^'47C"?X8>$OBUXR^
M'7A#2I]3U.'3=2UT _H2!!&1T-%?(?["=YXLOOV7_A]<>+;SQ9J2G5/B7#X%
MU7QW)J\WC+5_@M:_%?QS;? /5_%%QXA7_A(+O7-4^"4/@"^OK_Q!+<>(-1:=
M-0UVXFU:ZO9#]>4 %-9@O7/L I8GZ!03QW...].K\U_VSKCP*WQY_9RTW]IC
MQ!I_A?\ 8\NO ?Q^O/&.I>*O%.H>"_A7>_'S3KKX1-\'M+^+/B3[7H_AVUTI
M? $_QQU?P18>+-<M=!O_ !QIEI=06UUXMTCP@T(!^DQ=1CJ<^BLV/<X!VCKR
MV!P?0T[/Z\="?Y=/J>*_FN\:_$+X,R_!;X;_  \^+/QPUSPU^U+XS\!_%"R_
M9DUS]HCX]:Q\&Q^SK^SY#^T3\5]*^ 7[7_C&X\6^*_">M0_$^7X7)\/TL;B]
M?Q#\8_C!=>#]&\(75EHVA3_%[Q'8_P! 7BOX<Z1X]?X7:KJWB#73+\,_&VF?
M$?2+S1M4BTVV\0ZM9>$?%/A:./Q%'80I9ZIH5Y9>+[_59]+A2"R?4K;2[J$I
M%91HP!Z=N&"<\ XR 3SZ#'WCGCC/S?+U!%"L&&1GZ$%3^(8 CVR.>U?@CX;^
M)_PS\1?#+_@I1\-?A3^V=X8^*7B?3/C9X#^)<WB?7/VB5UOQ)XF^&6F_"']D
MR_\ C&LOBCX1KJVN?"WX9^*KM?&WPEU7Q?\ "OP9IG@KX,3:]J-UI6BZ3-H-
M[!7UE_P3BUG5=<O?VD+WPKI/A_P[^SF_CWP"WP2\,>#?'TOQ2\">'-3D^&&B
M3?%G2? OCY&?P]K6A0>*Y--DU.T^',U]\,]"\;2^+M(T'5=1U^V\6RJ ?I[1
M110 A(&<]AGH>GMZGV&3R..1EOF+DC#\9_Y928X]#LP?;&<]LU^:'[9_P^\<
M+\:O@#JGP[\>:QX/TO\ :E\0']CGX^V%E>:PDD_PO7PC\3?CEI7CGP3)9W!M
M/"WQ5\.6O@/XA?"_1?%0M8FC\.?&S5=5N;FXUKP-X'AMO@[]J#]GWX+?#S4_
M^"L'C/PS\/=!\)7_ (0_8\^#^O:#X@TXZCIG_",3_$G2_P!HBP^+.K:5>+>Q
MPZ._BC1-)L8_%NH61M9;FRL+>2_F"V\4B ']$*L&Z9^C*RG\F ./0XP<'TH+
M ==W4C 5B>."< $X_P!K&WD<\BOS!_9%G^&,7[3'Q<T7]D?7]$U[]DVQ^#/P
MYFUX?#SQ3)XN^"6C?'VZ\:^-U6S^&6JV^J:OX6M/$=Y\+8]*NOBIH?@6].F6
M+P_#W4O$6GZ?XBUI[C5>*_;4'[(W[/FA>#O#?QJ\97GB?Q3\3/&O[1/C'X0?
M!WXE?'YOA7X"\7?$#XCZ_9>,_%/C3QAXHO\ 7O"FD>%O!GP/DUF*+PWXQU+4
M[JY^%^C>))+;X>^'_%'Q1U;P5I\P!^N9=00.>>X#$#ZD A<]MQ&>U.K^=/QQ
M=:CIGA7QQ:^+_C=JGQ3_ &K/!?P,_8_M/^">/Q'\/>-]7ND^.7B7_A /#%KJ
MOQ ^$-MI^N36?Q&;XF?'V'Q:G[0=S&OB61_@O-X9F^)TS^ Y[6[N/Z*DY'?J
MV,X'&XXQCC;C&T]UP3SF@!U(2 0#WX'!Q^)Z#VSC/0<TM?!__!1&#Q7X4_9X
MUW]HOX9:BNF_%W]E$:E\>?A[#>S:F/#'BYO#N@ZII7C/X9^/+#20;W5O!?Q'
M\":OX@\.7T4*R7>@ZY+X<\:Z1&VN>%=,H ^[3(H.,.?<1R$=<?>"D?K[]*4.
MI)'S _[2LH./0L &_ GCGI7XV^.?V._A)H?[6/[ 6F>-?#EK\5?%<^E?M":C
M\2/B+XMM[RXUGXD>-?"OA[PSX\TOQ=XI@%[+I[RV/Q UW7_$7A;2)5FTSPFE
M_%H^@0VVGV%K$GSY^PWJGPI:[_8EN?V?O%NE:S^T/XC^)7QLF_;+T3P)XQU'
MQ+=2_#./0?C;/XMUC]I#0M-U;4]-\/\ B+2_B^GP=M/ 6J>-;72/&4/B:[GT
M#PM)+H-]XRTU@#^A;(&<\8&23P.<]^G;GGCC/44A8  G=ST 5BW_ 'R 6&.^
M1P>#@U\K_'?P9\-_#.@?&GXJ^//CCX@^!>B^.O 7PS\">,O';?$C0_A[HOA;
M0_ WB7QI=:8F@>)_$L)T_P "ZWXZN?B5J?@_6O$^F75CXIFMI]"'A/5M!\4Z
M9HFLVGY+6?Q6^$7CG]D;_@F_XT\0_%#X/?&+X.^'_@1I7PV^*G@CQ;^TMJ'@
M'PV_QK;X0?!R[TGQ'XG^(NE/XATC6/BA\(+&U\5>?\-?'.K6_P 0Y6\=WOC[
MP3IOB#XB^#M,TZ[ /Z$P<\BBOE7]A^?XJW/[)'[/D_QLGU6Z^)DWPO\ #4GB
M6YU^+4X?$-PSV[MH\_B%-=_XJ(>()?#IT>37#XG6/Q0VJM=OXFBBUYM1B3ZJ
MH **** "BBB@ HHHH **** "BBB@ HHHH \_^(OPN\#_ !7T?3]$\<Z,^JVF
MD:_I/BG1;FSU;7/#VLZ%XBT1YCI^M:#XB\,ZGHOB'0]12WN[[3;BYTG5+-[_
M $;4]5T/4?M>C:KJ-A==L;&S,XNC:VQN0<BX,$)G!^;&)BGFC&]L8?@,0.":
MM44 ,DC25&CD19$8$,CJKJP/!!5@5((X(((Q4,-E:6\30P6MO#"QRT44,44;
M':%RT<:*C?*H'S*> !T Q9HH  ,# [?B?Q)Y)]2>3WHHHH *PO$_ACP_XT\.
M:[X1\5Z18>(/#/B?1]2T#Q!H>J6ZW6FZQHNL6<VGZGIFH6K_ "7%G>V=Q-;W
M$+_*Z.>C!6&[10!R7AGP/X<\)>&M!\)Z5:7=QH_AO3H-+TH^(=8UKQAJRVMN
MI5#?>(_%^HZ[XDU>[8$F?4-8U?4-0N6)>YNIG):NMP , #&,8[8],>E%% %2
M&QLK=M\%K;0/L:/?#!%"X1FWL@>)$8*S_,5!P6^8C/-641(U"(H50  J@!0
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M+^/-=^'WA71M'^(=KXR^+7AGX%^._AKX0U30=,CU[QI\//CMX8O_ !79>/\
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M.QF*QM6$%3A4Q>(K8FI&FI2DH1G6G.48*4I244U%2E)VNW>\%EV7Y92E0R[
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MXNLH_"7AR]C\&Z,OA[P#X9>?69-3^P** /@[PG^Q,_AGXNV/Q%E^)BZEX?\
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; %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>chart-f590ec5e15305a15b12.jpg
<TEXT>
begin 644 chart-f590ec5e15305a15b12.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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ME^.7PB\<?"#QQX[MO$DVGOX@U/1$LOB/XY\9Z+X%OIXM-T_QWXFU"_N=7O\
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MOP[UW2O'5I#?>&H/[6\*7B:YI+7MDDLB8NG?L-^ ;K]DOQ[^R1XY\2Z_XO\
M!7Q)B\;_ -N3I::5H^F^&SXUUZ3Q-'HOPV\%RPZUX8\&^ ?!FKBU_P"$'^'<
M]OX@\,:7IMFFCZG;ZUIMS?6]SS'P9_X)_>!?A!K_ ()\6Z=JOABPU[POXA^*
MOB34[;X;_!;X6_!?PGK]_P#$[X>>$_AJ1+X6^'>DZ?#'_8&A^$;:\M+_ %6_
M\0ZU=ZGJFJQ-JMIX?72-!T@ Z/XB?M\?!+PQ<?#_ $OP/J<OQ1UGX@>,/V6M
M$LI?#.E>+[CP;I?AS]JCXE^"_!?@?Q!K?Q(T[PGJW@;0M5O_  QXKF^('A?P
M;X@US2/$'C#1-.M_L<-G::Q8:D_1VG[=W[,=_HGB?Q#9>/-5N-*\.6.DZI8W
M*_#KXFI_PL/2O$'C/3_ASX=U7X,POX.6X^-^E^(OB#J^C>"M U'X20^,K36?
M$FN^'M/TZ6X/B+0I=2\5\,_\$Y-&\':?\/O"WAWXT>.;'X?^&A^R)K/C3P>_
MA_PC=1?$+QY^QK;_  RTGX=>*[G6KBTDU?PS;>)?#WPH\(:1X[\.Z),UGJ+:
M'I%]HMWH,J^((O$W%?#S_@DY\(/A7X<U'0_ .OZ3X/U+P\OP]7X->-?"7P0^
M!_AGQ[X'D^%7Q!T/XF>![[QUXQTGP=!K_P :]0MM<\-:#HOB ^,-0T_3/%7A
M73D35]*D\:S2^.R ?:?[-W[0FG_M&:!\1?$>E>';[P[I_@;XU?%#X0VT>J)K
M%GJ>ICX:ZW%HD^L:GH?B#0?#FN^%]0O;EIDO/#.KZ:M_HUQ;R6UQ/,^6'T77
M@G[/GP-7X$^&_%^DS>,=8\>:SX\^)_CKXM>*/$>M:=I.DSW7BCXAZA;ZKKD-
MEINB10Z?8:/:WD30Z/9(LLUGIHMK6ZO-0N8);^Z][H **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KX6_X*%^/+?PK^S[=>
M&]+\;IX4^(WQ#\<_"'PM\.-*TWQ,- \;>+]7O/C?\+[+5-&\%6EI>VNNZU?'
M2-0N%U2VT6*Y-OI-Q<RZDL6G/.Y^Z:H7.E:9>W>GW]WI]C=7VDO<2Z7>W%I;
MS7>G274/V>ZDL+F2-I[-[BWS!.UM)$TT),4I>,[: /Q.^*O_  49^*OAWPQJ
M>E>"=9^$-[\7O#^E_MYS^+/"-]8W6J2>"]6^!'[5_P ,_A%\%H/&FBZ7XC_M
MCPY;:WX \?0:UJ5GJ,MIJ7BZ&>W\1>'C!I\+FJ'QV_;M_:?^#'B76_A/<7/P
M]U6\\)_&SXN^"M4^.<F@?#/P%X=FL?"/P!_9S^/7@'PA?>'_ (V_M(_"KP%I
M^NZ^_P >=;TK6;JR^)]WXDU#P%\)]>U[PGX-FUN^U74/"W[</H&AR7%Y=2:/
MI;W.H,'O[A].LWGO76*U@5KN5H#)<LL%E9P*T[2%8;6VB&([>%4=>Z%HNI1R
MPZAI.F7T,][:ZE/%=V%I<Q3:A8_9OL5_+'/#(DE[9FSM#:W;JUQ;&VM_(DC\
MF+8 ?%7QI\::!XO_ &4/AMXE^-OB+1_A)J_Q'T7X=ZE/H3_&?Q-\,_AGJ'Q,
MUSP=-XIL_A9XW^.'@.PU#5-'^%^L:[!<Z/J&OVCVMIXJ@M=,T3&KOXAA\-ZW
M^8OPJ\?>&O$OA[X8^%?VI/C/XD\#?L^:!X;_ &UX_"_CW2?VC/B!9> M6^+/
M@7]H+0X_#5K\,/VA%\1>&/&OQ=\-?"'X.ZS-:_LZ:GXKN[KQ#XI72?'^L2>&
M&UKX;VMEX9_H9OM/L=3L[G3M2L[6_L+R&2WN[*]MXKNTNK>52LL%S;7"207$
M,JDK)%-&\;@X=356?0M%NK*STVXTG39]/TZ6RGT^QFL;66SL9M-=)-.EL[62
M)H+673WBC>QD@CC>S>-&MC$54@ ^9_V/OBGK/C_X"_"33/BAXETFY_:'T7X'
M?!3Q#\=O"C7VGP>-?"OBCQUX&M]6MK_QQX3A6VO?".H^*I-/U?5%TV_TVPM_
MM=KK-I8QR6^FS;/R$N_BMX5N](^.?B_]BW]I/Q9X^\(>$O@5KFA?%#XB)^T;
M)\7/B;\=-8U/XS_"BP^)O[1WPT^'5OXBUEO#L/[/OPLTKXS06'Q0\(>$?A_X
M=\1^(/&>C:'\--#U'P/X"\*:A%_058^%_#^FZSKWB&RTBRM];\4+I4?B#5$B
M!O=6BT2TEL=(AO)W+/+!IUK<7,=I;Y6&$W5W*L8FNKB27,T/X>> _#.HS:QX
M<\%^$M!U:XMY+6?4]%\-:)I.HS6TKPR2V\M]IUA;74D,CV\#O$\S1N\,3,I:
M)"H!^).M_$O]E;P+J7QFT#7?V@?&FL_L:Z3XZ^!"?!CPSX3_ &B]7O;'XT_M
M&^*_AQ\5Y/B/^SEX)^*^N_$&TU;Q=X8L=!M/A-\:-<\+Q_%W0/ _A3QA?:QX
MG^(FL:3X+MO%T XC4/$-O8?#N.Q_:&_:?UZ&S\/?L5>(_B7^RUXR\ _M ^(]
M3TK4?CE=_%WX\OJWA_P3\4_#OB32Y?VF?B_\ /"4'[-_PJ\/)KT_BW5?'$EQ
MK&H7/A_5+GQ[XDAO?WQO_ /@?5=*M]"U/P?X6U#1+2>:YM='OO#NC7FEVUQ<
M/+)<3V^G7-C+9033R33232PP))*\LCR,S2.6N6GA+PM8:?I.E6/AS0;+3- N
MA?:'IUIH^FVUAHUZ'N)!>:59P6L=MIMV'NKIQ<V44$X:YG82 S2%@#G?A'J'
MCC5OA7\-M4^)FG0Z1\1M1\ ^#+_Q]I5LH2WTSQM>>&M+N?%FG0(H54AL?$$N
MHVL2*JJB1*JJ  *]#HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M ^8/C3^UI\,O@1\9_P!E?X%>,[#Q?=^,OVOOB!XX^&_PNNO#^E:9?:!IVO?#
M_P"&VM?%+6[CQG?7NMZ9>:3I<OA[0KJUTZ?2M.UZZN-7FMK::RM;1I[^#Z>!
M# ,.A (^A&:_$'_@I/\ \I)/^"%/_9UO[4'_ *QS\0:_;R/_ %<?^XO_ *"*
M 'T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=VE=7M_27WGR_>_MR>%O#?[.</[1'CWX7_'OP5;3!Q;_  VNO!R>(/&NIK%
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M?_)E&SQ/_P ]]"_\!]2_^3*WZ* ,#9XG_P">^A?^ ^I?_)E&SQ/_ ,]]"_\
M ?4O_DRLOQIXTL_!5G97EY975ZE[=M:(EJT"LC+!)/O<SR1KMQ&5 4D[B.,9
MKSO_ (7UH8ZZ#J__ '^T_P#^2:^?S#BKA_*\5/!YAF5+#8FG&$ITIT\1)QC4
MBIP=Z=&<7S1:>DGV=GH-)O;^MO\ -'K&SQ/_ ,]]"_\  ?4O_DRC9XG_ .>^
MA?\ @/J7_P F5Y,?CUH:Y+:%JZX.#NFT\8.<8.;D8.>,'G/%!^/>A#&=#U8;
MONYGT[GZ?Z3S^%<7^O7"?_0YH?\ @G%__,X<K[;_ / _S1ZSL\3_ //?0O\
MP'U+_P"3*-GB?_GOH7_@/J7_ ,F5Y,?CWH2_>T/5E^L^G#^=S2CX]:&1D:%J
MY!Y!$VGX(]?^/FC_ %ZX3_Z'-#_P3B__ )G"S[?UI_FCUC9XG_Y[Z%_X#ZE_
M\F5Q?Q$37AX)\1&[ETAK?["OFK;P7JS%?M,'$;2W+QJV>[(P[8YS72>#?&%I
MXSTZYU&SL[FRCMKUK)H[IH7=G6""<NI@>10A6=5 )#94\8P33^)O_(A^)O\
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M -7'_N+_ .@BOQ#_ ."D_P#RDD_X(4_]G6_M0?\ K'/Q!K]O(_\ 5Q_[B_\
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M_P"E,%?TAD__ ";E_P#9/YE_ZCXH:U:]4?$9ZGZFDI6ZGZG^=)7\WB"BBB@
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M$I""BBBOA "BBB@#ZJ^!'_(L:K_V'IO_ $WZ=79_$W_D0_$W_7@O_I3!7&?
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M=T-;KU7YGUVW4_4_SI*_*8_\%Q/^"49)/_#9G@ODG_FG'Q__ /G04G_#\/\
MX)1_]'F>"_\ PW'Q_P#_ )T%?S__ *OY]_T),W_\-F-_^4>?]68C]6J*_*,_
M\%QO^"4*E0W[9_@A6<E45OAU\?5:1@K.5C5OA"#(X17<H@9A&CR$;$=E=_P_
M#_X)1_\ 1YG@O_PW'Q__ /G04O[ S[_H29O_ .&S&^7_ $X\U_28'ZM5[O\
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ME6I&GBL/5P\Y0>#P,5.,:T(2<7*$H\R37-&2O=,#[6HHHK]* **** "BBB@
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M?X@72;Q@9;)=9LK.UM=1$1'VF"WBCDRJ 5XY\*?V2OV;/@?XFU3QG\*/@OX
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M.TMHHK>VMK>*."W@CCAAC2-%47* "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
,@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>biib-2020630x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:biib="http://www.biogenidec.com/20200630"
  xmlns:country="http://xbrl.sec.gov/country/2017-01-31"
  xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="biib-20200630.xsd" xlink:type="simple"/>
    <context id="FD2020Q2YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="I2020Q1July21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2020-07-21</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2020Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="D2020Q1Mar1-Mar31_us-gaap_BusinessAcquisitionAxis_biib_BIIB118Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BIIB118Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="D2019Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-07</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_biib_PostacquisitionequitycompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">biib:PostacquisitionequitycompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="I2019Q3Denmark">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2019-08-01</instant>
        </period>
    </context>
    <context id="I2019Q3Denmark_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-01</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_MajorCustomersAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_MajorCustomersAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_MajorCustomersAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_MajorCustomersAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FumarateMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_FumarateMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_InterferonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_FumarateMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_FumarateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_InterferonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FumarateMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FumarateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_FumarateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FumarateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_InterferonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_InterferonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_FumarateMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FumarateMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_FumarateMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FumarateMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_MajorCustomersAxis_biib_ContractManufacturingCustomerMember_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ContractManufacturingCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_MajorCustomersAxis_biib_DistributorTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_MajorCustomersAxis_biib_DistributorOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_MajorCustomersAxis_biib_DistributorTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_MajorCustomersAxis_biib_DistributorOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q3_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_MajorCustomersAxis_biib_DistributorOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_MajorCustomersAxis_biib_DistributorTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_MajorCustomersAxis_biib_DistributorTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_MajorCustomersAxis_biib_DistributorOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2020Q2_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_MajorCustomersAxis_biib_ContractManufacturingCustomerMember_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ContractManufacturingCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2020Q2_biib_ResearchanddevelopmentassetAxis_biib_TGNMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:TGNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2020Q2_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_A2.25SeniorNotesdueMay12030Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_A3.15SeniorNotesdueMay12050Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_A3.15SeniorNotesdueMay12050Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_A2.25SeniorNotesdueMay12030Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="I2020Q1April30_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="I2020Q1April30_dei_LegalEntityAxis_biib_SangamoCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:SangamoCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_CurrencyAxis_currency_JPY_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_srt_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_srt_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_srt_CurrencyAxis_currency_JPY_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_srt_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_srt_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="D2018Q4Nov1-Nov30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="FI2020Q2_biib_DerivativeMaturityAxis_biib_ShorttermderivativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_RangeAxis_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_biib_DerivativeMaturityAxis_biib_ShorttermderivativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_RangeAxis_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q4_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="I2015Q3Sept152015_us-gaap_DebtInstrumentAxis_biib_A2.90SeniorNotesDueSept152020Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.90SeniorNotesDueSept152020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-09-15</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_DebtInstrumentAxis_biib_A2.90SeniorNotesDueSept152020Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.90SeniorNotesDueSept152020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="I2020Q1April30_us-gaap_DebtInstrumentAxis_biib_A3.15SeniorNotesdueMay12050Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="I2020Q1April30_us-gaap_DebtInstrumentAxis_biib_A2.25SeniorNotesdueMay12030Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_DebtInstrumentAxis_biib_A2.90SeniorNotesDueSept152020Member_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.90SeniorNotesDueSept152020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2020Q2_srt_ProductOrServiceAxis_biib_TECFIDERAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_TECFIDERAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_TECFIDERAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_dei_LegalEntityAxis_biib_SangamoCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:SangamoCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_dei_LegalEntityAxis_biib_IonisPharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_dei_LegalEntityAxis_biib_IonisPharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SkyhawkTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="D2020Q1Feb01-Feb29_us-gaap_TypeOfArrangementAxis_biib_SangamoTherapeuticsInc.AgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SangamoTherapeuticsInc.AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="I2020Q1Jan31_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="D2020Q1Mar3120_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SkyhawkTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="D2019Q4Oct01-Oct31_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SkyhawkTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-07</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InventoriesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SkyhawkTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_UCBPharmaS.A.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_UCBPharmaS.A.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q4_biib_FutureContingentMilestoneTypesAxis_biib_RegulatoryMilestonesMember_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_biib_NeurimmuneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="D2018Q2Neurimmune_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_biib_NeurimmuneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="D2017Q4_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_biib_NeurimmuneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_biib_FutureContingentMilestoneTypesAxis_biib_RegulatoryApprovalMilestoneMember_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_biib_NeurimmuneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryApprovalMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_IncomeTaxAuthorityAxis_country_BR">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <unit id="segment">
        <measure>biib:segment</measure>
    </unit>
    <unit id="Assets">
        <measure>biib:Assets</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="KRW">
        <measure>iso4217:KRW</measure>
    </unit>
    <unit id="chf">
        <measure>iso4217:CHF</measure>
    </unit>
    <biib:AverageMaturityOfMarketableSecurities
      contextRef="FD2019Q2YTD"
      id="Fact-C114E491322C568ABA1A744B3E7C5BE9-wk-Fact-C114E491322C568ABA1A744B3E7C5BE9">P14M</biib:AverageMaturityOfMarketableSecurities>
    <biib:AverageMaturityOfMarketableSecurities
      contextRef="FD2020Q2YTD"
      id="Fact-A9C66C37062A5D9DACFC78BCD7B4DCB0-wk-Fact-A9C66C37062A5D9DACFC78BCD7B4DCB0">P14M</biib:AverageMaturityOfMarketableSecurities>
    <biib:IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_TECFIDERAMember"
      decimals="-5"
      id="Fact-0F5775DED8682DC1AB675E1333B08D8C-wk-Fact-0F5775DED8682DC1AB675E1333B08D8C"
      unitRef="usd">56000000</biib:IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet>
    <biib:IndefiniteLivedIntangibleAssetsUsefulLife
      contextRef="FD2020Q2YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      id="Fact-31ED2216CDAC55759A97D68277EE094E-wk-Fact-31ED2216CDAC55759A97D68277EE094E">Indefinite until commercialization</biib:IndefiniteLivedIntangibleAssetsUsefulLife>
    <biib:IndefiniteLivedIntangibleAssetsUsefulLife
      contextRef="FD2020Q2YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember"
      id="Fact-B3AD2CF1533A50B881F39662D60DE086-wk-Fact-B3AD2CF1533A50B881F39662D60DE086">Indefinite</biib:IndefiniteLivedIntangibleAssetsUsefulLife>
    <dei:AmendmentFlag
      contextRef="FD2020Q2YTD"
      id="Fact-DB0444439B6A5E29A9239182BD978EAB-wk-Fact-DB0444439B6A5E29A9239182BD978EAB">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="FD2020Q2YTD"
      id="Fact-FC7A0569D8CC5542A90A4CD6478092D1-wk-Fact-FC7A0569D8CC5542A90A4CD6478092D1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="FD2020Q2YTD"
      id="Fact-71F47813B6515D0CBF853EAA5A23238C-wk-Fact-71F47813B6515D0CBF853EAA5A23238C">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus
      contextRef="FD2020Q2YTD"
      id="Fact-209CEFC342B159C0AE975B87BC4FF518-wk-Fact-209CEFC342B159C0AE975B87BC4FF518">2020</dei:DocumentFiscalYearFocus>
    <dei:EntityCentralIndexKey
      contextRef="FD2020Q2YTD"
      id="Fact-AC6FEE9737725215A6B619A69722E8E3-wk-Fact-AC6FEE9737725215A6B619A69722E8E3">0000875045</dei:EntityCentralIndexKey>
    <us-gaap:AssetImpairmentCharges
      contextRef="FD2020Q2QTD"
      decimals="0"
      id="Fact-58119B3F11FF595466835DD38A2CB818-wk-Fact-58119B3F11FF595466835DD38A2CB818"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="FI2020Q2_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember"
      decimals="4"
      id="Fact-45B734C952ED5664A032C15EC6F136F6-wk-Fact-45B734C952ED5664A032C15EC6F136F6"
      unitRef="number">0.0118</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="FI2020Q2_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember"
      decimals="4"
      id="Fact-08A4DD95F86B5E36AAFFD5663CFC103E-wk-Fact-08A4DD95F86B5E36AAFFD5663CFC103E"
      unitRef="number">0.0083</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-F479CEE686A557A39B1292C500006F83-wk-Fact-F479CEE686A557A39B1292C500006F83"
      unitRef="usdPerShare">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2020Q2"
      decimals="INF"
      id="Fact-2502C2D242DF5732A98261B087729D18-wk-Fact-2502C2D242DF5732A98261B087729D18"
      unitRef="usdPerShare">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_A2.25SeniorNotesdueMay12030Member"
      decimals="INF"
      id="Fact-5F2A418B3B6513F42C2C5DBFC13B6F54-wk-Fact-5F2A418B3B6513F42C2C5DBFC13B6F54"
      unitRef="number">0.0225</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_A3.15SeniorNotesdueMay12050Member"
      decimals="INF"
      id="Fact-1DA94484BF276A1CE7F75DBFC4F846FB-wk-Fact-1DA94484BF276A1CE7F75DBFC4F846FB"
      unitRef="number">0.0315</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"
      decimals="INF"
      id="Fact-9F6180352F51598B806CFF94F9108A7C-wk-Fact-9F6180352F51598B806CFF94F9108A7C"
      unitRef="number">0.052</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"
      decimals="INF"
      id="Fact-128388B45DA758D2A43859B8919DB8D4-wk-Fact-128388B45DA758D2A43859B8919DB8D4"
      unitRef="number">0.0405</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"
      decimals="INF"
      id="Fact-9EF6B4A53B3E5BBF8B1E52097CC129B7-wk-Fact-9EF6B4A53B3E5BBF8B1E52097CC129B7"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember"
      id="Fact-381B3AA0E15A556397874933BA47AC35-wk-Fact-381B3AA0E15A556397874933BA47AC35">P15M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember"
      id="Fact-C98D2A938D5C5D9D8199FC945776998E-wk-Fact-C98D2A938D5C5D9D8199FC945776998E">P1M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="FD2020Q2YTD_biib_DerivativeMaturityAxis_biib_ShorttermderivativeMember"
      id="Fact-1E6B4A0D1B3B5AE6B12CE664ACCC94CB-wk-Fact-1E6B4A0D1B3B5AE6B12CE664ACCC94CB">P12M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="FD2020Q2YTD_srt_RangeAxis_srt_MaximumMember"
      id="Fact-EB615AF714EC570D828A4864F9BD6378-wk-Fact-EB615AF714EC570D828A4864F9BD6378">P18M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="FD2020Q2YTD_srt_RangeAxis_srt_MinimumMember"
      id="Fact-7E6B726C42B35215A105AE1F72093D4C-wk-Fact-7E6B726C42B35215A105AE1F72093D4C">P1M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeTermOfContract
      contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      id="Fact-1DE1EAFD691B5E9D80932448AAE6C850-wk-Fact-1DE1EAFD691B5E9D80932448AAE6C850">P7M</us-gaap:DerivativeTermOfContract>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2020Q2YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember"
      id="Fact-42C76B2795FC5AE69D7638F697EF928E-wk-Fact-42C76B2795FC5AE69D7638F697EF928E">P18Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2020Q2YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember"
      id="Fact-1318FC19621B5D0E890BEEFF84355E35-wk-Fact-1318FC19621B5D0E890BEEFF84355E35">P23Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2020Q2YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      id="Fact-8329806B71835A5E88EC70F0091F0DA3-wk-Fact-8329806B71835A5E88EC70F0091F0DA3">P28Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2020Q2YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember"
      id="Fact-F868DE7617D357F58E913DA6CAEF63BD-wk-Fact-F868DE7617D357F58E913DA6CAEF63BD">P4Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2020Q2YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember"
      id="Fact-509D3B79131C5C3383297F35B5EE7454-wk-Fact-509D3B79131C5C3383297F35B5EE7454">P13Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2020Q2YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      id="Fact-AB07A1A451725016B7E5743AB24B1640-wk-Fact-AB07A1A451725016B7E5743AB24B1640">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="FD2019Q2QTD"
      decimals="INF"
      id="Fact-A43B4C0875D58F43917D5DAFCCC6F939-wk-Fact-A43B4C0875D58F43917D5DAFCCC6F939"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="FD2019Q2YTD"
      decimals="INF"
      id="Fact-15336B38A3C85DAEBC9079C9DC743774-wk-Fact-15336B38A3C85DAEBC9079C9DC743774"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="FD2020Q2YTD"
      decimals="INF"
      id="Fact-B8C8E3BC108558E0A972BD9194F99DE6-wk-Fact-B8C8E3BC108558E0A972BD9194F99DE6"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-572BB4B7E4F653FAB76B8AB80F8F1EBF-wk-Fact-572BB4B7E4F653FAB76B8AB80F8F1EBF"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="FI2020Q2"
      decimals="INF"
      id="Fact-B4A452BE6D3C5C09982B249720250AD2-wk-Fact-B4A452BE6D3C5C09982B249720250AD2"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2020Q2_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember"
      decimals="-5"
      id="Fact-BF63EE7D272656B5A0865DA5F7F8F587-wk-Fact-BF63EE7D272656B5A0865DA5F7F8F587"
      unitRef="usd">170600000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_srt_MajorCustomersAxis_biib_ContractManufacturingCustomerMember_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember"
      decimals="-5"
      id="Fact-A56538F1F78F94F1DE3F5DA41DA87ECB-wk-Fact-A56538F1F78F94F1DE3F5DA41DA87ECB"
      unitRef="usd">329400000</us-gaap:Revenues>
    <dei:DocumentType
      contextRef="FD2020Q2YTD"
      id="d13624087e799-wk-Fact-8178FA0D45D857C7B4AF36DEB1CA842F">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="FD2020Q2YTD"
      id="d13624087e817-wk-Fact-D355492BBC175460B4D34ADAA9A2020E">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="FD2020Q2YTD"
      id="d13624087e827-wk-Fact-111F514759615D03A3828254DC43F9F2">2020-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="FD2020Q2YTD"
      id="d13624087e847-wk-Fact-18BC4385C6865292868B92C27656AE34">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="FD2020Q2YTD"
      id="d13624087e857-wk-Fact-ED9B9C1469A15FEEA943203A3FCEE995">0-19311</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="FD2020Q2YTD"
      id="d13624087e866-wk-Fact-EACA4FB7A446538488AD579F0D552F28">BIOGEN INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="FD2020Q2YTD"
      id="d13624087e888-wk-Fact-9508AEC63A0852F498C888A918123553">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="FD2020Q2YTD"
      id="d13624087e898-wk-Fact-60C6231898355F3A9D8A21B911ABAAFB">33-0112644</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="FD2020Q2YTD"
      id="d13624087e923-wk-Fact-BC6D187A26975015B99E0E5A964C9CCE">225 Binney Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="FD2020Q2YTD"
      id="d13624087e928-wk-Fact-4CD0C4F1719253B3B7946541FE983436">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="FD2020Q2YTD"
      id="d13624087e933-wk-Fact-108B31E0A99C5522A20C439F75980955">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="FD2020Q2YTD"
      id="d13624087e938-wk-Fact-0F1844528FC4597786F8EADC39103EF4">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="FD2020Q2YTD"
      id="d13624087e946-wk-Fact-93F60ED0CED05A67B5AAFD077FCBB137">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="FD2020Q2YTD"
      id="d13624087e951-wk-Fact-5BFC883A86095BF6871D808D22883601">679-2000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="FD2020Q2YTD"
      id="d13624087e1012-wk-Fact-9FEFF7474E5D530D823A19009CF18A8A">Common Stock, $0.0005 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="FD2020Q2YTD"
      id="d13624087e1022-wk-Fact-C40F77E9325358F68D4D6B1BB86C86F6">BIIB</dei:TradingSymbol>
    <dei:EntityCurrentReportingStatus
      contextRef="FD2020Q2YTD"
      id="d13624087e1042-wk-Fact-A0FF6BBD1ECA5ED9BFF41460502D4F78">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="FD2020Q2YTD"
      id="d13624087e1060-wk-Fact-B97C8FE628B45A50A6076E45E7C055E8">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="FD2020Q2YTD"
      id="d13624087e1095-wk-Fact-24829E5BA63D52CAB7F16AD2B1C40AA1">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="FD2020Q2YTD"
      id="d13624087e1141-wk-Fact-C45F229A83AB5CB7BC1AFD0D05B0DB26">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="FD2020Q2YTD"
      id="d13624087e1167-wk-Fact-2E10E3472D9E5D5AA8A0018C290E91F9">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="FD2020Q2YTD"
      id="d13624087e1177-wk-Fact-965B83E3819E50F48D1140256A1E05E0">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="I2020Q1July21"
      decimals="INF"
      id="d13624087e1195-wk-Fact-65FDFC55C6AD576A951F0041554C72D5"
      unitRef="shares">158313471</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d13627288e1067-wk-Fact-B152D3B5F3A05C7CAA044F72EA3120C1"
      unitRef="usd">2795700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d13627288e1086-wk-Fact-455E60BA69055CE8AECAC5095741DB0A"
      unitRef="usd">2880300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d13627288e1105-wk-Fact-3718F7E632B25D27847BA0BA45120ACA"
      unitRef="usd">5700300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d13627288e1125-wk-Fact-EE4EC8FA691555C0A7DE82D787D37BE4"
      unitRef="usd">5560300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d13627288e1140-wk-Fact-FB6FCA81223F5FE7A607645477111EBC"
      unitRef="usd">478300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d13627288e1159-wk-Fact-20474355737A5AB3954B4011223DE749"
      unitRef="usd">576400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d13627288e1178-wk-Fact-58C037C126CE5E9782E7F6AFA1368536"
      unitRef="usd">998700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d13627288e1198-wk-Fact-235F3E71E70A544C994CD254A0F195D0"
      unitRef="usd">1093800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d13627288e1218-wk-Fact-F3C79B768015565FA0C0EB179D69F338"
      unitRef="usd">407600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d13627288e1237-wk-Fact-46C1484140125886ACF7E143442F0214"
      unitRef="usd">160000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d13627288e1256-wk-Fact-E351B467EBD95DC7BA1A6E901C488CDA"
      unitRef="usd">516900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d13627288e1276-wk-Fact-9E90C511A4E4588682EE0D2A0C9F3B65"
      unitRef="usd">452400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13627288e1296-wk-Fact-62D84A2C364C577DA44131925927374D"
      unitRef="usd">3681600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13627288e1315-wk-Fact-6848435D107959608A78CDFF623C1FCA"
      unitRef="usd">3616700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13627288e1334-wk-Fact-4CD2481C46DE5C41BDD753FF5D2D020B"
      unitRef="usd">7215900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13627288e1354-wk-Fact-082E3F02F0A75CC6A55785289710BF28"
      unitRef="usd">7106500000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13627288e1456-wk-Fact-2881C54F9C785A4A804CD3438BE59ADD"
      unitRef="usd">411100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13627288e1475-wk-Fact-7B7F293170175DAFAA45517EA7FDFA3E"
      unitRef="usd">476300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13627288e1494-wk-Fact-F97C57D7B0145B379BA07A81ACDAFD4F"
      unitRef="usd">865500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13627288e1514-wk-Fact-E663E4B6D0FC538CA47ED87B47A58A20"
      unitRef="usd">1078300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13627288e1534-wk-Fact-545F8B395E0B5D4D8B8302649A4D9360"
      unitRef="usd">647600000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13627288e1553-wk-Fact-75B9D888AF2E5705A55276082BF4BCC6"
      unitRef="usd">484800000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13627288e1572-wk-Fact-8D580F88EF7955798FEE8D3F36C9AD30"
      unitRef="usd">1123900000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13627288e1592-wk-Fact-E2F41ABB8ADA5A018F296F5F9FE0BBA8"
      unitRef="usd">1048500000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13627288e1612-wk-Fact-88716ADAA8195DEFBBF65FE7C9BC363C"
      unitRef="usd">555100000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13627288e1631-wk-Fact-D398926E1CFB5F33B56996E29E5025AC"
      unitRef="usd">587600000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13627288e1650-wk-Fact-6ACAB8C017D75DC89D14D18DA12CC8A2"
      unitRef="usd">1125200000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13627288e1670-wk-Fact-1A4B579AFF0C5F47A5DA916AA054E467"
      unitRef="usd">1155300000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13627288e1691-wk-Fact-093CF28AF51D56AC9C178C57E0C20541"
      unitRef="usd">61500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13627288e1710-wk-Fact-FD9B7A01CCCF53378063A4D1471F9676"
      unitRef="usd">70100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13627288e1729-wk-Fact-5983CB099A665EB6970E589C89F1CF90"
      unitRef="usd">133000000.0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13627288e1749-wk-Fact-9E9EE51D826850DFA48CA3605826DA50"
      unitRef="usd">138300000</us-gaap:AmortizationOfIntangibleAssets>
    <biib:Collaborationprofitlosssharing
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13627288e1769-wk-Fact-F2B388227309526097FBCFB10E17189C"
      unitRef="usd">21800000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13627288e1788-wk-Fact-4958ACC3384B599BB607C0620E4A8AEC"
      unitRef="usd">63500000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13627288e1807-wk-Fact-956C8FEE37325419B50E76DD830EBF06"
      unitRef="usd">93500000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13627288e1827-wk-Fact-AC7A4562CF5E526A9913062BA57B6ED9"
      unitRef="usd">121600000</biib:Collaborationprofitlosssharing>
    <us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13627288e1847-wk-Fact-CB516727D8125C199D28BC02ACC98E4A"
      unitRef="usd">0</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
    <us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
      contextRef="FD2019Q2QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d13627288e1866-wk-Fact-E0A74BB3C9805B5D91EBF354AAF2C7AA"
      unitRef="usd">-2300000</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
    <us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13627288e1886-wk-Fact-CCDCC0B613C752A0B4788DBA33E7F2FF"
      unitRef="usd">0</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
    <us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13627288e1906-wk-Fact-9468395847FA54909BD0FF3C7830EB5F"
      unitRef="usd">113200000</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13627288e1926-wk-Fact-D2590DE582FB57A4B3475521C290EA50"
      unitRef="usd">-10000000.0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13627288e1945-wk-Fact-EA0A92078CAF5114A9DDE6B7E79E0436"
      unitRef="usd">20000000.0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13627288e1965-wk-Fact-1ED69AA194385201B48524E875F0B015"
      unitRef="usd">-5500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13627288e1985-wk-Fact-2D5631ACC4AA55F18A9E8E1BE5DDC18B"
      unitRef="usd">8500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:RestructuringCharges
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13627288e2006-wk-Fact-2E35D16EC55B556AB8D14737A56D03D8"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13627288e2025-wk-Fact-0855F5C2575157428A6870E75717EEFB"
      unitRef="usd">800000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13627288e2044-wk-Fact-CF725BD2C041581F965E07AC347E498E"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13627288e2064-wk-Fact-33F147C147535C44A1557A7E0A6BE656"
      unitRef="usd">1200000</us-gaap:RestructuringCharges>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13627288e2084-wk-Fact-5A806CFB3DE05E50B1B040C6894B925B"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13627288e2103-wk-Fact-5BDD4D579570542B9D02D7ADC319B453"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13627288e2122-wk-Fact-95EEAD25F3C058EFB92E2B4BE6E5D7E0"
      unitRef="usd">75000000.0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13627288e2142-wk-Fact-99A3CDD007EB5D948B282C7D3865470E"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:CostsAndExpenses
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13627288e2162-wk-Fact-71EDF945C1625A23801C3AF366AD4A9E"
      unitRef="usd">1707100000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13627288e2181-wk-Fact-77E1E92DB9A7518BB5E6C7CECD5BA8DE"
      unitRef="usd">1660800000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13627288e2200-wk-Fact-A86FAAC565545FCC92B87BF26A57E37D"
      unitRef="usd">3421600000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13627288e2220-wk-Fact-65B16EB561365B3BBB931DC845B9D329"
      unitRef="usd">3647900000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13627288e2240-wk-Fact-56D0B955948E51E79D06EEB83E3EBEA0"
      unitRef="usd">1974500000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13627288e2259-wk-Fact-6267945275DA596099A006B2235C5378"
      unitRef="usd">1955900000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13627288e2278-wk-Fact-CF03E0F0D74C56FEB819268AF46519F0"
      unitRef="usd">3794300000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13627288e2298-wk-Fact-69E2755E1105526AB2DC1AB9B5BE5B2B"
      unitRef="usd">3458600000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13627288e2318-wk-Fact-0D51E02D7DDE5C0E8E7A9F3566E66B60"
      unitRef="usd">63000000.0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13627288e2337-wk-Fact-55BFFA5FA59E5C88AB2D8F69B51FDAAD"
      unitRef="usd">-197400000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13627288e2357-wk-Fact-ABD76A880BD354B29882CFA24D852D20"
      unitRef="usd">-57500000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13627288e2378-wk-Fact-EEF1B208E84A576484A9D98454389FE0"
      unitRef="usd">159900000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13627288e2398-wk-Fact-15CFF958FCA75C3DA262F3D4877F6388"
      unitRef="usd">2037500000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13627288e2417-wk-Fact-F92B896983605050807AF216847FD3DE"
      unitRef="usd">1758500000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13627288e2436-wk-Fact-7F49859E4C81541C91411139852A9A2D"
      unitRef="usd">3736800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13627288e2456-wk-Fact-7437E9D01BB05863B64D1E2F608F3DB3"
      unitRef="usd">3618500000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13627288e2476-wk-Fact-15FFBD4EE73D5D2B8B78CD5F725441DC"
      unitRef="usd">446100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13627288e2495-wk-Fact-3669AFE313445E4585683ADA7AAD91C7"
      unitRef="usd">248100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13627288e2514-wk-Fact-0707EC3077505826ADFEC0CF301EBA0C"
      unitRef="usd">738200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13627288e2534-wk-Fact-F3C30D754426501CB970A0480E375CC2"
      unitRef="usd">670600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13627288e2555-wk-Fact-E82D70018EB35E49B9ED4B9D1092EC46"
      unitRef="usd">15100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13627288e2575-wk-Fact-DF75577404985E478F2563E78FEB4CFB"
      unitRef="usd">-16300000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13627288e2594-wk-Fact-B3CD3D16C9135EFD9DA3E256B292EF4E"
      unitRef="usd">400000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13627288e2615-wk-Fact-37101BD9FBD15AA8A0298E7BE1D10035"
      unitRef="usd">-45000000.0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ProfitLoss
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13627288e2635-wk-Fact-F3D57A6489675B3F80AF93FBE5F9C15F"
      unitRef="usd">1606500000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13627288e2654-wk-Fact-46DCDF7F62D35A1BA19A2C2DD7FB0AB9"
      unitRef="usd">1494100000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13627288e2673-wk-Fact-D07F9091FDDE5F65A9EF3F12BC88C032"
      unitRef="usd">2999000000.0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13627288e2693-wk-Fact-D7A6A22966455FDB9B8B93F33634D792"
      unitRef="usd">2902900000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13627288e2713-wk-Fact-451347AC18A553FA98E75031F387B9B7"
      unitRef="usd">64400000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13627288e2732-wk-Fact-15851F6402AF567A997FB8A39BDA0FB7"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13627288e2751-wk-Fact-E773C8539D5B5296A5CA4A51C9631206"
      unitRef="usd">57800000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13627288e2771-wk-Fact-85C6A3EC82A5546B843356BAC3450B72"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13627288e2796-wk-Fact-ADD31A6A5EBE5E7D8A2551FB858970C3"
      unitRef="usd">1542100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13627288e2815-wk-Fact-014416A7DF4E55AD89901C62A077D0C5"
      unitRef="usd">1494100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13627288e2834-wk-Fact-B46E75E522BC521D944CD595197A0DA3"
      unitRef="usd">2941200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13627288e2854-wk-Fact-91FF827803B156BD8E311A0B778D9521"
      unitRef="usd">2902900000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2020Q2QTD"
      decimals="2"
      id="d13627288e3038-wk-Fact-1E4BD2BF91618134CDB2591CC932F0BA"
      unitRef="usdPerShare">9.60</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2019Q2QTD"
      decimals="2"
      id="d13627288e3057-wk-Fact-C63DDCBC709041645DAA591CC959CDDF"
      unitRef="usdPerShare">7.85</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2020Q2YTD"
      decimals="2"
      id="d13627288e3076-wk-Fact-91F15E7A81316F7B2EBB591CC93FA598"
      unitRef="usdPerShare">17.65</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2019Q2YTD"
      decimals="2"
      id="d13627288e3096-wk-Fact-DA41C40E2222A7CA8D44591CC91C396A"
      unitRef="usdPerShare">15.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2020Q2QTD"
      decimals="2"
      id="d13627288e3116-wk-Fact-B4A4B94C9FC088BCD8CC591CC9292039"
      unitRef="usdPerShare">9.59</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2019Q2QTD"
      decimals="2"
      id="d13627288e3135-wk-Fact-03894815A9D8BA8D36F7591CC93CCEDC"
      unitRef="usdPerShare">7.85</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2020Q2YTD"
      decimals="2"
      id="d13627288e3154-wk-Fact-FDADD2C98C53B9EFB184591CC9268538"
      unitRef="usdPerShare">17.61</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2019Q2YTD"
      decimals="2"
      id="d13627288e3174-wk-Fact-EF46FEDCE6ACCA6DB4A1591CC94A2E4D"
      unitRef="usdPerShare">14.99</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13627288e3353-wk-Fact-99FE479F6EFA52F59E2D3DD5A91BFF8C"
      unitRef="shares">160600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13627288e3372-wk-Fact-0F8F00DB70B25725BDF588003BE32027"
      unitRef="shares">190300000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13627288e3391-wk-Fact-A7BA3E1F65C655ACB63EFBEDF4E5AE60"
      unitRef="shares">166700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13627288e3411-wk-Fact-22C74589209D549881B0B30906FF83A7"
      unitRef="shares">193400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13627288e3432-wk-Fact-AC9CFA06C14752C2822D10FC87E8F4FE"
      unitRef="shares">160900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13627288e3451-wk-Fact-AD06855122DD55CAA38318A14B520635"
      unitRef="shares">190400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13627288e3470-wk-Fact-8008A00FC876554890ED4AD4AC163885"
      unitRef="shares">167000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13627288e3490-wk-Fact-85F20EFF251E5B3C9894F550494B41BA"
      unitRef="shares">193700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13628796e985-wk-Fact-ADD31A6A5EBE5E7D8A2551FB858970C3"
      unitRef="usd">1542100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13628796e1004-wk-Fact-014416A7DF4E55AD89901C62A077D0C5"
      unitRef="usd">1494100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13628796e1023-wk-Fact-B46E75E522BC521D944CD595197A0DA3"
      unitRef="usd">2941200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13628796e1043-wk-Fact-91FF827803B156BD8E311A0B778D9521"
      unitRef="usd">2902900000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13628796e1140-wk-Fact-20D152D8C31452398FE56BF477364DB6"
      unitRef="usd">8700000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13628796e1159-wk-Fact-52749E634CF15A74B50A736D8F7F0843"
      unitRef="usd">3300000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13628796e1178-wk-Fact-B30F94F9AE775858A3CD0CD084FC8566"
      unitRef="usd">900000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13628796e1198-wk-Fact-A45EA26E025E52FDB836A0B6C43C734D"
      unitRef="usd">10200000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13628796e1218-wk-Fact-B50F57AD349A5CC59BB9CA686B97930A"
      unitRef="usd">-51200000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13628796e1238-wk-Fact-676F3D74FBC558E5834EBAC3C2A8605A"
      unitRef="usd">-37900000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13628796e1258-wk-Fact-B69D33DAE57259B88F2A294AA9BC8FC8"
      unitRef="usd">-17400000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13628796e1279-wk-Fact-A59C250C28915DD9BD68F56692696DE0"
      unitRef="usd">-21000000.0</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13628796e1300-wk-Fact-BF89450180C45E2DAEF2516991C3C547"
      unitRef="usd">-6200000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13628796e1320-wk-Fact-BAF3E383E126596AA65390603EECEE3C"
      unitRef="usd">11700000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13628796e1339-wk-Fact-D9E8471C594C5583B8E0DC5BECC2235B"
      unitRef="usd">16800000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13628796e1359-wk-Fact-4923ACFE615853FA88A3F6A8706CFED0"
      unitRef="usd">25700000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13628796e1379-wk-Fact-E3AEDCBE899E5626A888DFB01A2DA9A6"
      unitRef="usd">-100000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13628796e1398-wk-Fact-60B2D12DE3D85F85B3C02553D94C1D53"
      unitRef="usd">-100000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13628796e1417-wk-Fact-8E1A81F213505668AE18E9A33B8189EC"
      unitRef="usd">-900000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13628796e1437-wk-Fact-125C903F962B59A5BCB2C91F2D1ECCD3"
      unitRef="usd">-700000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13628796e1457-wk-Fact-529FB4E717A05D299B5C50666236355F"
      unitRef="usd">16900000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13628796e1476-wk-Fact-0EB7457C955655E6B986277FF93C757E"
      unitRef="usd">-10300000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13628796e1496-wk-Fact-751DB29C7DBC50818F5955DF1B5C6F5D"
      unitRef="usd">-47000000.0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13628796e1517-wk-Fact-DF2CD33DA9855515BF6086E959B24267"
      unitRef="usd">-28100000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13628796e1538-wk-Fact-4EE07EA71AE75C6CB808AB3BDB79D0D9"
      unitRef="usd">-31700000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13628796e1558-wk-Fact-E2573FCDAC995132BA12E51FA532B992"
      unitRef="usd">-33100000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13628796e1578-wk-Fact-41D6455C5A4252129BD8C5FF297E3741"
      unitRef="usd">-45800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13628796e1599-wk-Fact-6F359B4ACF055A4DA4E8C22AC9182DDB"
      unitRef="usd">-12500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13628796e1620-wk-Fact-A4557F57C4FD5C3C9507C78C8CB9E35C"
      unitRef="usd">1510400000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13628796e1639-wk-Fact-1059470360EB5CEC94D0BBABB5E145E0"
      unitRef="usd">1461000000.0</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13628796e1658-wk-Fact-E6413F4D177C5620ADDE79FF42D15E8D"
      unitRef="usd">2895400000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13628796e1678-wk-Fact-2E3D0F6C34915E23BFD320525EFCF045"
      unitRef="usd">2890400000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13628796e1699-wk-Fact-F3B2169F724B597790A61F76260980CE"
      unitRef="usd">-65500000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13628796e1718-wk-Fact-60920D850A69521281659CEB8F0D03CE"
      unitRef="usd">400000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13628796e1738-wk-Fact-20159077275B514190417592CF4D5DDD"
      unitRef="usd">-59600000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13628796e1758-wk-Fact-11A20FC25878549F9483B5F204F0639C"
      unitRef="usd">400000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13628796e1784-wk-Fact-021FE9119133528B8258FE34D0F1532E"
      unitRef="usd">1575900000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13628796e1803-wk-Fact-1A89C42175935468932BEF3981E6657F"
      unitRef="usd">1460600000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13628796e1822-wk-Fact-BDEF3267F7A65723BF7FDD84AC535552"
      unitRef="usd">2955000000.0</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13628796e1842-wk-Fact-ABD476C00A9C52A4982C4DA447D2112E"
      unitRef="usd">2890000000.0</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13630831e937-wk-Fact-02522BE0D0F052DB931AED6FC05A8227"
      unitRef="usd">2384900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13630831e956-wk-Fact-37A9AD9064055B35AC649A018B388FC4"
      unitRef="usd">2913700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13630831e971-wk-Fact-1278CFB1A3D050DE84DEF39500038A37"
      unitRef="usd">1942700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13630831e990-wk-Fact-E0941E6475ED52CB806609F597CFCDBD"
      unitRef="usd">1562200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13630831e1010-wk-Fact-A0D833B92E115601BB44711535FCEBC1"
      unitRef="usd">2133600000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13630831e1029-wk-Fact-545EFA543ACB5832A6E1B19B7CBA7F29"
      unitRef="usd">1880500000</us-gaap:AccountsReceivableNetCurrent>
    <biib:DuefromantiCD20therapeuticprograms
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13630831e1049-wk-Fact-2BBB4E43BB6753AFA583B8F9F2672F6F"
      unitRef="usd">441100000</biib:DuefromantiCD20therapeuticprograms>
    <biib:DuefromantiCD20therapeuticprograms
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13630831e1068-wk-Fact-1A781630359852B1B0C492E71833F3AD"
      unitRef="usd">590200000</biib:DuefromantiCD20therapeuticprograms>
    <us-gaap:InventoryNet
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13630831e1088-wk-Fact-38634221F2275B078613D9840B5268B1"
      unitRef="usd">952700000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13630831e1107-wk-Fact-5E24F47DCE6556D3B07F1C76326C17B7"
      unitRef="usd">804200000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13630831e1127-wk-Fact-14BBBBD97DE655DD92E12C0A1646466D"
      unitRef="usd">638800000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13630831e1146-wk-Fact-3BCE4915C76C534BAAE166C55650DCDE"
      unitRef="usd">631000000.0</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13630831e1166-wk-Fact-2089FA578C1B5CA79F126E0F222B2A8C"
      unitRef="usd">8493800000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13630831e1185-wk-Fact-65240D2E396D56F3A678A2AAA8468C57"
      unitRef="usd">8381800000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13630831e1205-wk-Fact-5F48A45E236B5F35BA736E0F1C36E387"
      unitRef="usd">922800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13630831e1224-wk-Fact-2ED3F2528ECD544A86C1D65E3294E230"
      unitRef="usd">1408100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13630831e1245-wk-Fact-515C4D50A90755F2931190A6ACFFE856"
      unitRef="usd">3330700000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13630831e1264-wk-Fact-3366BC2DB1C653B38F93576FF5B24AD1"
      unitRef="usd">3247300000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13630831e1284-wk-Fact-8E98B8F6497A5EA2B25F5603FFDEA49A"
      unitRef="usd">436200000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13630831e1303-wk-Fact-BA1B361682BE5B62BE68C9E88A08A487"
      unitRef="usd">427000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13630831e1323-wk-Fact-BFE27979689A5391A80AEDD28844D403"
      unitRef="usd">3383800000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13630831e1342-wk-Fact-324FDBF1B2EA5FB9ACA38A2A6E25F4FD"
      unitRef="usd">3527400000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13630831e1362-wk-Fact-8FC55EF7124D59B3A1E28F099D9D8F9D"
      unitRef="usd">5751000000.0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13630831e1381-wk-Fact-5E02EC613C7B5C7BA41E1722B85A855E"
      unitRef="usd">5757800000</us-gaap:Goodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13630831e1401-wk-Fact-075C147AD4CF5E2198781836CFCB7672"
      unitRef="usd">1710200000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13630831e1420-wk-Fact-7D3D48C5123359268F3F43D96D4CF52A"
      unitRef="usd">3232100000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13630831e1440-wk-Fact-C8A4557D4A705977A964BF8C62A779B9"
      unitRef="usd">1483300000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13630831e1459-wk-Fact-55F2168053825527956A26F8200EE397"
      unitRef="usd">1252800000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13630831e1484-wk-Fact-256D3819B22755B3AB35BA5509CF0E87"
      unitRef="usd">25511800000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13630831e1503-wk-Fact-56AF4C67BCE75A87A9204CE16C30C149"
      unitRef="usd">27234300000</us-gaap:Assets>
    <us-gaap:NotesPayableCurrent
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13630831e1605-wk-Fact-36560296280354E7A67A7F125DDEB727"
      unitRef="usd">0</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13630831e1624-wk-Fact-5A083527AC9D5BA39C2E624783047AC0"
      unitRef="usd">1495800000</us-gaap:NotesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13630831e1639-wk-Fact-AABD1CE9E1C653B7BD081D0AF91650F6"
      unitRef="usd">576700000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13630831e1658-wk-Fact-DA1B4D1D86225B8D8127D0F7C0B637DB"
      unitRef="usd">71400000</us-gaap:TaxesPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13630831e1679-wk-Fact-BCAF0DA8D933508E8260DE22573BBD6F"
      unitRef="usd">383900000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13630831e1698-wk-Fact-F5A18A7F7A1153F28FED115680BC8809"
      unitRef="usd">530800000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13630831e1718-wk-Fact-96180D2EFD6F50C4AB2607CAC10392DB"
      unitRef="usd">2486500000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13630831e1737-wk-Fact-ED32696AB6ED5D5F84AFD714902EF602"
      unitRef="usd">2765800000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13630831e1757-wk-Fact-5F0B5B0D752F568EB0C4E23E4E52CB76"
      unitRef="usd">3447100000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13630831e1776-wk-Fact-EC08852C28C95A01B284F52820CBEF97"
      unitRef="usd">4863800000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebt
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13630831e1796-wk-Fact-9DB4BF10A6B65A17B81235FB758FC6E9"
      unitRef="usd">7423800000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13630831e1815-wk-Fact-5F604C52469B533F887979C13E1DE9FE"
      unitRef="usd">4459000000.0</us-gaap:LongTermDebt>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13630831e1835-wk-Fact-31542E7B8BB559F3A085E6889C64D1DB"
      unitRef="usd">1461500000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13630831e1854-wk-Fact-25AE2CEDEB2F5D6E96179B4EFAC8A93A"
      unitRef="usd">2810800000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13630831e1874-wk-Fact-48F0441D74F05508B5D80B073C365B93"
      unitRef="usd">414800000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13630831e1893-wk-Fact-4831E533AE0F51EFB39B8FA20B649A8F"
      unitRef="usd">412700000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13630831e1913-wk-Fact-6299100E2B9B576C82E99FBE691E586C"
      unitRef="usd">1475400000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13630831e1932-wk-Fact-01F0411B800C53F49F5B13CE5B5A6E2B"
      unitRef="usd">1348900000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13630831e1952-wk-Fact-C283D8A684275716B4D967540715195F"
      unitRef="usd">14222600000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13630831e1971-wk-Fact-BF126DA2093C5929B5814F0E83EBDFB3"
      unitRef="usd">13895200000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="FI2020Q2"
      id="d13630831e1991-wk-Fact-53168BA5C52C50C18CD97671EE4B3986"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="FI2019Q4"
      id="d13630831e2009-wk-Fact-B4F92A0FF35251DA9E5BC7724B345AE0"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13630831e2111-wk-Fact-A54BD2F7512150B5B6419C125D82AA8A"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13630831e2130-wk-Fact-A89B2B1098805490ABF5DCB875705D5A"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13630831e2150-wk-Fact-619168E93F9551B5A93BE2D4F49E41B4"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13630831e2169-wk-Fact-F3541F4EA595564E8670E7546B5A1DAA"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13630831e2189-wk-Fact-0D57CCD4FEE0513E8F0ECEE6B62A4765"
      unitRef="usd">0</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13630831e2208-wk-Fact-45ED4794F81C552A886A1127AC418181"
      unitRef="usd">0</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13630831e2228-wk-Fact-FAED6FE93C26545A877123C092DC11AC"
      unitRef="usd">-181000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13630831e2248-wk-Fact-234099FE917C5DC385F4BC4F97FA7712"
      unitRef="usd">-135200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13630831e2269-wk-Fact-FA8BB677B32E5A1AB6B1A25D58B975C2"
      unitRef="usd">14466700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13630831e2288-wk-Fact-DB7806DE2CFA529EA2C50B38E6E38D99"
      unitRef="usd">16455400000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockValue
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13630831e2308-wk-Fact-CFABA07CF44559778E3BEE4A50728D38"
      unitRef="usd">2977100000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13630831e2328-wk-Fact-E7A4E5F67AF056EB92D61B8FC8D19968"
      unitRef="usd">2977100000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13630831e2349-wk-Fact-95B9BAAB16A3519D9686D4B16BCB9B14"
      unitRef="usd">11308700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13630831e2368-wk-Fact-BF917850400F5EB98164FDE8F07F89A9"
      unitRef="usd">13343200000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13630831e2388-wk-Fact-A59C4D3B638351F49150908D3A9A704F"
      unitRef="usd">-19500000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13630831e2408-wk-Fact-1917F9CDCC4B5F0C9EF795E2F51B057A"
      unitRef="usd">-4100000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13630831e2429-wk-Fact-7FC350EACFC650A3A25E503AFF1A8CB0"
      unitRef="usd">11289200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13630831e2448-wk-Fact-B97EF7525D435018B728ECB332CADA15"
      unitRef="usd">13339100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13630831e2473-wk-Fact-45858BB3B77F5DA09561532B04F52FE9"
      unitRef="usd">25511800000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13630831e2492-wk-Fact-08595EF14E4F58E98CF509D60BBD85E5"
      unitRef="usd">27234300000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13633138e934-wk-Fact-D07F9091FDDE5F65A9EF3F12BC88C032"
      unitRef="usd">2999000000.0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13633138e953-wk-Fact-D7A6A22966455FDB9B8B93F33634D792"
      unitRef="usd">2902900000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13633138e1009-wk-Fact-65268FFA54F55FB2975CA80D3CA3CF2A"
      unitRef="usd">232800000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13633138e1028-wk-Fact-34B26DB9EAC65A7DAF832D2B01E4C0C0"
      unitRef="usd">238100000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13633138e1048-wk-Fact-95EEAD25F3C058EFB92E2B4BE6E5D7E0"
      unitRef="usd">75000000.0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13633138e1067-wk-Fact-99A3CDD007EB5D948B282C7D3865470E"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13633138e1087-wk-Fact-7D48EE2E5C5E58028BC8B69AA478CAE6"
      unitRef="usd">115800000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13633138e1106-wk-Fact-C6175C1AD47A53E38DB1487A6CFBE5CD"
      unitRef="usd">98000000.0</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13633138e1126-wk-Fact-6B495BBB93B33EC3CFCB5960516DFFA3"
      unitRef="usd">3300000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13633138e1146-wk-Fact-5333FD33C930AC55402C5960FA413A13"
      unitRef="usd">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13633138e1166-wk-Fact-1ED69AA194385201B48524E875F0B015"
      unitRef="usd">-5500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13633138e1185-wk-Fact-2D5631ACC4AA55F18A9E8E1BE5DDC18B"
      unitRef="usd">8500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13633138e1206-wk-Fact-70640013A86F50FE83E833580A0074F1"
      unitRef="usd">0</us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax>
    <us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13633138e1225-wk-Fact-E8F1ABBC6F325103A679627C82C8757A"
      unitRef="usd">-113200000</us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13633138e1246-wk-Fact-F3D6E84A1C875DAC81E2BBBB0F051BD6"
      unitRef="usd">180200000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13633138e1265-wk-Fact-DCE730D8D5065969B1CF63047E8623EC"
      unitRef="usd">71600000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13633138e1285-wk-Fact-8BAE2575755A59648234B4F7DFF94CB1"
      unitRef="usd">39700000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13633138e1305-wk-Fact-3967753E14FC5FECAE863A4BEDD77692"
      unitRef="usd">199200000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13633138e1326-wk-Fact-5039873BE5A1557982CD201631605B15"
      unitRef="usd">-85300000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13633138e1345-wk-Fact-BA9F46F0DDBF545E908902B1FE1C6E13"
      unitRef="usd">-91100000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13633138e1406-wk-Fact-8E917E830333598FA5C5BA244FA3B825"
      unitRef="usd">268800000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13633138e1426-wk-Fact-30E991EF1D415855B60A8944E760A809"
      unitRef="usd">2900000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13633138e1447-wk-Fact-039BA42AEED85AE4B80AFF983B5E3EF0"
      unitRef="usd">-149100000</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13633138e1466-wk-Fact-E6564210B3575F61894F60DAD6BDE4E4"
      unitRef="usd">30600000</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13633138e1487-wk-Fact-2DA15F6B68D3527C89591ABA846D8B2E"
      unitRef="usd">188200000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13633138e1507-wk-Fact-BE12629DE38257A9A8FFCAB3FD4C50AD"
      unitRef="usd">-108700000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13633138e1527-wk-Fact-83323F5C32235D21AA4BEB7BC10941BA"
      unitRef="usd">-441400000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13633138e1547-wk-Fact-EC822C9A0C0E50959E5D37FB9FE62FC6"
      unitRef="usd">-216100000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13633138e1568-wk-Fact-CC0D4B0AED31553BAB9E43314D4A4CD4"
      unitRef="usd">504600000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13633138e1587-wk-Fact-3BCAEE4731605B2BA4671AE75FC9F045"
      unitRef="usd">306900000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13633138e1607-wk-Fact-D511858A2C57595D87A757FED99BEB26"
      unitRef="usd">-9900000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13633138e1626-wk-Fact-01A20A4505FE5ED09027CCBE3C317995"
      unitRef="usd">49700000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13633138e1647-wk-Fact-710EB4B7B600550EA3B7FFAA379DFCDE"
      unitRef="usd">3415800000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13633138e1666-wk-Fact-49497BB92A5F5FC8B7F8AD3020DAE31F"
      unitRef="usd">3423500000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13633138e1728-wk-Fact-22ABA6B6B6A35F598D8DBDA21EAD50E0"
      unitRef="usd">3879900000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13633138e1747-wk-Fact-1CCB591668FB51EFA12E7B8EDE0510D7"
      unitRef="usd">3255800000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13633138e1767-wk-Fact-19A7EFE2565258759A9A69D5974E16EF"
      unitRef="usd">3753900000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13633138e1787-wk-Fact-3D06CBACFC14534D876482C188871644"
      unitRef="usd">2075100000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13633138e1808-wk-Fact-BC1ACD6163DB57008263DEDC383F6580"
      unitRef="usd">0</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13633138e1827-wk-Fact-C0B80844E58D5F06807ABC3DD95E9B13"
      unitRef="usd">300000000.0</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13633138e1848-wk-Fact-11747CD28F9B5C65B7D4836C7937B004"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13633138e1867-wk-Fact-2EFB296C2B315DEEAB351D42394DF966"
      unitRef="usd">744400000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13633138e1888-wk-Fact-8244EFC4BCDF239F3B6E59650B5FD6FB"
      unitRef="usd">141800000</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13633138e1908-wk-Fact-C0793CD0CF2C0F2E580559650B3F6A2A"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13633138e1928-wk-Fact-2ED385F9D54A51648F1D5642FCC8AF28"
      unitRef="usd">254700000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13633138e1948-wk-Fact-C755A6BB7ADA5B47BE9928F443B03236"
      unitRef="usd">314000000.0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13633138e1969-wk-Fact-C255E698DE9C5C21BF2DBD9D6E0815AA"
      unitRef="usd">75000000.0</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13633138e1989-wk-Fact-D8367C34FA075D0FBCEB2A4866BB3CA7"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13633138e2009-wk-Fact-1BAD8A112C115295B151EB56D3214CA1"
      unitRef="usd">37000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13633138e2029-wk-Fact-DFE7CAAF34A55E0683D5D499D480ECC5"
      unitRef="usd">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:ProceedsFromHedgeInvestingActivities
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13633138e2049-wk-Fact-A2026A1BC1BA53192FD7596643F49DC6"
      unitRef="usd">-7800000</us-gaap:ProceedsFromHedgeInvestingActivities>
    <us-gaap:ProceedsFromHedgeInvestingActivities
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13633138e2069-wk-Fact-F835748739F0DAEE4E05596643F8C7E2"
      unitRef="usd">0</us-gaap:ProceedsFromHedgeInvestingActivities>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13633138e2089-wk-Fact-8BA582ED504A5665864F4006F80973DE"
      unitRef="usd">500000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13633138e2108-wk-Fact-03FD556E939F594CBA7867FA4B329864"
      unitRef="usd">309700000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13633138e2129-wk-Fact-30A6DC8B328F5922AAA53CCF5792058C"
      unitRef="usd">0</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13633138e2148-wk-Fact-A0D8B5AFE4B35D18BDA72E1EAD10EC81"
      unitRef="usd">4000000.0</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13633138e2169-wk-Fact-A9C893BB9C9C5D21A1FBB2DB10F32914"
      unitRef="usd">-389800000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13633138e2189-wk-Fact-9190E6A401205C26AC096EC0CCA35D9B"
      unitRef="usd">128000000.0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13633138e2250-wk-Fact-676B7B02A83D58DABA237A52DBFBD751"
      unitRef="usd">5029100000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13633138e2270-wk-Fact-2D9DDF9CFC805FEC9E6729D60CF69694"
      unitRef="usd">3057300000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13633138e2291-wk-Fact-F424671E04BB5EB4841B84EA4B462DE0"
      unitRef="usd">19200000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13633138e2311-wk-Fact-669BEFCF36B55876AE053C4EE2C105C2"
      unitRef="usd">23600000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13633138e2332-wk-Fact-A88891D6DF5402A65A735967316CCFDE"
      unitRef="usd">2967300000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13633138e2351-wk-Fact-8E32678B8AF123201D54596731632AE0"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13633138e2371-wk-Fact-1037A0888854550B99DA4DED3452CC76"
      unitRef="usd">1500000000.0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13633138e2391-wk-Fact-515B103726515FB39E8ABEB622AB51DB"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsForProceedsFromDerivativeInstrumentFinancingActivities
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13633138e2411-wk-Fact-2EC318CEE8E4E5EEC6C359689252F6A2"
      unitRef="usd">-3300000</us-gaap:PaymentsForProceedsFromDerivativeInstrumentFinancingActivities>
    <us-gaap:PaymentsForProceedsFromDerivativeInstrumentFinancingActivities
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13633138e2430-wk-Fact-D1AF4555F73AF0DE92BB5968924D88D4"
      unitRef="usd">0</us-gaap:PaymentsForProceedsFromDerivativeInstrumentFinancingActivities>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13633138e2450-wk-Fact-4D0951F9E9295168B5390AE1F2966E65"
      unitRef="usd">0</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13633138e2469-wk-Fact-2CC0F69FA25252399E19694EB3CB72A0"
      unitRef="usd">-4300000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13633138e2489-wk-Fact-292971BAE0985B3688C4562C837DDBBC"
      unitRef="usd">19000000.0</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13633138e2508-wk-Fact-0657E1B0B0E457E596B27CA299958E8E"
      unitRef="usd">21600000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13633138e2528-wk-Fact-C795D15852755CE4B5AD0323F195395F"
      unitRef="usd">-3558700000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13633138e2548-wk-Fact-668440EA31C55C31B439E51865F39A00"
      unitRef="usd">-3055000000.0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13633138e2570-wk-Fact-B09863BBA8BA5E69AB74EB67D35194D5"
      unitRef="usd">-532700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13633138e2590-wk-Fact-C7A757E8EE165DFA8F63518FD349F99D"
      unitRef="usd">496500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13633138e2610-wk-Fact-DE9C01A1C2615DB09AE2E8B9E7D04AB2"
      unitRef="usd">3900000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13633138e2629-wk-Fact-D99A5E7678695484BAB7855131BC7C1B"
      unitRef="usd">2300000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13633138e2649-wk-Fact-37A9AD9064055B35AC649A018B388FC4"
      unitRef="usd">2913700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2018Q4"
      decimals="-5"
      id="d13633138e2668-wk-Fact-8340724A8898505298400E2A0A6C607F"
      unitRef="usd">1224600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13633138e2693-wk-Fact-02522BE0D0F052DB931AED6FC05A8227"
      unitRef="usd">2384900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2019Q2"
      decimals="-5"
      id="d13633138e2712-wk-Fact-81A0C976A20C568D8E876C2ED871EB96"
      unitRef="usd">1723400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d13648331e1306-wk-Fact-1B2DC764BA8A5DCAA2EE61CCBBE893AD"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d13648331e1325-wk-Fact-88F246B15BEC57C7A30F4419EDB44B94"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d13648331e1339-wk-Fact-8005D3AC6C99592CBC69480F547BD483"
      unitRef="shares">191100000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d13648331e1359-wk-Fact-7BA03397245E5C44A8BEE03C4B6F61CD"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d13648331e1378-wk-Fact-A706A5D2BEF6556FB01B0A864C35E462"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d13648331e1397-wk-Fact-5D65436A0E18504CB51D59BEDB2C09A8"
      unitRef="usd">-149300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d13648331e1418-wk-Fact-9302648CDF6C5BC0955FD672AB69A0A5"
      unitRef="usd">15673100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d13648331e1432-wk-Fact-BC322FF8D7935FDD8010AB3938D52E9D"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d13648331e1452-wk-Fact-40D2CABD0EB553B2A2D1EFB39ED5840F"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d13648331e1473-wk-Fact-99B4F5D3F9515881ADDF93E4493EF17F"
      unitRef="usd">12546900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d13648331e1492-wk-Fact-0DD4FDAD478F54459D3369AAAE49CC26"
      unitRef="usd">-10000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q1"
      decimals="-5"
      id="d13648331e1512-wk-Fact-49EA246A917258E7946612AD978F6645"
      unitRef="usd">12536900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d13648331e1634-wk-Fact-055454D5201F56C39DD4A2E57E203FB6"
      unitRef="usd">1542100000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d13648331e1687-wk-Fact-39F15AE6EE7B5A3AB858D60E8FF19786"
      unitRef="usd">1542100000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d13648331e1706-wk-Fact-20325BDCFA925C048BF441E2ACA8AD9B"
      unitRef="usd">64400000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13648331e1725-wk-Fact-F3D57A6489675B3F80AF93FBE5F9C15F"
      unitRef="usd">1606500000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d13648331e1832-wk-Fact-086D2789677A5AACA693F89AB9443C62"
      unitRef="usd">-31700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d13648331e1906-wk-Fact-A2F51ABD2C87585BA61CC4544CC04491"
      unitRef="usd">-31700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d13648331e1926-wk-Fact-BA751F773A385D53A70B3DE38C478E3E"
      unitRef="usd">1100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13648331e1945-wk-Fact-36DB150BC29C5EAF9C280B975056D314"
      unitRef="usd">-30600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d13648331e2126-wk-Fact-A670C010CECFDA682A2B5925BE234BFF"
      unitRef="usd">0</biib:Noncontrollinginterestincreasedecreaseother>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d13648331e2145-wk-Fact-C71DE1891D995C4894137E86ECB5BFE9"
      unitRef="usd">-75000000.0</biib:Noncontrollinginterestincreasedecreaseother>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13648331e2165-wk-Fact-A97980F8FA3E6F3725645925BE073225"
      unitRef="usd">-75000000.0</biib:Noncontrollinginterestincreasedecreaseother>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2020Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d13648331e2312-wk-Fact-2A8659EAFBC85B21BF7376000C0782B8"
      unitRef="shares">9000000.0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2020Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d13648331e2327-wk-Fact-E6E0CF25B0E95478A72E3EC37242D11B"
      unitRef="usd">2808900000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2020Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d13648331e2348-wk-Fact-5602EF53D2CF52738A075CAC461A5D94"
      unitRef="usd">2808900000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2020Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d13648331e2387-wk-Fact-F606808ED6435DA0A968E1B1D1845F59"
      unitRef="usd">2808900000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2020Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d13648331e2442-wk-Fact-8AE3559C131956C98CE78E2E4DB05420"
      unitRef="shares">9000000.0</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2020Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d13648331e2458-wk-Fact-BB85F8182D9A5D66B9E2214EF8972EC4"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2020Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d13648331e2477-wk-Fact-E5536B5EACA553A1897903E07D84BA77"
      unitRef="usd">60700000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2020Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d13648331e2517-wk-Fact-A92695A398FA5C83AD9AFD0AFF4AE02E"
      unitRef="usd">2748200000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2020Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d13648331e2537-wk-Fact-A92D222BA76F5A4398633B3419F9C249"
      unitRef="shares">9000000.0</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2020Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d13648331e2551-wk-Fact-33DED60327B858B1B81A80F77BF846B1"
      unitRef="usd">-2808900000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2020Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d13648331e2571-wk-Fact-CC0E6DC293F25E69B9189400B2DB7FA2"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2020Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d13648331e2609-wk-Fact-0CD3B48B7D425A40BBF64DB44F2BA767"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d13648331e2663-wk-Fact-5BDE632BF5845A0FBA166F3C27BE209E"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d13648331e2678-wk-Fact-0E14B49710C550DC9BB9E28A029D38DB"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d13648331e2697-wk-Fact-DFA38C52DF595A89A70D79FA24B45AF0"
      unitRef="usd">11100000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d13648331e2789-wk-Fact-06EB1A181BAA5B399CBB618677236400"
      unitRef="usd">11100000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13648331e2827-wk-Fact-C9D877CF70EB57199995082C7BB184BC"
      unitRef="usd">11100000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d13648331e2881-wk-Fact-BD56B7B5509D5D73920598158969E265"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d13648331e2896-wk-Fact-4CCDDBDC230457CB82D456F55DB7FCFA"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d13648331e2915-wk-Fact-945ABC9D685854B2B557A26BDA6E985D"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d13648331e2954-wk-Fact-4A3A239142AF550597443A6D3E381678"
      unitRef="usd">-300000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d13648331e3008-wk-Fact-FC3D21BD011E50169296A2DAF4194550"
      unitRef="usd">-300000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13648331e3047-wk-Fact-947785AA23515C1D926EBAE830E36A6C"
      unitRef="usd">-300000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d13648331e3136-wk-Fact-3855C1B06B5459E8B3DD683B84AB6496"
      unitRef="usd">-49500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d13648331e3228-wk-Fact-EA142BE8233A5F87B9E8FF4477186185"
      unitRef="usd">-49500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13648331e3266-wk-Fact-A5B92CAFC4B25B5BA89D144B3AE7354D"
      unitRef="usd">-49500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityOther
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d13648331e3355-wk-Fact-276A1C70835E5477BEA275BE1BAF3B51"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d13648331e3447-wk-Fact-186413944BF6517AA4870947EE525761"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13648331e3485-wk-Fact-8F85328765D85E92BF0E91B6CD29C0B7"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d13648331e3506-wk-Fact-A3B3E04B8AF9D88B48755938480E7415"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d13648331e3525-wk-Fact-A2096089825669C9BF0459384AA9E29D"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d13648331e3538-wk-Fact-7A92727466AC29D91A3859384D92DCAA"
      unitRef="shares">182100000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d13648331e3557-wk-Fact-9141911DD7BD8AA93A0359384FE25ADB"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d13648331e3575-wk-Fact-8B8F9464A5DEFF3A2386593852765E12"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d13648331e3593-wk-Fact-AF8BDA1219D93B3C238B593854B6D0F8"
      unitRef="usd">-181000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d13648331e3613-wk-Fact-74A3D2473BD396D5142D593857582712"
      unitRef="usd">14466700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d13648331e3626-wk-Fact-69CC666AFE09624FE15A593859F362F4"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d13648331e3645-wk-Fact-BEFBD6012C92987CF3B159385C1F1213"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d13648331e3665-wk-Fact-0F0344A1DC29657402F259385E2F65ED"
      unitRef="usd">11308700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d13648331e3683-wk-Fact-901F758F8737EA072A3559385F8149F6"
      unitRef="usd">-19500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13648331e3702-wk-Fact-7FC350EACFC650A3A25E503AFF1A8CB0"
      unitRef="usd">11289200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d13648331e4275-wk-Fact-0532CEF37067C1F774F55937EE9982B1"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d13648331e4294-wk-Fact-EDA41C9816B4AE501BBF5937F1652AC7"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d13648331e4308-wk-Fact-168A5F00425A1F59CC095937F3D59A78"
      unitRef="shares">198000000.0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d13648331e4328-wk-Fact-5A48FAB8ACF884AFFA535937F7B4608C"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d13648331e4347-wk-Fact-80A6D767A4EAABDF40755937FA521B96"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d13648331e4366-wk-Fact-8E289BD0C2C4F84833C05937FC929F60"
      unitRef="usd">-135200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d13648331e4387-wk-Fact-E3696CEB303F17FD15305937FF3302FF"
      unitRef="usd">16455400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d13648331e4401-wk-Fact-864B7D23A1BE9035A323593801768548"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d13648331e4421-wk-Fact-AB5893F52AC030BD574159380421197A"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d13648331e4442-wk-Fact-1F69B17A7EF717290A14593806112980"
      unitRef="usd">13343200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d13648331e4461-wk-Fact-6FFD1B7D0230039914B1593806AE21DE"
      unitRef="usd">-4100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13648331e4481-wk-Fact-B97EF7525D435018B728ECB332CADA15"
      unitRef="usd">13339100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d13648331e4603-wk-Fact-BA0B8683C3659369DF9B59390DEA8D33"
      unitRef="usd">2941200000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d13648331e4656-wk-Fact-70AEAC5F2404BDE8FF9B5939122B6287"
      unitRef="usd">2941200000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d13648331e4675-wk-Fact-99586E27B428612A14CF593913C26D42"
      unitRef="usd">57800000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13648331e4694-wk-Fact-D07F9091FDDE5F65A9EF3F12BC88C032"
      unitRef="usd">2999000000.0</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d13648331e4801-wk-Fact-EB580169CE4FB00D98AB59391D1527C4"
      unitRef="usd">-45800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d13648331e4875-wk-Fact-224DEBF842550A08D66F593922BB3B2B"
      unitRef="usd">-45800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d13648331e4895-wk-Fact-1D9755227DD24929FB78593923E62C65"
      unitRef="usd">1800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13648331e4914-wk-Fact-28C659AD2AAE4E811912593926014255"
      unitRef="usd">-44000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d13648331e5114-wk-Fact-487D8FC07EE6E1E84CA0593A14D062F0"
      unitRef="usd">-75000000.0</biib:Noncontrollinginterestincreasedecreaseother>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13648331e5134-wk-Fact-F09C816D772B0429B051593A14D6167E"
      unitRef="usd">-75000000.0</biib:Noncontrollinginterestincreasedecreaseother>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d13648331e5281-wk-Fact-6789C7CDA04E97F3CDEC593AF2AAC88D"
      unitRef="shares">4100000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d13648331e5296-wk-Fact-4E11B491F48AE0F77D00593AD521D962"
      unitRef="usd">1279100000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d13648331e5317-wk-Fact-04AECE62EB89D8F40589593AD493362C"
      unitRef="usd">1279100000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d13648331e5356-wk-Fact-768CB22537EC046D99B9593AD4B14BA6"
      unitRef="usd">1279100000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d13648331e5411-wk-Fact-80D0D1FCC1C026992E87593B0FEFBA7F"
      unitRef="shares">4100000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d13648331e5446-wk-Fact-3963C8C969FB5329D439593B33A07439"
      unitRef="usd">71000000.0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d13648331e5486-wk-Fact-9589E41D2FE730AD31CF593B311D87B1"
      unitRef="usd">1208100000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d13648331e5506-wk-Fact-D6C6F68E0ED1F69FAC30593B104C7933"
      unitRef="shares">4100000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d13648331e5520-wk-Fact-B8C31CD48D306C483943593B325D7207"
      unitRef="usd">-1279100000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d13648331e5578-wk-Fact-A10550D33FF0748A3C73593B3384A173"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d13648331e5724-wk-Fact-41D2B68D90C84F3C13E7593B578C4BB6"
      unitRef="shares">12200000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d13648331e5739-wk-Fact-FCA3D771EB2CE382E427593B7E5B63DB"
      unitRef="usd">3750000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d13648331e5760-wk-Fact-736E2A674C0037E3E4CC593B7E28E268"
      unitRef="usd">3750000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d13648331e5799-wk-Fact-B34B64F22C63EDB87C5D593B7A78EF05"
      unitRef="usd">3750000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d13648331e5854-wk-Fact-B98047A06023E3395318593B5774812B"
      unitRef="shares">12200000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d13648331e5889-wk-Fact-92FC4732FFE7C444D398593B80CCB855"
      unitRef="usd">76200000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d13648331e5929-wk-Fact-C84B0BD131C178293117593B8700D3DC"
      unitRef="usd">3673800000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d13648331e5949-wk-Fact-C7828FE0D65DA60F1CB4593B564F0AB3"
      unitRef="shares">12200000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d13648331e5963-wk-Fact-FD1B54E02DDBD0048AFC593B84D9251E"
      unitRef="usd">-3750000000.0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d13648331e6021-wk-Fact-8D877BCB9B40C1A62E62593B852563B5"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d13648331e6075-wk-Fact-4544BDC43028052FC4F0593ED3631944"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d13648331e6090-wk-Fact-8E8327E914AACCC88AB7593ED63007BD"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d13648331e6109-wk-Fact-E16ADC5858ACAF789143593ED91C48F7"
      unitRef="usd">29100000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d13648331e6201-wk-Fact-18B9F520C64FD6041138593EDFC08C92"
      unitRef="usd">29100000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13648331e6239-wk-Fact-E7AEF4AAB874C7435F5B593EE25AF5CB"
      unitRef="usd">29100000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d13648331e6294-wk-Fact-7DD502AC8AD8C0D0E6E3593EE3899E91"
      unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d13648331e6309-wk-Fact-9714D3B3933F6F3D9245593EE675A566"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d13648331e6328-wk-Fact-6C6327D4DDC2114C57CE593EE8E8181A"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d13648331e6367-wk-Fact-9951CDA5434A93EAF401593EECF9BF9A"
      unitRef="usd">-48000000.0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d13648331e6421-wk-Fact-E91C95B6C616440C277F593EEFCFD0BF"
      unitRef="usd">-48000000.0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13648331e6460-wk-Fact-5B50E3E75770FF1D8CE0593EF0D635C9"
      unitRef="usd">-48000000.0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d13648331e6549-wk-Fact-1B2BA706AF398DA32BDC593FE6895B67"
      unitRef="usd">-118800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d13648331e6641-wk-Fact-0D961D4A0E7D1029A3C4593FED806CE1"
      unitRef="usd">-118800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13648331e6679-wk-Fact-B131A86A6CF17219B87D593FF0B8B8B0"
      unitRef="usd">-118800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityOther
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d13648331e6767-wk-Fact-79BC0DF63D9737BA160C593FF244F2E0"
      unitRef="usd">700000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d13648331e6860-wk-Fact-3F11C2C4BB4C9E90F06C593FF98D9D70"
      unitRef="usd">700000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13648331e6899-wk-Fact-955D6B15D4F275C0326D593FFC512783"
      unitRef="usd">700000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d13648331e6921-wk-Fact-A3B3E04B8AF9D88B48755938480E7415"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d13648331e6940-wk-Fact-A2096089825669C9BF0459384AA9E29D"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d13648331e6954-wk-Fact-7A92727466AC29D91A3859384D92DCAA"
      unitRef="shares">182100000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d13648331e6974-wk-Fact-9141911DD7BD8AA93A0359384FE25ADB"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d13648331e6993-wk-Fact-8B8F9464A5DEFF3A2386593852765E12"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d13648331e7012-wk-Fact-AF8BDA1219D93B3C238B593854B6D0F8"
      unitRef="usd">-181000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d13648331e7033-wk-Fact-74A3D2473BD396D5142D593857582712"
      unitRef="usd">14466700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d13648331e7047-wk-Fact-69CC666AFE09624FE15A593859F362F4"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d13648331e7067-wk-Fact-BEFBD6012C92987CF3B159385C1F1213"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d13648331e7088-wk-Fact-0F0344A1DC29657402F259385E2F65ED"
      unitRef="usd">11308700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d13648331e7107-wk-Fact-901F758F8737EA072A3559385F8149F6"
      unitRef="usd">-19500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13648331e7127-wk-Fact-7FC350EACFC650A3A25E503AFF1A8CB0"
      unitRef="usd">11289200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d13648331e7693-wk-Fact-4C29DC19910C5DA8BAF23B02FDC8A34C"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d13648331e7712-wk-Fact-7C467064CD115948A03AD8654F4091F0"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d13648331e7726-wk-Fact-99D54FDB981059AB90C591132366E78D"
      unitRef="shares">219000000.0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d13648331e7746-wk-Fact-80D1FA58EED3580EBC3741055B3A69DA"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d13648331e7765-wk-Fact-AA401332E0D15FEAA0BD2DA8D40EC4C7"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d13648331e7784-wk-Fact-EAAB9B0667B35E048614D3664BBF9B9D"
      unitRef="usd">-219800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d13648331e7805-wk-Fact-228E06D3060B55568279C378B9CB7DE6"
      unitRef="usd">17026700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d13648331e7819-wk-Fact-32C04627843B5CDFA24FB076F4725AAD"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d13648331e7839-wk-Fact-1E6FD9BAF9B95C438B03C29240BCABD9"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d13648331e7860-wk-Fact-C29F4E18EDA154DF4AE15928F05E6427"
      unitRef="usd">13829900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d13648331e7879-wk-Fact-77E0CFF502065AB691C0C9D573BEE2A8"
      unitRef="usd">-7900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1"
      decimals="-5"
      id="d13648331e7899-wk-Fact-B4F422DE92C52F09DA185928EFC0F0D1"
      unitRef="usd">13822000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d13648331e8021-wk-Fact-672FB66A87EA5E0BAFBA991A6C11629E"
      unitRef="usd">1494100000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d13648331e8074-wk-Fact-AA86C73529E25D399E1FB3A477041191"
      unitRef="usd">1494100000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13648331e8112-wk-Fact-46DCDF7F62D35A1BA19A2C2DD7FB0AB9"
      unitRef="usd">1494100000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d13648331e8219-wk-Fact-1C0510F54A3451559F80E49CF54C5254"
      unitRef="usd">-33100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d13648331e8293-wk-Fact-0B14D1C7DA5A5984995EBA875919DB40"
      unitRef="usd">-33100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d13648331e8313-wk-Fact-AF9A3F7A7D75571B90482C44AEC759AA"
      unitRef="usd">-400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13648331e8333-wk-Fact-96F51665C2AAD64B92865928EFA2327E"
      unitRef="usd">-33500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d13648331e8514-wk-Fact-C0C5C9B9857D554E8DBBAC3FFA989DC7"
      unitRef="usd">0</biib:Noncontrollinginterestincreasedecreaseother>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d13648331e8533-wk-Fact-A88E0B1CD14F5134BAA0F0953528C594"
      unitRef="usd">4200000</biib:Noncontrollinginterestincreasedecreaseother>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13648331e8552-wk-Fact-CA73D4CF84C0D4FB363D5928F09A46FA"
      unitRef="usd">4200000</biib:Noncontrollinginterestincreasedecreaseother>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d13648331e8698-wk-Fact-C1095B3E6CFC8423C3D8594651092E95"
      unitRef="shares">3900000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d13648331e8713-wk-Fact-5A7A4DF2BC5F1808BDCF59463E7CC545"
      unitRef="usd">909900000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d13648331e8734-wk-Fact-ED79EFD9EEF7B80ECD2259463E853142"
      unitRef="usd">909900000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d13648331e8773-wk-Fact-A4733C1B61EF5A8DFD9359463E8FB595"
      unitRef="usd">909900000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d13648331e8828-wk-Fact-8A33C0639FD0CC4CB58B59468C986757"
      unitRef="shares">3900000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d13648331e8863-wk-Fact-967D6A09D39564AEACDD5946B870863D"
      unitRef="usd">19700000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d13648331e8903-wk-Fact-C136413E99F06B2D33235946B87EF718"
      unitRef="usd">890200000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d13648331e8923-wk-Fact-6F2F2EBA7AB3AB888DEF59468C9D9BBE"
      unitRef="shares">3900000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d13648331e8937-wk-Fact-55C85A07E640A8EA4D885946B8741AB9"
      unitRef="usd">-909900000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d13648331e9141-wk-Fact-659529059AA55A05BDD8F79922E4C5CC"
      unitRef="shares">6500000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d13648331e9156-wk-Fact-7E796C5B4A635400A426C4F1E236D891"
      unitRef="usd">1491600000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d13648331e9177-wk-Fact-ABD7EA9F4F4E5FCF9CFF91B091895D40"
      unitRef="usd">1491600000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember"
      decimals="-5"
      id="d13648331e9216-wk-Fact-7C5B3D41BB5D1C77C3E35928EFE3CA6C"
      unitRef="usd">1491600000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d13648331e9271-wk-Fact-D543F465F16759D988CCC60CDB65624C"
      unitRef="shares">6500000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d13648331e9287-wk-Fact-B90652F5168A5F6B9CA398CA75488291"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d13648331e9306-wk-Fact-82984F5212F951648509C10E89950195"
      unitRef="usd">44900000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d13648331e9346-wk-Fact-5BC267088341533399A2C22073A182D2"
      unitRef="usd">1446700000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d13648331e9366-wk-Fact-B119E4201A0D52E788DEE9222E977EF8"
      unitRef="shares">6500000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d13648331e9380-wk-Fact-2DF6506A9C115BFAB71CD53DFDD37489"
      unitRef="usd">-1491600000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d13648331e9400-wk-Fact-13CC3833BBF1592C89FA7C39A852D23D"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember"
      decimals="-5"
      id="d13648331e9438-wk-Fact-5FDCB0EB0AB4188BBA755928F0B94C1C"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d13648331e9492-wk-Fact-D9B89DE30DBD53959E6C5BB45F43CE8D"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d13648331e9507-wk-Fact-F49154DCD2D55A02BD7BC56C085446D2"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d13648331e9526-wk-Fact-B5A55FF07A4A5847AA17292CDEF2ECAF"
      unitRef="usd">9600000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d13648331e9618-wk-Fact-1F6D706154C1573F8F930304162B85FF"
      unitRef="usd">9600000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13648331e9656-wk-Fact-3B1C4A9213BC9DEFA6F65928F021BEC2"
      unitRef="usd">9600000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d13648331e9711-wk-Fact-A2AB96753BE05BEC82189D7E3322334E"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d13648331e9726-wk-Fact-8FF8C7E2FE105432B96EEECBB4014F3F"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d13648331e9745-wk-Fact-44F4DCF0966A5884AF590577467E5709"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d13648331e9784-wk-Fact-482C40564B4D5C1C863A338EB64BDFCA"
      unitRef="usd">-1100000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d13648331e9838-wk-Fact-02042DD4EACD56819C37D092CD9F59E8"
      unitRef="usd">-1100000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13648331e9877-wk-Fact-A843345589DDA4F552C05928F003AA7D"
      unitRef="usd">-1100000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d13648331e9966-wk-Fact-296A17D6FBB45E13B754213E4185A757"
      unitRef="usd">-55000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d13648331e10005-wk-Fact-627389C020835E52B76A0DC962524ECA"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d13648331e10058-wk-Fact-3DF6C49AE7E15D6DBD70B00A6DD1042F"
      unitRef="usd">-55000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13648331e10096-wk-Fact-8D31167147F9CCD4B0D55928F07D196D"
      unitRef="usd">-55000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d13648331e10117-wk-Fact-C13B50DA24E2398EFBEF594D96A4D924"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d13648331e10136-wk-Fact-537D0F816D9CCEFBE4F3594D999A8152"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d13648331e10150-wk-Fact-ADA15D4EAAC59DD07467594D9C5CE217"
      unitRef="shares">208600000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d13648331e10170-wk-Fact-B1ABB7508646F331AD7B594D9F2E08D7"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d13648331e10189-wk-Fact-0E4CFA4F88D537FCFBF4594DA20A0FB2"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d13648331e10208-wk-Fact-1E3A79B575A7EC1E71B5594DA5280B7C"
      unitRef="usd">-252900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d13648331e10229-wk-Fact-778F793D09F7548292C6594DA95ED636"
      unitRef="usd">16182800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d13648331e10243-wk-Fact-3FCB5A794255746B06AE594DAD864C59"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d13648331e10263-wk-Fact-7D7ECBB599437B92C082594DB18B9DB2"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d13648331e10284-wk-Fact-6B3D4676EE46A1B02420594DB5EB2F08"
      unitRef="usd">12952900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d13648331e10303-wk-Fact-A52A44D92ECA04E2C0BE594DBA4AF661"
      unitRef="usd">-4100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2"
      decimals="-5"
      id="d13648331e10323-wk-Fact-05CB20CCB3DACA57CF01594DBDDD968F"
      unitRef="usd">12948800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d13648331e10894-wk-Fact-5688F03CB7D8654E71C4594D4D3D5515"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d13648331e10913-wk-Fact-EB5F5ACA83B2360E7AAE594D4FFA356E"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d13648331e10927-wk-Fact-69E12AEAB5BCAFA343B9594D52F33C6C"
      unitRef="shares">221000000.0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d13648331e10947-wk-Fact-60136F9D5DD4E19FD83C594D55B36056"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d13648331e10966-wk-Fact-6AA6B07E48B69D7D2FA1594D58A02D6D"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d13648331e10985-wk-Fact-BF0F761E8AC11393C481594D5BC1653D"
      unitRef="usd">-240400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d13648331e11006-wk-Fact-1E62CDF710041C8A03A1594D5F80ACE1"
      unitRef="usd">16257000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d13648331e11020-wk-Fact-7B5D48294B8105402C3D594D632CA123"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d13648331e11040-wk-Fact-D87FB8C171032E23D989594D66F7136F"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d13648331e11061-wk-Fact-CFB4088F5566EB9C8A6D594D6A4D582B"
      unitRef="usd">13039600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d13648331e11080-wk-Fact-9B79490193B2CC9D5708594D6D994EB7"
      unitRef="usd">-8000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4"
      decimals="-5"
      id="d13648331e11100-wk-Fact-DF1518A1E9E5819076BD594D72D04C80"
      unitRef="usd">13031600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d13648331e11222-wk-Fact-29791130FCE7F3F208EF594F36C860C4"
      unitRef="usd">2902900000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d13648331e11275-wk-Fact-530800AB1382E665F933594F3E7520EF"
      unitRef="usd">2902900000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13648331e11313-wk-Fact-D7A6A22966455FDB9B8B93F33634D792"
      unitRef="usd">2902900000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d13648331e11420-wk-Fact-95B78631F8E1A3A82113594F4E9E4A70"
      unitRef="usd">-12500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d13648331e11494-wk-Fact-6404A57F9255795C6F85594F59216AEF"
      unitRef="usd">-12500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d13648331e11514-wk-Fact-40E7B9D04206B9F7E6F3594F5B6876F9"
      unitRef="usd">-400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13648331e11534-wk-Fact-69E70D3A2E52066EA225594F5F5EFF33"
      unitRef="usd">-12900000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d13648331e11715-wk-Fact-8755C73DB0197D0D8673594F700C3EE7"
      unitRef="usd">0</biib:Noncontrollinginterestincreasedecreaseother>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d13648331e11734-wk-Fact-B30AD01239C43C89CDEC594F7261867E"
      unitRef="usd">4300000</biib:Noncontrollinginterestincreasedecreaseother>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13648331e11753-wk-Fact-C9AF7B8A49CF4617C29B594F74F3815A"
      unitRef="usd">4300000</biib:Noncontrollinginterestincreasedecreaseother>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d13648331e11899-wk-Fact-C1A326C98D2EA26DB8B1594F8DF317BA"
      unitRef="shares">3900000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d13648331e11914-wk-Fact-7B4D8EA326BFFF7F5A79594F9359BED0"
      unitRef="usd">909900000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d13648331e11935-wk-Fact-FB55BC24FBB6607B17FF594F9880BAE5"
      unitRef="usd">909900000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d13648331e11974-wk-Fact-382A851FC05B74E94DFA594FA16B40BA"
      unitRef="usd">909900000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d13648331e12029-wk-Fact-99F9CD0E05681E069F6D594FADC96071"
      unitRef="shares">3900000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d13648331e12064-wk-Fact-587B8B7320277F40E6A6594FB587C06D"
      unitRef="usd">19700000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d13648331e12104-wk-Fact-D121A9E1E6B025107DD4594FBE8A8FFE"
      unitRef="usd">890200000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d13648331e12124-wk-Fact-03AADB117136774A3643594FC29C834E"
      unitRef="shares">3900000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d13648331e12138-wk-Fact-EF268B90648FAF4EAFEE594FC7A24EA7"
      unitRef="usd">-909900000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d13648331e12342-wk-Fact-492F89FE92EFE37B93FF594FDE4EDA36"
      unitRef="shares">8900000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d13648331e12357-wk-Fact-563D32318D0499B353EE594FE2A14E23"
      unitRef="usd">2147400000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d13648331e12378-wk-Fact-C6EE03EC936D879B540F594FE60E752D"
      unitRef="usd">2147400000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember"
      decimals="-5"
      id="d13648331e12417-wk-Fact-D8AE5556255B55D27A6F594FEB935140"
      unitRef="usd">2147400000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d13648331e12472-wk-Fact-EC689CEFA715F484ADF3594FF1F2D9A1"
      unitRef="shares">8900000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d13648331e12488-wk-Fact-BAB399050FFFE946EE5D594FF65059E6"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d13648331e12507-wk-Fact-B5A1A8C2936A179D9977594FFA762024"
      unitRef="usd">110500000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d13648331e12547-wk-Fact-82DFF93592EA9F4CDE59595000465365"
      unitRef="usd">2036900000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d13648331e12567-wk-Fact-E54D702A1C6C785F269459500440A738"
      unitRef="shares">8900000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d13648331e12581-wk-Fact-AFD7E5B234EDB9D4D7215950092155F6"
      unitRef="usd">-2147400000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d13648331e12601-wk-Fact-91B2A0F6C2BAC2DF27BF59500D713AD8"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember"
      decimals="-5"
      id="d13648331e12639-wk-Fact-91F65B9148EDBCA06F0059501285583D"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d13648331e12693-wk-Fact-EA8E07ED468C486B1CFE595019468F6D"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d13648331e12708-wk-Fact-5D49EF2BE4C77F0D54BC59501BD6F6FD"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d13648331e12727-wk-Fact-F27BA03371C71C5B34BA59501EF533B6"
      unitRef="usd">26200000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d13648331e12819-wk-Fact-F3ADDA3BB7C9065A36C659502933F0C4"
      unitRef="usd">26200000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13648331e12857-wk-Fact-900000DBBB6E9664D8CE59502D0A677D"
      unitRef="usd">26200000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d13648331e12912-wk-Fact-0A08A2600B66EA629B1A59503168CBA9"
      unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d13648331e12927-wk-Fact-173CBD1D0F83C1F9A97D59503401BB37"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d13648331e12946-wk-Fact-A87F6402C6CBB4714A935950364B350A"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d13648331e12985-wk-Fact-245117E03C0488629C2059503A65E11B"
      unitRef="usd">-50000000.0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d13648331e13039-wk-Fact-20CB9AE7B2E13A1B095E5950413DE185"
      unitRef="usd">-50000000.0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13648331e13078-wk-Fact-C36E7729510640AD5DAB595044EE7840"
      unitRef="usd">-50000000.0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d13648331e13167-wk-Fact-16ED8973EAAE2409510859504E13543E"
      unitRef="usd">-104000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d13648331e13206-wk-Fact-DCC2CDDB6065E968F427595052EE448A"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d13648331e13259-wk-Fact-2A4BA0B9D089D70EE32659505C3C0BF7"
      unitRef="usd">-104000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13648331e13297-wk-Fact-1F8E809DBE3115C51A40595061234A27"
      unitRef="usd">-104000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d13648331e13318-wk-Fact-C13B50DA24E2398EFBEF594D96A4D924"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-5"
      id="d13648331e13337-wk-Fact-537D0F816D9CCEFBE4F3594D999A8152"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d13648331e13351-wk-Fact-ADA15D4EAAC59DD07467594D9C5CE217"
      unitRef="shares">208600000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d13648331e13371-wk-Fact-B1ABB7508646F331AD7B594D9F2E08D7"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-5"
      id="d13648331e13390-wk-Fact-0E4CFA4F88D537FCFBF4594DA20A0FB2"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d13648331e13409-wk-Fact-1E3A79B575A7EC1E71B5594DA5280B7C"
      unitRef="usd">-252900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-5"
      id="d13648331e13430-wk-Fact-778F793D09F7548292C6594DA95ED636"
      unitRef="usd">16182800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d13648331e13444-wk-Fact-3FCB5A794255746B06AE594DAD864C59"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-5"
      id="d13648331e13464-wk-Fact-7D7ECBB599437B92C082594DB18B9DB2"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d13648331e13485-wk-Fact-6B3D4676EE46A1B02420594DB5EB2F08"
      unitRef="usd">12952900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-5"
      id="d13648331e13504-wk-Fact-A52A44D92ECA04E2C0BE594DBA4AF661"
      unitRef="usd">-4100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2"
      decimals="-5"
      id="d13648331e13524-wk-Fact-05CB20CCB3DACA57CF01594DBDDD968F"
      unitRef="usd">12948800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-2B37AD037F305EEA96EFD49E89A3B402-0-wk-Fact-B2D0FA33446D598D8F9FD2F6BC6D8270">&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Business Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer's disease (AD) and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; and ophthalmology. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; neurocognitive disorders; acute neurology; and pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS and relapsing MS; and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Note 18, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form&#160;10-K).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe and have exclusive rights to commercialize these products in China. Additionally, we have exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11 referencing LUCENTIS and SB15 referencing EYLEA, in major markets worldwide, including the United States (U.S.), Canada, Europe, Japan and Australia. For additional information on our collaboration arrangements with Samsung Bioepis, please read &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Note 17, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these unaudited condensed consolidated financial statements (condensed consolidated financial statements). &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form&#160;10-K. Our accounting policies are described in the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Notes to Consolidated Financial Statements&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We operate as &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our condensed consolidated financial statements and there may be changes to those estimates in future periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;New Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2016 the FASB issued Accounting Standards Update (ASU) No. 2016-13, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2020. This standard requires entities to estimate an expected lifetime credit loss on financial assets ranging from short-term trade accounts receivable to long-term financings and report credit losses using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. This standard limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;This standard became effective for us on January 1, 2020, and based on the composition of our trade receivables, investment portfolio and other financial assets, current economic conditions and historical credit loss activity, the adoption of this standard did not have a material impact on our condensed consolidated financial statements and related disclosures. During the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recorded an immaterial amount associated with expected credit losses related to outstanding trade receivables in certain foreign countries that have been disproportionately impacted by the COVID-19 pandemic.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2018 the FASB issued ASU No. 2018-13,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt; Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard modifies certain disclosure requirements on fair value measurements. This standard became effective for us on January 1, 2020, and did not have a material impact on our disclosures. For the new disclosures regarding our Level 3 instruments, please read &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Note 7, Fair Value Measurements&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Internal Use Software&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2018 the FASB issued ASU No. 2018-15, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Intangibles&#x2014;Goodwill and Other&#x2014;Internal-Use Software (Subtopic 350-40): Customer&#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard clarifies the accounting for implementation costs in cloud computing arrangements. This standard became effective for us on January 1, 2020, and was adopted on a prospective basis, resulting in an immaterial amount of additional assets being recorded on our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In November 2018 the FASB issued ASU No. 2018-18, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard makes targeted improvements for collaborative arrangements as follows:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Accounting Standards Codification (ASC) 606, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adds unit-of-account guidance to ASC 808, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;This standard became effective for us on January 1, 2020, and did not have a material impact on our condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <biib:BusinessOverviewPolicyTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-6305126345EF5C519A7B72BFBFD02F02-0-wk-Fact-5682166345585B75825B9811C5BCC7D9">&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer's disease (AD) and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; and ophthalmology. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; neurocognitive disorders; acute neurology; and pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS and relapsing MS; and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Note 18, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form&#160;10-K).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe and have exclusive rights to commercialize these products in China. Additionally, we have exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11 referencing LUCENTIS and SB15 referencing EYLEA, in major markets worldwide, including the United States (U.S.), Canada, Europe, Japan and Australia. For additional information on our collaboration arrangements with Samsung Bioepis, please read &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Note 17, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these unaudited condensed consolidated financial statements (condensed consolidated financial statements). &lt;/span&gt;&lt;/div&gt;</biib:BusinessOverviewPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-60E0BBB904A256FBA1F759D1928BFBF1-0-wk-Fact-FEF216B0032A55CBBFDDD6110C20466A">&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form&#160;10-K. Our accounting policies are described in the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Notes to Consolidated Financial Statements&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We operate as &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="FD2020Q2YTD"
      decimals="0"
      id="d13633581e891-wk-Fact-B117E077F8A058CF91DBC388A514A5C1"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-1D8209BA92DD577983A87D352B9A4BE1-0-wk-Fact-32216D61DC355819971FC6B44B75AA66">&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <biib:InterestInSubsidiary
      contextRef="FD2020Q2YTD"
      decimals="INF"
      id="d13633581e915-wk-Fact-6F125E65AC325C6198B1F3F00691A4E7"
      unitRef="number">1</biib:InterestInSubsidiary>
    <us-gaap:UseOfEstimates
      contextRef="FD2020Q2YTD"
      id="TextSelection-9C673B1671795322AAB342617921CF86-0-wk-Fact-B8C45CE913C05B0FB5CED566ECCA19D2">&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our condensed consolidated financial statements and there may be changes to those estimates in future periods. &lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-247591EC079357DBAC0997706837BFB9-0-wk-Fact-F3FE430BA00C503D93B38B3B5CC2DFB8">&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2016 the FASB issued Accounting Standards Update (ASU) No. 2016-13, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2020. This standard requires entities to estimate an expected lifetime credit loss on financial assets ranging from short-term trade accounts receivable to long-term financings and report credit losses using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. This standard limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;This standard became effective for us on January 1, 2020, and based on the composition of our trade receivables, investment portfolio and other financial assets, current economic conditions and historical credit loss activity, the adoption of this standard did not have a material impact on our condensed consolidated financial statements and related disclosures. During the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recorded an immaterial amount associated with expected credit losses related to outstanding trade receivables in certain foreign countries that have been disproportionately impacted by the COVID-19 pandemic.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2018 the FASB issued ASU No. 2018-13,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt; Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard modifies certain disclosure requirements on fair value measurements. This standard became effective for us on January 1, 2020, and did not have a material impact on our disclosures. For the new disclosures regarding our Level 3 instruments, please read &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Note 7, Fair Value Measurements&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Internal Use Software&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2018 the FASB issued ASU No. 2018-15, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Intangibles&#x2014;Goodwill and Other&#x2014;Internal-Use Software (Subtopic 350-40): Customer&#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard clarifies the accounting for implementation costs in cloud computing arrangements. This standard became effective for us on January 1, 2020, and was adopted on a prospective basis, resulting in an immaterial amount of additional assets being recorded on our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In November 2018 the FASB issued ASU No. 2018-18, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard makes targeted improvements for collaborative arrangements as follows:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Accounting Standards Codification (ASC) 606, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adds unit-of-account guidance to ASC 808, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;This standard became effective for us on January 1, 2020, and did not have a material impact on our condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-C6E355882BA75664BCD9A858BBB8D48A-0-wk-Fact-BDDD7CEB5F985EA69E2F6A393E91FA0F">&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;BIIB118 Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2020 we acquired BIIB118 (formerly known as PF-05251749), a novel CNS-penetrant small molecule inhibitor of casein kinase 1, for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases from Pfizer Inc. (Pfizer). We plan to develop the Phase 1 asset for the potential treatment of sundowning in AD and irregular sleep wake rhythm disorder in Parkinson&#x2019;s disease. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with this acquisition, we made an upfront payment of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$75.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to Pfizer, which was accounted for as an asset acquisition and recorded as acquired in-process research and development (IPR&amp;amp;D) in our condensed consolidated statements of income as BIIB118 has not yet reached technological feasibility. We may also pay Pfizer up to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$635.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in potential additional development and commercialization milestone payments, as well as tiered royalties in the high single digits to sub-teens.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Acquisition of Nightstar Therapeutics plc&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2019 we completed our acquisition of all of the outstanding shares of Nightstar Therapeutics plc (NST), a clinical-stage gene therapy company focused on adeno-associated virus (AAV) treatments for inherited retinal disorders. As a result of this acquisition, we added &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; mid- to late-stage clinical assets, as well as preclinical programs, in ophthalmology. These assets include BIIB111 (timrepigene emparvovec), which is in Phase 3 development for the potential treatment of choroideremia, a rare, degenerative, X-linked inherited retinal disorder that leads to blindness and currently has no approved treatments, and BIIB112 (RPGR gene therapy), which is in Phase 2/3 development for the potential treatment of X-linked retinitis pigmentosa, which is a rare inherited retinal disease with no currently approved treatments.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the terms of this acquisition, we paid NST shareholders &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$25.50&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in cash for each issued and outstanding NST share, which totaled &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$847.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. In addition, we paid &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$4.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in cash for equity compensation, which is attributable to pre-combination services and was reflected as a component of the total purchase price paid. The fair value of equity compensation attributable to the post-combination service period was &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$26.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, of which &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$18.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was recognized as a charge to selling, general and administrative expense with the remaining &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$7.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as a charge to research and development expense in our condensed consolidated statements of income. These amounts were associated with the accelerated vesting of stock options previously granted to NST employees and were fully paid in cash as of June 30, 2019. We funded this acquisition through available cash and accounted for it as an acquisition of a business. We finalized purchase accounting for this acquisition in the fourth quarter of 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our acquisition of NST, please read &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Note 2, Acquisitions,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our 2019 Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="D2020Q1Mar1-Mar31_us-gaap_BusinessAcquisitionAxis_biib_BIIB118Member"
      decimals="-5"
      id="d13633690e797-wk-Fact-B3250946F8C15B0B892A59AF0E2876B0"
      unitRef="usd">75000000.0</us-gaap:ResearchAndDevelopmentInProcess>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones
      contextRef="D2020Q1Mar1-Mar31_us-gaap_BusinessAcquisitionAxis_biib_BIIB118Member"
      decimals="-5"
      id="d13633690e801-wk-Fact-F43A8ED3050A5082AA221EA054C22A24"
      unitRef="usd">635000000.0</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <biib:ClinicalAssetsAcquired
      contextRef="D2019Q2"
      decimals="INF"
      id="d13633690e811-wk-Fact-08424926B14D5070B8192552787B9536"
      unitRef="Assets">2</biib:ClinicalAssetsAcquired>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="2"
      id="d13633690e818-wk-Fact-B0DB27109C225CF9B0A0A0058F63687A"
      unitRef="usdPerShare">25.50</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d13633690e822-wk-Fact-EA168BFD5C8257D8BC64905145DB32EE"
      unitRef="usd">847600000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:OtherPaymentsToAcquireBusinesses
      contextRef="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d13633690e826-wk-Fact-E4314AA680F9596E89F10C7D599381BD"
      unitRef="usd">4600000</us-gaap:OtherPaymentsToAcquireBusinesses>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_biib_PostacquisitionequitycompensationMember"
      decimals="-5"
      id="d13633690e830-wk-Fact-AC9BA48EB90455E2AD50D524C6455DC3"
      unitRef="usd">26200000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-5"
      id="d13633690e834-wk-Fact-B272205CA0305A87884AA7C290AC1C6F"
      unitRef="usd">18400000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="FD2019Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="d13633690e839-wk-Fact-273F13D1E60B5B798D1F1A07A841A2BB"
      unitRef="usd">7800000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-E9C4B523BC785C6A981620CC94D0779E-0-wk-Fact-890DE79E24F85292BE9EAD5206F7F7D9">&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Divestiture of Hiller&#xf8;d, Denmark Manufacturing Operations &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2019 we entered into a share purchase agreement with FUJIFILM Corporation (FUJIFILM) to sell all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#xf8;d, Denmark. We determined that the assets and liabilities related to our Hiller&#xf8;d, Denmark manufacturing operations met the criteria to be classified as held for sale. For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recorded a loss of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$174.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in our condensed consolidated statements of income. This estimated loss included a pre-tax loss of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$113.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which reflected a &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$2.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; decrease to our original estimate as of March 31, 2019, reflecting our estimated fair value of the assets and liabilities held for sale as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, adjusted for our expected costs to sell our Hiller&#xf8;d, Denmark manufacturing operations of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$10.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and included our initial estimate of the fair value of an adverse commitment of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$120.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; associated with the guarantee of future minimum batch production at the Hiller&#xf8;d facility. The value of this adverse commitment was determined using a probability-weighted estimate of future manufacturing activity. In addition, we recorded a tax expense of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$61.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to the planned transaction during the six months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; this transaction closed and we received approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$881.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in cash, which may be adjusted based on the contractual terms discussed below. We determined that the operations disposed of in this transaction did not meet the criteria to be classified as discontinued operations under the applicable guidance.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As part of this transaction, we provided FUJIFILM with certain minimum batch production commitment guarantees. There is a risk that the minimum contractual batch production commitments will not be met. Our estimate of the adverse commitment obligation is approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$74.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We developed this estimate using a probability-weighted estimate of future manufacturing activity and may adjust this estimate based upon changes in business conditions, which may result in the increase or reduction of this adverse commitment obligation in subsequent periods. We also may be obligated to indemnify FUJIFILM for liabilities that existed relating to certain business activities incurred prior to the closing of this transaction. Our estimate of the fair value of the adverse commitment obligation is a Level 3 measurement and is based on forecasted batch production at the Hiller&#xf8;d facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition, we may earn certain contingent payments based on future manufacturing activities at the Hiller&#xf8;d facility. For the disposition of a business, our policy is to recognize contingent consideration when the consideration is realizable. Consistent with our assessment as of the transaction date, we currently believe the probability of earning these payments is remote and therefore we did not include these contingent payments in our calculation of the fair value of the operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As part of this transaction, we entered into certain manufacturing services agreements with FUJIFILM pursuant to which FUJIFILM will use the Hiller&#xf8;d facility to produce commercial products for us, such as TYSABRI, as well as other third-party products. In addition, we sold to FUJIFILM &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$41.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of raw materials that were remaining at the Hiller&#xf8;d facility on the closing date of this transaction in the third quarter of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. These materials were sold at cost, which approximated fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax
      contextRef="FD2019Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d13633801e801-wk-Fact-0C57B292811C573EB9888E8920CA2E59"
      unitRef="usd">174500000</us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax>
    <us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
      contextRef="FD2019Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d13633801e805-wk-Fact-AF7D8846FDC8976A34F85D6C05A654F2"
      unitRef="usd">113200000</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
    <us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax
      contextRef="FD2019Q2QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d13633801e809-wk-Fact-C8E05743A5A61037708B5D6C63D25FDA"
      unitRef="usd">2300000</us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="FD2019Q2QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d13633801e818-wk-Fact-BD4D010869AB55538643FB603D47C9C1"
      unitRef="usd">10000000.0</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="FI2019Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d13633801e822-wk-Fact-DE09EAD8A5B25D5D8A6843763653A988"
      unitRef="usd">120000000.0</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="FD2020Q2YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d13633801e826-wk-Fact-ED9352CD16B65696B7CFF0284B0B2990"
      unitRef="usd">61300000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration
      contextRef="I2019Q3Denmark_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d13633801e841-wk-Fact-9E53049ABBF95FCA814D68A67F94CA61"
      unitRef="usd">881900000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="FI2020Q2_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d13633801e848-wk-Fact-A2B0010FA02C50E3AD57943AB999D036"
      unitRef="usd">74000000.0</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <biib:InventoryrawmaterialssoldtoFUJIFILM
      contextRef="I2019Q3Denmark"
      decimals="-5"
      id="d13633801e874-wk-Fact-61A4865F17AD542E806318F69FA92C47"
      unitRef="usd">41800000</biib:InventoryrawmaterialssoldtoFUJIFILM>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-72504A8BA49F511FB69C027888491725-0-wk-Fact-5B78B6A2BED552F5AC2732C3729B2578">&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;"&gt;Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues by product are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:30%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Multiple Sclerosis (MS):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Fumarate*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;921.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;268.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,190.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;869.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;280.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,150.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Interferon**&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;345.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;135.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;481.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;379.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;174.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;554.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;TYSABRI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;244.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;187.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;432.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;264.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;211.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;475.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;FAMPYRA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;23.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;23.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;24.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;24.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Subtotal: MS product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,511.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;615.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;2,126.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,513.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;690.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2,204.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Spinal Muscular Atrophy:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;SPINRAZA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;210.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;284.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;494.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;230.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;257.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;488.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Biosimilars:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;BENEPALI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;106.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;106.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;120.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;120.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;IMRALDI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;44.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;44.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;47.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;47.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;FLIXABI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;20.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;20.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;16.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;16.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Subtotal: Biosimilar product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;171.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;171.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;184.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;184.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;FUMADERM&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;2.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;2.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,721.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,074.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;2,795.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,744.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,135.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2,880.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:34%;"/&gt;&lt;td style="width:32%;"/&gt;&lt;td style="width:34%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;*Fumarate includes TECFIDERA and VUMERITY. VUMERITY became commercially available in the U.S. in November 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;**Interferon includes AVONEX and PLEGRIDY.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:31%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Multiple Sclerosis (MS):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Fumarate*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,699.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;591.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;2,291.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,587.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;561.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2,149.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Interferon**&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;638.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;309.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;947.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;707.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;348.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,055.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;TYSABRI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;521.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;432.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;954.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;509.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;426.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;935.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;FAMPYRA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;51.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;51.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;47.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;47.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Subtotal: MS product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;2,859.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,385.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;4,244.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2,803.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,383.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;4,187.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Spinal Muscular Atrophy:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;SPINRAZA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;445.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;613.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,059.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;453.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;552.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,006.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Biosimilars:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;BENEPALI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;239.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;239.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;244.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;244.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;IMRALDI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;106.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;106.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;83.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;83.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;FLIXABI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;44.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;44.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;31.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;31.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Subtotal: Biosimilar product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;390.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;390.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;358.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;358.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;FUMADERM&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;7.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;7.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;3,304.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;2,395.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;5,700.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;3,257.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2,302.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;5,560.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:34%;"/&gt;&lt;td style="width:32%;"/&gt;&lt;td style="width:34%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;*Fumarate includes TECFIDERA and VUMERITY. VUMERITY became commercially available in the U.S. in November 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;**Interferon includes AVONEX and PLEGRIDY.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recognized revenues from two wholesalers accounting for &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;31.7%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17.9%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of gross product revenues for the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;30.8%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16.2%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of gross product revenues for the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recognized revenues from two wholesalers accounting for &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;30.5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;18.2%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of gross product revenues for the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;30.9%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16.3%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of gross product revenues for the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Balance, as of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;131.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,027.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;40.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,198.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Current provisions relating to sales in current year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;387.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,624.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;9.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;2,021.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(1.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(25.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(26.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Payments/credits relating to sales in current year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(251.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(1,018.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(1,270.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Payments/credits relating to sales in prior years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(126.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(612.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(10.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(749.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Balance, as of June 30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;139.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;994.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;41.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,174.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:66%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of&lt;br/&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Reduction of accounts receivable, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;223.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;197.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Component of accrued expenses and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;951.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,001.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total revenue-related reserves&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,174.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,198.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:9px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;"&gt;Revenues from Anti-CD20 Therapeutic Programs&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs are summarized below. For the purposes of this footnote we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:46%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Biogen&#x2019;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;257.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;377.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;598.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;768.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;220.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;199.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;399.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;325.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;478.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;576.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;998.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,093.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our collaboration arrangements with Genentech, please read &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Note 18,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;to our consolidated financial statements included in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;"&gt;Other Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Revenues from collaborative and other relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Profit (loss) earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Revenues earned under our technical development agreement, manufacturing services agreements and royalty revenues on biosimilar products with Samsung Bioepis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;4.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;52.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;8.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;77.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other royalty and corporate revenues:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Royalty&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;7.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;18.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;6.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other corporate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;395.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;105.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;489.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;369.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total other revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;407.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;160.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;516.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;452.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;"&gt;During the third quarter of 2019 we amended our agreement with a contract manufacturing customer, pursuant to which we licensed certain of our manufacturing-related intellectual property to the customer. In the second quarter of 2020 the customer received regulatory approval for its product that is being manufactured using certain of our manufacturing-related intellectual property. As a result, we are entitled to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$500.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;"&gt;in a series of three payments. The first payment became due upon regulatory approval of such product and was received during the&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;second&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; quarter of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;"&gt;Subsequent payments are due on the first and second anniversaries of the regulatory approval.&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other corporate revenues for the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, reflect &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$329.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;"&gt;related to the delivery of the license for certain of our manufacturing-related intellectual property under the amended agreement discussed above. We have allocated the remaining $170.6 million of the $500.0 million transaction price to the performance of manufacturing product supply services for the customer, which we expect to perform through 2026. The value allocated to the manufacturing services was based on expected demand for supply and the fair value of comparable manufacturing and development services&lt;/span&gt;.</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-D5342E96E1305769A18176AAEB496D84-0-wk-Fact-9C67282CE05256698E269FDEF5B429C1">&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues by product are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:30%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Multiple Sclerosis (MS):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Fumarate*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;921.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;268.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,190.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;869.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;280.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,150.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Interferon**&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;345.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;135.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;481.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;379.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;174.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;554.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;TYSABRI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;244.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;187.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;432.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;264.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;211.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;475.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;FAMPYRA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;23.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;23.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;24.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;24.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Subtotal: MS product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,511.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;615.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;2,126.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,513.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;690.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2,204.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Spinal Muscular Atrophy:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;SPINRAZA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;210.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;284.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;494.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;230.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;257.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;488.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Biosimilars:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;BENEPALI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;106.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;106.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;120.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;120.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;IMRALDI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;44.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;44.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;47.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;47.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;FLIXABI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;20.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;20.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;16.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;16.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Subtotal: Biosimilar product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;171.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;171.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;184.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;184.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;FUMADERM&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;2.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;2.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,721.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,074.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;2,795.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,744.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,135.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2,880.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:34%;"/&gt;&lt;td style="width:32%;"/&gt;&lt;td style="width:34%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;*Fumarate includes TECFIDERA and VUMERITY. VUMERITY became commercially available in the U.S. in November 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;**Interferon includes AVONEX and PLEGRIDY.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:31%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Multiple Sclerosis (MS):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Fumarate*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,699.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;591.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;2,291.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,587.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;561.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2,149.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Interferon**&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;638.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;309.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;947.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;707.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;348.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,055.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;TYSABRI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;521.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;432.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;954.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;509.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;426.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;935.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;FAMPYRA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;51.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;51.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;47.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;47.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Subtotal: MS product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;2,859.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,385.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;4,244.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2,803.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,383.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;4,187.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Spinal Muscular Atrophy:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;SPINRAZA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;445.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;613.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,059.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;453.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;552.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,006.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Biosimilars:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;BENEPALI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;239.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;239.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;244.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;244.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;IMRALDI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;106.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;106.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;83.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;83.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;FLIXABI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;44.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;44.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;31.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;31.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Subtotal: Biosimilar product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;390.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;390.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;358.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;358.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;FUMADERM&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;7.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;7.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;3,304.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;2,395.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;5,700.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;3,257.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2,302.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;5,560.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:34%;"/&gt;&lt;td style="width:32%;"/&gt;&lt;td style="width:34%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;*Fumarate includes TECFIDERA and VUMERITY. VUMERITY became commercially available in the U.S. in November 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;**Interferon includes AVONEX and PLEGRIDY.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_FumarateMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d13658793e1365-wk-Fact-7797743BEC4B5F7BB8E02226A345E945"
      unitRef="usd">921700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_FumarateMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d13658793e1384-wk-Fact-805328F0C8A6539F8ECAFD85EDC8C59E"
      unitRef="usd">268600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_FumarateMember"
      decimals="-5"
      id="d13658793e1404-wk-Fact-1C739B47666D56968D5BEF4F316FF605"
      unitRef="usd">1190300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FumarateMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d13658793e1423-wk-Fact-9CAC2E9FE61D56A19B329DC2F6349C9E"
      unitRef="usd">869800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FumarateMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d13658793e1442-wk-Fact-5E6D8311BCCB5D59BB8B9DEEB28F6E19"
      unitRef="usd">280400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FumarateMember"
      decimals="-5"
      id="d13658793e1462-wk-Fact-BBE81D675BD75B4EB80DBDDD64A1A95D"
      unitRef="usd">1150200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d13658793e1482-wk-Fact-EC53FFB747C854628685E45C41E78E1D"
      unitRef="usd">345600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d13658793e1501-wk-Fact-0E155F84DD555123B2640F864833FBDB"
      unitRef="usd">135800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_InterferonMember"
      decimals="-5"
      id="d13658793e1520-wk-Fact-E758E11749B15215ACB1881E74A5349E"
      unitRef="usd">481400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d13658793e1540-wk-Fact-C169BA1E3E4D54D8879C14210495F248"
      unitRef="usd">379700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d13658793e1559-wk-Fact-1EE065F9031F592DA392E381F24C803A"
      unitRef="usd">174700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_InterferonMember"
      decimals="-5"
      id="d13658793e1579-wk-Fact-928990C522D555DA875AED97F2C85B93"
      unitRef="usd">554400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d13658793e1604-wk-Fact-BDA86516B9045D28A319EDB49631A48F"
      unitRef="usd">244100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d13658793e1623-wk-Fact-2787798ECB9858EFB2EFDE8720E026CF"
      unitRef="usd">187900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember"
      decimals="-5"
      id="d13658793e1642-wk-Fact-0BFE98DC746152C2A90DE14102A51AEF"
      unitRef="usd">432000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d13658793e1662-wk-Fact-D361BBD2E9FA5C5390BAA3EE6430A08F"
      unitRef="usd">264300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d13658793e1681-wk-Fact-023808EEE67A550FA5BC0BF01FBC9A48"
      unitRef="usd">211000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_TysabriProductMember"
      decimals="-5"
      id="d13658793e1701-wk-Fact-5D47AA032D235BA5A7068C7C3C5BCDC6"
      unitRef="usd">475300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d13658793e1726-wk-Fact-86EC0E43B0A05407815261E47C5AC8B7"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d13658793e1745-wk-Fact-4A2FA8ECE75E5FCBB43CD80BB44E2658"
      unitRef="usd">23000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember"
      decimals="-5"
      id="d13658793e1764-wk-Fact-5276F4635A0E5CF7AB0351FEA0273499"
      unitRef="usd">23000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d13658793e1784-wk-Fact-C004816EA90B587BAA31C848B460D3B5"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d13658793e1803-wk-Fact-0EB1CC2D77545FEAB420C76ACAC7BC24"
      unitRef="usd">24100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember"
      decimals="-5"
      id="d13658793e1823-wk-Fact-F0FA4C866A0850DAAA7562FFF8738AA8"
      unitRef="usd">24100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d13658793e1848-wk-Fact-62AF04FA50A053D9A6FC83054F973B63"
      unitRef="usd">1511400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d13658793e1867-wk-Fact-33E0AD0E0F7558DC91C6CBDAE0CFC70B"
      unitRef="usd">615300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember"
      decimals="-5"
      id="d13658793e1886-wk-Fact-8E25BFA387F655B2A5261D82BA124930"
      unitRef="usd">2126700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d13658793e1906-wk-Fact-6C83493FA86853DFBC0B0B258A3C6F98"
      unitRef="usd">1513800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d13658793e1925-wk-Fact-AD4EA836BEA35EBCA07F7C402AF6CB7A"
      unitRef="usd">690200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember"
      decimals="-5"
      id="d13658793e1945-wk-Fact-A479BD01746456F6AFF67A5894B94D80"
      unitRef="usd">2204000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d13658793e2225-wk-Fact-1C5F43619A195AD19A5F3C4E3B63C470"
      unitRef="usd">210300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d13658793e2244-wk-Fact-BC94AEF3EC1C5249A69F4D6D4ED6EA0D"
      unitRef="usd">284300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember"
      decimals="-5"
      id="d13658793e2263-wk-Fact-0EA72877C8645BDDAF92BEEE5C91D3B1"
      unitRef="usd">494600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d13658793e2283-wk-Fact-4FE1448A85105E5887A4AE718AE13D3E"
      unitRef="usd">230600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d13658793e2302-wk-Fact-A3AA1D80CC5D592B89D4F4289DE72DD3"
      unitRef="usd">257600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember"
      decimals="-5"
      id="d13658793e2322-wk-Fact-2DBEF7B5017C525D9356385222261419"
      unitRef="usd">488200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d13658793e2601-wk-Fact-E7D000E1B3B85F3A8528D2D3B1138603"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d13658793e2620-wk-Fact-BF48DFBB91F6565FA822FD8CA973C54B"
      unitRef="usd">106200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember"
      decimals="-5"
      id="d13658793e2639-wk-Fact-73E3298C8DD85B1EA7CFE3BB9A5FEC6E"
      unitRef="usd">106200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d13658793e2659-wk-Fact-F6CF5A1A5283585E9221A8438384A92F"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d13658793e2678-wk-Fact-E196D9B4F4B15C249AB50AE9E4ABD147"
      unitRef="usd">120300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_BENEPALIMember"
      decimals="-5"
      id="d13658793e2698-wk-Fact-39B328952E2D59FE82E4DFA297EB0941"
      unitRef="usd">120300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d13658793e2723-wk-Fact-6395540CE04C582A96DFD9C1CBD384B4"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d13658793e2742-wk-Fact-98F8D19F93F053F9B310E3F4DB8BB6D6"
      unitRef="usd">44800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember"
      decimals="-5"
      id="d13658793e2761-wk-Fact-FCC31D53F34D8D4A61D959809BCBBDA0"
      unitRef="usd">44800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d13658793e2781-wk-Fact-1A5F571653B6590897F066DD4A0E2123"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d13658793e2800-wk-Fact-4C3742A934FB5109A2EB20BD0F532605"
      unitRef="usd">47300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_IMRALDIMember"
      decimals="-5"
      id="d13658793e2820-wk-Fact-D0DDE0A7773FFCAA135559809B938567"
      unitRef="usd">47300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d13658793e2845-wk-Fact-464AF8B9B3BE556F8A9FAA19CD4E576A"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d13658793e2864-wk-Fact-DCCF20FFC4D85A3DB242FDEDE48C2DEE"
      unitRef="usd">20600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember"
      decimals="-5"
      id="d13658793e2883-wk-Fact-A238E691DEFDD24411F759809BB65E4B"
      unitRef="usd">20600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d13658793e2903-wk-Fact-9CD98996F2375AAAB70246448E61C847"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d13658793e2922-wk-Fact-2A32171A609356E08D78DAB85F11B9AD"
      unitRef="usd">16800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FLIXABIMember"
      decimals="-5"
      id="d13658793e2942-wk-Fact-0ACDAED94448377EEE2559809BA6EE63"
      unitRef="usd">16800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d13658793e2967-wk-Fact-ACA2876153E75958BF457EC2E2AFE9EA"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d13658793e2986-wk-Fact-B17E578AF45659E4BE8848113AA43F54"
      unitRef="usd">171600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember"
      decimals="-5"
      id="d13658793e3005-wk-Fact-5D17F9AB0BB958C685051E02C3A5A1EB"
      unitRef="usd">171600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d13658793e3025-wk-Fact-F283E3A188D45BCC8FC4A8FD8524022A"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d13658793e3044-wk-Fact-0F4487BD63BE5F22B81963785C6F2EFF"
      unitRef="usd">184400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember"
      decimals="-5"
      id="d13658793e3064-wk-Fact-9E41D013B3075B278D8A0B70EB7F3566"
      unitRef="usd">184400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d13658793e3345-wk-Fact-3074371F982650E3923F54C0E5C0DD18"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d13658793e3364-wk-Fact-972A2FFC08695A2B9817998D10BEAC15"
      unitRef="usd">2800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember"
      decimals="-5"
      id="d13658793e3383-wk-Fact-9B0D9500FCDC5BD6BFFB4C787501F974"
      unitRef="usd">2800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d13658793e3403-wk-Fact-AABF35ED0BCB55328303B6FF704DA0C5"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d13658793e3422-wk-Fact-4086CD76E6B95A01B19683A4A9683DA1"
      unitRef="usd">3700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_FUMADERMMember"
      decimals="-5"
      id="d13658793e3442-wk-Fact-3524DDC2E0E05E78848092FACE2A5938"
      unitRef="usd">3700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d13658793e3472-wk-Fact-9ADDF07A2B02504BB64590CD5937ED89"
      unitRef="usd">1721700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d13658793e3491-wk-Fact-BBB2F39429605C95962E16A159CF0667"
      unitRef="usd">1074000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d13658793e3511-wk-Fact-B152D3B5F3A05C7CAA044F72EA3120C1"
      unitRef="usd">2795700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d13658793e3530-wk-Fact-1D73BE67E2195DBF9FB50F944B19B788"
      unitRef="usd">1744400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d13658793e3549-wk-Fact-2198D70605BC592084B098656F2E804D"
      unitRef="usd">1135900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d13658793e3569-wk-Fact-455E60BA69055CE8AECAC5095741DB0A"
      unitRef="usd">2880300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_FumarateMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d13658793e4171-wk-Fact-F0B2E9B3B939A20223935D7F24E19797"
      unitRef="usd">1699200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_FumarateMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d13658793e4190-wk-Fact-4D1EB91FB28ACFD706105D7F2A0811AA"
      unitRef="usd">591900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_FumarateMember"
      decimals="-5"
      id="d13658793e4210-wk-Fact-9B6C325A1127DB880E685D7F2EEEEC9E"
      unitRef="usd">2291100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FumarateMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d13658793e4229-wk-Fact-120009E3B70C986AE48B5D7F32A28FBA"
      unitRef="usd">1587500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FumarateMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d13658793e4248-wk-Fact-574C86E49849DA3F28C85D7F3A519B84"
      unitRef="usd">561500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FumarateMember"
      decimals="-5"
      id="d13658793e4268-wk-Fact-E7E0C3F322A1252F53145D7F3FD7B48B"
      unitRef="usd">2149000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d13658793e4288-wk-Fact-79D26EFD1F8B66EAA7D55D7F42EFF53E"
      unitRef="usd">638200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d13658793e4307-wk-Fact-7419E5E5E46D58559BCD5D7F49166D11"
      unitRef="usd">309200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_InterferonMember"
      decimals="-5"
      id="d13658793e4326-wk-Fact-068CD6AC57D0BCF2F4B05D7F4F763FB6"
      unitRef="usd">947400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d13658793e4346-wk-Fact-9C5CBA7D19C5A5E220F65D7F530E8992"
      unitRef="usd">707000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d13658793e4365-wk-Fact-39BA9DDB83D565232EA05D7F5864270B"
      unitRef="usd">348300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_InterferonMember"
      decimals="-5"
      id="d13658793e4385-wk-Fact-3AC0E90E3EA4F19423795D7F5E453327"
      unitRef="usd">1055300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d13658793e4410-wk-Fact-BADCD50D6540D74A4A195D7F61DC0490"
      unitRef="usd">521800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d13658793e4429-wk-Fact-31AD3468DE20AAFC37695D7F675DC163"
      unitRef="usd">432600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember"
      decimals="-5"
      id="d13658793e4448-wk-Fact-4537839D8D70EB6C6ABF5D7F6BEBE3FA"
      unitRef="usd">954400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d13658793e4468-wk-Fact-D06714F3B4E9030A7C9F5D7F6F5E6155"
      unitRef="usd">509300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d13658793e4487-wk-Fact-D9CD90BA884646B735CF5D7F750D361E"
      unitRef="usd">426400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember"
      decimals="-5"
      id="d13658793e4507-wk-Fact-8C0787BA79FD3A03CF3E5D7F79EC5084"
      unitRef="usd">935700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d13658793e4532-wk-Fact-D29ECCFEA44A870708915D7F7D311386"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d13658793e4551-wk-Fact-12E8B69995ADA698E0115D7F816D239D"
      unitRef="usd">51300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember"
      decimals="-5"
      id="d13658793e4570-wk-Fact-014EC1E4C4A0FB732ADC5D7F85FAABCC"
      unitRef="usd">51300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d13658793e4590-wk-Fact-E171E8BC0C14C36177FB5D7F89676BD1"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d13658793e4609-wk-Fact-4BD88F8666F9E0F456E85D7F8E9EF235"
      unitRef="usd">47000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember"
      decimals="-5"
      id="d13658793e4629-wk-Fact-0EFA14D07099E3DA3DF15D7F934D456E"
      unitRef="usd">47000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d13658793e4654-wk-Fact-A393BC433BCB92A682B55D7F95E8C65F"
      unitRef="usd">2859200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d13658793e4672-wk-Fact-589F3FBC9612323764995D7F9A01E419"
      unitRef="usd">1385000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember"
      decimals="-5"
      id="d13658793e4690-wk-Fact-3DCCD0F540FA9C8E26FB5D7F9FBBE1F5"
      unitRef="usd">4244200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d13658793e4709-wk-Fact-73D4B09C91950BC0FDD05D7FA3455D7E"
      unitRef="usd">2803800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d13658793e4727-wk-Fact-0E736608F52B0303B1745D7FA7D9D918"
      unitRef="usd">1383200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember"
      decimals="-5"
      id="d13658793e4746-wk-Fact-2BFCDFFB8FEFF6F0A2705D7FACB919BE"
      unitRef="usd">4187000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d13658793e5028-wk-Fact-1DE7AC89E23932497F1B5D7FBA421754"
      unitRef="usd">445700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d13658793e5047-wk-Fact-CAFDDA31A61611BD9BE55D7FBE7D5B71"
      unitRef="usd">613900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember"
      decimals="-5"
      id="d13658793e5066-wk-Fact-6CD8EC4C1C4CA7920F0F5D7FC263F932"
      unitRef="usd">1059600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d13658793e5086-wk-Fact-9C28DE2D705B8EE32CEE5D7FC54F91AC"
      unitRef="usd">453900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d13658793e5105-wk-Fact-DAEC50701B05891B051A5D7FC989BCAB"
      unitRef="usd">552800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember"
      decimals="-5"
      id="d13658793e5125-wk-Fact-A3B7C42E8122AE532E6D5D7FCE188AC3"
      unitRef="usd">1006700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d13658793e5406-wk-Fact-10DE7E43795121A70FE05D7FDBE5529B"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d13658793e5425-wk-Fact-9556956F9C2045EBE2325D7FE020E54E"
      unitRef="usd">239700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember"
      decimals="-5"
      id="d13658793e5444-wk-Fact-8BE3D450FED752D93D425D7FE4B3007F"
      unitRef="usd">239700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d13658793e5464-wk-Fact-565868CDAC1F20AB84015D7FE827BC90"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d13658793e5483-wk-Fact-7CCBA3984E19176F89185D7FED5C9D77"
      unitRef="usd">244300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember"
      decimals="-5"
      id="d13658793e5503-wk-Fact-DB27CBFCEEADF03DF08E5D7FF1E8612C"
      unitRef="usd">244300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d13658793e5528-wk-Fact-A188F304BE0B10B80C285D7FF4133400"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d13658793e5547-wk-Fact-9AC03B825FFE42BB8F695D7FF9D76AF6"
      unitRef="usd">106400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember"
      decimals="-5"
      id="d13658793e5566-wk-Fact-AA95B542ED3CEE84C06C5D7FFD7244B0"
      unitRef="usd">106400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d13658793e5586-wk-Fact-3AD74111B26C2D7F6A255D80005A220C"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d13658793e5605-wk-Fact-A80F4FF7E9C13D2E97215D8004E8EA0E"
      unitRef="usd">83000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember"
      decimals="-5"
      id="d13658793e5625-wk-Fact-9CC47A4B1A428C0E317D5D8008D0DCD1"
      unitRef="usd">83000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d13658793e5650-wk-Fact-DE05156163515BC24BF95D800B7D34DE"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d13658793e5669-wk-Fact-03D4398DB2DCD6EC29BC5D800FFFCAD8"
      unitRef="usd">44300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember"
      decimals="-5"
      id="d13658793e5688-wk-Fact-78B4E1590FBBBFB366755D8014DC8A78"
      unitRef="usd">44300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d13658793e5708-wk-Fact-4858F35E3516534343C95D8018F6CBDE"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d13658793e5727-wk-Fact-B7F48B12AE5FE4654CA95D801D521118"
      unitRef="usd">31500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember"
      decimals="-5"
      id="d13658793e5747-wk-Fact-A6193C0E70A60074DE455D80211F5715"
      unitRef="usd">31500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d13658793e5772-wk-Fact-C70D0A9D521A6DCBF5025D802316750C"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d13658793e5790-wk-Fact-646F73F6E0E86E6DF2985D8028E7C178"
      unitRef="usd">390400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember"
      decimals="-5"
      id="d13658793e5808-wk-Fact-7807EAF0210071F062DE5D802CD2D315"
      unitRef="usd">390400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d13658793e5827-wk-Fact-52C3A15C313BE71D94F45D802F8FEEA7"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d13658793e5845-wk-Fact-34682919FAC9AE63FDBA5D803400D5ED"
      unitRef="usd">358800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember"
      decimals="-5"
      id="d13658793e5864-wk-Fact-97D6F5FCC922B29F5E3F5D8038E2C1AA"
      unitRef="usd">358800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d13658793e6145-wk-Fact-16206ADBE5E530EED7695D80468EEF2B"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d13658793e6164-wk-Fact-B40AF35C632ADDC12AC75D804C165557"
      unitRef="usd">6100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember"
      decimals="-5"
      id="d13658793e6183-wk-Fact-0E3AB62D10E6611750A75D8051469434"
      unitRef="usd">6100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d13658793e6203-wk-Fact-41CA73BA4A30DB0CE6AA5D80548AC815"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d13658793e6222-wk-Fact-3DEB88C7DC00976B7A715D80591F4BCA"
      unitRef="usd">7800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember"
      decimals="-5"
      id="d13658793e6242-wk-Fact-623AD9F080707778BD935D805DC78BBF"
      unitRef="usd">7800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d13658793e6272-wk-Fact-7593621D9903756E79D25D8060657620"
      unitRef="usd">3304900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d13658793e6290-wk-Fact-C01303D29CAB1FCA2F6B5D8064A11A41"
      unitRef="usd">2395400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d13658793e6309-wk-Fact-3718F7E632B25D27847BA0BA45120ACA"
      unitRef="usd">5700300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US"
      decimals="-5"
      id="d13658793e6327-wk-Fact-B69B35758403071883555D806CC4C442"
      unitRef="usd">3257700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-5"
      id="d13658793e6345-wk-Fact-DAE16EB398290235D4815D8071FBE666"
      unitRef="usd">2302600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-5"
      id="d13658793e6364-wk-Fact-EE4EC8FA691555C0A7DE82D787D37BE4"
      unitRef="usd">5560300000</us-gaap:Revenues>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="FD2020Q2QTD_srt_MajorCustomersAxis_biib_DistributorOneMember"
      decimals="INF"
      id="d13658793e6409-wk-Fact-C25A764B34675B19BF5C7A7C1A570202"
      unitRef="number">0.317</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="FD2020Q2QTD_srt_MajorCustomersAxis_biib_DistributorTwoMember"
      decimals="INF"
      id="d13658793e6413-wk-Fact-4F6D0D253AA25063BADADE5DBC4F92C9"
      unitRef="number">0.179</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="FD2020Q2YTD_srt_MajorCustomersAxis_biib_DistributorOneMember"
      decimals="INF"
      id="d13658793e6425-wk-Fact-ADC579F62FF02E1A2F6D5D9DB40FE52C"
      unitRef="number">0.308</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="FD2020Q2YTD_srt_MajorCustomersAxis_biib_DistributorTwoMember"
      decimals="INF"
      id="d13658793e6430-wk-Fact-D7E73C7C32C5AE14E29E5D9DC986396F"
      unitRef="number">0.162</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_biib_DistributorOneMember"
      decimals="3"
      id="d13658793e6445-wk-Fact-3CA7D13A817E54F59C447366C3D15E73"
      unitRef="number">0.305</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_biib_DistributorTwoMember"
      decimals="3"
      id="d13658793e6449-wk-Fact-AED7A92713D95816A7961DEBDA76E762"
      unitRef="number">0.182</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_biib_DistributorOneMember"
      decimals="3"
      id="d13658793e6461-wk-Fact-EAA915138E1EE87392995D9E03956EA6"
      unitRef="number">0.309</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_biib_DistributorTwoMember"
      decimals="3"
      id="d13658793e6466-wk-Fact-31CC0CD6E365CA5982085D9E1FD657CF"
      unitRef="number">0.163</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-C1BA12976DDB57FC871F972D82E04AF2-0-wk-Fact-4859620AE4B551E9B080443D3568F518">&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Balance, as of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;131.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,027.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;40.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,198.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Current provisions relating to sales in current year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;387.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,624.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;9.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;2,021.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(1.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(25.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(26.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Payments/credits relating to sales in current year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(251.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(1,018.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(1,270.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Payments/credits relating to sales in prior years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(126.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(612.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(10.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(749.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Balance, as of June 30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;139.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;994.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;41.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,174.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember"
      decimals="-5"
      id="d13658793e6624-wk-Fact-D6466C88F4D5567BAEE2EE4AF24FEF51"
      unitRef="usd">131100000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember"
      decimals="-5"
      id="d13658793e6643-wk-Fact-869F723FF374547880841E9CC5735369"
      unitRef="usd">1027300000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember"
      decimals="-5"
      id="d13658793e6663-wk-Fact-577E1E7BBD1755FCB0DAED9B5302AA7F"
      unitRef="usd">40500000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13658793e6682-wk-Fact-29F90B4D0AA15CF88652A2F69FEF5B8D"
      unitRef="usd">1198900000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember"
      decimals="-5"
      id="d13658793e6702-wk-Fact-9EB295F1016C554FB939C2D9BC27AAD8"
      unitRef="usd">387500000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember"
      decimals="-5"
      id="d13658793e6721-wk-Fact-8DDB9B329C415E438C8AF1B4D198B9DB"
      unitRef="usd">1624200000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember"
      decimals="-5"
      id="d13658793e6740-wk-Fact-BDF2435202605C04A755124AA8225FFC"
      unitRef="usd">9900000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13658793e6760-wk-Fact-2B9E473E66245C0BB925166E81917B73"
      unitRef="usd">2021600000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember"
      decimals="-5"
      id="d13658793e6785-wk-Fact-5F3CDAD899D35F4FBE162174676FC820"
      unitRef="usd">1300000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember"
      decimals="-5"
      id="d13658793e6805-wk-Fact-888C767728875E048D1A2394BE0E2AE2"
      unitRef="usd">25700000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember"
      decimals="-5"
      id="d13658793e6825-wk-Fact-25F7861313535C16A4E79F8AC66F49CC"
      unitRef="usd">-700000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13658793e6845-wk-Fact-D8C593FDE2EE576B8EEF6AEA85938A5D"
      unitRef="usd">26300000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember"
      decimals="-5"
      id="d13658793e6871-wk-Fact-5617EA2EF5825D128C726D4EF104A3A6"
      unitRef="usd">251400000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember"
      decimals="-5"
      id="d13658793e6891-wk-Fact-2EE761EC42015F25B43FBEA11D7CC6A9"
      unitRef="usd">1018700000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember"
      decimals="-5"
      id="d13658793e6911-wk-Fact-9C493713E0555EE1B7B706EDC084C9CA"
      unitRef="usd">0</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13658793e6931-wk-Fact-7D4FD8DD23AF5A50B9B78D2ED9A704BA"
      unitRef="usd">1270100000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember"
      decimals="-5"
      id="d13658793e6957-wk-Fact-CE6AC519934858B887422FE789C39AE4"
      unitRef="usd">126500000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember"
      decimals="-5"
      id="d13658793e6977-wk-Fact-E6A56A4234BF5511BEE36E1534AA19A6"
      unitRef="usd">612900000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember"
      decimals="-5"
      id="d13658793e6997-wk-Fact-DA85E28A413057E6A22FAB5091FC162A"
      unitRef="usd">10000000.0</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13658793e7018-wk-Fact-412B9C697E1055698673AB6357B2E367"
      unitRef="usd">749400000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2020Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember"
      decimals="-5"
      id="d13658793e7049-wk-Fact-6FCCBE5DDB7B5B0DB09397085132F217"
      unitRef="usd">139400000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2020Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember"
      decimals="-5"
      id="d13658793e7068-wk-Fact-134388D683035B5BB476380CC14A8BA9"
      unitRef="usd">994200000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2020Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember"
      decimals="-5"
      id="d13658793e7088-wk-Fact-0C718AEB6EBE56A2B80CFF3F55B6D0C2"
      unitRef="usd">41100000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13658793e7107-wk-Fact-D8A0D00D9B9A5B1CA2E1F3B7297EF516"
      unitRef="usd">1174700000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-272892E34C4C5876AABF64F554440E09-0-wk-Fact-441147AC2A7550BB94A6ED9521929F7A">&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:66%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of&lt;br/&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Reduction of accounts receivable, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;223.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;197.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Component of accrued expenses and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;951.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,001.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total revenue-related reserves&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,174.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,198.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember"
      decimals="-5"
      id="d13658793e7217-wk-Fact-D4DAB612AE2E5A25ACA440A42360E9DC"
      unitRef="usd">223400000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember"
      decimals="-5"
      id="d13658793e7236-wk-Fact-08E9AFFF9C1E5381944CF2D4F7AA0E79"
      unitRef="usd">197800000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember"
      decimals="-5"
      id="d13658793e7256-wk-Fact-062DF7382F915519A5B9D146E1EF70DC"
      unitRef="usd">951300000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember"
      decimals="-5"
      id="d13658793e7275-wk-Fact-4231B4BD6644584EB68CBAD2CF09EF6D"
      unitRef="usd">1001100000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13658793e7305-wk-Fact-D8A0D00D9B9A5B1CA2E1F3B7297EF516"
      unitRef="usd">1174700000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13658793e7324-wk-Fact-29F90B4D0AA15CF88652A2F69FEF5B8D"
      unitRef="usd">1198900000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-45628B4DAF03538BA12A7B91C71AE4C3-0-wk-Fact-A26F447C604A5562BB3D8910C144995C">&lt;div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs are summarized below. For the purposes of this footnote we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:46%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Biogen&#x2019;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;257.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;377.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;598.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;768.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;220.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;199.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;399.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;325.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;478.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;576.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;998.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,093.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock>
    <biib:ShareOfCoPromotionProfits
      contextRef="FD2020Q2QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember"
      decimals="-5"
      id="d13658793e7562-wk-Fact-FF69F0DD76FB5F3893C65DACA86FCD0F"
      unitRef="usd">257500000</biib:ShareOfCoPromotionProfits>
    <biib:ShareOfCoPromotionProfits
      contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember"
      decimals="-5"
      id="d13658793e7581-wk-Fact-476B170DB1E255468AD6808F5EF708AC"
      unitRef="usd">377200000</biib:ShareOfCoPromotionProfits>
    <biib:ShareOfCoPromotionProfits
      contextRef="FD2020Q2YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember"
      decimals="-5"
      id="d13658793e7601-wk-Fact-9E8D68E9957D5C7FB3272B42621DB81A"
      unitRef="usd">598800000</biib:ShareOfCoPromotionProfits>
    <biib:ShareOfCoPromotionProfits
      contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember"
      decimals="-5"
      id="d13658793e7620-wk-Fact-A1AB8A0C8B185CE3AE8FE08BEEF6DCB3"
      unitRef="usd">768000000.0</biib:ShareOfCoPromotionProfits>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="FD2020Q2QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember"
      decimals="-5"
      id="d13658793e7640-wk-Fact-110C357A15CE5A41B23F93E3A548416C"
      unitRef="usd">220800000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember"
      decimals="-5"
      id="d13658793e7659-wk-Fact-01A214FC1D015C4CA9D0DFEE484001DB"
      unitRef="usd">199200000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="FD2020Q2YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember"
      decimals="-5"
      id="d13658793e7678-wk-Fact-D5A5D244B60D5387B064A5B788E3DC62"
      unitRef="usd">399900000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember"
      decimals="-5"
      id="d13658793e7698-wk-Fact-04822A30103D5A9EA4EC742FD66632F8"
      unitRef="usd">325800000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d13658793e7728-wk-Fact-FB6FCA81223F5FE7A607645477111EBC"
      unitRef="usd">478300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d13658793e7747-wk-Fact-20474355737A5AB3954B4011223DE749"
      unitRef="usd">576400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d13658793e7767-wk-Fact-58C037C126CE5E9782E7F6AFA1368536"
      unitRef="usd">998700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember"
      decimals="-5"
      id="d13658793e7786-wk-Fact-235F3E71E70A544C994CD254A0F195D0"
      unitRef="usd">1093800000</us-gaap:Revenues>
    <biib:OtherrevenuesTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-D3D2747AD38C5B559B9966923B98BAAB-0-wk-Fact-B70C3F5A6DC65E1292BB8C9CB018FEBB">&lt;div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Revenues from collaborative and other relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Profit (loss) earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Revenues earned under our technical development agreement, manufacturing services agreements and royalty revenues on biosimilar products with Samsung Bioepis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;4.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;52.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;8.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;77.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other royalty and corporate revenues:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Royalty&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;7.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;18.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;6.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other corporate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;395.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;105.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;489.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;369.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total other revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;407.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;160.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;516.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;452.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:OtherrevenuesTableTextBlock>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d13658793e8127-wk-Fact-22DC319828EC5DCA9AF8B73917B2A841"
      unitRef="usd">500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d13658793e8146-wk-Fact-E4B62E2E31AC5329A503BC109F552F20"
      unitRef="usd">-100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d13658793e8167-wk-Fact-9AB69968AB8E5F258534930D1F241FC3"
      unitRef="usd">700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d13658793e8186-wk-Fact-45F5EAEB7FA15630A708B40C0D2BE590"
      unitRef="usd">-500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_srt_MajorCustomersAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d13658793e8207-wk-Fact-32E2864C068656BA9A87D6F03504DFEB"
      unitRef="usd">4500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d13658793e8226-wk-Fact-A0B1C99BF9F95385BFFE1C7FDAE14999"
      unitRef="usd">52200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_srt_MajorCustomersAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d13658793e8245-wk-Fact-4CBD1787120583228681598139AF1869"
      unitRef="usd">8200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d13658793e8265-wk-Fact-D7B9719EA7EFFD191CB659813B74766D"
      unitRef="usd">77000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember"
      decimals="-5"
      id="d13658793e8377-wk-Fact-E872A407662D5EE08E83BD6BC59D3ED3"
      unitRef="usd">7100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember"
      decimals="-5"
      id="d13658793e8396-wk-Fact-AD7E82BBCEFE5E95B28ACE0F14842F64"
      unitRef="usd">2700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember"
      decimals="-5"
      id="d13658793e8415-wk-Fact-4C75EC3651E55B66BE157D66A5F37FE2"
      unitRef="usd">18500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember"
      decimals="-5"
      id="d13658793e8435-wk-Fact-669710715ED45103A762AE04A08FB590"
      unitRef="usd">6600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember"
      decimals="-5"
      id="d13658793e8460-wk-Fact-935AB887DC455E09A965E7F28496CFF8"
      unitRef="usd">395500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember"
      decimals="-5"
      id="d13658793e8479-wk-Fact-AE9942B8485C5515A0CD351D448B1146"
      unitRef="usd">105200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember"
      decimals="-5"
      id="d13658793e8498-wk-Fact-C6B87EC6CE62505E9DC0E85640ECFCD1"
      unitRef="usd">489500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember"
      decimals="-5"
      id="d13658793e8518-wk-Fact-3099F7FA688254B6A32186F05BB0EF12"
      unitRef="usd">369300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d13658793e8548-wk-Fact-F3C79B768015565FA0C0EB179D69F338"
      unitRef="usd">407600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d13658793e8567-wk-Fact-46C1484140125886ACF7E143442F0214"
      unitRef="usd">160000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d13658793e8587-wk-Fact-E351B467EBD95DC7BA1A6E901C488CDA"
      unitRef="usd">516900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember"
      decimals="-5"
      id="d13658793e8606-wk-Fact-9E90C511A4E4588682EE0D2A0C9F3B65"
      unitRef="usd">452400000</us-gaap:Revenues>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2019Q3_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember"
      decimals="-5"
      id="d13658793e8624-wk-Fact-F7FE673D71E5B0F109C35DA13E756F70"
      unitRef="usd">500000000.0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_srt_MajorCustomersAxis_biib_ContractManufacturingCustomerMember_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember"
      decimals="-5"
      id="d13658793e8664-wk-Fact-839B2A5E9F92020796AA5DA22186C835"
      unitRef="usd">329400000</us-gaap:Revenues>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-5789181EABBE52D09901D9B63CDF0BC9-0-wk-Fact-AE3C9F33AEA15456BA7BAD1F7B4B55D0">&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The components of inventory are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:64%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of&lt;br/&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Raw materials&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;244.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;169.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Work in process&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;509.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;460.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Finished goods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;198.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;174.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total inventory&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;952.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;804.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-8A8AF6FCC2F15B6CAD13C8EF817D8627-0-wk-Fact-FF97394C4F065571AEDA393E84FBC923">&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The components of inventory are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:64%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of&lt;br/&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Raw materials&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;244.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;169.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Work in process&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;509.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;460.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Finished goods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;198.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;174.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total inventory&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;952.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;804.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13648686e886-wk-Fact-9B2ACD6C351750F3A5408420CFFA84C4"
      unitRef="usd">244700000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13648686e905-wk-Fact-AD28146499E453F49A59D959832635A4"
      unitRef="usd">169700000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13648686e925-wk-Fact-68E9FE242DFD5B8695407576A47210DF"
      unitRef="usd">509100000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13648686e944-wk-Fact-94DCFC167DB65DD4B3D72E3E2390B0FB"
      unitRef="usd">460000000.0</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13648686e969-wk-Fact-CBF0300875F55501B84EA26DBA399AFC"
      unitRef="usd">198900000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13648686e988-wk-Fact-0CFF6E26339E58639CA21641EC42E50E"
      unitRef="usd">174500000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <biib:Inventorynetcurrentandnoncurrent
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13648686e1018-wk-Fact-CCA383FAD6DE51C2930A64B4D6F1DC7C"
      unitRef="usd">952700000</biib:Inventorynetcurrentandnoncurrent>
    <biib:Inventorynetcurrentandnoncurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13648686e1037-wk-Fact-9F732FC3A9DA51E5BDE3934413C60118"
      unitRef="usd">804200000</biib:Inventorynetcurrentandnoncurrent>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-32CB81C906FB5971BF1250DEC8792813-0-wk-Fact-F3A16DF07B9A54C6B8773BBB35207114">&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="26"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:21%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of June 30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Completed technology&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;4-28 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;7,379.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(5,014.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;2,364.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;7,379.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(4,881.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2,497.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;In-process research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Indefinite until commercialization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;954.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;954.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;965.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;965.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Trademarks&#160;and trade names&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Indefinite&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;64.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;64.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;64.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;64.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;8,398.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(5,014.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;3,383.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;8,408.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(4,881.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;3,527.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, amortization and impairment of acquired intangible assets totaled &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$61.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$133.0 million&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, compared to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$70.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$138.3 million&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in the prior year comparative periods. We had &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; impairment charges for the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Completed Technology&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Completed technology primarily relates to our acquisition of all remaining rights to TYSABRI from Elan Pharma International Ltd., an affiliate of Elan Corporation plc, and milestone payments made to Alkermes Pharma Ireland Limited, a subsidiary of Alkermes plc, following the approval of VUMERITY in the U.S. in &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;October 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, net of accumulated amortization.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;IPR&amp;amp;D Related to Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;IPR&amp;amp;D &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;"&gt;represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition.&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Included in IPR&amp;amp;D balances are adjustments related to foreign currency exchange rate fluctuations. &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;"&gt;We review amounts capitalized as acquired IPR&amp;amp;D for impairment annually, as of&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;October 31&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;"&gt;and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable.&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; The carrying value associated with our IPR&amp;amp;D assets as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, relates to the various IPR&amp;amp;D programs we acquired in connection with our acquisitions of NST, Convergence Pharmaceuticals Holdings Ltd. (Convergence) and Biogen International Neuroscience GmbH (BIN). The majority of the balance relates to our acquisition of NST in June 2019 whereby we acquired IPR&amp;amp;D programs with an estimated fair value of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$700.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Vixotrigine&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;"&gt;In the periods since we acquired vixotrigine (BIIB074), there have been numerous delays in the initiation of Phase 3 studies for the potential treatment of trigeminal neuralgia (TGN) as we engaged with the U.S. Food and Drug Administration (FDA) regarding the design of the Phase 3 studies and awaited data and insights from mid-stage clinical trials of vixotrigine in other indications that have since been completed.&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;"&gt;The fair value of the TGN asset is not significantly in excess of carrying value.&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the carrying value associated with our vixotrigine IPR&amp;amp;D assets was &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$160.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Estimated Future Amortization of Intangible Assets&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:81%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of&lt;br/&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2020 (remaining six months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;126.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;220.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;220.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;230.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;230.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;220.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:81%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of&lt;br/&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Goodwill, beginning of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;5,757.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(6.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Goodwill, end of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;5,751.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt; accumulated impairment losses related to goodwill. Other includes adjustments related to foreign currency exchange rate fluctuations.</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <biib:IntangibleAssetsExcludingGoodwillTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-E3ED1BB8317F55259D9073C28AA0F31A-0-wk-Fact-3DB4F0B12D4E5924A9AF6039E5DBC879">&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="26"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:21%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of June 30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Completed technology&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;4-28 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;7,379.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(5,014.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;2,364.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;7,379.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(4,881.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2,497.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;In-process research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Indefinite until commercialization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;954.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;954.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;965.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;965.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Trademarks&#160;and trade names&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Indefinite&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;64.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;64.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;64.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;64.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;8,398.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(5,014.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;3,383.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;8,408.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(4,881.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;3,527.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:IntangibleAssetsExcludingGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember"
      decimals="-5"
      id="d13650096e1140-wk-Fact-05127B7A495156939083CD6BEFEB1EC1"
      unitRef="usd">7379300000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember"
      decimals="-5"
      id="d13650096e1159-wk-Fact-08A5859201975E2390CEE7E8F0A9A910"
      unitRef="usd">5014400000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2020Q2_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember"
      decimals="-5"
      id="d13650096e1180-wk-Fact-0D4FFB3909C550CA8F0DEBABD56556FF"
      unitRef="usd">2364900000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember"
      decimals="-5"
      id="d13650096e1199-wk-Fact-FA968B3EA49F5C4AA354B763BF9CA0E6"
      unitRef="usd">7379300000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember"
      decimals="-5"
      id="d13650096e1218-wk-Fact-98BCD0594DA45DBDAC2BA147E24DBB2D"
      unitRef="usd">4881400000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember"
      decimals="-5"
      id="d13650096e1239-wk-Fact-FE195588F3EB50BDB3C94BA6B1EBDEB7"
      unitRef="usd">2497900000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2020Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d13650096e1264-wk-Fact-777BCC5C6A095BCEA2D29819488DA715"
      unitRef="usd">954900000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2020Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d13650096e1283-wk-Fact-24519E88C708541DB6D9705D7331DCA1"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2020Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d13650096e1303-wk-Fact-777BCC5C6A095BCEA2D29819488DA715"
      unitRef="usd">954900000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d13650096e1322-wk-Fact-C60759D04ED456BDB016D4C91DAE488C"
      unitRef="usd">965500000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d13650096e1341-wk-Fact-641EEE7732525DC9B86C90E65ED37E80"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d13650096e1361-wk-Fact-C60759D04ED456BDB016D4C91DAE488C"
      unitRef="usd">965500000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2020Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember"
      decimals="-5"
      id="d13650096e1391-wk-Fact-C9B1868FB8345462972100FB1E95676F"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2020Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember"
      decimals="-5"
      id="d13650096e1410-wk-Fact-1F145E6108C557E58F64CC5CEB56B73A"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2020Q2_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember"
      decimals="-5"
      id="d13650096e1430-wk-Fact-C9B1868FB8345462972100FB1E95676F"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember"
      decimals="-5"
      id="d13650096e1449-wk-Fact-286E5ADD95DD56E5988F487FE63BB252"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember"
      decimals="-5"
      id="d13650096e1468-wk-Fact-7A79C269516159098FD9BCB4A6CD451F"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember"
      decimals="-5"
      id="d13650096e1488-wk-Fact-286E5ADD95DD56E5988F487FE63BB252"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13650096e1523-wk-Fact-708E4713020F522DA09647BAA702581B"
      unitRef="usd">8398200000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13650096e1542-wk-Fact-80E1262768E65172BB934DF593BDB993"
      unitRef="usd">5014400000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13650096e1563-wk-Fact-BFE27979689A5391A80AEDD28844D403"
      unitRef="usd">3383800000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13650096e1582-wk-Fact-CE00BE4D45BA5B2D8A99F668F908247F"
      unitRef="usd">8408800000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13650096e1601-wk-Fact-E45BCFECB1D459E5BC1EFC4B0D2AA52E"
      unitRef="usd">4881400000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13650096e1622-wk-Fact-324FDBF1B2EA5FB9ACA38A2A6E25F4FD"
      unitRef="usd">3527400000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13650096e1654-wk-Fact-093CF28AF51D56AC9C178C57E0C20541"
      unitRef="usd">61500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13650096e1663-wk-Fact-FD9B7A01CCCF53378063A4D1471F9676"
      unitRef="usd">70100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="FD2020Q2QTD"
      decimals="INF"
      id="d13650096e1671-wk-Fact-C49EEDE049D0ED79701B5DAF1E2410C7"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="I2019Q2Nightstar_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d13650096e1732-wk-Fact-022E152128985C9599AF810C59F18ED8"
      unitRef="usd">700000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2020Q2_biib_ResearchanddevelopmentassetAxis_biib_TGNMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d13650096e1754-wk-Fact-DDE1BD2E57B0558BBE13D7F10D498D16"
      unitRef="usd">160200000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-5C5B67FEEC06598BA68DB984CEAB3E31-0-wk-Fact-B398398DA6545B478E55A4C07A2B06DE">he estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:81%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of&lt;br/&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2020 (remaining six months)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;126.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;220.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;220.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;230.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;230.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;220.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13650096e1837-wk-Fact-FCC74F4CA46C52589D5472544EE627B0"
      unitRef="usd">126000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13650096e1857-wk-Fact-D689393FBED45760BE41085B28B18394"
      unitRef="usd">220000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13650096e1882-wk-Fact-50938493107A5B6D98319CFC78A266AF"
      unitRef="usd">220000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13650096e1907-wk-Fact-9558F12C3E6A57B98830775499D5A10D"
      unitRef="usd">230000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13650096e1932-wk-Fact-9EA7D3391C665604A65D8A7AC1FA9F17"
      unitRef="usd">230000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13650096e1957-wk-Fact-F493878EC51A54A3A56005716E408B97"
      unitRef="usd">220000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-4CFC0A475C285224B1F0C1EBCC90C5A0-0-wk-Fact-A5697B9810F451E7B71B6D9F926C4867">&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:81%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of&lt;br/&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Goodwill, beginning of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;5,757.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(6.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Goodwill, end of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;5,751.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13650096e2051-wk-Fact-5E02EC613C7B5C7BA41E1722B85A855E"
      unitRef="usd">5757800000</us-gaap:Goodwill>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13650096e2071-wk-Fact-86C441EAABDD5D1A8B1ADE2BC53E64B4"
      unitRef="usd">-6800000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13650096e2102-wk-Fact-8FC55EF7124D59B3A1E28F099D9D8F9D"
      unitRef="usd">5751000000.0</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="FI2020Q2"
      decimals="-6"
      id="d13650096e2125-wk-Fact-F644120DD8C256C389C52377760CACEF"
      unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-1A3EFA44622A522FAB7CA7FB68BB841B-0-wk-Fact-CD292E878AF453F7B9B0BAE93BEF6EFB">&lt;div style="line-height:120%;padding-top:4px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of June 30, 2020 (In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&#160;Prices&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in Active&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&#160;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&#160;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,869.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,869.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Marketable debt securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,790.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,790.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Government securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;966.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;966.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;108.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;108.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Marketable equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;527.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;344.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;182.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Derivative contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;59.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;59.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;27.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;27.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;5,349.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;344.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;5,005.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Derivative contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;14.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;14.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;351.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;351.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;365.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;14.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;351.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2019 (In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&#160;Prices&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in Active&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&#160;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&#160;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2,541.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2,541.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Marketable debt securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,695.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,695.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Government securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,013.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,013.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;261.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;261.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Marketable equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;337.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;7.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;329.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Derivative contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;43.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;43.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;27.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;27.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;5,920.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;7.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;5,912.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Derivative contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;8.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;8.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;346.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;346.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;354.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;8.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;346.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-05220E166C6A51B18A07BC1DEADCE9A1-0-wk-Fact-472D8A4F385B57F9A5D8F8518A0649C5">&lt;div style="line-height:120%;padding-top:4px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of June 30, 2020 (In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&#160;Prices&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in Active&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&#160;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&#160;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,869.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,869.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Marketable debt securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,790.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,790.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Government securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;966.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;966.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;108.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;108.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Marketable equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;527.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;344.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;182.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Derivative contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;59.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;59.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;27.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;27.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;5,349.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;344.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;5,005.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Derivative contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;14.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;14.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;351.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;351.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;365.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;14.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;351.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2019 (In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&#160;Prices&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in Active&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&#160;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&#160;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;"&gt;Assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2,541.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2,541.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Marketable debt securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,695.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,695.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Government securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,013.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,013.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;261.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;261.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Marketable equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;337.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;7.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;329.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Derivative contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;43.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;43.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;27.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;27.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;5,920.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;7.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;5,912.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Derivative contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;8.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;8.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;346.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;346.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;354.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;8.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;346.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;There have been &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; material impairments of our assets measured and carried at fair value during the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. In addition, there were &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;no&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; changes in valuation techniques during the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities was determined through third-party pricing services. The fair value of Level 2 instruments classified as marketable equity securities represents our investment in Sangamo Therapeutics, Inc. (Sangamo) common stock and is valued using an option pricing valuation model as the investment is subject to certain holding period restrictions. For additional information on our investment in Sangamo common stock, please read &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Note 8, Financial Instruments&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these condensed consolidated financial statements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our investments in marketable equity securities also include shares of Ionis Pharmaceuticals, Inc. (Ionis) common stock acquired in June 2018. Our shares in Ionis common stock were initially subject to certain holding period restrictions that expired during the first quarter of 2020. The fair value of this investment was a Level 1 measurement as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Note 1, Summary of Significant Accounting Policies - Fair Value Measurements,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the significant unobservable inputs in the fair value measurement of our contingent consideration obligations as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:24%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:23%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of June 30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Valuation Technique&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable Input&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Range&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted Average&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Contingent consideration obligation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:middle;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;351.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Discounted cash flow&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Discount rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;0.83% to 1.18%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.92%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Timing of achievement of development milestones&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2021 to 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The weighted average discount rate was calculated based on the relative fair value of our contingent consideration obligations. In addition, we apply various probabilities of technological and regulatory success, ranging from high single digits to certain probability, to the valuation models to estimate the fair values of our contingent consideration obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Debt Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of June 30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2.900% Senior Notes due September 15, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,509.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,495.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;3.625% Senior Notes due September 15, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,061.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;997.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,038.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;996.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;4.050% Senior Notes due September 15, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,994.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,740.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,897.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,739.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2.250% Senior Notes due May 1, 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,514.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,490.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;5.200% Senior Notes due September 15, 2045&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;2,247.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,723.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2,107.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,722.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;3.150% Senior Notes due May 1, 2050&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,441.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,472.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;8,257.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;7,423.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;6,553.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;5,954.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:1px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:34%;"/&gt;&lt;td style="width:32%;"/&gt;&lt;td style="width:34%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:1px;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1) &lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;, our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2.900%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt; Senior Notes due September 15, 2020, were redeemed in full using the net proceeds from the issuance on April 30, 2020, of our senior unsecured notes for an aggregate principal amount of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;$3.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;. For additional information, please read &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;"&gt;Note 11, Indebtedness&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;"&gt;,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt; to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. For additional information related to our Senior Notes issued on September 15, 2015, please read &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Note 12,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Indebtedness,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K. For additional information related to our Senior Notes issued on April 30, 2020, please read &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Note 11, Indebtedness&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Contingent Consideration Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our acquisitions of Convergence and BIN, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:42%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Fair value, beginning of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;341.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;421.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;346.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;409.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Changes in fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;10.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(20.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(8.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Fair value, end of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;351.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;401.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;351.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;401.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$202.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$197.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our condensed consolidated balance sheets with the remaining balance reflected as a component of accrued expenses and other.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, changes in the fair value of our contingent consideration obligations were primarily due to changes in the interest rates used to revalue our contingent consideration liabilities, changes in the probability and the expected timing of the achievement of certain remaining developmental milestones and the passage of time.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, changes in the fair value of our contingent consideration obligations were primarily due to changes in the probability and the expected timing of the achievement of certain remaining development milestones, partially offset by a decrease in interest rates used to revalue our contingent consideration liabilities and the passage of time.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e1047-wk-Fact-43259A0A3AA950FBA1D6CFAD9C4E840E"
      unitRef="usd">1869600000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e1066-wk-Fact-03BEA37116635F758AC9196E250CCA31"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e1086-wk-Fact-C9090669BB9A558D8A420E26E5F33B36"
      unitRef="usd">1869600000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e1105-wk-Fact-512CABF52E875F9CA83964B1FAED583A"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e1212-wk-Fact-541573CE06065C4E8BE1FB4055BDCE7B"
      unitRef="usd">1790200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e1231-wk-Fact-2E6A66C5678B55D599EBAA8CE36C410A"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e1250-wk-Fact-7D79B62F0F4A5974820BFD925AD40A9D"
      unitRef="usd">1790200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e1270-wk-Fact-9A6B6AB0FF555177B41746B060EA5F1A"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e1295-wk-Fact-30D17D8F4858562DB752F594ADD75B89"
      unitRef="usd">966800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e1314-wk-Fact-A58E1CC8130C58CF8CDA97F148F91B2D"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e1333-wk-Fact-BC7803F6329350578466DA38520AD727"
      unitRef="usd">966800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e1353-wk-Fact-849792336D325E91AE0760A659054837"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e1378-wk-Fact-DD2F73F5529C50848D5AB2588A690700"
      unitRef="usd">108500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e1397-wk-Fact-7AB12618868552BF9F8AA74D829AADB3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e1416-wk-Fact-6ABFD096D53054919A20D7936FE2909F"
      unitRef="usd">108500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e1436-wk-Fact-B4525C3B3B0150C3B7C96A1BE9F7A766"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e1461-wk-Fact-0AEF86F5B5AD576D95CD8C2F40E2BD83"
      unitRef="usd">527000000.0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e1480-wk-Fact-4EF5F07D746E5EB195A30170529149AF"
      unitRef="usd">344300000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e1499-wk-Fact-E62EC012C7DB53D6A477190717801D4A"
      unitRef="usd">182700000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e1519-wk-Fact-30C0CC84635D5C3D82E989949AE7AF96"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e1544-wk-Fact-F4E93BC4BFE555BFB9AB4C79DA12989A"
      unitRef="usd">59900000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e1563-wk-Fact-D8933FB8EB865364B0A6FB12A9524184"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e1582-wk-Fact-00692A807D3F5B9187DCBC865D3F5005"
      unitRef="usd">59900000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e1602-wk-Fact-9F70CEEBCB7E5BEBB9D8A1D6ABAC1221"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e1627-wk-Fact-51408BD584D65293831166CBF28105D7"
      unitRef="usd">27700000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e1646-wk-Fact-1563606BE68857B0A1FCD1614D0CA0CB"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e1665-wk-Fact-C39611A7258452C0BD8E9C6D55D3A70D"
      unitRef="usd">27700000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e1685-wk-Fact-1CDC5591523E52B9A00FDF67A9165CD0"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e1715-wk-Fact-4468E57FBE385B66A76DB52413653676"
      unitRef="usd">5349700000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e1734-wk-Fact-EC76BD85C9F35AC4828096AE7F193F8F"
      unitRef="usd">344300000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e1754-wk-Fact-ACE2F60454945F1FBEB8D0F8F9A0155B"
      unitRef="usd">5005400000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e1773-wk-Fact-F9B13E73D6775DDFBFC42AA083711808"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e1886-wk-Fact-3B0BC080347D5ACBBD076A3C5AEE3B90"
      unitRef="usd">14300000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e1905-wk-Fact-9F63A8525895525FBF02126763337521"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e1925-wk-Fact-370F19437FCE5275B3BBC6B73170D0DD"
      unitRef="usd">14300000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e1944-wk-Fact-174D24DA86FC53BDA86418A927E1A281"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e1964-wk-Fact-A19C990EAFD35063A5E8C784983CFC41"
      unitRef="usd">351600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e1983-wk-Fact-D0575819235F5FD8BC24A36F61810E30"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e2002-wk-Fact-AC01EC5DE11758159F854C05EC0A9152"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e2022-wk-Fact-FD2B7FFD7E7455EAABF0B32BC4CC39F0"
      unitRef="usd">351600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e2052-wk-Fact-C4E3D53DC2C45994B38D2388FAAC56AE"
      unitRef="usd">365900000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e2071-wk-Fact-C6338079BB2D5C659A1B1FFC805B4DA7"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e2091-wk-Fact-BD11EC4FDBD352D4B3C1654CF9D61E94"
      unitRef="usd">14300000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e2110-wk-Fact-F31DEA33FDC25303A0532AC90625CF34"
      unitRef="usd">351600000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e2361-wk-Fact-84AC6FB055CC55C3A7EEFC67C2DD7FB4"
      unitRef="usd">2541100000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e2380-wk-Fact-D73ABFB7BA2B5136A434B700077817AD"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e2400-wk-Fact-A9C6FB96DA3E577C9FB1D2377EF40C6F"
      unitRef="usd">2541100000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e2419-wk-Fact-93A11C3411255C9D91D99743F4BFAF94"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e2526-wk-Fact-22DB5234DB7D585CB313C40FE989CCC3"
      unitRef="usd">1695100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e2545-wk-Fact-672D5FB637D65A76A0CE5457A1A48C34"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e2564-wk-Fact-037FDF7E86865F9592ACBBD5C670DAEE"
      unitRef="usd">1695100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e2584-wk-Fact-C147161271BF59458E54344F383CF098"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e2609-wk-Fact-CE89A364422C5873AF4B204D285EF1BD"
      unitRef="usd">1013900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e2628-wk-Fact-5637393B1807528BA7BCEBA75DCC7275"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e2647-wk-Fact-C43CEF12309C5C878B9EACEB8A2099EF"
      unitRef="usd">1013900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e2667-wk-Fact-BE8E7ABB2CB356DAADABCCA3686B666F"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e2692-wk-Fact-01B152C37C195238A7AA227A513DA6AD"
      unitRef="usd">261300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e2711-wk-Fact-0D879F36AA4F5A508D6E3B0C8D05D5C0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e2730-wk-Fact-EDE743DD7899551B970B901EC6122067"
      unitRef="usd">261300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e2750-wk-Fact-B5518B337F95571CA5EF377DAFB67291"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e2775-wk-Fact-F00B97A4585A53EEA20DA5BAB7DF40D6"
      unitRef="usd">337500000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e2794-wk-Fact-653F680695DD5A929AFB033318B3ED52"
      unitRef="usd">7900000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e2813-wk-Fact-91C0F07C11065E9B9920ADE354DE8771"
      unitRef="usd">329600000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e2833-wk-Fact-B5312CD9C6BA5C7DA1B0B0A3D523F43B"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e2858-wk-Fact-1D5C4FDC83445AD9A70261D56E620A42"
      unitRef="usd">43800000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e2877-wk-Fact-086EC2D9EFC556CF8CDD18C499A8BA9C"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e2896-wk-Fact-DF18D7BE971C5658B052F8D34DBC72E5"
      unitRef="usd">43800000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e2916-wk-Fact-F20AA435E669597FABAAA08C9EA68611"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e2941-wk-Fact-591189EC897C569C83F1C8FA127D84CD"
      unitRef="usd">27700000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e2960-wk-Fact-9E97DE7ADEA0573297B96D6D23C6E155"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e2979-wk-Fact-2E7A6281F0BE5E4AA650AD77B6EA1CCD"
      unitRef="usd">27700000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e2999-wk-Fact-B8CEEBF4C3DA5C908D9A7FD716630C21"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e3029-wk-Fact-AB1D42967D3755558D27EB6ED5401B77"
      unitRef="usd">5920400000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e3048-wk-Fact-77A3951657885B30B4524818756186F8"
      unitRef="usd">7900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e3068-wk-Fact-1946DF5D7256570785595B3650899AA6"
      unitRef="usd">5912500000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e3087-wk-Fact-FA962F6492AD5ECB95433417F7F92D3A"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e3200-wk-Fact-2EDAC1F8B249572E9511CAE3B3835FC6"
      unitRef="usd">8300000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e3219-wk-Fact-DC5695E37C715CC39E550BD16017383D"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e3239-wk-Fact-175E8740B88C5F40A6B63DECDD0066F1"
      unitRef="usd">8300000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e3258-wk-Fact-2933EEE48E7A51269D5866511F68D2BE"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e3278-wk-Fact-286F1A1625CA593B89812AAFB974A889"
      unitRef="usd">346100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e3297-wk-Fact-37CD55BDB5A058AA9971C1170743233D"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e3316-wk-Fact-C91567BF60905D56AFF6B232E09AE416"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e3336-wk-Fact-944606DE80BA58939933FF50D029FC04"
      unitRef="usd">346100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e3366-wk-Fact-14E277E8F4E655318495D16389EDD6F9"
      unitRef="usd">354400000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e3385-wk-Fact-A18726FF1701522FA0FF75559185EF5F"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e3405-wk-Fact-C921A935E3075C12A387C34590E313B7"
      unitRef="usd">8300000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e3424-wk-Fact-6D1689A8CC0152CCB334D64CCFDA2098"
      unitRef="usd">346100000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetImpairmentCharges
      contextRef="FD2020Q2YTD"
      decimals="INF"
      id="d13663888e3444-wk-Fact-694D6D1DA5845D70B8449FAEADE25A6E"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e3748-wk-Fact-A19C990EAFD35063A5E8C784983CFC41"
      unitRef="usd">351600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="FI2020Q2_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember"
      decimals="4"
      id="d13663888e3793-wk-Fact-FD45875B2A605E7AAB1784BEBB43EDF7"
      unitRef="number">0.0092</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-88DF1C200D975519BF18564769566706-0-wk-Fact-BF1609E6770B526680E49068E14329B7">&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of June 30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2.900% Senior Notes due September 15, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,509.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,495.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;3.625% Senior Notes due September 15, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,061.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;997.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,038.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;996.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;4.050% Senior Notes due September 15, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,994.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,740.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,897.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,739.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2.250% Senior Notes due May 1, 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,514.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,490.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;5.200% Senior Notes due September 15, 2045&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;2,247.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,723.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2,107.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,722.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;3.150% Senior Notes due May 1, 2050&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,441.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,472.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;8,257.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;7,423.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;6,553.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;5,954.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"
      decimals="-5"
      id="d13663888e4115-wk-Fact-40168E4AB5865FB1AFC923E3B86FDB4A"
      unitRef="usd">0</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"
      decimals="-5"
      id="d13663888e4134-wk-Fact-98DB2CCFE7155479B9C38D41283BCEA2"
      unitRef="usd">0</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"
      decimals="-5"
      id="d13663888e4154-wk-Fact-CE8C1C62476C5B1BBC510607278C8D11"
      unitRef="usd">1509600000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"
      decimals="-5"
      id="d13663888e4173-wk-Fact-B7098BDFE9355368846B4549E3B9C2C8"
      unitRef="usd">1495800000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"
      decimals="-5"
      id="d13663888e4193-wk-Fact-EE333E412B395204AD855AD3156CA641"
      unitRef="usd">1061000000.0</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"
      decimals="-5"
      id="d13663888e4212-wk-Fact-2165464F11E45AF39A68F987A433EE94"
      unitRef="usd">997300000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"
      decimals="-5"
      id="d13663888e4231-wk-Fact-F35E46D042DA5C618D0484E16A86AE8A"
      unitRef="usd">1038900000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"
      decimals="-5"
      id="d13663888e4251-wk-Fact-CDC8471BE1895E219AE059AF99B58FE6"
      unitRef="usd">996600000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"
      decimals="-5"
      id="d13663888e4276-wk-Fact-808DF43DA34D56BBB2C719F090E60A74"
      unitRef="usd">1994100000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"
      decimals="-5"
      id="d13663888e4295-wk-Fact-4189BCECB63E53E5A043DFA47398CF07"
      unitRef="usd">1740300000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"
      decimals="-5"
      id="d13663888e4314-wk-Fact-2DFE8D64C3475F2E95AF00413ADC5E51"
      unitRef="usd">1897200000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"
      decimals="-5"
      id="d13663888e4334-wk-Fact-698A9443F35F56DDADA0D9E5F0A5E496"
      unitRef="usd">1739500000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_A2.25SeniorNotesdueMay12030Member"
      decimals="-5"
      id="d13663888e4359-wk-Fact-E148A1FD47D7ED3A1ECC5DBD2ACDE8D3"
      unitRef="usd">1514100000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_A2.25SeniorNotesdueMay12030Member"
      decimals="-5"
      id="d13663888e4378-wk-Fact-374E21DF77AEE400670E5DBD2E555636"
      unitRef="usd">1490700000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_A2.25SeniorNotesdueMay12030Member"
      decimals="-5"
      id="d13663888e4397-wk-Fact-27C6B8AE579A3CF3E61C5DBD323DDC0F"
      unitRef="usd">0</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_A2.25SeniorNotesdueMay12030Member"
      decimals="-5"
      id="d13663888e4417-wk-Fact-1AF110488411FAB471375DBD360498CD"
      unitRef="usd">0</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"
      decimals="-5"
      id="d13663888e4442-wk-Fact-248BAD0A5FE453F580A6503792AC414B"
      unitRef="usd">2247100000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"
      decimals="-5"
      id="d13663888e4461-wk-Fact-0B43F9E947835CC884220B7EBB604813"
      unitRef="usd">1723200000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"
      decimals="-5"
      id="d13663888e4480-wk-Fact-9E52B1DA168F540FB119847959F5C513"
      unitRef="usd">2107900000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"
      decimals="-5"
      id="d13663888e4500-wk-Fact-AC2AF4AACBB35F2085A6A6D0942DC7D6"
      unitRef="usd">1722900000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_A3.15SeniorNotesdueMay12050Member"
      decimals="-5"
      id="d13663888e4525-wk-Fact-9B93E16ECCD5D85DAA7F5DBD6455957C"
      unitRef="usd">1441300000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_A3.15SeniorNotesdueMay12050Member"
      decimals="-5"
      id="d13663888e4544-wk-Fact-6D38758F3065F55CA9355DBD6868F397"
      unitRef="usd">1472300000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_A3.15SeniorNotesdueMay12050Member"
      decimals="-5"
      id="d13663888e4563-wk-Fact-44B35A17AE6B2A0562D55DBD6C044A32"
      unitRef="usd">0</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_biib_A3.15SeniorNotesdueMay12050Member"
      decimals="-5"
      id="d13663888e4583-wk-Fact-0E3C2534F0247524064A5DBD6F604CFC"
      unitRef="usd">0</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentFairValue
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13663888e4613-wk-Fact-77E75A6E53065422B10A2A429E152ABF"
      unitRef="usd">8257600000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:NotesPayable
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13663888e4632-wk-Fact-C35F2DCD15EA5A45A149BB09831F209F"
      unitRef="usd">7423800000</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentFairValue
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13663888e4652-wk-Fact-4619ACE828F95026BEF4E6BF9FE10650"
      unitRef="usd">6553600000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:NotesPayable
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13663888e4671-wk-Fact-351818C4E5465B198910AB5ACA4CD886"
      unitRef="usd">5954800000</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"
      decimals="INF"
      id="d13663888e4723-wk-Fact-AB9F17C6602BF12CDF6F5DD4ABEB3A35"
      unitRef="number">0.02900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="I2020Q1April30_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="d13663888e4727-wk-Fact-3886DB8A1CA1AB4CFA015873BC68D740"
      unitRef="usd">3000000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-CEA900C1716D589483FC71B4C35E43FF-0-wk-Fact-F2EF2F879EEE5DFD91E4B1DF1EFB2317">The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:42%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Fair value, beginning of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;341.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;421.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;346.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;409.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Changes in fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;10.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(20.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(8.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Fair value, end of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;351.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;401.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;351.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;401.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e4990-wk-Fact-85E036149B6A51AEA583829FB109BC0A"
      unitRef="usd">341600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e5009-wk-Fact-4371AA25A502533680987AD381BE5164"
      unitRef="usd">421300000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e5029-wk-Fact-286F1A1625CA593B89812AAFB974A889"
      unitRef="usd">346100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e5048-wk-Fact-3964A49703DE559DBD3667AC9F121D5B"
      unitRef="usd">409800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13663888e5068-wk-Fact-D2590DE582FB57A4B3475521C290EA50"
      unitRef="usd">-10000000.0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13663888e5087-wk-Fact-EA0A92078CAF5114A9DDE6B7E79E0436"
      unitRef="usd">20000000.0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13663888e5107-wk-Fact-1ED69AA194385201B48524E875F0B015"
      unitRef="usd">-5500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13663888e5127-wk-Fact-2D5631ACC4AA55F18A9E8E1BE5DDC18B"
      unitRef="usd">8500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13663888e5153-wk-Fact-1CC5BFBCD41659848F2DF6E37BCC0D9E"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13663888e5172-wk-Fact-2EF5ADA64DE6585E9E917E7A8AB48865"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13663888e5191-wk-Fact-63DE40A01D42512491B51527BF1D9997"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13663888e5211-wk-Fact-C05E1A60089B57FDBA33D2D386BDC984"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e5241-wk-Fact-A19C990EAFD35063A5E8C784983CFC41"
      unitRef="usd">351600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e5260-wk-Fact-609FA712998E5C379FEC4E72D1B73259"
      unitRef="usd">401300000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e5280-wk-Fact-A19C990EAFD35063A5E8C784983CFC41"
      unitRef="usd">351600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d13663888e5299-wk-Fact-609FA712998E5C379FEC4E72D1B73259"
      unitRef="usd">401300000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13663888e5327-wk-Fact-4F86DD0D53E855908FBC53B20136CCA2"
      unitRef="usd">202500000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13663888e5331-wk-Fact-B3F2A9BDB0D9546EA92DBA1CE6C5F4E5"
      unitRef="usd">197700000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-ED477C549F0B5CE48C36AC196521EB31-0-wk-Fact-DCC7236EA564508A8A60218BE7A15509">&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of&lt;br/&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;139.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;384.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Overnight reverse repurchase agreements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;247.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;368.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,363.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,628.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Short-term debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;118.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;159.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,869.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2,541.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and short-term debt securities approximate fair value due to their short-term maturities. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our marketable equity securities gains (losses) are recorded in other income (expense), net in our condensed consolidated statements of income. The following tables summarize our marketable debt and equity securities:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of June 30, 2020 (In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Corporate debt securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,282.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,283.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;502.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;3.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;506.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Government securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;657.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;658.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;307.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;308.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Mortgage and other asset backed securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;107.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;107.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total marketable debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;2,859.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;7.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;2,865.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;428.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;114.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(15.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;527.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2019 (In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Corporate debt securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,057.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,058.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;633.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;3.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;636.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Government securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;502.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;503.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;510.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;510.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Mortgage and other asset backed securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;260.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;260.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total marketable debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2,965.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2,970.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;218.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;132.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(13.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;337.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Summary of Contractual Maturities: Available-for-Sale Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of June 30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Due in one year or less&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,942.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,940.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,562.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,560.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Due after one year through five years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;862.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;858.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,234.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,230.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Due after five years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;60.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;59.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;173.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;173.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total marketable debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;2,865.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;2,859.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2,970.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2,965.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The average maturity of our marketable debt securities available-for-sale as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, was approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;14&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Proceeds from Marketable Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:42%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Proceeds from maturities and sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,490.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,766.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;3,879.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;3,255.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Realized gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;11.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Realized losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(5.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(24.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Strategic Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, our strategic investment portfolio was comprised of investments totaling &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$583.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$393.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, which are included in investments and other assets in our condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Note 7, Fair Value Measurements&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these condensed consolidated financial statements, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The increase in our strategic investment portfolio for the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, was primarily due to our purchase of Sangamo common stock, as discussed below, and an increase in the fair value of our remaining investment in Ionis common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our June 2018 investment in Ionis common stock, please read &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Note 18,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;to our consolidated financial statements included in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:17px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Sangamo Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;February 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; we entered into a collaboration and license agreement with Sangamo to develop and commercialize ST-501 for tauopathies, including AD; ST-502 for synucleinopathies, including Parkinson&#x2019;s disease; a third neuromuscular disease target; and up to nine additional neurological disease targets to be identified and selected within a five-year period. The companies will leverage Sangamo&#x2019;s proprietary zinc finger protein technology delivered via AAV to modulate the expression of key genes involved in neurological diseases.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with the closing of this transaction in &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;April 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; we purchased approximately&#160;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;24 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;shares of Sangamo common stock.&#160;This equity method investment will be remeasured each reporting period and carried at fair value due to our election of the fair value option. The effects of certain holding period restrictions on the investment are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk free-interest rate to match the remaining term of the restrictions on our investment in Sangamo&#x2019;s common stock and a dividend yield of zero based upon the fact that Sangamo and similar companies generally have not historically granted cash dividends.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our collaboration agreement with Sangamo, please read &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Note 17, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-A845CDDE5AD25A1EA035137098ACC8AD-0-wk-Fact-62E9757124655A50B09A9DF3EE393946">&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of&lt;br/&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;139.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;384.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Overnight reverse repurchase agreements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;247.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;368.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,363.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,628.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Short-term debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;118.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;159.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,869.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2,541.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2020Q2_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember"
      decimals="-5"
      id="d13667934e883-wk-Fact-A4887989DB22592B8DA6647CD3146177"
      unitRef="usd">139900000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember"
      decimals="-5"
      id="d13667934e902-wk-Fact-15B3ED467D4751048899D7A61C9BB48D"
      unitRef="usd">384400000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2020Q2_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember"
      decimals="-5"
      id="d13667934e922-wk-Fact-EADF1827BA2D525181DEEB6E79CA54CB"
      unitRef="usd">247700000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember"
      decimals="-5"
      id="d13667934e941-wk-Fact-31392073853D5FE998558E781E1CB262"
      unitRef="usd">368800000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2020Q2_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-5"
      id="d13667934e966-wk-Fact-02AAEA4D79685EDD8B8956960B2B5C64"
      unitRef="usd">1363700000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-5"
      id="d13667934e985-wk-Fact-7BE4290D63FC58ACB3B02276447535EC"
      unitRef="usd">1628500000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2020Q2_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember"
      decimals="-5"
      id="d13667934e1010-wk-Fact-038A95F16A1F5D8C85BCF78FB8BD34A8"
      unitRef="usd">118300000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember"
      decimals="-5"
      id="d13667934e1029-wk-Fact-FFD415E87C835D44BD98160B74C3F63A"
      unitRef="usd">159400000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13667934e1059-wk-Fact-6B5BA6205AD45D43B683A2806454C88F"
      unitRef="usd">1869600000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13667934e1078-wk-Fact-E5DE680527745FC0A1ACE48AEBADC7AB"
      unitRef="usd">2541100000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-AC72975927385956A20AF7ABC432DC8F-0-wk-Fact-57A5D27647FC594CBEE6ACA7910FD5D1">The following tables summarize our marketable debt and equity securities:&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of June 30, 2020 (In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Corporate debt securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,282.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,283.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;502.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;3.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;506.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Government securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;657.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;658.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;307.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;308.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Mortgage and other asset backed securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;107.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;107.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total marketable debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;2,859.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;7.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;2,865.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;428.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;114.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(15.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;527.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2019 (In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Corporate debt securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,057.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,058.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;633.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;3.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;636.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Government securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;502.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;503.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;510.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;510.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Mortgage and other asset backed securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;260.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;260.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total marketable debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2,965.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2,970.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;218.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;132.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(13.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;337.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember"
      decimals="-5"
      id="d13667934e1340-wk-Fact-E42D4E6B1ADF56FBAA9D919BF234F0D4"
      unitRef="usd">1282500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember"
      decimals="-5"
      id="d13667934e1359-wk-Fact-3F386F8A2C9E5DF98DF8631F897F14E0"
      unitRef="usd">1500000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember"
      decimals="-5"
      id="d13667934e1379-wk-Fact-682A7376BFBC53CC8348BB38CB2DF8F9"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember"
      decimals="-5"
      id="d13667934e1399-wk-Fact-52B86D2604F456BCA61A207789C17D68"
      unitRef="usd">1283900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember"
      decimals="-5"
      id="d13667934e1419-wk-Fact-F7413C04E9285534BC51B79E3D506A17"
      unitRef="usd">502800000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember"
      decimals="-5"
      id="d13667934e1438-wk-Fact-788C98677F795CE29DA3D7CD8A59C7DC"
      unitRef="usd">3800000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember"
      decimals="-5"
      id="d13667934e1457-wk-Fact-39951E7E27125D16AFE889A00B07135A"
      unitRef="usd">300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember"
      decimals="-5"
      id="d13667934e1478-wk-Fact-014298B959D758D69479E24A893A6695"
      unitRef="usd">506300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember"
      decimals="-5"
      id="d13667934e1590-wk-Fact-53D0EBA15FE35EB5BD704559843C967B"
      unitRef="usd">657700000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember"
      decimals="-5"
      id="d13667934e1609-wk-Fact-5F04150F2D6555A4954BAAA7FFF1DCC9"
      unitRef="usd">500000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember"
      decimals="-5"
      id="d13667934e1628-wk-Fact-A65886E4002050F6B73B88C489FA3902"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember"
      decimals="-5"
      id="d13667934e1648-wk-Fact-708FCD0C93E15025B01756475BD99E3C"
      unitRef="usd">658200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember"
      decimals="-5"
      id="d13667934e1673-wk-Fact-B2FFE7A2A2785F2D8CFAC04131FB59D5"
      unitRef="usd">307900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember"
      decimals="-5"
      id="d13667934e1692-wk-Fact-D27E0E5C78835B2FBF61AACFE7AF1C59"
      unitRef="usd">800000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember"
      decimals="-5"
      id="d13667934e1711-wk-Fact-4CEC26B6FBED5369B5EB04EF1495FED9"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember"
      decimals="-5"
      id="d13667934e1732-wk-Fact-4BBD9695FDEE5E82ADE400F5428061AD"
      unitRef="usd">308600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"
      decimals="-5"
      id="d13667934e1844-wk-Fact-1C1EB5B0BD7F5483960A0F94B6C1CF70"
      unitRef="usd">600000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"
      decimals="-5"
      id="d13667934e1863-wk-Fact-99BE94C0859F5E1AB6C07774414BC176"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"
      decimals="-5"
      id="d13667934e1882-wk-Fact-63F96E8223525BAB9E39BBEF359664E5"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"
      decimals="-5"
      id="d13667934e1902-wk-Fact-A2FB4AEBCF1E5536A5A276D8E974808E"
      unitRef="usd">600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"
      decimals="-5"
      id="d13667934e1927-wk-Fact-4B00716D24F855C7995A1743B3B83B0B"
      unitRef="usd">107600000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"
      decimals="-5"
      id="d13667934e1946-wk-Fact-CCBA8537CC8256F189E38A400D14984D"
      unitRef="usd">700000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"
      decimals="-5"
      id="d13667934e1965-wk-Fact-1E51B54FEB275284A90347DA596C6D53"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"
      decimals="-5"
      id="d13667934e1986-wk-Fact-EFE87958595C5894BF6662832A2CDC07"
      unitRef="usd">107900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13667934e2016-wk-Fact-489746C7BF7C5BF2BF1AE9DB0B15E040"
      unitRef="usd">2859100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13667934e2035-wk-Fact-931F8D36F0EE5210ABA1F84FEBD92195"
      unitRef="usd">7300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13667934e2055-wk-Fact-E22C14C2EE115E0E8CD4DE28B47CD700"
      unitRef="usd">900000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13667934e2075-wk-Fact-E5F70307BF6E5CFDB4F094B7B27B4EC1"
      unitRef="usd">2865500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-5"
      id="d13667934e2101-wk-Fact-5179C25D44E05D778BBDD2917F9B5E75"
      unitRef="usd">428000000.0</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-5"
      id="d13667934e2120-wk-Fact-25F9FB07B4665B4EBAA930A7ABD5E010"
      unitRef="usd">114600000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-5"
      id="d13667934e2140-wk-Fact-CE2FE1FDB728588F85A609FD993D2810"
      unitRef="usd">15600000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-5"
      id="d13667934e2160-wk-Fact-A54083F9A0775E33B371BFEFA83808D9"
      unitRef="usd">527000000.0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember"
      decimals="-5"
      id="d13667934e2402-wk-Fact-7EF0A7D1AFE153158B9D83F169785EDD"
      unitRef="usd">1057200000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember"
      decimals="-5"
      id="d13667934e2421-wk-Fact-40FF30CE2BFC5117B7DC2CE927907357"
      unitRef="usd">1000000.0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember"
      decimals="-5"
      id="d13667934e2441-wk-Fact-909CA2503D4A517F9F58ABA553EB089B"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember"
      decimals="-5"
      id="d13667934e2460-wk-Fact-59EF3E4857DD5B2B9456FAA158E30E80"
      unitRef="usd">1058200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember"
      decimals="-5"
      id="d13667934e2480-wk-Fact-E9636A4973F3530DB17C83B7E2A137A5"
      unitRef="usd">633900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember"
      decimals="-5"
      id="d13667934e2499-wk-Fact-197476FE8C7C5FE086CFE3EF072E1280"
      unitRef="usd">3000000.0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember"
      decimals="-5"
      id="d13667934e2518-wk-Fact-38E43DCD4A1A53459CCF263CE2764D89"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember"
      decimals="-5"
      id="d13667934e2538-wk-Fact-811C177311195B6BB6515EDE405544B2"
      unitRef="usd">636900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember"
      decimals="-5"
      id="d13667934e2650-wk-Fact-A3A647F014AF52FEAB4441EB978E462D"
      unitRef="usd">502900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember"
      decimals="-5"
      id="d13667934e2669-wk-Fact-8F742281F7BA583F9CD4BAE55046FD12"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember"
      decimals="-5"
      id="d13667934e2688-wk-Fact-1224358A232C52AEB53CD86B3234DC1E"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember"
      decimals="-5"
      id="d13667934e2708-wk-Fact-ECF3433F2F715FB784CC153CCF04C853"
      unitRef="usd">503300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember"
      decimals="-5"
      id="d13667934e2733-wk-Fact-575FE3D590985E75AFD3B5D2D52FAF2F"
      unitRef="usd">510100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember"
      decimals="-5"
      id="d13667934e2752-wk-Fact-C7584E20D8335EAD883A3F5EFFC7A64C"
      unitRef="usd">800000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember"
      decimals="-5"
      id="d13667934e2771-wk-Fact-B2AA1052CBC7590EA1F472141583E447"
      unitRef="usd">300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember"
      decimals="-5"
      id="d13667934e2792-wk-Fact-DD192DE9BF435142955D2DEA1DE301C8"
      unitRef="usd">510600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"
      decimals="-5"
      id="d13667934e2904-wk-Fact-164B390A7D7750A5BC44A8393C30F215"
      unitRef="usd">700000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"
      decimals="-5"
      id="d13667934e2923-wk-Fact-E8F687A1C2185A349E7EAD92A716F83C"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"
      decimals="-5"
      id="d13667934e2942-wk-Fact-77686B47DE015725A0FA075E4B266272"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"
      decimals="-5"
      id="d13667934e2962-wk-Fact-2625FB10B0D954AEBEC29B23AB3FD936"
      unitRef="usd">700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"
      decimals="-5"
      id="d13667934e2987-wk-Fact-11CC7A7B9E715564B1D5537B91B0128A"
      unitRef="usd">260200000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"
      decimals="-5"
      id="d13667934e3006-wk-Fact-B06B242467015EC1A26217C7249B5ED6"
      unitRef="usd">800000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"
      decimals="-5"
      id="d13667934e3025-wk-Fact-79E85FC32427517E9686446D3F433546"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"
      decimals="-5"
      id="d13667934e3046-wk-Fact-38C2B2D0B33A5F38A227DE5AC54A620C"
      unitRef="usd">260600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13667934e3076-wk-Fact-FDC632492EB459DE960D1A700DC94738"
      unitRef="usd">2965000000.0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13667934e3095-wk-Fact-2252F3E19A5C5189898F1D282AF38228"
      unitRef="usd">6000000.0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13667934e3115-wk-Fact-46ECB65BFDA154C19964C5CCC922FBED"
      unitRef="usd">700000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13667934e3135-wk-Fact-1D563550F864522694E8B4EE58DCD71D"
      unitRef="usd">2970300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-5"
      id="d13667934e3161-wk-Fact-43E3618CB8F55463B9CB5E79C0270DAC"
      unitRef="usd">218400000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-5"
      id="d13667934e3180-wk-Fact-4009A687B35F56299E6DBB942CC08B5B"
      unitRef="usd">132100000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-5"
      id="d13667934e3200-wk-Fact-E9223FC2E5FE506B85E89EF2039D33B7"
      unitRef="usd">13000000.0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-5"
      id="d13667934e3220-wk-Fact-1569ED8E71BA5D5085D5F97B47E8514F"
      unitRef="usd">337500000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-959C738AF19E5D3DB028F7DD97FD2023-0-wk-Fact-D6E5AD7C233A5BBA8C9AF2873E93904C">&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of June 30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Due in one year or less&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,942.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,940.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,562.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,560.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Due after one year through five years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;862.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;858.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,234.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,230.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Due after five years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;60.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;59.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;173.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;173.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total marketable debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;2,865.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;2,859.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2,970.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2,965.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13667934e3481-wk-Fact-7DA91672D72559E1A10D4A0FEA80C1C1"
      unitRef="usd">1942700000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13667934e3500-wk-Fact-7E2DA530DD125EBC8E6FFF06DF3E339E"
      unitRef="usd">1940800000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13667934e3520-wk-Fact-D8405E3B616F5B029512DC9C7AD0C302"
      unitRef="usd">1562200000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13667934e3539-wk-Fact-E083DB5FE52256758F8CB96B13075EB5"
      unitRef="usd">1560800000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13667934e3559-wk-Fact-5239B65FCD18527596661F4FB402C687"
      unitRef="usd">862600000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13667934e3578-wk-Fact-30AD363E17925B7F9F7E315DF2872650"
      unitRef="usd">858500000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13667934e3597-wk-Fact-D29A0072A5185CA69F6BD429FBD154D7"
      unitRef="usd">1234500000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13667934e3617-wk-Fact-3F2E302EF380571FBDC4E6D627856AE3"
      unitRef="usd">1230400000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13667934e3642-wk-Fact-39B79FBFAC595D5F9D5BCE76A33E9F8F"
      unitRef="usd">60200000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13667934e3661-wk-Fact-69E4C9D6F6EB58A2BEDD592293B08076"
      unitRef="usd">59800000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13667934e3680-wk-Fact-C609E077BA4758B3AE79590506259F37"
      unitRef="usd">173600000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13667934e3700-wk-Fact-8C4A1108D35F546C80215D8B3CB44D14"
      unitRef="usd">173800000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13667934e3730-wk-Fact-9E90798C4BF95FD7B1EB03256BAA20DD"
      unitRef="usd">2865500000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13667934e3749-wk-Fact-489746C7BF7C5BF2BF1AE9DB0B15E040"
      unitRef="usd">2859100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13667934e3769-wk-Fact-9A51B71F22855F2CB87824B5936329CF"
      unitRef="usd">2970300000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13667934e3788-wk-Fact-FDC632492EB459DE960D1A700DC94738"
      unitRef="usd">2965000000.0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:RealizedGainLossOnInvestmentsTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-5063E2B7156D5A0DA4887CEEDD608AC1-0-wk-Fact-92471B2904D55C37A5468E81D83A97E4">&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:42%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Proceeds from maturities and sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,490.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,766.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;3,879.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;3,255.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Realized gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;11.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Realized losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(5.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(24.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:RealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13667934e4052-wk-Fact-8FC35F12C7F45A039F6BA8DBF730E0C1"
      unitRef="usd">1490600000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13667934e4071-wk-Fact-BC3CE604F1BC51FD9997AA298645CA25"
      unitRef="usd">1766600000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13667934e4091-wk-Fact-22ABA6B6B6A35F598D8DBDA21EAD50E0"
      unitRef="usd">3879900000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13667934e4110-wk-Fact-1CCB591668FB51EFA12E7B8EDE0510D7"
      unitRef="usd">3255800000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13667934e4130-wk-Fact-71571774D3CC54F3AC236DD3B4962540"
      unitRef="usd">6100000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13667934e4149-wk-Fact-68F9BBB8EDF255CC81687117AC2CF2F8"
      unitRef="usd">1000000.0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13667934e4168-wk-Fact-F6A9228CDECD54088EE4D954E88BF77E"
      unitRef="usd">11800000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13667934e4188-wk-Fact-600D43CA2C025BC495B776F1C54E8354"
      unitRef="usd">1600000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13667934e4213-wk-Fact-A90BB57CB56454768845FF822B34886C"
      unitRef="usd">5200000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13667934e4233-wk-Fact-341223BBA153527CBB98FE16E248FC08"
      unitRef="usd">300000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13667934e4253-wk-Fact-86FCAC2762F9515EA7A5938DAC205464"
      unitRef="usd">24300000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13667934e4274-wk-Fact-92C31C2A877B526EBD2C256571CEC127"
      unitRef="usd">600000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <biib:StrategicInvestmentPortfolio
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember"
      decimals="-5"
      id="d13667934e4311-wk-Fact-AA8F3B18C9FC5927B9BA45DBA17FBC37"
      unitRef="usd">583200000</biib:StrategicInvestmentPortfolio>
    <biib:StrategicInvestmentPortfolio
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember"
      decimals="-5"
      id="d13667934e4315-wk-Fact-D9A2DFE8AFC95C24B4AAD38FDBAE4BF2"
      unitRef="usd">393900000</biib:StrategicInvestmentPortfolio>
    <biib:Investmentincommonstocksharespurchased
      contextRef="I2020Q1April30_dei_LegalEntityAxis_biib_SangamoCommonStockMember"
      decimals="-6"
      id="d13667934e4375-wk-Fact-9E9F33E523088043ABA35DD96250DFAD"
      unitRef="shares">24000000</biib:Investmentincommonstocksharespurchased>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-1CF2C5E7CA8758C0BB1AC89D0B97AC81-0-wk-Fact-E1B265DC0F9E5A959256DE8D8C258C29">&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Foreign Currency Forward Contracts - Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due to the global nature of our operations, portions of our revenues and operating expenses are recorded in currencies other than the U.S.&#160;dollar. The value of revenues and operating expenses measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes, we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues and operating expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign currency forward contracts in effect as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, had durations of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;18&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months, respectively. These contracts have been designated as cash flow hedges and unrealized gains or losses on the portion of these foreign currency forward contracts that are included in the effectiveness test are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses of such contracts are recognized in revenues when the sale of product in the currency being hedged is recognized and in operating expenses when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from accumulated other comprehensive income and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that has been impacted by the hedged item.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Notional Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of&lt;br/&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Euro&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;2,477.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,892.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;British pound&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;125.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Swiss franc&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;69.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Japanese yen&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;53.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Canadian dollar&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;48.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total foreign currency forward contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;2,773.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,892.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net losses of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$16.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and net gains of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$0.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. We expect the net losses of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$16.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to be settled over the next &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;18&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months, of which &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$7.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of these losses are expected to be settled over the next &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenues or operating expenses. We consider the impact of our and our counterparties&#x2019; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, credit risk did not materially change the fair value of our foreign currency forward contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="19"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Operating Income (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;23.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;29.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="19"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Operating Income (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;50.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;44.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;7.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;7.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(1.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(1.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(1.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Interest Rate Contracts - Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have entered into interest rate lock contracts or interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes and to reduce our overall cost of borrowing. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Interest Rate Swap Contracts&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with the issuance of our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.90%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes due September 15, 2020, we entered into interest rate swaps with an aggregate notional amount of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$675.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which were originally set to expire on September 15, 2020. The interest rate swap contracts were designated as hedges of the fair value changes in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.90%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes attributable to changes in interest rates. The carrying value of our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.90%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, included approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$2.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to changes in the fair value of these interest rate swap contracts. In &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;May 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; we settled our interest rate swap contracts, in conjunction with our early redemption of our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.90%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes, resulting in a gain of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$3.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, and was recorded as a component of interest expense in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Net Investment Hedges - Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;49.9%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The share purchase transaction was completed in November 2018 and, upon closing, we paid &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;759.5 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$676.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) to Samsung BioLogics. Our investment in the equity of Samsung Bioepis is exposed to the currency fluctuations in the South Korean won. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In order to mitigate the currency fluctuations between the U.S. dollar and South Korean won, we have entered into foreign currency forward contracts. Foreign currency forward contracts in effect as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, had remaining durations of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;four&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months. These contracts have been designated as net investment hedges. We recognize changes in the spot exchange rate in accumulated other comprehensive income (loss). The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$13.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and net losses of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. We exclude fair value changes related to the forward rate from our hedging relationship and will amortize the forward points in other income (expense), net in our condensed consolidated statements of income over the term of the contract. The pre-tax portion of the fair value of the forward points that were included in accumulated other comprehensive income (loss) in total equity reflected gains of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$2.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables summarize the effect of our net investment hedge in our condensed consolidated financial statements:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="29"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:19%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="29" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Other Comprehensive Income (Effective Portion) (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Net Income &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Amounts Excluded from Effectiveness Testing) (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(8.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;11.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;3.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="29"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:19%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="29" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Other Comprehensive Income (Effective Portion) (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Net Income &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Amounts Excluded from Effectiveness Testing) (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;15.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;23.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;3.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;6.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;4.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our collaboration arrangements with Samsung Bioepis, please read &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Note 17, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Foreign Currency Forward Contracts - Other Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The aggregate notional amount of these outstanding foreign currency forward contracts was &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$999.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$793.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Net gains of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$8.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$5.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to these contracts were recorded as a component of other income (expense), net for the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, compared to net gains of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$0.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and net losses of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$3.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in the prior year comparative periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Summary of Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:39%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:30%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance Sheet Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of&lt;br/&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;"&gt;Cash Flow Hedging Instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Asset derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;32.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;33.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Investments and other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Liability derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Accrued expenses and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;4.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other long-term liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;9.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;"&gt;Net Investment Hedging Instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Asset derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;20.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;"&gt;Fair Value Hedging Instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Liability derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Accrued expenses and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;"&gt;Other Derivative Instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Asset derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;6.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;8.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Liability derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Accrued expenses and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-1EF122B3A676563A9F65EF4772265EA8-0-wk-Fact-31990A2A65895AAEB1A72F1B0ECA9813">&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Notional Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of&lt;br/&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Euro&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;2,477.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,892.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;British pound&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;125.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Swiss franc&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;69.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Japanese yen&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;53.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Canadian dollar&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;48.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total foreign currency forward contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;2,773.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,892.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2020Q2_srt_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d13672625e965-wk-Fact-E79B53C33305522AB94BCAF720489D1A"
      unitRef="usd">2477300000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2019Q4_srt_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d13672625e984-wk-Fact-41690C3B230B517299A814BF1D311471"
      unitRef="usd">1892400000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2020Q2_srt_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d13672625e1004-wk-Fact-8EEC2B35785A5042AC52DBA9D0F1E596"
      unitRef="usd">125100000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2019Q4_srt_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d13672625e1023-wk-Fact-C9C20FD4C46F53798E87696046D8B6F6"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2020Q2_srt_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d13672625e1048-wk-Fact-47CDF57957425818920D9643FDB0A89A"
      unitRef="usd">69000000.0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2019Q4_srt_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d13672625e1067-wk-Fact-3DE40B2FBE835DE3B9A4021FF6F78FDD"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2020Q2_srt_CurrencyAxis_currency_JPY_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d13672625e1092-wk-Fact-502A9E7CAD3355CFB049AC97D81E405E"
      unitRef="usd">53900000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2019Q4_srt_CurrencyAxis_currency_JPY_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d13672625e1111-wk-Fact-7D242D3320F65446BC33CBCEE56CE9E4"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2020Q2_srt_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d13672625e1136-wk-Fact-F76E3681D4635C24BC42C1BE5C267DC3"
      unitRef="usd">48100000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2019Q4_srt_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d13672625e1155-wk-Fact-14491AD02A625E5484239749CAE2702B"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2020Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d13672625e1185-wk-Fact-35234052AFDB5AAEAE1CAF544673AF34"
      unitRef="usd">2773400000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d13672625e1204-wk-Fact-EBE23851E52D51AD854DE3BEFC1FCF9D"
      unitRef="usd">1892400000</us-gaap:DerivativeNotionalAmount>
    <biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13672625e1224-wk-Fact-79B35DE3663D538184F4D3BB138079AD"
      unitRef="usd">-16800000</biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax>
    <biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13672625e1228-wk-Fact-4D7CB6EFE16C5E569E9A41416D0335E6"
      unitRef="usd">500000</biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax>
    <biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13672625e1240-wk-Fact-79B35DE3663D538184F4D3BB138079AD"
      unitRef="usd">-16800000</biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax>
    <biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="FI2020Q2_biib_DerivativeMaturityAxis_biib_ShorttermderivativeMember"
      decimals="-5"
      id="d13672625e1249-wk-Fact-E16E1C84B32E5C4A94AAE5C6DEF64925"
      unitRef="usd">-7900000</biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-1340D95C486E5A7A8A2F618E2D47C281-0-wk-Fact-858BA349FC5D52E2AC064B7ED6ECBF40">&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="19"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Operating Income (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;23.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;29.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="19"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Operating Income (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;50.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;44.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;7.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;7.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(1.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(1.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(1.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember"
      decimals="-5"
      id="d13672625e1620-wk-Fact-3767BCFD08C85D13A06680F269984D04"
      unitRef="usd">23700000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember"
      decimals="-5"
      id="d13672625e1639-wk-Fact-13526C547A7D5F02998F08D6D786A150"
      unitRef="usd">29800000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember"
      decimals="-5"
      id="d13672625e1669-wk-Fact-A30F1AB4506F51638795D6A0185F3C8B"
      unitRef="usd">-1600000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember"
      decimals="-5"
      id="d13672625e1689-wk-Fact-F00F7056A7C2594F97F18D18CC1C1A55"
      unitRef="usd">3700000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="d13672625e1709-wk-Fact-C7605F45AA5254A8B3AC204F44EB832A"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="d13672625e1728-wk-Fact-561943D4E08E5DD7B8052B3B979D2DD2"
      unitRef="usd">-700000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="d13672625e1759-wk-Fact-8DB80BC09BB1558FA5B0CB53D6CCA238"
      unitRef="usd">-200000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="d13672625e1779-wk-Fact-E04A1EFA510E55A7A94927BC826C9EB4"
      unitRef="usd">-300000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember"
      decimals="-5"
      id="d13672625e2138-wk-Fact-2B356EA89B99BD51FEEE5DE4B3293436"
      unitRef="usd">50700000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember"
      decimals="-5"
      id="d13672625e2157-wk-Fact-C3CFF6D7BC9FF8F82FBE5DE4B7D0D454"
      unitRef="usd">44600000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember"
      decimals="-5"
      id="d13672625e2187-wk-Fact-64888DFFAC7A5A4C2E0C5DE5151B44D8"
      unitRef="usd">7700000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember"
      decimals="-5"
      id="d13672625e2206-wk-Fact-FD0C3BC9E25F5DA63E4C5DE519D59555"
      unitRef="usd">7400000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="d13672625e2226-wk-Fact-9FB5EF5D5270723FE09A5DE4BE011C5C"
      unitRef="usd">-100000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="d13672625e2246-wk-Fact-84A80DDD500645CB84ED5DE4C31EA2E7"
      unitRef="usd">-1200000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="d13672625e2277-wk-Fact-59BCA3711DB74BF918EF5DE51DCE1B2E"
      unitRef="usd">-1100000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="d13672625e2297-wk-Fact-13851BBB1E9B3300B8885DE524EB0510"
      unitRef="usd">-1200000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"
      decimals="INF"
      id="d13672625e2328-wk-Fact-AB9F17C6602BF12CDF6F5DD4ABEB3A35"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2020Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d13672625e2332-wk-Fact-9CBCA90A2E5655C08B319903D59FE0E6"
      unitRef="usd">675000000.0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"
      decimals="INF"
      id="d13672625e2336-wk-Fact-AB9F17C6602BF12CDF6F5DD4ABEB3A35"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"
      decimals="INF"
      id="d13672625e2340-wk-Fact-AB9F17C6602BF12CDF6F5DD4ABEB3A35"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember"
      decimals="-5"
      id="d13672625e2349-wk-Fact-B3098F00AC015641A2D5CE3378F735CE"
      unitRef="usd">2300000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2020Q2_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"
      decimals="INF"
      id="d13672625e2363-wk-Fact-AB9F17C6602BF12CDF6F5DD4ABEB3A35"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember"
      decimals="-5"
      id="d13672625e2367-wk-Fact-EE52AF304708393DE47958A222652E72"
      unitRef="usd">3300000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction
      contextRef="FI2019Q2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="2"
      id="d13672625e2390-wk-Fact-37E261D9A6B958FBB0B52EE61E0050D1"
      unitRef="number">0.05</biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="FI2020Q2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="3"
      id="d13672625e2394-wk-Fact-68118BDBA14B59BAAE1CE2F32822EC68"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="D2018Q4Nov1-Nov30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-8"
      id="d13672625e2398-wk-Fact-CCB7C2B85AC35AB599BDF91D0763D35A"
      unitRef="KRW">759500000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="D2018Q4Nov1-Nov30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d13672625e2402-wk-Fact-AA624D37D2305267A7AC120F143579FD"
      unitRef="usd">676600000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d13672625e2417-wk-Fact-AC59343788525076AD4FC6245FE5AE0A"
      unitRef="usd">13900000</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d13672625e2421-wk-Fact-991D5352EDEFD51FD8815DE6DDB927DF"
      unitRef="usd">1500000</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax
      contextRef="FI2020Q2_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d13672625e2434-wk-Fact-7E2F30D75FDB5E379EE6DBF1AA81FED4"
      unitRef="usd">1100000</us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax>
    <us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax
      contextRef="FI2019Q4_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d13672625e2438-wk-Fact-99286567D4A35B2194FE58F51759D581"
      unitRef="usd">2900000</us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax>
    <us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-8EFB0D78065B544ABA27E883B374598E-0-wk-Fact-80FA21CE0C215B3CBCDBD563ACACE51E">&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables summarize the effect of our net investment hedge in our condensed consolidated financial statements:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="29"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:19%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="29" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Other Comprehensive Income (Effective Portion) (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Net Income &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Amounts Excluded from Effectiveness Testing) (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(8.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;11.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;3.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="29"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:19%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="29" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Other Comprehensive Income (Effective Portion) (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Net Income &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Amounts Excluded from Effectiveness Testing) (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;15.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;23.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;3.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;6.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;4.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d13672625e2972-wk-Fact-4AD74C71E8085B0786C90CE7A512BD90"
      unitRef="usd">-8800000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d13672625e2992-wk-Fact-ADD22A9C85E35D68A83D530480B684E2"
      unitRef="usd">11600000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease
      contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d13672625e3022-wk-Fact-F3D06CAF90795DD7925F82ABFD51FBF3"
      unitRef="usd">3500000</biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease>
    <biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease
      contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d13672625e3041-wk-Fact-615D2967C17A5266BA8EFC1429C5CB5F"
      unitRef="usd">2300000</biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2020Q2QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-5"
      id="d13672625e3071-wk-Fact-49EAF5EF61055920A924E3B2DECBADB7"
      unitRef="usd">800000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2019Q2QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-5"
      id="d13672625e3090-wk-Fact-5CE553BB11135F0185CAA1D5626366F8"
      unitRef="usd">2200000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d13672625e3612-wk-Fact-2826E72DC22A10CE8CBF5DE79B086C16"
      unitRef="usd">15400000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d13672625e3631-wk-Fact-F353E654ABB2E156277E5DE79DBDA46B"
      unitRef="usd">23400000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease
      contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d13672625e3661-wk-Fact-E1F593402B9A515BA3C05DE7A22CCBB8"
      unitRef="usd">3200000</biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease>
    <biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease
      contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d13672625e3680-wk-Fact-CA6FC6EF39FCC4EA0EC45DE7A4E72625"
      unitRef="usd">6700000</biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-5"
      id="d13672625e3710-wk-Fact-016C8B6C70AC4A6B3B8C5DE7A8061BC5"
      unitRef="usd">1700000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="FD2019Q2YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-5"
      id="d13672625e3729-wk-Fact-93CFCDA2EDEAE5CE71055DE7AB709EA2"
      unitRef="usd">4400000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2020Q2_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember"
      decimals="-5"
      id="d13672625e3757-wk-Fact-D46B11A0E7275AAFA7F9A40D6BC8E36A"
      unitRef="usd">999300000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2019Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember"
      decimals="-5"
      id="d13672625e3761-wk-Fact-7718B1EAE10E5BE79A6F2F3A36686D2E"
      unitRef="usd">793800000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13672625e3773-wk-Fact-35F5689C9E115EC0A3C8E6A489812EB4"
      unitRef="usd">8300000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13672625e3778-wk-Fact-3C2F2372D3836A323EBA5DED3886E08D"
      unitRef="usd">5900000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13672625e3794-wk-Fact-4B1D880A2260586FAE3DC85E5A2969A9"
      unitRef="usd">900000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13672625e3798-wk-Fact-7EBAA2F59C99293608115DED77600F27"
      unitRef="usd">-3900000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-E72D0DD3FE4250FFB1AE03A931C2D9AF-0-wk-Fact-489DF5D592895C3980440A569FDB0E78">&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:39%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:30%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance Sheet Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of&lt;br/&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;"&gt;Cash Flow Hedging Instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Asset derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;32.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;33.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Investments and other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Liability derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Accrued expenses and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;4.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other long-term liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;9.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;"&gt;Net Investment Hedging Instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Asset derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;20.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;"&gt;Fair Value Hedging Instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Liability derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Accrued expenses and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;"&gt;Other Derivative Instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Asset derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;6.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;8.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Liability derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Accrued expenses and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d13672625e3980-wk-Fact-84624AEC73575BA1AE3228FFB0E1B8EA"
      unitRef="usd">32200000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d13672625e3999-wk-Fact-95C18B44AB015C2FB310601AA99607C6"
      unitRef="usd">33800000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d13672625e4029-wk-Fact-4793A5F6EAD9528F80D840FD970DAE30"
      unitRef="usd">700000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d13672625e4048-wk-Fact-2692F55E3AB45DA6A57AE221C4DE299C"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d13672625e4083-wk-Fact-BEBA39AE0D8056778141B67755F09A2B"
      unitRef="usd">4400000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-5"
      id="d13672625e4102-wk-Fact-1CFB60B84D615D00B700E4BECBC75189"
      unitRef="usd">2000000.0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember"
      decimals="-5"
      id="d13672625e4137-wk-Fact-54273A6F3EA95F92BEAC819BB07EDD61"
      unitRef="usd">9000000.0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember"
      decimals="-5"
      id="d13672625e4156-wk-Fact-EE36E6BF3A3B5C9AB5799672083F48C2"
      unitRef="usd">1700000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d13672625e4303-wk-Fact-5A3B802DC4A051A1A487DFD5701EF22D"
      unitRef="usd">20700000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember"
      decimals="-5"
      id="d13672625e4322-wk-Fact-373E1458EB6550B79D635F3A3C0A1F68"
      unitRef="usd">2000000.0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember"
      decimals="-5"
      id="d13672625e4470-wk-Fact-FDCC2CEAD7E1577F8FB7CAC181C433AE"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember"
      decimals="-5"
      id="d13672625e4489-wk-Fact-B3098F00AC015641A2D5CE3378F735CE"
      unitRef="usd">2300000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember"
      decimals="-5"
      id="d13672625e4636-wk-Fact-FDB60388323457109F599F5057B1E633"
      unitRef="usd">6400000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember"
      decimals="-5"
      id="d13672625e4655-wk-Fact-BCB23D0E1FF0558D920D23380DF3494D"
      unitRef="usd">8000000.0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember"
      decimals="-5"
      id="d13672625e4690-wk-Fact-38E6893604E157B6B79408554A11D5DF"
      unitRef="usd">800000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember"
      decimals="-5"
      id="d13672625e4709-wk-Fact-29272D2A90B850B4B67A04D97C913229"
      unitRef="usd">2400000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-1881D073CD44514CBFA7E4FCA73F40B8-0-wk-Fact-7B540FAF09B959D6BF478245146E000F">&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1,687.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1,590.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, depreciation expense totaled &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$51.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$99.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, compared to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$47.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$99.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in the prior year comparative periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Solothurn, Switzerland Manufacturing Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In order to support our drug development pipeline, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be partially operational by the end of 2020. Upon completion, this facility will include 393,000 square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and 51,000 square feet of administrative space. As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1.7 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1.9 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, capitalized as construction in progress related to this facility. For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we placed approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$256.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of fixed assets in service related to this facility. As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had contractual commitments of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$16.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; outstanding related to the construction of this facility.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13668392e792-wk-Fact-7670470D20CA567F8D01C3A019548B51"
      unitRef="usd">1687000000.0</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13668392e796-wk-Fact-45EE64AD6B305C3FB9D619D80BADA52C"
      unitRef="usd">1590900000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:Depreciation
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13668392e827-wk-Fact-450352BC374651319FA896E754DE1059"
      unitRef="usd">51300000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13668392e831-wk-Fact-99D00901D5235202BF725DEFEB7E05F6"
      unitRef="usd">99700000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13668392e835-wk-Fact-A2F0B45383E5569D97491E98F1C8E84D"
      unitRef="usd">47000000.0</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13668392e839-wk-Fact-CBD77CAF33035CB7CF165DF01EFF0A6E"
      unitRef="usd">99900000</us-gaap:Depreciation>
    <us-gaap:ConstructionInProgressGross
      contextRef="FI2020Q2_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember"
      decimals="-8"
      id="d13668392e858-wk-Fact-9E8F08C69A4E5DFFA0EF337BBDAE5A3D"
      unitRef="usd">1700000000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="FI2019Q4_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember"
      decimals="-8"
      id="d13668392e862-wk-Fact-2B99CF5F8F0D5C37A7758CB12C4B1627"
      unitRef="usd">1900000000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2020Q2_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember"
      decimals="-5"
      id="d13668392e875-wk-Fact-AEFF4E8456B853E0B90DBAC33AC86C39"
      unitRef="usd">256800000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:OtherCommitment
      contextRef="FI2020Q2_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember"
      decimals="-5"
      id="d13668392e883-wk-Fact-666C54C1EFBE5374BE99D325B077D865"
      unitRef="usd">16200000</us-gaap:OtherCommitment>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-FAE2D5E4F7101ABB5AF358720F4BCD96-0-wk-Fact-13792A95824C4F13FBD65872D127FAC3">&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Indebtedness&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#006ebf;"&gt; &lt;/span&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;"&gt;2020 Senior Notes &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;April&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we issued senior unsecured notes for an aggregate principal amount of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$3.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; (2020 Senior Notes), consisting of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:0px;padding-top:8px;text-indent:30px;"&gt;&lt;span style="padding-top:8px;font-family:Franklin Gothic Book,sans-serif;font-size:10pt;padding-right:18px;"&gt;&#x2022;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;text-transform:default;"&gt;&lt;span&gt;$1.5 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;text-transform:default;"&gt;&lt;span&gt;2.25%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes due &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;text-transform:default;"&gt;May&#160;1, 2030&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, valued at &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;text-transform:default;"&gt;&lt;span&gt;99.973%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of par; and&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:0px;padding-top:8px;text-indent:30px;"&gt;&lt;span style="padding-top:8px;font-family:Franklin Gothic Book,sans-serif;font-size:10pt;padding-right:18px;"&gt;&#x2022;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;text-transform:default;"&gt;&lt;span&gt;$1.5 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;text-transform:default;"&gt;&lt;span&gt;3.15%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes due &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;text-transform:default;"&gt;May&#160;1, 2050&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, valued at &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book;font-size:10pt;text-transform:default;"&gt;&lt;span&gt;99.174%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of par.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our 2020 Senior Notes are senior unsecured obligations and may be redeemed at our option at any time at &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the principal amount plus accrued interest and, until a specified period before maturity, a specified make-whole amount. Our 2020 Senior Notes contain a change-of-control provision that, under certain circumstances, may require us to purchase our 2020 Senior Notes at a price equal to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;101%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the principal amount plus accrued and unpaid interest to the date of repurchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We incurred approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$24.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of costs associated with this offering which have been recorded as a reduction to the carrying amount of the debt on our condensed consolidated balance sheet. These costs will be amortized as additional interest expense using the effective interest rate method over the period from issuance through maturity. The discounts will be amortized as additional interest expense over the period from issuance through maturity using the effective interest rate method. Interest on our 2020 Senior Notes is payable &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;May 1&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;November 1&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of each year, commencing November 1, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;"&gt;2.90% Senior Notes due September 15, 2020 &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On September 15, 2015, we issued &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1.5 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; aggregate principal amount of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.90%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes due September 15, 2020, at &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;99.792%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of par. Our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.90%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes were senior unsecured obligations. We also entered into interest rate swap contracts where we received a fixed rate and paid a variable rate. In May 2020 we used the net proceeds from the sale of our 2020 Senior Notes to redeem our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.90%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes prior to their maturity and recognized a net pre-tax charge of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$9.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upon the extinguishment of these notes. This charge, which was recognized in interest expense in other income (expense), net in our condensed consolidated statements of income for the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, reflects the payment of a &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$12.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; early call premium and the write off of remaining unamortized original debt issuance costs and discount balances, partially offset by a &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$3.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; gain related to the settlement of the associated interest rate swap contracts. For additional information on our interest rate swap contracts, please read &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Note 9, Derivative Instruments&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="I2020Q1April30_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="d13672729e795-wk-Fact-3886DB8A1CA1AB4CFA015873BC68D740"
      unitRef="usd">3000000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="I2020Q1April30_us-gaap_DebtInstrumentAxis_biib_A2.25SeniorNotesdueMay12030Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="d13672729e804-wk-Fact-6C1E93ED5342363F19085876B03B0018"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="I2020Q1April30_us-gaap_DebtInstrumentAxis_biib_A2.25SeniorNotesdueMay12030Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="d13672729e808-wk-Fact-F434EC30234CEDDFA811587BB95607E7"
      unitRef="number">0.0225</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <biib:PercentageParValueOfSeniorNotes
      contextRef="I2020Q1April30_us-gaap_DebtInstrumentAxis_biib_A2.25SeniorNotesdueMay12030Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="d13672729e816-wk-Fact-A632471F8B3BD7A05EB05882D29FCD73"
      unitRef="number">0.99973</biib:PercentageParValueOfSeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="I2020Q1April30_us-gaap_DebtInstrumentAxis_biib_A3.15SeniorNotesdueMay12050Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="d13672729e825-wk-Fact-EB257EE1F85C1D8882145876C36D4020"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="I2020Q1April30_us-gaap_DebtInstrumentAxis_biib_A3.15SeniorNotesdueMay12050Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="d13672729e829-wk-Fact-B3880A9157B0B0E32107587BCA7230AB"
      unitRef="number">0.0315</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <biib:PercentageParValueOfSeniorNotes
      contextRef="I2020Q1April30_us-gaap_DebtInstrumentAxis_biib_A3.15SeniorNotesdueMay12050Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="d13672729e837-wk-Fact-9661B795479D4DBE09465883051D5DC5"
      unitRef="number">0.99174</biib:PercentageParValueOfSeniorNotes>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="FD2020Q2YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="d13672729e844-wk-Fact-2451513B60065839B0CC589BB4FC6623"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <biib:DebtInstrumentMakeWholeProvisionRedemptionPricePercentage
      contextRef="FD2020Q2YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="d13672729e848-wk-Fact-869397EDBCB674497B5B589C3531C9B3"
      unitRef="number">1.01</biib:DebtInstrumentMakeWholeProvisionRedemptionPricePercentage>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13672729e855-wk-Fact-DF9A9F54F7C54EB21E6758999F9D6AE4"
      unitRef="usd">24400000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="I2015Q3Sept152015_us-gaap_DebtInstrumentAxis_biib_A2.90SeniorNotesDueSept152020Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="d13672729e873-wk-Fact-39C934A246CA4D5C3A9F588885EC0C12"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="I2015Q3Sept152015_us-gaap_DebtInstrumentAxis_biib_A2.90SeniorNotesDueSept152020Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="d13672729e877-wk-Fact-1594FE42B75E5BEC18B658886DCC9002"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <biib:PercentageParValueOfSeniorNotes
      contextRef="I2015Q3Sept152015_us-gaap_DebtInstrumentAxis_biib_A2.90SeniorNotesDueSept152020Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="d13672729e881-wk-Fact-5BA8BD220699D3789C6D5888F69D6335"
      unitRef="number">0.99792</biib:PercentageParValueOfSeniorNotes>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="I2015Q3Sept152015_us-gaap_DebtInstrumentAxis_biib_A2.90SeniorNotesDueSept152020Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="d13672729e885-wk-Fact-1594FE42B75E5BEC18B658886DCC9002"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="I2015Q3Sept152015_us-gaap_DebtInstrumentAxis_biib_A2.90SeniorNotesDueSept152020Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="d13672729e889-wk-Fact-1594FE42B75E5BEC18B658886DCC9002"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <biib:PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain
      contextRef="FD2020Q2YTD_us-gaap_DebtInstrumentAxis_biib_A2.90SeniorNotesDueSept152020Member_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-5"
      id="d13672729e894-wk-Fact-CA36D5972BDEE72FE7EC58A93FA8DE47"
      unitRef="usd">9400000</biib:PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain>
    <biib:EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts
      contextRef="FD2020Q2YTD_us-gaap_DebtInstrumentAxis_biib_A2.90SeniorNotesDueSept152020Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-5"
      id="d13672729e910-wk-Fact-F02DC503537C4FDDACD058A7BEAFDF8E"
      unitRef="usd">12700000</biib:EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="FD2020Q2YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember"
      decimals="-5"
      id="d13672729e914-wk-Fact-EE52AF304708393DE47958A222652E72"
      unitRef="usd">3300000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-CD491248FF6B5C2D867D3BB2265A9032-0-wk-Fact-51E711DA3E8851F388489AC91AE602A8">&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Share Repurchases&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; our Board of Directors authorized a program to repurchase up to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$5.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of our common stock (&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Share Repurchase Program). Our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Share Repurchase Program does not have an expiration date. All shares repurchased under our December 2019 Share Repurchase Program will be retired. Under our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Share Repurchase Program, we repurchased and retired approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of our common stock at a cost of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$2.8 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$3.7 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; during the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1.3 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; remained available under our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Share Repurchase Program as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2019 our Board of Directors authorized a program to repurchase up to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$5.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of our common stock (March 2019 Share Repurchase Program), which was completed as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. All shares repurchased under our March 2019 Share Repurchase Program were retired. Under our March 2019 Share Repurchase Program, we repurchased and retired approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of our common stock at a cost of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1.3 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; during the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Accumulated Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:32%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains (Losses) on Net Investment Hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;4.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;7.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;25.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(32.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(139.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(135.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(9.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;33.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;18.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(47.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(3.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;9.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(50.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(1.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(42.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(17.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;16.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(47.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(45.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Balance, June 30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;5.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(9.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;41.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(31.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(186.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(181.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:32%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains (Losses) on Net Investment Hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Balance, December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(4.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;34.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;3.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(31.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(243.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(240.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;11.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;22.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;30.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(28.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;36.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(43.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(4.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(48.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;10.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(21.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;25.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(28.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(12.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Balance, June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;13.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;29.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(30.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(271.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(252.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the amounts reclassified from accumulated other comprehensive income:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="18"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:33%;"/&gt;&lt;td style="width:23%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Income Statement Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amounts Reclassified from Accumulated Other Comprehensive Income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Gains (losses) on securities available for sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;&lt;span&gt;3.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(12.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;&lt;span&gt;(0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;2.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Gains (losses) on cash flow hedges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;&lt;span&gt;23.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;29.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;50.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;44.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(1.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;&lt;span&gt;0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;4.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;&lt;span&gt;27.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;31.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;42.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;48.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="FI2019Q4_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember"
      decimals="-8"
      id="d13676089e797-wk-Fact-CF23E4E3A9685AB6B629BC240257914C"
      unitRef="usd">5000000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2020Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d13676089e814-wk-Fact-390A951FE1955FB1A31E81FF978C9087"
      unitRef="shares">9000000.0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d13676089e818-wk-Fact-7A124B06819E398E555A5E03FA91B3BA"
      unitRef="shares">12200000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="FD2020Q2QTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d13676089e822-wk-Fact-3B1EAB8C0D58511CBF78864485D99242"
      unitRef="usd">2800000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d13676089e826-wk-Fact-92A4C4D61C1BF2CC2D2A5E0415603F07"
      unitRef="usd">3700000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="FI2020Q2_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember"
      decimals="-8"
      id="d13676089e843-wk-Fact-2DB7A19C318A2D9085055E04F1B4B045"
      unitRef="usd">1300000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="FI2019Q2_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember"
      decimals="-8"
      id="d13676089e858-wk-Fact-A8D8625FFC4F5EEBB70EA51DB088EA1B"
      unitRef="usd">5000000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember"
      decimals="-5"
      id="d13676089e866-wk-Fact-C95D21032E095E8DE6D65E054A2E7081"
      unitRef="shares">4100000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="FD2020Q2YTD_us-gaap_ShareRepurchaseProgramAxis_biib_March2019ShareRepurchaseProgramMember"
      decimals="-8"
      id="d13676089e870-wk-Fact-BBC02EE20EDE393E40ED5E0577D4C6F5"
      unitRef="usd">1300000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-CBC5342090CE54FAA07C7D837655C9D9-0-wk-Fact-7BFA4E55863855648A4597A17FD6D21B">&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:32%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains (Losses) on Net Investment Hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;4.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;7.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;25.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(32.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(139.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(135.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(9.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;33.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;18.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(47.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(3.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;9.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(50.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(1.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(42.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(17.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;16.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(47.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(45.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Balance, June 30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;5.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(9.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;41.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(31.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(186.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(181.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:32%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains (Losses) on Net Investment Hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Balance, December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(4.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;34.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;3.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(31.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(243.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(240.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;11.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;22.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;30.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(28.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;36.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(43.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(4.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(48.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;10.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(21.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;25.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(28.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(12.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Balance, June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;13.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;29.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(30.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(271.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(252.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d13676089e1087-wk-Fact-1C7F6484D085544A9F5EFB7C6CE9977D"
      unitRef="usd">4200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d13676089e1106-wk-Fact-EB3F8539AFE258C9885D79C2166782EF"
      unitRef="usd">7800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d13676089e1126-wk-Fact-C4B90E05E2415FAC8164A240DD0A0249"
      unitRef="usd">25100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d13676089e1145-wk-Fact-5A76F385C5C9545CAB5AFA203382C731"
      unitRef="usd">-32800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d13676089e1165-wk-Fact-1F0DEF179FCF5EC4ABC1CBFDC4EBDBE4"
      unitRef="usd">-139500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13676089e1186-wk-Fact-234099FE917C5DC385F4BC4F97FA7712"
      unitRef="usd">-135200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d13676089e1207-wk-Fact-C992AF05983551B4BBD4B798A67B08F8"
      unitRef="usd">-9000000.0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d13676089e1227-wk-Fact-D92825315E8C569686D85D00371444AB"
      unitRef="usd">33200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d13676089e1246-wk-Fact-68548ED4811459E58DD9CC28269F0AA0"
      unitRef="usd">18600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d13676089e1266-wk-Fact-7260F0C1F57458C7A3A07F61C3B2ECAC"
      unitRef="usd">900000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d13676089e1285-wk-Fact-0AFA5C0058425F8486883359D9315E41"
      unitRef="usd">-47000000.0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13676089e1306-wk-Fact-4A58EB7BBED4C9DEF993597DCB7C9163"
      unitRef="usd">-3300000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d13676089e1332-wk-Fact-448B47C9E0FE5076A279C94F0C1C6C10"
      unitRef="usd">9900000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d13676089e1351-wk-Fact-B9C09693F0615DB28105559DC26DAD73"
      unitRef="usd">-50600000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d13676089e1371-wk-Fact-5598817093125E3EA145188128D379BA"
      unitRef="usd">-1800000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d13676089e1392-wk-Fact-8365D8DCEA67529992216145497936E4"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d13676089e1411-wk-Fact-CBAE1B669B9D5E4A911976017B9E5EA1"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13676089e1431-wk-Fact-98AA12E1F4E3FA935114597DCB902B96"
      unitRef="usd">-42500000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d13676089e1457-wk-Fact-FCDEE87D1CC8B6D80E49597DCB9D1164"
      unitRef="usd">900000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d13676089e1476-wk-Fact-808B8EC0E04ECFD582AF597DCB8048F0"
      unitRef="usd">-17400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d13676089e1496-wk-Fact-C8DB37BE8B88B7DB7DDF597DCBA1D2F0"
      unitRef="usd">16800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d13676089e1516-wk-Fact-4C02D6B1AD8C37C0D7E6597DCB741F4C"
      unitRef="usd">900000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d13676089e1535-wk-Fact-0BFEA12E5E6DEBE11E2C597DCB703334"
      unitRef="usd">-47000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13676089e1556-wk-Fact-41D6455C5A4252129BD8C5FF297E3741"
      unitRef="usd">-45800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d13676089e1587-wk-Fact-46191F5FB667FEBF5160597DCB94E324"
      unitRef="usd">5100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d13676089e1606-wk-Fact-158091AC18BE8A5D10C4597DCB6BCBEE"
      unitRef="usd">-9600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d13676089e1627-wk-Fact-ED36E2C37B7FF2F1C87A597DCB871AE5"
      unitRef="usd">41900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d13676089e1646-wk-Fact-9DD578EFD5B8F7DCE6BD597DCB985E05"
      unitRef="usd">-31900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d13676089e1666-wk-Fact-258B6D72D3C8027B9D70597DCB8B307A"
      unitRef="usd">-186500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13676089e1687-wk-Fact-FAED6FE93C26545A877123C092DC11AC"
      unitRef="usd">-181000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d13676089e1877-wk-Fact-1041573FE2A15781906A192892E471F9"
      unitRef="usd">-4000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d13676089e1897-wk-Fact-8BD9E5866D9350ACAC3EA0A4A9D9D608"
      unitRef="usd">34700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d13676089e1917-wk-Fact-81AC3A3FBE1D531181A1F4E68B85890C"
      unitRef="usd">3500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d13676089e1936-wk-Fact-786F84546A795322B19367D937E68CFE"
      unitRef="usd">-31300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d13676089e1956-wk-Fact-B029EA30C01E5E00A9803B41BF6B392F"
      unitRef="usd">-243300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4"
      decimals="-5"
      id="d13676089e1977-wk-Fact-AAF053D70C055B0286050E7AA13AE9A7"
      unitRef="usd">-240400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d13676089e1998-wk-Fact-D18F3861D7135E0AAF2605FBE7E8314A"
      unitRef="usd">11000000.0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d13676089e2017-wk-Fact-25F367A06ED15BB195E41FE14730BDCC"
      unitRef="usd">22300000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d13676089e2036-wk-Fact-2B55E7C594585AA4A1ADD7AA4233E527"
      unitRef="usd">30100000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d13676089e2056-wk-Fact-0FA78CA32CBC55259C097355931CB5A4"
      unitRef="usd">700000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d13676089e2075-wk-Fact-0F56E7949FAA530DA33D2EB227D92900"
      unitRef="usd">-28100000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13676089e2096-wk-Fact-050A860F478142803FF8597DE0AA0918"
      unitRef="usd">36000000.0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d13676089e2121-wk-Fact-85CC27470BDC5138838F02286BC760EE"
      unitRef="usd">-800000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d13676089e2141-wk-Fact-381C985621EB57D58E4437F211B196E0"
      unitRef="usd">-43300000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d13676089e2161-wk-Fact-6828BC38D7025DFFAB3C82077250795B"
      unitRef="usd">-4400000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d13676089e2182-wk-Fact-89290E1A9C585B77A343B468B9AF1F2B"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d13676089e2201-wk-Fact-65BE63C3F36457279D2933E065B92CF7"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13676089e2221-wk-Fact-29C59C9A341977C9D0D5597DE0BB765A"
      unitRef="usd">-48500000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d13676089e2247-wk-Fact-F07F9A84714B2655533E597DE0A47986"
      unitRef="usd">10200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d13676089e2266-wk-Fact-F7F2711431F1F9CBB93E597DE1419134"
      unitRef="usd">-21000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d13676089e2286-wk-Fact-E1C0757745C4D3992993597DE11732A9"
      unitRef="usd">25700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d13676089e2306-wk-Fact-E26A696F704B64C8DCE9597DE12B9AC3"
      unitRef="usd">700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d13676089e2325-wk-Fact-2D021B78D5A28A0756CB597DE151D9A9"
      unitRef="usd">-28100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13676089e2346-wk-Fact-6F359B4ACF055A4DA4E8C22AC9182DDB"
      unitRef="usd">-12500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d13676089e2377-wk-Fact-DD691984067283BA036D597DE0F4766D"
      unitRef="usd">6200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d13676089e2396-wk-Fact-6957A694D8D88646D706597DE1673CD5"
      unitRef="usd">13700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d13676089e2416-wk-Fact-DBE40AC1A4D3EA3C645B597DE0AEAD0D"
      unitRef="usd">29200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"
      decimals="-5"
      id="d13676089e2435-wk-Fact-174252CB0BA9320B5DCC597DE0B6B7AD"
      unitRef="usd">-30600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-5"
      id="d13676089e2455-wk-Fact-3A528888578747788A59597DE0B29D66"
      unitRef="usd">-271400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q2"
      decimals="-5"
      id="d13676089e2476-wk-Fact-BBCF323C5FF952B894C29C4F6E74AF41"
      unitRef="usd">-252900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-FFD064FD103C5E279CA43DBAF1AE10C9-0-wk-Fact-8741B41C209F53689FB933FF779B7147">&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the amounts reclassified from accumulated other comprehensive income:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="18"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:33%;"/&gt;&lt;td style="width:23%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Income Statement Location&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amounts Reclassified from Accumulated Other Comprehensive Income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Gains (losses) on securities available for sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;&lt;span&gt;3.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(12.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;&lt;span&gt;(0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;2.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Gains (losses) on cash flow hedges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;&lt;span&gt;23.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;29.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;50.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;44.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(1.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;&lt;span&gt;0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;4.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;&lt;span&gt;27.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;31.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;42.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;48.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2020Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d13676089e2826-wk-Fact-7C98812BD9C55A3680E2B7C16042BEBD"
      unitRef="usd">3900000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d13676089e2845-wk-Fact-C3777DA0F08A51D59A7D9CED3F086E89"
      unitRef="usd">700000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2020Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d13676089e2865-wk-Fact-A036B8B89A065C99BDC8EA95A7667A7B"
      unitRef="usd">-12500000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d13676089e2885-wk-Fact-F7FA80F64E4952D3971F0065F0AD8C44"
      unitRef="usd">1000000.0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2020Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d13676089e2910-wk-Fact-FC3592B48C7C5AF3826B00DB3958AF65"
      unitRef="usd">-800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d13676089e2930-wk-Fact-BDD82F2A54975ABA803E435910753E54"
      unitRef="usd">-100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2020Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d13676089e2951-wk-Fact-F96EBEC3A68F5A1FAB547270FC8B9180"
      unitRef="usd">2600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-5"
      id="d13676089e2970-wk-Fact-D8186826F1365E6ABDE9F45EEA4E23C9"
      unitRef="usd">-200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d13676089e3093-wk-Fact-0D9917016FF15EEE925FC6551CA1F796"
      unitRef="usd">23700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d13676089e3112-wk-Fact-9EB84A7AE5505D85B00F9704E72A3A90"
      unitRef="usd">-29800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d13676089e3132-wk-Fact-53D75AB628395BDF905D547FC658B688"
      unitRef="usd">50700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d13676089e3151-wk-Fact-10B4FA2B88F85E40923BF367D6DBFA73"
      unitRef="usd">-44600000</us-gaap:Revenues>
    <us-gaap:OperatingExpenses
      contextRef="FD2020Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d13676089e3181-wk-Fact-90F5E68154E75D269BB60DDF32CF6EF7"
      unitRef="usd">0</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d13676089e3200-wk-Fact-8B96F1DF45295E458832136583101405"
      unitRef="usd">700000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="FD2020Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d13676089e3221-wk-Fact-CAF5B802D2395A978D5ED4FFED7435B2"
      unitRef="usd">100000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d13676089e3241-wk-Fact-499900F0D06C57429F53493CE85D791C"
      unitRef="usd">-1200000</us-gaap:OperatingExpenses>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2020Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d13676089e3272-wk-Fact-BFFC69DF9D9457C1A803555D0E73B584"
      unitRef="usd">100000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d13676089e3291-wk-Fact-ACEA7E804C3D5837A99AA2061B8CFDCB"
      unitRef="usd">0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2020Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d13676089e3311-wk-Fact-5318AA7C816D5151B0E5BF2F299A4EF6"
      unitRef="usd">200000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d13676089e3330-wk-Fact-D0F104797E16511797E21A10633E535A"
      unitRef="usd">100000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2020Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d13676089e3360-wk-Fact-EA22EB726DAF52C8A03DB2090AD3D489"
      unitRef="usd">-100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d13676089e3380-wk-Fact-A219BE61A8F0553A9C790FE06336C782"
      unitRef="usd">-100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2020Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d13676089e3401-wk-Fact-1B3ACC4F15585F6CA57981CEFFB983F9"
      unitRef="usd">-200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-5"
      id="d13676089e3421-wk-Fact-9B44200CC55F58A0A610CB5F4D7A61D1"
      unitRef="usd">-200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2020Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d13676089e3545-wk-Fact-8AA5F7E66EF95B18A3D3729FC95847A0"
      unitRef="usd">900000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d13676089e3564-wk-Fact-ADE4C70C5903504EBB8F4BC1ECEAE3B9"
      unitRef="usd">2200000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2020Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d13676089e3584-wk-Fact-DF4CE364648F500B9B9FC86411B33B8F"
      unitRef="usd">1800000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-5"
      id="d13676089e3603-wk-Fact-E22EFBD831DE5EB0B70242D19773F266"
      unitRef="usd">4400000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d13676089e3730-wk-Fact-DCA87853E94759E6890524BF606681B5"
      unitRef="usd">27700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d13676089e3749-wk-Fact-9EBCFEF7A8F454238AC4B381BE7BC6D7"
      unitRef="usd">31800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d13676089e3769-wk-Fact-17AC087A2DF555738B92BC2BD4CEF45B"
      unitRef="usd">42500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="-5"
      id="d13676089e3788-wk-Fact-0C196FC2151D53D18666DE4B6452A52D"
      unitRef="usd">48500000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-7804D1E00F3E5AA0AC274D533132565C-0-wk-Fact-5FD3FE4176E159F0B78F1B77DFA0B630">&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic and diluted earnings per share are calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:42%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;"&gt;Numerator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Net income attributable to Biogen Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,542.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,494.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;2,941.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2,902.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;"&gt;Denominator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;160.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;190.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;166.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;193.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Market stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Dilutive potential common shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Shares used in calculating diluted earnings per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;160.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;190.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;167.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;193.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-A06BD5DCC9955CA69500EDEC21DEA1D2-0-wk-Fact-0FDDE133DEB655BBAA520013E26645EE">&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic and diluted earnings per share are calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:42%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;"&gt;Numerator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Net income attributable to Biogen Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1,542.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,494.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;2,941.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2,902.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;"&gt;Denominator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;160.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;190.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;166.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;193.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Market stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Dilutive potential common shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Shares used in calculating diluted earnings per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;160.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;190.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;167.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;193.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13677347e1108-wk-Fact-ADD31A6A5EBE5E7D8A2551FB858970C3"
      unitRef="usd">1542100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13677347e1127-wk-Fact-014416A7DF4E55AD89901C62A077D0C5"
      unitRef="usd">1494100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13677347e1147-wk-Fact-B46E75E522BC521D944CD595197A0DA3"
      unitRef="usd">2941200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13677347e1166-wk-Fact-91FF827803B156BD8E311A0B778D9521"
      unitRef="usd">2902900000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13677347e1273-wk-Fact-99FE479F6EFA52F59E2D3DD5A91BFF8C"
      unitRef="shares">160600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13677347e1292-wk-Fact-0F8F00DB70B25725BDF588003BE32027"
      unitRef="shares">190300000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13677347e1311-wk-Fact-A7BA3E1F65C655ACB63EFBEDF4E5AE60"
      unitRef="shares">166700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13677347e1331-wk-Fact-22C74589209D549881B0B30906FF83A7"
      unitRef="shares">193400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2020Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="-5"
      id="d13677347e1443-wk-Fact-EE82D1472EEE5086858B770F2D5CBB67"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="-5"
      id="d13677347e1462-wk-Fact-32875F48EDE1584C8B7174F6BB2B912E"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2020Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="-5"
      id="d13677347e1481-wk-Fact-78259022B47A56FF92F25CF2C6770B6F"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="-5"
      id="d13677347e1501-wk-Fact-ACD45666C6C3533B9D213900413EBB9A"
      unitRef="shares">200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2020Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember"
      decimals="-5"
      id="d13677347e1526-wk-Fact-294FBB18C1405844B7D5BF66DCAD0B7E"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember"
      decimals="-5"
      id="d13677347e1545-wk-Fact-4EEA905124E356958373DBE14037822C"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2020Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember"
      decimals="-5"
      id="d13677347e1564-wk-Fact-6C0EECD7A6FA5E67ADEAC4A2741365A9"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember"
      decimals="-5"
      id="d13677347e1584-wk-Fact-697BE0A70EEB5BBEBC574F511B547C79"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2020Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember"
      decimals="-5"
      id="d13677347e1609-wk-Fact-79065ED115955ED897549FE4F81D8C42"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember"
      decimals="-5"
      id="d13677347e1628-wk-Fact-B2FAE05A4326537198DB746D8B3E4973"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2020Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember"
      decimals="-5"
      id="d13677347e1647-wk-Fact-B2BE8F3296765860BBE6B83DF15F1849"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember"
      decimals="-5"
      id="d13677347e1667-wk-Fact-FA3D4412C1BC5CBC89AC58C3D0F2BFC0"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13677347e1692-wk-Fact-8EED78D1E5385EF9AFDDD4CFC93C1982"
      unitRef="shares">300000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13677347e1711-wk-Fact-039C3ECB0BBA58DF96A44ABD1F14F475"
      unitRef="shares">100000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13677347e1730-wk-Fact-3E942606560D5FD29F1A901AF4C32ACE"
      unitRef="shares">300000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13677347e1750-wk-Fact-DCE7B5C2C4365729BD614883A3282DAB"
      unitRef="shares">300000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13677347e1776-wk-Fact-AC9CFA06C14752C2822D10FC87E8F4FE"
      unitRef="shares">160900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13677347e1795-wk-Fact-AD06855122DD55CAA38318A14B520635"
      unitRef="shares">190400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13677347e1814-wk-Fact-8008A00FC876554890ED4AD4AC163885"
      unitRef="shares">167000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13677347e1834-wk-Fact-85F20EFF251E5B3C9894F550494B41BA"
      unitRef="shares">193700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-172B5C53A54C559DB9E6FAE51D3E04E9-0-wk-Fact-EB93B31FF80259B889D848B8922E6F64">&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Share-based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Research and development &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;15.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;28.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;48.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;49.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;30.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;54.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;73.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;82.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Subtotal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;45.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;82.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;121.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;132.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Capitalized share-based compensation costs &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(2.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(3.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(6.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;44.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;80.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;118.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;126.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Income tax effect&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(7.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(13.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(20.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(21.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;37.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;66.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;98.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;105.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Market stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;7.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;7.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;26.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;15.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;34.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;31.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;72.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;66.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Cash settled performance units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Performance units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;2.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;12.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;12.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;14.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Performance stock units settled in cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(4.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;4.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;5.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;3.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;7.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;8.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;NST stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;26.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;26.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Subtotal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;45.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;82.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;121.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;132.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Capitalized share-based compensation costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(2.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(3.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(6.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;44.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;80.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;118.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;126.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We estimate the fair value of our obligations associated with our performance units, cash settled performance units and performance stock units settled in cash at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recognized each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-DAF16CD844825DDB9C5F5806BF1D6DD5-0-wk-Fact-8E4D21CB0E2F5147880BC5CD333A728D">&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Research and development &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;15.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;28.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;48.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;49.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;30.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;54.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;73.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;82.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Subtotal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;45.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;82.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;121.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;132.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Capitalized share-based compensation costs &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(2.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(3.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(6.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;44.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;80.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;118.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;126.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Income tax effect&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(7.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(13.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(20.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(21.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;37.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;66.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;98.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;105.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="d13679699e1024-wk-Fact-6F0EE9D9CC055AE6B40BBE0098CC11E2"
      unitRef="usd">15200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="d13679699e1043-wk-Fact-C1C0514934005EFABD6C8C3D0E20CC0D"
      unitRef="usd">28100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="d13679699e1063-wk-Fact-CD4D37A660DF511FAEB66794ECD5173A"
      unitRef="usd">48500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="d13679699e1082-wk-Fact-ECEE7AB4F7E050F096F7F4D763DE4F9F"
      unitRef="usd">49800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-5"
      id="d13679699e1102-wk-Fact-3301A243A337595A9DB194D7950ECE75"
      unitRef="usd">30300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-5"
      id="d13679699e1121-wk-Fact-2B1FCDA23A37514DABA1489825AE872D"
      unitRef="usd">54800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-5"
      id="d13679699e1140-wk-Fact-64B7FA0BE7D2559194E777FF49F5A500"
      unitRef="usd">73400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-5"
      id="d13679699e1160-wk-Fact-4C9121A9138754FC937EF4B84C51B8C9"
      unitRef="usd">82600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13679699e1185-wk-Fact-8EA981E4D98A5A099ACA6B24DC1286A5"
      unitRef="usd">45500000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13679699e1204-wk-Fact-592AF4FF64B35A8EA4C153DB3223137B"
      unitRef="usd">82900000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13679699e1223-wk-Fact-67DA7FAD963E5D1D87A5D89B29C0F5B9"
      unitRef="usd">121900000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13679699e1243-wk-Fact-5F62E4814ABF5A718CC5F44D3C530D4A"
      unitRef="usd">132400000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13679699e1268-wk-Fact-3D7317494E4A5633B55AD6AB4F63D387"
      unitRef="usd">1500000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13679699e1288-wk-Fact-44C5303F9BC55A3F96F5DC0EB810FD82"
      unitRef="usd">2800000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13679699e1308-wk-Fact-EE13EA9512525311AC0D9E39B22F62D3"
      unitRef="usd">3000000.0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13679699e1329-wk-Fact-472F6A1BAC9559D2AEC69ABA07E98C09"
      unitRef="usd">6100000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13679699e1355-wk-Fact-AD224E7CB4805A5FBC9500475B9AAFC0"
      unitRef="usd">44000000.0</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13679699e1374-wk-Fact-4A41B0FD52F95ABF92BBC48DDDFD9CB0"
      unitRef="usd">80100000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13679699e1393-wk-Fact-7FE99B8B62FA52D49EDD3A5E6484D786"
      unitRef="usd">118900000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13679699e1413-wk-Fact-FFCBA5223E3E519C81540A974D332931"
      unitRef="usd">126300000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13679699e1438-wk-Fact-4FF875876C1D51EEB39DC55F57FACA47"
      unitRef="usd">7000000.0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13679699e1458-wk-Fact-105DFF199D795062815E40395EEAAAE0"
      unitRef="usd">13600000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13679699e1478-wk-Fact-1F14E7E6231554EFAC6FC00CA7C91AFD"
      unitRef="usd">20300000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13679699e1499-wk-Fact-B8A211784AB255B29DE39523CFB3ED99"
      unitRef="usd">21000000.0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d13679699e1530-wk-Fact-49A48BABBFA950E6B7E23888FF5918A2"
      unitRef="usd">37000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d13679699e1549-wk-Fact-FD7ADE6AF913518298810363D85AD384"
      unitRef="usd">66500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d13679699e1569-wk-Fact-BDEB358E43DF555BB2D7F05993D0BC1A"
      unitRef="usd">98600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember"
      decimals="-5"
      id="d13679699e1588-wk-Fact-3AC3B690105754F2AEC2AA582783EEB9"
      unitRef="usd">105300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-6483417850755B359E8D98C62FE62932-0-wk-Fact-7B79C7B3B3BA53FFBADDB0E790AF6DB8">&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Market stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;7.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;7.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;26.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;15.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;34.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;31.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;72.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;66.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Cash settled performance units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Performance units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;2.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;12.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;12.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;14.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Performance stock units settled in cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(4.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;4.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;5.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;3.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;7.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;8.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;NST stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;26.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;26.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Subtotal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;45.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;82.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;121.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;132.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Capitalized share-based compensation costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(2.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(3.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(6.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;44.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;80.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;118.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;126.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q2QTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="-5"
      id="d13679699e1833-wk-Fact-A0BF9F0519B35DF3BB36BF4C267C5BB6"
      unitRef="usd">7400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="-5"
      id="d13679699e1852-wk-Fact-CC1A4774D5A85E7EA463EF154E51EBB4"
      unitRef="usd">7800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q2YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="-5"
      id="d13679699e1872-wk-Fact-690824FCCBBF5E5CB7382AC36D943B5D"
      unitRef="usd">26500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember"
      decimals="-5"
      id="d13679699e1891-wk-Fact-4A98695537525365AEE844A787424297"
      unitRef="usd">15500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q2QTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="-5"
      id="d13679699e1911-wk-Fact-EC70A411CD7253E5A323D25C919302CB"
      unitRef="usd">34500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="-5"
      id="d13679699e1930-wk-Fact-40833D7E05615B98AE18285E3FD4EA80"
      unitRef="usd">31800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q2YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="-5"
      id="d13679699e1949-wk-Fact-B49AB36CE73C57338E2408D24B2B66DA"
      unitRef="usd">72000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember"
      decimals="-5"
      id="d13679699e1969-wk-Fact-333A17E571065DBEBEECCA61DCE799CE"
      unitRef="usd">66500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q2QTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember"
      decimals="-5"
      id="d13679699e1994-wk-Fact-1135BFF18CF756A2A1855A79C00FB356"
      unitRef="usd">-100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember"
      decimals="-5"
      id="d13679699e2014-wk-Fact-89E00B5AAB1B51FC92BFAE7DF55BEF23"
      unitRef="usd">400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q2YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember"
      decimals="-5"
      id="d13679699e2033-wk-Fact-E6C917D2B4BE5EB88D33987048EF4C7C"
      unitRef="usd">-1700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember"
      decimals="-5"
      id="d13679699e2054-wk-Fact-4B79B1F4651F5B20BD6F062237A47D84"
      unitRef="usd">-600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q2QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="-5"
      id="d13679699e2080-wk-Fact-0579BB5F4FEC5EB2BBCAAB0584608067"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="-5"
      id="d13679699e2099-wk-Fact-362AF416DB1E519EB26928C518469988"
      unitRef="usd">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q2YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="-5"
      id="d13679699e2118-wk-Fact-6E51247FE5A55F89B409DF3A666E7193"
      unitRef="usd">-100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="-5"
      id="d13679699e2139-wk-Fact-8119EB47A1C4593EB7BA2CA76F1EF947"
      unitRef="usd">800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q2QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember"
      decimals="-5"
      id="d13679699e2164-wk-Fact-BF1E1722FF74563BBC33076F134384DB"
      unitRef="usd">2100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember"
      decimals="-5"
      id="d13679699e2183-wk-Fact-0BFC53768E3E5F2EB5F07CB3BFC08899"
      unitRef="usd">12100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q2YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember"
      decimals="-5"
      id="d13679699e2202-wk-Fact-782CBEBF0FC75D92A0FDBB8FE8932118"
      unitRef="usd">12400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember"
      decimals="-5"
      id="d13679699e2222-wk-Fact-590E627D7B125D57961C04F49B6F122B"
      unitRef="usd">14100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q2QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember"
      decimals="-5"
      id="d13679699e2247-wk-Fact-586343B3C8C45292AFE900B155BC88DD"
      unitRef="usd">-4000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember"
      decimals="-5"
      id="d13679699e2267-wk-Fact-028C840C1DD455A090BAEC0D538F38BC"
      unitRef="usd">900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q2YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember"
      decimals="-5"
      id="d13679699e2286-wk-Fact-8949766D093158D18144FA44A011D330"
      unitRef="usd">4900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember"
      decimals="-5"
      id="d13679699e2306-wk-Fact-985D5CB42AB15DBCAA602A89B1A9627E"
      unitRef="usd">1900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q2QTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember"
      decimals="-5"
      id="d13679699e2331-wk-Fact-719D9102E96C59299B20C120962B486F"
      unitRef="usd">5600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember"
      decimals="-5"
      id="d13679699e2350-wk-Fact-91F5F3544C1A56BF9F3EE1107E183224"
      unitRef="usd">3400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q2YTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember"
      decimals="-5"
      id="d13679699e2369-wk-Fact-9878FD3EE134508089895B00D7CA8DE2"
      unitRef="usd">7900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember"
      decimals="-5"
      id="d13679699e2389-wk-Fact-4745882D05985364B64C16EAA6CB5094"
      unitRef="usd">8000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="FD2020Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d13679699e2414-wk-Fact-496FBECDDB8953098A1DCC88C4EA04F0"
      unitRef="usd">0</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d13679699e2433-wk-Fact-7002510126925A2FA31C60CCC5FADD9C"
      unitRef="usd">26200000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="FD2020Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d13679699e2452-wk-Fact-03518CED06F25ABDB8ACBE30AA610FC1"
      unitRef="usd">0</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_BusinessAcquisitionAxis_biib_NightstarMember"
      decimals="-5"
      id="d13679699e2472-wk-Fact-814CE5E44C66528D8A499D9C4FED73A7"
      unitRef="usd">26200000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13679699e2497-wk-Fact-8EA981E4D98A5A099ACA6B24DC1286A5"
      unitRef="usd">45500000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13679699e2516-wk-Fact-592AF4FF64B35A8EA4C153DB3223137B"
      unitRef="usd">82900000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13679699e2535-wk-Fact-67DA7FAD963E5D1D87A5D89B29C0F5B9"
      unitRef="usd">121900000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13679699e2555-wk-Fact-5F62E4814ABF5A718CC5F44D3C530D4A"
      unitRef="usd">132400000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13679699e2581-wk-Fact-3D7317494E4A5633B55AD6AB4F63D387"
      unitRef="usd">1500000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13679699e2601-wk-Fact-44C5303F9BC55A3F96F5DC0EB810FD82"
      unitRef="usd">2800000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13679699e2621-wk-Fact-EE13EA9512525311AC0D9E39B22F62D3"
      unitRef="usd">3000000.0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13679699e2642-wk-Fact-472F6A1BAC9559D2AEC69ABA07E98C09"
      unitRef="usd">6100000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13679699e2673-wk-Fact-AD224E7CB4805A5FBC9500475B9AAFC0"
      unitRef="usd">44000000.0</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13679699e2692-wk-Fact-4A41B0FD52F95ABF92BBC48DDDFD9CB0"
      unitRef="usd">80100000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13679699e2712-wk-Fact-7FE99B8B62FA52D49EDD3A5E6484D786"
      unitRef="usd">118900000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13679699e2731-wk-Fact-FFCBA5223E3E519C81540A974D332931"
      unitRef="usd">126300000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-2250ACC617E95B4493181C83C8E519F9-0-wk-Fact-9B37EC344EB054D8878CA1A51F55697A">&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Coronavirus Aid, Relief and Economic Security Act&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In response to the COVID-19 pandemic, the Coronavirus Aid, Relief and Economic Security Act (CARES Act) was signed into law in the U.S. in March 2020. The CARES Act lifts certain deduction limitations originally imposed by the Tax Cuts and Jobs Act of 2017 (2017 Tax Act). Corporate taxpayers may carryback net operating losses (NOLs) originating during 2018 through 2020 for up to five years, which was not previously allowed under the 2017 Tax Act. The CARES Act also eliminates the 80% of taxable income limitations by allowing corporate entities to fully utilize NOL carryforwards to offset taxable income in 2018, 2019 or 2020. Taxpayers may generally deduct interest up to the sum of 50% of adjusted taxable income plus business interest income (30% limit under the 2017 Tax Act) for tax years beginning January 1, 2019 and 2020. The CARES Act allows taxpayers with alternative minimum tax credits to claim a refund in 2020 for the entire amount of the credits instead of recovering the credits through refunds over a period of years, as originally enacted by the 2017 Tax Act.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition, the CARES Act raises the corporate charitable deduction limit to 25% of taxable income and makes qualified improvement property generally eligible for 15-year cost-recovery and 100% bonus depreciation. The enactment of the CARES Act did not result in any material adjustments to our income tax provision for the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, or to our net deferred tax assets as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;TECFIDERA&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On June 22, 2020, the U.S. District Court for the Northern District of West Virginia (the West Virginia Court)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;entered judgment for Mylan Pharmaceuticals, Inc. (Mylan) that the asserted claims of our U.S. Patent No. 8,399,514&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(the '514 Patent) are invalid for lack of written description. The '514 Patent covers treatment of MS with 480 mg of&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;dimethyl fumarate per day as provided for in our TECFIDERA label, and the litigation was filed pursuant to the Drug&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act. We appealed the&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;judgment on June 23, 2020, to the U.S. Court of Appeals for the Federal Circuit (Federal Circuit) and filed an&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;emergency motion for an injunction pending resolution of the appeal. On June 30, 2020, the Federal Circuit entered&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;an interim injunction enjoining Mylan from launching its generic version of TECFIDERA pending the Federal Circuit's&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;consideration of our request for an injunction pending appeal. In the event that our request for an injunction pending appeal is denied, generic entry could occur during the appeal. &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;"&gt;The commercialization of a generic version of TECFIDERA would have an adverse impact on our TECFIDERA sales and our results of operations.&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we have assessed the realizability of our deferred tax assets that are dependent on future expected sales of TECFIDERA in the U.S. and reduced the value of certain deferred tax assets by approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1,324.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and reduced the value of deferred tax liabilities associated with global intangible low-taxed income (GILTI) and tax credits by approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1,268.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the income tax expense associated with these reductions was approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$56.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. For additional information, please read &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Note 19, Litigation&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Tax Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Statutory rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;21.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;21.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;21.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;21.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;State taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Taxes on foreign earnings&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(3.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(4.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(3.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(4.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Tax credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Purchased intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Divestiture of Denmark manufacturing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Internal reorganization of certain intellectual property rights&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(5.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(2.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;TECFIDERA impairment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;2.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;GILTI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other permanent items&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Effective tax rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;21.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;14.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;19.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;18.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:17px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;"&gt;Changes in Tax Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, compared to the same period in &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;"&gt; the increase in our effective tax rate was primarily due to an internal reorganization of certain intellectual property rights related to the intercompany sale of the intellectual property in 2019 and the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$56.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;"&gt;income tax expense related to the establishment of a valuation allowance against certain deferred tax assets, the realization of which is dependent on future sales of TECFIDERA in the U.S.&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, as discussed above. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, compared to the same period in &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;"&gt;the increase in our effective tax rate was primarily due to the impacts of the valuation allowance described above and the internal reorganization of certain intellectual property rights, partially offset by the&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$61.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; tax expense recognized in &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;"&gt;related to the planned divestiture of our Hiller&#xf8;d, Denmark manufacturing operations. Although we recognized a loss on the divestiture of our Hiller&#xf8;d, Denmark manufacturing operations, the divestiture required us to write off certain deferred tax assets and resulted in a taxable gain in certain jurisdictions.&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As a result of the internal reorganization of certain intellectual property rights, we recorded a deferred tax asset of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$856.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and a deferred tax liability of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$685.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Accounting for Uncertainty in Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2013 or state, local or non-U.S. income tax examinations for years before 2012.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In April 2020 we became aware of a withholding tax regulation that could be interpreted to apply to certain of our previous transactions. As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we have recorded an immaterial reserve reflecting this uncertain tax position.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration matters and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We estimate that it is reasonably possible that our gross unrecognized tax benefits, exclusive of interest, could decrease by up to approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$75.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in the next 12 months as a result of various audit closures, settlements and expiration of the statute of limitations.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <biib:DeferredTaxAssetsValueReductioninValue
      contextRef="FI2020Q2_srt_ProductOrServiceAxis_biib_TECFIDERAMember"
      decimals="-5"
      id="d13680947e861-wk-Fact-F60074E12A2158BF44B65E0CF082616B"
      unitRef="usd">1324000000.0</biib:DeferredTaxAssetsValueReductioninValue>
    <biib:DeferredTaxLiabilitiesValueReductioninValue
      contextRef="FI2020Q2_srt_ProductOrServiceAxis_biib_TECFIDERAMember"
      decimals="-5"
      id="d13680947e865-wk-Fact-C4B5BB1CBD4B49CBF1525E0E5625D8F2"
      unitRef="usd">1268000000.0</biib:DeferredTaxLiabilitiesValueReductioninValue>
    <biib:IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_TECFIDERAMember"
      decimals="-5"
      id="d13680947e882-wk-Fact-56AF0BD7F78B356AD5BE5E124E6BAC98"
      unitRef="usd">56000000.0</biib:IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-EC4FFC5A16635319B6FDC77FAC052835-0-wk-Fact-D7570D2AF2F05A9CB32C6C65A62ABADD">&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Statutory rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;21.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;21.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;21.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;21.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;State taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Taxes on foreign earnings&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(3.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(4.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(3.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(4.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Tax credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(1.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Purchased intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Divestiture of Denmark manufacturing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Internal reorganization of certain intellectual property rights&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(5.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(2.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;TECFIDERA impairment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;2.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;GILTI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other permanent items&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Effective tax rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;21.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;14.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;19.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;18.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="FD2020Q2QTD"
      decimals="3"
      id="d13680947e1058-wk-Fact-8C86E4D0F8755986BB7204821A887871"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="FD2019Q2QTD"
      decimals="INF"
      id="d13680947e1073-wk-Fact-B42A80FC93965EEDB6A8D896BA0ECC50"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="FD2020Q2YTD"
      decimals="3"
      id="d13680947e1088-wk-Fact-FABF826420BA5B058E39D783A6F01C17"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="FD2019Q2YTD"
      decimals="INF"
      id="d13680947e1103-wk-Fact-43A68CA1354C5221805F97E6890436DD"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="FD2020Q2QTD"
      decimals="3"
      id="d13680947e1120-wk-Fact-419A67DC132D541EA471A80E90367984"
      unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="FD2019Q2QTD"
      decimals="3"
      id="d13680947e1134-wk-Fact-AB329A6513415B7C88A39E86367C1389"
      unitRef="number">0.009</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="FD2020Q2YTD"
      decimals="3"
      id="d13680947e1148-wk-Fact-0E7604997BD9534F86936E4C4F0D8AF0"
      unitRef="number">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="FD2019Q2YTD"
      decimals="3"
      id="d13680947e1162-wk-Fact-B100586ACFA15C89BF0CA17F11B81405"
      unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="FD2020Q2QTD"
      decimals="3"
      id="d13680947e1178-wk-Fact-CE6EA9BEFCCE58CA8B1A09DB1C6BE31F"
      unitRef="number">-0.034</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="FD2019Q2QTD"
      decimals="3"
      id="d13680947e1193-wk-Fact-80B967C62AB55B8CBB1CDCC72A72063E"
      unitRef="number">-0.046</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="FD2020Q2YTD"
      decimals="3"
      id="d13680947e1208-wk-Fact-CD2840535165508FADA13B0D53F57ACF"
      unitRef="number">-0.037</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="FD2019Q2YTD"
      decimals="3"
      id="d13680947e1223-wk-Fact-DDB812C242355B1E8C5C808D7C122D64"
      unitRef="number">-0.046</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="FD2020Q2QTD"
      decimals="3"
      id="d13680947e1240-wk-Fact-1644EB88FEF45BA28D76E2BC94178C67"
      unitRef="number">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="FD2019Q2QTD"
      decimals="3"
      id="d13680947e1255-wk-Fact-1347483E96725C2E9E1A82BED07632E3"
      unitRef="number">0.009</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="FD2020Q2YTD"
      decimals="3"
      id="d13680947e1270-wk-Fact-53A65CABB4E250BEAF3AB7C86E13EE72"
      unitRef="number">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="FD2019Q2YTD"
      decimals="3"
      id="d13680947e1285-wk-Fact-4EF28B3D53B85B29A6E0F8C8E69A52B5"
      unitRef="number">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization
      contextRef="FD2020Q2QTD"
      decimals="3"
      id="d13680947e1302-wk-Fact-CE1BD57C122F5543801F908F6F1FB435"
      unitRef="number">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization
      contextRef="FD2019Q2QTD"
      decimals="3"
      id="d13680947e1316-wk-Fact-2D3A2A94E5FA59238230AD7CE0DF7844"
      unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization
      contextRef="FD2020Q2YTD"
      decimals="3"
      id="d13680947e1330-wk-Fact-B892EDB4D4DF57E69F23E9022BBE6045"
      unitRef="number">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization
      contextRef="FD2019Q2YTD"
      decimals="3"
      id="d13680947e1344-wk-Fact-5E54BE6A37A35C1F8B9829317C50E1AF"
      unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets
      contextRef="FD2020Q2QTD"
      decimals="3"
      id="d13680947e1360-wk-Fact-216C48D536F058CEA7A0C8E2FE450B16"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets
      contextRef="FD2019Q2QTD"
      decimals="INF"
      id="d13680947e1374-wk-Fact-745F5A8ECAF454148E123A5E5A1B9C64"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets
      contextRef="FD2020Q2YTD"
      decimals="3"
      id="d13680947e1388-wk-Fact-97280AF29530543A91D25CFC66BD1E89"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets
      contextRef="FD2019Q2YTD"
      decimals="INF"
      id="d13680947e1402-wk-Fact-106358C83D315EC383FEEC8EDD2CE4E9"
      unitRef="number">0.022</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets>
    <biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization
      contextRef="FD2020Q2QTD"
      decimals="3"
      id="d13680947e1418-wk-Fact-444A18851D2E551EAD10167AF16F4063"
      unitRef="number">0</biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization>
    <biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization
      contextRef="FD2019Q2QTD"
      decimals="3"
      id="d13680947e1432-wk-Fact-BB2B9AA1D8DE51A1B8594F0BE082FC13"
      unitRef="number">-0.050</biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization>
    <biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization
      contextRef="FD2020Q2YTD"
      decimals="3"
      id="d13680947e1447-wk-Fact-CFAD104B6DCA53A295D006770CF4E37F"
      unitRef="number">0</biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization>
    <biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization
      contextRef="FD2019Q2YTD"
      decimals="3"
      id="d13680947e1461-wk-Fact-1638664F716056E69AF37DA4EEFC63C2"
      unitRef="number">-0.024</biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="FD2020Q2QTD"
      decimals="3"
      id="d13680947e1478-wk-Fact-C866C04AF8D5EA3B12F75E1589C045CB"
      unitRef="number">0.027</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="FD2019Q2QTD"
      decimals="3"
      id="d13680947e1492-wk-Fact-66DE97DA84D3D97EEF655E1589278178"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="FD2020Q2YTD"
      decimals="3"
      id="d13680947e1506-wk-Fact-3850E9728B93B29DA0B45E1589225D82"
      unitRef="number">0.015</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="FD2019Q2YTD"
      decimals="3"
      id="d13680947e1520-wk-Fact-5793FD2118EB9BF3E2CE5E1589314DCA"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <biib:EffectiveTaxRateReconciliationGILTItax
      contextRef="FD2020Q2QTD"
      decimals="3"
      id="d13680947e1536-wk-Fact-CA94AAA055DB550C8694FFF64D3E7E67"
      unitRef="number">0.015</biib:EffectiveTaxRateReconciliationGILTItax>
    <biib:EffectiveTaxRateReconciliationGILTItax
      contextRef="FD2019Q2QTD"
      decimals="3"
      id="d13680947e1550-wk-Fact-912C86EA09365137B0FBFF6F8E07C583"
      unitRef="number">0.014</biib:EffectiveTaxRateReconciliationGILTItax>
    <biib:EffectiveTaxRateReconciliationGILTItax
      contextRef="FD2020Q2YTD"
      decimals="3"
      id="d13680947e1564-wk-Fact-7AEA321706335F46A64D9D708E0934FD"
      unitRef="number">0.011</biib:EffectiveTaxRateReconciliationGILTItax>
    <biib:EffectiveTaxRateReconciliationGILTItax
      contextRef="FD2019Q2YTD"
      decimals="3"
      id="d13680947e1578-wk-Fact-D60F05ED6F6C50158F2BCB202F90C3C2"
      unitRef="number">0.017</biib:EffectiveTaxRateReconciliationGILTItax>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="FD2020Q2QTD"
      decimals="3"
      id="d13680947e1595-wk-Fact-4CFE37B185FA5FF4A13AAE800692EF6C"
      unitRef="number">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="FD2019Q2QTD"
      decimals="3"
      id="d13680947e1609-wk-Fact-C9E55500EB3059EBAD2BEEF20490EAA5"
      unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="FD2020Q2YTD"
      decimals="3"
      id="d13680947e1623-wk-Fact-4C9A6977D7645BC3A2351BFF739DE5E1"
      unitRef="number">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="FD2019Q2YTD"
      decimals="3"
      id="d13680947e1637-wk-Fact-29255E3C02D253B2BD5D1E80ABA0E964"
      unitRef="number">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="FD2020Q2QTD"
      decimals="3"
      id="d13680947e1653-wk-Fact-ADFA2C7D21BC5F85868D9F6004F70EE8"
      unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="FD2019Q2QTD"
      decimals="3"
      id="d13680947e1667-wk-Fact-2B7E95A915895135B8D687D58513A4C7"
      unitRef="number">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="FD2020Q2YTD"
      decimals="3"
      id="d13680947e1681-wk-Fact-EFCBBE408EE3588AA2FCCB396A7AE212"
      unitRef="number">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="FD2019Q2YTD"
      decimals="3"
      id="d13680947e1695-wk-Fact-61D29694A08753B4AB1FDE89FAA4154C"
      unitRef="number">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2020Q2QTD"
      decimals="3"
      id="d13680947e1711-wk-Fact-F6ACA36E8C7353019911074FADE7A3AE"
      unitRef="number">0.219</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2019Q2QTD"
      decimals="3"
      id="d13680947e1726-wk-Fact-E499BEA83FB45545B20B526B4727D893"
      unitRef="number">0.141</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2020Q2YTD"
      decimals="3"
      id="d13680947e1741-wk-Fact-2F4B80FB429F59F5A089F0B943DED0D3"
      unitRef="number">0.198</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2019Q2YTD"
      decimals="3"
      id="d13680947e1756-wk-Fact-7671811DDD8556AA953C119333F24738"
      unitRef="number">0.185</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <biib:IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_TECFIDERAMember"
      decimals="-5"
      id="d13680947e1796-wk-Fact-56AF0BD7F78B356AD5BE5E124E6BAC98"
      unitRef="usd">56000000.0</biib:IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="FD2019Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_DenmarkManufacturingOperationsMember"
      decimals="-5"
      id="d13680947e1826-wk-Fact-A892349FA3B95B78A33DF793BCBF6D46"
      unitRef="usd">61300000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="FI2019Q2"
      decimals="-5"
      id="d13680947e1843-wk-Fact-66C7B9A580998D3F3E5B5E1822097DC5"
      unitRef="usd">856700000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="FI2019Q2"
      decimals="-5"
      id="d13680947e1847-wk-Fact-02EBBA457EE6E35F317D5E188E3B8819"
      unitRef="usd">685300000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13680947e1878-wk-Fact-CE2B2E6A73BD5AC1880DA4020D29EA65"
      unitRef="usd">75000000.0</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-27D0A8C169D457CC9A2DBC6B13BBAB46-0-wk-Fact-DC37DC4A1F6C5BC793DCDF969535173C">&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Income (Expense), Net&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Components of other income (expense), net, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:42%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Interest income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;7.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;29.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;32.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;60.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(66.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(47.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(110.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(95.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Gain (loss) on investments, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;106.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(173.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;29.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;203.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Foreign exchange gains (losses), net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;10.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(8.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;4.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(7.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(7.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total other income (expense), net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;63.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(197.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(57.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;159.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gain (loss) on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, compared to the same period in &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the change in other income (expense), net primarily reflects net gains of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$106.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;"&gt;recognized on our investments related to our holdings in equity and debt securities, compared to net losses totaling&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$173.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in the prior year comparative period. The net gains recognized during the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;"&gt;primarily reflect an increase in the fair value of Ionis common stock of approximately&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$67.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;"&gt;and an increase in the fair value of Sangamo common stock of approximately&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$40.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;"&gt;compared to the same period in 2019, the change in other income (expense), net was primarily due to approximately&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$203.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;"&gt;of net gains recognized on our investments related to our holdings in equity and debt securities during the six months ended June&#160;30, 2019.&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our gain (loss) on investments, net that relates to our equity securities held as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:42%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Net gains (losses) recognized during the period on equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;102.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(174.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;42.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;201.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Less: Net gains (losses) recognized during the period on equity securities sold during the period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(42.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;42.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Unrealized gains (losses) recognized during the period on equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;102.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(131.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;42.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;159.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Accrued Expenses and Other&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of&lt;br/&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Revenue-related reserves for discounts and allowances&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;951.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,001.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;212.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;309.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Royalties and licensing fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;203.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;220.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Collaboration expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;172.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;281.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Current portion of contingent consideration obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;149.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;148.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Construction in progress&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;24.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;78.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;774.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;726.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total accrued expenses and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;2,486.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2,765.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Long-term Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities were &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1,475.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1,348.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, and included accrued income taxes totaling &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$743.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$803.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Included within accrued taxes as of June&#160;30, 2020 and December&#160;31, 2019, is an accrual for a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings (the Transition Toll Tax) of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$635.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$697.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-C2E3A01FBA1B5C8CAB3B3CC6A0B053A2-0-wk-Fact-BADD2785A0835D759C7A313F50725FF5">&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Components of other income (expense), net, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:42%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Interest income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;7.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;29.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;32.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;60.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(66.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(47.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(110.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(95.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Gain (loss) on investments, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;106.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(173.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;29.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;203.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Foreign exchange gains (losses), net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;10.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(8.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;4.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(7.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(7.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total other income (expense), net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;63.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(197.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;(57.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;159.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InvestmentIncomeInterest
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13682938e1024-wk-Fact-A6DB1A4A55155CC3B2A39F6E39223180"
      unitRef="usd">7600000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13682938e1043-wk-Fact-0C4284452BEC56F8952754DB07A8EA5C"
      unitRef="usd">29100000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13682938e1063-wk-Fact-AD642FE8052D58C083A493F22D42CD7B"
      unitRef="usd">32000000.0</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13682938e1082-wk-Fact-2ACBF047ACB15A2B81D168C84E59BB12"
      unitRef="usd">60300000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13682938e1102-wk-Fact-A7F9D19E8915591C85D807952C55AC71"
      unitRef="usd">66000000.0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13682938e1122-wk-Fact-147350126F4E565B9A0A9F972EF7AB5C"
      unitRef="usd">47700000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13682938e1142-wk-Fact-B761067B3EC25444B16C8C2BFBF4C261"
      unitRef="usd">110300000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13682938e1163-wk-Fact-84DD9F21B78154E7A2B4B2A2EF0C3F23"
      unitRef="usd">95600000</us-gaap:InterestExpense>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13682938e1189-wk-Fact-7AE6A948139B906A17205973C8002C57"
      unitRef="usd">106800000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13682938e1208-wk-Fact-5E4F85BBA04990D4928959743911C491"
      unitRef="usd">-173400000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13682938e1228-wk-Fact-92D02ACF8AEC59B188C80D6DD23CF312"
      unitRef="usd">29500000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13682938e1248-wk-Fact-B58921FC7BF55518AB3D87546F940DD9"
      unitRef="usd">203000000.0</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13682938e1273-wk-Fact-32A75BE6407057B9B579834783BE53CA"
      unitRef="usd">10400000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13682938e1292-wk-Fact-86D38F06B5995FF585B21D4063AF85E3"
      unitRef="usd">1700000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13682938e1311-wk-Fact-E3A62912CFCB53A1ABB91CE2C7CF62EC"
      unitRef="usd">-8500000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13682938e1332-wk-Fact-5697BC60771753A8ABB788B3CBFA257E"
      unitRef="usd">-500000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13682938e1358-wk-Fact-81252ACD8F7D58229DC4760BF522F588"
      unitRef="usd">4200000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13682938e1377-wk-Fact-DE741F0FD926541286118CB4CD246922"
      unitRef="usd">-7100000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13682938e1397-wk-Fact-9D412F28F5F65442A5174B274F885F6F"
      unitRef="usd">-200000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13682938e1418-wk-Fact-18D1CAFE5DC953748E5F44C494B8F348"
      unitRef="usd">-7300000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13682938e1449-wk-Fact-0D51E02D7DDE5C0E8E7A9F3566E66B60"
      unitRef="usd">63000000.0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13682938e1468-wk-Fact-55BFFA5FA59E5C88AB2D8F69B51FDAAD"
      unitRef="usd">-197400000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13682938e1489-wk-Fact-ABD76A880BD354B29882CFA24D852D20"
      unitRef="usd">-57500000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13682938e1509-wk-Fact-EEF1B208E84A576484A9D98454389FE0"
      unitRef="usd">159900000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13682938e1544-wk-Fact-7AE6A948139B906A17205973C8002C57"
      unitRef="usd">106800000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13682938e1554-wk-Fact-5E4F85BBA04990D4928959743911C491"
      unitRef="usd">-173400000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="FD2020Q2QTD_dei_LegalEntityAxis_biib_IonisPharmaceuticalsMember"
      decimals="-5"
      id="d13682938e1571-wk-Fact-2F13BAF8CCC9755460335E2943A44AD0"
      unitRef="usd">67200000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="FD2020Q2QTD_dei_LegalEntityAxis_biib_SangamoCommonStockMember"
      decimals="-5"
      id="d13682938e1581-wk-Fact-FD89F153532C26765B2F5E295FF03ADB"
      unitRef="usd">40900000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity
      contextRef="FD2019Q2QTD_dei_LegalEntityAxis_biib_IonisPharmaceuticalsMember"
      decimals="-5"
      id="d13682938e1601-wk-Fact-D7B70F8BB34046B6E2765E2CE8A747BD"
      unitRef="usd">203000000.0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity>
    <us-gaap:GainLossOnInvestmentsTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-B386B15BE63B509BA15A6E56C3D94180-0-wk-Fact-0D0D74FAD15954CBA1E6007BFFAB54EA">&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our gain (loss) on investments, net that relates to our equity securities held as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:42%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Net gains (losses) recognized during the period on equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;102.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(174.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;42.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;201.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Less: Net gains (losses) recognized during the period on equity securities sold during the period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(42.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;42.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Unrealized gains (losses) recognized during the period on equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;102.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;(131.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;42.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;159.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:GainLossOnInvestmentsTextBlock>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13682938e1839-wk-Fact-AF1B8EED660B5C82B079531F5DFAC91C"
      unitRef="usd">102900000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13682938e1858-wk-Fact-A8C9D26CADD45A54BAFED15CE6E8F743"
      unitRef="usd">-174200000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13682938e1879-wk-Fact-AD5D2E5AF8465F6BA7F0928D4A541013"
      unitRef="usd">42000000.0</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13682938e1898-wk-Fact-F001A4D780BB5451958BC1D0CF923577"
      unitRef="usd">201900000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13682938e1918-wk-Fact-6F454240710456C6A5F94C4D9D3603B6"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13682938e1937-wk-Fact-4A5FFE8C8FF853E0A07C6769E52B636F"
      unitRef="usd">-42900000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13682938e1957-wk-Fact-90F44F41FFF25C188B014B18FBE12DC7"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13682938e1977-wk-Fact-091EFC55F8D151AFBCBADE7A1DEC5368"
      unitRef="usd">-42400000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d13682938e2007-wk-Fact-1DF02394FA7B561FA0F3BEA943E62A65"
      unitRef="usd">102900000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d13682938e2026-wk-Fact-307D2DED024D5695B77850A07C66F7A9"
      unitRef="usd">-131300000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13682938e2047-wk-Fact-5BCD9DCA17755FE99061B971B30AADE7"
      unitRef="usd">42000000.0</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d13682938e2066-wk-Fact-1D16EA165C6957149C85B7C604AFC551"
      unitRef="usd">159500000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-29F1AC35671D5E6C84557B01CF312989-0-wk-Fact-9DCB23BAFC2B5844A03C5B5D07F2DC9F">&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of&lt;br/&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Revenue-related reserves for discounts and allowances&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;951.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1,001.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;212.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;309.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Royalties and licensing fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;203.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;220.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Collaboration expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;172.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;281.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Current portion of contingent consideration obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;149.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;148.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Construction in progress&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;24.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;78.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;774.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;726.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total accrued expenses and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;2,486.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;2,765.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember"
      decimals="-5"
      id="d13682938e2175-wk-Fact-062DF7382F915519A5B9D146E1EF70DC"
      unitRef="usd">951300000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember"
      decimals="-5"
      id="d13682938e2194-wk-Fact-4231B4BD6644584EB68CBAD2CF09EF6D"
      unitRef="usd">1001100000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13682938e2214-wk-Fact-B6560F6A388558E4A6AF45A6C0A84F21"
      unitRef="usd">212000000.0</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13682938e2233-wk-Fact-94CE95FA92F655928086492951539203"
      unitRef="usd">309100000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13682938e2258-wk-Fact-B5D68139945C5C99B92AA14C25EF478A"
      unitRef="usd">203000000.0</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13682938e2277-wk-Fact-227E91809B445AE2B1AFFA6733D104DC"
      unitRef="usd">220900000</us-gaap:AccruedRoyaltiesCurrent>
    <biib:Collaborationexpensesaccrual
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13682938e2302-wk-Fact-CCACACF5619A5C6EA020BEA4FB444B12"
      unitRef="usd">172900000</biib:Collaborationexpensesaccrual>
    <biib:Collaborationexpensesaccrual
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13682938e2321-wk-Fact-D8E899F4350657C99531B9B8BF292289"
      unitRef="usd">281600000</biib:Collaborationexpensesaccrual>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13682938e2346-wk-Fact-EF742BB54D96512E90B43AAF0EBCAFB4"
      unitRef="usd">149100000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13682938e2365-wk-Fact-5CEFAEE5CEE0569480C09A3B63836377"
      unitRef="usd">148400000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:ConstructionPayableCurrentAndNoncurrent
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13682938e2390-wk-Fact-3B6BBB6ED6BA588794839BCEC817DBD4"
      unitRef="usd">24100000</us-gaap:ConstructionPayableCurrentAndNoncurrent>
    <us-gaap:ConstructionPayableCurrentAndNoncurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13682938e2409-wk-Fact-0CDC22D0A32D5E169A007D1BF059FEF9"
      unitRef="usd">78000000.0</us-gaap:ConstructionPayableCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13682938e2434-wk-Fact-D654B8EE899C5BD3BBE26238073BED17"
      unitRef="usd">774100000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13682938e2453-wk-Fact-FA1CDFC70074596CA6D6CB286187C4E5"
      unitRef="usd">726700000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13682938e2483-wk-Fact-96180D2EFD6F50C4AB2607CAC10392DB"
      unitRef="usd">2486500000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13682938e2502-wk-Fact-ED32696AB6ED5D5F84AFD714902EF602"
      unitRef="usd">2765800000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13682938e2527-wk-Fact-6299100E2B9B576C82E99FBE691E586C"
      unitRef="usd">1475400000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13682938e2531-wk-Fact-01F0411B800C53F49F5B13CE5B5A6E2B"
      unitRef="usd">1348900000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13682938e2543-wk-Fact-AF17F52A08B95E0989B9E5304858989F"
      unitRef="usd">743200000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13682938e2548-wk-Fact-184AE306B27B5D719D8275DE752FB906"
      unitRef="usd">803300000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d13682938e2552-wk-Fact-4DD9C93FD397806AE8275E32743B5258"
      unitRef="usd">635000000.0</us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense>
    <us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense
      contextRef="FD2019Q4YTD"
      decimals="-5"
      id="d13682938e2556-wk-Fact-71FBAFC5E34AA3C91B0C5E329C24E6F0"
      unitRef="usd">697000000.0</us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-75E9AAF871F05EF0BACA6FC47390EE52-0-wk-Fact-1AD9FC307B225BCC919CDB0DDE2A897C">&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Eisai Co., Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;BAN2401 and Elenbecestat Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have a collaboration agreement with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize BAN2401, a monoclonal antibody that targets amyloid beta aggregates, and elenbecestat, the oral BACE (base amyloid cleaving enzyme) inhibitor, two Eisai product candidates for the potential treatment of AD (the BAN2401 and Elenbecestat Collaboration).&#160;In September 2019 we and Eisai discontinued the global Phase 3 studies of elenbecestat in early AD. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Eisai serves as the global operational and regulatory lead for BAN2401 and all costs, including research, development, sales and marketing expenses, are shared equally between us and Eisai. If BAN2401 receives marketing approval, we and Eisai will co-promote BAN2401 and share profits equally. In addition, the BAN2401 and Elenbecestat Collaboration provides both parties with certain rights and obligations in the event of a change in control of either party.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The BAN2401 and Elenbecestat Collaboration also provided Eisai with an option to jointly develop and commercialize aducanumab, our anti-amyloid beta antibody candidate for AD (Aducanumab Option), and an option to jointly develop and commercialize one of our anti-tau monoclonal antibodies (Anti-Tau Option). In October 2017 Eisai exercised its Aducanumab Option and we entered into a new collaboration agreement for the joint development and commercialization of aducanumab (Aducanumab Collaboration Agreement). Eisai has not yet exercised its Anti-Tau Option.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the Aducanumab Collaboration Agreement, the two companies will continue to jointly develop BAN2401 in accordance with the BAN2401 and Elenbecestat Collaboration; however, we are no longer required to pay Eisai any milestone payments for products containing BAN2401 and we are no longer entitled to any potential development and commercial milestone payments from Eisai in relation to aducanumab. For additional information on our BAN2401 and Elenbecestat Collaboration, please read &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Note 18, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A summary of development and sales and marketing expense related to the BAN2401 and Elenbecestat Collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:52%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total development expense incurred by the collaboration related to the advancement of BAN2401 and elenbecestat&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;33.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;68.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;77.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;136.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Biogen's share of BAN2401 and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;17.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;34.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;38.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;68.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total sales and marketing expense incurred by the collaboration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;nm&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;6.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;nm&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Biogen's share of BAN2401 sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;nm&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;3.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;nm&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:34%;"/&gt;&lt;td style="width:32%;"/&gt;&lt;td style="width:34%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:1px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;nm&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt; - For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;, sales and marketing expenses related to the BAN2401 and Elenbecestat Collaboration were immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Aducanumab Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the Aducanumab Collaboration Agreement, we and Eisai will co-promote aducanumab with a region-based profit split and we lead the ongoing development of aducanumab. Beginning January 1, 2019, Eisai is reimbursing us for&#160;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;45%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;of development costs incurred by the collaboration for the advancement of aducanumab (aducanumab development expense). &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2019, based on a pre-specified futility analysis, we discontinued the global Phase 3 trials, EMERGE and ENGAGE, designed to evaluate the efficacy and safety of aducanumab in patients with early AD. A new analysis of a larger dataset from these trials, conducted in consultation with the FDA, showed that the Phase 3 EMERGE study met its pre-specified primary and secondary endpoints. In the first quarter of 2019, as a result of the decision to discontinue the Phase 3 EMERGE and ENGAGE trials following the futility analysis, we accrued approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$45.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to the termination of various clinical trials and research and development contracts net of the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;45%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Eisai reimbursement of development costs incurred under the Aducanumab Collaboration Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2020 we completed the submission of a Biologics License Application (BLA) to the FDA for the approval of aducanumab. For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized net profit-sharing income of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$33.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to reflect Eisai's &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;45%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; share of the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$75.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; milestone expense related to the submission of the BLA to the FDA for approval of aducanumab.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Sales and marketing expense are shared in proportion to the same region-based profit split that will be utilized to co-promote aducanumab. For additional information on the Aducanumab Collaboration Agreement, please read &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Note 18,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A summary of development, sales and marketing and milestone expense related to the Aducanumab Collaboration Agreement is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:52%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total aducanumab development expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;35.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;3.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;55.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;165.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Biogen's share of aducanumab development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;19.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;30.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;91.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total aducanumab sales and marketing expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;45.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;67.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;21.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;25.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;37.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;11.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total aducanumab collaboration third party milestone expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;75.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;75.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Eisai's share of aducanumab milestone expense reflected in collaboration profit sharing in our condensed consolidated statements of income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;33.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;33.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition, we and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;UCB Pharma S.A.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have a collaboration agreement with UCB Pharma S.A. (UCB) to jointly develop and commercialize dapirolizumab pegol, an anti-CD40L pegylated Fab, for the potential treatment of systemic lupus erythematosus and other future agreed indications. Either we or UCB may propose development of dapirolizumab pegol in additional indications. If the parties do not agree to add an indication as an agreed indication to the collaboration, we or UCB may, at the sole expense of the applicable party, pursue development in such excluded indication(s), subject to an opt-in right of the non-pursuing party after proof of clinical activity. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;All costs incurred for agreed indications, including research, development, sales and marketing expenses, are shared equally between us and UCB. Upon marketing approval, we and UCB will co-promote dapirolizumab pegol and share profits equally. A summary of development expense related to the UCB Collaboration Agreement is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:52%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total UCB development expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;6.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;nm&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;25.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;nm&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Biogen's share of UCB development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;3.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;nm&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;12.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;nm&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:34%;"/&gt;&lt;td style="width:32%;"/&gt;&lt;td style="width:34%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:1px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;nm&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt; - For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;, development expenses related to the UCB collaboration agreement were immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Research and Discovery Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Sangamo Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2020 we entered into a collaboration and license agreement with Sangamo to develop and commercialize ST-501 for tauopathies, including AD; ST-502 for synucleinopathies, including Parkinson&#x2019;s disease; a third neuromuscular disease target; and up to nine additional neurological disease targets to be identified and selected within a five-year period. The companies will leverage Sangamo&#x2019;s proprietary zinc finger protein technology delivered via AAV to modulate the expression of key genes involved in neurological diseases. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with the closing of this transaction in April 2020 we purchased &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$225.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of Sangamo common stock, or approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;24 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares at &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$9.21&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; per share, which are subject to transfer restrictions. We recorded an asset in investments and other assets in our condensed consolidated balance sheets to reflect the initial fair value of the Sangamo common stock acquired and a charge of&#160;approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$83.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;to research and development expense in our condensed consolidated statements of income to reflect the premium paid for the Sangamo common stock. We also made an upfront payment of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$125.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; that was recorded as research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We may also pay research, development, regulatory and commercial milestone payments that could total up to approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$2.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; if we select all of the targets allowed under this agreement and all the specified milestones set forth in this agreement are achieved. Of this amount, up to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$80.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; relates to the selection of targets, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$1.9 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$380.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels. In addition, we may pay tiered royalties on potential net commercial sales of any products developed under this collaboration in the high single digit to double digit sub-teen percentages.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Skyhawk Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2019 we entered into a collaboration and research and development services agreement with Skyhawk Therapeutics, Inc. (Skyhawk) pursuant to which the companies are leveraging Skyhawk's SkySTAR technology platform with the goal of discovering innovative small molecule treatments for patients with neurological diseases, including MS and SMA. We are responsible for the development and potential commercialization of any therapies resulting from this collaboration and we may also pay Skyhawk up to a total of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$2.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in milestone payments as well as potential royalties on net commercial sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with this agreement, we made an upfront payment of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$74.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to Skyhawk, of which &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$38.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was recorded as research and development expense in our condensed consolidated statements of income and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$35.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was recorded as prepaid research and development expenditures within investments and other assets in our condensed consolidated balance sheets. These prepaid research and development services are expensed as the services are provided. In October 2019 we amended this agreement to add an additional discovery program. In connection with this amendment, we made a payment to Skyhawk of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$15.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Samsung Bioepis&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Joint Venture Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.&#160;In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;49.9%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The share purchase transaction was completed in November 2018 and, upon closing, we paid &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;759.5 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$676.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) to Samsung BioLogics. As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, our ownership percentage remained at approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;49.9%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in income (loss) of investee, net of tax in our condensed consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our initial investment, we suspended recognizing additional losses. In the first quarter of 2019 we restarted recognizing our share of Samsung Bioepis' (income) losses, and we began recognizing amortization on certain basis differences resulting from our November 2018 investment. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Upon investment, the equity method of accounting requires us to identify and allocate differences between the fair value of our investment and the carrying value of our interest in the underlying net assets of the investee. These basis differences are amortized over their economic life. The total basis difference was approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$675 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and relates to inventory, developed technology, IPR&amp;amp;D and deferred tax balances. The basis differences related to inventory and developed technology will be amortized, net of tax, over their estimated useful lives of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; years and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; years, respectively, one quarter in arrears. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our joint venture partner, Samsung BioLogics, is currently subject to an ongoing criminal investigation that we continue to monitor. While this investigation could impact the operations of Samsung Bioepis and its business, we have assessed the value of our investment in Samsung Bioepis and continue to believe that the fair value of the investment is in excess of its net book value.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized net income on our investment of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$15.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$0.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, reflecting our share of income and amortization of basis differences.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the carrying value of our investment in Samsung Bioepis totaled &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;668.3 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$557.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;670.8 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$580.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;), respectively, which is classified as a component of investments and other assets in our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;2019 Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11 referencing LUCENTIS and SB15 referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. Samsung Bioepis will be responsible for development and will supply both products to us.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with this transaction, we made an upfront payment of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$100.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to Samsung Bioepis in January 2020, of which &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$63.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was recorded as research and development expense in 2019 and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$37.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was recorded as an intangible asset in 2019. We may pay Samsung Bioepis up to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$210.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in additional development, regulatory and sales-based milestones, including a &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$15.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; development milestone which is expected to be paid during the third quarter of 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We also acquired an option to extend the term of our 2013 commercial agreement for BENEPALI, IMRALDI and FLIXABI by an additional five years, subject to payment of an option exercise fee of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$60.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, and obtained exclusive rights to commercialize these products in China.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;2013 Commercial Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We reflect revenues on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenues, net in our condensed consolidated statements of income and record the related cost of revenues and sales and marketing expenses in our condensed consolidated statements of income to their respective line items when these costs are incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We share &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;50%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized net profit-sharing expense of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$55.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$127.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, to reflect Samsung Bioepis' &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;50%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; sharing of the net collaboration profits, compared to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$63.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$121.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in the prior year comparative periods. As discussed above, we have an option to extend this agreement by an additional five years, subject to the payment of an option exercise fee of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$60.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Other Services&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Simultaneous with the formation of Samsung Bioepis, we also entered into a technical development services agreement, a manufacturing agreement and a license agreement with Samsung Bioepis. For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$4.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$8.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in revenues related to these services, which is reflected in collaborative and other relationships revenues as a component of other revenues in our condensed consolidated statements of income, compared to &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$52.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$77.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in the prior year comparative periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Following the divestiture of our Hiller&#xf8;d, Denmark manufacturing operations in August 2019, FUJIFILM assumed &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;"&gt;responsibility for the manufacture of clinical and commercial quantities of bulk drug substance of biosimilar products for Samsung Bioepis. We no longer recognize revenues for the manufacturing completed after the Hiller&#xf8;d, Denmark manufacturing facility divestiture date under our technical development services and manufacturing agreements with Samsung Bioepis.&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; For additional information on the divestiture of our Hiller&#xf8;d, Denmark manufacturing operations, please read &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Note 3, Divestitures&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts receivable from Samsung Bioepis related to the agreements discussed above were &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$13.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$85.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. There were &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; amounts payable to Samsung Bioepis as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. Amounts payable to Samsung Bioepis as of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, consisted of the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$100.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upfront payment related to the 2019 transaction, as discussed above.&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our collaboration arrangements with Samsung Bioepis and our other significant collaboration arrangements, please read &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Note 18,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt; Form 10-K.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-8BF478338FCC5DDF9973198E09645591-0-wk-Fact-BE43A789EBD95A96994C687A11562176">&lt;div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:52%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total development expense incurred by the collaboration related to the advancement of BAN2401 and elenbecestat&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;33.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;68.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;77.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;136.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Biogen's share of BAN2401 and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;17.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;34.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;38.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;68.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total sales and marketing expense incurred by the collaboration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;1.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;nm&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;6.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;nm&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Biogen's share of BAN2401 sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;nm&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;3.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;nm&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock>
    <biib:ExpenseIncurredByCollaboration
      contextRef="FD2020Q2QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d13685232e1050-wk-Fact-24B0181BF0A55FD9A3F5CDE6FC8F8E06"
      unitRef="usd">33900000</biib:ExpenseIncurredByCollaboration>
    <biib:ExpenseIncurredByCollaboration
      contextRef="FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d13685232e1069-wk-Fact-06C554752E6E5BE48A5B084638301E22"
      unitRef="usd">68600000</biib:ExpenseIncurredByCollaboration>
    <biib:ExpenseIncurredByCollaboration
      contextRef="FD2020Q2YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d13685232e1089-wk-Fact-8F8C2C626BEEA327AB885E34AC33AF19"
      unitRef="usd">77500000</biib:ExpenseIncurredByCollaboration>
    <biib:ExpenseIncurredByCollaboration
      contextRef="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d13685232e1108-wk-Fact-ACCE44D173831759796B5E34AE26126F"
      unitRef="usd">136600000</biib:ExpenseIncurredByCollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2020Q2QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d13685232e1128-wk-Fact-83ADB661E66D5CF893E48F1E9EFE2F61"
      unitRef="usd">17000000.0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d13685232e1147-wk-Fact-61AC8A3FE200554F92E16235AB52871E"
      unitRef="usd">34300000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2020Q2YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d13685232e1166-wk-Fact-F195CBBE14A2B47CA7005E34AF79B198"
      unitRef="usd">38700000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d13685232e1186-wk-Fact-43DD6AE39C83065F981A5E34B16D1479"
      unitRef="usd">68300000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d13685232e1211-wk-Fact-C7E658BB2ABC54E49B386F7F0BF50572"
      unitRef="usd">1400000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d13685232e1249-wk-Fact-B6BA30C4046CA7071F665E34B2BCCC9A"
      unitRef="usd">6300000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d13685232e1294-wk-Fact-260224478FEB53C2A2572C6A171A12F6"
      unitRef="usd">700000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d13685232e1332-wk-Fact-76A305CD364E19D0D4E85E34B5EF9B5E"
      unitRef="usd">3200000</biib:Expensereflectedwithinstatementsofincome>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="FD2020Q2YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="INF"
      id="d13685232e1419-wk-Fact-D8A49C8E2E0B56F18925AF5EDB45CDD2"
      unitRef="number">0.45</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <us-gaap:LossOnContractTermination
      contextRef="FD2019Q1QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d13685232e1426-wk-Fact-3683B50FE1FA77D97E675E3E6EA41C6F"
      unitRef="usd">45000000.0</us-gaap:LossOnContractTermination>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="FD2020Q2YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="INF"
      id="d13685232e1430-wk-Fact-D8A49C8E2E0B56F18925AF5EDB45CDD2"
      unitRef="number">0.45</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="FD2020Q2QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d13685232e1449-wk-Fact-4F45C4FAE4FCB96F81105E53E7C0F0EC"
      unitRef="usd">33800000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="FD2020Q2YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="INF"
      id="d13685232e1453-wk-Fact-D8A49C8E2E0B56F18925AF5EDB45CDD2"
      unitRef="number">0.45</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <biib:AdditionalMilestonePayment
      contextRef="FI2020Q2_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d13685232e1458-wk-Fact-9F9B667CA87C4DCCC24A5E5321CB03A7"
      unitRef="usd">75000000.0</biib:AdditionalMilestonePayment>
    <biib:SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-7E7EE262CE55520C830A6C626AB42387-0-wk-Fact-46313772E00E5B9EBF2050BCAFE7E4D6">&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A summary of development, sales and marketing and milestone expense related to the Aducanumab Collaboration Agreement is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:52%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Six Months &lt;br/&gt;Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total aducanumab development expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;35.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;3.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;55.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;165.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Biogen's share of aducanumab development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;19.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;30.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;91.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total aducanumab sales and marketing expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;45.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;67.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;21.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;25.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;37.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&lt;span&gt;11.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total aducanumab collaboration third party milestone expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;75.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;75.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Eisai's share of aducanumab milestone expense reflected in collaboration profit sharing in our condensed consolidated statements of income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;33.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"&gt;&lt;span&gt;33.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</biib:SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d13685232e1699-wk-Fact-CF0AA41EB1A25204871D449ED321A582"
      unitRef="usd">35900000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d13685232e1718-wk-Fact-FDA662E6D2245851B7D8F0715B193DE4"
      unitRef="usd">3200000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d13685232e1738-wk-Fact-2BB2BDBBF2F5562F8660DDBA27126DC3"
      unitRef="usd">55000000.0</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d13685232e1757-wk-Fact-5236EE837DEC564393BAF644AD3D546F"
      unitRef="usd">165800000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d13685232e1777-wk-Fact-18D07605A9335078BA1643DE944825F7"
      unitRef="usd">19700000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d13685232e1796-wk-Fact-1E07250B24DB5C3487C1888ECC9BE4BC"
      unitRef="usd">1700000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d13685232e1815-wk-Fact-A4B98581686255439B2F8972AED419F9"
      unitRef="usd">30300000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d13685232e1835-wk-Fact-72C13813E4BF51AD802FFB9634D53F20"
      unitRef="usd">91200000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d13685232e1860-wk-Fact-A487DC95556853EFBF06DB52D61C3AA6"
      unitRef="usd">45200000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d13685232e1879-wk-Fact-B7AFD3E4B523598894153A8D84E7B8B8"
      unitRef="usd">200000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d13685232e1898-wk-Fact-A3DF0EA6866D5419919F6FAE29208E63"
      unitRef="usd">67900000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d13685232e1918-wk-Fact-D59347E8057459DF89B5BE7CBC1BCC17"
      unitRef="usd">21200000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d13685232e1943-wk-Fact-175B192DD67D59A8A80FCC03F7439565"
      unitRef="usd">25200000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d13685232e1962-wk-Fact-443E60B9A662563894E20892111E9069"
      unitRef="usd">100000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d13685232e1981-wk-Fact-AB5567F0714F575CB47D4FC8E61BA7BD"
      unitRef="usd">37500000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d13685232e2001-wk-Fact-038E559B25FC58089BBB35D93EF17BD6"
      unitRef="usd">11700000</biib:Expensereflectedwithinstatementsofincome>
    <biib:AdditionalMilestonePayment
      contextRef="FI2020Q2_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d13685232e2026-wk-Fact-9F9B667CA87C4DCCC24A5E5321CB03A7"
      unitRef="usd">75000000.0</biib:AdditionalMilestonePayment>
    <biib:AdditionalMilestonePayment
      contextRef="FI2020Q2_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d13685232e2064-wk-Fact-9F9B667CA87C4DCCC24A5E5321CB03A7"
      unitRef="usd">75000000.0</biib:AdditionalMilestonePayment>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="FD2020Q2QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d13685232e2109-wk-Fact-4F45C4FAE4FCB96F81105E53E7C0F0EC"
      unitRef="usd">33800000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="FD2020Q2YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d13685232e2147-wk-Fact-9A3820B0B6C3391C706F5E53FAA65B7F"
      unitRef="usd">33800000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_UCBPharmaS.A.Member"
      decimals="-5"
      id="d13685232e2370-wk-Fact-D0C834C43024E625D6C05E55A6E49527"
      unitRef="usd">6500000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_UCBPharmaS.A.Member"
      decimals="-5"
      id="d13685232e2399-wk-Fact-79AD3C5E580C1328B1FC5E55CC5297E6"
      unitRef="usd">25500000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_UCBPharmaS.A.Member"
      decimals="-5"
      id="d13685232e2430-wk-Fact-33E50E24CA168CC591675E55ABF02D1A"
      unitRef="usd">3200000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_UCBPharmaS.A.Member"
      decimals="-5"
      id="d13685232e2459-wk-Fact-CBDF34B1C674DA9769F95E55D1079084"
      unitRef="usd">12700000</biib:Expensereflectedwithinstatementsofincome>
    <biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased
      contextRef="D2020Q1Feb01-Feb29_us-gaap_TypeOfArrangementAxis_biib_SangamoTherapeuticsInc.AgreementMember"
      decimals="-5"
      id="d13685232e2539-wk-Fact-04B0843A3BBB57249BCBBB65FD2A0AC1"
      unitRef="usd">225000000.0</biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased>
    <biib:GlobalLicensingCollaborationAgreementSharesPurchased
      contextRef="D2020Q1Feb01-Feb29_us-gaap_TypeOfArrangementAxis_biib_SangamoTherapeuticsInc.AgreementMember"
      decimals="-6"
      id="d13685232e2543-wk-Fact-3751AD56A73F54798681767AA3923998"
      unitRef="shares">24000000</biib:GlobalLicensingCollaborationAgreementSharesPurchased>
    <biib:GlobalLicensingCollaborationAgreementSharesPurchasedPerShare
      contextRef="D2020Q1Feb01-Feb29_us-gaap_TypeOfArrangementAxis_biib_SangamoTherapeuticsInc.AgreementMember"
      decimals="2"
      id="d13685232e2547-wk-Fact-F518BEA9DC8052A48430A32643E37CD0"
      unitRef="usdPerShare">9.21</biib:GlobalLicensingCollaborationAgreementSharesPurchasedPerShare>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="D2020Q1Feb01-Feb29_us-gaap_TypeOfArrangementAxis_biib_SangamoTherapeuticsInc.AgreementMember"
      decimals="-5"
      id="d13685232e2551-wk-Fact-DC42B008E32B54D88FADEBD4AB2153D7"
      unitRef="usd">83000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="D2020Q1Feb01-Feb29_us-gaap_TypeOfArrangementAxis_biib_SangamoTherapeuticsInc.AgreementMember"
      decimals="-5"
      id="d13685232e2555-wk-Fact-8AFB6556ABB75B9A8F4ADAA6320D4DE9"
      unitRef="usd">125000000.0</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments
      contextRef="D2020Q1Feb01-Feb29_us-gaap_TypeOfArrangementAxis_biib_SangamoTherapeuticsInc.AgreementMember"
      decimals="-8"
      id="d13685232e2562-wk-Fact-2B19FDC46366537EBFED67A256665C42"
      unitRef="usd">2400000000</biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments>
    <biib:GlobalLicensingCollaborationAgreementPaymentSelectionofTargets
      contextRef="D2020Q1Feb01-Feb29_us-gaap_TypeOfArrangementAxis_biib_SangamoTherapeuticsInc.AgreementMember"
      decimals="-5"
      id="d13685232e2566-wk-Fact-2934A70D1D655DB9B480B33DEA420588"
      unitRef="usd">80000000.0</biib:GlobalLicensingCollaborationAgreementPaymentSelectionofTargets>
    <biib:GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones
      contextRef="D2020Q1Feb01-Feb29_us-gaap_TypeOfArrangementAxis_biib_SangamoTherapeuticsInc.AgreementMember"
      decimals="-8"
      id="d13685232e2570-wk-Fact-114ADBDA75DF5507BE71210E83D9E093"
      unitRef="usd">1900000000</biib:GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones>
    <biib:GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones
      contextRef="D2020Q1Feb01-Feb29_us-gaap_TypeOfArrangementAxis_biib_SangamoTherapeuticsInc.AgreementMember"
      decimals="-5"
      id="d13685232e2574-wk-Fact-4906000E13805D8DA454AE321CFE1CE3"
      unitRef="usd">380000000.0</biib:GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones>
    <biib:AdditionalMilestonePayment
      contextRef="FI2020Q2_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember"
      decimals="-8"
      id="d13685232e2584-wk-Fact-3B1F947F6CDE53A197831A7ECF5304EE"
      unitRef="usd">2400000000</biib:AdditionalMilestonePayment>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember"
      decimals="-5"
      id="d13685232e2592-wk-Fact-66A347493A0D564196729C330CD31455"
      unitRef="usd">74000000.0</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember"
      decimals="-5"
      id="d13685232e2596-wk-Fact-731CAC3F7227551AA3B59900988A6FB4"
      unitRef="usd">38500000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="FI2019Q2_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember"
      decimals="-5"
      id="d13685232e2600-wk-Fact-1B368C4BB4325ECA89D82236FB6F0569"
      unitRef="usd">35500000</us-gaap:PrepaidExpenseAndOtherAssets>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="D2019Q4Oct01-Oct31_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember"
      decimals="-5"
      id="d13685232e2604-wk-Fact-4C5A960BB55953CDB324038853F07D51"
      unitRef="usd">15000000.0</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction
      contextRef="FI2019Q2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="2"
      id="d13685232e2617-wk-Fact-37E261D9A6B958FBB0B52EE61E0050D1"
      unitRef="number">0.05</biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="FI2020Q2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="3"
      id="d13685232e2621-wk-Fact-68118BDBA14B59BAAE1CE2F32822EC68"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="D2018Q4Nov1-Nov30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-8"
      id="d13685232e2625-wk-Fact-CCB7C2B85AC35AB599BDF91D0763D35A"
      unitRef="KRW">759500000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="FD2018Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d13685232e2629-wk-Fact-A7C8464CFC3E55D48BE321B68A254770"
      unitRef="usd">676600000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="FI2020Q2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="3"
      id="d13685232e2638-wk-Fact-68118BDBA14B59BAAE1CE2F32822EC68"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-6"
      id="d13685232e2648-wk-Fact-16C789A91294528889D1F02E79BA1A05"
      unitRef="usd">675000000</us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <biib:Equitymethodinvestmentbasisdifferenceamortizationperiod
      contextRef="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_InventoriesMember"
      id="d13685232e2652-wk-Fact-0B6D14C82B335E7A9CD913DA9CA7BA40">P1Y6M</biib:Equitymethodinvestmentbasisdifferenceamortizationperiod>
    <biib:Equitymethodinvestmentbasisdifferenceamortizationperiod
      contextRef="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_FairValueByAssetClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      id="d13685232e2656-wk-Fact-12EC492096ED511DBF363A1E4964B12C">P15Y</biib:Equitymethodinvestmentbasisdifferenceamortizationperiod>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="FD2020Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d13685232e2678-wk-Fact-F14281DAC4625C73ADCEB06EEB80CA11"
      unitRef="usd">15100000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d13685232e2682-wk-Fact-FB2D9EDEF356A0379BA85E5742A5ADB7"
      unitRef="usd">400000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:EquityMethodInvestments
      contextRef="FI2020Q2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-8"
      id="d13685232e2697-wk-Fact-0B65248DC6215903921C263A9F56BF71"
      unitRef="KRW">668300000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="FI2020Q2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d13685232e2701-wk-Fact-2F81BE7E53465FE89DC4D8D0E25324BC"
      unitRef="usd">557500000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-8"
      id="d13685232e2705-wk-Fact-CF87EB0D08C655F989DD20C322667660"
      unitRef="KRW">670800000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d13685232e2710-wk-Fact-520631BF43805C26991934ECD0C4B51F"
      unitRef="usd">580200000</us-gaap:EquityMethodInvestments>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="D2020Q1Mar3120_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d13685232e2724-wk-Fact-56BB62E9322B558A9E357ADB5BF87163"
      unitRef="usd">100000000.0</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="D2020Q1Mar3120_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d13685232e2728-wk-Fact-BD5E653D992E5E9790DA24EF4834291D"
      unitRef="usd">63000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="I2020Q1Jan31_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d13685232e2732-wk-Fact-5677741AA0965A9CB136659779366973"
      unitRef="usd">37000000.0</us-gaap:PrepaidExpenseAndOtherAssets>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones
      contextRef="D2020Q1Mar3120_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d13685232e2736-wk-Fact-2D8CD223612154F287685C87560936FE"
      unitRef="usd">210000000.0</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <biib:AdditionalMilestonePayment
      contextRef="I2020Q1Jan31_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d13685232e2740-wk-Fact-1F9E981914EF59AF81A66570C479B62F"
      unitRef="usd">15000000.0</biib:AdditionalMilestonePayment>
    <biib:ContractOptionExerciseFee
      contextRef="D2020Q1Mar3120_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d13685232e2747-wk-Fact-A04AF3FBFD2C57289DA2088826DD4883"
      unitRef="usd">60000000.0</biib:ContractOptionExerciseFee>
    <biib:Biogenshareofcopromotionprofitsorlosses
      contextRef="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="2"
      id="d13685232e2760-wk-Fact-D1347BA419E959B89DD1DB9D653F4B42"
      unitRef="number">0.50</biib:Biogenshareofcopromotionprofitsorlosses>
    <biib:Collaborationprofitlosssharing
      contextRef="FD2020Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d13685232e2776-wk-Fact-DBABA8FE291C52C3ADA5EE60C53C31B0"
      unitRef="usd">55400000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing
      contextRef="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d13685232e2781-wk-Fact-C4DE89598E2BD157C2F85E57F7259ACB"
      unitRef="usd">127200000</biib:Collaborationprofitlosssharing>
    <biib:Biogenshareofcopromotionprofitsorlosses
      contextRef="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="2"
      id="d13685232e2785-wk-Fact-D1347BA419E959B89DD1DB9D653F4B42"
      unitRef="number">0.50</biib:Biogenshareofcopromotionprofitsorlosses>
    <biib:Collaborationprofitlosssharing
      contextRef="FD2019Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d13685232e2789-wk-Fact-F2D23752A84F53E8B6E3D77071794799"
      unitRef="usd">63400000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing
      contextRef="FD2019Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d13685232e2793-wk-Fact-88EC8C3BC2D6A9AA4F825E584143FE02"
      unitRef="usd">121500000</biib:Collaborationprofitlosssharing>
    <biib:ContractOptionExerciseFee
      contextRef="D2020Q1Mar3120_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d13685232e2797-wk-Fact-A04AF3FBFD2C57289DA2088826DD4883"
      unitRef="usd">60000000.0</biib:ContractOptionExerciseFee>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d13685232e2819-wk-Fact-3B5D13BCD83459CB88C1D8C6A6C98FBF"
      unitRef="usd">4500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d13685232e2823-wk-Fact-22E2DF8FD1164BDE127E5E58C13899C4"
      unitRef="usd">8200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d13685232e2828-wk-Fact-6CCBA3F908C15427AF0457F1D0C114CF"
      unitRef="usd">52200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      id="d13685232e2832-wk-Fact-27AACAC2826741C1882D5E58EC94FD25"
      unitRef="usd">77000000.0</us-gaap:Revenues>
    <us-gaap:DueFromRelatedParties
      contextRef="FI2020Q2_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d13685232e2853-wk-Fact-D78107B4063055418D99F7CA9ABC10E0"
      unitRef="usd">13300000</us-gaap:DueFromRelatedParties>
    <us-gaap:DueFromRelatedParties
      contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d13685232e2857-wk-Fact-ECC96733488B5DC9BB0C21391FF08BA1"
      unitRef="usd">85000000.0</us-gaap:DueFromRelatedParties>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="FI2020Q2_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d13685232e2869-wk-Fact-2E6C6C7949E9F4A9E9C05E5C4933E398"
      unitRef="usd">0</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="FI2019Q4_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember"
      decimals="-5"
      id="d13685232e2882-wk-Fact-4AA6389FCDDD56ED8905CFD32ECCAF52"
      unitRef="usd">100000000.0</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:VariableInterestEntityDisclosureTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-1FBD52E1DB64545D9E82B627EAC5D955-0-wk-Fact-516634095D045D94B24166246D159828">&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Consolidated Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Neurimmune SubOne AG&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have a collaboration and license agreement with Neurimmune SubOne AG (Neurimmune) for the development and commercialization of antibodies for the potential treatment of AD, including aducanumab (as amended, the Neurimmune Agreement). We are responsible for the development, manufacturing and commercialization of all collaboration products. The Neurimmune Agreement is effective for the longer of the duration of certain patents relating to a licensed product or &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; years from the first commercial sale of any product using such a licensed compound.  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#x2019;s economic performance and we are required to fund &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;100%&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the research and development costs incurred in support of the collaboration. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2017 we amended the terms of the Neurimmune Agreement and made a &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$150.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; payment to Neurimmune in exchange for a &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; reduction in the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab. In May 2018 we made an additional &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$50.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; payment to Neurimmune to further reduce the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab, by an additional &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. Our royalty rates payable on products developed under the Neurimmune Agreement, including royalty rates payable on potential commercial sales of aducanumab, now range from the high single digits to sub-teens. As we consolidate the results of Neurimmune, &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;we treated these payments as distributions and recognized them as charges to noncontrolling interests in the fourth quarter of 2017 and the second quarter of 2018, as applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Additionally, under the terms of the Neurimmune Agreement, we are required to pay Neurimmune a milestone payment of&#160;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$75.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;upon the regulatory filing with the FDA for approval of aducanumab and a milestone payment of&#160;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$100.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&#160;if aducanumab is launched in the U.S. In July 2020 we and our collaboration partner Eisai announced that we completed the submission of a BLA to the FDA for the approval of aducanumab. As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recorded accrued expenses of approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$75.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;"&gt;related to this milestone payment as it was probable that the submission of the BLA would be completed and the milestone earned.&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;"&gt;This milestone payment is expected to be paid during the third quarter of 2020.&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; For the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized net profit-sharing income of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$33.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to reflect Eisai's &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;45%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; share of the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$75.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; milestone expense. We treated this milestone payment as a distribution and recognized it as a charge to noncontrolling interest for the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. For additional information on our collaboration arrangements with Eisai, please read &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Note 17, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development costs for which we reimburse Neurimmune are reflected in research and development expense in our condensed consolidated statements of income. During the &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, amounts reimbursed were immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The assets and liabilities of Neurimmune are not significant to our condensed consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than contractually required amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the Aducanumab Collaboration Agreement, Eisai had an option to share in the benefit and cost associated with the royalty reductions discussed above; however, Eisai did not elect to share in the benefit and cost with respect to either the October 2017 or May 2018 royalty reductions, which will impact the amount of profits (losses) on potential commercial sales of aducanumab to be shared with Eisai. For additional information on our collaboration arrangements with Eisai, please read &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Note 17, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;, &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Unconsolidated Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have relationships with various variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$22.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$22.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our investments in Neurimmune and other variable interest entities, please read &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Note 19, Investments in Variable Interest Entities,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:VariableInterestEntityDisclosureTextBlock>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="D2017Q4_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_biib_NeurimmuneMember"
      decimals="-5"
      id="d13683115e819-wk-Fact-997E9435C65D5A6582F52756129940CB"
      unitRef="usd">150000000.0</us-gaap:PaymentsToMinorityShareholders>
    <biib:Reductioninroyaltyratepayableoncommercialsales
      contextRef="D2017Q4_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_biib_NeurimmuneMember"
      decimals="2"
      id="d13683115e823-wk-Fact-EED417FA9E8E5FBFB396F61F2BD4F2EC"
      unitRef="number">0.15</biib:Reductioninroyaltyratepayableoncommercialsales>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="D2018Q2Neurimmune_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_biib_NeurimmuneMember"
      decimals="-5"
      id="d13683115e827-wk-Fact-064DA3712A435C0D8E46526DA32DB72A"
      unitRef="usd">50000000.0</us-gaap:PaymentsToMinorityShareholders>
    <biib:Additionalreductioninroyaltyratepayableoncommercialsales
      contextRef="D2018Q2Neurimmune_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_biib_NeurimmuneMember"
      decimals="2"
      id="d13683115e831-wk-Fact-99F74A94D145568D8F281294051F054B"
      unitRef="number">0.05</biib:Additionalreductioninroyaltyratepayableoncommercialsales>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="FI2019Q4_biib_FutureContingentMilestoneTypesAxis_biib_RegulatoryMilestonesMember_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_biib_NeurimmuneMember"
      decimals="-5"
      id="d13683115e841-wk-Fact-B7CDA7F09EBF5032A1DAC22B39CA6632"
      unitRef="usd">75000000.0</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="FI2019Q4_biib_FutureContingentMilestoneTypesAxis_biib_RegulatoryApprovalMilestoneMember_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_biib_NeurimmuneMember"
      decimals="-5"
      id="d13683115e845-wk-Fact-A929A072532E5FDBB054FD0C4F2762CC"
      unitRef="usd">100000000.0</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="FI2019Q4_biib_FutureContingentMilestoneTypesAxis_biib_RegulatoryMilestonesMember_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_biib_NeurimmuneMember"
      decimals="-5"
      id="d13683115e853-wk-Fact-B7CDA7F09EBF5032A1DAC22B39CA6632"
      unitRef="usd">75000000.0</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="FD2020Q2QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="-5"
      id="d13683115e880-wk-Fact-4F45C4FAE4FCB96F81105E53E7C0F0EC"
      unitRef="usd">33800000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="FD2020Q2YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember"
      decimals="INF"
      id="d13683115e884-wk-Fact-D8A49C8E2E0B56F18925AF5EDB45CDD2"
      unitRef="number">0.45</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="FI2019Q4_biib_FutureContingentMilestoneTypesAxis_biib_RegulatoryMilestonesMember_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_biib_NeurimmuneMember"
      decimals="-5"
      id="d13683115e889-wk-Fact-B7CDA7F09EBF5032A1DAC22B39CA6632"
      unitRef="usd">75000000.0</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities
      contextRef="FI2020Q2"
      decimals="-5"
      id="d13683115e961-wk-Fact-0EC1C92334AD517690D05DC8718AED69"
      unitRef="usd">22400000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
    <biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13683115e965-wk-Fact-F5D549E793FAB8ED6D735EE8D299EF61"
      unitRef="usd">22700000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-7F11942EFF075932B07CB6F0A6163135-0-wk-Fact-26C7FE6252CC5146A73DD278511C8902">&lt;div style="line-height:120%;padding-top:8px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Note 1, Summary of Significant Accounting Policies,&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#x2019; legal theories; and (v) the parties' settlement positions. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Loss Contingencies &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;IMRALDI Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In September 2018 Fresenius Kabi Deutschland GmbH (Fresenius Kabi) commenced proceedings for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris, alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis UK Limited that Biogen has commercialized in Europe, infringes the French counterpart of European Patent No. 3 148 510 (the '510 Patent), which was issued in June 2018 and expires in May 2035. No hearing has been scheduled. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2018 Fresenius Kabi commenced preliminary injunction proceedings against Biogen (Denmark) Manufacturing ApS and Biogen Denmark A/S in Denmark's Maritime and Commercial High Court alleging infringement of Danish Utility Models. In June 2019 the Danish court denied Fresenius Kabi's request for a preliminary injunction and Fresenius Kabi has appealed that decision. In July 2020 the Danish Patent Board of Appeal revoked the Utility Models that were the subject of Fresenius Kabi&#x2019;s October 2018 request for a preliminary injunction. Fresenius Kabi has not yet appealed those revocations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2020 Fresenius Kabi commenced preliminary injunction proceedings against Biogen (Denmark) Manufacturing ApS and Biogen (Denmark) A/S in Denmark&#x2019;s Maritime and Commercial High Court alleging infringement of another Danish Utility Model. No hearing has been scheduled in that action.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In November 2018 Fresenius Kabi commenced infringement proceedings for damages and injunctive relief against Biogen Italia S.R.L. in the District Court of Milan relating to the Italian counterpart of the &#x2018;510 Patent, and against Biogen GmbH in the D&#xfc;sseldorf Regional Court relating to the German counterpart of the &#x2018;510 Patent. In Italy, Fresenius Kabi has surrendered the Italian counterpart of the &#x2018;510 Patent and has moved to dismiss its infringement action. A hearing in the proceeding in Germany has been set for April 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2019 Gedeon Richter PLC (Gedeon Richter) commenced proceedings against Biogen GmbH in the D&#xfc;sseldorf Regional Court alleging infringement of the German counterpart of European Patent No. 3 212 667 (the '667 Patent), which was issued in September 2018 and expires in October 2035, and seeking damages and injunctive relief. A hearing has been set for November 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2019 Biogen Idec Ltd. (Biogen UK) and Samsung Bioepis UK Limited filed an action in the United Kingdom Patents Court to revoke the United Kingdom (U.K.) counterpart of the '667 Patent. In January 2020 the U.K. court revoked the patent.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2019 Biogen B.V. (Netherlands) and Samsung Bioepis UK Limited filed an action in the District Court of the Hague, Netherlands to revoke the Dutch counterpart of the '667 Patent. Gedeon Richter filed a separate action for infringement in the same court. A hearing was held in May 2020 on the request for revocation and the infringement action and a decision is pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;An estimate of the possible loss or range of loss in the pending IMRALDI patent litigation described above cannot be made at this time. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Qui Tam Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2015 a qui tam action filed by Michael Bawduniak on behalf of the U.S. and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts and seeks single and treble damages, civil penalties, interest, attorneys&#x2019; fees and costs. No trial date has been set. The U.S. has not made an intervention decision. An estimate of the possible loss or range of loss cannot be made at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Dispute with Former Convergence Shareholders&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In November and December 2019 Shareholder Representative Services LLC, on behalf of the former shareholders of Convergence, sent us correspondence asserting claims of &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$200.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for alleged breach of the contract under which we acquired Convergence. We dispute the claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:174%;padding-top:12px;text-align:left;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Dispute with Jacobs Switzerland GmbH&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Jacobs Switzerland GmbH, the general contractor for the construction of our large-scale biologics manufacturing facility in Solothurn, Switzerland, claims approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;31.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Swiss Francs (approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$33.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) relating to construction costs. We dispute the claim.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Petition for Inter Partes Review&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2018 Mylan filed a petition that was granted by the U.S. Patent Trial and Appeal Board (PTAB) for &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;inter partes&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; review of the '514 Patent, which covers treatment of MS with 480 mg of dimethyl fumarate per day as provided for in our TECFIDERA label. In February 2020 the PTAB issued a final written decision upholding the patentability of the &#x2018;514 Patent and in April 2020 Mylan filed an appeal in the Federal Circuit, which is pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Hatch-Waxman Act Litigation relating to TECFIDERA Orange-Book Listed Patents&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In 2017, 2018 and 2019 we filed patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, against Accord Healthcare Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Aurobindo Pharma U.S.A., Inc., Cipla Limited, Glenmark Pharmaceuticals Ltd., Graviti Pharmaceuticals Pvt. Ltd., Hetero USA, Inc.,&#160;Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Prinston Pharmaceutical Inc., Sandoz Inc., Sawai USA, Inc., Shilpa Medicare Limited, Slayback Pharma LLC, Torrent Pharmaceuticals Ltd., TWi Pharmaceuticals, Inc., Windlas Healthcare Pvt. Ltd. and Zydus Pharmaceuticals (USA) Inc. (the Delaware Defendants) in the U.S. District Court for the District of Delaware (the Delaware Court) and against Mylan in the West Virginia Court. The litigation against Aurobindo Pharma U.S.A., Inc., Glenmark Pharmaceuticals Ltd. and Sawai USA, Inc. was dismissed in the fourth quarter of 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A trial against the remaining Delaware Defendants was held in the Delaware Court in December 2019 and we are awaiting a decision.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On June 22, 2020, the West Virginia Court entered judgment for Mylan that the asserted claims of the &#x2018;514 Patent are invalid for lack of written description. We appealed the judgment on June 23, 2020, to the Federal Circuit and filed an emergency motion for an injunction pending resolution of the appeal. On June 30, 2020, the Federal Circuit entered an interim injunction enjoining Mylan from launching its generic version of TECFIDERA pending the Federal Circuit's consideration of our request for an injunction pending appeal.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have entered into settlement agreements with some of the Delaware Defendants and we now anticipate market entry of a generic product equivalent to TECFIDERA before the &#x2018;514 Patent expires in February 2028.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;European Patent Office Oppositions&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In 2016 the European Patent Office (EPO) revoked our European Patent No. 2 137 537, which covers the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. We have appealed to the Technical Boards of Appeal of the EPO and a hearing has been set for January 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2018 the EPO revoked Forward Pharma&#x2019;s European Patent No. 2 801 355, which expires in October 2025. Forward Pharma has filed an appeal to the Technical Boards of Appeal of the EPO and a hearing has been set for February 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;TYSABRI Patent Revocation Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In November 2017 Bioeq GMBH, affiliated with the Polpharma Group, brought an action in the Polish Patent Office seeking to revoke Polish Patent No. 215263 (the Polish '263 Patent), which corresponds to our European Patent No. 1 485 127 (the E.U. '127 Patent) and covers administration of natalizumab (TYSABRI) to treat MS. The Polish '263 Patent expires in February 2023. No hearing has been set in this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Swiss Pharma International AG, also affiliated with the Polpharma Group, filed actions in the District Court of the Hague, Netherlands (January 2016), the German Patents Court (March 2016) and the Commercial Court of Rome (November 2017) seeking to invalidate the Dutch, German and Italian counterparts, respectively, of the E.U. '127 Patent, which also cover administration of natalizumab (TYSABRI) to treat MS and expire in February 2023. The Dutch and German counterparts were ruled invalid. The decision in the Dutch action was affirmed on appeal and the German appeal has been withdrawn. No hearing has been set in the Italian action.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;'755 Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May&#160;2010 Biogen MA Inc. (formerly Biogen Idec MA Inc.) filed a complaint in the U.S.&#160;District Court for the District of New Jersey alleging infringement by Bayer Healthcare Pharmaceuticals Inc. (Bayer) (manufacturer, marketer and seller of BETASERON and manufacturer of EXTAVIA), EMD Serono, Inc. (EMD Serono) (manufacturer, marketer and seller of REBIF), Pfizer (co-marketer of REBIF) and Novartis Pharmaceuticals Corp. (Novartis) (marketer and seller of EXTAVIA) of our U.S. Patent No. 7,588,755 (the '755 Patent), which claims, among other things, the use of interferon beta for immunomodulation. The complaint seeks monetary damages, including lost profits and royalties. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Bayer, Pfizer, Novartis and EMD Serono all filed counterclaims seeking declaratory judgments of patent invalidity and non-infringement and seeking monetary relief in the form of costs and attorneys' fees. Bayer had previously filed a complaint against us in the same court, on May 27, 2010, seeking a declaratory judgment that it does not infringe the '755 Patent and that the '755 Patent is invalid, and seeking monetary relief in the form of attorneys' fees, costs and expenses. Bayer has also requested &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;ex parte&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; reexamination by the U.S. Patent and Trademark Office of Claim 1 of the &#x2018;755 Patent, which request was granted in January 2020 and is pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In September 2018 the trial court entered judgment against EMD Serono and Pfizer that the '755 Patent is infringed and valid and ordered a new trial on damages. EMD Serono and Pfizer filed an appeal in the U.S. Court of Appeals for the Federal Circuit, which is pending. The trial court has not yet scheduled the new damages trial or a trial against Bayer and Novartis.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Annulment Proceeding in General Court of the European Union relating to TECFIDERA&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2018 Pharmaceutical Works Polpharma SA (Polpharma) filed an application in the General Court of the European Union seeking to annul a decision of the European Medicines Agency (EMA) in which the EMA refused to validate Polpharma&#x2019;s application to market a generic version of TECFIDERA on the grounds that TECFIDERA benefits from regulatory data protection (RDP). Polpharma disputes that TECFIDERA benefits from RDP. Biogen and the European Commission were granted leave to intervene in the case in support of the EMA and the case is pending. A hearing was held on&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#ff0000;"&gt; &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;July 13, 2020, and we are awaiting a decision.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Government Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have learned that state and U.S. governmental authorities are investigating our sales and promotional practices and have received related subpoenas. We are cooperating with the investigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have received subpoenas and other requests from the U.S. government for documents and information relating to our relationship with non-profit organizations that assist patients taking drugs sold by Biogen and the government has challenged some of our contributions to these organizations. We have reached an agreement in principle with the government to resolve this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Tax Matter&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We previously reported that the State Treasury of Goias, Brazil issued tax assessments for the period 2013 through February 2018 relating to tax on the circulation of goods and totaling approximately &lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;span&gt;$70.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; including interest and penalties.&#160;In May 2020 the tax auditor recommended the cancellation of these assessments. We do not anticipate reporting on this matter further.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Product Liability and Other Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="FI2019Q4"
      decimals="-5"
      id="d13685541e853-wk-Fact-EAF08B59FD5558EEABC2FA3752BE6C21"
      unitRef="usd">200000000.0</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <biib:DisputedClaimsRelatingtoConstructionCosts
      contextRef="FI2020Q2"
      decimals="-6"
      id="d13685541e863-wk-Fact-CA9C347139CCAD692BAB5EEC2CCFEE07"
      unitRef="chf">31000000.0</biib:DisputedClaimsRelatingtoConstructionCosts>
    <biib:DisputedClaimsRelatingtoConstructionCosts
      contextRef="FI2020Q2"
      decimals="-6"
      id="d13685541e867-wk-Fact-4788D1A2CD2AFB78CA345EEC7654A6ED"
      unitRef="usd">33000000.0</biib:DisputedClaimsRelatingtoConstructionCosts>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="FD2020Q2YTD_us-gaap_IncomeTaxAuthorityAxis_country_BR"
      decimals="-5"
      id="d13685541e961-wk-Fact-8DBEF3477A6153DFA64FFDF85A8C0D9E"
      unitRef="usd">70000000.0</us-gaap:LossContingencyDamagesSoughtValue>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639332957336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jul. 21, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-19311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOGEN INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000875045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0112644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">225 Binney Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">679-2000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0005 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BIIB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158,313,471<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639333219128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Income (Unaudited) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 3,681.6<span></span>
</td>
<td class="nump">$ 3,616.7<span></span>
</td>
<td class="nump">$ 7,215.9<span></span>
</td>
<td class="nump">$ 7,106.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Cost and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales, excluding amortization and impairment of acquired intangible assets</a></td>
<td class="nump">411.1<span></span>
</td>
<td class="nump">476.3<span></span>
</td>
<td class="nump">865.5<span></span>
</td>
<td class="nump">1,078.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">647.6<span></span>
</td>
<td class="nump">484.8<span></span>
</td>
<td class="nump">1,123.9<span></span>
</td>
<td class="nump">1,048.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">555.1<span></span>
</td>
<td class="nump">587.6<span></span>
</td>
<td class="nump">1,125.2<span></span>
</td>
<td class="nump">1,155.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="nump">61.5<span></span>
</td>
<td class="nump">70.1<span></span>
</td>
<td class="nump">133.0<span></span>
</td>
<td class="nump">138.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="nump">21.8<span></span>
</td>
<td class="nump">63.5<span></span>
</td>
<td class="nump">93.5<span></span>
</td>
<td class="nump">121.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown', window );">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">113.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">(Gain) loss on fair value remeasurement of contingent consideration</a></td>
<td class="nump">10.0<span></span>
</td>
<td class="num">(20.0)<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="num">(8.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total cost and expenses</a></td>
<td class="nump">1,707.1<span></span>
</td>
<td class="nump">1,660.8<span></span>
</td>
<td class="nump">3,421.6<span></span>
</td>
<td class="nump">3,647.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">1,974.5<span></span>
</td>
<td class="nump">1,955.9<span></span>
</td>
<td class="nump">3,794.3<span></span>
</td>
<td class="nump">3,458.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">63.0<span></span>
</td>
<td class="num">(197.4)<span></span>
</td>
<td class="num">(57.5)<span></span>
</td>
<td class="nump">159.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income tax expense and equity in loss of investee, net of tax</a></td>
<td class="nump">2,037.5<span></span>
</td>
<td class="nump">1,758.5<span></span>
</td>
<td class="nump">3,736.8<span></span>
</td>
<td class="nump">3,618.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">446.1<span></span>
</td>
<td class="nump">248.1<span></span>
</td>
<td class="nump">738.2<span></span>
</td>
<td class="nump">670.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in loss of investee, net of tax</a></td>
<td class="num">(15.1)<span></span>
</td>
<td class="nump">16.3<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="nump">45.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,606.5<span></span>
</td>
<td class="nump">1,494.1<span></span>
</td>
<td class="nump">2,999.0<span></span>
</td>
<td class="nump">2,902.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="nump">64.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">57.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 1,542.1<span></span>
</td>
<td class="nump">$ 1,494.1<span></span>
</td>
<td class="nump">$ 2,941.2<span></span>
</td>
<td class="nump">$ 2,902.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 9.60<span></span>
</td>
<td class="nump">$ 7.85<span></span>
</td>
<td class="nump">$ 17.65<span></span>
</td>
<td class="nump">$ 15.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 9.59<span></span>
</td>
<td class="nump">$ 7.85<span></span>
</td>
<td class="nump">$ 17.61<span></span>
</td>
<td class="nump">$ 14.99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">160.6<span></span>
</td>
<td class="nump">190.3<span></span>
</td>
<td class="nump">166.7<span></span>
</td>
<td class="nump">193.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">160.9<span></span>
</td>
<td class="nump">190.4<span></span>
</td>
<td class="nump">167.0<span></span>
</td>
<td class="nump">193.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 2,795.7<span></span>
</td>
<td class="nump">$ 2,880.3<span></span>
</td>
<td class="nump">$ 5,700.3<span></span>
</td>
<td class="nump">$ 5,560.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">478.3<span></span>
</td>
<td class="nump">576.4<span></span>
</td>
<td class="nump">998.7<span></span>
</td>
<td class="nump">1,093.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 407.6<span></span>
</td>
<td class="nump">$ 160.0<span></span>
</td>
<td class="nump">$ 516.9<span></span>
</td>
<td class="nump">$ 452.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationprofitlosssharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration profit (loss) sharing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationprofitlosssharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2443-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639333935624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 1,542.1<span></span>
</td>
<td class="nump">$ 1,494.1<span></span>
</td>
<td class="nump">$ 2,941.2<span></span>
</td>
<td class="nump">$ 2,902.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gains (losses) on securities available for sale, net of tax</a></td>
<td class="nump">8.7<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">10.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax', window );">Unrealized gains (losses) on cash flow hedges, net of tax</a></td>
<td class="num">(51.2)<span></span>
</td>
<td class="num">(37.9)<span></span>
</td>
<td class="num">(17.4)<span></span>
</td>
<td class="num">(21.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease', window );">Gains (losses) on net investment hedges</a></td>
<td class="num">(6.2)<span></span>
</td>
<td class="nump">11.7<span></span>
</td>
<td class="nump">16.8<span></span>
</td>
<td class="nump">25.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Unrealized gains (losses) on pension benefit obligation, net of tax</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Currency translation adjustment</a></td>
<td class="nump">16.9<span></span>
</td>
<td class="num">(10.3)<span></span>
</td>
<td class="num">(47.0)<span></span>
</td>
<td class="num">(28.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="num">(31.7)<span></span>
</td>
<td class="num">(33.1)<span></span>
</td>
<td class="num">(45.8)<span></span>
</td>
<td class="num">(12.5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">1,510.4<span></span>
</td>
<td class="nump">1,461.0<span></span>
</td>
<td class="nump">2,895.4<span></span>
</td>
<td class="nump">2,890.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="nump">65.5<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="nump">59.6<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income attributable to Biogen Inc.</a></td>
<td class="nump">$ 1,575.9<span></span>
</td>
<td class="nump">$ 1,460.6<span></span>
</td>
<td class="nump">$ 2,955.0<span></span>
</td>
<td class="nump">$ 2,890.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613674-111683<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the cumulative translation adjustment from gain (loss), after tax, on foreign currency derivatives, that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b),(c),(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639334346744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,384.9<span></span>
</td>
<td class="nump">$ 2,913.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">1,942.7<span></span>
</td>
<td class="nump">1,562.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">2,133.6<span></span>
</td>
<td class="nump">1,880.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DuefromantiCD20therapeuticprograms', window );">Due from anti-CD20 therapeutic programs</a></td>
<td class="nump">441.1<span></span>
</td>
<td class="nump">590.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">952.7<span></span>
</td>
<td class="nump">804.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">638.8<span></span>
</td>
<td class="nump">631.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">8,493.8<span></span>
</td>
<td class="nump">8,381.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Marketable securities</a></td>
<td class="nump">922.8<span></span>
</td>
<td class="nump">1,408.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">3,330.7<span></span>
</td>
<td class="nump">3,247.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">436.2<span></span>
</td>
<td class="nump">427.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">3,383.8<span></span>
</td>
<td class="nump">3,527.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">5,751.0<span></span>
</td>
<td class="nump">5,757.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax asset</a></td>
<td class="nump">1,710.2<span></span>
</td>
<td class="nump">3,232.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Investments and other assets</a></td>
<td class="nump">1,483.3<span></span>
</td>
<td class="nump">1,252.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">25,511.8<span></span>
</td>
<td class="nump">27,234.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Current portion of notes payable</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1,495.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Taxes payable</a></td>
<td class="nump">576.7<span></span>
</td>
<td class="nump">71.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">383.9<span></span>
</td>
<td class="nump">530.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accrued expenses and other</a></td>
<td class="nump">2,486.5<span></span>
</td>
<td class="nump">2,765.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,447.1<span></span>
</td>
<td class="nump">4,863.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable</a></td>
<td class="nump">7,423.8<span></span>
</td>
<td class="nump">4,459.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">1,461.5<span></span>
</td>
<td class="nump">2,810.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">414.8<span></span>
</td>
<td class="nump">412.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,475.4<span></span>
</td>
<td class="nump">1,348.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">14,222.6<span></span>
</td>
<td class="nump">13,895.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Biogen Idec Inc. shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.001 per share</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.0005 per share</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(181.0)<span></span>
</td>
<td class="num">(135.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">14,466.7<span></span>
</td>
<td class="nump">16,455.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost</a></td>
<td class="num">(2,977.1)<span></span>
</td>
<td class="num">(2,977.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Biogen Inc. shareholders&#8217; equity</a></td>
<td class="nump">11,308.7<span></span>
</td>
<td class="nump">13,343.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="num">(19.5)<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">11,289.2<span></span>
</td>
<td class="nump">13,339.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 25,511.8<span></span>
</td>
<td class="nump">$ 27,234.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DuefromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivable from anti-CD20 therapeutic programs for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DuefromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31931-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639326351272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0005<span></span>
</td>
<td class="nump">$ 0.0005<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639334484392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 2,999.0<span></span>
</td>
<td class="nump">$ 2,902.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation, amortization and impairments</a></td>
<td class="nump">232.8<span></span>
</td>
<td class="nump">238.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">75.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">115.8<span></span>
</td>
<td class="nump">98.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain on interest rate swap</a></td>
<td class="num">(3.3)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Contingent consideration</a></td>
<td class="nump">5.5<span></span>
</td>
<td class="num">(8.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax', window );">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">113.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">180.2<span></span>
</td>
<td class="nump">71.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi', window );">Unrealized (gain) loss on strategic investments</a></td>
<td class="num">(39.7)<span></span>
</td>
<td class="num">(199.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">85.3<span></span>
</td>
<td class="nump">91.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(268.8)<span></span>
</td>
<td class="num">(2.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties', window );">Due from anti-CD20 therapeutic programs</a></td>
<td class="nump">149.1<span></span>
</td>
<td class="num">(30.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(188.2)<span></span>
</td>
<td class="nump">108.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(441.4)<span></span>
</td>
<td class="num">(216.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income tax assets and liabilities</a></td>
<td class="nump">504.6<span></span>
</td>
<td class="nump">306.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other changes in operating assets and liabilities, net</a></td>
<td class="nump">9.9<span></span>
</td>
<td class="num">(49.7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flows provided by operating activities</a></td>
<td class="nump">3,415.8<span></span>
</td>
<td class="nump">3,423.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">3,879.9<span></span>
</td>
<td class="nump">3,255.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(3,753.9)<span></span>
</td>
<td class="num">(2,075.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherProductiveAssets', window );">Contingent consideration paid related to Fumapharm AG acquisition</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(300.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition of Nightstar Therapeutics plc, net of cash acquired</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(744.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates', window );">Purchase of Sangamo Therapeutics, Inc. stock</a></td>
<td class="num">(141.8)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(254.7)<span></span>
</td>
<td class="num">(314.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="num">(75.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisitions of intangible assets</a></td>
<td class="num">(37.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromHedgeInvestingActivities', window );">Proceeds from settlement of net investment hedge</a></td>
<td class="num">(7.8)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity', window );">Proceeds from sales of strategic investments</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">309.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(4.0)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flows provided by investing activities</a></td>
<td class="num">(389.8)<span></span>
</td>
<td class="nump">128.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of treasury stock</a></td>
<td class="num">(5,029.1)<span></span>
</td>
<td class="num">(3,057.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments related to issuance of stock for share-based compensation arrangements, net</a></td>
<td class="num">(19.2)<span></span>
</td>
<td class="num">(23.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from borrowings</a></td>
<td class="nump">2,967.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of borrowings</a></td>
<td class="num">(1,500.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities', window );">Cash proceeds from settlement of swap</a></td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Net distribution to noncontrolling interest</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="nump">19.0<span></span>
</td>
<td class="nump">21.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flows used in financing activities</a></td>
<td class="num">(3,558.7)<span></span>
</td>
<td class="num">(3,055.0)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(532.7)<span></span>
</td>
<td class="nump">496.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(3.9)<span></span>
</td>
<td class="num">(2.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of the period</a></td>
<td class="nump">2,913.7<span></span>
</td>
<td class="nump">1,224.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of the period</a></td>
<td class="nump">$ 2,384.9<span></span>
</td>
<td class="nump">$ 1,723.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from an individually significant component disposed of or held-for-sale attributable to parent. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3444-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash outflow or inflow from derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromHedgeInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 27<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3581-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromHedgeInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity securities classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639330441288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Equity Statement - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred stock</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Retained earnings</div></th>
<th class="th"><div>Treasury stock</div></th>
<th class="th"><div>Parent</div></th>
<th class="th"><div>Noncontrolling interest</div></th>
<th class="th"><div>2018 Share Repurchase Program</div></th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Common stock</div>
</th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Additional paid-in capital</div>
</th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Retained earnings</div>
</th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Treasury stock</div>
</th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Parent</div>
</th>
<th class="th"><div>2019 Share Repurchase Program</div></th>
<th class="th">
<div>2019 Share Repurchase Program </div>
<div>Common stock</div>
</th>
<th class="th">
<div>2019 Share Repurchase Program </div>
<div>Additional paid-in capital</div>
</th>
<th class="th">
<div>2019 Share Repurchase Program </div>
<div>Retained earnings</div>
</th>
<th class="th">
<div>2019 Share Repurchase Program </div>
<div>Treasury stock</div>
</th>
<th class="th">
<div>2019 Share Repurchase Program </div>
<div>Parent</div>
</th>
<th class="th"><div>December 2019 Share Repurchase Program</div></th>
<th class="th">
<div>December 2019 Share Repurchase Program </div>
<div>Common stock</div>
</th>
<th class="th">
<div>December 2019 Share Repurchase Program </div>
<div>Additional paid-in capital</div>
</th>
<th class="th">
<div>December 2019 Share Repurchase Program </div>
<div>Retained earnings</div>
</th>
<th class="th">
<div>December 2019 Share Repurchase Program </div>
<div>Treasury stock</div>
</th>
<th class="th">
<div>December 2019 Share Repurchase Program </div>
<div>Parent</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(221.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 13,031.6<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (240.4)<span></span>
</td>
<td class="nump">$ 16,257.0<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">$ 13,039.6<span></span>
</td>
<td class="num">$ (8.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">2,902.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,902.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,902.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(12.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12.5)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Noncontrollinginterestincreasedecreaseother', window );">Noncontrolling interest, increase (decrease) other</a></td>
<td class="nump">4.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,147.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,147.4)<span></span>
</td>
<td class="num">$ (2,147.4)<span></span>
</td>
<td class="num">$ (909.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (909.9)<span></span>
</td>
<td class="num">$ (909.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to Share Repurchase Progams, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (110.5)<span></span>
</td>
<td class="num">$ (2,036.9)<span></span>
</td>
<td class="nump">$ 2,147.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (19.7)<span></span>
</td>
<td class="num">$ (890.2)<span></span>
</td>
<td class="nump">$ 909.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">26.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">26.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under award plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(50.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">104.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2019</a></td>
<td class="nump">12,948.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(252.9)<span></span>
</td>
<td class="nump">16,182.8<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">12,952.9<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(208.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(219.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2019</a></td>
<td class="nump">13,822.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(219.8)<span></span>
</td>
<td class="nump">17,026.7<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">13,829.9<span></span>
</td>
<td class="num">(7.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,494.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,494.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,494.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(33.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33.1)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Noncontrollinginterestincreasedecreaseother', window );">Noncontrolling interest, increase (decrease) other</a></td>
<td class="nump">4.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,491.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,491.6)<span></span>
</td>
<td class="num">(1,491.6)<span></span>
</td>
<td class="num">$ (909.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (909.9)<span></span>
</td>
<td class="num">(909.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to Share Repurchase Progams, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (44.9)<span></span>
</td>
<td class="num">$ (1,446.7)<span></span>
</td>
<td class="nump">$ 1,491.6<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19.7)<span></span>
</td>
<td class="num">(890.2)<span></span>
</td>
<td class="nump">$ 909.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">9.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">9.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under award plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(1.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">55.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2019</a></td>
<td class="nump">12,948.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(252.9)<span></span>
</td>
<td class="nump">16,182.8<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">12,952.9<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(208.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(198.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">13,339.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(135.2)<span></span>
</td>
<td class="nump">16,455.4<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">13,343.2<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">2,999.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,941.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,941.2<span></span>
</td>
<td class="nump">57.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(44.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45.8)<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Noncontrollinginterestincreasedecreaseother', window );">Noncontrolling interest, increase (decrease) other</a></td>
<td class="num">(75.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,279.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,279.1)<span></span>
</td>
<td class="num">$ (1,279.1)<span></span>
</td>
<td class="num">$ (3,750.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,750.0)<span></span>
</td>
<td class="num">$ (3,750.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to Share Repurchase Progams, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (71.0)<span></span>
</td>
<td class="num">$ (1,208.1)<span></span>
</td>
<td class="nump">$ 1,279.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (76.2)<span></span>
</td>
<td class="num">$ (3,673.8)<span></span>
</td>
<td class="nump">$ 3,750.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">29.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">29.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under award plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(48.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">118.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="num">(0.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">11,289.2<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(181.0)<span></span>
</td>
<td class="nump">14,466.7<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">11,308.7<span></span>
</td>
<td class="num">(19.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(182.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(191.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2020</a></td>
<td class="nump">12,536.9<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="num">(149.3)<span></span>
</td>
<td class="nump">15,673.1<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">12,546.9<span></span>
</td>
<td class="num">(10.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,606.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,542.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,542.1<span></span>
</td>
<td class="nump">64.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(30.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31.7)<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Noncontrollinginterestincreasedecreaseother', window );">Noncontrolling interest, increase (decrease) other</a></td>
<td class="num">(75.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(75.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,808.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,808.9)<span></span>
</td>
<td class="num">(2,808.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to Share Repurchase Progams, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (60.7)<span></span>
</td>
<td class="num">$ (2,748.2)<span></span>
</td>
<td class="nump">$ 2,808.9<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">11.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">11.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under award plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">49.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">$ 11,289.2<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (181.0)<span></span>
</td>
<td class="nump">$ 14,466.7<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">$ 11,308.7<span></span>
</td>
<td class="num">$ (19.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(182.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Noncontrollinginterestincreasedecreaseother">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling interest, increase (decrease) other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Noncontrollinginterestincreasedecreaseother</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockRetiredCostMethodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockRetiredCostMethodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639332275368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Business Overview</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer's disease (AD) and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; and ophthalmology. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; neurocognitive disorders; acute neurology; and pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS and relapsing MS; and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 18, Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K).</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe and have exclusive rights to commercialize these products in China. Additionally, we have exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11 referencing LUCENTIS and SB15 referencing EYLEA, in major markets worldwide, including the United States (U.S.), Canada, Europe, Japan and Australia. For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 17, Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these unaudited condensed consolidated financial statements (condensed consolidated financial statements). </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Basis of Presentation</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K. Our accounting policies are described in the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Notes to Consolidated Financial Statements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We operate as </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>one</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidation</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>100%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our condensed consolidated financial statements and there may be changes to those estimates in future periods. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">New Accounting Pronouncements</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements or disclosures.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Credit Losses</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the FASB issued Accounting Standards Update (ASU) No. 2016-13, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2020. This standard requires entities to estimate an expected lifetime credit loss on financial assets ranging from short-term trade accounts receivable to long-term financings and report credit losses using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. This standard limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This standard became effective for us on January 1, 2020, and based on the composition of our trade receivables, investment portfolio and other financial assets, current economic conditions and historical credit loss activity, the adoption of this standard did not have a material impact on our condensed consolidated financial statements and related disclosures. During the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recorded an immaterial amount associated with expected credit losses related to outstanding trade receivables in certain foreign countries that have been disproportionately impacted by the COVID-19 pandemic.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Fair Value Measurements</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 the FASB issued ASU No. 2018-13,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard modifies certain disclosure requirements on fair value measurements. This standard became effective for us on January 1, 2020, and did not have a material impact on our disclosures. For the new disclosures regarding our Level 3 instruments, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 7, Fair Value Measurements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Internal Use Software</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 the FASB issued ASU No. 2018-15, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard clarifies the accounting for implementation costs in cloud computing arrangements. This standard became effective for us on January 1, 2020, and was adopted on a prospective basis, resulting in an immaterial amount of additional assets being recorded on our condensed consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Collaborative Arrangements</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2018 the FASB issued ASU No. 2018-18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard makes targeted improvements for collaborative arrangements as follows:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Accounting Standards Codification (ASC) 606, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adds unit-of-account guidance to ASC 808, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Arrangements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This standard became effective for us on January 1, 2020, and did not have a material impact on our condensed consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639331186536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">BIIB118 Acquisition</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2020 we acquired BIIB118 (formerly known as PF-05251749), a novel CNS-penetrant small molecule inhibitor of casein kinase 1, for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases from Pfizer Inc. (Pfizer). We plan to develop the Phase 1 asset for the potential treatment of sundowning in AD and irregular sleep wake rhythm disorder in Parkinson&#8217;s disease. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with this acquisition, we made an upfront payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$75.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Pfizer, which was accounted for as an asset acquisition and recorded as acquired in-process research and development (IPR&amp;D) in our condensed consolidated statements of income as BIIB118 has not yet reached technological feasibility. We may also pay Pfizer up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$635.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in potential additional development and commercialization milestone payments, as well as tiered royalties in the high single digits to sub-teens.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acquisition of Nightstar Therapeutics plc</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2019 we completed our acquisition of all of the outstanding shares of Nightstar Therapeutics plc (NST), a clinical-stage gene therapy company focused on adeno-associated virus (AAV) treatments for inherited retinal disorders. As a result of this acquisition, we added </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>two</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> mid- to late-stage clinical assets, as well as preclinical programs, in ophthalmology. These assets include BIIB111 (timrepigene emparvovec), which is in Phase 3 development for the potential treatment of choroideremia, a rare, degenerative, X-linked inherited retinal disorder that leads to blindness and currently has no approved treatments, and BIIB112 (RPGR gene therapy), which is in Phase 2/3 development for the potential treatment of X-linked retinitis pigmentosa, which is a rare inherited retinal disease with no currently approved treatments.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of this acquisition, we paid NST shareholders </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$25.50</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cash for each issued and outstanding NST share, which totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$847.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In addition, we paid </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$4.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cash for equity compensation, which is attributable to pre-combination services and was reflected as a component of the total purchase price paid. The fair value of equity compensation attributable to the post-combination service period was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$26.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of which </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$18.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recognized as a charge to selling, general and administrative expense with the remaining </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$7.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as a charge to research and development expense in our condensed consolidated statements of income. These amounts were associated with the accelerated vesting of stock options previously granted to NST employees and were fully paid in cash as of June 30, 2019. We funded this acquisition through available cash and accounted for it as an acquisition of a business. We finalized purchase accounting for this acquisition in the fourth quarter of 2019.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our acquisition of NST, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 2, Acquisitions,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our 2019 Form 10-K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639327054184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Divestitures Divestitures<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DivestituresAbstract', window );"><strong>Divestitures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Divestitures</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Divestiture of Hiller&#248;d, Denmark Manufacturing Operations </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 we entered into a share purchase agreement with FUJIFILM Corporation (FUJIFILM) to sell all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#248;d, Denmark. We determined that the assets and liabilities related to our Hiller&#248;d, Denmark manufacturing operations met the criteria to be classified as held for sale. For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recorded a loss of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$174.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in our condensed consolidated statements of income. This estimated loss included a pre-tax loss of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$113.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which reflected a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$2.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> decrease to our original estimate as of March 31, 2019, reflecting our estimated fair value of the assets and liabilities held for sale as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, adjusted for our expected costs to sell our Hiller&#248;d, Denmark manufacturing operations of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$10.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and included our initial estimate of the fair value of an adverse commitment of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$120.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with the guarantee of future minimum batch production at the Hiller&#248;d facility. The value of this adverse commitment was determined using a probability-weighted estimate of future manufacturing activity. In addition, we recorded a tax expense of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$61.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the planned transaction during the six months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> this transaction closed and we received approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$881.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cash, which may be adjusted based on the contractual terms discussed below. We determined that the operations disposed of in this transaction did not meet the criteria to be classified as discontinued operations under the applicable guidance.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As part of this transaction, we provided FUJIFILM with certain minimum batch production commitment guarantees. There is a risk that the minimum contractual batch production commitments will not be met. Our estimate of the adverse commitment obligation is approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$74.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We developed this estimate using a probability-weighted estimate of future manufacturing activity and may adjust this estimate based upon changes in business conditions, which may result in the increase or reduction of this adverse commitment obligation in subsequent periods. We also may be obligated to indemnify FUJIFILM for liabilities that existed relating to certain business activities incurred prior to the closing of this transaction. Our estimate of the fair value of the adverse commitment obligation is a Level 3 measurement and is based on forecasted batch production at the Hiller&#248;d facility.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we may earn certain contingent payments based on future manufacturing activities at the Hiller&#248;d facility. For the disposition of a business, our policy is to recognize contingent consideration when the consideration is realizable. Consistent with our assessment as of the transaction date, we currently believe the probability of earning these payments is remote and therefore we did not include these contingent payments in our calculation of the fair value of the operations.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As part of this transaction, we entered into certain manufacturing services agreements with FUJIFILM pursuant to which FUJIFILM will use the Hiller&#248;d facility to produce commercial products for us, such as TYSABRI, as well as other third-party products. In addition, we sold to FUJIFILM </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$41.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of raw materials that were remaining at the Hiller&#248;d facility on the closing date of this transaction in the third quarter of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. These materials were sold at cost, which approximated fair value.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DivestituresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Divestitures [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DivestituresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639330326152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues Revenues<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenues</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Product Revenues</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues by product are summarized as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:30%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United<br/>States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of<br/>World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United<br/>States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of<br/>World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Multiple Sclerosis (MS):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Fumarate*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>921.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>268.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,190.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>869.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>280.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,150.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Interferon**</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>345.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>135.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>481.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>379.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>174.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>554.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TYSABRI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>244.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>187.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>432.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>264.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>211.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>475.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FAMPYRA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>23.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>23.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>24.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>24.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Subtotal: MS product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,511.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>615.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>2,126.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,513.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>690.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2,204.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Spinal Muscular Atrophy:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">SPINRAZA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>210.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>284.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>494.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>230.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>257.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>488.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Biosimilars:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">BENEPALI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>106.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>106.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>120.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>120.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">IMRALDI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>44.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>44.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>47.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>47.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FLIXABI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>20.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>20.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>16.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>16.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Subtotal: Biosimilar product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>171.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>171.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>184.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>184.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FUMADERM</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,721.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,074.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>2,795.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,744.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,135.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2,880.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:34%;"/><td style="width:32%;"/><td style="width:34%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">*Fumarate includes TECFIDERA and VUMERITY. VUMERITY became commercially available in the U.S. in November 2019.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">**Interferon includes AVONEX and PLEGRIDY.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United<br/>States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of<br/>World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United<br/>States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of<br/>World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Multiple Sclerosis (MS):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Fumarate*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,699.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>591.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>2,291.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,587.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>561.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2,149.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Interferon**</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>638.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>309.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>947.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>707.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>348.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,055.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TYSABRI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>521.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>432.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>954.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>509.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>426.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>935.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FAMPYRA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>51.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>51.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>47.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>47.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Subtotal: MS product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>2,859.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,385.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>4,244.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2,803.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,383.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>4,187.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Spinal Muscular Atrophy:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">SPINRAZA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>445.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>613.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,059.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>453.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>552.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,006.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Biosimilars:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">BENEPALI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>239.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>239.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>244.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>244.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">IMRALDI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>106.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>106.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>83.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>83.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FLIXABI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>44.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>44.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>31.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>31.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Subtotal: Biosimilar product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>390.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>390.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>358.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>358.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FUMADERM</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>6.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>6.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>3,304.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>2,395.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>5,700.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>3,257.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2,302.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>5,560.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:34%;"/><td style="width:32%;"/><td style="width:34%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">*Fumarate includes TECFIDERA and VUMERITY. VUMERITY became commercially available in the U.S. in November 2019.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">**Interferon includes AVONEX and PLEGRIDY.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognized revenues from two wholesalers accounting for </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>31.7%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>17.9%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of gross product revenues for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>30.8%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>16.2%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of gross product revenues for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognized revenues from two wholesalers accounting for </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>30.5%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>18.2%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of gross product revenues for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>30.9%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>16.3%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of gross product revenues for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Balance, as of December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>131.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,027.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>40.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,198.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Current provisions relating to sales in current year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>387.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,624.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>9.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>2,021.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Adjustments relating to prior years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(25.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(26.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Payments/credits relating to sales in current year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(251.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(1,018.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(1,270.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Payments/credits relating to sales in prior years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(126.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(612.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(10.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(749.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Balance, as of June 30, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>139.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>994.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>41.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,174.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:66%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>June 30,<br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Reduction of accounts receivable, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>223.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>197.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Component of accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>951.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,001.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total revenue-related reserves</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,174.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,198.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:9px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Revenues from Anti-CD20 Therapeutic Programs</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs are summarized below. For the purposes of this footnote we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div style="line-height:120%;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:46%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>257.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>377.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>598.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>768.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other revenues from anti-CD20 therapeutic programs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>220.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>199.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>399.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>325.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total revenues from anti-CD20 therapeutic programs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>478.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>576.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>998.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,093.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Genentech, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 18,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Other Revenues</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues are summarized as follows:</span></div><div style="line-height:120%;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Revenues from collaborative and other relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Profit (loss) earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Revenues earned under our technical development agreement, manufacturing services agreements and royalty revenues on biosimilar products with Samsung Bioepis</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>4.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>52.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>8.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>77.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other royalty and corporate revenues:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Royalty</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>7.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>18.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>6.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other corporate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>395.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>105.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>489.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>369.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total other revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>407.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>160.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>516.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>452.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;">During the third quarter of 2019 we amended our agreement with a contract manufacturing customer, pursuant to which we licensed certain of our manufacturing-related intellectual property to the customer. In the second quarter of 2020 the customer received regulatory approval for its product that is being manufactured using certain of our manufacturing-related intellectual property. As a result, we are entitled to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$500.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;">in a series of three payments. The first payment became due upon regulatory approval of such product and was received during the</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">second</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> quarter of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </span><span style="font-family:Franklin Gothic Book,sans-serif;">Subsequent payments are due on the first and second anniversaries of the regulatory approval.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span></div><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other corporate revenues for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflect </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$329.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;">related to the delivery of the license for certain of our manufacturing-related intellectual property under the amended agreement discussed above. We have allocated the remaining $170.6 million of the $500.0 million transaction price to the performance of manufacturing product supply services for the customer, which we expect to perform through 2026. The value allocated to the manufacturing services was based on expected demand for supply and the fair value of comparable manufacturing and development services</span>.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639334722088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The components of inventory are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:64%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>June 30,<br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>244.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>169.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Work in process</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>509.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>460.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Finished goods</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>198.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>174.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total inventory</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>952.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>804.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639327132776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Intangible Assets</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"/></tr><tr><td style="width:21%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of June 30, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Life</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Completed technology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">4-28 years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>7,379.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(5,014.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>2,364.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>7,379.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(4,881.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2,497.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">In-process research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Indefinite until commercialization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>954.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>954.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>965.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>965.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Trademarks&#160;and trade names</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Indefinite</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>64.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>64.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>64.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>64.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>8,398.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(5,014.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>3,383.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>8,408.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(4,881.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>3,527.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, amortization and impairment of acquired intangible assets totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$61.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$133.0 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$70.1 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$138.3 million</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods. We had </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>no</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> impairment charges for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Completed Technology</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Completed technology primarily relates to our acquisition of all remaining rights to TYSABRI from Elan Pharma International Ltd., an affiliate of Elan Corporation plc, and milestone payments made to Alkermes Pharma Ireland Limited, a subsidiary of Alkermes plc, following the approval of VUMERITY in the U.S. in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">October 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, net of accumulated amortization.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">IPR&amp;D Related to Business Combinations</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IPR&amp;D </span><span style="font-family:Franklin Gothic Book,sans-serif;">represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Included in IPR&amp;D balances are adjustments related to foreign currency exchange rate fluctuations. </span><span style="font-family:Franklin Gothic Book,sans-serif;">We review amounts capitalized as acquired IPR&amp;D for impairment annually, as of</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">October 31</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;">and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> The carrying value associated with our IPR&amp;D assets as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, relates to the various IPR&amp;D programs we acquired in connection with our acquisitions of NST, Convergence Pharmaceuticals Holdings Ltd. (Convergence) and Biogen International Neuroscience GmbH (BIN). The majority of the balance relates to our acquisition of NST in June 2019 whereby we acquired IPR&amp;D programs with an estimated fair value of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$700.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Vixotrigine</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;">In the periods since we acquired vixotrigine (BIIB074), there have been numerous delays in the initiation of Phase 3 studies for the potential treatment of trigeminal neuralgia (TGN) as we engaged with the U.S. Food and Drug Administration (FDA) regarding the design of the Phase 3 studies and awaited data and insights from mid-stage clinical trials of vixotrigine in other indications that have since been completed.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;">The fair value of the TGN asset is not significantly in excess of carrying value.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the carrying value associated with our vixotrigine IPR&amp;D assets was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$160.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Estimated Future Amortization of Intangible Assets</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;"> </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:81%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>June 30,<br/>2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2020 (remaining six months)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>126.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>220.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>220.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>230.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2024</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>230.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2025</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>220.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Goodwill</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:81%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>June 30,<br/>2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Goodwill, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>5,757.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(6.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Goodwill, end of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>5,751.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>no</span></span> accumulated impairment losses related to goodwill. Other includes adjustments related to foreign currency exchange rate fluctuations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639329669208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of June 30, 2020 (In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">Assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,869.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,869.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Marketable debt securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,790.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,790.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Government securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>966.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>966.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Mortgage and other asset backed securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>108.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>108.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Marketable equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>527.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>344.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>182.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>59.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>59.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Plan assets for deferred compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>27.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>27.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>5,349.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>344.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>5,005.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">Liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>14.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>14.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Contingent consideration obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>351.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>351.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>365.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>14.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>351.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2019 (In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">Assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2,541.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2,541.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Marketable debt securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,695.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,695.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Government securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,013.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,013.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Mortgage and other asset backed securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>261.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>261.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Marketable equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>337.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>7.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>329.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>43.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>43.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Plan assets for deferred compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>27.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>27.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>5,920.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>7.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>5,912.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">Liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>8.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>8.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Contingent consideration obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>346.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>346.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>354.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>8.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>346.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There have been </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>no</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> material impairments of our assets measured and carried at fair value during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In addition, there were </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> changes in valuation techniques during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities was determined through third-party pricing services. The fair value of Level 2 instruments classified as marketable equity securities represents our investment in Sangamo Therapeutics, Inc. (Sangamo) common stock and is valued using an option pricing valuation model as the investment is subject to certain holding period restrictions. For additional information on our investment in Sangamo common stock, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 8, Financial Instruments</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our investments in marketable equity securities also include shares of Ionis Pharmaceuticals, Inc. (Ionis) common stock acquired in June 2018. Our shares in Ionis common stock were initially subject to certain holding period restrictions that expired during the first quarter of 2020. The fair value of this investment was a Level 1 measurement as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 1, Summary of Significant Accounting Policies - Fair Value Measurements,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the significant unobservable inputs in the fair value measurement of our contingent consideration obligations as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:24%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:10%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of June 30, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Valuation Technique</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable Input</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Range</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted Average</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Contingent consideration obligation</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td rowspan="2" style="vertical-align:middle;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>351.6</span></span></div></td><td rowspan="2" style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Discounted cash flow</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Discount rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">0.83% to 1.18%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.92%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Timing of achievement of development milestones</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2021 to 2027</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The weighted average discount rate was calculated based on the relative fair value of our contingent consideration obligations. In addition, we apply various probabilities of technological and regulatory success, ranging from high single digits to certain probability, to the valuation models to estimate the fair values of our contingent consideration obligations.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Debt Instruments</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of June 30, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2.900% Senior Notes due September 15, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,509.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,495.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3.625% Senior Notes due September 15, 2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,061.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>997.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,038.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>996.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">4.050% Senior Notes due September 15, 2025</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,994.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,740.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,897.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,739.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2.250% Senior Notes due May 1, 2030</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,514.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,490.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">5.200% Senior Notes due September 15, 2045</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>2,247.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,723.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2,107.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,722.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3.150% Senior Notes due May 1, 2050</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,441.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,472.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>8,257.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>7,423.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>6,553.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>5,954.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:1px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:34%;"/><td style="width:32%;"/><td style="width:34%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:1px;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1) </sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">, our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2.900%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"> Senior Notes due September 15, 2020, were redeemed in full using the net proceeds from the issuance on April 30, 2020, of our senior unsecured notes for an aggregate principal amount of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>$3.0 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">. For additional information, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">Note 11, Indebtedness</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"> to these condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. For additional information related to our Senior Notes issued on September 15, 2015, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 12,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K. For additional information related to our Senior Notes issued on April 30, 2020, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 11, Indebtedness</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration Obligations</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisitions of Convergence and BIN, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:42%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Fair value, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>341.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>421.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>346.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>409.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Changes in fair value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>10.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(20.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(8.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Fair value, end of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>351.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>401.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>351.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>401.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$202.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$197.7 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our condensed consolidated balance sheets with the remaining balance reflected as a component of accrued expenses and other.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, changes in the fair value of our contingent consideration obligations were primarily due to changes in the interest rates used to revalue our contingent consideration liabilities, changes in the probability and the expected timing of the achievement of certain remaining developmental milestones and the passage of time.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, changes in the fair value of our contingent consideration obligations were primarily due to changes in the probability and the expected timing of the achievement of certain remaining development milestones, partially offset by a decrease in interest rates used to revalue our contingent consideration liabilities and the passage of time.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639328261304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Financial Instruments</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>June 30,<br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>139.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>384.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Overnight reverse repurchase agreements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>247.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>368.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,363.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,628.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Short-term debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>118.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>159.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,869.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2,541.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and short-term debt securities approximate fair value due to their short-term maturities. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketable equity securities gains (losses) are recorded in other income (expense), net in our condensed consolidated statements of income. The following tables summarize our marketable debt and equity securities:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of June 30, 2020 (In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized<br/>Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Corporate debt securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,282.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,283.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>502.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>3.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>506.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Government securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>657.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>658.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>307.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>308.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Mortgage and other asset backed securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>107.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>107.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total marketable debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>2,859.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>7.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>2,865.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Marketable equity securities, non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>428.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>114.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(15.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>527.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2019 (In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Corporate debt securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,057.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,058.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>633.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>636.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Government securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>502.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>503.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>510.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>510.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Mortgage and other asset backed securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>260.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>260.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total marketable debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2,965.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>6.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2,970.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Marketable equity securities, non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>218.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>132.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(13.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>337.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Contractual Maturities: Available-for-Sale Debt Securities</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of June 30, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized<br/>Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized<br/>Cost</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Due in one year or less</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,942.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,940.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,562.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,560.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Due after one year through five years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>862.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>858.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,234.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,230.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Due after five years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>60.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>59.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>173.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>173.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total marketable debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>2,865.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>2,859.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2,970.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2,965.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The average maturity of our marketable debt securities available-for-sale as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proceeds from Marketable Debt Securities</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:42%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Proceeds from maturities and sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,490.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,766.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>3,879.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>3,255.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Realized gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>6.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>11.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Realized losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(5.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(24.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(0.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Strategic Investments</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our strategic investment portfolio was comprised of investments totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$583.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$393.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, which are included in investments and other assets in our condensed consolidated balance sheets. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 7, Fair Value Measurements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in our strategic investment portfolio for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was primarily due to our purchase of Sangamo common stock, as discussed below, and an increase in the fair value of our remaining investment in Ionis common stock.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our June 2018 investment in Ionis common stock, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 18,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:17px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Sangamo Therapeutics, Inc.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we entered into a collaboration and license agreement with Sangamo to develop and commercialize ST-501 for tauopathies, including AD; ST-502 for synucleinopathies, including Parkinson&#8217;s disease; a third neuromuscular disease target; and up to nine additional neurological disease targets to be identified and selected within a five-year period. The companies will leverage Sangamo&#8217;s proprietary zinc finger protein technology delivered via AAV to modulate the expression of key genes involved in neurological diseases.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the closing of this transaction in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">April 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we purchased approximately&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>24 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;shares of Sangamo common stock.&#160;This equity method investment will be remeasured each reporting period and carried at fair value due to our election of the fair value option. The effects of certain holding period restrictions on the investment are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk free-interest rate to match the remaining term of the restrictions on our investment in Sangamo&#8217;s common stock and a dividend yield of zero based upon the fact that Sangamo and similar companies generally have not historically granted cash dividends.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration agreement with Sangamo, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 17, Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639331193192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Instruments</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Hedging Instruments</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due to the global nature of our operations, portions of our revenues and operating expenses are recorded in currencies other than the U.S.&#160;dollar. The value of revenues and operating expenses measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes, we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues and operating expenses.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign currency forward contracts in effect as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, had durations of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months, respectively. These contracts have been designated as cash flow hedges and unrealized gains or losses on the portion of these foreign currency forward contracts that are included in the effectiveness test are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses of such contracts are recognized in revenues when the sale of product in the currency being hedged is recognized and in operating expenses when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from accumulated other comprehensive income and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that has been impacted by the hedged item.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Notional Amount</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>June 30,<br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Euro</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>2,477.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,892.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">British pound</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>125.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Swiss franc</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>69.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Japanese yen</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>53.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Canadian dollar</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>48.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total foreign currency forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>2,773.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,892.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net losses of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$16.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and net gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$0.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. We expect the net losses of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$16.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to be settled over the next </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months, of which </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$7.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of these losses are expected to be settled over the next </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenues or operating expenses. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, credit risk did not materially change the fair value of our foreign currency forward contracts.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"/></tr><tr><td style="width:23%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months Ended June 30,</span></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income (in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Operating Income (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>23.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>29.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"/></tr><tr><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months Ended June 30,</span></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income (in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Operating Income (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>50.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>44.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>7.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>7.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(1.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(1.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Interest Rate Contracts - Hedging Instruments</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have entered into interest rate lock contracts or interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes and to reduce our overall cost of borrowing. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Interest Rate Swap Contracts</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the issuance of our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.90%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes due September 15, 2020, we entered into interest rate swaps with an aggregate notional amount of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$675.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which were originally set to expire on September 15, 2020. The interest rate swap contracts were designated as hedges of the fair value changes in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.90%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes attributable to changes in interest rates. The carrying value of our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.90%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, included approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$2.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to changes in the fair value of these interest rate swap contracts. In </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">May 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we settled our interest rate swap contracts, in conjunction with our early redemption of our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.90%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes, resulting in a gain of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$3.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and was recorded as a component of interest expense in our condensed consolidated statements of income.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Net Investment Hedges - Hedging Instruments</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>49.9%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The share purchase transaction was completed in November 2018 and, upon closing, we paid </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>759.5 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$676.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) to Samsung BioLogics. Our investment in the equity of Samsung Bioepis is exposed to the currency fluctuations in the South Korean won. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In order to mitigate the currency fluctuations between the U.S. dollar and South Korean won, we have entered into foreign currency forward contracts. Foreign currency forward contracts in effect as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, had remaining durations of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">four</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months. These contracts have been designated as net investment hedges. We recognize changes in the spot exchange rate in accumulated other comprehensive income (loss). The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$13.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and net losses of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. We exclude fair value changes related to the forward rate from our hedging relationship and will amortize the forward points in other income (expense), net in our condensed consolidated statements of income over the term of the contract. The pre-tax portion of the fair value of the forward points that were included in accumulated other comprehensive income (loss) in total equity reflected gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1.1 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$2.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the effect of our net investment hedge in our condensed consolidated financial statements:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="29"/></tr><tr><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/></tr><tr><td colspan="29" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months Ended June 30,</span></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Net Income </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Amounts Excluded from Effectiveness Testing) (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(8.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>11.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>3.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="29"/></tr><tr><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/></tr><tr><td colspan="29" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months Ended June 30,</span></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Net Income </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Amounts Excluded from Effectiveness Testing) (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>15.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>23.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>6.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 17, Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Other Derivative Instruments</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The aggregate notional amount of these outstanding foreign currency forward contracts was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$999.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$793.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Net gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$8.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$5.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to these contracts were recorded as a component of other income (expense), net for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, compared to net gains of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$0.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and net losses of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$3.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Derivative Instruments</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:39%;"/><td style="width:1%;"/><td style="width:30%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>June 30,<br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">Cash Flow Hedging Instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Asset derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>32.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>33.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Investments and other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Liability derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>9.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">Net Investment Hedging Instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Asset derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>20.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">Fair Value Hedging Instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Liability derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">Other Derivative Instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Asset derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>6.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>8.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Liability derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639329679512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1,687.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1,590.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, depreciation expense totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$51.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$99.7 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$47.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$99.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Solothurn, Switzerland Manufacturing Facility</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In order to support our drug development pipeline, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be partially operational by the end of 2020. Upon completion, this facility will include 393,000 square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and 51,000 square feet of administrative space. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1.7 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1.9 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, capitalized as construction in progress related to this facility. For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we placed approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$256.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of fixed assets in service related to this facility. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had contractual commitments of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$16.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> outstanding related to the construction of this facility.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639329674200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indebtedness (Notes)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Indebtedness</a></td>
<td class="text"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Indebtedness</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#006ebf;"> </span><div style="line-height:120%;padding-top:8px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">2020 Senior Notes </span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">April&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we issued senior unsecured notes for an aggregate principal amount of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$3.0 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> (2020 Senior Notes), consisting of the following:</span></div><div style="line-height:120%;padding-left:0px;padding-top:8px;text-indent:30px;"><span style="padding-top:8px;font-family:Franklin Gothic Book,sans-serif;font-size:10pt;padding-right:18px;">&#8226;</span><span style="font-family:Franklin Gothic Book;font-size:10pt;text-transform:default;"><span>$1.5 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;text-transform:default;"><span>2.25%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes due </span><span style="font-family:Franklin Gothic Book;font-size:10pt;text-transform:default;">May&#160;1, 2030</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, valued at </span><span style="font-family:Franklin Gothic Book;font-size:10pt;text-transform:default;"><span>99.973%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of par; and</span></div><div style="line-height:120%;padding-left:0px;padding-top:8px;text-indent:30px;"><span style="padding-top:8px;font-family:Franklin Gothic Book,sans-serif;font-size:10pt;padding-right:18px;">&#8226;</span><span style="font-family:Franklin Gothic Book;font-size:10pt;text-transform:default;"><span>$1.5 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of </span><span style="font-family:Franklin Gothic Book;font-size:10pt;text-transform:default;"><span>3.15%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes due </span><span style="font-family:Franklin Gothic Book;font-size:10pt;text-transform:default;">May&#160;1, 2050</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, valued at </span><span style="font-family:Franklin Gothic Book;font-size:10pt;text-transform:default;"><span>99.174%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of par.</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our 2020 Senior Notes are senior unsecured obligations and may be redeemed at our option at any time at </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>100%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the principal amount plus accrued interest and, until a specified period before maturity, a specified make-whole amount. Our 2020 Senior Notes contain a change-of-control provision that, under certain circumstances, may require us to purchase our 2020 Senior Notes at a price equal to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>101%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the principal amount plus accrued and unpaid interest to the date of repurchase.</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We incurred approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$24.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of costs associated with this offering which have been recorded as a reduction to the carrying amount of the debt on our condensed consolidated balance sheet. These costs will be amortized as additional interest expense using the effective interest rate method over the period from issuance through maturity. The discounts will be amortized as additional interest expense over the period from issuance through maturity using the effective interest rate method. Interest on our 2020 Senior Notes is payable </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">May 1</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">November 1</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of each year, commencing November 1, 2020. </span></div><div style="line-height:120%;padding-top:8px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#006ebf;font-style:italic;font-weight:bold;">2.90% Senior Notes due September 15, 2020 </span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On September 15, 2015, we issued </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1.5 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> aggregate principal amount of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.90%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes due September 15, 2020, at </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>99.792%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of par. Our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.90%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes were senior unsecured obligations. We also entered into interest rate swap contracts where we received a fixed rate and paid a variable rate. In May 2020 we used the net proceeds from the sale of our 2020 Senior Notes to redeem our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.90%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes prior to their maturity and recognized a net pre-tax charge of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$9.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upon the extinguishment of these notes. This charge, which was recognized in interest expense in other income (expense), net in our condensed consolidated statements of income for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflects the payment of a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$12.7 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> early call premium and the write off of remaining unamortized original debt issuance costs and discount balances, partially offset by a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$3.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> gain related to the settlement of the associated interest rate swap contracts. For additional information on our interest rate swap contracts, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 9, Derivative Instruments</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639332486840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share Repurchases</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> our Board of Directors authorized a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$5.0 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Share Repurchase Program). Our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Share Repurchase Program does not have an expiration date. All shares repurchased under our December 2019 Share Repurchase Program will be retired. Under our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Share Repurchase Program, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>9.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>12.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$2.8 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$3.7 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1.3 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> remained available under our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Share Repurchase Program as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019 our Board of Directors authorized a program to repurchase up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$5.0 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock (March 2019 Share Repurchase Program), which was completed as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. All shares repurchased under our March 2019 Share Repurchase Program were retired. Under our March 2019 Share Repurchase Program, we repurchased and retired approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.1 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1.3 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accumulated Other Comprehensive Income (Loss)</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:32%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains (Losses) on Net Investment Hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Balance, December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>25.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(32.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(139.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(135.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(9.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>33.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>18.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(47.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(3.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>9.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(50.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(1.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(42.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Net current period other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(17.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>16.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(47.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(45.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Balance, June 30, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>5.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(9.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>41.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(31.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(186.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(181.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:32%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains (Losses) on Net Investment Hedge</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Balance, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(4.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>34.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>3.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(31.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(243.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(240.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>11.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>22.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>30.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(28.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>36.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(43.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(4.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(48.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Net current period other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>10.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(21.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>25.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(28.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(12.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Balance, June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>6.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>13.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>29.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(30.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(271.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(252.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amounts reclassified from accumulated other comprehensive income:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"/></tr><tr><td style="width:33%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amounts Reclassified from Accumulated Other Comprehensive Income</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Gains (losses) on securities available for sale</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(12.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Income tax benefit (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Gains (losses) on cash flow hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"><span>23.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>29.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>50.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>44.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(1.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Income tax benefit (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total reclassifications, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"><span>27.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>31.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>42.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>48.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639332486840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per Share</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic and diluted earnings per share are calculated as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:42%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">Numerator:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Net income attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,542.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,494.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>2,941.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2,902.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">Denominator:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Weighted average number of common shares outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>160.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>190.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>166.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>193.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Effect of dilutive securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Time-vested restricted stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Market stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Performance stock units settled in stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Dilutive potential common shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Shares used in calculating diluted earnings per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>160.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>190.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>167.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>193.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639327999704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Payments</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share-based Compensation Expense</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Research and development </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>15.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>28.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>48.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>49.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Selling, general and administrative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>30.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>54.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>73.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>82.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Subtotal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>45.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>82.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>121.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>132.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Capitalized share-based compensation costs </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(2.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(3.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(6.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Share-based compensation expense included in total cost and expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>44.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>80.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>118.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>126.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Income tax effect</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(7.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(13.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(20.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(21.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Share-based compensation expense included in net income attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>37.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>66.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>98.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>105.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Market stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>7.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>26.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>15.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Time-vested restricted stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>34.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>31.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>72.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>66.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Cash settled performance units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(0.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Performance units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Performance stock units settled in stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>12.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>12.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>14.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Performance stock units settled in cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(4.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>4.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Employee stock purchase plan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>7.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>8.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">NST stock options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>26.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>26.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Subtotal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>45.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>82.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>121.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>132.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Capitalized share-based compensation costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(2.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(3.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(6.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Share-based compensation expense included in total cost and expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>44.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>80.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>118.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>126.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We estimate the fair value of our obligations associated with our performance units, cash settled performance units and performance stock units settled in cash at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recognized each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639328261304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Coronavirus Aid, Relief and Economic Security Act</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In response to the COVID-19 pandemic, the Coronavirus Aid, Relief and Economic Security Act (CARES Act) was signed into law in the U.S. in March 2020. The CARES Act lifts certain deduction limitations originally imposed by the Tax Cuts and Jobs Act of 2017 (2017 Tax Act). Corporate taxpayers may carryback net operating losses (NOLs) originating during 2018 through 2020 for up to five years, which was not previously allowed under the 2017 Tax Act. The CARES Act also eliminates the 80% of taxable income limitations by allowing corporate entities to fully utilize NOL carryforwards to offset taxable income in 2018, 2019 or 2020. Taxpayers may generally deduct interest up to the sum of 50% of adjusted taxable income plus business interest income (30% limit under the 2017 Tax Act) for tax years beginning January 1, 2019 and 2020. The CARES Act allows taxpayers with alternative minimum tax credits to claim a refund in 2020 for the entire amount of the credits instead of recovering the credits through refunds over a period of years, as originally enacted by the 2017 Tax Act.</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, the CARES Act raises the corporate charitable deduction limit to 25% of taxable income and makes qualified improvement property generally eligible for 15-year cost-recovery and 100% bonus depreciation. The enactment of the CARES Act did not result in any material adjustments to our income tax provision for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, or to our net deferred tax assets as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">TECFIDERA</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On June 22, 2020, the U.S. District Court for the Northern District of West Virginia (the West Virginia Court)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">entered judgment for Mylan Pharmaceuticals, Inc. (Mylan) that the asserted claims of our U.S. Patent No. 8,399,514</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(the '514 Patent) are invalid for lack of written description. The '514 Patent covers treatment of MS with 480 mg of</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">dimethyl fumarate per day as provided for in our TECFIDERA label, and the litigation was filed pursuant to the Drug</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act. We appealed the</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">judgment on June 23, 2020, to the U.S. Court of Appeals for the Federal Circuit (Federal Circuit) and filed an</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">emergency motion for an injunction pending resolution of the appeal. On June 30, 2020, the Federal Circuit entered</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">an interim injunction enjoining Mylan from launching its generic version of TECFIDERA pending the Federal Circuit's</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">consideration of our request for an injunction pending appeal. In the event that our request for an injunction pending appeal is denied, generic entry could occur during the appeal. </span><span style="font-family:Franklin Gothic Book,sans-serif;">The commercialization of a generic version of TECFIDERA would have an adverse impact on our TECFIDERA sales and our results of operations.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have assessed the realizability of our deferred tax assets that are dependent on future expected sales of TECFIDERA in the U.S. and reduced the value of certain deferred tax assets by approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1,324.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and reduced the value of deferred tax liabilities associated with global intangible low-taxed income (GILTI) and tax credits by approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1,268.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the income tax expense associated with these reductions was approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$56.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For additional information, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 19, Litigation</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Rate</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:45%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Statutory rate</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">State taxes</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Taxes on foreign earnings</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(3.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(4.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(3.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(4.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Tax credits</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Purchased intangible assets</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Divestiture of Denmark manufacturing operations</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Internal reorganization of certain intellectual property rights</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(5.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(2.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TECFIDERA impairment</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">GILTI</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other permanent items</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Effective tax rate</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>21.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>14.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>19.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>18.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:17px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;">Changes in Tax Rate</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;"> the increase in our effective tax rate was primarily due to an internal reorganization of certain intellectual property rights related to the intercompany sale of the intellectual property in 2019 and the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$56.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;">income tax expense related to the establishment of a valuation allowance against certain deferred tax assets, the realization of which is dependent on future sales of TECFIDERA in the U.S.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as discussed above. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;">the increase in our effective tax rate was primarily due to the impacts of the valuation allowance described above and the internal reorganization of certain intellectual property rights, partially offset by the</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$61.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> tax expense recognized in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;">related to the planned divestiture of our Hiller&#248;d, Denmark manufacturing operations. Although we recognized a loss on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, the divestiture required us to write off certain deferred tax assets and resulted in a taxable gain in certain jurisdictions.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As a result of the internal reorganization of certain intellectual property rights, we recorded a deferred tax asset of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$856.7 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and a deferred tax liability of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$685.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounting for Uncertainty in Income Taxes</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2013 or state, local or non-U.S. income tax examinations for years before 2012.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2020 we became aware of a withholding tax regulation that could be interpreted to apply to certain of our previous transactions. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have recorded an immaterial reserve reflecting this uncertain tax position.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration matters and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We estimate that it is reasonably possible that our gross unrecognized tax benefits, exclusive of interest, could decrease by up to approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$75.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the next 12 months as a result of various audit closures, settlements and expiration of the statute of limitations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639327994408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Other Consolidated Financial Statement Detail</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Income (Expense), Net</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Components of other income (expense), net, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:42%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Interest income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>7.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>29.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>32.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>60.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(66.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(47.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(110.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(95.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Gain (loss) on investments, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>106.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(173.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>29.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>203.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Foreign exchange gains (losses), net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>10.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(8.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(7.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(7.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total other income (expense), net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>63.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(197.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(57.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>159.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the change in other income (expense), net primarily reflects net gains of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$106.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;">recognized on our investments related to our holdings in equity and debt securities, compared to net losses totaling</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$173.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the prior year comparative period. The net gains recognized during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;">primarily reflect an increase in the fair value of Ionis common stock of approximately</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$67.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;">and an increase in the fair value of Sangamo common stock of approximately</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$40.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;">compared to the same period in 2019, the change in other income (expense), net was primarily due to approximately</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$203.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;">of net gains recognized on our investments related to our holdings in equity and debt securities during the six months ended June&#160;30, 2019.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our gain (loss) on investments, net that relates to our equity securities held as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:42%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Net gains (losses) recognized during the period on equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>102.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(174.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>42.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>201.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Less: Net gains (losses) recognized during the period on equity securities sold during the period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(42.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>42.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Unrealized gains (losses) recognized during the period on equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>102.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(131.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>42.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>159.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accrued Expenses and Other</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other consists of the following:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>June 30,<br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Revenue-related reserves for discounts and allowances</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>951.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,001.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Employee compensation and benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>212.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>309.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Royalties and licensing fees</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>203.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>220.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Collaboration expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>172.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>281.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Current portion of contingent consideration obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>149.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>148.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Construction in progress</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>24.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>78.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>774.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>726.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>2,486.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2,765.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Long-term Liabilities</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities were </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1,475.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1,348.9 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, and included accrued income taxes totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$743.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$803.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Included within accrued taxes as of June&#160;30, 2020 and December&#160;31, 2019, is an accrual for a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings (the Transition Toll Tax) of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$635.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$697.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639329865240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative and Other Relationships</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Eisai Co., Ltd.</span></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BAN2401 and Elenbecestat Collaboration</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize BAN2401, a monoclonal antibody that targets amyloid beta aggregates, and elenbecestat, the oral BACE (base amyloid cleaving enzyme) inhibitor, two Eisai product candidates for the potential treatment of AD (the BAN2401 and Elenbecestat Collaboration).&#160;In September 2019 we and Eisai discontinued the global Phase 3 studies of elenbecestat in early AD. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Eisai serves as the global operational and regulatory lead for BAN2401 and all costs, including research, development, sales and marketing expenses, are shared equally between us and Eisai. If BAN2401 receives marketing approval, we and Eisai will co-promote BAN2401 and share profits equally. In addition, the BAN2401 and Elenbecestat Collaboration provides both parties with certain rights and obligations in the event of a change in control of either party.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The BAN2401 and Elenbecestat Collaboration also provided Eisai with an option to jointly develop and commercialize aducanumab, our anti-amyloid beta antibody candidate for AD (Aducanumab Option), and an option to jointly develop and commercialize one of our anti-tau monoclonal antibodies (Anti-Tau Option). In October 2017 Eisai exercised its Aducanumab Option and we entered into a new collaboration agreement for the joint development and commercialization of aducanumab (Aducanumab Collaboration Agreement). Eisai has not yet exercised its Anti-Tau Option.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the Aducanumab Collaboration Agreement, the two companies will continue to jointly develop BAN2401 in accordance with the BAN2401 and Elenbecestat Collaboration; however, we are no longer required to pay Eisai any milestone payments for products containing BAN2401 and we are no longer entitled to any potential development and commercial milestone payments from Eisai in relation to aducanumab. For additional information on our BAN2401 and Elenbecestat Collaboration, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 18, Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of development and sales and marketing expense related to the BAN2401 and Elenbecestat Collaboration is as follows:</span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total development expense incurred by the collaboration related to the advancement of BAN2401 and elenbecestat</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>33.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>68.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>77.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>136.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Biogen's share of BAN2401 and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>17.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>34.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>38.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>68.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total sales and marketing expense incurred by the collaboration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">nm</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>6.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">nm</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Biogen's share of BAN2401 sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">nm</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">nm</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:34%;"/><td style="width:32%;"/><td style="width:34%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">nm</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"> - For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">, sales and marketing expenses related to the BAN2401 and Elenbecestat Collaboration were immaterial.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Aducanumab Collaboration Agreement</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the Aducanumab Collaboration Agreement, we and Eisai will co-promote aducanumab with a region-based profit split and we lead the ongoing development of aducanumab. Beginning January 1, 2019, Eisai is reimbursing us for&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>45%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;of development costs incurred by the collaboration for the advancement of aducanumab (aducanumab development expense). </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019, based on a pre-specified futility analysis, we discontinued the global Phase 3 trials, EMERGE and ENGAGE, designed to evaluate the efficacy and safety of aducanumab in patients with early AD. A new analysis of a larger dataset from these trials, conducted in consultation with the FDA, showed that the Phase 3 EMERGE study met its pre-specified primary and secondary endpoints. In the first quarter of 2019, as a result of the decision to discontinue the Phase 3 EMERGE and ENGAGE trials following the futility analysis, we accrued approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$45.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the termination of various clinical trials and research and development contracts net of the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>45%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Eisai reimbursement of development costs incurred under the Aducanumab Collaboration Agreement.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2020 we completed the submission of a Biologics License Application (BLA) to the FDA for the approval of aducanumab. For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized net profit-sharing income of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$33.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to reflect Eisai's </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>45%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share of the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$75.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> milestone expense related to the submission of the BLA to the FDA for approval of aducanumab.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sales and marketing expense are shared in proportion to the same region-based profit split that will be utilized to co-promote aducanumab. For additional information on the Aducanumab Collaboration Agreement, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 18,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of development, sales and marketing and milestone expense related to the Aducanumab Collaboration Agreement is as follows:</span></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total aducanumab development expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>35.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>55.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>165.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Biogen's share of aducanumab development expense reflected in research and development expense in our condensed consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>19.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>30.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>91.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total aducanumab sales and marketing expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>45.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>67.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>21.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>25.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>37.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>11.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total aducanumab collaboration third party milestone expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>75.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>75.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Eisai's share of aducanumab milestone expense reflected in collaboration profit sharing in our condensed consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>33.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>33.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">UCB Pharma S.A.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with UCB Pharma S.A. (UCB) to jointly develop and commercialize dapirolizumab pegol, an anti-CD40L pegylated Fab, for the potential treatment of systemic lupus erythematosus and other future agreed indications. Either we or UCB may propose development of dapirolizumab pegol in additional indications. If the parties do not agree to add an indication as an agreed indication to the collaboration, we or UCB may, at the sole expense of the applicable party, pursue development in such excluded indication(s), subject to an opt-in right of the non-pursuing party after proof of clinical activity. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All costs incurred for agreed indications, including research, development, sales and marketing expenses, are shared equally between us and UCB. Upon marketing approval, we and UCB will co-promote dapirolizumab pegol and share profits equally. A summary of development expense related to the UCB Collaboration Agreement is as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total UCB development expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>6.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">nm</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>25.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">nm</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Biogen's share of UCB development expense reflected in research and development expense in our condensed consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">nm</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>12.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">nm</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:34%;"/><td style="width:32%;"/><td style="width:34%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">nm</sup></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"> - For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">June&#160;30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">, development expenses related to the UCB collaboration agreement were immaterial.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Research and Discovery Arrangements</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Sangamo Therapeutics, Inc.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2020 we entered into a collaboration and license agreement with Sangamo to develop and commercialize ST-501 for tauopathies, including AD; ST-502 for synucleinopathies, including Parkinson&#8217;s disease; a third neuromuscular disease target; and up to nine additional neurological disease targets to be identified and selected within a five-year period. The companies will leverage Sangamo&#8217;s proprietary zinc finger protein technology delivered via AAV to modulate the expression of key genes involved in neurological diseases. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the closing of this transaction in April 2020 we purchased </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$225.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of Sangamo common stock, or approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>24 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares at </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$9.21</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> per share, which are subject to transfer restrictions. We recorded an asset in investments and other assets in our condensed consolidated balance sheets to reflect the initial fair value of the Sangamo common stock acquired and a charge of&#160;approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$83.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;to research and development expense in our condensed consolidated statements of income to reflect the premium paid for the Sangamo common stock. We also made an upfront payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$125.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> that was recorded as research and development expense.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may also pay research, development, regulatory and commercial milestone payments that could total up to approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$2.4 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> if we select all of the targets allowed under this agreement and all the specified milestones set forth in this agreement are achieved. Of this amount, up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$80.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> relates to the selection of targets, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1.9 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$380.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels. In addition, we may pay tiered royalties on potential net commercial sales of any products developed under this collaboration in the high single digit to double digit sub-teen percentages.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Skyhawk Therapeutics, Inc.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2019 we entered into a collaboration and research and development services agreement with Skyhawk Therapeutics, Inc. (Skyhawk) pursuant to which the companies are leveraging Skyhawk's SkySTAR technology platform with the goal of discovering innovative small molecule treatments for patients with neurological diseases, including MS and SMA. We are responsible for the development and potential commercialization of any therapies resulting from this collaboration and we may also pay Skyhawk up to a total of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$2.4 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in milestone payments as well as potential royalties on net commercial sales. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with this agreement, we made an upfront payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$74.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Skyhawk, of which </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$38.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recorded as research and development expense in our condensed consolidated statements of income and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$35.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recorded as prepaid research and development expenditures within investments and other assets in our condensed consolidated balance sheets. These prepaid research and development services are expensed as the services are provided. In October 2019 we amended this agreement to add an additional discovery program. In connection with this amendment, we made a payment to Skyhawk of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$15.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Samsung Bioepis</span></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Joint Venture Agreement</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.&#160;In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>49.9%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The share purchase transaction was completed in November 2018 and, upon closing, we paid </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>759.5 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$676.6 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) to Samsung BioLogics. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our ownership percentage remained at approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>49.9%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in income (loss) of investee, net of tax in our condensed consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our initial investment, we suspended recognizing additional losses. In the first quarter of 2019 we restarted recognizing our share of Samsung Bioepis' (income) losses, and we began recognizing amortization on certain basis differences resulting from our November 2018 investment. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon investment, the equity method of accounting requires us to identify and allocate differences between the fair value of our investment and the carrying value of our interest in the underlying net assets of the investee. These basis differences are amortized over their economic life. The total basis difference was approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$675 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and relates to inventory, developed technology, IPR&amp;D and deferred tax balances. The basis differences related to inventory and developed technology will be amortized, net of tax, over their estimated useful lives of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.5</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> years and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>15</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> years, respectively, one quarter in arrears. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our joint venture partner, Samsung BioLogics, is currently subject to an ongoing criminal investigation that we continue to monitor. While this investigation could impact the operations of Samsung Bioepis and its business, we have assessed the value of our investment in Samsung Bioepis and continue to believe that the fair value of the investment is in excess of its net book value.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized net income on our investment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$15.1 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$0.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, reflecting our share of income and amortization of basis differences.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the carrying value of our investment in Samsung Bioepis totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>668.3 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$557.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>670.8 billion</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$580.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">), respectively, which is classified as a component of investments and other assets in our condensed consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">2019 Transaction</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11 referencing LUCENTIS and SB15 referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. Samsung Bioepis will be responsible for development and will supply both products to us.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with this transaction, we made an upfront payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$100.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Samsung Bioepis in January 2020, of which </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$63.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recorded as research and development expense in 2019 and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$37.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recorded as an intangible asset in 2019. We may pay Samsung Bioepis up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$210.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional development, regulatory and sales-based milestones, including a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$15.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> development milestone which is expected to be paid during the third quarter of 2020. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also acquired an option to extend the term of our 2013 commercial agreement for BENEPALI, IMRALDI and FLIXABI by an additional five years, subject to payment of an option exercise fee of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$60.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and obtained exclusive rights to commercialize these products in China.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">2013 Commercial Agreement</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We reflect revenues on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenues, net in our condensed consolidated statements of income and record the related cost of revenues and sales and marketing expenses in our condensed consolidated statements of income to their respective line items when these costs are incurred. </span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We share </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>50%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized net profit-sharing expense of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$55.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$127.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, to reflect Samsung Bioepis' </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>50%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> sharing of the net collaboration profits, compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$63.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$121.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods. As discussed above, we have an option to extend this agreement by an additional five years, subject to the payment of an option exercise fee of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$60.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Services</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Simultaneous with the formation of Samsung Bioepis, we also entered into a technical development services agreement, a manufacturing agreement and a license agreement with Samsung Bioepis. For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$4.5 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$8.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in revenues related to these services, which is reflected in collaborative and other relationships revenues as a component of other revenues in our condensed consolidated statements of income, compared to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$52.2 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$77.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Following the divestiture of our Hiller&#248;d, Denmark manufacturing operations in August 2019, FUJIFILM assumed </span><span style="font-family:Franklin Gothic Book,sans-serif;">responsibility for the manufacture of clinical and commercial quantities of bulk drug substance of biosimilar products for Samsung Bioepis. We no longer recognize revenues for the manufacturing completed after the Hiller&#248;d, Denmark manufacturing facility divestiture date under our technical development services and manufacturing agreements with Samsung Bioepis.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 3, Divestitures</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts receivable from Samsung Bioepis related to the agreements discussed above were </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$13.3 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$85.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. There were </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>no</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> amounts payable to Samsung Bioepis as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Amounts payable to Samsung Bioepis as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, consisted of the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$100.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upfront payment related to the 2019 transaction, as discussed above.</span></div><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Samsung Bioepis and our other significant collaboration arrangements, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 18,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span> Form 10-K.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639328261304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentsInVariableInterestEntitiesAbstract', window );"><strong>Investments in Variable Interest Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Investments in Variable Interest Entities</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidated Variable Interest Entities</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Neurimmune SubOne AG</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration and license agreement with Neurimmune SubOne AG (Neurimmune) for the development and commercialization of antibodies for the potential treatment of AD, including aducanumab (as amended, the Neurimmune Agreement). We are responsible for the development, manufacturing and commercialization of all collaboration products. The Neurimmune Agreement is effective for the longer of the duration of certain patents relating to a licensed product or </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> years from the first commercial sale of any product using such a licensed compound.  </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#8217;s economic performance and we are required to fund </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the research and development costs incurred in support of the collaboration. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2017 we amended the terms of the Neurimmune Agreement and made a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$150.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> payment to Neurimmune in exchange for a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>15%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reduction in the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab. In May 2018 we made an additional </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$50.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> payment to Neurimmune to further reduce the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab, by an additional </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Our royalty rates payable on products developed under the Neurimmune Agreement, including royalty rates payable on potential commercial sales of aducanumab, now range from the high single digits to sub-teens. As we consolidate the results of Neurimmune, </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">we treated these payments as distributions and recognized them as charges to noncontrolling interests in the fourth quarter of 2017 and the second quarter of 2018, as applicable.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additionally, under the terms of the Neurimmune Agreement, we are required to pay Neurimmune a milestone payment of&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$75.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;upon the regulatory filing with the FDA for approval of aducanumab and a milestone payment of&#160;</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$100.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;if aducanumab is launched in the U.S. In July 2020 we and our collaboration partner Eisai announced that we completed the submission of a BLA to the FDA for the approval of aducanumab. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recorded accrued expenses of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$75.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;">related to this milestone payment as it was probable that the submission of the BLA would be completed and the milestone earned.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;">This milestone payment is expected to be paid during the third quarter of 2020.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized net profit-sharing income of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$33.8 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to reflect Eisai's </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>45%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share of the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$75.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> milestone expense. We treated this milestone payment as a distribution and recognized it as a charge to noncontrolling interest for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For additional information on our collaboration arrangements with Eisai, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 17, Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development costs for which we reimburse Neurimmune are reflected in research and development expense in our condensed consolidated statements of income. During the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, amounts reimbursed were immaterial.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The assets and liabilities of Neurimmune are not significant to our condensed consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than contractually required amounts.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the Aducanumab Collaboration Agreement, Eisai had an option to share in the benefit and cost associated with the royalty reductions discussed above; however, Eisai did not elect to share in the benefit and cost with respect to either the October 2017 or May 2018 royalty reductions, which will impact the amount of profits (losses) on potential commercial sales of aducanumab to be shared with Eisai. For additional information on our collaboration arrangements with Eisai, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 17, Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to these condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Unconsolidated Variable Interest Entities</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have relationships with various variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$22.4 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$22.7 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our investments in Neurimmune and other variable interest entities, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 19, Investments in Variable Interest Entities,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentsInVariableInterestEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments In Variable Interest Entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentsInVariableInterestEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639329853800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract', window );"><strong>Loss Contingency, Information about Litigation Matters [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Litigation</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 1, Summary of Significant Accounting Policies,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#8217; legal theories; and (v) the parties' settlement positions. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Loss Contingencies </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">IMRALDI Patent Litigation</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2018 Fresenius Kabi Deutschland GmbH (Fresenius Kabi) commenced proceedings for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris, alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis UK Limited that Biogen has commercialized in Europe, infringes the French counterpart of European Patent No. 3 148 510 (the '510 Patent), which was issued in June 2018 and expires in May 2035. No hearing has been scheduled. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2018 Fresenius Kabi commenced preliminary injunction proceedings against Biogen (Denmark) Manufacturing ApS and Biogen Denmark A/S in Denmark's Maritime and Commercial High Court alleging infringement of Danish Utility Models. In June 2019 the Danish court denied Fresenius Kabi's request for a preliminary injunction and Fresenius Kabi has appealed that decision. In July 2020 the Danish Patent Board of Appeal revoked the Utility Models that were the subject of Fresenius Kabi&#8217;s October 2018 request for a preliminary injunction. Fresenius Kabi has not yet appealed those revocations.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2020 Fresenius Kabi commenced preliminary injunction proceedings against Biogen (Denmark) Manufacturing ApS and Biogen (Denmark) A/S in Denmark&#8217;s Maritime and Commercial High Court alleging infringement of another Danish Utility Model. No hearing has been scheduled in that action.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2018 Fresenius Kabi commenced infringement proceedings for damages and injunctive relief against Biogen Italia S.R.L. in the District Court of Milan relating to the Italian counterpart of the &#8216;510 Patent, and against Biogen GmbH in the D&#252;sseldorf Regional Court relating to the German counterpart of the &#8216;510 Patent. In Italy, Fresenius Kabi has surrendered the Italian counterpart of the &#8216;510 Patent and has moved to dismiss its infringement action. A hearing in the proceeding in Germany has been set for April 2021.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2019 Gedeon Richter PLC (Gedeon Richter) commenced proceedings against Biogen GmbH in the D&#252;sseldorf Regional Court alleging infringement of the German counterpart of European Patent No. 3 212 667 (the '667 Patent), which was issued in September 2018 and expires in October 2035, and seeking damages and injunctive relief. A hearing has been set for November 2020.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2019 Biogen Idec Ltd. (Biogen UK) and Samsung Bioepis UK Limited filed an action in the United Kingdom Patents Court to revoke the United Kingdom (U.K.) counterpart of the '667 Patent. In January 2020 the U.K. court revoked the patent.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2019 Biogen B.V. (Netherlands) and Samsung Bioepis UK Limited filed an action in the District Court of the Hague, Netherlands to revoke the Dutch counterpart of the '667 Patent. Gedeon Richter filed a separate action for infringement in the same court. A hearing was held in May 2020 on the request for revocation and the infringement action and a decision is pending.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An estimate of the possible loss or range of loss in the pending IMRALDI patent litigation described above cannot be made at this time. </span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Qui Tam Litigation</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2015 a qui tam action filed by Michael Bawduniak on behalf of the U.S. and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts and seeks single and treble damages, civil penalties, interest, attorneys&#8217; fees and costs. No trial date has been set. The U.S. has not made an intervention decision. An estimate of the possible loss or range of loss cannot be made at this time.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Dispute with Former Convergence Shareholders</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November and December 2019 Shareholder Representative Services LLC, on behalf of the former shareholders of Convergence, sent us correspondence asserting claims of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$200.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for alleged breach of the contract under which we acquired Convergence. We dispute the claims.</span></div><div style="line-height:174%;padding-top:12px;text-align:left;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Dispute with Jacobs Switzerland GmbH</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Jacobs Switzerland GmbH, the general contractor for the construction of our large-scale biologics manufacturing facility in Solothurn, Switzerland, claims approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>31.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Swiss Francs (approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$33.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) relating to construction costs. We dispute the claim.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Matters</span></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Petition for Inter Partes Review</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2018 Mylan filed a petition that was granted by the U.S. Patent Trial and Appeal Board (PTAB) for </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> review of the '514 Patent, which covers treatment of MS with 480 mg of dimethyl fumarate per day as provided for in our TECFIDERA label. In February 2020 the PTAB issued a final written decision upholding the patentability of the &#8216;514 Patent and in April 2020 Mylan filed an appeal in the Federal Circuit, which is pending.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Hatch-Waxman Act Litigation relating to TECFIDERA Orange-Book Listed Patents</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2017, 2018 and 2019 we filed patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, against Accord Healthcare Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Aurobindo Pharma U.S.A., Inc., Cipla Limited, Glenmark Pharmaceuticals Ltd., Graviti Pharmaceuticals Pvt. Ltd., Hetero USA, Inc.,&#160;Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Prinston Pharmaceutical Inc., Sandoz Inc., Sawai USA, Inc., Shilpa Medicare Limited, Slayback Pharma LLC, Torrent Pharmaceuticals Ltd., TWi Pharmaceuticals, Inc., Windlas Healthcare Pvt. Ltd. and Zydus Pharmaceuticals (USA) Inc. (the Delaware Defendants) in the U.S. District Court for the District of Delaware (the Delaware Court) and against Mylan in the West Virginia Court. The litigation against Aurobindo Pharma U.S.A., Inc., Glenmark Pharmaceuticals Ltd. and Sawai USA, Inc. was dismissed in the fourth quarter of 2019.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A trial against the remaining Delaware Defendants was held in the Delaware Court in December 2019 and we are awaiting a decision.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On June 22, 2020, the West Virginia Court entered judgment for Mylan that the asserted claims of the &#8216;514 Patent are invalid for lack of written description. We appealed the judgment on June 23, 2020, to the Federal Circuit and filed an emergency motion for an injunction pending resolution of the appeal. On June 30, 2020, the Federal Circuit entered an interim injunction enjoining Mylan from launching its generic version of TECFIDERA pending the Federal Circuit's consideration of our request for an injunction pending appeal.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have entered into settlement agreements with some of the Delaware Defendants and we now anticipate market entry of a generic product equivalent to TECFIDERA before the &#8216;514 Patent expires in February 2028.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">European Patent Office Oppositions</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2016 the European Patent Office (EPO) revoked our European Patent No. 2 137 537, which covers the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. We have appealed to the Technical Boards of Appeal of the EPO and a hearing has been set for January 2021. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2018 the EPO revoked Forward Pharma&#8217;s European Patent No. 2 801 355, which expires in October 2025. Forward Pharma has filed an appeal to the Technical Boards of Appeal of the EPO and a hearing has been set for February 2021. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TYSABRI Patent Revocation Matters</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2017 Bioeq GMBH, affiliated with the Polpharma Group, brought an action in the Polish Patent Office seeking to revoke Polish Patent No. 215263 (the Polish '263 Patent), which corresponds to our European Patent No. 1 485 127 (the E.U. '127 Patent) and covers administration of natalizumab (TYSABRI) to treat MS. The Polish '263 Patent expires in February 2023. No hearing has been set in this matter.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss Pharma International AG, also affiliated with the Polpharma Group, filed actions in the District Court of the Hague, Netherlands (January 2016), the German Patents Court (March 2016) and the Commercial Court of Rome (November 2017) seeking to invalidate the Dutch, German and Italian counterparts, respectively, of the E.U. '127 Patent, which also cover administration of natalizumab (TYSABRI) to treat MS and expire in February 2023. The Dutch and German counterparts were ruled invalid. The decision in the Dutch action was affirmed on appeal and the German appeal has been withdrawn. No hearing has been set in the Italian action.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">'755 Patent Litigation</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May&#160;2010 Biogen MA Inc. (formerly Biogen Idec MA Inc.) filed a complaint in the U.S.&#160;District Court for the District of New Jersey alleging infringement by Bayer Healthcare Pharmaceuticals Inc. (Bayer) (manufacturer, marketer and seller of BETASERON and manufacturer of EXTAVIA), EMD Serono, Inc. (EMD Serono) (manufacturer, marketer and seller of REBIF), Pfizer (co-marketer of REBIF) and Novartis Pharmaceuticals Corp. (Novartis) (marketer and seller of EXTAVIA) of our U.S. Patent No. 7,588,755 (the '755 Patent), which claims, among other things, the use of interferon beta for immunomodulation. The complaint seeks monetary damages, including lost profits and royalties. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bayer, Pfizer, Novartis and EMD Serono all filed counterclaims seeking declaratory judgments of patent invalidity and non-infringement and seeking monetary relief in the form of costs and attorneys' fees. Bayer had previously filed a complaint against us in the same court, on May 27, 2010, seeking a declaratory judgment that it does not infringe the '755 Patent and that the '755 Patent is invalid, and seeking monetary relief in the form of attorneys' fees, costs and expenses. Bayer has also requested </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">ex parte</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reexamination by the U.S. Patent and Trademark Office of Claim 1 of the &#8216;755 Patent, which request was granted in January 2020 and is pending.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2018 the trial court entered judgment against EMD Serono and Pfizer that the '755 Patent is infringed and valid and ordered a new trial on damages. EMD Serono and Pfizer filed an appeal in the U.S. Court of Appeals for the Federal Circuit, which is pending. The trial court has not yet scheduled the new damages trial or a trial against Bayer and Novartis.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Annulment Proceeding in General Court of the European Union relating to TECFIDERA</span></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2018 Pharmaceutical Works Polpharma SA (Polpharma) filed an application in the General Court of the European Union seeking to annul a decision of the European Medicines Agency (EMA) in which the EMA refused to validate Polpharma&#8217;s application to market a generic version of TECFIDERA on the grounds that TECFIDERA benefits from regulatory data protection (RDP). Polpharma disputes that TECFIDERA benefits from RDP. Biogen and the European Commission were granted leave to intervene in the case in support of the EMA and the case is pending. A hearing was held on</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#ff0000;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">July 13, 2020, and we are awaiting a decision.</span></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Government Matters</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have learned that state and U.S. governmental authorities are investigating our sales and promotional practices and have received related subpoenas. We are cooperating with the investigation.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have received subpoenas and other requests from the U.S. government for documents and information relating to our relationship with non-profit organizations that assist patients taking drugs sold by Biogen and the government has challenged some of our contributions to these organizations. We have reached an agreement in principle with the government to resolve this matter.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Matter</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We previously reported that the State Treasury of Goias, Brazil issued tax assessments for the period 2013 through February 2018 relating to tax on the circulation of goods and totaling approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$70.0 million</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> including interest and penalties.&#160;In May 2020 the tax auditor recommended the cancellation of these assessments. We do not anticipate reporting on this matter further.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Product Liability and Other Legal Proceedings</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyInformationAboutLitigationMattersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639332138344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_BusinessOverviewPolicyTextBlock', window );">Overview</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer's disease (AD) and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; and ophthalmology. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; neurocognitive disorders; acute neurology; and pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS and relapsing MS; and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 18, Collaborative and Other Relationships,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> (</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K).</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe and have exclusive rights to commercialize these products in China. Additionally, we have exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11 referencing LUCENTIS and SB15 referencing EYLEA, in major markets worldwide, including the United States (U.S.), Canada, Europe, Japan and Australia. For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 17, Collaborative and Other Relationships</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these unaudited condensed consolidated financial statements (condensed consolidated financial statements). </span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K. Our accounting policies are described in the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Notes to Consolidated Financial Statements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in our </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We operate as </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>one</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>100%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our condensed consolidated financial statements and there may be changes to those estimates in future periods. </span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New accounting pronouncements</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements or disclosures.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Credit Losses</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the FASB issued Accounting Standards Update (ASU) No. 2016-13, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2020. This standard requires entities to estimate an expected lifetime credit loss on financial assets ranging from short-term trade accounts receivable to long-term financings and report credit losses using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. This standard limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This standard became effective for us on January 1, 2020, and based on the composition of our trade receivables, investment portfolio and other financial assets, current economic conditions and historical credit loss activity, the adoption of this standard did not have a material impact on our condensed consolidated financial statements and related disclosures. During the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recorded an immaterial amount associated with expected credit losses related to outstanding trade receivables in certain foreign countries that have been disproportionately impacted by the COVID-19 pandemic.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Fair Value Measurements</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 the FASB issued ASU No. 2018-13,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard modifies certain disclosure requirements on fair value measurements. This standard became effective for us on January 1, 2020, and did not have a material impact on our disclosures. For the new disclosures regarding our Level 3 instruments, please read </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Note 7, Fair Value Measurements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Internal Use Software</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 the FASB issued ASU No. 2018-15, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard clarifies the accounting for implementation costs in cloud computing arrangements. This standard became effective for us on January 1, 2020, and was adopted on a prospective basis, resulting in an immaterial amount of additional assets being recorded on our condensed consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Collaborative Arrangements</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2018 the FASB issued ASU No. 2018-18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard makes targeted improvements for collaborative arrangements as follows:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Accounting Standards Codification (ASC) 606, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adds unit-of-account guidance to ASC 808, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Arrangements</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This standard became effective for us on January 1, 2020, and did not have a material impact on our condensed consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessOverviewPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes an overview of the company and its operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessOverviewPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639326368024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Revenues by product</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues by product are summarized as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:30%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United<br/>States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of<br/>World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United<br/>States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of<br/>World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Multiple Sclerosis (MS):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Fumarate*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>921.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>268.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,190.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>869.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>280.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,150.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Interferon**</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>345.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>135.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>481.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>379.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>174.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>554.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TYSABRI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>244.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>187.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>432.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>264.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>211.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>475.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FAMPYRA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>23.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>23.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>24.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>24.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Subtotal: MS product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,511.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>615.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>2,126.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,513.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>690.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2,204.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Spinal Muscular Atrophy:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">SPINRAZA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>210.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>284.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>494.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>230.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>257.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>488.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Biosimilars:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">BENEPALI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>106.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>106.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>120.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>120.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">IMRALDI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>44.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>44.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>47.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>47.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FLIXABI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>20.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>20.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>16.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>16.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Subtotal: Biosimilar product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>171.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>171.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>184.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>184.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FUMADERM</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,721.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,074.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>2,795.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,744.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,135.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2,880.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:34%;"/><td style="width:32%;"/><td style="width:34%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">*Fumarate includes TECFIDERA and VUMERITY. VUMERITY became commercially available in the U.S. in November 2019.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">**Interferon includes AVONEX and PLEGRIDY.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United<br/>States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of<br/>World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United<br/>States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of<br/>World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Multiple Sclerosis (MS):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Fumarate*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,699.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>591.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>2,291.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,587.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>561.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2,149.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Interferon**</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>638.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>309.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>947.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>707.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>348.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,055.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TYSABRI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>521.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>432.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>954.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>509.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>426.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>935.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FAMPYRA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>51.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>51.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>47.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>47.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Subtotal: MS product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>2,859.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,385.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>4,244.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2,803.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,383.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>4,187.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Spinal Muscular Atrophy:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">SPINRAZA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>445.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>613.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,059.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>453.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>552.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,006.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Biosimilars:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">BENEPALI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>239.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>239.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>244.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>244.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">IMRALDI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>106.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>106.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>83.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>83.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FLIXABI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>44.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>44.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>31.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>31.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Subtotal: Biosimilar product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>390.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>390.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>358.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>358.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FUMADERM</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>6.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>6.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>3,304.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>2,395.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>5,700.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>3,257.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2,302.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>5,560.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:34%;"/><td style="width:32%;"/><td style="width:34%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">*Fumarate includes TECFIDERA and VUMERITY. VUMERITY became commercially available in the U.S. in November 2019.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">**Interferon includes AVONEX and PLEGRIDY.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock', window );">Analysis of change In reserves</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Balance, as of December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>131.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,027.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>40.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,198.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Current provisions relating to sales in current year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>387.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,624.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>9.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>2,021.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Adjustments relating to prior years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(25.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(26.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Payments/credits relating to sales in current year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(251.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(1,018.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(1,270.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Payments/credits relating to sales in prior years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(126.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(612.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(10.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(749.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Balance, as of June 30, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>139.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>994.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>41.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,174.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock', window );">Total reserves included in consolidated balance sheets</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:66%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>June 30,<br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Reduction of accounts receivable, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>223.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>197.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Component of accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>951.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,001.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total revenue-related reserves</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,174.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,198.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs are summarized below. For the purposes of this footnote we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div style="line-height:120%;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:46%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>257.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>377.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>598.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>768.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other revenues from anti-CD20 therapeutic programs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>220.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>199.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>399.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>325.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total revenues from anti-CD20 therapeutic programs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>478.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>576.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>998.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,093.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OtherrevenuesTableTextBlock', window );">Other revenues</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues are summarized as follows:</span></div><div style="line-height:120%;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Revenues from collaborative and other relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Profit (loss) earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Revenues earned under our technical development agreement, manufacturing services agreements and royalty revenues on biosimilar products with Samsung Bioepis</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>4.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>52.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>8.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>77.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other royalty and corporate revenues:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Royalty</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>7.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>18.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>6.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other corporate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>395.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>105.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>489.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>369.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total other revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>407.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>160.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>516.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>452.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Analysis of amount of and change in product revenue reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherrevenuesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other revenues [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherrevenuesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from anti-CD20 therapeutic programs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of total product revenue reserves included in consolidated balance sheets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639329867608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Components of inventory</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The components of inventory are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:64%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>June 30,<br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>244.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>169.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Work in process</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>509.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>460.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Finished goods</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>198.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>174.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total inventory</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>952.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>804.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639324985784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock', window );">Intangible assets</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"/></tr><tr><td style="width:21%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of June 30, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Life</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Completed technology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">4-28 years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>7,379.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(5,014.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>2,364.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>7,379.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(4,881.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2,497.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">In-process research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Indefinite until commercialization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>954.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>954.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>965.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>965.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Trademarks&#160;and trade names</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Indefinite</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>64.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>64.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>64.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>64.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>8,398.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(5,014.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>3,383.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>8,408.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(4,881.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>3,527.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Estimated future amortization for acquired intangible assets</a></td>
<td class="text">he estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:<div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:81%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>June 30,<br/>2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2020 (remaining six months)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>126.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>220.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>220.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>230.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2024</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>230.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2025</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>220.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Summary of roll forward of the changes in goodwill</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:81%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>June 30,<br/>2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Goodwill, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>5,757.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(6.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Goodwill, end of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>5,751.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible assets excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IntangibleAssetsExcludingGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639333125480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of assets and liabilities recorded at fair value</a></td>
<td class="text"><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of June 30, 2020 (In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">Assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,869.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,869.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Marketable debt securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,790.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,790.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Government securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>966.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>966.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Mortgage and other asset backed securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>108.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>108.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Marketable equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>527.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>344.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>182.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>59.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>59.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Plan assets for deferred compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>27.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>27.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>5,349.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>344.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>5,005.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">Liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>14.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>14.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Contingent consideration obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>351.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>351.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>365.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>14.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>351.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2019 (In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">Assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2,541.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2,541.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Marketable debt securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,695.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,695.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Government securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,013.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,013.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Mortgage and other asset backed securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>261.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>261.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Marketable equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>337.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>7.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>329.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>43.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>43.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Plan assets for deferred compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>27.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>27.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>5,920.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>7.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>5,912.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">Liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>8.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>8.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Contingent consideration obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>346.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>346.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>354.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>8.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>346.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Summary of fair and carrying value of debt instruments</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of June 30, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2.900% Senior Notes due September 15, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,509.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,495.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3.625% Senior Notes due September 15, 2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,061.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>997.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,038.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>996.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">4.050% Senior Notes due September 15, 2025</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,994.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,740.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,897.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,739.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2.250% Senior Notes due May 1, 2030</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,514.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,490.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">5.200% Senior Notes due September 15, 2045</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>2,247.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,723.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2,107.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,722.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3.150% Senior Notes due May 1, 2050</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,441.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,472.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>8,257.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>7,423.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>6,553.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>5,954.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair value of contingent consideration obligations</a></td>
<td class="text">The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:<div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:42%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Fair value, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>341.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>421.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>346.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>409.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Changes in fair value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>10.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(20.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(8.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Fair value, end of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>351.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>401.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>351.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>401.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639325099784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>June 30,<br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>139.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>384.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Overnight reverse repurchase agreements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>247.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>368.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,363.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,628.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Short-term debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>118.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>159.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,869.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2,541.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesTextBlock', window );">Marketable debt and equity securities</a></td>
<td class="text">The following tables summarize our marketable debt and equity securities:<div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of June 30, 2020 (In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized<br/>Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Corporate debt securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,282.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,283.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>502.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>3.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>506.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Government securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>657.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>658.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>307.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>308.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Mortgage and other asset backed securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>107.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>107.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total marketable debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>2,859.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>7.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>2,865.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Marketable equity securities, non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>428.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>114.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(15.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>527.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2019 (In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Corporate debt securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,057.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,058.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>633.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>636.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Government securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>502.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>503.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>510.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>510.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Mortgage and other asset backed securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>260.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>260.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total marketable debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2,965.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>6.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2,970.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Marketable equity securities, non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>218.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>132.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(13.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>337.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Summary of contractual maturities: available-for-sale securities</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of June 30, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized<br/>Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized<br/>Cost</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Due in one year or less</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,942.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,940.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,562.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,560.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Due after one year through five years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>862.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>858.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,234.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,230.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Due after five years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>60.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>59.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>173.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>173.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total marketable debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>2,865.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>2,859.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2,970.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2,965.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock', window );">Proceeds from marketable debt securities</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:42%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Proceeds from maturities and sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,490.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,766.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>3,879.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>3,255.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Realized gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>6.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>11.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Realized losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(5.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(24.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(0.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized gains and losses on investments reported in the statement of income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639328511928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock', window );">Foreign currency forward contracts that were entered into to hedge forecasted revenue</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Notional Amount</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>June 30,<br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Euro</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>2,477.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,892.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">British pound</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>125.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Swiss franc</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>69.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Japanese yen</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>53.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Canadian dollar</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>48.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total foreign currency forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>2,773.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,892.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of the effect of cash flow derivatives designated as hedging instruments on the condensed consolidated statements of income</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"/></tr><tr><td style="width:23%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months Ended June 30,</span></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income (in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Operating Income (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>23.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>29.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"/></tr><tr><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months Ended June 30,</span></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income (in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Operating Income (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>50.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>44.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>7.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>7.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(1.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(1.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr></table></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Summary of the effect of derivatives designated as net investment hedging instruments on our consolidated statement of income</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the effect of our net investment hedge in our condensed consolidated financial statements:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="29"/></tr><tr><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/></tr><tr><td colspan="29" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months Ended June 30,</span></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Net Income </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Amounts Excluded from Effectiveness Testing) (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(8.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>11.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>3.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="29"/></tr><tr><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/></tr><tr><td colspan="29" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months Ended June 30,</span></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Net Income </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Amounts Excluded from Effectiveness Testing) (in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>15.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>23.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>6.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Summary of fair value and presentation of derivatives</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:39%;"/><td style="width:1%;"/><td style="width:30%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>June 30,<br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">Cash Flow Hedging Instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Asset derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>32.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>33.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Investments and other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Liability derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>9.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">Net Investment Hedging Instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Asset derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>20.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">Fair Value Hedging Instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Liability derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">Other Derivative Instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Asset derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>6.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>8.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Liability derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the notional amounts of outstanding derivative positions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639332047896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:32%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains (Losses) on Net Investment Hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Balance, December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>25.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(32.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(139.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(135.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(9.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>33.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>18.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(47.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(3.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>9.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(50.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(1.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(42.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Net current period other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(17.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>16.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(47.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(45.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Balance, June 30, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>5.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(9.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>41.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(31.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(186.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(181.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:32%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains (Losses) on Net Investment Hedge</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Balance, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(4.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>34.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>3.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(31.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(243.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(240.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>11.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>22.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>30.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(28.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>36.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(43.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(4.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(48.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Net current period other comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>10.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(21.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>25.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(28.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(12.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Balance, June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>6.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>13.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>29.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(30.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(271.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(252.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amounts reclassified from accumulated other comprehensive income:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"/></tr><tr><td style="width:33%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amounts Reclassified from Accumulated Other Comprehensive Income</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Gains (losses) on securities available for sale</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(12.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Income tax benefit (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Gains (losses) on cash flow hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"><span>23.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>29.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>50.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>44.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(1.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Income tax benefit (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Gains (losses) on net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other income (expense)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total reclassifications, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"><span>27.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>31.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>42.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>48.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639334722088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and diluted earnings per share</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic and diluted earnings per share are calculated as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:42%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">Numerator:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Net income attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1,542.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,494.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>2,941.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2,902.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">Denominator:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Weighted average number of common shares outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>160.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>190.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>166.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>193.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Effect of dilutive securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Time-vested restricted stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Market stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Performance stock units settled in stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Dilutive potential common shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Shares used in calculating diluted earnings per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>160.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>190.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>167.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>193.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639329869176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-based compensation expense included in condensed consolidated statements of income</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Research and development </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>15.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>28.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>48.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>49.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Selling, general and administrative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>30.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>54.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>73.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>82.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Subtotal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>45.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>82.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>121.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>132.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Capitalized share-based compensation costs </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(2.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(3.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(6.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Share-based compensation expense included in total cost and expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>44.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>80.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>118.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>126.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Income tax effect</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(7.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(13.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(20.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(21.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Share-based compensation expense included in net income attributable to Biogen Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>37.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>66.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>98.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>105.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of share-based compensation expense associated with each of our share-based compensating programs</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Market stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>7.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>26.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>15.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Time-vested restricted stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>34.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>31.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>72.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>66.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Cash settled performance units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(0.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Performance units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Performance stock units settled in stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>12.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>12.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>14.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Performance stock units settled in cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(4.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>4.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Employee stock purchase plan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>7.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>8.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">NST stock options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>26.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>26.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Subtotal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>45.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>82.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>121.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>132.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Capitalized share-based compensation costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(2.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(3.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(6.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Share-based compensation expense included in total cost and expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>44.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>80.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>118.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>126.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639424225880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:45%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Statutory rate</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">State taxes</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Taxes on foreign earnings</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(3.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(4.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(3.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(4.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Tax credits</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Purchased intangible assets</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Divestiture of Denmark manufacturing operations</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Internal reorganization of certain intellectual property rights</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(5.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(2.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TECFIDERA impairment</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">GILTI</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other permanent items</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Effective tax rate</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>21.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>14.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>19.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>18.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639326165992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Other income (expense), net</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Components of other income (expense), net, are summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:42%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Interest income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>7.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>29.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>32.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>60.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(66.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(47.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(110.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(95.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Gain (loss) on investments, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>106.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(173.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>29.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>203.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Foreign exchange gains (losses), net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>10.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(8.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(7.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(7.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total other income (expense), net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>63.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(197.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>(57.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>159.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestmentsTextBlock', window );">Gain (loss) on investments in equity securities</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our gain (loss) on investments, net that relates to our equity securities held as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:42%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Net gains (losses) recognized during the period on equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>102.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(174.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>42.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>201.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Less: Net gains (losses) recognized during the period on equity securities sold during the period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(42.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>42.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Unrealized gains (losses) recognized during the period on equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>102.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>(131.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>42.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>159.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued expenses and other</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other consists of the following:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of<br/>June 30,<br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br/>December 31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Revenue-related reserves for discounts and allowances</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>951.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1,001.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Employee compensation and benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>212.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>309.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Royalties and licensing fees</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>203.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>220.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Collaboration expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>172.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>281.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Current portion of contingent consideration obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>149.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>148.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Construction in progress</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>24.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>78.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>774.1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>726.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>2,486.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>2,765.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized and unrealized gain (loss) on investment in security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639329674200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock', window );">Summary of Activity Related to BAN2401 and Elenbecestat Collaboration</a></td>
<td class="text"><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total development expense incurred by the collaboration related to the advancement of BAN2401 and elenbecestat</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>33.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>68.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>77.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>136.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Biogen's share of BAN2401 and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>17.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>34.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>38.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>68.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total sales and marketing expense incurred by the collaboration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">nm</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>6.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">nm</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Biogen's share of BAN2401 sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">nm</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">nm</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock', window );">Summary of Activity Related to Aducanumab Collaboration</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of development, sales and marketing and milestone expense related to the Aducanumab Collaboration Agreement is as follows:</span></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br/>Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Six Months <br/>Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total aducanumab development expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>35.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>55.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>165.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Biogen's share of aducanumab development expense reflected in research and development expense in our condensed consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>19.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>30.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>91.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total aducanumab sales and marketing expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>45.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>67.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>21.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>25.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>37.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"><span>11.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total aducanumab collaboration third party milestone expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>75.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>75.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Eisai's share of aducanumab milestone expense reflected in collaboration profit sharing in our condensed consolidated statements of income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>33.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;"><span>33.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639329857304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2020 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InterestInSubsidiary', window );">Interest in subsidiary (less than given percentage)</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest in subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639331271384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Acquisition (Details Textual)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>Assets</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 07, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ClinicalAssetsAcquired', window );">Clinical Assets Acquired | Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_BIIB118Member', window );">BIIB118</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="nump">$ 635.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember', window );">Nightstar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Total transaction value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">847.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPaymentsToAcquireBusinesses', window );">Payments for pre-combination equity compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Nightstar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized', window );">Fair value of post-combination equity compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Nightstar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized', window );">Fair value of post-combination equity compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=biib_PostacquisitionequitycompensationMember', window );">Post-acquisition equity compensation | Nightstar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized', window );">Fair value of post-combination equity compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ClinicalAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical Assets Acquired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ClinicalAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated additional payments upon achievement of development and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expenses and losses recorded for each transaction with the acquiree that was recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPaymentsToAcquireBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPaymentsToAcquireBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_BIIB118Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_BIIB118Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_NightstarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=biib_PostacquisitionequitycompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=biib_PostacquisitionequitycompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639324861144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Acquisition (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 07, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 5,751.0<span></span>
</td>
<td class="nump">$ 5,757.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember', window );">Nightstar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_NightstarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639333328104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Divestitures (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Aug. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown', window );">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 113.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InventoryrawmaterialssoldtoFUJIFILM', window );">Inventory raw materials sold to FUJIFILM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember', window );">Denmark Manufacturing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Consideration expected to be received for sale of Denmark Manufacturing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 881.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Future minimum batch production for Denmark Manufacturing Operations</a></td>
<td class="nump">$ 74.0<span></span>
</td>
<td class="nump">$ 120.0<span></span>
</td>
<td class="nump">74.0<span></span>
</td>
<td class="nump">120.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax', window );">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown', window );">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 113.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense', window );">Expected costs to sell disposal group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Tax expense on disposal group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InventoryrawmaterialssoldtoFUJIFILM">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory raw materials sold to FUJIFILM</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InventoryrawmaterialssoldtoFUJIFILM</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2443-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639429328536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues by Product (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">$ 3,681.6<span></span>
</td>
<td class="nump">$ 3,616.7<span></span>
</td>
<td class="nump">$ 7,215.9<span></span>
</td>
<td class="nump">$ 7,106.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FumarateMember', window );">Fumarate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">1,190.3<span></span>
</td>
<td class="nump">1,150.2<span></span>
</td>
<td class="nump">2,291.1<span></span>
</td>
<td class="nump">2,149.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FumarateMember', window );">Fumarate | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">921.7<span></span>
</td>
<td class="nump">869.8<span></span>
</td>
<td class="nump">1,699.2<span></span>
</td>
<td class="nump">1,587.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FumarateMember', window );">Fumarate | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">268.6<span></span>
</td>
<td class="nump">280.4<span></span>
</td>
<td class="nump">591.9<span></span>
</td>
<td class="nump">561.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">481.4<span></span>
</td>
<td class="nump">554.4<span></span>
</td>
<td class="nump">947.4<span></span>
</td>
<td class="nump">1,055.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">345.6<span></span>
</td>
<td class="nump">379.7<span></span>
</td>
<td class="nump">638.2<span></span>
</td>
<td class="nump">707.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">135.8<span></span>
</td>
<td class="nump">174.7<span></span>
</td>
<td class="nump">309.2<span></span>
</td>
<td class="nump">348.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">432.0<span></span>
</td>
<td class="nump">475.3<span></span>
</td>
<td class="nump">954.4<span></span>
</td>
<td class="nump">935.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">244.1<span></span>
</td>
<td class="nump">264.3<span></span>
</td>
<td class="nump">521.8<span></span>
</td>
<td class="nump">509.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">187.9<span></span>
</td>
<td class="nump">211.0<span></span>
</td>
<td class="nump">432.6<span></span>
</td>
<td class="nump">426.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">23.0<span></span>
</td>
<td class="nump">24.1<span></span>
</td>
<td class="nump">51.3<span></span>
</td>
<td class="nump">47.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">23.0<span></span>
</td>
<td class="nump">24.1<span></span>
</td>
<td class="nump">51.3<span></span>
</td>
<td class="nump">47.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">2,126.7<span></span>
</td>
<td class="nump">2,204.0<span></span>
</td>
<td class="nump">4,244.2<span></span>
</td>
<td class="nump">4,187.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">1,511.4<span></span>
</td>
<td class="nump">1,513.8<span></span>
</td>
<td class="nump">2,859.2<span></span>
</td>
<td class="nump">2,803.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">615.3<span></span>
</td>
<td class="nump">690.2<span></span>
</td>
<td class="nump">1,385.0<span></span>
</td>
<td class="nump">1,383.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">494.6<span></span>
</td>
<td class="nump">488.2<span></span>
</td>
<td class="nump">1,059.6<span></span>
</td>
<td class="nump">1,006.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">210.3<span></span>
</td>
<td class="nump">230.6<span></span>
</td>
<td class="nump">445.7<span></span>
</td>
<td class="nump">453.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">284.3<span></span>
</td>
<td class="nump">257.6<span></span>
</td>
<td class="nump">613.9<span></span>
</td>
<td class="nump">552.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">106.2<span></span>
</td>
<td class="nump">120.3<span></span>
</td>
<td class="nump">239.7<span></span>
</td>
<td class="nump">244.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">106.2<span></span>
</td>
<td class="nump">120.3<span></span>
</td>
<td class="nump">239.7<span></span>
</td>
<td class="nump">244.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">44.8<span></span>
</td>
<td class="nump">47.3<span></span>
</td>
<td class="nump">106.4<span></span>
</td>
<td class="nump">83.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">44.8<span></span>
</td>
<td class="nump">47.3<span></span>
</td>
<td class="nump">106.4<span></span>
</td>
<td class="nump">83.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">20.6<span></span>
</td>
<td class="nump">16.8<span></span>
</td>
<td class="nump">44.3<span></span>
</td>
<td class="nump">31.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">20.6<span></span>
</td>
<td class="nump">16.8<span></span>
</td>
<td class="nump">44.3<span></span>
</td>
<td class="nump">31.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">171.6<span></span>
</td>
<td class="nump">184.4<span></span>
</td>
<td class="nump">390.4<span></span>
</td>
<td class="nump">358.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">171.6<span></span>
</td>
<td class="nump">184.4<span></span>
</td>
<td class="nump">390.4<span></span>
</td>
<td class="nump">358.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">3.7<span></span>
</td>
<td class="nump">6.1<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">3.7<span></span>
</td>
<td class="nump">6.1<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">2,795.7<span></span>
</td>
<td class="nump">2,880.3<span></span>
</td>
<td class="nump">5,700.3<span></span>
</td>
<td class="nump">5,560.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">1,721.7<span></span>
</td>
<td class="nump">1,744.4<span></span>
</td>
<td class="nump">3,304.9<span></span>
</td>
<td class="nump">3,257.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">$ 1,074.0<span></span>
</td>
<td class="nump">$ 1,135.9<span></span>
</td>
<td class="nump">$ 2,395.4<span></span>
</td>
<td class="nump">$ 2,302.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FumarateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FumarateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_InterferonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_InterferonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TysabriProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TysabriProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FAMPYRAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_MSProductRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_SPINRAZAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_BENEPALIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_BENEPALIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_IMRALDIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_IMRALDIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FLIXABIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FLIXABIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_BiosimilarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FUMADERMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FUMADERMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639333472472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reserves for Discounts and Allowances (Details 1)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">$ 1,198.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">2,021.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="num">(26.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(1,270.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(749.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">1,174.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember', window );">Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">131.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">387.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="num">(1.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(251.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(126.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">139.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember', window );">Contractual adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">1,027.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">1,624.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="num">(25.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(1,018.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(612.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">994.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember', window );">Returns</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">40.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">9.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(10.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">$ 41.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to product revenue reserves relating to sales in prior years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current provisions to product revenue reserves relating to sales in current year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to current year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to prior year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639325139352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Reserves for Discounts and Allowances (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">$ 1,174.7<span></span>
</td>
<td class="nump">$ 1,198.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember', window );">Reduction of accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">223.4<span></span>
</td>
<td class="nump">197.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">$ 951.3<span></span>
</td>
<td class="nump">$ 1,001.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639334297288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues from Anti-CD20 Therapeutic Programs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">$ 3,681.6<span></span>
</td>
<td class="nump">$ 3,616.7<span></span>
</td>
<td class="nump">$ 7,215.9<span></span>
</td>
<td class="nump">$ 7,106.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_RocheGroupGenentechMember', window );">Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareOfCoPromotionProfits', window );">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</a></td>
<td class="nump">257.5<span></span>
</td>
<td class="nump">377.2<span></span>
</td>
<td class="nump">598.8<span></span>
</td>
<td class="nump">768.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OtherrevenuesfromantiCD20therapeuticprograms', window );">Other revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">220.8<span></span>
</td>
<td class="nump">199.2<span></span>
</td>
<td class="nump">399.9<span></span>
</td>
<td class="nump">325.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">$ 478.3<span></span>
</td>
<td class="nump">$ 576.4<span></span>
</td>
<td class="nump">$ 998.7<span></span>
</td>
<td class="nump">$ 1,093.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherrevenuesfromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherrevenuesfromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareOfCoPromotionProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share of co promotion profits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareOfCoPromotionProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_RocheGroupGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_RocheGroupGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639331510184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Revenues (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 3,681.6<span></span>
</td>
<td class="nump">$ 3,616.7<span></span>
</td>
<td class="nump">$ 7,215.9<span></span>
</td>
<td class="nump">$ 7,106.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">7.1<span></span>
</td>
<td class="nump">2.7<span></span>
</td>
<td class="nump">18.5<span></span>
</td>
<td class="nump">6.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember', window );">Other corporate revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">395.5<span></span>
</td>
<td class="nump">105.2<span></span>
</td>
<td class="nump">489.5<span></span>
</td>
<td class="nump">369.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenues related to amendment of contract manufacturing agreement</a></td>
<td class="nump">170.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">407.6<span></span>
</td>
<td class="nump">160.0<span></span>
</td>
<td class="nump">516.9<span></span>
</td>
<td class="nump">452.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative arrangement | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative arrangement | ZINBRYTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 4.5<span></span>
</td>
<td class="nump">$ 52.2<span></span>
</td>
<td class="nump">$ 8.2<span></span>
</td>
<td class="nump">$ 77.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_ZINBRYTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_ZINBRYTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639338543528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Other Revenues</a></td>
<td class="nump">$ 3,681.6<span></span>
</td>
<td class="nump">$ 3,616.7<span></span>
</td>
<td class="nump">$ 7,215.9<span></span>
</td>
<td class="nump">$ 7,106.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_DistributorOneMember', window );">Distributor One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors', window );">Percentage of revenues from major distributors</a></td>
<td class="nump">31.70%<span></span>
</td>
<td class="nump">30.50%<span></span>
</td>
<td class="nump">30.80%<span></span>
</td>
<td class="nump">30.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_DistributorTwoMember', window );">Distributor Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors', window );">Percentage of revenues from major distributors</a></td>
<td class="nump">17.90%<span></span>
</td>
<td class="nump">18.20%<span></span>
</td>
<td class="nump">16.20%<span></span>
</td>
<td class="nump">16.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember', window );">Other corporate revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenues related to amendment of contract manufacturing agreement</a></td>
<td class="nump">$ 170.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 170.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Other Revenues</a></td>
<td class="nump">395.5<span></span>
</td>
<td class="nump">$ 105.2<span></span>
</td>
<td class="nump">489.5<span></span>
</td>
<td class="nump">$ 369.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember', window );">Other corporate revenues | Contract Manufacturing Customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Other Revenues</a></td>
<td class="nump">329.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">329.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Other Revenues</a></td>
<td class="nump">$ 407.6<span></span>
</td>
<td class="nump">$ 160.0<span></span>
</td>
<td class="nump">$ 516.9<span></span>
</td>
<td class="nump">$ 452.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity wide percentage of revenue from major distributors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EntityWidePercentageOfRevenueFromMajorDistributors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_DistributorOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_DistributorOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_DistributorTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_DistributorTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_ContractManufacturingCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_ContractManufacturingCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639326279208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Components of inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 244.7<span></span>
</td>
<td class="nump">$ 169.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">509.1<span></span>
</td>
<td class="nump">460.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">198.9<span></span>
</td>
<td class="nump">174.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Inventorynetcurrentandnoncurrent', window );">Total inventory</a></td>
<td class="nump">$ 952.7<span></span>
</td>
<td class="nump">$ 804.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Inventorynetcurrentandnoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory, net current and noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Inventorynetcurrentandnoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639415207880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 07, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of Intangible Assets (Excluding Goodwill)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Contingent consideration impairment</a></td>
<td class="num">(10,000,000.0)<span></span>
</td>
<td class="nump">20,000,000.0<span></span>
</td>
<td class="num">(5,500,000)<span></span>
</td>
<td class="nump">8,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Total intangible assets, gross</a></td>
<td class="nump">8,398,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,398,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,408,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(5,014,400,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,014,400,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,881,400,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">3,383,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,383,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,527,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="nump">61,500,000<span></span>
</td>
<td class="nump">$ 70,100,000<span></span>
</td>
<td class="nump">133,000,000.0<span></span>
</td>
<td class="nump">$ 138,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Expected future amortization expense, 2019 (remaining three months)</a></td>
<td class="nump">126,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Expected future amortization expense, 2020</a></td>
<td class="nump">220,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Expected future amortization expense, 2021</a></td>
<td class="nump">220,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Expected future amortization expense, 2022</a></td>
<td class="nump">230,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Expected future amortization expense, 2023</a></td>
<td class="nump">230,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Expected future amortization expense, 2024</a></td>
<td class="nump">220,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">7,379,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,379,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,379,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">2,364,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,364,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,497,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(5,014,400,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,014,400,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,881,400,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">23 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">28 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife', window );">Indefinite lived intangible assets useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Indefinite until commercialization<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and Net</a></td>
<td class="nump">954,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 954,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">965,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trademarks and Trade Names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife', window );">Indefinite lived intangible assets useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Indefinite<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and Net</a></td>
<td class="nump">64,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember', window );">Nightstar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_TGNMember', window );">TGN [Member] | In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and Net</a></td>
<td class="nump">$ 160,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indefinite lived intangible assets useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IndefiniteLivedIntangibleAssetsUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:durationStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_NightstarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_TGNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_TGNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639326526552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details 1)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Summary of roll forward of the changes in goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning of period</a></td>
<td class="nump">$ 5,757.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Other</a></td>
<td class="num">(6.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, end of period</a></td>
<td class="nump">5,751.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment losses related to goodwill</a></td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639339381720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 2,865.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,970.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,869.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,541.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">527.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">337.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">59.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">27.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">5,349.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,920.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">14.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">351.6<span></span>
</td>
<td class="nump">$ 341.6<span></span>
</td>
<td class="nump">346.1<span></span>
</td>
<td class="nump">$ 401.3<span></span>
</td>
<td class="nump">$ 421.3<span></span>
</td>
<td class="nump">$ 409.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">365.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">354.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,790.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,695.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">966.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,013.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">108.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">261.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">344.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">344.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,869.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,541.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">182.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">329.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">59.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">27.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">5,005.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,912.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">14.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">14.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,790.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,695.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">966.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,013.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">108.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">261.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">351.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">346.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">351.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">346.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair values as of the balance sheet date of all assets of deferred compensation plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PlanAssetsForDeferredCompensationFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractAssetFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639337455928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details 1) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">$ 7,423,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,954,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt instruments, fair value</a></td>
<td class="nump">8,257,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,553,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,509,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,495,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">$ 1,061,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,038,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">$ 997,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">996,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.050% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">$ 1,994,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,897,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">$ 1,740,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,739,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member', window );">2.250% Senior Notes due May 1, 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">$ 1,514,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">$ 1,490,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">$ 2,247,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,107,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">$ 1,723,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,722,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member', window );">3.150% Senior Notes due May 1, 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">$ 1,441,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">$ 1,472,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">3.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.250% Senior Notes due May 1, 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.150% Senior Notes due May 1, 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639333593832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Contingent consideration impairment</a></td>
<td class="num">$ (10.0)<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="num">$ (5.5)<span></span>
</td>
<td class="nump">$ 8.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, beginning of period</a></td>
<td class="nump">341.6<span></span>
</td>
<td class="nump">421.3<span></span>
</td>
<td class="nump">346.1<span></span>
</td>
<td class="nump">409.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, end of period</a></td>
<td class="nump">$ 351.6<span></span>
</td>
<td class="nump">$ 401.3<span></span>
</td>
<td class="nump">$ 351.6<span></span>
</td>
<td class="nump">$ 401.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639334567576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration obligations</a></td>
<td class="nump">202,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">202,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 197,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Contingent consideration impairment</a></td>
<td class="num">(10,000,000.0)<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="num">(5,500,000)<span></span>
</td>
<td class="nump">$ 8,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Future payment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.050% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639334667512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details) - Discount rate<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business Combination, Contingent Consideration, Liability, Measurement Input</a></td>
<td class="nump">0.0083<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business Combination, Contingent Consideration, Liability, Measurement Input</a></td>
<td class="nump">0.0118<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business Combination, Contingent Consideration, Liability, Measurement Input</a></td>
<td class="nump">0.0092<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639329046264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 1,869.6<span></span>
</td>
<td class="nump">$ 2,541.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">139.9<span></span>
</td>
<td class="nump">384.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember', window );">Overnight reverse repurchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">247.7<span></span>
</td>
<td class="nump">368.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">1,363.7<span></span>
</td>
<td class="nump">1,628.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember', window );">Short-term debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 118.3<span></span>
</td>
<td class="nump">$ 159.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639331415768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">$ 2,859.1<span></span>
</td>
<td class="nump">$ 2,965.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">7.3<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(0.9)<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">2,865.5<span></span>
</td>
<td class="nump">2,970.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable equity securities, fair value</a></td>
<td class="nump">2,865.5<span></span>
</td>
<td class="nump">2,970.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember', window );">Corporate debt securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">1,282.5<span></span>
</td>
<td class="nump">1,057.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">1,283.9<span></span>
</td>
<td class="nump">1,058.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesNonCurrentMember', window );">Corporate debt securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">502.8<span></span>
</td>
<td class="nump">633.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">3.8<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">506.3<span></span>
</td>
<td class="nump">636.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember', window );">Government securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">657.7<span></span>
</td>
<td class="nump">502.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">658.2<span></span>
</td>
<td class="nump">503.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesNonCurrentMember', window );">Government securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">307.9<span></span>
</td>
<td class="nump">510.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">308.6<span></span>
</td>
<td class="nump">510.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember', window );">Mortgage and other asset backed securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember', window );">Mortgage and other asset backed securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">107.6<span></span>
</td>
<td class="nump">260.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">107.9<span></span>
</td>
<td class="nump">260.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember', window );">Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Marketable equity securities, amortized cost</a></td>
<td class="nump">428.0<span></span>
</td>
<td class="nump">218.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable equity securities, gross unrealized gains</a></td>
<td class="nump">114.6<span></span>
</td>
<td class="nump">132.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable equity securities, gross unrealized losses</a></td>
<td class="num">(15.6)<span></span>
</td>
<td class="num">(13.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable equity securities, fair value</a></td>
<td class="nump">$ 527.0<span></span>
</td>
<td class="nump">$ 337.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639334338328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract', window );"><strong>Summary of Contractual Maturities: Available-for-Sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due in one year or less, amortized cost</a></td>
<td class="nump">$ 1,942.7<span></span>
</td>
<td class="nump">$ 1,562.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in one year or less, estimated fair value</a></td>
<td class="nump">1,940.8<span></span>
</td>
<td class="nump">1,560.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years, amortized cost</a></td>
<td class="nump">862.6<span></span>
</td>
<td class="nump">1,234.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years, estimated fair value</a></td>
<td class="nump">858.5<span></span>
</td>
<td class="nump">1,230.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost', window );">Due after five years, amortized cost</a></td>
<td class="nump">60.2<span></span>
</td>
<td class="nump">173.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue', window );">Due after five years, estimated fair value</a></td>
<td class="nump">59.8<span></span>
</td>
<td class="nump">173.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">2,859.1<span></span>
</td>
<td class="nump">2,965.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">$ 2,865.5<span></span>
</td>
<td class="nump">$ 2,970.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639326432632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities and sales</a></td>
<td class="nump">$ 1,490.6<span></span>
</td>
<td class="nump">$ 1,766.6<span></span>
</td>
<td class="nump">$ 3,879.9<span></span>
</td>
<td class="nump">$ 3,255.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Realized gains</a></td>
<td class="nump">6.1<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">11.8<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Realized losses</a></td>
<td class="num">$ (5.2)<span></span>
</td>
<td class="num">$ (0.3)<span></span>
</td>
<td class="num">$ (24.3)<span></span>
</td>
<td class="num">$ (0.6)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639329661896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details Textual)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AverageMaturityOfMarketableSecurities', window );">Average maturity of marketable securities, months</a></td>
<td class="text">14 months<span></span>
</td>
<td class="text">14 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AverageMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average remaining time to maturity of marketable debt securities, available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AverageMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639332904248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments Financial Instruments (Details Textual 2) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity', window );">Proceeds from sales of strategic investments</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 309.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember', window );">Strategic Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_StrategicInvestmentPortfolio', window );">Strategic investment portfolio</a></td>
<td class="nump">$ 583.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other noncurrent assets | Strategic Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_StrategicInvestmentPortfolio', window );">Strategic investment portfolio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 393.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=biib_SangamoCommonStockMember', window );">Sangamo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Investmentincommonstocksharespurchased', window );">Investment in common stock, shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Investmentincommonstocksharespurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in common stock, shares purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Investmentincommonstocksharespurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_StrategicInvestmentPortfolio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Strategic investment portfolio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_StrategicInvestmentPortfolio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity securities classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=biib_SangamoCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=biib_SangamoCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639337327368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Details)<br> $ in Millions, &#8361; in Billions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax', window );">Gain/Loss on fair value of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain on interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease', window );">Gains (losses) on net investment hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.2)<span></span>
</td>
<td class="nump">$ 11.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.8<span></span>
</td>
<td class="nump">25.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">Net gains (losses) of other income (expense) related to foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.3)<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5.9)<span></span>
</td>
<td class="nump">3.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">999.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 999.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 793.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other noncurrent assets | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,773.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,773.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,892.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">675.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">675.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging [Member] | Foreign exchange contract | Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging [Member] | Interest rate swap | Accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeTermOfContract', window );">Remaining duration of Net Investment Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax', window );">Unrealized gain (loss) on net investment hedges in AOCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax', window );">Derivative qualifying as net investment hedge, excluded component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease', window );">Gains (losses) on net investment hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.8)<span></span>
</td>
<td class="nump">11.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.4<span></span>
</td>
<td class="nump">23.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease', window );">Gains (losses) on net investment hedge, excluded component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">6.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging | Foreign exchange contract | Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember', window );">Interest Expense | Interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain on interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | Cash flows, revenue | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Gain (loss) on reclassification of cash flow hedges, effective portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.7<span></span>
</td>
<td class="nump">29.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.7<span></span>
</td>
<td class="nump">44.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet', window );">Gain (loss) recognized in net income, excluded component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.6)<span></span>
</td>
<td class="nump">3.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.7<span></span>
</td>
<td class="nump">7.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Operating expense | Cash flows, operating expenses | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Gain (loss) on reclassification of cash flow hedges, effective portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet', window );">Gain (loss) recognized in net income, excluded component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other income (expense) | Net Investment Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet', window );">Gain (loss) recognized in net income, excluded component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">$ 4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">Euro | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,477.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,477.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,892.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_GBP', window );">British pound | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CHF', window );">Swiss franc | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_JPY', window );">Japan, Yen | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CAD', window );">Canadian dollar | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction', window );">Percentage of stake in entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to acquire additional investment in equity method investment</a></td>
<td class="nump">$ 676.6<span></span>
</td>
<td class="nump">&#8361; 759.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 676.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeMaturityAxis=biib_ShorttermderivativeMember', window );">Short-term derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax', window );">Gain/Loss on fair value of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated gain (loss) from increase (decrease) in value of excluded component of derivative hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=112277219&amp;loc=d3e80784-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118948506&amp;loc=SL51823488-111719<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118948506&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624177-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of gains and losses (net) on derivative instruments designated and qualifying as hedging instruments representing (a) the amount of the hedge ineffectiveness and (b) the amount, if any, excluded from the assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1),(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109977999&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeRemainingMaturity1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeRemainingMaturity1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5618551-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the cumulative translation adjustment from gain (loss), after tax, on foreign currency derivatives, that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b),(c),(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_GBP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_GBP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_JPY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_JPY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CAD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CAD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DerivativeMaturityAxis=biib_ShorttermderivativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DerivativeMaturityAxis=biib_ShorttermderivativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639329055576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">$ 1,687.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,687.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,590.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">51.3<span></span>
</td>
<td class="nump">$ 47.0<span></span>
</td>
<td class="nump">99.7<span></span>
</td>
<td class="nump">$ 99.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember', window );">Solothurn, Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">1,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets placed into service</a></td>
<td class="nump">256.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">256.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Contractual commitments for the construction of the facility</a></td>
<td class="nump">$ 16.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639334423064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indebtedness (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Sep. 15, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payments of financing costs</a></td>
<td class="nump">$ 24,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Derivative, gain on derivative</a></td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member', window );">2.250% Senior Notes due May 1, 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member', window );">3.150% Senior Notes due May 1, 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">3.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Debt instrument, redemption price, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage', window );">Debt instrument, make whole provision redemption price, percentage</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.250% Senior Notes due May 1, 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Percentage par value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.973%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.150% Senior Notes due May 1, 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Percentage par value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.174%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.90% Senior Notes Due Sept 15, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Percentage par value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.792%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts', window );">Payment of early call premium and write off of remaining unamortized debt issuance costs</a></td>
<td class="nump">$ 12,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember', window );">Interest Expense | Senior Notes | 2.90% Senior Notes Due Sept 15, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain', window );">Pre-tax charge, payment of early call premium and write off of remaining unamortized debt issuance costs, net of derivative gain</a></td>
<td class="nump">9,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember', window );">Interest Expense | Interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Derivative, gain on derivative</a></td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Make Whole Provision Redemption Price, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageParValueOfSeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Par Value Of Senior Notes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageParValueOfSeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pre-tax Charge, Payment of Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs, Net of Derivative Gain</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A2.90SeniorNotesDueSept152020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A2.90SeniorNotesDueSept152020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639333061016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Repurchases (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,029.1<span></span>
</td>
<td class="nump">$ 3,057.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=biib_December2019ShareRepurchaseProgramMember', window );">December 2019 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="nump">9.0<span></span>
</td>
<td class="nump">12.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="nump">$ 2,800.0<span></span>
</td>
<td class="nump">$ 3,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=biib_March2019ShareRepurchaseProgramMember', window );">2019 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Amount remaining under 2019 Share Repurchase Program</a></td>
<td class="nump">$ 1,300.0<span></span>
</td>
<td class="nump">$ 1,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_December2019ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_December2019ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_March2019ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_March2019ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639333431096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (135.2)<span></span>
</td>
<td class="num">$ (240.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">$ (181.0)<span></span>
</td>
<td class="num">$ (252.9)<span></span>
</td>
<td class="num">(135.2)<span></span>
</td>
<td class="num">(252.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.3)<span></span>
</td>
<td class="nump">36.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42.5)<span></span>
</td>
<td class="num">(48.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(30.6)<span></span>
</td>
<td class="num">(33.5)<span></span>
</td>
<td class="num">(44.0)<span></span>
</td>
<td class="num">(12.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(181.0)<span></span>
</td>
<td class="num">(252.9)<span></span>
</td>
<td class="num">(181.0)<span></span>
</td>
<td class="num">(252.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(31.7)<span></span>
</td>
<td class="num">(33.1)<span></span>
</td>
<td class="num">(45.8)<span></span>
</td>
<td class="num">(12.5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized gains (losses) on securities available for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
<td class="num">(4.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="nump">5.1<span></span>
</td>
<td class="nump">6.2<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
<td class="nump">6.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9.0)<span></span>
</td>
<td class="nump">11.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.9<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">10.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="nump">5.1<span></span>
</td>
<td class="nump">6.2<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
<td class="nump">6.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Unrealized gains (losses) on cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">34.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(9.6)<span></span>
</td>
<td class="nump">13.7<span></span>
</td>
<td class="num">(9.6)<span></span>
</td>
<td class="nump">13.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.2<span></span>
</td>
<td class="nump">22.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50.6)<span></span>
</td>
<td class="num">(43.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17.4)<span></span>
</td>
<td class="num">(21.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(9.6)<span></span>
</td>
<td class="nump">13.7<span></span>
</td>
<td class="num">(9.6)<span></span>
</td>
<td class="nump">13.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Gains (losses) on net investment hedge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.1<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="nump">41.9<span></span>
</td>
<td class="nump">29.2<span></span>
</td>
<td class="nump">41.9<span></span>
</td>
<td class="nump">29.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.6<span></span>
</td>
<td class="nump">30.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.8)<span></span>
</td>
<td class="num">(4.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.8<span></span>
</td>
<td class="nump">25.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="nump">41.9<span></span>
</td>
<td class="nump">29.2<span></span>
</td>
<td class="nump">41.9<span></span>
</td>
<td class="nump">29.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Unfunded status of postretirement benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32.8)<span></span>
</td>
<td class="num">(31.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(31.9)<span></span>
</td>
<td class="num">(30.6)<span></span>
</td>
<td class="num">(31.9)<span></span>
</td>
<td class="num">(30.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(31.9)<span></span>
</td>
<td class="num">(30.6)<span></span>
</td>
<td class="num">(31.9)<span></span>
</td>
<td class="num">(30.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Currency translation adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(139.5)<span></span>
</td>
<td class="num">(243.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(186.5)<span></span>
</td>
<td class="num">(271.4)<span></span>
</td>
<td class="num">(186.5)<span></span>
</td>
<td class="num">(271.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47.0)<span></span>
</td>
<td class="num">(28.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47.0)<span></span>
</td>
<td class="num">(28.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">$ (186.5)<span></span>
</td>
<td class="num">$ (271.4)<span></span>
</td>
<td class="num">$ (186.5)<span></span>
</td>
<td class="num">$ (271.4)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17B<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL34724394-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639337479512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="nump">$ 63.0<span></span>
</td>
<td class="num">$ (197.4)<span></span>
</td>
<td class="num">$ (57.5)<span></span>
</td>
<td class="nump">$ 159.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">446.1<span></span>
</td>
<td class="nump">248.1<span></span>
</td>
<td class="nump">738.2<span></span>
</td>
<td class="nump">670.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="num">(3,681.6)<span></span>
</td>
<td class="num">(3,616.7)<span></span>
</td>
<td class="num">(7,215.9)<span></span>
</td>
<td class="num">(7,106.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">1,542.1<span></span>
</td>
<td class="nump">1,494.1<span></span>
</td>
<td class="nump">2,941.2<span></span>
</td>
<td class="nump">2,902.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">27.7<span></span>
</td>
<td class="nump">31.8<span></span>
</td>
<td class="nump">42.5<span></span>
</td>
<td class="nump">48.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized gains (losses) on securities available for sale | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="nump">3.9<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="num">(12.5)<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="num">(0.8)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Unrealized gains (losses) on cash flow hedges | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="num">(23.7)<span></span>
</td>
<td class="nump">29.8<span></span>
</td>
<td class="num">(50.7)<span></span>
</td>
<td class="nump">44.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating Expenses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Gains (losses) on net investment hedge | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="nump">$ 4.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639332589944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 1,542.1<span></span>
</td>
<td class="nump">$ 1,494.1<span></span>
</td>
<td class="nump">$ 2,941.2<span></span>
</td>
<td class="nump">$ 2,902.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding</a></td>
<td class="nump">160.6<span></span>
</td>
<td class="nump">190.3<span></span>
</td>
<td class="nump">166.7<span></span>
</td>
<td class="nump">193.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive potential common shares</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in calculating diluted earnings per share</a></td>
<td class="nump">160.9<span></span>
</td>
<td class="nump">190.4<span></span>
</td>
<td class="nump">167.0<span></span>
</td>
<td class="nump">193.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember', window );">Performance stock units settled in stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1500-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639327067320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">$ (49.5)<span></span>
</td>
<td class="num">$ (55.0)<span></span>
</td>
<td class="num">$ (118.8)<span></span>
</td>
<td class="num">$ (104.0)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="nump">45.5<span></span>
</td>
<td class="nump">82.9<span></span>
</td>
<td class="nump">121.9<span></span>
</td>
<td class="nump">132.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="num">(1.5)<span></span>
</td>
<td class="num">(2.8)<span></span>
</td>
<td class="num">(3.0)<span></span>
</td>
<td class="num">(6.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="nump">44.0<span></span>
</td>
<td class="nump">80.1<span></span>
</td>
<td class="nump">118.9<span></span>
</td>
<td class="nump">126.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Income tax effect</a></td>
<td class="num">(7.0)<span></span>
</td>
<td class="num">(13.6)<span></span>
</td>
<td class="num">(20.3)<span></span>
</td>
<td class="num">(21.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">15.2<span></span>
</td>
<td class="nump">28.1<span></span>
</td>
<td class="nump">48.5<span></span>
</td>
<td class="nump">49.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">30.3<span></span>
</td>
<td class="nump">54.8<span></span>
</td>
<td class="nump">73.4<span></span>
</td>
<td class="nump">82.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember', window );">Total share-based compensation expense, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 37.0<span></span>
</td>
<td class="nump">$ 66.5<span></span>
</td>
<td class="nump">$ 98.6<span></span>
</td>
<td class="nump">$ 105.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639332851928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">$ (49.5)<span></span>
</td>
<td class="num">$ (55.0)<span></span>
</td>
<td class="num">$ (118.8)<span></span>
</td>
<td class="num">$ (104.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="nump">45.5<span></span>
</td>
<td class="nump">82.9<span></span>
</td>
<td class="nump">121.9<span></span>
</td>
<td class="nump">132.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="num">(1.5)<span></span>
</td>
<td class="num">(2.8)<span></span>
</td>
<td class="num">(3.0)<span></span>
</td>
<td class="num">(6.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="nump">44.0<span></span>
</td>
<td class="nump">80.1<span></span>
</td>
<td class="nump">118.9<span></span>
</td>
<td class="nump">126.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">7.4<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">26.5<span></span>
</td>
<td class="nump">15.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">34.5<span></span>
</td>
<td class="nump">31.8<span></span>
</td>
<td class="nump">72.0<span></span>
</td>
<td class="nump">66.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember', window );">Cash settled performance shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember', window );">Performance stock units settled in stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">2.1<span></span>
</td>
<td class="nump">12.1<span></span>
</td>
<td class="nump">12.4<span></span>
</td>
<td class="nump">14.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember', window );">Performance stock units settled in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">(4.0)<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">5.6<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
<td class="nump">7.9<span></span>
</td>
<td class="nump">8.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember', window );">Nightstar | Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized', window );">NST stock options</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 26.2<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 26.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of share-based compensation expense associated with different programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expenses and losses recorded for each transaction with the acquiree that was recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_NightstarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639332418520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Deferred tax assets, other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 856.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Deferred tax liabilities, other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 685.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Decrease in unrecognized tax benefits is reasonably possible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember', window );">Denmark Manufacturing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Tax expense on disposal group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61.3<span></span>
</td>
<td class="nump">$ 61.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TECFIDERAMember', window );">TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DeferredTaxAssetsValueReductioninValue', window );">Deferred tax assets, decrease in value</a></td>
<td class="nump">$ 1,324.0<span></span>
</td>
<td class="nump">1,324.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DeferredTaxLiabilitiesValueReductioninValue', window );">Deferred tax liabilities, decrease in value</a></td>
<td class="nump">1,268.0<span></span>
</td>
<td class="nump">1,268.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet', window );">Income tax expense associated with reductions in deferred tax assets and liabilities</a></td>
<td class="nump">$ 56.0<span></span>
</td>
<td class="nump">$ 56.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DeferredTaxAssetsValueReductioninValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Value, Reduction in Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DeferredTaxAssetsValueReductioninValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DeferredTaxLiabilitiesValueReductioninValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Value, Reduction in Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DeferredTaxLiabilitiesValueReductioninValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax Expense, Reduction in Deferred Tax Assets and Liabilities, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TECFIDERAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TECFIDERAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639337638920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation between the U.S. federal statutory tax rate and effective tax rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Taxes on foreign earnings</a></td>
<td class="num">(3.40%)<span></span>
</td>
<td class="num">(4.60%)<span></span>
</td>
<td class="num">(3.70%)<span></span>
</td>
<td class="num">(4.60%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Credits and net operating loss utilization</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(0.90%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization', window );">Purchased intangible assets</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets', window );">Denmark assets held for sale</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization', window );">Internal reorganization of certain intellectual property rights</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(5.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(2.40%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses', window );">TECFIDERA impairment</a></td>
<td class="nump">2.70%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EffectiveTaxRateReconciliationGILTItax', window );">GILTI</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Permanent items</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">21.90%<span></span>
</td>
<td class="nump">14.10%<span></span>
</td>
<td class="nump">19.80%<span></span>
</td>
<td class="nump">18.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Intellectual Property Rights Reorganization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveTaxRateReconciliationGILTItax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Tax Rate Reconciliation, GILTI tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveTaxRateReconciliationGILTItax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to disposition of asset. Includes, but is not limited to, intra-entity transfer of asset other than inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639332660888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNetAbstract', window );"><strong>Other Income (Expense), Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">$ 7.6<span></span>
</td>
<td class="nump">$ 29.1<span></span>
</td>
<td class="nump">$ 32.0<span></span>
</td>
<td class="nump">$ 60.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(66.0)<span></span>
</td>
<td class="num">(47.7)<span></span>
</td>
<td class="num">(110.3)<span></span>
</td>
<td class="num">(95.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Gain (loss) on investments, net</a></td>
<td class="nump">106.8<span></span>
</td>
<td class="num">(173.4)<span></span>
</td>
<td class="nump">29.5<span></span>
</td>
<td class="nump">203.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gains (losses), net</a></td>
<td class="nump">10.4<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
<td class="num">(8.5)<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="nump">4.2<span></span>
</td>
<td class="num">(7.1)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(7.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">63.0<span></span>
</td>
<td class="num">(197.4)<span></span>
</td>
<td class="num">(57.5)<span></span>
</td>
<td class="nump">159.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract', window );"><strong>Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Net gains (losses) recognized during the period on equity securities</a></td>
<td class="nump">102.9<span></span>
</td>
<td class="num">(174.2)<span></span>
</td>
<td class="nump">42.0<span></span>
</td>
<td class="nump">201.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Less: Net gains (losses) recognized during the period on equity securities sold during the period</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(42.9)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(42.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gains (losses) recognized during the period on equity securities held as of March 31</a></td>
<td class="nump">102.9<span></span>
</td>
<td class="num">$ (131.3)<span></span>
</td>
<td class="nump">42.0<span></span>
</td>
<td class="nump">$ 159.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">1,174.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,174.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,198.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Collaboration expenses</a></td>
<td class="nump">212.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties and licensing fees</a></td>
<td class="nump">203.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationexpensesaccrual', window );">Collaboration expenses</a></td>
<td class="nump">172.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">281.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of contingent consideration obligations</a></td>
<td class="nump">149.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionPayableCurrentAndNoncurrent', window );">Construction in progress</a></td>
<td class="nump">24.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">774.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">774.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">726.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total accrued expenses and other</a></td>
<td class="nump">2,486.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,486.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,765.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">$ 951.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 951.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,001.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationexpensesaccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration expenses accrual</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationexpensesaccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30700-110894<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net realized gains or losses on investments during the period, not including gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.3(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639428993976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Gain (loss) on investments, net</a></td>
<td class="nump">$ 106.8<span></span>
</td>
<td class="num">$ (173.4)<span></span>
</td>
<td class="nump">$ 29.5<span></span>
</td>
<td class="nump">$ 203.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,475.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,475.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,348.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Accrued income taxes</a></td>
<td class="nump">743.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">743.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">803.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net gains recognized on the increase in fair value of equity securities</a></td>
<td class="nump">102.9<span></span>
</td>
<td class="num">(131.3)<span></span>
</td>
<td class="nump">42.0<span></span>
</td>
<td class="nump">159.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity', window );">Proceeds from sale of available-for-sale securities, equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">$ 309.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense', window );">Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 635.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 697.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=biib_IonisPharmaceuticalsMember', window );">Ionis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net gains recognized on the increase in fair value of equity securities</a></td>
<td class="nump">67.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity', window );">Proceeds from sale of available-for-sale securities, equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 203.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=biib_SangamoCommonStockMember', window );">Sangamo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net gains recognized on the increase in fair value of equity securities</a></td>
<td class="nump">$ 40.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity securities classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net realized gains or losses on investments during the period, not including gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.3(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income tax expense from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=biib_IonisPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=biib_IonisPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=biib_SangamoCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=biib_SangamoCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639450223720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Collaborations (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Eisai's share of aducanumab milestone expense reflected in collaboration profit sharing in our condensed consolidated statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.1<span></span>
</td>
<td class="num">$ (16.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="num">$ (45.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseIncurredByCollaboration', window );">Expense Incurred By Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.9<span></span>
</td>
<td class="nump">68.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77.5<span></span>
</td>
<td class="nump">136.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.0<span></span>
</td>
<td class="nump">34.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38.7<span></span>
</td>
<td class="nump">68.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai', window );">Percentage of future development costs related to Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossOnContractTermination', window );">Loss on research and development contracts terminated with Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Eisai's share of aducanumab milestone expense reflected in collaboration profit sharing in our condensed consolidated statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SangamoTherapeuticsInc.AgreementMember', window );">Sangamo Therapeutics, Inc. Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased', window );">Global Licensing Collaboration Agreement, Amount, Shares Purchased</a></td>
<td class="nump">$ 225.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementSharesPurchased', window );">Global Licensing Collaboration Agreement, Shares, Purchased</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare', window );">Global Licensing Collaboration Agreement, Shares Purchased Per Share</a></td>
<td class="nump">$ 9.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="nump">$ 125.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments', window );">Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments</a></td>
<td class="nump">2,400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets', window );">Global Licensing Collaboration Agreement, Payment, Selection of Targets</a></td>
<td class="nump">80.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones', window );">Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones</a></td>
<td class="nump">1,900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones', window );">Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones</a></td>
<td class="nump">380.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 83.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SkyhawkTherapeuticsMember', window );">Skyhawk Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Eisai | Aducanumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.9<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.0<span></span>
</td>
<td class="nump">165.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.7<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.3<span></span>
</td>
<td class="nump">91.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | UCB Pharma S.A. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Eisai | BAN2401 and Elenbecestat</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Eisai | Aducanumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.2<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.9<span></span>
</td>
<td class="nump">21.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.2<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.5<span></span>
</td>
<td class="nump">$ 11.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpenseIncurredByCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total expense incurred by collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpenseIncurredByCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expenseincurredbythecollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense incurred by the collaboration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expenseincurredbythecollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expensereflectedwithinstatementsofincome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense reflected within statements of income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expensereflectedwithinstatementsofincome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Amount, Shares Purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Payment, Selection of Targets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Shares, Purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Shares Purchased Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of future development costs related to Eisai</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageoffuturedevelopmentcostsrelatedtoEisai</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total upfront and milestone payments made to collaborative partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The loss recognized on termination of a contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 275<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84167019&amp;loc=d3e54681-109401<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SangamoTherapeuticsInc.AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SangamoTherapeuticsInc.AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SkyhawkTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SkyhawkTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_AducanumabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_AducanumabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_UCBPharmaS.A.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_UCBPharmaS.A.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_E2609andBAN2401Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_E2609andBAN2401Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639337301368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Equity Method Investments (Details)<br> $ in Millions, &#8361; in Billions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Nov. 07, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Our share of Samsung Bioepis gains (losses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (15.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.4)<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.5<span></span>
</td>
<td class="nump">121.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,681.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,616.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,215.9<span></span>
</td>
<td class="nump">$ 7,106.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction', window );">Percentage of stake in entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of stake in entity maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to acquire additional investment in equity method investment</a></td>
<td class="nump">$ 676.6<span></span>
</td>
<td class="nump">&#8361; 759.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 676.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity', window );">Amortization of basis differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 675.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions', window );">Loss recorded on Samsung Bioepis joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">557.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 557.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 668.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 580.2<span></span>
</td>
<td class="nump">&#8361; 670.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Biogenshareofcopromotionprofitsorlosses', window );">Biogen share of co-promotion profits or losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 127.2<span></span>
</td>
<td class="nump">$ 121.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossOnContractTermination', window );">Loss on research and development contracts terminated with Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Our share of Samsung Bioepis gains (losses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ContractOptionExerciseFee', window );">Contract Option Exercise Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Due from Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative arrangement | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.2<span></span>
</td>
<td class="nump">$ 77.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_InventoriesMember', window );">Inventory | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod', window );">Equity method investment basis difference amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod', window );">Equity method investment basis difference amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis=biib_NeurimmuneMember', window );">Neurimmune | Regulatory Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential Future Milestone Payments Commitment To Third Party Approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Biogenshareofcopromotionprofitsorlosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Biogen share of co-promotion profits or losses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Biogenshareofcopromotionprofitsorlosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationprofitlosssharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration profit (loss) sharing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationprofitlosssharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ContractOptionExerciseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract Option Exercise Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ContractOptionExerciseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity method investment basis difference amortization period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Equitymethodinvestmentbasisdifferenceamortizationperiod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated additional payments upon achievement of development and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential future milestone payments commitment to third party approximately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total upfront and milestone payments made to collaborative partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The loss recognized on termination of a contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 275<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84167019&amp;loc=d3e54681-109401<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_InventoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_InventoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis=biib_NeurimmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis=biib_NeurimmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639332262968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Oct. 31, 2017</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Payments to Noncontrolling Interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (4.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities', window );">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Eisai's share of aducanumab milestone expense reflected in collaboration profit sharing in our condensed consolidated statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.1<span></span>
</td>
<td class="num">$ (16.3)<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="num">$ (45.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis=biib_NeurimmuneMember', window );">Neurimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Payments to Noncontrolling Interests</a></td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Reductioninroyaltyratepayableoncommercialsales', window );">Reduction in royalty rate payable on commercial sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Additionalreductioninroyaltyratepayableoncommercialsales', window );">Additional reduction in royalty rate payable on commercial sales</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember', window );">Regulatory Milestones [Member] | Neurimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential Future Milestone Payments Commitment To Third Party Approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryApprovalMilestoneMember', window );">Regulatory Approval Milestone [Member] | Neurimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential Future Milestone Payments Commitment To Third Party Approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Eisai's share of aducanumab milestone expense reflected in collaboration profit sharing in our condensed consolidated statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai', window );">Percentage of future development costs related to Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Additionalreductioninroyaltyratepayableoncommercialsales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional reduction in royalty rate payable on commercial sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Additionalreductioninroyaltyratepayableoncommercialsales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of future development costs related to Eisai</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageoffuturedevelopmentcostsrelatedtoEisai</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential future milestone payments commitment to third party approximately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Reductioninroyaltyratepayableoncommercialsales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in royalty rate payable on commercial sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Reductioninroyaltyratepayableoncommercialsales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis=biib_NeurimmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis=biib_NeurimmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryApprovalMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryApprovalMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140639326419576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation (Details)<br> SFr in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss Contingency, Estimate of Possible Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DisputedClaimsRelatingtoConstructionCosts', window );">Disputed claims relating to construction costs</a></td>
<td class="nump">$ 33.0<span></span>
</td>
<td class="nump">SFr 31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_BR', window );">Brazil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Brazil tax assessment, including interest and penalties</a></td>
<td class="nump">$ 70.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DisputedClaimsRelatingtoConstructionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disputed Claims Relating to Construction Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DisputedClaimsRelatingtoConstructionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14435-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118943654&amp;loc=d3e12021-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>114
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M>-/ ED\\%NG.(NTLLBF+O%DC7F4H-1?B>YMO> %+.'W5FUIVIDSN;<X)35@
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M"7T_KE/*]H;;/RP_N=D(94'BFH#QZ.(\ M-=ULYQN@GSOM*.;D\P*WK?T/@
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MVU1C%R(3:M7(V&X)YR3V.)Z,("5AD/[5,X%A^"-9UJF P\CC=3+2E(1I.@F
MSO'0?,.^$287]31UJK4[0,A#IVI#;>*QVA&:) S-$PQPK<OND-0H[T^RGOHH
MM./%K;,8)S8-YVMKAP]6+U$_.80,=X(NB('P%[>!Q.[O(NLXP6%$(F^]0D8"
MD_^S!QRN"^4[A\G<%W(C0DD8H8$"RE6'.*6[>)IF]F9(+/TQ]M0 9$0I6;VJ
M>MJ*FM7YRZLG,E*.A"EWE%JUY$RU\M%/ >+ 4Q)AN^US&9(H64]. (X5CR C
MSX",/?:'U9.*0BC5@H-X'S.@'6T;B93G9!,Q*4V+T WC;0&("WB9U4*ZS*"
M]O2W9&0>>89Y1QGAII$P FP ]V:U"8>SU=HZ;2$O/O2D(]YH&&_?^+Y?$./[
ML$SJ(%F<1*<IP6'F4SFRC(99U@74/H (WUDRM7L\^RR9OIAG=.09?;X)+ 0
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M:18S=!YO')73:O4<=EY7;!9:1)@KQ6^G[PZGGR[3'>=E0Z6SV8=<X5B2V7
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M5VJ^]&RFF^]E9U(O<QS)"K7 4J2T<$]H\PW*/+15S=]]9E4+W7)WA6)%:9J
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M_;"EDXH'0U+<84]7\S/BSM3K#3ZUS9YNI86O;Y&,B'O*&926OHVQXE@,6=6
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ME2GXZP9%6UE:@.<K@^K=#.B [B<=+_\+4$L#!!0    ( +6$]E!PVIEM2@H
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MRH@7(HQ/QB>XQHO)>"(^W2I347PA#^ 6 AK5RRK71BDVK8@F\_%<Q+/%>$&
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M=1Z)6UQ !'N4.J>TY#<,=["GXA# HS(%[UYVK,X>^2D3L,>H8#ZV;_"=/ R
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MO^_0F@<#Q(T!0"0U\5<ZN7N0D,Z96.-K@F@OET+6JJXU3=1CZ4J6LU0V9Y/
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M+A.-Q.&17IR<M>A],B5X?83RB-')9 3VUHR2)> _/Y;R9@,]V@ZT-YZPB=J
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M/!3I.!WOP9OV:4X#WO01O&LD*:Z5R[1QC27QY^7,>8N6^&L/^%$/?A3 CY[
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M>"R0+5E>@.]S@[2['^R@OX1>_ -02P,$%     @ M83V4'L]T^4/!@  2!(
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M%;=='#8$)L$C E$G$+'=K2*V\K6PXOA0JR5IMQIH;L"NLC2,*VJ7E"NK\;2
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MZ'@^$79H%H>%-UUHT%;&H]T+TQK]-5DFP/G:&+];L()]QW[^-U!+ P04
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MZ/\H 6NC1V#+2KJ<A]CYW,,W6\L@8N0"2D)@"J:G"&]X=Z$,'$HKQ.@22!2
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MRLZ2T"P[97W7F[.+HC U"#:#36P <>9ICZA_%).F@(^$C6./ZP?;\\_<>!%
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MY_,!,_%/0%PX787;]TH[W.7#YXXXLLH#X'RC,;@V"\^@^QUS_B=02P,$%
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M=*HC&:V<BYZJ8M7B"O:PA 18Y?D4ZW1BS!C(TVB!:T+I62Y@+2"JL'$0&X%
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MI[MN.J'15^D,H2%B>7W+DKE];=-[(APB0X9C-)V4=Z7MQGNM-MUS)REWNR!
MS8"8NAZTF^O<K.F,:]0UW*4_".?AG+];CS8-9Y=V.4UXZWL%D>%G37?#"KIT
M?P/0"%V<LZ[-<>3TJ!D)'4\]^M+J#9P(DB-_R]<&F6^)G-9U'6_9%<&4X^CV
MW>%@RMS-HGU/D-)WJ<V#5-06G%<%C=A/(#:^]%-J[5DM.PZYL+E=*WK5]9<
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M3X"+TM:DJ@+L=N:YW.QGJS1WT*HW2_UR/1?[OJE69!7;I5T6L]$X!MU5D?O
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M;&+A/Q39DO^H$K+I(EOPKW,(0>5T [Z?9I"&^T ;5']EZ\7_ 5!+ P04
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M2&T<XL@.!V>P-IZTQAX^X/6.=<B/F%<C<=//Z@<&AI: RW\ -K("Y_  WWI
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M[">635B7,30$%PM*EUGPB!SR'RVB-BNPWL0(0G*%><1O74'(1=2>W&26RI.
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M6N2UOBW_1/'ZX5"<YCQZ=G2T_O*$-(;W]V*__&(4$FEI1Z$L2\<'X>U.UW!
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MP[^I;?FO6;4C>=\!7$&M#DR0$ETHU"WU9>1@R*=:G[#,!(E+EK5%S#;M4"V
M? _@!3$61A%_YN"S&*0G,S[$%+"'D(X1T9=8#O3.6,.YT4DYC^A,O_0P$S+]
M<T#0,>"N0B2"G9@<M6WD]@;JLHP1+X^^0M20A-^<A8+WD+K"?NS@SH.7#.MK
M=I$O=[A0"&JRZ)[(Q.GY]?G-\/("H9DI4VK0CLCD9=<@Z!. 6G W=CN_/KT]
MOT1D7]T.+\]DE8YAZK1*]63=JE_OKBX(C1DA+R]^'Y[*2@1U8A_LAI6WYU<7
M(R J5?@&&)E_%J'.GJ,ZYA*^C)[F 5'(61^ $B[K5T>X"KG0J1IJ-$<\[ZEA
MDV[)DHWUHQLN7 =#>CRCJU=]XD"-3P\/>VI>WHW.KS]?"$SAVY=]HW^]/!^R
M!5+]S=65S[<DI,M_*!#O4"<1VV/*3="FN[WQ'KP_TAE<-0@6&ZC?=$[>PXG#
MBMA[8O7/@)U'X;L*?%[_(/@H1A_Q5Y5I*$AJ41U"6RP__0M,VG[&P\"7#=W+
MRZ9[>;FQ>SFEBBZ%"&)G)6NSJI79O T('GF2R"?;?@JO9UH,/:@!^8?-4#,C
M3>U#_ WNYL\'O-1Z;N:X8L/78!@FJ@JFN4"] AB.!S-#^$>%E9!-JZFV17L"
M+2:95AY."X!=(,XI6B'T/3$G'?8&T25B*G&CV[X2-1R[(&Z\DD8("<D(G)=2
M7M8$.2C%\&:'0-;T(K=;F<HYW/-'I0L(A%V+)]7IOY2?NRI!:0@QRXB3?:LR
M&:2PL*1L)Q[_A?DIO$ED4I'[3%(R<Z5Y6C3[)4\J7M<R=<=-124V/BKLI#7)
M-6^)E!EU1?K0B#3N1L2*XUC0*N=E ^HS&Z\/&M.)P<3&5+YW3;8V)=%KLW]E
MOH;/=)T59"E72-L=,  \*W?4YRXT<?\"G^$A])0]8Z^T[Z3"[@Y+8=->K%/S
MD3B/BDF"_U'90DI^$RRB![Y&1\Q9"V049/,MO9P71B#*VP=TGSR=$=+R6Y69
M9K8"M"*OD RUW2PBS((U1Z)BX'GA#+BS/K@^:EI!:"9%^( 3+5L&DNJKB8<&
ME&S]9.+N0;8TY#.7=4_P9B:0\?]DLK$!H5\U"/UJ([2VR;$&F3<O__1,[$4E
MIQGL6GQ$C9LC[FL([?4'Y'0;6\UD1U D/%ISH7M\IR>)D: P(*!$0YCK+N;4
M;"YDSD'15;=&$[@ K3JV74K![RGQ=#UDH7BD;4"'':D-C$D"1\X '0=_J6/;
M8"^7@FXR@4(E <;#]9R6+C5J&^GHT566('!(6Q8=FZ%7Q,*RH'8/D50KT^#4
M&H-WS$Q3%3D"60(#"W&@'(FH"L_,8PE));)R052C-5]AR*Z"J;Z*YJT]@!NE
M@ 7UW!3 CZ0&E,EXXH(VJT>* 02#_\"6O(X$8-B@H,X(BE#7HFYH\I0G-M@*
M3W!^S0U#P6:7\L1G75P(K]5Y3@65RF!BRT#!<O!3'<VE[:F/E3"H3V4^/ $>
MJ>W#'3G?+? 5CWD*'D1T#,Q5NSL7ZO1AM2]8)K;,]I'LZ":)G4G9QK9ZXETQ
M410TO&J@ E(R%Z<G<*PA^<4"A*4H&8/N[JQ0Q"6]8>D)F:PG',>+KLW$=<$;
MX4=Q4Q(L7!JT7.@EFU)J,Z,AC_P> IV*>@2WZ-':=O30I<\,Y!1/-JN H.0A
MTMK_%+\3MD9S.HL)0B-F7S"J.A4WF+U 3?4RE"H*4H![)TZ).1:(ET<?41%"
MIT(CZ !LK4%<P2=1NE#Z;<+TUPVFO]X(RG>"BM 7=@$)6@7K&W=8?7?PF4UM
MA*,(#7\N]0ZTPY/9:'J@OYM6S('Z5L6SEB3"X56:B]$Y&LGR>CJM4TO(EZ%!
M.46=3'<1)%1%T+Y-;,+I-2 ,Y&0O4-VS*H /P)ND]LTPC'9J*1*7%0Z_&<]2
M>%]^MK,U&"GUC'#PS)&C)]SN(#+-O4XJHB"<!>L43!')+F9>8"3@Z4ZQOX8H
M"I@FPH2Y TF-^D<\DO-&:AY1C)!"CVVV(#!(K+F7=*&9.WI9Y,2@QN^:["WF
M%H!'?0)_([I,N</^3LIU9)^X2EP0(669OY.^9IT'Q-[LA);]L\]HP4JO[*EA
M5%;<?HF Y/O8POF%T&#I@QLS"75EQF@>"-8HO$0C.FWTZ<O%V2[8/<VO#-6[
MA65&3#@-;.&FK/DM !N/PL+\:["&%O>GT<U0N'?1HQ,.PJ"93/Z14"'(D\0M
MN"0.J*FMICBY$C(:(2O9Z6 'W':NO3*@65NP7YHG;FG,;AW1(3<&06&3&PF;
M@&R=74+ 4)3,44]@!S1Y0JRZZFBZ.@SX1UVR6?2ZRR91^;J'(1R;<,5NG-!V
M@"%0 0.93)(RYG%4UFB,W2P9=%EQC[?4OLI0%F$K,M*,IS7HTG68V]!Y7 &:
M3^0R'7 K>2@C),Y KNJICDTW!:4^UT=-6TV(Y&\F99M:X,*PI5![.\5(2&U[
MN&U\%<8%&P<SQTV).-Y8(J[AMMZ, >8D=[-\J^K%YNT^<$K:E.DK_3_@P%A[
M D>9!59)!TK6;1OSSITZ>O0LUD7LU:G#?VK[PW!\NL-D5?K \#T:K9(73%QL
M30M].G9YJ73C0B*KX#A$[+F.<.,%,^^INXPI/&^[0"O&I:#RY,\)O:W"5#%V
MW-#6@,JG<"#3,:$D$@7+&$5$/=^HP*'%>+J4G[4B%U-R=\+XN;'DBFYCOZ=&
MZ.IMJ2Z%)((T<UM^='#X2LP, ]:BK33T'4\\U/9P?+>CKMT>+]T]?#'H>.@B
M\V51R?F[CT[<_HS^.5(OCE[MO%%7*#<0J[G(ZCU)8Z:56PJ8LZ1MH]]:5..I
M.""64Y"S%5$0GXW+[M;4 ?4\W38>#-3R&43[#=A+O/%0QA<D LI?$U\-<6D:
M(.*-(4GYMN"!^B!#]&!J.!,B49;8.@-NHVK@$L1UR?1<SOP<5&:7V@P2+FZH
MM ^4OFX-$U ->2SLE\UJ!L.CN\ZAS+)DDM&13KY(76Q06S4G$;>M#' 9C3H?
M/R6YA!P"][NWPL5I>"(W&+ !9+-^3O6L'97W9TUABN%J\0KKO_LP7K_7-B'M
M=E%#=JE6HB9-2B0T9 FM-TU2J@P%@2X8:ND&,H%K/)01 -9>:JLJG3JI>V_N
M*WU)<TS.U+B*ZEL"U$GTJW]RROFR@?P,=9K'PX\#@CK5TC^B,GWKMR>CL?HS
M#/E^0-_0K(=M 8\2U7VN13<QQB!?>?8L'TD<!!,(N[M'C:-KF&G7>QV1^A+;
M:7<[A$/!(ZG'ND],U$\L4JSB*'^41A(CQ&J9=(0W)7(7DB]T$!+Q;:#S*RRU
MX17%]108Z#J=XN-D EFBR*67,VIBT%[0RW58RZ&[B1FZ\.7@"8[WHRNV,4/_
MS\/MU6T';'W&].^YP]9%)\;I,C%M1 QQ!$,YR$#'<4(UD- /@4ZR@N2S_BS-
M8Q=UKR#A?F-GW:M(Q@P9D!C#,U;4?W(DH4-I&H[=EO\G#!WP0*'XA4.Q4T>X
MI@VK&1@<X?[QTZJ&@A#JUK'4K97[U(7J^.@ A>JL;?P^% AN>GV42EN7EYGN
M4[>29^VESII3'N<.,)4(B&^,UVDYB^Z>5#+:7$P[!OAWT_''8KD7DQ_"H(E(
M71_:9Y" 9QQ8<DG-A'K!&!MJ^8H+S]?K/-*[X7Q&*H41(Y4=FGR,W;1<$+]\
M5IR\I!=42BK)%-U__8_CH\.CDX_.Q=PW-5>RX8OZP-W>@=OC:E(*^WEYL/L+
MQ=4H-!J\[O6)[W(N<M-%_?:%=$\C;N0NZCI,%X-JE+@JQC=I7O&R83LE0R @
MSRZH(QO3:Z*1H<LN?O?T2>!%B2XD\NK+MXX8MB^&]).4X7QVU)S=G]#]>V%(
ME((!5VH#W8:Y9IC,TX>ZZ98A^&I8XS?Z&MH1J-7$R#0OX.%F=.[=RQ&![LTJ
MA]TK?434-;UO26_F_$!,/7FMJ+=9C3\'QQ0G[)UE#?P<7](>0YER02#:/,[6
MD]]>';QZBC#HIJFG1O?-@_04=KWO %5_%MM[94%[?L?,+?P;11%[].HD2-:
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M)LE'2;S*/&E7^&<HWK8@,^V1F6[%SN,5/H>]UXQ_]5']/P+ 8[P3XI"]4/\
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MBK;3J!?M-^[ENG)^(YE-&K'&!W3?FCO#JZ1C*66-VDK28' UC>:]BT7NXT/
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M4K)ML/8-XP7+B080 *2BS]1DL"X9MP.#R26CDLB\M$XQ[\QP"T_3O.3L4P-
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M2"8#?"<94U559HE=T@92(JM4DXO(@_0!3A]2YV#>5M'V27W[ZERHB] ;D[H
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M:!K/SB.PO83V"S+[(%M;0RR"P6SXKX/6._#[VG!7C@N?8/R/K?X%4$L#!!0
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M<$!Y:ZRJ>V4@J(7L1O;8G\-;%.)>(?:X.T<>Y??,LL5<JRUI)PUK;N)#]=H
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M8 ;.ZNZFUBVL:OSM:*4L[EI^6N)RR[43P/>U4G:W< [VU^7%7U!+ P04
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M<XUNCL*R<0\7&._@SBNM\6AX@NDIS/X"4$L#!!0    ( +6$]E"1\XEE;P0
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MAQ8^O-P#G[V#/9CL@_LH6*]:V*L6NGRC?U'MQQ?TD;F!4O\\PC'J.4:.8WR
MXY.4>8-Z[].Z15XZI!WL31I-HF'B;W85;8/BMT&3P44?]J:L<5_6^&A97^T@
M:4/5D1:C/E?TWV2,>X[X:+US<5XIF5D6!1JHR@I"18Z[88,[K\(-9O;]3_%?
M"D^"X _E_)VQLSORGJHU$YIP6"$J&$RP>]7NG=8PLG*3^"0-SK4[%KBJ0=D
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M85-:V(NZO79E4:TL<BI3++A2V%$C+H1AKQNVQX6^P9_OC%PCS]&A\ RF\&U
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M78"6Q]ORAI.L.(Z]$BX.=\7E :, 4PD0S_>$\-.--%#_DV'Y'U!+ P04
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MS?/=J0XIVK+4=A2O[<W><*7KA&WN="4'80!ZON1<?79,L>C_#=D_4$L#!!0
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M08W2.IC[K1!Z9UB"<?3G?P!02P,$%     @ M83V4/('/WED!P  ;3,  !D
M  !X;"]W;W)K<VAE971S+W-H965T-3,N>&ULM5M=;YM(%/TK(VL?6JEK,Y]
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MO86I=F2^+=]+/.12YFFYN>%LQ84>H+Y?YZI9]8Y^U=&\"YO_#U!+ P04
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M\;2823N2K<W?>L:D^O>;YDK5?\!U@/J^8$SN.EH@KRC[?P!02P,$%     @
MM83V4(V@IGF_ P  4!   !D   !X;"]W;W)K<VAE971S+W-H965T-38N>&UL
MQ5AM;]LV$/XKA+ "+=!:HF3)=F ;B-^P%LL0-&OW8=@'1CK;1"71):DX_?<C
M)46R8IJQUP+)AYBD[GGNGCOZ*'J\9_R;V )(])BEN9@X6REW5ZXKXBUD1/38
M#G+U9,UX1J2:\HTK=AQ(4H*RU/4]+W(S0G-G.B[7;OETS J9TAQN.1)%EA'^
M8P8IVT\<[#PM?*:;K=0+[G2\(QNX _EE=\O5S&U8$II!+BC+$8?UQ+G&5RL\
MTH#2XBN%O3@8(RWEGK%O>O(QF3B>C@A2B*6F(.KC >:0III)Q?&])G4:GQIX
M.'YB7Y7BE9A[(F#.TK]I(K<39^B@!-:D2.5GMO\=:D&AYHM9*LK_:%_91IZ#
MXD)(EM5@%4%&\^J3/-:).  H'C/ KP'^N8"@!@3G OHUH/\<T#\!"&M >"X@
MJ@%1F?LJ666F%T22Z9BS/>+:6K'I05FN$JT23'.]L^XD5T^IPLGIBE".OI*T
M '0#1!0<U+:1 KU=@"0T%>@O>)0%2=^A#^C+W0*]_>W=V)7*L8:[<>UD5CGQ
M3S@)T W+Y5:@99Y 8L O[/C(@G>5X$:U_Z1ZYEL)/Q5Y#P7>>^1[OF>(9WXV
M'(],<G[.^_+GO*_L\ 7$"HY-\$XN@V8'!25?<()O5@BU(@2ZCK\75%#=,-ZC
MN2H8S3=J+^FAH EP4K:2?_Y0UNBCA$S\:_'>;[SW2^_]$]ZOA5#MEV8[M8_U
MSD7QEO -"-,FK9A&)9/NN ]3E?V'P[K9+#KAA4UXH36\@S3$G32P^Y1NRJ$Q
MU(HU/ A$[970TW_/0C[;<A4>B<.CP:!KV1$9-2*C_R>R+8M)8W04^0?L>8;(
MY]%1Y+[1<&&@#$VY6!XS#D-+)@9-)@;63*P*J3HHVI$?IT0/7MJ#\Q<M%B]:
M+&T6'6'#1MC0*LSOC3SO#;J#G#*._F02!$K4F7'<P3KTHX9^] H]!'OM(>A9
MY=6Z\E(7S25P$!(I;V \[.QD.E=OC(?<Q;BNG(,S'5N9@E[DA^9J^38'?NO
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M)OT1GBW=/CZM857M+_R9LOA\^.42'VS0+@#WYTK9C>'>D/ 7H'@%4$L#!!0
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M\$(:TR@^6WQI\"(_>(^(+Y.W.(B-[,%B%L)V^M,5J*&+_- ](;Y,L@;&X77
MJ/NS6\,7'X#O\?&%S63:DB7:K1P;&6N$8W_"[8\R;";9.!@/H[XVTZQ<:<?O
M;ZQ1C_VHOU4[<4W7#-!\";C<, &HFD4)'NCB4<WI2<<:;M5,\-GJ-!K(V _D
M(RHU9A4D,)?"9N0H,F#-8GQB*<09<G5#OL/":](5J'F,#_#XA'"+#BOTF705
M:I9C?\I](-#,--NRMC8CU]IJWF,_[T\(LN/.-ZQ)CL]6!2&:S.2U51!BJV[$
MQG)8S% 4N'X<$XUD\E8U$&)R-S#27*N1XWPC&LWDS:H@Q%H%(7V9!ZRZ.C7+
MR6L*(<16X# S&8M9N=*.\XVTZM]^YOM*I+Z]KKE-SE;]()K%Q,]B?^&7'@X_
MD[X$];,V8BE:P[%SOVA,D]=4K=?'AZ;):@B)R1"+&4:N')EHJ),#4#]M&)[@
MM=168&B.PRRN7$!'<DKT^4#\F?YKKA#JIMLW5B$RV#@Q;K\PCH?]>ZU1Z[:S
MO&I6NM9JW4'*5LI/(5>-6^QO;_<ODF^K"] '+B7/JL<-HTLF2@/U_8IS^?)2
MWJDV=^BS_P%02P,$%     @ M83V4.\,@3T3 P  J0D  !D   !X;"]W;W)K
M<VAE971S+W-H965T-C N>&ULK99=;]HP%(;_BA7MHI7:?)(0*D!J0=4ZJ5)5
MU.W:#2=@U8F9[4"[7[_C)$T# <JJW8 =G_?X>8\=.\.-D"]J":#):\9S-;*6
M6J^N'$<E2\BHLL4*<AQ)A<RHQJY<.&HE@<Y+4<8=WW4C)Z,LM\;#\MF#' ]%
MH3G+X4$25609E6\WP,5F9'G6^X-'MEAJ\\ 9#U=T 3/03ZL'B3VGR3)G&>2*
MB9Q(2$?6M7<U\5PC*"-^,MBH5IL8*\]"O)C.W7QDN88(."3:I*#XMX8)<&XR
M(<?O.JG5S&F$[?9[]MO2/)IYI@HF@O]B<[T<6;%%YI#2@NM'L?D.M:'0Y$L$
M5^4OV52Q46B1I%!:9+48"3*65__TM2Y$2^#U#@C\6N"?*@AJ05 :K<A*6U.J
MZ7@HQ89($XW93*.L3:E&-RPWRSC3$D<9ZO3XEN4T3QCEY"Y76A:X0EJ1LREH
MRK@B_CFY)$^S*3G[=DZ^$9:3>\8YUE\-'8W3FR1.4D]U4TWE'YCJ1Y';)' O
MB._Z[A[YY+A\"@G*/2/W!MMR!TTWSOW&N5_F"P[DFU4;EXB43$2N)6ZH LMP
M3W4AF6:@KLCU&HM GSE<XOMR.:,<R R2>O@(0M @!"5"[Y"E DQ)10[D#:@D
M0A(.2ET0F@FIV1^8DT0HO:_45>*H3&Q>U?78&_1\NS]TUNV2[@D+(]_VF[ M
M[E[#W?L:-RC-\-5"[I0R2=:4%["/ODK?WZ9W[7B'?D]8&+7#MNC#AC[\E)ZF
M&N2' ;V4HE@L28I'2OGDI#4(.W@QUC;:,=&-\OR@9X?[342-B>A_F#AU0:*N
ME3!N,596NE%HQ;5[^ZWT&RO]$ZW\6_G['1K<&_X.<C?(ZP>M-=HBCAOB^ O$
MI]8Z[B"%@\[6[P89[@,[?]!P#XYR7W]:TT%G6C]&.F^'K@H+VV&#Z,".]MR/
MJ\@]CK=UW*ICQVU]W[B=X\V/H["S;_?%#?JN'>P0.ZU[U'S$W%.Y8+G"PRU%
MH6OWT;&LO@NJCA:K\FI]%AHOZK*YQ&\ID"8 QU,A]'O'W-;-U]GX+U!+ P04
M    " "UA/9065[^$.("  !_"   &0   'AL+W=O<FMS:&5E=',O<VAE970V
M,2YX;6RE5MMNVR 8?A5D[:*56A]CMZF22,VA6B=5BEIUNYAV0>P_"2J&%'#3
M[ND'V/$<UXFB[28!_!WX?C!XL.7B1:X!%'K/*9-#9ZW4YL;S9+J&'$N7;X#I
M)TLN<JQT5ZP\N1& ,TO*J1?Z?N+EF#!G-+!C<S$:\$)1PF ND"SR'(N/,5"^
M'3J!LQMX)*NU,@/>:+#!*W@"];R9"]WS:I6,Y, DX0P)6 Z=V^!FEAB\!7PG
ML)6--C))%IR_F,Y]-G1\,R&@D"JC@/7?&TR 4B.DI_%::3JUI2$VVSOU.YM=
M9UE@"1-.?Y!,K8?.M8,R6.*"JD>^_0I5GMCHI9Q*^XNV)3;6X+20BN<56<\@
M)ZS\Q^]5'1H$K=--""M"V";T#A"BBA"=ZM"K"+U3'>**8*-[979;N"E6>#00
M?(N$06LUT[#5MVQ=+\+,/GE20C\EFJ=&=X1AEA),T3V32A1Z"RB)SJ:@,*$2
M1>?H$CT_3='9EW/T!1&&'@BE>H7EP%/:WHAX:64U+JW" U81>N!,K26:L0RR
M#O[T.#\YPO=T[#I[N,L^#H\*?BN8BR+_ H5^Z'?,9W(R/>AWQ?D_]]D_N^\5
M(ZHW0F3UH@-Z]^P-I+++?X&FL% (LPS-7@NB/M 3I(4@BH!$/V\7>I_H]_O7
M$=->;=JSIKT#IG/!4X!,HJ7@N=[6:N=BO"6FT+G-2LW$:IIS\&T4]/J^FPR\
MM^;J=<"NDJ0-FWZ&1==7?;>_#YMUP,(X=J]KV%X!XKH \=$"/ *FY#=D:*6/
M],ZP)?^JX9NX02MIB8F;25LA/ZL$06/N9<0.4*-:>_F2.E]R6C[*I>Q>S>13
M82]C-VPE[ #Y;M0*V0$*>VW4K%.J'=-KG*@YB)6]RB1*><%4^4[5H_5M>6LO
MB=;X.+B9!!WC4WV[EI?A7_GR:G[ 8J7W J*PU%:^>Z6719377=E1?&//\P57
M^G:PS;7^0@!A /KYDG.UZQB#^IMC] =02P,$%     @ M83V4!?RW$D^ @
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M?5 !S>MJ_JR@2M)DRI6E ^'JYN1( <GJZA+_R4B)5?Y"J(?'&/G<J(E4S[V
M#JRNJUG]W6J5[2D8O.;-$4X"7@Z_#"R@8-V9'"S@6%U=L#; BD+\.8S"XF$0
M,%? PA27U@@CGQLU =-[  -BU]7$K@3LA5QH !<;BZE!,X!H#74U^QS0>,CV
M NJV!<88^1(CO8%L.R?@=T/-[Y>\Q"7?5MNR!GXL;5^VS(Q&BV?R'H\!A&NH
M*]PGUH8\6FN*'<<0%ME(.U]BI[E>/VK ]8::ZWVAC?-"N("7#7MRN(!R#775
M^U2X'('&;,?J8J4V:H\4^-M0\_<9SK?H,J)N2S[/?UV3^#/)_J9 J-9458%$
M:;(YHA#&-9&$W<Y6>V! P\;D_0L3V-545[K/(4 >LCG_W:[1L(G/35HKJ:_E
M9@*AFVI"OV0C_[WL^TI@E"ZR?IE3S3#0L3EYD\,$JC75U>^SX#,4M1V'SU"T
M@CE\AD2[C![X&BW\@?X%*2A(=7^80ZB:*B!8<_*.A0D<:JIKVQO"'MNSJ^VQ
MV\2:39)LI-WNJX'HSG"+R 1&-M6,_"G)"(["?^@5S[K357.ZOSG/GJ.^^W#F
M2X<M-H<UH]L<]DVQ.ZSU/?PP@:[-T>7VUSW-9_W 9I^JI"R+0T;<T3X@K,\7
M[])$T$Z^-,126YMIW<4QPLB7&.E]+7$3I,!45^0O>*!BBIV2(W?F*A\02'PT
M;69WYT-B974+IZ7$2C?ZRB8+],M2Z]>X&1F+OR5JDC'KE!\7$B-=:#9*(W6Z
M5TN)D=TG@19(H*660#F'CBIBVCT4!=U8('_6Y/)G@?Q9H^5O5(/$DHB6V"$9
M9>5;HHSVW'%;('^66O[J^N2BJD6D)8MJYAH/CR=70PO4T!I^[ON$1]-B^][H
MJR0LD#E++7,WY(XD>S:#96&_IH5]?HBR^FCO8E#- *B3-7G#W0(5L(95H"';
M&5E%].H/U^&JKCQ6CSES1: $N%Z3<ML>VJ49,Y.N#RE).UT"E%AY0@=$8F4)
MJV@IL3+-AL2T]QV +-C#LO X171^TDU2%CSAHSRPI^]C1<$66?I(4,$+B94P
M<U<2(T>8$JE1CU#:H JV6A4^[ @K3*D0D)I;FBLC[?Z>/W.1V" -]N328(,T
MV&II^'Z+Q!Z\?[JP104Y$G5&;J5U+P>)E3;KD1H;I,8>WBTUV0H1FV(T$6&W
MCM2J6SC)K(3R>BFWZIL44$5;W83[(-^<\Z_L3DY]7VHW]DA-WGZS005MM0I.
MBK)X'R>TM"]L\990?+8KB23LVUI*(IF]- C";*MO&R_V63I0"K^@Z6J#AMN3
M-_4<4#]G;%-O5-/5D=S0F(XC+,V1=K[$3M4C=T##'+6&G69A$5+.WM%,@N^'
MH@,*YDRN8 XHF#/VYF8<BJ).:+HE="_&F?F.2N3:"8'D.&K)N;T/\QRM,YRL
MOB-X0/;.Y+= #K"Z,^D6)AZM]4A#V(DY;.-+;/I@:VQC56O(KWB'DT/T)TF^
M(VI X,[D=U8.L+(S=BO3.-0DMSA"__-JE)7/K48@YX(.N&H=.,,)#D*<H""-
M(IQ]/_A<H'!W\IU-+M"Q.W9GTRCX>+16A>$*A#G*RN=6(S;/NR  KEH ])FW
M6/R,;DD2IAE+B,Y9L"?EVR&J^0)"=B??O.0"O;KJ6IH/.RF'W>H$2;%0!V-3
M\;.L>?1TOW8Z0.BNFM!O<9SOZ7HX#5.R"U6]41>8U9U\/Y+;V#^OKG0_DFQ%
M5RVN-D'G!?Y"6-U/#X7%@^P]J8%XUFPAA6#Y=+]V1L#.KIJ=+[[NZ=#1-2FV
M:="X'3M$'^X3DN7;<(<@:^E5ICZ!Z?5>9D]W;+^K )SMJ3G[(WZH7G L4H17
M-..,(!P$(6>SQI,-!F8U(W$U(_";[(5'?MXFC]F.W>UCG7$SS6BVGRRO^Q3D
M<C!<.W\0"$]=X]]NTZRH-E($]?)0S2RH@S=YL>X!5WL_[FV#@5-I^O#C8 \T
MP/O!;\UYXLMNCE 3#1A5N<P;+PW')-N4;YSG].Q4SZO7 NNC]5OM[\IWN3O'
M3[4W9YKD^+GVYE)V_$I[LZS>98?35J_67^-LPQXX1F1-A["8L5N,K'I;O?I2
MI+OR5>;/:5&D<?EQ2S"]DID!_7V=4CWD7]@)ZO\SX.3_4$L#!!0    ( +6$
M]E#.[OK270,  .P*   9    >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;+56
MVV[C-A#]%4+8AUT@M2ZV9"NP#22^H%LT@+'&M@]%'QB)MHBE2"\YBI-^?8>2
MHI5M13&ZJ!\LDIHS9\YP1,[TJ/0WDS$&Y#D7TLR<#.!PZ[HFR5A.S4 =F,0W
M.Z5S"CC5>]<<-*-I"<J%&WA>Y.:42V<^+=<V>CY5!0@NV4834^0YU2_W3*CC
MS/&=UX4O?)^!77#GTP/=LRV#KX>-QIG;>$EYSJ3A2A+-=C/GSK]=^YX%E!9_
M<'8TK3&Q4AZ5^F8GG].9X]F(F& )6!<4'T]LP82PGC".[[53I^&TP/;XU?NZ
M%(]B'JEA"R7^Y"ED,V?BD)3M:"'@BSK^RFI!H?67*&'*?W*L;*.10Y+"@,IK
M,$:0<UD]Z7.=B!8 _70#@AH0G />8AC6@.&U#*,:,+J6(:P!X;6 J 9$9>ZK
M9)697E*@\ZE61Z*M-7JS@W*[2C0FF$M;65O0^)8C#N8;C46JX>6&; 250*A,
MR>I[P0]8/4 ^+AE0+LPG\@OYNEV2CQ\^D0^$2_+ A<#",%,7, CKRDUJPON*
M,'B#<$@>E(3,D)5,6=J!7_;CHQZ\B^*;# 2O&;@/>AW^5L@!&7HW)/ "KR.>
MQ=5P/^Z2\W/LJY]C7_?#ERQ!N-\%/\GEL*FF8>EO^)^JZ:_?T9Q\!I:;OWO(
M1@W9J"0;O4%VER1%7@@*+,6S!,_5A%-[6G759.4I+CW9P_9I[D>3\=1]:N_4
M-4;KRBAJ&X6Q-X@;LQ,M8:,E[-6R?"?^"CUNL8;^8'@:VB*\B']T+O'23QP/
MSHQ6X85$-(J]UL_O5ALU:J->M5LE%&2%EC=D>^3P#]-8+7W?\KAQ//[_ZV_2
MD$UZ52SP_ -=5#<DGHD'K?::F<XSL?(4MJMF['EGFW.-T7IR6:1QR^A$2=PH
MB7N5K/DS?D/4& :&' 1-<,8E*&*8?N()ZU(47U12$$:#R9FD]ZQ.PO6]'Y>6
M]U[J06-34E!!$I7G'.P&&X*=%H&,X5IK:]2N7-O1A L.+YU7EG?Y54>#X$S,
M>U:5&+=U&>=,[\NVR6!(A83J)&U6F];LKFQ(SM;O_=N%W[&^]&]75>/UPWW5
M!SY0O>?2$,%V2.4-QEA+NFJMJ@FH0]D*/"K QJ(<9MB.,FT-\/U.*7B=6(*F
MP9W_"U!+ P04    " "UA/90LGXV0>0$  !8%P  &0   'AL+W=O<FMS:&5E
M=',O<VAE970V-BYX;6RUF&%OZC84AO^*A7:E>Z5>$MM02D61VL+5F-8)W>IN
M'Z9]<!,#41,[LQUHI_WX'2=I3$LP[5KZH23!Y_5KGY,'VZ.-5/=ZQ;E!#UDJ
M]$5G94Q^'@0Z6O&,Z:[,N8!O%E)ES,"M6@8Z5YS%95"6!B0,3X.,):(S'I7/
MYFH\DH5)$\'G"NDBRYAZO.*IW%QT<.?IP?=DN3+V03 >Y6S);[GYD<\5W 6-
M2IQD7.A$"J3XXJ)SB<^G],P&E"U^3_A&;UTC.Y0[*>_MS2R^Z(36$4]Y9*P$
M@X\UO^9I:I7 Q]^U:*?ITP9N7S^I?RL'#X.Y8YI?R_2/)#:KB\Y9!\5\P8K4
M?)>;GWD]H+[5BV2JR_]H4[<-.R@JM)%9'0P.LD14G^RAGHBM -!I#R!U 'D9
MT-L30.L ^C)@L">@5P?T7FNI7P>40P^JL9<3-V&&C4=*;I"RK4'-7I2S7T;#
M?"7"%LJM4?!M G%F/!,QOS,\%EQK]'G"#4M2_05]13]N)^CS3U]&@8%>;-L@
MJA6O*D6R1_$4W4AA5AI-03I^'A^ N\8B>;)X1;R"OQ2BBVAX@DA(PA8_UZ\.
MQ\.6\(D__#)7WMZG_O!;GG<1[I>]]SV309M\T5*/[M&;0+;03&BC"GA=#?KS
M5VB 9H9G^B^/?*^1[Y7RO3WR<_9H9362"[1(!!-1(I8HDMKHMDJHQ(:EF$72
M>DQZO=#^C8)UBXU^8Z/OM3'A*EDSBY 3M 3:(4!*W#QK<]+?<4+I<R-5K>RV
MVV/UM+%ZZK5*NJ0??D*W7"12H=^DX1K%!4<W[!%AFW8:>O(R:'H9'"/M9XW\
MF7<0M7M1ND^$X8IK@Q0SK7/MU[(3\LGC:=AX&GIU:!?[)[;OFU@<.@"&QYA:
MO$58_(&3>T#,SHIO=C%QMLAK;)43ZQ-T9,)'01-V;,)^.'UC$4<LDX4P;1S'
MNS2J$+"?1]@!"1\B$@PN:09W HNDF&=YN=C)51(!J'*N(O@*EE>M>?7KXS#L
MAJ$WLXY(V(^D':\9N^=HLY(I!Z]RG=2KO#<.P-\I#O&A 3C8X<&K2Q/]B]Z'
M6.P@B,^.4L".:-B/M$,%/-PI8$"@MX")PQP)/XY"DP-BAQA/'!R)GV?SIN90
MSA1:LQ02"XL/O66WU:!?=CCL#@?4:]&!DKP>E%"-[_M=(@ZGY"@X)0ZGY%TX
M);LX/5B-#J?$C[LW5J-?[-!O(G'D)'Z(_>]J],M"->)!SVO1L9&\D8W#E\4X
M <^P[3#UMN/EKN5YOPZ.Y"AP) Z.Y#UPG)*WPY$Z.-(/A./T@%B9$M]6S\&1
M'@6.TP.R4(Z#(?%:='"D?CC6&T;KBC.5/J*(I2DL*'B6%!EB(D8;E1CK>F';
MP'/8SMD]92$@U\HD__ 8Q>6"1>L"]IM\_VZSMO*L!,C 5P!;NVKJ'<;L*>?3
MAYP+S>'-^M@7C3HLT]XQ7C3JV$O]N)PK_M6P!Q2MF%K:9=^14GB"!"]5W<Z]
MW,RWIK:RW-]*[=!WD$ =TJF?O2V9G6V_X$AO6.Z;5T=F>I0].G4(IOZ=]=M/
M16I!W[%(Y278.D',.)2%/;K5D$>@<752USQMCH<ORT/1%\^O\/EU=<CK9*HS
MYQNH-MB4H)0O0#+L#B#9JCK&K6Z,S,MSRCMIC,S*RQ5G,$#; +Y?2'CKZAO;
M07.8/OX/4$L#!!0    ( +6$]E =[PDM6@,  %8,   9    >&PO=V]R:W-H
M965T<R]S:&5E=#8W+GAM;+57WV_:/!3]5ZZB/6P2(W'"CU(!4@N=MD^KA(JV
M/4Q[<(,A4>.8V4[9OK]^UW8(H0U9MXD7B)U[CL\]N=Q<QCLA'U3"F(8?/,O5
MQ$NTWE[ZOHH3QJGJBBW+\<Y:2$XU+N7&5UO)Z,J">.:'03#P.4US;SJV>PLY
M'8M"9VG.%A)4P3F5/Z]9)G83CWC[C;MTDVBSX4_'6[IA2Z8_;1<25W[%LDHY
MRU4J<I!L/?&NR.4-Z1N C?B<LIVJ78-)Y5Z(![/XL)IX@5'$,A9K0T'QZY'-
M6)89)M3QO23UJC,-L'Z]9W]GD\=D[JEB,Y%]25<ZF7@7'JS8FA:9OA.[]ZQ,
MR J,1:;L)^Q<[##T("Z4%KP$HP*>YNZ;_BB-J &0IQD0EH#PI8"H!$1/ ;T3
M@%X)Z+T4T"\!-G7?Y6Z-FU--IV,I=B!--+*9"^N^1:-?:6X*9:DEWDT1IZ?+
MA$H&=VQ;R#A!PQ6\GC--TTR]@;?P:3F'UZ_>@#)1"M(<;M,LPP>L.O"JOAS[
M&L482C\N#[YV!X<G#H[@5N0Z47"3K]BJ 3]KQP]:\#Z:4#D1[IVX#EL)_ROR
M+D1!!\(@#)KT_!M\_F(X&37 ;]KA<Q8CG#3!C\R(JK*(+%]T@F^64:5 K&&I
M1?P 7S_B??B@&5??6MA[%7O/LO=.L"_H3^PU6@$V.NPV^]HSY\6"<^P?RAS;
M]! <\< 2FR;X..T'X:A+QOYCW>SG85'0'W:C*NQ(=[_2W6_5C2XS?L^D=1F>
M_G1@(<5&4MYBT* Z:' &^X<5^[ U#4?Z7'@'K@J=")G^SU9PQ461ZZ9*=.2C
MHT<0!,W.7E22+EHEW9TL@@Y0C1M*=\HNU-1J''F_)FET7! S%S&L19"P&S:+
M'E6B1V<JX^O1,P_#BYJ'3O/SH&AXRF@2'!I^T*KZ;VN7U%XIY S52\(#?WC&
M^IV7["\K8'+HF"0Z8PG/2O9ZA?9J;>U8U*'1DK-UVI*Y;A.)3MIT:*&DO8>Z
MYX):S!2;YALH\/W]1QVUG"[Z[?+*)'X3Y9+P:_,39W)C!U>%#J%2-T!4N]5P
M?&5'PB?[,W(Y=R/N@<9-W+=4;M)<0<;62!ETARA,NB'6+;38VBGM7FB<^>QE
M@H,_DR8 [Z^%T/N%.:#Z*S']!5!+ P04    " "UA/90_JA%,1D'  !%+
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M2\H!<K8<Z(A;IW.]2XR@MBZ1E$\Z*'] 7B$&(C?,2"-,GY']K'F=UM1"2?E
M[/)A=<PRF@1? <\$=41^>=]H\^^QW*S8R(34;AZ07W#O0?(GL?/GT#<?C+<
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MIX(=&<#V5;!U(;UN5D934S/6J"<Y9">Y(=:#]MY-?KGLJ1_;MGX]K2!X=B6
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MW<  2HNO!+:R]8R,E!7GCV9QDTPMQS ""K$R+K#^>X(Y4&H\:1X_:J=6$],
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M(^;!B&._H>/6T+%7Z6XGBPVF,R5A7%.^9H\5SJQ*@79V2;]8W$_=0SF$N6>
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MPC;(PSG7X4:+K3W(>11:B]I>;H#BSMV\@,]70NB7&Q.@/6V<_P=02P,$%
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MX)X"_#, KP!XE\[@%P#_TAF" A"< L(S@+  9(MIY<'*(CW%&H]'4NR0--;
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M?5@*F=_+\A<M-MD]8B$TW$JRQS7<98DT!O!]*81^?S$3E+?C\3]02P,$%
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MHAF-Q@W.PDVRUHA]SL4JZ\AQ)G7J7^C,3:R^716[UIH;6R7:K:9)M0#8W -
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M?OIQ2^%\(1(!^'W-(=_YEV2"XG6JXW\ 4$L#!!0    ( +6$]E (2-V1WP0
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M UE47?:-##OL9=TS4O+H6F@G:A:^.:-D'3AJMNQPPJD19 (@DR-"_I-$D"F
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M;GS)9_/?P*_^ %!+ 0(4 Q0    ( +6$]E '04UB@0   +$    0
M      "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ M83V4&=:
M-Q'N    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL
M4$L! A0#%     @ M83V4)E<G",0!@  G"<  !,              ( !S $
M 'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "UA/900NY<] T%  "\
M%   &               @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
M4$L! A0#%     @ M83V4"TQ"GO;!P  %B(  !@              ("!4 T
M 'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( +6$]E#]QP<%
MB@0  ,T0   8              " @6$5  !X;"]W;W)K<VAE971S+W-H965T
M,RYX;6Q02P$"% ,4    " "UA/90%T^U>.T&   %'0  &
M@($A&@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ M83V
M4+UP=.1" @  /04  !@              ("!1"$  'AL+W=O<FMS:&5E=',O
M<VAE970U+GAM;%!+ 0(4 Q0    ( +6$]E [5A0@G @  .0C   8
M      " @;PC  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M" "UA/90+I+%D]@,   26   &               @(&.+   >&PO=V]R:W-H
M965T<R]S:&5E=#<N>&UL4$L! A0#%     @ M83V4.]@C:+)$@  Y3,  !@
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M970Q,BYX;6Q02P$"% ,4    " "UA/90XP\Y=< '  !4$@  &0
M    @('H:   >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (
M +6$]E L_8'^[PH  -XA   9              " @=]P  !X;"]W;W)K<VAE
M971S+W-H965T,30N>&UL4$L! A0#%     @ M83V4'#:F6U*"@  <1L  !D
M             ("!!7P  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"
M% ,4    " "UA/9075;YH;4,  #;*P  &0              @(&&A@  >&PO
M=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( +6$]E#98[KK$@0
M !$*   9              " @7*3  !X;"]W;W)K<VAE971S+W-H965T,3<N
M>&UL4$L! A0#%     @ M83V4.^0(6G\!0  D X  !D              ("!
MNY<  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " "UA/90
M>SW3Y0\&  !($@  &0              @('NG0  >&PO=V]R:W-H965T<R]S
M:&5E=#$Y+GAM;%!+ 0(4 Q0    ( +6$]E F.^\(4 ,  #L'   9
M      " @32D  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%
M  @ M83V4 F9/=2D!   O0L  !D              ("!NZ<  'AL+W=O<FMS
M:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " "UA/90OW'.9V<,  #F'P
M&0              @(&6K   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+
M 0(4 Q0    ( +6$]E"+;(ATKP8  )H1   9              " @32Y  !X
M;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ M83V4#WIC<%U
M%@  <4L  !D              ("!&L   'AL+W=O<FMS:&5E=',O<VAE970R
M-"YX;6Q02P$"% ,4    " "UA/90(K",PQ8)  #S&P  &0
M@('&U@  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( +6$
M]E"Y#,^)S10  , Z   9              " @1/@  !X;"]W;W)K<VAE971S
M+W-H965T,C8N>&UL4$L! A0#%     @ M83V4*@MY[36$@  7#4  !D
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M=#,Q+GAM;%!+ 0(4 Q0    ( +6$]E"KOEL<[ 4  $X0   9
M  " @3@> 0!X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @
MM83V4#S]=ZZ8!0  &A0  !D              ("!6R0! 'AL+W=O<FMS:&5E
M=',O<VAE970S,RYX;6Q02P$"% ,4    " "UA/90WH3JD@(%  !N#@  &0
M            @($J*@$ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4
M Q0    ( +6$]E N-:HN'0,  -,&   9              " @6,O 0!X;"]W
M;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ M83V4"J=4BLL!
M.@L  !D              ("!MS(! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX
M;6Q02P$"% ,4    " "UA/90.A/HME8#  !=!P  &0              @($:
M-P$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( +6$]E ?
MH$>LG00  (H+   9              " @:<Z 0!X;"]W;W)K<VAE971S+W-H
M965T,S@N>&UL4$L! A0#%     @ M83V4%'=ZED !   M L  !D
M     ("!>S\! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4
M" "UA/90QY,P1$("   6!0  &0              @(&R0P$ >&PO=V]R:W-H
M965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( +6$]E"1\XEE;P0  %02   9
M              " @2M& 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L!
M A0#%     @ M83V4"']4 I- @  " 8  !D              ("!T4H! 'AL
M+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " "UA/90>*COR"4$
M  ".#@  &0              @(%530$ >&PO=V]R:W-H965T<R]S:&5E=#0S
M+GAM;%!+ 0(4 Q0    ( +6$]E -&U= G@D  #U#   9              "
M@;%1 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ M83V
M4++0Q6!5!   /A0  !D              ("!AEL! 'AL+W=O<FMS:&5E=',O
M<VAE970T-2YX;6Q02P$"% ,4    " "UA/905"LSI&4"   =!@  &0
M        @($28 $ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0
M   ( +6$]E#(UW%Q=@,  )\+   9              " @:YB 0!X;"]W;W)K
M<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ M83V4/?)>TH)!   <!
M !D              ("!6V8! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q0
M2P$"% ,4    " "UA/90(!++KPT$  #]$   &0              @(&;:@$
M>&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( +6$]E!%!K!0
M8@(  "<&   9              " @=]N 0!X;"]W;W)K<VAE971S+W-H965T
M-3 N>&UL4$L! A0#%     @ M83V4*Y G0#6!@  ;R4  !D
M ("!>'$! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " "U
MA/906TW6TWX"   &!@  &0              @(&%> $ >&PO=V]R:W-H965T
M<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( +6$]E#R!S]Y9 <  &TS   9
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M970U-RYX;6Q02P$"% ,4    " "UA/902&/NFAD#  "1"P  &0
M    @('0D0$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    (
M +6$]E"%%,]AJP4  $\?   9              " @2"5 0!X;"]W;W)K<VAE
M971S+W-H965T-3DN>&UL4$L! A0#%     @ M83V4.\,@3T3 P  J0D  !D
M             ("! IL! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"
M% ,4    " "UA/9065[^$.("  !_"   &0              @(%,G@$ >&PO
M=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( +6$]E 7\MQ)/@(
M %<%   9              " @66A 0!X;"]W;W)K<VAE971S+W-H965T-C(N
M>&UL4$L! A0#%     @ M83V4'I)#50J P  ) H  !D              ("!
MVJ,! 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4    " "UA/90
M41V=$[ *   _0   &0              @($[IP$ >&PO=V]R:W-H965T<R]S
M:&5E=#8T+GAM;%!+ 0(4 Q0    ( +6$]E#.[OK270,  .P*   9
M      " @2*R 0!X;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%
M  @ M83V4+)^-D'D!   6!<  !D              ("!MK4! 'AL+W=O<FMS
M:&5E=',O<VAE970V-BYX;6Q02P$"% ,4    " "UA/90'>\)+5H#  !6#
M&0              @('1N@$ >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+
M 0(4 Q0    ( +6$]E#^J$4Q&0<  $4L   9              " @6*^ 0!X
M;"]W;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @ M83V4!DC7:KW
M!   \A8  !D              ("!LL4! 'AL+W=O<FMS:&5E=',O<VAE970V
M.2YX;6Q02P$"% ,4    " "UA/90W?/51@ $  !^#P  &0
M@('@R@$ >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( +6$
M]E"XXHFR*P0  -<0   9              " @1?/ 0!X;"]W;W)K<VAE971S
M+W-H965T-S$N>&UL4$L! A0#%     @ M83V4%$5S@ F!0  H!D  !D
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M=#<V+GAM;%!+ 0(4 Q0    ( +6$]E []C;7H0<  &HE   9
M  " @<_K 0!X;"]W;W)K<VAE971S+W-H965T-S<N>&UL4$L! A0#%     @
MM83V4) DIYCB!P  6B4  !D              ("!I_,! 'AL+W=O<FMS:&5E
M=',O<VAE970W."YX;6Q02P$"% ,4    " "UA/90"$C=D=\$   )$P  &0
M            @(' ^P$ >&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4
M Q0    ( +6$]E"2-BB S (  &\'   9              " @=8  @!X;"]W
M;W)K<VAE971S+W-H965T.# N>&UL4$L! A0#%     @ M83V4'N;V,J, @
MH \   T              ( !V0," 'AL+W-T>6QE<RYX;6Q02P$"% ,4
M" "UA/90EXJ[',     3 @  "P              @ &0!@( 7W)E;',O+G)E
M;'-02P$"% ,4    " "UA/905$XKH,T%  !U-   #P              @ %Y
M!P( >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ M83V4+3%"JYH @  1R\
M !H              ( !<PT" 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ M83V4"P!9SL; @  #BX  !,              ( !$Q "
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     %@ 6  ?&   7Q("

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>654</ContextCount>
  <ElementCount>452</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>143</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Condensed Consolidated Statements of Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003000 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003501 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1005000 - Statement - Condensed Consolidated Statement of Equity Statement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement</Role>
      <ShortName>Condensed Consolidated Statement of Equity Statement</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2114100 - Disclosure - Divestitures Divestitures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DivestituresDivestitures</Role>
      <ShortName>Divestitures Divestitures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2118100 - Disclosure - Revenues Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesRevenues</Role>
      <ShortName>Revenues Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2119100 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2120100 - Disclosure - Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill</Role>
      <ShortName>Intangible Assets and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2121100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2122100 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2123100 - Disclosure - Derivative Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstruments</Role>
      <ShortName>Derivative Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2124100 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment</Role>
      <ShortName>Property, Plant and Equipment Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2128100 - Disclosure - Indebtedness (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.biogenidec.com/role/IndebtednessNotes</Role>
      <ShortName>Indebtedness (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2130100 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2131100 - Disclosure - Earnings per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsPerShare</Role>
      <ShortName>Earnings per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2132100 - Disclosure - Share-based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPayments</Role>
      <ShortName>Share-based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2133100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2134100 - Disclosure - Other Consolidated Financial Statement Detail</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</Role>
      <ShortName>Other Consolidated Financial Statement Detail</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2135100 - Disclosure - Collaborative and Other Relationships</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationships</Role>
      <ShortName>Collaborative and Other Relationships</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2136100 - Disclosure - Investments in Variable Interest Entities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities</Role>
      <ShortName>Investments in Variable Interest Entities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2137100 - Disclosure - Litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Litigation</Role>
      <ShortName>Litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2201201 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2318301 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RevenuesRevenues</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2319301 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Inventory</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2320301 - Disclosure - Intangible Assets and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables</Role>
      <ShortName>Intangible Assets and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2321301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurements</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2322301 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstruments</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2323301 - Disclosure - Derivative Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsTables</Role>
      <ShortName>Derivative Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstruments</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2330301 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2331301 - Disclosure - Earnings per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsPerShare</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2332301 - Disclosure - Share-Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsTables</Role>
      <ShortName>Share-Based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2333301 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxes</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2334301 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2335301 - Disclosure - Collaborative and Other Relationships (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables</Role>
      <ShortName>Collaborative and Other Relationships (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CollaborativeAndOtherRelationships</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2401402 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Business Acquisition (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual</Role>
      <ShortName>Business Acquisition (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Business Acquisition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/BusinessAcquisitionDetails</Role>
      <ShortName>Business Acquisition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2414401 - Disclosure - Divestitures (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DivestituresDetailsTextual</Role>
      <ShortName>Divestitures (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DivestituresDivestitures</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2418402 - Disclosure - Revenues by Product (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesByProductDetails</Role>
      <ShortName>Revenues by Product (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2418403 - Disclosure - Reserves for Discounts and Allowances (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1</Role>
      <ShortName>Reserves for Discounts and Allowances (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2418404 - Disclosure - Reserves for Discounts and Allowances (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2</Role>
      <ShortName>Reserves for Discounts and Allowances (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2418405 - Disclosure - Revenues from Anti-CD20 Therapeutic Programs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails</Role>
      <ShortName>Revenues from Anti-CD20 Therapeutic Programs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2418406 - Disclosure - Other Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherRevenuesDetails</Role>
      <ShortName>Other Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2418407 - Disclosure - Revenues (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesDetailsTextual</Role>
      <ShortName>Revenues (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RevenuesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2419402 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InventoryTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2420402 - Disclosure - Intangible Assets and Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails</Role>
      <ShortName>Intangible Assets and Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2420403 - Disclosure - Intangible Assets and Goodwill (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1</Role>
      <ShortName>Intangible Assets and Goodwill (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2421402 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2421403 - Disclosure - Fair Value Measurements (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails1</Role>
      <ShortName>Fair Value Measurements (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2421404 - Disclosure - Fair Value Measurements (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails2</Role>
      <ShortName>Fair Value Measurements (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2421405 - Disclosure - Fair Value Measurements (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual</Role>
      <ShortName>Fair Value Measurements (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2421406 - Disclosure - Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails</Role>
      <ShortName>Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2422402 - Disclosure - Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails</Role>
      <ShortName>Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2422403 - Disclosure - Financial Instruments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails1</Role>
      <ShortName>Financial Instruments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2422404 - Disclosure - Financial Instruments (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails2</Role>
      <ShortName>Financial Instruments (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2422405 - Disclosure - Financial Instruments (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails3</Role>
      <ShortName>Financial Instruments (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2422406 - Disclosure - Financial Instruments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual</Role>
      <ShortName>Financial Instruments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2422407 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2</Role>
      <ShortName>Financial Instruments Financial Instruments (Details Textual 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2423402 - Disclosure - Derivative Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsDetails</Role>
      <ShortName>Derivative Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstrumentsTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2424401 - Disclosure - Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails</Role>
      <ShortName>Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2428401 - Disclosure - Indebtedness (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IndebtednessDetails</Role>
      <ShortName>Indebtedness (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IndebtednessNotes</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2430402 - Disclosure - Share Repurchases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareRepurchasesDetails</Role>
      <ShortName>Share Repurchases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2430403 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2430404 - Disclosure - Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2431402 - Disclosure - Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsPerShareDetails</Role>
      <ShortName>Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsPerShareTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2432402 - Disclosure - Share-Based Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails</Role>
      <ShortName>Share-Based Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2432403 - Disclosure - Share-Based Payments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails1</Role>
      <ShortName>Share-Based Payments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2433402 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2433403 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2434402 - Disclosure - Other Consolidated Financial Statement Detail (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2434403 - Disclosure - Other Consolidated Financial Statement (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual</Role>
      <ShortName>Other Consolidated Financial Statement (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2435402 - Disclosure - Collaborative and Other Relationships - Collaborations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails</Role>
      <ShortName>Collaborative and Other Relationships - Collaborations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2435403 - Disclosure - Collaborative and Other Relationships - Equity Method Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails</Role>
      <ShortName>Collaborative and Other Relationships - Equity Method Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2436401 - Disclosure - Investments in Variable Interest Entities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails</Role>
      <ShortName>Investments in Variable Interest Entities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="biib-2020630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2437401 - Disclosure - Litigation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LitigationDetails</Role>
      <ShortName>Litigation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Litigation</ParentRole>
      <Position>80</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="biib-2020630x10q.htm">biib-2020630x10q.htm</File>
    <File>biib-20200630.xsd</File>
    <File>biib-20200630_cal.xml</File>
    <File>biib-20200630_def.xml</File>
    <File>biib-20200630_lab.xml</File>
    <File>biib-20200630_pre.xml</File>
    <File>biib-2020630xex311.htm</File>
    <File>biib-2020630xex312.htm</File>
    <File>biib-2020630xex321.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>biogenlogoa11.jpg</File>
    <File>chart-0b610af5b7e35be4879.jpg</File>
    <File>chart-225be0f1a328510aba7.jpg</File>
    <File>chart-25639f4e732a5a1ea99.jpg</File>
    <File>chart-25c6349f335257b28b2.jpg</File>
    <File>chart-3395c23c9be152f4b2f.jpg</File>
    <File>chart-3bef3451f3d85124b28.jpg</File>
    <File>chart-45031cdc71e753f6a7b.jpg</File>
    <File>chart-48bec865e66533dbc2f.jpg</File>
    <File>chart-54b677add07d50a682a.jpg</File>
    <File>chart-5cd5aa12b0d45778869.jpg</File>
    <File>chart-5fb3afa34aee5813b17.jpg</File>
    <File>chart-7e6903008512512eaee.jpg</File>
    <File>chart-8629c965f44558b0817.jpg</File>
    <File>chart-8e7d74fd3876590095c.jpg</File>
    <File>chart-900b27e36dcb52c1a00.jpg</File>
    <File>chart-9591fb6751065456834.jpg</File>
    <File>chart-95f4f71dfede5b0db43.jpg</File>
    <File>chart-aeab2001c05c53f8b61.jpg</File>
    <File>chart-ca42041222025d3abbc.jpg</File>
    <File>chart-ca66c4c36dc65756984.jpg</File>
    <File>chart-e53e3e38390450fb989.jpg</File>
    <File>chart-f590ec5e15305a15b12.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/currency/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>120
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "biib-2020630x10q.htm": {
   "axisCustom": 5,
   "axisStandard": 33,
   "contextCount": 654,
   "dts": {
    "calculationLink": {
     "local": [
      "biib-20200630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "biib-20200630_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "biib-2020630x10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "biib-20200630_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "biib-20200630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "biib-20200630.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd",
      "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 723,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2019-01-31": 29,
    "http://www.biogenidec.com/20200630": 5,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 39
   },
   "keyCustom": 65,
   "keyStandard": 387,
   "memberCustom": 67,
   "memberStandard": 69,
   "nsprefix": "biib",
   "nsuri": "http://www.biogenidec.com/20200630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001000 - Document - Cover Page",
     "role": "http://www.biogenidec.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114100 - Disclosure - Divestitures Divestitures",
     "role": "http://www.biogenidec.com/role/DivestituresDivestitures",
     "shortName": "Divestitures Divestitures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118100 - Disclosure - Revenues Revenues",
     "role": "http://www.biogenidec.com/role/RevenuesRevenues",
     "shortName": "Revenues Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119100 - Disclosure - Inventory",
     "role": "http://www.biogenidec.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120100 - Disclosure - Intangible Assets and Goodwill",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill",
     "shortName": "Intangible Assets and Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121100 - Disclosure - Fair Value Measurements",
     "role": "http://www.biogenidec.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122100 - Disclosure - Financial Instruments",
     "role": "http://www.biogenidec.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123100 - Disclosure - Derivative Instruments",
     "role": "http://www.biogenidec.com/role/DerivativeInstruments",
     "shortName": "Derivative Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124100 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment",
     "role": "http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment",
     "shortName": "Property, Plant and Equipment Property, Plant and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128100 - Disclosure - Indebtedness (Notes)",
     "role": "http://www.biogenidec.com/role/IndebtednessNotes",
     "shortName": "Indebtedness (Notes)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130100 - Disclosure - Equity",
     "role": "http://www.biogenidec.com/role/Equity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001000 - Statement - Condensed Consolidated Statements of Income (Unaudited)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
     "shortName": "Condensed Consolidated Statements of Income (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131100 - Disclosure - Earnings per Share",
     "role": "http://www.biogenidec.com/role/EarningsPerShare",
     "shortName": "Earnings per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132100 - Disclosure - Share-based Payments",
     "role": "http://www.biogenidec.com/role/ShareBasedPayments",
     "shortName": "Share-based Payments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133100 - Disclosure - Income Taxes",
     "role": "http://www.biogenidec.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134100 - Disclosure - Other Consolidated Financial Statement Detail",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail",
     "shortName": "Other Consolidated Financial Statement Detail",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135100 - Disclosure - Collaborative and Other Relationships",
     "role": "http://www.biogenidec.com/role/CollaborativeAndOtherRelationships",
     "shortName": "Collaborative and Other Relationships",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136100 - Disclosure - Investments in Variable Interest Entities",
     "role": "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities",
     "shortName": "Investments in Variable Interest Entities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137100 - Disclosure - Litigation",
     "role": "http://www.biogenidec.com/role/Litigation",
     "shortName": "Litigation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:BusinessOverviewPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2201201 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:BusinessOverviewPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318301 - Disclosure - Revenues (Tables)",
     "role": "http://www.biogenidec.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319301 - Disclosure - Inventory (Tables)",
     "role": "http://www.biogenidec.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320301 - Disclosure - Intangible Assets and Goodwill (Tables)",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables",
     "shortName": "Intangible Assets and Goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321301 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322301 - Disclosure - Financial Instruments (Tables)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2323301 - Disclosure - Derivative Instruments (Tables)",
     "role": "http://www.biogenidec.com/role/DerivativeInstrumentsTables",
     "shortName": "Derivative Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330301 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)",
     "role": "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables",
     "shortName": "Accumulated Other Comprehensive Income (Loss) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331301 - Disclosure - Earnings per Share (Tables)",
     "role": "http://www.biogenidec.com/role/EarningsPerShareTables",
     "shortName": "Earnings per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2332301 - Disclosure - Share-Based Payments (Tables)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsTables",
     "shortName": "Share-Based Payments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2333301 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.biogenidec.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2334301 - Disclosure - Other Consolidated Financial Statement Detail (Tables)",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables",
     "shortName": "Other Consolidated Financial Statement Detail (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2335301 - Disclosure - Collaborative and Other Relationships (Tables)",
     "role": "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables",
     "shortName": "Collaborative and Other Relationships (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003000 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401402 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "role": "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentInProcess",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Business Acquisition (Details Textual)",
     "role": "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
     "shortName": "Business Acquisition (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "D2019Q2",
      "decimals": "INF",
      "lang": null,
      "name": "biib:ClinicalAssetsAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Assets",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406403 - Disclosure - Business Acquisition (Details)",
     "role": "http://www.biogenidec.com/role/BusinessAcquisitionDetails",
     "shortName": "Business Acquisition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414401 - Disclosure - Divestitures (Details Textual)",
     "role": "http://www.biogenidec.com/role/DivestituresDetailsTextual",
     "shortName": "Divestitures (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "I2019Q3Denmark",
      "decimals": "-5",
      "lang": null,
      "name": "biib:InventoryrawmaterialssoldtoFUJIFILM",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418402 - Disclosure - Revenues by Product (Details)",
     "role": "http://www.biogenidec.com/role/RevenuesByProductDetails",
     "shortName": "Revenues by Product (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2QTD_srt_ProductOrServiceAxis_biib_FumarateMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418403 - Disclosure - Reserves for Discounts and Allowances (Details 1)",
     "role": "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1",
     "shortName": "Reserves for Discounts and Allowances (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": "-5",
      "lang": null,
      "name": "biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418404 - Disclosure - Reserves for Discounts and Allowances (Details 2)",
     "role": "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2",
     "shortName": "Reserves for Discounts and Allowances (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418405 - Disclosure - Revenues from Anti-CD20 Therapeutic Programs (Details)",
     "role": "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails",
     "shortName": "Revenues from Anti-CD20 Therapeutic Programs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2QTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember",
      "decimals": "-5",
      "lang": null,
      "name": "biib:ShareOfCoPromotionProfits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418406 - Disclosure - Other Revenues (Details)",
     "role": "http://www.biogenidec.com/role/OtherRevenuesDetails",
     "shortName": "Other Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:OtherrevenuesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418407 - Disclosure - Revenues (Details Textual)",
     "role": "http://www.biogenidec.com/role/RevenuesDetailsTextual",
     "shortName": "Revenues (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2QTD_srt_MajorCustomersAxis_biib_DistributorOneMember",
      "decimals": "INF",
      "lang": null,
      "name": "biib:EntityWidePercentageOfRevenueFromMajorDistributors",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003501 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:InventoryDisclosureTextBlock",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419402 - Disclosure - Inventory (Details)",
     "role": "http://www.biogenidec.com/role/InventoryDetails",
     "shortName": "Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:InventoryDisclosureTextBlock",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420402 - Disclosure - Intangible Assets and Goodwill (Details)",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
     "shortName": "Intangible Assets and Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420403 - Disclosure - Intangible Assets and Goodwill (Details 1)",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1",
     "shortName": "Intangible Assets and Goodwill (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:GoodwillOtherIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421402 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:NotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421403 - Disclosure - Fair Value Measurements (Details 1)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
     "shortName": "Fair Value Measurements (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:NotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421404 - Disclosure - Fair Value Measurements (Details 2)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
     "shortName": "Fair Value Measurements (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421405 - Disclosure - Fair Value Measurements (Details Textual)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
     "shortName": "Fair Value Measurements (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FI2020Q2_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421406 - Disclosure - Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails",
     "shortName": "Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FI2020Q2_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422402 - Disclosure - Financial Instruments (Details)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails",
     "shortName": "Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422403 - Disclosure - Financial Instruments (Details 1)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
     "shortName": "Financial Instruments (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422404 - Disclosure - Financial Instruments (Details 2)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails2",
     "shortName": "Financial Instruments (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:RealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422405 - Disclosure - Financial Instruments (Details 3)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails3",
     "shortName": "Financial Instruments (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:RealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422406 - Disclosure - Financial Instruments (Details Textual)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual",
     "shortName": "Financial Instruments (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422407 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
     "shortName": "Financial Instruments Financial Instruments (Details Textual 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FI2020Q2_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember",
      "decimals": "-5",
      "lang": null,
      "name": "biib:StrategicInvestmentPortfolio",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423402 - Disclosure - Derivative Instruments (Details)",
     "role": "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
     "shortName": "Derivative Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "lang": null,
      "name": "biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424401 - Disclosure - Property, Plant and Equipment (Details)",
     "role": "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails",
     "shortName": "Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfFinancingCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428401 - Disclosure - Indebtedness (Details)",
     "role": "http://www.biogenidec.com/role/IndebtednessDetails",
     "shortName": "Indebtedness (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfFinancingCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsForRepurchaseOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430402 - Disclosure - Share Repurchases (Details)",
     "role": "http://www.biogenidec.com/role/ShareRepurchasesDetails",
     "shortName": "Share Repurchases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FI2019Q4_us-gaap_ShareRepurchaseProgramAxis_biib_December2019ShareRepurchaseProgramMember",
      "decimals": "-8",
      "lang": null,
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430403 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)",
     "role": "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
     "shortName": "Accumulated Other Comprehensive Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:NonoperatingIncomeExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430404 - Disclosure - Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)",
     "role": "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails",
     "shortName": "Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005000 - Statement - Condensed Consolidated Statement of Equity Statement",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
     "shortName": "Condensed Consolidated Statement of Equity Statement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431402 - Disclosure - Earnings per Share (Details)",
     "role": "http://www.biogenidec.com/role/EarningsPerShareDetails",
     "shortName": "Earnings per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432402 - Disclosure - Share-Based Payments (Details)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
     "shortName": "Share-Based Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432403 - Disclosure - Share-Based Payments (Details 1)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1",
     "shortName": "Share-Based Payments (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2QTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOther",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433402 - Disclosure - Income Taxes (Details Textual)",
     "role": "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
     "shortName": "Income Taxes (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOther",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433403 - Disclosure - Income Taxes (Details)",
     "role": "http://www.biogenidec.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434402 - Disclosure - Other Consolidated Financial Statement Detail (Details)",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
     "shortName": "Other Consolidated Financial Statement Detail (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RealizedInvestmentGainsLosses",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434403 - Disclosure - Other Consolidated Financial Statement (Details Textual)",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual",
     "shortName": "Other Consolidated Financial Statement (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AccruedIncomeTaxesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435402 - Disclosure - Collaborative and Other Relationships - Collaborations (Details)",
     "role": "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
     "shortName": "Collaborative and Other Relationships - Collaborations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember",
      "decimals": "-5",
      "lang": null,
      "name": "biib:ExpenseIncurredByCollaboration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435403 - Disclosure - Collaborative and Other Relationships - Equity Method Investments (Details)",
     "role": "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
     "shortName": "Collaborative and Other Relationships - Equity Method Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "I2018Q4Samsung_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsToMinorityShareholders",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436401 - Disclosure - Investments in Variable Interest Entities (Details)",
     "role": "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails",
     "shortName": "Investments in Variable Interest Entities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "lang": null,
      "name": "biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101100 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:LossContingencyEstimateOfPossibleLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437401 - Disclosure - Litigation (Details)",
     "role": "http://www.biogenidec.com/role/LitigationDetails",
     "shortName": "Litigation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:LossContingencyEstimateOfPossibleLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106100 - Disclosure - Acquisitions",
     "role": "http://www.biogenidec.com/role/Acquisitions",
     "shortName": "Acquisitions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-2020630x10q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 143,
   "tag": {
    "biib_A2.25SeniorNotesdueMay12030Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2.25% Senior Notes due May 1, 2030 [Member]",
        "label": "2.25% Senior Notes due May 1, 2030 [Member]",
        "terseLabel": "2.250% Senior Notes due May 1, 2030"
       }
      }
     },
     "localname": "A2.25SeniorNotesdueMay12030Member",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_A2.90SeniorNotesDueSept152020Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2.90% Senior Notes Due Sept 15, 2020 [Member]",
        "label": "2.90% Senior Notes Due Sept 15, 2020 [Member]",
        "terseLabel": "2.90% Senior Notes Due Sept 15, 2020"
       }
      }
     },
     "localname": "A2.90SeniorNotesDueSept152020Member",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_A2018ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2018 Share Repurchase Program [Member]",
        "label": "2018 Share Repurchase Program [Member]",
        "terseLabel": "2018 Share Repurchase Program"
       }
      }
     },
     "localname": "A2018ShareRepurchaseProgramMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_A3.15SeniorNotesdueMay12050Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "3.15% Senior Notes due May 1, 2050 [Member]",
        "label": "3.15% Senior Notes due May 1, 2050 [Member]",
        "terseLabel": "3.150% Senior Notes due May 1, 2050"
       }
      }
     },
     "localname": "A3.15SeniorNotesdueMay12050Member",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_AVONEXMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "AVONEX",
        "label": "AVONEX [Member]",
        "terseLabel": "AVONEX"
       }
      }
     },
     "localname": "AVONEXMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_AcquisitionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Acquisitions [Abstract]",
        "label": "Acquisitions [Abstract]"
       }
      }
     },
     "localname": "AcquisitionsAbstract",
     "nsuri": "http://www.biogenidec.com/20200630",
     "xbrltype": "stringItemType"
    },
    "biib_AdditionalMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional milestone payment.",
        "label": "Additional Milestone Payment",
        "terseLabel": "Additional Milestone Payment"
       }
      }
     },
     "localname": "AdditionalMilestonePayment",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Additionalreductioninroyaltyratepayableoncommercialsales": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional reduction in royalty rate payable on commercial sales",
        "label": "Additional reduction in royalty rate payable on commercial sales",
        "terseLabel": "Additional reduction in royalty rate payable on commercial sales"
       }
      }
     },
     "localname": "Additionalreductioninroyaltyratepayableoncommercialsales",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adjustments to product revenue reserves relating to sales in prior years.",
        "label": "Adjustments To Product Revenue Reserves Relating To Sales In Prior Years",
        "negatedLabel": "Adjustments Relating To Prior Years"
       }
      }
     },
     "localname": "AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AducanumabMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aducanumab [Member]",
        "label": "Aducanumab [Member]",
        "terseLabel": "Aducanumab"
       }
      }
     },
     "localname": "AducanumabMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Analysis of amount of and change in product revenue reserves.",
        "label": "Analysis Of Amount Of And Change In Product Revenue Reserves [Table Text Block]",
        "terseLabel": "Analysis of change In reserves"
       }
      }
     },
     "localname": "AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.",
        "label": "Available For Sale Securities Debt Maturities After Five Years Amortized Cost",
        "verboseLabel": "Due after five years, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.",
        "label": "Available For Sale Securities Debt Maturities After Five Years Fair Value",
        "verboseLabel": "Due after five years, estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AverageMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average remaining time to maturity of marketable debt securities, available-for-sale securities.",
        "label": "Average Maturity Of Marketable Securities",
        "verboseLabel": "Average maturity of marketable securities, months"
       }
      }
     },
     "localname": "AverageMaturityOfMarketableSecurities",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_BAN2401Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "BAN2401 [Member]",
        "label": "BAN2401 [Member]",
        "terseLabel": "BAN2401"
       }
      }
     },
     "localname": "BAN2401Member",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BENEPALIMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "BENEPALI [Member]",
        "label": "BENEPALI [Member]",
        "terseLabel": "BENEPALI"
       }
      }
     },
     "localname": "BENEPALIMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BIIB111Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "BIIB111 [Member]",
        "label": "BIIB111 [Member]",
        "terseLabel": "BIIB111"
       }
      }
     },
     "localname": "BIIB111Member",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BIIB112Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "BIIB112 [Member]",
        "label": "BIIB112 [Member]",
        "terseLabel": "BIIB112"
       }
      }
     },
     "localname": "BIIB112Member",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BIIB118Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "BIIB118 [Member]",
        "label": "BIIB118 [Member]",
        "terseLabel": "BIIB118"
       }
      }
     },
     "localname": "BIIB118Member",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BasicAndDilutedEarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Basic and diluted earnings per share.",
        "label": "Basic And Diluted Earnings Per Share [Abstract]",
        "verboseLabel": "Basic and diluted earnings per share"
       }
      }
     },
     "localname": "BasicAndDilutedEarningsPerShareAbstract",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_Biogenshareofcopromotionprofitsorlosses": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Biogen share of co-promotion profits or losses",
        "label": "Biogen share of co-promotion profits or losses",
        "terseLabel": "Biogen share of co-promotion profits or losses"
       }
      }
     },
     "localname": "Biogenshareofcopromotionprofitsorlosses",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_BiosimilarsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Biosimilars",
        "label": "Biosimilars [Member]",
        "terseLabel": "Biosimilars"
       }
      }
     },
     "localname": "BiosimilarsMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BioverativMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bioverativ [Member]",
        "label": "Bioverativ [Member]",
        "terseLabel": "Bioverativ"
       }
      }
     },
     "localname": "BioverativMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BusinessOverviewPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Describes an overview of the company and its operations.",
        "label": "Business Overview [Policy Text Block]",
        "verboseLabel": "Overview"
       }
      }
     },
     "localname": "BusinessOverviewPolicyTextBlock",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_CashSettledPerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash settled performance shares [Member]",
        "label": "Cash settled performance shares [Member]",
        "terseLabel": "Cash settled performance shares"
       }
      }
     },
     "localname": "CashSettledPerformanceSharesMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CashflowsoperatingexpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash flows, operating expenses [Member]",
        "label": "Cash flows, operating expenses [Member]",
        "terseLabel": "Cash flows, operating expenses"
       }
      }
     },
     "localname": "CashflowsoperatingexpensesMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CashflowsrevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash flows, revenue [Member]",
        "label": "Cash flows, revenue [Member]",
        "terseLabel": "Cash flows, revenue"
       }
      }
     },
     "localname": "CashflowsrevenueMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ClinicalAssetsAcquired": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Clinical Assets Acquired",
        "label": "Clinical Assets Acquired",
        "terseLabel": "Clinical Assets Acquired"
       }
      }
     },
     "localname": "ClinicalAssetsAcquired",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "integerItemType"
    },
    "biib_Collaborationexpensesaccrual": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration expenses accrual",
        "label": "Collaboration expenses accrual",
        "terseLabel": "Collaboration expenses"
       }
      }
     },
     "localname": "Collaborationexpensesaccrual",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Collaborationprofitlosssharing": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration profit (loss) sharing",
        "label": "Collaboration profit (loss) sharing",
        "terseLabel": "Collaboration profit (loss) sharing"
       }
      }
     },
     "localname": "Collaborationprofitlosssharing",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ContractManufacturingCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract Manufacturing Customer [Member]",
        "label": "Contract Manufacturing Customer [Member]",
        "terseLabel": "Contract Manufacturing Customer"
       }
      }
     },
     "localname": "ContractManufacturingCustomerMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ContractOptionExerciseFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract Option Exercise Fee",
        "label": "Contract Option Exercise Fee",
        "terseLabel": "Contract Option Exercise Fee"
       }
      }
     },
     "localname": "ContractOptionExerciseFee",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ContractualAdjustmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual adjustments.",
        "label": "Contractual Adjustments [Member]",
        "terseLabel": "Contractual adjustments"
       }
      }
     },
     "localname": "ContractualAdjustmentsMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CorporateDebtSecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Corporate debt securities Current.",
        "label": "Corporate Debt Securities Current [Member]",
        "verboseLabel": "Corporate debt securities Current"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesCurrentMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CorporateDebtSecuritiesNonCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Corporate Debt Securities Non Current.",
        "label": "Corporate Debt Securities Non Current [Member]",
        "verboseLabel": "Corporate debt securities Non-current"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesNonCurrentMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Current provisions to product revenue reserves relating to sales in current year.",
        "label": "Current Provisions To Product Revenue Reserves Relating To Sales In Current Year",
        "terseLabel": "Current Provisions Relating To Sales In Current Year"
       }
      }
     },
     "localname": "CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Make Whole Provision Redemption Price, Percentage",
        "label": "Debt Instrument, Make Whole Provision Redemption Price, Percentage",
        "terseLabel": "Debt instrument, make whole provision redemption price, percentage"
       }
      }
     },
     "localname": "DebtInstrumentMakeWholeProvisionRedemptionPricePercentage",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_December2019ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "December 2019 Share Repurchase Program [Member]",
        "label": "December 2019 Share Repurchase Program [Member]",
        "terseLabel": "December 2019 Share Repurchase Program"
       }
      }
     },
     "localname": "December2019ShareRepurchaseProgramMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DeferredTaxAssetsValueReductioninValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Assets, Value, Reduction in Value",
        "label": "Deferred Tax Assets, Value, Reduction in Value",
        "terseLabel": "Deferred tax assets, decrease in value"
       }
      }
     },
     "localname": "DeferredTaxAssetsValueReductioninValue",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DeferredTaxLiabilitiesValueReductioninValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Value, Reduction in Value",
        "label": "Deferred Tax Liabilities, Value, Reduction in Value",
        "terseLabel": "Deferred tax liabilities, decrease in value"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesValueReductioninValue",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DeferredtaxliabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred tax liability [Member]",
        "label": "Deferred tax liability [Member]",
        "terseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredtaxliabilityMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DenmarkManufacturingOperationsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Denmark Manufacturing Operations [Member]",
        "label": "Denmark Manufacturing Operations [Member]",
        "terseLabel": "Denmark Manufacturing Operations"
       }
      }
     },
     "localname": "DenmarkManufacturingOperationsMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetailsTextual",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DerivativeMaturityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative Maturity [Axis]",
        "label": "Derivative Maturity [Axis]",
        "terseLabel": "Derivative Maturity [Axis]"
       }
      }
     },
     "localname": "DerivativeMaturityAxis",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_DerivativeMaturityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Derivative Maturity [Axis]",
        "label": "Derivative Maturity [Domain]",
        "terseLabel": "Derivative Maturity [Domain]"
       }
      }
     },
     "localname": "DerivativeMaturityDomain",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)",
        "label": "Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)",
        "terseLabel": "Gains (losses) on net investment hedge, excluded component"
       }
      }
     },
     "localname": "Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DisputedClaimsRelatingtoConstructionCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disputed Claims Relating to Construction Costs",
        "label": "Disputed Claims Relating to Construction Costs",
        "terseLabel": "Disputed claims relating to construction costs"
       }
      }
     },
     "localname": "DisputedClaimsRelatingtoConstructionCosts",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DistributorOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Distributor one.",
        "label": "Distributor One [Member]",
        "terseLabel": "Distributor One"
       }
      }
     },
     "localname": "DistributorOneMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DistributorTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Distributor two.",
        "label": "Distributor Two [Member]",
        "terseLabel": "Distributor Two"
       }
      }
     },
     "localname": "DistributorTwoMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DivestituresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Divestitures [Abstract]",
        "label": "Divestitures [Abstract]"
       }
      }
     },
     "localname": "DivestituresAbstract",
     "nsuri": "http://www.biogenidec.com/20200630",
     "xbrltype": "stringItemType"
    },
    "biib_DuefromantiCD20therapeuticprograms": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Receivable from anti-CD20 therapeutic programs for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.",
        "label": "Due from anti-CD20 therapeutic programs",
        "verboseLabel": "Due from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "DuefromantiCD20therapeuticprograms",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_E2609andBAN2401Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "E2609 and BAN2401 [Member]",
        "label": "E2609 and BAN2401 [Member]",
        "terseLabel": "BAN2401 and Elenbecestat"
       }
      }
     },
     "localname": "E2609andBAN2401Member",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs",
        "label": "Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs",
        "terseLabel": "Payment of early call premium and write off of remaining unamortized debt issuance costs"
       }
      }
     },
     "localname": "EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Intellectual Property Rights Reorganization",
        "label": "Effective Income Tax Rate Reconciliation, Intellectual Property Rights Reorganization",
        "terseLabel": "Internal reorganization of certain intellectual property rights"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EffectiveTaxRateReconciliationGILTItax": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective Tax Rate Reconciliation, GILTI tax",
        "label": "Effective Tax Rate Reconciliation, GILTI tax",
        "terseLabel": "GILTI"
       }
      }
     },
     "localname": "EffectiveTaxRateReconciliationGILTItax",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EisaiMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Eisai [Member]",
        "label": "Eisai [Member]",
        "terseLabel": "Eisai"
       }
      }
     },
     "localname": "EisaiMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ElenbecestatCollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Elenbecestat Collaboration [Member]",
        "label": "Elenbecestat Collaboration [Member]",
        "terseLabel": "Elenbecestat Collaboration"
       }
      }
     },
     "localname": "ElenbecestatCollaborationMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employee stock purchase plan.",
        "label": "Employee Stock Purchase Plan [Member]",
        "verboseLabel": "Employee stock purchase plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_EntityWidePercentageOfRevenueFromMajorDistributors": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Entity wide percentage of revenue from major distributors.",
        "label": "Entity Wide Percentage Of Revenue From Major Distributors",
        "terseLabel": "Percentage of revenues from major distributors"
       }
      }
     },
     "localname": "EntityWidePercentageOfRevenueFromMajorDistributors",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction",
        "label": "Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction",
        "terseLabel": "Percentage of stake in entity"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_Equitymethodinvestmentbasisdifferenceamortizationperiod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity method investment basis difference amortization period",
        "label": "Equity method investment basis difference amortization period",
        "terseLabel": "Equity method investment basis difference amortization period"
       }
      }
     },
     "localname": "Equitymethodinvestmentbasisdifferenceamortizationperiod",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Estimated additional payments upon achievement of development and commercial milestones.",
        "label": "Estimated Additional Payments Upon Achievement Of Development And Commercial Milestones",
        "terseLabel": "Estimated additional payments upon achievement of development and commercial milestones"
       }
      }
     },
     "localname": "EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ExpenseIncurredByCollaboration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total expense incurred by collaboration.",
        "label": "Expense Incurred By Collaboration",
        "terseLabel": "Expense Incurred By Collaboration"
       }
      }
     },
     "localname": "ExpenseIncurredByCollaboration",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Expenseincurredbythecollaboration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expense incurred by the collaboration",
        "label": "Expense incurred by the collaboration",
        "terseLabel": "Expense incurred by the collaboration"
       }
      }
     },
     "localname": "Expenseincurredbythecollaboration",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Expensereflectedwithinstatementsofincome": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expense reflected within statements of income",
        "label": "Expense reflected within statements of income",
        "terseLabel": "Expense reflected within statements of income"
       }
      }
     },
     "localname": "Expensereflectedwithinstatementsofincome",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_FAMPYRAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "FAMPYRA [Member]",
        "label": "FAMPYRA [Member]",
        "terseLabel": "FAMPYRA"
       }
      }
     },
     "localname": "FAMPYRAMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FLIXABIMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "FLIXABI [Member]",
        "label": "FLIXABI [Member]",
        "terseLabel": "FLIXABI"
       }
      }
     },
     "localname": "FLIXABIMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FUMADERMMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "FUMADERM [Member]",
        "label": "FUMADERM [Member]",
        "terseLabel": "FUMADERM"
       }
      }
     },
     "localname": "FUMADERMMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FacilityLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Facility Location [Axis]",
        "terseLabel": "Facility Location [Axis]"
       }
      }
     },
     "localname": "FacilityLocationAxis",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_FacilityLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Facility Location [Domain]",
        "terseLabel": "Facility Location [Domain]"
       }
      }
     },
     "localname": "FacilityLocationDomain",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair Value, Indefinite Lived Intangible Assets, Discount Rate",
        "label": "Fair Value, Indefinite Lived Intangible Assets, Discount Rate",
        "terseLabel": "Fair value, in-process research and development, discount rate"
       }
      }
     },
     "localname": "FairValueIndefiniteLivedIntangibleAssetsDiscountRate",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_FumarateMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fumarate [Member]",
        "label": "Fumarate [Member]",
        "terseLabel": "Fumarate"
       }
      }
     },
     "localname": "FumarateMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FutureContingentMilestoneTypesAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future Contingent Milestone Types [Axis]",
        "label": "Future Contingent Milestone Types [Axis]",
        "terseLabel": "Future Contingent Milestone Types [Axis]"
       }
      }
     },
     "localname": "FutureContingentMilestoneTypesAxis",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_FutureContingentMilestoneTypesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Future Contingent Milestone Types [Axis]",
        "label": "Future Contingent Milestone Types [Domain]",
        "terseLabel": "Future Contingent Milestone Types [Domain]"
       }
      }
     },
     "localname": "FutureContingentMilestoneTypesDomain",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Amount, Shares Purchased",
        "label": "Global Licensing Collaboration Agreement, Amount, Shares Purchased",
        "terseLabel": "Global Licensing Collaboration Agreement, Amount, Shares Purchased"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementAmountSharesPurchased",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones",
        "label": "Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones",
        "terseLabel": "Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones",
        "label": "Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones",
        "terseLabel": "Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Payment, Selection of Targets",
        "label": "Global Licensing Collaboration Agreement, Payment, Selection of Targets",
        "terseLabel": "Global Licensing Collaboration Agreement, Payment, Selection of Targets"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementPaymentSelectionofTargets",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments",
        "label": "Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments",
        "terseLabel": "Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementSharesPurchased": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Shares, Purchased",
        "label": "Global Licensing Collaboration Agreement, Shares, Purchased",
        "terseLabel": "Global Licensing Collaboration Agreement, Shares, Purchased"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementSharesPurchased",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Shares Purchased Per Share",
        "label": "Global Licensing Collaboration Agreement, Shares Purchased Per Share",
        "terseLabel": "Global Licensing Collaboration Agreement, Shares Purchased Per Share"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementSharesPurchasedPerShare",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "biib_GovernmentSecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Government securities Current.",
        "label": "Government Securities Current [Member]",
        "verboseLabel": "Government securities Current"
       }
      }
     },
     "localname": "GovernmentSecuritiesCurrentMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_GovernmentSecuritiesNonCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Government Securities Non Current.",
        "label": "Government Securities Non-current [Member]",
        "verboseLabel": "Government securities Non-current"
       }
      }
     },
     "localname": "GovernmentSecuritiesNonCurrentMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_IMRALDIMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "IMRALDI [Member]",
        "label": "IMRALDI [Member]",
        "terseLabel": "IMRALDI"
       }
      }
     },
     "localname": "IMRALDIMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_InLicensedPatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In-licensed patents.",
        "label": "In Licensed Patents [Member]",
        "terseLabel": "Acquired and in-licensed rights and patents"
       }
      }
     },
     "localname": "InLicensedPatentsMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Income Tax Expense, Reduction in Deferred Tax Assets and Liabilities, Net",
        "label": "Income Tax Expense, Reduction in Deferred Tax Assets and Liabilities, Net",
        "terseLabel": "Income tax expense associated with reductions in deferred tax assets and liabilities"
       }
      }
     },
     "localname": "IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_IndefiniteLivedIntangibleAssetsUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indefinite lived intangible assets useful life.",
        "label": "Indefinite Lived Intangible Assets Useful Life",
        "terseLabel": "Indefinite lived intangible assets useful life"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsUsefulLife",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "durationStringItemType"
    },
    "biib_IntangibleAssetsExcludingGoodwillTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intangible assets excluding goodwill.",
        "label": "Intangible Assets Excluding Goodwill [Table Text Block]",
        "verboseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsExcludingGoodwillTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_InterestInSubsidiary": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest in subsidiary.",
        "label": "Interest In Subsidiary",
        "verboseLabel": "Interest in subsidiary (less than given percentage)"
       }
      }
     },
     "localname": "InterestInSubsidiary",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_InterferonMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interferon",
        "label": "Interferon [Member]",
        "terseLabel": "Interferon"
       }
      }
     },
     "localname": "InterferonMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_Inventorynetcurrentandnoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inventory, net current and noncurrent",
        "label": "Inventory, net current and noncurrent",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "Inventorynetcurrentandnoncurrent",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_InventoryrawmaterialssoldtoFUJIFILM": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inventory raw materials sold to FUJIFILM",
        "label": "Inventory raw materials sold to FUJIFILM",
        "terseLabel": "Inventory raw materials sold to FUJIFILM"
       }
      }
     },
     "localname": "InventoryrawmaterialssoldtoFUJIFILM",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.",
        "label": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities",
        "verboseLabel": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities"
       }
      }
     },
     "localname": "InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Investmentincommonstocksharespurchased": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investment in common stock, shares purchased",
        "label": "Investment in common stock, shares purchased",
        "terseLabel": "Investment in common stock, shares purchased"
       }
      }
     },
     "localname": "Investmentincommonstocksharespurchased",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "sharesItemType"
    },
    "biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investments By Consolidated And Nonconsolidated Entities [Axis]",
        "label": "Investments By Consolidated And Nonconsolidated Entities [Axis]",
        "terseLabel": "Investments By Consolidated And Nonconsolidated Entities [Axis]"
       }
      }
     },
     "localname": "InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Investments By Consolidated And Nonconsolidated Entities [Axis]",
        "label": "Investments By Consolidated And Nonconsolidated Entities [Domain]",
        "terseLabel": "Investments By Consolidated And Nonconsolidated Entities [Domain]"
       }
      }
     },
     "localname": "InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_InvestmentsInVariableInterestEntitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investments In Variable Interest Entities.",
        "label": "Investments in Variable Interest Entities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsInVariableInterestEntitiesAbstract",
     "nsuri": "http://www.biogenidec.com/20200630",
     "xbrltype": "stringItemType"
    },
    "biib_IonisPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ionis Pharmaceuticals [Member]",
        "label": "Ionis Pharmaceuticals [Member]",
        "terseLabel": "Ionis"
       }
      }
     },
     "localname": "IonisPharmaceuticalsMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_MSProductRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "MS Product Revenues [Member]",
        "label": "MS Product Revenues [Member]",
        "terseLabel": "MS Product Revenues"
       }
      }
     },
     "localname": "MSProductRevenuesMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_March2019ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "March 2019 Share Repurchase Program [Member]",
        "label": "March 2019 Share Repurchase Program [Member]",
        "terseLabel": "2019 Share Repurchase Program"
       }
      }
     },
     "localname": "March2019ShareRepurchaseProgramMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_MarketStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Market stock units.",
        "label": "Market Stock Units [Member]",
        "verboseLabel": "Market stock units"
       }
      }
     },
     "localname": "MarketStockUnitsMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Mortgage and other asset backed securities Current.",
        "label": "Mortgage And Other Asset Backed Securities Current [Member]",
        "verboseLabel": "Mortgage and other asset backed securities Current"
       }
      }
     },
     "localname": "MortgageAndOtherAssetBackedSecuritiesCurrentMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Mortgage And Other Asset Backed Securities Non Current.",
        "label": "Mortgage And Other Asset Backed Securities Non Current [Member]",
        "verboseLabel": "Mortgage and other asset backed securities Non-current"
       }
      }
     },
     "localname": "MortgageAndOtherAssetBackedSecuritiesNonCurrentMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_NeurimmuneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Neurimmune.",
        "label": "Neurimmune [Member]",
        "terseLabel": "Neurimmune"
       }
      }
     },
     "localname": "NeurimmuneMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_NightstarMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nightstar [Member]",
        "label": "Nightstar [Member]",
        "terseLabel": "Nightstar"
       }
      }
     },
     "localname": "NightstarMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails",
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_Noncontrollinginterestincreasedecreaseother": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Noncontrolling interest, increase (decrease) other",
        "label": "Noncontrolling interest, increase (decrease) other",
        "terseLabel": "Noncontrolling interest, increase (decrease) other"
       }
      }
     },
     "localname": "Noncontrollinginterestincreasedecreaseother",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_OthercorporaterevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other corporate revenues [Member]",
        "label": "Other corporate revenues [Member]",
        "terseLabel": "Other corporate revenues"
       }
      }
     },
     "localname": "OthercorporaterevenuesMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_OtherrevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other revenues [Abstract]",
        "label": "Other revenues [Abstract]"
       }
      }
     },
     "localname": "OtherrevenuesAbstract",
     "nsuri": "http://www.biogenidec.com/20200630",
     "xbrltype": "stringItemType"
    },
    "biib_OtherrevenuesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other revenues [Table Text Block]",
        "label": "Other revenues [Table Text Block]",
        "terseLabel": "Other revenues"
       }
      }
     },
     "localname": "OtherrevenuesTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_OtherrevenuesfromantiCD20therapeuticprograms": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.",
        "label": "Other revenues from anti-CD20 therapeutic programs",
        "terseLabel": "Other revenues from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "OtherrevenuesfromantiCD20therapeuticprograms",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_OutLicensedPatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Out-licensed patents.",
        "label": "Out Licensed Patents [Member]",
        "terseLabel": "Out-licensed patents"
       }
      }
     },
     "localname": "OutLicensedPatentsMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments/ returns applied against product revenue reserves relating to current year.",
        "label": "Payments Returns Applied Against Product Revenue Reserves Relating To Current Year",
        "negatedLabel": "Payments/Returns Relating To Sales in Current Year"
       }
      }
     },
     "localname": "PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments/ returns applied against product revenue reserves relating to prior year.",
        "label": "Payments Returns Applied Against Product Revenue Reserves Relating To Prior Year",
        "negatedLabel": "Payments/Returns Relating To Sales in Prior Year"
       }
      }
     },
     "localname": "PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PercentageParValueOfSeniorNotes": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage Par Value Of Senior Notes",
        "label": "Percentage Par Value Of Senior Notes",
        "terseLabel": "Percentage par value of senior notes"
       }
      }
     },
     "localname": "PercentageParValueOfSeniorNotes",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_PercentageoffuturedevelopmentcostsrelatedtoEisai": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of future development costs related to Eisai",
        "label": "Percentage of future development costs related to Eisai",
        "terseLabel": "Percentage of future development costs related to Eisai"
       }
      }
     },
     "localname": "PercentageoffuturedevelopmentcostsrelatedtoEisai",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_PerformanceStockUnitsSettledinCashMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Performance Stock Units Settled in Cash [Member]",
        "label": "Performance Stock Units Settled in Cash [Member]",
        "terseLabel": "Performance stock units settled in cash"
       }
      }
     },
     "localname": "PerformanceStockUnitsSettledinCashMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PerformanceStockUnitsSettledinStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Performance Stock Units Settled in Stock [Member]",
        "label": "Performance Stock Units Settled in Stock [Member]",
        "terseLabel": "Performance stock units settled in stock"
       }
      }
     },
     "localname": "PerformanceStockUnitsSettledinStockMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PlanAssetsForDeferredCompensationFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair values as of the balance sheet date of all assets of deferred compensation plans.",
        "label": "Plan Assets For Deferred Compensation Fair Value Disclosure",
        "verboseLabel": "Plan assets for deferred compensation"
       }
      }
     },
     "localname": "PlanAssetsForDeferredCompensationFairValueDisclosure",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PostacquisitionequitycompensationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Post-acquisition equity compensation [Member]",
        "label": "Post-acquisition equity compensation [Member]",
        "terseLabel": "Post-acquisition equity compensation"
       }
      }
     },
     "localname": "PostacquisitionequitycompensationMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Potential future milestone payments commitment to third party approximately.",
        "label": "Potential Future Milestone Payments Commitment To Third Party Approximately",
        "terseLabel": "Potential Future Milestone Payments Commitment To Third Party Approximately"
       }
      }
     },
     "localname": "PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pre-tax Charge, Payment of Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs, Net of Derivative Gain",
        "label": "Pre-tax Charge, Payment of Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs, Net of Derivative Gain",
        "terseLabel": "Pre-tax charge, payment of early call premium and write off of remaining unamortized debt issuance costs, net of derivative gain"
       }
      }
     },
     "localname": "PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]",
        "label": "Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]"
       }
      }
     },
     "localname": "ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract",
     "nsuri": "http://www.biogenidec.com/20200630",
     "xbrltype": "stringItemType"
    },
    "biib_Reductioninroyaltyratepayableoncommercialsales": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reduction in royalty rate payable on commercial sales",
        "label": "Reduction in royalty rate payable on commercial sales",
        "terseLabel": "Reduction in royalty rate payable on commercial sales"
       }
      }
     },
     "localname": "Reductioninroyaltyratepayableoncommercialsales",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_RegulatoryApprovalMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Regulatory Approval Milestone [Member]",
        "label": "Regulatory Approval Milestone [Member]",
        "terseLabel": "Regulatory Approval Milestone [Member]"
       }
      }
     },
     "localname": "RegulatoryApprovalMilestoneMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_RegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Regulatory Milestones [Member]",
        "label": "Regulatory Milestones [Member]",
        "terseLabel": "Regulatory Milestones [Member]"
       }
      }
     },
     "localname": "RegulatoryMilestonesMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ResearchanddevelopmentassetAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research and development asset [Axis]",
        "label": "Research and development asset [Axis]",
        "terseLabel": "Research and development asset [Axis]"
       }
      }
     },
     "localname": "ResearchanddevelopmentassetAxis",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_ResearchanddevelopmentassetDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Research and development asset [Axis]",
        "label": "Research and development asset [Domain]",
        "terseLabel": "Research and development asset [Domain]"
       }
      }
     },
     "localname": "ResearchanddevelopmentassetDomain",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ReserveforCashDiscountsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reserve for Cash Discounts [Member]",
        "label": "Reserve for Cash Discounts [Member]",
        "terseLabel": "Discounts"
       }
      }
     },
     "localname": "ReserveforCashDiscountsMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenues from anti-CD20 therapeutic programs",
        "label": "Revenues from anti-CD20 therapeutic programs [Table Text Block]",
        "terseLabel": "Revenues from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "RevenuesfromantiCD20therapeuticprogramsTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_Revenuesfromanticd20therapeuticprogramsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenues from anti-cd20 therapeutic programs",
        "label": "Revenues from anti-cd20 therapeutic programs [Member]",
        "terseLabel": "Revenues from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "Revenuesfromanticd20therapeuticprogramsMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_RocheGroupGenentechMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Roche group Genentech.",
        "label": "Roche Group Genentech Member",
        "terseLabel": "Genentech"
       }
      }
     },
     "localname": "RocheGroupGenentechMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SPINRAZAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "SPINRAZA [Member]",
        "label": "SPINRAZA [Member]",
        "terseLabel": "SPINRAZA"
       }
      }
     },
     "localname": "SPINRAZAMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SamsungBiosimilarAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Samsung bio-similar agreement.",
        "label": "Samsung Biosimilar Agreement [Member]",
        "terseLabel": "Samsung Bioepis"
       }
      }
     },
     "localname": "SamsungBiosimilarAgreementMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/OtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SangamoCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sangamo Common Stock [Member]",
        "label": "Sangamo Common Stock [Member]",
        "terseLabel": "Sangamo"
       }
      }
     },
     "localname": "SangamoCommonStockMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SangamoTherapeuticsInc.AgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sangamo Therapeutics, Inc. Agreement [Member]",
        "label": "Sangamo Therapeutics, Inc. Agreement [Member]",
        "terseLabel": "Sangamo Therapeutics, Inc. Agreement"
       }
      }
     },
     "localname": "SangamoTherapeuticsInc.AgreementMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]",
        "label": "Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]",
        "terseLabel": "5.200% Senior Notes due 2045"
       }
      }
     },
     "localname": "SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]",
        "label": "Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]",
        "terseLabel": "4.050% Senior Notes due 2025"
       }
      }
     },
     "localname": "SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]",
        "label": "Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]",
        "terseLabel": "3.625% Senior Notes due 2022"
       }
      }
     },
     "localname": "SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]",
        "label": "Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]",
        "terseLabel": "2.900% Senior Notes due 2020"
       }
      }
     },
     "localname": "SeniorNotesTwoPointNinePercentDueTwentyTwentyMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share based compensation expense included in costs and expenses.",
        "label": "Share Based Compensation Expense Included In Costs And Expenses",
        "terseLabel": "Share-based compensation expense included in total costs and expenses"
       }
      }
     },
     "localname": "ShareBasedCompensationExpenseIncludedInCostsAndExpenses",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ShareOfCoPromotionProfits": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share of co promotion profits.",
        "label": "Share Of Co Promotion Profits",
        "terseLabel": "Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA"
       }
      }
     },
     "localname": "ShareOfCoPromotionProfits",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ShorttermderivativeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short-term derivative [Member]",
        "label": "Short-term derivative [Member]",
        "terseLabel": "Short-term derivative"
       }
      }
     },
     "localname": "ShorttermderivativeMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SkyhawkTherapeuticsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Skyhawk Therapeutics [Member]",
        "label": "Skyhawk Therapeutics [Member]",
        "terseLabel": "Skyhawk Therapeutics"
       }
      }
     },
     "localname": "SkyhawkTherapeuticsMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SolothurnSwitzerlandMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Solothurn, Switzerland [Member]",
        "label": "Solothurn, Switzerland [Member]",
        "terseLabel": "Solothurn, Switzerland"
       }
      }
     },
     "localname": "SolothurnSwitzerlandMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_StrategicInvestmentPortfolio": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Strategic investment portfolio.",
        "label": "Strategic Investment Portfolio",
        "verboseLabel": "Strategic investment portfolio"
       }
      }
     },
     "localname": "StrategicInvestmentPortfolio",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_StrategicInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Strategic investments.",
        "label": "Strategic Investments [Member]",
        "terseLabel": "Strategic Investments"
       }
      }
     },
     "localname": "StrategicInvestmentsMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summary of total product revenue reserves included in consolidated balance sheets.",
        "label": "Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Table Text Block]",
        "terseLabel": "Total reserves included in consolidated balance sheets"
       }
      }
     },
     "localname": "SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summary of share-based compensation expense associated with different programs.",
        "label": "Summary of share based compensation expense associated with different programs [Abstract]"
       }
      }
     },
     "localname": "SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table]",
        "label": "Summary of Activity Related to Aducanumab Collaboration [Table Text Block]",
        "terseLabel": "Summary of Activity Related to Aducanumab Collaboration"
       }
      }
     },
     "localname": "SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table]",
        "label": "Summary of Activity Related to E2609 and BAN2401 Collaboration [Table Text Block]",
        "terseLabel": "Summary of Activity Related to BAN2401 and Elenbecestat Collaboration"
       }
      }
     },
     "localname": "SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_TECFIDERAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "TECFIDERA [Member]",
        "label": "TECFIDERA [Member]",
        "terseLabel": "TECFIDERA"
       }
      }
     },
     "localname": "TECFIDERAMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_TGNMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "TGN",
        "label": "TGN [Member]",
        "terseLabel": "TGN [Member]"
       }
      }
     },
     "localname": "TGNMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_TimeVestedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Time vested restricted stock units.",
        "label": "Time Vested Restricted Stock Units [Member]",
        "verboseLabel": "Time-vested restricted stock units"
       }
      }
     },
     "localname": "TimeVestedRestrictedStockUnitsMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_TysabriProductMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "TYSABRI product [Member]",
        "label": "TYSABRI product [Member]",
        "terseLabel": "TYSABRI"
       }
      }
     },
     "localname": "TysabriProductMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_UCBPharmaS.A.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "UCB Pharma S.A. [Member]",
        "label": "UCB Pharma S.A. [Member]",
        "terseLabel": "UCB Pharma S.A. [Member]"
       }
      }
     },
     "localname": "UCBPharmaS.A.Member",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.",
        "label": "Unrealized Gain (Losses) on Foreign Currency Derivatives, Net, before Tax",
        "negatedLabel": "Gain/Loss on fair value of foreign currency forward contracts"
       }
      }
     },
     "localname": "UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total upfront and milestone payments made to collaborative partner.",
        "label": "Upfront And Milestone Payments Made To Collaborative Partner",
        "terseLabel": "Upfront and milestone payments made to collaborative partner"
       }
      }
     },
     "localname": "UpfrontAndMilestonePaymentsMadeToCollaborativePartner",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ZINBRYTAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ZINBRYTA [Member]",
        "label": "ZINBRYTA [Member]",
        "terseLabel": "ZINBRYTA"
       }
      }
     },
     "localname": "ZINBRYTAMember",
     "nsuri": "http://www.biogenidec.com/20200630",
     "presentation": [
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_BR": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "BRAZIL",
        "terseLabel": "Brazil"
       }
      }
     },
     "localname": "BR",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "All Currencies [Domain]",
        "terseLabel": "All Currencies [Domain]"
       }
      }
     },
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_CAD": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Canada, Dollars",
        "verboseLabel": "Canadian dollar"
       }
      }
     },
     "localname": "CAD",
     "nsuri": "http://xbrl.sec.gov/currency/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_CHF": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Switzerland, Francs",
        "terseLabel": "Swiss franc"
       }
      }
     },
     "localname": "CHF",
     "nsuri": "http://xbrl.sec.gov/currency/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_EUR": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Euro Member Countries, Euro",
        "verboseLabel": "Euro"
       }
      }
     },
     "localname": "EUR",
     "nsuri": "http://xbrl.sec.gov/currency/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_GBP": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "United Kingdom, Pounds",
        "terseLabel": "British pound"
       }
      }
     },
     "localname": "GBP",
     "nsuri": "http://xbrl.sec.gov/currency/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_JPY": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Japan, Yen",
        "terseLabel": "Japan, Yen"
       }
      }
     },
     "localname": "JPY",
     "nsuri": "http://xbrl.sec.gov/currency/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Currency [Axis]",
        "terseLabel": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r174",
      "r279",
      "r283",
      "r476"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum",
        "verboseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r172",
      "r279",
      "r281",
      "r473",
      "r474"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesByProductDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesByProductDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r173",
      "r279",
      "r282",
      "r475",
      "r486",
      "r487"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsAbstract",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted Average"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Reduction of accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r21",
      "r41",
      "r175",
      "r176",
      "r280"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "auth_ref": [
      "r37",
      "r434",
      "r458"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.",
        "label": "Accrued Income Taxes, Noncurrent",
        "terseLabel": "Accrued income taxes"
       }
      }
     },
     "localname": "AccruedIncomeTaxesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]",
        "verboseLabel": "Accrued Expenses and Other"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedLiabilitiesMember": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.",
        "label": "Accrued Liabilities [Member]",
        "terseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "AccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r25",
      "r26",
      "r62"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "verboseLabel": "Royalties and licensing fees"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "auth_ref": [
      "r83",
      "r88",
      "r89",
      "r287",
      "r356"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "terseLabel": "Unfunded status of postretirement benefit plans"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r56",
      "r241"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r88",
      "r96",
      "r355"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Unrealized gains (losses) on cash flow hedges"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r80",
      "r81",
      "r82",
      "r88",
      "r89"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]",
        "terseLabel": "Unrealized gains (losses) on securities available for sale"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r88",
      "r393"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from increase (decrease) in value of excluded component of derivative hedge, including portion attributable to noncontrolling interest.",
        "label": "Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Gains (losses) on net investment hedge"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r86",
      "r87",
      "r88"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "periodEndLabel": "Accumulated other comprehensive income (loss), net of tax ending balance",
        "periodStartLabel": "Accumulated other comprehensive income (loss), net of tax beginning balance",
        "terseLabel": "Balance, January 1, 2018",
        "verboseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r85",
      "r88",
      "r89",
      "r356"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r78",
      "r88",
      "r89",
      "r356"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Currency translation adjustments"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "verboseLabel": "Other Consolidated Financial Statement Detail"
       }
      }
     },
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentForAmortization": {
     "auth_ref": [
      "r128",
      "r231"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.",
        "label": "Amortization",
        "negatedTerseLabel": "Amortization of basis differences"
       }
      }
     },
     "localname": "AdjustmentForAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net income to net cash flows from operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r290",
      "r296",
      "r299"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "negatedTerseLabel": "Compensation related to share-based payments",
        "verboseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, after Tax",
        "totalLabel": "Subtotal",
        "verboseLabel": "Subtotal"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r128",
      "r224",
      "r231"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "verboseLabel": "Amortization and impairment of acquired intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax": {
     "auth_ref": [
      "r394"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax, of accumulated gain (loss) from increase (decrease) in value of excluded component of derivative hedge.",
        "label": "AOCI, Derivative Qualifying as Hedge, Excluded Component, after Tax",
        "terseLabel": "Derivative qualifying as net investment hedge, excluded component"
       }
      }
     },
     "localname": "AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/OtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r190",
      "r285"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "verboseLabel": "Mortgage and other asset backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r128",
      "r237"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Asset impairment charges"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r168",
      "r432",
      "r457"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r22",
      "r23",
      "r74"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r396"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "verboseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r183"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r184"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r181",
      "r207"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.",
        "label": "Available-for-sale Securities",
        "terseLabel": "Marketable equity securities, fair value",
        "totalLabel": "Available-for-sale Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r183"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.",
        "label": "Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Marketable equity securities, gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.",
        "label": "Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Marketable equity securities, gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.",
        "label": "Available-for-sale Securities, Amortized Cost Basis",
        "totalLabel": "Marketable equity securities, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Available-for-sale Securities, Debt Maturities [Abstract]",
        "verboseLabel": "Summary of Contractual Maturities: Available-for-Sale Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r188"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Amortized Cost",
        "verboseLabel": "Due after one year through five years, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r185",
      "r188",
      "r451"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value",
        "verboseLabel": "Due after one year through five years, estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r187"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost",
        "verboseLabel": "Due in one year or less, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r185",
      "r187",
      "r450"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value",
        "verboseLabel": "Due in one year or less, estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r178",
      "r182",
      "r207"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Marketable debt securities",
        "verboseLabel": "Fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r180",
      "r207"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r180",
      "r207"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Available-for-sale Securities [Table Text Block]",
        "verboseLabel": "Marketable debt and equity securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r291",
      "r298"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r374",
      "r378"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails",
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r326",
      "r327"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails",
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition, Contingent Consideration [Line Items]",
        "terseLabel": "Business Acquisition, Contingent Consideration [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails",
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Price per share"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r333",
      "r334",
      "r337"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "periodEndLabel": "Fair value, end of period",
        "periodStartLabel": "Fair value, beginning of period",
        "terseLabel": "Contingent consideration obligations"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r333",
      "r335"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "verboseLabel": "Current portion of contingent consideration obligations"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Business Combination, Contingent Consideration, Liability, Measurement Input"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r333",
      "r335"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "verboseLabel": "Contingent consideration obligations"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Acquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r329"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and Equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities": {
     "auth_ref": [
      "r329"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r303",
      "r329"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedTerseLabel": "Deferred Tax Liability"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": {
     "auth_ref": [
      "r329"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets",
        "terseLabel": "In-process research and development"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails",
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r328",
      "r329"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "terseLabel": "Total purchase price"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets": {
     "auth_ref": [
      "r329"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosures related to transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination by type of transaction.",
        "label": "Business Combination, Separately Recognized Transactions [Axis]",
        "terseLabel": "Business Combination, Separately Recognized Transactions [Axis]"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of transaction that is recognized separately from the acquisition of assets and assumptions of liabilities in a business combination by transaction.",
        "label": "Business Combination, Separately Recognized Transactions [Domain]",
        "terseLabel": "Business Combination, Separately Recognized Transactions [Domain]"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized": {
     "auth_ref": [
      "r325"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The expenses and losses recorded for each transaction with the acquiree that was recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.",
        "label": "Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized",
        "terseLabel": "Fair value of post-combination equity compensation",
        "verboseLabel": "NST stock options"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "verboseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash and Cash Equivalents [Line Items]",
        "terseLabel": "Cash and Cash Equivalents [Line Items]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "auth_ref": [
      "r29",
      "r196"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "verboseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r124",
      "r130",
      "r131"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of the period",
        "periodStartLabel": "Cash and cash equivalents, beginning of the period",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r124",
      "r412"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash Equivalents, at Carrying Value [Abstract]",
        "verboseLabel": "Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging [Member]"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r342",
      "r343",
      "r345"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "verboseLabel": "Collaborative and Other Relationships"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationships"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/OtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "verboseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r67",
      "r252",
      "r444",
      "r465"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r40",
      "r266"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "negatedPeriodEndLabel": "Ending balance, shares",
        "negatedPeriodStartLabel": "Beginning balance, shares"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, par value $0.0005 per share"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r92",
      "r94",
      "r95"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r92",
      "r94",
      "r349",
      "r350",
      "r364"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r92",
      "r94",
      "r348",
      "r364"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive income attributable to Biogen Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r132",
      "r351",
      "r365",
      "r366"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "verboseLabel": "Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r240"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConstructionPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r443",
      "r466"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables.",
        "label": "Construction Payable",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r285",
      "r288",
      "r477"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "verboseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales, excluding amortization and impairment of acquired intangible assets"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total cost and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "verboseLabel": "Cost and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Indebtedness"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r33",
      "r35",
      "r36",
      "r433",
      "r435",
      "r455"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r417",
      "r419"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r408"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "verboseLabel": "Debt instruments, fair value"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Senior notes interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Debt instrument, redemption price, percentage"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r65",
      "r135",
      "r267",
      "r270",
      "r271",
      "r272",
      "r416",
      "r417",
      "r419",
      "r454"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "auth_ref": [
      "r194"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Gain",
        "terseLabel": "Realized gains"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "auth_ref": [
      "r194"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Loss",
        "negatedLabel": "Realized losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesMember": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions.",
        "label": "Debt Securities [Member]",
        "verboseLabel": "Short-term debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "auth_ref": [
      "r308"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "terseLabel": "Decrease in unrecognized tax benefits is reasonably possible"
       }
      }
     },
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r313"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax asset"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r128",
      "r133",
      "r316",
      "r320"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r304",
      "r313"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "verboseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r302",
      "r314",
      "r315"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Deferred tax assets, other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill": {
     "auth_ref": [
      "r302",
      "r314",
      "r315",
      "r339",
      "r340"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from goodwill.",
        "label": "Deferred Tax Liabilities, Goodwill",
        "terseLabel": "Deferred tax liabilities, goodwill"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r302",
      "r314",
      "r315"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "terseLabel": "Deferred tax liabilities, other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r128",
      "r239"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r128",
      "r165"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation, amortization and impairments"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r75",
      "r76",
      "r376",
      "r428"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Fair Value, Gross Asset",
        "terseLabel": "Derivative asset, fair value"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r75",
      "r76",
      "r376",
      "r428"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Fair Value, Gross Liability",
        "terseLabel": "Derivative liability, fair value"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r375",
      "r377",
      "r384",
      "r389"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "verboseLabel": "Derivative Instruments"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r373",
      "r375",
      "r384"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet": {
     "auth_ref": [
      "r381",
      "r388"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net",
        "terseLabel": "Gain (loss) on reclassification of cash flow hedges, effective portion"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet": {
     "auth_ref": [
      "r382",
      "r392"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of gains and losses (net) on derivative instruments designated and qualifying as hedging instruments representing (a) the amount of the hedge ineffectiveness and (b) the amount, if any, excluded from the assessment of hedge effectiveness.",
        "label": "Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net",
        "terseLabel": "Gain (loss) recognized in net income, excluded component"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r368",
      "r369"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative, Notional Amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeRemainingMaturity1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Remaining Maturity",
        "verboseLabel": "Range of durations of foreign currency forward contracts"
       }
      }
     },
     "localname": "DerivativeRemainingMaturity1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativeTermOfContract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Term of Contract",
        "terseLabel": "Remaining duration of Net Investment Hedges"
       }
      }
     },
     "localname": "DerivativeTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivatives [Line Items]"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "verboseLabel": "Designated as hedging instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Developed technology"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DilutiveSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]",
        "verboseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "DilutiveSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Disaggregation of Revenue [Abstract]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesByProductDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesByProductDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Revenues by product"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "verboseLabel": "Share-based Payments"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPayments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax": {
     "auth_ref": [
      "r1",
      "r3",
      "r5",
      "r15"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a discontinued operation.",
        "label": "Discontinued Operation, Provision for Loss (Gain) on Disposal, Net of Tax",
        "terseLabel": "Loss on divestiture of Hiller\u00f8d, Denmark manufacturing operations, net of tax"
       }
      }
     },
     "localname": "DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r5",
      "r12",
      "r15",
      "r305",
      "r322"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Tax Effect of Discontinued Operation",
        "terseLabel": "Tax expense on disposal group"
       }
      }
     },
     "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetailsTextual",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Consideration",
        "terseLabel": "Consideration expected to be received for sale of Denmark Manufacturing Operations"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense": {
     "auth_ref": [
      "r13"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Other Expense",
        "terseLabel": "Expected costs to sell disposal group"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown": {
     "auth_ref": [
      "r128",
      "r238",
      "r243"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations.",
        "label": "Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down",
        "terseLabel": "Loss on divestiture of Hiller\u00f8d, Denmark manufacturing operations"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/DivestituresDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r19",
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Divestitures"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDivestitures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetailsTextual",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueFromRelatedParties": {
     "auth_ref": [
      "r138",
      "r422",
      "r441",
      "r468"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.",
        "label": "Due from Related Parties",
        "terseLabel": "Due from Related Parties"
       }
      }
     },
     "localname": "DueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r138",
      "r422",
      "r442",
      "r467"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties",
        "terseLabel": "Due to Related Parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "verboseLabel": "Net income per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r101",
      "r142",
      "r145",
      "r147",
      "r148",
      "r149",
      "r152",
      "r447",
      "r471"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Basic earnings per share attributable to Biogen Inc."
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r101",
      "r142",
      "r145",
      "r147",
      "r148",
      "r149",
      "r152",
      "r447",
      "r471"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Diluted earnings per share attributable to Biogen Inc."
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Earnings per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": {
     "auth_ref": [
      "r412"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
        "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
        "negatedTerseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r137",
      "r306",
      "r307"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "verboseLabel": "Reconciliation between the U.S. federal statutory tax rate and effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r306",
      "r307",
      "r319"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "verboseLabel": "Statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets": {
     "auth_ref": [
      "r306",
      "r319"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to disposition of asset. Includes, but is not limited to, intra-entity transfer of asset other than inventory.",
        "label": "Effective Income Tax Rate Reconciliation, Disposition of Asset, Percent",
        "terseLabel": "Denmark assets held for sale"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDispositionOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r306",
      "r307",
      "r319"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "verboseLabel": "Taxes on foreign earnings"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization": {
     "auth_ref": [
      "r306",
      "r307",
      "r319"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depreciation and amortization.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation and Amortization, Percent",
        "verboseLabel": "Purchased intangible assets"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses": {
     "auth_ref": [
      "r306",
      "r307",
      "r319"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent",
        "terseLabel": "TECFIDERA impairment"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "auth_ref": [
      "r306",
      "r307",
      "r319"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "verboseLabel": "Permanent items"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r306",
      "r307",
      "r319"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r306",
      "r307",
      "r319"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "verboseLabel": "State taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r306",
      "r307",
      "r319"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "negatedLabel": "Credits and net operating loss utilization"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r62"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Collaboration expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "auth_ref": [
      "r297"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Amount Capitalized",
        "negatedTerseLabel": "Capitalized share-based compensation costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r296"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, Tax Benefit",
        "negatedLabel": "Income tax effect"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity": {
     "auth_ref": [
      "r200"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.",
        "label": "Equity Method Investment, Difference Between Carrying Amount and Underlying Equity",
        "terseLabel": "Amortization of basis differences"
       }
      }
     },
     "localname": "EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity Method Investment, Ownership Percentage",
        "verboseLabel": "Percentage of stake in entity maximum"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r54",
      "r169",
      "r198"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Investment in Samsung Bioepis"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "auth_ref": [
      "r197"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "totalLabel": "Net gains (losses) recognized during the period on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]",
        "terseLabel": "Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLossAlternativeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {
     "auth_ref": [
      "r197"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Realized Gain (Loss)",
        "verboseLabel": "Less: Net gains (losses) recognized during the period on equity securities sold during the period"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r197"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "terseLabel": "Net gains recognized on the increase in fair value of equity securities",
        "verboseLabel": "Unrealized gains (losses) recognized during the period on equity securities held as of March 31"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r30",
      "r34",
      "r196",
      "r440",
      "r456",
      "r485"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Marketable equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]",
        "verboseLabel": "Summary of assets and liabilities recorded at fair value"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r396",
      "r397",
      "r398",
      "r406"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Fair Value by Asset Class",
        "verboseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r396",
      "r406"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r285",
      "r286",
      "r288",
      "r397",
      "r424"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r396",
      "r397",
      "r400",
      "r401",
      "r407"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueHedgingMember": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.",
        "label": "Fair Value Hedging [Member]",
        "terseLabel": "Fair Value Hedging [Member]"
       }
      }
     },
     "localname": "FairValueHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r285",
      "r286",
      "r288",
      "r397",
      "r425"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "verboseLabel": "Quoted Prices in Active Markets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r285",
      "r286",
      "r288",
      "r397",
      "r426"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "verboseLabel": "Significant Other Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r285",
      "r286",
      "r288",
      "r397",
      "r427"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "verboseLabel": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r402",
      "r406"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "verboseLabel": "Fair value of contingent consideration obligations"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r403"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedLabel": "(Gain) loss on fair value remeasurement of contingent consideration",
        "negatedTerseLabel": "Contingent consideration",
        "terseLabel": "Contingent consideration impairment"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r404"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedLabel": "Payments",
        "terseLabel": "Future payment"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r405",
      "r407"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "verboseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "auth_ref": [
      "r374",
      "r379",
      "r391"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]"
       }
      }
     },
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r208",
      "r209",
      "r210",
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "verboseLabel": "Estimated life, (in years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r230"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r232"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months",
        "terseLabel": "Expected future amortization expense, 2020"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year",
        "terseLabel": "Expected future amortization expense, 2019 (remaining three months)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r232"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five",
        "terseLabel": "Expected future amortization expense, 2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r232"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four",
        "verboseLabel": "Expected future amortization expense, 2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r232"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three",
        "terseLabel": "Expected future amortization expense, 2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r232"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two",
        "verboseLabel": "Expected future amortization expense, 2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r225",
      "r227",
      "r230",
      "r234",
      "r431"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r230",
      "r431"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Cost"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r225",
      "r229"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r230"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.",
        "label": "Foreign Currency Contract, Asset, Fair Value Disclosure",
        "verboseLabel": "Derivative contracts"
       }
      }
     },
     "localname": "ForeignCurrencyContractAssetFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.",
        "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure",
        "verboseLabel": "Derivative contracts"
       }
      }
     },
     "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r409",
      "r410",
      "r411"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "verboseLabel": "Foreign exchange gains (losses), net"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r285",
      "r387"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "verboseLabel": "Foreign exchange contract"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": {
     "auth_ref": [
      "r375"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.",
        "label": "Gain (Loss) on Derivative Instruments, Net, Pretax",
        "negatedTerseLabel": "Gain on interest rate swap",
        "terseLabel": "Derivative, gain on derivative",
        "verboseLabel": "Gain on interest rate swap"
       }
      }
     },
     "localname": "GainLossOnDerivativeInstrumentsNetPretax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": {
     "auth_ref": [
      "r375",
      "r383"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.",
        "label": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments",
        "negatedLabel": "Net gains (losses) of other income (expense) related to foreign currency forward contracts"
       }
      }
     },
     "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestmentsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security.",
        "label": "Gain (Loss) on Securities [Table Text Block]",
        "terseLabel": "Gain (loss) on investments in equity securities"
       }
      }
     },
     "localname": "GainLossOnInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r216",
      "r217"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "netLabel": "Goodwill",
        "periodEndLabel": "Goodwill, end of period",
        "periodStartLabel": "Goodwill, beginning of period",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "verboseLabel": "Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r218",
      "r220"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "verboseLabel": "Accumulated impairment losses related to goodwill"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "auth_ref": [
      "r219"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Other Increase (Decrease)",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "GoodwillOtherIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "verboseLabel": "Summary of roll forward of the changes in goodwill"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r373",
      "r390"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r128",
      "r235"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Impairment of Intangible Assets (Excluding Goodwill)"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In Process Research and Development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r136"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income tax expense and equity in loss of investee, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r99",
      "r128",
      "r166",
      "r198",
      "r445",
      "r469"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Equity in loss of investee, net of tax",
        "negatedTerseLabel": "Our share of Samsung Bioepis gains (losses)",
        "terseLabel": "Eisai's share of aducanumab milestone expense reflected in collaboration profit sharing in our condensed consolidated statements of income"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions": {
     "auth_ref": [
      "r128"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.",
        "label": "Income (Loss) from Equity Method Investments, Net of Dividends or Distributions",
        "terseLabel": "Loss recorded on Samsung Bioepis joint venture"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax": {
     "auth_ref": [
      "r246"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of income (loss) from an individually significant component disposed of or held-for-sale attributable to parent. Excludes discontinued operations.",
        "label": "Income (Loss) from Individually Significant Component Disposed of or Held-for-sale, Excluding Discontinued Operations, Attributable to Parent, before Income Tax",
        "negatedTerseLabel": "Loss on divestiture of Hiller\u00f8d, Denmark manufacturing operations"
       }
      }
     },
     "localname": "IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetailsTextual",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r0",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r14",
      "r16",
      "r17",
      "r18",
      "r245",
      "r247"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r310",
      "r311",
      "r312",
      "r318"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r133",
      "r167",
      "r321"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income Tax Expense (Benefit)",
        "verboseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income tax assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDueFromRelatedParties": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.",
        "label": "Increase (Decrease) in Due from Related Parties",
        "negatedLabel": "Due from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Increase (Decrease) in Equity Securities, FV-NI",
        "negatedLabel": "Unrealized (gain) loss on strategic investments"
       }
      }
     },
     "localname": "IncreaseDecreaseInEquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities, net:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedLabel": "Other changes in operating assets and liabilities, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r146",
      "r151"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "verboseLabel": "Stock units"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r226",
      "r233"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r233"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "verboseLabel": "Cost and Net"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r226",
      "r233"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "terseLabel": "Total intangible assets, gross"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r223",
      "r228"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "totalLabel": "Intangible assets, net",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "verboseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r97",
      "r164",
      "r415",
      "r418",
      "r448"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseMember": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing interest expense.",
        "label": "Interest Expense [Member]",
        "terseLabel": "Interest Expense"
       }
      }
     },
     "localname": "InterestExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestIncomeExpenseNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Interest Income (Expense), Net [Abstract]",
        "verboseLabel": "Other Income (Expense), Net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest rate swap"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoriesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale.",
        "label": "Inventories [Member]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoriesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r47",
      "r214"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryDetails": {
       "order": 3.0,
       "parentTag": "biib_Inventorynetcurrentandnoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "verboseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r20",
      "r72",
      "r213"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory, Net [Abstract]",
        "verboseLabel": "Components of inventories"
       }
      }
     },
     "localname": "InventoryNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r49",
      "r214"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryDetails": {
       "order": 1.0,
       "parentTag": "biib_Inventorynetcurrentandnoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "verboseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r48",
      "r214"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryDetails": {
       "order": 2.0,
       "parentTag": "biib_Inventorynetcurrentandnoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "verboseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r105",
      "r163"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r478",
      "r480",
      "r482",
      "r484"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r478",
      "r480",
      "r482",
      "r484"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investment Type Categorization [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "verboseLabel": "Summary of contractual maturities: available-for-sale securities"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r396"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Marketable equity securities"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "verboseLabel": "Litigation"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Litigation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r46",
      "r438",
      "r463"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r396"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "verboseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r36",
      "r261",
      "r435",
      "r459"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "verboseLabel": "Notes payable"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r65",
      "r260"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r252",
      "r253",
      "r255"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Value",
        "terseLabel": "Brazil tax assessment, including interest and penalties"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "auth_ref": [
      "r254",
      "r256",
      "r258"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "terseLabel": "Loss Contingency, Estimate of Possible Loss"
       }
      }
     },
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyInformationAboutLitigationMattersAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Loss Contingency, Information about Litigation Matters [Abstract]"
       }
      }
     },
     "localname": "LossContingencyInformationAboutLitigationMattersAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossOnContractTermination": {
     "auth_ref": [
      "r430"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The loss recognized on termination of a contract.",
        "label": "Loss on Contract Termination",
        "terseLabel": "Loss on research and development contracts terminated with Eisai"
       }
      }
     },
     "localname": "LossOnContractTermination",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r71",
      "r437",
      "r462"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "verboseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r124"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash flows used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r124"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash flows provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r124",
      "r125",
      "r129"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash flows provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r90",
      "r93",
      "r100",
      "r129",
      "r151",
      "r446",
      "r470"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income attributable to Biogen Inc.",
        "totalLabel": "Net income attributable to Biogen Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsPerShareDetails",
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "verboseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r90",
      "r93",
      "r353",
      "r363"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss) attributable to noncontrolling interests, net of tax"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hedges of a net investment in a foreign operation.",
        "label": "Net Investment Hedging [Member]",
        "terseLabel": "Net Investment Hedging"
       }
      }
     },
     "localname": "NetInvestmentHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Rest of World"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not designated as hedging instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net",
        "verboseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r36",
      "r435",
      "r459"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable",
        "verboseLabel": "Notes payable, carrying value"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Current portion of notes payable"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableFairValueDisclosure": {
     "auth_ref": [
      "r60"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of notes payable.",
        "label": "Notes Payable, Fair Value Disclosure",
        "verboseLabel": "Notes payable, fair value"
       }
      }
     },
     "localname": "NotesPayableFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenseMember": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing expenses associated with normal operations.",
        "label": "Operating Expense [Member]",
        "terseLabel": "Operating expense"
       }
      }
     },
     "localname": "OperatingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "negatedTerseLabel": "Operating Expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r421"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r420"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r62"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "verboseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Investments and other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.",
        "label": "Other Commitment",
        "terseLabel": "Contractual commitments for the construction of the facility"
       }
      }
     },
     "localname": "OtherCommitment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r80",
      "r81",
      "r86"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax",
        "verboseLabel": "Unrealized gains (losses) on securities available for sale, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r88",
      "r96"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "terseLabel": "Other comprehensive income (loss), before reclassifications, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).",
        "label": "Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax",
        "terseLabel": "Unrealized gains (losses) on cash flow hedges, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r77",
      "r414"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "verboseLabel": "Currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r91",
      "r94",
      "r96",
      "r266"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r91",
      "r94",
      "r348",
      "r349",
      "r355"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss), net of tax",
        "totalLabel": "Total other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "verboseLabel": "Other comprehensive income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "auth_ref": [
      "r84",
      "r86"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "negatedLabel": "Unrealized gains (losses) on pension benefit obligation, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r374",
      "r391"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Component of accrued expenses and other"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r24",
      "r25",
      "r62"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Total accrued expenses and other",
        "verboseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "verboseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).",
        "label": "Other Nonoperating Income (Expense) [Member]",
        "terseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherPaymentsToAcquireBusinesses": {
     "auth_ref": [
      "r114"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.",
        "label": "Other Payments to Acquire Businesses",
        "terseLabel": "Payments for pre-combination equity compensation"
       }
      }
     },
     "localname": "OtherPaymentsToAcquireBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]",
        "terseLabel": "Parent",
        "verboseLabel": "Total share-based compensation expense, net of tax"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net cash outflow or inflow from derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments.",
        "label": "Payments for (Proceeds from) Derivative Instrument, Financing Activities",
        "negatedTerseLabel": "Cash proceeds from settlement of swap"
       }
      }
     },
     "localname": "PaymentsForProceedsFromDerivativeInstrumentFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r112",
      "r116",
      "r139"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r119"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Purchases of treasury stock",
        "terseLabel": "Payments for repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r121"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "terseLabel": "Payments of financing costs"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r119"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedLabel": "Payments related to issuance of stock for share-based compensation arrangements, net"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r109",
      "r113",
      "r179"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r114",
      "r336"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Total transaction value"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r114"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Acquisition of Nightstar Therapeutics plc, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r114"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "terseLabel": "Payments to acquire additional investment in equity method investment"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r114"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.",
        "label": "Payments to Acquire in Process Research and Development",
        "negatedTerseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "PaymentsToAcquireInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedTerseLabel": "Acquisitions of intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates": {
     "auth_ref": [
      "r114"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).",
        "label": "Payments to Acquire Interest in Subsidiaries and Affiliates",
        "negatedTerseLabel": "Purchase of Sangamo Therapeutics, Inc. stock"
       }
      }
     },
     "localname": "PaymentsToAcquireInterestInSubsidiariesAndAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherProductiveAssets": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.",
        "label": "Payments to Acquire Other Productive Assets",
        "negatedTerseLabel": "Contingent consideration paid related to Fumapharm AG acquisition"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToMinorityShareholders": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.",
        "label": "Payments to Noncontrolling Interests",
        "negatedTerseLabel": "Net distribution to noncontrolling interest",
        "terseLabel": "Payments to Noncontrolling Interests"
       }
      }
     },
     "localname": "PaymentsToMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance units"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock, par value $0.001 per share"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.",
        "label": "Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid research and development expenses"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromHedgeInvestingActivities": {
     "auth_ref": [
      "r112",
      "r126"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.",
        "label": "Proceeds from Hedge, Investing Activities",
        "terseLabel": "Proceeds from settlement of net investment hedge"
       }
      }
     },
     "localname": "ProceedsFromHedgeInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Proceeds from borrowings"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r118",
      "r121",
      "r139"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r109",
      "r110",
      "r179"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from maturities and sales",
        "verboseLabel": "Proceeds from sales and maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity": {
     "auth_ref": [
      "r111",
      "r179"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the sale of equity securities classified as available-for-sale securities.",
        "label": "Proceeds from Sale of Available-for-sale Securities, Equity",
        "terseLabel": "Proceeds from sales of strategic investments",
        "verboseLabel": "Proceeds from sale of available-for-sale securities, equity"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product, net"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/RevenuesByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r90",
      "r93",
      "r123",
      "r168",
      "r171",
      "r348",
      "r352",
      "r354",
      "r363",
      "r364"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income",
        "totalLabel": "Net income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r55",
      "r240"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Fixed assets placed into service"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r31",
      "r32",
      "r242",
      "r464"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "verboseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": {
     "auth_ref": [
      "r38",
      "r436",
      "r460"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.",
        "label": "Purchase Commitment, Remaining Minimum Amount Committed",
        "terseLabel": "Future minimum batch production for Denmark Manufacturing Operations"
       }
      }
     },
     "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RealizedGainLossOnInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of realized gains and losses on investments reported in the statement of income.",
        "label": "Realized Gain (Loss) on Investments [Table Text Block]",
        "verboseLabel": "Proceeds from marketable debt securities"
       }
      }
     },
     "localname": "RealizedGainLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RealizedInvestmentGainsLosses": {
     "auth_ref": [
      "r472"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net realized gains or losses on investments during the period, not including gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity.",
        "label": "Realized Investment Gains (Losses)",
        "terseLabel": "Gain (loss) on investments, net"
       }
      }
     },
     "localname": "RealizedInvestmentGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]",
        "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]"
       }
      }
     },
     "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r88",
      "r89",
      "r96"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "terseLabel": "Amounts reclassified from accumulated other comprehensive income, net of tax"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Repayment of borrowings"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepurchaseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investments represented by an agreement between the entity and another party for the sale and repurchase of identical or substantially the same securities at a date certain for a specified price. Such agreements are generally short-term in nature.",
        "label": "Repurchase Agreements [Member]",
        "terseLabel": "Overnight reverse repurchase agreements"
       }
      }
     },
     "localname": "RepurchaseAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r301",
      "r488"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r301"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r128",
      "r249",
      "r250",
      "r251"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring charges"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r43",
      "r273",
      "r461"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r278"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Revenues related to amendment of contract manufacturing agreement"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r98",
      "r161",
      "r162",
      "r170"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "negatedTerseLabel": "Product revenues",
        "netLabel": "Other Revenues",
        "terseLabel": "Product revenues",
        "totalLabel": "Total revenues from anti-CD20 therapeutic programs",
        "verboseLabel": "Total revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/RevenuesByProductDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesFromAntiCd20TherapeuticProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalty"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesMember": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.",
        "label": "Sales [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "SalesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesReturnsAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A revision in the estimated reserve needed for product returns and price or other concessions granted to customers.",
        "label": "Sales Returns and Allowances [Member]",
        "terseLabel": "Returns"
       }
      }
     },
     "localname": "SalesReturnsAndAllowancesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "verboseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r186",
      "r189",
      "r191",
      "r192",
      "r193",
      "r195",
      "r449",
      "r452"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of information about a contingent payment arrangement including the terms that will result in payment and the accounting treatment that will be followed if such contingency occurs, including the potential impact on earnings per share if the contingency is to be settled in shares of common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]",
        "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r326",
      "r327"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails",
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "verboseLabel": "Summary of fair and carrying value of debt instruments"
       }
      }
     },
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]",
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "verboseLabel": "Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "verboseLabel": "Summary of share-based compensation expense associated with each of our share-based compensating programs"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r375",
      "r384",
      "r390"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "verboseLabel": "Summary of the effect of cash flow derivatives designated as hedging instruments on the condensed consolidated statements of income"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "verboseLabel": "Summary of fair value and presentation of derivatives"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "verboseLabel": "Basic and diluted earnings per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "verboseLabel": "Reconciliation between the U.S. federal statutory tax rate and effective tax rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r290",
      "r295",
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r290",
      "r295",
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "verboseLabel": "Share-based compensation expense included in condensed consolidated statements of income"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r396",
      "r397"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "verboseLabel": "Summary of assets and liabilities recorded at fair value"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r225",
      "r229"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r221",
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "verboseLabel": "Summary of roll forward of the changes in goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r28",
      "r50",
      "r51",
      "r52"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Components of inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.",
        "label": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Summary of the effect of derivatives designated as net investment hedging instruments on our consolidated statement of income"
       }
      }
     },
     "localname": "ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the notional amounts of outstanding derivative positions.",
        "label": "Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]",
        "verboseLabel": "Foreign currency forward contracts that were entered into to hedge forecasted revenue"
       }
      }
     },
     "localname": "ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "verboseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r56",
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSeparatelyIdentifiableAssetsAcquiredAndLiabilitiesAssumedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r68",
      "r134",
      "r263",
      "r264",
      "r265",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "auth_ref": [
      "r357",
      "r358",
      "r359",
      "r360",
      "r361"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table]",
        "terseLabel": "Schedule of Variable Interest Entities [Table]"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Estimated future amortization for acquired intangible assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r104",
      "r212"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]",
        "verboseLabel": "Share-based Compensation Expense included in consolidated statements of income"
       }
      }
     },
     "localname": "ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r289",
      "r292"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of significant accounting policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r70",
      "r266"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r39",
      "r40",
      "r266",
      "r273",
      "r293"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "terseLabel": "Issuance of common stock under award plan, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued": {
     "auth_ref": [
      "r40",
      "r266",
      "r273"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.",
        "label": "Stock Issued During Period, Shares, Treasury Stock Reissued",
        "terseLabel": "Issuance of common stock under stock option and stock purchase plans, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesTreasuryStockReissued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r70",
      "r266",
      "r273"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock under stock award plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued": {
     "auth_ref": [
      "r39",
      "r40",
      "r266",
      "r273",
      "r275"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.",
        "label": "Stock Issued During Period, Value, Treasury Stock Reissued",
        "terseLabel": "Issuance of common stock under stock option and stock purchase plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueTreasuryStockReissued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock Repurchase Program, Authorized Amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Amount remaining under 2019 Share Repurchase Program"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r39",
      "r40",
      "r266",
      "r273"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "negatedTerseLabel": "Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r40",
      "r44",
      "r45",
      "r177"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Biogen Inc. shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Biogen Idec Inc. shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r346",
      "r347",
      "r362"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "verboseLabel": "Equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes": {
     "auth_ref": [
      "r479",
      "r481",
      "r483"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate cost of investments for Federal income tax purposes.",
        "label": "Tax Basis of Investments, Cost for Income Tax Purposes",
        "terseLabel": "Tax Basis of Investments, Cost for Income Tax Purposes"
       }
      }
     },
     "localname": "TaxBasisOfInvestmentsCostForIncomeTaxPurposes",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense": {
     "auth_ref": [
      "r317"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income tax expense from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act.",
        "label": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense",
        "terseLabel": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "verboseLabel": "Taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TrademarksAndTradeNamesMember": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trademarks and Trade Names [Member]",
        "terseLabel": "Trademarks and Trade Names"
       }
      }
     },
     "localname": "TrademarksAndTradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease": {
     "auth_ref": [
      "r413"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the cumulative translation adjustment from gain (loss), after tax, on foreign currency derivatives, that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.",
        "label": "Derivatives used in Net Investment Hedge, Net of Tax, Period Increase (Decrease)",
        "terseLabel": "Gains (losses) on net investment hedges"
       }
      }
     },
     "localname": "TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r69",
      "r275"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockRetiredCostMethodAmount": {
     "auth_ref": [
      "r40",
      "r266",
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.",
        "label": "Treasury Stock, Retired, Cost Method, Amount",
        "negatedTerseLabel": "Retirement of common stock pursuant to Share Repurchase Progams, at cost"
       }
      }
     },
     "localname": "TreasuryStockRetiredCostMethodAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r40",
      "r266",
      "r273"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "negatedTerseLabel": "Repurchase of common stock, at cost, shares",
        "terseLabel": "Repurchase of common stock, at cost, shares"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r69",
      "r275",
      "r276"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock, at cost"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r266",
      "r273",
      "r275"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Repurchase of common stock, at cost"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementOfEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/OtherRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r285",
      "r439",
      "r477"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "verboseLabel": "Government securities"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax": {
     "auth_ref": [
      "r380"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.",
        "label": "Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax",
        "terseLabel": "Unrealized gain (loss) on net investment hedges in AOCI"
       }
      }
     },
     "localname": "UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r140"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Total Reserves",
        "verboseLabel": "Revenue-related reserves for discounts and allowances"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1",
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityDisclosureTextBlock": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.",
        "label": "Variable Interest Entity Disclosure [Text Block]",
        "verboseLabel": "Investments in Variable Interest Entities"
       }
      }
     },
     "localname": "VariableInterestEntityDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Variable Interest Entity [Line Items]",
        "terseLabel": "Variable Interest Entity [Line Items]"
       }
      }
     },
     "localname": "VariableInterestEntityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r149"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "totalLabel": "Dilutive potential common shares"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r144",
      "r149"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted earnings per share attributable to Biogen Inc.",
        "totalLabel": "Shares used in calculating diluted earnings per share"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "verboseLabel": "Weighted-average shares used in calculating:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r143",
      "r149"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of common shares outstanding",
        "verboseLabel": "Basic earnings per share attributable to Biogen Inc."
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3151-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3444-108585"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3581-108585"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(d),(e))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1500-109256"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26626-111562"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=2122178"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27232-111563"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27337-111563"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27340-111563"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=116654751&loc=SL75117546-209714"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6904-107765"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12021-110248"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31917-109318"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117331294&loc=d3e36027-109320"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116868840&loc=d3e2207-128464"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "c",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "740",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=117412053&loc=d3e9972-128506"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "740",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=117412053&loc=d3e9979-128506"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=d3e5710-111685"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=d3e5728-111685"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=SL6759159-111685"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=d3e5747-111685"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=SL6228884-111685"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-02)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-03)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(i)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(iii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL109998896-113959"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624181-113959"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=116861445&loc=SL5629052-113961"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Subparagraph": "(a)(1),(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=112277219&loc=d3e80784-113994"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=112277219&loc=d3e80784-113994"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b),(c),(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b,c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=SL51823488-111719"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "275",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=84167019&loc=d3e54681-109401"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6)(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10(3))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62557-112803"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.3)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.3(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117420044&loc=d3e19393-158473"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(2)(i))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(8)(d))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12C(1)(a))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12C(11)(d))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(7)(d))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r489": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r491": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r492": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r493": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r494": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20,22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>121
<FILENAME>0000875045-20-000022-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000875045-20-000022-xbrl.zip
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M6.9@^FA-R1I2CD00DTM"%((EA?[G YGI'";IS+]<$+P1X7?2I-)!T9DKYR!
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M3.:RN.YFEP3E_SH*J2JPIFA?U947<NV+'2BP'K=Y)5$7K)I5:GP[(#7?03<
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MW/WQ4++_E:=_W1#_^4C2S=PE7(%??OA_4$L#!!0    ( +6$]E"/*O_3,"H
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M:Z&"#JNI2<Q3$BP'&7V$R(6$J), 187PAAD=V-EO]/7'K^'1J[WT^S&%A ,
MFX2.:/L%X&W%&D0N^&0M:!T9Q#)^>+ 4-(X=8PUZLKI#X$ =&ZU'KO0+U7YB
M/#YV6KYI7B]3::8KV2)>,[+XGBWB>I,M8DM_MRR)[7 I,6:!6T+ 9&? &"D@
M*R8]R45Q=K!AZGCPW;M\.+1JJ8/;C(6[%_WN/M:$H!G)0H (EH!T(0!#<P^\
M,<F0S%QF9^^E]S?<.T)3=:FFK;_R^.%&&\Z(80FRXQ:$P98Y)24P80,E-":?
M^XD,?!:=W@M YV9$MEJ].[RR1F1J5'8)9 @4#",1LM8,C HA:F<TT<_$E.SF
M[]9 KM[9MR=2X.V>1W85:P03*J%A#-2) -3&"%('G#19%,XD@DBW6NLYO1G9
MB2<]8W2:':./!>GW^:_S=>*=UKM%#\HU,60>,_*>4=2E7&8%FLH(ACOK@\6_
MY@Z'HVK:F9TXT3=(]<S+^UG,D<*__+&)QWZ8YWZKV;F_>&-*9 U1'DWJ[(!%
MF8"716[&C4<UB=9U%U>DICG:B2(#856+*2W8<-L*KKT0)#%04@7PJR,=RACP
M.F1E*!I:IL.II9JV:*<>[X#'R<),;KEY2(3);:$&N2L%&MAH"P4&/'$#(6%+
M!5<N1*<I=QTBC?1SZ?E>$3J!!]H^3N#A\XV/1@H9$X2,[5.94_ 9)[P4212$
MLL!E!VUOG@L#^@+G>^?_Z\\/<7F'O]=.TK3CQOLJJ:/:WE=?5Y@6-\U7S&?5
M:;/M0YJ-2K*R4$Y5IM=I_>^MI8(?+M&,21^QY;_DG,(N#5%7D,9PX;3/'")-
M 1R3%(B(#/5K(#AF21;MXIL'.MF3%J6%Z#U^16K%E]_0/<#FW7H.%V$Q^KKO
MJ%_[2IJ02-3E5*/C2@&Z&1ZT325)!T%S(PEF\MEO0)\S@1Z>,1JR9RJN&N71
MHN1>V+U&M'FH,5X:QH4!IQA.:C%[;(Y$_*2QP@N6B.U@Z-?AV% =]WC5Z'C4
MZKD#U[,41IM[B*[':=4CDWAQ5<YF__>]NY*V.@;[BS?)I\R$<1 =HZ"XCF C
M,\"C* %O))G4(?Z\SFIS)<X,A&>]Y"CSA.\J2OIU^IK&T]4JZ=L)PA;23A6S
MIV23LM24) Y<,PVLM%DG:[#A%N$DA.K<P<VLLQ)=B4/]0UF+/M\3])?\0&A\
M[U,_VPLTF7@;#9/@\0,V,T? 25V"958X(ZTQEIS[$G4ELO2&8+5523>:E#GU
M/>K'&1I^BU4"J=N[G!&V#[.TV)G/JVT5#?'!>14-,.\U9&(M.(H_LE66\8S_
MF0Y;';).[IU*1!H0U%K4>N-&LU4VH5]7Z856?O[?1XO+OTZFOMSXM+[3\GJY
M"B2;3L)HO)ZH/Y:-XAE"B>-H-+\]+W2#R#K=3<'\)H'5#FY6DZ&Q2<5@1(1$
MO0$?4P+L$($_A",F&Y>['!&ME%BJ$KG/N5?J;1S>9.DK-UZ]G40$-B[=>/SM
MSAT991*93LJ=@J/Y]13[XGU^/_N/-(Z;"(M;7WQU<5HY&+/$9]:]-9W,[V>"
M6J\\ODQY.DNWZ^H[]R;/0L(F1$=$]!Q("!I,P#X,E"@(6D8J%!=!= C,TC_4
MR'J^?7:R#;M?_BAV6GJ9)BGOS#:YIV3#!:,^107,JH3.I$@X'2><CIDSV=&L
M8I<<^W4V;JKYY7U#65%MWUL-Q;EFO8MR&]WVYNMOH]U:M44%C5->\Q0BN"P3
M*$-*.@[JP5NNG&,RNMPA5,S^:$IO&$BK;AR774X$:STD-N-AW^;QMC(-4U93
M$A,(GAQDZAA0A[Z!<2R[:'R(NL/Z("4_%'?ZA/%T.NCQB9R#--#CX@VQ7GM!
ML>'240@"1TQ4.%B,4#EGH9@A74A$?R@2#83HZ?CT>IF*_;BZ[&H5LK!G5[5E
M#4U@+E$>.-#H-%A/*7BM,QA+,GIC7*C4(5">LA^<57V!>CIBW9PE.I1.=\HU
MF7DNLHG A)! &?H6+"@#V9$@!;%1I@[+T93_X"3J!N5)Y[@9^J'M,CJW*=X$
MHXDL<63.&@<N4,3!< :&,A]E< A[!QN;_E ;&P,!>G(ZW7J@M\E-CV'5XUH:
M93GW1%L0F@40.)@@FK*_C.HXLIBT9ET22->)VC\UN7K!]70<6SD7MV!M[OC9
M=PZY;24-B]PE9WD)A9>@E2B7=# )SD?A+0W>"]6!83_6EL.@N-9BV!-8K2_&
M[1@!N:62AF2BG2$*'(L.5"SW.FB' TZCU> BS3@2SSW2Z/E'0/;3,Q4C($-*
M<;7_4#83$-Y?W:*LPWU[GY\^(;P[7/*8&K$K0E;22;"*HKK0.(YI5 $LR\3K
MZ%129W_G[5"4>!Q;60GB:C1TWU:!$I^GJPO?9VGWX?1=]#NLIA*<2EV2Z']G
M*@!MW@2$)(V_BJ2IRBS;#M/R:9<X>N?=X-B>C&\K\P+QB\NPNC]^7SK(=A4T
M01$KF$Y@M=,EDBP#8:KDW>*2F."5\!W<BM.N?0S.KKX@/1FI7B[GHTE"L==7
M.Z[,E_5?XB'4VE%-HYSW5$2+IK4VP DK^V7*0_0Y&).U\KF?.PY^1(+U"^S)
M:'9SL=O;R:>EGX_BR,W6F7TO<E[%8NVVUXZHKO&6E2OCT'X('F6TP@-S ?N"
M2D]YDD3Q#K/F:6-#!Z?=, "?C'Y/YH<YA'1/5H+0FY@5*3MO-"/T68(IVR=)
M$&$C5TK(\[\"]%14ZQ/6$^JWS>&-[6<[#M-M.ZMJC!)"&9O &,? &F; !!&!
M,A6-E3HXDX\GVVF#%ROHM;[!/>64>B]YS8'SY[VR378EKY]G0");^4()O UH
M65 C*1=2>=TA/Z7YT4G5&<U3K*7]1XI?TF$KO6V*-T1)(I2CH%W)S*$)!TJ$
M!C07T"HP+$3;(23#_JBK9#WB>:J5V5TK>^L R@,69?=7U@3AG=*2@",N%K.
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M;P2@YRY(]I82>?8&_AFQ= "\SXFM^.6K68JCG:>\#ZNHT8HD&B)%, R!1((
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M 4B]A!*^(\7;9XKTM[$8CPFM<1C*FH?BV$KD=56M#^F7(W9NTCQ! 2-J@-4
M*1N<91J(O-4\!$:T_='L_@[ZQV- #PBU3B;X=IS)M^-,/I]4 4XVS3;_+RJ)
M#^43G-%%PBQ51$!OB+>",4\4)K56LF':],"U8;O;O6>4+K)JL'&.MK5L]Y7=
M;- J$0$_1;SF!'F(,*>0F%I/HVU[CZ"_D_CQ1H%XP%R$ )N;G+<"FZ**DZIS
M2DV9<*!YHKQ26%3WO5./&8(!S!I-J#EL'X/V=WB_)TK$06C0(.0Q-VJJYM-W
MV;(2W:ZJ(\=OUU5@-S0_%6HT["9AC@AJ%0R^,'0(&""LVB%A.U2J[^^T?^2
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M)&&"6B3#W,U874=;^Q #M#])/VBIEY:&;HW#8-YLMGPD8\=BHV?WE6@10$6
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M18+RD5H]EMP)DK\-HG_[YLCE:FQ6YI_6J=TOYE7NRC=+IL.]T58WV\T.O7B
M=-*=4(M=*MC+!G5QCK9+0HR,%=(D.%*80 2XX.O]?^((1E0TBB5[3G!</-%
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MA 4&RF":$/Q[8)QAKM[ED"#X-:.?/J\X^:^E$08=%1_WW!ZKRS;@Z,FV"=9
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M$X#7V@7? XX[E[F;P4Y8OQ-"/QH/1ID / ;S7\;L[X-75I2OBV6#K+COGDT
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M%M9Q_Z3OXR]WQ3*;_U86Z[ME?,1\?147L-1FLY2M\ZLO<2'<W*$NCU: 'V,
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M(T:EDE80@$HVBO$$;])ZTM4+!G1'9[Q-:#G[%87^E3\LFA>SY3^.6 YUW8(
M&'.CO9=(6TM\?'=VX8\ ".#:GUH.[//4I^G0(T#C4R%MK,OL<I4B9X_[<M1T
M"P9)PR!SRG/+F:0:5X7I ,! N&E;#OTH\2 S>L/K/3-DDG;#](AQ7KOA(BZ@
MW_[([AH;#D\[!&8-MP0R SP@&A- 3;6KC[_;4?VZ&OK@]**L X9#)W3&TOW'
M8G$3AWN;5LTD^Q&+X;7FP3B>,E$)C"!7$FOAU*X2!X">=_"]&CA;4Y^60@_
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M%0 CR@E.N0- QME.P<IGS@+!1\UCT++*20<=%GWATC(ER3&5;L=S,+#H>9,
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M;=&++]>[<36YD3G6-5C&G$&40!FWMM!C!?#F:#<5S6((-3+51I7ZV.U,7;>
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M*D""C07( *33%,"H,*0:F^$=%,;?@,(Z8=%:3]I]=E_5QP_U>GK:*BAG):%
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M_NY^S)$T:]4 NAWSTG]^1"+_[__U_P%02P,$%     @ M83V4 U_6!CO+P$
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M^%(2J,3R696PQ2BKA6J8%Y3$Q4E7J8QO\:U7&WFHXY%(I4VP,J54Z]LIP=3
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MI.^+ZE@R(K)=$(480!MXGF6YIN6V>A[[( 316VD+RP'1-^*?PS<H?I:=-?+
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M6?585,G^E[(X/%;#S1A6L+MY*>F0[KK@ILBKU\IXP\B//( = ($//-?R8F^
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MW;G& ?3M(QWPSW(^@.TX40!MTX$PM &*0M\?9G+?1[(SXYI\T#]KC@ZAWYI
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M.9OF!CB?.LE;$1*F 1#W"&M+433I!]T6N?%#.AQ(3>F5EO$E,[3F<[N.4:7
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MP+$7B^4:*S6]1!IR!YBNF!ABL=Q9M3Q/SP9G)U@TQV=@MH5J#%B-'JR(>B_
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MZ-OO%5M\=FF:^1W<UMGGK,[2(Y H#NW HPM1'.#( 1 3V^Z!^"0*Q1[/U@!
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MW6/7$75\=ZR]^JCB=X1?\ #R-BU+%AIU=KJM4Y3FZ6U6;TR  ;!L!UEVY!-
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M["BL]C XR>OL713;IL&B^.0Q/=39UG@LB[LR>9B]:R?)N:P&:B1;I0P.Y'=
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M)S)Q8(<^_737=;RP76ZPSP\]V^,KU";^N2+]6JK^6@>'?Y +\O+V,-='B-A
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M13+"CJPH#;L<B_6+UT,HC;%/8S</"8EQ0.(X'3.O,&8X@@B2J@W+8K2'I?M
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M$QO>MMQ%IVC$$ZBCDT)WOI7.[OD6N>_CVFDUKIV6@ZM*VQROTC<DDH6_3J>
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MWI=-\5CNMM7RL2^1MXLX#B(_S[R$1GG @HCX)-KGG(QF@&<:#%BS+F(<HR-
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MEO^E6._*140Q"E&$:<Y<3HNX[W"41T*Q#]S H6+!NDSM03FM0/7.>2P:Y[O
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M%P# RMP!;803M"JRV_9ZV*GGV^6A"NE%TNG%*Z^$M>, U^D5PS7W8(ZI=84
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M4J*KJW$D((;&Z9$3Q)X9OKK+\:BHHAI5$LIHG#(U=92F3DPKCWE[2B]',;,
MS1R'O]351F2&S.#CE[]_!;T!:A/J -\+?0(C$@6AW9UMY :"T*7B(V:IKS4]
M8.[ R(P+Y5@1&2X;(T1RM-SA4!HLRY$B,U8V1H[B4%F4),&1\J%[)P?*2APL
M0/,4@9>CXR^A<A^_]4+:3T(.#P#XD1U#-BJ/'!OY(?(P[5Z+XJ8(#(FPWJD:
M,*Q\'[]9/:YANEWF6*TR:P)Z. 5A<LIXA"L5E50F34(OIR!/33F52!13T1-.
MG]+3L1PM0%E'NU!J;#,RUUE\N?ST%?Q_@YX[OH>P[2+;A5S+PR!&_F !11(B
M*_F]AK5U0"-S3X$D,0(Z:I 3.?D<@*AHIBPO,M<RF.-'\;8%89X$KT]XYN I
M-52D80$BJ(J\'-\()"0/DD_D"_AP.0S4"4[\P 8!C6) [=")XJ2W !!TQ"5/
M\GL-2]Z 1J)KRQ(C('D&.9&3O &(BN3)\B(A>0;Y49,\<9[$).^Y@Z<D3Y&&
M!4B>*O)R?".067G^^!5\P(,! ECQ2+PH"OTD(AX_\N$.!MPPBL27G:6^UO2:
M<P=&9DE5CA4!N3-'B)S:]3B4UIGE2)%99#9&CN(*LRA)@NO,A^Z=7&16XF !
M.J<(O!P=?YGUD0^7_Q? P0"_XS&T(0E1!'#DVDD2#0LP((P"*+X^(O6UIM='
M.C R2P%RK(BLCQ@C1')]I,.AM#XB1XK,^H@Q<A371T1)$EP?.73OY/J($@<+
M4#E%X.7H^,L,7_.RSN_S;5H-TX*8V  3%_$C#Z%#(ILDPR(,<""2&,%*?[7I
M0>P>D,QX39XAD:&L47(D1[-[+$H#6GF"9,:T1HE2'-8*-"3! >U+[TZ.:95I
M6( 0C@!?:FD*,F7?[Q_95W[].%C @0.P[2''=H/ 1[;3O;')+1#'0^)UG]SW
MFB[\>C0R18XD,2*EGSE.)&N_'HA2\2?)BTSU9XX?Q?)/F"?!^N^9@R<+0#4:
M%B!\JLC+\8U 3/+JJEGM7G'\+2MOJ_3A+E^G6_ CKU=V[$ ,(Q"[U ZH#Z,H
M&)9+0!)%CHCXC;-@6 8/\5A_<$2"/7\D;^>U<3K*Y%12ABV1@[O,SX-#N^Q/
M+P_LGB7BB%KH(6Y>W=#D0ZFS*4EH27;[TA(N[].\6,6N0V&($\]#)'9QZ-)X
ML 4!=81.IXVS,*F6=)ADU$2=.0$UF82T,6KR%E_Z].04%:?T9#1U"]"3\3Z4
M.AN3F)ZL^:-+U=/J]V^K.'%@$OIQ3$#BHR1&T!NVJD$('*$C71)?9U@I?O_U
MV^FG4Y0I.*\"AKR7Z_*_?[J\(MCZ=@6NR#>9KEX/?;W.UK_>EM__=^\.[^[1
M\ ?>VZ.#WKYW^4C75N!CWGZL KA4CKW<'3>?RN+W84HFC$D2^SCR48R](,#0
M1\/X!+HV$+IZ0^5[#??9KUG=7@#X7V6U/?VLX7AVSO=BT\3(=6>&@OU7>BY
MSR4^!Q0<Z=YCB%K&Y3Q*R,OQS42NYP];RE?0<6/B$)?]/T XA#$$<?_UB$2V
MT#RI])<:[O/#>8;JK0,T1AKXP,*9UBU-U#*:MCSL<F0#D4UG359_29_2ZVU&
MT[SZ6[I]S'!>K[=E_5AE*^  %R< 1R$F#BMYL>OVUW_Z$/N.*W>]\%AK,IU
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M>];@WX5U_73P.6OPT>).6G^T+@DN<"Z 6T$!?B?1E]/P20-O1/'-A>5,TEA
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M%Q9N:9@V]P)\-O=*\+*03BP%^57NE?97]+C)MW2[>^J01LP.#1#F#\SZOD-
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M\JLJ+>KN:6RP^>_'3GI8;GGU(D7&_N;S#0/RA8'GTQIKEI/J#&?=?U=>"&-
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MIIF24Y0=27-.+QVAY(R6C"%P&4(RRH.7]VB.9D-XB:LMCWL34=RNGP5V2/P
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M2F^ 6+U:/PNG>O3> +=JBC^0:-V4E36S_'=0%!* ))O+3@&RS@@F 26.A-+
MU6^?AK=)0A\&/-'8#K9=CV";>,.7DTCL23/)KS0LZPS(VW?[CZ)$0*/-L"&G
MQ>:)D!!6,X2H"2C#,E(1=]Z<4CYY=Q>@< J@RU$AEIO4O2PVV<WI61'X]#']
M[[)"6Z:=;?GLVP&E$4B\R"84!)@2,$R00!L3J0=B=-LVO3UV!_>7[:GY18EA
MM[$(B$WMSDF^G.2.Y]W(M*XD@6?F=DV%8AD3O,:\*Z=IT%KU=(_A4WJ?];5H
MX'G #>PD8C! &+#_M\F !$6)IU%3E>S/KJL75HO;:H%;'+GDH-=H=+3HK?'
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MY&M^/GGS)6WX@?6^0L;8]@+/3IB1D'V_9P<Q&FS%" D]6CG.@F'M9+A^V?;
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M3/N1%\@,AK48-#PD?K7G\L(JIA[5B? T<L>?,,W+Z)YZ75+8X2?)EXYBYT
MR(\'?G[Y:\8OZF%4\Q<KZW6Z_7N65BLW=BE%!%./TCARPGB_YS FGB]TS'A*
M/(;'B1S;FJ?>F\?FL6*]^ "WE77 +RS>\ZR?JM8!/KQI6/_-K/NR:.[T;1[4
M&,/Q9=0<X=-<5QU&D@R1W'G1O?/+_;"X(\NIM@295RR_=,=U&8(_J<<2!9H9
MMLVDBT_9C^;JKVS[/?O8ZMHJCA*/("_V:1+&$;&1"W>@0A02<YE"&LI"DH1K
MF\P%\@$RD0:,QF:*#, =L#H/K,Z%)6O_2[JUR;YR'-^CXJL[.TKL1W)L1N=Y
MPKGZJUSY@8LAX9?(P3# B0U"9U@LCZEM4VV[%D=@,+[O1UC9'9/*+AP2$X)N
M(A93Z#C'S72\7+)Z]]QJ$VW96+U'K9;V<91$JS%J4)GYS,(*N%[D$&Q'R <)
M<K&/@N&FS\2!ML'26QS#4FINU[@RBX7$F#9KC\9TZLRA+UZ?.4B]"BT5L7>K
MT7)>CE=I!5;-Z31EW66%4.PEKN-20 B,DL!V\;"E(<&^8YLNH85 +*>&]DPK
MM5A03 FU]FA,IM,<^=)EFF/4JM)2X7JO(BWGY&B-5N#4H$2SSZZ@%[D0>"@*
M;>K[<>#3 ._ 4+&+[ U#6$HA[1N79Z& &)-GW;&83I[9OUF\/+//ZI5GF7"]
M6WF6<G*\/,MS*BK/7ZIRG66;FC)6OJ4,1['YF#*]R9NGSS?@>YJS#V\S6E;\
ME]^R-?]-GM4KWX\ J^D#XB0T"(@;>6%W"S6)B0-CJ3>336$P+- #;(NW*.N^
M0\QPM>=1:P9UX@4J11K/]'[3@5E&]S?N93EM<Y<3 )Q=-WLC+\U_S=)M_L]L
M\UO[=)P3V7[H(Y=X[,? B^V@VY]*$@]&GM3LID:SAKOY@,6Z96 D3R#I)%>L
MOIJ)5[F:BH.T]BA9$37@_.6FK'[AVLEW?/6\<[#3*JDXB6?$TT DEJ&7)APK
MC;=B$ZKX@=\$PL;,((Q]'T0$V6$8V7%L]P!\[(2AW+$DC8:%^N^8XTB['KIE
M<,Y4.\89UBF-^JB=0!H_3'[WD#B)HZ51*A+O21KE'%.21@7NQ*6QRK^S$>KW
M[+*HFZJ]^Z]F->R_9YO;O+@%:_:K%AO.ZS53AL<JN\I^-)#Q].>*NC B!";(
MA6&<($AQV*MU "%%DBLO1J$87W_9H[<.X,NJJ,E@B.KJ0J(@J[3'Z&\'[SUR
M:P_=VF.W_N#HK1;^Q'?%CV'ZK!Q/$,"E"/04KKZ2[,GX%17Q;^N[;/.XS3[?
M?&[NLNI3690/6<4P%K>7Q;J\S_K9QRN>6_9@(A<%V YHB"(?)&YD8Z];Q4<4
MN0X"<O)M"(1QX6[16GD+T?JI7XKY^?P)TDFC(*;;"Z!?3K$'P/P(6!>#0\S6
M91^0'O;/3*@Y<FLVN58C^(Q0&X[8,B3:M)/EI+U 3I;YC 8OW3\7E\7WK&[:
M3+$W&@04>PFUH1.!@-#0(S$=C&*,I"9@1YHR/.G*T5D_\7F%GZVR8%J[@\A^
MMK)_/.;-DU7OAD%RLCN693%YG9!@.1GMN/TP<+L?3,XNF.<I.R.,FKA>A@#J
M<J8TTAY5ZTRP7E>/V>9#GE[GV[:YO5!4.PH#VX$TP=A%U/6],'1[ ,R\(WFN
M2:-AX_5DCW#8U-.-04N>C53+R?%DRY:0D[*L7C8.5!_@G%WUQ$D4*@VU16(9
M:FC"L9,EH&;NA%6R29ML>*V3UYR@V*#R_J'*[I@@M/,&[=\.[\]%),)A'"<(
MTSAP(Y1$<?M@9^  X&)/N/=J-FNP"P](>1]^!G$8]<WU?*,DA^=ZL*%H+*0;
MF_+N95\VRJ)HAVZ'DD?,\OKK4\:P7:4_OO"M?F4!FJ;*KQ^;5F?*+VG%L._0
MA0D*$N & 5,=A.TP"2'NT<$D#"672Z9"-=$$W/J9#G33<?\F5S%-%B<Q05YB
M@.2$NHO,487N1IS="[Q,Q9DK%U;OC'7HC=645N?/;**N*0YGQ'[J2"\C"4SN
M=3EO_]*7-$YO"P6;_W[L!O.#!RLG($[@VJ$71#;? A"2Q!G@4=^1?$Q],EC&
MT\;O1?5L+V<WP9AUTV#[R40K';RR;LK*ZK;<%)UJ->D/?1E&;U#'IYC9HJD]
MQ[RU@6KOSX65WC3LZZ[.!';R'",3",4D8R36R\\R9MR62#,&>=>19_9;%>K_
M?&1:>?/$-RC4?*="MDN1*S^Q:1#$?A10C_@X(&$0#+A"#*76H<RC,;Q4=3:K
MK-/ZSKK9EG]9=RUH,XE$4]3&9Y#I Z8]=1RX8.U]L-+:^O<^@OL!S'(RAA#Q
MBJE";U"7GR,T^RN1'$PPK2,K?.%_P<9$Q:;]U)>2C8.R)J_:B3:8%=E-WGQA
M'>U8#L,D=GSH0,=WH\AWDR!(R&ZLQ/XK=SQB+I3&SU*<S2(/G6?6=>>$55YO
M\]OVD+"9?&(TWN.SS.R!UI9[?NJ<^KD]R,%SSTU>L!;0^V!Q)X8!RM=LO4WK
M.K_)U]U= PL?PXP(DF*>FJ)9+#][3<*"1$Z;+BHZ,AT;E67Y;8$>JRHKUD]7
M%0.6KIO.@?9/V[;W'0'K8@+LD'@^\>($^L#G!V]ZL#Y$KKY9-X,@C<_!#:"M
M9H_32G= ]>4PDY$<G\(6$D+MHZ?>+VL7Y@//VFU-![X]RV!+'%2I!TDQ@TW0
M*I:?P*8@02)_31:3B?86K*!G P*!0RF-/(Q)X)(AJ2(8VD#FJ3?36*2F[N1?
M@>L>&RY/[B;H=Z +#;*6N!!M;@%:.'++UQNMWNI=<)9D651!C@#::5;B ->)
MDC!P$/"]P(L1M >+. 12#T&.L6.XYZ,CO5VN]AQ%HE@!.15_<E6@\.:>XYMZ
MIA70,Q2>$4<=Q"]#^+1X4NIOEMH$Z[EL?F*LE$7#&-JVY_>:C#7D9A5BA!.:
MA# F(4&V$WFA/Z#R'.@,<]!7XLN6IB$I3#A?R:]='I/!X=A=^J+[%L\<81_N
M/!FQI&D\K*-E=KI03BO%SSVQ!E<6H\TBO*OIM]:(+E[C]7HKG@<,L*PA5[ _
M=<\]'RVY3Z&,'?ZVD(^!Y_HQ(5Y$D@$E0(G4<'EJ;#,4T:_2!LS+VZS@XO2K
MMNQ@)I"CL\7L,324/79^G=ROO_1\HA(9M?QBM TL/M^8]5X\_TP0!?D3\"BM
M[_AI-/8?\H_'_'NZ;4_@/S]@ZD? "2+/31R/^I'O.S!*NNN>2.A"!%5/P6LQ
M;GQU\-OC_7U:/7'EN<F+M%CGZ=9*VZOQK;_RYN[PEG7VF6U6UU9SEQ968EN;
M](E?#L(#GVW:3^?]_DN^[M3^D.T]5SU9KR>(8JEFQNC)99+#$_9H8+S]X0#M
M@L[9B]!Y1OX-Q649ZF[*N9-G[@UP**K-IS?C[RW'?AQ#)PI"$%,* Y_N;MTG
M4<P@R0FR#HO&5?AC6OV9=;7=AE]'S'OSR"N7M# MIII34RPGE:]/(RWI B8!
M[L[HHD[FER&&6CTJS;53.=D[N/\)]7M*LPU\0KPF3M?-8[H=WB/!:?/RXCL[
M='%,(?:A[28>TUXO\ =((::QG!X:A3)EN;K>(SXH4O]M?Y9TW]]5-=1LV,3$
M=3'QDE/= ]C6'K=U_60=(+<&Z!;'/KL6CZ'ZC$A/$L%EJ/<TKI8S]! YO3]\
M+^7U#8#/$;@A#AT:88]Z+-,@-V9_'A @DOAR\J[3LG$U?_F>V_,B6%6UM9(O
M)M)SL2ZGR<_>=SJXC_10J^?68 DFSTBNB7@L0V&->%::;\VJ4[@TS:N_I=O'
MX;G.XO"JP(]9RJ_NWWPNOG*MJ/+B%J9U_A)C$B,<A11%(( @)HD-NAO'?!J%
M)/83U1G>*;!-65'WT[Y\\F%[<%MGE:UYL]Y8:6/=,)>M[]QGU>G<20(J.]N[
MM$BJ3P9S3ZS6E8O^P>0VGH>WKP[^<.G?>62U+LTN_UI#(C2A/&7HEY%"9O+]
MY'3T]!%064FL*GXU0(N30R1UD]_S/8 []/7G&_Y2V,&#,R^'&M2%,0C]F")
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M>FP8Z']*W,-B*@CZA%XW^X8EG?^BP[M@X=YS.E*B%8+S?L18Q3D%V57F4*?
M?BJ+3;9Y9!^[WF;]O0,X>ZBR=3_Q4VS ?5DUO;BLW"CR(Q\@SXYC"' (8G<8
M)%#HXT!_):X;H?'"?'_=:UXT[!<<MY76M?#IIEGCIT_ YPR<*95_YI/5.\6/
M3>_=ZIZ).W!LP?E ,D0CDX:I!O%^,HLQ!A32C]EHZ,Q1.*\?RCKG/WZ^ :V0
MKIPH\&$(,<))'$01Q%&,!S2>:X<RKY*:PF!XTS+.BONT^K-/+=9=MMWPN2"K
M3K<&UG:5@J OF9CFWU3".,#-MXJVR!><$([0/%+TQP3N_0C[*"\5Q'L\JV(7
M3 I N2R:;,O/]3ZFVR\5GY=HGK[FMW=-_35CE*?%D$" $Q%*0ML.$T2="$7(
M]P9\<8@]\4LHIT1E6,0YSJI(MU;U#!;7BC7#G.8%'T7L7+$>>E^LJG5&YDK%
M26-Y7OF7'493N>#0&6OPQNK<L9[[L]BXRERGN=3X*EZY.6F<!:_FU$CQJ2,A
MLX1Q 2=!YO&[G+L#33/%>'G_D.85[X0?2E:]U"O;B6Q6IJ#(#_T8)6Z,'3#
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MPI2>PEZ[BE*ZBGKM:L,MXX0FNNWVS@^#PK<(RTOX,:I^H97U(44*PQ.^IUL
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MQKJ8AA\6T:%EKL;_9[G>WDZ9-@T:RC0.6EZ P& 6#%+!L6*P1L,'L2;PFOQ
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M#>W=HDC.-H2??&]T7JO!6.7 6BW-CY^XZ6*=#VMW4(F4YC)B/","&2  -)0
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MA!(,:A;6T7IL <*4>--#U'+:D7/5/K*7>5.Q=R,[5#R3BCJIC8'"":J5  #
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M.7S+:Z-,B\#V?D#\-FR8;\*/C4Z%MX4S&=,)(T& L58!R1QGHAZ5QR8ECO
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M4Y(P02V20>=@#-66D@]64TH(A0'FZVF1)&=CV)O^_S3J<>++[Y/;RK0(H")
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MKU/)?RAN5\^WIXO?\_M]>\*NHIGCQGK-E2(JV*L&85??>!N-T+6\+FR3 4D
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M1G6,][K?QXVM0_4R@X72G'$IB?(0",ED#: S)"E [J#\D=L5_'/#JT6(^_8
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M\<C$_X.DGIM#.J>TQ)@]FK/$_#*?>C:L@YT%U>PV@GR?1OP]?O.1F(^W/AX
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M6LQ O>$KX)JE#WNOO&DC[-R0\M/POJR0<NR!,#HYHW%JM3-6$E[/70A_84E
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M]^4\*29?BA_E_"B)WOQ\4,PY%>TQ!I!GQJM4"6D[-PTX99>K^>:+^Z7&VP'
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MQ?<$+"R@5%" K4X>I4 @7F/IB<D))AVE)_GH.-Z'F-X+Y;O<PX]^1T 08\>
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M0"&@<8TWLTX,^J([1%:&?DG8'_+G/WA_6Y0WJ^G'R<VAT/XFS8,4S%#$E2'
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MI"FG??G^OIQ?)1_R8OJFGVR+7D($"4)OL5$>6LCBGJQW<X/8Y;RJCLCFZXM
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M!A$![)G4M^^)%;L#'$. ?0+Z-?V-XIC9ZL;/JS_^H[B\+CYMT#V&?6W>%#S
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M$QUL2ZR4S5Q*B0=G<A2D)]U5PZ Z<A3D"8"-#&V#(J\V"Q()*U%$3BKLE20
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MY G"-&JIM!AQ: &&VCF)MQ8)=&=VU="T AVGU67W5.6FJNO>U%6U6E4794K
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MZK0L@M8*E@3B%>1Y!6K=P)-/C$2+*WN'WMUEE3FS)(H#< 2E,*!(ZRYM/WF
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MF(BWU]I+S'0W]7B;QH_\8IY=XN&SIO;/"&^@-QV[CNTMGZ_PK2,H6%_F76#
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M!P&<=SLG8H*:-$'M=D_-)[#]!5[SO!V$?=R'&I"DKJFDKD5 PHY6+F_'1K+
M3F:!\M[/67D?+$C\U9+XJVW (.E< Z7#MH&@^2BQOUAKGK>#A#2)IELP17(
M4+RK"M6\+O87<\WSMHOULW=#FL1OW9_ZK6A<(Z:M17!KGK>#Z+!Z<Q0!T0&B
M T=W[X<X8(%T;W2V=-<G^TABQ49BQ0/DP&0FH*/FI-VNAA3-VC %W74W0Z:@
M6S$%O7_'LW@L)'$\W70\^SXX<A^.AYB,=BR,:GZ-W;NA1)*<8<8L[W-.S9>W
M^@O.YGG;1;?Z;D@30WC\:D_K0$ "JS;D8JV#!2GT--\==0!0O*]N0T#1/"B.
M4!56X7M&KI?@H.L6.4GHQBZ*BFC+"H,)9A>$5>D>. ^F'?H04$5?47@[!KNI
MO58_($75O>O>_P$C'X)P8OL.NHT#Y\<WWXVC6Q3''H+H+?VI6V@Z(,=./F&6
MG6_,LD%D<Q7[S1T<M'<@]G] PH!&-_#/T'7@O^:B('A=Q.LFW#H.5-NQY]Q1
MH4KL:Q_L:_.[(Q\5M)=V^ /%Q*+6(;2:/T.!X_+B>6)#VX?0EMG0YG=\.+H-
M)3%J-V/4 =I7 M5N0K5YJWKTS)]$INV-3-N1W1_5<A(XMA>. ZR+DD2I#XE2
MNTZ[)39TP#:T^0CSZ"Z=)$/=3(::=_?+)::L<7+6W? ER$ZJ6>CHN$5I!^1G
MY*/0]E1_I(XFKN\"*],^2_-E"C)%'8/="L+G[1Q;43Z4TL^RM2,0ZB"$FK="
MVT*HBPVF&R%DB(MRE@/X30  SAO9H3,&'3+0$_*":=J/ERE0#W&Q ;U#";!W
M@0MQ.2UR.=V$$'$Y/0, R7PZ;D.:G[K9%D(D:FDH:NEFHDS@TB!<FL^)B'7I
M"%R:=T:[P(4$M#T"P"[1" % C^,+]=D.1W>O4]33B<(R>61J;WU3Q%LXK&XD
MP3L:=!\2F](XU+I'!2PZWMU2 8*F^U&:#PW?90FZV(6WM2D8Z *C>F#,@L02
MVW"+3;?MP2Q"K*:*1 =$] /0>A(!D-20Y +-Y@+-.X$-8(&9DG.H7\X@!<1Z
MZH8$A35.@4!A.,YB#13,R=0+7E%F1;\FH3.V(X3WM.L^#M:0-A00K"X3%;\N
M,.MZBNOP&3]F([0D<GT41:KS9^)&[FP&(H71E?LXCC%MG89-\7,M,U9A9HO7
MUK RQ^T2+X=2VUIMK A."4[;84\WPVF_XJI6U%O:+GHR+SLP.&P661%+T,-@
M98.Y5V()A@6'->4WDF@/83:&3,ZW;G*^^8KL!LZ" (/L=D3F;P?@)#80.9F=
M(5 @!4]2\&P33M\5OI"6DSX&+QND.R3G[7MJLP$(2 0[))&3L(6$+>W!*:FZ
MM*[JTO9I.Q*X#")ZW: .0R;P2(Y+RG*#F]I_=]Q RAT]C1KX%7M^:;:7*0Q"
M<;JIWB@-PVW/<"/'"Z($]$A[A3^F061[G\,@F4;P""\!9C[B,? ZUT_0Z!H^
M+-T&I70J@('\">2<E[:?/-A.G(1PSWQ<M[!V'+[E(-Z$<6UU<0Q[RC'[ O!%
M9M?^B,+XCZ]A,$J<^#J\1>&3ZY0C'E.W+@SS1NT&I("8\RIBBOAFD9K#R=GU
M09IPUUN[4US9@SLBDNN]BRDJ:T34@RE.C9#[QQ?T:'MF2L%<RK>V_VA/ CV8
M3((N5:* H/,E@G))UU$T%.W. \BC";";@4HI%Z_5C8O =Z.OD)I.; <EL>O8
M7D>"X'KMJ*=I:'DW$?O0S.(&\:T*OT,2-['OEV81][[9_^PN7 ^Y?E##$/Q6
M^NS2]( ;V6XWH+<F_%KFZYXF)(][$L$6'U8IU&)F9"[5(=G<]1D'43ZB?+U3
MOG;D@.6*<C\P3X3=E*7=X B%GF&MQ?;UG>=9$$5[;V,'"6F&IG*##VF:;Z-9
M[IWH!^9;*>R&*S?%A#*1=%^GE$DLVA?'..!8M/G:-DGZB*+U7-':$W>2I&]H
M*C?XI*\=7HZ$D\-1N0%[N?;,UMX"+$>)!^PQ_TR C$L4CX/1A?^$HC@5QYM?
M$;JR)R6%O+4G4>(_:FX0N1/7LT/U,40IES=2J.*J'GB>?1]DYK8TJ#MJ]AY6
MSGH;5_/RL/I07%XMBD%, &Q1EKK]\3JVGW_<C2%PF*:]5QWI)MO$.M82U]&2
M53F3)J:/F+XVFKYFT^ L/F L= \? ?]DE8V,8-:47[83$ .>+<FP[5#>R")N
M1.GQG"2[G9-D3UFELZ%DV_'3 E/8FPCLZ,Z:@&LP/@Z']W@9U6:>K=NPV<RG
M-86)>;"_O #LG<%^EL Q?[-]CB%B;H^8,Z^R-S'/-)GXB%[XB(/9@^4)!H*5
MSF.E?45U JY>@JO9J=&\('-IAQS#TB26:1LRMLR1N<-L<D F*HX^4=$N_\/(
MO_/$__32_S#R*4-O 2YYKUNIY%O.7#LQF#KXYX;Y-#$VAS0V6^$A';XW/%QD
MMB97#6)O^F%O2HDWF ^(::0])MX--1Q9MAO^P_82I+VJ481BW;.C:&'F/>\[
M0Z,[Y(S]P L>7V_24PX(ZO8_]5XKCOGT^QIYM#:H[T>#WGI]P2_PXR!TN[)5
M>>\TY(T$!J$3696?M.,UVHZWG+3N8>IFXQ[+CH>'[:YH';KCDB%+^=O:5+'G
M:N1Q)T%(>VWK(I@.M->V:Z$;T1*B)6W4DN8G-);W #KB^LYONI;MI7Q[IIYU
M0P$ZN/*R@LM#\0#+6W82;!-L]Z)0L_$>&B8KTHKMCS3UBN5I9@F_9".-=ZWJ
MKV3NGE!/=M/HAHO9HC&H0\!OI;";CY673R$FPFY3D:V1+<")@R4.MN<.MO$)
M23[#M97$28CT] 391URG<3T4Q8&/,,=*Q^_>H,?$L^,@?)V-*+0G.YAJ5JJ*
MM%=X7!1X[@B^<@3RO0H %O-?3,PMM_SP*Y2$[F22^*@;&I;"9CWG<GS5L^Z=
MX,Y.S]J-\?FW+7/^2'.Q^UP=E?4/LW-*A@K(KB!AJ3V8%K9J#X;A>VT/E@I+
M2 #3"<!(V_4/2WOM'WZO[U2GTS!XLKW92.)"MW2A-1PDGG0/GK2^NG]GOZA)
M/ Y"-S^,U D2/PY?_]!NV@ZTQ=1DF9"33SDEY]I-7X/_Q'<S^>8?7Y;8!-D1
MJ& &X?QZ\9CBVOS!^$EOGIIV>T:U#\TN;_G,)!I5/="- IYEI/-OM\:6#_23
M9:-8W)CS$/YSRT=&8SM$E73G@DVO;T_X5Q3>XEO+3QZY3Z ,983@.ZZ2"630
M8!5+NK AL_['PF<L/JCT!@/Y >3FM>]83>GB2Y:>55R:D;:2+W^_^><J0,#E
M+1GMC!]6/5#_J[7N@1_=EW,@.TA"!T79GV-DC\!@_/H1B/KT:_H/.\,*8S*:
MJ+.*P#"R( BJ(@@ZPS&F)K*:8>KT"=QD+]P(_Z"B^-4#B^FY/CH=([R8X)QA
MZ?_SRP,H^&GD_A>=,_0T_@5NCJ:V7PQ/KS[8$]=[!8\P!NL05]QQ'WZ$]^'[
MBM>67IY=7/L=4WLT L]]&@?3<W[Z\@NV.J>VYS[ZYPX8$A16O+?TO.)V#SW$
MYW1QO^MCLY_^77ZA'X03VUMX)8/'P"-C^]Y#E(,\+[_ZVPE]DOX-Y#G%WQ7<
MN0,W$5%7Z)FZ"2:VO_RU$SM\=/WL\^PD#HH?PO2#TE^>W5$\AM' C/L@!.&?
M.K@!9AJA\^(_RES!CTJ_&$ 2CR@8@@7PVPF#Y1^/\#_"V=7\@TNO6#'J"87I
MR=GYB^Z#. XFQ3=E?YVSTQ<J#6&HO]#I_WY9D !<7F!O^>_Y$V8_95Q@,Q&4
MI!K ISQXP?/YV!V!)'_)Y2? P#W@]O_^A1'I7Y: .^/)QQ0*;P"]'P#SJS_9
M"FW_![R!^AS$8]>AM"#X\2&R_>@T E(>EI^4_OF<?<M]X(W@T=^N+NY,@[J]
M4^_,VT425Q'1[$??FOJWFXN["_.64J\,ROR7_E?UZK-)Z=>7EQ>WMQ?75WNB
MA-T;)6PU)?^THS&  9**#QG*C#/]C&)I@5<V)Z&,*'$=HN2]D217DV2!T5S4
MF.R?X*O\P$_=/CP7>Z@1PXDL#P$XDA3E]/G'J64[\:G,2+*ET@8O&+(@Z9+&
MJQ8G&J;&Z*K,L]8)Y=LXIA\A]]P(G 2'CSAW ^N;Q: WZ&$AKS@HM9#I_SZ3
MU *)G\KD'^;EU.88>:N>'7**>_)X[%J/)\[]W?(EA=_!%Q["UVUN:-70M3WJ
MF^\ZP0A1E[<U-GJU:H(ZSE33X 0P3*RFZ8PD\"*M\0;'JX:J*BK6-K-*-7]/
M(-=$H?=Z@Z9!&-=K*?6 @17_=N*"("%+!QX&WKWM>4%\'[Q@+ZQ(O/A+G9:]
M]<ZUP@'F'T0RRQ \IB/Y_9MZ<V?>?/E.W9A?KV_NJ*_?;FZ_J5=WU-TU!?[R
M#IQB9I49CKJ^H1CAI]'/U+5%W?W5I$K^=.9+5?T.7V84CC]$Y".4^)G*@)>W
M"M:VX!A=ZZ>H>(RH/PN 4EE1@T)@]T;4'JUWS0?\^O8%SV,W1J?86"+ ^'-H
M3T_6:"<[UTZ&82R!X25!$1G!H#F5DUF9%7A#YSE+L=@J[?R:DFQF!9[-=/,<
M5R,G,' \LE]?$:3A_LFGOR4^HCCZ X7O6:>BAV;L%FYQ&9*;9).'^_#K&^+0
MB4,_M$/G2R9#UL XR((NRJ+ *JPLRIK"ZJPD"J)J<GQEK TPCUS<8K,7C\X3
MCUYM#.YNU*O;"^RW.^+2E<;MIQY,)FZ$YV HRP7#=956X*G-\U!(.&>Z81J*
MIN@,+RHJ(UBFJ2H\QV*O:NFFJ2A"63?2N;E7_,[LE0?+11?II4]!E@RS)O_L
MFA1G\G(GCU04.GBJ-'A$OA<\!C;#G/UG^GA"V5Y<^7O^13EU'/9CN;G/M?LC
M//6]=2%V<V,KBG- J;K*6YJD\KPH<#(ORZHA2(I%&X+ 6JS\%E WZ#%M4?1C
MO.[RL 4.MJ;6IEU<?S:OJ(LK_>S@=8ZZ;]@BH%LEMKV5OF;EF/0IYVX,+W3@
MT3^9+R#H5(Q4\$"%,_%1=D1%4^3@B>41!:]PXXARQFGB\?.>:I5DKJ,^4.36
M!HJ\4A\I\BLN2=L$D4<(4QJPUYN805F>F4%%H&75U$5.I66P>[PBZW!951B9
M83E!X-Z:0=Q&$4[3]=V!GS9ZZUD#A0YA\!;A9X1OQ:T\^ 4X:S609S_;>!;^
MW1'H ?.#^B!TKP9MQ3P7 ?0;0"MS0(NT+K(< S\!?"U.50Q991E-81A54U5+
M>POH._OE(N\SRA8KK(T:.>Z49AA6Y/G-L=IH4MNL'TZ-!!6$%#P!$H#_)*$;
MC5P'LQH<<ZW#;?2CW;*52[\]?+1]][_IWS\36]0.JAL \\79S=GM&65.IE[P
MBIL\VXC>17M&705G59!]=XU!WB([76W!%9:;67!-%PU&EE165"2!9@1-44S:
M%%1%Y'5%U\VW%EP=C4(41?F_OL G,T?*^5E6H#37]]$K=1N'",6'GWVN<9,?
MMBBL*.S<7_*Z0>N\Q4B,P@J<QFF2 @DQSU@F>%">$VNYK<-_7H=WP;-_)%[K
M]N0^=$>/J!L\YN:(9FA9XQB35A5%%P2655E@.:=8DJ#(M")4%*]R'J>>\SK\
M"E$R.*3#U1P6R;Q4&^/P5@R>@YBV&)GG!5:V=%Y0)$D6+=E4#9U3&)HS+;Z6
MP5\#2$.\?[O3U<G+[B2??*)9AF>;9^A^ZAF'^]"?MI \/R_C*9PETB:8,/A_
M014E38 @WZ ER=(UC>&DLN2QQ5)#9!]*UA54B8S4F.A_WK;O2Q&8&5\%S=)E
MF5-E$0R49HFRQ!@R+1LL"[^*-%/F*U[D[7T=!_YQZ^VBI)RR-$UW0;>VF=D^
M? R;&[\/%#@5+\$?1OW7G5)X'O,#9?LC*D8>FF*!4MFRB=+(CA1_;=#SG*"%
MVN___8O,,M(O$34-@21W:GL4>D%.@O<=@)$0,J-HBQKPBF@XS<C6%GT/9F)/
M/MT"66&Z2"VG'X5H1$V3,$IP$3P.*!B1Y@<,^]/]SYA/N -'=>+S@@$=*E_O
MJ38MKJU-<RNZ&)@5EZ3=;EMQC=NJ9V+BCD8>ZGJ!\.33G1M[Z80.LITQY>!#
M!EI2F%A>][ Y$[9?[-!_,8=VZIAN7R?@;G]:-LI#$7*INZKG K_*YVE3M48O
MSAAOU$.!=WJ&V\<E%[93<;T?7-IM>H2A&7:>,%FF94F\Q)N"(7"T(;.<RB@T
MK>B00ZNR6@[L\PCBE6'O4ZN[(K#'S3X@J]LX<'Y\H/XW?0:!N4!-[9!ZPD?"
MM'M.CQCNQA'*SA&J\[0E2:;"L0(GR)!Z&KPA:HRFR:(NB]9"13+W$IF36 %/
M[>)"(Q@<H%^IP.,=)#E7=C2R_Z0^>\$]9("WD.XZ,75IAS]*%?Q#3)3D^1+'
M'C;UN_!'>.X'4?>OE#-&S@]J K2!)T7I#"Q.\TKM4#\Q>:EH;$?4@^M!EFA[
M'HS #<4X>?PS<7'J"!GC/<H'P(/S[''6]!J$>=-KGDB6\D^S<.>07.++N.F5
M&L%5"/#PT&F(')2&>PR;/2]=TA!1/\%#'^#_HP1"@&@<X!:M8F5(/+;C95*>
M[<7OQ1^;W9Q3\W-6X/B)+9%\CQ"P/;G_#P8!W)2.ASOQ]^0/2_>$2;\D_5P[
MBBF%SIXPLE^C\^P_W_YS\^(;0_-S$ZC2EB5JFL&8NBK@UE?+XAE>I 6:-7A+
MJFA.U),PA&_,FL"Q18SM.(D.4]'^CJ(=:VYK3-5;GE4]Y)] 'L9*]/8Q+WOY
M@&T^9OLP-VB:2<$[RUNMM&%8CT&%)VX<@^:G]CP,?.S.O%<*@6M[I2ZPIP'M
MPI4^PX[MK"M]R;K-GU$NE-TD'LKXSD-4"P8LWXYJ9OYN3^^HG_!_2K^P''N6
MCP)"T\;2*6XL/8J]RSY_9L%0]/->3)-(SV?G%4F7+5-D98T75(%615H235XP
M)9T6!+/"-)7XCMF>6RIBFHAI&H9I AM@4YX=0OAC.PZ8IA!O()>J9XBCD<I?
M*8#N:>6%: (V#=X2%JX>%&D"E+U^P!$8/ Z"%=RX_4@]AL%S/"XNGT% AM)O
M&Z$'UT_7C$782N$I$9;^I>X+T\O,+\6PM0/JOZ\8B .PDYJO/,']^-C<@F6\
M/V6+6+(<0)YO#I*2Y-C.->3O:49#6#NCP7(KYAA6=-NON,;*&SVR+2L]]VT@
M-G*JBC!SJBPOLXHI:*K(&0*KJYID,:)JL!JC\[2J,M6KVT(=M/ Q"%^WZ+K/
M]BI,%=?)[\:]]U^JE;_=)9,5ZT'7"'03/SVL>E"3PDN''-)?JV]QW7H>K%G1
MO&KQ.9M+.U_/O<-L22N5=H=X=B&$RN#?4OEON:#]/>(GUJS;UNPV"[ S^F=1
M=O9G'D5W@"OO!O@F,1;#,Z5I)<%B6465.543=$W2= 9WBAJTH-&&QE8TNJ>,
MUI((TH!H12EU[QMK-&J?^ZZIA+YNTW=,2VM6UR@ZP(GC6%=QOC\+:S*TR?$2
M:RBXL415996F&5EG%=I4&$MY:UT+YGY.>:L7Y9_C6ME.3>H^K*CNX0[MRJ*D
M^U U59).D$ VY ?I_$82995!H";;;R^>;2M5S#[@60G\+N\5O_S9A5?#:RD?
M/>.R8XB>W"C-KGS;=S"X(/#&VP+@P?A(BI$=CG#3=8#W>J_I0N9^LG^N*OB=
MK=W^[_@EY?UM.+5S23D:(\\KY$_]!%)-"[O9EB;S&:O:.NK/9W4S"]]1M.-,
M$2/-38(B"IK,F9S,@$F@+5XV(!ZC64%4&9,63+HBX,(4O=L2O!7*JKSH +-$
M!YJ>R1Y[%6SV^ V]^?LK9&TUE[C-)UN]@L&?G5!1J($;10G.H/*U()7-BQF?
M9AV,'Z@@B5-+ADV:G3YJ[R+^6^*]9N]EF6+WSCV_XD,Z9[SWQRX8!RN=[@6.
M+EN'4LE;%"S#T@5!%_&^6Z*J"(Q%TSPC"+P.443%FMA,2JF0TN-1HNNY0!:M
MQ45J+!C,398YH?!I'>GO^8$M8"<=%W*["$9>62=4!.$:2B=IRANK G9&09P/
M/?G$"/('CN$^\!)3&(V"S.4@8V],S5%[MIO"+6T^7U-M&]Z$V*&.VMA/C)]3
MEM^S=%K'ZE2O!>=L+!P<,P[GR'I$I_<ALG^<V@\Q"L]M[]E^C3"+Q^'B.3D*
M#WF$P$J<)'%XMV159&A%LWA)8!5&5=)-9G<Y)R=?<6B_3S&KM_ZGQB$V+W_9
MY./?;QQJCA^X2[4.O!(^30^W*\Y$9Z\6T\YKPO>[Z2KH9Q">_T60(%X4JPBL
MVONP4P18US>7>4Q.G_Z>]DLP["_4;$]^*NO>["AQ>6_LG)IL-W/*W/<&[AM]
M#MX"/>/U?!_TXW[!CJO#F;6;ZAQ$L(PCV-*HTJZHVA<3[U2L7U_=F5=W6YQ+
M-'^5LJ]O5FI]TX9]0(,->];ONKEBTTUYU1+EYH*E3:=3]PJ_"AUI:X6\*VQ8
M/*6..<HI=:ML[*$9]=4N[6)5/?%7TML:WC6QW>?!&:/>W&4HNBAJ:5F05'#K
MG?%[]6MG\;ME6JHL,[HE<K3 RIRLT[JATHPH*:I!J\HA2;<NKM0K_4+] A$N
MCA35N_+)>78M4!J?83Q2VDE([2.IK=BF^Y!N\N3318PF%'.VC9P/1?,;&O=@
M3N?6D^-4AM%,1I)44Q 5#6\@J1BZ(K FS_![M)Y@+&?SC.D6B=GRS)\2WTY&
M;HQ&/]?8S38H5K/:U#\+0DCM(ZFM0G(C,NVF#^ YCI4U3@%[+PF*J:BL*0N,
MQ#"*(?(ZP^S1!^@!+M'@KA/XKS1?3!O\2PXA>*#P:143M)A+%*7*._AHE*Y&
MNW5?J,L@78&;E2L73E!,A[ THVSK58X0NBQW?C4C4X$D*(34?I+:*B031[2Q
MT6)965=8F6<LA14TBU=T4]<9G@7+I5NJ*!W;$>&VMA"-81S>?R)S2Q3Q2(<2
MKD@\$B&UGZ2V"LG$(VULM"Q68&1%5'B1TP3)H!6&8U5=-'B1,071% _OD33;
MLWT'4;=CA.)H,2E24R_UULL8R$&XB39OIDC;4@?K=]:+4")^AY#:3U);A63B
M=S8V6HS):*+.*@+#R((@J(H@Z S'F)K(:H:ITT?/A.QH3%D@RZBZ+$=2GU72
M5"15%G5>55B+%EB3E6E5,S1#EL$'J2IOG'R2B0LBI/:3U%8AF;B@S6<0=)F7
M%%UG-5X0:,G 1Q_J',/SJLD9#+N?=1%;N"#SS\2-7TGY[6#B5(@/(J3VD]16
M(9GXH(V-EBYRBJ$)LJ(RG$!KIF*HG"5#_,SQLB*HVAY]T%40HPAO;5'CC*JZ
MUP;J2M9+A>&(+R&D]I/4H70_LP/H?M9,6C%%F4FWM>!D,&LJWK6&H5E=-71]
MG]W/E[9O/Z9N8[:%B>%&3A)%>-,-G)RHONV]1FZ:[,R]#79'V:9.>,P-BA(O
MRX>NIWB+5+PA_$#=T'KA\:3';5BV>4"D#L4-<0-P0SPG2[RE*8PN&H+&6:IN
MBHHDL):A,9HI['.VYW>\@Y\+&0SN:,,>!7[PBK^Q0_*"*,&[;JGW05(<KT?=
MN-&/@7J9];*16.)E"*G])'4H7H8?@)<Q:9EG==HR=)H5%)E6>%V33,Y01,LT
M!$/8[X1.' 9>E'J8KV'@H!%V*@-U(>L9+ZU,5-9O*W%\P\/21[0\@]]7HY&-
M-43(JW7&E$5(K@7 KR88&FLQ-*_RM&KPW"%IO[[[JWE#-M48>O@Q(%*'$FD-
M85,-PV1D068M6F=HP> E559YDP?#J1D2;^PUG_^"'FTO"['2PXF'&F.M9[E$
MEI<-RZ(.B-2!.(]\(UYU "[$8DQ%E#B+X21+L"19,WF1UB5+-!1:8:1]=K[@
MXBZ%]_</PJ%ZC_7<)MYC8"9U0*0.Q'L,HJ,%K)7)LAQMRK(B2)*F:JHJF(8D
MTSS'2;*Q1YY^\[/3K5"(>_5M#Y7;]&^1DP *7935@+]%Z3$'>9XR5#>S7C@*
M3]P,(;6?I [%S8@#<#.<P1BR*2NRH>J"CO^+934(H!7!U#C=W.>6@>;+V+UW
M!]MLOY[3RF:3AVQ[)@^)43WL-&FMJ+MI;&1=,RP60B=3D 6&US7.H!E.4$U=
MUGF9,?=H;&Z!2W8\X%Z%];Q6JBLAVY[*O+E2;'^N97906EE71O7GI[V=XC]I
M[,O9)0T?[7PDG\"H+"^KLL&HC&!QC*I#JD&#*"5&5G0N/4^1',E7T7EPD"/Y
MRG8@/2RL)/DCG_EV=7UG9M[DQORLWA@75Y\IZ_KFG_"?IU^NK_^._[Z]4^_,
MR^W.#2N3N'0<6AIS'_<883>BPO1@OO2,6=OU(WQ.[+,=CDX]N-O-3C@O=A>(
MQW9,V2&B[A&^,K%':.&T<[S/0'H,.EZK,SN0^&OH/N'3OTNECB_PK\=T40YU
M@_#!M/C,;CR>412!^@G?A0_QSHYB3P\U3C&&Q\.@X!Y_*?X"?.D>^>C!C6>O
MP\T_+/W+K?V J+_:X7V0GH7,,K]4?%IZ /O=&$5H%=D3^Q7>DI[ZCH_O=M$(
MGV0>)<Z8>@[PT>]V5+S5=B<?BM<5/\%W.^X4GK9\Y1YY+GIZ\[,3)-YH^4<4
MQ>ZDXAGH98J<>/E7( 8Y=O3F]\? ]I9_2UG[YGU \_)/4\_VW_P6I')Y^]1I
M$$4N6(CEWY]=[\W89TQP\1NN@@7IN? Y;^%O,.&35&:1"T"W0VJ";"S_,XP>
M%"*\[Y\;97@$^$]M''$D>"" <H5@0_0(5^#'\T7]W>JTNV6%+FOD\NEWU%ME
MKCJLCLM/W<LCJ6WJ MOYY(5 3,Q>NC?KDDI4W'KU_1H*UI_ZO#<"L(68:^^(
MLB=!XL<?*-!$#"2,3&P3X#?\)\ S!&WV$Q3]DEI3^!'AX?!RT-[ 1Q^H,'BU
MO?BU!/*I_9IA,0&3'U*>Z^!=E/W'#U1Z_B%8K]1,?H W_9F \<IL8$@!B[!)
MP"$X93^&*$/T+U1LOU"@>^FX3'EFG^*XV9=Y'E@,^][U</TY_6H'@84&R$?8
M1J)3>XHMI>V!+@$]<1"^XMNBU$!'=CH, G]DAV  \1M&0+873/$7I./2MTRF
M0(@]6Y"941N!"J7$P>>@$-Z0\G $['2C.,P6UV"+YD?X)<!O0,=_[<+N@Z6R
M_4=L5<#B1@B_!QLZ@ (%G@6;@5>XVQG#($2%;O3C%ZHPFR/JP7;ST^[QH[+[
MT]=[;L:+E#OX!Q>,O!NFU.!A492Q=MUIT<1H$*,!3\H<<K;@^ .%?68&,U"I
M"%_!7L>S4XL!SBE5)Q@6NDZF%V'P'&=:Y=F)#PJ&XYT$/%ZZP P;(?PL=XHP
MC?BAH\0AX"3@W-RC9=[K Z J3O?I+TQ>%H O&N,/.$2"0 K[@ ^4E_90EGS7
MO)LR S7 $S"-X8H=II\;V-E@0#F*[3!S?SCL3#U1 L_$%X%OKU1:N@&%P&XL
M/>\,_KMDA-,[P7+'7N;O9IH#^A%#E @_I!I5:-PDP'J8O@#H ]^:WI'JS,SN
ME[UQ_A2B3D2=-B$@0WF6GGR@2G]!&!+C."[S =GOP<,# )#"."Q"L\Q78*/^
M9$->4X(C: ,^7SZ-S@H%Q+&-ET3N$PPB""4(W=3@CUR(\./<Z.9_S V^?OV/
M"^.442@<8X/EO@>$^6!O,ZLXVSOE ]P+Z!NE&706M!2!.MC<9#KU7BF(O%W(
M5  ER0,\/0E3/[,Z58 \!^C!_*/BT+7SI9!H,O6"5X2()28XWQCGLUI4"=T
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MI=.86"LU:9,'V_,R89]D)MP1E&X/&!>%GZC@AS4S()0. 5D(:5'3:16%J4;
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M)X,(2+)&S*X[<+:W1$%S <.WAL&=Y5$AJ_ Z14&QH+07 B1(3:U#\3_)@I7
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M6!F=\S5Q_0M4_R*HQZ+5XJN9ZW?..&R/#5@8]:(*G6M0E@"R1"H,SBGCN S
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M[\ AQZC5#>2+SIO-SUW)V2I9-BR9\,9494H$8&>(LL*9J!<DE@&B57$!1_W
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MAF2K&0>923MET@_CT56\JN][O:M!D=S0X=ELQ^Y5*M>6$VQ7H%56HU4,ECE
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M6)[@+:WPI!UX9][.O%TK_Q(I>S(=%]/R<_R*BKBS=[UT8CI!M9"9C$PMB7>
MHA+G'"1G@2'$@T1*T&8)R!]K2SQ54"*MI$V_=^EMHW9+Q.7\]$ROZZ577,M%
M0S0X .Y5Y%=0S!HM)!=!,T.)BKCL HIM;C-KMP!TYMLU]73(M98[(UI<BWA1
MI+FS,F)91G03HG5TD:T-(!1!(.UC$:\(Y3K09T/6A9N\MDU@N=;R%I/P3G9G
M(+B6;Z:1DP9T\)&6P6%IG!;$I_*(&'DK'UV-6AK'+;9H:'=I*G=H>,0&O+4.
M#3]=3V:I:C\_6(,YZX?N@NNX%GW3RDI%C5%6V5G/91R,(<Y@%*)_@!ONP2.%
MW%\KQ$ZEVHR>#=MEEW(0/@N4Y_V,6D!/884\UPSAZ%98PK5%BGN+K-51KZC&
MSM55S$1[T@03N59QLF71A>T3%+/G3S=T..\/B^%I/S=T6- &[HR-SPT=WDR$
M\=YVUVEJ3W@]_M[+I2I6] L(H#O"YX(;81#1*8=..FTTH4)#] R"<0*>"DA\
M+*]NQN?HW(XN+T?#XS0RG39@WT-$M5I'-@O]-V,8W_YRX+/ %A6PB5/.!66#
ME:D5K%6>"Z(<1S9PQ=6C->-> NPV.SP@$/LT[VG=6:J_F7[U6M#]R>0Z:OQR
MGL439V":0;W)13$NWW\J4E3Q='1Y50XG\U+2Q7B<VLO/OJ:5]O$[K1$4KC+W
M&&%<8(^8,> -DPP;R;QFAG'B'NCJ=#.6'^=#>3(Z*;[]LS^]N(B>7+PM*;T@
MC:%)0VAK(]AI22NU3[)LR+(ARX8FUBFNL,ZY,C[80+D!D()KCX!:YCVQ.$4$
MN\-ZB]TFZ#[/2F)GE<2]-.!/H_%X]#6>7$[Y73X3B5)2+21**15VW 5@B&@.
M6E!07%#,K0U/I_P>W BZH_/?1L//)^7XLNOV4F0OGEJK?D7.,,H$O>8%.@H5
M/TM/"1?22!TPH9$U'; ;^%&BG^ZPNBC\\AZ:G27/C^757- EGSMS9QN>-!45
M>C&B0J/(H#*B%I!1RFGFO*,,B+6BL<7U;C@FZZ-,O <M]WS)SG+FXHT']Z)<
M7(N+ 0:3$$UX?!0,55YJXPU/7= !NT:RS.)HS@R\LPP\RW.Y>J($Q>1K<97Y
M>&E?EM6"7<1;BJ7U7GKFP7O+;?)EI2) 4@'W!;/Q73R[+T7JQW8PG$S'U^DS
MX38]:=V)LMG9S02[D6A=%)^T6L-V6(>HDR$(J@-R7A%CYOAD3DKWU!IV*_C,
M-+RS-)PVM)SUXVSI?[J>3=/IJ!='+\V0\6@P2'FG_9OF'9F,ER?C6B8:<T@!
M#BJB//[FT@!52'L<B.+<\R>*NOW>'X[B//X^6VE*"T_E>(MVM&:*S12[9HJM
M[0LCUJ+ 5=!1\D+T;I5/9<^9-]0:0?03#<$70]T+*701B<M:E;B93'.EB V"
M\'(T6MO!12)]"FRT1TJ"H5Q*RX 3*ZEPSIAFI8B:4*[IY]F0=>'$/IVCM<Y=
M7)EY-YEY=W(K)M0+.G$0'AMDD&?Q4?1[#1%6$Z442"^?3+18"L@M)F#A5A.P
MWMAVS+=0X.&FIL.#NS ST7>WF RDWKM,@<,@@0@ ZYD![5+3LH!5=)TA++A7
M^]4BU7L LMTNA;FH0U82NZ(DGK44M:I3G$O&D-<4VV@I*#:,*@]8<@A4:=1P
M\E>Q%!TX_&ES6,LMS'+UJ3=3*V*N3?K#T[0_O.S]%*?-[%&J-S67+*DEXNQ!
MZH[\)<Z\7 !Z-1%2VV9JD)*<&J-3*6C/E3:"><.%HX 5<XVH?;(KZ7]?#<7'
M,BVSG$[+L_2&'I[=?Z'VR0_Q(D;1$,T'V-T,M/]V.KA.]S0^N$@[ #\6T]*?
MGY>GJ^?)+6*>@)+<;#G+E+S4\)"I4*CFKV@!PDOO,0<7M P\&@D9'&4J*.4V
MS52T6#I3\59+S6]9P&,;-<5\4J1\N_)FJO12&XG>_/&D-\K:HHN5#(YKV3]>
M680UMO%5<%%H:$^\-,H+AY@VC>R\^9 =G=>Q?32\,10_F(=.FSCNJYP?D$E[
M R&Y* CKK1:5BKI><"&Y B:9B0)? F"*C146-W+<5P-ABTL0NYPDL(V$:Q]C
MT[W>I_)S?SA,BPRI#-Q%V;N:B;N\SM =#=?:,E*AE78*<88 # 5MX[L:86FH
ME,$VDG!7DNT_F(2#F4E@[6P$QW0S5ALR<6\ <;_-18'G8,VK-0%)&1*$:2F5
M! 1$28:0)QII;CD2C=7#MF$M6X$UWB.$Y62#G9$"97QU 1'P@A&F<83/1M>?
M!N5*V%_9VG=._'_NXE8]*Y(VTEPNIXD4K7*S"!!B/'(HH%0K5U&LO>/!(M"2
M$-&Q\4RQBE8T$96LW6#%TO,EBZ+N1-'ZK>$KDD<G9FZCK=F"]DO@JHB7Q!I9
M);@FR *73GHIN"7>28&]48TZ).W[=&W8+[PG"-UGZ[1?KZO^_CI-[5GO7I_]
MK)U.G#/E^XMYUPQ,T%_N35L6YVCM?$_+M'OQ!6>\^*Q\_$KRN;9PKL=EV2M.
M4^7C8O@]!<6&HVDY2?M3HRJ>E!%6Q?59?SJKCCR,[#*ODSR<>3&SRLHW.;O%
M()Y.?&&6*+[?N/C;>_+CS6A>Z[NG;U:'MT+^ )39SXOQ[7=?%9_+]Y_&9?&O
M]\5Y/--?BL'7XOLDGL%?+\8W%UG,S.2$6<F$LI:85)=).!5$2I1C3'OJ,"'I
M;XI[=V>Q2[ZQS\6*=O[JH98XO8MQLIY_FBB&/ 4BJ! 4F+.:8Z1,8")Z]5@K
MT@[7/'@.?SM)%BFY9#;9^/KB9]&P4X]-J<;]>Q)/I+5)1"I7 )]"(<X>ND!S
M</1W?]@[.+3[/7WH>L=_F.,#=Z _'OCCQ2W&)EV1/3IT_O#8NUY\='STVX'3
M)_')\4G\];L_/#GN'86>_Z\_#D[^9SLO\*<[$[B7<@#C,091%DQ^WLBK>3'Y
M+$(VM;^_)]_1+5GU$S/,G]</,$QB:W"/WS":B]N9].B=EH/!S;O_\0Z]FSV/
M)WYZ^_R!^W'2OXST=%A^[7T<718-9^>R&'_N#^>G5UQ/1[<OS'VGV2M?^V?3
MBU^4V@?.F:!*2D:CQ_V76[D6)\2@N)J4O]P^^/5'8?;N+G)V%R!F\.[QP-K\
MB)C_Y==W#>4X?X\^_A9N^ZW6C[75)__$6VR-QQ)K/!9L\XU:Y[&> .Q6'VNQ
M>[BI*P2MA3L>EJ +K0?R35H/;/!VU[?H0_04RO&X3//BT>9Y;ST,FN?"7/[/
M.GKEB3!O%3H>?>TNT^\%-G/MTT#'4TO1TF(P\S^NBOY9] IFCT^+J_XTOIXG
MQ\Y.CM/3Z\OK64>?V8P8S0KXS.;&Z/)J7%Z4PTG_2SE[93":/)+QGJ?*#DR5
MC^6TZ ]OYDE9C%.>YJ[/A]T6&"<+-&K>F:GP$M/0Q;389--Q,IK>J _3'WTN
MA[V#X>G^[/FD5E-P5G)3_#JW+_^^[D^_YRFULVQS>*\$[VQ.W);AW772R99F
M$4OSJ 7)P;/U[H+;Y.DR*VF;[<EN#;J^'%T/'RGFOC.#GI&^@X.>D;X[@YZO
M+U_?)E]?9J)='O3,1+LSZ/GZMOCZ=C1:8HI!:J"^U_N]&)]>]"C>ZZ7=F%T4
M>7S1YN-Y.&^6KKOXAO4?-Z:)?6CK]LV_JMIF2S\5MU_\Z#8U)BG%)::(5^VR
M#7%6<&:TU."LUL1[CJTUQDM%=;-BX"RUY3@M.\WI].AZ.ID6PW2_'MQ%B__O
MS9_^W^/;K3!^%B",WW0U&J;]#/I;?W+WJ;L\JMDQ?B\O/Y7CVD:VV;+%9(-[
MBBTW45Y["VZK6-DD*]J%\>QV[#NW$4MMWUVA",&;,IT$JAV^,A#&#0;C+0@K
M-$6!,:R\,XP9U:C:-#-H-RNN<Q-X,+RIE?IA-$Y'T]-Y,\RT#^1D='\A[N!F
M#6X=1G:SNS9F"[M5%C;+L,=L":TJP$F$P%%MN54*%+'&<L4D"L"$<?'S:Y=A
MM0.LI,$:_>?P/LY&(AN)+,.R#%O!=$)E.H71*)I201AXL(QI:;Q'U#+#0_1D
M&Q[L!LFPIXSLLA5;4+:OV;YF^YKMZTKV55153+5 7(,CQ@<.P(-!V" M.;,4
M/..-'@$;9%_UV>T&K ]%_^Q@:.>[KK*MS;8VV]IL:]=D:Q_M]79K;)6X,[;@
M.##*-?)8 F+6 ':@C'>&6*2TW&1C6VUHG#7$MO5MC/&L1I?ERPSO(HWA,%.M
M=J%HMS'<=H!WF:YQV;AGXYZ-^_-"FN%*2"N*2'S=NL MF&C. 8+C@FC#E4:Z
MT<=S@VS[[0YD?[/YN#4%C6&/"YIE=+:T>=UH8<'(:%5FVEA*2 C2"46C.7$2
M8:0-550Z(/Z!CI]=+QS=;DUO?>F(T'V9E5Y6>EGI9:6WD589*JO,D"-6&X>\
M :"&:.*P#]$L>P>2H4;GIPV2>D_;[Y4==K*GA%B/WLN&/!OR;,BS(7^IRRZJ
M)E1*&1; T:  @Y18.Q<4]8S%'P$W._AMD!W_$(7V<-J>HT[V@/'UM-W.CGJV
MK]F^;JU]?58HJTHH(^=8<-HQ(0,P!LI1RI76VK/4*J;1)6N##.S#7]W!$A?:
M1UDN9[F<S7DVYQLHEZ'6\Y IKPGC6F%!0'JA&.>8:*>B=>><K76%JR7-2W=:
M\^["'O1W?SLLI[W^+$'EM7EB<[!_MY^OO1N2/;=7H/J%B_WD>9SG\0;/XSQW
M\]S=UKF;;7">QWD>YWF<YW&>QWD>YWF<Y_$:XY.<LFJU"8#!_V?O79O;1I*T
MT;^"\.S$Z8Y0:^I^Z8[=B+K.:D^W[;'4<]YYOVS )&QQFR*UO(SM^?6G"J0$
M2I0M2B8ID,B>"9E7L  \^>2365E9S'."<.3"4>T],R1P&0BBT:[--KV=C#\,
M9K^.I]-[.49?YQC)WRY\:PKI3S@C^ZFK EN'^!?\%& 7_!3@&'#<(1QOIK=4
MLYJ=ZHBY"2($:;FAQBJNO$!!Q8BU5'O06]NN@@25!1;>=0N7*^W#4]Q$N/4N
M&DVX0TS9W (W$..,,E[;W5OX-LKPOF'Q@ITR,'<P]PZ;^TK+ZT@]ER:]HX7D
MED:%3-0TVL"C=IBOK8?8P-RWXI4%$J?\J,VT&Y58=>.@A)25SD'+RJSBAV%"
MT8\GQ:B:%>,/Q:S\_-)DUAX[A@ 3_!'@&'#<%AP#=@&[AXI=X&# ,> 8< PX
M!ARW <>;K:E6*RWAD!*>R)RBD88;XXS0-"IMK&:,NO6&[5_KUIO3-J^KV9L/
M%^7G;65K7Z1),,6GLK4KJ#<E%5@D#<0##A0<* 3C@-W.8!<X&' ,.#Y\'&\6
MQ.B5PA)#(L?&>N*4Y(I;DS>E9YPQYQ!C&K]D$/.<HC*(4R!. 6YYL2(631IJ
ML49R'*6DABKN.3426>H#58Y)%6AX26K9<37;GC9?!HT!/-!6C<&::C8JO,4<
M64>TX\%$[8A"5DN.N/ 4LZT2P5:% CH5(!2>(Q2Z44;G!]-%V[QL +-Q,;KC
M58K!TJV\-(&VASL@S@8?"#@&'+<%QX!=P.ZA8A<X&' ,. 8< XX!QX!CP#'@
M&' ,.(;8#K![^-@%#@8< XX/'\>;U$PDH*^48PF)',+(!1>]$8H88KDFW 9"
MF8VWC3_>#P;O?[Y;Q' SVS08]?+6TE6_6OP[SK.I;>GS]:]J,NZ7T\L5$X<R
M"3#]HS7]1\HD"%XIDW 2^X"5QEYK[IC2#%,9E C.<AN#?FG;W]=&G)*W>"/.
M5E== -\ WSS"-Z+A&Z.E5BBJ:&@0D4K"!5MH#20I(7SK? ,DT0:2Z$9IUKOJ
M>C[I729,YBYFO?'5U3@?=]S[HTAO3.?E:)8KMA)>"U_U:A]6$(1U<7Z9)&ZQ
M\O6WD_''27EU4I2S=!RHYH(H'5PGX!APW#X< W8!NX>*7>!@P#'@&' ,. 8<
M XX!QX!CP#'@N-NQW68I?8J;EI3$*,%U,-$ZQ2W!-DHJ!4+((:F(5?=76E_D
MK/U\\N4\)T;KS.?4]/YW/IA4_0UF#?/GFT3I,D]:3QGF*8/_OLFKYK3JPY]=
MS!T^<1KRSIC79A^G]4D\JVF#AAD%F'8$_[H3CB+-9H5!!.0BX18%S9E41I)
M@Z.2,.(Q7MO*[(Z]_[T<SJL;BG+C7'XPNQP?*ED]M[T,.5%(G6I@*V K8*L=
ML!53MVS%!2(A<NJ)BYQ(J@R2W!G'!#;<Z[7>-0?-5EO>Q15H"F@*: J2%H#C
MCN)X0W>[LI-Y%$@DIQ&\8)1[@XP6*F"+/5:,1Z[;[6[!9T)IXSY*&V<)X%G,
M06DC>&#PP."! <?'CN,N8G<S]<A8,_VE3*"<:X<IUEPXK5R0*I# O$6<$71?
M/=:JL?&'?3/J+YQKW\\GZ;J\3>,<]\^74THM3=JX6@# ;%A;1&B7::KK[G:C
M]?Z,-^EE:Q6/"BOBM>%>"*L#(9B%J+0DP7T[O;SDJB;2-5?IBLX.DJF@@P!H
M'B"3Y^@?N3*USCD5E@?C3'ID<"(1C6A TBMFC91'Q28FW;I\0<KAVW+0/QNY
M\GHP*X=;R\0)!+M$@0("TH*$ ^"X>SC>S/ER+%?::1"AN:%:1<.=HB9)^NB1
MB9&9@,C:=F<'[7S3>,O!J.J'<C)*]W"ZQ?DOR=0I <<+CA<RI%M)-W!ZAZ,\
M(23% B)RPQ)7"4HM95CG3=G8VO3Z421(#WW! .@?T#\MI1:.FTT>J0]>($JD
M55Q9;!4V"D4I;51,V+6-I ]:_GQ'6?\FS<WV6 0$Y +DTE)RD0VY.(>"\(YH
M&@D/0EN-E68(6>*MC(8<%;E CV7@$> 12#8"CKN"XXW\H4#ZUA\BYZEERDK/
M2(KCD;51,&\9BW5LW_*)/G!JCY%!-PK9SZ:Y6+VWWJ$WW8EJLGP\OJZ-H1SU
MFQKW1?7Z]3 =^J69M#TD LX0G"'@&'#<%AQW$;N;"3E!F_8"U@=!B8U<,6Y0
MM 8+$:DCT@:"]-JD<2W@LM]\: ;FGLH;U!_;UNXOVRHS[Y:0ZS(!=-V1;48&
MLBD&1P$SR[3$R'&.O-,VEX,K@XCV5/FUSDA?(8-Z&?2+<0%$=$ $0 3/( +=
ME&GX:*ARG/C(-3=*&XF\U-&01 _<Q(?7L;T$$>RZ!AOC4PRT +1PE+0 @2[@
M&' ,.&X+C@&[@-U#Q2YP,. 8<'SX.-XH5)9JI1)"!(L-5M@:PRW5VEDKL!)2
MDO1YU)Y0><N]=2$R!A8X6A8 ;P8X/@8<;^3-U,K>&$Y[):6+$@7+)=;I/XX4
M<=):K)AUN_-FX)*@*N\)57GEIW+2KROP7IKRVF/MX+7 :P&. <=MP7$7L;N9
MXE+-RD+KN;#2<HZTYUY231#7"G.EA0Y$\"<5X-5OOJD+UJ?A<S7I#:90@ <$
M (ZLS62@Q2T9,.>\M]X1BAB7SBKB&1>1\[S*V$7SE/#KQ;@ "O" "( (GDX$
M&O-;(M",&^NT%XHKSBQ)^D :(JPW(FC%?6N(8.L%>$ *0 K=( 4(<P''QX#C
MS3J5:LX:F6NH(51C1DS2MBG>E8Q1(SP-5&$A56N\V_=U&=VDTQ8ZI=!J]#&$
M0:M12*R!MSP.[';=6P*. <?'@..-5!]%J%E='!WU!%N/, X<8:&)%H9X$QG6
M+,G UJB^YU1*@M8#K0<\ _X2_"7@^'O\)9,K<P!2*FX,H1QSA[TF(E@3%$6!
M"B.>5(OY-'\)3J\%3J\;Q9Y9@E6C:5D;PZ0:)GW6+V;CHBXH^>E]WO.CN"Z_
M9,T&K1;!*8)3!!P#CEN'8\ N8/=0L0L<##@&'!\^CC>IL:/I4;-AF.(IK+9(
M6,ZX#LI2[X6B5C%C!=/B?GQMAL-Q+\<G=:V]S:'):O02/N>'5:L*ZS8)T)D^
MY5!C!Z1PE*0 S@UP##@&'+<%QX!=P.ZA8A<X&' ,.#Y\'&\4*!/2%&X%@QFQ
M01%*#8]*VA0LQ\B8E%@)K-:6J.\W4-Y5M1;$Q< !1\L!X,L Q\> X\U\F6B2
MOH9;39R)CEG"+;=&:8\9L]0$23E;6UC]G;X,'!*TM[MSH/K9IZH>Q/OQ,%_M
M-[-TG5Z:U]ICTN":P#4!C@'';<$Q8!>P>ZC8!0X&' ..#Q_'&X6YE#?]PX@4
M!CN)%.6!,REM,$1R&[ UD5J.'UP[=)GBD6HR761;ZZBD5<5,T"4,3+][I@\N
M#' ,. 8<MP7'@%W [J%B%S@8< PX/GP<;Q0.LY56&E@)AJEFS$;!L32&*8DT
MDR'P=%"Q[W#X>[?BA.@7++T;E@X>"W!\##C>S&.I)H&KHN*4*"FX5SQH8B,*
M&EOA/-$.6?F]'@O<#E0C/5B-9,MAWGSSI/BO^:@J*#HI,F:><T?'DP3&FY.F
MUY^+_GC^?E@5?T+U?]LU]>6OY4_@]%/3\7#0O_VE ^,!CE;J%:FE 3&K3-1>
M*9N$*^>:*J90D ROU=ZO;,RTV!+NS7PVG96C?+WND<'9@@R>JETGU8=J,JGZ
M+=\([MGH>QZ20#R\5,KQL1O]+#;9*3AVSC+_]B)TW15V)HU*,P1I@916A NA
MG4XJC=7L;(P.1#^\3=<=E78VZ@WG^7*]'4_RKYG9;#)X/Y^5Z=)?C%^/1YFR
M)^-A.JN/9XF\$[G.]L'C[1"%0.*[(_%]&MIW7!)0D<_E*=JLX)1&$TDD$\*X
M1$L:&ZIJGO*:>&?6]A7=N8K<UE["]Y;(8$5.,1 0$- >"0CT)>C+K?(V7VD!
MCQG6&'LOK5=)4U*#:,W;,1!NO&VQOMS*#M%KO>2!W('<@=R!W ^6W.7*%(]5
M43/!#/<AQKPCJA*9W#F1@@=,6DSNAU7/#SP// \\#SR_SXV<$I$W6>*HK#>8
M8.TUM=0EHK<UT3,K/(H/;W?=$J+O]>97\WI7GKJ>(']L4EU6H^G@GU4:U?BJ
MVG[G+:SP*6J% UAGOYWAN U;3H%G <\"GJ7=$83 C6.1S%!/F*364RT\QXSX
MVK%(KHAL=03QKIJ5@U'5#^5DE(X]W5J."+,3)L2I;(7_@ "B*S3?W6G(QY2P
M($TUF]#."2%,#$@+PF+ W-2$I6/Z7&1[GX>\F%3E=#[YLO692$)/52LH""0L
M<!M(6)"PK7()K,F"VQ"M%P@3IXE6TD5J<>T2'(Z88-IB#?MMY_'=:1!RHJ5L
MR8PG>!'P(N!%P(NT*1$B&B>"(J*,&>P=T8)+AD@DM1,)) H>6EV'_9UKP>^G
M/_ )10K2'Y#^ '('<F\ON3\:(J@FS:T1CI*KJ"25P2!)#*W70/*H,--Q;:/>
M%K'[PX?>P93IEO>&@$ ! @7P)>!+#L*7/.)*)"+-C&ETE*-@7'2"(T,-X8$C
M:F+$1CF+]NE*MJ/VB=*GI!74WTZU7[?Q^$M]>VY?K_^N#"?=J^JGRT4;#$S0
MGW]9&5^ORC=Q]??(MC!]<Z3UD</88&PP-A@;C W&!F-[P;$]HD:>,+;%D<ZK
MJBA[O?%5.N"7I!"+T7A638O9N)A=5M,J*<(RB<M9E3OFC?IY:\GZ4:VE<A%V
M\6$P*D>]03E,PUDF(*:G!W4C;EZ^/];UH;WZ]KGL\#;I>T*R_GLYN3GV=?FQ
M^NG]I"K_^*G\D$;Z<SG\5'Z9IA'\Y7*R/,G-1K[LYE9^WZ@?;N567$YR;/&G
MJ68H4$XDE?46I\X(C+2-3'*BL=%D*U?N*^WD+K+P+L8?"I<CH 36VRM;KLGQ
MKR'C)5&\#'%PCY>R_V"_O+,W?PVOB[/7[K0PKWUQ_KL]/_-GYMU9.&^E73YZ
M1N[-:Q]>GP=?I$?G;WX]\^8B/3F_2/_\%EY?G!=O8A'^]OO9Q3^*GXH?\HT=
MC.95_\?#/-T?;CGWI$A'3;\Q3!'T=%MGL\5X]GO'L/+].SDV=/UY\?U!=CF+
MYZL_,,H)B.&=M!%&B^QC'5<7O6HX7+[[[Z_0J_IY&GCOYOD#YWTQN$I^[W7U
MJ7@WOBK76LA=E9./@]%B>.5\-KYY89'ZK%_Y-.C/+M.GT\DO,P_I5@_+ZVGU
M\\V#7^[G&5[==O2\;4C+^*O53,'=AI_+WQ!__N7F0_??HU]_"V_[K:W_UD$/
M_AMOL3W^EMSC;_%#OE#[_*UO&.Q!_]9FU["CG8LWZC\N'NL_?B?]O9['WFH;
M\C5/O>M+=-OT,1U]W/OC&=,#1]!.%K"PD/GUVAH 0@("?55,QI\6CQ_;H&#'
MG+EW&#2M7.J(X[H<]%,<4#_N+;JZ #BZ"XZF_4.-B''N ;' QFHCB/J5X7@Z
M!:AT%BHW"[IK+%3+5=T=QT.W!<;-\BB0&$^DAEW HLW4<3&>+=6''8P_5J/B
M;-0[K9_7"["7Y5=U8SCYRX)?ZE(L@%1GO<W=.KL:$X-EL5W7G0XPS29,\U4&
M@>39\S?O.S:X+'J. )]TZJ:;J_%\-.OX30=+[^!-!TOOSDV'\X/S:_/Y@2?J
M\DT'3]2=FP[G=\#GU]%LR>TFZ;[JU;T<"HKS1NGX_L*!O?<(.**%VXRL;):#
M."4N1"J1D Y'*5G,/4!D"%HK8O'W=8[%^F_L2/=!/ZS5VJWJIW'HCJ*+33&@
MY\6".C6[I<[@#<-.*RPL,X$C;&W,U!FQX,0XN:^>%]LGV79L+P8,>Q0,"S+L
M*UQ"4;.1.!;*\(@0(]S@Q"+.(5US"?5<&[FVE=7.9=BN-A+7:KM;4 %)' 5)
M@ P#&?84ZB0-=7+#5#16&1>58B9&PVE-G=(R@91KL0P[@+V\@5^!7X%?.\>O
M3#;;:2,CO!32L&",]9$A66<($\\2;/7>N@0_@U]-_Y"VTP:J!:H%JCTZJGVD
M(SNCHMG'3P6BM/7($<>BRA]PJ.;:O(E3%'MKH_L<KGV1':TIWVZ37FB_#N0.
MY [DOBT=K1H=':C0P@5+$8U81H\Y77![I!21&%O,[;O;5%J<,,Y/&<AH8%J8
M-MI0,#*$&\$HF)6>4(-MT(AR0TE.?BJ$I5"<[7_>Z& V?@:E!_P#2@^4WM98
MF32L;"Q7FL9<!80HLIY+5N^]C-*'L):FQ5+O\/9>!B('(@<B!R+?4LB>B+RI
MRHI"6RR-#%%B230RF-4\+C F6K4Y';OM[8_I"65T/[E6"-2!7X%?#Y9?'Q7*
MHA'*(D:/K?2(4(2HUIC9A5 6)A#L0XL)=E\[$#-0RZ"6@<V!S=NIEE5#YE9G
MG<P)]XQRA)651 5G*27.>(/Y/LE\2Y*7ZBY7TW9A$?JK_WA=S8I!79_RTGZB
M/;9_6]VXO0L"@=L+N/J-N_T C@''+<8Q8!>P>ZC8!0X&' .. <> 8\ QX!AP
M##C>8WY2(-KD)PVR2BCJJ.":"NVCMNF!1CX8Y2F]GY]\.QE_&,Q^'4^G]W*,
MGB""_D;^<>';4D=/3C3#^YF=!UN'^!?\%& 7_!3@&'#<(1QOIK=XLYA=(A.,
MXY$PQ*P/*B[U%B;$"J+6^F-N7V]MN0@25!98.%CX2O-PK;D2@4C+B!*8&,Q<
MK"V<.B(\([NW\&U4X7W#XKG<SZ)#,'<P]Y::^TK#:X]DU$CCZ'W@47"C0Z01
M$^N4<H@^Q]RWXY6UWD]36:C$VFDE5MTW*"%EI7'0LC*K^&&84/3C23&J9L7X
M0S$K/[\TF;7'CB' !'\$. 8<MP7'@%W [J%B%S@8< PX!AP#C@'';<#Q9DNJ
MU4I'N&!Y>BJT"RQ:A+Q69C'KXC$GTK'[29JO->O-:9O7U>S-AXOR\[:RM2_2
M(YCQ%C>.VY148)$T$ \X4'"@$(P#=CN#7>!@P#'@^/!QO&$0LU)80@CSP4;%
M".?((.6%J M+"+&66F)?,HAY3E$9Q"D0IP"WO%@1B](-M6"O)>>$2.\)R[LJ
M6:EJ:J%!$"?6NA3MDUIV7,V&H9@->."H>> QC:%Q4\U&5+)V;3PQ)K"@,-:8
MU$0@$,ZZ8ZM$L%6AP/93[79\0J$;971^,%VTS<L&,!L7HSM>I1@LW<I+$VA[
MN /B;/"!@&/ <5MP#-@%[!XJ=H&# <> 8\ QX!AP##@&' .. <> 8XCM +N'
MCUW@8, QX!AP##@&'+<!QQO-^7.\,N?/E/0J.B1#$ $'Q9Q!7%.#F4>"Q-L-
M?=\/!N]_OEN-<S-M.ACU\A;I5;]:_#O.90%M*@#:I(1 <B@A@%I#X)N=\ UM
M^"8B[1067DIB$2/:(HZ7?".PD&'K? ,DT0:2Z$:=T;OJ>C[I729,YI9<O?'5
MU3@?=]S[HTAO3.?E:);+CQ)>B]_*],$B;\U9G%^6DZI8^>[;R?CCI+PZ*<I9
M.@C4)8%.![\). 8<MP_'@%W [J%B%S@8< PX!AP#C@''@&/ ,> 8< PX[G9L
MMUD^GZBFN:*02COIO$$L:!FI\\'E?'XDQCBE_/TUPQ<Y93^??#G/6=$Z\SDU
MO?^=#R95?X,IP_SY)E&ZS)/6\X5YON"_ZZ1JSJD^_,'%K.$3)R#O#'AMWG%:
MG\&S>@^P4PQS"3#A",YU!P2EFSWW6,#8,HTC4R:@**5'=8&#YP1[+=:VZ+EC
M[W\OA_/JAI_<.!<>S"['!\E4SVZ1<D*D!JH"J@*JV@5542QOJ0HQ$UP0)%BE
MO8H,<:5KJF*:4D'<\5#5EK<A!8X"C@*.@EP%X+BC.-[0UZYNQ2V4LX1P*H-#
M3'BM[=+76LRL$2WVM> PH99Q'[6,LX3NK.2@EA%\+_A>\+V XZ/&<1>QNYEN
M9+B9[U+((X^C<]@A(K0F0<FD&RV*(5HCXWW=6.O%QA_VS:B_\*Q]/Y^DZ_(V
MC7/</U].([4Q5^-JUP_37VV1GUWF*/"UX&L!QX>/XPW]+FOR-50+ZI330D?+
M*=&>T9ROL90:)-/C;^9KEAZWR=28JW1)9^WTMR;=MWPURN';<M _&[GR>C K
MAUO+_4@,BUC!\P)C@><%''</QQMZ7M5X7LV5#@Q[$H.DR'B*7:P]+\9>28N/
MQ_.FP9:#4=4/Y624;N!TF],M2$&\"UX7<G+;V;^.<]00E!=.1*$""A['%!\8
M1W.%I\6(.:DI/;Z4W*'7I(/R >734EXAZ)97K'))ZWBF/$7"I0]H1FOA0[B7
M!,GC$3[?43F^2=NL/5:; +, LT!N ' ,. 8< XX[BN/-E)Y4MTK/8)0B2D]I
MC$@R9:B3"Z5'%3-8KD60+5)ZS\E._:N:C/OE]'+%XH]8F76E7'?CUJ.^ZM70
M@8I=\(_@'P''@.,#Q3%@%[![J-@%#@8< XX!QX!CP#'@&' ,. 8< XZ['=MM
M5ILJR<KNA=@3*Y37R"D6J<,TU*LQN52.6?OM+A[;[CYZDU<]E&(O3$X)E*1"
M22HXV!V0%-7-EH?.4"\E#I:X0!4)C-0D)0.W@GK[,JV&7H2MGEM 3T\D1[!L
M#=@*V&HG;"6:JE=)12!&2.80HC+0P)Q;L!51@0AU5&RUY3ZD0%- 4T!3D+4
M''<4QQNZ6]T$!Y8R*U@DQ D:O%72<5^[6R-5B(BWV]V"SWQ9G]F5VL:-6Y%"
M;2-X8/# '?; @./CP'$7L;N9>E2\F?^R6B$F#1*(T$"IYA2KQ?R79 J3M=3R
M?EL?["AILZ.&I# =!ID;\+?@;P''7<3QAKY7-9D;3:)CDI(8@W2,,4]U[7L5
M<LXJ_NW,S<X6C>[(YYK^CIN2"G"^X'R!M,#Y HZ[A^/-G*\FC?-UBEED/:;8
M8:F(IAC7-55*(N2I__96J8?F?'?6EY2>"$E/%3A><+R0G=N,I![C*+;"48F8
M5 S("^Z-0!$[R^KDG& 1&?O"?4FA6AT$4&OX! 30)MPB:%-3[K'E+"#BO?4(
M,65B7:6IF->$XW!4^F?'[4GW6($"Y +D ED"P#'@&' ,..XHCC<1>P*1E3UG
MO9+2.JLM0PX;08(@M=CCA(L43[9;[$&'4NA0F@]T-LV5NKWU_J3I3E23Y>/Q
M=6T,Y:C?%/@N2G>OA^G0+\VD[2$1<(;@# ''@..VX+B+V-U,R$G>M*OAC%GO
M&$5$(9[KAV+>J2QX*BC6C#TX(Y#]YD-3 /=4WJ#^V :R[B5K;!'L G2T#-!U
M3[89&^BFTX(*BA(9-&;&..>4,E;6;" H0M+Z#=F@7@3Z8F0 (1T0 1#!TXD
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M@0=$ $3P#"(@ZI8(A$M/I6?>.X(Q<URZ4!.!"@HK;%I#!%NOP -2 %+H!BE
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M"MBJR721D*[#ME85?'VS^:K<9NK@>U%V/"NW@)6 E< [@QV '8 ==-T. /N
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MO_]2C.YXC&*P=!D'E\R :6=P)@"KSL,*H 10ZA9#05H5X 9P [@!W !N #>
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M*OBL@R"1(R2.QWB#-+PA(HDD6".-I<8JI7R(RTR-U]:N-<T__$S-@91Y@FX
MW; C\Z>R*<WD3G&#9! ,&14,\THM90/#QNKCD0W?49JYR1X>VY[Y!O,'\X<H
M%> &< .X =P.%6Y=J?W:N(U4$G4*JK[:#5K@2( 5P*KSJ42 6!LA=B#,!7 #
MN '< &X -X ;P W@!G [MO!@HQ(EC1EN2@VXYD0CKHWAW"!NO5=1:DU(8(X[
MM]<&4B9GH@ZAJD"<<JA)ZAI3'*UCVI UN+AE#1FD%HY;9@3E#"'#B' LXD"H
M\$KCEUE0OU_Z>'81_@G3^%0 ?P!_=(L_9%/A9*R7P>C((@L\NJA=C!I;I+'2
MW#-T'/RQY;910!Q ',=%'! 1 ]Q:YZ<(7M&Y2>-2S["UW&,GI:.!YLW>0@S4
M&?'MZ/CE_!0XFQTYFZZ4#FW<-@I*A\!E@<L"6!TGK%H,I9VI']G,#7C.:&2"
M1RPDUUXKY9P3R'DKN"!L3?WL=QGBMJ/U'36+@JF"#A+'@?BCW:QE3/%1D^FS
M&@E.(L="&1Z%U<Y0K9R1G"E%'IDIV-E:QGURQ\81V+^JR;A?3B]7U "L7 1C
M?VEC?TPQ4-3D2Y)%*Q9Y F_4R>29XD@[C(+2FB<C_7:C[8.Q=M/?;9LNQJ#!
M)-#(T= (Q+8 M_9Y+=9X+6X=$1(I11GFE%*M#7&$($D-5L1_>R.C@_%:.VO1
MA4\8$]!8LGL4<H2T\1AKB(8U+,8ZL&2D!GE.@LQ=NH(FA 0M98AKS?T..SMV
M(*6TH!A ,>S(]!6Z-7WBH^!(F!3;8FZCL1([SZF/WE/)U LUZ&I1^>LFS;FV
M7V$ Q@_&OQOC9Z@Q?DR=H^EE:R/FFCBEHY&.:J-XBA5>JAU]VVI7(9D-=MXJ
M.X<L%,"M=6Z%-KMS\>B=1<$B8QE6REHC>2XUC<AJYO"W2TU?SJV ;^A4:>C9
M-)=_]M9[RLU'_6JR?#R^KL%>COI-U>BB,/1ZF Y]<,DD*-L#IP*PZCRL6@RE
M7>D339IB4&V5]H$B;SVGFNN0%X!;QB.C+JBUL+?6)=E=/)3?OB=>!O7'-E K
M>RWD/$J9T@$[/1#ZWY'-<M047T:F,6?>>>)S<Q=BO;2."X<49TRL3VQ_Q6;K
MA6PO9K+=#BO 7H_=7LG*E#(WG,>(I&&&*R:-P9)HXGR()#@36V.ONZZ U# O
M!,8+^6* &\ -X 8A/T#L>"$&C 9P [CM*=@2N)EPQ5%XB03FS&$N:5114T01
MPX)8E:*PU@1;6VXC![$5V"JX!H!;=^"VF6M8:6],+7;,:(*I==J':$04BUH<
M@FUP.\R; []#/<U:/4WYJ9STZ]J9@XM2H<8!? # JO.P:C&4=B0G)&[ZJ!EB
MK!:24QL03_HA(51I+P.EA%#*PI-*9^HWW]05EM/PN9KT!E,HG0$[[13][\IF
M5Z;B58S*R4!BP(@S2I(!AQ"<M0QA%NF3LD,O9K)0.@/V>LSVROBMO3(6F7<1
M:2$,5XJ9R#7B4C(A Y=H;4GVB]GKUDMGP';!=EMENQ"" =Q:U^]+*M;X"D4<
M0UPPRSQWV"E!#:4JV/2*C\ZTQE=\7\NNC9IPG&+HV]4U*C@J\P=OTT:(':VW
M ;@!W%HG;M1*'PE$$"/>LV"<YT)A[:CT*"\BT2DD#@^W)7P)<?.<LB:0-"!I
MND4 X&\ ;NWS-ZM;.2M&*>-<:>\-BYP3AQ:U4H@:(S?M"_ ,?P-. [:Z_-[Z
MJZQ-JM&TK%$^J89)N/3SWI;U9/=/[W.?YN*Z_)+%S'/Z%KT?3_K5Y.;,\?7G
M8CH>#OK%GU#]WQ%6T3QVQN"56N"5 )8 RY:D&P&* ,46,N2AZ78($P%N;2O/
MT2N;I1 M#)9>Q-PQ+F!J)6<$T\"PXD9R>3]*-,/AN)?%>%WT:K,.7Y7JX7-^
M6+6J)F>3,)/S4P3E.6"[X"H ;D<9N^W&E>!T8DVIIR"2*NT008KRP(F5PB#O
MM""<L+!>OK-?7[*];?9V6=@)04A+X^%#,U_P)FV$&(@7@!O ;6_BA#?E-]1'
MX9@V00;,O?#62V01,L)[C!A96S>V7W&RJYH;B&O!5E_:5L$U -S:YQKTRI)B
M3S$6$C,9M7.>6>27.WQ)C[58JY3Y3M< _-[-HI;ZV:>J'L3[\;"?CFS+86XR
M=%+\UWQ4%12=%!DEWYTVH->?B_YX_GY8'7GV">.FWLUA:CGRAK! J%8AVA"Y
M9EX+D_X0=M^*5];G+QIXO)G/IK-RE*_"/=L]6]CN4S7=I/I032:))EK=MN-1
MZ( 7;D4)QJZ->O?5C/^VRVMPV#Q&&S7"\[*0J+#P28QD%F.1UCRFM5&8/]SC
M\#+YDVHR7?#1V:@WG.>+\'8\R3]G9K/)X/U\5J;K=C%^/1YE<IN,A^E$/IXE
MFDLT=']'TITP7@L3[$!W7:6[]M@^;[:P-]Y@GI>(&<>U]RAW2:EMWW$7"%ZK
MQMBYAME6W[%[80M!:JO-4,&H.V74RX/F3SQ_AO2(!,[SKD=[&% V#&BQL59R
MI 03,;UMO+0U T82D/)K#-@B];.5AF_WB!)M=?G3HUC;BF$!AP*' H?NFT.5
M;CH-!.:B85$IGX+)Z**-+'.H(<B@:-L<06ZEX+<UH230*= IT&D;Z?21A?0X
MU[ V&U(%:J2V7'(C@\-!8LMK/N5$(2M=F_FTUYM?S>O5TV]FR9#RQR;5936:
M#OY9I5&-KZKM%YT03D[U/GEVG7T.V&([VB@&*!LH^[L4,"&- I921:FI1SI*
MSE3>JEW4C*UY\(**%C/V]I8IW.^D(DZP(J<*!#"P:6O8M$6"C]&F5C@ZF[2>
M9H1SR81%PH2:/KP2S/&UGO4[GX:YLU?=5B=BZ'X) 90:< LHM2-7:H]SK6BX
M5GJ9=^_A6C,J;1)J2)',M18KJWVKDY7?9N7O#Z-/M)3[G?\!>@9Z!GH^<GI^
ME)U7=N00EGHFI B!"8-M4LD$U>S,@R41/=RTNAWL_)PE==\*GQ,=[SNO">$S
M<"AP:!LY]%&)2U$C<0TGAN4U*,$9Q$*2N+9.)UC#3!0"MYA$'S[T]K4N YT+
M.A<X&CAZCSJ7DH:B$7>6(.>2W#7.<.DBPC5%>^^U4 _O*KPCBMZ26&4*YGJ6
M"XO_4M^%V]?KORO#2;>D^NERL3 7$_3G7U;&UZORO5K]/;(MM-X<:7WDSQ[;
M(U?O"6/[ZE6%L<'88&PP-A@;C*V58SNOJJ+L]5(\6XZ^)+%5C,:S:IKWCIE=
M5M,JB:LRZ;2\G4P27_W<J:5^5.N5>I>9#X-1.>H-RF$:SC)&GIYNZ63W(QYN
M7KX_UO6AO?KVN>SP-F%\3ZW5?R\G-P>_+C]6/[V?5.4?/Y4?TE!_+H>?RB_3
M-(2_7$Z69[G9T)=-7,KO&_;#'5R*RTG6Z7^::H8"Y412*2EGWAF!D;:124XT
M-IILY=)]I8O,15:WQ?A#X7(TL;HA4KFF>;\&C9>$<6\\'$]^_A/N\5+V'VR3
M<_;FK^%U<?;:G1;FM2_.?[?G9_[,O#L+YZTTS$?/R+UY[</K\^"+].C\S:]G
MWERD)^<7Z9_?PNN+\^)-+,+??C^[^$?Q4_%#OK&#T;SJ_WB8I_O#+>F>%.FH
MZ3>&>2NY;9W-%H/&[QW#RO?OI)C0]>?%]P?9YRR>K_[ * ?SPSM9%XP6*;8Z
M>"UZU7"X?/??7Z%7]?,T\-[-\P?.^V)PE1S?Z^I3\6Y\5:XEY*[*R<?!:#&\
M<CX;W[RPR._5KWP:]&>7Z=/IY)?A?;K5P_)Z6OU\\^"7^\'\J]M&7K<MYAA_
MM1J.W^WSM?P-]>=?;CYT_SWZ];?PMM\BVS[@00_^&V^Q/?Z6V.-O\4.^4,=Z
M4]H'@)8V+-QZ,OT!9[Y15U'1IMTRUKSU/B[3;3.L=/QQ[X]N3M(!'AK)7R\2
M # D,-!7Q63\:?%X%^V'G\"?+P*%ILM!'8%<EX-^B@OJQ[U%PP, 2+<!TBS;
MKE$QSFNW%_A87<!=OS(<3Y^S S; Y7C@<K-FM,9#M5PXVG%,@."X69X"DN.)
M%+$+:+2=0B[&LZ4:L8/QQVI4G(UZI_7S>G7ILM2I[J$D?UGP3%WV!+#JM.>Y
M6]=6XV*P+&[KN@,"QMF4<;[*)"^:9#NF_7C:CH5%UP0@C,[=>',UGH]F';_Q
M8/$=O?%@\=VZ\7!^<'YM/C_P2."1NG?CP2/!^1WD^;6T!FEOFZ;ZJE<W(B@H
MKC=.57O"P(&O>U:ZZ>_#A5(146>E5X*S(+&KMXI@GGK.,?_.3I?J;^RH-TUM
MV6+G8R>\]AAS.YLZ'#]W:=ST; B61VZ<4=02*E"09M&EE\5H*!=A;ST;MLYR
M;=K=!BBNHQ37'ILGS2;O0@=,3#"66V>2F3-J=;9Y3B*E3JQMQ;)SO;*K#5()
M/D5@S&#,H%<.F[O8"G?E;=ZC]MQ[%K".7E%7<Q>W2;[P_6U*LEV6:]76ID!P
M0'! </LD."$:@C-&6"0#4U9H+SV)IFZBQY5!Q O?8H(S_</;=Q2X#K@.N&Z+
M7/=H4V>M>+-1?411"AR4<1A331U3"[*S#@M.6TUV+[(I*$.G;(LDN$X-!VQO
MT,(9^/3X^/01.L4(B94]E@5Q/LKT(L,N"4:ZU(Y1(>/"_GKD/YU.=[EC)^$2
M\H! =8=G^X]IJ;S#>K,'G.4^[]++K,*(,T0<]=GX!27.8$+WGM4_E/TV000!
M,QS,_>VF"'J<"%E#A%[):)7#,N].$0CU6M73FT(D943%_K:AV#9EMG S3.!.
MX,Z#N;_=Y,Y'J5/@6^ITT3*D5.1<B&!U"B'%0D.:/ %!;(NI<]L[5=(31/6I
M@+ 1" X(KM4$][@X5(TXU%9JIA'6U!+GM.<2J9KAO-8L6-EBAMO7-I)JJ\DR
M4(A H =S?[M)H(_Q)T8KP77$'"N#@PY<88VDL+5"E,0CYA3:)W]N2^;A#LB\
M+BQS?/4?KZM9,:CGWO=$9-LSWO4[>O.5V]JG)Y\1!!4'VN8!8-556 &4 $K=
M8JBGJU: &\ -X 9P [@!W !N>TD!$4)N4T!$2XTQ1=$%&6DD2(7(-8M4."60
M8_=30&\GXP^#V:_CZ?1>&L<3A/7?R#\N?%N*1<F)1N14;S$;!#;9R5@):/\X
M(':TM ]P [BU3V7(9FD@IT@A9"RFB@0A>-24UBHC2$Y06*OBW+[*V')%$6@+
ML,066"(0/\"M=<1/5SH2>FF$(40+P3B/WFJKK*:14D&9EYH\@_B!O;M7"E O
MRB_N[/2Z+ TH?LB[O?YX4HRJ63'^4,S*SP<77\)<'/ [P*KSL (H 92ZQ5 0
M\ #< &X -X#;DY9 L95&(9I;J03%405LJ$EPQ75FE04=F)%K)?Q?:V^60^[7
MU>S-AXOR\[9RKB_250V34_[2*YXV-7Y8U 24 ![H .$&$ .( :,!W !NK8?;
MIIIZ90M P1 S7$9-.)>:.Q$5SYJ::X*%6:]6V*>F?DX= \AFD,U@]0]9/<>-
MU3,4I-4>I>A:6!UE$+&.I+D52HJH7]+J]]4MI 4-R8$$@ 3V3 *4K>ZF)Y&G
MA@2>:$ $0\C"]4<>8J1K?7>_BP2V[+^W6<]R#*;;C=*8Y;X\-<;JUBL9XN^_
M%*,[+J,8+'W&P>4S8.H9O G JO.P B@!E+K%4)!9!;@!W !N #> &\ -X 9P
M:W<8 ! [#H@!HP'< &[;FGUY;/)%XJ9+A)*<.TF]15A+C[P2LIZ!E0@Y&L+M
M=@[O!X/W/]^=$KU);P]&O;SK5M6O%O^.\_Q,6WI(_*N:C/OE]'+%% ]_ 3*8
MZ-&;Z,K\J*7(>(0)U8Y1I[3SP=4F2@1.YAI>VD2W42CQC5E6=DK!9L%F#\!F
M>=.#PVD3I56&:1>9P-(1;6N;99$JS,W6;18,K5LE".^JZ_FD=YEPD3MP].JM
MJ--QQ[T_BO3&=%Z.9L5L7"3,%+^5Z8-%1DI1[U-=K'SW[63\<5)>G13E+!T$
M2A7 1X"/ %@='JQ:#"5(&AT'Q Z$N0!N #> &\ -X 9P [@!W !NQQ8>;+C$
M2FG=I".QH40XK3P)A@AOE<4Y':E\I%A:<W^)U47..,XG7^K-A^NDT=3T_G<^
MF%3]#68-\N>;'-,RQ51/&>1TYW_7^:C\M8<_N)@X>.(<Q)T!KTT]3.LS>%92
ME,(2K^[1Q=%ZIPVI0Z\LT9:6>14R?=@8HXS<2)VI0U.N;?!KS<[N6.+?R^&\
MNF$.-\ZS@K/+\4%RR'-G53320"% (9VC$-K4&$7+N76$16N%0-)B&>O][K12
MR)K CX="MKSC#7 '<,<Q<0<$QP"W%KHJV:A=JHA1'$>'N)4L:.:CR:[*8&$9
M>B10?EE7!?YF)_ZF*^5$LP3:K&^@G CJ/L!W :PZ#:L60VE7,H@@TLP7:!VU
M\R@@+A0.2.@H?"V#O-,I@L?W95 M?QH_T#>C_L*C]/U\DB[%VS2T<?]\F89O
M8^3N:I<'TP<0OW?&*4'\#G!K-=PV=5RBB=^YDE9929,WDS(R%(01V7'9](9#
MPG\S?E^ZK"9R-U?C^6C63H=ETJW*EZ,<OBT'_;/1LB?EUG(!6)]*<%W )4?"
M)>"Z &[M<UT8-:[+IZ=&!QR$181C)+UGM>L*RJ@8P_&XKC38<C"J^J&<C-(]
MFV[-9RF-3@DXK:ZQR!$RQZ/$01KB0-08;W-;%RJD9"9]JF[AXHAVBK(UXCC\
M9,V!5'N"<@#EL"O[I^K6_D,D0EF=PF 5363!Q!!J^Y>&I&?R>(3#=U1H;K*?
MQ[:GO\'^P?XA4 6X =P ;@"W0X5;5PK -NXGE42=@M*O=H,6.!)@!;#J?#(1
M(-9&B!T(<P'< &X -X ;P W@!G #N '<CBT\V+!*B3)R.]G(-(E*QZ!)B(%*
MJ^FBEX,/+'A#Q5X[29F<BCJ$N@(%RT"Z1Q5'ZYDVI0TNF[I\03TE%"N/F-:6
M<KJH40C$8!8(?9EU]?OEC^=6-9(3S.0I P(! ND8@<BFR,F)$! -3E/AE=26
M,U3KCB!0D)Q\>V'/P1#(EOM' 7, <QP7<T!0#'!KGZ-BN%&Z7IG .1>$<\NY
M)]*(A:-*H3+'[(7ZI3[JJ,#;[,C;=*5\:./^45 ^!#X+?!; ZCAAU6(H[4[^
MR&9^(#BAM O12,PC4\SX6"]&C#@2K\T+=X[:=KR^HZY1,%W00>8X$(>TJQ6-
M3#7)/FLLU1IQ%&,,FHD0>-U^+@J.N [?GF3<V8K&?9+'QC'8OZK)N%].+U?T
M *Q?!&M_:6M_5#-PU*1,+#?8*$<T%09+[;66LC9W(P5!A!V'N9O^CAMV873*
M038 D1P)D4!\"W!KH=]BC=]2Q,=Z'S02C([,^<!U^A]"B E.Q;?W-3H8O[6S
M;EWD!%$!D6[W..0(>>-1VA -;03.O$3$8"><5#P2H5E-&XPA(ZDZKA39@=34
M@F8 S; KVU?XUO9-]#)P2R@+WFJ?B(#@VO9U^I?'(\EL[;A/U_8+#<#ZP?IW
M9/T"-=:OL24&1>&(-2X%#T3:6%N_EY@:O^;Y#]/ZO[>(%5+:8.BM,G3(1 '<
MVN=7Z,IV73@*;C5F*JE*9Y"("&6_@HGB7-$7VO5D)S6G1^D<NE$C>C;-=:"]
M]09S\U&_FBP?CZ]KM)>C?E,^NJ@0O1ZF0Q]<0@GJ]\"K *PZ#ZL60VEG D73
M)N5M5$ R>":48TI8[&*H!8I.K\3U;=EJ89+]Q4,Y[GOJ95!_; .Y\I(5G>@4
M'X-0Z8"E'H@#V)752M2487+/=(C$!N:DC,AS9EUMM=:+*.*F5ELO:GLQH^UV
M9 $&>_0&2YJ9Y9Q0-HA2B5WZ/[>465,;;(B<4KLVN_1B!KOK6D@BMKH/')@O
MF"]DC0%N #> 6X?C?H!8&R$&C 9P [CM*]Q2N)EVC=1X;ZBUTFDDN*'"B1QN
M$4UI1&YMW=J+A5O;;BL'T158*S@'@%MWX+:A<UCI>*Q1_L];:T700C"O7#WE
M13PR0LH=)L^!X:&P9KVPIOQ43OIU$<W!1:I0[ !> &#5>5BU&$J[$A0:-YW5
MD$'*$(&0%2(80;3%]>0>Q4(Y:_23:FCJ-]_4M9;3\+F:] ;3 ZBAH<>@23I@
MJ0?B '9FM2M3\EA29SWV*"KJ<-1&2U];+4/86BJ?$@:\F-%"#0T8[%$;+!/-
M"FTEHV"(..&L91(SDSN\)(,5S%*.3&L,=NLU-&"\8+RM,EX(PP!N[>L IA6_
M=1:$<8QE0-0AIE2*R1RI%UY2(WC V+;&67Q?$Z]-FG)P=(J@E5?7R."H" #\
M31LA=K3^!N &<&N=O*%HI:\$0<YJ$Z0E 5.#+=*\GL-FF/J U5J#TQ>3-\\I
M< )1 Z*F8Q0 '@?@UD*/L[K-,Q5!2J(Y1H(AX[DWMO8X+ 2IUG?/W)[' ;>Q
M4[?1C4JL+$^JT;2L<3ZIADF[]/.^E_6L]T_O<_?FXKK\DO4,M#("OP)^!6!U
M<+ "* &4NL50$&@!W%H-MXVJ7"A>V8,$B^"5EC08$PA#.=Y2=9P5,.6,AOMQ
MEAD.Q[VL9NOR49N%[*K6#9_SPZI5I2V;!&H8L:U&:F"]8+W@+ !N;8;;9LZ"
MH*8DTCM'G/=6(,&#%BHR(K.SX"0$QM1:2>1^G<7V]J># LC#--6C,D_P!FV$
MV-%Z X ;P*U]XH.OU* 89@VRVB.EO40A4%(WV>&..F3CV@*J_8J/716>0& *
MQOKBQ@J^ >#6/M^@5[*8406%M+>!8LP=QX;5RR\$)I09LFW?  3?T<*.^MFG
MJA[$^_&PGXYLRV%NN7-2_-=\5!44G109)L^X<>_'DWXUN3EI>OVYZ(_G[X=5
M\:>Z@11ZUG5;'C1_ J<C3L?#0?_V@+N?;WW@>FUFW!2OE()A:CGRAK! J%8A
MVA"Y9EX+D_Z0M>Z**PO8%STNWLQGTUDYRM?FGDF?+4SZJ5IO4GVH)I/$'M_=
MV6*7F:9' ?4\<(#GWFV>JD4\\-0*P2?0P+_M\LH<(R'21NUP*G,;$2R\=B[3
M(8NT)D2MC<*</%@;>YE^K9I,%\1V-NH-Y_G2O!U/\L^9V6PR>#^?E>EJ7HQ?
MCT>9)2?C87*,'\\27R8^N[\/Z$ZHLQ49>N!-X,T]T\538Z3GTPAO-J$WWF#N
M63#&<>T]DDS(FD8<=X'@M:!IY[IJ1^W""%*G O@!^*$U_+#KE1?=TUO[(U#9
M$*C%QEK)D1),Q/2V\=+6!!I)0,H_W-*M'3IL*TW>=KJU*; LL"RP;%=95J.F
MW6U@+AH6E?(I\(TNVL@RRQJ"#(JVS='N5LJ7(>P%P@7"!<+]+L)]=.T]0TVE
M#0[42&VYY$8&AX/$EM>,RXE"5KHV,VZO-[^:U\NMW\R2J>6/3:K+:C0=_+-*
MHQI?5=NOT2&<G.I],O$Z/QV337>TV0RP/+#\CF4UHXVLEE)%J:E'.DK.%-$D
M[UF82%[SX 5]>(OX=I#\]A9ZW*_%$2=8D5,%JAKXMC5\VV;1R-@MG]#H;-*+
MFA'.)1,6"1-J/O%*,,?7=J79^6S2G;WRMCJ?1/?+$*#V@'U [8':>SH]BX:>
MI4^AO+5<:T:E36(/*9+IV6)EM6]U%O7;1/[]T?N)EG*_4U? Z,#HP.C Z$^.
MWU=V'!&6>B:D"(&)W)&;L+SC2")T'BR)2+68T)^S5O);47MB\'UG8"%J!Y8%
MECU,EGU4-W/4Z&;#B6%YF5%P!K&0=+.MTQK6,!.%P"VFV8</O7T!S4 \@W@&
M6@=:;[=XYJ1A=<2=)<BYI*&-,URZB'#-ZM[[W-=LGZR^)07,%,Q;+1>A_Z6^
M"[>OUW]7AI-N2?73Y0)!F* __[(ROEZ5[]7J[Y%MP??F2.LCA['!V&!L,#88
M&XQM*V-[Q*L^86R+(YU755'V>BG,+$=?DJ I1N-9-<W[V<PNJVF5!$R9M%#>
MXB8)G'YNG5,_JC5!O?/-A\&H'/4&Y3 -9QFZ3D_73O;F&MP_^?5S??7MB[/#
M2X')/=51_[V<W!S\NOQ8_?1^4I5__%1^2$/]N1Q^*K],TQ#^<CE9GF59:].I
M$U1[RY4V.>5@@_:&1D44HDQI;FS^3GGG\FQVSLN.-^7WG>_#[6Z*RTD6JG^:
M:H9"DM222DDY\\X(C+2-3'*BL=%D*]?\*RUW+K*\*\8?"I?E].H.2F7+3*<W
M'HXG/_\)]W@I^P^=BCU[\]?PNCA[[4X+\]H7Y[_;\S-_9MZ=A?-6DL&C9_3Z
MS44X7X3Z%V\*]^:U#Z_/@\^/SM_\>N;-17H2SUZ;U^[,_%J<7Z07?@NO+P[T
M='^XY;[[F9O'6.T;%JR?&A7I;[B06[[A03"3*(;JJ+C(LT:8**RI4<1(2_D=
MOJE#J*)7#8?+U,"_OT*OZN?I\+V;YP\,[F)PE5S#Z^I3\6Y\58Y^*=;OS=TF
M89\&_=GESU0L4E#+X'0UG/MF3[$4?V[N#+*GO9,K0HL?W9(37X*%RW15Q4-@
MP3<W9U\_>/J4R#]=RB<XUNWJGT?/Y'Q^=55.OF36/T^#'7Q( Q_-"I-4R7PT
MRYKD;5(;O4$UW?<U+AY+0RQR,J_G5^GPO;66@@0M6PK>RS@U)]F<X\TI7J0#
MV.&X]\>KVK+ST_-J6-4YGY^(I=)X1&6DB(=@M C1,QV2SJ"6(?)34P-NB4?1
M4,J8\%PKKZ).0XK".N$5D6B1L!J,YE7?S)[\._A544U[Y756<)-Y]0BT5C.2
M*IEE3?*#K"9G/].<C]RAJ'N7FQ)5HUXBKO2MA::]E;BO[&#\L1J=O,IO%*^6
M*C@]??6IRG_GTU=%.>H7K\;SR:NB[F^4O[;X5G$VZIW6;P]FT[N:>#I_/QWT
M!^4DW=!U+;S1=<+DWH7"8I<7:FD*A$OZOER^F0_Z<U[4.N@]J&_FTW0"TVGQ
M)I'-/P?5I[LG^B33>#\8O/_YYH WQZM-XLLW#4(D?&(B*.,AYMZ@.GD[26RT
MT2,2[Q@$%XI@D3_*%;>2*\*M5A@[;IV37G_3(![]G<,QB"5X!].B+#X.Q^]3
MX/9^,+Z^+"=79:^:UUZC6%I"<O"]>8[XQJ.B/YCV\LQ1&O=)T:_^60W'UYF;
MLP'TJ^%@\5;Q:3P9]I/?KY*YC<;_+&?IC6Q=D_(Z&4/.=!?7U?@Z"9#TE?H+
M@]EED<<ZGD^+436?)"1^K >1CUR_T*_2B-,1ZF.E<53E-!VJG!:?DF;)_][N
MPEK_3GT21=G_GW0^H\RII\6;^22=TZ0J/D[&G]+OE;GN,(TP)_JKXFH^G WR
MD*:]83493].U^>&W\Q^; 0RNKN:C/*XOOQ1F^*]T*Q.J_Y_IS5B*'XS_<7DA
M<OP[*']9?.]J/NW-A^4D?[#.J4]/EC^:SWR:KE\ZS=L/E;-)N@]?BA_.?S.+
MPY577\;UB^E\\AE.<I3=C-'\>O[C+\55NBOY5Q_^D;?EY(]!HJ91,]Q?ZF.G
MH\XNR^%5?5JGQ?]7Y8M2E,/I>/MW/<$S,6B1ACGYF#]^YRXDM[]Z?>L+UQLG
M%WESNQ<GE4;=F\^J6XA\69S&=3D8G28J+LKE@OR3A(J,WZN\&73BKG]5&=_3
M0;*6<E+_6MG_9V[KVL^OUUB;UJ<_G5]?CR>S>J3]R?SC[;E_69YM??+UE:X^
M)!PGTI]=3L;SCY>U]\@_.9C5;Z??F*X(F4DU3<?L+5S.[4%/\NM5.>E=KAW^
M>C+^."FOIO4;[V]H=O43XWJH>7*IAO?S7,R^F2<;81)Z?U395-,Y]N>]66.$
M%\'%,Q_>F9/B[[__%MZ=7?SCI#!_?_,Z_)^3XNVOX:_OSGQZY>(?Y\:^.ZLO
M332_O?W'.U.32KX%LX2GVSOPV_DOQ?G;L]?OS/_]RB>2F2TP%'__S:1?_NWA
MCTW3=4^6<3TL_W>>_DEP')3)_!8FD\WELOQG#J<F>>5:<[OR@9O<6#UW.EV0
M7;KOU\FO9#2DL_S]_YC7#_]P<I\__>>X_S'9;S+>X9>KZ\L4=IT4O82Z46:$
M^I7>E\QVPVK^1W4U*(L?W*^_+LACG.VOSMK5=I$,Z.;7_O,?+OSZE8OR\(_6
M!TQ'_J7XJ_F___C[5[Z;/K X[3PWNN"TFP/\4KQQ[\+??S]_^)O7DT$= M3(
M3U<O6_YOY_7!,K=?3S-KY#O:G-CU>%93;?83L\%/+HF*%<:YGD^F\VQ\Z2*/
M:_(?#LOWX\EBU^YRDK#[<9&K7-R3OU:YR*;J79XL9-T/MR_\>)(<Y:?+]/TO
M/XT_C1)TK^HRFSSL?![OQKWT]Z^)"*Y/BYA.[H:(TL@&H\7,;O[-\>BI TD>
M*3N7=)WZQ18C'W23>;LC\%[]Q^MT00NL3@K7##'=AGS%Z_7VQ;OL93.2+@?7
MTY,MCR@%6[>WZI'L\@UE]&_\BAF-YND3[ZH%?X_R;;A:Y*DP^NG_O87<ET2W
M137*W]SZZ'W5JV&Q^%F*[_8*W]Y%^F'KA]S-.._>@A^?&06]A(M:43 +&;#B
M=[,QK&J+I16G(.&?M2NN-506S\,:JEEC?*DAVDB0QD,D^96DQ.<T]OXTS\'4
MKXT3O?0'O?R))?TE-YFE0RTQIK/T]22'1C6F+ZMR.+OLY=^<?IDFZTA.Z6(I
M2<Z3?I@GTDQRO[I.8M&-3T^*7V?]1&WWWDH$ET?X/^-!.L%_IE'/T_%J+EKY
MX*^U3OK*419O_E@KKX6#KX<^S>K<AM?AK?GU++'HJ*AF9=+QO>IZMGI!)LL0
M/7-\>&W?A5\3"?_VSOSJ%]\J^^E27\VORO=?^]9__O[;618.M3/_]>S_&+OX
M9N+?X>#SX!O??!=^.W/)^6?)?.O#ZYS,9"E<0Y*;UPL:K!U]]3F13^V@ECX]
MW;*[<G.19%@1.(6[3#1V6C0]HX9?ZHNUZ0$_C5?<W1WAOGI>-[]X4IQ;C.^<
MYJ^_N_#ZXFSA4=.[_.Y%_\>OP=17X*K\G_&-2)LVJGXUH,A _'U4SPC6M:HI
M#OG]]/PTW7U7CM*M.EE>L9/BO\ILEOD7S7PZ2['+H-R&A[P'WQ?RDW)#/[F'
M >W&%7_']&_QPQ,^_./]\.4O=S)'QY0QRSFQ99*IO*UC?'*B:7&%5H_S'S8'
M)%F0OLTQY6A6O_H=Z;B;3'5]W#<?[F6IOVR2F$,!66LU8H9P$:W!47+ML28J
MGPQ>2<S%$ D6%B%*#.?.IE/U7F",'$%,"',PF;6S.K]<Y 1)36<?$I&.R@5W
MG=Q(VXUMZ"8N+G.*J_\_B4'KUT_JKPZF];Q(':\E^DSQ9=6;3^I43!(2DZ2&
MTP='5984.:S*8J$L/I2#2?,+^<MY3 _^>/["($^_#JZ*ZYR;Z]=^+!>*3/HY
M>;*@XK*9HDD17#I*HN)IL4C6)1]7BYKKV4*H?\5O+#3B7XUY^V,6+]4=C[ J
M]-,]F!;_.R\G:53IT).'Q?[?BNGE>#Y,NFOI$&IW/OJ?^6A1.5P/.Y_V"JW]
M_^R]:7,C-Y8N_%<8U>,;Y0Z5!OM2CID(K+Z:U[5,2>YNSY<.2DJ5V*9(75)T
MN>;7OP RR4QJ*9&JY YWM"UNF0G@/ _..3C+,PL1B3T^_"-1,O<-D9W4S4OO
M:',IJZ.HI,Q>!O"->N?U&JYIATUJD&DNCI\MSBQ'INW=-<S-+J]D$M7);9JN
MH^@7GS' T0Q!)6Y*J$5[^$TQ>')O/R_[7P5(%4&E#^]U \S3!A.Q,AR5QP25
M_G,[&=T.HU_^2S?Z*D?AO?"ET?!F#FZ/(NQ\$JX^##\-J)KCO>@L[0_'P2")
M#_[_)KU1:5'-$T<YF/"=2?\N[8)!^RRUQ_',]&]]ZN^N1T71_H+&%6S]JN/>
MG^T_Z4UXYWJ\*G=*[+A6N5)2VS4$6K_%4>*W*')3F(3+!/$+UG<IT96#KY*F
M0(Q3$9L*U=4DR&AR*H4WTAX[^%IY)^,)<!#8N,_.[Z.[XJS_^W3@1222UB?_
MVWD]&%,!"R&;]?@A=X!S+Q2@PG@)K398"$4A4=0\R-4,BNYY,?IP5?H$8[#&
M:?$YL<W#SH\SY;>N(%5^MYFP V;Y.F N7R<,\"+F[ 1;^3(PXZO_' Z*YW)U
MV@-A+9O5(Q_MRY'MMVW"1VS$G8@PQM\?89P#A7.@\+:/Z/VA!@H?U4%$"\4,
M/^\06B04[WLB^= 2#I7M][#5!F,[#K"YZRW@]H)6H$"!@?NLI9Q+@97@-G"D
MEHIHUW1[880@LPQ:@VG0=J3DT!NF"=&<*L78SKB]/BSIV J;1YRN)YU/1T$G
M"(;DU#\U=_3>#*RL'#/55Z=G-W^$S]+6T*LRLSOQV"2=S7VYCG$<7\I IZB_
M3Z,.SH.J<M4+CS'Z6AY0S WBX>_#LT2-/UZF^#,:O9?16=&OSO0&F]&6)6P4
MD/(04<>H,AA1PZ 4&GKL 6!A7R:.SX5=3E/83P:GT]G]NHB2/)B4U49J'?GD
MO9]IR8%8OMT:_6%C]!]6IR:7EEP1!C6\Z5V,T^';J(C.S*"N)I_#\*;HO.X/
MQ^,?.]U&OG]<V,%<QO],L&9A;4\(?T/D8XA;>8M@$P9A+X]7HD48]ZZ@]-U_
MPBA>4>)'\0RI%N5151T[WGD\N;BN9?/\:_I]%5H4E>Y[3WW;'96Q8FFYI_&=
ME8>GPE*8UW&Y%J7O+Y@(-P&@E0/WHLF%WVW&-FH&K-E'?UF$"0CC2I;,=9',
M]6^30@H:?(I9RI/<[NUM]'='!W6_=U>="-[>CH;=B^ORH']ZVY)(IG=-)\#G
MX>$[K^&/Y?V'7\HH\\O>*$6)-<0B.=6;H86-R(.I!*5G2NOY&I57')Z'N2[U
MBW#9[OEX.#KO1%%/OSKJ5-Z,=/H<OQ%N6\3G+V<@^CM&PYNCYM73@"Z2GWUV
M+MV/4S;W<$G*N]-I2EZZ<5$>7US.''2]((C5*(.IDZ:R]$0GNS-%C?Y9G79<
MS)VWCIJGK(VXL.:!<8K1J[2C8*O&%8JC'K>R[M&*O;B.]TJ^ZMECSC]8] Q-
M4DC%'+QNNE\K=U*$UJ29/Y .=D:15N??&A3Q[9L8Q5QMC?6$#$?I3A'DD32>
ML9[W1]_[M=S\79CYFWBFU(+*%R[YX6IVP<>4/&D8QQHR#KFD08U32F."6'B%
MH/&"-;-PA"'4. FQ 50#K\,+2QESQB@H+=H9)>\L(:0HO?WEX>:R!YJ5 W\<
MI3V&.75_#WPRG>>CSK\FEY_K [> T\G-;8F51"(1,-VKJRDCEL<810R1CV11
MQG4';$?UL1_@VNLG5CR*&V[BZ%'Q1Q%,I/+J06N+3SV>!9C&*]6'#4F?3*SQ
M.05]I>NF[S8N?=SY$(-; BX_#R,^S],9?""4XH]N?Q+]IHF\GAK@32"@X65R
MG!4E3YW'():YWT0?WG5@E>$H.=?B4P?%-Y[()+HKE=WH@ZN8[_Z<?8D<WN\5
M?Y0L%Z/MAX-(94=396%Z8O(E",%UTM?2)^58KE(HT.]Q<(UG/Q].RB6X"$R;
MSD+C>(NG5J"<[[0(]4EJ6K/X@T=7Y;BC+NXFZ5"[?,"X]I>]JYA]E0Z4RM"4
MV33M2&SAV?3$(-RS*+?'<MKCE)@/?SNQ;Z#LQ&C (FJ 7WKI "SJ &'?2N?Q
MLU?5IID""ZMHPJ,G#L#FP]!GT>!S>2A!88](J::_3$P8_5&M2MC9AU^2DG@4
MXQDF5^'.D]*E?!&&GR0SZ,LIXN#)C(88N5@M\LUM?_BU*-Y,85<!^*@:<'%;
ME+)=[9J-JU12'47Y.BQIF(?)H#+[FL/IQLRF:F^- 1+%E[F8@AF;I&R4I!Z$
MBR1M<+8(]9%_A:; 58,R+F^0K,RH,L7X]=E/CIJ^[3E-?KI6@Z!RA;F*D_0Y
MQ;X=A8VGBH)+2811NYB]<S$)L \/6)%%&9"7:")IC#?=RZ+)$Z7N-[W553V2
MZ*K_MIGRK9B'49%F*NAU#46G-+GKF_=F:U5%BAQ.0%=,A6^F*8_"FD>9G(M-
M^ Y=)%R_$7LU=_6%([$0X51"9P"7F'*KE0%2<@Z8P%Q[+9N16-@[@H%6 !@*
ML)588Z%Q4%H,LEZ+;WL:G[M/"RF2&S(:?=IT>C?)&Q#_>Y1892[ZJ;DVB:)Z
M83<NHQ4B-.O@E8:\G,:>.-W1Y3@\0OA/Y[57I_K'9/N7A\C5YYVPJZ8?G \O
M>T6]N7<OA[=1/9GB/]K^P?B*/JND*:6SMX#1X\ZO@^2=2I?]TANG([E ,9$,
M@H8P_))LV,MA.@V?J@SI+HD%XVTJI2_:AH.T!97#&\^&D'@I:0Q?R[^[G<@/
M<6=H<."R1#0<-8- OCN7^@D!@F(-Q$*1@)@\&O!D1D78ECN_))M\9QTK,68C
M9KVP4N*#+$^EY%&9_S4%*G5>J]-??^R\'QZGG[Z!^&@=(68U'D\&XT!'I;2]
MZ<RM1.?UV? V7!\C]N/;SKO4JF06.SG_S1B'^-@E6_=EEL%.:7+K&),:CV'[
M&%Q6RM*P$Z:VGM52V4S03&31C>[(.9ZHO8!)1RS?"T/]KZ#V17<(+"-QXB,$
M\V#&3C/#;N:-C.Z02C](:1]_1J=D$<VGJR+QZ$4Y>=$)E72]V=15ME9TX41I
M2>K^^#J8>F^B]RP^W.7,0S2N/%53/VU_&+$0OU9=;_!Y:N&E6-'&39,56H9"
M-)ZN_.!F>%D$VZ.;*#CY\Y-N-8@!MO>_53)Q8.!@&__1*UU,,?JB3$4)<Q">
MK3>^CJITG?,P']56A4$,IX\WZHU_'U=Y$G]T>_TXNC=!?7T3U?2@#I_?A>T@
M/$MU)A%#,2:#H(O&3)'ITQV5L7ZS%1H,O]2K5"OT\:[G4T=X<O*.[V+,;.+Y
MR\G%--TCJ.BCNW3YE($TU38'P41(0<GW!2*ZC>_&]TR]^=FO[_QYD*Y\M=AX
M*\]Y==FPN992/6^+QI2:H@@4DR*>R[=*.:BFH+1^_PCJ=<RGN6JN7N.1YI^X
M=]6\7!"'48II^5[C<T-T/;]@Y\7%/!O$U9@D:-[#?BG8T561C+0J\?UV6#%&
MY18J85JC,U4DF$I+)X+Q*FS[PX;7]CX#!.,RPBWFVD\-J3J3N4S&JATC33:I
M/.)?CQZH+O.0N.Q=)FVG/57E<5]2@+)-YG(.0\UAJ(^'H7YI4'!,6KR9"6-%
M<P$2PR!M4; 2W\]VK'F&:NPEP[KAYD,P-E,= ] #0S53'M.65AY+%46*(0S&
MS6U9"3U<?N9]JFV;![ZK!8+WYM*7=B9\C^3PO1R^E\/W<OC>XN%[SWO%6HD"
M?%D8WY:Z0WS4L_^6].R&T?V]CI'U.4+4Y/,DV$G!\A8/72'!)*^<'2*:Y6OP
M=70>G\^I=T,@\./;CJU//\,M;XHOP]'OT1_2]/L7S6]]*HVI.E_T\;NLQ '2
M5.2#(1Y]GN.92M,XQQTUGS'Z&6H#[J8A6/<ON:PYM)@M,6<3^"KH)OJ1Y_T!
MG\,3I'B/\)-?XN%7!R?#O'(H;:;< 3]Z8GEWO;[!=Q6UWP^V/2D/'ON=&$QS
M.KRZ^](=%7O(M70MCN4PF]%W&>VL__,7@2#ZZ>?A\#*=;<\JA%0?3"?^37/B
M.Z]/)^=WI=N9@C<D<K.I#H/3[_A/XZ8_/5+3R;3>4*D^F'38?C)U6,:\_8[I
M#R>7G=A-<))^INHHN4!^P>([B:?FI['PZD61E/(8E;MR\K[H=T<E>T\S[!O#
MZLT/JXPAB+9K&LO%;"SS$7_?1^71EYN<1J5_*R8\#V<AM2DL9AIH488"/VZP
MIR*3,W]OY=,^+\KHP,K2_[:':2[U>F^I9[Z"3D,F=_<0['VLQAK+ R[ 2&(M
MC/3T),\T0" BRR0L?IVZ*A,[59D&Y\7=E^@,FGT]8:5\Q0!;O8[7_3U21'?T
M.=4.#<0PJHK>CJLZ!'.5F)I#[(Y3.<KAE_';>9E:J@O"?2%KCNZ%71$H64-7
M!'"_*P)NKRW"M/.G0(@MU?ISN68$;6/4-+:<&,5>60UST=E3>7]2KLITBHM>
M>*@@8W7)F6H'FYYGC:<!CIU)(*#1X^?@)ADP%^4F]UJ=FA\CIM9"#9^JITO'
MK---OSI4G"H=[1]AQZ/H8GIVM, $E[7*IQ%QTSHT50A5&:,?DY+27^4$IX+0
M99S:N'=7>E7"QAU+BL2??I[TRB)&X5)AON-T-]?P]K;?B[Z@.J2P.A0L R<;
MEN/1M!Y*5:MN</F4]?D80.8Z260Z.DPZ4I>! J+XOAE>O9FFOLP$-,5PF+CC
M;EA56 $)Q%RDN  EW3R%R]>)I:/:W8W8"MQY$>8GF%0Q-&Q<VBL_EH028SG*
MS)Q(&"G1IYGC]6V^2172(NE,PQN:'_;&TT#:%#ES$0N"AJ]5SYBJ4F=\9WP_
M]L ?P]X1ZUFE+6S:52-NM]7.49W0UKI'0L."BL<L'CYZ'V?9 8USX!3:7WJ[
M>J/+:1+HM Q]N?DW(EXJ+:6"7N]JN3TZ/D2]3S_6GVH.$;MBU*W#-]Q&G,G#
M0_?Y0_8GCMVK#G)<, 4=H!1(2+WATBD+C'>$24 0L"_O(#?GD6B)S0ZBI1QJ
M<=,]L)9RZB*HWF5,VIXTC9LVQS+#F_->F294'\9],P'$,!<KC BD%:>,$6VL
M5((*K;6P1*AFNJJUEANGJ9>".L6D0YXI++&3T"O@OYD \NQ]7IX LOV90/KD
M1$,H.@W!VUD7YKN4PA<EL4S'K^IN3H?X.N;2I1J\OP]B)93NN//1OP$44<B)
M3.U2!L-X;FG>G[ZY+09%5&_N.N.;:'[?#(.X3%(R_77OO'<W3'U4+KKC(CSC
M[T&P@\D.CV85%NNJ]_/M8H+\UP7ASXNPN?:&HV;]N6E!NO'7F]N@CL2XT%$,
M#YUFS-Z.OUY<][IW$8$/?C2K5Y<4M8]787I&55N8\L6/*1/OMM]-28%5BF)Z
MX(_7:02ES_^Y88R#OA5FL#I)4+;, QR-BL^I=\ZX7Q2WG2\Q3WIT_?7N^F;6
M#"M^?=;8:W8J5#WV#I?F".PR*!J%FE/(;K>&5-5AXC)E%4QNP_(D+?3K=$)7
M5'CGWYZNO!.THX)+7C,H1D&#(LP+ ZD&6DBDJ%0>."0XT^ ^K7^J,F;5X-+6
MF:XG@X^C8:Q).E^'I]P=8, G?!/^A>$_J\O\<[H[-.A'_=D;_S,6^/EG!=QW
M15FO9U; 9S*^;%;O>4-GQ7O8-VOW<'K\L'A/)TQPO\EZ*SBR+\$WS61)1W7W
M_:VQX42"7D-J*HUY&F$[KBFM-WAS6T[TTZG+KT\^?OH_W9O;G^R/+RGX$VXW
M)<[K;FDC?2UB)9_NQ76TT8J+Z\&,>*X"?GLI<[[LR)>*'L068T'&ISPTN8U3
ML1E)%Z"NR.H)5L)9#"A0% BD%$+0*4")04@A,E=C:EI/X[)N@?*QA.WXU]L@
MJX&+B_) Y\-5 P<!%6;6">5=+]BR=\-!L9VH8'@CL C?;71":R09/=NUZ&8Z
MGU,&'<\GL?>*")'1\&NW?]>;M<]-J?>=Z%B+V3F]S[TRTVP\.7]S5P10/%]Z
M9B<BO6F.],Z1WCG2.T=Z+QSIO8#YNT\&;V-/C>!^GUJ7W06KY:PNZ!W,K/[%
MSD023M/79=5 ^+:?@DU2]XKYP49#=MH<H)%H-;[NCLIB+$_/1N?U^].S9"-/
MB^>$F8X%(&.Y]*H8^M?'VF\'HV<P?-/(!/NC-YK$'M#J;S_65N6T<T^X3FJW
M,2KN>E7*<=E%.1#7?'F<1TVLL!"KR*9[KHQI4C%AK6("01"1B&E(+ 4\6%-0
M(AKV,<&UI)C-J9BFFD^5HNU4I>(_4!6A_&_4T/;*;S]5Q/294O]W7X;K*_5_
MT[M\D[+<P^I7,C.KOS3-F6VH;[?QW*GZ>-I/.G6!N=?WNRS*6(4H3GNOE+HQ
M[+P.6ONHN.TEX2QBKY<_AG\4%S].3;!>T@I+GP>>4SF?\7Q<7 ]'PU@%,O8L
MCF@8!>C$'@5UUX"CSC_>A '\GLRTI^2Y/ 'K%]W+,J4\_.!RUGVYRB#N?ZTL
MK[(@9VQ+4^.E/*0IQXLZKS]]_/G3'!0?'2KZ]Z4&.QM'>OJ LK ZO51.;3CN
M-JY?SL+CHTTA_\DG$L91#^R1$>U(-;1?!Y?5F7RLV#!^DHINN[W+3N#,DEVO
MP^83BV)MR/R%HG;T *L1#VITL':I\5(#%?X'J/ ,,\'54_[[QKYY&D?T,9A%
MQ3Q+G90L-=M$%K-G9U]_S*+]6(S2W9I$AYZ@N?N&+:+']*%ANTJ#]J([3L4(
M.]%),JML$FL%-';;F4Q,$70W#,K*ZK:MYV0#H9EL. 69T-Y2(X)*984VC$A
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MO7WV==P]'_6J+ZQ?RT>$',.#-LZSJ^V0H=\(9$1<<"Z%,UH**IS7R'GK!$?
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MX^=I4<DDMD\DMGU:X.88;@O5NT7IC\BZ-1*4PG(03&YMJ$1 $ VD8#06)A2
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M$S(Z]QF=C,[0B:56TEHML*6,(HR<2GLE%8P@#EIWXFV'KDQ$JRU3,DPS3%<
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M$TLFED,FEH:_$EMC+/"4 *^D$0ZQTE\IO=8.^B7\(M]%+&V87T>(D*Q_K-=
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M *^[3%FJJ$6$: 8LQ8)KP(BBF@OAL#4,M;SS;])*PH$#5I>FG'?^_2*'W>&
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MKBP6AFI*I9:2,8FPED(KI1OE0#4'!GNJF#6,.H@DTEH8:32 PCNM=Z8<Z+V
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M+R?_EHUOS:&L>2VW82TS8'=W? <#V$,Y:"E5CP,7YNPI>=RXPKP^TG""(T5
ML*.0I<X!X036EFE#I<7.+AE(\\U*_U-CJ1+.]FRC5D,"LZ-CFR&[.\A<%(NR
M<2)AN1-(:^-\+!M/-1+*.. A$01Y1EKLNK$J+*)6(] RY+8 <H>Z2Q+8/$_@
M_S][;][42'+M#7^5BK;GC7$$C7-?>NYU1*YSN4\//6Z8Z_#[SQ.%5#2Z(R2L
MDIK!G_[)+"TE(0$"2J E)VQ:2ZDJEW-^9\FS4&?"5]!1JAG3#E)N&5/48^X=
M:K"APZ8X$XIT<'\P/+L[K+DN,^*:&1F3' (.J;.$0H 59T@Y0!007K\XLO)-
MF9$=LWT0DP=B38_=^3,7?L*>QR5#:C"_&L)87:==8JJT$-P:0JD#4DE&'?=(
M$,F,KUM--]4OM*+@&0%/CZ :;")/FU4N4A/Y/0: W>'S=3F;R]J&=U(2I 41
MU% *J0+&8@HM(4)#2)[1^FV]SID;YFP(:+-A1-O:*#XQ<)+@3_*YK#M^&Z8%
M=X89QQ %U$EK@!.4$>",-_:9A42>[EVV83XG0B8)G@#@4"4XA35G8R"EYUXQ
M(1 EFBF,H& >4*V!\_ 9OK[UNA)N6C=G\A@?@@1_H3-"[)@SXKP_S+NS KJK
M&I(="IP]@TPWW??[76AAZUM[[Y!J1TDM #PV7&K.!("4,NJ#"0><AEQ:)CW&
M33IGIO[ER9>JUYY\6PF%YK0[P!MU.+^<:I)ZMT]X^$XB\+VZ;F^W"CM7'8DP
M$V-&( $042&8,IX[2# AR ,$-Q%(LF$$"U3?: +,D^20@&J?@.I!>=1(O_3#
MTNI>MF1;J/*)N2A83*$FC#MM);6&:P45<Q) 0X0P5FT@OF?#@$DA.Y9;H?(U
MPF()9G<"9K<.3=]/6=Q"F%P3&!FH0Y)E $%#(53$D:A)"N0<L"B8Q,$4UHQN
M(-9JT[8P1<?D38%Q*_&O\I;^M6I//_V\D7N/U_5T=!U^TEJ87"#3XN/5N$<:
M1."'!2:*7MC[LZ_>=WH!*8>?<(P96W\YGN*+#W^SXT)RL6E&N&+0SOXUR@?#
M6(WN,HO$FMT66:#LJBUP+% W*S0WKAV75_0=J>=>9;K6I*+ 478S&I2C//Q@
MV,]NPR"NXBV[@9Y[9;AG*Q!3'@88'A=OOW"3CU5CM'!1)[!0MUN$C_-N+%YW
M$WYT%^]7M029/.DX.QDW_RB+,*9[$T%@X=IL4+2*SO=PZT'Q;10>TA_<9?E-
MN/7W\(3 -5EG6$[+Y(5?YL.L4V8719Q9/<18N:^L)OOB21QGJ@R+."C*47=X
M5"WVH,C"\G:&W?";,,4I7;T>^N:))8B#)\ /D=H1R+UC'%L.'=7 0R -IE9!
M[#AEGC\4:/JUN Z+$I;@UR#N(Q#U H9=!+JNFMW=0\:3"AGQ^YX14;#*NIXV
M=KZ'C8UMR*NW^,/?PG=Y+ ;9B:4>8Z><V/K])K^K*D(>9^>!]"\[@W(X_2R0
M<BML6=8>%=GH)NS^*C8(-RI'@5VG;!#K-]SF9<T[[1EV;-^:+-UQC K-#W0.
M9AJ_^7PCUL9N>MP O9V-+LKB7Z-(25,JJX KTE-_C,)C>HLT,\'CO-<+5#,H
M\YI*BU5T=[PY8JIE<\2>3F^4CY6>#4OG>\^KH/8\_.RLB.(@?/*1(PJ($EH1
MZ8.6Z363!B NA" 2AB\_XC%<AEL4;35\]L])([KS9#[WPL#K(K-1;L9-;7P#
M*SQKGBPB<3:/,YT_FA_I=?CDJLS&:ECCM__O4:\8&] 8'&4; 9VC0"67D5S?
M39]AM3XCL-1(42>]C)/EDBD5]!D4XUN,P,\PYM8I7VLF"O(O\UKA]+I)=:WW
MC8Q!<H4EN -:SU2SGA@"[:(;!<S=5+9,;(P*EEYA9HR+<\<;3NV@V@9J=\I@
M4D0[)K_H?R^.LW\4V54>FSMWN_W6>'"5E)MHPMF?(0?';+JVTY'^N5(\9Y\&
M<NF5$S*^">9C,9WA3:U(QY\N6EQ3-:T<W=QT[^K2X%-4KBVRF156_'$363+<
M?7+GJ#GV1]^N(@BPL=X8)/)H83[CH3Q0ASSJAQ=Y7) P]O'MHZ(8YA^P-HYD
M,KKXMM(2\LY@\H@PH5;_^B8?1%O\WOWCY?,%T:?/FQ'GDDAO#EX:D-Y!_!XO
MC_&>6E+]R:O;E\'60A1:YHFUE!@I*4>84X"$MN&^/@SKK_GTAY7S(E!XMSO1
M5?[S0S#)XOMP^];T_60MYM49**;JRF1QSCO780]/B]OL:S]LP$_9\FHL!I;=
M=MK#JT^8C5V\$S_1VG%H80P?'E>^YIZ/PO,7?+%@_- &-AK51R>4"RC9^,O%
M/O:T001<ZX'/ZE<:EO*GYZWE&R[=22](K*CCO_42WE?\EQQ^"UZZA\ZP[JL#
M9ZVKHCWJ%E\N9Q,SH\$@O#J/=XW8H -:_OYA!52$L4HHH%-:.XHLD!) *S7#
MQGJ@C?P(YC)H<'0N8^44I"26V>=:6>BY)II2&UBZ".+])KI+!Z/BPPLG,YN"
M#:*LVR]'@\<G()10GGECD(=4,Q-&A(UP7D!N!4-\;@+>2XXE,<0#1BF'REF%
M)7:"^#!3A)<F\&PS;&IVH4:=HDMW.J\:#U_?]'N5H1L$56>Z:I756XZNKX-5
M^^^H!D1Y&V3E[?VZEFMRYF3H<U<O8=[\S./[^=OUHG;075@L.,')9TF)QX3"
MO=&.10 $81X3#W\K%H&]*8M/TQ=+-G,M1V:A^/+#PV)C_ A&?I@3,HO?P9=]
M11N_XZL?MG;T]B9R$[8DN'L%DO]XTINJQ^6!-H!<OP#E6Z:M/8-D@C46K->W
MB7U904(J(G=U5!?]'1D&1]6;>7='(JAMA)K-TLU#E))5U&&+5N5FR3 \RB;T
M N7!%O3^FM\&RSSL1B?OIFR;U(?W,/OP$L$$*\1<D\OH3S:6&4PAI\!C10D0
M! 'CO1+! GK0Z@H,]<N4GTZ+X9?+KT7T;2WYFD_&!EP3E0D)2=UQ$PCM;@;+
MUH+(>K A 9TK=(H$)(Q(Z0C%GDA%I954"HP8IJH1V(#R[Z21Q!.Y'R5-#T-1
M^T=_\'O6B<='_591'JBJEDJ[/@%%:*Z8I'#2.T20]99JP6308#CE3!&.(+#^
M02B*E';2^W5,9V^CPE @4ZGS@V'.W>'!-;F.U)$HDECC#63<:D:M)3H>_#KL
M$)9  [_42/E%7->0!D :3CU-&L!&-0#?Z77*JZ*=?>OWVTD!2 K *BAB=<%&
MHSW   A./:440"V(4XA9K;"4RIL'H6A*:#]'.GL;!0!*T6Q29U( MI@Y=X<'
MU^0Z4=?8B1Y"YH*UCZ6C@F%I%(*,0&<(<A2X1KBN*1< )XW61MPU!6 W*Z1U
M[@=?'1;*/.-@,]782#4V-J-G03!75],8A07VRC+K*#1(8J 8T<0R#ZWA,T4K
MAO[7>-\KAJUQD&'>:X<G3=YL3,62M-D65JEN1H+.5#=CO^MF3,$.UP6%I.<8
M>8.5M"HV#=/688D)@=@P *%X)=@UI-D*0#98W3_5PEBLA;&B-L;T9_=#I9>C
MP-9/<F@Z"GPI[*OZ>S6H [6_%1\O!D7^^\?\,@SU4]Z]S>_*&-A[-5A,[PER
MGUCC$"*,44^-UN'_'@H)N8=(L87TGF>$CT^8--]$5%QV-8@L]J=2$N P11QS
MCFF8AF(02.T)ITA")=$F(_.J!(L8G!>3*F,P_FQ+\A74L[12CP45-DPO$QT&
MMFC.VZNFHD^^_.Q.LY-3<YRI4YN=_:;/3NR)^GKBSM9/'=BF&9U^.7=G8X7B
M_$MFOIQ:=WKF;'QU]N7SB57GX8T_.56GYD1]SL[.PP>_N-/S'9WNCZ->/FIW
MAD7[J,[-OQ^;7G/P',"EA+U7[L]:R5\L)>R]/&$O*%[?.I%*55D6L;A'KYU%
M5^-MI]O=CRR^Z6Q4KUU/=SS;-5/A,#):0",!B^TV.0P2'%%@G1%<(@'Q?"H<
M5I!9#[B6BI*J9P['6NL@1P&'L1#Q(]4]GGP.?'$F'43W$LH@VV0J7>T[P1?Y
MY,MXTT^=8>"*UEJDN$@,S]KZB9&QN-GNCU9W%!=D2A!/)W$Z["S46N"@KE&*
M8LP>X-@@H13P&*JYC<=6$P\T1)8X*A%14GD&HK/?ZKA_.Y,#.;</>;5N1UFP
MTJ(JEK=:H^O1N()"?MT/*/?O*K_]*.M<W^2=096PW[K*!]^*,8[D[?\=E<.J
M:-!1RI]L*'\2L2<3*-%CV8F\Z7S'QF_XR%?B#9_UEO,Z[#4\C#B=-PWS3[/>
M K_Z#+,AW*9,W@<I81OR=K-ISFZ6\G5?3S<[1!X/$L1"9NYKDW)3,84F6Q_N
M6SZX*X>=F/7<?M D><_1?>Y<%@<.B*F P2))F'XY3"212&)>:-9>FJU$,37G
M.4JDFTAW_ERQ2&"6*"+)MT022;XETMT_TETMWP[#^VWZUS?=HJHK7K2N>OUN
M_]NV)*J\750M^8A$=E?D@P--TVU\?H>6@G/(&384 ,D*"$D== $H1%QS122%
ME$DL@<#&,NV\T] 9>#\4*.92#HO/L:?5_>B0GP?]\H$\YEFCQD=^KN_&74&Z
M>3G7$>3+:/AYTO_NU[P*8VVLEP<_PEP>X[?(C=[.&/97\TK"T52:\IDG8.^
MAC\^!8>TKNP A**"RGA&QFE56L8XQYWP0$DEX5+[QD?P;,[*FC=H=@@@Z1&
MI-G&MT^15(T.KR&RM^2L%QT*)F!-P+K[P/H4KHHY-=,2[W6 4VDH!48%0+5.
M*VTIHY3YI9)YC\#@:?% )O=68B@ZPHRD CP)U;9!=AU8$>$I#LE:O_-*,J&Q
MJ]K/&:(4ID1SAK671@''7F_NQC3KK42BYLW=!#@)< X2<)ZR*-%<"1LIM+&
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M("B!5C,K.:"68PRM4<^)*WG90>K68<6_BT&_G9=7D<@$@NBG!!0)* X3*##
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M@D4P'VD2P:&6GIE:*++4[! 9ES'9=-40LPU98AN.FSS_CP4)NS+^X9_G2S'
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MS./&)C?3X\3;'[2+P70F\.:/K.QW.^WL3Z#Z[W 1&?&Y!FD$"&VI()91)+'
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M$V#9?9P]Z7TORN'UWM1S#!+FF.X#CB6.W6>.E75 -:/8,P&8I-92)9$,*A'
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MKR#B5A S2PNZZ'0N/D5JJ["S#,!J)Z1FYBAM+[PGB!_S!B'P*?)*6E/"@'?
M %9'W,I@9%G'E74*4(Z1Y+%#';,(&^8@I6^( <G_DD E@<K.@@JO2].A "@,
M">B!=M01I1@%RG*NF5/0O*EBL<<>G*2K)%C9?UB1-:QH89S3GAAL%342B'C<
MZRV'X6)@$-P!6#DT']#6@LK+?$2$[)B/Z+P_S+N'B:G/H$L<Z++='\4TJ8T
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M<254,'H$V[2I\RBWO\+?<9"]P1)3)TG_)._+NC XP]81H "T! 6[B4BH@R:
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MZK8"AOO7#6CC\1\L]O,:^U-KF'<L)7*:4&F];PDL5!P :R3A>&T9_]MR3TT
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MXY6[]__]02#(_US:OX#+?_8/[K\]\&YF/AKT'T?>*G:SP>1C?^_!?3[\<_F
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MK1T*,+)S'B./B'_[NE,=^=9B,!&#B2:#"0YKFPD@,T(SPX$R1#&-M3"ES12
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MSWL=Y+%0_UR?7M@+N[A=7JWH'>\Q6AP.*&P( Q#4'>*@234#6A#+(+4 : Z
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M=DU:3 I3PIT]Q!U2XPX6T$A!&8).4VZI<(1@[A&$&DKF5LRMCN/.KL?"M9R
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M:507H+B#LG<3O-WOS,VG0)742?0&<\ZM AX(1:&E4O& K\[B\ 9S8J4MWS-
M-:9H)E!]U;Z>J>;T8(#U(?'8/<2]K?GM7M_M(##?W9+U$NP%JW$Z-J;20@NI
M *-&2FV-<$I2Q1GCBJ^T/GRF\ONOA-,=Z=_X%.'O>;W 74Y(/I"D>!^/XBUH
M<^:.$L SXHBDR&+)H0<!VSU05ABR,G/GF8IW O3G]NMJ==9/-Q7O8TJ_V/GZ
M=@:KB[326?XM.Z_Z>QQ[1&']WNIM!L"[8$H\Z%=_RK:0L"[B\093B301AANJ
M/!:(:0"LQI(*Y=E* \=E'=&WA01:=)E);O5V+0OP7G36L.B [7 /Z2?X:W^M
MW>Y!('$-8]I:@3Q2E$A.E0[:-78D(!L$G&)'5S3JM6$L.;)?!F-ITDV"HZ/0
MQM9T T@*:]U+,J>=P8H)3Q7T2E/"$0?>""VA "_2O9(3X+D]8=MM8YA2&CJ,
M/OL#,FLK0[Q6AJR @@5#SH>/J6-*6R<]H<XIXA V*W']9RE#"5<V5X;:[#F]
M[\I0I_R1BS86]/HY#4'VPS69EKJ#I7:E"J<K^Y&._M"7?41+3<R=COZ(F/M5
M%;-7+&CKY=/++.YW=AD'UDP[0OP[VY'/Q1_%:-Z9=7?5=7!PCLL-R[,PD/C&
MXP"LE) #R+R'U#DG$?6&40J-@I[+E7;\2UH[\+#QCL8-HI;'#2;798?Q9W]@
M9DT<@1#=X(AT6A#%E:,44"NH!L!+#HCC2&$E5R(B#^/(0<5MV\21M1KBRU;3
M3Q)N=  W#DYO61=>< TO%-N8'<*0P))JZV4 &4IX5%6$9D(\3TTYF$C(CM04
MVG)]8U)3.@PW^X,JZ^)((W$# DV\0EH(+Z@C0"*L??BF959[Q?'SU)2$(QNJ
M*82TFK*12C-2:<8+4.33LD(K6Q1D)$_:D6FDFWK2H*A%BP2>.B8@#38OM8A)
MK1FPUF-D/'.>WQ4M-U2WR-U)+K7-=-5_%Y-Q/UPPTK9 $/V<--4C@:']09LU
M<P$Q HTA35HR#ZTG%,F@JE(A,(II@0)#  E8J>]: T^2:^VU6_OL>^Y?@I\#
MUH+61BE4:SU&>:H%0!9A297DPE)GB??.<H*I1AMJ/<FR?BY*M5FN=7!5IPG,
MCE"7(C5*$2DE !Y8P SE!,6QET1BXP2U7$*SH2Z54&K3]ENIH")Y$0_-BYB:
MQ2<=>F-/(N)UL%M[;YBT7EI)*#<P]D2@E%K@.-94O*3)6/(H=E:W3B[%#N#1
M_L#.NK@B:RU8&:>X$X 8;*G 7$FI% (,:F&\-2_I1IL\BZ\<J4CHT0'T.#AM
M9DV0P1 V,O6@4(H; 9FED$(-'-4>>13 ACB_4E!PK"VO=Z:\M&EI)^6ER_"S
M/RBS+JXT^L19X"$@7'('&84P_H&@@H!A["BF*G5>WF.C*"7P)=?;"\ D]59.
M*NM+>RMCS&IAXQ1"3G/$K/(4&:$ MAH!"93%EJS.USK.WLJ[CAJE(/=S*3^A
MWZ%IS$^BF*A13"$HM6-0"0\HQ4H:+H%W465FAHN5W)SC;*V\WRBV/V"5T.CH
M=+%U08N 1H6>QLH8XB&E@GIF%.520..\UU)@_S+5*UGYG>B >G"J5\*VX].T
M2",+6FI"$ #&4.IIL!85@\!HZHGEX4\+4]_F_0>M_<&F/<@R3#TOTU)39]=T
M]*FS:SKAQ-SIZ(^9N8^U;?.HF&6#F^DM5>_FCC! *AKILB_AX/RDFQ:-4%)/
MIA=*4<\=8\Y+JJ%0V&*.I#>2"L+52@/68RT:>>BZT3%APTG]$9[FC^(_YX$(
M+KZ'O5'3TD?AOO6&\W[1O[E!^%5X(WSAM_$D/K^:S2:#\_DL/Q\69^.PNW$7
M)^/AL-S?63$).-=B]I5,69U'@G;[ VKKHA8C=8C:.F(X,%0"3 %Q6@M/M('.
M..6P7HGV'&M)RD&@%FK5'YO J0/@='"JV+H8)FH,LYX8AQEA1'@*@)8Z:%V"
M$0@UQ@'/4L7+ 6$8;+6_?M*\N@QN^X-A:Z(6 _7@'X>0\]H*#*VC3@/- 2+(
M0LDY]HB]I$[OH(+6!X%:Y#TY!,TKA;#34@]FJ2G*E8[^B*)<Z803<Z>C/]!E
M;Z:8P7V+UIZ-9_DPF]RQ1*9ORU#V^"(6('>4_ ^=O5]S?>?C2;^8+)\>7W_+
M^N-YL.JR/X'RGXTVX$&YL+A;_"D,MYJ.AX/^S9TZ4 IQ3RS[/[:QJ4\*SL<V
M=Z,]W(.$ -YLF&*4X()B)PFGTC$A 45$>P88$U"OS(\X*6:U9V,OD@#:"$GQ
M=B<;;DRUK;!U\@;O!;1W#L&W!-'[B<3K0BV1S>'7QCO/E?"$$H2%,D3C +*.
M:\/LRNBO)Z"V@YD++4 M;CET]B34)D0]&D3=5V4YZ<9;R]#@K,9GR)4!@BMD
M/:648Z$ET@9I2XP+B+W:^/AI5;AC\<TV8H3H/4VJ< +NI HG5?B9JK 0-U +
M#)3,&P0IM!1;*!ACUA'-"$6*(KN!*GR 4"MV#+6=1-0R:/#G,@%F^7XKUP[[
M&LEH,)KGBXVM=OID?A4NTBN7^]?_FY=4/ 7>.JH<%HA:RBG60@:- %KCH41>
M@'"+/^?+2Y?/FO6*X7#!OW]Y ]Z4K\,#]):O%\_?9'DHE@&8Q8+.!E?%-#LI
MOF:?QU?YZ.=L=66WPRE?!_W9Y0?,*AFQ((NUHR_A&6X?<X" XMTB. 01^*&Y
MLRC<_Q:8@^JF+\>4\M(+84^Y"$AQGZ<3XN6![NJ.[Y_#=&$O?W[>9NYP[UP^
M&85SFV;7Q20[O<PGQ:[W,GN*TV\QXT.Z]5TQL5S7;\6D7-59^(T>CGN_ORG9
M.+X\+89%B:3ON #$0@> QX&W%5 &<1*D$88844;-N]I)3KW%WA'(F8-4>J"Y
M\%!S;KT"FN' S45 ].L(C)-Y\6;#IS_M71;]^;#X='%W'3J?#GIJU+>#X3Q(
MGK,R&_"QM2G M*76&"DI-8I)"H"S+@A<ZQ2TJ+&V &W608RMTXQ2K560OP!
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MEH_Z6;_XHQB.KZ/GZS[G]Q$P0>OKVVY6VE83%O^CS6Z9^YFP]<P<3LFD+"!
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ML#K(L>20/*<O=YEM4KJ.RMJ;Q5>F"5A3U<U]\$J;,U01(HX;302@BGH=8!8
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M1)%AH6^$"92,">/<<*[Y2C7.G?B0>+LA;<\GDOVL.=,!YS: <^_P<4N(>)C
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M$-G"&MQ3+5G:2LZSAUN;W;-G9C>C)/O-R,\.]#7KPZ0NX#B\43(N[Q(L0_=
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M$<%(,?%*5:YKY_@S*J!\J<(FU; ?U<Q>S75G=4]8UUR^0\Q-,:)KAMIVYY(
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MFUK>P5$4;Z5.R!EL?'*3>W 0XV243D%P%$<>&,];*AFR;8(Z&7IQ>C&>VJH
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M/>3#98[;80!E4%LW,:)8H$B%E&,6!D1%H=$^-T8+/U0(+5LW98.03WE1Q&#
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M'T@DL:&$$]@ )X+G'3XL5;C*=[-ZE2OAM[LL-1V01JGI2(21+7:#,&(TQB*
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M3$V.'PQZHT&[U3GI=DX[PVZGWSSK-'N=KMD<#-J-I%@];H@LFME>>Q>VZ_E
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MF.%='G@XA?2%Z]')V?GIZ'((FL,8\SQ@S\[8V$^'S7"A94#5HN1@Q[CW;3B
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M%U>?TK-67L=O@?4$"X:F!?OD(C1"YF%BNE>P:=Y_X@_WEJV,U+BZM9V%95P
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MBFMSE'+F^$67:/T>IK2'(U6^"P>-%2I%237Y3GQP3K%ID.[(7XO5T(S4ECH
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M;V0AH2>"I.&SSR;,OJ,^SAP5,HC&"X^Y%B\0(4P<3S1VQC,BO7K**RN;])5
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M_?.GT;]JQI>/HU\NST_A&UD%1IABPXLO?UX.8P4G4V/YP;CZ<O[I<OB_:ZZ
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M_B'L$UYOPY)TEF7]Q2[E@Y\?/0?J7B:[P@\&#!/V40828O&R .%Q:P5L6K[
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M,S;W3E4)\:#SPK=%WIIKC'V+4IJ2#1].)AZ5(V \@/NZDYXYY)E*OSF9BVA
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M.IZ-B2^A1=^,O>D288:F=)8?LSZ&IQP_,)F?,C?>#IG +&\\JN)83=/"9\.
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M<D>#U5=?SC]=#O]W^/3I/=X;H-]M#B:#;F?6;G<Z_7&C;ZY&K]=>DXY>Z]X
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M]V0)U?B#&2Z"UKLW=/0$^*ARR%8&AWN.R'H.0T@K:Q:RO"O@+SX[E:P0!<L
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MPM(%<.A=:*J^2_'TRZ?K#Y\G_V^RU>!))8".J!0E@N'[1;>L# ON[ V)4:)
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M4*5KH?)=!"-N'<4#EL0IUPJBP)]^<.LCJYSB_2P3/T ]%M@M(%%<%8?7[P@
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M\OW9Y/-_PZ<.)P%Q2L&,'/%:.G/J]([UMEO0;$"WK3>QNPPE&,=H0DM4O6\
M9>RWG),4A $E=2_=?:WFI\:$ZSN4#4J!%ZI5AY8-@#1N1)GO@2$^R)V0"HQ+
MH*U_7!*4+S_\8P+_3-,K/"^X):4>\TJX083PA;>.7! PF'!CVV&"J0%(B]]
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MB\' [MG=@6,/^L/^8#SJ;=@Q.Y\YH!US3 (86W((\S+2;C:1:ERB"MJQ2"<
MHB3S.UFNTIMS<S?G9A<FZ,*XZ\<26Y&:%9@;SZEN*KDXFNJ,V[ FOWW\</E_
M&VD+TD8:.Z4M?+T\O[J^N/P\L=X _Z%]W :AY[S-^NUD/4FR5C,:R73+NK2M
M'.CS4Q4K@?U74[/:H+#\/:6'W[R(6L^J]:P7;^IFYNN6HDW5NQL3!I!43$JB
M(/Y.VLE/ETAY6=KAFYH"E'#U?E!"@Y.,7^A&)S5GJ#G#T[I7RB#^BKI*@'<
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MH%TFERRX_< $]:D@SU 0'89&K6<]&>.MB/;]T1"/VWF=ZH-?I%*D7>L7JNL
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M*7(<NEF[,>YU]I(JM6YVS*A:'8Q$'.P/.LU.K=D<%:J]&/3J])J]*N%6K9"
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M+/EM)7W'!7L:^Y:&[E*$\'X0NF&0S!>FNU2*T$=VI[XQE@S\J&E]] \?KYC
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MLBL<GI+X"%&6(J&$W_D,03P;.KP6(#-EJ- Y"8%[6G"S,K2F201 C]"2@S?
MN6\(6+[M)0Z'US(U&7\,PE@"D><";W3)L*N&H@O09,GW"_\+P/8BV(.4?^9N
M2!&[IEFA;C_':D G\,0T"&E3P,Y#R<#:=@U\,N,-"-QXG4$]Q0D@]U"A$P%
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M$)SZ! +<"Z(5_(M:K%!H9RH\ ENTD/AP2>SP"9@!';RZK$#Y1)6^%X9K5!&
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M?+-6@?)0-BA03+'18+ET=63)<'8Z\D9ZP0J_P':V\P26#,(UQX_A-S*D<7T
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M\!-$K5LR>*8F%NHR&L/](D)?.LUCA,G7[8" #[EY%X-KBM^XCCDYG8VV?R=
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M)[X495^(G1 25>:91J*Y(0'KX\C/O"!*PN)<Q.TS0IO61^S$E\;TIR)RR<%
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MLK/3 Y%QYW")D91_JE$WV@KF%:Q(W-"  -TK9BG1&^E&2[4V\QB2=Q@#A6,
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M@HN_6P"-\$,[E5V&8_?B[=L71\\?XGO00;*P,]*L%HA;S,NY#;CQ6'>][OA
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MAH0-VABL,_.<RD>!N)C.>\5'$ 8$\NPDF.9W&Y[LZ8I2C9B-HU"73+8;,W>
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MRA5@")_++F4&<FR6=GX_>^3KJBZR-3"3T.(C8MJE];_F.:0.3%U#_S=N8/R
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M'PEO<17P[&#V>)TW?O*W3'C I1+%:5++MH</S<T%*SSSV%ZXKZ/(X,PM#^8
MQ@PVGN;Q?OI*SJHS;E6DU..P&H_KX_1-^X)#5*PXKF<$EI^]'"0W4^6Z,[\L
MH\;9>F*&'PL=M\3R=_SDKH^U'<9+,H]7CQ>M987A]Y!3#;XG@!"FCG"\:K !
MD*CB85RE&^Y052.??C1$)B4X?7]#:Q$O<K,FN9"IM520*DEQ$VH@+_/:(S]%
MVG\;W^CJ6C[EY>@V=@^>6W_;49\YB$G"?>68? ^1)H0ZPSUZCL:I-]"<H(30
M8L&LPHQ?'OJTFY;$+3;=-2P34R';G$R"0QK7%(-Z#B@$='LD)3:9,,Z:/Q3<
MGD=P3\E^'_[^Q(_U_;+__:?F^?'3UR<G#X]>/WOV_/'3IR].7YR>/G[]ZNFS
MHT</'SY]]NI/.@4R9HP^8\8H/I%.;FT1G?@3Z7CV.'V:#;W?6VN;:(^<\%[I
M__<_2F!T:< 7RR9G:4$YH-=V,UNS<>9;O, /^P<%6^](U;"YV:%B'_WNQ^3Q
MTV?'SY\,C@G 4.O).X?;'WK;F[W9DY@4]^2NLTY0]2B*:DVD_-@+V2V!/.)?
M',DQ:PGU"RC\/VNP;40> VSKK=.U-@ 7RV[]LC''TW>[SU9_,M2G@XK_4327
M\&]]N1*<_2)<V P2N!9$XC)(1/2T!( X/K+O84] ZT(<X&FX:LQW\D///?8H
M"OL1&*7__:?CQW_ZCZVH";K'R<-_4QB+\&_'E_SIZ<V^=K,_/;GU*W[6Q]_M
M9E<#6Z95VU9+61'TK^^.5Y\FR,HR^?,1_B>$LX!=TBM7_YNOH'^%OB#^YD_;
MW*D(;O+LMBS=EH/['=+=70<]P\-T%\, <0# MKY;Y)FU%=>P^'EI(^1\ *=#
M1_/P^[F-?/*G>[TDV,/^?(OB0V4#<1JYG[$H03]7\ZWGPQ_YM-C_U] CBC.2
MW<LG_>;/#[[RG?9PW&G!BC@%=-.YX<4+Z9-[N7#?I7E&S[@28X"[[EX^[#=_
M^=IWV7B>C>?9YWC25)[21I$RI/+<4*8J-O?RL4_+LNI0H8Z9 K9G*49O8?06
M[H\=.X7JZ2<J^KY"%=_)?P&7T+U<OM6<F#F:R0<H0_R4;B;_U[23%\9E#+/)
M/P!L="^?'C!6]]LZ_ 4I6J&X5I7-D*78.>.QQQD-V!-U7F#V\NLTEI<;R'3V
M\;R&+H8#3N=G^)\;O?C6"<:1N*L9]F"!=#:UEWV</'GZ.+'6_3:'8]>U>^,9
MY)+7'SN!^[1R;_)^OWMZ[W3A_N4NIO_>;]>'QX\.CQZ/>_5+WJOC*3.NW/U<
MN>,I\V6<,B?)R=,GAT^_B,WZ=81MD X8@[:OY3A]F#P\>F+__\O8H>-Q.AZG
M7_1Q^O#XZ/!QW$X_[M4O:J^.I\RX<O=SY8ZGS)=QRAPG)X^/#K^,#,O7$;3]
MO2O-&+5]-><I2A&?W.I@C*?IO5NW=X"A^0)/VRM&:?]/X]^QV6\Z-J,QN'?&
M8#S$QD-L#]?M>$B-(>%]VZPW"PF/]RTFQ-Z*,1Z\PBMZ:+VBK (-^]U=QFL9
M,[H;-L_W'+#[L;>?)<^?'=\T.WOCP;S9P(P'^7W=->-)?SO&Y=Z[ @^/3PZ?
MW@@X>N.Q&<W!'V .=F]:_8('X:M]\=U;_;[400A4<2*F-+G#M:@E[YHKZVT9
MZ6]?)3F?74.SVXGB-,3HBSK>H6)ZMX)?W#H7UE\>'QY-IM1.=_M$6XZ*TY.(
M$8_[CE+F664:) DF+0#075GE3!T)"B>@45.(%KD?+$WGON.=4%=F"GRTK9W*
M[)!Z-*\WA29X!**EQJN1,@IUL!:;VY_$YW8.EW<UA_ >MWY5Z^6<W-TC\X(8
M6'TB]T5Z4W<\+7\Y.7QV=WOK3N;E+P\/G][=(]\E5V"[J(W9DU%N\D^W_Z1V
MC;<+D%P#6:I;OSQ@(.@P?WB4!&"(6[L%2D^NB-^^V%C3?L>[\_CPX=TM]=HL
MTQPT#UBHTP9BUSZ34C1A^SB5MT07_AE\NI]0ZO0:#IWZPE7>W#K]\MTYUHA(
M6='/M,1:?A?K%D>>%^[Q72W<JQW*'18 *2H,N)*[+9X_S(]\='C\Y3ME=VKV
M[Y0->?0:=CIJ]H*\_]&MD?<_?'7\ZMGK9\^?O3I]^?@E_'1R\N+IPS?/'[]^
M\?#EZV/XSDW(^V\UW7O5W.P'"?Z3K23XKS\M\FG>[A'ON^$GGA3 W0^B(R <
M#V?2/ <A89#<Z.HR;Q9THH.N!XEHY,WD/XE W=KG]R0X94WYFZKF83H^.OC/
MH6W)"_;EFT>OGSXZ>OW\^9/GCT\?O7CVY-FCXY,WQT]?/'W\Y/7+1_&"W7V-
M]'=XD"8=HF2W0S0[L+\#";+OB/M^\P>NM=?__;>W+]Y^H'%\^_.KU_\=9E#5
M<%SY:G\PV[P=R?.\I,>S/G0EOZ#L,_[FE@CI'_YI._;D:K+TQ]O_]/39#8C4
M][C586A!DIG8A0ONLSX9WC<S,U;R^0[]<UCQ]IY$=GI/P#F?#9&DCZ.OZ]VO
MM3A>F696YRN2V9M/!M?WCAO>CLQG'K9;]P1LQ'=/ULJ]*#W?U8SV7R8-)GMP
MK;*S ."--V]"1X6=-Z>"M6C;5?/=M]^NU^M#^[G#\^KBV]-ZM@!%YF]-=I[6
MWV9IFW[[[.GCHT>/O[57/#Y^_O#XY/')T?')LV?'S[[-GCU^^O3A\\Q\>G1R
MN&B7M[G(SE#&9W+6K58%BKVEQ>0M^BE=;1(LY&43(K24,#&Q_FB[-J:<O,BK
M<_L_;\O9(4E('9X=3E[8)YC\+"IQIPUJ7HI*,ZC[21!.*KYVG_]05%/[T9\K
MT'=-VS:=L5_+!F!RBE>7?[T(D]$LC=I6AY,WZ!VK+SXZ/!%YRI==78/L:>@4
M3YX=_!]QJLOH/;V;G%[3^'S&K<@^Y.-K!27W ^T^ONH?_:I?Q3'Z\/CP^'_=
MDWF^]P[GOAZRTSR?'H#1?O+PZ)/Y]/#X^+8/RI<P4'.06F?O%(ZPEXO<@)]J
M9ATJ)O\RMY\@ <*F2^UI8P^?,X/:R9)J/9'OGJ7U-"U-<_#+I\)L)J>D@WIR
M='0R'CQ?I37^BE[U:SEX3L:#YVL[>&X]0KODX'F3EVF)\N/CP3-:X_%5QX.'
M#IX3&_&,)\]7=O*<W''(L_5H>7[T9#Q:1GO[M;_J5W&T'!^-)\L??K)\QOG^
M@'6:PNXFJ-H [K.VX48SF=?54I=_D-+HZ?>[H(^@[H.'Q3_IHXQO1")'7V*"
MXE#:0O')/FW^WR_>_SCYYFT)9^3D]:?6E$T.R)@776-_TS1\,WC&']/RO$O/
MS8/O)M_D#^BV&#%54-4"T*[]"3D7L+1UUMK_@;H75J+LJU1+D]AO7ONK+ZOE
MJC8+>+(+HR^4/YA<<I$7:6%#.'MR+HQI&_C"Q;7OG#:+R1L[1?#UBTOO%G[Q
M]3^[O-U@;>V;"WEAJL+9,W[+)7S,Z2]V>"-S^.4= >.K?HFO^I4<[(_NS<'^
M1<--/O/A/8/!G !DG<[L2R'"DQN>SWPPPRF]]2BX+I_ '8[+  C^#WJ2_[4-
MLTY(%L"UK/-V,;D7#WN/AFW[N#E8O(S=?K:@Q"Q#-V]!>?;RQ:LW)T]?G[Q^
M_.SQ\:.7+QZ^.CI^^/CT]<MG+Q\].WY]TQ:49U%.ZQ8AHI+A^G/S_-'1ZX>/
M3YX^?/KTX>-'KUZ>/CD^>O[BS:.GCT^>'Y\^/[E+=/4'Q-ZC9V]70ZGZ1]*>
M%;MYZ\QE>MV?N\'A[.T//Y]^^,?[UV<W:Y5!HLC/V2NC4Y)P8M7&1C2U#W P
M)6EFG74)<@.HP-G"1H=&\I+'SQ\^2OB+YWG3UG"I1=I,LLX>C;.T@^ '#\R:
MCDE[FZF9-':R""\(+3I3LTB+^62ZP0MA)I<_@+#$KK1?PNOY7N4;=&"C!_+P
M>=R,=!"W7_$([U$K"G5S/'IT^/3DR>,G)X]_7[O)\=7M)M#1<B\:1[:$,R='
M8SSS^TW#B[>__/#ZY\G;GU_N2W+BGLS[78@OW*-U\6WS[3;?\>]F/J_-9O+J
M</(R75G#5MVWE?,9QVD<#'4E#_#\KWP&;!"FR>'\A-3I5SPL6T!(7_&(?+.J
M<SL6*SL8<S<L%0W+@[M@6CR^8P_[[]9S)>MX<G)')!']Y,9>1.A/!B+T_R'_
MF%;9YC_^IPW&VV7Q'_\?4$L#!!0    ( +6$]E"<1CY#@P@  .8V   6
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MLII)J]BA2NS#&JR2N^EL-,<2W7_Z9(H,\^+?!12>[@3H<X*+[P#T_0#$MAA
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MYR-^:601\P)2.10@2#AZQ<,69XB%*=-A.A[3[PF+J7G\IE [R9"<Z>_4$/&
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M"2XOUUW,1?D&<=$M2Q9G1MR+T<MAOU)]9U4^V,E3I<ED=[':Q#F':VZ0$UV
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M;V$Q,2YJ<&?LO >XXU:9/^P[?6YR2260 ,DPJ41,9,F6+0]IJI9LR[:*+=O
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MRIQ)O2+8?-Z<-$"N%Z;S'*&%ME <KNQ5IRS 3+&YDOQVHUQ$Z9[2[A61\6I
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M1RI4CE@?23RZ[A%9@'M3O@XJ"(XB/' J<'>-CN].*1(4."20A,%38M0"=RC
MG5[#?3 &! %X@,@$N#F"!,IMEI?X3.PS=09E7&/(](1I?4QF:B:Z7;*7<&,A
M&[DX)>7.DO'%E:1XLV8^+'6I=D\,O4IGU1Z;(+Z-.(4N+GB^$0D-:NR,Q@T@
MKIE<["?M?I.,\S+<99".4AP-UG6XBF3FP*^I(W0,'#F9ZRJV')8DQ S-L@7R
MPK1J<PADESK,>*AQ+A\TW7(.K!FB/$SN^U-K&(QF>MA K1!K3J9--9A6W.EL
MMIC'6F49K64*3LW3I-AC@(6(0X8"!J"OY31F:)):(P*&[4GM,>^,,F?$Y)'.
MI:S 266Y3;']AFLLF56#EFAGK,F]7'6'($*0I:Z\M=FV&HR3F3TO=;9/VIB,
MV+IK>B;;*^&SSBK-G6D1ZJ[&#=E+!*6'=27?!!7B5!^PB#5 )% 'FY&F3F,=
M('QDH:.WG_L/GIKV&R [8NXHF"Z,<%2QO5G'FVI:.&L&LUDE3^(9M(2U=469
MTFL+8-;V1.-$32S58%UE9[65D603)2TU&A6"7BA>) D3<9A[O)OC101.B7*E
M:I2:.8K'JL$H9!2!?+I"^&YU!&O00&G[;A$GVK728"3@KID$;6AH=Y=!'0ZT
M3GFA.DY7+CF-B1PN13R /,SDY'+:G*$S*PI;LVQK<YS7A_-ZRT@J85SK&-.X
M5C>8"CSN-H9YTFDS.&H-:TV_'W=J'C.LI#*S9*2R49]U%ZOZ./ Y3T7KLHBQ
M51(@KBY>5=&E9$T$)TDDL6_5E^F"1#0AM+%)$F2IYBEH96%.<F.P'+4#&5UD
M?;1YCR];FW_PUM$O#K08Z)4XIM%*D"RU^; XF _JJZ0&H2.TV27KT-1H-4"]
MX/H#4;"11<[P_#20)KXN>1.%,.UQ2^Q4;-V=I;6T$ZV:E4X;D9O9,LV((4Q9
MBZ$5IW1[(EA+I33/YGFSF&QM0OWVO#PSG>* G[">-1%7Z4#HX72]HS:<O-/)
M *X<D?..0K5078G3@>_3ANL(+C($*0@=VG8H#8V0(V3#!Y712(OG?=/]2U]
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MM4"$R81N917TT1%LV\2BC?JP:;/8" *^XZ4Z!T\X( D\4%>Z.;5+#8#Z%C&
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M):12*(RQ#5BAR_,%#GP![W0-[F[WN&QD@J1:KJ7]JE5,])&<+"FO&<Y A>W
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M.V+@R_EX5JR8$AH[C,L$?!.8_)_P!P$ #1[IJR0('_FDJ*S:1C)CA%@S9SK
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M6ZS "+'2;,4N#;DW"17O1YT"+7RR 7ZP$=+N3G=%SM\4W+YRG#"D0!]]O>]
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MHI1V)4=OX4==:/Q B?=BD>^(U .D#GEOE;DJP4X)?_I/-L.*_7L<FQ/DB,Q
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M79/"G>_;,,GUU <]BR_E/Q3@\@5B)$I$#TTF]PA5I'"*#"G<E^LT*?/1"'B
MV\01-5#5N)$H?3[%[5W<TFNALQJ8S;WM4\PP#\'U[(#]G;"P*QVN6*"0T8?P
MTY$4$!CV@#_!C%F^-+*2 J:&WK N'DF;U7"7)5:+Y'*4%;$\6+^'3%_DO-2Z
M^@TZH5&K9N1YL-N$Z,W?N'-;HGLEV7[HR:\MWOK^Z@.(.F+4C@>G3.46H;-Y
M>N%7)X 14*T6[H#V[I,^V<8OCVN_/O*^^N'HNPX_VOHR-]11K.48N1:R=*O3
M\7OQ,R\IR^IUC&X3@GH>/5^5-1'A$)$@SGD8JE8T#@*10O_($^E#>!N39AD
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M;J"+S0'BN&>0F_1Q%.X^/!IXPB<XWK6]_A%5^]>.15.OH]LOET<2RY7U_9X
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M*;4-*06!+FTN#5#TB$&UAN=^Q6MQE/7(<"ML>_K'?"LX5AC[2V@K4UVN Y=
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MT)XS$O++1@Y^T$/]NI+V%'6A44<HR/-#]52YV!1V[FZ);,J;>DV>&Q"*#"]
M4*$$)8(D2[=A+[X)3-P,3$YN@R?G\W1EQOB#;9=9#,&<68#O<:8KMX&V*ZPF
MPB8<]4F!Q3'!U/^94320 ,7'* 379)E28C\R70Z,W/'JI<[(?5+#ESOI$GS-
M,LYW2RJ+Z'8D;;+S6;.OD8]U\T5@1H$=O_T.F+)A@3;H5VQ8,HH$,-9Q3"-O
MPK#R[J5%",G^PFXE^;5>[+#4PX$<<JNJLB&;2+J'9S-^6PR$PBL!DKE&*,[Q
M_J)OL&&W"0ULV.8\@OX=49S/AFVQ87Q,7L0,8@D-,.G_^]^'_X'BXQ85P=R#
MFO*R%%S&4996L*AU'2:2#<- F4E("G@RD;H(!@/!;-A*-T U!!R?LF%K()Q^
M FA'Y%&A?Y, ^G["3TJYU"AB8I!XBC 7!UT0"[H"04WFU:N3 RR(2@78,"*4
MBI RP*$V-FR6B: HLV$?@2>0Z,]"%T81!B*W(?K??:+_7CKC0,N>=>>EE4-6
MPZ^K#"[6RO(15N37SU9W[RP:C8?B=C$M&=? -I49[*0N[UK]=NILB*Q<<G$9
M3.N1@X56_;A K>T(1G!C&E!TN3O?J=AP+UKWBI+[]X'?8,#$Q]X HYL* KKJ
M4M>$Z4K_6.&6C!C/@E#J/2X8^'NM]=M[DU\;+/A.?4,!'QMF!>7#WU*VUJ[N
M5) #U$XH:CU"V0&U>PJ19-1P!&FR38[U:2)K^//;37E1?BA\G9W$FM.+J^?8
ML+<8Q-3J3JNDQY8#8)RI"9^0=K-X@P(33_V]-&&:GC#1 UICZO34!9G5P)V_
M*1 C!-0^ :9%B/R$92B'2ZNXP^K"UZW0I9V9WWQ(2JQZQ/J '2K5RP**DN:X
M#3(;-G\?<94J#ZJ[09G SJK8,W0+1( KFA.S?U"46Z@MA"4"K"DA;O\U0#;"
M0%Q9>P"88D%_S/B+",SQH(J,F R2#3-\@"ZR5;#IS(N8TF?#FN5:=BJ.DG#H
M_YWV!?_?ESQM$4'N:]!0&W0[:'Y,X-LFUWSY4:W"*\RP//C&*K!M@,BXA-@2
M>K0#C2PQ:"@KO85_H^S[[?POO3@RU[_PS:)H%93G"#[ 'A]\3"S;X4#:)Y+C
M31YKJ^"]9=%M\,VFH;5R,L$..'6+JD,+I<X&RTRMY;BO'"02+8I=/WXK]<2>
MJM7B^&,B@!HP%50(2/N.?O =+.X%C9I**V^/*,YXK%>_L>J 3'R1&C;&R2H#
M!8G7NZ4Z2%*6RN3%XGFPG?C&[)YOP4"J5\<KKJ7H)^+I#"/FI>)W_K&3C?&&
M6MHU^YW/<N RL]>4ST](UEDHMR#*8F([ZH7NN(S>D:-JKIO]EX]5, G_H59'
M9-M@QY8]1)B0DW:;T94@>]EP858+_N.*ZY[%S>A_>=J8IR0<,]0.&&B$?.,G
MZW@]8NMH+QO& 8V7#,U$IQRY=B* XDG&4C613R7SO%+N>]7^0I>4>B*9[K&$
MK]]W?,)O%'T!@.)G"28G4]K'L1*59F[?]1!=QDVS@5OV3V,9D[TFK5Z6(??;
M[?4 ^V.OT@@:G1E4*=[9N)[LZG;"'MQ"Y*H,9"25\"#<7>A)G*J\4PTENWX!
M]-TMA>IHY^=_DKY4?9BX^'.J5(_HYYNU>8_P&1BL)[G0Y2 1J\5(C[3! XNR
M=.;SF"ZBWZU1]$-.\'! (W:3?^S&B=\_HQHE S4U1G+3W]\X>0-?CS:L5Y[,
M(*G<.;+5""%PB0@-MS]OGZEDH4J3R98V1,O%^7<@/I-!Z/S=AI7I WG_:]7K
M\5BRS\2HVJ4<5L*$J6KG_17WEW\0E).!("?J1\S?>F1!_T(0!)Q104+W6ZH'
MM"MTC_%_)C.D'?:_!H:-/H *VQ(!7IX&BNZO;AY@D>7Z<+M(BF=N21ENMVK[
M#@!3Z)6=5;5==#V'FUUIU"-E-NG#X3W$>['4_3;22X<QWTS6RY[:G$I\>J!2
MJOBXF^GD@^BBZS7"B]T$&#">2#A@06HF5U$ZM4S;(]-*>+]>FGPKF.OT /XX
MCY\^L,Z-"J;G!.GC ^OQ^=] VD[W C.&4("R1X8)?K31MX7 *A.V4J3F1E-F
MZU1BJW)1%O/Q:M%.FR9Q!L4B?@K"HE 2V"(!LWXO146 ^TY"]ZI&U23'D8[G
M"&G'[\1#WIS4QMR/V'Q+K?-;S\I/,QO>']7<%,!6UGMOFX"\,%;:<B&]4IZ"
MTRVW_5K]SJ&\.YU9?..,CFG+^H$3N8:;IMA'N':5C<JK$_;WZYLO-S2MQ=4#
M^17;U=CDHA+57VHD^P*\= DO>2_3>('Q2C8KB_@0_P7Q$$67& A&..%/6-ZR
M<6$%3SB>2*?EYHE:/0PJ&0T0_;DF]I"[Z;I>&W_,@3469@&H/</D?#2._,-3
MTV']8VMHZ(%]7%1SO_>WQ";3S:?J$8A'1T]FS9<.JV7%/ 4'^*@MJ^G#&L.,
MV"3?SL_C(Q&Q-EB:$;@W]UG%0@SA)!HK10UD'N2;D,U)J3^%)?$=FQOXW73P
MU^9!2\TKS;)S3ZR0#.D4_,F+I"3(--YZH8ULI'&4<*8&!4R%&QZ+Q2E$SM>(
MRRMAY+%H#WS?*RGJ9[F3-FX>N5.$RFBF.8&$J0H:KXPO7M?'Z.);ABF(HQMX
M^NF59AEYM=MCW+T_AET=O_\L@X^QIK2;%\EZ=CC*351$W'1E'\4]8N1A1Y9
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MB<,5QJPR-9FT+X\2[E+2@DX1;_58YG>)\)?;N30GB@LI3]S\'C9>X,4)W*(
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M;+\G)/3CH]8,84<)4H'O5T-RQ-K.0:= UD9I:P2AKF_;3EV9.O,JD44 =?C
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MPJBJB, X=O>%D%[CP8G'S4]&HJ0H\>X1L2&O>/NAP?*^,[%40UC *M$=8J!
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MU>QWU"C+7C_#C%#3$7M RU($HS/K@T[G+'3( /D8>C;-@&$*#H>5..KVMEC
M+V*?)3PKJO:(4M-'T,0A!F?@(J KAXC#H+&"]EFM*>YJ\KHO*#5+)\S$< -(
MZ:3DT)1(%\&\SA;'QY#)XH7III8T0SJ;:P1S]X++*NR%I]*H3EYQ%'1- D^D
M(L^*WZ$84$MI<Y,!8:->!)Y5"@^/RRS!M, U$+4=I<AK 'O:N)D1%-Y%IP10
MU$'3=-(3S% \AIT,*R-I8(V3'V]6"7<,QG<N)E:,I-6+]L4V8ST':VUF%>&6
M1%UJ&Q7>9/9U ;+GJ5Z&S-A-';.78IOW\!8N.\7=(VXCJ)!<1BK^)*\E]GC
MH;<G,2JV=YW43A"@EDGIYNDF>Y:<#%CQ:(!]00:T)]P/;]$OZ><>'I[[@V C
MQHE4)YMFV>:$S":U#H0]"%V!1M6B'=-D[>8B%MEH9"[*^)"$1K*&J*WEN/#%
MR\FBR)%.Z4I$=07;'[W"?7LL/#!W4O];6IS.QV17C*V:6*N+I4N6AQ,F$M0R
M'.H>D.PE?YI)"FW>.7F#"[S*G+FH.)<\OAF+D&YV%(I+=B+<PI?HC!P?/ 7C
M3_&Z"2Z)=N/CL[N'YC?-)6)9TG7U??7=-O+3?Z"=2-:$*X7,+D,L6R]$!R;P
MQK:SXQLS;!$&(72@Y09)ME$\\V<B-0U7OK4R\=7>/J> VU/ZP<*BN#"K@KOA
MYZ;L]92T?[<;.?WM^7M8LC#S3F0?<7WRT%2(,?2Q(-VV)JZ#O&I +(]IG<TQ
MA[P8KA-TA7 9H$G:4Q8LWH12'>5;%5/PX&Q(/R,6C_!1:E1G-<^\?B2FDO'
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M[7/NO/?YWYO\$G+&\97DAN\_Q*A\9( O]![J3&*0-*F0)EU)8/Y<_X^?GL@
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M@YX].,3PB2V#@[RIK!#=$:EIX+'Q23^_!F[CGLLP#><S_<*LRKEGYTXZV]"
MUYAFPZ3JEAB!9[-YLQJT5*X&&D7$=\:UJ,%>(A)1X EV9<_4,15@*CO>N8<=
MCM[VGK0EZ5O'_-W80[8&7G@/L*6@*N)FB&W0JVG#L^^8A*YY3(]8!NP'Q,XR
M("G?8PT./(R"UQW+?7[=C5E/F$$'?(C-UL,\'&&K;_NV^VJN]I+S_BFK3>07
MC:$&OG(QQ37A(J_89_?>TTGAGXY&)YS__6;&F$O;TB7G79:>NX KYH*'[PH*
MI"L08;K4/,>_WW]46".I9)FD/S(.%3K 26[>;3Y)\DO<]@"LI4LP>\EVHVU1
M]"]5A*5;S+_L^_I@SYK-;PAGW?@/UV_: 2QQVP6H+C.?<#J ++V/E@PX041)
M]J6C<F6 P:^3G1D8+4PDY0K"R]OOBZW U/R)ZL0!DE=_#'45\8+P$MB=FD\G
M60^? O5Q\ 6V;HL6W,Q30X@VM+-)6Q>C^?4TN)!4AS$B-F('G:SY#\U2/R7?
M[*,<Q^B'AV @6PE]!@_=)LC!C<(+B.XB',F?PR4-8[2C&%Y0%O\YG,?'Z7+@
M+@_8Y>1"X^&>N'N1WXEY?D\9T &I68)C1"%6Q56XD;G_+KWU9G1.]F8;8X?]
MQ2LV7]5B]19]/%RUL7'SC4^#93,FM_G\_/<U,V:'+V#H,#GMXQ44B*6NCN#0
MKMHV^_'O9$&WAU\)/K.H63)@I52?= 2L3!8;@#V'P9YDYJEN<^'I$32*M/<A
MO!WL867@3]TCGMUI*<;@0WFSJXEF'H_ ,-;D/$4!;V]?8IMV>#%OHH>E=A6U
ME*%1273<U0COI)3;=G5A##QY6<Y!?%0:PQX4=:"W0JZ5&5)-TCK8TZ30J-&.
M!F+:\8E\9S.V?BV]?!3/\3%T6&@-47C0]RVH/=YZ*.:(7W<TL3"Z+'B@ZB#Z
M3:_0NQ(U=CA_\^\II@<UHGUN/"U;]=(G[_R-_-LY4LK(_*]-ML<B"R)*4,!J
M5NQ:5.ST0O%4,O%<7;05Z6BO=8LNO-!5LJTP0+I5? 2BLHO]]HQ$B2/ 5SSX
M(7:E=?K]N2(5/^S3H7)HY;4Q;O#;+\?W+&56<9?2[\\PC.,,.X;J5&.G1Y1L
MV5MW^H15 FV_Q9XL3Y+K5%HJWT;/GYZB)OG:Q:$UGN7RASEQ^O-3BH7CJX]M
M?#R0?JC?>,LAC[5A0.ZN#R.CQ.A _QQK8?_5=9O_6'.F8M6&TM>2;,[A&X7/
M&(7->6=?F)N,,N=']]R#L^^^]9J@:+KJS)3GHDO:C'.FQL9ZBC3:;S\/R)';
M 928\S]-D2M_CG P&G73RTEJ?(^3C^IR]@Z\+;_.&2TK_7%RM9\_:U.;\=KD
M;M*Q,2QBJ1VFH5"I^U.*)#-"!DR=WN)@[?=S[_Z-MYF6Z@CLR7%)6V[N(,7=
M\K2YWJ'O00KQ^&U?G[LP&#0H<3NRVD0N=QM[XXNUJ$?,^KJ>Q>4(A$Z<:I0!
MAO1L\BK7->..O>L+=WS,_M"BMN9A>3I+9 5GOUC_:(WZ\N<[CJ\Z?LG]'>Z=
M0YA$_BL%5!V5 =E^LU)MRO,T0QD0&B\#%E,*9$"KO ";T=]AGU/_\T3NSM"+
M9S(]M,JO/Y"^?J2(+]OVE_J1B;^V;#[GHM/FEP Y;"R%AIG:6[NT(RRO[>/O
MS;%%O;NY=V;O4>]<SS5R-TUS/#8\V2P._7_P_"M<O&/PS#H0D\J_*7RS4PLK
MU_>MIJ_WYZ._MME<OC&1LWS94VQVXW <6O-QSO@4LKXS1=JI?&1]ZP;E3CY\
MWEVG*7?FN*;<3F-G'"O;H9T@#Y\-.'/_P_4Y,'A\^->Z;7SEZ!:0 WS(Q=^
M1T/#HGCF.RUGHFY=J'U718SB9;PL\MJ5;[DF<M0#R'^C!%R_ME6RJ9#RHJE
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MXUC&FS[Z,-[>U6X#/;>N_.C? X/.N<YWW7WW^[JH*K5L+@EX-OQZQ#=D"1Z
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M+'"]2VKKE_PVV;AFBX&RQ1%FR6X/_336GGT>I]*7"S,?;[0FX-U%%T3\)\Q
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M>>LR<V<\->OR!T]7)O8,5<S^:4<,@>&@([QR@U;,9J%5F<\43[>\_,\^E$F
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MU,XB$@8(><P+9R6LB,LD3J+30PKFV95U;B'](6[H623T$Y0Z)UA*1$J;I]J
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M<.DISO=L+T#IB,04D?$8193W1"A*V??J;>ZG\PQ/M.I4=9CWMT.SR F*G V
M:%WG]<9'K"^TAQ[SJ1K0T=^=EI3$\I!FX\HX=;(ZUP- L@E20F? A5VA=FPB
MPNC]'!^ME]M4NTN"*5<GDY@[WI?XK%0D+!JJV@D,3@.$NT'8+<3LEIQ#,0RK
M0JBD-<X&O1_<^^#Q5!B9Q:N ;,KW]"X@(%NS7*L+P8:W!8I-H<_IU#FW7-;L
ML.W5ZM<_=J;]M7"_;17VG#9Y&$'%J01A(EEK5F'7QS_=AYRX%2TBU@82G ^/
MZ<6C-2$#@1WI/(!C$V)JQC?P)->(V_!M; ^P'"F\/('=-.5:7%GB>Q/*-Y0]
M4]57)3MJ8M-/WO$1G++T:*%) 6X3@\W;X4LO(%LN38[H.O&-M1[C@^5X\S#-
MB*25MEF0/QZ'4$1Y32 2QK9#W=XZ<60=H0_HV#*!2TS#2S@K=&*['3L)J/
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MT.T)Y<SY%LG-#Z$HI?$Y\M+?:$I[^X2HP0,%DMDYUAQ6P[:_Z>F3/C3L2NH
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MS=]]4?O*3[8 RZL>K/:#>Y[BK7'VSK?VK=$:>53L[W-_<WB/FU?X23PC[PO
MS7C4;PQ:E2!&C8%/]8DE%NKTFX\KTK:+./LWQ+,"50]].5#VUY/:MY^M<.N_
MG3JO7 U%LX,1NJX80-KR4-4%WA@^&3!@;;@+,Z9Z[\5S:5]3L^B4^S?75Q/C
M5=]<VVAWB^B90%-]2!E>B_WL#'Z&I35MQTT2.SS"^V%PFV8T\53/EX-M:%YM
MX%'HVC]/5GG-NP!RK[F(G;/^T4C2,2NS*?0H3QJ*2<2>3!<&[OE;;BETTSWL
M70%#&ANCA*^UMM"?";8"$6Q#=_[:>Z30QU"G#';XCL&]N;W\$AGL)#"9EE9;
M,](_'=_1H$_-)AQ)"+=>NI._(=Z3NO;V0LW1NLMIQ[5Y;N?JM']]U0?^9/:S
MO&IW@W^FI ;IYQLJ>Q6=?C+H=_JX>EKX8.$]CW4\GXC82KM;K!.%J1=<(@YF
M?<CLS]4M-;^V^UE6K7X=QK=<>3OH4VEWHFJ""]S DT7:T%]A^CQ@XH5H*P@;
ML-9ZF$VS?"?:/]S1+,07O=^&L)BS;Y/!/H6\_[5G,52JG"E'%PM^G"2CU59:
MYH%!SI28 A=K)]2!"'W=>^%ZK^<W0,??<WH[Z,;D+D&7W:&!._/,9N*&K*48
M)<"FM)HS;;1EZ.N+ 02Z12^$?228I+5N5NL[Z;\!DT0&XZ?URZML6\0O1_LN
MOTY 2:=;([TJ+7]77^5&3YLV77O%'=>B>SRC_HPJ.E/R4[K9IVCEQKKV?F94
MK\J3@X7XN\/% ;?N[XBI $ZS):,;7W2ZF3HY8BO!M^/<YP&CXF1KM$@)(X--
M;1\6WZ=]1B]KR6"_Z4A"L)B?ZX91LX8D&:PLS^_GGXQ8U">T!.;7GH@@I760
MEA9VR& #T=YS;3%2BPVDT;9)&>SXNXY'67M6]HDW_+/%MA(JM)7!\HJ@(S+8
M60E:OJ@8=;]%PG\TYRND$-*O0XQ4E! Q)(]-!UQ#<NWN2U3Z2?L*-V)\J7I'
MFG5RE<%\#V5*K"<*Q'GWJ!+*'GEG89CI9NVBL2@?D_^?W>J_%I%S$PM37<%X
M0:W9UN_1;]K?S(SU 21]F/@(1.-1M*%>(0V,3&-T24)\R4R$$1&!I6LT A4I
MHA/X.J+^/[?EY,:<Q/?08_^$E%YS)MMQJE@47*HM1H(6Z4@#WDL93+WKT8PN
MIH&<B_0' ^"J5JVW2\PE;<'WO_R,EZ W)_UEIWCCM[4,34(DZ(E:)1TBZ3;V
MJD&L0*"27$L*E\&2$6KB**!B4%@P2+ %+;I*+, 1*E!ZK!FDLGH_-DHW8._$
M,](:[2UTPKB7<]M(%1"%'THF6/*YFD>JPKW#.$%-5:)+:BY$ND1D=, !'I7R
M&^)_8YN?*">6]N/K$( 7"MKJMEU!!E.5J\:?GDKB>[ULHV^,RR&W4&8H/#6*
ME)NH] KFX6SY-T4:;R)99 A<[R'$BVC1%*GS.N+_@\.8_=*/I)^7,!M)LWYH
M"3(\=K'W/S^EGY<\+X;/=H&I2H=)/+W?8>_D#3VSLZ OU'H>J!3G(ZUEL! Q
M59X\!T.8?,JOG2_(4O8]FO3!*.K^Q>G/Z[9_45^'7%9*<3O^&2W//;OC\GPW
M?KZ(N2D^:(ZN$G]_NX2Z5_;HKDI>SGG!8"/QKGP.]Z.^E(L]Y9*HYR('I\SJ
M!1O&[Z2)NS75H 7_ZC<5N;Z84Y8S$ O[;:MT *()Z:T2FRI426=(-__/SN9Y
MX;^MN;,S!UQB<KV7Y?UDR\R\ /-KL6B<D=<AJI+R2=]7,2Q6'&4PE2P9;.:;
MN[PHOU5^'[<CZ:6C9L:C9;#R"^?ZG74D&XEK_]D_3[04&<AUO$<LSX!GTDJY
MG:-E[%EQ#$[YCLHG'435M2L*BZ"C;C!5DO?;?_)B&RW#OE!*.9E_G?/N@Z+]
ML8/BS/]E(1HZ:_OQNF;;G;5/*/PS_.T6#H05LLH'3[>&QV>;\8-<SX_D-'GG
MMP2^K5G:6!OP*>G I^ZS"9O7K*:%__GXC[R )]S Q*9W/WI[6QM%/K4=S9Q+
M%3;+=Z0$"SUJ^!7%C>9GN=\"_];)\=Y]4.GR+D6@@$7:I-=),I :0"4S C)K
MD_AP86\2<O]Y#F;N&C#(CI^9&K]**8W0#[X]2@+0GVT["E(Z:,*QSZ&L0C\*
M8?\%VG3KC^K(D&N\L4@/U8+YC5,0]5LB^>M8I0/VI[ZH0T]7!FN@UTTDS.<\
MAXS0JPB'H0N\0+B*.%!>P,E<2*N3H1%#@5R0\"@L7Z(RX5D 4-EW"D>R!?93
MC1X6OS\;(EPXFP"JL/5Q&49"E)KJL2.XE9^HJOF2R5_Q5Z?>RT-8D*X/7&V+
M D[*46[K>5OU#J2%R%<Z*.(76MTQ&1,9BG^[\'ESUILQ?Y^"+;SK9Y,5:)R[
M8H<'U^0M1-,!\<-"S-K[2DFRC];!^-<DV' P4TV9'7'%[OZNB822(04YMJT3
M)LESRP$A@ZVY@Q&?HT"N#? 5!3E[0WN?RV "G5^B1]*QX-TCJ,L]6.%)*A.E
M2K!\$&YG]J7I:HDUE/D$[RV@9O6DW9H>%!\%])(:T>NZ> @C@F4A!UW'4DI'
MAC[&WQE01?F#:C56\[,ON:I.U1,4CHCOV@'7(0YP_%@R6%JP'M4)BIZ@)!LA
M(2T^?!-^TA>X6@QBVKG:2]RL<?TAJ3&^8EFJH7H%;_M:UP^SOK%7!W]XTOD9
M&-PB0).K*_%9@QY-+>#.W,K'2I\9 "4,L:@HET3 7PZKG7+R3$WX3<ZU1A3Y
M0G5;2/=C[I.445@Y6"&,'#?-!!M#/A.4CR)V").DW18Z@=$@7$%L1#K!9Z>B
M>:2U>+WVD@-%G5*C6_+0P-U"][GH#OF\J<:JZDZZI+@!%2T3Z,WX1S)8QTH!
MN;;- L=GG,X6MK<R)#<==:4#O@A5\TBY*MPEZ/<AE0'6&7!C77T+.-^%,L1C
M>;W)9N;BBZV;;\GM@9)Y"S_;0A.5NPUX-G19:K05U*&FJ55'*9$SE#Y0_]=!
M.1![408$'U#K#/0*8/&)23R2FO@,M(E/VA 6;$9YS1FI>PKM81>:W&C3*,4O
MM!/W Z]&,ZP2M8*>UP_-6CNX.PU;>9Q[[_[*F#VN.QHYMV08XI9HZ=NV<O6Z
MW+WPC/I0WY7D1FGB>;<,EN,GY_J-I'!:&F*=HQFD./$W0Z4M$53L&-]G%R2E
M4S<0#5SYD*.!' >?0=G1/*XNQ!P??CC\HV$N?IX7FCO;,&?1S@G-0KI]Q4<'
M##^U"HOI0?9$"9V)%Z2?$'5Q[%Y.--^UG:H)6;(QZ]OV8"=ZO)9Q[ 1Y?X/J
MW:%?@"^?M)9P;* WEZY&< ;0V6WV<36?>VNA/&9A*@HN]A%BU@= V4Q.:,92
M>)O;(WH]3P6 ES72*"0E*PI'BT6J1QKI#C7.9TB-H00!)2.8F,8K5A,P6W48
MR0;,&P13OH5Z<(3N_O#Q@Z +E3_F@6-*$3?&OW0_\ ^:L9L;3SN;R/NXU"MO
M">EO@:\Y5,W%>2WB&XP1TI2/2H\2[TA>9@7D,V893\9GI%N@CX)LS"J\"E/?
MD<9#<938P=H#8K?HN#B]C,9LD@&>S/355THNX78$/"W%54;8>6,6.(A9)7[O
M.ND(%4X*BU04ED"--7BTRZ@,%H[8A!?PY$O0T)M2\!,;O]QUC6B8895KR8YW
M;2\VZ7@.H9T'":H54,2Z1J[N.#[E,%"02D?@0YF<<6IYN/Y]?7(9:I;!+X<<
MP&J6?K+8$+HIH&4C&C YCG81OB2]-L-J_""/G!$#$7>%!W0Q>Y7Q14?U[L3?
MMJ6K0QX3I'3BNL$VUTC=.AR/H@%YHT%#*AGI41X^Q9,<51QWW 0U.T-IP H\
MPZZ F>C'DS2RXW.'XM<RY)[P96?\$.="^K=LG[HVR%2 SJ)KCYC%'@RYUO#!
M"J4Y'7][C-ACG:/W=Q/YO:.ZM \!)^Z!YD]!X0E --^6B=OL#RFRN#HQ##5Q
M$  G(P\]AO)XHYFQQ>ZL$4>3P=I%"W7\(P_]P$BL1Z2]/T#.'64247V7S6LZ
MZWCNUO<*S?4FR*_AN3+8VH9>]2.\[-[K=!6$'MT</\I'L1'K\99,^F[R:Y12
MC34\N1"3)#8I)V@ /WL?<O I)ZE\=+)X#PCG>RQGSK9MJH"8_SP4M&2(<NU;
MJCV"OK? N#C_D<1W95$H) VI/30HU1Y-IM&WX6T<E+H<=2!XB" [2%$ IXQU
MD( \5.=\ACK$^9J>R<\]8-KX68LY;M G&+DP:-6K#U6@-*"%3@7D(:,,A65;
ML3%'20);)(EU_4E@UJ]*(;L_)@'SD<I?%'(\[^&0Q(TN-\+VFFV[8R,='>C\
M<NM@?M_$S?P_L-/34)=T_2:! 8DL!Q/RG(+ H%IYR3U1L?WD>/=9+-)W\%/5
MZ.(QY(O*XNU9-G^W-]OM8_ZU]EA7'Y"SPSO[X+G[>E;346KNZURFHH_[W]'?
M[Q>YX^K RW#S6N/7_)9.J@IHZ-9]1_U-_;7WOK@[&J_/;2Z^%<DQ?;E][.-.
MDF//?VP)IP<*OP#?+R* 6K$S2T,&,];-G9'!@JVXT&6,F@S6;POJ2;7CY2Y@
MR^C*[N>;Q[LE60D6OQ*.=$M+?DGA=6)5">,VJ>\2"O UEL%NRRF#Z"=ZE 5A
MI 8%+,:BA]A9+AY&\O5\8T5B_0G%23,9&0R@M)_Q:RU5J(:3ZYI<_MH;D(RI
M>>J$2$DHE>NJTS/YH=,4J;?$_Q?F1Y9$WDB30_W],81CT#W#I>+:+^$3B8;]
MYG.\%T>C^;I>;^J-T\X=W/M <W_O*H;<>/[/%SY+%6ND"-,&I/O%YZ&>T@_X
M0.\^A"L4PI-XNLTON1LL%E]&GA&>VS@P,*[KXH5D_CC^U]6D$NS"O,Z?A&XX
M;UG+EY::;W<*N!MZJ*4_PO3;09TGN6YN,]L;T+2CB=QT_\[ #,%[@X>N.OKY
M$>? ]>JG9IR;GFULL;[FG>.;^6-DO$!Z?8D*_Z[H-O2F;_&*2S'!2?KW\S?;
M!LZMDW0I68L?6_P/^#BP/6 G;6]NT\&&5RZNE[0:-=]=O?AZ]?U=)C#-A%58
MB(7AQ$V</(4"GNVE\TE_F[ QGQ!+2K0W4LK&2\[Q9P)G=_G6=GMOGQ2>JO2^
M _:T7&LQWA/\?K1Q=JX>Y0U.:I$?!J:]>A5O=:UJ\@Q]I,9TX<_NW=^^3M[&
M7;Z0$#SJ]]EHR1EO*[::?$U;V:6+@4Q!/1G,5(X:Z?<A'1G,>95<6-8X;I/!
MOCJ0W$BA%^5ZER/7Q0@93)PD%DE*Y:K;=Q4N;R-AI)^A;?W!JG(5/@3LD6:M
M*9"N)\ASX5T\BE?IN(;4_YL<7=K1&8Q?:%?AU;/RX _VBG?2Y'FB)+PAQVJG
M#RBQZ4,Y_U(?,NIFU3])![C*6UZD[\G8/MJX=;MEYZV.+49ZHQ^4;CB?_V/C
M6H4D%LQUB[XT=W9QSO'UH;IG]<\7#E]CG&],'OO[@UJOY=M<V]E/8W&AE[]U
M'L#^BI2DT1T)QB!F#@NXLL818/[3\IKIDNW##Y[543Q&> F9(4!<YM.@U<UV
MY]5W?C#[EG?@7=;5R-5U/JBAGY+A%?A7S%M'5%_MD:SG&:.EOCGEK,7SI;[W
MI]YVB=P/G'GKL7-XT"\@R+HU= F>U/A]E-<V<&J/5ZU.R6AV_NZ_JG0L9F?K
M?C:O';@:_O'EQ\JA@%V/&'+46;_KT?7_.@X?6+>TFAC3N&:H.S(RZLJ45>9J
MS;_?1JX>M56K<QDXX(2[3$,N[/.J.[+>:N"-[\'\L@M>"J!'5_M+C"(A%/3+
MC$%P;'^'$O_9:\P(,&%'1O,N="73UW6;MSQM*N)Q5<9[<+40V96$^(3F5\/7
M3Q5>*LBLZG6HY[",KC>9K>KD7J;TTA:DQ7O &180-BCM*S$#?^1.%!^6P3PA
M&AC2/FZ% IH9$P7<1AL&J,A<N:V/2B68Q*E6=CE$LPMM"GASNP\B;4,2'G Q
MD&^W'![5N._; OT7/Y0UDX7J?Z*T/MR8K).@B0T*4,J_>?SGZMV??5HYG:\
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M['/TM[OQC?RPW%Y'\D7IM+Y9E]&[.0YMHYE;:.RZ90Q9M1KRW6 -4711CW
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MD;\WIW?"M< /=\_("R-P[Y1@37* B=O/\T&ZJX#?Y)XA<GI+6:'?J@AZ9\/
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M,65B>1I WM/:D28\_JYK3X=5EV3F(X<K3P7?A:**,5/EQ-54S%@NW#6(96=
M-W]/7HC&T[X-PIK$T=9%%+N"NG]DG/%_R2TLW\.+]Y//SN^4TWY6:$-"W5BZ
M+!5I&A6NWN<!SS/':M4A";7:TH5+I!V^*0Z9%-5U8[KSU=1O AO[P958CB"8
M=9:ULA]WMF5R/RB27)!;[H8W V+)+&S<I%K]0)CCR($!8]-R/[T3B_!.6O^Z
ML+Q&*%U1?2#HAQ(\4)UK2LMJU7"2CUL/$F8Y+ZV$O!B?S_8Z#%E' K^7XY#D
MV+$P>R$)%J.%?XG%W],4\6(LS"Z\\4#C:3+^(,AO>&GLP-I]:*06(SCI@OM#
MP[N-)$(]P#&QQK2ZD9,;'2EN+:$*V3/3W)G_E'2;?QO%W'C,H4L]L95/+726
M>4!GEMCN 6Z4V%PZZ)81<F.V92BWTRS35VA?0WJ!TIZB+K/B(V,9Q/A7'K;Q
M+3Z0!U7_F$@$SL,4?R[@"OJM87JR_^?G0/6W]H'[+1\JI R_G#?;AS^;K>-V
ML[S'"1OHOH 6!H@M%5;. */3=CNND_4?OQ;$3BH R"29-O9(F]0(09JC_FJD
MT:CL"UX>(&2' 7"47AM!J4Y1%F!!1>W9A$,U0%QLC8+*+)TD>LM]/+&\5\P
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M"'&W+UXOEOEU0 "K0^\KLI7 2CTH,\LH\S[^)6M6B,!)3Q8TO;GX<> +FRH
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MO7\J\<$$CQ<L^A&7[W6]Y<CSI]-+S5)L_!RZ>TWPU9$_& 7RW[&PL[77++[
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M6@\[MNP=:AK+;4]E=9YE0OM:(UGZ GS[+8\>3>]3,+= N-N8H8 ^(EV/I>/
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M*HLJ+2B9JZP%V:#'>/UNF]/)+]BJ>'M&:B0%CNPBJD%]*>608P=Y'<'_SJ2
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MA26O%%+G"M@G6AO%%JR42X!O<4BP72BEX#_G18M%4E4I+ CP6EWLI"_9=$J
M*4OZ#Z_EX$_1D:[M)'\2^C5_U8B)X<3"P>*;-HLBP9 $^($FPP%B+0E0>*)-
M A#_YDNQ*)J#7=4]2P*UV<*JU89OS_]N_<LE1/H8(B4J75=[Z,0(YQG]-C?-
M]U;#YF*#_<>/)]F^W+JV[B<=MRSN?N"E7EW J&]NT/LN+>[^#Z=1_MI1_EIO
M<^ZX/2E2R$+D[XL^6;E^J:FD:;/;D2W3-]R.J %_-]; -R6 K*$$N'>'U*%
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MS,^@BVX(0Z<0*5B 9D@(A,E<1<5,HRF]="X.^Y[M#7\"NQ=/@G[:GFU<4EJ
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MSD<F?_/#VW:AY:V]-%IHR#;(V7N.K6$YUZ<V0]LU-.32/+1LXK7<2/)@VTF
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ML& _J</TMRPN1-%*7K@I<'>0:?RITV&7Z,'7#\*GE7_>]FI^'=]3]:^R_+1
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MHK19-L0RH7G:5HAP#J!P6.:9 EZSO'R)]V%TJI#2S$C)SB$Y#9",\T-FX5_
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MBN#3O*HQ#D6C-HX_;8YK!+)26?MA'P#5'&+WRZA2IA]6Q3JU6A^GQREW%83
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M^B.R"R/'BZ33)FF<A@^M&NP!= K5%/-Q%(\%(NG!!4R,N.>\SWZ07 B.LW
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M&288H\L_X3V>?R#2GPEVOJAE+RY%F[R/L%,FS, FQ*\T?:A>*VYJS#QSU[Q
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M!%0E8-(U[:O\C)0P61(#40H1&1EZ0A/);$'\YI$'EG(BNJL^3_KQ9'NV();
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MT$%8MG2/&ZTV>^54OMR'&2Z:/;M<488S8HIV3_!TV#N_3T@%*9UM ,L ;H=
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MCA,/%40TO;PGA06<;'CYZ)3OF:\,4W+[488V\:+,JX2J>AO'4TP0>9=TF#1
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MV@;RZ_^5V7E-3VWFWA:K:YO$.X )I?,EIR[G43]>9526:#>%N8;D93TL'\[
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MB>5=B?P,20\0MI:(+H":CZ_&E!+B.))8#,O3*+5.C'5I'"C@G!K&1] O0@/
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M.OD"J*;\YXF@U<7VECG\S@_2?Y8J]];?HN2"QE$0^56PJ?E7<A$3-Y&!= [
MA? +'KU.=Q\RE$X;_*=G[NH'-]CSY@?O#MG$V&V[:6C#B/H21MS[)?!J5/B-
M :!+Q2MO;YE2D*#D$>JTB=H2SDPY^]RH6]./S$[+\Y^,3HM@"7I7AU&R^+GK
M59!:U4OG\$LZS@]_S&!RFAS.U+AZ7%B)[#'Z\RJ;:<;2F1\(X\HH?C3O2M$>
M"B%[@*:5/'1"_4'21.?67US^R7[4;@%R_<6B@=V:%56]Z/STX.T&?S$2[O">
M836UCI>6X]%./37!;^:TX[L6)X',5**"4*Q&MA-5H&CN7U40G>><R%W?&^//
M26[[Q!]I'F+AYL B*)N[M(B5IRHIB6!M2=T$S$M\>@OQ$!01&5F&)W.;\E*Y
M<-GQP.J .P6=+20: NA$:8E@+RE,P2[FNJ([I^JN"%8Z>\]H2.-<Y9H95.*2
M2O!^]7G3UHVG3(IAESY>W'5*6F)#U?VCG3%,T)^AY^&8>:2_2@E<>CWN^LSA
MM?NE9/R=MXG8XF*;HUUY=XXZGRGXY)P5]T.@:7F0>P1O[Q@/_GZL*/7H4G%!
MSF1WP;&K1S_C&Y2">I:S7(/.C9G[+@:Y)CJ,]Y9'G@4%._I,1#!9@E6/P+J<
M<!QRD6@SL/.!F&_8 C704?A%!%,@(@@[!RIJ^8FT7;V6KMPN)<&V7DLX;QM-
M#1_Y\4YHKD1\!%RQG9,I'TQ16HKNQ J5YDHK9O)T* ZKKB<;0$0BVI\D3="%
M-@OW@ETM,BH3[$1#JA87N^.G6#DRUH^$;#H+6N-=78?*(DB: 8AOXQH@*<G
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M1?$MMZ+M]W]XHSR+;6?S:X>.HZ5%,$X+79H^O1<!G(<+SMNU((7^Q>K";4[
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M*)UKUX+>\:GP?&A-;SXH<<_2LW+F<<Y?BCXV^=\NL +MH_!U)V=P5U]LI-V
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M:CNQE[0=*? OPXM@RP] ?BM)0> 'DC-I>D&D#>)A@D.(ECR-=R NY5<$?+M
MM8\OL /8)P8MGWN[#5#QJSH)=LEH[U>>@]L&W1,K_G+\076AWC!>DW@RK=ZQ
M+UW1\<,CS4"-@]M[+39^W\0-,5O^#A"+@%G>4,LEH(/[-3<8\.9.Q1-E HDJ
MH$KR=8(>+S.5=@ BYPMV-T#^-__=1T5Q[36DZA1"*]Y0'T<&;BN")>;JQ$=8
MF1^\,B1P*X0B3UVY.8O>A+*"IYN36RB;\>3F>A%,AJ@OV#44O@O.-?O;1";R
M)'@V\!.7+^,)T1EJP@PN2:9S?V[93\U]W;^^!Q\S# GW">H[T[L4O MC7>T=
M[5AN/;F^:=EI_=72$WK0.H*GTL(?+FK+4UY_$SHO<(IZ&2B"56=F7.VK0:A,
M(^ T)0*R9\^@<:::  \Z/^6*D8*>1%09&0_.L0SF5"HZ50;]#M)$@,G)5_J,
M_V@M4X8MEMVKUW/+47MFAE8KXBN@66[>!\X8MC4G,S$<*0=%,]]ZX:T9=2@%
MX.NC2Q)W"3A0JVUUK+/I>9.PM )?WTZT CW2!':5P3D/%]C??CYFP9,7S\ K
M UZEP?ZH\S#ST1,BV-]"=!-$XF5*08\B=OEQSM'0D'5884P22#3!TS%@!"6N
MEA)'VU83>$F,L8E%@>7X4L[#G-L91*V:(>-,A%W9MW$9"X:F$<7VSU ;J7ZE
ME93LM3)O4@1U+6/H53UH,7@G/D8H67I7!-(UJ#(EGRH"B89]U+";P)!3=TTL
MI\,QD0:ZYT]889P&KO:'&I03].N5Z_OL2ZVG;"E^@D!(J5!P&?2?XW!S9\?,
MO^*&^;P2PO4^+JW;8*EXR?&]4$[L(N>-.\U_!>=& O,_4 <R+@3?L(LZD&X7
M8S3WI)\X%,AABT6EGX\UMY,R_\28G5+GNZL?'5092Y)&R4^?9>-M8ZYU?/0B
M,P_0#N2BY6>4!\>U>W5 MWNE$:#LV*]P1V^ZS*CWR,\%&]FWO3/R79<W3(M@
M$NB &.]VE#F(:>:GLJ4C</%T58(>!PX76).DQO#YS#QS8"65*L%U\O<%QBI3
M+7?QD#+&<C/!KR$R,X><+'#)#U;32:Z=W[KJI#GC8SYE \HFEV+]H.3E=.AI
M2. .E/0Z&:6/[VA1@(9XJ(1!%;7Z>$OY%RS(8X*=UIXD9N##=)!RM];'Z*\:
M\1"_E%XVKV1@X(>B^3N^7? -\EC)@2<;(^3PZ4[50-B$78L,G"N.FU:$FR _
MP3(2=&WQW01,,>:5ASA=L1&4Y+P- .;O1;A\\+AA8W7O(D5>;&R(E*5,.:BZ
M56UEF9QJ,H9ML0]X[(5("H^1.M&KP'2G#P'TZ_!8NB;*ZJ=P!T 2)Z%T!)P@
M"4RSL0A5JB*/!,/S6SK 2,?&VNKX$T#&5)HX;GM"V'\WN2GM%_;GMN>I]55<
MR>5:W1W45!V(R$ S=%I6X6E_6[;QA-M-)O3&-F&@; X\B2U'< ,P-E"$. R0
MV["ITSI)X5<@"PXF\\Y6,I>]U;X4<G49^-K(S;!F$J4&:RB:!$P5T/P!!0=\
MBRZ5!(;AJUT^J.D*T^,?4&ZAY4Y9W6P[T?SKV#3VF:_^>C+!CSN+UH2"A<J9
M<0(=8&WY'A#)H$@+^X5; 0JC<<U;)D*X"^_O#)C6T3=65!#W6-$9,>I<'6:3
MEAT4PI71:55#M_#R(0^;W@KJX;#"V1Y?K"_Q7FQL?Y[]U&AVYHNOL#G8#EBM
MV-DTB%8!:-@(IZ**%Z.[S.;P,VA[ [&REAA0U<=+'.DYH2^YI>J0);P2/_WK
MME5F@@##.Q^.2R:-]'Q:#E%L&3< OC0T-.?[8(.\(JD><<1^RB9]="!E>(AG
M-R>"%<\HJSEEMOY[_HL.(+U:4?RBF9LNHX]/QF1]M;*=8JZ8N1^:F?;3LPO7
M]_W=?QK<K2+WUG/'ILE44B@F38W>@AD6P1CC$NN/ES*B&:2:\J*T"+%LI!D-
M"0T@3'-DR 1;PA%7/$,[,"38^08?[3*XF+*$W!AT1^4>P>2U>GJ&Q]FW@^4U
M3<XR4FYQOP[<@<=2ZDVF6JVL.3;M=VG;\!1.<BPI *, L1GLC<+=&!YR&]1N
M!]K63\RB=\[6L>#IB_,[R\3&.+X;)"40$1"]A:9<2ZT97 RN!80O7[#%'0'W
ML0S)93$RO,PX-$ 6W(0V@6E(N?8")G"RCSM0)- *?AV3+U10@IYS,B28#Z*\
MLM@CA?<;5'M0?=5K* &VC#OF]"3Y2_8DZ6]L%:85G<R;0"<1]0C7 '0&;2>Q
M0Z@/%F70Y"'_CW3))<JF618[C6I3 (G'1:@Q1#N SV_!*@BBE"O%>.B?0-P/
M,7J[;( D,?S)8%O(RT2M_@I4Y^OS/XTW_/NR4+/Z6!-$VJ$9K+10)]C+@TG?
M3#@&.F<7XRT8]30]"M>V'H3[@$/)7$ G=K'\L/2*KQ:PQ$]8C"(X11:/!M)V
M <M/>3[B6S2K7T)WALX/ZE-#2-<MNA3PB.7 0:(*004DM2 0Q#[L5G$\(."#
M.0U0T4>:RGN SNPT$NLVN$FEDJ\8@E@_RFAJPOX>OCAI(ADYMRFO4"4Y*ZDF
M3[ZG\3% T^-*;HS1=%=J ZG%RO7CZJ_G0)$7@$VFAD5N::*EEPK^W>?#@TMZ
M:8U];'@P8&G%J52"=#SI1Z9M?ZLCWN')SLJL>-;8A9@2EN3U*<%"GPAVB737
MC%[=/L<'2&TBF#S)'ZL$-2Y?K^FUU)F@[QP3=K'E\WM_$> O(3B3*/'VP5RX
M&#Z,;,"V!]S&?VJBIPE87"'!!B&+VAV@E@X9M=(V-O6=M?AY'+4&&8"1S?_^
M+J&$A_/@?Q<UYC)(<E2S(HALYW-2-61)[VBE?-;4Z8'==1^::I//]2(YC;VU
M1^?XN++'PL_?/=F^K)30PL75W^B_V1*69FMH@@84!O@QSG:%O1 < PK)G%R]
MV3?ZY8:UQ_1Y@<BEX%R#(U).N@R>1_]4T\#^OL5T"P,M3-9\64VIGA5JG,5"
M7OA_^%+X_R^*WE>A#IY\#JA,WMN_F!QK2#E74^-W$_8^\]-CO:+[45?[I$\[
M)HVU:VF K4]X/Z\^T7"_E.JV2UK[H'M)L8U#?D((\=0'FV/!KVXY?H'_]8J&
M%B>.'E[F'ZA7! /.H__L;UKC4%)-T#N@D%HGSXGHJF)?KQ_C\.KVR9-[#F?J
M6PB84:,C'Q95*W,_'>7M[P+9PY"J7S[V6W\EP69[^/1OUX=:R#LF,ZC@_@RR
M05Y#1<48R6T]PFI[VD')CSK=BG\\OJ5XZ2VLN*R_7Y)1Y,'3!%IE J7!%Y -
M!\>R_LA^5][>IH[1A)QG0*&>V.C(?UO:O?B$9.JE&*_'$#3$N":_"(?/J(WG
MELVJU3YLXWOG,DG O6\SYH_()=/L>OA<;BDR]DJ?T +:^(/-/;=<A=^_9'*L
MC5)I\R;HL=I6<K'W#.9:0PPMN0PBGWL+Y"5S]=9*T?!9&O(]5C)@]?E*JK*3
M 0Q5_HIV:$@$PR&&>2>A)CC#A1<#/T-QZJ4=PD(++<LYK]'?T/!*E,PL5EI@
MQ#70\G[*$<$P39H'H=Q"O/M2S;&(;00K[G/T&6"0NNPU=S:P>Q77 F>5+N.A
M\ZME)#F4 63!Z L@'L'!9N6"R+\+VIYR4RR5./Q4M8R,>:II'P87\A+:U$K4
M!(M2(YYJ^4@PA"H#Y29=\C,Y[GE=YK"8+38$$$ OOX!<UDY"^;S*!)0Z-IC<
M4#_'!U%BR2*7>P[X59H_W<G%U^S2:MD[Q;SS?+[A/#[3.J_/XU3(DI4Y]X3^
M8/;H-MM'D:]FO.J[%V$N-@3TVD4!'HH'+B]\/ 1I\FQC+:U#N/81>TJFI8H?
MAQSQD3>PC!MR%YYRH[U?L$5\T89W5$OT?WKWS#WJ">?W%_4"#6=MM_"QJ,\[
MLO)M"Z(6' [E^DX>O,4R_/WNMO,LDXO:_1&@N:1]73@P]!B^#9@IN]'/.5N]
M^E7WG@)EG\[9ASXE0_&/9FQ[?@3-[Q-.O*+OL)OO !?OR[[DR)Y"_-;5$<'T
M2Y>2)[K2(DCJ!%T GAXQ59?M"<*3C)L\SF;UCGIYFXR-6DP>\I:X;ZW);U2]
MS3HZ&CS,E97NA()EK)6>8"1T(V:CM^F;!#W:5S0W>?:W:[[] 9:!CRD_Q.3V
MGW$%$+&;=_J:SJ:'KE\N>4LEK8YYW&7VY$LXLLX6!#CD[:\.FRK=I7&Y++=I
MT<I4;-#M/R1^'!?6_K9C2]D0;Q .B6!Q\=Y0=<NX$C8%N[V=T96$5J!>73N!
M-^/06^;MN/2_:QNC<S.'/V-3/7Q-!XF[(6QH?*G  OA.VP6Y<,=NP>7L;W*=
M5.P/3^=@TTQD9!?.]\D,]=*DULM)_H@4]YXQO#5W);X6/XY4_?H/,E0_-(0#
M*"=SV#N@8O[U6D='J9$-A7C7UG%5,$AJ-CKL#>3HVTMU?9TNS@+CUF_>2O2<
M\_B'>&"]'K5AVE<1*N;"MT-,#"@L!ZK%@IJFXPMACT>7.M+E?HY+]EVD@TJ5
M24L9OHPNYFKK<K+)K^>%^#P9HS-T<G-#7L%5/^X_X='%O5M)#/I(^G($U%A.
M. VL) NP$:^"1+#M*"W"9>@J-QBM]C.G,B'CZP= (_"(X'2_L7J&+TO="G<"
M6*JH+V2/SBA[(/>9JAR,C @.D9<^COKPJCH\!NL\M/C<Z$*O8=::PV#X["X/
M)VK&E?._%M<=!O5&])X,7KGGYICNR7VJ?)YW7^_OGW>W9^C^[X\&;R<>W4A0
MW[H!#5J]_6DD@AFNC#^:.Y>P5?7BML7=\G_4%HR>B4%/K_TJ;>1;3!C<7'-D
M> WKWX4C#2_T3=72-/'L/_<1S[T1:^4B&($"5)8+M\59*@]O)K7,NLP<%IB.
MU\[F72 M=*+YC\3]O['!=@?,"@8CGJ0A$P5H@ED.*=!RV \]7,)9S^PG5@H\
M7<GHFM5)4O+P"#G;^U>91?GUO*8QP9HAHU?^OMT;K075@E=T.WF0%$>_C$A
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M CMW!N8&@\$V4O[_/P?J__4Y4J+A_P-02P,$%     @ M83V4%VKUI3&E
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MCBJ!$.\//9P4^G?:;VF"R),X\@;#3/L]H20#8#C%SO<91.[0E0>^T7AQ/L<
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MPK#[*^![143Y.,XV!O+!)LW;N91RH6"7@3U,1CT#U,VH1<0*4Q9RU@_-3I@
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M!IE+MHEK!GFP?J/?(PW;I-KN!J*VL"@*E?R3&#9,] )]VM'*C APRJ^'>$R
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MK)^ :'SGU$BL#C=LZZBESX0%A"HCXJ QGD7R#08XHBC''[X[[-_$:&;0<P=
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MC01TE&'7,L)U,8*=3XZWMR2Z0\X1ZD_S7Q=55Y';FH;^Z*V0C! 2V\,X\HR
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M65AN=/'$=[M*^&M<6JK&\5YOWZD O5.^SZXPQZ\9]<]SZB=^-:K&/;ME1SF
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M=X:M:PJT3!!E01(->.4",NE1-1.XL*IIT38&\"V!KXW6GE$EL-USW'1U"IQ
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M?PZ=B[.N-OM.UX\)2*8&5X7[K![ J>>!FGS*(F+?_IEVQ#8/W_PA>@D!?V(
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MP<OO?:ZYNJ,\'8U _S1_I91MSM^\!O5)#C(=IQ("FO+_:0$'&=CK#?*O7#O
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MO(0050187MMX(#P+8F[Q]:4(!]PKWK 2GH#*WL>=X)XS0^P%Z9R%5,9: .T
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M;7K#(-69VZV"*  ??69INW4TV^7X=52R1E"92Z>H-AM7A7<&+5$&"53C4AN
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M[7 V1K2CWW!9YM;W@1?%IVO-]QH6#Z3\A>MU2WKAEEZ8-]@J-]YL)OR\-VN
M,\\Q>?.ZT-?A->5UV!T1:-/0RA\2)!6EOYSN6OX6OV$]@D5^$NL!T]%X6:&E
ME.LDX *!YN')U10<RK<<*[AASO22L4<P6!GE1HO-[=0+4KQ2(2=;NE@:%[#
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M( @-YY Q>!AP8UK0>4FGGG:$[Q8]N4&7O39K/O?@"32BU\L9L..NQN(MA";
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M$,?^DC/(+;-FLD>S)) $*;.0]\.H-*T0GQ*ANB"E6&@-6,=1U4MP)B %"/<
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M,/&B-<!K%3$44+W@-7IA\%9#;2QATG>A-XCO((%P7-N2\-NQ#9S0I[^.%5(
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MPTE8>AR652E]!J3#,K:>B+AV*JX6+I_6,PQM@HS9E[Z9M'YXV)>._0*'0]1
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MF_+0_Y], 7YDY33H2LD(QL)W6309MOS*ZY)L=@36(])0^T"?$BR_-=@>;'A
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MQ&JBKD)3B,.GI5,W59,NWY+Q"P)/<ERKN2+9C+U'B'D%10*.?@U0?C7A9*;
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M\,S 5PA])!Q<$9!8"_IX"@:<NDEWX&%N:]HP,PC> .7L@$$]X%/%7]CX$<K
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MR(N'2%.;"3HP2C\(PMN))J!F:U7$X+>.(Y9<)?&I47XCT$6V*)!CH709 <;
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M+SO2T97L"6:AY"DB:[?FLSB)GC^D&-B0>8[6 FOK:D)GJG8M[;EY%*V'7^C
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M(_J=ML55_1')!SX+82LJJ._=G$*1CF4DH+>SWP/6;8H,>B[''?AS*S>:A4K
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M-_2++QTS4!^DM:?[K 4Y%=J;#<8KE(8MJ'BBO5LOS?3\Y'S_U-7[O!@,9#Y
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M76O7K9-9)_>/76O61OY307F=[/;]ZU4.N\N="U/=<>#6!K4C=_,KFC?JFYT
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MNFY#?S349#E4=%=_E??I(38H+<T-^57E.6F<A*V$MU"UQ;K2*%QJ -&VCMY
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M,NO^@+=1__W#6Y%XRIK:JHV!#F*6;J2WYQD#\$1BI 06XR[N109$\A"TO!W
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MW,&$(#[?;A?H/1K= ]3Y3DI@*E4YVV6K[EDW!_!ST2,?[NFJGKPCRER^\M!
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M @8D+D]GEQ&:DXTO6D<6L]<%'5#.BHET8#6>J>9)M (FIR3&TP*I4@=5EQC
M1Z@1G8=(.XF1G$7,^C  /M;7$3NQ$\Q+HM%05F'-RQFV^(VJH2PC8^@R: 3?
M1#C!_Z9@UQLAG >@FR8Y\"2\Q%7&;AEM1\D>/]A\YVVZA5>MVS;*K=_/_OVU
M73LZQ-3/\/ %Q>?A$!/U\,45_UE@+5--HO!2YNJD=PC1KPU=.<S_'E^5)#BV
MPE7K?Z]@T:1A\IH8:Z[R9.Q-V<;IYF_4Q^1.GPF$YW%.X%#4$GD=H8>5[YM.
M3\2QY; -DMCRZ?S4[*H)"1HJYDN=C@/*MR+ID5BOX0J F59_^/'=&;,"K[:?
M:Q0V_19T0@PCND.FJ#S0FF_':\].G7 $&KNL=0GC'>B52 1_06^:6>>0TFJF
M^'WTSF1V1I'*P*KC+$'A&G'/Q'9@(95A&>&X3"':E$'Q?=V.*P/\):@]A,PN
MF0G')%.V;@ITZYS0@"HF\:N(OH!M/GD^!/CA"_C.!P@0Z@0;MD;$K "SB= B
M6$Z7;9$<A1Q*IR>,FP:CI6[L?$SW@B[!^@A N6D51>]3"P@+6@':-HO:$A]#
MV8? V-E(K14N1X8LZ($VF('%]SH<K\&J2-MQE0NA%QIK:QIO#0ZN#@_\%)+*
MW?1XP[=W'0Z[+=RKT'H$A\/@Z,UHRX@?7?;VGC&1A%" ? L9#HA/_ZC6RS<Q
MV@H8,?EM<9%G:G3MS9^JF'>MS_OSQ^-=MYYGP&3D>@3%" 'X2C8CQ,[A\:@2
MX9LWN#[(U&S>.,:680&5@#8]^4E'F/3ESL,K_6<F]H+XM!@/@\B[-G8Y69_;
M"MYM_#R)N^_NMH 6J>9))#@LY(U3^-0Z6A?V/UP'N+\B4YH<(H>A]3DR+?]?
MV,;BJZRC5@ZC9BGDUELJ]"TWIM[U5[J"LV/DONYZ.2Q%1X&.WSBB7UQB3@D5
M(IV96#GL<V&D]_Y-S/?VV!]@-9GO2I/#OK_+GC.P_@<:90*/.0I]#@TX>6R-
M];^O5HEXS1L9R8XFV:%XL,QO=$3K_T_U>3[V_D#PE[@]0:^^S'\4];H=&]Y=
M]R>2V7CF0YS?A]BX  =^[#?NRQ;7?VU<_,\*R1!25-=GB_0A>EZ33,^3U9MU
MZDO9M/\D<O_^?QR#^%\LONUD.GK>',SND.V!>A])-@$+K"RO/E&(E"IQ%KL0
MCS5"UXA>,8@T'\:N8929QV.B%:#]+9E<QH6,_0M8V#7$R&<?B0?!U91;](1
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M:SC P0RU&CSR'R?H=CN69PO@\)DB2Z#6]3SS_839B"U6AT ].BPY<#%X9,D
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MGR-KC#/*K^-]=!$Z(SS N%S?[7BM]_Y0AO#=Z%:/@5 %M:W#SOTC_'&%>!G
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MCU+NG52QUH2PIYJ,]HZT8D'EDTQI@9FT6-"/W"U ;X \ B"G1Q#4%QD#_,!
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M['H1'?E!!<@&Q=AF6?%!:D;TTD 54E.:)7":%N-D UB@ '*:3""BH'5Q8*P
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M]GB[GDQT,$^#Z-_?ZE="=.38.='@$!=-8:I)K,$31X9MG7[=T??;3-#FY!-
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M#0.Y! <A]A9#?4+B ?#!QK1O:+X^4%7B5DC?6[] "5J+U\5E\1,CWK!U2;;
M:+TQ= B>*3.2?40TNJ42UP$%@EAV@6)LL!NCI2=DZPHFX5P7+/!GYB,<:7TK
MF-U-U2<> _IN++:D20XOZ_[),*@M. S:/X"GS5='CRT&&+K3+@[2 Q+"+8ZB
M&SB\%8RU,U3U ,&[,H#"+Y3#NM;<<WG V!9$,& YH!QLH) CA#\GH?+(W4M,
M^M?+YPUW3<TS$K.:R]I:[W1LOER!8M;RYMXW<$WS):NA_0TD@V%B>"4AOI=D
M"'E'1CN[">P6]:G9W^B9(8,W'''0T(EZ^G#KL8;P#?Y?BD/#$Y_T.(]4M];
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M-J&VR/JY4]=CYC4[L.N1NL#$PF$IU8)XM8S $<1,%(+;L'JD?L3J1>;-/ZE
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M$ZVZS)<E@,:ID.R LDMZ"=NZ:P[M9.#;:* ;+8EITVMC]W@$6FZ+B9U)AM?
MO;15\QN?:!SVUYLB=6LA_J:/8RR9W:<3'S8*O9MB+06X5IJ<R/J6\ZWV90U^
M<5H2?>6BFD6E3QWB@",=J-84 6W=B"A(V%'<S-V 1V]D;OU&4PB/1,G6T!/@
M/:*+D*. FJ!E*>RCIYSMX>+ZS+PJH9L"FGI(GG3C<^J1'E$T/];AZ(L^^IP&
M5@&ZY !,1'5"!ITOY6QQ/-4T7@XN56MO(U0C;&C"RH271Z+B)8"*=B_#U(3C
M3AG9"=T<Y29G+U!+(>/.$^Z)3-U?N$ZOL,$*&O!61,L*WZ;R"?7SI1?.C$H
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M2E@EJ((F.:^O%$(:;1@#H4D2:0N4-CJ06&,8D;A^8@0-GD0F)A"='A%28\_
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ML1:TD*VZ+45=)BN3/SL(+<4$$_A.DU_P2^I/57/<,@JQN4ALW8!-8?W8"N7
M##4)X/(;?7P=#79KEP"5Y#T2H)=X]-\>$6O\FR;Q_<?3&%P'_Y>-:__EF4N
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ME^KL?ASP9->__EW^_^&#7NS^#U!+ P04    " "UA/90+9B+\5&,   4E
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M6-AMTO->,;'S'-A"2Q2>%R"3?3Y0]Q#CV86:@_2"FV9&],&KBW,MME\/I_7
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MAF,%L=578KVC"(JC^%4M-DU^.N!03Z131NESIGYOE-[.N:.OI>0I#:7V X/
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MNK8[_"MQ!+;TH[29\92_UK_.=\[O#'O6F'JY[Z^/!<>_WD0&^HH>2.5KEG(
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M:SA)UN&BP((R<)1&5@2LTJK]E*7KZ@%W:CS09F; )B;C/)EHULBFMNSO8]S
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MW^,!1C&E9$%K81I,X=HQ CS[[#%6K2BI%06)[40A21ZQ?[T<T3,T9P@*\?\
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M-@9I,3&/-:0]S15]Q)K_!&)JJLFNO ;3E.)GBP44SP01/EMPB"Z>\6^5L<U
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M8.$ZAL*P*?P'X*/L]D(JJ[3]<I58^B[6FT]=,P0?[V9O@G*Y5-?N.?S[-\%
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ML'[*'LD46I\8)\V$MU? V+NC))X:>!C*:@G5[E%L(*=YO(".<Y 6XHT%M"A
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M*,J^[4T9N:^=;=)'B\0FYS$,Q#VSWA;CCC/17)G5DK0V9\P.D]NL( ]6LGA
MV!;L0*I7_[;  8ZBLZW6 /P6.].6PK60+;:=:4"QARYCVQ?-Y5Q!?241D(B9
MF302ZGVP+&S0 64P'N>993>'UATF8$R@&M X'-A7\B"8G(,RF(@+^:.]O:J@
MQ(,F+W#**_^ %T363,CL(R_I?1AZ-_F](/@5+5Q3>DOVTHYD91\=I2O,10I.
MIA[/D;R^=K!:__R2<9=UWFY3I02B8R=_J/JT><*OM\7SG8\9,[FO/E[.#;DL
M\+NS^=GU?)(][DDN5>Y])ET=B!;S82.\K PBWD=S7Q!Q*7&,= I23!?0]PYB
M-A/UX>W0Y5%I.G4-9"A&IMXN7 ;$R.Z \;),Z%09Y 8EN4.I"XRV<, SD[J6
M_$G'SH47##@G'NV0^M;W*A$>6*(/K26NHH6CQ@-Q[>8H;M2I]CQ9;)QI<N-I
M4,)#J6.,R<R.K-&F8-]G4#QH(_'D9J\;.\H"_DBYF=]1%Q:1.MC73ET#L'\Q
M/32PUK//8D9[ULYDZK7\T/7R$Y?-'P5-8ZB,<'1NU9[?71I#?[+[8_(7QEQ0
M8E0C';()NGNL=W;X3(?DX,#TECH?IQF-V"!J"9&4<#K:O.&E@;CW\\ZJL=WC
M.28!'[1\?U3?M$;]VX-NZJ83*JZMZ182"^9)A"H6@80J1-+I.V)+HFSGH!@:
MD'@?D4CI;'.(+_<G>[;E2UN:+O#:G$PY=<$$<V:*$A'>I0FOOMLAX86N@0J
M4R$ ,KU.N#)D!":"R>854K\[('(?B&YEF@61N6)\*A4%"9O9FK5/(.E#\JGV
M0M-@SA4V>D!A2L X#YZKN]L9Y;@+U9I'M>BFN(=+LM?15A&^$$JX-1$C:SE/
M7W1_OLH0?'8HV#K^SJ(*\WITPE_[<KG93-0GEY@//_L0+0<+?\K.OO7[);[A
M$&_7@]3CB82UGOJN:]_6 HS41^6@1WM]1CG/.9OD?P0\FSJX,[C-/Z-H@FV6
M$Q5PT#JX!Y4VFV#ON;_<+\5!OBG*;[O>Z1^18U(/J&!T^)0JL8(5TW/@6-M7
MQ4NK-2!].FN4GIY?()UQK*;LAN@/*"Z-T*L'//"%K*J?Q'2+5P$C7L--%T1S
MS5G);!21;<\X"IB\J"9O(PLEFC+ZZ)"=3BMU,V>ZCIXIK.$D-]J"6MY0%MC'
M4RE6_3)%+WLC@)L.!H;V+U;4(;5M9K2Q\*:N9'-I-@5=3O$?=(L21<6V<W0Q
MZI0@#E2Q5*5#XL4?L2L49H8)4<R14$8:!QFE0K$/(<AFJZ7 FTD#<G0+V[C;
M>J#XBZ.7 WYE1(/WY+;/UQOOSO<]BLK_LJ[WY<'8C<<W>FGC"YXVL*XTZE=/
M""Y=KX*PK0+VK=(?[&:K[(\#G[/O3RS\M/R7?8\),O]Z>\&[U@=1Y[*,'QV^
M%[#V\+.,)5=H&,'8-4KT/=@-2L2L4_0&C671(H7)'#7.:8E</[)0&VIBAHYC
M5\/1E=!)PYA'D.'!GKD$UP.+Q;BV+KK["<@>#/;GPZ[BK.%@T5A:K86*V05
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M7S?G(GS0EH5/%9+H:-$#RJZ*H7?#Q R&F#84+AI+8Z^DZ$(M)!':,K*'0N%
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MSXQ)?\2$/<1( RCK!(03OW)(,()7@*@,J9O'>8TJ48A6,"!-K*KEZ#)2V):
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M@W6* LGXEM#OH>TBE.Y$<5@%F=:Z,'\5QA8'Z&1\?/Y;(,%\5^=M1J3-\_S
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MSNC[**O8[VS;H&<!:U<\/2V$O!"+<*FF!A[HOM?AH>^-<AX0";9;Z@I&\!,
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MA/BR5RU/#5)+G)P[N^N[7 A>A-[MT':PW-F7R- .:IZB&$00I;QCM81K>%Y
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M"&KE@5)T@X]6#Z0\&VRH6'FII5<3:E\[K&=2Y5 ,-=E1^%7!:,'RH,&2T49
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M-0$?9,/J7S>-H6!T6\_CE'QX,NKT2Z1#YYBLYTK1^K+XKC4(96#<Q Z(F<V
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MP/-#%:XW#J:<A[Y:0<^=&8K:$YWHB>MOZN?<R><[;5.T#]C0.RO+@L:%X63
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M+QOR+J\UU9C:W]>PN;NH?6%$YJ]8B?6U?>"@VASB=!E^02=X@^7P@WU/<G2
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MNI)VA=SYY,4L04"[2OO7#GN;)G6F:J_ )M>)%J63\BW_3'CF/0T</Y,<M_O
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M06,DV@0R$Q.96,E2X8JVZN_V2&Q<]@9A'Y*P#S=FH,Q&_G?=-O]?@_CEW7\
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M<?I.5-?F5A4,G J!V2+]3BL>^CWB#OY$=@H'LP>4U"WN@JE-?32^6.U41\3
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M'E00=8 O-QR76;&R0O9[QY93OMX\IC"IH0&SI8"*$J51'_MM]N?!K,2?MZ6
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M,>Y\'<^\$9;'BL[.M.>PO5.T'CR5=@'(N&4F=C))@USS08%Y,^R8^Y#Q><1
M*AM\).F:".([T]#>4#N7^4/2G12I7(@^4SW"MN_THPM%$Z\ME#T*L 59/(M
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M\$LG<1RK($.Q7R<RQ:YW)K/VS$S"'Q"QKK/,JS8R 9UA@]8@<@T&,!?\?^,
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M8$6+*(D7(3M*O(3<<C#=FR[VFR,\& ^$%(A 4(%X/K&2X@'4URCC)N+V%9X
MK)I$F+6N8EKV\+)YRI<%_#JH\/B7.)J2X'BI6'-0S0W*!'E=X[L@O0IJO]%N
M(.Q+$-!S3%9Y =Z$GE/Y':="V3',(0F3S$6E3#%>;9:[ XH #$2="D3G41;!
M8!:M/PF% 7R#7F)3?-TD,KVQF?35+%W)!L^Y&Z,.P?LG)]:'(VL.6[)=>['[
MRZ:1U0%IMSL,YJM.C]I^<*R\PZG)WWVYX&33/MS'0>R*R2B21W]L4EC;N-X@
MJ\1HKT9^921U<V^<.MX]9??1[?VUI-UA[(8,$\T=>7T[CN_>NV-C[LHK-#QJ
M*H=SK@S&@CV4P[+[;/I&^2!C/6ZEO.<$E3_2=%6.(0XWJW83-A.--J<RXQB(
M" ?/)V<KJ+W5H+'X^J <"9\<@@\)F;J$&1Z29:GF#3H79!IDA%G+LVAMAWB1
M-$/YZV;7JS83Z=3MP*=4,48_G*<'^U2-0%7.@'M$\-9L(37[[HSQ02]]BBO4
M!##Y_CZ=\BJ1I=4@?*!L%!H6N6:QJIE?.>B[$8VE:!"9L<![X^ZU@7RQ_8"^
MX195YR?I_&AWU?0R5E^M9?F;>Z6KHFS\]QTBH2*\7YWWX#1,B\9,K_S89^'\
MS4<Z9^TY(']I:ZAF 89<UK_W&R;JEV;]0LG,K,K<@]+].,'EE3U;TV:VY'>8
M7'?=GO[[0?PFRC9IK+P/9_RLE[O;[O:D(2,=Q>C"7"&LKY6OGZ8:#!EV._S-
MVT([BTZ>8#V1%8JV#&=L3Q,$]N),R5])ZN2++SB;XC68]P)M"^H;9CQ":&??
M4=L9FSDQ($^2"J(S81^0\9RA5\>>>%LE"0<'OY8 ]?P3;SAZP%(7UPZJDAZ<
MH9H!IN/I,6+"IO92*Z#N\6?YYH'Z1=5>3N1RZ)T*)Y',;&3N?(_\B5E^1=>#
M&]-#:QO>!P255=Q^_##HS*C3.>+%J[^N"&MD-5T;&C^W\K2E,&OMG>VY6B=Z
MCO8M#)=ZX#T;&A*KZZVL@OM>C[S[:F55;_1UYO+(VAL519]FW*PNF%YGY;\_
M^OV8P.+)=>1S1C9:Q\:"MP6.X<DR%8APG@ZT),;S"2NH;PT4"%VL<PRXW-U=
M--&)R6PL70]2J$:0&I _N0LJ33(.&L*'8;3?MXG";6EK8.M>&T*Z'UJ=Q4RU
M2V#F4$Z*D=D%S:Z5GY6U1*BD\4^2$R>9<W[U9*+$6VF7VI':,PS470C&GL:B
M05Z'W 2JB*HET]KQ^O)=,W+K[':Y'?0,&.EI&Z8ZLOH6W9$ZD)<?#Q#D<@Z0
MA#0CLM!VEOXV&YE.7=FWR!=%V;<%:_7#+OX?7_-"A"4: O^)A)NNER9&AH:T
M(@WK;T:<$'+[F^,*G&\]O;1F;B*98OH@PMY?2:'8 XGWQL>Y%9?+QSX7!;V^
M'?? +5[R _,U=GK.Y'&IQ'U^X875QZM?C>9EIO>M*0LKH$TBKURJ)FC_18&0
M:I&598]'Q1(RT6I?>2'DA1+W8\#47+IJ&T,SG,?RS9ST2G&H6.HL(78YT/(6
M<KU$H763V>K'DJP#W\3*0CIYNK!*/?E:?X=R6@GBUI.=A09%R#GS+VW5E*-#
M^-")=PJ$+]35Y Z23D([@2?'H;N86I,^)D]X-E@)DT_![.#IBZ-GW"J#\1DF
MO,36_7.6P5W3E:Q$LK^.=H)/^E6*0<6[0Y737&W@-:/*?T9,:'S4\,8FV]$B
M*>YW/_]K?2.O+<AQY[;J#8AR,86KHIYWQIU">#OK_C>W;3^M7D[4^;'B!>[*
M1:]5^0?5G*EAU+_1P'&D)K7W$GX+NQ4_^7CB';QGV";*GL]5A^) ^[;Q/5"[
MU>*<89O?)=P:Y<)/!1>VZ<!*FZ:RE(4Y.S3']C@A;:,:DC0@YL]#<$!$DM"B
M)]=O!GF5Q[(M[,2\BW].8/%R8G=0-[^%"H6!:!W81_AQB"?<F=S6^"9\R:&+
M5U7?&E49X43(=DY[";I41-U_9U;V:-TD*_/<$03Z:"_AEMQ,:1,R*(<!ORM?
M8#\Q[2I7'?"8[T0F^QMT8ZZHB?"Y.L[".??VA*8.9C)!@YUK*+[$1/+/)@'=
MG>.JV>)A/LT *O8"+MT _8X]ZYU?G,/SEU]759,ON PZS*^3CXYCP8+;0%6[
M7!^H>DXW@(G0$_%\UKA>0Y\-/8>G2<$#+6U#A+44B_M0=\<(+0]V$WM==3#O
M/& @HA39/2L/>DO!H%71?HRC V9@8C SQ2;7U>\NLN^AA? W63-6[[(434Z4
M/.J#<86:4,WQ/JS!/<A.@>C"&?:QIN4[9GBZ7FVAP)B@(^)O[J;D=E18QT^V
M.M6P2]K(K >]#14TG[M[(?NO@BUFI%.R CEV3/ZF=.40Y\QE(C"^GX79-,/5
M3%0@4M&Z.J*JY#C?_MA7!B<2:Z(\E]KE:\"P]#C'L"%#CR&LN9BN0B9U.$1]
MS"<$M#TDDWS>Q,T=7S7MOZ/<^"?!@>@)(]:_)<O135Z'D6^2X>IP1%G6CO^X
MK?J$S,6SJ_B8J^A-"L0YVM5@ZT=@TD0.CSB?8?031 *:9_G+OG>2[D:,+"E!
M.VUDN-/R@K@K?KAY_,[E^],7H<3#S>S^JC[67,*,V*]H9(1H$>!2*D=67=VP
M2B-E)2XEE*=)F[RO0'R[Z05M\Y*5D.8.*1"U,> :'LE8@?!#2[,5B+M9B"1=
M[X,J_]6V[_10^(?,[-0;1G9[7YCL4XG;=<Q=K7NWYPK3WS+[CIS?Y_!H SKX
M')A/&(0Q0$\72IYZZ;QME+6[@;[]KQO-]WA(6DXW95PH*U*5O<][6F!.*':\
MN&+SF0*' K_"D.\.0+7#)BI2+Z]N_:Y]-0ZG_:V9)VQN37EJW+_G\6#G:ZV+
M$<>B_8@;?+=O_-G.7,_[V"E@P.)7\XTF4SN\JW;=/'XB.CL_QS_K8M:%X8A(
M"A'X+M$"[?E>AI00B%U.[>7N!0VZ\(9OQ\@A0D$'0:GKPNX,)JPRV>K"GV0Y
M%#!$+4%J1P"?X<XQZLS49%=: SFYR^&MP[GB Z_S0T)$!T*ZFI>R$[RNX1^G
M=])2T&MQ>K#J( Y_"#06"J[!3M$5Y(?#?I#[Y(1&$+E_DL+;@(T01N!T9QI.
MOY_5_-$DMQ_FX$6S@HT1VN$.W6\7=F)QQDGVWKR\[WRO.6/POC9>:)-_C?9I
MG5 @/W6"QG>C*!WAO3XO6)L<HT#<UH,8\,_V:Q2(-\Q,&I"_6X&8>@:@09V+
M^.55KVB ITZ/O)PR,?8I,3Z9]JME0+M^(R%,5LZU""32-+@&AP _R640+T'S
M3R\RDAGJ0A!]E>(67Q5HVITRO\#(])_/3.?C$9!75ZDQF%9@A76:)&P8G=;R
MCW#X6B/RTB->EIO*4FA"*X"698GU /W1!O 1*!4D'(%:09U.FB9N+4472I^<
MT)J5&T))]Y6KSV6< QA=1@:#%+RPQ+JM5/?-0C5LG%06"9+KASL*'D?*C4'[
MK"_L+0%'>-_04 0F%[_@X*94)"\-VK<R^G\^\,<%=>6$$+05"*'9&05"\+L"
MD5%\0SDA1D3EH-]+"8N&G^3SUI^5__*K)0+>TR=?-T(Y!L8UM4^H043AX'RR
MS1D8#RR=&H(=0;&0U[5.;C^M--UG0*,*84#R0ZC?%_R28%=3 QU>.D9(.\=Z
M=K>?8U'U+G*X,>[+Q"K<ND#8C):AG!_[O#A")D%;;D5NY'<1-.&(!^'-YJEU
M&.8"82V4^)QJU&^#7D^^:-)O8ZGC!#2EV=18A'^U8K=>7/XP'CR+DI=]4U(-
MP(1M"KL8RUM,%(@V\W3\#V^"._5OAAXV4:Q :$-%_,YF::2D *57\O&^9=7T
M):I'1_.-:V[V;\_XMQ1D?Q@UWJ=QSRDF>!A)[F^'W4M^V8?5()3V=7ZR#3N6
M^[.OX8H-6-/UMA9-OJ>>[!K4CJXP>;;3X_M/E3<YA9?.=#_S)-+YYR"*7<CZ
MM]4O=3_Z%Z!LRL2>/FC'M%WW;[),"G>;/O0_,Y94VI'ZZ][KZS9-AFW^3;)I
M=HYP71_-0G=;JLK7HVL@<Y$YG3V+3"DU]P/"VDN,V\>W0(DB!>+=]^#!KU;4
M[?YD/S[5!$S+OVS?A4EC;+X0QU E-@:;<$#+/^7K"[T!M@*1PIJS'%(@^,,1
M4D1T\I\AFZ<J':=&N E>[](E,72Q"U/JU DPGQ^GA UC]YJGL#$9OB/.J<R,
MJGYSU)_V\=N_O=M&CI/*'/U:>VV1NFT?H9M2_B?UE;.G"H^RFUCTQ4]]8Q4S
M?;"@*<IR)+A^8FAV'BN0V(%5730=OO1H.&\S)ZJ</-5)TU @(FCZ9'// 8Z]
MT)"VAASF!HA@6\A5)$6K0XEN!@FEU7;90IE3EP/[=EZ=*"@F #1KT"Z6^7DC
M=YU^"_N!:$D-) 6^\U&".:<J<O]QL"Z'QO::,Y5BS;_41 F9:SN%;[&FP#5\
MGGP34"<OJ?;_O$H4 3%D%4"V&]0F5G>A;29 "5+A)[;(0\<-J&-=DF\>7)A_
MQ*)#YLPO5X6O5HD,TF!;8,@2^3-4$U4U0CF4AS2$ED[0=#O/,I4-R.C2?8J3
M:"S2;M"JGF-^=W2,"'3K\TS32HBAMK9-C5>-EXB$*^B5M5R+<4HT"XJ9?(JS
M('1?M.*$%U%6^22VC)FAD1.S:].<JOBB Z[\@B$N:H#CI7(KV&2 8TN,$H[*
M_*>.-&6U&6#Q17A(689[8UQ_E"\Q9Q]*!2]Y:'D?FD5OL_!2)9_TA%[5PS&#
M^'#:-=J3B5P;WF9_"AX*>3!#6(N- 8F2? @#V/L/857*PY?]KL*8N$FDP30:
M5<&#'.]3O/,[AL;1(.'JZG$;,*U):#&O:8AI42!^HV\BSW8&;X(Z :G(+U.^
M$]]!3\-KF0*E3TB@&5^XFHL#4@LSJ49DQR[NIDPL ;CT$I^&UXP*ZZ?\S-VF
M=*29VP%&NBWQ**8,:,K![K6K$?Y8C(I_ ^^5[J3^7:H!3- I:*% J8ZL"36*
M)[NIGQ,C7'A36V]30G-I(+ZP86H(SB4,'Q\AAQPN]AZX@-TO3-I[GN(HK*D[
M+)_G+P??B;L<8],$;Y':R 6E"-+*'B$Z3:[;>T&IB%6=1ON!O'*2I#J.B$21
MA]N;QM>"A&Q,7&*+M.1DAY'),&S\(!!*5!I1M\NUD7XH[[2!]QESNSN?"9"?
MZ/+5O+_WE\.]TN'%P:2I9&JW/EZ+28F2'IH=$73/YR@0!G)]B- = VM#M CP
M/,6T:&:VD[8>@XD5Y 0[L)NA:"!?R ("!&)IRWR:/LKY2W,JBPCT^( K32Y"
M!3MJN3_J_=IQ>D#AU85"Y40E+]1A#O69#6-]1*[]L<\; EXPR:.=*$$NY<S#
MC7"WY64FN8HPQ!YS.4A+>A!I?U+EH-3O8651HHULBP*QK;+T%=[U][*LG3G_
M\2$A?% IU/D*Q$LW_&0J7A+'8ZO*&P0=*!F'+@ND?<7(KUDH[RY??]H,#YQ
M*@'E>H@VC>\G[__SY9;KYO#>>3H\KG4[^W( W/ 4:7UAOG [+]S82_=RM/S[
MH7_(93<;\Y6^3+ZKD9<U)2&7RQ/"\4NS)Q2(#UEV_VX/\7E'/2TL"S]5F:Q
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MFO$9"[G^+^</1>V)<!AJF&< UYT5B(-U2J)</<R G1&DWM/H_W",4@BF2X8
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M_3$LE@[8$#;,5+D2!;R>6LY;/F3X/!B!OLH;^8XS[Z_D0RY:">*_P.5ALZ\
M.5](("=S"<#%UW\C61H4#+OW$/'; G.OT+P9Y%%*W":2TW2D^9CGF/D[ 950
ML9#_Z-934K[6=4^R*XO4R7W(ASP7DN1#W*\)FK6Z!J(E"5,91;^ONJ.VU3UF
MG(E5IJTGF]4GN(II[;\Z6,:&EHW-@W=3VB:.H84QZ^DXFPDO5P4*^"20"%Z\
MAW/)GSOUJ=S+5;EQY$ACQ4#T5GX<]VQFG6/PD@.@<[U_K2R$:UTVNWDW@9$@
MU"7QB>D70Y?@G@YF4G9A*]MEE:6 I&=X)8PC/6IQ+>DI3YGM$;?F FM35F@
M7(FEX_._;_X3/Z.QB]BN .,D/?5"[L+KC.)'@BFR7/D<+*$U4[1)$'55.*=2
MT(-)BJO:AK-DB3+;OYRY!F X8._8MX;:PX>T=K"E3V'Q/0O,IM0\M_RYLX^L
M,E@2?M5UON3C2*4P()03#XXRD'$/<#Z@+2-)G'N!/1.%4V&HQHVPT!'<"Y.&
ML"@#C_8WHIW*6J DT+G2QI,:Y*($"=&);1=-/%L0L'5Y8=,JC]G)7G[#2)+
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MJ$=$]=GI^0SGP9=V5I$D]9=> P\",E[X607FDX3-9:8FZSV6[ER1*%B<1P:
M]FQ\&S,XO-H/-@ZB!)Q./#!,SH6='Q\*2RKGRJMYHR$NWS&\8VR33-(D6A8[
MTF8_<:"&0JUN/%?=:/G@UH^4/X:/W3*I)DM][P!J65I)'3=379 ?D-(XM;S>
M+ Q"'?C1Q$H2P]"LDIB]XMY/U'0;MPW"5-M=#]?WZ85F:)0A'?R$L!QJ"P\9
MT=90GL*4)Y]*]_G^GN9A!F0O?V&8AB-VSQ*!Q Y@ A9=2Q'F'3,>6TCEG4"(
M9#"4\R9OD9J54 6[J6_9=KVQ)RH'UQ1)TJK?K)+/EOG[%KB&.F\4_+[?Z[PW
M083L(/QT[6JSU&Q1#N[X0+/D"] L"R1>:03+3KPLG=VL@LG@3W]AJD&:V--D
MQ\N<1Y:E-F#YND5*!_YLY@QS3X5[R2V, 4&S<"JE[6YUCOVW8<[KT3M[Y@>G
MVXI?NLNHA5[9KC;=Y^6579JU+SE]^MD;\UM;1KN*W$\4?+(V!\WQW#)+*W_G
MWDS>@'-%0UJ5N8Y-O_Y)_#*^4R"C4&0S ?]YV<M[I6O^0T"E$MF\-GJ5>^=R
M8O/NB^6)'^<)C*-](?872PN^2\X--*"_3??C8=B4  %O[[CCO_X/=..)9W/N
M(]C'$0T!KS^1K,A1VLZYV'!: ) '$#+AR)^G9U7>(G*A14)-A#OWT=QT30KO
M4VD;'V+6"6N80OXT<:,LVL;Q(0/>Q,YXNNN*W^J77C+]YT;0/&&N6G]IA/)K
M0P#KX6EH[J,2"MUO/6,CW0<O=V<T["-W/=4X;4W@-!OK=TBUK@(=,3W#V^-"
M8,\CQD,%FCF-",H'\2%=Q672#@_1#_;?XJ!'N/HSXZG-_\O?)9PQWMY@?R.Z
M(EX_MB#S.F4?^9S=G4R,G1D[8RHJ^?M.TUV/]Y\CM6UN-PCHYJ$SI,[>Q-W_
MG.1#HNP8S680PL?9MJ+UPV%7UTC%DY&4X=)7N>45,@_1:Z(NR);*40:8]_K/
MP-H553^NE.WJML/V<3"-9S(>S/M (_$REC6XVSDW)#MWJF[6"09)J#,NV=Y!
M-M/T:*/-'CB"_$8K^A"D*H2J/[:VN$.U3VQD8[O@]XX+KPF;.T>^8RO94ZZO
MB+Q?O81G/,U:[KG>%L8][2$>DT 7Y4G[H)=5MP$*P\($;X0S2;OSNYZASK)D
M6Q!FS7+<DS3*=]06@]":&K?SR_M_JS?#&OF07>,"81G-W'YC-;0+V^@\I1[!
MAQP5?A8:OH2F'?CW@@_8++""GP32%S8ZI@ICVWN[$VTGH0<?(Z4^K),6MY4.
MB9>6/=:I#N\TE6\YUR.._\6PYS[]!=U2'!0H5DV1355A/J3N+\KB6?1F4@S,
M1-I^;F8XZG_<'B42_GK2(]^_QUC'PD1ZQ^^4OELS6I!N_RT>*"R(.Y_M1VOD
M9&H=*GRO(KV=R#ML<"!QW_/RXOFK&PZ7Q"3$PQ2W'!UH#K@K_<S*ZIJJ6+)<
MWL=^6HL,^4Y/45G1@V1UM0?%;RODC]R0>JPQX_<?BQ>."D98BA^@2^"A^'X!
M+>^*ND?6\"]PQ<& Y6K-](F7H:$/M9=QMBS#\S+':X?NN4OL+753DX]ZX_RQ
M\^)!=1Z*=65/LWN+#/ -C_+\I=GLG>E<82YS8FK%HRPSCD:4[_KGT3_EL"+S
M-+AA!^/.BJ&&FOGFZ/KBH^,R&U"!.X^QB;QP I0 9 XA-[)R>(JU+-/MG3QE
M@8XV+B;\NH3NXD/F$WWXD.MT\/P&(:![>\*#B?SVS_(@ ?#@0[RW'3;0:\PX
MKH 21B^! K[P!R6& J*\B-R^_G^;S_F?S6];=U/F%05Y'PE?#J$T?D56G/Z]
M=C;9RQO9K/Q)6?B\!K/F+JR1)J-C<YRYQX%=ZPI77AD-8+U:<M.]11WN)#_]
M.S5$^43P7R''8X^MZ7$3"Y9&V6_>"'/0;=]EK;MBJJTB$V-X!Q1X)0)R1I?U
MPAMLO\0+@13'Q!XM^W;T?ETE&YXQ0EYK\?D/QHDS6E4'NOV/77^RISUDVFV\
M&S\]B3!+^ S&ZY?$<9Q?GG&P3:HLZMG(--RM9:_^OLJUECZX+=Q62I&,Z#Y=
MK?'@02_\OO/['\&;/<J.)5JZ!%U_9,V>EVX>#/C>&F*^H^-'WLDWM[TU3KH]
M1"U:L*J[R>8=^KO/^>KO-OZ#]-CH%67F&7U]'L4[T8 "M3HK2F;YD#T(T>Z<
M>5IYLBY==B4[W47#IIEZ)_7()%*B+LY!TZ,VY*_]Q4S]NW_,DVKO[R*<Y4.
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MTQPQ4B[RCE@TV[2%%I-DI%H$^J$&=34NA?W\/@H6M Z[PH'A,DBRXN*CSI0
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M(9:\F2L[_B%JG+4?[?WRET;7=LDKEY*N#)&OY2D8O="J#(O;XTGJ SR-3Z%
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MK-Q#[B0JS;A,07[Y:.[<UM4M!?]IBM8&T)_4\?E[\%!;ZLV&)I+<K[IA[ND
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M'ST#$.=9?$BY/Q\R*XJ>%6?:(!G*(X_XD(^*=HN$69C_$GIF]?&&/T 8ZA)
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MUO4*ZKSXB&3B Z3$56/_S@LMR^?GT*]=-;=C<.[,!:0RZ,V337K"506V.(E
M<"M1C#?(VP,06QNWG,2#>$I8#RO@; UE9WDY_H@QI35,D:G:UJ1B"OHPQ54[
M%)#MK!S0WF2@G'PZ('^AWQ7MBD\,#Q_,-)OYGI+TM@>R")&&5 N"[1#>V!,)
M&6.45[#"U#ETQDI"\U$,>K\1BGW0Q5& ] S?+&:)(F@$)6'GEA\:)T5R4:Q;
M@7XQA+'^3QP?J?8)+>!K0T-+C@O:RS&8;/\$/T@4TD1BB*,C+--%/J1H7E;!
M,JGC]\O.5 &QS?*BMRW,>'%-; SJ>8_QE9FV=?V;I^;GW#5, S5=?PY>8Q^6
MDWCG("TT'4OP1<4I4-I1HP+E/R&\G;J6$-I*J"HKB OB0Z*;=49X6B"J)=AG
MDBYLX5<TWWQRA"M?B VU'EY]N@;?Z?5(+A&GEZL8GV!O\VZXK*K)2ES4[LGR
MR4?0<&*MWDR'\26&2=>SYKU8(B,FG.").@#26^D[>8=1+/A>L,N4?:5V<@$I
MOU!#@\:O+LF7"IQQXC";$(F'@93V9MEJ<M7PJG<UP,MZ2Q<,A'V,IIU6&B;.
M2GJ"!-*X_J 0.PXNT977!ERD,H<*N"K>N6$YO ,RX!M&@G!;<HCC<_I8_M\-
M!_L1U,HM!!==RARW_"?F:\HTX3&Z M6!C&%-(J/Q&KB[ #*A61[_A:?)+DAH
ME@0]/E!$UHA""S1Z'-DD#Q38A7=HI/DD-J<=?8 ;(BL0,'L](O$GP-:!7A,@
M6D#^Q-'M:1R\RF YHCOWUJSNCK7@A&;]VG ]6-RI>;083]7;T;Z-L@MWGFV5
M4H0U;*UMUB RK]2RH2[LD1@FH!J^6G9:;-U5!5A;B5P-P5D&%WW'-"L!G%<L
M%\$NRI59X*.16\.:9!_"/</> U@8!S.,E\/)L0GM,!B>BMXCP ,<UIO1 !9\
M:):K RAMW3IM? A4CR3C*B!!M!^ES0J\P?X50=*$MZ8_)&8CBM/78_7^F8I;
M00%-J21FF,Y<;VP#H=W8]L/F\AN@P!% QY #@G<W-<>7<"\ /8TLJ(BCROB'
MAN0A(V,&2094=:"<F;OR4Q'V'IMF)4N+H(T[AQ731.[-<']1^1 WPC-]2F77
MX@I Z.1#) D>:!FPD7.O:L!(=9(B/\[KI4OF#"SCH%D@M TO_"YY,5! /G1,
MV)W)S,:/5:%S.+1?/LX$MA]QV%,A'M3I:-[91+4QG/T#L05JL8-;^!!EO P6
MRH(^+FC,:"5(D/4+P#13EXL'?=8TSI$DG\]<&SI<4]]4'7-C ,YH'*@^M[CB
M5YK*^SSE0'>E/?7-7]W\B7Q,%S;2WT+B#H$!@'NK36_ 6^YY(#^-D:&Q4*A9
MIEU]7I.%@:]Y9VB=$;54;V79#\XT#9V@KL8;:JF@GB^55I5H&",F:#2X\]N=
MO^]G_O_UHUX]11+/^_KQ#VS93+*(_(Z<V'$S>7G%%[=OW_:_U*__[:QF/_K3
M-0IP"SYF=OSEGEJ@352SF,+V.8)4__BY'@G\+?9Z1\I$,_WWFS()+9>0&#@-
MR7E.Q<OCK :YDD$,"Y(02'5)51)M\9]]%#L8J#N@T)*Z'13:^@X^IOHKZR<T
MX\5&FA]2))P-/?+5O\YYOW+FGR5_+5#;!H).K>986I6^^&OF>&R*=>-08<WS
M1\;P7]_P)[Y4Z,TRYKJD>EUSU5H^OY .R1^PLK3ST6AR1%D]VU[/CM-8[LW:
MI_$11V '6P+"[8), EW1S=C:HB<B]-@>3ZHRMAR6<JK[M;EJ0$$76J;<+^AD
M_O9:1]/PFTGO)O6]2SKJKG0G2]5-HP#[9QA*K>GBDO1S#,^0O1[#4P"?@K^8
M'A%:1H;,[ILG2>6:>"4<CDU?7#;R\-?+/3,ZIRPYP@V>-%RP</%SR.RR'"@8
MU.W6=VRN:B97._T-K? D/=.EC^5,_@..^VTA0**=@/ '=*W3A+LHBHZNN4FE
MX/XO'^B5ZXDC'WA:0V1;]LZ! :@8]I*]P^Z)$@)CVY>C"@S5O"QR6-A,R,\.
MC ]#UT5PVK?3?8T4?5B#8!/##AB:20A,BDE-DZHIP!2.@UUH:F)C]NS#9N5&
MZI_LXQW#)8S;&9V/O#MRJO/6P\N6<?X^ :J1/C/#3,BF:QR8O<(9!V32%M&,
MWC&KF;;-;*QJAZL\L)^2.^M7#MIT7AUC>L17P7:!MQ:43PVO^<!:#* QMK?8
MVB]#F3"%!86.@FCN>486@:FQE?J^(C#-T&2[@2OEQH*&$T0%: _K1(LACO/Z
M7%7 "$9OS,.S719@RB12PA18:-V$QZ\A93WY$"FRD'\1%C_3HE#^DN1X(<?[
M475MS$K.T+VU>"W"Y;[L@1_D^]"&DZ087(! 6\ENIW!%&$J&G2,PB64CLZQY
MM#1/&G<\BJO(($ACGZP%D1(4QGMB)F$'M#/V),GPLH MAPS4T/(B+B1'(!P5
MAGVJ7&R@XEX*/TI\TV\W?Z57RRUN":1S&,,[*=YUW_LAGMSLQ+$1,K9V\_TM
MS,2A :Z<>!7O7.:**SD1"NU5#3_ Z>))-5HB[9J:  OZ-Q-FB<]1IX7+_PC1
M3Y+.@6BV'X/>Z;>_ETF,GE!]ST8DWRF9  FVWE@]4?%+)B.KLV6^\$!CPN7A
M>U7C 7\,'ZZB4%<R+(:KQD1_4*N5#*VO*G1=KZPC]L]"LN,V[#G/P5H6+%H?
M(1'?6HE)/E&YI_;X.B<Z'?Y%[UFZX]C&Y>^7IB':^1.GQG[&J/@AY [X[Q>*
M>G_/-?15EZ2FK ACR).!:2U[R#Y7?,X<]_<;\^L/2USWVQ<I7C KJ4KY5>G<
M"TV9]+Y[L-JZ[^V<6O'I9_-('\<W!W]VVD2Z%-AH39CW-](OS1=K_)S"#U'D
M/@DM92K.\/*F^9"I^6U1T)TTCU #"0RHI->2Z/RCG@BW0K0Q&>D17NZK,GXD
M#O)S;PHR2+]&^-%&,Y2M$5,W)A_W86KUU\F;K6[X6CO6_4%/:F!3F<'9R"*F
M=RWB4<6ZL\VTY<1\U\MDMJL#<:0LYD.;C,(+SRW,UJ,;#&4K["73?=6*:;K#
M"5I2PYM*X](V4DE?H5_#M[U7I>:BLBGG$')\2,L%'ZX#TV\?J1T>A09*\ >Y
MYNRT):%)NH#J2@5!XWA"PTO+Y4@/-?QQ%^R8 QC.\&F0K0!6VIZ#P0S3^* O
M! DS?Z:EG-GIN71TG)[X_G4'JOA(GPU^%%UIA-B-?OH3YP3,@PY<<]R10WS(
MW9'$"OC3M L$.:4S\'WB!\%F,],GK)0N5R]/+1]!<E?03[S,AP"Q:L./A:E5
M]E_Y$!$^Q)OPA*Z(@'/1H!JPXC1839'ER@PT*WI/J W^U4]*B@BRA#(ID8LX
MS.2X>POO=.+Y0*@TIG93-L\]@%-V=FW@0L A#M*G8AQ+KNV C35R_@)M<[A^
M@WJ$V$<WFTJX$ "58.3/H@N#)MKD"\PLM\G=5?$=Z;XQ;AZ^PS1.):/;]D:_
M+DKFUEQPK>5D@JW+P%_L-NP#C?9_(&$1)KA11A+-X\,7((=!:B?%.Z;%("11
M;#G&#PI;75S.D:TV>&^5#]F/M6VMQ"YTZ)NV2\VF[]*7Q :TW*]]NE901]7]
M=&_Q,"7@'GMNY$QI)GR[7& ERH[9=V!,!U'>2"IG=D3?X$YU$[?A6>VIWNVB
MR29]YF7[ZV51U=_?S]40H$$).ET&$Z1#/KE@0*O<\,0QMOCRRYS/:9%"LYL:
MTQ09_ AESRI*!M,L#*S$!M*5L0WHIT01W ZF.+25EM TQ3N E-\?X\\0#W5N
MV,N1G*,E)C MI=H5;I]VJ1YNS*9K9^5J=9?J2UVR8""7DH$ 5E*GECM#O_7-
MPZZNTYX4T<7F$]_!D;;-A*:9Z)GWS6P^Y"D"UN+^)\\YP.NZ,QW[@,>'6+*5
M7X_@%887<Y)77<RW#Z=>W[&6\)_>4F4S2&"UKO.:M"FKF8Z-)B?*TY=+__TB
M$.TZFEHR_59#P[<$,G!Z@K"QR$M.W_Y=]8 P4<?3'-6P^7\@Y+@67XS.9/^"
MQ?RA^$;Z-D=^YK7''DHI\9T#H;>LEB<D8#"=<VS:V.4QYI.#]%U[KOYU!;*F
MF"P]R4I^K< EJ0/=TZ]2A4_Q:!RZ38=U^Q9,P.X]EHQ?L! HS-KHSP"'<E\S
MQ_7IAR-3IW!J:]=NPJ36>(22H0+[E'DR^?MSF^D?F^WU?M[HEV.AQO'2UB;X
MXK#P7\2NE2<3JB"1 $1T$J%D[QRL(A/U06 GQ[0DKE+A_U7+N;XU=65Q.!0A
M(@,9Y*:HA!8M=1@:JUP4X9RIR*!E,%Y&P-"2QU&YQ9!IP7*$0T+E$BZ%C$]M
MTVHA@ *6@%01&2 DRH&D#"(C9$! $Y(\J"0@YU@(&TC"A/X-,Q_V'[#VAW>M
M=^W]_$!#3PCW /YEH\H'?*X3%$I]\352J22H'A$_\NKK*ZK1B+S3XD*Y-;5
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M'U)M499FW@-IUSXIUX$PQ]5@0#8R<$AT$PWAV$93L/DB:*<R2.!HL.R6\+Q
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M-%9]F6T(.ZE$%3-6^(0BC%O87\8BL=HPJG78!AX:H:46F,&$,K)^#].T?++
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MAN<ZG/3?/-S&O3+D*OI$<.JSLK@;3A720L1LS0F9.<R .EJHJYF^@I75@O@
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M\A80Q1G6Z&7:&*:+45J*#*_'CJ<8(=Y5 XBWJ ,]2=D".<\G6@*H(77"D)T
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M'$_=H>(;Z>M_1SJ 3D)+#IH&'*C08,[X'ADB&(LB62)LM0^&L.X%:,*'WY%
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MX*QDV:A*50],*A9:_M]M0W;.PUU%TTM:*SGT+VR"DM1]W2LA3NSS^/6^V6&
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MH9NSGH?1]3E=*-L7&Q6]<P'GN-K]O9/.,1V=*_LRY>Z&?81^N27NI%D>U+\
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MIGCWK[5 >V[YE/I(8M(/7X=TMH+BB-C]_-;+#W+V<=826YRME>%I4DB]9Q6
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MN2W/P2P[HN:Q8MI87A-MH_-A,,5F&Z/(V7FN[;E?>,2KG5-.M415T)?I-GV
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M9^LC866NMD&%.=2<T?J7-QI[9ZB-F*?C4QTMI!2.LK4C4,RO*ZL^/^6#!"L
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M?U;W0>S6Y=TI1HNG7FX@&(,92T:T& LM6OQ\#H!-#::HJJ=@3$3V//$>F"'
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M;_3@O*YAD[%$FQ!Z<_9?G%D=-+B^+DP6!-MQ?&9S<5]XM K'D$";6@PVAAI
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MNH35)('FT-V[PPK,4$U@WYR%AB_CZ-#L&+I<!,T S?#F0>K>B7JY,%YA&&1
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MV[Y=(KWRV\;/IL\^SW;9AU4?Z;++\3]O*I?=E:Y1'YMO0Q0^2^H,_#9+<<C
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MA4^,:\H4'=[O\.L=_=5A,R[&T0IDR0H >K+C02#2KPK<FHNH[WY;9AGD*:,
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M\;AW &P[")\-USSAM'NQU2Z4]49.D+!O<%&<+1"^E:,*LF(;C<JA@&8N(B9
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M%__%;H/W_9V%, ?1?Y_E]]5[_Y-GRUXK0#O%(;PV;3A6B1K_5O?M\)\.O/N
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M2P?)L/%ME<]F4XM('G"6@$RI3QF924C\C2=F2"VB0<.6RVTQ 5&"K'@6M![
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MRA*KI]""L:^5*!D)F.%S=2CZ0!:?F$C$( R?T^&G'M=J+F%J37"71S!C.<;
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MI/K9@<PT;C V<>&/<M"K;70YY"X6)OX$VX%U'9B5K\E8\="#0H1_1-0[$J-
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M2;Y;B?+JQRHTX\2T#NXZ6/7K_[>2%CK2J4YGR"0Q>TIZG\R6!/(9K^>;_=:
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MKX$F*&;$76'E1*N<5\,Y&79;99<T("P/LI]^_ CG.?1GXVHK@WYF,"!$LA0
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M3<9$EI3S'H2S9\;C=-E/"5G>P=_,&/:!)96+5&&?316]&@@?TQ37?1/YK7C
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MB&&FS;,F[$Y)"VL=\118+;P*1MUB8+E?P4M%8]O@2EZE]2NWR%)_.ANO2'2
MF_B<)'T _N7[U 9_G)(9&R]/H+&9RKF#SDW,[@JC;L/>VMB9SCT][WF8\L=
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M'DE;B"EL)!#>^]Q\Q)HJ^=-G<Z]WT"&#^[R-\[ KNYH3F7L&1HZ.3#G54_W
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M-CGRF6K0 8HN,9L[THZI9+*DL(]"X:*NC0,^!Z<HQC2#MC-9J3L<%1XMKZY
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M?6BVFDZH@$H7[8!PMN<[*2R@/%0(9Y<["0JEL Y=.[0E><BZ<)!#7> AQ'#
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M1"G"DQB['58N4MH&P.)6ZB>14 J;.6JQ>G[Q%BC)%Z3IP14DW3A%TFV:ZC-
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M=%9X;[=H8Y.2@+X=\A$LU@&MTTTN%5$Y+>$>=#9FHP>D['D2(L1(86_"9Z*
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M9:,_<[/80$B 3XI<0,W$:?1.S\^!0\MY)450)-OZ>DXA%.FMM[<F6^359[*
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MD:GLK**.MXQGT&NFE@B*E=M2SSBDY1FIX%0LLX=C<B,&C9V/_PHH'3_UHM!
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M?K?&. ,-4.-)(8)W9M=[4%[Y$Z.[>GV;:_'&[RRZSGT.#M*;[!H]49/[/.S
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MPR!GZUF1 ^#36&40^B3CSVKE=6^D#.BX5E"+_^%5ZU:T$E/'V>C%W=:M_M9
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M9_>SGE1;F07P?Q9JNNGYK/HUNR[N4XZZT:^N\,@FUU<T5?(H+)+KK"!>6([
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MVZI42[<?8?.2*]">3,>NG[9"9Y+Y&[JOAM'1FSPAUVG,X E1Z !S,W1?Y#"
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M7EI'VDPP:!?OD=@LB;HBX,2#H&X;ZRK*$/R8P->&.X$NS*'*6:OLE\O9]*
MU7EA9:A[?T-VO4$N[46H>VU#XHN!NNQ/F&TRE;_=2A>ASKX>1"0P'/DK:$4<
M2J5A(%+[DGTMB$G:79W$06E1SW-?7+DP,*]!ES,^U6*,L\^*ZJTI;>(*G_>+
M^[]\]?K2/'Y<,DLZ)E#\BJOH[&HZ^0HY3<<4:ARCQ;,469<Q26AUYK;@:*KT
M@A >7(M51!T1=XP@P#LL190UUK@]*:I)LE0K!'L8UA8)3*W0,\,=_$HYQ]XP
M.J%@Q0..6WEQ=,?M0__E;IME9GPWL#:3-#%\LA:DCU\'G<)N(CJ]!L-X',06
M9D)I;=*8$TWG^;LQ'XK*5(D4KM)9\/1U?M0ODZ*'=+?<8]<#% 9AHAJP]/>-
M&JX"^)S,$PDLUIK,R8ZNZBY>6DTCJ8DN M14I*N )0WEG"!O(W!;6?3^1@%>
MC7BQ"H3?<GDPE@_'O(2P?&,=/]2RG\)(>XOFZ<6&J/Z<LLY5NLS(R-9&J BL
MDTAF=A!4,IMAQ9-V]\V)X2(O*(_OY*<[QQK2O%XVRNDG7@)RIVTNJ3?X/5UF
MULD_JIN3,*B3[I,G:.'37#IS)^D]JSJZE:(3S%-AZA,5H8"Q+AV([-##0#^%
M2EL+%'O,OIX;MOU$]W/P^S2?<^]L78%6D[5=_T(<QK-[5OBX/OYTG\EWX6S1
M[>D;>GC2FZE,*['E1U+]!(KQ24:0U I/H];@F[>14!";/]&.U11=YY+4B7"H
M,ASDM3.- 8?X.92,R (:BQ*0-WP662;QU1X4!?_EVVK2W*6 )=J"\%:6U#!4
MW;YLGR 9[.;)?JS*P@70Q#M5/#,''QSS!.ONK,&",11$]3@-=&I#:#*T1LF)
MO/6H/01RFS\JKZ4A*0-I)H"G-M2U.<MQ1M;W+] V!Z/47O7.EM"A2X^))X!9
ME<F+*_8U8$EA:7MD@3I*B7O%FI>(K;*8S0&"O!H&Q*KB+O)FAE39R.3(3F"A
ME[D-R$]\&&:>)!BN)@OB=LY/WN*BJQG'B#]&9M1N?[!]YH>)"(_,<HKXLV>9
MQX;'\S8S-T]Z^&^#' !A,U6>@8XMZWP^,BG>#'R7L!+JY_F"3<8ZXFF>4VV=
M4U[QJYI7W-%L\L'*R&$M;?.!=R]?U=3>D>KYO=%7-+SZF.BQ<AQ"+SZ!X@!*
ML\ZA7AFV<%@.4_=IGJ?8:7ZS@3+[58"X5?L#&A#T5_-]<)7[?#(">6,.S5R3
M))$)+F)C;8$L1'\R!)7/P9/HG<??#_]CHCW%4Q>IHN=ZEC%S'BN8CTC9E9/B
MM]3U1%F%4E#N>&\1@(]G!5=B%X_VB6)C'Z<@%5^9I#Y/:D5K3J%4P8U/AQXM
M*U#*C2N;&M^%A)F2ZX9*XT6&E3-,#1!5Q?^JY0JJQ^OW?4<:O,"&+ Y8T1(G
M!N;;NZ/J(YVF+N$RS)U]3F8Y6YS!>:1_';3V.>VM;^CKD"Z6$FV#4G[W,8RH
M@NUL^ 9"*9NECH]TQ@A(=RL)L9BF5^!X,3\/#9\2;^]EG-WZEX3E>6<^76$8
M\-/"=!:G"F:<T]C+5H,=\,6HLG2I">$@VP\L32)9BWO0U<S?W(K=AMP)W&/S
MUB&Q?*PZ872R(8DBLB@3>7#%NA05HA'HD8)$EP1G,W?=.U8-P!.1Y")_G)4W
M5#ML!Q7C<!6\::MST+5IQL^QFZM/Q7!"Q.+%3 1EPJV:/-3(QR>2]+$4V)1N
M*U6%: 'ZC+%#&H+B]YOE5514&K20%("NVPP[G91R\D4H7.0E<&J2.5X 5R/@
M,13?EZ#Z,%I.K$0\ .WEWQL5WF&N!R2#WX(JC'B.>0+9GJCJ-J*9I;VM?,SH
MCU)]E6AI9G/QAYSUD?UT/WNG2GN!G-/)P'I"Y>.3$":#_*IN=FK%P9<0,S-&
M:V:M([J]!OZNE_![*%9S\L\9YT*;OL[B6>Y40:QT3<-*0$9^KT6X='WMZ]I4
M7,B3NU)G9"9RVK$9Y!H$FYQ)VM>OY0;U+EGAY_:N'!*A(>?1+OG@$>G&U8<,
M+\!00$M!R1(.MZN1CH#R'U-0K#"PGH[1(A[K+?QD@K1[2CSQBL$E(:9U-@ O
M2@$F1F5&<V+VCX^62Z*CNZ7:MV<2%FA*7%8@;7#%$6Q/(NF'\#:B-+V)MD!!
M4O'OLPDMTIH;$"(];Q2E<#*>[6U6G-FPB"\[,81)DB*0G1LMY,F7"CM0=W%1
M:OGA-C4%/&XQ[+_WH_Y?>JMNK;9=+RP(+CR=P#-*T?QNV?+]6I&!C)3ED2-E
MN';4D9M$C8U'=5>NOQF]:7]"O2GCQL./?_QX7H%X:)_U B"$/NA3MW ^_Z?'
MMXBS>:EQO7I7/\#=Q3U<UH2X8PVV_O$:;.Q!X-["?(MF(U?]4\)4N[L6"A7U
MLAJ2U]LNLU]]=/)KZI+$32?$A0/(=:.E;Z3$!MXI;V#PQK#/'FR AN@3(/L"
MJM]/\7470C]3PK9?KFCL>;#GQS6DF5Y(K-//B"F<U\C4U-=5'H"Y\"35<+Y*
M?B2O]KL?[^L7"Y)7UY0+K8652E9G(J<DKHO<Z@/? N4LIO0875F#A6$&L:,(
MMG K9@QQAP>TDU0!83IJ(Q$&/1P3KA<Y0K%E,]>(KHT@(M-T%2<PS^%71M@!
MUSN=!-A,L18AR!&4_.T70NGQ'-[OJ_!NYX@"H:I1M"I!V$)]Q4L9KQI ;?<2
MG8;L-M*?BDX E[&##916\D:B90TPD$PG:Q <[+J9>H0V[!;H(SPEEW07V+4&
M:RWE6&BJU0/4H[%"#5_(Z3QX4F:6K@JQ!%1H'X(R_XQQ\#'T7YL65$1111!<
M$,TQ2;V.D@6P<TKA 4I0$'AH@M\N,O315CD/H4L(/#Z:@U?4>UZ@V_</-"$Q
M10H$:_X_T58;J=$T LL!U*.DCWZ!*M9@TJ9@$!NK0UC!T"&W8JCN33])8[5B
M)Z#3])2563-C2=(EO>=M0EX ,1R2,FB2SG#FYTNU>->6WH@=Q:I ZIPA-+L7
ME"]EK\&V3GFXNTI8X+!7*#!U%/'R_OK_-P>%^XG!K)8S;7"D0R#^-MU$1J0)
M%->Q/9'R?&IJ70_1I6].Y!PV9I(^ NLC[20<$ZM,#=&2C.<E$9L79&M?#]3>
MC5 H0]VK(-J!9\%\5D+DJH+))F\OZ GV,V(Q&VH&;=DL>88,R#X!+(GT<EFS
MN!5#<7<#)KW&1'D$UY"4'+D&2[/:6,$7*OH0%D<FV,L*U$MC1T1>HS-K,$6G
M<#ZY%KK^HXL3[W(KK.33Q\(7,-*];FXER7"&"IPG)VOZ5PDZ;%3XZ@F,D!(<
M"4Y&$.&@?EXY\1C0=4N$*YPBTPW>T ;KSM*QF@1N<XQI@6%=+Z8=#X=J.]HD
M]C*7X/[A\]>IVJ#67+^V>X(PUV(H:>5/$3G'%F(#U<<!CQ:6 O$BY,HW&5J#
M>8&L]%+HEB ,W:PT2:X>D,QL/&D7=P&;9!([FK=Z#J\6N@8#NJEPX?Y9D;/R
MY A<1Q/4_O;M8U/0,RAV#H9X&1=S9I/NCMLV#KN8<'2-#"<#_INT7$L@O,LG
MI!^(7<RF\(6)]SAHQ84,)_:(ZDM&'01_(0'U-M:++U#LB3ZAD-[D80>@ZB_Q
M>?"0_EK<,T*\6^JX8+'+H8<NS]M(^L@#SJ$SHALLFFDRTRPYAAN(/T=AHV49
MQ\#H=DU,$G,'H1C?WL[+8"F+E'[?YF$X!M\$:9 T0S2#)%HO3W"W(9_I$^OA
M4/"T]L5:R7@RH$#>Z;ZY\=X V.I8D>Z1+IMPG@X=6A60H;W83%.>/.0]X A9
MY5(XUI)@AN ZJIX9V;21V\Y3JD3ID+H]K"CMEJ@=$&E"\O,*(HOG!(E+%6\'
M'.Z0@X1*A%<MW!/= QSFGFJ)\K;T>-CV1'4Z^;T,O+<2+KK81\3P.^W1,"<^
M5D7D#6!G9X"9%K0<2B]4DYHH0HQ24\4H:&+%AV#H#PI3\1/  C5]EFA3 06-
MYC,+^9TR9[KG:6J$K/&)-R.R]5RDL< /?Z:!>Q-]80^MG:=(;K8G&4T5J("T
MY%FQ*M$@6SB*;Q%F(+8R#X=XH%7ISP:PW#58$&)(3F#PAI(2$]U<00=B?'$I
M DL4PG]F1+J?X5@\M6@>4[F8,TK=RE8HC=M?5.HL,!E>6HRO0>G_OA>WF75G
MR?O\<O1<^W-HHW.$0#T]LLG>V7I1">J,&T5K4#0]?0C[UV KYD)!4!+V%'G+
ML2>=S][Q$4KRQ^B3"QFFMD&*,C/?5*$EA&@KKVUH(A.)1R2@@[I4_42F0"J!
MPOY)2#H#"#F$!%IR#7PP%3UDCE$-'4'6 131ODW$[?N_/R?I6"0:$R]9<)SN
MO-9!5;^,VYEXA\%*(8?1AGYB69 J'Z\ >8S624 (X@KPLQ8"GHI>&TU TYJT
M0*]GX8REQL(;@?,#AR8US;[G@W V:@]TL,+;#[?LW5$X'>-?^J2KI*-D9']1
MV &9N0#57]]6+HL'F>:K!<@ 8(4_P";?L5KB"+="U7Q6*S9MZ<<0P4. 3S6=
M1)H U+. 3H9)PE@\'QM/#"H/L5J#I2]0DZW<,DK3&'9A%T;QTMX^OJ$CNKF0
M[]3R%;&C@ 7M64HEF@FP&3IJ5'Y.8DT3EN\AT<-$A*K1%>*EL8/\I 'B8; 1
M"UD^)EBPAQX,V94/!NL<AG"Q8T)%^-#Z?HVH1A.8)Y8('S!&TTV%&3$7)V\B
M*K=ZC"$HZ-%BK"927K &4Q*I8V^J%1R6&($Q'ZC3((/&W/Y9= '* (2^@+"%
M+">2!K,?!O!S #2[DMSJKP6J9UQA!9,W$<CNO0Q<D'J\6!T7L[_QAD#;QX\K
MK-F$M\D>6!1 5(M6\^I&R);_U9"_^S?_= WV3?01_>*"0&\35>*YU?M,;7'W
MLGYQ''^^YSL#4>(%>7B">9!4:_^ CMZ]#^LQRB%U5<.3PDLT&"FO&YN.!7XB
M4G.#XN>=K3D\Z><U:[", B0XT4*3)Y#Y']/XY"$5SG+7S7ETBEA&$M)64%4(
MM)8&?,N%YT0OH"YA##(8P\I!T>UKL.JVJK&N]2(O4)LY9W@>\,\)B+V&/DT.
MPJ3F3K2QXG4V00\%^/4XA#SQF,#:V<V,(CU3-<)^%J*9F220Q[)S7';V&9GF
M7]2V=LMQ",/9I?GTF,9=M]$Z]Y+BVSU?Z6<2N?('_,K_[K:A%S("=,("0IU
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M")(F%VXN2E"P+2(2J;,4R$YU93#:*PN] &3O4W<5M*0CLP\9+]YT"\VA$R5
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M*".HAIIO&9>C671K],=ZLOZ<4V]25U!/UO8V_Q:D CZJ10"Y$3.V,F2RH)0
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MCMG1N20SEWF&O<9P'&*C6^4C/=YJ6D28^-IK@#X#D.\2G6TG7#U_[KT<S_2
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MTB3OH81\*)B/=AV:6BXDZMT-)8G;^@LE>RN!Z5B+Z95F:6*"%M7#5?H0KRZ
M79/VMQ=Q?NVUY&#?4Q<--'KH6RV8UC6G!0E#NE5KW0^0[PDPUK &0TR(M[,$
M2 [ P6= N%@DB.=J4Q<QDM)=>Z(+ BMYJBBO8TM :1KCM II%VB6E$N]K>+
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M6S@F\<K+N!AE6TQPJXB:?S7^TRNA69!93OI0B.HCX>GD+IM"N6>[,;@W%Y/
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M0WX 7ZN=7!56/(QE5E93OA@S46[PG+LZ:#>\<UBPW!];N,>TPJG=;F?V&+;
M.^Y6H]9T_K$!RX^V>7=K"U.W7+KM7K4-_ZG;3FXXB.+:&1+I5S^TJKL\4W^K
M:FI>(%VW/52%X!*S9?_ZSB+*%K^*TGC#%1M2.C8<VK)UP^KD19<9!.V1J[6G
MLF$[L)6V1_J@@K4:Z68OQR]"6@_3^?U55Q!S<F^U8@M)EZRO&\L)96,"; Z6
MG<BEMQ> !N)KW0@6=N^!=PLY&J1Q'K;<5,D-=+R=H!7OMQU)9-3OY@4R=)"W
MU4Y7+ 1,^GK@<ZS87-.?MPH^DM\/Y3L"+@&^:Y.$]*1[XP:[B)HT)Z@*X/"]
MCC0A^2)3LV[8/GL ZA4Y)987<+[4XNX%5&;A0&S\#.^="U&9>J'!7E-'3]&Q
MC,D_[Z+(S"[O*#+->7<_2S[(PFO;;HIV@-N;,ZZUI6.B0:/+W[=M=OQZ9&%J
M^\$NY)6ECM)F\.0ES?N_FP?]6JV9)AF?4)AZF+43WW9I4>O:N'&]U$;#:T[K
MF>=V$=;0UBV$(!UX@V?MW"U6MX9UV$QM=K/Y9=+R(F3Y&%VK1Z?%YC5/CW$"
M%RTH+Y.FB?1ZX]?'M1UOQQM1OU!4J!=>UJX)4^7</VYYNZ1TW/4DXT0?O8&M
M6QL,\B2Q("X!/@*RG[-7%5<(WN=+_,'N+YE "?_PN]I5P%PSUPK*7]@U3C<&
MC(:8P6+2FH8L,Z#XR2BBVU4RJ]A>&SA_^FZN@TAJW#]UIA4I,T[-;7YX?:QG
M:>D';Y_LW%M/'OEX#CB<(E^X\IN<7V5Y553/T*E%QTR%B4OOKD]6.]RZOV.F
M-\N5<+"T-**@Q,S,M^-M?]\7,[,2_2_CE_J77L]-_SSN;';6Z%IYZH?]WPZT
M;2Z[AGW.3L*I6VSFZ<'!/&F"#.//4X?FQ 0^28[^7DN&T;!S# ;G6UK2!4WF
M"959RT$:71]2 E*'-T%9D08^/00_\Y4?ZD7^EHPE\/9V"Q+3 Z=2SHFU"N=<
MI;F+L4FWJYWR1M%:(N4Q^.[4B&'.E$<)E2QQ0^52 W;E.%O['@3;';/#@;Q&
MQ!#*#2JB,AH(FLBF<61[4@-B!3T#^EOK>^FVY1VS+EAUB.C! ]J2:^TI0H8^
M56@YP7J?A&72%W7,\D5!UO6^:IWP/J]/;WDGA9FJ;5Z"\!M.%P7]/3UJ@3HE
M-P(."[F=U:&W'6\^O;AD2A!-,WH88.V%LE [^XC[0T/<W$LY@Z/I/F]OA3YT
M#I-\-_\2,C9E^"1+XC(]\]+LTY4O^M-2HP?;:3-RT!H1,9F^ K2>E&$6U*AH
MV1.T0T@).*4OO)/4F4R7 \#(%%.QGKW"GU=^-&&8&&.3.]>426ZV8:3,)!-%
MIXN'DU0.1&X__BY$>K*)IP$KE%"C.AM1MY+$=>Y-:5KIV"F3R?H"VOX>PFE!
MGPQS%&JN<@$I[M!&H.P0=,^\R+"#PQ.>\$7)Y%,PR7?LPH"G<YXO(=Z0%U&W
M<\K4MWDLKSR"ZJ6^,OP(\PI-*[=O=]X8=R7PEIWO-2XF53XN?6>19+LY,O2<
MAU=41__;S=304VM7=8F2S=/D@YXWA?Z"<7/4^/][R'UM:S'O%PMYSPE724]:
MG@LTQ_2W==L%+9!HN\$J/B7V"37X8/N7$#V"#X#E)_N)XFI"Q:Y.[KWEA9D&
MS@Q5_["+$O4QFXN\2\&%K62R46Q=H6NDXCO^T>YC2_1U:^HQ+.C.F-[2-ACI
M%2O"&FSDL+,,LWBC#%-6+'U(F$VAK^V=^L@8%\LPYQDS:KM6,_K3JZ1*:0QH
M:P?ANQ5KRM4;B6WEP:O'<'"&]\RA)8J2O&(99L\G :(<PD)<<Q;<C\HP]R],
MRS!+;)QD&.,>J8;<%6E!(>/=LS 9)EK/0(9)]4>ZNGFCQVMDF/J4ZS+,RPJ>
M(^971F"@8,;,1X89;MDOPWSL)U184N:US&08X.0#QM<@2ONNU;C_MY?_+_92
M*+'V",-3^LO[RJ495I>JK,+TSTX-5$IO!U2>:1BA#P[$?1"6WG?$:+C]YT%?
MRZA'$^:3(1O8PUZP$?1'RS#'1D0J]"$GI(0PA_;)W:L@)LKS3628FS<8]<L9
MDQ.,0*ST)#O><N$2;OZI#/.!)%U\2/ZKXLPL8;< R+OMEA(^M\9 _T$*9GCX
MAMP4*94->!0?B"0,8V.]B(GI!/Z4'G>M_\A18.XJ+1C4&JZZ3#=X6-MYXLD[
M.V?PF[#6Y1'-LN;=ER_N3?UZW%S+S[=$+\O)$]: I"HBSU./(.3@:/X@*[XB
M'ED+O1KQ!I+3KN"5D-=96Z69B!;L*'W -:4ZB)T:%R(/3C?V^.ZL@E:91.5W
MJHORF]DKH0G7I-WZ.\&J:/HZ)[%@*8=/5)X86@9PHT'OQO"BR[B.@_O."]:,
MAD=D1=N7]2JNJ;]W;6O6B#R&_2G+GKC[0Z_(D%>NU5CG@"QG .&"%D1>FH/R
M^L,NA &LT"_6(LB=7UV9 9RAV0%Z[ ;;0DI2^I<"<HFST#42/B4R-3\&NN9?
M_3+\E+&8JO,+@(TM'NX(=24V;POT%%01IIQ%07XMN+(XWC!1!7F'*OOG>CIB
MOTEK4!VE^8V<*WB]IR *8/V:TZ*Y9M)RT\X6L4"1FAD$[QY641?&W9L_S1+J
M5-CX-1+7P'O+NKZ84BS:EOB':5]3_!*D\>+M28>V#?E9M5=Z!3WL70H:;O^C
M@8O' 8<9WYU-X!7YR-LJR3T9IF<G%$TJTV9?M=M^ST4EJ[3(*V".&+2JP6'G
M-=L]G\2>2QI/5&1MU C^HT#$6T,8SKW@I 5K,)&EOWRUV1<M*9'FWZQYDATE
MPY0*&A<?\HQ?XW?JR)K6K<NW[5><,1';=]?U)I2/F9Y=]_2JOZ9_&\4B>.WY
M,'J3R][7]R__>B#UVM(=]8MAWFJ_.UGZ+W/O"#<>*O;:\8?]*N4]#\>^]MQ,
M#7(O..!Q].A<<5VGPMF:2_H#152^D!0?\KT\D^$&?*[*_6"!/9\WWA/P<&Q.
MA1RL\JF,Z'>);%G>//1U:.B+O&'0QP_URN#4;</0=(8NO+WZZ9.:9ST6MDG%
M5LZG.[_X1;]]6II.]1VZ5#1RN^]3Q6U_0^KIVXHISK]=3-GW^V_YHDFV^_?T
M;9'$S^2O;"AIS;14Z2L;UKHJPWRN'QN!+C'J8;NVBM]15L^_>RHEP/+-FL\)
M?OMSJ2ZMVA\>Y3:T&'BG.6:Z:9XZO/A1HJ&RAIPV-"+,]A[P,BN];UI\IT+S
M=NL9326WWP[U*5$='R?*^9^\.K#TNL*SO3]-;GH*U9AT(:>O_M@ 0;3%CS=C
M_HH!^&Z783+DB01^*X(5?HZLDV&4S)^S9[8'"/X0P*>K)W0F7 ^^'4(:0JK+
M:A).5SZ-3]5MMQX,,92/'EB+"X1G%G_\/2NG+C(?9?]'.M<"'G'9&8=*$W_I
M*.X6W_C:OU,M3EAQ_=/1P_9+%WOT 43MSW:N=WX#[KRV6AZSX=<AXY7\?;6G
M/Q<>SFTU.5IWI#4P>4SCR^W*]I2>SOEV>I6]:N)KI+^#,+HQGS$<FB_#Z.<L
MD-%F>2\/%8=7>MAP.,]%+=_Q-",H #>CT<D#;#IE&):;M.(!XYW[0;1J)HB(
M_2[MD*-^DAZT[^YVM95AY(L)T"QNP,M)JF Q#:N6RS#B+KG__1J_BXMI];BI
M_(4-QP-P6A4#YOWRPHLY>;!"EY8+5&-U5U2H<I@H+]C?__-/CH^\ HK#(NS"
M//J',G,\!P-N]TK2LM;=$/,OEKWAO _4#N*\^S9AXQGGIG\_UV5=<H.354[@
MM1>?#G;=ZLX[E9"A9+#E\.,]32>O74Z&U "2A $-W/_QH,CC2@E=@T8"YNKU
M",> ",A6F-S2--V'B$5FUTNH!A[2FY:<9>_I+]FZ'^/,U28(JB$J2L*YJ\)G
M!.U9+)9;=5YH'INE#WSJO4SS5&2%JJR6GTT12P:D=XKIN ""Q@B4^UN60J^=
MST-(ZT O0Z@+\HM'$F<*]]5U65!G/@)EY&66%=7;R[^.E?;M7+2AY,&=^+;\
M  8.KSPNPRAN8?AO)B;XKB!%5;/B[H&Q[,;6*5^5S0TKH=-3C1?3V[LK*(^;
M5MWZ4*QKQ=G6/+?=1?DG)\/.AALTM1-"2O]V-VD6PY^TV/\"? AXPV[")2&+
M@?SZ3"516U.003-!CZL!+P:_T0P!2@M%C3QDG]$RM+7KMVJ@&\6_9EX\"3M9
M08C';P6GF>4?VXN%W$J>MG5,+6%4AJG$Q5;(,#AX%8B=% !E0GKMT.JR=D0Q
ML#KL*LU 9!['U=?&1PL92=5;YDMB >.1X^#G9'SRPC[8$&B+#N'$\Y9-TP)R
M @3*6VKW<+%9WWQ[SIZI("@_5NQC*R.;81OHI?"Z&!N'_ZG=+D H9(0]^!"H
M;=J;*5'QK3\1,8@[4GYK;9=%I&^';49 24CQT8[60U%*A9X?*X^9!7U,?5?X
M;42B":0UDI@2G)X9W>0XM:_([CQX ;L:LFTDX2H8<5JD<G;"S *+R55IK_!F
M)=V #7@9PM<7Z;ANBZ- 6L."JW8K?[Z$#4SL:4>S>265;GJP=X%\?*'M3[5R
MV6*TJ&VJV ")2@]#%+T8X#BALIPUOSQ  .FA^=7R4/[@_Z[<_@^6*#S:6QF6
M@;2&!@5_FA)(+@G9IR>G!)]LIP8K*K\TGSO_AR[&,SMQ ^9?QK, ^/QP*V6%
M@]"6I4D-Q&I\6%_'B_O<6WZG=K>-3=P^YMX;8*BS0X%RGNT^Y0>K#-5\B-]G
MD! YB($RE(U'*-!&'+SBP;8X^1]@<F<))KEU00_>=>J,_OCS;5GW+QLLEB?=
M)V@+X[#J8P7*;@U,ON3,4<-C7:6U/(7$>_([,'YKGLO?6_5]^J_YSOP:D(?L
MR[1&FB8(TBU=F[^UJ:,$[G:!#',",I>:_4KMUG CO=WU@U9M&,?G?.\=(&'/
M%'T$B'&^+BZ>>N6%%]Y*0-NMM@E&=Y<99CD;<XU\<\8)F9$MP 2REZ+,>&\L
M^&Y)+Q!:PREEN(55K3+,88 _6D<:#<7U]3-@"%5,PQ8XV/%?9\>S>30UXH(M
M489AZQ#@)2B!B\_YUVGAS4,*A,DI D([@]),;2RRGO4OLQ*W71JH8$"SZ#M8
MAK8^?P*4V RJO$T5#FH=ZBFQ>&JVKE.H_E)9LR<[0./%=:'RH](1,^SKY[_J
M0R6WGQ(3>%_701E(+4H6#_S*(5@U'FDXY9FU*=JM.*X5O).X[?QAMT(GE<.Y
M5F)#L6&^Q@>O@,GNN IRMWX0"CHY#2>14][3"]\>,,!^@C $(B*QZ!3\,?U>
M6LTN0$)NP;,RC)I!$F'4BHFHG:CEC0G21 O,EW3"B-3GN_<8$?+17RDOWY#V
M?N:KQ57&Z"MT&:H+$NORY8X,X_8@9$:&\>S@DK-94(*N)PH'Y00@2>F3#',0
MYFE]P+N@F$L8GWXE.(!-UE^IBUTND!M=VT& /EVD*X$<)DR.B/#SNV>?T>?5
M$C(=1LF_&7KCY-)?5JQ9_=.)U*=R*3'ID*A.,&P-,RT%"XN]99@QL@>OX4-P
MXR7VBE-WE$]O2O[9RKCB0.A]7=.E!]Q2](L= QJ6N]&Z1%_8H66J+->T\;39
MB='(S=),M&K:DMF(_&Z4ZKG]Z_3(J\US)_Y3B C_.GWFB'%'WJ(H-M+<)L/(
MH7Q,M.%/\TV?-.3^E"H%V55558,?=RO;EM:\2C 8O"J^V'1<;++F[;;S/7G9
MEY=O^*>12.WQ/Y50^^9)DV'0)Y<M*X-"-M&>W:=^3@ .OOSMNF'R8["Z.FYE
MA]6Y'Y_P7\4<A\Y1^DTYJ HT\.VU:+OJ-=W 6HHTXY3,[0R&IY.R5G3 NPGQ
M##^*&O1H6D2(JB67(&U#*D!N<S)H'Y<II$ _P^Z$1D**8*4E!6?:FQ*$:$.D
MX5^C16<S\@/U#>MZ0P1]09M=R]MGWA"<'Z?L+PIIM0W"O]IY]BSEE(O+CL-#
M?88U=>F?OW[J6=W^<Z^'^H?]^\9.76_="L> UO&UA%RDC[OS7>VYH950=-A#
MFC_D0Q:B",HK9TU9"^,1K>-4%M]7@82%C;MIML.\*S:LR3$A24T0J)DD8BRB
M[005FU2V-Q)6?@8OWK%S5 KTW=!!J6"_O]X)$EXCW)Q2T67""L;P QGFZPTB
MM(XHS:1,H=$L"@:7\!SPUC+,B\X\&>9]G9\,DYL>2[^$RL2_E&)Q-(H,<SW?
M%27&X6@D72R7P]\:T<@;/6*\IRNA!^[H6SIJ>'R[]H.6+Z]SZF+8++"$O7#\
MT&H9YK$K[VL@=#Z<]1 )G</Q.=_5:K?*,+]F,#YVS^?'"+[:O&9,>IA+7?C8
M[%G&S8,=B1LX@L7_K@Y7-=#0NU['-@IFAWGS[@IAH7\Z<&FG# /'EW$6-#X3
MYIG'S@^&<UY#R7^KVIO%75+BMP><CVY_4PP1O.>4[ZIDGF1IE0S3T<-9R@F#
M5&28=6_"D'I-&6;>JWN6ALZ-3J,N.&')F%5?85E>1_@ET@&U;'9#5.*&>XO^
M:CP,K HZD1=H_?!VAWUN\J<.HT^=GEZVW@,NVW+?B 8&*W)K5C_/^NCU(8.:
M]-KT\X;U$;-.OR2*@JP/Q75KNA2<.2NNVM=E5G[KTL>J6^OV=6^Y]ZRV\]:#
M4^X,<M#YX-/8_E^C/+/WOY<'LE&08ZO0#6D!B7HX43[?""*#?F)<?5L"?B=D
M?P_IJ=[BJP%R&J5ZB!ZE.X,_QRZ]G0.N&J0=$6)5G4UB[+:#-?5#*Z"[84(?
M<[?>\BE-@A:U\&"-]*,>01WZ>B%<U?DC>'5&Q-/J_*42"&L),A!^U#<&C]84
M0-[-/%4+DGH]%M;0098K@<M]Y!O3B]DQLX,N_"RC=S.<RW1#Z'S8I=\MG^8Q
M^?AM()=%$>&4!D>]V%=S@"RVB)SD0Y!<9KA_R!KI_1ZBIZ@A!T7_-P&.ARSW
M8IG &M&H1DNPN+956L@+Z#!*^,WO$*]TA-5W6=UI"\,F6D<S.?ZHT<6G1W'W
M!&O6I@L:JR\0(\[31G:7G[!\??%Z=4$-=]%/E1=[2C46:RKD;#L5;[;K$,$.
M)"#.@6P)#M5['1\5;[@YKH(_RCEJ'%K$<9O%O>6*H5 99KUU'&%2G0*G<W7U
M_I;6ML]M(B>YRL"'Z^3JY"?X-/DM:MZCT[J[OC08$'/?;#VT0__W)X1";:E[
M ^6[WFF"9#-C/BT.YX@R58<._R+B9)T3$N?J@7;#$!SBWBY->RC#O'OY"$52
M,]0EK\*EP+[!50G_Z3#AR2QN?HTE"59XQ_A.W*43<M1$XIN#KFE<*,-<KL;*
M,!M'D=8NQNCOW0Q "RWQ3_:8H-YEH#6REZ#.Z$4M'/MYU3O&J7'"S+9 'J2$
MMN*O64\Y\95:CR&#QL,N)8'6YW/C32F6W&O7]^/;,?U307F[=^C),&$60=?P
M9W['F1#0HM-$'?+;'RTRS*$)E;-U'I]IYP:)73*,S0'W+JFK$6-]_-_>(QY$
MY!DO@GW0PG?D(;<KJ(X1?O4ZE[Y89@;]RGOV^%1'\?N707HWKPX/J97&3A7W
M*^A><W/[>NDWGFDD29[QTO,&X[TK2;JW427(G-B-.^IVC-T7SI(JIW.01:,$
M.#]GP=Q-AKF?>@3%'!]%-(-FI0<,SB8V_LEZW+_\Z)Y*]6;U/_]PYD_NN&PU
M^N?X= _8>F=0MD]IWQJZSSO;5N%X0NM6U<4I]F]EY8,\@["[GT_^VE=E^G31
M[#\_F5@W>OYE_7/8'H+' E1W&89BQ!,#^81;&/II#A^;'&X^M1$D-&Z%_"0L
MD@*U2C0=7>N6/8Y;1E]/?\N5AYS/"R&:]? ;DU]J0;\K%6V:A$;3X"-:\_L>
M#MGVYCTAK8#:#K@H^9@U+)UYL^D-X^<6:'9>AODCPF/$=(2%V%A/K1*W8:D9
M1Z0%(=BE 6QU>-T)0(*+)6#HNA,\!93&,.>JM6).W:UU%+=I0M@FWQTVB= -
MXBHOVJZ>HMDV;$"Z[VT)#H@W7-(P<21MQI]N3R1QOLY()O[+QRWWV3HH"0WH
M9$SZHD2@X\T>GAV:M_]MS!$QX!O=A$F" CI_C=7.3MS\_<6/QJKP%]24MN.O
ML.4_:BT-R14RV\-YKTP"T*8]'?4/WB#$&Z,W9HHH\P!)NC&JIOI/!VK_D&&0
MO9Z]TL1@G-2A:,>7']F][^_9?72<GO^]P^/KOV' GZE6C$<-O$2&N?:Y!@6U
M)(;4-'">B\YOE!FBVTOGS2?$:_?[LA_A[Z.6S=_<C?87N;\:1RC%!MRRFB<W
M#1S#@LX'K:\E;[((6U%KIF_RW?#PDQ4O!)NO%IYS]<J^3#"WF'[_&U$98KL\
M!7J?<]X+#=LM,[=[M..-7N;!GIV6;]9/'ZBMXG:&+H9(Y(B'8U4>_9%O:CW4
M# E:%@/.IZ]<-'UP^-(A)#W@$,EK+#V26T!+S\I7N%7NE9*KEQX "@2&&ZK"
M2M\[639X.@7ON.$_I2D:]C:(I[?CVRRGV_]?&OQ?38._#T7A"*Q1.D@8?H #
M]MQ.,=C.X'L@G=&M'GN-O"7VX'S-DFN/D"DEY_)KI+--MG<\1DV:-WXIL7/.
MKQM,/?;"0L?Q6+I(Y\9+28W(4""W0<ZPI"-,Y9G!8H\1E"S]Y7]H1OV:43ZG
M'2)8T"J286;*#G':[%"2?L,K7\H<YLT\DQ/_XN;(V/FW_RGE/)Q/7-C\W&/^
M@:\*\.&<_XWCC=7'Y4RTDZ^N/Z+S6+13UR9Z]+E:!]?ROQ:7YO\L+@,9 1.$
M&;.7,DRTCZT,DY2S0$1%TOV+1%A[3 #[A/P((<KRINS]D-@^ D#.9X A?_I)
M250B!K6M?)8]K_4[RF)+,F68IG9I/FK+NQH31"5D&C&K7KY!GHUT]C!&?5)E
MF"7583*,UG%2HXOT,$6!FKASQJDBMFC7I;?W3_UT-3(;>Z=)_:[.'\H;VG9R
M?BE1%U'@>#J:*APT/3ON;'Z)DN"/CIF,]_DHD^VRX:=,=-/]&OT*YM/_G"6%
MPYE-@]RRXHK<)-+.CF+^^@_U0:7T]_LO?'M2\-+H8@EQC9TVZ#7'N"SXJMO+
MF%1#>79N,<GCN>#KT=_9$G44B-RVROM$HC14_E^M8?VS.T+?N9&ZLO\O^<A+
MT]JC"D_IG_G\N*^L=3 L*/CSE\$:G-_IOC*E3&BPYM,H><]?OZ8%[Y)AHM!U
M7CD3AF,)DE!>A2)2VM:H+56&!#*,P<$,E$[,LI';@:N^C_R/'WALFL6YP1-?
M"$S25P/J2:3>2H9Y62AL^MMCD \,5=['?4"+- H5_*D>XUGJC!<3:.A*C_-F
MS97Q2=V(F^V!#=D\V@HW1^-]VZ^SCH-M!R-'Y?Q_\)D8"-WG>EP";Z*>,9.W
M_,O$GPY\#48K1\V/)-GXFC&K^EA</4NZ"^J$$MSAL8W>!?/L$6?2B^R_M9\_
MA=E7S7<:T$$<TJ>E4:9HT544CD,ZR('7J4A#H PS;KR6'!!.?S@?APJB\1\2
MYOH??EE/IUE>F WW5H2O.'?N_/OY2/^_%B7HP#9BH8T$^$$JLM1=AO'S7CC$
MF-"%=W/>M26C/=EBC"<Q1ZML[/1]4BH/\&Q+%J Z[C1[ (LL;0$7Q(Q$]^?L
MI7AM>A>I'*5R*3 E] %YOCE36&-*D1P!64R+FJ0)DLJ8U]M'K9>* RLU5Q17
MLFWO^@V-7W.T:S\%'T(C_Q5-,D,[%XZG[QBA,BWZ=!73J;+\>H:0UU*?('Y6
M>[WW(^2T5GC*H4L_W*,>2HYM.KDC,%=77T<ML7CV@V[=;>WD [.73NX,=NGK
MN)K;JE/B1S8KPK9K;_Z:AN"8: -#^6_.:X"$Z+!8:%L;W8!R&R%Z2_1[])N=
ME@P3)Q;+,&CG7@XK+LCCT8YB?!X]^!KU_89O\,)/A*,/.:_0)%! .U_4H=)?
M>96,J-4Y9\ZQ5;GXTN2&0HUKY@TK3YXK*BYMX#8[#51TI3'X  II-QDSE[)0
M9_'/@S^6SU3 O5\S)UVVG05;G61\=V*/]%V9K_PK@$+.,6$M=639OJ4$H"]+
M:9CU/1^'0W/GG4<7%Q6>T2C3'TZ9=XH-,;6:D_0!(6$7PT-^.NXDPRP?$+>]
MW.1WX1OPA[5NY"?WR<TS/.5MKUL5,L3C)R_ %U7_^-J[M*OIQ-;5U ,4=6::
MX2FO/PPV7LC[[G[V98W_Y+RYQSSC^L)=1_H61N->'+!/,&_?IL@05D*H 6^S
M65 \JJX&9!BG9\/3L)5 G_"]RV-*1' E!-BC.HZ)*$&=AR'W8JK'+BCZTZ@-
M(\X2JS4>;LS*M[I?!!7N;F>[=LSBU!]P5T<WAP_>D@XE ""-2 D3%K+BM9EQ
MIK6[3T7DO(D(L/XX/5D!"L2XEB E2:"4/<MFL?5A19%/A /$%N$2AZQ =@RB
M'$#"%5>P%\%FTDP:!?6W,(\M*L;QAZP@!U$2;HT_3O<L_J<FL>EV_F$HZ1A
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M+.-OM4[Y1ZTC18WT8C?233]$"6U]B^\?OL\[@WYOWKDI48#6>N'^>L]7S<5
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M6P65_G6P%IPDJ(B*2D":V54Y$$+H,Q?3D\%D1 NKS-97,>'[V@-SL &_F3#
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M=SP'^N)@\U3 EUP8I<T[,\3<BG6$-PV\/ZA2XLL7B8K0\#;511'D][!WN;+
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M.#7JP9\LP]2VM]Z<'GC;9"LJ@;)Y, (/S"ZYQRU@4!C.$&PI)"B1-\!H/L,
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M-D+/UY,"S ;ZBF$#LXXHP/PGX77+U)57+<V('8Q,!ZL>VA8)"&?'2O#W $H
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M)TGR^&XIP-$/DYQ=.?O-[\NWSCG""++_"_O)OPO5?^>_#X006+: 0R)%R=(
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M5)[ ^]M9._I#YZE)/%3-G"HQ7QV^\PB.:?&I2_Y4  Z71#T9A<,]XSK&M:%
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MBZT?_SP8D>(?82=("7_TAK$YI>4CIKD+TA]K0L21-O6'HH$IH7/,@AG"K'D
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M+J#?I3'O'/E!J=1G9, RYN?]Y3+@_5:V#'!RIV^M9X]:BA/,V2)Y#_AI.,P
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M 4U"X?#/%2)22=$G]_<?'DZ?$'3\_-PCB8?K//J]MVG@$KTV>J/Y,$^3HOI
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M6V!.T$XD#]55YTHVP51E$7P7++E7/E9N4X_>!^\X11@ S7&N'K3R>K%J?'5
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M*YI=BL\[5>]U]MWY7D%HWO9?VZ8>#'64R,T?31;GRX $C@QHW"8#QN=L-&5
M/(_WXP>;5JO1'(@,.J*%-ET*,H#S$OKQZ;MHYC)I0Q=SW.%W,J<29EAO;&0
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MFJ'$A+)Q2)^_7'";.>D.6M4(QBRZ2<I+"/TI;B6GDVK FTEZ[ ^-LL9U#M5
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MK4R*-<,GM$JI0.Y1H(O2A=3G$0(AW@3Y1J&H&"Z?\IP_9D)T;PO,F O:A&,
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MM"Q<R"!:2P>)ZJ!.%E%YMKG4N'&0%/DJUS*\D]?(2Z-OZ16>DI='#;$[9"Q
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MVC4:;60$%'4Q<EI;\LH!1@'*4FS7",2PR?/6#WV\0&QZO#SU-^,'?LOME*+
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M;1W']XA>0]>%E P93/F[V+ERVH^.Z%_B9<I@*O'4G,"OO?E(W-*8U?+Q_BI
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M.-1X24)WN(N<0?5T"_E?*2R$)C[V)$#*)II$DC87!1NM[2<:STJUA^(]X6=
M>LFC0.C&#,=WN-Y3,)/TC?8D:DMOHY3!YXQ;U,^NR,D--A$HZH!S9X5%78;A
M+,1FPC[0A<]@X;3QN:*$!FBV4GRD64(A&N-#72 W09TQ6ZH+5'=14KD49G9;
M2.EVD)/39E<!W?/D8]>/R=$+Y&42_"HHF\7>MP+B:]'/4Y17+:5]X\[@9 >:
MC#*'TI]"*6V' #\V"@6(*#7B8T!IPZIMM">?#!<[R1%/[%Q'2(12!#WY0:<A
M\^2KQ9*A]V-+DLK*C#I @(03S@PT&5J< *WU;%JJ(M$-":]3+%Q KUP3,BOF
M*DEK%++J)&E!5*%=-UJ+X/+1FIHQ;DS2(3CVB35 1 A(D\$*""I5>#/6#W26
M$QK'#R8=CUBJ,1VRV1BO/_VMU*/5;2X%<#D^0#E!\0(963&T8%R7G);QQ*8(
M#:DI_B7=:B;$#L*:=;3'$VV064Z8)T?!6'=LIF4,OUV96>J8&P#PTBWCZK9@
ME"/U;+HS*STB D0DCMAAM7.V]3_FG2#',$493%(OW4M(!C-J^,C<VI2JJ&7L
M>H(.&-F&%E*OEYI)'A(\JZ.)VX;_O2U<13#O:\,($.J(?-ZZ-K1QI$@H^)"?
M>"6Z,BJI.F-N@<931>?-E7^4AV#T)".=U(CNY*6%F%*Z4098H^C27?)8^1.[
M+M)ADD7.06N@=D>AM( CG)7+M>A4 B(6U.\RVHE3AJXNG^IK"AH+'#AF^W.V
M1<_HVLK2MQI):KDRO,Q\\W\&6>+?Y$!R6P9[ZXZ>2$>+XADT)6E#+TM/TD:6
MG"5]1TIO6,AY@723?X$,!G@CH.W>;(O#/$ NYIKX/[5.C>R6LNGH\),[_3#C
MVR*6M4SL+I]ZL4E21CXQ));C?TX.Z07CY^8!9R7)WD=;<G)>2]_)KYPZ3Y'C
M3'&X7."4KQ[PD\'*<DAB[4B*^/PUNZEG\+GW6&F&N?SG JI(8 ZZT8:TLK5:
M!NNX>%\&Z]ZE0/S_MQ7J?=(E2DX(2D)!7\3D(72=])].MV;F.*WCWXM/T1Y@
M.9BTC^?:?"[^=K-Z_XQM\X'(EML=HN3I?SR25_W4LRCO=^<;//P4$IS]_J?3
M*_..)TXAD06=82-GO EWQHWULZHSRN;-PM_ (WV=?C1^S1][^"PQ\=N55/Y<
MD5WO3YU38;],_<COP0_YZ.B WW]\MCQ[T:2_$K]Z/"=?]X?+_=BW?:WM[\BC
M#-$5D#Q_%- /@H(G9GO3?@9'Z:AA$OBD?!EL2SF4"0B[5-G7<=IE*G72VP*D
M2K2#39\G]C!H>_V)TW"+*N9<<B6/.X.*)[^EJ#(F[JU0\]HL^*0,;_QJ9W%U
MZA(FK9"RGFB)?Q7X-]0>(QS#=132]X&9V1J'_NZS9N1A !Z;K@D,9PKU&>O%
M*@"'38(3CE$F=FK_@<\]P1$G/#G+FUY&W-)S$VNS13.@=EUD&93<25&*?Q]^
M\O[\HL3,'8H4M+MYT^\;%U[,Z7\[P/;^_/G8WRY[GOW-8KD9%/QVYKQNF'PY
M&B6M\1;.;B<'VLP!TLF!Q2QOH2^C 3HG5.ZQW#WNW:.Y\G"L)?]KR\"CFW<+
M[:D76O(_!9S)]E58SEP\#SI8UKAEGA?4O'0-^*R14V>VR<O]8^L9,]W#)=&\
M.R9;QZK(7[>F'&Q3K=GZX<&+MQ479UW5,S?[/K@ +/+]5!\+<Z*\TLV[*T\S
M,KU./O@5NK.7BS&0AXTSC9R%T(MGZ&*$B UXY0ZF )$E/0 %KO*[2\#]/6P'
M7%=,D)R$93GI/,)WHC=#)8+P+-1Z?"P;I3=$^RD,)@EZ4U$&4U('J*9F:L6H
M2-!W+EH&VV@SF1/+"&>,> @2Y@:>0NQNAM(%22%=&]^\S+]X%^@?9<K9IE1#
M? 3@,=&YQ&T#;<&/HD.%F?,;'P6)CY'/@.%=%H;: UU)Z$R:A\IQDCJW5\C3
M^@PU"G0*8BXOKAI:@'4RV$0SI>5$X.G N5)-"&V4Z?RY4#7:F[ 73$MR6NXS
M3[Q4-H1E*U?W)*I;.#7?_$QC13Q;4'_:H/Q$[O@EN5"M,^!:4?F8-#T?+/?H
M$__Z&H#1K7>%/C#9>YMT 4G K7G54*+TIJU9?=0C];EO%3TOQ,S]R1-@]O8=
MP:T/$Z-W'9./5?R]\E9GN7_8-N$0LEKGAEKN@\KN4VGGCE=46VU]5JX77S=7
M]05TWW6&\^G-*Z_QV:31E82/1#6LO[2/HHYRB%KIICP]),"FDY2)VA#2-1@5
M06W;7H5'LTCJ;0%"7>GGGTXZ*L*4Z.X0P^*?<\#K<4RJ=41]V\+SP";B//:?
MV__5D2>+3^(_.9D#1&=UP7</Y92+F RCO9X[!"LF2,L\O7+\A+]GLOK:']RC
M?RZK/;F(OWLF2V(FK[*_RR__C12!''44H%F\#01OU)I^ZP4EO/YQT/2NW8TV
M\\3*L9XG6'R^]?U;(L]0EI[8)S#W</?!LHSQ4_8!F^=RSN/@V4YKA5*M?V*M
MC-]OO]76LCO-++=0Q[I@1U,BJ/G'V[T53]C%4741YF[W#U::BAI72C>M!$">
M[#:_6\#EHRB3@GB*U^D?4\(?N^\Y6?_Z@W;EP4_JGB,OS3_DZ[XX??+.A5_>
M4#TCJNW$ B(S?MKX:L&1OG@_-]<+<?$#WP,"#(^%A?VN&W L;)OJ(1CGUP\S
M]D+!J(X4&=XE@[4R?OJ(XZ?0,V@L;R&[:2R 8"]8.[[MX>N/-'+1JJ/GV=M5
M8[ $94*>^A:ELZ%YG%]"R*=S93D_?MZL<WSKP*@/)_Y^?C/E@E7,GKYQQ\CZ
M[R8O&8.7+:WG4=UOWW*_K9X<I.F_\D1[_=W\DDYO;:&U%)^6E$S=SGQ]IA-*
M]=M;EE;C ;<R>#(C-.][Z* IQ* >!KP<]K(NV]IQO&(T+_'\@X?EU3_#Y]=U
MAV\E)*3Y7Z+HW#_)"B5Q'/:5%7)8_;4YSV;^R-N[..1D7;Y[R6#F8%]ZI57D
MBXZ0&-2R5&>9C5NQI.C(06 2FI7!BA9)G5)H7@8[VBB0(Z,\K0U)/Z2OL&K2
M'CH*J,YO<YF8CV7Q-C:M8E0B?9/&RX2O>G-*59LAPLKELJ>D<R.TEBR5Q49,
MS=EH#]OB.,4!+T;4,$<O77H_LOQ(_'X)6H2!V,G/HJ0&+QN PG2!)[J[E<Q,
M,6-*C<'EM*88/[:14_\SZWGOA4X9#'[NQ6 Q0H=GB [\6&]I-7?9N(^F RIE
MSL5)O">]AQ=GY=CUS-?NAN'!8=$#AYJW:?OVW<Y8;_[Q3B2&&ZWU?:#:.__X
M6(1/C5=EV 8O2QD,UD;M.NI[VIFLZ]#0=:;CN!JUV/W9&5VO+;DTWY<SI\N]
M"PU#1IX./NUC.M#.';1"_$_.SGVJ>,=0V[X)B457*R<791B(J<.3CH"N#R<:
M!5]N"Q2Y=ED7S2L_MV3X>.W0O=CL.UA!*SH95)*RS_-S7[WO@4I@><*,3#2)
M*$SZGHI,NV09S]#"3*"51O'EW4GP#!NT$?2-@QF(=R1OP)MAAJS.4\X.3]"&
MF_;M0#2,6(ZWE$_SN$JG!F/JL%68M&E^=5Z-FTEU>G4P_VM634;G0.7\H]MW
M0NT'<HKSSD^:'WJ[2;7&SNJ89_U!'U"[WJ$@P$V-M=2X"3H66C,Q)02'&N#*
MWF\?!@Q49]VI^=ESZ\&Y,X<KGGYX:*+D77>P=QX'F5*[D;ET8\E+='B*#@NM
M1329Y=K(8+DV_U";\J/9XU9#3:]&;K\F6CTT;AN@J5S\]F'&NG17U>G2C5IA
M.?:P+3ENH@>4>-(8XA\_H%=.,UD9H:M)T@^JF;>&P\""UKQNZ_U'0 C>;73>
M.M9B%^FFX/>9X^I>"D^HW\V\:&W-OJN^Y2;2)?+%U: @G$5$S,BJ=22#Z)HP
M>;FO1==>JKWB=^[OD1"'?\SY?RSN7>1MY%<)#]]U.'FG%%=2'ZX79=Y3N,_+
M,[CB[IB<O_D0K]V;NXKNI.^N)7>?;Z"5L4=F3I4BU8+4O%7)<$!XTJ?._.T^
M[SO%.5>]_[SJV;P8\3A'&HQN/9RSZ]':_VB[[8O/9/AFV!2&Y7-WE6+,+_QE
M;J[O\1QC&7S-QZQP=8UE ]ATS?THD00Q19D@-<TIO!(?%")Y)(.%(3;C7P6#
M8U3F_ '^.DXJ?2?^]NG<KA9N>!JM![MQ%JL1UYO5&AJ1E,=-(#NM90!_13$V
M+KXW&A:RQS<UE7@4RV!==+WG0Z@? R8,BM??)6>:FO\>,FELOGVJH;$]Y7C_
MAU]\UU<TVF#8\X$P1O.-B3>:.K>FA]4_LVJL"WT+YA5_1V3S &_2+W<SL6JU
M]$.+2#ZH87LH%=MR4P:K)4OD=>_C4>)V>55WE\&^[J0 ARFK#CQNJ@SF/RE0
M(8Z[2>O1R_+$.*0)6]GU^-JF_ZQ!9M)-)!G,5&?UN PVDBO'\AILIL5"U']^
M?/:@LM2C7ED&>]Z8B5ZZDHI2Z"+]LJ'OE,$^K9./9J7WF]*/!GG$+(,[I0AH
MTMJ7FYE^Z0NG*:SO6ZH_.#_9R=,,^51?&_WT0RD,%+A([E;/_N59Q7U3.Y6T
M]#F0E-UF'>^X:][&HC:BKFB<J X]5E$0##/J2)T_:""ETUA(T@Z>0>T<0J'P
M/IT<E.*PV&4BY8 ;B&-ALTE;>"< 2<O\OFK/=?_T6S?P9R,7J=GS?,>IF$?]
M5:!'I!_ZUK-C"1W&WRY3 B._W/CCV-0QQ;RE#J>\ZZEY%^*I2V9V$SFZ]'/%
MPJ]YIQFTY^]L@P+O_)U36ZVWZ5EP4GSACKO'AD7QZI5S[7>"SI@+"\^EU1A8
M(H&BC#:?KC^^>S)_>3HU< C.#X2->2A3W=2R^<I<_ZM_W_UC86/@ ^![I:Z3
M6W/\5UR8CV6BK\,#<(CAUV8!VG6TFG4ZHG7QU-,M@TU-$HK4@& ++'?F8P3L
MZS1JVK+4'G#+%>O+2=$^@'J\_24H314HUU+@449[H7R=+,+VRNEQ+<I),*,=
M)T1HV^4L!JLO/)24[^QSBISHP<&"\.,D38(;R)[?*,!E$_7:H)O@*!^;_P@H
MNG'92:T>G;WG4ELTOU<U!/)@HM0YM-A'7?SI^#$LLY5=8"5V7"> -)B("W^W
M#/[[L%?=37%"H^"8X1KG/QRN/U!X;ZKD9+5Q9WZY8FE%WN^WN]W?'#0  \Y!
MFPIT$)L[,W[G!Y8>4,NKH%-/=:KTE6.4,$6SQ=VW*^BO+)[>ST>/O<7'1UJ]
M"\]]\8!X*LBTZPM8D\'Z^L+IE9I-7KD>+51O:?:BS8/"H# '>3372.XK.]@?
M#?)-W^/;U#LP34CDZY+"<:K1Q%V<A749KU8MH% ^(H.N'T@( *Q>3>QJ(SV*
M*M7-929)4X$6ST$$FZM3L+V];PFA#W6CU2&_(P,$RV?!4'EP:O>XJ5S8MASM
MOXQJE%,DQ0EQ'+3HY@)0F",KI,Y+]_[]!ZE/]S'8@\U_.:Q-^LMQRPU&LIR(
M7I/!?IRE.\GCWA18D%;U<3KQM+_Z_Q'O!%6\ZW8S0@HT-'IZ=OF4K[L?%A?I
MDV?BVWCWV$"UEN^KXKN))N:NMN[$FL44P8S8;S$-2!GN=%&1W-YS<0VF5"OZ
M_&Z/W>\;MN8,U&S:&K_)N\[[3R8_5 FCO/&XZH,[]R6'H&KI4:JJ/"?A<JTX
M$/^>5&K&1*I_@M!L(QW062(O\XNU,=KBD.::"4LW3+_X7.5;2ZL=S8.+R@]]
ME?.M@L90,_Z71ST'?2T,HX;U'VI__]ZI<FA!3JX_+G2A?UCB,Z6ODQC2DOIH
ML6#@.W*U5IQ.=%D\6H;1N@[JJYRQ\U"3UO<]N7L[;J:_EV]=XO6^V],L/'0%
M+DH7S/Y^ +/^RDB"%E;))Z_A]-F[@J?\V3_B R^[6W].G*B_[5G[J:ZWCYK+
M,Z*OA83"AY,L])8HZ2Z@GE$Q8M]/W!M)4D1I1PT3D<.7XX.FK4Q!<D>P]_>>
M(W1MHZVOFCY:D[0\:^RRJ-0X9H(@V.K[QKC5AQ;[$?GHQO<++$HVPV#/$L8(
M0@K8683(V!J"<_L0RO 3?N$(X*0^5:@:A=:TM![%9A5;-E&TVEP$V/F8Y*/]
MR"UE$]1TS_C-Q8HAQH//K/7'E'[.Y$@K*U]_"C.P,; TN!CN]=" ;G\VL";U
M3O4U49/%F<XS/J\_:.V].W-NXNN-!T:;TLT%>T><;/4WYG9]I(K-@KHNK6KD
M4?-97U\:!K[(&T_\\ACXE78.8R/2 D8(*4H&;\Z4DSO[6(,GWYT[<]$_YV-G
MZ+Z1=R&.:ZZS^-*AEY)'8GNSCCI,1Q*Y@&B!_\PC&/:A_GW\N+'M#)^WL0-8
MZ"#NZ*/%F,X,"&QO"V+L_ J^?9\\3!M8, 6>H%2:0'9)+3U50-H:E61XE\7M
M)0%NHB(("_@=,U('>#E.R9%\3SM!5;N I]:5#)!>2W?1(>'$JS'C$Q^;\M6O
MU$- #V#&&@Z$BW=*]5]PG)1K0D*<C';FLHRQ13Z J*C:[1?G:'36Q .*1AIK
M(DJ>G&>Z!#.A%B?S]NY.F_UP9U>G-U/BSI\YGK[KS:FZP+LG#M<=%(8'5J%5
M;G2=^[L37\ZZMX>I4.Q=H"9\+J87!J5WO4VD#-><B^24[GZV/:\@S"!LU_D&
M];0&S5T"<WZ(WH,?,Z=W?<5_9J_+DRC*\S/L??@5N;)>+RFMMUXUKAK!"!F:
M[T.K]6N07I0PY'5QC$EE=OM][R!FV*6^P)*7ITQ:]^E^.9.HZ[:L2;E"&L-^
ML8"BY&:"9; WJ]+W%)'=+&^%VA:&_?PT18Y?\:2_J )<9<5I_$+F8VH$4*!M
M4>Q]YUDC8<SBK>=;C&>8Z9?QNN;OI"H9K/'[Y>KTLT'V?]9@6'LZ/0^K5NOW
M9$)7Z/X^>><VC$UO==V7TV^^\Z^978\9=WL7MCW.V07[MU5<BKF4EV= /E7@
M)O0X]7[G'UT[^]\8G#JJ_V;GK=:*4X_-$Q(-LT[G:VI?/:]U6OT8K!@F/@\J
M74,90#]%SR!.:'0Y_N*;2W1KL?4 (8C/R"+1KMZ=<+X8+:PAK(4Z!#')KWGK
M8HB;\5P(\A.N;P<X?)<9E]-0:N4,0VT!I4F_7499$Y%4]<HLBQ0!>RW&"-^\
MF;)W/L96VL'0E)H%0M]6116<I6#T"<II,&693;JQS%!&+M89BS"MD@>7B<K_
M4%1,0=<RT(.%,FZB"/W$>XX^+V+K7'FSI1Q!UF=M!$#IEL"S4$A08_*J_X&"
M%!GL_FS! ?GWP4DE_H)8L]DU5[KID)PA[([+",I T!+F'11/WDO+?R5R E=N
M;?[!5-VP,6%LQ\.<41?4(([KOQ3=:XD6/!B6RKE\CZ?21]+@GPP=QD2%O/S>
MPD#;,9*'N'FYN6>QX'H&SE@&\T.LYLI@CW)@;.EPNPQ6%ALD@S&*X3(8<M=_
M?\#B<@Z,]?]Q+X8E*6:!&RODO,848-?N60QV<X/B5YUG?F!#\#P!D0;$=I%T
MG6QJHKBD&U+D[/@.@,J*[EV++V:R_GV1 <'/1W325<%P\9XJX*LT7=.A\)4
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M%#N"%%8EQ#@W,:;$7"_H<<<9$(YQ%K<+YHG=<MNBUM+,*JQ[O.G]"MJ=D(/
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M^:GP/>,Z2A\"\(T^+S,%C/P=@%UJV[Y04.<4'4SIKDVIFEHIS8RMG1*U/FO
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MPYTGNO.Z.SW,D$EX.!L^[RSM/$V8+%/GI@V'&\!!,TQKF+,G0S7C\_O@LFX
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M%Q0]8WCF\JZ6CQ\A>SYR$\[.F5,--V?((.5,;#E\YD 834UV',B9'6X.9%<
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M=Y5I'>M0[C!XA%LAE79.(5G2--#YC/Z=O?"CV8>\5=J$1G?(X#W I@I4"TW
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M.;(XWD.H!'L?>,"_./*4T9F80VD0*"G"]- (J6J:CP*" [A8)@Q%(ATJ@+[
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MOX>YS(=IJ#VY&W.C^9A)PPM'KD*40@PA]NJ@,@AW=">9<$=&HE59(0Q/"O[
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M>%AGBRC41!L='9/K^A2IC752#E5D>\1:Z?S+I@D><+X$EVF?UW"^V-6@:UK
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M)N>"=;P<?G Y\U6Q"Q)7"P3)U#WO^GBD&N2RHN/)](R28S]9O TYKB:FC?E
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MOH:F_S__?_#_Y3!:'OE?4$L#!!0    ( +6$]E!8UW$Z=DP  %M6   =
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MIN5"9=GR^-\7?*K* !;H$;N-3CI:CWP:XHE,%"T3X-<3@\"6QK:U(O-NIG+
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M3;4>*:BU@2B+SM"]E%A?JVYS&[=MUG@^7K&!4YS,L'E L#OD4KY<"C34.E0
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M<+6<4.%IZ_%2BAOQT5SU$+6RI:47GA+TFG4TDKV>]C+09'[.ENGX[DN2/B@
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M+,<B$GTHXVTDJAFG=?+BN%^7CWY7804]S2"JU\>&GS)^+FKW8*O H6KGFB,
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M$8,K3'V2D]U&%S_+XC""^<7C_@)L<J:.'HA)NB0%_,08OF4S^@9I#60$YON
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M-C%U.AG);:L#%RP3ILDK?:&HWMGAAD$DZ/>,QUT5@%H+6KQX"$4?:9^)L+'
M*5#:L13LU))VUCA<ZA9L@[%&GST]L9Q/'[D<3^S'P8'6@(C3)9Y>V(_8DY^:
M.[S[N2=\FVQR9G+>;Q-^/OFYWKS\_7;A)SO]0]_)V8S]]P/ #(."!X\<[N\:
M38MV"PS4"-]U.=#MCF>:^Z_W(&=CGQVBW9 V6"%0;V0!DO=46>N]?')*6-:W
M"I/&,EB;55/0 6@ ,G)_ 3K&H)1%VE#T$"5>A=1+5;0V%R!7^4)V'L*YQIPP
M_L6J6DS<#"+5M83@AY<AC(0@%""<[TD;!)_<3-$89548QDALX,D^@U%!P:_(
M\M9(/E['WK(%'872?@DYY0?X;NTMGZ&FL%:3UD'X?5TA5$XK<\-'**RQUB&1
MUZKC:EHO!=2LT3Q"*"8VZU(T'[ON78G=0A#B%37JL,BRDZF,B$$J&D"N>>4/
M.E&:O@1$PP+E1N7<L[",SF]<ME5J9EBATOYUYS*P$XY5D4><_'*=:)LB$M]G
MU?8U8&-U-G6+MI03*#P\&[L*AY)-[44N'>5PV5)@12 G,WK#LPN##0,-8=4+
MQDTM\<8A<TE;0L9<=5R,?*PN/,QMT K@I]J#C_QWRY_1\]Q#/*W!]S_9DI9]
M?./6GM%#YKI?\=R&<BMC^](C<3HKZ=Z1>YP3/7SHK /E T&T@2):4%LN*U !
MH2XZ *(;D"N(6R%*(8$\H6,$5>7JMH]+@4"\&JDU*[4,%3_T>>-T"MH-1+"#
M]!I9JN8U#,25QRD>32B%SND[+]JSC[<S7 4:X]/)FW8MS(V/",26?.HK2@QW
M564R>M6)$>9FH7M.*"Z(3UU=G3HS(VFM8;1O]^LF7OTQ(6BK\OT^Y]&K8Z5/
M;L 5>H](MDSQ)+U3NMP^E!(1"3K<>_P]%[:ND-V899G P(:!"HV:F 04$G+T
MZ@IM0XZN&O :U;'J&:>[ZOP8< -S\X+.^^-*"$4_]H0.++J<,#8Q&::GG*;9
MP>R\,DK!Q24BPL7EQ 9Z965EE):7BXO7A30%'/PK)&FPM[=W</?$1'D0/W60
MLT(0M4*09 9;E[_YG9R=TLK@X7R+GI.66DUO&<.M:XX<OO]MM#.)JG_^D$;(
MBZ)'=%?TV,)$?PB*!JE( =WF,BEP>H0US2WV\/]'T=%,7 %3R;/'I<#3:>X"
MOJNL LJ&;T FLL;JR=-%*R71L-SX\HFU:/C31.S8)!OF6_83I7>I>)2<L\DH
M%'U4-&(TS["U7WU8QG?R'Q5T@]%GR5+RZV ?>&A[EB2#'HE=2GYS,HW\T14K
M/M"H%&2"Z4&Z^I!;Z"WBR_"<]G3259KM-/(MZ\ 3EH CD-2X2H&''-9>CP<+
MB*_88/XD^#M"^(VU^'Y5I9L]R4(&GE0N[#^P7E#]?Q/^'W$]'2/]P\YO=DCZ
MP>%S[ F]QR[\V$CPML9,'2P\M_$6TV.=^U 6W1X@^09PGS;FK@-1F5=XM!O8
M9PU.#W%6?K2'1)?;KE!%$2[+?C#]&CZR:%1>R.R=<^NZ1*M<S"8\T3U(VAY0
ME=:Z9-SK8,%4GMBL\P&3WF6V&'EDWMSFD(+1!;JV\UZS+@&+>=#MTN39IZFX
MF.>IWZ[H=W",FUY5.:X2/XS,Q<%4#KT*_=]#M<CN/^&5+V]2MJ,</_D*%A]>
MUW]X6Z^;=.8FQ6T^"?#<LLO&\=OFUS/(NP^6_?L+0NH_(K")1S=:)\%J;6P4
M0G3H',Q$%++FPUE9C(-2(*U"&^9%.] +B0=_'47$_%G11VDWD%/; EFS.K!W
M71="KY+5R%_L0$LQP41RI][;_U6:7)RY]Q]H?J2))'MZ89QI\ =<WRZN(K?+
MD1>N1;$*=I'G+4TD;T3OI( ;:)<ZUD/R;TSI%F-^%A3^2P"2+1/^_)+)/P4:
MP3Z"]0H_KXQCS:ZHAM?92RL;PL\;[<(LRL-Y4'+W1GGAR$+^2-E?Z*WO*1U(
MOYHOY)+LFG]_:OS7E.4E=%X*Z W'28&Q'X)?M7!L@@,E\S)%E%PMF*R]I(@W
MO*15_X[8K_1?G]?\:Q-9P[[+. "3I:@_8)6Q\E;6 ;E9FKCXQ-T" O6+F$(D
M+=HU'V]@?GXBH_7'<[4X\T5[G1OJ&530M(\)5_/W?G/MY"YGT>G_7EFH+2XQ
M69 ?XT)[?AW4WR&?LI<"MC814D#.DB7ZO;KD@2)R? 7KNR&-//1M3@JDNHEO
MJ(ME9R9%ZP>E /AV$-85Y*>Z<+SEPO='9W,E>QQG9;'3:GTL83 \2HM1>!(P
MSQ5<RLJP,D@:"ROYI-[S>44=L^;E<>29FHL/WX^7<+=;;E:J?#Z\G(FGE9!L
MR*\58$[^%/;TR+)68AVVU5<?QHI4V(H:2/&! CC7/1K^?/XSW5+OL].$N*?T
M=5]6^@N?2\?DSY.O!*Q;TE!?;7:YMFS/YZ@O:SF/7KQZ\I)O0-&NCB+:6W%'
M?VJ,VZI\&@T+?L4=6:7HI)CJUF*CH9)[Y0\CQ)"C*%F3)HXOD@)=I!P?:B-W
M?I4(!AY?6(@4[O"8CH,%D\%7*="/OD<>16W&N=>Y@>M&245IZ7\[.QG<\$M-
MTW"0X;GJV@_56MZ^7C&=Y9_,T[M[TU3Q*SB3"EO.:;QV?RV;MAS7]%] 8HM\
MHB;'E_K(9E9@F^#U"3EA$\*7/Z3\+-Q6/!"Z_) CG;C:"O'@KT\)/OWE*0%'
M9!7C31A@"^\9)#B%[M[E]5;X6\WSVHLMV\Y9J=U4+5 MH.W_]4S#9ANQM=IC
M#G7IO;AV-J(NVY)<]O,>HVZ &5GS.;;M\U\\T_AO$/5O[3_CGSWH!*2:.7[Y
MZ&SX^=2<8A^V13H^_/S+B/0[3OISAY_+*#P:5UARZP^O;?V[FTCNY+_^V$(<
M$0_7K6+84\_"VV!]8KX2>H)^_ZS? X%1S^0;QC8^]E/-*ELFMVEE6MK]H".F
MJ:4F%9%F2[I9R-#ONFG7*B-7:FP\'E"4$?$Z+];WQ)!#5H#A";Y'[H6@CH)0
MA'7[JX)WVRYT45-)F]TW#^ITIK-;51PTTVHR/O^6N7/<7^F;EX-BYDY!)./4
MFQT'M,I O&1EYL, SQ:8I.2[/AGM'%EP2!:X*.W_QFZD*DHVB#"0$5\K.[M.
M_>"S3HEI $L1/TYT>^#IR<RW>";\V5BN4UC@";W$9!^BNM3UAJ(1#T5<\&PS
MJX*5I XS,9I6@+L46$(.F%PMV@,9A5X1H)-(!E!^"681"2'8$HN7M<)R;CU&
ME=!;;QU@TL1*V!G05QL?9ZUWIA9[<_+B3#G"75P2JJWE(IQ@Q9A/OKW\8F[M
MF<MW+_Y&B-9)#_R8%+K&6GGMX\M@WCB5?COP_B.[C"-WZFX:\,7IJW/"*TL_
M9#K^F.:&/<(6,1]+;I)Y1 )%AO5T.JC@J1)3"B@>OL[#9$<=?A[??#7C\$?]
M\XXM>-6<N^TAT=],'Q."]LU35*\]+R#\,4]9C66F'PVV1TR>4T"V8F\RUT/Y
M0A,V6>@V>=-"A>B9?1B,O\E<<F%0H]<,O8IPN\EW@Z9E(U)!A(/B^7N8JI"=
M:^1.:TM>-GD981V+;DPTY+W#72NJ8-3TTKW*P]R[.;.8VVB<S6G41J(7*-=$
MEO6%SA[O%#D)<;,!O2B%"[Z64 "(.P8-@.%-YC:.?+,%RKB,(,6$78I;W"MR
MZ N1 JMH4:+SP3"8KH1>GLCF+\_.'V/N$<ZQJ0HC3W'A]^+;"$RF0<XZ?VAT
M1VE,7N+QXJ@'F>8!;O$5;K.!X,UBBT<_]4>.I)]LN*/GUH5R.3=3/1<^,17)
M#5YP0>H0#UQ)4;,?EF1APZ1 %7T:'4L/H$\JCV@V-;K9HO+/K^E^^LJ[2>NU
MLKOIQNW'SD8U9D';'7=AML7*^KDDGMM98G_B9EK%W?0S:1?2SQA_O;&ZZ\ 2
M_IY"RL446 *S:?,JC)U2X%0V^4O/C(X6J!QZW^\N9UW&:0]UYUS?L:.Q!SN<
MS5'/XN-WA8S45^5M<73OH3[(?3-/G]._-MQ"FY>Y@)U=1Q9O>$'++!M%_G/A
M;X9N28%-?GLEC%/D&=4_HO[G-9XRO]8<NXB \[1(;/42G<B:V@AE2QCJ4L#Y
M%&U$D2IQA3'_.1F>J9MX6% [@[T':OU)*[=XE2Y0AYVPK?P_/W4T1[[.G5K?
M1QY7@?.^L-Q7Y9_IYBBD)7%^?UO2$"@%1@TVX +"224+@?_AJ<OQA4VA4D"G
M#SG3@!>O[9GGU,FUD[<N4M7)R7^0X\VEP."IV(=)1N#37[/N9<5AIU $O(3Y
M ST=]8/YF9; 7$=^/<]C+2S6_") M8M769'";,F!:_'BE#'RZ%K?7Y5J],\'
M.?^^D3;\CV%,E .7[P_$2Q!VT4SRD2QT0%.X6J(CN;*0K;!K]J'XX:0H3!!1
MKH?M-9M4ZL>1G]-N$O<4?L)Z0GCGWE!WKU;<\:=/8X,JYS^]0\T=B]KR+=F$
M'R]2SY3(;^3[A+^=<Q)7,K3,&58V](*;7"4)2A&CW?HEE678L$=.8:O.@Y^=
M3$3CQ>U&Z]C'-P\)/]X\CG\R]'7\:7>@1]F[=>^R?#_<.;_]Q.?@O2=#3Y'B
MGY>5Z3VJW2%SJ\='0^[DZEV[SY]ZKGLP[X:"KGZT<E+#E[ Y8>E!_"0O);G"
M46FBVZWB8)AS\^ZOQXR-5#N?>;]NS-QVC?:&!9&0(E6*A&):3X8NH=!2X.>#
M? DR7@K(YL-P^EZ(E6A1*%) ]-U(B)PAVT1\N<9JV]8\4RW>/;W(J-R^"->E
M3L<QY "><0L_.S99$:.23*[R%M_7O?]HA35WL^X?*TOV/;B^3U;1S.=SR3WW
M'Q/N7RJ\2VKO&[_;P::_5CW#NW]N[V_K:_1W;NC[,@0;7T"NWWSB*78 7:_H
M5K4;$X]%GFCF'4\ZJ,Z3WUGC[OZ1ASVK-\$9=6'Q(++0&;U@W;9,"O!J("D@
M!3Y$4> E2H$\'=BO<>_QF7\N\KK8RS=_%)T3V2(<DQS *Y(_&G#GS<F[[20*
MB;^V*8N$+K8M$SJ*NOZVT5'L<I@ PD)?Z!BIUU"[-CMB\2)DM?>EC97&=ICL
MQP:!PU_235]<@PYII:*F2F?7+&#CUOF=CVH%9W:^(.V5.W0-%Q-XYNG=F]:;
M+!/9[])VE1]2N?/B*+&T^MSGRJN1ZF5B]&OQ<6A&"FPP5I"P37X]1#"?FB&:
M@_X2A9_PDF) A_0"S@BRBA;MGS5P-"+QCL@"FHM-Z&_5N%C<<!*Q?>AW8%H?
M]%TC!1!LV&9N4J#C&P$>1ZFE10I(0M9\@:+O^'UD&C9[-'R]E[KUYO>A;MQI
MX8FLZ0)!7.&Z34?2M]C6O#'?%%&4,WL&[5Y">XO]BS" 21D;9 W=V9M$9OM#
M>N]7KH<'7SDFF+R[*NVA'5*T59N_Z^W;YVL^?GB<EVPD V(_KIL3RYM21!9G
MR?..U.'^&PLO[$E'X%&$4F#H#GGZ6BY,Z]A7P%^NREF&%(K0T":D6,?_UY>-
M/A')4F#8UG%V>:04V/\;3.B5[G(E;L/SLZ?(^ZA+T%].])#';2QAJ3(Z+H$Y
M^NMX/GY!B!5OB6*MDJR&W45&#_WAJ]%.&Z>3![SJGWICRIQ"-2FP.M!)V$'/
MN6_+),<\H[(44E>G6@WKUF+7D^OK64+'%/^&\&_W3O_RK]>[=SO7,,C"<J:U
MZ(=A+#@E,O1;?-3RU=TZY ?ZP>_WMQM0@<@CA'!ADW7RCL*9@([2]8[T',7?
M3F,^.F^E5=X.<%C/:*U,"[/SHAV?I_K\[=QW"T6DKB:1=W!""_MS%;Y0YXN1
M2"DPWWZ$_-=6(<.F+YO_94?RW^PXXZ<W$Y@DRD<+O?'0II7I2HO^T,:3;XZY
M0Z'@C*?#R@_NYOB8#:]Y:SX]7'Y:TSKFHN/Y,!$:(9%WE *.]X98(LN_S2AY
MU<;Z[@17"EZ%%LRI#UGW3=]%EAW_#V?-+(6_SJTZ+QY:I$Z3R*_C17JXO^A%
M!Z&7UZ_YD*.XZBF$!X4_TB_=O,E"-QQL61%<?W84^,:D1N^Z*$ TSML0'8[>
M:\_'J!PY;N3QZDSID:+<M8RC.<YW\E<8;ME<;/"$X_7=O*]KQG':Z"^JP_QS
M,K0[0K+BD_"WZ-E/PJO#2?98J(JKL\?/827ZRYTP_:4C?7*%Q,OHH1IXT=8(
MZ'W;LFGDST/_$L2T"A"S_?W.GEV64:\$.Y/N!&]RXUVF@RNIZ-DPP\K9'51#
MM/[\M?+6=T;8]'YD68C'5Y._,MY1K$0A!<[,!RDN;V#[ZYJY95Q#:8N(J>8Z
M-'WJBG05,L=OJ;6_OL<7UK]D ?F_R@(D%HY+9+W(4;15>;,4B.?!\0O__O[3
M&J[,<0+!+WM;K40_-9U<4/6'T:E9"DQ1T&T52V<]_EG?XN9KA+!7L!)YDX=0
MQ8$>& 2"$,OM_0."C=HVP&Z9ON-8^2(!F<U3->'><E!0'"XGU4A>HX5NZ(]=
ML]-D9,OB)A&^@[F3U<#CW1;4%T"X%J:.%(@A$%H6@R4J%7O ZAC1CNU2@([F
MK>]EL,:[(KY$QDKZ9LD6W ]B-EMQK>FRVV=+!9?O/M9V^I8>Z)!KA/! [+$=
M$NX\>A.W7_7*[S'Y[V][=Z35=2V="(3%N_,_?RA<9F5<LZ/=K5>[=^M91YE&
M71MS_5A<(B=9PA*YHI( _PQFM&0>*S&XE7_D,;!NPXTIVA7)A-.ML;[BNG7K
MFAVNW ]K>6*S>>DW3/\<KSB9*"= <UZ> !VH2NGQ34B.YQP?'?4U=:%YAFXB
MWR8T'4)'G65E&9WTNWWH#I3\:E"_PL+RW;+OJ1^,FN/'^S*>OYMN^=<)J;?&
M)J'PSG-G]VC,O&X9[KRN]97V0 HP/:1 8B$'_1KNDF,/6)ZRN2:"O998,-77
M3N8:28'&KN_Z,FG[=(IO[%/\^__ZWFMZL)'J'$D_:C=49Y&S$E+P%-^3K!59
M=M%MR:>Z6OE<19$7U,*O\ZNOI-\=7<7&/R2\M'WA,A^4\?;KC]Q!^8(:>DTJ
MNN3Y\EW[VC#DPG5+2\=>S:'N &W&D7+B*=A8.IX+B,6O9"B+Y&@]/3;!I;*S
M9.3^^-WFUQJU=_^YQOQ34F CW"-T]5_>1CN$Z>J;1J=;AI]+&;MU/X6MIQW<
MIC$YL@^YAQ@(A?*I&B(W\2V&*V]QQ:5I?"Q2A^$AH&E]<HHX?X'C'S>#Z8^?
MC84"SE]3JGM_"U/J8I(LBN1%6G,"1FRZ+P^^*W%2[3_ITX;HR/W7&2]ON!FU
M8D9.[^?J<^&I-:-6"Y&1)3+,?[UJL?D[G ;7:5) #?/Z];IU-G+!J34+;ON4
M_L7VM]]A;:4 \<_+^7I]-$SXO\4*TU=<R=0@O!2HC]/!:E[F=;/OYE@-J.O5
M7*UA_/3(Y+A9R:69=;2+!JGKS+4=O'!:]EOP&W=]:EN_KV19]!I:2?*#W=L>
M+*P%)"=;-Y_?4R^W?OVJRY'*5H=E U8!7Q0S;]5NX17XK1?4Z''[LL+^'B\2
M<MN7@%T[[]_4B;=>/ST\>%WKV=]LO%N1O'!=LN](QW_^+8(_T)689FK*<QQ7
M>!BM2< )?,N$I(%952B,AUQ--!7:Y*8,E7'EB"[=3R1RKF#U81#=!!%M>1/!
M321=H7^J^8MAR.CA"&E-+U'=XI9)C+5'Z07UL%SS7!@[G&;40?664E8 .<XB
M=S7$$J#5<;GZ8&QQDF27:%5VO8Y:%U.1*"/.#B4#.$M/4KS ]0S7E@&2J& 5
M5MW@NO6ZDD\B6THC=]5,&645E\8N-^+IQ);1XD@I<&E8U"?JB?/HV.6$ZB9-
M5R8%U.+-UO%:@QO(JF94!,'(';2YXZO9_6/&"ZT<>)DPT"#9)IQ+9!CTU<9*
M\A#Q#)>'@556A@E^56!FW')X:L.#X++D$.K'BEFO=M*V4>3Z2DS4H'*'Q"AP
MT**;I!\X:-;)ZZX48XZ#WVAG:OT*^1-'C'R<C2W=^B9#/@YU_0@U&I#_L>EY
M5665WPZ.E_X^=90IP8Y?][4OD7&<U\;9SAVB19V"O&L="J]<XYG(C[DSE;HO
MBH(+H-M-Y-7E,YBUNR[T>M*+V7N1*I"7 [7Q32GDR,[*$5-OFG,14%*7(_5
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M2NOCX$HY<D3SK#LM7,A.\%4UWT+\@G=.I;I;T>Q!"L%2(:(76O?"_;JJ8%W
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MAE*89UTB45M=:9Z;\D!E[*"80+L_->8^@-NYY36<(OMF4&3/N @RSUK"&P&
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M4$L! A0#%     @ M83V4 U_6!CO+P$ JL / !4              ( !3=@
M &)I:6(M,C R,# V,S!?;&%B+GAM;%!+ 0(4 Q0    ( +6$]E ;USZ-H\<
M &O)"0 5              "  6\( @!B:6EB+3(P,C P-C,P7W!R92YX;6Q0
M2P$"% ,4    " "UA/90\DY.>$\(! #[#CP %               @ %%T (
M8FEI8BTR,#(P-C,P>#$P<2YH=&U02P$"% ,4    " "UA/90G$8^0X,(  #F
M-@  %@              @ '&V 8 8FEI8BTR,#(P-C,P>&5X,S$Q+FAT;5!+
M 0(4 Q0    ( +6$]E#J1R>JCP@  +XY   6              "  7WA!@!B
M:6EB+3(P,C V,S!X97@S,3(N:'1M4$L! A0#%     @ M83V4.U49)37!0
M"BH  !8              ( !0.H& &)I:6(M,C R,#8S,'AE>#,R,2YH=&U0
M2P$"% ,4    " "UA/90I#+#TJ.^  "B]   $0              @ %+\ 8
M8FEO9V5N;&]G;V$Q,2YJ<&=02P$"% ,4    " "UA/90]5+H0O9\  "<B0
M'0              @ $=KP< 8VAA<G0M,&(V,3!A9C5B-V4S-6)E-#@W.2YJ
M<&=02P$"% ,4    " "UA/90ZMAZA_"-  !3EP  '0              @ %.
M+ @ 8VAA<G0M,C(U8F4P9C%A,S(X-3$P86)A-RYJ<&=02P$"% ,4    " "U
MA/9080HX)*).   @5P  '0              @ %YN@@ 8VAA<G0M,C4V,SEF
M-&4W,S)A-6$Q96$Y.2YJ<&=02P$"% ,4    " "UA/90;'/BY^I]   1BP
M'0              @ %6"0D 8VAA<G0M,C5C-C,T.68S,S4R-3=B,CAB,BYJ
M<&=02P$"% ,4    " "UA/90YS)!%29\  #UA   '0              @ %[
MAPD 8VAA<G0M,S,Y-6,R,V,Y8F4Q-3)F-&(R9BYJ<&=02P$"% ,4    " "U
MA/907:O6E,:4   3G0  '0              @ '< PH 8VAA<G0M,V)E9C,T
M-3%F,V0X-3$R-&(R."YJ<&=02P$"% ,4    " "UA/90(7@B^"V5  "@G0
M'0              @ '=F H 8VAA<G0M-#4P,S%C9&,W,64W-3-F-F$W8BYJ
M<&=02P$"% ,4    " "UA/90I((J1GM_  !7C0  '0              @ %%
M+@L 8VAA<G0M-#AB96,X-C5E-C8U,S-D8F,R9BYJ<&=02P$"% ,4    " "U
MA/907\:_!0Q3  ![70  '0              @ '[K0L 8VAA<G0M-31B-C<W
M861D,#=D-3!A-C@R82YJ<&=02P$"% ,4    " "UA/90+9B+\5&,   4E
M'0              @ %" 0P 8VAA<G0M-6-D-6%A,3)B,&0T-3<W.#@V.2YJ
M<&=02P$"% ,4    " "UA/90EB;;D386 0 7+0$ '0              @ '.
MC0P 8VAA<G0M-69B,V%F83,T865E-3@Q,V(Q-RYJ<&=02P$"% ,4    " "U
MA/90B,.'2YY,  !.5@  '0              @ $_I T 8VAA<G0M-V4V.3 S
M,# X-3$R-3$R96%E92YJ<&=02P$"% ,4    " "UA/90(2[GY->(  "HD
M'0              @ $8\0T 8VAA<G0M.#8R.6,Y-C5F-#0U-3AB,#@Q-RYJ
M<&=02P$"% ,4    " "UA/90T+_8V.*9  "3J   '0              @ $J
M>@X 8VAA<G0M.&4W9#<T9F0S.#<V-3DP,#DU8RYJ<&=02P$"% ,4    " "U
MA/90@<V0"7%    $3   '0              @ %'% \ 8VAA<G0M.3 P8C(W
M93,V9&-B-3)C,6$P,"YJ<&=02P$"% ,4    " "UA/90Y>TAC9Q+  "*5
M'0              @ 'S5 \ 8VAA<G0M.34Y,69B-C<U,3 V-30U-C@S-"YJ
M<&=02P$"% ,4    " "UA/90Y&"=-D:=  "AIP  '0              @ '*
MH \ 8VAA<G0M.35F-&8W,61F961E-6(P9&(T,RYJ<&=02P$"% ,4    " "U
MA/90[)@VLHI&  "M40  '0              @ %+/A  8VAA<G0M865A8C(P
M,#%C,#5C-3-F.&(V,2YJ<&=02P$"% ,4    " "UA/9013'U8#E"   #3P
M'0              @ $0A1  8VAA<G0M8V$T,C T,3(R,C R-60S86)B8RYJ
M<&=02P$"% ,4    " "UA/90[ZD+<3I2  #O7   '0              @ &$
MQQ  8VAA<G0M8V$V-F,T8S,V9&,V-3<U-CDX-"YJ<&=02P$"% ,4    " "U
MA/90""23A7NL  #KM@  '0              @ 'Y&1$ 8VAA<G0M934S93-E
M,S@S.3 T-3!F8CDX.2YJ<&=02P$"% ,4    " "UA/906-=Q.G9,  !;5@
M'0              @ &OQA$ 8VAA<G0M9C4Y,&5C-64Q-3,P-6$Q-6(Q,BYJ
8<&=02P4&     "  (  *"0  8!,2

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
